<SEC-DOCUMENT>0001012477-25-000010.txt : 20250303
<SEC-HEADER>0001012477-25-000010.hdr.sgml : 20250303
<ACCEPTANCE-DATETIME>20250303091656
ACCESSION NUMBER:		0001012477-25-000010
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		123
CONFORMED PERIOD OF REPORT:	20241231
FILED AS OF DATE:		20250303
DATE AS OF CHANGE:		20250303

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			AVADEL PHARMACEUTICALS PLC
		CENTRAL INDEX KEY:			0001012477
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37977
		FILM NUMBER:		25694479

	BUSINESS ADDRESS:	
		STREET 1:		BLOCK 10-1 BLANCHARDSTOWN CORPORATE PARK
		STREET 2:		BALLYCOOLIN
		CITY:			DUBLIN
		STATE:			L2
		ZIP:			15
		BUSINESS PHONE:		636-449-1830

	MAIL ADDRESS:	
		STREET 1:		16640 CHESTERFIELD GROVE ROAD
		STREET 2:		SUITE 200
		CITY:			CHESTERFIELD
		STATE:			MO
		ZIP:			63005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FLAMEL TECHNOLOGIES SA
		DATE OF NAME CHANGE:	19960422
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>avdl-20241231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253,d:d52fa9b3dc2341649ffd3f8e14993a22-->
<html xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ecd="http://xbrl.sec.gov/ecd/2024" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns:avdl="http://www.avadel.com/20241231" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:us-gaap="http://fasb.org/us-gaap/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:cyd="http://xbrl.sec.gov/cyd/2024" xmlns:srt="http://fasb.org/srt/2024" xmlns:country="http://xbrl.sec.gov/country/2024" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>avdl-20241231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-32">0001012477</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-33">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-34">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-35">2024</ix:nonNumeric><ix:nonNumeric contextRef="c-104" name="us-gaap:LesseeOperatingLeaseTermOfContract" id="f-539">P1Y</ix:nonNumeric><ix:nonFraction unitRef="number" contextRef="c-182" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-901">25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-183" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-902">25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-903">25</ix:nonFraction><ix:nonFraction unitRef="number" contextRef="c-185" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-904">25</ix:nonFraction></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="avdl-20241231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="institution"><xbrli:measure>avdl:institution</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="tranche"><xbrli:measure>avdl:tranche</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>avdl:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-28</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-02-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoHealthGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumFrontierTherapiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoHealthGroupInc.Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumFrontierTherapiesLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:LeaseholdImprovementsFurnitureFixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:LeaseholdImprovementsFurnitureFixturesAndFittingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-03-29</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-08-01</xbrli:startDate><xbrli:endDate>2023-08-01</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-29</xbrli:startDate><xbrli:endDate>2023-03-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-31</xbrli:startDate><xbrli:endDate>2024-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avdl:A163jCreditsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:FscHoldingsLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:U.S.HoldingsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:U.S.HoldingsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avdl:OrphanDrugTaxCreditMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:LitigationCaseAxis">avdl:FirstJazzComplaintMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-15</xbrli:startDate><xbrli:endDate>2024-04-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-03-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-05-08</xbrli:startDate><xbrli:endDate>2024-05-08</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-08</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avdl:AmericanDepositarySharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-03-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestOneYearFollowingAchievementOfMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-06-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:InducementPlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-02-01</xbrli:startDate><xbrli:endDate>2024-02-29</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:A2017AvadelEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:A2017AvadelEmployeeSharePurchasePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-10-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001012477</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_1"></div><div style="min-height:18pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">&#9746;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the fiscal year ended</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December&#160;31</ix:nonNumeric>, 2024</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">&#160;&#160;</span></div><div><span><br/></span></div><div style="padding-left:108pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">OR&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:107%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:107%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">For the transition period ____________ to ____________&#160;&#160;&#160;</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Commission file number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-37977</ix:nonNumeric></span></div><div style="margin-bottom:6pt;text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:16pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">AVADEL PHARMACEUTICALS PLC</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:47.166%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.367%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:47.167%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:edgarprovcountryen" id="f-8">Ireland</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">98-1341933</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">State or other jurisdiction of incorporation or organization</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(I.R.S. Employer Identification No.)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">10 Earlsfort Terrace</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-11">Dublin 2</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCountry" format="ixt-sec:countrynameen" id="f-12">Ireland</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-13">D02 T380</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Not Applicable</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">(Zip Code)</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="9" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Registrant&#8217;s telephone number, including area code: +<ix:nonNumeric contextRef="c-1" name="dei:CountryRegion" id="f-14">353</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">1</ix:nonNumeric>-<ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">901-5201</ix:nonNumeric></span></div></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(b) of the Act:</span></div><div style="margin-bottom:4pt;margin-top:5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:42.234%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading Symbol (s)</span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Name of exchange on which registered</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Ordinary Shares, nominal value $0.01 per share</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">AVDL</ix:nonNumeric></span></td><td colspan="3" style="border-left:1pt solid #000000;border-right:1pt solid #000000;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Market</ix:nonNumeric></span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:120%">Securities registered pursuant to Section&#160;12(g) of the Act: None</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric>&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d) of the Act.&#160;&#160; Yes&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;<ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric>&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2)&#160;has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric>&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#168;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically, every Interactive Data File required to be submitted and pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric>&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer&#8221;, &#8220;accelerated filer&#8221;, &#8220;smaller reporting company&#8221;, and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Large accelerated filer</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#253;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Non-accelerated filer </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Smaller reporting company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Emerging growth company </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">&#9744;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.  </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">&#253;</ix:nonNumeric> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9744;</ix:nonNumeric></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:112%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167;240.10D-1(b). </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#9744;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#160;&#160; </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#9744;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> &#160;&#160;&#160;&#160;No&#160;&#160;</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">&#253;</ix:nonNumeric></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The aggregate market value of voting stock held by non-affiliates of the registrant as of the last business day of the registrant&#8217;s most recently completed second fiscal quarter was $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="0" name="dei:EntityPublicFloat" format="ixt:num-dot-decimal" scale="0" id="f-30">1,342,171,790</ix:nonFraction> based on the closing sale price of the registrant&#8217;s ordinary shares as reported by the Nasdaq Global Market on June 28, 2024. Such market value excludes 743,475 ordinary shares, $0.01 per share nominal value held by each officer and director and by shareholders that the registrant concluded were affiliates of the registrant on that date. Exclusion of such shares should not be construed to indicate that any such person possesses the power, direct or indirect, to direct or cause the direction of the management or policies of the registrant or that such person is controlled by or under common control with the registrant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">The number of the registrant&#8217;s ordinary shares, $0.01 per share nominal value, outstanding as of February&#160;26, 2025 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">96,629,435</ix:nonFraction>.</span></div><div style="height:18pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span><br/></span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">TABLE OF CONTENTS</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:11.930%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:74.595%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.175%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Page #</span></td></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_10">Summary Of The Material Risks Associated With Our Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_10">3</a></span></div></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_13">Cautionary Disclosure Regarding Forward-Looking Statements</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_13">4</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_16">PART I</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_19">Business</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_19">6</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_22">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_22">21</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_25">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_25">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 1C.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_28">Cybersecurity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_28">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 2.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_31">Properties</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_31">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 3.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_34">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_34">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 4.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_37">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_37">56</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_40">PART II</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 5.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_43">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_43">57</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 6.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_46">Reserved</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_46">59</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_49">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_49">60</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 7A.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_70">Quantitative and Qualitative Disclosures About Market Risks</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_70">70</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 8.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_73">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_73">72</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_193">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_193">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9A.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_196">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_196">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9B.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_199">Other Information</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_199">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 9C.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_202">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_202">103</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_205">PART III</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 10.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_208">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_208">104</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 11.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_211">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_211">107</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 12.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_214">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_214">121</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 13.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_217">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_217">123</a></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 14.</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_220">Principal Accounting Fees and Services</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_220">124</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_223">PART IV</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Item 15.</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_226">Exhibits</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_226">126</a></span></div></td></tr><tr><td colspan="6" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="6" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_229">SIGNATURES</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#id52fa9b3dc2341649ffd3f8e14993a22_229">130</a></span></div></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-2-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_10"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SUMMARY OF THE MATERIAL RISKS ASSOCIATED WITH OUR BUSINESS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to numerous material and other risks and uncertainties, including those described in Part I, Item 1A &#8220;Risk Factors&#8221; in this Annual Report on Form 10-K. The principal risks and uncertainties affecting our business include the following:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our business depends heavily on our ability to successfully commercialize LUMRYZ (sodium oxybate), our lead product, in the United States (&#8220;U.S.&#8221;) and in other jurisdictions where we may obtain marketing approval. There is no assurance that our commercialization efforts with respect to LUMRYZ will be successful or that we will be able to generate revenues at the levels or on the timing we expect, or at levels or on the timing necessary to support our goals.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Coverage and reimbursement may be limited or unavailable in certain market segments for LUMRYZ or any future products, if approved, which could make it difficult for us to sell LUMRYZ or any future products profitably.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">LUMRYZ may not maintain regulatory exclusivities, including orphan drug exclusivity, or the benefits of such exclusivities, which may adversely affect the sales of the product.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">LUMRYZ is subject to ongoing enforcement of post-marketing requirements and we could be subject to substantial penalties, including withdrawal of LUMRYZ from the market, if we fail to comply with all regulatory requirements. In addition, the terms of the marketing approval of LUMRYZ and ongoing regulation of our product may limit how we manufacture and market LUMRYZ and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We incurred a net loss in 2024 and may incur a net loss in 2025; if we are not able to achieve profitability in the future, the value of our ordinary shares may fall.</span></div><div style="padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt">We may require additional financing, which may not be available on favorable terms or at all, and which may result in dilution of the equity interest of the holders of our ordinary shares.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The distribution and sales of LUMRYZ are subject to significant regulatory restrictions, including the requirements of a Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;) and safety reporting requirements, and these regulatory requirements subject us to risks and uncertainties, any of which could negatively impact sales of LUMRYZ.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Disruptions at the U.S. Food and Drug Administration (&#8220;FDA&#8221;), the U.S. Drug Enforcement Administration and other government agencies caused by funding shortages, global health concerns or recent changes in administration could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We rely, and intend to continue to rely, on a limited number of suppliers for the manufacture and supply of LUMRYZ, and if we experience problems with those suppliers, or they fail to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, our business would be materially and adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we cannot adequately protect our intellectual property and proprietary information, we may be unable to effectively compete.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">If we are unable to maintain effective sales, marketing and distribution capabilities, or maintain agreements with third parties to market, sell and distribute LUMRYZ, our business, results of operations, financial condition and prospects will be materially and adversely affected.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We cannot be certain that any product candidates will receive marketing approval. Without marketing approval, we will not be able to commercialize any product candidates. </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">We may become involved in lawsuits to protect our products and/or enforce our patents or other intellectual property, which could be expensive, time consuming and/or unsuccessful.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The price of our ordinary shares has been volatile and may continue to be volatile.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-3-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_13"></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cautionary Disclosure Regarding Forward-Looking Statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K includes &#8220;forward-looking statements&#8221; within the meaning of Section 27A of the Securities Act of 1933, as amended (the &#8220;Securities Act&#8221;), and Section 21E of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Any statements about our expectations, beliefs, plans, objectives, assumptions or future events or performance are not historical facts and may be forward-looking. These statements are often, but are not always, made through the use of words or phrases such as &#8220;may,&#8221; &#8220;will,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;expects,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;anticipates,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; &#8220;predicts,&#8221; &#8220;projects,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; and similar expressions, or the negative of these terms, or similar expressions.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, these statements involve estimates, assumptions, risks and uncertainties which could cause actual results to differ materially from those expressed in them. Any forward-looking statements are qualified in their entirety by reference to the factors discussed throughout this prospectus, and in particular those factors referenced in the section &#8220;Risk Factors&#8221; in Part I, Item 1A of this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that are based on our management&#8217;s beliefs and assumptions and on information currently available to our management. These statements relate to future events or our future financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements include, but are not limited to, statements about:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our ability to successfully commercialize LUMRYZ in the U.S. for the treatment of cataplexy or excessive daytime sleepiness (&#8220;EDS&#8221;) in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">patients seven years of age and older with narcolepsy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> plans with respect to our commercial infrastructure and marketing, market access and commercial activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our ability to maintain and receive additional regulatory approvals for LUMRYZ in any other jurisdictions outside the U.S., and any related restrictions, limitations, and/or warnings in the label of LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations regarding the rate and degree of market acceptance for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our abi</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">lity to enter into strategic partnerships for the commercialization, manufacturing and distribution of LUMRYZ in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our reliance on a single product, LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations regarding timing of and our ability to execute the pivotal REVITALYZ trial of LUMRYZ in idiopathic hypersomnia (&#8220;IH&#8221;);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our ability to seek, maintain and receive additional U.S. regulatory approvals as well as commercialize LUMRYZ for indications beyond narcolepsy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our dependence on a limited number of suppliers for the manufacturing of LUMRYZ and certain raw materials used in LUMRYZ and any failure of such suppliers to produce LUMRYZ or deliver sufficient quantities of such raw materials, which could have a material adverse effect on our business, including commercialization of LUMRYZ in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our ability to finance our operations on acceptable terms, either through the raising of capital including the incurrence of convertible or other indebtedness, issuance of equity or royalty-based financings, or through strategic financing or commercialization partnerships;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations regarding the pricing and reimbursement and the extent to which patient financial assistance programs are utilized for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations about the potential market size and market participation for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations regarding litigation related to LUMRYZ; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our expectations regarding our cash runway to support the commercialization of LUMRYZ in the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The potential impacts of inflation and rising interest rates on our business and future operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Our ability to hire and retain key members of our leadership team and other personnel; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">The potential impacts due to global political instability and conflicts, such as terrorism, civil unrest, war and natural disasters in foreign countries on our business, financial condition and results of operations; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">Competition existing today or that may arise in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These forward-looking statements are neither promises nor guarantees of future performance due to a variety of risks and uncertainties and other factors more fully discussed in the &#8220;Risk Factors&#8221; section in Part I, Item 1A of this Annual Report on Form 10-K and the risk factors and cautionary statements described in other documents that we file from time to time with the SEC. Given these uncertainties, readers should not place undue reliance on our forward-looking statements. These forward-looking statements speak only as of the date on which the statements were made and are not guarantees of future performance. Except as may be required by applicable law, we do not undertake to update any forward-looking statements after the date of this Annual Report or the respective dates of documents incorporated by reference herein or therein that include forward-looking statements, even if new information becomes available in the future. </span></div><div><span><br/></span></div><div><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-4-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:31.5pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOTE REGARDING TRADEMARKS</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We own various trademark registrations and applications, and unregistered trademarks, including, but not limited to, AVADEL</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, LUMRYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RYZUP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, REST-ON</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, RESTORE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> and REVITALYZ</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.47pt;font-weight:400;line-height:115%;position:relative;top:-3.48pt;vertical-align:baseline">TM</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. Trade names, trademarks and service marks of other companies appearing in this Annual Report are the property of their respective holders. Solely for convenience, the trademarks and trade names in this Annual Report may be referred to without the &#174; and &#8482; symbols, but such references should not be construed as any indicator that their respective owners will not assert, to the fullest extent under applicable law, their rights thereto. We do not intend to use or display other companies&#8217; trademarks and trade names to imply a relationship with, or endorsement or sponsorship of us by, any other companies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may use our website, LinkedIn or our X account (@AvadelPharma) to distribute material information. Our financial and other material information is routinely posted to and accessible on the Investors section of our website, available at www.avadel.com. Investors are encouraged to review the Investors section of our website because we may post material information on that site that is not otherwise disseminated by us. Information that is contained in and can be accessed through our website, our LinkedIn posts or our X posts are not incorporated into, and does not form a part of, this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-5-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_16"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">PART I</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_19"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Business.&#160;</span></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Dollar amounts in thousands, except per-share amounts, information set forth under Part III, and as otherwise noted)</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Overview</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, LUMRYZ is the only commercial product in our portfolio. We continue to evaluate opportunities to expand our product portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ was approved by the FDA on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted seven years of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Orphan Drug Exclusivity (&#8220;ODE&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently marketed oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over currently marketed, twice-nightly oxybate treatments by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose. The ODE will continue until May 1, 2030. In June 2023, we announced the U.S. commercial launch of LUMRYZ for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has required implementation of a REMS to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions.   </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous LUMRYZ-related U.S. patents have been issued having expiration dates spanning from mid-2037 to early-2042, and there are additional patent applications currently in development and/or pending at the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), as well as foreign patent offices. We currently have 30 U.S. patents listed for LUMRYZ in FDA&#8217;s Orange Book.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">With respect to clinical data generated for LUMRYZ, we conducted a Phase 3 clinical trial of LUMRYZ (the &#8220;REST-ON trial&#8221;), which was a randomized, double-blind, placebo-controlled study that enrolled 212 patients who received at least one dose of LUMRYZ or placebo, and was conducted in clinical sites in the U.S., Canada, Western Europe and Australia. Positive top line data from the REST-ON trial were announced on April 27, 2020. REST-ON trial results have been published by Kushida et al.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our open-label extension/switch study of LUMRYZ (&#8220;RESTORE&#8221;) examined the long-term safety and maintenance of efficacy of LUMRYZ in patients with narcolepsy who participated in the REST-ON trial, as well as dosing and preference data for patients who switched from twice-nightly sodium oxybate to once-at-bedtime LUMRYZ, regardless of whether they participated in the REST-ON trial. In May 2021, inclusion criteria were expanded to allow for oxybate na&#239;ve patients to enter the study. The last patient visit occurred in October 2023. RESTORE results for the largest cohort, those who switched from twice-nightly oxybates, have been published, which include the 94% preference for the once-nightly dosing regimen that LUMRYZ provides. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe LUMRYZ has the potential to demonstrate improved dosing compliance, safety, and patient satisfaction over other treatment options for cataplexy or EDS in patients seven years of age and older with narcolepsy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avadel has initiated a pivotal trial in IH, REVITALYZ, which is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 study designed to evaluate the efficacy and safety of LUMRYZ, in treating IH. We expect to enroll approximately 150 adults in the study who are diagnosed with IH. On July 31, 2024, we announced that the first patient was dosed in this study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The primary objective of REVITALYZ is to demonstrate reduction in daytime sleepiness as measured by the primary endpoint, change in total score of the Epworth Sleepiness Scale at week 14. Secondary endpoints will evaluate the effect of LUMRYZ on </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">additional efficacy parameters including patient and clinician global impression of change, IH severity, and a measure of the functional outcomes of sleep.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Our Drug Delivery Technologies </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own drug delivery technologies that address formulation challenges, potentially allowing the development of differentiated drug products for administration in various forms (e.g.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> capsules, tablets, powders or liquid for oral use; or injectables for subcutaneous administration) that could be applied to a broad range of drugs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A brief discussion of each of our drug delivery technologies is set forth below.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MICROPUMP</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">MICROPUMP technology allows for the development of modified release solid, oral dosage formulations of drugs. A version of our MICROPUMP technology is being employed in LUMRYZ. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">LIQUITIME</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LIQUITIME technology allows for development of modified release oral products in a liquid suspension formulation, which may make such formulations particularly well suited for children and/or patients having issues swallowing tablets or capsules. Although we own this technology, we are currently not pursuing any commercial pharmaceutical drug development opportunities using it.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">MEDUSA. Our MEDUSA technology allows for the development of modified-release injectable dosage formulations of drugs (e.g., peptides, polypeptides, proteins, and small molecules). Although we own this technology, we are currently not pursuing any commercial pharmaceutical drug development opportunities using it.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Competition</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the pharmaceutical and biotechnology industry continues to be intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies who have approved, or who are developing, niche branded or generic specialty pharmaceutical products or drug delivery platforms. Furthermore, major technological changes can happen quickly in the pharmaceutical and biotechnology industries. Such rapid technological change, or the development by our competitors of technologically improved or differentiated products, could render our products, product candidates, or drug delivery platforms obsolete or noncompetitive.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ competes with twice-nightly oxybate formulations, as well as a number of daytime wake promoting agents including lisdexamfetamine, dextroamphetamine, methylphenidate, amphetamine, modafinil, and armodafinil, which are widely prescribed, as well as solriamfetol and pitolisant. Generic pharmaceutical products will continue to play a large role in the U.S. healthcare system. LUMRYZ may face competition from manufacturers of generic twice-nightly oxybate formulations. In January 2023, Hikma Pharmaceuticals plc, announced that it launched an authorized generic version of Jazz Pharmaceuticals plc&#8217;s (&#8220;Jazz&#8221;) Xyrem (sodium oxybate). In July 2023, Amneal Pharmaceuticals, Inc. announced that it launched an authorized generic version of Jazz&#8217;s Xyrem (sodium oxybate).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, there are other products in development that may be approved in the future that could have an impact on the narcolepsy treatment market, including, for example, reboxetine, orexin 2 receptor agonists, flecainide / modafinil combination, histamine H3 antagonists/inverse agonists, or GABAB agonists.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company was incorporated on December 1, 2015 as an Irish private company limited by shares, and re-registered as an Irish public limited company, or plc, on November 21, 2016. Our registered address is at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland and our phone number is +353-1-901-5201. We file annual, quarterly and current reports, proxy statements and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;). Our website is www.avadel.com, where we make available free of charge our reports (and any exhibits and amendments thereto) on Forms 10-K, 10-Q and 8-K as soon as reasonably practicable after they are electronically filed with or furnished to the SEC. These filings are also available to the public at www.sec.gov. We do not incorporate the information on or accessible through our website into this Annual Report on Form 10-K.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have five direct wholly-owned subsidiaries: (a) Avadel US Holdings, Inc., (b) Flamel Ireland Limited, which conducts business under the name Avadel Ireland, (c) Avadel Investment Company Limited, (d) Avadel Finance Ireland Designated Activity Company and (e) Avadel France Holding SAS. Avadel US Holdings, Inc., a Delaware corporation, is the holding entity of (i) Avadel Management, LLC, and (ii) Avadel CNS Pharmaceuticals, LLC. Avadel Finance Ireland </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-7-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Designated Activity Company is the holding entity of Avadel Finance Cayman Limited. Avadel France Holding SAS is the holding entity of Avadel Research SAS. A complete list of our subsidiaries can be found in Exhibit 21.1 to this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Intellectual Property</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parts of our product pipeline and strategic alliances utilize our drug delivery platforms and related products of which certain features are the subject of patents or patent applications. We seek patent protection for our inventions and also rely upon trade secrets, know-how, continuing technological innovations and licensing opportunities to maintain and develop competitive positions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Numerous LUMRYZ-related U.S. patents have been issued having expiration dates spanning from mid-2037 to early-2042, and there are additional patent applications currently in development and/or pending at the USPTO, as well as foreign patent offices.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions of biopharmaceutical companies like us are generally uncertain and involve complex legal, scientific and factual questions. In addition, the coverage claimed in a patent application can be significantly reduced before the patent is issued, and patent scope can be reinterpreted by the courts after issuance. Moreover, many jurisdictions permit third parties to challenge issued patents in administrative proceedings, which may result in further narrowing or even cancellation of patent claims. We cannot predict whether the patent applications we are currently pursuing will issue as patents in any particular jurisdiction or whether the claims of any of our licensed or owned patents will provide sufficient protection from competitors. Any of our licensed or owned patents may be challenged, circumvented, or invalidated by third parties. For more information, please see the information set forth under the caption &#8220;Risks Related to Our Intellectual Property &#8211; If we cannot adequately protect our intellectual property and proprietary information, we may be unable to effectively compete&#8221; in the &#8220;Risk Factors&#8221; included in Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supplies and Manufacturing</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The active pharmaceutical ingredient (&#8220;API&#8221;) in LUMRYZ, sodium oxybate, is a Schedule I controlled substance in the U.S., and the finished FDA-approved formulation of LUMRYZ is a Schedule III controlled substance in the U.S. per current federal regulations. As a result, LUMRYZ is subject to regulation by the U.S. Drug Enforcement Administration (&#8220;DEA&#8221;) under the Controlled Substances Act (&#8220;CSA&#8221;), and its manufacturing and distribution are highly restricted. Quotas from the DEA are required in order to manufacture both sodium oxybate and LUMRYZ in the U.S. Similar rules, restrictions and controls would apply to LUMRYZ in the event LUMRYZ is marketed outside of the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We attempt to maintain multiple suppliers in order to mitigate the risk of shortfall and inability to supply market demand. The API for LUMRYZ is currently manufactured by two outsourced contract development and manufacturing organizations (&#8220;CDMOs&#8221;) in the U.S. The LUMRYZ drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S. We expect to continue to outsource the production of sodium oxybate and drug product for LUMRYZ to current good manufacturing practices (&#8220;cGMP&#8221;) -compliant, DEA- and FDA-audited CDMOs pursuant to supply agreements. We may establish supply relationships with additional CDMOs to manufacture API and/or LUMRYZ in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Government Regulation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the U.S. at the federal, state, and local level and in other countries extensively regulate, among other things, the research and clinical development, testing, manufacture, quality control, approval, labeling, packaging, storage, record-keeping, promotion, advertising, distribution, post-approval monitoring and reporting, marketing, pricing, and export and import of drug products, such as those we are developing and marketing. Generally, before a new drug can be marketed, considerable data demonstrating its quality, safety, and efficacy must be obtained, organized into a format specific to each regulatory authority, submitted for review, and approved by the regulatory authority.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drugs are also subject to other federal, state, and local statutes and regulations. The process of obtaining regulatory approvals and the subsequent compliance with appropriate federal, state, local, and foreign statutes and regulations require the expenditure of substantial time and financial resources. Failure to comply with the applicable regulatory requirements at any time during the product development process, approval process, or after approval, may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the regulatory authority's refusal to approve pending applications, withdrawal of an approval, clinical holds, untitled or warning letters, voluntary product recalls or withdrawals from the market, product seizures, total or partial suspension of production or distribution, injunctions, debarment, fines, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-8-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">refusals of government contracts, restitution, disgorgement, or civil or criminal penalties. Any agency or judicial enforcement action could have a material adverse effect on us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Drug Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (&#8220;FDCA&#8221;) and its implementing regulations. Drugs are also subject to other federal, state, and local statutes and regulations. Drug candidates must be approved by the FDA through the New Drug Application (&#8220;NDA&#8221;) process before they may be legally marketed in the U.S. The process required by the FDA before a drug may be marketed in the U.S. generally involves the following:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of extensive preclinical, sometimes referred to as nonclinical, laboratory tests, animal studies, and formulation studies all performed in accordance with applicable regulations, including the FDA's good laboratory practice (&#8220;GLP&#8221;) regulations;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an Investigational New Drug Application (&#8220;IND&#8221;), which must become effective before human clinical trials may begin and must be updated annually;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials in accordance with applicable IND and other clinical trial-related regulations, sometimes referred to as good clinical practices (&#8220;GCPs&#8221;) to establish the safety and efficacy of the proposed drug for its proposed indication;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">submission to the FDA of an NDA for a new drug;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">a determination by the FDA to file the NDA for review;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA pre-approval inspection of the manufacturing facility or facilities at which the API and finished drug product are produced to assess compliance with the FDA's cGMP requirements;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential FDA audit of the clinical trial sites that generated the data in support of the NDA;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees for FDA review of the NDA; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">FDA review and approval of the NDA prior to any commercial marketing or sale of the drug in the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The data required to support an NDA are generated in two distinct development stages: preclinical and clinical. The preclinical development stage generally involves synthesizing the active component, developing the formulation, and determining the manufacturing process, as well as carrying out non-human toxicology, pharmacology, and drug metabolism studies in the laboratory, which support subsequent clinical testing. The conduct of the preclinical tests must comply with federal regulations, including GLPs. The sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature, and a proposed clinical protocol, to the FDA as part of the IND. An IND is a request for authorization from the FDA to administer an investigational drug product to humans. The central focus of an IND submission is on patient safety and the general investigational plan and the protocol(s) for human trials. The IND automatically becomes effective 30 days after receipt by the FDA, unless the FDA raises concerns or questions regarding the proposed clinical trials and places the IND on clinical hold within that 30-day time period. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. The FDA also may impose a partial clinical hold that would limit a trial, for example, to certain doses, for a certain length of time or to a certain number of subjects. The FDA may also impose clinical holds on a drug candidate at any time before or during clinical trials due to safety concerns or non-compliance. Accordingly, we cannot be sure that submission of an IND will result in the FDA allowing clinical trials to begin, or that, once begun, issues will not arise that could cause the trial to be suspended or terminated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The clinical stage of development involves the administration of the drug candidate to human subjects under the supervision of qualified investigators, generally physicians not employed by or under the trial sponsor's control, in accordance with GCPs, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the clinical trial, dosing procedures, subject selection, and exclusion criteria, and the parameters to be used to monitor subject safety and assess efficacy. Each protocol, and any subsequent amendments to the protocol, must be submitted to the FDA as part of the IND. Further, each clinical trial must be reviewed and approved by an independent institutional review board (&#8220;IRB&#8221;) at or servicing each institution at which the clinical trial will be conducted. An IRB is charged with protecting the welfare and rights of trial participants and considers such items as whether the risks to individuals participating in the clinical trials are minimized and are </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-9-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reasonable in relation to anticipated benefits. The IRB also approves the informed consent form that must be provided to each clinical trial subject or his or her legal representative and must monitor the clinical trial until completed. There are also requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials are generally conducted in three sequential phases that may overlap or be combined, known as Phase 1, Phase 2, and Phase 3 trials. Phase 1 trials generally involve a small number of healthy volunteers who are initially exposed to a single dose and then multiple doses of the drug candidate. The primary purpose of these clinical trials is to assess the metabolism, pharmacologic action, side effects, tolerability, and safety of the drug. Phase 2 clinical trials typically involve studies in disease-affected patients to determine the dose required to produce the desired benefits. At the same time, safety and further pharmacokinetics and pharmacodynamics information is collected, as well as identification of possible adverse effects and safety risks and preliminary evaluation of efficacy. Phase 3 trials generally involve large numbers of patients at multiple sites (from several hundred to several thousand subjects) and are designed to provide the data necessary to demonstrate the efficacy of the drug for its intended use, its safety in use, and to establish the overall benefit/risk relationship of the drug and provide an adequate basis for physician labeling. The duration of treatment is often extended to mimic the actual use of a drug during marketing. Generally, two adequate and well-controlled Phase 3 trials are required by the FDA for approval of an NDA. Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA. Additionally, written IND safety reports must be submitted to both the FDA and the qualified investigators for serious and unexpected adverse reactions, any findings from other clinical studies, tests in laboratory animals, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> testing that suggests a significant risk for human subjects, or any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor must submit an IND safety report within 15 calendar days after the sponsor determines that the information qualifies for reporting. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction within seven calendar days after the sponsor's initial receipt of the information. Phase 1, Phase 2, and Phase 3 trials may not be completed successfully within any specified period, if at all. There also are requirements governing the reporting of ongoing clinical trials and completed clinical trial results to public registries. Information about certain clinical trials, including clinical trial results, must be submitted within specific timeframes for publication on the www.clinicaltrials.gov website.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA, the IRB, or the clinical trial sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects or patients are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution if the clinical trial is not being conducted in accordance with the IRB's requirements or if the drug has been associated with unexpected serious harm to patients. Additionally, some clinical trials are overseen by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board or committee. This group provides authorization for whether or not a trial may move forward at designated check points based on access to certain data from the trial. We may also suspend or terminate a clinical trial based on evolving business objectives and/or competitive climate. Concurrent with clinical trials, companies usually complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the drug in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, cGMPs impose extensive procedural, substantive, and recordkeeping requirements to ensure and preserve the long-term stability and quality of the final drug product. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">NDA and the FDA Review Process</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following trial completion, trial data are analyzed to assess safety and efficacy. The results of preclinical studies and clinical trials are then submitted to the FDA as part of an NDA, along with proposed labeling for the drug and information about the manufacturing process and facilities that will be used to ensure drug quality, results of analytical testing conducted on the chemistry of the drug, and other relevant information. The NDA is a request for approval to market the drug and must contain adequate evidence of safety and efficacy, which is demonstrated by extensive preclinical and clinical testing. Data may come from company-sponsored clinical trials intended to test the safety and efficacy of a use of a drug, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the investigational drug product for a particular indication or indications to the satisfaction of the FDA. FDA approval of an NDA must be obtained before a drug may be offered for sale in the U.S.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-10-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Prescription Drug User Fee Act (&#8220;PDUFA&#8221;), as amended, each NDA must be accompanied by a user fee known as an application fee. The FDA adjusts the PDUFA user fees on an annual basis. PDUFA also imposes an annual prescription drug product program fee for human drugs. Fee waivers or reductions are available in certain circumstances, including a waiver of the application fee for the first application filed by a small business. Additionally, no user fees are assessed on NDAs for products designated as orphan drugs, unless the product also includes a non-orphan indication.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Within 60 days following submission of an original NDA, the FDA reviews the application to determine if it is substantially complete before the agency accepts it for filing. The FDA may refuse to file any NDA that it deems incomplete or not properly reviewable at the time of submission, including for failure to pay required fees, and may request additional information. In this event, the application must be resubmitted with the additional information. The resubmitted application also is subject to review before the FDA accepts it for filing. The FDA typically makes a decision on whether to accept an NDA for filing within 60 days of receipt. Once the submission is accepted for filing, the FDA begins an in-depth, substantive review of the NDA. Under the performance goals established under the PDUFA, the FDA has agreed to review 90% of standard NDAs for new molecular entities (&#8220;NMEs&#8221;) in ten months from the filing date and 90% of priority NME NDAs in six months from the filing date. The goals for reviewing standard and priority non-NME NDAs are ten months and six months, respectively, measured from the receipt date of the application. The FDA does not always meet its PDUFA goal dates for standard and priority NDAs, and the review timeline may be formally extended by submission of a major amendment in response to an FDA request or by submission of an unsolicited amendment.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After the NDA submission is accepted for filing, the FDA reviews the NDA to determine, among other things, whether the proposed drug is safe and effective for its intended use, and whether the drug is being manufactured in accordance with cGMP to assure and preserve the drug's identity, strength, quality, and purity. The FDA may refer applications for novel drugs or drug candidates that present difficult questions of safety or efficacy to an advisory committee, typically a panel that includes clinicians and other experts, for review, evaluation, and a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. In the course of its review, the FDA may re-analyze the clinical trial data, which could result in extensive discussions between the FDA and the applicant during the review process.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Before approving an NDA, the FDA typically conducts a pre-approval inspection of the manufacturing facilities for the new drug to determine whether they comply with cGMPs. The FDA will not approve the drug unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the drug within required specifications. In addition, before approving an NDA, the FDA may also audit data from clinical trials to ensure compliance with GCP requirements. After the FDA evaluates the application, manufacturing process, and manufacturing facilities where the drug product and/or its API will be produced, it may issue an approval letter or a Complete Response Letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. A Complete Response Letter indicates that the review cycle of the application is complete and the application is not ready for approval. A Complete Response Letter usually describes all of the specific deficiencies in the NDA identified by the FDA. The Complete Response Letter may require additional clinical data and/or additional pivotal clinical trial(s), and/or other significant, expensive and time-consuming requirements related to clinical trials, preclinical studies, or manufacturing. If a Complete Response Letter is issued, the applicant may either resubmit the NDA, addressing all of the deficiencies identified in the letter, challenge the determination set forth in the letter by requesting a hearing, or withdraw the application. Even if such data and information are submitted, the FDA may ultimately decide that the NDA does not satisfy the criteria for approval. Data obtained from clinical trials are not always conclusive and the FDA may interpret the same data differently than the applicant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that the FDA will ultimately approve a drug product for marketing in the U.S. If a drug receives marketing approval, the approval may be significantly limited to specific diseases, dosages, or patient subgroups, or the indications for use may otherwise be limited, which could restrict the commercial value of the drug. Further, the FDA may require that certain contraindications, warnings, precautions, or adverse events be included in the drug labeling or may condition the approval of the NDA on other changes to the proposed labeling, development of adequate controls and specifications, or a commitment to conduct post-marketing testing or clinical trials, and surveillance to monitor the effects of approved drugs. For example, the FDA may require Phase 4 testing which involves clinical trials designed to further assess a drug's safety and may require testing and surveillance programs to monitor the safety of approved drugs that have been commercialized. The FDA may also place other conditions on approvals including the requirement for a REMS to assure the safe use of the drug. If the FDA concludes a REMS is needed, the sponsor of the NDA must submit a proposed REMS. The FDA will not approve the NDA without an approved REMS, if required. A REMS could include medication guides, physician communication plans, or elements to assure safe use, such as restricted distribution methods, patient registries, and other risk minimization tools. Any of these limitations on approval or marketing could restrict the commercial promotion, distribution, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-11-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prescription, or dispensing of drugs. Drug approvals may be withdrawn for non-compliance with regulatory standards or if problems occur following initial marketing.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pediatric Information and Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pediatric Research Equity Act (&#8220;PREA&#8221;), as amended, an NDA or supplement to an NDA for a drug that includes a new active ingredient, new indication, new dosage form, new dosing regimen, or new route of administration must contain data to assess the safety and efficacy of the drug for the claimed indications in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the drug is safe and effective. The FDA may grant deferrals for submission of data or full or partial waivers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor who is planning to submit a marketing application for a drug subject to PREA must submit an initial Pediatric Study Plan (&#8220;PSP&#8221;) within 60 days of an end-of-Phase 2 meeting or as may be agreed between the sponsor and the FDA. The initial PSP must include an outline of the pediatric study or studies that the sponsor plans to conduct, including study objectives and design, age groups, relevant endpoints, and statistical approach, or a justification for not including such detailed information, and any request for a deferral of pediatric assessments or a full or partial waiver of the requirement to provide data from pediatric studies along with supporting information. The FDA and the sponsor must reach agreement on the PSP. A sponsor can submit amendments to an agreed-upon initial PSP at any time if changes to the pediatric plan need to be considered based on data collected from preclinical studies, early phase clinical trials, and/or other clinical development programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A drug product can also obtain pediatric exclusivity in the U.S., which is another type of regulatory market exclusivity in the U.S. Pediatric exclusivity, if granted, adds an additional six months to existing exclusivity periods and patent terms. This six-month exclusivity, which runs from the end of other exclusivity protection or patent term, may be granted based on the voluntary completion of a pediatric trial that fairly responds to an FDA-issued written request for such a trial.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may grant orphan drug designation to drugs intended to treat a rare disease or condition that affects fewer than 200,000 individuals in the U.S., or if it affects 200,000 or more individuals in the U.S., there is no reasonable expectation that the cost of developing and marketing the drug for this type of disease or condition will be recovered from sales in the U.S. Orphan drug designation entitles a party to potential financial incentives such as opportunities for grant funding towards clinical trial costs, tax advantages, and user-fee waivers. In addition, if a product receives the first FDA approval for the indication for which it has orphan designation, the product is entitled to orphan drug exclusivity, which means the FDA may not approve any other application to market the same drug for the same indication for a period of seven years, except in limited circumstances, such as a showing of clinical superiority over the product with orphan exclusivity.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Orphan drug exclusivity may be lost if the FDA determines that the request for designation was materially defective or if the manufacturer is unable to assure sufficient quantity of the drug to meet the needs of patients with the rare disease or condition. Orphan drug designation must be requested before submitting an application for marketing approval. Orphan drug designation does not convey any advantage in, or shorten the duration of, the regulatory review and approval process.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">505(b)(2) New Drug Applications</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an alternative path to FDA approval for modifications to formulations or uses of a product previously approved by the FDA pursuant to an NDA, known as a &#8220;reference drug&#8221;, an applicant may submit an NDA under Section 505(b)(2) of the FDCA. Section 505(b)(2) was enacted as part of the Hatch-Waxman Amendments and permits the filing of an NDA where at least some of the information required for approval comes from studies not conducted by, or for, the applicant, and for which the applicant has not obtained a right of reference. If the 505(b)(2) applicant can establish that reliance on the FDA&#8217;s previous findings of safety and effectiveness for a reference drug is scientifically and legally appropriate, it may eliminate the need to conduct certain preclinical studies or clinical trials of the new product. The FDA may require the applicant to perform additional bridging studies or measurements, including clinical trials, to support the change from the previously approved reference drug. The FDA may then approve the new drug candidate for all, or some, of the label indications for which the reference drug has been approved, as well as for any new indication sought by the 505(b)(2) applicant. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Post-Marketing Requirements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following approval of a new drug, a pharmaceutical company and the approved drug are subject to continuing regulation by the FDA, including, among other things, establishment registration and drug listing, monitoring and recordkeeping activities, reporting to the applicable regulatory authorities of adverse events with the drug, providing the regulatory authorities with </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-12-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">updated safety and efficacy information, drug sampling and distribution requirements, and complying with promotion and advertising requirements, which include, among others, standards for direct-to-consumer advertising, restrictions on promoting drugs for uses or in patient populations that are not described in the drug&#8217;s approved labeling (known as off-label promotion), limitations on industry-sponsored scientific and educational activities, and requirements for online promotional activities. Although physicians may prescribe drugs for off-label uses, the FDA takes the position that manufacturers may not market or promote such off-label uses. Modifications or enhancements to the drug or its labeling or changes of the site or process of manufacture are often subject to the prior approval of the FDA and other regulators, which may or may not be received after undergoing review.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any distribution of pharmaceutical samples must comply with the U.S. Prescription Drug Marketing Act (&#8220;PDMA&#8221;), a part of the FDCA. The Drug Supply Chain Security Act (&#8220;DSCSA&#8221;) was enacted in 2013 with the aim of building an electronic system to identify and trace certain prescription drugs distributed in the U.S. The DSCSA mandates resource-intensive obligations for pharmaceutical manufacturers, wholesale distributors, and dispensers including the quarantine and prompt investigation of a suspect product to determine if it is illegitimate, and notifying trading partners and the FDA of any illegitimate product. Drug manufacturers and other parties involved in the supply chain for prescription drug products must also comply with product tracking and tracking requirements, such as placing a unique product identifier on prescription drug packages. This identifier consists of the National Drug Code, serial number, lot number, and expiration date, in the form of a 2-dimensional data matrix barcode that can be read by humans and machines.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., once a drug is approved, its manufacture is subject to comprehensive and continuing regulation by the FDA. FDA regulations require that drugs be manufactured in specific facilities per the NDA approval and in accordance with cGMP. We rely, and expect to continue to rely, on third parties for the production of clinical and commercial quantities of our approved drug and drug candidates in accordance with cGMP regulations. cGMP regulations require among other things, quality control and quality assurance as well as the corresponding maintenance of records and documentation and the obligation to investigate and correct any deviations from cGMP. Drug manufacturers and other entities involved in the manufacture and distribution of approved drugs are required to register their establishments with the FDA and certain state agencies and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP and other laws. Accordingly, manufacturers must continue to expend time, money, and effort in the area of production and quality control to maintain cGMP compliance. These regulations also impose certain organizational, procedural, and documentation requirements with respect to manufacturing and quality assurance activities. NDA holders using contract manufacturers, laboratories, or packagers are responsible for the selection and monitoring of qualified firms, and, in certain circumstances, qualified suppliers to these firms. These firms and, where applicable, their suppliers are subject to inspections by the FDA at any time, and the discovery of violative conditions, including failure to conform to cGMP, could result in enforcement actions that interrupt the operation of any such facilities or the ability to distribute drugs manufactured, processed, or tested by them. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may issue enforcement letters or withdraw the approval of the product if compliance with regulatory requirements and standards is not maintained or if problems occur after the drug reaches the market. Corrective action could delay drug distribution and require significant time and financial expenditures. Later discovery of previously unknown problems with a drug, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may require revisions to the approved labeling to add new safety information, including the addition of new warning and contraindications; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">mandated corrective advertising or communications with doctors;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the drug, suspension of the approval, complete withdrawal of the drug from the market or product recalls;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve applications or supplements to approved applications, or suspension or revocation of drug approvals;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">drug seizure or detention, or refusal to permit the import or export of drugs; or</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Marketing Exclusivity</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-13-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Marketing exclusivity provisions under the FDCA can delay the submission or the approval of certain marketing applications for competing products. The FDCA provides a five-year period of non-patent marketing exclusivity within the U.S. to the first applicant to obtain approval of an NDA for a new chemical entity. A drug is a new chemical entity if the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance. During the exclusivity period, the FDA may not accept for review an abbreviated new drug application (&#8220;ANDA&#8221;) or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. The FDCA also provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs or 505(b)(2) applications for drugs containing the active agent for the original indication or condition of use. Five-year and three-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the preclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and effectiveness. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Controlled Substances Regulations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Narcotics and other APIs, such as sodium oxybate, are &#8220;controlled substances&#8221; under the CSA. The CSA, regulates the manufacture and distribution of narcotics and other controlled substances, including stimulants, depressants and hallucinogens in the U.S. The CSA is administered by the DEA, a division of the U.S. Department of Justice, and is intended to prevent the abuse or diversion of controlled substances into illicit channels of commerce. The DEA classifies controlled substances into five schedules. Schedule I substances by definition have a high potential for abuse, have no currently &#8220;accepted medical use&#8221; in the U.S., lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. may be listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse. The API in LUMRYZ, sodium oxybate, is a Schedule I controlled substance in the U.S., and the FDA-approved LUMRYZ product is a Schedule III controlled substance in the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For drugs manufactured in the U.S., the DEA establishes annually an aggregate quota for the amount of substances within Schedules I and II that may be manufactured or produced in the U.S. based on the DEA&#8217;s estimate of the quantity needed to meet legitimate medical, scientific, research and industrial needs. The quotas apply equally to the manufacturing of the API and production of dosage forms. The DEA may adjust aggregate production quotas a few times per year, and individual manufacturing or procurement quotas from time to time during the year, although the DEA has substantial discretion in whether to make such adjustments for individual companies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The DEA limits the quantity of certain Schedule I controlled substances that may be manufactured and procured in the U.S. in any given calendar year through a quota system and, as a result, quotas from the DEA are required in order to manufacture sodium oxybate in the U.S. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA-approved LUMRYZ product is classified as a Schedule III controlled substance and subject to DEA quota requirements as well as state and federal regulations relating to manufacturing, storage, distribution and physician prescription procedures, including limitations on prescription refills. In addition, the third parties who perform our clinical and commercial manufacturing, distribution, dispensing and clinical studies for LUMRYZ are required to maintain necessary DEA registrations and state licenses.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any person or firm that manufactures, distributes, dispenses, imports, or exports any controlled substance (or proposes to do so) must register with the DEA. The applicant must register for a specific business activity related to controlled substances, including manufacturing or distributing, and may engage in only the activity or activities for which it is registered. The DEA conducts periodic inspections of registered establishments that handle controlled substances for compliance with its rules and regulations. Failure to comply with relevant DEA regulations, particularly as manifested in the loss or diversion of controlled substances, can result in regulatory action including civil penalties, refusal to renew necessary registrations, or proceedings to revoke those registrations. In certain circumstances, violations can lead to criminal prosecution. In addition to these federal statutory and regulatory obligations, there may be state and local laws and regulations relevant to the handling of controlled substances or listed chemicals. Governments outside of the U.S. have similar controlled substance laws, regulations and requirements in their respective jurisdictions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-14-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Other Regulatory Matters</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Manufacturing, sales, promotion, and other activities following drug approval are also subject to regulation by numerous regulatory authorities in addition to the FDA, including, in the U.S., the Centers for Medicare &amp; Medicaid Services (&#8220;CMS&#8221;), other divisions of the U.S. Department of Health and Human Services (&#8220;HHS&#8221;), the DEA for controlled substances, the Consumer Product Safety Commission, the Federal Trade Commission, the Occupational Safety &amp; Health Administration, the Environmental Protection Agency, and state and local governments. In the U.S., sales, marketing, and scientific/educational programs must also comply with state and federal fraud and abuse laws. Pricing and rebate programs must comply with the Medicaid rebate requirements of the U.S. Omnibus Budget Reconciliation Act of 1990 and more recent requirements in the Patient Protection and Affordable Care Act as amended by the Health Care and Education Reconciliation Act of 2010 (or collectively, the &#8220;ACA&#8221;). If drugs are made available to authorized users of the Federal Supply Schedule of the General Services Administration, additional laws and requirements apply. The handling of any controlled substances must comply with the U.S. Controlled Substances Act and Controlled Substances Import and Export Act. Drugs must meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. Manufacturing, sales, promotion, and other activities are also potentially subject to federal and state consumer protection and unfair competition laws.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous foreign, federal, state, and local environmental, health, and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment, and disposal of hazardous materials and wastes. In addition, our leasing and operation of real property may subject us to liability pursuant to certain U.S. environmental laws and regulations, under which current or previous owners or operators of real property and entities that disposed or arranged for the disposal of hazardous substances may be held strictly, jointly, and severally liable for the cost of investigating or remediating contamination caused by hazardous substance releases, even if they did not know of and were not responsible for the releases.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical drugs is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage, and security requirements intended to prevent the unauthorized sale of pharmaceutical drugs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with regulatory requirements subjects firms to possible legal or regulatory action. Depending on the circumstances, failure to meet applicable regulatory requirements can result in criminal prosecution, fines, or other penalties, injunctions, voluntary recall or seizure of drugs, total or partial suspension of production, denial or withdrawal of product approvals, or refusal to allow a firm to enter into supply contracts, including government contracts. In addition, even if a firm complies with the FDA and other requirements, new information regarding the safety or efficacy of a product could lead the FDA to modify or withdraw product approval. Prohibitions or restrictions on sales or withdrawal of our approved drug or any future products marketed by us could materially affect our business in an adverse way.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes, or the interpretation of existing regulations could impact our business in the future by requiring, for example: (i) changes to our manufacturing arrangements; (ii) additions or modifications to product labeling; (iii) the recall or discontinuation of our product; or (iv) additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Healthcare Laws</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of pharmaceutical products. Arrangements with third-party payors and customers can expose pharmaceutical manufactures to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute and the federal False Claims Act (&#8220;FCA&#8221;), which may constrain the business or financial arrangements and relationships through which companies research, sell, market and distribute pharmaceutical products. In addition, transparency laws and patient privacy laws can apply to the activities of pharmaceutical manufactures. The applicable federal, state and foreign healthcare laws and regulations that can affect a pharmaceutical company&#8217;s operations include without limitation:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Anti-Kickback Statute, which prohibits, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback, bribe, or rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order or recommendation of any good, facility, item or service for which payment may be made, in whole or in part, under the Medicare and Medicaid programs, or other federal healthcare programs. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Violations are subject to civil and criminal fines and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-15-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">penalties for each violation, plus up to three times the remuneration involved, imprisonment, and exclusion from government healthcare programs. In addition, the government may assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the federal False Claims Act or federal civil monetary penalties. The Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other. There are a number of statutory exceptions and regulatory safe harbors protecting some common activities from prosecution, but such exceptions and safe harbors are drawn narrowly and require strict compliance in order to offer protection;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal civil and criminal false claims laws, including the FCA, and civil monetary penalty laws, which prohibit any person or entity from, among other things, knowingly presenting, or causing to be presented, a false, fictitious or fraudulent claim for payment to, or approval by, the federal government or knowingly making, using or causing to be made or used a false record or statement, including providing inaccurate billing or coding information to customers or promoting a product off-label, material to a false or fraudulent claim to the federal government. As a result of a modification made by the Fraud Enforcement and Recovery Act of 2009, a claim includes &#8220;any request or demand&#8221; for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. The FCA also permits a private individual acting as a &#8220;whistleblower&#8221; to bring actions on behalf of the federal government alleging violations of the FCA and to share in any monetary recovery;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal Health Insurance Portability and Accountability Act of 1996 (&#8220;HIPAA&#8221;), which created federal criminal statutes that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up by any trick or device a material fact or making any materially false statements in connection with the delivery of, or payment for, healthcare benefits, items or services relating to healthcare matters. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating HIPAA without actual knowledge of the statute or specific intent to violate it;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (&#8220;HITECH&#8221;), and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information held by covered entities and their business associates as well as their covered subcontractors. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state attorneys general new authority to file civil actions for damages or injunctions in U.S. federal courts to enforce the federal HIPAA laws and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The federal legislation commonly referred to as the Physician Payments Sunshine Act, created under the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions) to report annually to CMS, information related to payments or other transfers of value made to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors), certain other licensed health care practitioners and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal government price reporting laws, which require us to calculate and report complex pricing metrics in an accurate and timely manner to government programs;</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Federal consumer protection and unfair competition laws, which broadly regulate marketplace activities and activities that potentially harm consumers; and</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including, but not limited to, research, distribution, sales and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state and local laws that require drug </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-16-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require the reporting of information related to drug pricing; state and local laws requiring the registration of pharmaceutical sales representatives; and state laws governing the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. For example, Washington state&#8217;s My Health My Data Act, which took effect in March 2024, affords consumers with privacy rights with respect to certain consumer heath information and creates a private right of action which could increase the risk of litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of pharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of pharmaceutical products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., to help patients afford our approved product, we may utilize programs to assist them, including patient financial assistance programs and co-pay coupon programs for eligible patients. Government enforcement agencies have shown increased interest in pharmaceutical companies' product and patient financial assistance programs, including reimbursement support services, and a number of investigations into these programs have resulted in significant civil and criminal settlements. In addition, at least one insurer has directed its network pharmacies to no longer accept co-pay coupons for certain specialty drugs the insurer identified. Our co-pay coupon programs could become the target of similar insurer actions. In addition, in November 2013, the CMS issued guidance to the issuers of qualified health plans sold through the ACA's marketplaces encouraging such plans to reject patient cost-sharing support from third parties and indicating that the CMS intends to monitor the provision of such support and may take regulatory action to limit it in the future. The CMS subsequently issued a rule requiring individual market qualified health plans to accept third-party premium and cost-sharing payments from certain government-related entities. In September 2014, the Office of Inspector General (&#8220;OIG&#8221;) of the HHS issued a Special Advisory Bulletin warning manufacturers that they may be subject to sanctions under the federal anti-kickback statute and/or civil monetary penalty laws if they do not take appropriate steps to exclude Part D beneficiaries from using co-pay coupons. Accordingly, companies exclude these Part D beneficiaries from using co-pay coupons. It is possible that changes in insurer policies regarding co-pay coupons and/or the introduction and enactment of new legislation or regulatory action could restrict or otherwise negatively affect these patient support programs, which could result in fewer patients using affected products, and therefore could have a material adverse effect on our sales, business, and financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third party patient financial assistance programs that receive financial support from companies have become the subject of enhanced government and regulatory scrutiny. The OIG has established guidelines that suggest that it is lawful for pharmaceutical manufacturers to make donations to charitable organizations who provide co-pay assistance to Medicare patients, provided that such organizations, among other things, are bona fide charities, are entirely independent of and not controlled by the manufacturer, provide aid to applicants on a first-come basis according to consistent financial criteria and do not link aid to use of a donor's product. However, donations to patient financial assistance programs have received some negative publicity and have been the subject of multiple government enforcement actions, related to allegations regarding their use to promote branded pharmaceutical products over other less costly alternatives. Specifically, in recent years, there have been multiple settlements resulting out of government claims challenging the legality of their patient financial assistance programs under a variety of federal and state laws. It is possible that we may make grants to independent charitable foundations that help financially needy patients with their premium, co-pay, and co-insurance obligations. If we choose to do so, and if we or our vendors or donation recipients are deemed to fail to comply with relevant laws, regulations or evolving government guidance in the operation of these programs, we could be subject to damages, fines, penalties, or other criminal, civil, or administrative sanctions or enforcement actions. We cannot ensure that our compliance controls, policies, and procedures will be sufficient to protect against acts of our employees, business partners, or vendors that may violate the laws or regulations of the jurisdictions in which we operate. Regardless of whether we have complied with the law, a government investigation could impact our business practices, harm our reputation, divert the attention of management, increase our expenses, and reduce the availability of foundation support for our patients who need assistance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of any product depend, in part, on the extent to which such product will be covered by third-party payors, such as federal, state, and foreign government healthcare programs, commercial insurance and managed healthcare organizations, and the level of reimbursement for such product by third-party payors. Decisions regarding the extent of coverage and amount of reimbursement to be provided are made on a plan-by-plan basis. These third-party payors are increasingly reducing coverage and reimbursement for medical products, drugs and services. For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-17-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable regulatory approvals. Additionally, companies may also need to provide discounts to purchasers, private health plans or government healthcare programs. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, operations and financial condition. Factors that payors consider in determining reimbursement are based on whether the product is (i) a covered benefit under its health plan; (ii) safe, effective, and medically necessary; (iii) appropriate for the specific patient; (iv) cost-effective; and (v) neither experimental nor investigational. Additionally, a third-party payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product and the level of coverage and reimbursement can differ significantly from payor to payor.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of healthcare costs has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party payor reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive regulatory approval, less favorable coverage policies and reimbursement rates may be implemented in the future. Decreases in third-party reimbursement for any product or a decision by a third-party payor not to cover a product could reduce physician usage and patient demand for the product and also have a material adverse effect on sales.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Healthcare Reform</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In both the U.S. and certain foreign jurisdictions, there have been, and continue to be, a number of legislative and regulatory changes to the health care system. Among policy makers and payors in the U.S. and elsewhere, there is significant interest in promoting changes in healthcare systems with the stated goals of containing healthcare costs, improving quality and/or expanding access. In the U.S., the pharmaceutical industry has been a particular focus of these efforts and has been significantly affected by major legislative initiatives. In particular, in 2010, the ACA was enacted, which, among other things, increased the minimum Medicaid rebates owed by most manufacturers under the Medicaid Drug Rebate Program, extended the Medicaid Drug Rebate Program to utilization of prescriptions of individuals enrolled in Medicaid managed care organizations, subjected manufacturers to new annual fees and taxes for certain branded prescription drugs, and provided incentives to programs that increase the federal government&#8217;s comparative effectiveness research.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative and regulatory changes have been proposed and adopted in the U.S. since the ACA was enacted:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The U.S. Budget Control Act of 2011, among other things, included aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect on April 1, 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2031.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 2, 2013, the U.S. American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On April 13, 2017, CMS published a final rule that gives states greater flexibility in setting benchmarks for insurers in the individual and small group marketplaces, which may have the effect of relaxing the essential health benefits required under the ACA for plans sold through such marketplaces.</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On May 30, 2018, the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act. </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On&#8239;May 23, 2019, CMS published a final rule to allow Medicare Advantage Plans the option of using step therapy for Part B drugs beginning January 1, 2020.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-18-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On March 11, 2021, President Biden signed the American Rescue Plan Act of 2021 into law, which eliminated the statutory drug rebate cap, set at 100% of a drug&#8217;s average manufacturer price, for single source and innovator multiple source drugs, beginning January 1, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws and regulations may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for our product and any of our product candidates for which we may obtain regulatory approval or the frequency with which any such product or product candidate is prescribed or used.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There has been heightened governmental scrutiny in the U.S. of pharmaceutical pricing practices in light of the rising cost of prescription drugs and biologics. In August 2022, the Inflation Reduction Act of 2022, or the IRA, was signed into law. The IRA includes several provisions that may impact our business, depending on how various aspects of the IRA are implemented. Provisions that may impact our business include a $2,000 out-of-pocket cap for Medicare Part D beneficiaries, the imposition of new manufacturer financial liability on most drugs in Medicare Part D, permitting the U.S. government to negotiate Medicare Part B and Part D pricing for certain high-cost drugs and biologics without generic or biosimilar competition, requiring companies to pay rebates to Medicare for drug prices that increase faster than inflation, and delay until January 1, 2032&#8239;the implementation of the HHS rebate rule that would have limited the fees that pharmacy benefit managers can charge. Further, under the IRA, orphan drugs are exempted from the Medicare drug price negotiation program, but only if they have one orphan designation and for which the only approved indication is for that disease or condition.&#8239;If a product receives multiple orphan designations or has multiple approved indications, it may not qualify for the orphan drug exemption. The implementation of the IRA is currently subject to ongoing litigation challenging the constitutionality of the IRA&#8217;s Medicare drug price negotiation program. The effects of the IRA on our business and the healthcare industry in general is not yet known. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition,&#8239;President Trump reversed some of President Biden&#8217;s executive orders including rescinding Executive Order 14087 entitled &#8220;Lowering Prescription Drug Costs for Americans&#8221;. President Trump may issue new executive orders designed to impact drug pricing. A number of these and other proposed measures may require authorization through additional legislation to become effective. Congress and the Trump administration have indicated that they will continue to seek new legislative measures to control drug costs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states in the U.S. have also increasingly passed legislation and implemented regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Capital Resources </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Avadel, the way we work is as important as the results we achieve. Our global organization fosters an entrepreneurial environment, where purpose, innovation, integrity, and collaboration come together to transform medicines to transform lives.  Our organization fosters our culture based on being relentless for patients, having confidence with humility, being courageous, taking insight to impact and togetherness (the &#8220;Avadel Values&#8221;). In everything we do, we live the Avadel Values so we can be the best for our patients, our community, and each other. Success for us is defined through how we improve the lives of patients and how we achieve our objectives as one team.   </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are committed to offering employees a rewarding and entrepreneurial work experience where patients are at the center of everything we do. Our people are our greatest competitive advantage, and our values serve as the foundation of our culture. We consider our relations with our employees to be good and are focused on maintaining a highly engaged and motivated workforce.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employee Demographics</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 188 full-time employees. None of our employees are subject to a union or other collective bargaining agreement. In addition to our employees, we contract with third parties in certain areas of the business such as clinical, regulatory, and manufacturing. We expect to continue to build and grow our organizational capabilities with a focus on talent attraction, development, engagement, and retention.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Inclusion</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel is committed to fostering a culture of inclusion. Avadel pursues fair employment practices in every aspect of its business and is committed to a productive work environment for its employees. We strive to create a level of connectivity that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-19-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">goes beyond working together. Rooted in the trust we earn every day, our team is inclusive and works every day to lift each other up in pursuit of improving the lives of the patients we serve.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avadel is committed to facilitating an open, honest, inclusive, transparent, and productive work environment where we work together as ONE team and ONE culture to be our best for patients, customers, and each other. We believe that all employees and applicants should be treated with courtesy, dignity, and respect. It is our intent to comply with federal, state, and local laws, regulations, and guidelines in our employment practices and in our service to our clients. This policy applies to all terms and conditions of employment including, but not limited to, hiring, placement, promotion, termination, layoff, recall, transfer, leaves of absence, compensation, and training.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation and Benefits </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Avadel, we prioritize the well-being of our employees by offering a comprehensive benefits package. We know that benefits play an important role in helping to ensure the health and financial security of our employees. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commitment to our employees includes benefit and compensation programs that value the contributions our employees make. We strive to provide pay, benefits, and services that are competitive and create incentives to attract and retain employees. In addition to competitive pay, we offer bonus and share-based compensation packages for all levels of employees within the organization as well as a company match for employee retirement programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Health and Wellness</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our healthcare plans allow employees to choose what works best for them and their families. We offer competitive health, dental, vision and life insurance for all employees as well as competitive vacation packages along with time off for holidays and other forms of leave for all employees. Further, we offer a variety of tools allowing employees to prioritize wellness, including retirement planning, employee stock purchase program, legal services, employee assistance programs, and more.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Career Growth and Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are invested in the development of each of our employees. We provide opportunities to lead and participate in cross-functional teams, coaching, leadership development, and more. We provide reimbursement to our employees for professional seminars, conferences and training. In alignment with our business strategy, it is our goal to empower all employees to take full advantage of their professional growth opportunities, to lead them to long-term job satisfaction and organizational success. Through professional development, our employees can broaden their skills for their current and future roles.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-20-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_22"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">             </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">An investment in Avadel involves a high degree of risk. You should carefully consider the risks described below, as well as the other information included or incorporated by reference in this Annual Report on Form 10-K, before making an investment decision. Avadel&#8217;s business, financial condition, results of operations and cash flows could be materially adversely affected by any of these risks. The market or trading price of Avadel&#8217;s securities could decline due to any of these risks. In addition, please read &#8220;Cautionary Disclosure Regarding Forward-Looking Statements&#8221; in this Annual Report on Form 10-K, where we describe additional uncertainties associated with Avadel&#8217;s business and with the forward-looking statements included or incorporated by reference in this Annual Report on Form 10-K. Please note that additional risks not presently known to us or that we currently deem immaterial may also impair Avadel&#8217;s business and operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Lead Product</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business depends heavily on our ability to successfully commercialize LUMRYZ in the U.S. and in other jurisdictions where we may obtain marketing approval. There is no assurance that our commercialization efforts with respect to LUMRYZ will be successful or that we will be able to generate revenues at the levels or on the timing we expect, or at levels or on the timing necessary to support our goals.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In May 2023, LUMRYZ was approved by the FDA, and in June 2023, we announced the U.S. commercial launch of LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy. LUMRYZ was also approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older in October 2024. Our business currently depends heavily on our ability to successfully commercialize LUMRYZ in the U.S. We may never be able to meet our expectations with respect to our ongoing LUMRYZ commercialization activities or revenues. There is no guarantee that the infrastructure, systems, processes, policies, relationships, and materials we have built for the commercialization of LUMRYZ in the U.S., or that we may build for other jurisdictions where we may obtain marketing approval, will be sufficient for us to achieve success at the levels we expect. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third parties, or if we are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects will be materially adversely affected. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may encounter issues and challenges in generating sufficient revenues to result in a profit. We may also encounter challenges related to reimbursement of LUMRYZ, including potential limitations in the scope, breadth, availability, or amount of reimbursement covering LUMRYZ. Similarly, healthcare settings or patients may determine that the financial burdens of treatment are not acceptable. We may face other limitations or issues related to the price of LUMRYZ. Our results may also be negatively impacted if we have not adequately sized our field teams or our physician segmentation and targeting strategy is inadequate or if we encounter deficiencies or inefficiencies in our infrastructure or processes. Other factors that may hinder our ability to successfully commercialize LUMRYZ and generate sufficient revenues to result in a profit, include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the acceptance of LUMRYZ by patients and the medical community;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the differentiation of LUMRYZ from other available approved or investigational drugs and treatments for cataplexy or EDS in patients seven years of age and older with narcolepsy; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of coverage and adequate reimbursement from managed care plans, private insurers, government payors (such as Medicare and Medicaid and similar foreign authorities) and other third-party payors for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">patients&#8217; ability and willingness to pay out-of-pocket for LUMRYZ in the absence of coverage and/or adequate reimbursement from third-party payors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the ability of our third-party manufacturer(s) to manufacture commercial supplies of LUMRYZ in sufficient quantities at acceptable costs, to remain in good standing with regulatory agencies, to maintain applicable registrations and licenses, and to maintain commercially viable manufacturing processes that are, to the extent required, compliant with cGMP regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to remain compliant with laws and regulations that apply to us and our commercial activities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">FDA- or other foreign regulatory agency-mandated package insert requirements and successful completion of any related FDA or other foreign regulatory agency post-marketing requirements, including a REMS;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prevalence, duration and severity of potential side effects or other safety or tolerability issues that patients may experience with LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the actual market size for LUMRYZ, which may be different than expected; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the length of time that patients who are prescribed our drug remain on treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the sufficiency of our drug supply to meet commercial demand which could be negatively impacted if our projections regarding the potential number of patients are inaccurate, we are subject to unanticipated regulatory requirements, or our current drug supply is damaged, destroyed, or otherwise negatively impacted at our manufacturing sites, storage sites, or in transit; and</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-21-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain, enforce, and defend third party challenges to our intellectual property rights in and to LUMRYZ.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any of these issues could impair our ability to generate sufficient revenues to result in a profit or to meet our expectations with respect to the amount or timing of revenues or profits. Any issues or hurdles related to our commercialization efforts may materially adversely affect our business, results of operations, financial condition, and prospects. There is no guarantee that we will be successful in our ongoing commercialization efforts with respect to LUMRYZ. We may also experience significant fluctuations in sales of LUMRYZ from period to period and, ultimately, we may never generate sufficient revenues from LUMRYZ to reach or maintain profitability or sustain our anticipated levels of operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 29, 2023, we entered into a royalty purchase agreement (&#8220;RPA&#8221;) with RTW Investments, L.P. (&#8220;RTW&#8221;) for up to $75,000 of royalty financing in two tranches. The first tranche of $30,000 became available upon satisfaction of certain conditions which included our first shipment of LUMRYZ. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The second tranche became available to use, at our election, when we achieved quarterly net revenue of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$25,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> prior to the quarter ending June 30, 2024. We allowed the second tranche to expire on August 31, 2024 and paid a one-time commitment fee of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">$2,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to RTW based on the terms of the RPA.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> On August 1, 2023, we received the first tranche of $30,000. As a result of receiving the first tranche, we are required to make quarterly royalty payments calculated as 3.75% of worldwide net product revenue of LUMRYZ, up to a total payback of $75,000. Even if we are able to successfully commercialize LUMRYZ, certain obligations we have to third parties, including, without limitation, our obligation to pay RTW royalties on certain LUMRYZ revenues under the RPA may reduce our profitability. Any inability on our part to successfully commercialize LUMRYZ in the U.S. and any other international markets where it may be approved or any significant delay, could have a material adverse impact on our ability to execute upon our business strategy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish effective sales, marketing and distribution capabilities for LUMRYZ or enter into agreements with third parties to market, sell and distribute LUMRYZ, or if we are unable to achieve market acceptance for LUMRYZ, our business, results of operations, financial condition and prospects will be materially adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We received final approval from the FDA for LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy in May 2023, and in October 2024 we also received approval from the FDA for LUMRYZ for the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age or older. We are continuing to develop the systems, processes, policies, relationships and materials necessary for the successful commercialization of LUMRYZ in the U.S. for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. If we are unable to establish adequate sales, marketing and distribution capabilities, whether independently or with third part</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ies, or if we are unable to do so on commercially reasonable terms, our business, results of operations, financial condition and prospects will be materially adversely affected. We may encounter issues, delays or other challenges in commercializing LUMRYZ. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than our activities commercializing LUMRYZ to date, we have limited experience in building and managing a commercial team, conducting comprehensive market analyses, obtaining state licenses and reimbursement, and managing distributors and a sales force for our medicines. For example, our results may be negatively impacted if we have not adequately sized our field teams, if our targeting strategy is inadequate, or if we encounter deficiencies or inefficiencies in our infrastructure or processes. We will be competing with other companies that currently have extensive and well-funded sales and marketing operations. As a result, our ability to successfully commercialize LUMRYZ may involve more inherent risk, take longer, and cost more than it would if we were a company with substantial experience in commercializing medicines.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We will have to compete with other pharmaceutical and biotechnology companies to recruit, hire, train and retain marketing and sales personnel. If we are unable to, or decide not to, further develop internal sales, marketing, and commercial distribution capabilities for LUMRYZ in any country or region, we may pursue collaborative arrangements regarding the sales and marketing of LUMRYZ. However, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or, if we are able to do so, that they will have effective sales and marketing capabilities. Any revenue we receive in such a collaborative arrangement will depend upon the efforts of such third parties. We may have little or no control over the marketing and sales efforts of such third parties, and our revenue from product sales may be lower than if we had commercialized LUMRYZ ourselves. We may also face competition in our search for third parties to assist us with the sales and marketing efforts for our medicines.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these issues could impair our ability to successfully commercialize LUMRYZ or to generate substantial revenues or profits or to meet our expectations with respect to the amount or timing of revenues or profits. There is no guarantee we will be successful in our commercialization efforts with respect to LUMRYZ or with respect to any other product candidate that may be approved in the future.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-22-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the market opportunities for LUMRYZ are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenues may be adversely affected and our business may suffer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ is a formulation of sodium oxybate approved by the FDA to be taken once at bedtime for the treatment of cataplexy or EDS in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients seven years of age and older with narcolepsy</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Our estimates of the market opportunities for LUMRYZ are based on the estimated market size for the twice-nightly administration of sodium oxybate, and our expectations with regard to LUMRYZ&#8217;s potential to take share of this market segment as well as attract oxybate-na&#239;ve patients and patients who have previously discontinued twice-nightly oxybate treatment. These estimates have been derived from a variety of sources, including scientific literature, surveys of clinics, patient foundations, and market research, but may prove to be incorrect. Further, studies may change the estimated market opportunities. The potential target population for LUMRYZ may turn out to be lower or more difficult to identify than expected. Even if we obtain significant market share for LUMRYZ in the treatment of narcolepsy, because that potential target population for LUMRYZ is small, we may never achieve profitability without obtaining marketing approval for additional indications. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these factors may negatively affect our ability to recognize revenues from sales of LUMRYZ and our ability to achieve and maintain profitability and, as a consequence, our business may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ may not gain market acceptance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ may not gain market acceptance among physicians, patients, healthcare payors and medical communities. The degree of market acceptance of LUMRYZ will depend on a number of factors, including, but not limited to:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the clinical indications for which LUMRYZ is approved and any restrictions placed upon the product in connection with its approval, including the REMS or any other equivalent obligation by other regulatory authorities, patient registry requirements or labeling restrictions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the prevalence of narcolepsy-related EDS and cataplexy in the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">scheduling classification of sodium oxybate as a controlled substance regulated by the DEA;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">demonstration of the clinical safety and efficacy of LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the absence of evidence of undesirable side effects of LUMRYZ that delay or extend trials for additional indications or in geographies outside the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">acceptance by physicians and patients of LUMRYZ as a safe and effective treatment;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">availability of sufficient product inventory to meet demand;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">physicians&#8217; decisions relating to treatment practices;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">physician and patient assessment of the burdens associated with obtaining or maintaining the certifications required under the LUMRYZ REMS;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the lack of regulatory delays or other regulatory actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">its cost-effectiveness and related access to payor coverage;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">its potential advantage over alternative treatment methods;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the availability of third-party reimbursement or other assistance for patients who are uninsured or underinsured; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the marketing and distribution support it receives.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If LUMRYZ fails to achieve market acceptance, our ability to generate revenue will be limited, which would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ is subject to ongoing enforcement of post-marketing requirements, and we could be subject to substantial penalties, including withdrawal of LUMRYZ from the market, if we fail to comply with all regulatory requirements. In addition, the terms of the marketing approval of LUMRYZ and ongoing regulation of our product may limit how we manufacture and market LUMRYZ, and compliance with such requirements may involve substantial resources, which could materially impair our ability to generate revenue.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ, along with the manufacturing processes, post-approval clinical data, labeling, advertising, and promotional activities for LUMRYZ, are subject to continual requirements of and review by the FDA and other applicable regulatory authorities. These requirements include, but are not limited to, restrictions governing promotion of an approved product, submissions of safety and other post-marketing information and reports, registration and listing requirements, cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, and requirements regarding drug distribution and recordkeeping.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-23-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., the FDA and other federal and state agencies, including the Department of Justice, closely regulate compliance with all requirements governing prescription drug products, including requirements pertaining to marketing and promotion of drugs in accordance with the provisions of the approved labeling and manufacturing of products in accordance with cGMP requirements. Violations of such requirements may lead to investigations alleging violations of the FDCA, CSA and other statutes, including federal and state healthcare fraud and abuse laws as well as state consumer protection laws. Our failure to comply with all regulatory requirements, or later discovery of previously unknown adverse events or other problems with our products, manufacturers, or manufacturing processes, may yield various results, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">litigation involving patients taking our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on such products, manufacturers, or manufacturing processes;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on the labeling or marketing of a product;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">restrictions on product distribution or use;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">requirements to conduct post-marketing studies or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">warning or untitled letters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdrawal of the products from the market;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refusal to approve pending applications or supplements to approved applications that we submit;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">voluntary recall of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fines, restitution, or disgorgement of profits or revenues;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspension or withdrawal of marketing approvals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">damage to relationships with any potential collaborators;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">unfavorable press coverage and damage to our reputation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refusal to permit the import or export of our products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product seizure; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-compliance by us or any future collaborator with regulatory requirements, including safety monitoring or pharmacovigilance, and with requirements related to the development of products for the pediatric population can also result in significant financial penalties. Similarly, failure to comply with applicable regulatory requirements regarding the protection of personal information can also lead to significant penalties and sanctions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, we and our CDMOs will continue to expend time, money, and effort in all areas of regulatory compliance, including manufacturing, production, product surveillance, quality control and distribution. Under the DSCSA, for certain commercial prescription drug products, manufacturers and other parties involved in the supply chain must meet chain of distribution requirements and maintain electronic, interoperable systems for product tracking and tracing and for notifying the FDA of counterfeit, diverted, stolen, and intentionally adulterated products or other products that are otherwise unfit for distribution in the U.S. Prescription drug products must also meet applicable child-resistant packaging requirements under the U.S. Poison Prevention Packaging Act. We, our CDMOs and other third parties upon whom we rely will be subject to applicable controlled substances laws, regulations and requirements. Additionally, under the Food and Drug Omnibus Reform Act of 2022 (&#8220;FDORA&#8221;), sponsors of approved drugs must provide 6 months&#8217; notice to the FDA of any changes in marketing status, such as the withdrawal of a drug, and failure to do so could result in the FDA placing the product on a list of discontinued products, which would revoke the product&#8217;s ability to be marketed. If we are not able to comply with post-approval regulatory requirements, we could have the marketing approvals for LUMRYZ withdrawn by regulatory authorities and our ability to market LUMRYZ could be limited, which could adversely affect our ability to achieve or sustain profitability and subject us to substantial penalties. As a result, the cost of compliance with post-approval regulations may have a negative effect on our operating results and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If our competitors develop and market technologies or products that are safer, more effective or less costly than ours, or obtain regulatory approval and market such products before we do, our commercial opportunity may be diminished or eliminated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the pharmaceutical and biotechnology industry is intense and is expected to increase. We compete with other pharmaceutical and biotechnology companies. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The introduction of new products in the U.S. market that compete with, or otherwise disrupt the market for, LUMRYZ or any future product candidates we may develop, if approved, would adversely affect sales of our products. For example, we expect LUMRYZ to face competition from manufacturers of generic twice-nightly sodium oxybate formulations who have reached settlement agreements with the current brand product marketer. In January 2023, Hikma Pharmaceuticals plc, announced the launch of an authorized generic version of Jazz&#8217;s Xyrem (sodium oxybate). In July 2023, Amneal Pharmaceuticals, Inc. announced that it launched an authorized generic version of Jazz&#8217;s Xyrem (sodium oxybate).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are other potential future </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-24-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">competitive products that could impact the marketplace. For example, there are some potential competitors who have reached settlement agreements with the current branded, twice-nightly product marketer, which allows for entry of other generic products in 2026, or earlier, under certain circumstances. Beyond generics, there are other potential future competitive products that could impact the narcolepsy treatment marketplace.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the FDA approves a competitor&#8217;s application for a product candidate before our application for a similar product candidate, and grants such competitor a period of exclusivity, the FDA may take the position that it cannot approve our 505(b)(2) application for a similar product candidate until the exclusivity period expires. Additionally, even if our 505(b)(2) application for a product candidate is approved first, and we receive a period of statutory marketing exclusivity, we may still be subject to competition from other companies with approved products or approved 505(b)(2) NDAs for different conditions of use that would not be restricted by a grant of exclusivity to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our competitors have substantially greater financial, technological, manufacturing, marketing, managerial and research and development resources and experience than we do. Furthermore, acquisitions of competing companies by large pharmaceutical companies could enhance our competitors&#8217; resources. Accordingly, our competitors may be able to develop, obtain regulatory approval and gain market share for their products more rapidly than us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or other applicable regulatory authorities approve generic products that compete with LUMRYZ or any future product candidates, the sales of LUMRYZ and any future product candidates, if approved, could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA, including a 505(b)(2) NDA, is approved, the product becomes a &#8220;listed drug&#8221; which can be referenced by potential competitors in support of approval of an ANDA or subsequent 505(b)(2) application. FDA regulations and other applicable regulations and policies provide incentives to manufacturers to create modified versions of a drug to facilitate the approval of an ANDA or other application for similar alternatives or substitutes. If these manufacturers demonstrate that their product has the same active ingredient(s), dosage form, strength, route of administration, and conditions of use, or labeling, as our product or any future product candidates, they might only be required to conduct a relatively inexpensive study to show that their generic product is absorbed in the body at the same rate and to the same extent as, or is bioequivalent to, our product or any future product candidates. In some cases, even this limited bioequivalence testing can be waived by the FDA. Laws have also been enacted to facilitate the development of generic drugs based on recently approved NDAs. Competition from generic equivalents to our product or any future product candidates could substantially limit our ability to generate revenues and therefore to obtain a return on the investments we have made in our product or any future product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">With the passage of the CREATES Act, we are exposed to possible litigation and damages by competitors who may claim that we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of their ANDAs and 505(b)(2) applications.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2019, President Trump signed legislation intended to facilitate the development of generic and biosimilar products. The bill, previously known as the CREATES Act, authorizes sponsors of ANDAs and 505(b)(2) applications to file lawsuits against companies holding NDAs that decline to provide sufficient quantities of an approved reference drug on commercially reasonable, market-based terms. Drug products on FDA&#8217;s drug shortage list are exempt from these new provisions unless the product has been on the list for more than six continuous months or the FDA determines that the supply of the product will help alleviate or prevent a shortage. For the purposes of the statute, the term &#8220;commercially reasonable, market-based terms&#8221; is defined as (1) the nondiscriminatory price at or below the most recent wholesale acquisition cost for the product, (2) a delivery schedule that meets the statutorily defined timetable, and (3) no additional conditions on the sale.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To bring an action under the statute, an ANDA or 505(b)(2) sponsor must take certain steps to request the reference product, which, in the case of products covered by a REMS with elements to assure safe use (such as LUMRYZ), include obtaining authorization from the FDA for the acquisition of the reference product. If the sponsor does bring an action for failure to provide a reference product, there are certain affirmative defenses available to the NDA holder, which must be shown by a preponderance of evidence. If the sponsor prevails in litigation, it is entitled to a court order directing the NDA holder to provide, without delay, sufficient quantities of the applicable product on commercially reasonable, market-based terms plus reasonable attorney fees and costs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the statutory provisions authorize a U.S. federal court to award the product developer an amount &#8220;sufficient to deter&#8221; the NDA holder from refusing to provide sufficient product quantities on commercially reasonable, market-based terms if the court finds, by a preponderance of the evidence, that the NDA holder did not have a legitimate business justification to delay providing the product or failed to comply with the court&#8217;s order.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-25-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we intend to comply fully with the terms of these new statutory provisions, we are still exposed to potential litigation and damages by competitors who may claim we are not providing sufficient quantities of our approved products on commercially reasonable, market-based terms for testing in support of ANDAs and 505(b)(2) applications. Such litigation would subject us to additional costs, damages and reputational harm, which could lead to lower revenues. The CREATES Act may enable generic competition with LUMRYZ and any of our future product candidates, if approved, which could impact our ability to maximize product revenue.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot keep pace with the rapid technological change in our industry, we may lose business, and LUMRYZ, our technologies or any future products could become obsolete or noncompetitive.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success also depends, in part, on maintaining a competitive position in the development of products and technologies in a rapidly evolving field. Major technological changes can happen quickly in the biotechnology and pharmaceutical industries. If we cannot maintain competitive products and technologies, our competitors may succeed in developing competing technologies or obtaining regulatory approval for products before us, and the products of our competitors may gain market acceptance more rapidly than our product and any future product candidates. Such rapid technological change, or the development by our competitors of technologically improved or different products, could render our product and any future product candidates or our technologies obsolete or noncompetitive.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with healthcare providers, physicians, prescribers, purchasers, third-party payors, charitable organizations and patients will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Healthcare providers, physicians and third-party payors in the U.S. and elsewhere play a primary role in the recommendation and prescription of biopharmaceutical products. Arrangements with third-party payors and customers can expose biopharmaceutical manufacturers to broadly applicable fraud and abuse and other healthcare laws and regulations, including, without limitation, the federal Anti-Kickback Statute (&#8220;AKS&#8221;), and the FCA, which may constrain the business or financial arrangements and relationships through which such companies sell, market and distribute biopharmaceutical products. In particular, the research of our product candidates, as well as the promotion, sales and marketing of healthcare items and services, as well as certain business arrangements in the healthcare industry, are subject to extensive laws designed to prevent fraud, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, structuring and commission(s), certain customer incentive programs and other business arrangements generally. Activities subject to these laws also involve the improper use of information obtained in the course of patient recruitment for clinical trials.  See the section entitled, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8212; Government Regulation &#8212; Healthcare Laws</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The distribution of biopharmaceutical products is subject to additional requirements and regulations, including extensive record-keeping, licensing, storage and security requirements intended to prevent the unauthorized sale of biopharmaceutical products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform, especially in light of the lack of applicable precedent and regulations. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ensuring that our internal operations and future business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations. If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to significant penalties, including administrative, civil and criminal penalties, damages, fines, disgorgement, the exclusion from participation in federal and state healthcare programs, individual imprisonment, reputational harm,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the curtailment or restructuring of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, defending against any such actions can be costly and time consuming, and may require significant financial and personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired. If any of the physicians or other </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-26-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment. If any of the above occur, our ability to operate our business and our results of operations could be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Coverage and reimbursement may be limited or unavailable in certain market segments for LUMRYZ or any future products, if approved, which could make it difficult for us to sell LUMRYZ or any future products profitably.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The success of LUMRYZ or any future products, if approved, depends on the availability of coverage and adequate reimbursement from third-party payors. We cannot be sure that coverage and reimbursement will be available for, or accurately estimate the potential revenue from, our products or assure that coverage and reimbursement will be available for any product that we may develop, such as LUMRYZ. See the section entitled, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8212; Government Regulation &#8212; Coverage and Reimbursement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients who are provided medical treatment for their conditions generally rely on third-party payors to reimburse all or part of the costs associated with their treatment. Coverage and adequate reimbursement from governmental healthcare programs, such as Medicare and Medicaid, and commercial payors are critical to new product acceptance.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities and other third-party payors, such as private health insurers and health maintenance organizations, decide which drugs and treatments they will cover and the amount of reimbursement. Coverage and reimbursement by a third-party depend upon a number of factors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the U.S., no uniform policy of coverage and reimbursement for products exists among third-party payors. As a result, obtaining coverage and reimbursement approval of a product from a government or other third-party payor is a time-consuming and costly process that could require us to provide to each payor supporting scientific, clinical and cost-effectiveness data for the use of our products on a payor-by-payor basis, with no assurance that coverage and adequate reimbursement will be obtained. In the U.S., the principal decisions about reimbursement for new medicines under government healthcare programs are typically made by CMS. CMS decides whether and to what extent a new medicine will be covered and reimbursed under Medicare and private payors tend to follow CMS to a substantial degree. Even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate for us to achieve or sustain profitability or may require co-payments that patients find unacceptably high. Additionally, third-party payors may not cover, or provide adequate reimbursement for, long-term follow-up evaluations required following the use of product candidates, once approved. Patients are unlikely to use our products unless coverage is provided and reimbursement is adequate to cover a significant portion of their cost. There is significant uncertainty related to insurance coverage and reimbursement of newly approved products. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for future product candidates, once approved.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the U.S. Increasingly, third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. We cannot be sure that reimbursement will be available for any product we commercialize and, if reimbursement is available, the level of reimbursement. In addition, many pharmaceutical manufacturers must calculate and report certain price reporting metrics to the government, such as average sales price and best price. Penalties may apply in some cases when such metrics are not submitted accurately and timely. Further, these prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs. Payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and other third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our products. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-27-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that healthcare reform measures may be adopted in the future that may result in more rigorous coverage criteria and in additional downward pressure on the price we receive for any approved product. The implementation of cost containment measures or other healthcare reforms may prevent us from being able to generate revenue, attain profitability, or commercialize our products. Legislative and regulatory proposals have been made to expand post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be changed, or what the impact of such changes on the marketing approvals or clearances of our products, if any, may be. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in some foreign countries, the proposed pricing for a drug must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the European Union (&#8220;EU&#8221;) provides options for its member states (&#8220;Member States&#8221;) to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. To obtain reimbursement or pricing approval, some of these countries may require the completion of clinical trials that compare the cost effectiveness of a particular product candidate to currently available therapies. A Member State may approve a specific price for the medicinal product, or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country having price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for our product or any of our future products. Historically, products launched in the EU do not follow price structures of the U.S. and generally prices tend to be significantly lower.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in regulations, statutes or the interpretation of existing regulations could impact our business in the future by requiring, for example, changes to our manufacturing and supply arrangements; additions or modifications to product labeling; the recall or discontinuation of our products; modifications to pricing and costs; or additional record-keeping requirements. If any such changes were to be imposed, they could adversely affect the operation of our business. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability. See the section entitled, &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Business &#8212; Government Regulation &#8212; Healthcare Reform</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, increasing efforts by governmental and third-party payors in the U.S. and abroad to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product or any future products. There has been increasing legislative and enforcement interest in the U.S. with respect to specialty drug pricing practices. Specifically, there have been several recent U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for drugs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, legislatures are increasingly passing legislation and implementing regulations designed to control pharmaceutical and biologic product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, financial condition, results of operations and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product and any future products or put pressure on our product pricing, which could negatively affect our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These laws, and future state and federal healthcare reform measures may be adopted in the future, any of which may result in additional reductions in Medicare and other healthcare funding and otherwise affect the prices we may obtain for our product and any future products or the frequency with which any such products are prescribed or used. Additionally, we expect to experience pricing pressures in connection with the sale of any future products due to the trend toward managed healthcare, the increasing influence of health maintenance organizations, cost containment initiatives and additional legislative changes.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our reporting and payment obligations under U.S. governmental pricing programs, we could be subject to additional reimbursement requirements, penalties, sanctions and fines, which could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-28-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We participate in the U.S. Department of Veterans Affairs, Federal Supply Schedule (&#8220;FSS&#8221;) pricing program, and the Tricare Retail (&#8220;Tricare&#8221;) Pharmacy program and have obligations to report the average sales price for certain of our drugs. Pricing and rebate calculations are complex, varying across products and programs, and are often subject to interpretation by us, governmental or regulatory agencies and the courts, which can change and evolve over time. Civil monetary penalties can be applied if we are found to have knowingly submitted any false price or product information to the government, if we are found to have made a misrepresentation in the reporting of our average sales price or if we fail to submit the required price data on a timely basis. We cannot assure you that our submissions will not be found to be incomplete or incorrect.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to applicable law, knowing provision of false information in connection with price reporting under the U.S. Department of Veterans Affairs, FSS or Tricare Retail Pharmacy programs can subject a manufacturer to civil monetary penalties. These program obligations also contain extensive disclosure and certification requirements. If we overcharge the government in connection with our arrangements with FSS or Tricare, we are required to refund the difference to the government. Failure to make necessary disclosures and/or to identify contract overcharges can result in allegations against us under the False Claims Act and other laws and regulations. Unexpected refunds to the government, and responding to a government investigation or enforcement action, would be expensive and time-consuming, and could have a material adverse effect on our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ may be found to cause undesirable side effects</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">that limit the commercial profile or result in other significant negative consequences or delay or prevent further development or regulatory approval with respect to new indications, or cause regulatory authorities to require labeling statements, such as boxed warnings.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Undesirable side effects caused by LUMRYZ could limit the commercial profile of LUMRYZ or result in significant negative consequences such as a more restrictive label or other limitations or restrictions. Undesirable side effects caused by LUMRYZ could cause us or regulatory authorities to interrupt, delay or halt non-clinical studies and clinical trials or could result in a more restrictive label or the delay, denial or withdrawal of regulatory approval by the FDA or other regulatory authorities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials by their nature utilize a sample of the potential patient population. With a limited number of patients and limited duration of exposure, certain side effects of LUMRYZ may only be uncovered with a significantly larger number of patients exposed to the drug, and those side effects could be serious or life-threatening. For example, we initiated a pivotal trial in IH, REVITALYZ, which is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 study designed to evaluate the efficacy and safety of LUMRYZ given as a once-at-bedtime dose, in treating IH. We expect to enroll approximately 150 adults in the study who are diagnosed with IH. On July 31, 2024, we announced that the first patient was dosed in this study. If any participants in the trial report any serious adverse events deemed to be related to LUMRYZ, or if LUMRYZ is not observed to have long-term efficacy, our business, financial condition, results of operations and growth prospects could be adversely affected. If we or others identify undesirable side effects caused by LUMRYZ (or any other drug), a number of potentially significant negative consequences could result, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may withdraw or limit their marketing approval of such drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may require the addition of labeling statements, such as a &#8220;boxed warning&#8221; or additions to an existing boxed warning, or a contraindication, including as a result of inclusion in a class of drugs for a particular disease;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may refuse to approve label expansions for additional indications for any approved drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may be required to change the way such drugs are distributed or administered, conduct additional clinical trials or change the labeling of the drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">regulatory authorities may require a modification of an existing REMS to mitigate risks;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may be subject to regulatory investigations and government enforcement actions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we may decide to remove the drug from the marketplace;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we could be sued and held liable for injury caused to individuals exposed to or taking the drug; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our reputation may suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us from achieving or maintaining market acceptance of LUMRYZ and could substantially increase the costs of commercializing LUMRYZ and significantly impact our ability to successfully commercialize LUMRYZ and generate revenues.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may incur significant liability if governmental authorities allege or determine that we are engaging in commercial activities or promoting LUMRYZ in a way that violates applicable regulations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-29-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Physicians have the discretion to prescribe drug products for uses that are not described in the product&#8217;s labeling and that differ from those approved by the FDA or other applicable regulatory agencies. Off-label uses are common across medical specialties. Although the FDA and other regulatory agencies do not regulate a physician&#8217;s choice of treatments, the FDA and other regulatory agencies regulate a manufacturer&#8217;s communications regarding off-label use and prohibit off-label promotion, as well as the dissemination of false or misleading labeling or promotional materials. Manufacturers may not promote drugs for off-label uses. Accordingly, we may not promote LUMRYZ in the U.S. for any indications other than for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The FDA and other regulatory and enforcement authorities actively enforce laws and regulations prohibiting promotion of off-label uses and the promotion of products for which marketing approval has not been obtained. A company that is found to have improperly promoted off-label uses, including promoting unapproved dosing regimens, may be subject to significant liability, which may include civil and administrative remedies as well as criminal sanctions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining regulatory approval of LUMRYZ in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of LUMRYZ in other jurisdictions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Obtaining and maintaining regulatory approval of LUMRYZ in one jurisdiction does not guarantee that we will be able to obtain or maintain regulatory approval in any other jurisdiction, while a failure or delay in obtaining regulatory approval in one jurisdiction may have a negative effect on the regulatory approval process in others. For example, while the FDA has granted approval of LUMRYZ in the U.S. for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, comparable regulatory authorities in foreign jurisdictions may not approve LUMRYZ in those countries for the same or similar indication, if at all. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the U.S., including additional preclinical studies or clinical trials, as clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the U.S., a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval. Obtaining foreign regulatory approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of LUMRYZ in certain countries. If we seek regulatory approval of LUMRYZ in international markets and we fail to comply with the regulatory requirements in those markets or fail to receive applicable marketing approvals, our ability to realize the full market potential of LUMRYZ may be reduced.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Laws and regulations governing international operations we have and may expand in the future may preclude us from developing, manufacturing, and selling certain product candidates and products outside of the U.S. and require us to develop and implement costly compliance programs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As we seek to expand our operations outside of the U.S., we must dedicate additional resources to comply with numerous laws and regulations in each jurisdiction in which we plan to operate. The Foreign Corrupt Practices Act (&#8220;FCPA&#8221;) and its Irish equivalent prohibit any individual or business from paying, offering, authorizing payment, or offering anything of value, directly or indirectly, to any foreign official, political party, or candidate for the purpose of influencing any act or decision of such third party in order to assist the individual or business in obtaining or retaining business. The FCPA also obligates companies whose securities are listed in the U.S. to comply with certain accounting provisions requiring the company to maintain books and records that accurately and fairly reflect all transactions of the company, including international subsidiaries, and to devise and maintain an adequate system of internal accounting controls for international operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compliance with the FCPA is expensive and difficult, particularly in countries in which corruption is a recognized problem. In addition, the FCPA presents particular challenges in the pharmaceutical industry, because, in many countries, hospitals are operated by the government, and doctors and other hospital employees are considered foreign officials. Certain payments to hospitals in connection with clinical trials and other work have been deemed to be improper payments to government officials and have led to FCPA enforcement actions. Similar laws in other countries, such as the U.K. Bribery Act 2010, may apply to our operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various laws, regulations, and executive orders also restrict the use and dissemination outside of the U.S., or the sharing with certain non-U.S. nationals, of information classified for national security purposes, as well as certain products and technical data relating to those products. As we expand our presence outside of the U.S. in key European markets, we must dedicate additional resources to comply with these laws, and such laws may preclude us from developing, manufacturing, or selling certain product candidates and products outside of the U.S., which could limit our growth potential and increase our development costs.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-30-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure to comply with laws governing international business practices may result in substantial civil and criminal penalties and suspension or debarment from government contracting. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges for violations of the FCPA's accounting provisions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Governments outside of the U.S. tend to impose strict price controls, which may adversely affect our revenues, if any.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In some countries, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing authorization for a product. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of LUMRYZ to other available therapies. If we seek approval for LUMRYZ outside of the U.S. and reimbursement of LUMRYZ is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, our business could be harmed.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Failure to comply with domestic and international privacy and security laws could inhibit our ability to collect and process data globally, and could result in the imposition of significant civil and criminal penalties.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The legislative and regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. The costs of compliance with privacy and security laws, including protecting electronically stored information from cyber-attacks, and potential liability associated with any compliance failures could adversely affect our business, financial condition and results of operations. Our processing of personal data regarding individuals in the European Economic Area, or EEA, including personal health data, is subject to the European Union&#8217;s General Data Protection Regulation, or EU GDPR. Following the withdrawal of the United Kingdom from the European Union, or Brexit, the EU GDPR has been incorporated into the United Kingdom&#8217;s laws, or UK GDPR, alongside the UK Data Protection Act 2018, and together with the EU GDPR, is referred to as (&#8220;GDPR&#8221;). Our processing of personal data domestically in the U.S. requires us to comply with  privacy and security regulations, including but not limited to, U.S. state consumer privacy laws such as the California Consumer Privacy Act (&#8220;CCPA&#8221;).  In addition, more than a dozen other U.S. states have enacted comparable laws addressing the privacy and security of health information, some of which are more stringent than federal patient privacy laws. These laws require us to ensure that the personal data we collect is gathered legally and under strict conditions and to protect such personal data from misuse and exploitation. Our failure to comply with the GDPR, CCPA or other similar laws may subject us to significant fines and penalties that could adversely affect our business, financial condition and results of operations, including the threat of class action litigation. Even if we have not been determined to have violated such laws, consumer class actions or regulatory investigations may require significant resources to defend and generate negative publicity, which could harm our reputation and our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular indication and fail to capitalize on indications that may be more profitable or for which there is a greater likelihood of success.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because we have limited financial, managerial and research and development resources, we must prioritize our research programs and will need to focus LUMRYZ on the potential treatment of certain indications or in certain populations. As a result, we may forego or delay pursuit of opportunities for other populations or indications that later prove to have greater commercial potential. For example, we initiated a clinical trial for LUMRYZ in idiopathic hypersomnia in 2024. Our resource allocation decisions may cause us to fail to capitalize on profitable market opportunities. Our spending on current and future research and development programs, including evaluating LUMRYZ in additional indications, may not yield any commercially viable products or result in additional approvals for LUMRYZ. If we do not accurately evaluate the commercial potential or target market for LUMRYZ, we may also relinquish valuable rights to LUMRYZ through collaboration, licensing or other royalty arrangements in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to LUMRYZ. Any such event could have a material adverse effect on our business, financial condition, results of operations and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Product Candidate Development</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical development of drugs is costly and time-consuming, and the outcomes are uncertain. A failure to prove that LUMRYZ or any future product candidates are safe and effective in clinical trials could materially and adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:93%">Clinical trials are expensive and can take many years to complete, and the outcome is uncertain. Failure can occur at any time during the clinical trial process. The results of preclinical studies and early clinical trials of product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical testing. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-31-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to issues relating to the results generated in clinical trials, clinical trials can be delayed or halted for a variety of reasons, including delays or failures in:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement with regulatory authorities on acceptable clinical trial design, conduct or statistical analysis plan;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">generating and submitting additional data required by regulatory authorities before we are permitted to initiate or resume a clinical trial;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining regulatory approval to commence a trial; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reaching agreement on acceptable terms with prospective contract research organizations (&#8220;CROs&#8221;) and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining institutional review board or ethics committee approval at each site; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">recruiting suitable patients to participate in a trial; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our third-party contractors&#8217; ability to comply with regulatory requirements or contractual obligations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">having patients complete a trial or return for post-treatment follow-up; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">clinical sites dropping out of a trial; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">adding new sites; or </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">obtaining clinical materials or manufacturing sufficient quantities of our candidates for use in clinical trials. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, our product candidates may have undesirable side effects or other unexpected characteristics, or reports from clinical testing of other therapies may raise safety or efficacy concerns about our product candidates, that could cause us or our investigators, regulators, IRBs or ethics committees to suspend or terminate ongoing clinical trials. Evolution in the standard of care or changes in applicable governmental regulations or policies during the development of a product candidate that require amendments to ongoing clinical trials and/or the conduct of additional preclinical studies or clinical trials may lead to delays and additional expenses to us. Lack of adequate funding could also prevent us from completing a clinical trial or development program. Many of the factors that cause or lead to a delay in the initiation or completion of clinical trials may also ultimately lead to the delay or denial of regulatory approval or limit the market acceptance and commercial potential of our product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We cannot be certain that a</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">product candidate will receive marketing approval. Without marketing approval, we will not be able to commercialize a product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may devote significant financial resources and business efforts to the development of product candidates. We cannot be certain that any current or future product candidates will receive marketing approval.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of a product candidate and issues relating to its approval and marketing are subject to extensive regulation by the FDA in the U.S. and by comparable regulatory authorities in other countries. We are not permitted to market a product candidate in the U.S. until we receive approval of an NDA by the FDA. The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of regulatory authorities. In addition, approval policies, regulations, or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An NDA must include extensive preclinical and clinical data and supporting information to establish a product candidate&#8217;s safety and effectiveness for each desired indication. An NDA must also include significant information regarding the chemistry, manufacturing and controls for the product candidate. Obtaining approval of an NDA is a lengthy, expensive and uncertain process, and we may not be successful in obtaining approval. Any delay or setback in obtaining final approval or the commercialization of a product candidate may adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has substantial discretion in the drug approval process, including the ability to delay, limit or deny approval of a product candidate for many reasons. For example, the FDA:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">could determine that we cannot rely on the Section 505(b)(2) regulatory pathway or other pathways we may select, as applicable, for a product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">could determine that the information provided was inadequate, contained clinical deficiencies or otherwise failed to demonstrate the safety and effectiveness of a product candidate for any indication;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may not find the data from bioequivalence studies and/or clinical trials sufficient to support the submission of an NDA or to obtain marketing approval in the U.S., including any findings that the clinical and other benefits of a product candidate outweigh their safety risks;</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-32-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may disagree with our trial design or our interpretation of data from preclinical studies, bioequivalence studies and/or clinical trials, or may change the requirements for approval even after it has reviewed and commented on the design for our trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may determine that we have identified the wrong listed drug or drugs or that approval of our Section 505(b)(2) application for a product candidate is blocked by patent or non-patent exclusivity of the listed drug or drugs or of other previously approved drugs with the same conditions of approval as our product candidate, as applicable;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may identify deficiencies in the manufacturing processes or facilities of third-party manufacturers with which we enter into agreements for the manufacturing of a product candidate;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may audit some or all of our clinical research study sites to determine the integrity of our data and may reject any or all of such data;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may approve a product candidate for fewer or more limited indications than we request, or may grant approval contingent on the performance of costly post-approval clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may not determine that a product candidate is clinically superior to any previously approved same drug;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may change its approval policies or adopt new regulations; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">may not approve the labeling claims that we believe are necessary or desirable for the successful commercialization of a product candidate. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if a product is approved, the FDA may limit the indications for which the product may be marketed, require extensive warnings on the product labeling or require expensive and time-consuming clinical trials and/or reporting as conditions of approval. Regulators of other countries and jurisdictions have their own procedures for the approval of product candidates with which we must comply prior to marketing in those countries or jurisdictions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have received marketing approval from the FDA for LUMRYZ in the U.S. and will evaluate filing potentially elsewhere.  There can be no assurances, however, that viable approval pathways outside of the U.S., will be available for LUMRYZ or that the FDA or other regulatory authorities will approve any future product candidates.We also may experience delays in obtaining marketing approvals for additional indications for LUMRYZ or for any future product candidates. For example, we are conducting a pivotal clinical trial of LUMRYZ in IH and if that trial is successful, we may seek approval of LUMRYZ in that indication; however, a sponsor of another sodium oxybate product has orphan drug exclusivity until August 2028 for the use of that product in IH. As a result, we may not be able to obtain approval for an IH indication for LUMRYZ until the expiration of the other product&#8217;s orphan drug exclusivity, unless we are able to demonstrate the clinical superiority of LUMRYZ over the approved sodium oxybate product. Xywav has an ODE in IH that expires August 12, 2028. Assuming we are allowed to seek FDA approval, if we aren&#8217;t successful demonstrating clinical superiority, final FDA approval would be delayed until expiry of the Xywav ODE.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Delays in approvals or rejections of marketing applications in the U.S. or other countries may be based upon many factors, including regulatory requests for additional analysis, reports, data, preclinical studies and clinical trials, regulatory questions regarding different interpretations of data and results, changes in regulatory policy during the period of product development and the emergence of new information regarding a product candidate.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our current and future product candidates may not reach the commercial market for a number of reasons.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug development is an inherently uncertain process with a high risk of failure at every stage of development. Successful research and development of pharmaceutical products is difficult, expensive and time consuming. Many product candidates fail to reach the market. Our success will depend on the development and successful commercialization of new drugs and products that utilize our drug delivery technologies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if product candidates and</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drug delivery technologies appear promising during development, there may not be successful commercial applications developed for them for a number of reasons, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the FDA, the European Medicines Agency (&#8220;EMA&#8221;), the competent authority of a EU Member State or an IRB, or an Ethics Committee (EU equivalent to IRB), or our partners may delay or halt applicable clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our partners may face slower than expected rate of patient recruitment and enrollment in clinical trials, or may devote insufficient funding to the clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">drug delivery technologies and drug products may be found to be ineffective or to cause harmful side effects, or may fail during any stage of pre-clinical testing or clinical trials;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our partners may find that certain products cannot be manufactured on a commercial scale and, therefore, may not be economical or feasible to produce; </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-33-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">we or our partners may face delays in completing our clinical trials due to circumstances outside of our control, including natural disasters, labor or civil unrest, global health concerns or pandemics or acts of war or terrorism; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">product candidates could fail to obtain regulatory approval or, if approved, could fail to achieve market acceptance, could fail to be included within the pricing and reimbursement schemes of the U.S. or EU Member States, or could be precluded from commercialization by proprietary rights of third parties. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Risks Related to Our Financial Position and Capital Requirements</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We incurred a net loss in 2024 and may incur a net loss in 2025, and if we are not able to achieve profitability in the future, the value of our shares may fall.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We incurred a net loss of $48,832 for the year ended December&#160;31, 2024. We may not become profitable in the near future and may never achieve profitability. The amount of our future net losses or net profitability will depend, in part, on the rate of our future expenditures and our ability to recognize revenues from the commercialization of LUMRYZ in the U.S. We have devoted significant financial resources to research and development, including our clinical development activities, the pursuit of regulatory approval and commercial launch for LUMRYZ. Our future revenues will depend upon the size of any markets in which LUMRYZ and any future products receive approval, and our ability to achieve sufficient market acceptance, reimbursement from third-party payors and adequate market share for our product and any future products in those markets. In addition, we have significantly increased our sales organization and supporting commercial infrastructure to support the commercial launch of LUMRYZ and, accordingly, we will continue to incur significant expenses related to the commercialization of LUMRYZ. Because of the numerous risks and uncertainties associated with the commercialization of pharmaceutical products, we are unable to predict the extent of any future losses or when we will become profitable, if at all. Our ability to operate profitably depends upon a number of factors, many of which are beyond our direct control. These factors include:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to obtain, build and expand manufacturing capacity, including capacity at third-party manufacturers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the effectiveness of our sales and marketing strategy;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the demand and market size for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the level of product and price competition for LUMRYZ;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to develop new partnerships and additional commercial applications for LUMRYZ and any future product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timely receipt of approval for the commercialization of LUMRYZ outside the U.S.;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the potential expansion of LUMRYZ into other populations; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to control our costs;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the initiation of additional research, preclinical, clinical or other programs as we seek to identify and validate additional product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to acquire or in-license other product candidates and technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">our ability to maintain, protect and expand our intellectual property portfolio; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">general economic conditions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even though the FDA has granted approval of our NDA for LUMRYZ for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, we may never recognize revenue in amounts sufficient to achieve and maintain profitability. The net losses we incur may fluctuate significantly from quarter to quarter and year to year, such that a period-to-period comparison of our results of operations may not be a good indication of our future performance. In any particular quarter or quarters, our operating results could be below the expectations of securities analysts or investors, which could cause our stock price to decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We may require additional financing to successfully commercialize LUMRYZ and implement our operating plans, which may not be available on favorable terms or at all, and which may result in dilution of the equity interest of the holders of our ordinary shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may require additional financing to fund the commercialization of LUMRYZ and possible development or acquisition of new products and businesses. We may consume available resources more rapidly than currently anticipated, resulting in the need for additional funding. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any additional fundraising efforts may divert our management from their day-to-day activities, which may adversely affect our ability to commercialize </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we cannot obtain financing when needed, or obtain it on favorable terms, we may be required to curtail our plans to continue to develop drug delivery technologies, develop new products, or acquire additional products and businesses. Other factors that will affect future capital requirements and may require us to seek additional financing include:</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-34-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the development and acquisition of new products and drug delivery technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the progress of our research and product development programs; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the timing of, and amounts received from, future product sales, product development fees and licensing revenue and royalties. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If adequate funds are not available, we may be required to significantly reduce or refocus our product development efforts, resulting in loss of sales, increased costs and reduced revenues. Alternatively, to obtain needed funds for acquisitions or operations, we may seek to issue ordinary shares, or issue equity-linked debt, or we may choose to issue preferred shares, in either case through public or private financings. Additional funds may not be available on terms that are favorable to us and, in the case of such equity or equity-linked financings, may result in dilution to the holders of our ordinary shares. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could also be required to seek funds through arrangements with collaborative partners, and we may be required to relinquish rights to our product or future product candidates or otherwise agree to terms unfavorable to us, any of which may have a material adverse effect on our business, operating results and prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We may be required to or choose to obtain further funding through public equity or equity linked offerings, debt financings, royalty-based financing arrangements, collaborations and licensing arrangements or other sources. To the extent that we raise additional capital through the sale of equity, convertible debt securities or other equity-based derivative securities, investors will be diluted, and new investors could gain rights, preferences and privileges senior to the holders of our ordinary shares. Furthermore, the issuance of additional securities, whether equity or debt, by us, or the possibility of such issuance, may cause the market price of our ordinary shares to decline and existing shareholders may not agree with our financing plans or the terms of such financings. If we raise additional funds through collaborations or marketing, distribution or licensing, or royalty-based financing arrangements with third parties, we may have to relinquish valuable rights to future revenue streams or product candidates or grant licenses on terms that may not be favorable to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Our ability to obtain additional financing may be limited by the terms of our financing arrangements and the provisions of Irish law.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Restrictions in our existing and future financing arrangements and mandatory provisions of Irish law may adversely affect our ability to obtain additional financing. For example, future debt agreements or other financing arrangements may include covenants that limit our ability to engage in specified transactions, including prohibiting us from incurring additional secured or unsecured debt, paying dividends or redeeming equity securities or similar or more restrictive terms that limit our ability to raise additional financing when needed. In addition, Irish law requires that our directors must have specific authority from shareholders to allot and issue new shares generally, or to issue new shares for cash to new shareholders without offering such shares to existing shareholders pro-rata to their existing holdings (including, in each case, rights to subscribe for or otherwise acquire any shares), even where such shares form part of our authorized but unissued share capital. At our 2021 annual general meeting of shareholders, our shareholders renewed such authorizations, subject to certain parameters, for a period expiring December 20, 2026. If we are unable to obtain renewal of such authorization from our shareholders, our ability to use our authorized but unissued share capital to effect or to obtain additional financing, could be adversely affected. Irish law also provides that, in the event of an actual or potential takeover offer being made for us, various actions, including issuing shares, options or convertible securities, material acquisitions or disposals, entering into contracts other than in the ordinary course of business or any action, other than seeking alternative offers, may be prohibited unless approved by our shareholders or the Irish Takeover Panel. These restrictions may prevent or delay us from taking actions that we believe are in our best interest or from obtaining financing on favorable terms, in adequate amounts or at all, which may adversely impact our results of operations and financial condition. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our net loss and use of cash in operating activities may limit our ability to fully pursue our business strategy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We reported a net loss of $48,832 in 2024. We reported cash used in operating activities of $46,907. Cash, cash equivalents and marketable securities as of December&#160;31, 2024 totaled $73,777. Our business strategy is to primarily focus on the commercialization of LUMRYZ for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy in the U.S. The successful pursuit of all components of our strategy will require substantial financial resources, and there can be no assurance that our existing cash, cash equivalents and marketable securities assets and the cash generated by our operations will be adequate for these purposes. Failure to implement any component of our strategy may prevent us from achieving profitability in the future or may otherwise have a material adverse effect on our financial condition and results of operation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulation</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The distribution and sale of LUMRYZ are subject to significant regulatory restrictions, including the requirements of a REMS and safety reporting requirements, and these regulatory requirements subject us to risks and uncertainties, any of which could negatively impact sales of LUMRYZ.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-35-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The API of LUMRYZ is sodium oxybate, a central nervous system depressant known to be associated with facilitated sexual assault as well as with respiratory depression and other serious side effects. As a result, the FDA requires that sponsors of sodium oxybate products, such as LUMRYZ, maintain a REMS to help ensure that the benefits of the drug outweigh the serious risks of the drug. The REMS for LUMRYZ imposes, among other requirements, controls and restrictions on the distribution of the product in the U.S. Any failure to demonstrate our substantial compliance with such REMS obligations, including as a result of business or other interruptions, or a determination by the FDA that the REMS is not meeting its goals, could result in enforcement action by the FDA, lead to changes in our REMS obligations, negatively affect sales of LUMRYZ, result in additional costs and expenses for us or require us to invest a significant amount of resources, any of which could materially and adversely affect our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot predict whether the FDA will request, seek to require or ultimately require modifications to, or impose additional requirements on, the REMS for LUMRYZ in the future. Any modifications approved, required or rejected by the FDA could change the safety profile of LUMRYZ, and have a significant negative impact in terms of product liability, public acceptance of LUMRYZ for treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy, and prescribers&#8217; willingness to prescribe, and patients&#8217; willingness to take, LUMRYZ, any of which could have a material adverse effect on our business. Modifications approved, required or rejected by the FDA could also make it more difficult or expensive for us to distribute LUMRYZ, make distribution easier for sodium oxybate competitors, disrupt continuity of care for LUMRYZ patients or negatively affect sales of LUMRYZ in the U.S.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pharmaceutical companies, including their agents and employees, are required to monitor adverse events occurring during the use of their products and report them to the FDA. As required by the FDA, and similarly for other regulatory agencies, the adverse event information we collect for LUMRYZ must be regularly reported to the FDA and could result in the FDA requiring changes to LUMRYZ&#8217;s labeling, including additional warnings or boxed warnings, or requiring us to take other actions that could have an adverse effect on patient and prescriber acceptance of LUMRYZ. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any failure to demonstrate our substantial compliance with a REMS required for LUMRYZ or any other applicable regulatory requirements to the satisfaction of the FDA or another regulatory authority could result in such regulatory authorities taking actions in the future which could have a material adverse effect on sodium oxybate product sales and therefore on our business, financial condition, results of operations and growth prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Disruptions at the FDA, the DEA and other government agencies caused by funding shortages or global health concerns could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ability of the FDA to review and approve new products can be affected by a variety of factors, including government budget and funding levels, ability to hire and retain key personnel and accept the payment of user fees, and statutory, regulatory and policy changes. Average review times at the agency have fluctuated in recent years as a result. In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Disruptions at the FDA, DEA and other agencies may also increase the time necessary for new product candidates to be reviewed or approved by necessary government agencies, which would adversely affect our business. For example, over the last several years the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions, which could have a material adverse effect on our business. Further, future government shutdowns could impact our ability to access the public markets and obtain necessary capital in order to properly capitalize and continue our operations. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ may not maintain regulatory exclusivities, including orphan drug exclusivity, or the benefits of such exclusivities, which may adversely affect the sales of the product</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Orphan Drug Act, as amended, the FDA may designate a drug as an orphan drug if it is intended to treat a rare disease or condition, which is defined as a patient population of fewer than 200,000 individuals in the U.S., or a patient population of 200,000 or more where there is no reasonable expectation that the cost of developing the drug for the rare disease or condition will be recovered from sales of the drug in the U.S. Generally, if a drug with orphan drug designation subsequently receives the first marketing approval for the disease or condition for which it has such designation, the drug is entitled to a </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-36-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">period of marketing exclusivity, which precludes the FDA from approving another marketing application for the same drug for the same disease or condition for seven years, except in limited circumstances, such as if the FDA concludes that a subsequent same drug is clinically superior to the first approved orphan drug through greater safety, greater effectiveness, or a major contribution to patient care. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ obtained orphan drug designation for the treatment of narcolepsy from the FDA in January 2018. Upon the approval of LUMRYZ in May 2023 by the FDA for the treatment of cataplexy or EDS in adults with narcolepsy and a finding of clinical superiority of LUMRYZ relative to marketed oxybate products, the FDA granted LUMRYZ seven years of orphan drug exclusivity. Additionally, LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older in October 2024, and was granted orphan drug exclusivity for this patient population through October 2031. Even though we have obtained orphan drug exclusivities for LUMRYZ, those exclusivities may not effectively protect LUMRYZ from competition because different drugs can be approved for the same condition. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Moreover, there can be no assurance that third parties will not attempt to disrupt the commercialization of LUMRYZ through litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any orphan drug exclusive marketing rights may be lost if the FDA later determines the request for designation was materially defective or we are unable to assure sufficient quantity of LUMRYZ to meet the needs of patients with narcolepsy. The FDA may reevaluate its regulations and policies under the Orphan Drug Act. We do not know if, when or how the FDA may change the orphan drug regulations and policies in the future, and it is uncertain how any changes might affect our business. Depending on what changes, the FDA may make to its orphan drug regulations and policies, our business could be adversely impacted.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The API in LUMRYZ, sodium oxybate, is a controlled substance subject to U.S. federal and state controlled substance laws and regulations and applicable controlled substance legislation in other countries, and our failure, or the failure of third-parties on whom we rely, to comply with these laws and regulations, or the cost of compliance with these laws and regulations, could materially and adversely affect our business, results of operations, financial condition and growth prospects.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ contains a controlled substance as defined in the CSA. Controlled substances are subject to a number of requirements and restrictions under the CSA and implementing regulations, including certain registration, security, recordkeeping, reporting, manufacturing and procurement quotas, import, export and other requirements administered by the DEA. The DEA classifies controlled substances into five schedules: Schedule I, II, III, IV or V. Schedule I substances by definition have a high potential for abuse, no currently &#8220;accepted medical use&#8221; in the U.S., lack accepted safety for use under medical supervision, and may not be prescribed, marketed or sold in the U.S. Pharmaceutical products approved for use in the U.S. which contain a controlled substance are listed as Schedule II, III, IV or V, with Schedule II substances considered to present the highest potential for abuse or dependence and Schedule V substances the lowest relative risk of abuse among such substances. Schedule I and II drugs are subject to the strictest controls under the CSA, including manufacturing and procurement quotas, heightened security requirements and additional criteria for importation. The API of LUMRYZ, sodium oxybate, is regulated by the DEA as a Schedule I controlled substance, and FDA-approved products containing sodium oxybate, including LUMRYZ, are currently Schedule III. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Individual states have also established controlled substance laws and regulations. Although state-controlled substances laws often mirror federal law, they may separately schedule our product or future product candidate(s). We or our partners may also be required to obtain separate state registrations, permits or licenses in order to be able to manufacture, research, distribute, import, export, administer or prescribe controlled substances for clinical trials or commercial sale, and failure to meet applicable regulatory requirements could lead to enforcement and sanctions by the states in addition to those from the DEA or otherwise arising under federal law.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">U.S. facilities conducting research, manufacturing, distributing, importing or exporting, or dispensing of controlled substances must be registered (licensed) to perform these activities and must comply with the security, control, recordkeeping and reporting obligations under the CSA, DEA regulations and corresponding state requirements. DEA and state regulatory bodies conduct periodic inspections of certain registered establishments that handle controlled substances. Obtaining and maintaining the necessary registrations, obtaining and maintaining quotas and complying with the regulatory obligations may result in delay of the importation, export, manufacturing, distribution or research of our product and any future product candidates or products. Furthermore, failure to maintain compliance with the CSA and DEA and state regulations by us or any of our contractors, distributors or pharmacies can result in regulatory action that could have a material adverse effect on our business, financial condition and results of operations. In addition, if we change any third-party upon whom we rely to conduct our research, manufacturing, distributing, importing, exporting, or dispensing activities, doing so will result in additional costs and expenses and may take a significant amount of time, and we may be unsuccessful in identifying a new, satisfactory third-party, any of which could materially and adversely affect our business, financial condition, and results of operations. DEA and state </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-37-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory bodies may seek civil penalties, refuse to renew necessary registrations, or initiate proceedings to restrict, suspend or revoke those registrations. In certain circumstances, violations could lead to criminal penalties.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because LUMRYZ contains sodium oxybate, to conduct clinical trials with LUMRYZ in the U.S. for additional indications beyond what the FDA has already approved, each of our research sites must submit a research protocol to the DEA and obtain and maintain a DEA researcher registration that allows those sites to handle and dispense LUMRYZ and to obtain the product candidate. If the DEA delays or denies the grant of a researcher registration to one or more research sites, the clinical trial could be significantly delayed, and we could lose clinical trial sites. In the event the product candidate would be made outside the U.S., the importer for the clinical trials must also obtain a Schedule I importer registration and an import permit for each import.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and our manufacturing partners in the U.S. are subject to the DEA&#8217;s annual manufacturing and procurement quota requirements. The annual quota allocated to us or our U.S. manufacturing partners for sodium oxybate may not be sufficient to meet commercial demand of LUMRYZ. Consequently, any delay or refusal by the DEA in establishing our, or U.S. manufacturing partner&#8217;s, procurement and/or production quota for controlled substances could delay or stop our commercial activities and future development/clinical activities, which could have a material adverse effect on our business, financial position and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ is classified as a Schedule III substance based on current applicable regulations, which allows an importer to import it for commercial purposes if it obtains the appropriate registrations and licenses from the DEA, including an importer registration and files an application for an import permit for each import. The DEA provides annual assessments/estimates to the International Narcotics Control Board, which guides the DEA in the amounts of controlled substances that the DEA authorizes to be imported. To the extent an importer is utilized for commercial purposes, failure by any current importer or future importer that we identify as an importer, if any are available, to obtain and maintain the necessary import authority from the DEA and other applicable regulatory authorities, including specific quantities, could affect the availability of LUMRYZ and have a material adverse effect on our business, results of operations and financial condition. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Governments outside of the U.S. have similar controlled substance laws, regulations and requirements in their respective jurisdictions, and our failure, or the failure of third parties upon whom we rely, to comply with applicable controlled substance laws, regulations and requirements or secure necessary authorizations would result in similar risks to those described above.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are required to obtain regulatory approval of any proposed product names for our product candidates, and any failure or delay associated with such approval may adversely impact our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any name we intend to use for our product candidates will require approval from the FDA or other regulatory authorities in jurisdictions where we may seek approval regardless of whether we have secured a trademark registration from the USPTO or similar protection in other jurisdictions. The FDA and other regulatory authorities each typically conduct a review of proposed product names, including an evaluation of potential for confusion with other product names. The FDA or other regulatory authorities in jurisdictions where we may seek approval may object to any product name we submit if, for example, it believes the name inappropriately implies medical claims. If the FDA or other regulatory authorities in jurisdictions where we may seek approval objects to any of our proposed product names, we may be required to adopt an alternative name for our product candidates. There is no guarantee we will be able to use the same proprietary name for a product in each jurisdiction where we market that product. If we adopt an alternative name, we would lose the benefit of any existing trademark applications for such product and may be required to expend significant additional resources in an effort to identify a suitable product name that would qualify under applicable trademark laws, not infringe the existing rights of third parties and be acceptable to the FDA or other regulatory authorities. Final acceptance of a proposed proprietary name occurs as part of the final approval of a drug product. We may be unable to build a successful brand identity for a new proprietary name or trademark in a timely manner or at all, which would limit our ability to commercialize a product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to our Reliance on Third Parties</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely, and intend to continue to rely on a limited number of suppliers</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">for the development, manufacture and supply of LUMRYZ, and if we experience problems with these suppliers, or they fail to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, our business would be materially and adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Currently, we use a limited number of providers for the development, supply of clinical materials and supply of commercial batches for our product, LUMRYZ. We do not own or operate manufacturing facilities for clinical or commercial manufacture of LUMRYZ. We have limited personnel with experience in drug manufacturing, and we lack the capabilities to manufacture LUMRYZ on a clinical or commercial scale. There can be no assurance that our clinical development or commercial product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-38-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">supplies will not be limited, interrupted, or of satisfactory quality or continue to be available at acceptable quantities or prices to meet demand. If the supplies of these products or materials were interrupted for any reason (including but not limited to, natural disasters, labor or civil unrest, global health concerns or pandemics or acts of war or terrorism, delays at the manufacturer, delays related to quality control, and delays related to the supply chain), our manufacturing, clinical development or commercial activities of LUMRYZ (or any future product or product candidate) could be delayed. These delays could be extensive and expensive, especially in situations where a substitution is not readily available or required variations of existing regulatory approvals and certifications or additional regulatory approval.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our third-party suppliers may not be required to, or may be unable to, provide us with any guaranteed minimum production levels or have sufficient dedicated capacity for our drug. Failure to obtain adequate supplies in a timely manner could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We contract with third parties for the manufacture of LUMRYZ for clinical testing and commercialization, and expect to continue to do so for any future products and product candidates. This reliance on third parties increases the risk that we will not have sufficient quantities of LUMRYZ or any future products or product candidates, or such quantities at an acceptable cost, which could delay, prevent or impair our development or commercialization efforts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently own or operate, nor do we have any plans to establish in the future, any manufacturing facilities. We rely, and expect to continue to rely, on third parties for the manufacture of LUMRYZ for clinical testing and commercial manufacture of LUMRYZ as well as any other future products and product candidates we develop. This reliance on third parties increases the risk that we will not have sufficient quantities of our product candidates or products, or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development and commercialization efforts. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The facilities used by CDMOs generally must be inspected by the FDA pursuant to pre-approval inspections conducted as a part of the FDA&#8217;s review of an NDA. We do not control the manufacturing process of, and will be completely dependent on, our CDMOs for compliance with cGMPs in connection with the manufacture of LUMRYZ and any future products and product candidates. If our CDMOs cannot successfully manufacture materials that conform to our specifications and the strict regulatory requirements of the FDA and any other applicable regulatory authorities, they will not be able to pass regulatory inspections and/or maintain regulatory compliance for their manufacturing facilities. In addition, we have no control over the ability of our CDMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of LUMRYZ or any future products or product candidates, or if it finds deficiencies or withdraws any such approval in the future, we may need to find alternative manufacturing facilities, which would significantly impact our ability to market LUMRYZ or any future product or develop and obtain regulatory approval for any future product candidates, if granted final approval by the FDA or other applicable regulatory authority. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CDMOs upon whom we rely are also required to comply with the CSA, DEA regulations and other applicable controlled substance laws, regulations and requirements in other countries, where applicable, including those relating to licensing and registration requirements. The inability of our CDMOs to maintain compliance with applicable controlled substance laws, regulations and requirements and obtain and maintain the necessary licenses and registrations could have a material adverse effect on our business, including our clinical trials, commercial activities, financial position and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any CDMO with whom we contract fails to perform its obligations, we may be forced to enter into an agreement with a different CDMO, which we may not be able to do on reasonable terms, if at all. In such scenario, our clinical trials or commercial supply could be delayed significantly as we establish alternative supply sources. In some cases, the technical skills required to manufacture a product or product candidate may be unique or proprietary to the original CDMO and we may have difficulty, or there may be contractual restrictions prohibiting us from, transferring such skills to a back-up or alternate supplier, or we may be unable to transfer such skills at all. In addition, if we are required to change CDMOs for any reason, we will be required to verify that the new CDMO maintains facilities and procedures that comply with quality standards and with all applicable regulations, including those relating to controlled substances. We will also need to verify, such as through a manufacturing comparability study, that any new manufacturing process will produce a product or product candidate according to the specifications previously submitted to or approved by the FDA or other regulatory authority. The delays associated with the verification of a new CDMO could negatively affect our ability to commercialize a product or develop a product candidate in a timely manner or within budget. Furthermore, a CDMO may possess technology related to the manufacture of a product or product candidate that such CDMO owns independently. This would increase our reliance on such CDMO and may require us to obtain a license from such CDMO in order to have another CDMO manufacture the product or product candidate. In addition, in the case of CDMOs that supply a product or product candidate, changes in manufacturers often involve changes in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-39-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">manufacturing procedures and processes, which could require that we conduct bridging studies between our supply from the prior CDMO and that of any new manufacturer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, our failure, or the failure of our third party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect our business and supplies of a product or product candidates. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">reliance on the third party for regulatory compliance and quality assurance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product or product candidate we develop may compete with other product candidates and approved products of other parties for access to manufacturing facilities. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. Any performance failure on the part of our existing or future manufacturers could delay clinical development, marketing approval or commercialization efforts. If our current CDMOs cannot perform as agreed, we may be required to replace such manufacturers. We may incur added costs and delays in identifying and qualifying any such replacement. Our current and anticipated future dependence upon others for the manufacture of LUMRYZ and any future products may adversely affect our future profit margins and our ability to commercialize such products on a timely and competitive basis.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We outsource important activities to consultants, advisors and outside contractors.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We outsource many key functions of our business and therefore rely on a substantial number of consultants, advisors and outside contractors. If we are unable to effectively manage our outsourced activities or if the quality, accuracy, or availability of the services provided by such third parties is compromised for any reason, our development activities may be extended, delayed or terminated which would have an adverse effect on our development program and our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We depend on key personnel to execute our business plan. If we cannot attract and retain key personnel, we may not be able to successfully implement our business plan.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are highly dependent on the expertise of Gregory Divis, our Chief Executive Officer and Thomas McHugh, our Chief Financial Officer, as well as the other key members of our management, legal, scientific, clinical and commercial team. Although we have entered into employment letter agreements with our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing and sales and marketing personnel will also be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain regulatory approval of and commercialize drugs. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have substantially increased our number of employees over the last year, and we expect to expand our organization as a result of the commercialization of LUMRYZ. As a result, we may experience difficulties in managing this growth, which could disrupt our operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-40-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had 188 full-time employees. Our full-time employee base increased substantially in 2024 to advance the commercialization of LUMRYZ in the U.S. Our management may need to divert a disproportionate amount of its attention away from our day-to-day activities and devote a substantial amount of time to managing these growth activities. We may not be able to effectively manage the expansion of our operations, which may result in weaknesses in our infrastructure, operational mistakes, loss of business opportunities, loss of employees and reduced productivity among remaining employees. Our growth could require significant capital expenditures and may divert financial resources from other projects, such as the development of additional product candidates. If our management is unable to effectively manage our growth, our expenses may increase more than expected, our ability to recognize and/or grow revenues could be reduced and we may not be able to execute our business strategy. Our future financial performance and our ability to commercialize LUMRYZ and compete effectively will depend, in part, on our ability to effectively manage any future growth.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third parties to conduct our clinical trials, and if they do not properly and successfully perform their contractual, legal and regulatory duties, we may not be able to obtain regulatory approvals for or commercialize any future product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely on CROs and other third parties to assist us in designing, managing, monitoring and otherwise carrying out our clinical trials, including with respect to site selection, contract negotiation and data management. We do not control these third parties and, as a result, they may not treat our clinical trials as a high priority, which could result in delays. We are responsible for confirming that each of our clinical trials is conducted in accordance with its general investigational plan and protocol, as well as the FDA&#8217;s and foreign regulatory agencies&#8217; requirements, commonly referred to as good clinical practices, for conducting, recording and reporting the results of clinical trials to ensure that the data and results are credible and accurate and that the trial participants are adequately protected. The FDA and foreign regulatory agencies enforce good clinical practices through periodic inspections of trial sponsors, principal investigators and trial sites. If we, CROs or other third parties assisting us or our trial sites fail to comply with applicable good clinical practices, the clinical data generated in our clinical trials may be deemed unreliable, and the FDA or its non-U.S. counterparts may require us to perform additional clinical trials before approving our marketing applications. We cannot assure you that, upon inspection, the FDA or foreign regulatory agencies will determine that any of our clinical trials comply with good clinical practices. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If third parties do not successfully carry out their duties under their agreements with us, if the quality or accuracy of the data they obtain is compromised due to failure to adhere to our clinical protocols, including dosing requirements, or regulatory requirements, or if they otherwise fail to comply with clinical trial protocols or meet expected deadlines, our clinical trials may not meet regulatory requirements. If our clinical trials do not meet regulatory requirements or if these third parties need to be replaced, our clinical trials may be extended, delayed, suspended or terminated. If any of these events occur, we may not be able to obtain regulatory approval of any future product candidates or succeed in our efforts to create approved line extensions for certain of our existing products or generate additional useful clinical data in support of these products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we or our partners fail to comply with these laws and regulations, the FDA, or other foreign regulatory agencies, may take actions that could significantly restrict or prohibit commercial distribution of LUMRYZ or the clinical development of any future product candidates. If the FDA or other foreign regulatory authorities determine we are not in compliance with these laws and regulations, they could, among other things:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issue warning letters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">impose fines;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">seize products or request or order recalls;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">issue injunctions to stop future sales of products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">refuse to permit products to be imported into, or exported out of a particular country;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">suspend or limit our production;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdraw or vary approval of marketing applications;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdraw approval of marketing applications; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">initiate criminal prosecutions. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may rely on collaborations with third parties to commercialize LUMRYZ and any future products. Such strategy involves risks that could impair our prospects for realizing profits from such products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that commercialization of LUMRYZ and any future products outside of the U.S. may require collaboration with third-party partners involving strategic alliances, licenses, product divestitures or other arrangements. We may not be successful in entering into such collaborations on favorable terms, if at all, or our collaboration partners may not adequately perform under </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-41-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">such arrangements, and as a result our ability to commercialize these products will be negatively affected and our prospects will be impaired.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face significant competition in seeking appropriate collaborators. Whether we reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator&#8217;s own evaluation of a potential collaboration. Such factors a potential collaborator will use to evaluate a collaboration may include the design or results of clinical trials, the likelihood of final approval by foreign regulatory authorities, the potential market for LUMRYZ or any future products, the potential of competing products, the existence of uncertainty with respect to our ownership of our intellectual property, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative products, product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for LUMRYZ or any future product or product candidates. The terms of any additional collaborations or other arrangements that we may establish may not be favorable to us.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also be restricted under collaboration agreements from entering into future agreements on certain terms with potential collaborators. Collaborations are complex and time-consuming to negotiate and document. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate additional collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of any future product candidates for which we are seeking to collaborate, reduce or delay its development program, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to develop future drug candidates, commercialize LUMRYZ outside of the U.S. or bring any future products to market and generate product revenue.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any future collaborations we enter into may not be successful. The success of our collaboration arrangements will depend heavily on the efforts and activities of our collaborators. Collaborators generally have significant discretion in determining the efforts and resources they will apply to these collaborations. Disagreements between parties to a collaboration arrangement regarding clinical development and commercialization matters can lead to delays in the product development process or commercializing the applicable product and, in some cases, termination of the collaboration arrangement. These disagreements can be difficult to resolve if neither party has final decision-making authority. Collaborations with pharmaceutical or biotechnology companies and other third parties often are terminated or allowed to expire by the other party. Any such termination or expiration would adversely affect us financially and could harm our business reputation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we cannot adequately protect our intellectual property and proprietary information, we may be unable to effectively compete.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our success depends, in part, on our ability to obtain and enforce patents and other intellectual property rights for LUMRYZ, as well as future products, product candidates and technology (including our drug delivery technologies) and to preserve our trade secrets and other proprietary information. If we cannot do so, our competitors may exploit our technologies and deprive us of the ability to realize revenues and profits from our LUMRYZ, future products and product candidates, and technologies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent our product and any future products and product candidates may benefit from protections afforded by patents, we face the risk that patent law relating to the scope of claims in the pharmaceutical and biotechnology fields is continually evolving and can be the subject of uncertainty and may change in a way that would limit protection. If challenged, a court or other body may determine that our patents may not be valid or enforceable. For example, our patents may not protect us against challenges by companies that submit drug marketing applications to the FDA, or the competent authorities of EU Member States or other jurisdictions in which we may attempt to compete, in particular, where such applications rely, at least in part, on safety and efficacy data from our product or any future product or product candidate. In addition, competitors may obtain patents that may have an adverse effect on our ability to conduct business, or they may discover ways to circumvent our patents. The scope of any patent protection may not be sufficiently broad to cover our product or any future product or product </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-42-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">candidate, or to exclude competing products. Any patent applications we have made or may make relating to our potential products or technologies may not result in patents being issued. Even after issuance, our patents may be challenged in the courts or patent offices in the U.S. and elsewhere. Such challenges may result in loss of exclusivity or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical product candidates, or limit the duration of the patent protection of LUMRYZ or a future product or product candidate. Further, patent protection once obtained is limited in time, after which competitors may use the claimed invention without obtaining a license from us. Because of the time required to obtain regulatory marketing approval, the remaining period of effective patent protection for a marketed product is frequently substantially shorter than the full duration of the patent. While a patent term extension can be requested under certain circumstances, the grant of such a request is not guaranteed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our partnerships with third parties expose us to risks that they will claim intellectual property rights on our inventions or fail to keep our unpatented inventions and proprietary information confidential.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, the value of our technology could be materially adversely affected and our business would be harmed.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trademarks, copyrights, trade secrets and know-how to develop, maintain and strengthen our competitive position.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We rely, in part, on confidentiality agreements with our employees, suppliers, consultants, advisors and partners to protect trade secrets, know-how and proprietary information related to, for example, current and future products, product candidates, and manufacturing processes. These agreements may not provide adequate protection for our trade secrets, know-how and other proprietary information in the event of any unauthorized use or disclosure, or if others lawfully develop the information. If these agreements are breached, we cannot be certain we will have adequate remedies. Further, we cannot guarantee that third parties will not know, discover or independently develop equivalent trade secrets, know-how or other proprietary information, or that they will not gain access to our trade secrets, know-how or other proprietary information or disclose same to the public. Therefore, we cannot guarantee we can maintain and protect our trade secrets, know-how and other proprietary information. Misappropriation or other loss of our intellectual property would adversely affect our competitive position and may cause us to incur substantial litigation or other costs.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we and our partners do not adequately protect the trademarks and trade names for our current and future products, then we and our partners may not be able to build name recognition in our markets of interest and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our competitors or other third parties may challenge, infringe or circumvent the trademarks or trade names for our current and future products. We and our partners may not be able to protect these trademarks and trade names. In addition, if the trademark or trade name for a product infringes the valid rights of others, we or our partners may be forced to stop using the trademark or trade name, which we need for name recognition in our markets of interest. If we cannot establish name recognition based on our trademarks and trade names, we and our partners may not be able to compete effectively, and our business may be adversely affected.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. or ex-U.S. patent laws could diminish the value of patents in general, thereby impairing our ability to protect current and future products.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in either the patent laws or interpretation thereof in the U.S. or in ex-U.S. jurisdictions could increase uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. For example, the Leahy-Smith America Invents Act of 2011 (&#8220;AIA&#8221;), changed the previous U.S. &#8220;first-to-invent&#8221; system to the current system that awards a patent to the &#8220;first-inventor-to-file&#8221; for an application for a patentable invention. This change alters the pool of available materials that can be used to challenge patents in the U.S. and limits the ability to rely on prior research to lay claim to patent rights. Under the current system, disputes are resolved through new derivation proceedings, and the AIA includes mechanisms to allow challenges to issued patents in reexamination, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> review and post grant proceedings. The AIA also includes bases and procedures that may make it easier for competitors to challenge our patents, which could result in increased competition and have a material adverse effect on our business and results of operations. The AIA may also make it harder to challenge third-party patents and place greater importance on being the first inventor to file a patent application on an invention. The AIA amendments to patent filing and litigation procedures in the U.S. may result in litigation being more complex and expensive and divert the efforts of our technical and management personnel.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-43-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the patent positions of companies in the development and commercialization of pharmaceuticals may be particularly uncertain. Depending on future actions by the U.S. Congress, the U.S. federal courts, and the USPTO, or by similarly legislative, judicial, and regulatory authorities in other jurisdictions, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Third parties may claim that our current or future product infringes their rights, and we may incur significant costs resolving these claims. Additionally, legal proceedings related to such claims could materially delay or otherwise adversely affect commercialization plans related to such product. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third parties may claim infringement of their patents and other intellectual property rights by the manufacture, use, import, offer for sale or sale of a commercial product. Further, in connection with us seeking regulatory approval for a product candidate, a third party may allege that our product candidate infringes its patents or other intellectual property rights and file suit to delay/prevent regulatory approval and/or commercialization of such product. In response to any claim of infringement, we may choose or be forced to seek licenses, defend infringement actions or challenge the validity or enforceability of those patent rights in court or administrative proceedings. If we cannot obtain required licenses on commercially reasonably terms, or at all, are found liable for infringement or are not able to have such patent rights declared invalid or unenforceable, our business could be materially harmed. We may be subject to claims (and even held liable) for significant monetary damages (including enhanced damages and/or attorneys&#8217; fees), encounter significant delays in bringing products to market or be precluded from the manufacture, use, import, offer for sale or sale of products or methods of drug delivery covered by the patents of others. Even if a license is available, it may not be available on commercially reasonable terms or may be non-exclusive, which could result in our competitors gaining access to the same intellectual property. We may not have identified, or be able to identify in the future, U.S. or non-U.S. patents that pose a risk of potential infringement claims.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition to potential future claims of infringement, we may experience delays in obtaining marketing approvals for additional indications for LUMRYZ or otherwise be delayed in marketing LUMRYZ for such other indications as a result of an ongoing injunction based on a prior claim of infringement. For example, on August 27, 2024, the United States District Court for the District of Delaware granted an injunction to prevent LUMRYZ from being approved or marketed for IH or other indications beyond those it has already received approval for. The injunction is currently set to expire in February 2036. While we have appealed that injunction, we may not prevail in that appeal. Accordingly, we may invest a significant amount of time and expense in preparing to seek approval for LUMRYZ in IH or other candidate indications only to be subject to significant delay or even additional patent litigation before such candidate indications may be approved or commercialized, if at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the possibility of intellectual property infringement claims, a third party could submit a citizen&#8217;s petition to the FDA requesting relief that, if granted, could materially adversely affect the NDA and/or underlying product candidate. For example, such a third-party petition could, if granted, materially adversely affect the likelihood and/or timing of NDA approval, content of final product labeling, and/or resulting regulatory exclusivity (if any) for such product.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties making claims against us may be able to sustain the costs of patent litigation more effectively than we can because they have substantially greater resources. In addition, any claims, with or without merit, that our product, future products or future product candidates infringe proprietary rights of third parties could be time-consuming, result in costly litigation or divert the efforts of our technical and management personnel, any of which could disrupt our relationships with our partners and could significantly harm our financial positions and operating results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">An NDA submitted under Section 505(b)(2) subjects us to the risk that we may be subject to a patent infringement lawsuit that would delay or prevent the review or approval of any future product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Section 505(b)(2) permits the submission of an NDA where at least some of the information required for approval comes from preclinical studies or clinical trials that were not conducted by, or for, the applicant and for which the applicant has not obtained a right of reference. A 505(b)(2) NDA enables the applicant to reference published literature for which the applicant does not have a right of reference and the FDA&#8217;s previous findings of safety and effectiveness for a previously approved drug.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For 505(b)(2) NDAs, the patent certification and related provisions of the Hatch-Waxman Amendments apply. Accordingly, if the applicant relies for approval on the safety or effectiveness information for a previously approved drug, referred to as a listed drug, the applicant is required to include patent certifications in its 505(b)(2) NDA regarding any applicable patents covering the listed drug. If there are applicable patents listed in the FDA publication Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book, for the listed drug, and the applicant seeks to obtain approval prior to the expiration of one or more of those patents, the applicant may submit a Paragraph IV certification indicating its </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-44-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">belief that the relevant patents are invalid or unenforceable or will not be infringed by the manufacture, import, use, offer for sale or sale of the product that is the subject of the 505(b)(2) application. Otherwise, the 505(b)(2) NDA cannot be approved by the FDA until the expiration of any patents listed in the Orange Book for the listed drug. There can be no assurance that we will not be required to submit a Paragraph IV certification in respect of any future product candidates for which we seek approval under Section 505(b)(2).</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following any Paragraph IV certification, an applicant will be required to provide notice of that certification to the NDA holder and patent owner. Under the Hatch-Waxman Amendments, the patent owner may file a patent infringement lawsuit after receiving such notice. If a patent infringement lawsuit is filed within 45 days of the patent owner&#8217;s or NDA holder&#8217;s receipt of notice (whichever is later), a one-time, automatic stay of the FDA&#8217;s ability to approve the 505(b)(2) NDA is triggered, which typically extends for 30 months unless patent litigation is resolved in favor of the Paragraph IV filer, the patent is removed from FDA&#8217;s Orange Book or the patent expires before that time. Accordingly, we may invest a significant amount of time and expense in the development of one or more product candidates only to be subject to significant delay and patent litigation before such product candidates, if approved, may be commercialized, if at all.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, a 505(b)(2) NDA will not be approved until any applicable non-patent exclusivity listed in the Orange Book for the listed drug, or for any other drug with the same protected conditions of approval as our product, has expired. The FDA also may require us to perform one or more additional clinical trials or measurements to support the change from the listed drug, which could be time consuming and could substantially delay our achievement of regulatory approval. The FDA also may reject any future 505(b)(2) NDAs and require us to submit traditional NDAs under Section 505(b)(1), which would require extensive data to establish safety and effectiveness of the product for the proposed use and could cause delay and additional costs. In addition, the FDA could reject any future 505(b)(2) application and require us to submit a Section 505(b)(1) NDA or a Section 505(j) ANDA if, before the submission of our 505(b)(2) application, the FDA approves an application for a product that is pharmaceutically equivalent to ours and determines that our product is inappropriate for review through the 505(b)(2) pathway. These factors, among others, may limit our ability to commercialize any future product candidates, if approved, successfully. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we or our partners are required to obtain licenses from third parties, our revenues and royalties on any future commercialized products could be reduced.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The development of certain products based on our drug delivery technologies may require the use of raw materials (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proprietary excipient), active ingredients, drugs (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">e.g.,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> proprietary proteins) or technologies developed by third parties. The extent to which efforts by other researchers have resulted or will result in patents and the extent to which we or our partners are forced to obtain licenses from others, if available, on commercially reasonable terms is currently unknown. If we or our partners must obtain licenses from third parties, fees may be required for such licenses, which could reduce the net revenues and royalties we receive on any future commercialized products that incorporate our drug delivery technologies.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patent terms may be inadequate to protect the competitive position of our product or any future products for an adequate amount of time.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patents have a limited lifespan. In the U.S., if all maintenance fees are timely paid, the natural expiration of a utility patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product or any future products are obtained, once the patent life has expired, we may be open to competition from competitive products, including generics or biosimilars. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates, if approved, are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees, renewal fees, annuity fees and various other governmental fees on patents and/or applications will be due to be paid to the USPTO and various governmental patent agencies outside of the U.S. in several stages over the lifetime of the patents and/or applications. We rely on our outside counsel to coordinate payment of these fees due to patent agencies. The USPTO and various non-U.S. governmental patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. We employ reputable law firms and other professionals to help us comply, and in many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. However, there are situations in which non-compliance can result in </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-45-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, our competitors might be able to enter the market and this circumstance would have a material adverse effect on our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be able to protect our intellectual property rights throughout the world.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents on our product and any future products and product candidates in all countries throughout the world would be prohibitively expensive, and intellectual property rights in some countries outside the U.S. can be less extensive than those in the U.S. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the U.S., or from selling or importing products made using our inventions in and into the U.S. or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the U.S. These products may compete with our product and any future products, and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many companies have encountered significant problems in protecting and defending intellectual property rights in non-U.S. jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, which could make it difficult for us to stop infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in non-U.S. jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property we develop or license.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Risks Related to Our Business and Industry</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business could be adversely affected by the effects of health epidemics, in regions where we or third parties on which we rely have significant manufacturing facilities, concentrations of potential clinical trial sites or other business operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health epidemics in regions where we have concentrations of potential clinical trial sites or other business operations could adversely affect our business, including by causing significant disruption in the operations of third parties upon whom we rely. For example, the COVID-19 pandemic presented a substantial public health and economic challenge around the world and affected employees, patients, communities and business operations, as well as the economy and financial markets. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health epidemics could continue to produce significant and prolonged disruption of, or volatility in, global financial markets, reducing our ability to access capital, which could in the future negatively affect our liquidity. In addition, to the extent the lingering effects of the COVID-19 pandemic adversely affect our business and results of operations, it may also have the effect of heightening many of the other risks and uncertainties described elsewhere in this &#8220;Risk Factors&#8221; section.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">We are currently operating in a period of political and economic uncertainty and capital markets disruption, which has been significantly impacted by geopolitical instability, ongoing military conflicts, including the conflict between Russia and Ukraine and the conflict in Israel, and high inflation and rising interest rates, any of which could have a material adverse effect on our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">U.S. and global markets are experiencing volatility and disruption caused by political and economic uncertainty, including as a result of the ongoing Russia-Ukraine conflict and the effects of sanctions imposed on Russia as a result of the conflict, as well as the recent conflict in Israel and the Gaza Strip. In February 2022, a full-scale military invasion of Ukraine by Russian troops began. Although the length and impact of the ongoing military conflict is highly unpredictable, the conflict in Ukraine has led to market disruptions, including significant volatility in commodity prices, credit and capital markets, as well as supply chain interruptions, which has contributed to record inflation globally. In addition, global markets may experience additional disruptions as a result of the current armed conflict in Israel and the Gaza Strip, with Israel having declared war on Hamas, a U.S. designated Foreign Terrorist Organization, due to recent attacks. Furthermore, President Trump&#8217;s administration is expected to advocate for new policies, legislative changes, and administrative actions that could have additional impacts on our business. We are continuing to monitor inflation, the situations in Ukraine and Israel and global capital markets and assessing their potential impact on our business, including the impact on the supply chains we rely on for the manufacture of LUMRYZ or other future product candidates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-46-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although, to date, our business has not been materially impacted by the events described above, geopolitical tensions, or record inflation, it is impossible to predict the extent to which our operations will be impacted in the short and long term, or the ways in which such matters may impact our business. The extent and duration of the conflicts in Ukraine and Israel, geopolitical tensions, record inflation and resulting market disruptions are impossible to predict but could be substantial. Any such disruptions may also magnify the impact of other risks we face.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We operate globally and, if approved, we may sell our products in countries throughout the world. Significant political, trade, or regulatory developments in the jurisdictions in which we may sell our products, such as those stemming from the change in U.S. federal administration, are difficult to predict and may have a material adverse effect on us. Similarly, changes in U.S. federal policy that affect the geopolitical landscape could give rise to circumstances outside our control that could have negative impacts on our business operations. For example, on February 1, 2025, the U.S. imposed a 25% tariff on imports from Canada and Mexico, which were subsequently suspended for a period of one month, and a 10% additional tariff on imports from China. Historically, tariffs have led to increased political and trade tensions.  In response to tariffs, other countries have implemented retaliatory tariffs on U.S. goods. Political tensions as a result of trade policies could reduce trade volume, investment, technological exchange and other economic activities between major international economies, resulting in a material adverse effect on global economic conditions and the stability of global financial markets. Any changes in political, trade, regulatory, and economic conditions, including U.S. trade policies, could have a material adverse effect on our financial condition or results of operations.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Litigation and Legal Matters</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our patents or other intellectual property. If we were to initiate legal proceedings against a third party to enforce a patent covering our product or any future product or product candidate, the defendant could counterclaim that the patent is invalid and/or unenforceable. In patent litigation in the U.S., defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO or made a misleading statement during prosecution. There is risk that a court could rule in favor of the defendant with respect to such a counterclaim of patent invalidity and/or unenforceability.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Interference or derivation proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms or at all, or if a non-exclusive license is offered and our competitors gain access to the same technology. Our defense of litigation or interference or derivation proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise the funds necessary to continue our clinical trials, continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help us bring future product candidates, if approved, to market.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the substantial amount of discovery that can occur in connection with intellectual property-related litigation and/or administrative proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation/proceeding. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ or may employ individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we endeavor to ensure that our employees, consultants and independent contractors do not use the proprietary information or know-how of others in their work for us, we may be </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-47-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed intellectual property, including trade secrets or other proprietary information, of any of our employee&#8217;s former employer or other third parties. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying any awarded monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and/or be a distraction to management and other employees.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We and companies to which we have licensed or will license any future products or technologies and subcontractors we engage or may engage for services related to the development and manufacturing of our product or any future product candidates are subject to extensive regulation by the FDA and other regulatory authorities. Our and their failure to meet strict regulatory requirements could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, and companies to which we may license any future product or technologies, as well as companies acting as subcontractors for our product developments, including but not limited to non-clinical, pre-clinical and clinical studies, and manufacturing, are subject to extensive regulation by the FDA, other U.S. authorities and equivalent non-U.S. regulatory authorities, particularly the European Commission and the competent authorities of EU Member States. Those regulatory authorities may conduct periodic audits or inspections of the applicable facilities to monitor compliance with regulatory standards, and we remain responsible for the compliance of our subcontractors. If the FDA or another regulatory authority finds failure to comply with applicable regulations, the authority may institute a wide variety of enforcement actions, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">warning letters or untitled letters;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">fines and civil penalties;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">delays in clearing or approving, or refusal to clear or approve, products;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">withdrawal, suspension or variation of approval of products; product recall or seizure;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">orders to the competent authorities of EU Member States to withdraw or vary national authorization;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">orders for physician notification or device repair, replacement or refund;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">interruption of production;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">operating restrictions;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">injunctions; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;padding-left:14.5pt">criminal prosecution.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any adverse action by a competent regulatory agency could lead to unanticipated expenditures to address or defend such action and may impair our ability to produce and market applicable products, which could significantly impact our revenues and royalties that we would be eligible to receive from our potential customers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may face product liability claims related to our product or future products, or claims related to clinical trials for any future product candidates.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The testing, including through clinical trials, manufacturing and marketing, and the use of our product and any future products and product candidates may expose us to potential product liability and other claims. If any such claims against us are successful, we may be required to make significant compensation payments. Any indemnification that we have obtained, or may obtain, from CROs or pharmaceutical and biotechnology companies or hospitals conducting human clinical trials on our behalf may not protect us from product liability claims or from the costs of related litigation. Insurance coverage is expensive and difficult to obtain, and we may be unable to obtain coverage in the future on acceptable terms, if at all. We currently maintain general liability insurance and product liability insurance. We cannot be certain that the coverage limits of our insurance policies or those of our strategic partners will be adequate. If we are unable to obtain sufficient insurance at an acceptable cost, a product liability claim or recall could adversely affect our financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, any indemnification we have obtained, or may obtain, from pharmaceutical and biotechnology companies with whom we are manufacturing our current product or developing, or will develop, any future products may not protect us from product liability claims from the consumers of those products or from the costs of related litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we use hazardous biological and/or chemical materials in a manner that causes injury, we may be liable for significant damages.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our research, development and manufacturing activities involve the controlled use of potentially harmful biological and/or chemical materials, and are subject to U.S., EU, state, national and local laws and regulations governing the use, storage, handling and disposal of those materials and specified waste products. We cannot completely eliminate the risk of accidental </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-48-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">contamination or injury from the use, storage, handling or disposal of these materials, including fires and/or explosions, storage tank leaks and ruptures and discharges or releases of toxic or hazardous substances. These operating risks can cause personal injury, property damage and environmental contamination, and may result in the shutdown of affected facilities and the imposition of civil or criminal penalties. The occurrence of any of these events may significantly reduce the productivity and profitability of a particular manufacturing facility and adversely affect our operating results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently maintain property, business interruption and casualty insurance with limits that we believe to be commercially reasonable but may be inadequate to cover any actual liability or damages.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Ownership of Our Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our ordinary shares has been volatile and may continue to be volatile.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading price of our ordinary shares has been, and is likely to continue to be, highly volatile. The market value of an investment in ordinary shares may fall sharply at any time due to this volatility. During the year ended December&#160;31, 2024, the closing sale price of ordinary shares as reported on the Nasdaq Global Market ranged from </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.94 to $18.82. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2023, the closing sale price of ordinary shares as reported on the Nasdaq Global Market ranged from $6.41 to $16.48. The market prices for securities of drug delivery, specialty pharma, biotechnology and pharmaceutical companies historically have been highly volatile. Factors that could adversely affect our share price include, among others:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fluctuations in our operating results;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our LUMRYZ sales and anticipated product revenue;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of competitive products or technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">announcements of technological partnerships, innovations or new products by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actions with respect to the acquisition of new or complementary businesses;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">governmental regulations;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments in patent or other proprietary rights owned by us or others;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">public concern as to the safety of drug delivery technologies developed by us or drugs developed by others using our technologies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of pre-clinical testing and clinical studies or trials by us or our competitors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adverse events related to LUMRYZ or any future products or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">lack of efficacy of LUMRYZ or any future products or product candidates;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">litigation;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perception by the market of specialty pharma, biotechnology, and high technology companies generally; </span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general market conditions, including the impact of the current financial environment; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the dilutive impact of any new equity or convertible debt securities we may issue or have issued.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we pay dividends, the dividends may be subject to Irish dividend withholding tax.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In certain circumstances, as an Irish tax resident company, we may be required to deduct Irish dividend withholding tax (currently at the rate of 25%) from dividends paid to our shareholders. Shareholders who are resident in the U.S., EU countries (other than Ireland) or other countries with which Ireland has signed a tax treaty (whether the treaty has been ratified or not) generally should not be subject to Irish dividend withholding tax so long as the shareholder (a) where the shareholder is a body corporate, is not under the control of persons resident in Ireland and (b) has provided its broker, for onward transmission to our qualifying intermediary or other designated agent (in the case of shares held beneficially), or us or our transfer agent (in the case of shares held directly), with all the necessary documentation by the appropriate due date prior to payment of the dividend. However, some shareholders may be subject to dividend withholding tax, which could adversely affect the price of ordinary shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Risk Factors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions of our articles of association could delay or prevent a third-party&#8217;s effort to acquire us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our articles of association could delay, defer or prevent a third-party from acquiring us, even where such a transaction would be beneficial to the holders of our ordinary shares, or could otherwise adversely affect the price of our ordinary shares. For example, certain provisions of our articles of association:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-49-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">permit our Board of Directors to issue preferred shares with such rights and preferences as they may designate, subject to applicable law;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impose advance notice requirements for shareholder proposals and director nominations to be considered at annual shareholder meetings; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of a supermajority of the voting power of our shares entitled to vote at a general meeting of shareholders to amend or repeal any provisions of our articles of association.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe these provisions, if implemented in compliance with applicable law, may provide some protection to holders of our ordinary shares from coercive or otherwise unfair takeover tactics. These provisions are not intended to make us immune from takeovers. They will, however, apply even if some holders of our ordinary shares consider an offer to be beneficial and could delay or prevent an acquisition that our Board of Directors determines is in the best interest of the holders of our ordinary shares. Certain of these provisions may also prevent or discourage attempts to remove and replace incumbent directors.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, mandatory provisions of Irish law could prevent or delay an acquisition of the Company by a third party. For example, Irish law does not permit shareholders of an Irish public limited company to take action by written consent with less than unanimous consent. In addition, an effort to acquire us may be subject to various provisions of Irish law relating to mandatory bids, voluntary bids, requirements to make a cash offer and minimum price requirements, as well as substantial acquisition rules and rules requiring the disclosure of interests in our ordinary shares in certain circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These provisions may discourage potential takeover attempts or bids for our ordinary shares at a premium over the market price or they may adversely affect the market price of, and the voting and other rights of the holders of, our ordinary shares. These provisions could also discourage proxy contests and make it more difficult for holders of our ordinary shares to elect directors other than the candidates nominated by our Board of Directors and could depress affect the market price of our ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Irish law differs from the laws in effect in the U.S. and might afford less protection to the holders of our ordinary shares and any actual or potential takeover offer for the Company will be subject to Irish Takeover Rules.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Holders of our ordinary shares could have more difficulty protecting their interests than would the shareholders of a corporation incorporated in a jurisdiction of the U.S.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As an Irish-incorporated company, we are governed by Irish law, including the Irish Companies Act 2014 and the Irish Takeover Rules, which differs in some significant, and possibly material, respects from provisions set forth in various U.S. state laws applicable to U.S. corporations and their shareholders, including provisions relating to interested directors, mergers and acquisitions, takeovers, shareholder lawsuits and indemnification of directors. The duties of directors and officers of an Irish company are generally owed to the company only. Therefore, under Irish law shareholders of Irish companies do not generally have a right to commence a legal action against directors or officers and may only do so in limited circumstances. Directors of an Irish company must act with due care and skill, honestly and in good faith with a view to the best interests of the company. Directors must not put themselves in a position in which their duties to the company and their personal interests conflict and must disclose any personal interest in any contract or arrangement with the company or any of our subsidiaries. A director or officer can be held personally liable to the company in respect of a breach of duty to the company. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It may not be possible to enforce court judgments obtained in the U.S. against us in Ireland based on the civil liability provisions of U.S. federal or state securities laws. In addition, there is some uncertainty as to whether the courts of Ireland would recognize or enforce judgments of U.S. courts obtained against us or our directors or officers based on the civil liabilities provisions of U.S. federal or state securities laws or hear actions against us or those persons based on those laws. We have been advised that the U.S. currently does not have a treaty with Ireland providing for the reciprocal recognition and enforcement of judgments in civil and commercial matters. Therefore, a final judgment for the payment of money rendered by any U.S. federal or state court based on civil liability, whether or not based solely on U.S. federal or state securities laws, would not automatically be enforceable in Ireland. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, any actual or potential takeover offer for our company will be subject to the Irish Takeover Rules. Under the Irish Takeover Rules, during the course of an offer or at any earlier time during which our Board has reason to believe that an offer for our company may be imminent, the Board will not be permitted to take any action, other than seeking alternative offers, which might frustrate the making of an offer for our ordinary shares unless we obtain approval from our shareholders or from the Irish Takeover Panel for such action. Potentially frustrating actions that are prohibited during the course of an offer, or at any earlier time during which our Board has reason to believe an offer is or may be imminent, include (i) the issuance of shares, options or convertible securities or the redemption or purchase of own shares, (ii) material acquisitions or disposals, (iii) entering into contracts other than in the ordinary course of business or (iv) any action, other than seeking alternative offers, which may result in frustration of an offer. Accordingly, if these restrictions become applicable to us, we may be unable to take, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-50-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or may be delayed in taking, certain actions, in connection with a financing, commercial or strategic transaction or otherwise, that we believe are in the best interest of the Company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments of U.S. courts, including those predicated on the civil liability provisions of the federal securities laws of the U.S., may not be enforceable in Irish courts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An investor in the U.S. may find it difficult to:</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effect service of process within the U.S. against us and our non-U.S. resident directors and officers;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">enforce U.S. court judgments based upon the civil liability provisions of the U.S. federal securities laws against us and our non-U.S. resident directors and officers in Ireland; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">bring an original action in an Irish court to enforce liabilities based upon the U.S. federal securities laws against us and our non-U.S. resident directors and officers.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Judgments of U.S. courts, including those predicated on the civil liability provisions of the federal securities laws of the U.S., may not be enforceable in Cayman Islands courts.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been advised by our Cayman Islands legal counsel, Maples and Calder, that the courts of the Cayman Islands are unlikely (i) to recognize or enforce against us judgments of courts of the U.S. predicated upon the civil liability provisions of the securities laws of the U.S. or any State; and (ii) in original actions brought in the Cayman Islands, to impose liabilities against us predicated upon the civil liability provisions of the securities laws of the U.S. or any State, so far as the liabilities imposed by those provisions are penal in nature. In those circumstances, although there is no statutory enforcement in the Cayman Islands of judgments obtained in the U.S., the courts of the Cayman Islands will recognize and enforce a foreign money judgment of a foreign court of competent jurisdiction without retrial on the merits based on the principle that a judgment of a competent foreign court imposes upon the judgment debtor an obligation to pay the sum for which judgment has been given provided certain conditions are met. For a foreign judgment to be enforced in the Cayman Islands, such judgment must be final and conclusive and for a liquidated sum, and must not be in respect of taxes or a fine or penalty, inconsistent with a Cayman Islands judgment in respect of the same matter, impeachable on the grounds of fraud or obtained in a manner, and or be of a kind the enforcement of which is, contrary to natural justice or the public policy of the Cayman Islands (awards of punitive or multiple damages may well be held to be contrary to public policy). A Cayman Islands Court may stay enforcement proceedings if concurrent proceedings are being brought elsewhere.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Security incidents and other disruptions could compromise confidential information, expose us to liability and cause our business and reputation to suffer.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the ordinary course of our business, we collect and store on our networks various intellectual property including our proprietary business information and that of customers, suppliers and business partners. The secure maintenance and transmission of this information is critical to our operations and business strategy. Despite our security measures, we, like other companies in our industry, may experience threats to our information systems and infrastructure. These threats may include computer hacking, phishing attacks, ransomware, dissemination of computer viruses, worms and other destructive or disruptive software, attacks by hackers due to employee error, malfeasance or other disruptions. Any such incident could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, investigations by regulatory authorities in the U.S. and EU Member States, disruption to our operations and damage to our reputation, any of which could adversely affect our business.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We could suffer financial loss or the loss of valuable confidential information. Although we develop and maintain systems and controls designed to prevent these events from occurring and we have a process to identify and mitigate threats, the development and maintenance of these systems, controls and processes is costly and requires ongoing monitoring and updating as technologies change and efforts to overcome security measures become increasingly sophisticated. Moreover, despite our efforts, the possibility of these events occurring cannot be eliminated entirely and there can be no assurance that any measures we take will prevent cyber-attacks, information security incidents, or data breaches that could adversely affect our business. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have broad discretion in the use of our cash and may not use it effectively.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management has broad discretion in the use of our cash and may not apply our cash in ways that ultimately increases the value of any investment in our securities. We currently intend to use our cash to fund commercialization activities for LUMRYZ, to fund clinical trials for product candidates, to fund research and development activities for potential new product candidates, and for working capital, capital expenditures and general corporate purposes. As in the past, we expect to invest our excess cash in available-for-sale marketable securities, including corporate bonds, U.S. government securities, other fixed </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-51-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income securities and equities; and these investments may not yield a favorable return. If we do not invest or apply our cash effectively, our financial position and the price of our ordinary shares may decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently do not intend to pay dividends and cannot assure the holders of our ordinary shares that we will make dividend payments in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid a cash dividend on any of our ordinary shares and do not anticipate declaring cash dividends in the foreseeable future. Declaration of dividends will be at the sole discretion of our Board of Directors and depend upon, among other things, future earnings, if any, the operating and financial condition of our business, our capital requirements, general business conditions and such other factors as our Board of Directors deems relevant.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our effective tax rate could be highly volatile and could adversely affect our operating results.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our future effective tax rate may be adversely affected by a number of factors, many of which are outside of our control, including:</span></div><div><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the jurisdictions in which profits are determined to be earned and taxed;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the valuation of our deferred tax assets and liabilities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in share-based compensation expense;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in domestic or international tax laws or the interpretation of such tax laws;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in available tax credits;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">adjustments to estimated taxes upon finalization of various tax returns; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the resolution of issues arising from tax audits with various tax authorities.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any significant increase in our future effective tax rates could impact our results of operations for future periods adversely.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax law could adversely affect our business and financial condition.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to income and other taxes in the U.S. and foreign jurisdictions. Changes to applicable U.S. or foreign tax laws and regulations, or their interpretation and application (which changes may have retroactive application), including with respect to net operating losses and research and development tax credits, could adversely affect us or holders of our ordinary shares. In recent years, many such changes have been made and changes are likely to continue to occur in the future. Future changes in tax laws could have a material adverse effect on our business, cash flow, financial condition or results of operations. We urge investors to consult with their legal and tax advisors regarding the implications of potential changes in tax laws on an investment in our ordinary shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Our ability to use our net operating loss carryforwards and certain other tax attributes may be limited</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had $227,344 of net operating losses in the U.S. Of the $227,344 of net operating losses in the U.S., $10,365 were acquired due to the acquisition of FSC Therapeutics and FSC Laboratories, Inc., (collectively &#8220;FSC&#8221;) and $212,637 are due to the losses at Avadel US Holdings, Inc. The portion due to the acquisition of FSC will expire in 2034 through 2035 and may not be fully utilized before they expire. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under U.S. federal tax legislation enacted in 2017, informally titled the Tax Cuts and Jobs Act (&#8220;Tax Act&#8221;), U.S. federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such U.S. federal net operating losses is limited. Under Sections 382 and 383 of the U.S. Internal Revenue Code of 1986 (the &#8220;Code&#8221;) if a corporation undergoes an &#8220;ownership change&#8221; (generally defined as a greater than 50 percentage-point cumulative change (by value) in the equity ownership of certain shareholders over a rolling three-year period), the corporation&#8217;s ability to use its pre-change net operating losses and other pre-change tax attributes to offset its post-change taxable income or taxes may be limited. We may also experience ownership changes as a result of this offering or future issuances of our stock or as a result of subsequent shifts in our stock ownership, some of which are outside our control. We have completed an analysis to determine that no events have triggered an ownership change in the past. If any ownership changes are determined to be triggered in the future, our ability to use our current net operating losses to offset post-change taxable income or taxes would be subject to limitation. We will be unable to use our net operating losses if we do not attain profitability sufficient to offset our available net operating losses prior to their expiration.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-52-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, we had approximately $71,588 of net operating losses in Ireland that do not have an expiration date. While these losses do not have an expiration date, substantial changes in the activities performed in these jurisdictions could have an impact on our ability to utilize these tax attributes in the future.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">U.S. Holders of our ordinary shares may suffer adverse U.S. tax consequences if we are classified as a passive foreign investment company.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, if, for any taxable year, at least 75% of our gross income is passive income, or at least 50% of the value of our assets is attributable to assets that produce passive income or are held for the production of passive income, including cash, we would be characterized as a passive foreign investment company (&#8220;PFIC&#8221;) for U.S. federal income tax purposes. For purposes of these tests, passive income includes dividends, interest, and gains from the sale or exchange of investment property, rents, and royalties other than rents and royalties that are received from unrelated parties in connection with the active conduct of a trade or business. Our status as a PFIC depends on the composition of our income and the composition and value of our assets (for which purpose the total value of our assets may be determined in part by the market value of our ordinary shares, which are subject to change) from time to time. If we are characterized as a PFIC, U.S. Holders (as defined below under &#8220;Material U.S. Federal Income Tax Considerations for U.S. Holders&#8221;) of our ordinary shares may suffer materially adverse tax consequences, including having gains realized on the sale of our ordinary shares treated as ordinary income, rather than capital gain, the loss of the preferential rate applicable to dividends received on our ordinary shares by individuals who are U.S. Holders, and having interest charges apply to distributions by us and the proceeds of sales of our ordinary shares. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we were not a PFIC for the taxable year ending December&#160;31, 2024 and, based on the expected value of our assets, including any goodwill, and the expected nature and composition of our income and assets, we expect that we will not be a PFIC for our current taxable year. However, our status as a PFIC is a fact-intensive determination subject to various uncertainties, and we cannot provide any assurances regarding our PFIC status for the current, prior or future taxable years.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Certain U.S. Holders that own 10 percent or more of the vote or value of our ordinary shares may suffer adverse U.S. tax consequences because our non-U.S. subsidiaries are expected to be classified as controlled foreign corporations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Each &#8216;&#8216;Ten Percent Shareholder&#8217;&#8217; (as defined below) in a non-U.S. corporation that is classified as a &#8216;&#8216;controlled foreign corporation&#8217;&#8217; (a &#8220;CFC&#8221;), for U.S. federal income tax purposes generally is required to include in income for U.S. federal tax purposes such Ten Percent Shareholder&#8217;s pro rata share of the CFC&#8217;s &#8216;&#8216;Subpart F income&#8217;&#8217; and investment of earnings in U.S. property, even if the CFC has made no distributions to its shareholders. Subpart F income generally includes dividends, interest, rents, royalties, &#8216;&#8216;global intangible low-taxed income,&#8217;&#8217; gains from the sale of securities and income from certain transactions with related parties. In addition, a Ten Percent Shareholder that realizes gain from the sale or exchange of shares in a CFC may be required to classify a portion of such gain as dividend income rather than capital gain. A non-U.S. corporation generally will be classified as a CFC for U.S. federal income tax purposes if Ten Percent Shareholders own, directly or indirectly, more than 50% of either the total combined voting power of all classes of stock of such corporation entitled to vote or of the total value of the stock of such corporation. A &#8216;&#8216;Ten Percent Shareholder&#8217;&#8217; is a U.S. person (as defined by the Code) who owns or is considered to own 10% or more of the total combined voting power of all classes of stock entitled to vote or 10% or more of the total value of all classes of stock of such corporation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that we were not a CFC in the 2024 taxable year, but that our non-U.S. subsidiaries were CFCs in the 2024 taxable year. We anticipate that our non-U.S. subsidiaries will remain CFCs in the 2024 taxable year, and it is possible that we may become a CFC in the 2025 taxable year or in a subsequent taxable year. The determination of CFC status is complex and includes attribution rules, the application of which is not entirely certain. U.S. Holders should consult their own tax advisors with respect to the potential adverse U.S. tax consequences of becoming a Ten Percent Shareholder in a CFC, including the possibility and consequences of becoming a Ten Percent Shareholder in one or more of our non-U.S. subsidiaries that are anticipated to be treated as CFCs. If we are classified as both a CFC and a PFIC, we generally will not be treated as a PFIC with respect to those U.S. Holders that meet the definition of a Ten Percent Shareholder during the period in which we are a CFC, subject to certain exceptions.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">We incur significant costs as a result of operating as a public company, and our management is required to devote substantial time to compliance requirements, including establishing and maintaining internal controls over financial reporting. We may be exposed to potential risks if we are unable to comply with requirements to maintain internal controls over financial reporting or if we identify material weaknesses. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, publicly listed in the U.S., we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended (the "Exchange Act") and the listing rules of the Nasdaq Stock Market ("Nasdaq"), and incur significant legal, </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-53-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">accounting and other expenses to comply with applicable requirements. These rules impose various requirements on public companies, including requiring certain corporate governance practices. Our management and other personnel devote a substantial amount of time to these requirements. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, the Sarbanes-Oxley Act of 2002 (the "Sarbanes-Oxley Act") requires, among other things, that we maintain effective internal controls for financial reporting and disclosure controls and procedures. In particular, we must perform system and process evaluations and testing of our internal controls over financial reporting to allow management to report on the effectiveness of our internal controls over financial reporting, as required by Section 404 of the Sarbanes-Oxley Act. Such compliance may require that we incur substantial accounting expenses and expend significant management efforts. </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple error or mistake. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Sales of a substantial number our ordinary shares by us or existing security holders in the public market could cause our share price to fall.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Sales of a substantial number of our ordinary shares by us or existing security holders in the public market or the perception that these sales might occur could depress the market price and could impair our ability to raise capital through the sale of additional equity securities. We are unable to predict the effect that such sales may have on the prevailing market price of our ordinary shares. In addition, the sale of substantial amounts of our ordinary shares could adversely impact its price. As of February&#160;26, 2025, we had outstanding 96,629 ordinary shares, options to purchase 11,795 ordinary shares, with an average exercise price of $8.52 and unsettled restricted shares relating to 133 ordinary shares. The sale or the availability for sale of a large number of our ordinary shares in the public market could cause the market price of our ordinary shares to decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we expect we will need to raise additional capital to fund our future activities, we may in the future sell substantial amounts of our ordinary shares or securities convertible into or exchangeable for ordinary shares.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock relies in part on the research and reports that industry or financial analysts publish about us or our business. We do not have control over these analysts. There can be no assurance that existing analysts will continue to provide research coverage or that new analysts will begin to provide research coverage. Although we have obtained analyst coverage, if one or more of the analysts covering our business downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock, we could lose visibility in the market for our stock, which in turn could cause our stock price to decline.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">A transfer of ordinary shares may be subject to Irish stamp duty.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transfers of ordinary shares could be subject to Irish stamp duty (currently at the rate of 1% of the higher of the price paid or the market value of the shares acquired). Payment of Irish stamp duty is generally a legal obligation of the transferee. The potential for stamp duty to arise on transfers of ordinary shares could adversely affect the price of our ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our business is subject to evolving corporate governance and public disclosure regulations and expectations with respect to environmental, social and governance ("ESG") matters, that could expose us to numerous risks.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">We are subject to the evolving rules and regulations with respect to ESG matters of a number of governmental and self-regulatory bodies and organizations, such as the SEC, NASDAQ, the EU, and the Irish and other governments and regulatory </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-54-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">authorities, that could make compliance more difficult and uncertain. In addition, regulators, customers, investors, employees and other stakeholders are increasingly focused on ESG matters and related disclosures. These changing rules, regulations and stakeholder expectations have resulted in, and are likely to continue to result in, increased general and administrative expenses and increased management time and attention to comply with or meet those regulations and expectations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">Developing and acting on ESG initiatives and collecting, measuring and reporting ESG-related information and metrics can be costly, difficult and time consuming. Further, ESG-related information is subject to evolving reporting standards including the SEC's proposed climate-related reporting requirements, the EU Corporate Sustainability Reporting Directive, and the EU Corporate Sustainability Due Diligence Directive. Our ESG initiatives and goals could be difficult and expensive to implement, and we could be criticized for the accuracy, adequacy, consistency or completeness of our ESG disclosures. Further, statements about our ESG-related initiatives and goals, and progress against those goals, may be based on standards for measuring progress that are still developing, internal controls and processes that continue to evolve and assumptions that are subject to change in the future. In addition, we could be criticized for the scope or nature of such initiatives or goals, or for any revisions to these goals. If our ESG-related data, processes and reporting are incomplete or inaccurate, or if we fail to achieve progress with respect to our ESG goals on a timely basis, or at all, our reputation and financial results could be adversely affected, and we could be exposed to litigation.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:107%">Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:107%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Various macroeconomic factors could adversely affect our business and the results of our operations and financial condition, including changes in inflation, interest rates and overall economic conditions and uncertainties such as those resulting from the current and future conditions in the global financial markets. Recent supply chain constraints have led to higher inflation, which if sustained could have a negative impact on any future product candidate development, commercialization activities for LUMRYZ and any future products, and operations. If inflation or other factors were to significantly increase our business costs, our ability to develop our current pipeline and new therapeutic products may be negatively affected. Interest rates, the liquidity of the credit markets and the volatility of the capital markets could also affect the operation of our business and our ability to raise capital on favorable terms, or at all, in order to fund our operations. Similarly, these macroeconomic factors could affect the ability of our third-party suppliers and manufacturers to manufacture clinical trial and commercial materials.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Adverse developments affecting the financial services industry, such as actual events or concerns involving liquidity, defaults, or non-performance by financial institutions or transactional counterparties, could adversely affect the Company&#8217;s current and projected business operations and its financial condition and results of operations.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Actual events involving limited liquidity, defaults, non-performance or other adverse developments that affect financial institutions, transactional counterparties or other companies in the financial services industry or the financial services industry generally, or concerns or rumors about any events of these kinds or other similar risks, have in the past and may in the future lead to market-wide liquidity problems.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Although we assess our banking and customer relationships as we believe necessary or appropriate, our access to funding sources and other credit arrangements in amounts adequate to finance or capitalize our current and projected future business operations could be significantly impaired by factors that affect the Company, the financial institutions with which the Company has credit agreements or arrangements directly, or the financial services industry or economy in general.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">These factors could include, among others, events such as liquidity constraints or failures, the ability to perform obligations under various types of financial, credit or liquidity agreements or arrangements, disruptions or instability in the financial services industry or financial markets generally, or concerns or negative expectations about the prospects for companies in the financial services industry.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The results of events or concerns that involve one or more of these factors could include a variety of material and adverse impacts on our current and projected business operations and our financial condition and results of operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, investor concerns regarding the U.S. or international financial systems could result in less favorable commercial financing terms, including higher interest rates or costs and tighter financial and operating covenants, or systemic limitations on access to credit and liquidity sources, thereby making it more difficult for us to acquire financing on acceptable terms or at all.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%">  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any decline in available funding or access to our cash and liquidity resources could, among other risks, adversely impact our ability to meet our operating expenses, financial obligations or fulfill our other obligations, result in breaches of our financial and/or contractual obligations or result in violations of federal or state wage and hour laws.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-55-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_25"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B.&#160;&#160;&#160;&#160;Unresolved Staff Comments.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_28"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C.&#160;&#160;&#160;&#160;Cybersecurity.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cybersecurity Risk Management and Strategy</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-37" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-36" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">At Avadel, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards.</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cybersecurity policies and procedures as part of our overall risk management process. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-39">We leverage the support of third-party information technology and security providers</ix:nonNumeric>, including for periodic security testing and risk assessments which are designed to identify, assess, and manage cybersecurity risks. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40">We perform cybersecurity risk analyses of select third-party service providers and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents.</ix:nonNumeric></span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-41">We did not experience any material cybersecurity threats or incidents for the year ended December&#160;31, 2024</ix:nonNumeric>.</span></div></ix:nonNumeric><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Governance Related to Cybersecurity Risk</span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-43" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-42" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-44">Senior Director of Information Technology (&#8220;IT&#8221;)</ix:nonNumeric>, who reports to the Chief Financial Officer,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is responsible for the strategic leadership and direction of the Company&#8217;s cybersecurity program. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-45" escape="true">The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-46" escape="true">As part of the Company&#8217;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-47" escape="true">The <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-48" escape="true">Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.</ix:nonNumeric></ix:nonNumeric></span></div></ix:nonNumeric></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-49" escape="true">The audit committee of our <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-50">Board of Directors</ix:nonNumeric> has responsibility for oversight of the Company&#8217;s cybersecurity risk management and receives cybersecurity updates from management at regularly scheduled meetings.</ix:nonNumeric> </span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_31"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Properties.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have commercial and administrative activities located in Chesterfield, Missouri. In January 2025, our lease expired which consisted of 24,236 square feet of office space. Effective February 2025, we decreased our office space to consist of 17,065 square feet, and the amended lease expires in January 2029. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations&#8221; in Part II, Item 7 of this Annual Report on Form 10-K for more information regarding our investment activities and principal capital expenditures over the last two years.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_34"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Legal Proceedings.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information regarding legal proceedings we are involved in, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13: Contingent Liabilities and Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_37"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Mine Safety Disclosures.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-56-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_40"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PART II</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_43"></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;5.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock Data (per share):</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal trading market for our ordinary shares is the Nasdaq Global Market under the symbol &#8220;AVDL&#8221;. There is no foreign trading market for our ordinary shares or any other equity security issued by us.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;26, 2025, there were 96,629 ordinary shares outstanding, and our closing stock price was $7.97 per share.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of February&#160;26, 2025, there were 130 holders of record of our ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dividends</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid a cash dividend on any of our shares and do not anticipate declaring cash dividends in the foreseeable future.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by Item 5 of Form 10-K regarding equity compensation plans is incorporated herein by reference to Item 12 of Part III of this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Issuer Purchases of Equity Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not repurchase any of our equity securities during the year ended December&#160;31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Recent Sales of Unregistered Securities</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Irish taxes applicable to U.S. holders</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The following is a general summary of the main Irish tax considerations applicable to the purchase, ownership and disposition of our ordinary shares by U.S. holders. It is based on existing Irish law and practices in effect on February 28, 2025,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">and on correspondence with the Irish Revenue Commissioners. Legislative, administrative or judicial changes may modify the tax consequences described below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The statements do not constitute tax advice and are intended only as a general guide. Furthermore, this information applies only to our ordinary shares held as capital assets and does not apply to all categories of shareholders, such as dealers in securities, trustees, insurance companies, collective investment schemes and shareholders who acquire, or who are deemed to acquire, their ordinary shares by virtue of an office or employment. This summary is not exhaustive and shareholders should consult their own tax advisers as to the tax consequences in Ireland, or other relevant jurisdictions where we operate, including the acquisition, ownership and disposition of ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Withholding tax on dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">While we have no current plans to pay dividends, dividends on our ordinary shares would generally be subject to Irish dividend withholding tax (&#8220;DWT&#8221;) at 25%, unless an exemption applies. In advance of payment of any dividends, we intend to seek confirmation from the Irish Revenue Commissioners that dividends on our ordinary shares that are owned by residents of the U.S. and held beneficially through the Depositary Trust Company (&#8220;DTC&#8221;) would not be expected to be subject to DWT provided that the address of the beneficial owner of the ordinary shares in the records of the broker is in the U.S.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Dividends on our ordinary shares that are owned by residents of the U.S. and held directly (outside of DTC) will not be subject to DWT provided that the shareholder (a) where the shareholder is a body corporate, is not under the control of persons resident</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-57-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in Ireland and (b) has completed the appropriate Irish DWT form and this form remains valid. Such shareholders must provide the appropriate Irish DWT form to our transfer agent at least seven business days before the record date for the first dividend payment to which they are entitled.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any shareholder who is resident in the U.S. receives a dividend subject to DWT, he or she should generally be able to make an application for a refund from the Irish Revenue Commissioners on the prescribed form.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Income tax on dividends</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Irish income tax, if any, may arise in respect of dividends paid by us. However, a shareholder who is neither resident nor ordinarily resident in Ireland and who is entitled to an exemption from DWT, generally has no liability for Irish income tax or to the universal social charge on a dividend from us, unless he or she holds his or her ordinary shares through a branch or agency in Ireland which carries out a trade on his or her behalf.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Irish tax on capital gains</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A shareholder who is neither resident nor ordinarily resident in Ireland and does not hold our ordinary shares in connection with a trade or business carried on by such shareholder in Ireland through a branch or agency, should not be within the scope of the charge to Irish tax on capital gains on a disposal of our ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A shareholder who is an individual and who is temporarily not resident in Ireland may, under Irish anti-avoidance legislation, still be liable for Irish tax on capital gains on any chargeable gain realized upon the disposal of our ordinary shares during the period in which such individual is a non-resident.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Capital acquisitions tax</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Irish capital acquisitions tax (&#8220;CAT&#8221;) is comprised principally of gift tax and inheritance tax. CAT could apply to a gift or inheritance of our ordinary shares irrespective of the place of residence, ordinary residence or domicile of the parties. This is because our ordinary shares are regarded as property situated in Ireland as our share register must be held in Ireland. The person who receives the gift or inheritance has primary liability for CAT.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">CAT is levied at a rate of 33% above certain tax&#8209;free thresholds. The appropriate tax&#8209;free threshold is dependent upon (i) the relationship between the donor and the recipient, and (ii) the aggregation of the values of previous gifts and inheritances received by the recipient from persons within the same category of relationship for CAT purposes. Gifts and inheritances passing between spouses are exempt from CAT. Prior to October 2, 2024, children had a tax-free threshold of &#8364;335,000 in respect of taxable gifts or inheritances received from their parents. This threshold has been increased in respect of gifts or inheritances received by children from their parents on or after October 2, 2024. As such, children have a tax-free threshold of &#8364;400,000 in respect of taxable gifts or inheritances received from their parents on or after October 2, 2024. Our shareholders should consult their own tax advisers as to whether CAT is creditable or deductible in computing any domestic tax liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Stamp duty</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Irish stamp duty may become payable in respect of ordinary share transfers. However, a transfer of our ordinary shares from a seller who holds shares through DTC to a buyer who holds the acquired shares through DTC should not be subject to Irish stamp duty. A transfer of our ordinary shares (i) by a seller who holds ordinary shares outside of DTC to any buyer, or (ii) by a seller who holds the ordinary shares through DTC to a buyer who holds the acquired ordinary shares outside of DTC, may be subject to Irish stamp duty, which is currently at the rate of 1% of the price paid or the market value of the ordinary shares acquired, if greater. The person accountable for payment of stamp duty is generally the buyer or, in the case of a transfer by way of a gift or for less than market value, all parties to the transfer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A shareholder who holds ordinary shares outside of DTC may transfer those ordinary shares into DTC without giving rise to Irish stamp duty provided that the shareholder would be the beneficial owner of the related book&#8209;entry interest in those ordinary shares recorded in the systems of DTC, and in exactly the same proportions, as a result of the transfer and at the time of the transfer into DTC there is no sale of those book&#8209;entry interests to a third party being contemplated by the shareholder. Similarly, a shareholder who holds ordinary shares through DTC may transfer those ordinary shares out of DTC without giving rise to Irish stamp duty provided that the shareholder would be the beneficial owner of the ordinary shares, and in exactly the same proportions, as a result of the transfer, and at the time of the transfer out of DTC there is no sale of those ordinary shares to a third party being contemplated by the shareholder. In order for the share registrar to be satisfied as to the application of this Irish stamp duty treatment where relevant, the shareholder must confirm to us that the shareholder would be the beneficial owner of the related book&#8209;entry interest in those ordinary shares recorded in the systems of DTC, and in exactly the same </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-58-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">proportions or vice&#8209;versa, as a result of the transfer and there is no agreement for the sale of the related book&#8209;entry interest or the ordinary shares or an interest in the ordinary shares, as the case may be, by the shareholder to a third party being contemplated.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Performance Graph</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following graph compares the cumulative 5-year return provided to shareholders of Avadel&#8217;s ordinary shares relative to the cumulative total returns of the Nasdaq Composite Index and the Nasdaq Biotechnology Index. We believe these indices are the most appropriate indices against which the total shareholder return of Avadel should be measured. The Nasdaq Biotechnology Index has been selected because it is an index of U.S. quoted biotechnology and pharmaceutical companies. An investment of $100 (with reinvestment of all dividends) is assumed to have been made in our ordinary shares and in each of the indexes on January 1, 2020 and our relative performance is tracked through December&#160;31, 2024. The comparisons shown in the graph are based upon historical data and we caution that the stock price performance shown in the graph is not indicative of, or intended to forecast, the potential future performance of our stock.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><img src="avdl-20241231_g1.jpg" alt="Picture1.jpg" style="height:383px;margin-bottom:5pt;vertical-align:text-bottom;width:684px"/></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This performance graph shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Exchange Act. Notwithstanding any statement to the contrary set forth in any of our filings under the Securities Act or the Exchange Act that might incorporate future filings, including this Annual Report on Form 10-K, in whole or in part, this performance graph shall not be incorporated by reference into any such filings except as may be expressly set forth by specific reference in any such filing.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_46"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Reserved.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:9pt;text-align:justify;text-indent:-9pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-59-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_49"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_52"></div><div style="margin-bottom:9pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">You should read the discussion and analysis of our financial condition and results of operations set forth in this Item 7 together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties, and reference is made to the &#8220;Cautionary Disclosure Regarding Forward-Looking Statements&#8221; set forth immediately following the Table of Contents of this Annual Report on Form 10-K for further information on the forward looking statements herein. In addition, you should read the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis and elsewhere in this Annual Report on Form 10-K.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#212529;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Information pertaining to fiscal year 2022 was included in the Company&#8217;s Annual Report on Form 10-K for the year ended December&#160;31, 2023, on pages 62 through 72, under Part II, Item 7, &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; which was filed with the SEC on February 29, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-60-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_55"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Overview</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, LUMRYZ is the only commercial product in our portfolio. We continue to evaluate opportunities to expand our product portfolio</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">LUMRYZ</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ was approved by the FDA on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted seven years of  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">ODE</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> to LUMRYZ for the treatment of cataplexy or EDS in adults with narcolepsy due to a finding of clinical superiority of LUMRYZ relative to currently marketed oxybate treatments. In particular, the FDA found that LUMRYZ makes a major contribution to patient care over currently marketed, twice-nightly oxybate treatments by providing a once-nightly dosing regimen that avoids nocturnal arousal to take a second dose. The ODE will continue until May 1, 2030. In June 2023, we announced the U.S. commercial launch of LUMRYZ for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has required implementation of a REMS to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions.    </span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Numerous LUMRYZ-related U.S. patents have been issued having expiration dates spanning from mid-2037 to early-2042, and there are additional patent applications currently in development and/or pending at the U.S. Patent and Trademark Office (&#8220;USPTO&#8221;), as well as foreign patent offices. We currently have 30 U.S. patents listed for LUMRYZ in FDA&#8217;s Orange Book.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to clinical data generated for LUMRYZ, we conducted a Phase 3 clinical trial of LUMRYZ (the &#8220;REST-ON trial&#8221;), which was a randomized, double-blind, placebo-controlled study that enrolled 212 patients who received at least one dose of LUMRYZ or placebo, and was conducted in clinical sites in the U.S., Canada, Western Europe and Australia. Positive top line data from the REST-ON trial were announced on April 27, 2020. REST-ON trial results have been published by Kushida et al.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, our open-label extension/switch study of LUMRYZ (&#8220;RESTORE&#8221;) examined the long-term safety and maintenance of efficacy of LUMRYZ in patients with narcolepsy who participated in the REST-ON trial, as well as dosing and preference data for patients who switched from twice-nightly sodium oxybate to once-at-bedtime LUMRYZ, regardless of whether they participated in the REST-ON trial. In May 2021, inclusion criteria were expanded to allow for oxybate na&#239;ve patients to enter the study. The last patient visit occurred in October 2023. RESTORE results for the largest cohort, those who switched from twice-nightly oxybates, have been published, which include the 94% preference for the once-nightly dosing regimen that LUMRYZ provides. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe LUMRYZ has the potential to demonstrate improved dosing compliance, safety, and patient satisfaction over other treatment options for cataplexy or EDS in patients seven years of age and older with narcolepsy.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avadel has initiated a pivotal trial in IH, REVITALYZ, which is a double-blind, placebo-controlled, randomized withdrawal, multicenter Phase 3 study designed to evaluate the efficacy and safety of LUMRYZ, in treating IH. We expect to enroll approximately 150 adults in the study who are diagnosed with IH. On July 31, 2024, we announced that the first patient was dosed in this study.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The primary objective of REVITALYZ is to demonstrate reduction in daytime sleepiness as measured by the primary endpoint, change in total score of the Epworth Sleepiness Scale at week 14. Secondary endpoints will evaluate the effect of LUMRYZ on additional efficacy parameters including patient and clinician global impression of change, IH severity, and a measure of the functional outcomes of sleep.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-61-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Key Business Trends and Highlights</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In operating our business and monitoring our performance, we consider a number of performance measures, as well as trends affecting our industry as a whole, which include the following:&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Healthcare and Regulatory Reform:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Various health care reform laws in the U.S. may impact our ability to successfully commercialize our products and technologies. The success of our commercialization efforts may depend on the extent to which the government health administration authorities, the health insurance funds in the E.U. Member States, private health insurers and other third-party payers in the U.S. will reimburse consumers for the cost of healthcare products and services.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Competition and Technological Change: </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competition in the pharmaceutical and biotechnology industry continues to be intense and is expected to increase. We compete with academic laboratories, research institutions, universities, joint ventures, and other pharmaceutical and biotechnology companies, including other companies developing niche branded or generic specialty pharmaceutical products or drug delivery platforms. Furthermore, major technological changes can happen quickly in the pharmaceutical and biotechnology industries. Such rapid technological change, or the development by our competitors of technologically improved or differentiated products, could render our products, product candidates, or drug delivery platforms obsolete or noncompetitive.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Pricing Environment for Pharmaceuticals:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The pricing environment continues to be in the political spotlight in the U.S. As a result, the need to obtain and maintain appropriate pricing for pharmaceutical products may become more challenging due to, among other things, the attention being paid to healthcare cost containment and other austerity measures in the U.S. and worldwide.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.15pt">Generics Playing a Larger Role in Healthcare:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Generic pharmaceutical products will continue to play a large role in the U.S. healthcare system. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ may face competition from manufacturers of generic twice-nightly sodium oxybate formulations. In January 2023, Hikma Pharmaceuticals plc, announced that it launched an authorized generic version of Jazz&#8217;s Xyrem (sodium oxybate). In July 2023, Amneal Pharmaceuticals, Inc. announced that it launched an authorized generic version of Jazz&#8217;s Xyrem (sodium oxybate).</span></div><div style="padding-left:33.75pt;text-indent:-54pt"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Access to and Cost of Capital:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Similar to other businesses in our industry and at our stage of development, we will continue to rely on external sources of capital to fund our business. The process of raising capital and the associated cost of such capital for a company of our financial profile can be difficult and potentially expensive. If the need were to arise to raise additional capital, access to that capital may be difficult, expensive and/or dilutive and, as a result, could create liquidity challenges for us.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Continuing Net Loss from Operations:</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">have a recent history of generating losses from operations and expect to continue generating losses until revenues from the commercialization of LUMRYZ are sufficient to generate positive cash flow. LUMRYZ is the only commercialized product in our portfolio, and we will incur substantial expenses to continue our commercial launch of LUMRYZ. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Highlights of our consolidated results for the year ended December&#160;31, 2024 are as follows:&#160;</span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net product revenue was $169,117 for the year ended December&#160;31, 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compared to net product revenue of $27,963 for the year ended December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. LUMRYZ was approved by the FDA on May 1, 2023 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for the treatment of cataplexy or EDS in adults with narcolepsy and we began shipping product to our customers in June 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Gross profit was $153,840 during the year ended December&#160;31, 2024, compared to gross profit of $27,117 for the year ended December&#160;31, 2023. Cost of products sold increased during the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023, due to higher sales of LUMRYZ and an estimated ongoing royalty on net product revenue in the current period. Prior period cost of products sold included a greater portion of inventory purchased or produced that was expensed as research and development prior to FDA approval.</span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total operating expense was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$196,239</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2024, compared to total operating expense of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$164,966</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2023. Selling, general &amp; administrative expenses increased $29,338 during </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-62-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:33.75pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the year ended December&#160;31, 2024,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> driven by increased headcount and costs associated with the commercial launch of LUMRYZ, offset by lower legal costs. R</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">esearch and development expenses increased $1,935 during the year ended December&#160;31, 2024 </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">due to new clinical work to evaluate the efficacy and safety of LUMRYZ given as a once-at-bedtime dose in IH, offset by lower pre-commercial related expenses for LUMRYZ for the treatment of cataplexy or EDS in adults living with narcolepsy.</span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating loss was </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$42,399</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the year ended December&#160;31, 2024 compared to operating loss of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$137,849</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the same period last year.</span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Diluted net loss per share was $0.51 for the year ended December&#160;31, 2024 compared to diluted net loss per share of $2.00 in the same period last year.</span></div><div style="padding-left:33.75pt;text-align:justify"><span><br/></span></div><div style="padding-left:33.75pt;text-align:justify;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Cash, cash equivalents and marketable securities decreased to $73,777 at December&#160;31, 2024 from $105,111 at December&#160;31, 2023. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The $31,334 decrease in cash, cash equivalents and marketable securities during the year ended December&#160;31, 2024 was driven primarily by net cash used in operating activities of $46,907, offset by net proceeds of $9,250 from the issuance of shares off the at-the-market offering program and $6,720 of proceeds from stock option exercises and employee share purchase plan issuances.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-63-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_58"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Critical Accounting Policies and Estimates</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to use judgment in making estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the periods presented. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have identified certain policies and estimates as critical to our business operations and the understanding of our past or present results of operations. These policies and estimates are considered critical because they had a material impact, or they have the potential to have a material impact, on our consolidated financial statements and because they require us to make significant judgments, assumptions or estimates. We believe that the estimates, judgments and assumptions made when accounting for the items described below were reasonable, based on information available at the time they were made. However, actual results may differ from those estimates, and these differences may be material. For a complete list of significant accounting policies, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 1: Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We sell products to specialty pharmacies and consider those specialty pharmacies to be our customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. Our gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue from product sales are recognized when the customer obtains control of our product and our performance obligations are met, which occurs typically upon receipt of delivery to the customer. As is customary in the pharmaceutical industry, our gross product sales are subject to a variety of price adjustments in arriving at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect our best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Payment Discounts and Specialty Pharmacy Fees</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Payment discounts and specialty pharmacy fees represent the estimated obligations resulting from contractual commitments with our customers. We offer customers discounts off of list price and fees for the distribution of our products. Reserves for these discounts and fees are established in the same period that the related revenue is recognized, resulting in a reduction of gross product sales and accounts receivable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Patient Financial Assistance Programs</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We offer certain patient financial assistance programs. We have multiple programs to assist patients, including patient financial assistance programs. We estimate a reserve for these patient financial assistance programs primarily based on expected utilization by patients. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of gross product sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Rebates</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-64-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rebates and other fees represent the estimated obligations resulting from agreements with payors. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We estimate a reserve for rebates and other fees based on contractual rates and estimates regarding our expectations of future patient utilization rates. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These reserves are established in the same period that the related revenue is recognized, resulting in a reduction of gross product sales.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Returns</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain a returns policy that offers customers a right to return product within a defined period before and after the expiration date of that product. We record the estimate of product returns as a reduction of gross product sales in the period the related product revenue was recognized. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our income tax (benefit) provision, deferred tax assets and liabilities, and liabilities for unrecognized tax benefits reflect management&#8217;s best estimate of current and future taxes to be paid. We are subject to income taxes in Ireland, France and the U.S. Significant judgments and estimates are required in the determination of the consolidated income tax (benefit) provision.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes arise from temporary differences between the tax basis of assets and liabilities and their reported amounts in the financial statements, which will result in taxable or deductible amounts in the future. In evaluating our ability to recover our deferred tax assets in the jurisdiction from which they arise, we consider all available positive and negative evidence, including scheduled reversals of deferred tax liabilities, projected future taxable income or loss, tax-planning strategies, and results of recent operations. The assumptions about future taxable income or loss require the use of significant judgment and are consistent with the plans and estimates we are using to manage the underlying businesses. The Company's cumulative loss position is significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets in 2024. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The calculation of our tax liabilities involves dealing with uncertainties in the application of complex tax laws and regulations in a multitude of jurisdictions across our global operations. A tax benefit from an uncertain tax position may be recognized when it is more likely than not that the position will be sustained upon examination, including resolutions of any related appeals or litigation processes, on the basis of the technical merits.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We record unrecognized tax benefits as liabilities and adjust these liabilities when our judgment changes as a result of the evaluation of new information not previously available. Because of the complexity of some of these uncertainties, the ultimate resolution may result in a payment that is materially different from our current estimate of the unrecognized tax benefit liabilities. These differences will be reflected as increases or decreases to income tax expense in the period in which new information is available.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have not recorded a deferred tax liability for any income or withholding taxes that may arise as the result of the distribution of unremitted earnings within our Company. As of December&#160;31, 2024, we had unremitted earnings of $3,755 outside of Ireland as measured on a U.S. GAAP basis. Based on our estimates that future domestic cash generation will be sufficient to meet future domestic cash needs along with our specific plans for reinvestment, we have not recorded a deferred tax liability for any income or withholding taxes that may arise from a distribution that would qualify as a dividend for tax purposes. It is not practicable to estimate the amount of deferred tax liability on such remittances, if any. We believe that our estimates for deferred income taxes and the amount of benefits recognized for uncertain tax positions are appropriate based on current facts and circumstances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-65-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. We have determined that we operate in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. We elected to make November 30 the annual impairment assessment date for goodwill. However, we could be required to evaluate the recoverability of goodwill outside of the required annual assessment if, among other things, we experience disruptions to the business, unexpected significant declines in operating results, divestiture of a significant component of the business or a sustained decline in market capitalization. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We can test for goodwill impairment by first performing a qualitative assessment to determine whether a quantitative goodwill test is necessary or we can elect to forgo the qualitative assessment and perform the quantitative goodwill test. We elected to perform a qualitative assessment of goodwill in 2024 and 2023. Upon performing the qualitative assessment of goodwill, qualitative factors are assessed to determine whether it is more likely than not that the fair value is less than the carrying amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on the results of the annual qualitative assessment of goodwill for 2024, we concluded it is not more likely than not that the fair value of the reporting unit is less than the carrying amount and therefore, did not perform a quantitative goodwill test or record an impairment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company continuously monitors for events and circumstances that could negatively impact the key assumptions in determining fair value. While the Company believes the judgments and assumptions used in the goodwill impairment assessment are reasonable, different assumptions or changes in general industry or market and macro-economic conditions could change the estimated fair values and, therefore, future impairment charges could be required, which could be material to the consolidated financial statements. </span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-66-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_61"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Results of Operations</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of our financial results (in thousands, except per share amounts):&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.274%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="9" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Comparative Statements of Loss: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,043&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,705&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,338&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">31,273&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,450&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,670.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(944)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,777)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,698&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax benefit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">254&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,832)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,276)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">111,444&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(69.5)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.00)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.49&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:3pt double #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(74.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.274%"/><td style="width:0.1%"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gross Profit:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:5pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,963</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">141,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">504.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 7pt 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,705.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 7pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">126,723&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">467.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit as a percentage of net product revenue</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">91.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">97.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net product revenue was $169,117 during the&#160;year ended&#160;December&#160;31, 2024. LUMRYZ was approved by the FDA on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy and we began shipping product to our customers in June 2023. Cost of products sold increased $14,431 during the&#160;year ended ended&#160;December&#160;31, 2024 as compared to the same period in the prior year. The increase in cost of products sold during the period was due to higher sales of LUMRYZ and an estimated ongoing royalty on net product revenue in the current period. Additionally, prior period cost of products sold included a greater portion of inventory purchased or produced that was expensed as research and development prior to FDA approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="12" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Research and Development Expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,935&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses increased $1,935 or 14.6% during the year ended December&#160;31, 2024 as compared to the same period in 2023. This increase was driven by new clinical work for LUMRYZ in treating IH during the period of $8,200 and higher compensation costs of $1,400 due to increased headcount, offset by lower pre-commercial related expenses for LUMRYZ for the treatment of cataplexy or EDS in adults living with narcolepsy of $7,700.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-67-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Selling, General and Administrative Expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">181,043&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">151,705&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,338&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Selling, general and administrative expenses increased $29,338 or 19.3% during the year ended December&#160;31, 2024 as compared to the same period in 2023. This increase was primarily driven by higher costs associated with the commercial launch of LUMRYZ of $15,400 and higher compensation costs of $15,100 due to increased headcount, offset by lower legal fees of $6,600 and $1,300 of costs related to financing activities incurred in 2023 that did not recur in the current period. The increase in selling, general and administrative expense during the year ended December&#160;31, 2024 also includes $5,500 of nonrecurring fees associated with terminating our ADSs.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.607%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.747%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Investment and other income, net:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,063&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4670.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Investment and other income, net increased $4,063 or 4,670.1% for the year ended December&#160;31, 2024 as compared to the same period in 2023. This increase was driven primarily by higher net realized gains of approximately $3,400.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:46.469%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.271%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.274%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-bottom:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 vs. 2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss on Extinguishment of Debt:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:middle"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,129&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(100.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Over the course of April 3 and April 4, 2023, we completed an exchange of $96,188 of our $117,375 4.50% exchangeable senior notes due October 2023 (the &#8220;October 2023 Notes&#8221;) for $106,268 of a new series of 6.0% exchangeable notes due April 2027 (the &#8220;April 2027 Notes&#8221;). We accounted for the exchange of the October 2023 Notes for the April 2027 Notes as an extinguishment of $96,188 of our October 2023 Notes. We recorded a loss on the extinguishment of $13,129 as a result of the exchange. On June 26, 2023, and in accordance with the terms of the Indenture, the Company completed the Mandatory Exchange of $106,268 of aggregate principal amount of the April 2027 Notes, which represents all of the April 2027 Notes outstanding under the Indenture.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_64"></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Liquidity and Capital Resources&#160;</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Overview of Sources and Uses of Cash</span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue started following the launch of LUMRYZ in June 2023. For the twelve month period ending December 31, 2025, we project that our fixed commitments will include (i) payments on our royalty financing obligation, (ii) capital commitments, and (iii) lease payments. We project that our long-term fixed commitments will include (i) payments on our royalty financing obligation, (ii) capital commitments, and (iii) lease payments. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risk Management&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adequacy of our cash resources depends on the outcome of certain business conditions including the cost of our ongoing LUMRYZ commercialization activities, our cost structure, and other factors set forth in &#8220;Risk Factors&#8221; within Part I, Item 1A of this Annual Report on Form 10-K. We will need to commit substantial resources to support the commercialization of LUMRYZ which could result in future losses or otherwise limit our opportunities or affect our ability to operate our business. Our assumptions concerning the outcome of certain business conditions may prove to be wrong or other factors may adversely affect our business, and as a result we could exhaust or significantly decrease our available cash, cash equivalents and marketable securities balances which could, among other things, force us to raise additional funds and/or force us to reduce our expenses, either of which could have a material adverse effect on our business. Additionally, we are unable to estimate the near or long term impacts of inflation, and rising interest rates, which may have a material adverse impact on our business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-68-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe our existing cash, cash equivalents and marketable securities, along with cash anticipated from sales of LUMRYZ, provides sufficient capital to meet our operating, royalty obligation and capital requirements for the next twelve months following the date of this Annual Report.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Debt Arrangements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2023, we entered into a royalty purchase agreement (&#8220;RPA&#8221;) with RTW Investments, L.P. (&#8220;RTW&#8221;) for up to $75,000 of royalty financing in two tranches. On August 1, 2023, the Company received the first tranche of $30,000. As a result of receiving the first tranche, we are required to make quarterly royalty payments calculated as 3.75% of worldwide net product revenue of LUMRYZ, up to a total payback of $75,000. The Company allowed the second tranche to expire on August 31, 2024 and paid a one-time commitment fee of $2,000 to RTW based on the terms of the RPA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a four year commitment with a CDMO to manufacture the LUMRYZ drug product of approximately $3,000 to $4,200 per year as determined by the terms of the agreement with the CDMO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December 31, 2024, we have leases for office space and a production suite. We have a current obligation of $683 due within one year and a long-term obligation of $1,270 due between January 1, 2026 and December 31, 2028. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 9: Leases </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for further details for further details.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Consolidated Statement of Cash Flows</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash flows from operating, investing and financing activities, as reflected in the consolidated statements of cash flows, are summarized in the following table:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Change</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Cash (Used In) Provided By</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">$</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">%</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating activities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(46,907)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128,511)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">81,604&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(63.5)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51,780&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(50,093)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,873&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(203.4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Financing activities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">135,335&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(119,365)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(88.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities was $46,907 for the year ended December&#160;31, 2024, compared to cash used in operating activities of $128,511 in the prior year. Net cash used in operating activities for the year ended December&#160;31, 2024 was driven by net loss of $48,832 and unfavorable changes in working capital of $20,315, offset by favorable non-cash adjustments of $22,240 comprised primarily of share-based compensation expense. For the year ended December&#160;31, 2023, net cash used in operating activities was driven by net loss of $160,276 and unfavorable changes in working capital of $2,999, offset by favorable non-cash adjustments of  $34,764.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by investing activities was $51,780 for the year ended December&#160;31, 2024 compared to net cash used in investing activities of $50,093 in the prior year. Net cash provided by investing activities for the year ended December&#160;31, 2024 was due to net proceeds received from the excess of sales over purchases of marketable securities of $51,780. Net cash used in investing activities for the year ended December&#160;31, 2023 was due to net purchases of marketable securities over proceeds received from the excess of sales of  $50,093 as a result of investing the proceeds of our financing activities.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-69-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Net cash provided by financing activities for the year ended December&#160;31, 2024 of $15,970 was a result of net proceeds of $9,250 from the issuance of shares from the at-the-market offering program and $6,720 of proceeds from stock option exercises and employee share purchase plan issuances. Net cash provided by financing activities for the year ended December&#160;31, 2023 of $135,335 was a result of net proceeds of $134,151 received in exchange for issuing 12,205 ordinary shares and 4,706 Series B Preferred Shares in the April 3, 2023 public offering, proceeds of $30,000 received for the first tranche of the RPA, net proceeds from the issuance of shares off the at-the-market offering program of $11,913 and $2,293 of proceeds from stock option exercises and employee share purchase plan issuances, offset by settlement of the October 2023 Notes of $21,165, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">settlement of the</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> February 2023 Notes of $17,500 and debt issuance costs of $4,357.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_67"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Matters</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;text-decoration:underline">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to potential liabilities generally incidental to our business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. We accrue for potential liabilities when it is probable that future costs (including legal fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on our consolidated financial position, results of operations, cash flows or liquidity. For information regarding legal proceedings we are involved in</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 13: Contingent Liabilities and Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_70"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;7A.&#160;&#160;&#160;&#160;Quantitative and Qualitative Disclosures About Market Risk.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Interest Rate Risk</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to interest rate risk as a result of our portfolio of marketable securities. The primary objectives of our investment policy are as follows: safety and preservation of principal and diversification of risk; liquidity of investments sufficient to meet cash flow requirements; and competitive yield. Although our investments are subject to market risk, our investment policy specifies credit quality standards for our investments and limits the amount of credit exposure from any single issue, issuer or certain types of investment. Our investment policy allows us to maintain a portfolio of cash equivalents and marketable securities in a variety of instruments, including U.S. federal government and federal agency securities, European Government bonds, corporate bonds or commercial paper issued by U.S. or European corporations, money market instruments, certain qualifying money market mutual funds, certain repurchase agreements, tax-exempt obligations of states, agencies, and municipalities in the U.S. and Europe, and equities.&#160;A hypothetical 50 basis point change in interest rates would not result in a material decrease or increase in the fair value of our securities due to the general short-term nature of our investment portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Foreign Exchange Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to foreign currency exchange risk as the functional currency financial statements of a non-U.S. subsidiary is translated to U.S. dollars. The assets and liabilities of this non-U.S. subsidiary having a functional currency other than the U.S. dollar is translated into U.S. dollars at the exchange rate prevailing at the balance sheet date, and at the average exchange rate for the reporting period for revenue and expense accounts. The cumulative foreign currency translation adjustment is recorded as a component of accumulated other comprehensive loss in shareholders&#8217; equity. The reported results of this non-U.S. subsidiary will be influenced by their translation into U.S. dollars by currency movements against the U.S. dollar. Our primary currency translation exposure is related to one subsidiary that has functional currencies denominated in euro. A 10% strengthening/weakening in the rates used to translate the results of our non-U.S. subsidiaries that have functional currencies denominated in euro as of December&#160;31, 2024 would have had an immaterial impact on net loss for the year ended December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Transactional exposure arises where transactions occur in currencies other than the functional currency. Transactions in foreign currencies are recorded at the exchange rate prevailing at the date of the transaction. The resulting monetary assets and liabilities are translated into the appropriate functional currency at exchange rates prevailing at the balance sheet date and the resulting gains and losses are reported in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investment and other</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income (expense), net</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the consolidated statements of loss.&#160;As of December&#160;31, 2024, our primary exposure is to transaction risk related to euro net monetary assets and liabilities held by </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-70-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">subsidiaries with a U.S. dollar functional currency. Realized and unrealized foreign exchange gains resulting from transactional exposure were immaterial for the year ended December&#160;31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Inflation Risk</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Inflation generally affects us by increasing our costs of labor and supplies and the costs of our third parties we rely on for the development, manufacture and supply of our products. We do not believe that inflation had a material effect on our business, financial condition or results of operations during the year ended December&#160;31, 2024. Although we do not believe that inflation has had a material impact on our financial position or results of operations to date, we may experience some effect in the near future (especially if inflation rates rise) due to an impact on the costs to conduct clinical trials, the costs to commercially launch LUMRYZ, labor costs we incur to attract and retain qualified personnel, and other operational costs. Inflationary costs could adversely affect our business, financial condition and results of operations.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-71-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_73"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;8. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Financial Statements and Supplementary Data.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_76"></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-51">169,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-52">27,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-53">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-54">15,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-55">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-56">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-57">153,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-58">27,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-59">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-60">15,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-61">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-62">20,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-63">181,043</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-64">151,705</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SellingGeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-65">74,516</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Restructuring expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-66">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="3" id="f-67">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:RestructuringCharges" format="ixt:num-dot-decimal" scale="3" id="f-68">3,345</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-69">196,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-70">164,966</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-71">98,561</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-72">42,399</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-73">137,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-74">98,561</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income (expense), net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-75">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-76">87</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-77">536</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-78">10,830</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-79">9,886</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-80">12,342</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-81">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-82">13,129</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-83">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-84">49,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-85">160,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-86">111,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-87">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-88">501</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-89">26,025</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-90">48,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-91">160,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-92">137,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - basic</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-93">0.51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-94">2.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-95">2.29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-96">0.51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-97">2.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-98">2.29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-99">95,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-100">80,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-102">60,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average number of shares outstanding - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-103">95,141</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-104">80,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-105"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-106">60,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-72-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_79"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-107">48,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-108">160,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-109">137,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other comprehensive (loss) income, net of tax:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation (loss) income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-110">623</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-111">331</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" scale="3" id="f-112">597</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income, net of income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-113">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-114">0</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-115">0</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" scale="3" id="f-116">790</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-117">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-118">1,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total other comprehensive (loss) income, net of tax</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-119">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-120">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-121">2,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-122">50,245</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-123">157,102</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-124">139,865</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-73-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_82"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED BALANCE SHEETS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:63.468%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.885%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">ASSETS</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-125">51,371</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" format="ixt:num-dot-decimal" scale="3" id="f-126">31,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-127">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:MarketableSecuritiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-128">73,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-129">34,097</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:num-dot-decimal" scale="3" id="f-130">12,103</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-131">20,298</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-132">10,380</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-133">6,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-134">6,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-135">134,208</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-136">134,202</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Property and equipment, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-137">453</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-138">585</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease right-of-use assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-139">1,702</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseRightOfUseAsset" format="ixt:num-dot-decimal" scale="3" id="f-140">2,591</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Goodwill</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-141">16,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-142">16,836</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-143">11,037</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-144">10,484</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-145">164,236</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="3" id="f-146">164,698</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current portion of operating lease liability</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-147">582</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="f-148">934</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-149">7,328</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccountsPayableCurrent" format="ixt:num-dot-decimal" scale="3" id="f-150">11,433</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-151">40,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-152">24,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-153">273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="f-154">261</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-155">48,834</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-156">36,855</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Long-term operating lease liability</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-157">1,122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OperatingLeaseLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-158">1,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:RoyaltyFinancingLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-159">35,249</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:RoyaltyFinancingLiabilityNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-160">32,760</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other non-current liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-161">5,183</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-162">5,654</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-163">90,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Liabilities" format="ixt:num-dot-decimal" scale="3" id="f-164">76,959</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholders&#8217; equity:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preferred shares, nominal value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-165"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-166">0.01</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-167"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-168">50,000</ix:nonFraction></ix:nonFraction> shares authorized; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="3" id="f-169"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-170">zero</ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-171"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-172">5,194</ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="3" id="f-173">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PreferredStockValue" scale="3" id="f-174">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:17.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ordinary shares, nominal value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-175"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-176">0.01</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-177"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-178">500,000</ix:nonFraction></ix:nonFraction> shares authorized;&#160;<ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-179"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-180">96,518</ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2024 and <ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-181"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-182">89,825</ix:nonFraction></ix:nonFraction> issued and outstanding at December&#160;31, 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-183">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CommonStockValue" scale="3" id="f-184">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional paid-in capital</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-185">891,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AdditionalPaidInCapitalCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-186">855,452</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated deficit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-187">794,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="3" id="f-188">745,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-189">24,580</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" sign="-" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" format="ixt:num-dot-decimal" scale="3" id="f-190">23,167</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-191">73,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-192">87,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total liabilities and shareholders&#8217; equity</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-193">164,236</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-194">164,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:36pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-74-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF SHAREHOLDERS&#8217; EQUITY</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.166%"><tr><td style="width:1.0%"/><td style="width:32.093%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:5.517%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.220%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.883%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.325%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.828%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.325%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:1.0%"/><td style="width:7.835%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Ordinary shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Preferred shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Additional</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Accumulated<br/>other<br/>comprehensive</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Total<br/>shareholders&#8217;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">paid-in capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">deficit</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">loss</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">equity (deficit)</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-195">58,620</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-196">586</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-197">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-198">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-199">549,349</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-200">447,756</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-201">23,940</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-202">78,244</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-203">137,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-204">137,464</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-205">2,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-206">2,401</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Change in fair value of October 2023 Notes conversion feature</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-207">5,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" format="ixt:num-dot-decimal" scale="3" id="f-208">5,508</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under at-the-market offering program, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-209">3,588</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-210">36</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-211">25,282</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-212">25,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-213">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-214">45</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-215">451</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-216">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-217">2,456</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-218">2,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="f-219">144</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-220">1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueOther" scale="3" id="f-221">1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueOther" format="ixt:fixed-zero" scale="3" id="f-222">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee share purchase plan share issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="3" id="f-223">75</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-224">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-225">221</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-226">222</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-16" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-227">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-228">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-19" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-229">62,878</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-230">628</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-20" decimals="-3" name="us-gaap:SharesOutstanding" scale="3" id="f-231">488</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-232">5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-233">589,783</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-234">585,220</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-235">26,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-236">21,145</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-25" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-237">160,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-238">160,276</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-239">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-240">3,174</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under at-the-market offering program, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-241">1,564</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-242">16</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-243">11,897</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-244">11,913</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-245">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-246">16</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">April 2023 public offering, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-247">12,205</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-248">122</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-249">4,706</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-250">47</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-251">133,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-252">134,151</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Mandatory Exchange of April 2027 Notes, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-253">12,347</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-254">123</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-255">101,689</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-256">101,812</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Settlement of October 2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="3" id="f-257">408</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-258">4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-259">18</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-260">22</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-261">343</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-262">4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-263">2,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-264">2,062</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="f-265">33</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee share purchase plan share issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="3" id="f-266">47</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-267">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-268">230</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-269">231</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-270">15,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-271">15,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-42" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-272">89,825</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-273">898</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-43" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-274">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-43" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-275">52</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-44" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-276">855,452</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-45" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-277">745,496</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-278">23,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-279">87,739</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-280">48,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-281">48,832</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Other comprehensive loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-282">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-283">1,413</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Issuance of common stock under at-the-market offering program, net of issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="3" id="f-284">640</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="3" id="f-285">6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-286">9,244</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" format="ixt:num-dot-decimal" scale="3" id="f-287">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Amortization of deferred issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-288">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="3" id="f-289">3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Conversion of preferred stock into ordinary shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-290">5,194</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-291">52</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-292">5,194</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-53" decimals="-3" sign="-" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="3" id="f-293">52</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" format="ixt:fixed-zero" scale="3" id="f-294">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Exercise of stock options</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-295">735</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="f-296">8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-297">5,351</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" format="ixt:num-dot-decimal" scale="3" id="f-298">5,359</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Vesting of restricted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesOther" scale="3" id="f-299">11</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Employee share purchase plan share issuance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" scale="3" id="f-300">113</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-52" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="f-301">1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-302">1,360</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" format="ixt:num-dot-decimal" scale="3" id="f-303">1,361</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-51" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-304">20,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" format="ixt:num-dot-decimal" scale="3" id="f-305">20,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Balance, December 31, 2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-54" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-306">96,518</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-307">965</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-55" decimals="-3" name="us-gaap:SharesOutstanding" format="ixt:fixed-zero" scale="3" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="3" id="f-309">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-310">891,791</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-311">794,328</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-312">24,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-313">73,848</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-75-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_88"></div><hr style="page-break-after:always"/><div style="min-height:36pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONSOLIDATED STATEMENTS OF CASH FLOWS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:63.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.150%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.011%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.494%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.013%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from operating activities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-314">48,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-315">160,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-316">137,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Adjustments to reconcile net loss to net cash used in operating activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Depreciation and amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-317">2,681</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-318">1,766</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DepreciationAndAmortization" format="ixt:num-dot-decimal" scale="3" id="f-319">1,493</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization of debt discount and debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:fixed-zero" scale="3" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-321">2,796</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AmortizationOfFinancingCostsAndDiscounts" format="ixt:num-dot-decimal" scale="3" id="f-322">6,052</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Changes in deferred taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="f-323">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:fixed-zero" scale="3" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInDeferredIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-325">26,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-326">20,387</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-327">15,811</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensation" format="ixt:num-dot-decimal" scale="3" id="f-328">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-329">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-330">13,129</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-331">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other adjustments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" scale="3" id="f-332">828</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-333">1,262</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherOperatingActivitiesCashFlowStatement" format="ixt:num-dot-decimal" scale="3" id="f-334">2,042</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net changes in assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts receivable</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-335">21,994</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:num-dot-decimal" scale="3" id="f-336">12,103</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsReceivable" format="ixt:fixed-zero" scale="3" id="f-337">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Inventories</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-338">9,219</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:num-dot-decimal" scale="3" id="f-339">9,532</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInInventories" format="ixt:fixed-zero" scale="3" id="f-340">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="f-341">416</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-342">2,155</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" format="ixt:num-dot-decimal" scale="3" id="f-343">30,950</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accounts payable &amp; other current liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-344">4,093</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-345">1,545</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayable" format="ixt:num-dot-decimal" scale="3" id="f-346">3,108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-347">16,424</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-348">16,892</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInAccruedLiabilities" scale="3" id="f-349">227</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 18.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other assets and liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-350">1,849</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-351">2,354</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" format="ixt:num-dot-decimal" scale="3" id="f-352">3,534</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-353">46,907</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-354">128,511</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" format="ixt:num-dot-decimal" scale="3" id="f-355">70,304</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of property and equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-356">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" format="ixt:fixed-zero" scale="3" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="f-358">716</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from sales of marketable securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-359">327,781</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-360">187,136</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" format="ixt:num-dot-decimal" scale="3" id="f-361">83,828</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Purchases of marketable securities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-362">276,001</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-363">237,229</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsToAcquireMarketableSecurities" format="ixt:num-dot-decimal" scale="3" id="f-364">3,414</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by (used in) investing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-365">51,780</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-366">50,093</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" format="ixt:num-dot-decimal" scale="3" id="f-367">79,698</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:6pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from issuance of shares off the at-the-market offering program</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-59" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-368">9,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-369">11,913</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-370">25,318</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from stock option exercises and employee share purchase plan</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-371">6,720</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-372">2,293</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" format="ixt:num-dot-decimal" scale="3" id="f-373">2,682</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from April 2023 public offering, net of issuance costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-374">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-34" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:num-dot-decimal" scale="3" id="f-375">134,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfCommonStock" format="ixt:fixed-zero" scale="3" id="f-376">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for February 2023 Notes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="f-377">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="f-378">17,500</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="f-379">8,653</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for October 2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="f-380">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:num-dot-decimal" scale="3" id="f-381">21,165</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-3" name="us-gaap:RepaymentsOfSeniorDebt" format="ixt:fixed-zero" scale="3" id="f-382">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Payments for debt issuance costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:fixed-zero" scale="3" id="f-383">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-384">4,357</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:PaymentsOfDebtIssuanceCosts" format="ixt:num-dot-decimal" scale="3" id="f-385">4,804</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proceeds from royalty purchase agreement</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-386">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-387">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-388">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net cash provided by financing activities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-389">15,970</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-390">135,335</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" format="ixt:num-dot-decimal" scale="3" id="f-391">14,543</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:12pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of foreign currency exchange rate changes on cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-392">639</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-393">455</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="f-394">664</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net change in cash and cash equivalents</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-395">20,204</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-396">42,814</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" format="ixt:num-dot-decimal" scale="3" id="f-397">23,273</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at January 1</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-398">31,167</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-399">73,981</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-400">50,708</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash and cash equivalents at December 31</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-401">51,371</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-402">31,167</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" format="ixt:num-dot-decimal" scale="3" id="f-403">73,981</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:5pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Supplemental disclosures of cash flow information:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest paid</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-404">7,181</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-405">5,250</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:InterestPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-406">9,660</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income taxes refunded, net</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-407">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" format="ixt:fixed-zero" scale="3" id="f-408">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" format="ixt:num-dot-decimal" scale="3" id="f-409">29,058</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to consolidated financial statements.</span></div><div style="height:31.5pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-76-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_91"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands, except per share data)</span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_94"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 1:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-410" continuedAt="f-410-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span></ix:nonNumeric></div><div><span><br/></span></div><ix:continuation id="f-410-1" continuedAt="f-410-2"><ix:nonNumeric contextRef="c-1" name="avdl:NatureOfBusinessPolicyPolicyTextBlock" id="f-411" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is registered as an Irish public limited company. The Company&#8217;s headquarters are in Dublin, Ireland with operations in Dublin, Ireland and St. Louis, Missouri, United States (&#8220;U.S.&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (&#8220;EDS&#8221;) in patients seven years of age and older with narcolepsy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted Orphan Drug Exclusivity (&#8220;ODE&#8221;) to LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy for a period of seven years until May 1, 2030. In June 2023, the Company commercially launched LUMRYZ in the U.S for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has required implementation of a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, the Company&#8217;s only commercialized product is LUMRYZ. The Company continues to evaluate opportunities to expand its product portfolio.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="avdl:LiquidityAndGoingConcernPolicyTextBlock" id="f-412" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adequacy of the Company&#8217;s cash resources depends on the outcome of certain business conditions including the cost of the Company&#8217;s ongoing LUMRYZ commercialization activities, the Company&#8217;s cost structure, and other factors set forth in &#8220;Risk Factors&#8221; within Part I, Item 1A of this Annual Report on Form 10-K.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-413" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. and the requirements of Form 10-K. The consolidated financial statements include the accounts of the Company and all subsidiaries. All intercompany accounts and transactions have been eliminated.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PriorPeriodReclassificationAdjustmentDescription" id="f-414" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified within the notes to the consolidated financial statements to condense line items of the same nature to conform with the current year presentation.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-415" continuedAt="f-415-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and marketable securities are held at <ix:nonFraction unitRef="institution" contextRef="c-6" decimals="INF" name="avdl:NumberOfFinancialInstitutions" format="ixt-sec:numwordsen" scale="0" id="f-416">three</ix:nonFraction> financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. The Company has not experienced any losses on its cash, cash equivalents, or marketable securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to the sale of LUMRYZ. The Company extends credit to its customers, specialty pharmacies. Customer creditworthiness is monitored, and collateral is not required. Amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible. As of December&#160;31, 2024, the Company did not recognize any allowances for credit </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-77-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-410-2" continuedAt="f-410-3"><ix:continuation id="f-415-1" continuedAt="f-415-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses. As of December&#160;31, 2024, three customers accounted for <ix:nonFraction unitRef="number" contextRef="c-68" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-417">100</ix:nonFraction>% of gross accounts receivable, Caremark LLC (&#8220;Caremark&#8221;), which accounted for <ix:nonFraction unitRef="number" contextRef="c-69" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-418">53</ix:nonFraction>% of gross accounts receivable; Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for <ix:nonFraction unitRef="number" contextRef="c-70" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-419">25</ix:nonFraction>% of gross accounts receivable; and Optum Frontier Therapies LLC (&#8220;Optum&#8221;), which accounted for <ix:nonFraction unitRef="number" contextRef="c-71" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-420">22</ix:nonFraction>% of gross accounts receivable. As of December&#160;31, 2023, three customers accounted for <ix:nonFraction unitRef="number" contextRef="c-72" decimals="INF" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-421">100</ix:nonFraction>% of gross accounts receivable, Caremark, which accounted for <ix:nonFraction unitRef="number" contextRef="c-73" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-422">52</ix:nonFraction>% of gross accounts receivable; Accredo, which accounted for <ix:nonFraction unitRef="number" contextRef="c-74" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-423">28</ix:nonFraction>% of gross accounts receivable; and Optum, which accounted for <ix:nonFraction unitRef="number" contextRef="c-75" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-424">20</ix:nonFraction>% of gross accounts receivable. </span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:continuation id="f-415-2">The Company attempts to maintain multiple suppliers for its active pharmaceutical ingredient (&#8220;API&#8221;) and manufacturing in order to mitigate the risk of shortfall and inability to supply market demand, but is subject to risk due to a limited number of providers. The API is currently manufactured by two outsourced contract development and manufacturing organizations (&#8220;CDMOs&#8221;) in the U.S. The drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRecognitionPolicyTextBlock" id="f-425" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue includes sales of LUMRYZ. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer&#894; (ii) identify the performance obligations in the contract; (iii) determine the transaction price&#894; (iv) allocate the transaction price to the performance obligations in the contract&#894; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#8217;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells LUMRYZ to specialty pharmacies and considers those specialty pharmacies to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. The Company&#8217;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes the cost of the API, manufacturing and distribution costs, packaging costs and freight. LUMRYZ was approved by the FDA on May 1, 2023 and the Company began shipping product to its customers in June 2023. Cost of products sold includes inventory purchased or produced that was expensed as research and development costs prior to FDA approval.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryPolicyTextBlock" id="f-426" continuedAt="f-426-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories consist of raw materials, work in process and finished products, which are stated at lower of cost or net realizable value, using the first-in, first- out method. Raw materials used in the production of pre-clinical and clinical products are expensed as research and development costs. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. </span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-78-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-410-3" continuedAt="f-410-4"><ix:continuation id="f-426-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-427" continuedAt="f-427-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (&#8220;R&amp;D&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of costs related to outside services, personnel expenses, clinical studies and other R&amp;D expenses. Outside services and clinical studies costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third-party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other R&amp;D expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&amp;D expenditures are charged to operations as incurred. Raw materials used in the production of pre-clinical and clinical products are expensed as R&amp;D costs.  &#160;</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-427-1">The Company recognizes refundable R&amp;D tax credits received for spending on innovative R&amp;D as an offset of R&amp;D expenses.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:AdvertisingCostsPolicyTextBlock" id="f-428" continuedAt="f-428-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expenses. </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-428-1">The Company expenses the costs of advertising as incurred.</ix:continuation> Branded advertising expenses were $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-429">12,186</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:num-dot-decimal" scale="3" id="f-430">6,452</ix:nonFraction> for the years ended December&#160;31, 2024 and 2023. Branded advertising expenses were <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AdvertisingExpense" format="ixt:fixed-zero" scale="0" id="f-431">immaterial</ix:nonFraction> for the year ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesPolicyTextBlock" id="f-432" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations, cash flows or liquidity.</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-433" continuedAt="f-433-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation. </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-433-1">The Company accounts for share-based compensation based on the estimated grant-date fair value. The fair value of stock options is estimated using Black-Scholes option-pricing valuation models (&#8220;Black-Scholes model&#8221;). As required by the Black-Scholes model, estimates are made of the underlying volatility of Avadel stock, a risk-free rate and an expected term of the option or warrant. The Company estimates the expected term using a simplified method, as the Company does not have enough historical exercise data for a majority of such options upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-434" continuedAt="f-434-1" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of December&#160;31, 2024, the Company's cumulative loss position was significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-79-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-410-4" continuedAt="f-410-5"><ix:continuation id="f-434-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax expense line in the consolidated statements of loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-435" continuedAt="f-435-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-435-1"> Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.</ix:continuation>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-436" continuedAt="f-436-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are considered to be available for sale and are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in shareholders&#8217; equity, with the exception of unrealized gains and losses on equity instruments and allowances for expected credit losses, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-436-1">For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis.</ix:continuation>  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-437" continuedAt="f-437-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-437-1"> Property and equipment is stated at historical cost less accumulated depreciation.</ix:continuation> <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-438" continuedAt="f-438-1" escape="true">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  </ix:nonNumeric></span></div><ix:continuation id="f-438-1" continuedAt="f-438-2"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:77.639%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.161%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-76" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-439">3</ix:nonNumeric> years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements, furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-77" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-440">2</ix:nonNumeric>-<ix:nonNumeric contextRef="c-78" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:duryear" id="f-441">10</ix:nonNumeric> years</span></div></td></tr></table></div></ix:continuation><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="f-442" continuedAt="f-442-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill.</span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-442-1"> Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable.</ix:continuation> The Company determined that <ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-443"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:GoodwillImpairmentLoss" format="ixt:fixed-zero" scale="0" id="f-444">no</ix:nonFraction></ix:nonFraction> impairment of goodwill existed at December&#160;31, 2024 and 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-445" continuedAt="f-445-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets. </span></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-445-1">Long-lived assets include fixed assets and right of use assets at contract manufacturing organizations. Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset or other market-based value approaches. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. Certain long-lived assets are amortized using the straight-line method over a <ix:nonNumeric contextRef="c-79" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-446">five year</ix:nonNumeric> useful life. Amortization on long-lived assets is considered to be manufacturing overhead costs and is either capitalized into inventory or expensed in the period incurred.</ix:continuation> The Company determined that <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-447"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsHeldForUse" format="ixt:fixed-zero" scale="0" id="f-448">no</ix:nonFraction></ix:nonFraction> impairment of long-lived assets existed at December&#160;31, 2024 and 2023. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-449" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract is a lease at the inception of the arrangement. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. Short term leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease payments are recognized in the consolidated statements of loss on a straight-line basis over the lease term. The Company&#8217;s lease contracts do not provide a readily determinable implicit rate. The Company&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease. The Company&#8217;s lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the consolidated statements of loss.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-80-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-450" continuedAt="f-450-1" escape="true"><ix:continuation id="f-410-5" continuedAt="f-410-6"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span></ix:continuation></ix:nonNumeric><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-450-1"><ix:continuation id="f-410-6">The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. These estimates and assumptions are based on the best information available to management and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company&#8217;s consolidated financial statements. Actual results could differ from those estimates under different assumptions or&#160;conditions.</ix:continuation></ix:continuation>  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_100"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 2: <ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" id="f-451" continuedAt="f-451-1" escape="true">Newly Issued Accounting Standards</ix:nonNumeric></span><ix:continuation id="f-451-1" continuedAt="f-451-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-452" escape="true"><ix:continuation id="f-451-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the provisions of ASU 2023-07 for the annual period beginning on January 1, 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18: Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding segment disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for annual periods beginning after December 15, 2024. Adoption of ASU 2023-09 will not have a material effect on the Company&#8217;s financial position or results of operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 220-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact adopting ASU 2024-03 will have on its financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Issued Climate-Related Disclosure Rule</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) issued a final rule requiring public companies to disclose climate-related information in their registration statements and annual reports. For large accelerated filers, the initial disclosure rules are effective for annual periods for the year ending December 31, 2025. In April 2024, the SEC voluntarily stayed the final rule pending the completion of judicial review by the Court of Appeals for the Eighth Circuit. The Company is monitoring the development of litigation related to the SEC&#8217;s rule, and is currently evaluating the effects of the final rule on its disclosures, processes and procedures.</span></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_103"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> NOTE 3: <ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerTextBlock" id="f-453" continuedAt="f-453-1" escape="true">Revenue Recognition</ix:nonNumeric></span></div><ix:continuation id="f-453-1"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s source of net product revenue during the years</span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists solely of sales of LUMRYZ in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, three customers accounted for <ix:nonFraction unitRef="number" contextRef="c-80" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-454">100</ix:nonFraction>% of sales. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" id="f-455" continuedAt="f-455-1" escape="true">The following table presents a summary of the percentage of total gross sales to customers</ix:nonNumeric></span><ix:continuation id="f-455-1" continuedAt="f-455-2"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></ix:continuation></div><ix:continuation id="f-455-2"><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:53.870%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.683%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:20.687%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales by Customer:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caremark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-81" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-456">44</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-82" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-457">39</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accredo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-83" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-458">37</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-84" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-459">41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-85" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-460">19</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-86" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-461">20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no net product revenue during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_106"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> NOTE 4: <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-462" continuedAt="f-462-1" escape="true">Fair Value Measurements</ix:nonNumeric></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-81-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-462-1"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, the Company uses fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may generally use one or each of the following techniques: &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices for identical assets or liabilities in active markets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that reflect estimates and assumptions. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" id="f-463" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:35.649%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.709%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.714%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 5)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-464">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-465">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-466">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-467">73,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-468">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:fixed-zero" scale="3" id="f-469">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-470">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-471">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-472">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:num-dot-decimal" scale="3" id="f-473">73,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-474">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-98" decimals="-3" name="us-gaap:AssetsFairValueDisclosure" format="ixt:fixed-zero" scale="3" id="f-475">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review of fair value hierarchy classifications is conducted on a quarterly basis.&#160;Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the year ended December&#160;31, 2024, there were no transfers in and out of&#160;Level&#160;1, 2, or 3. During the&#160;years ended December&#160;31, 2024, 2023, and 2022, the Company did not recognize any allowances for credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the consolidated balance sheets at carrying value, which approximates fair value due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Financing Obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the royalty financing obligation under the Royalty Purchase Agreement (&#8220;RPA&#8221;) approximated its fair value and was measured using the estimates of forecasted net product revenue based on current contractual and statutory requirements, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns (Level 3 inputs). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10: Royalty Financing Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the Company&#8217;s royalty financing obligation.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_109"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> NOTE 5:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock" id="f-476" continuedAt="f-476-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities&#160;</span></ix:nonNumeric></div><ix:continuation id="f-476-1" continuedAt="f-476-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in available-for-sale debt securities that are recorded at fair market value. The change in the fair value of available-for-sale debt investments is recorded as accumulated other comprehensive loss in shareholders&#8217; equity, net of </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-82-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-476-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax effects. As of December&#160;31, 2024 and 2023, the Company considered any decreases in fair value on its marketable securities to be driven by factors other than credit risk, including market risk.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-477" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s available-for-sale securities&#8217; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-478">22,242</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-479">164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-480">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-481">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-482">22,242</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-483">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-484">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-485">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:44.861%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.675%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.678%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-486">72,990</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-487">954</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-488">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-489">73,944</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" format="ixt:num-dot-decimal" scale="3" id="f-490">72,990</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="f-491">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="3" id="f-492">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-493">73,944</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines realized gains or losses on the sale of marketable securities on a specific identification method. The Company reflects these gains and losses as a component of investment and other income (expense), net in the accompanying consolidated statements of loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized gross realized gains of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" format="ixt:num-dot-decimal" scale="3" id="f-494">1,625</ix:nonFraction>,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="f-495">988</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="f-496">584</ix:nonFraction> for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. These realized gains were offset by <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:fixed-zero" scale="0" id="f-497">no</ix:nonFraction> gross realized losses for the year ended December&#160;31, 2024 and gross realized losses of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-498">2,791</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss" format="ixt:num-dot-decimal" scale="3" id="f-499">2,338</ix:nonFraction> for the years ended December&#160;31, 2023 and 2022, respectively. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock" id="f-500" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of the Company&#8217;s investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:33.554%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.234%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.240%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Debt Securities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5-10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-501">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-503">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-504">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-505">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" format="ixt:num-dot-decimal" scale="3" id="f-506">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-507">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-508">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" format="ixt:fixed-zero" scale="3" id="f-509">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" format="ixt:num-dot-decimal" scale="3" id="f-510">22,406</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its investment in available-for-sale marketable debt securities as current assets in the consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in the Company&#8217;s investment portfolio.</span></div></ix:continuation><div id="id52fa9b3dc2341649ffd3f8e14993a22_112"></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">6</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">: <ix:nonNumeric contextRef="c-1" name="us-gaap:InventoryDisclosureTextBlock" id="f-511" continuedAt="f-511-1" escape="true">Inventories</ix:nonNumeric></span></div><div><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfInventoryCurrentTableTextBlock" id="f-512" escape="true"><ix:continuation id="f-511-1"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of inventories at December&#160;31, 2024 and 2023 were comprised of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"/><td style="width:58.251%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.487%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.536%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.490%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inventory:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-513">5,199</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-514">5,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-515">4,963</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryWorkInProcessNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-516">2,037</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-517">10,136</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryFinishedGoodsNetOfReserves" format="ixt:num-dot-decimal" scale="3" id="f-518">3,052</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-519">20,298</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:InventoryNet" format="ixt:num-dot-decimal" scale="3" id="f-520">10,380</ix:nonFraction>&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-83-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_115"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 7:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-521" continuedAt="f-521-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span></ix:nonNumeric></div><ix:continuation id="f-521-1" continuedAt="f-521-2"><ix:continuation id="f-438-2"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:66.103%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.567%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Property and Equipment, net:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-522">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-523">832</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-524">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="f-525">634</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" format="ixt:num-dot-decimal" scale="3" id="f-526">1,013</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="f-527">881</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-528">453</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="f-529">585</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-521-2">Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-530">132</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-531">254</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:Depreciation" scale="3" id="f-532">162</ix:nonFraction>, respectively.</ix:continuation>&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_118"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 8:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock" id="f-533" continuedAt="f-533-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span></ix:nonNumeric></div><ix:continuation id="f-533-1"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill is $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-534"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:Goodwill" format="ixt:num-dot-decimal" scale="3" id="f-535">16,836</ix:nonFraction></ix:nonFraction> at December&#160;31, 2024 and 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-536"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="INF" name="us-gaap:AssetImpairmentCharges" format="ixt:fixed-zero" scale="0" id="f-537">No</ix:nonFraction></ix:nonFraction> impairment loss related to goodwill was recognized during the years ended December&#160;31, 2024 or 2023.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_121"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 9: <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-538" continuedAt="f-538-1" escape="true">Leases</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-538-1" continuedAt="f-538-2"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and a production suite. All leased facilities are classified as operating leases with remaining lease terms between&#160;<span style="-sec-ix-hidden:f-539">one</span>&#160;and&#160;<ix:nonNumeric contextRef="c-105" name="us-gaap:LesseeOperatingLeaseTermOfContract" format="ixt-sec:durwordsen" id="f-540">four years</ix:nonNumeric>. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material variable lease payments. For the Company&#8217;s leased production suite, contract consideration was allocated to lease and non-lease components on the basis of relative standalone price. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-541" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs, which are included in selling, general and administrative expenses in the consolidated statements of loss for the years ended December&#160;31, 2024, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:42.888%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.533%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.935%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.386%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-542">1,058</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-543">1,039</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OperatingLeaseCost" format="ixt:num-dot-decimal" scale="3" id="f-544">1,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-545">128</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-546">123</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:SubleaseIncome" scale="3" id="f-547">116</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-548">930</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-549">916</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:LeaseCost" scale="3" id="f-550">912</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company reduced its operating lease liabilities by $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-551">1,091</ix:nonFraction> for cash paid. During the year ended December&#160;31, 2023, the Company increased its operating lease liabilities by $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-552">1,803</ix:nonFraction> due to an increase in the lease term for the production suite, offset by $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OperatingLeasePayments" format="ixt:num-dot-decimal" scale="3" id="f-553">1,036</ix:nonFraction> for cash paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s operating leases have a weighted-average remaining lease term of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> <ix:nonNumeric contextRef="c-6" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-554">3.3</ix:nonNumeric> years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a weighted-average discount rate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="number" contextRef="c-6" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-555">8.4</ix:nonFraction>%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s lease contracts do not provide a readily determinable implicit rate. The Company&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-556" continuedAt="f-556-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows:</span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-84-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span><br/></span></div><ix:continuation id="f-556-1"><ix:continuation id="f-538-2"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:80.076%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="f-557">683</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="f-558">477</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="f-559">477</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="f-560">316</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:OperatingLeaseLiabilityToBePaidAfterYearFour" format="ixt:fixed-zero" scale="3" id="f-561">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" format="ixt:num-dot-decimal" scale="3" id="f-562">1,953</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="f-563">249</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OperatingLeaseLiability" format="ixt:num-dot-decimal" scale="3" id="f-564">1,704</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:center"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_130"></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 10: <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-565" continuedAt="f-565-1" escape="true">Royalty Financing Obligation</ix:nonNumeric></span></div><div><span><br/></span></div><ix:continuation id="f-565-1"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2023, the Company and Avadel CNS Pharmaceuticals, LLC entered into the RPA with RTW Investments, L.P. (&#8220;RTW&#8221;) for up to $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="avdl:RoyaltyFinancingProceedsMaximum" format="ixt:num-dot-decimal" scale="3" id="f-566">75,000</ix:nonFraction> of royalty financing in <ix:nonFraction unitRef="tranche" contextRef="c-107" decimals="INF" name="avdl:DebtInstrumentNumberOfTranches" format="ixt-sec:numwordsen" scale="0" id="f-567">two</ix:nonFraction> tranches. The first tranche of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-568">30,000</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> became available upon satisfaction of certain conditions which included the Company&#8217;s first shipment of LUMRYZ. The second tranche became available to use, at the Company&#8217;s election, when the Company achieved quarterly net revenue of $<ix:nonFraction unitRef="usd" contextRef="c-109" decimals="-3" name="avdl:RoyaltyFinancingQuarterlyNetRevenueTarget" format="ixt:num-dot-decimal" scale="0" id="f-569">25,000</ix:nonFraction> prior to the quarter ending June 30, 2024. The Company allowed the second tranche to expire on August 31, 2024 and paid a one-time commitment fee of $<ix:nonFraction unitRef="usd" contextRef="c-110" decimals="-3" name="avdl:PaymentsForRoyaltyOneTimeCommitmentFee" format="ixt:num-dot-decimal" scale="0" id="f-570">2,000</ix:nonFraction> to RTW in accordance with the terms of the RPA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 1, 2023, the Company received the first tranche of $<ix:nonFraction unitRef="usd" contextRef="c-108" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-571">30,000</ix:nonFraction>. The Company is required to make quarterly royalty payments calculated as <ix:nonFraction unitRef="number" contextRef="c-106" decimals="4" name="avdl:RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" scale="-2" id="f-572">3.75</ix:nonFraction>% of worldwide net product revenue of LUMRYZ, up to a total payback of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="avdl:RoyaltyFinancingProceedsMaximum" format="ixt:num-dot-decimal" scale="3" id="f-573">75,000</ix:nonFraction>. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RPA is recorded as a royalty financing obligation on the consolidated balance sheets based on the Company&#8217;s evaluation of the terms of the RPA. The accounts receivable and inventory balances of LUMRYZ are pledged as collateral for the RPA. There are no subjective acceleration clauses or provisions, and there are no covenants in violation or other clauses that would cause the full amount of the royalty financing obligation to be callable. As such, the RPA is recorded as a long-term obligation on the consolidated balance sheets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company imputes interest using the effective interest method and records interest expense based on the unamortized royalty financing obligation. The Company&#8217;s estimate of the interest rate under the RPA is based primarily on forecasted net revenue and the calculated amounts and timing of net royalty payments to reach the total payback of $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-3" name="avdl:RoyaltyFinancingProceedsMaximum" format="ixt:num-dot-decimal" scale="3" id="f-574">75,000</ix:nonFraction>. As of December&#160;31, 2024 and December&#160;31, 2023 the effective interest rate is estimated as <ix:nonFraction unitRef="number" contextRef="c-111" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-575">25.2</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-112" decimals="3" name="us-gaap:DebtInstrumentInterestRateEffectivePercentage" scale="-2" id="f-576">30.4</ix:nonFraction>%, respectively. The Company accounts for changes in the imputed interest rate resulting from changes in forecasted net product revenue using the prospective method. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-577" escape="true"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table shows the activity within the royalty financing obligation account:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.549%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.344%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.347%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Financing Obligation:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-578">33,490</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:fixed-zero" scale="3" id="f-579">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of the first tranche of the royalty financing obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:fixed-zero" scale="3" id="f-580">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:ProceedsFromIssuanceOfLongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-581">30,000</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of imputed interest expense on royalty financing obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-582">10,830</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-583">3,743</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payments made to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="avdl:RepaymentOfRoyaltyLiability" format="ixt:num-dot-decimal" scale="3" id="f-584">5,181</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="avdl:RepaymentOfRoyaltyLiability" scale="3" id="f-585">253</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: one-time payment for expiration of second tranche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avdl:PaymentsForRoyaltyOneTimeCommitmentFee" format="ixt:num-dot-decimal" scale="3" id="f-586">2,000</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avdl:PaymentsForRoyaltyOneTimeCommitmentFee" format="ixt:fixed-zero" scale="3" id="f-587">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-588">37,139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:LongTermDebt" format="ixt:num-dot-decimal" scale="3" id="f-589">33,490</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payable to RTW classified within accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:LongTermDebtCurrent" format="ixt:num-dot-decimal" scale="3" id="f-590">1,890</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:LongTermDebtCurrent" scale="3" id="f-591">730</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-111" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-592">35,249</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-3" name="us-gaap:LongTermDebtNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-593">32,760</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accretion of imputed interest expense is reflected as interest expense in the consolidated statements of loss. For the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the total interest expense related to the royalty financing obligation was $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-594">10,830</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-595">3,743</ix:nonFraction>, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">respectively. The remaining interest expense incurred for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023 was related to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the <ix:nonFraction unitRef="number" contextRef="c-116" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-596">4.50</ix:nonFraction>% exchangeable senior notes due February 2023 (&#8220;February 2023 Notes&#8221;) and the <ix:nonFraction unitRef="number" contextRef="c-117" decimals="4" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-597">4.50</ix:nonFraction>%  exchangeable senior notes due October 2023 (&#8220;October 2023 Notes&#8221;, together, the &#8220;2023 Notes&#8221;). The Company had <ix:nonFraction unitRef="usd" contextRef="c-118" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:fixed-zero" scale="0" id="f-598">no</ix:nonFraction> interest expense related to the royalty financing obligation during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-85-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_133"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 11:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-599" continuedAt="f-599-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span></ix:nonNumeric></div><ix:continuation id="f-599-1" continuedAt="f-599-2"><ix:nonNumeric contextRef="c-1" name="avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" id="f-600" escape="true"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the following years ended December 31, are as follows:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss Before Income Taxes:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-119" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-601">3,708</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-120" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-602">45,835</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-121" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-603">53,684</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-122" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-604">45,371</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-123" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-605">114,942</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-124" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-606">57,755</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-607">49,079</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-608">160,777</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-609">111,439</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="avdl:ScheduleOfIncomeTaxPaymentsTableTextBlock" id="f-610" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax (benefit) provision consists of the following for the years ended December 31:&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Income Tax (Benefit) Provision:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-611">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="3" id="f-612">661</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-613">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-614">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="3" id="f-615">661</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:CurrentIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-616">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-617">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="3" id="f-618">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-619">25,896</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-620">247</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-621">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" scale="3" id="f-622">129</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-623">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="3" id="f-624">160</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-625">26,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-626">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-627">501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-628">26,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-629" escape="true"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between income taxes at the statutory rate and the Company&#8217;s (benefit) provision for income taxes is as follows for the following years ended December 31:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Reconciliation to Effective Income Tax Rate:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-630">6,135</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-631">20,097</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-632">13,916</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences in international tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-633">2,991</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-634">6,635</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential" format="ixt:num-dot-decimal" scale="3" id="f-635">9,921</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Return to Provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-636">2,632</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" id="f-637">856</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes" scale="3" id="f-638">101</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-639">4,982</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-640">24,332</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-641">48,734</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-642">1,444</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="3" id="f-643">798</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-644">1,424</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="f-645">218</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="f-646">160</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxContingencies" scale="3" id="f-647">258</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes (net of federal)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="3" id="f-648">778</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-649">5,614</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" format="ixt:num-dot-decimal" scale="3" id="f-650">4,467</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" scale="3" id="f-651">848</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" format="ixt:num-dot-decimal" scale="3" id="f-652">4,362</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" format="ixt:num-dot-decimal" scale="3" id="f-653">4,239</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" scale="3" id="f-654">30</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" scale="3" id="f-655">899</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" format="ixt:fixed-zero" scale="3" id="f-656">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-657">139</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-658">438</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:IncomeTaxReconciliationOtherReconcilingItems" scale="3" id="f-659">225</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-660">247</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-661">501</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:IncomeTaxExpenseBenefit" format="ixt:num-dot-decimal" scale="3" id="f-662">26,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the income tax benefit was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-663">247</ix:nonFraction>, a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="avdl:IncreaseDecreaseInIncomeTaxExpenseBenefit" scale="3" id="f-664">254</ix:nonFraction> from income tax benefit of $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:IncomeTaxExpenseBenefit" scale="3" id="f-665">501</ix:nonFraction>. The change in the effective tax rate for the year ended December 31, 2024 is primarily driven by the reversal of unrecognized tax benefits during the year. The effective tax rate for 2022 was impacted by the valuation allowance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company or one of its subsidiaries files income tax returns in Ireland, France, U.S. and various states. The Company is no longer subject to Irish, French, U.S. Federal, and state and local examinations for years before 2020. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-86-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-599-2" continuedAt="f-599-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-666" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.826%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.860%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Unrecognized Tax Benefit Activity</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-667">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-668">3,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-669">3,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-670">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-671">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease" format="ixt:fixed-zero" scale="3" id="f-672">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statute of limitations expiration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="f-673">311</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" scale="3" id="f-674">108</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" format="ixt:fixed-zero" scale="3" id="f-675">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-676">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-677">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" format="ixt:fixed-zero" scale="3" id="f-678">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-679">2,724</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-680">3,035</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:UnrecognizedTaxBenefits" format="ixt:num-dot-decimal" scale="3" id="f-681">3,143</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that within the next twelve months the unrecognized tax benefits could decrease by approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" format="ixt:num-dot-decimal" scale="3" id="f-682">1,637</ix:nonFraction> and the interest could increase by an immaterial amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, 2023 and 2022, there are $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-683">2,724</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-684">3,035</ix:nonFraction>,and $<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" format="ixt:num-dot-decimal" scale="3" id="f-685">3,143</ix:nonFraction> of unrecognized tax benefits that if recognized would affect the annual effective tax rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax provision. During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized approximately $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-686">56</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-687">268</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="3" id="f-688">258</ix:nonFraction> in interest and penalties, respectively. The Company had approximately $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-689">2,427</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" format="ixt:num-dot-decimal" scale="3" id="f-690">2,372</ix:nonFraction> for the payment of interest and penalties accrued at December&#160;31, 2024 and 2023, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets (Liabilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax provisions reflect the effect of temporary differences between consolidated financial statement and tax reporting of income and expense items. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-691" continuedAt="f-691-1" escape="true">The net deferred tax assets (liabilities) at December&#160;31, 2024 and 2023 resulted from the following temporary differences:&#160;</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-691-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Liabilities: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-692">68,568</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-693">71,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-694">9,791</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" format="ixt:num-dot-decimal" scale="3" id="f-695">7,347</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:DeferredTaxAssetsRoyaltyIncome" format="ixt:num-dot-decimal" scale="3" id="f-696">9,334</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:DeferredTaxAssetsRoyaltyIncome" format="ixt:num-dot-decimal" scale="3" id="f-697">8,378</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and Other Accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:num-dot-decimal" scale="3" id="f-698">4,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" format="ixt:fixed-zero" scale="3" id="f-699">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" format="ixt:num-dot-decimal" scale="3" id="f-700">4,095</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" format="ixt:num-dot-decimal" scale="3" id="f-701">4,065</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-702">1,568</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" format="ixt:num-dot-decimal" scale="3" id="f-703">1,738</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense carryforward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-704">1,460</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetInterestCarryforward" format="ixt:num-dot-decimal" scale="3" id="f-705">1,368</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-706">1,176</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsOther" format="ixt:num-dot-decimal" scale="3" id="f-707">1,322</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets" scale="3" id="f-708">970</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets" format="ixt:num-dot-decimal" scale="3" id="f-709">1,159</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-710">101,565</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsGross" format="ixt:num-dot-decimal" scale="3" id="f-711">96,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:fixed-zero" scale="3" id="f-712">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxLiabilitiesPrepaidExpenses" format="ixt:fixed-zero" scale="3" id="f-713">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-714">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredIncomeTaxLiabilities" format="ixt:fixed-zero" scale="3" id="f-715">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-716">101,565</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-717">96,428</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-718">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsLiabilitiesNet" format="ixt:fixed-zero" scale="3" id="f-719">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-87-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-599-3" continuedAt="f-599-4"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-720">71,588</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of net operating losses in Ireland that do not have an expiration date and $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-721">227,344</ix:nonFraction> of net operating losses and $<ix:nonFraction unitRef="usd" contextRef="c-127" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-722">5,809</ix:nonFraction> 163(j) carryforwards in the U.S. Of the $<ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-723">227,344</ix:nonFraction> of net operating losses in the U.S., $<ix:nonFraction unitRef="usd" contextRef="c-128" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-724">10,365</ix:nonFraction> were acquired due to the acquisition of FSC Therapeutics and FSC Laboratories, Inc., (collectively &#8220;FSC&#8221;) and $<ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-725">212,637</ix:nonFraction> are due to the losses at US Holdings, of which $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-3" name="us-gaap:OperatingLossCarryforwards" format="ixt:num-dot-decimal" scale="3" id="f-726">4,342</ix:nonFraction> are state net operating losses. The portion due to the acquisition of FSC will expire in 2034 through 2035. The remaining U.S. net operating loss and 163(j) carryforwards do not have an expiration date. A valuation allowance is recorded if, based on the weight of available evidence, it is more likely than not that a deferred tax asset will not be realized. This assessment is based on an evaluation of the level of historical taxable income and projections for future taxable income. For the year ended December&#160;31, 2024, the Company recorded a net increase to the valuation allowance related primarily to current year net operating losses of $<ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:OperatingLossCarryforwardsValuationAllowance" format="ixt:num-dot-decimal" scale="3" id="f-727">5,137</ix:nonFraction>. The U.S. net operating losses are subject to an annual limitation as a result of the FSC acquisition under Internal Revenue Code Section 382 and will not be fully utilized before they expire. In addition to net operating losses and 163(j) carryforwards, the Company has U.S. Orphan Drug tax credit carryforwards of $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-728">3,059</ix:nonFraction> as well as U.S. Research and Development credits of $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-3" name="us-gaap:TaxCreditCarryforwardAmount" format="ixt:num-dot-decimal" scale="3" id="f-729">1,036</ix:nonFraction>. The Orphan Drug Credit and Research and Development credits will expire in 2040 through 2044. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cumulative loss position is significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company has recorded a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a valuation allowance against all of its net operating losses in Ireland, France and the U.S. as of December&#160;31, 2024 and 2023. The Company intends to continue maintaining a full valuation allowance on the Irish, French and U.S. net operating losses until there is sufficient evidence to support the reversal of all or some portion of these allowances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company has unremitted earnings of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:UndistributedEarnings" format="ixt:num-dot-decimal" scale="3" id="f-730">3,755</ix:nonFraction> outside of Ireland as measured on a U.S. GAAP basis.  Whereas the measure of earnings for purposes of taxation of a distribution may be different for tax purposes, these earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends or if the Company were to sell its stock in the subsidiaries, net of any prior income taxes paid. It is not practicable to estimate the amount of deferred tax liability on such earnings, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R&amp;D Tax Credits Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-599-4">The French and Irish governments provide tax credits to companies for spending on innovative R&amp;D. These credits are recorded as an offset of R&amp;D expenses and are credited against income taxes payable in years after being incurred or, if not so utilized, are recoverable in cash after a specified period of time, which may differ depending on the tax credit regime. As of December&#160;31, 2024, the Company&#8217;s net research tax credit receivable amounts to $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="f-731">587</ix:nonFraction> and represents an Irish gross research tax credit. As of December&#160;31, 2023, the Company&#8217;s net research tax credit receivable amounts to $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" format="ixt:num-dot-decimal" scale="3" id="f-732">1,654</ix:nonFraction> and represents a French gross research tax credit of $<ix:nonFraction unitRef="usd" contextRef="c-133" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="f-733">837</ix:nonFraction> and an Irish gross research tax credit of $<ix:nonFraction unitRef="usd" contextRef="c-134" decimals="-3" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="3" id="f-734">817</ix:nonFraction>.</ix:continuation> </span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_136"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 12:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherLiabilitiesDisclosureTextBlock" id="f-735" continuedAt="f-735-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets and Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric></div><ix:continuation id="f-735-1" continuedAt="f-735-2"><ix:nonNumeric contextRef="c-1" name="avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" id="f-736" escape="true"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various other assets and liabilities are summarized for the years ended December 31, as follows:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaid Expenses and Other Current Assets: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-737">5,154</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseCurrent" format="ixt:num-dot-decimal" scale="3" id="f-738">4,373</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsCurrent" scale="3" id="f-739">882</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-740">2,235</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-741">6,036</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" format="ixt:num-dot-decimal" scale="3" id="f-742">6,608</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:14pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock" id="f-743" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Assets:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use assets at contract manufacturing organizations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-744">10,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-745">9,905</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:OtherNoncurrentReceivables" scale="3" id="f-746">337</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:OtherNoncurrentReceivables" scale="3" id="f-747">579</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-748">11,037</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherAssetsNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-749">10,484</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-88-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-735-2"><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-750" escape="true"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:61.418%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.908%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.910%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrued Expenses:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-751">18,028</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedProfessionalFeesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-752">11,961</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for variable consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:RemainingPerformanceObligationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-753">14,218</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:RemainingPerformanceObligationReserveCurrent" format="ixt:num-dot-decimal" scale="3" id="f-754">4,044</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-755">6,515</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedSalariesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-756">7,492</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty payable to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:RoyaltyFinancingLiabilityCurrent" format="ixt:num-dot-decimal" scale="3" id="f-757">1,890</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:RoyaltyFinancingLiabilityCurrent" scale="3" id="f-758">730</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-759">40,651</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:AccruedLiabilitiesCurrent" format="ixt:num-dot-decimal" scale="3" id="f-760">24,227</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:OtherNoncurrentLiabilitiesTableTextBlock" id="f-761" escape="true"><div style="margin-bottom:4pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:61.895%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.667%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.670%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Liabilities:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-762">5,151</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities" format="ixt:num-dot-decimal" scale="3" id="f-763">5,407</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:GuarantyLiabilities" scale="3" id="f-764">32</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:GuarantyLiabilities" scale="3" id="f-765">247</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-766">5,183</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:OtherLiabilitiesNoncurrent" format="ixt:num-dot-decimal" scale="3" id="f-767">5,654</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_139"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 13:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-768" continuedAt="f-768-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liabilities and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></ix:nonNumeric></div><ix:continuation id="f-768-1" continuedAt="f-768-2"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation &#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations, cash flows or liquidity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, Jazz Pharmaceuticals, Inc. (&#8220;Jazz&#8221;) filed a formal complaint (the &#8220;First Complaint&#8221;) initiating a lawsuit in the United States District Court for the District of Delaware (the &#8220;Court&#8221;) against Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Management Corporation, Avadel Legacy Pharmaceuticals, LLC, Avadel Specialty Pharmaceuticals, LLC, and Avadel CNS Pharmaceuticals, LLC (collectively, the &#8220;Avadel Parties&#8221;). In the First Complaint, Jazz alleges the sodium oxybate product (&#8220;Proposed Product&#8221;) described in the NDA owned by Avadel CNS Pharmaceuticals, LLC (&#8220;Avadel CNS&#8221;) will infringe at least one claim of U.S. Patent No. 8731963, 10758488, 10813885, 10959956 and/or 10966931 (collectively, the &#8220;patents-in-suit&#8221;). The First Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#8220;Avadel Answer&#8221;) with the Court in response to the First Complaint. The Avadel Answer generally denies the allegations set forth in the First Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patents-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of each patent-in-suit, and ii) a declaratory judgment of invalidity of each patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Jazz filed its Answer (&#8220;Jazz Answer&#8221;) with the Court in response to the Avadel Answer. The Jazz Answer generally denies the allegations set forth in the Avadel Answer and sets forth a single affirmative defense asserting that Avadel has failed to state a claim for which relief can be granted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2021, the Court issued an oral order requiring the parties to i) confer regarding proposed dates to be included in the Court&#8217;s scheduling order for the case, and ii) submit a proposed order, including a proposal for the length and timing of trial, to the Court by no later than July 21, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Court issued a scheduling order establishing timing for litigation events including i) a claim construction hearing date of August 2, 2022, and ii) a trial date of October 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, consistent with the scheduling order, Jazz filed a status update with the Court indicating that Jazz did not intend to file a preliminary injunction with the Court at this time. Jazz further indicated that it would provide the Court with an </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-89-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-768-2" continuedAt="f-768-3"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">update regarding whether preliminary injunction proceedings may be necessary after receiving further information regarding the FDA&#8217;s action on Avadel CNS&#8217;s NDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Court entered an agreed order dismissing this case with respect to Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Specialty Pharmaceuticals, LLC, Avadel Legacy Pharmaceuticals, LLC, and Avadel Management Corporation. A corresponding order was entered in the two below cases on the same day.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2022, Jazz filed an amended Answer to the Avadel Parties&#8217; Counterclaims (&#8220;the Jazz First Amended Answer&#8221;). The Jazz First Amended Answer is substantially similar to the Jazz Answer except insofar as it adds an affirmative defense for judicial estoppel and unclean hands. Corresponding amended answers were filed in the two below cases on the same day.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2022, Avadel CNS filed a Renewed Motion for Judgment on the Pleadings, with respect to its counterclaim against Jazz seeking to have U.S. Patent No. 8731963 (the &#8220;REMS Patent&#8221;) delisted from the Orange Book and seeking to have the motion resolved concurrent with the parties&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing on August 31, 2022. On July 7, 2022, Jazz filed a response styled as Objections to Avadel CNS&#8217; Motion for Judgment on the Pleadings. On July 14, 2022, Avadel CNS replied to Jazz&#8217;s response, and on July 21, 2022, Avadel CNS requested oral argument on its delisting motion simultaneous with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing. On August 24, 2022, the Court ordered Jazz to respond substantively to Avadel CNS&#8217; motion, which Jazz did on August 26, 2022. Avadel CNS filed its reply on August 28, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing was postponed. On September 7, 2022, the case was reassigned to a new judge, and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing was held on October 25, 2022. At the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing, Avadel CNS reiterated its request for an expedited hearing on the Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent. On October 28, 2022, the Court granted Avadel CNS&#8217; request and scheduled the hearing for November 15, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court held the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing on November 15, 2022 and issued a claim construction ruling on November 18, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on November 18, 2022 the Court granted Avadel&#8217;s Renewed Motion for Judgment on the Pleadings and ordered Jazz to request delisting of the REMS Patent from the Orange Book. On November 22, 2022, Jazz appealed that decision and on December 14, 2022, the Federal Circuit issued a stay of the delisting order until further notice. Oral argument was held February 14, 2023. On February 24, 2023, the United States Court of Appeals for the Federal Court affirmed the previous ruling from the Court, ordering the delisting of the REMS Patent from the Orange Book, which has since occurred. On March 7, 2023, in response to a joint stipulation filed by the parties, the Court issued an order dismissing Jazz&#8217;s infringement claims against the Avadel Parties relating to the REMS Patent as well as Avadel Parties&#8217; noninfringement and invalidity counterclaims relating to the REMS Patent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule to accommodate additional claim construction proceedings. That stipulation remains pending before the Court. On April 26, 2023, the parties filed their Supplemental Joint Claim Construction Brief.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2023, the Court issued a modified scheduling order establishing a new trial date of February 26, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2023, in response to a Court order, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule with an updated proposed schedule to accommodate additional claim construction proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 4, 2023, the Court entered a modified version of the parties&#8217; proposed schedule, which was revised on August 28, 2023. The parties&#8217; Second Supplemental Joint Claim Construction Brief was filed on October 10, 2023, and a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hearing regarding the disputed terms occurred on November 1, 2023. The Court issued its claim construction order on December 15, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 15, 2023, Avadel renewed its request to consolidate this litigation with the litigation described in the Avadel Complaint below. On November 3, 2023, the Court denied that request.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the parties filed cross motions for summary judgment. The parties filed opposition briefs on December 15, 2023. The parties filed reply briefs on December 22, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2024, the Court denied the parties&#8217; summary judgment motions. On February 15, 2024, the Court held its Pretrial Conference. Trial was held from February 26, 2024 to March 1, 2024 (the &#8220;February Patent Trial&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jury returned a verdict of no infringement for U.S. Patent No. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10758488 and infringement of U.S. Patent No. 11147782, with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> damages of $<ix:nonFraction unitRef="usd" contextRef="c-135" decimals="-3" name="us-gaap:LossContingencyAccrualCarryingValueCurrent" scale="3" id="f-769">234</ix:nonFraction>,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are included in the consolidated balance sheets in accrued expenses at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2024, the Court issued a Supplemental Scheduling Order setting a June 4, 2024 hearing on Jazz&#8217;s request for a permanent injunction or ongoing royalty. Briefing on Jazz&#8217;s request closed on May 20, 2024, and the hearing was held June 4, 2024. On August 27, 2024, the Court issued an opinion and order enjoining Avadel from infringing claim 24 of U.S. Patent No. </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-90-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-768-3" continuedAt="f-768-4"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11147782. That injunction excluded certain categories of conduct, including permitting Avadel to continue making, using and selling LUMRYZ for the treatment of narcolepsy and for use in ongoing clinical trials and studies. The August 27, 2024 opinion and order also granted Jazz&#8217;s motion for an ongoing royalty, pending additional briefing on the appropriate royalty rate. That briefing closed on September 23, 2024. While a future ongoing royalty is pending briefing and a decision by the Court, the Company recorded an estimated liability for a royalty based on information available as of December 31, 2024. It is reasonably possible that a change in the estimate may occur pending the Court&#8217;s decision. On August 28, 2024, Avadel filed a notice of appeal concerning the August 27, 2024 injunction (the &#8220;Patent Appeal&#8221;). On September 3, 2024, Avadel moved in District Court to stay the August 27, 2024 injunction pending appeal. Briefing on that motion closed on September 16, 2024. On September 24, 2024, the District Court denied Avadel&#8217;s motion to stay the injunction pending appeal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, Avadel moved the U.S. Court of Appeals for the Federal Circuit to stay the injunction pending appeal. Briefing on that motion closed on September 27, 2024. On October 2, 2024, the Federal Circuit granted Avadel&#8217;s motion in part, staying the injunction with respect to Avadel&#8217;s initiating new clinical trials or studies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 10, 2024, the Federal Circuit entered a briefing schedule concerning the Patent Appeal. On September 30, 2024, Avadel filed its opening brief. Jazz filed its response brief on November 7, 2024. Avadel filed its reply brief on November 18, 2024. On October 2, 2024, the Federal Circuit placed the Patent Appeal on the February 2025 oral argument calendar. On February 7, 2025, the Federal Circuit heard oral argument in the Patent Appeal. The Patent Appeal remains pending.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Jazz Complaint </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, Jazz filed another formal complaint (the &#8220;Second Complaint&#8221;) initiating a lawsuit in the Court against the Avadel Parties. In the Second Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11077079. The Second Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#8220;Second Avadel Answer&#8221;) with the Court in response to the Second Complaint. The Second Avadel Answer generally denies the allegations set forth in the Second Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity of the patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Court issued an oral order stating that this case should proceed on the same schedule as the case filed on May 12, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2021, Jazz filed another formal complaint (the &#8220;Third Complaint&#8221;) initiating a lawsuit in the Court against the Avadel Parties. In the Third Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11147782. The Third Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses. This case will proceed on the same schedule as the cases associated with the First and Second Complaints above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2021, the Court entered a revised schedule for the First, Second and Third Complaints, setting a new claim construction date of August 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#8220;Third Avadel Answer&#8221;) with the Court in response to the Third Complaint. The Third Avadel Answer generally denies the allegations set forth in the Third Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fourth Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, Jazz filed another formal complaint (the &#8220;Fourth Complaint&#8221;) initiating a lawsuit in the Court against Avadel CNS. In the Fourth Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-91-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-768-4" continuedAt="f-768-5"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least one claim of the REMS Patent, which was asserted in the First Complaint. The FDA required Avadel CNS to file a Paragraph IV certification against the REMS Patent, which Avadel CNS did under protest, consistent with its Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent from the Orange Book, which was later ordered to be delisted in the above First Jazz Complaint action. Avadel CNS provided the required notice of its Paragraph IV certification to Jazz, and Jazz reasserted the REMS Patent in a separate action following receipt of that notice. The Fourth Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 21, 2022, Jazz served the Fourth Complaint. On October 21, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#8220;Fourth Avadel Answer&#8221;) with the Court in response to the Fourth Complaint. The Fourth Avadel Answer generally denies the allegations set forth in the Fourth Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims for i) a declaratory judgment of non-infringement of the patent-in-suit, ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit, iii) delisting of the patent-in-suit from the Orange Book; iv) monopolization under the Sherman Antitrust Act of 1890 (the &#8220;Sherman Act&#8221;); and v) attempted monopolization under the Sherman Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 9, 2022, Jazz filed a Motion to Dismiss Avadel&#8217;s Antitrust Counterclaims.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avadel filed its opposition brief on December 27, 2022, and Jazz filed its reply brief on January 6, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 11, 2023, Avadel filed a request for oral argument on the motion. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Dismiss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 7, 2024, Jazz filed its Answer to Avadel&#8217;s Counterclaims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 6, 2023, the parties filed a stipulation of dismissal, dismissing Jazz&#8217;s claims with respect to the REMS Patent and Avadel CNS&#8217;s related non-infringement and invalidity counterclaims. The Court entered that stipulation on March 7, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2023, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by March 14, 2024, and ii) a deadline for case dispositive motions of September 20, 2024. On January 23, 2024, the parties submitted a stipulation to extend the case schedule. On January 24, 2024, the Court ordered an extension of the case schedule, including i) completion of fact discovery by June 20, 2024 and ii) a deadline for case dispositive motions by January 31, 2025. On January 24, 2024, the Court issued an order setting a pretrial conference for October 30, 2025 and a 5-day trial to begin on November 3, 2025. On April 22, 2024, the parties submitted a stipulation extending certain pretrial deadlines, including i) extending completion of fact discovery to September 27, 2024 and ii) extending the deadline for case dispositive motions to April 4, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2023, Jazz filed a Motion to Stay the case, pending resolution of its Motion to Dismiss. Briefing on that Motion to Stay closed on August 10, 2023. On March 13, 2024, Jazz filed a Supplemental Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Stay.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2024, Jazz filed a Motion for Reargument or in the Alternative to Certify an Appeal. Avadel filed its opposition brief on June 28, 2024. Jazz filed its reply brief on July 12, 2024. On September 25, 2024, Jazz sought leave to file a supplemental brief in support of its Motion to Stay.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2024, the Court granted leave to Jazz to file its supplemental brief, which Jazz filed on October 7, 2024. Avadel filed its response on October 21, 2024. Jazz filed its reply on October 28, 2024. Jazz&#8217;s motion remains pending.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Avadel Complaint</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2022, Avadel CNS and Avadel Pharmaceuticals plc (collectively the &#8220;Avadel Plaintiffs&#8221;) filed a formal complaint (the &#8220;Avadel Complaint&#8221;) initiating a lawsuit in the Court against Jazz and Jazz Pharmaceuticals Ireland Ltd. (collectively, the &#8220;Jazz Parties&#8221;). In the Avadel Complaint, the Avadel Plaintiffs allege that the Jazz Parties breached certain confidential disclosure agreements and misappropriated certain of the Avadel Plaintiffs&#8217; trade secrets. The Avadel Complaint further includes typical relief requests such as injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses, as well as seeking correction of inventorship of certain Jazz patents, for which the Jazz Parties claim ownership, to include former Avadel Plaintiffs&#8217; scientists.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, Jazz answered the Avadel Complaint. The Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, Jazz filed a Motion for Judgment on the Pleadings seeking to have all Counts dismissed for failure to state a claim upon which relief can be granted. The Avadel Plaintiffs&#8217; response to that Motion was filed with the Court on July 29, </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-92-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-768-5" continuedAt="f-768-6"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. Jazz&#8217;s reply was filed with the Court on August 5, 2022. On February 2, 2023, the Court held a hearing on Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, the Court held a hearing on Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Court denied Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the parties submitted competing proposed scheduling orders, and Avadel requested consolidation with the above First Jazz Complaint litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That request for consolidation was denied on November 3, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, the parties submitted an updated joint proposed scheduling order. On January 30, 2024, the parties agreed to a 6-week stay of discovery and submitted a proposed stipulation extending certain case deadlines to accommodate the same. On February 9, 2024, the parties submitted an updated proposed scheduling order consistent with that stipulation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">setting the close of fact discovery for August 9, 2024 and a trial date of December 15, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That proposed scheduling order remains pending before the Court as of the date of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2024, Jazz filed a Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Stay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2024, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by August 9, 2024, ii) a deadline for case dispositive motions of May 30, 2025, and iii) a 5-day jury trial beginning December 15, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2024, the Court entered a stipulation by the parties extending certain case deadlines, including i) extending close of fact discovery to November 1, 2024 and ii) dispositive motions to July 18, 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2024, Jazz filed an Amended Answer to the Avadel Complaint. The Amended Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, Avadel and Jazz stipulated to stay proceedings pending the resolution of the Patent Appeal above, which the Court entered on September 9, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2025, Avadel CNS and Flamel Ireland Limited (&#8220;Flamel&#8221;) filed a formal complaint (the &#8220;Second Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Second Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12167991 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Second Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jazz Parties&#8217; Answer is due on April 21, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2025, Avadel CNS and Flamel filed a formal complaint (the &#8220;Third Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Third Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12186298 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Third Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jazz Parties&#8217; Answer is due on April 21, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fourth Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2025, Avadel CNS and Flamel filed a formal complaint (the &#8220;Fourth Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Fourth Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent Nos. 12226388 and 12226389 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Fourth Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-93-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-768-6" continuedAt="f-768-7"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jazz&#8217;s Administrative Procedure Act Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2023, Jazz filed an Administrative Procedure Act suit against the FDA, the U.S. Department of Health and Human Services, the Secretary of Health and Human Services and the Commissioner of Food and Drugs (the &#8220;Federal Defendants&#8221;) in the United States District Court for the District of Columbia (the &#8220;DC Court&#8221;) related to the NDA for LUMRYZ. This suit alleges that the FDA&#8217;s approval of LUMRYZ was an unlawful agency action and asks the DC Court to set aside FDA&#8217;s approval of LUMRYZ. On June 28, 2023, the DC Court granted Avadel CNS&#8217;s unopposed motion to intervene in the case to defend the FDA&#8217;s decision. On August 14, 2023, the Court entered a scheduling order establishing timing for litigation events including early summary judgment briefing closing December 22, 2023. On September 22, 2023, Jazz filed its Motion for Summary Judgment. On October 20, 2023, the FDA and Avadel filed their Cross Motions for Summary Judgment. Briefing on the parties&#8217; motions closed January 4, 2024. On February 14, 2024, the Court set hearing for oral argument on the parties&#8217; motions for February 27, 2024. On February 21, 2024, the Court rescheduled the oral argument to April 9, 2024. On April 2, 2024, the Court rescheduled the oral argument to May 10, 2024. On May 10, 2024, the Court heard oral argument on the parties&#8217; motions. On October 30, 2024, the Court granted FDA and Avadel&#8217;s Motions for Summary Judgment with respect to the sole count in Jazz&#8217;s complaint and denied Jazz&#8217;s Motion for Summary Judgment regarding the same. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2024, Jazz filed a notice of appeal concerning the Court&#8217;s October 30, 2024 ruling (the &#8220;APA Appeal&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2025, Jazz filed its opening brief in the APA Appeal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel&#8217;s response brief is due March 17, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jazz&#8217;s reply brief is due April 7, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div></ix:continuation><div><span><br/></span></div><div style="margin-bottom:12pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-768-7">The Company has a <ix:nonNumeric contextRef="c-1" name="us-gaap:LongtermPurchaseCommitmentPeriod" format="ixt-sec:durwordsen" id="f-770">four year</ix:nonNumeric> commitment with a CDMO to manufacture the LUMRYZ drug product of approximately $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-3" name="avdl:ContractualObligationAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-771">3,000</ix:nonFraction> to $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-3" name="avdl:ContractualObligationAnnualAmount" format="ixt:num-dot-decimal" scale="3" id="f-772">4,200</ix:nonFraction> per year as determined by the terms of the agreement with the CDMO</ix:continuation>.</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_142"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 14: <ix:nonNumeric contextRef="c-1" name="avdl:EquityTransactionsDisclosureTextBlock" id="f-773" continuedAt="f-773-1" escape="true">Equity Instruments and Transactions</ix:nonNumeric></span></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-773-1" continuedAt="f-773-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-774">500,000</ix:nonFraction> authorized ordinary shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ordinary shares&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a nominal value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-775">0.01</ix:nonFraction> per ordinary share. Effective April 15, 2024, the Company&#8217;s ordinary shares became directly listed on the Nasdaq Stock Market. The Company caused a mandatory exchange of its </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Depositary Shares (&#8220;ADSs&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the underlying ordinary shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a <ix:nonFraction unitRef="number" contextRef="c-136" decimals="INF" name="avdl:AmericanDepositorySharesConversionRatio" format="ixt-sec:numwordsen" scale="0" id="f-776">one</ix:nonFraction>-for-one basis. Accordingly, the Bank of New York Mellon (&#8220;BNY Mellon&#8221;), as Depositary for the ADSs, issued a notice of termination of its American Depository Receipt program (&#8220;ADR Program&#8221;) of ADSs to the registered holders of ADSs according to the requirements under the deposit agreement dated January 3, 2017 (the &#8220;Deposit Agreement&#8221;) among the Company, BNY Mellon and holders of ADSs. The Deposit Agreement terminated on July 15, 2024. As of December&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesIssued" format="ixt:num-dot-decimal" scale="3" id="f-777"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:CommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-778">96,518</ix:nonFraction></ix:nonFraction> ordinary shares issued and outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is authorized to issue preferred shares in series, and with respect to each series, to fix its designation, relative rights (including voting, dividend, conversion, sinking fund, and redemption rights), preferences (including dividends and liquidation) and limitations. The Company has <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-779">50,000</ix:nonFraction> authorized preferred shares, with a nominal value of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-780">0.01</ix:nonFraction> per preferred share. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-137" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-781">5,194</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Non-Voting Convertible Preferred Shares and Series B Non-Voting Convertible Preferred Shares were converted to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-138" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" format="ixt:num-dot-decimal" scale="3" id="f-782">5,194</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ordinary shares at the option of the holders. Accordingly, there were no preferred shares issued and outstanding at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Shelf Registration Statement on Form S-3</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2024, the Company entered into an Open Market Sale Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company may offer and sell its ordinary shares, from time to time, with respect to an at-the-market offering program (&#8220;ATM Program&#8221;) under which Jefferies will act as sales agent. The Sales Agreement provides that Jefferies will be entitled to aggregate compensation for its services of an amount up to <ix:nonFraction unitRef="number" contextRef="c-139" decimals="3" name="avdl:SaleOfStockSalesAgentCommissionPercent" scale="-2" id="f-783">3.0</ix:nonFraction>% of the gross proceeds of any ordinary shares sold through Jefferies under the Sales Agreement. The Sales Agreement replaces the Company&#8217;s previous Open Market Sale Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with Jefferies, dated February 4, 2020 (the &#8220;ADS Sales Agreement&#8221;), which provided for the sale of ADSs by the Company. The Company terminated the ADS Sales Agreement upon effectiveness of the Sales Agreement following the mandatory exchange of the ADSs and the direct listing of the ordinary shares on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Stock Market on April 15, 2024.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-94-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-773-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ordinary shares will be offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(File No. 333-267198), filed with the SEC on August 31, 2022, as amended, and declared effective by the SEC on September 12, 2022, as supplemented by the prospectus supplement dated May 8, 2024 (the &#8220;Prospectus Supplement&#8221;). The Company may offer and sell ordinary shares having an aggregate offering price of up to $<ix:nonFraction unitRef="usd" contextRef="c-140" decimals="-3" name="avdl:SaleOfStockMaximumAggregateOfferingPrice" format="ixt:num-dot-decimal" scale="0" id="f-784">100,000</ix:nonFraction> under the Prospectus Supplement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to termination, the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-141" decimals="-3" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" scale="3" id="f-785">640</ix:nonFraction> ordinary shares pursuant to the ADS Sales Agreement during the three months ended March 31, 2024, resulting in net proceeds to the Company of approximately $<ix:nonFraction unitRef="usd" contextRef="c-142" decimals="-3" name="us-gaap:SaleOfStockConsiderationReceivedOnTransaction" format="ixt:num-dot-decimal" scale="3" id="f-786">9,250</ix:nonFraction>. The Company has <ix:nonFraction unitRef="shares" contextRef="c-143" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:fixed-zero" scale="0" id="f-787">not</ix:nonFraction> issued or sold ordinary shares under at-the-market offering programs subsequent to March 31, 2024.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_145"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 15: <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-788" continuedAt="f-788-1" escape="true">Share-Based Compensation</ix:nonNumeric></span><ix:continuation id="f-788-1" continuedAt="f-788-2"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:continuation></div><ix:continuation id="f-788-2" continuedAt="f-788-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="f-789" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense included in the Company&#8217;s consolidated statements of loss for all share-based compensation arrangements was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.840%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-based Compensation Expense:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-144" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-790">19,532</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-145" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-791">15,248</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-146" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-792">6,844</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-147" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-793">856</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-148" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-794">563</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="f-795">169</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-796">20,388</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-797">15,811</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-798">7,013</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company expects $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" format="ixt:num-dot-decimal" scale="3" id="f-799">22,513</ix:nonFraction> of unrecognized expense related to granted, but non-vested share-based compensation arrangements to be incurred in future periods. This expense is expected to be recognized over a weighted average period of <ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-800">2.0</ix:nonNumeric> years.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company granted options with performance conditions to employees of which <ix:nonFraction unitRef="number" contextRef="c-150" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-801">50</ix:nonFraction>% vest upon the achievement of certain commercial milestones related to LUMRYZ and the other <ix:nonFraction unitRef="number" contextRef="c-151" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-802">50</ix:nonFraction>% vest <ix:nonNumeric contextRef="c-151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-803">one year</ix:nonNumeric> following achievement of those milestones (&#8220;2022 Performance Options&#8221;). In May 2023, the achievement of the milestones related to the 2022 Performance Options became probable, and the Company recognized the compensation costs that would have been recognized had the performance factor been considered probable since the inception of the award. In June 2023, achievement of these milestones were met and <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-804"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-805">50</ix:nonFraction></ix:nonFraction>% of the 2022 Performance Options vested. In June 2024, <ix:nonNumeric contextRef="c-151" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-806">one year</ix:nonNumeric> passed since achievement of these milestones were met and the remaining <ix:nonFraction unitRef="number" contextRef="c-152" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-807"><ix:nonFraction unitRef="number" contextRef="c-153" decimals="2" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" scale="-2" id="f-808">50</ix:nonFraction></ix:nonFraction>% of the 2022 Performance Options vested. As of December&#160;31, 2024, the Company has recognized $<ix:nonFraction unitRef="usd" contextRef="c-154" decimals="-3" name="us-gaap:AllocatedShareBasedCompensationExpense" format="ixt:num-dot-decimal" scale="3" id="f-809">8,009</ix:nonFraction> in share-based compensation for the 2022 Performance Options. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess tax benefit related to share-based compensation recorded by the Company was not material for the years ended December&#160;31, 2024, 2023, and 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon exercise of stock options, or upon the issuance of restricted share awards or performance share unit awards, the Company issues new shares.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, there were <ix:nonFraction unitRef="shares" contextRef="c-155" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" format="ixt:num-dot-decimal" scale="3" id="f-810">4,259</ix:nonFraction> shares authorized for stock option grants, restricted share award grants, and performance share unit award grants in subsequent periods.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Board of Directors approved the Avadel Pharmaceuticals plc 2021 Inducement Plan (the &#8220;Inducement Plan&#8221;), which allows the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company to accept employment and provide them with a proprietary interest in the Company. The maximum number of shares reserved and available for issuance under the Plan is <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="-3" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="3" id="f-811">2,000</ix:nonFraction> shares. As of December&#160;31, 2024, the Company had <ix:nonFraction unitRef="shares" contextRef="c-156" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="3" id="f-812">841</ix:nonFraction> shares available for issuance under this Inducement Plan in subsequent periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining the Fair Value of Stock Options</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the total fair value of stock options on the grant date using the Black-Scholes option-pricing model and recognizes each grant&#8217;s fair value as compensation expense over the period that the option vests. Other than the 2022 Performance Options described above, options are granted to employees of the Company and become exercisable ratably over <ix:nonNumeric contextRef="c-157" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-813">four years</ix:nonNumeric> following the grant date and expire <ix:nonNumeric contextRef="c-157" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-814">ten years</ix:nonNumeric> after the grant date. During the years ended December 31, 2022 and 2023, the Company issued stock options to its Board of Directors as compensation for services rendered that are exercisable <ix:nonNumeric contextRef="c-158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-815"><ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-816"><ix:nonNumeric contextRef="c-160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-817"><ix:nonNumeric contextRef="c-161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-818">one year</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> following the grant date and expire <ix:nonNumeric contextRef="c-159" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-819"><ix:nonNumeric contextRef="c-162" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-820"><ix:nonNumeric contextRef="c-158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-821">ten years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> after the grant date. During the year ended December&#160;31, 2024, the Company </span></div></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-95-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-788-3" continuedAt="f-788-4"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued stock options to its Board of Directors as compensation for services rendered that are exercisable over either a <ix:nonNumeric contextRef="c-158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-822"><ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-823"><ix:nonNumeric contextRef="c-160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-824"><ix:nonNumeric contextRef="c-161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-825">one year</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> period or ratably over <ix:nonNumeric contextRef="c-163" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-826">three years</ix:nonNumeric> following the grant date and expire <ix:nonNumeric contextRef="c-159" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-827"><ix:nonNumeric contextRef="c-162" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-828"><ix:nonNumeric contextRef="c-158" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" format="ixt-sec:durwordsen" id="f-829">ten years</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> after the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="avdl:ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" id="f-830" escape="true"><div style="margin-bottom:14pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions under the Black-Scholes option-pricing model for stock option grants as of December&#160;31, 2024, 2023 and 2022 are as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.840%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Option Assumptions: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option grants:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-164" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-831">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-165" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-832">6.2</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-166" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-833">6.1</ix:nonNumeric></span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-834">104.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-835">100.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-836"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" id="f-837">93.4</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-838">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-839">3.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="4" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-840"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="f-841">2.7</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-164" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-842">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-165" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-843">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-844"><ix:nonFraction unitRef="number" contextRef="c-166" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" format="ixt:fixed-zero" scale="3" id="f-845">&#8212;</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected term of the options represents the period of time between the grant date and the time the options are either exercised or forfeited, including an estimate of future forfeitures for outstanding options. Given the limited historical data, the simplified method has been used to calculate the expected life.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected volatility is calculated based on an average of the historical volatility of the Company&#8217;s stock price for a period approximating the expected term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company has not distributed any dividends since its inception and have no plan to distribute dividends in the foreseeable future.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-846" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the combined stock option activity and other data for the Company&#8217;s stock option plans for the year ended December&#160;31, 2024 is as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"/><td style="width:34.782%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.194%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.535%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.196%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Stock Option Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-847">10,299</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-848">7.29</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="3" id="f-849">2,961</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-850">13.75</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="3" id="f-851">734</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="f-852">7.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="3" id="f-853">468</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-854">11.65</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="3" id="f-855">266</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" id="f-856">16.30</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="3" id="f-857">11,792</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-858">8.53</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-859">6.8</ix:nonNumeric></span></td><td colspan="3" style="padding:0 1pt"/><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-860">34,411</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" format="ixt:num-dot-decimal" scale="3" id="f-861">7,799</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="f-862">6.53</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-863">5.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:num-dot-decimal" scale="3" id="f-864">32,380</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-865">5,781</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:num-dot-decimal" scale="3" id="f-866">2,612</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="3" id="f-867">877</ix:nonFraction>, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-868">11.34</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-869">9.14</ix:nonFraction>, and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-870">4.02</ix:nonFraction> per share, respectively.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Awards</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share awards represent Company shares issued free of charge to employees of the Company as compensation for services rendered. The Company measures the total fair value of restricted share awards on the grant date using the Company&#8217;s stock price at the time of the grant. Restricted share awards granted to employees vest ratably over a range of <ix:nonNumeric contextRef="c-158" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-871"><ix:nonNumeric contextRef="c-159" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-872"><ix:nonNumeric contextRef="c-160" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-873"><ix:nonNumeric contextRef="c-161" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-874">one year</ix:nonNumeric></ix:nonNumeric></ix:nonNumeric></ix:nonNumeric> to <ix:nonNumeric contextRef="c-167" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-875">four years</ix:nonNumeric> on each anniversary of the grant date. Compensation expense for such awards granted is recognized over the applicable vesting period. Additionally, during the year ended December&#160;31, 2024, the Company issued restricted stock awards to its Board of Directors that vest on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-162" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" format="ixt-sec:durwordsen" id="f-876">one-year</ix:nonNumeric> anniversary of the award.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-96-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-788-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" id="f-877" escape="true"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted share awards as of December&#160;31, 2024, and changes during the year then ended, is reflected in the table below.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:48.533%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.350%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:23.353%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Share Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Restricted Share Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-168" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-878">23</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-168" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-879">8.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-880">142</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-881">15.36</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="3" id="f-882">11</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-883">8.20</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-169" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-884">4</ix:nonFraction>)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-885">12.60</ix:nonFraction>&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-170" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="3" id="f-886">150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-170" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-887">14.88</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of restricted share awards granted during the year ended December&#160;31, 2024 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-169" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-888">15.36</ix:nonFraction> per share. <ix:nonFraction unitRef="shares" contextRef="c-171" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-889"><ix:nonFraction unitRef="shares" contextRef="c-172" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-890">No</ix:nonFraction></ix:nonFraction> restricted share awards were granted during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Units Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance share units awards (&#8220;PSUs&#8221;) represent Company shares issued free of charge to employees of the Company as compensation for achieving specified results. The Company measures the total fair value of performance share unit awards on the grant date using the Company&#8217;s stock price at the time of the grant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-173" decimals="2" name="avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" format="ixt:fixed-zero" scale="0" id="f-891">No</ix:nonFraction> performance share awards were granted during the year ended December&#160;31, 2022. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, there were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-174" decimals="-3" name="avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" scale="3" id="f-892">555</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> performance share awards that did not have an accounting grant date due to the discretionary nature of the performance criteria. Accordingly, no grant date fair value was established and there were <ix:nonFraction unitRef="shares" contextRef="c-175" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-893">no</ix:nonFraction> performance share awards considered granted during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"><ix:nonFraction unitRef="shares" contextRef="c-176" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" scale="3" id="f-894">185</ix:nonFraction> of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">performance share awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that were tied to performance during the second half of 2023 were forfeited. <ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:fixed-zero" scale="0" id="f-895">No</ix:nonFraction></span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> performance share awards were granted during the year ended December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Board of Directors approved the Avadel Pharmaceuticals plc 2017 Avadel Employee Share Purchase Plan (&#8220;ESPP&#8221;). The total number of Company ordinary shares which may be issued under the ESPP is <ix:nonFraction unitRef="shares" contextRef="c-177" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="3" id="f-896">1,000</ix:nonFraction>. The purchase price at which a share will be issued or sold for a given offering period will be established by the Compensation Committee of the Board (&#8220;Committee&#8221;) (and may differ among participants, as determined by the Committee in its sole discretion) but will in no event be less than <ix:nonFraction unitRef="number" contextRef="c-178" decimals="INF" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" scale="-2" id="f-897">85</ix:nonFraction>% of the lesser of: (a) the fair market value of a Share on the offering date; or (b) the fair market value of a Share on the purchase date. During the years ended December&#160;31, 2024, 2023 and 2022 the Company issued <ix:nonFraction unitRef="shares" contextRef="c-179" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-898">113</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-180" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-899">47</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-181" decimals="-3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="3" id="f-900">75</ix:nonFraction> ordinary shares to employees, respectively. Expense related to the ESPP for the years ended December&#160;31, 2024, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was immaterial.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_151"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 16:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-905" continuedAt="f-905-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></ix:nonNumeric></div><ix:continuation id="f-905-1" continuedAt="f-905-2"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net loss per share is calculated by dividing net loss by the diluted number of shares outstanding during each period. Except where th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the conversion of the  Company&#8217;s preferred shares, the exercise of outstandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng equity compensation awards, and ordinary shares expected to be issued under the Company&#8217;s ESPP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a choice to settle the conversion obligations under the 2023 Notes in cash, shares or any combination of the two. The Company utilized the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result was anti-dilutive. This method assumed the conversion of the 2023 Notes into shares of the Company&#8217;s ordinary shares and reflected the elimination of the interest expense related to the 2023 Notes. The Company had no 2023 Notes remaining as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive effect of the stock options, restricted share awards, preferred shares and ordinary shares expected to be issued under the Company&#8217;s ESPP has been calculated using the treasury stock method.</span></div><div style="text-align:justify"><span><br/></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-906" continuedAt="f-906-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands for the years ended December&#160;31, 2024, 2023 and 2022, is as follows: </span></div></ix:nonNumeric></ix:continuation><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-97-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><ix:continuation id="f-906-1"><ix:continuation id="f-905-2" continuedAt="f-905-3"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.771%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.788%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Loss Per Share: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-907">48,832</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-908">160,276</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" sign="-" name="us-gaap:NetIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-909">137,464</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-910">95,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-911">80,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-912"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" format="ixt:num-dot-decimal" scale="3" id="f-913">60,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee and director equity awards outstanding, preferred shares and 2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-914">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-915">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment" format="ixt:fixed-zero" scale="3" id="f-916">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-917">95,141</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-918">80,174</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-919"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" format="ixt:num-dot-decimal" scale="3" id="f-920">60,094</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-921">0.51</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-922">2.00</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-923">2.29</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-924">0.51</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-4" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-925">2.00</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-926">2.29</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><ix:continuation id="f-905-3"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential ordinary shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-927">1,410</ix:nonFraction></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="c-4" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="3" id="f-928">513</ix:nonFraction>, and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-3" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" format="ixt:num-dot-decimal" scale="3" id="f-929">17,941</ix:nonFraction> were excluded from the calculation of weighted average shares for the years ended December&#160;31, 2024, 2023 and 2022, respectively, because their effect was considered to be anti-dilutive or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. For the years ended December&#160;31, 2024, 2023 and 2022, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in these periods.</span></ix:continuation><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_154"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 17:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:ComprehensiveIncomeNoteTextBlock" id="f-930" continuedAt="f-930-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span></ix:nonNumeric></div><ix:continuation id="f-930-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" id="f-931" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of accumulated other comprehensive loss for the year ended December 31, net of tax effects:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:49.338%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.840%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-932">24,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-933">24,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-934">23,855</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-935">623</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-936">331</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-191" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-937">597</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-938">24,744</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-939">24,121</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-940">24,452</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable debt securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-941">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-942">1,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" scale="3" id="f-943">85</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income, net of income tax expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-944">0</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-4" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-945">0</ix:nonFraction>, and $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-3" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="f-946">0</ix:nonFraction>, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" scale="3" id="f-947">790</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-3" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-948">2,843</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-198" decimals="-3" sign="-" name="us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" format="ixt:num-dot-decimal" scale="3" id="f-949">1,804</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-199" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-950">164</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-3" name="us-gaap:StockholdersEquity" scale="3" id="f-951">954</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-952">1,889</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-953">24,580</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-954">23,167</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-3" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="3" id="f-955">26,341</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect on the Company&#8217;s consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_157"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">NOTE 18:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-956" continuedAt="f-956-1" escape="true"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span></ix:nonNumeric></div><ix:continuation id="f-956-1" continuedAt="f-956-2"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-957"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-958">one</ix:nonFraction></ix:nonFraction> segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. The Company&#8217;s Chief Operating Decision Maker is the Chief Executive Officer (&#8220;CEO&#8221;). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All products are included in <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-959"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-960">one</ix:nonFraction></ix:nonFraction> segment because the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-961" continuedAt="f-961-1" escape="true"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the Company&#8217;s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.</span></div></ix:nonNumeric></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-98-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><ix:continuation id="f-956-2"><ix:continuation id="f-961-1"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:61.180%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.742%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.746%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-962">169,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:num-dot-decimal" scale="3" id="f-963">27,963</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" format="ixt:fixed-zero" scale="3" id="f-964">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:num-dot-decimal" scale="3" id="f-965">15,277</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" scale="3" id="f-966">846</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:CostOfGoodsAndServicesSold" format="ixt:fixed-zero" scale="3" id="f-967">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-968">153,840</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:GrossProfit" format="ixt:num-dot-decimal" scale="3" id="f-969">27,117</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:GrossProfit" format="ixt:fixed-zero" scale="3" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-971">15,196</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-972">13,261</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:ResearchAndDevelopmentExpense" format="ixt:num-dot-decimal" scale="3" id="f-973">20,700</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-974">84,962</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-975">79,596</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:GeneralAndAdministrativeExpense" format="ixt:num-dot-decimal" scale="3" id="f-976">52,655</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-977">76,478</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-978">56,419</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SellingAndMarketingExpense" format="ixt:num-dot-decimal" scale="3" id="f-979">15,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-980">19,603</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-981">15,690</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:SegmentReportingOtherItemAmount" format="ixt:num-dot-decimal" scale="3" id="f-982">9,915</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-983">196,239</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-984">164,966</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:OperatingExpenses" format="ixt:num-dot-decimal" scale="3" id="f-985">98,561</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-986">42,399</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-987">137,849</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:OperatingIncomeLoss" format="ixt:num-dot-decimal" scale="3" id="f-988">98,561</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:InvestmentIncomeNet" format="ixt:num-dot-decimal" scale="3" id="f-989">4,150</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-990">87</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:InvestmentIncomeNet" scale="3" id="f-991">536</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-992">10,830</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-993">9,886</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:InterestExpenseDebt" format="ixt:num-dot-decimal" scale="3" id="f-994">12,342</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-995">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" sign="-" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:num-dot-decimal" scale="3" id="f-996">13,129</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" name="us-gaap:GainsLossesOnExtinguishmentOfDebt" format="ixt:fixed-zero" scale="3" id="f-997">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-200" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-998">49,079</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-201" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-999">160,777</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-202" decimals="-3" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" format="ixt:num-dot-decimal" scale="3" id="f-1000">111,439</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/>*For the years ended December&#160;31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December&#160;31, 2022, the other segment items category also includes restructuring expense.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-monetary long-lived assets primarily consist of property and equipment, goodwill, and operating right-of use-assets.&#160;<ix:nonNumeric contextRef="c-1" name="us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock" id="f-1001" continuedAt="f-1001-1" escape="true">The following table summarizes non-monetary long-lived assets by geographic region as of December&#160;31, 2024 and 2023:</ix:nonNumeric></span></div><ix:continuation id="f-1001-1"><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:65.566%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.835%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.839%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets by Geographic Region: </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-126" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1002">17,513</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-203" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1003">18,413</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-125" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1004">12,210</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-204" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1005">11,751</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1006">29,723</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:NoncurrentAssets" format="ixt:num-dot-decimal" scale="3" id="f-1007">30,164</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on long-lived assets was immaterial for the years ended December&#160;31, 2024, 2023 and 2022.</span></div></ix:continuation><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-99-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_190"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Avadel Pharmaceuticals plc</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Avadel Pharmaceuticals plc  (the "Company") as of December 31, 2024 and 2023 the related consolidated statements of loss, comprehensive loss, shareholders' equity, and cash flows, for each of the three years in the period ended December 31, 2024, and the related notes and the schedule listed in the Table of Contents at Item 15 (collectively referred to as the "financial statements"). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the three years in the period ended December 31, 2024, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013) </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated March&#160;3, 2025, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Net Product Revenue- Reserves for Variable Consideration&#8211; Patient Financial Assistance Programs and Rebates &#8211; Refer to Note 1 to the financial statements</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:111%">Critical Audit Matter Description</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">As described in Note 1 to the financial statements, the Company's revenue from product sales is recognized in accordance with Accounting Standards Codification Topic 606 ("ASC 606") when the customer obtains control of the product. The Company&#8217;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis. The Company estimates a reserve for patient financial assistance programs primarily based on expected utilization by patients.  The Company estimates a reserve for rebates based on contractual rates and estimates regarding their expectations of future patient utilization rates. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Given the complexity and </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-100-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">judgment involved in determining the significant assumptions used in estimating the reserve for patient financial assistance programs and rebates, auditing such estimates required a high degree of auditor judgment and increased extent of audit effort.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">How the Critical Audit Matter Was Addressed in the Audit </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Our audit procedures related to the reserve for patient financial assistance programs and rebates included the following, among others</span><span style="color:#000000;font-family:'Calibri Light',sans-serif;font-size:11pt;font-weight:400;line-height:100%">: </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We tested the effectiveness of controls over management&#8217;s process to account for variable consideration associated with the reserve for patient financial assistance programs and rebates, including underlying assumptions and key inputs into the Company's process to calculate the patient financial assistance programs and rebate accruals. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We evaluated the Company's methodology and assumptions in developing the reserves for patient financial assistance programs and rebates accrual models, including assessing the completeness and accuracy of the underlying data used by management in their estimates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We tested the mathematical accuracy of the reserve for patient financial assistance programs and rebates.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">We performed retrospective reviews comparing management&#8217;s estimates of the expected reserve for patient financial assistance programs and rebates to actual amounts incurred subsequent to the dates of estimation, to evaluate management's ability to accurately forecast the reserves.</span></div><div><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St. Louis, Missouri&#160;&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2025&#160;&#160;</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-101-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the shareholders and the Board of Directors of Avadel Pharmaceuticals plc </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have audited the internal control over financial reporting of Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> issued by COSO.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December 31, 2024, of the Company and our report dated March&#160;3, 2025, expressed an unqualified opinion on those financial statements.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div style="margin-bottom:9pt;margin-top:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="text-align:justify"><span><br/></span></div><div><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St. Louis, Missouri</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2025</span></div><div><span><br/></span></div><div><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="text-align:right"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-102-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_193"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9. &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None. </span></div><div style="padding-left:4.5pt;text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_196"></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Controls and Procedures.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Evaluation of Disclosure Controls and Procedures</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Management of the Company, with the participation of its Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the Company&#8217;s disclosure controls and procedures as of December&#160;31, 2024, the end of the period covered by this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended (&#8220;Exchange Act&#8221;), means controls and other procedures of a company that are designed to provide reasonable assurance that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#8217;s rules and forms. Disclosure controls and procedures are also designed to provide reasonable assurance that such information is accumulated and communicated to the Company&#8217;s management, including its Chief Executive Officer and Chief Financial Officer, to allow timely decisions regarding required disclosure.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on their evaluation, as of the end of the period covered by this Annual Report on Form 10-K, the Company&#8217;s Chief Executive Officer and Chief Financial Officer have concluded that the Company&#8217;s disclosure controls and procedures (as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act) were effective as of December&#160;31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Management&#8217;s Report on Internal Control over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Securities Exchange Act of 1934, as amended. Our internal control over financial reporting is designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements in accordance with U.S. generally accepted accounting principles.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect all misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2024. In making this assessment, our management used the criteria set forth in </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Based on this assessment, management concluded that, as of December&#160;31, 2024, the Company&#8217;s internal control over financial reporting is effective based on those criteria.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s independent auditors have issued their auditors&#8217; report on the Company&#8217;s internal control over financial reporting. That report appears above in this Annual Report on Form 10-K.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Changes in Internal Control Over Financial Reporting</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no changes in our internal control over financial reporting identified in connection with the evaluation required by paragraph (d) of Exchange Act Rule 13a-15 or 15d-15 that occurred during the year ended December&#160;31, 2024 that have materially affected, or are reasonably likely to materially affect, our internal controls over financial reporting. </span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_199"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9B. &#160;&#160;&#160;&#160;Other Information.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">During the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, none of the Company&#8217;s directors or officers (as defined in Rule 16a-1(f) of the Securities Exchange Act of 1934) <ix:nonNumeric contextRef="c-205" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1008"><ix:nonNumeric contextRef="c-205" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-1009">adopted</ix:nonNumeric></ix:nonNumeric>, <ix:nonNumeric contextRef="c-205" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1010"><ix:nonNumeric contextRef="c-205" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-1011">terminated</ix:nonNumeric></ix:nonNumeric> or modified a Rule 10b5-1 trading arrangement or non-Rule 10b5-1 trading arrangement (as such terms are defined in Item 408 of Regulation S-K). </span></div><div style="margin-bottom:9pt;text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_202"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;9C. &#160;&#160;&#160;&#160;Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-103-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_205"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-bottom:9pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PART III</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_208"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;10. &#160;&#160;&#160;&#160;Directors, Executive Officers and Corporate Governance.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth for each director and the executive officers of the Company, their ages and positions with the Company as of March&#160;3, 2025.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.297%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.447%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Age</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">58</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer and Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Counsel &amp; Corporate Secretary</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Geoffrey M. Glass</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">51</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair of the Board of Directors</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naseem S. Amin, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Eric J. Ende, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mark A. McCamish, M.D., Ph.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linda S. Palczuk</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">63</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peter J. Thornton</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Director</span></td></tr></table></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Gregory J. Divis </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">was appointed Chief Executive Officer and became a member of the Board of Directors (the &#8220;Board&#8221;) in June 2019, after having served as Interim Chief Executive Officer from January 2019 to May 2019. He was appointed Executive Vice President and Chief Commercial Officer of Avadel in January 2017 and was promoted to Chief Operating Officer in March 2018. Before joining Avadel, Mr. Divis served as an Executive in Residence at Linden Capital Partners, a healthcare-focused private equity firm. Mr. Divis brings to this role more than 25 years of experience in the pharmaceutical industry and is responsible for managing commercial strategy and execution across all of the Company&#8217;s portfolio products. Mr. Divis is a graduate of the University of Iowa.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Thomas S. McHugh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was appointed as Chief Financial Officer in December 2019. Before joining Avadel, Mr. McHugh was the Senior Vice President, Finance at Ironshore Pharmaceuticals, a pharmaceutical company, from November 2018 to November 2019. Mr. McHugh earned a B.S. in Finance from Bentley University and a M.S. in Accounting from Northeastern University.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Jerad G. Seurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been our General Counsel and Corporate Secretary, as well as the Company&#8217;s Compliance Officer, since September 2020. Mr. Seurer was originally appointed Vice President and Deputy General Counsel at Avadel in October 2017. Mr. Seurer is currently licensed to practice law in Missouri, Minnesota and South Dakota, and is also a registered practitioner at the United States Patent &amp; Trademark Office. Mr. Seurer earned a B.S. in Biology, M.A. in Biology, and J.D. in Law from the University of South Dakota.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Geoffrey M. Glass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> has been a member of the Board since July 2018 and became Chair of the Board in December 2018. Since January 2021, Mr. Glass has served as the Chief Executive Officer of Kiniciti, LLC, a company focused on accelerating the advancement of the cell and gene therapy sector. He is also currently the Chairman of the Board at Ncardia, a drug discovery company focused on cardiovascular and neurological diseases, serving in that role since November of 2021. Further, since June of 2022, Mr. Glass has served as Chairman of the Board at Abzena, a biologics and bioconjugates development company. Mr. Glass has also been the Operating Partner at LongueVue Capital. Previously, he was the Chief Executive Officer (from January 2018 through September 2018), and a member of the board of directors (from November 2017 through December 2018), of Sancilio Pharmaceuticals, a specialty pharma company. Mr. Glass was also a member of the board of directors for Locus Biosciences, a biotechnology company that develops CRISPR-engineered precision antibacterial products, from August 2015 to October 2017. From April 2009 to April 2015, Mr. Glass served as an executive committee member at Patheon N.V., a pharmaceutical contract development and manufacturing company. While at Patheon, he held a number of senior leadership roles including President of Banner Life Sciences (a Patheon subsidiary), Executive Vice President of Sales and Marketing, and Senior Vice President, Strategy, Corporate Development and Integration for Patheon. Before Patheon, Mr. Glass worked in various executive positions at Valeant Pharmaceuticals (now Bausch Health), including Senior Vice President, Asia Region, and Senior Vice President, Chief Information Officer, and in both roles was a member of the company&#8217;s executive committee. Mr. Glass began his career as a consultant in the life sciences practice for Capgemini Consulting (formerly EY Consulting). He received degrees in Economics and Political Science from the University of Arizona.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-104-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr. Glass&#8217;s extensive management and financial experience makes him well qualified to serve as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dr. Naseem S. Amin </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been a member of the Board since May 2024. He currently serves as Chief Executive Officer of Orphalan SA. Dr. Amin has served as the Chief Executive Officer at GMP-Orphan since June 2017 and has served as the Chairman of Arix Bioscience plc, a global venture capital company focused on investing in life sciences, since April 2020. Dr. Amin had served as the Chief Scientific Officer of Smith and Nephew Plc until 2014. Previously, Dr. Amin was Senior Vice President, Business Development at Biogen Idec from 2005 to 2009 and was with Genzyme Corporation from 1999 to 2005, most recently as Head, International Business Development and where he has also led the clinical development of five currently marketed therapeutic products. Dr. Amin began his career at Baxter Healthcare Corporation, where he served as Director, Medical Marketing and Portfolio Strategy, Renal Division. Dr. Amin is a Venture Partner at Advent Life Sciences, serves as an Advisory Board member for Imperial College, Department of Biomedical Engineering, and serves as Chairman of OPEN-London, a non-profit organization focused on encouraging and mentoring South Asians from Pakistan who are interested in starting entrepreneurial companies. Dr. Amin has also served on the board of directors of Bellerophon Therapeutics, Inc. from May 2021 to March 2024. Dr. Amin received his medical degree from the Royal Free School of Medicine, London, and an MBA from the Kellogg Graduate School of Management, Northwestern University.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that Dr. Amin&#8217;s broad experience in the biotechnology industry makes him well qualified to serve as a director.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dr. Eric J. Ende </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has been a member of the Board since December 2018. Dr. Ende is the President of Ende BioMedical Consulting Group, a privately held consulting company focused on the life sciences industry, a position he has held since 2009. Since May 2017, Dr. Ende has been a member of the board of directors of Matinas BioPharma, Inc., a clinical-stage biopharmaceutical company, where he is currently Chairman of the Board in addition to serving on the Nominating and Corporate Governance Committee. Dr. Ende also serves on the board of directors at Neubase Therapeutics, a company focused on genetic medicines development, and at Mount Sinai Innovation Partners Technology, a healthcare research and development organization. From November 2019 to June 2020, Dr. Ende served on the board of directors and as a member of the Audit, Compensation and Science Committees of Progenics Pharmaceuticals, Inc., a biopharmaceutical company, until it was acquired by Lantheus Holdings, Inc. From January 2015 to October 2016, he served as Chairman of the Unsecured Creditor&#8217;s Committee in the bankruptcy of Egenix, Inc. From 2010 to 2011, Dr. Ende served on the board of directors and as a member of the Audit and Risk Management Committees of Genzyme Corp., a biotechnology company, until it was acquired in 2011 by Sanofi S.A. From 2002 through 2008, Dr. Ende was the senior biotechnology analyst at Merrill Lynch; from 2000 through 2002 he was the senior biotechnology analyst at Bank of America Securities; and from 1997 to 2000 he was a biotechnology analyst at Lehman Brothers. Dr. Ende received an MBA in Finance and Accounting from NYU - Stern Business School in 1997, an MD from Mount Sinai School of Medicine in 1994, and a BS in Biology and Psychology from Emory University in 1990.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr. Ende&#8217;s experience as a director for other pharmaceuticals companies makes him well qualified to serve as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Dr. Mark A. McCamish</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a member of the Board since December 2019. Since November 2020, Dr McCamish has served as President, Chief Executive Officer and member of the board of directors of IconOVir Bio, Inc., a biotechnology company focused on development of oncolytic virus therapies. From May 2017 to April 2020, Dr. McCamish served as President, Chief Executive Officer and member of the board of directors of Forty Seven, Inc, a clinical-stage biopharmaceutical company, which was acquired by Gilead Sciences, Inc. in April 2020. From July 2009 to April 2017, Dr. McCamish served as Global Head of Biopharmaceutical Development at Sandoz Inc., a pharmaceutical company. He has over 30 years of experience in corporate management, clinical and pharmaceutical research and academics. Dr. McCamish currently serves on the board of directors of Rafael Holdings, Inc., a publicly traded biopharmaceutical company focused on development of cancer and immune therapies, and he has also served on the board of directors of Vincerx Pharma, Inc. from December 2020 to May 2021. Dr. McCamish received both a Bachelor&#8217;s and a Master&#8217;s degree from the University of California at Santa Barbara, a Ph.D. in Human Nutrition from the Pennsylvania State University and an M.D. from the University of California at Los Angeles. He is Board Certified in Internal Medicine and Nutrition and Metabolism.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Dr. McCamish&#8217;s broad experience in the life sciences industry makes him well qualified to serve as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Linda S. Palczuk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a member of the Board since July 2018. From September 2019 to December 2022, Ms. Palczuk served as the Chief Operating Officer and a director of Envara Health, Inc., a medical nutrition technology company. Before that, Ms. Palczuk was the Chief Operating Officer of Verrica Pharmaceuticals, Inc., a late-stage biopharmaceutical company focused on medical dermatology products, from February 2018 to April 2019. Prior to joining Verrica Pharmaceuticals, from July 2017 to February 2018, Ms. Palczuk was President and Chief Executive Officer at Osiris Therapeutics, Inc., a regenerative medicines biotechnology company. Prior to her position at Osiris Therapeutics, Ms. Palczuk had an extensive and successful 30-year career with AstraZeneca Pharmaceuticals and its legacy companies, serving in senior-level commercial and general </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-105-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">management roles, including Vice President, Mature Brands and Vice President, Global Commercial Excellence from January 2012 until March 2015, Vice President, Sales &amp; Marketing from March 2009 to December 2011, and Vice President, Sales from April 2006 to February 2009. From June 2015 until July 2017, Ms. Palczuk was an independent consultant providing business expertise within the pharmaceutical sector. Ms. Palczuk received a BA degree in Biology from Franklin and Marshall College and an MBA degree from the Alfred Lerner College of Business and Economics at the University of Delaware.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Ms. Palczuk&#8217;s extensive pharmaceutical and biotechnology management experience makes her well qualified to serve as a director.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Peter J. Thornton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has been a member of the Board since June 2017. Since January 2022, he is the President and Chief Financial Officer of Envetec Sustainable Technologies Limited, an Irish cleantech company focused on the carbon neutral treatment of biohazardous clinical material and plastics at source. From January 2014 to January 2022, he was the Chief Financial Officer of Technopath Clinical Diagnostics, which was acquired by LGC Group in January 2021. Prior to joining Technopath Clinical Diagnostics, from September 2011 to December 2013, Mr. Thornton was Senior Vice President - Business Integration for Alkermes plc, a global biopharmaceuticals company headquartered in Dublin, Ireland. From July 2007 to September 2011, he was Senior Vice President &#8212; Corporate and Business Development for Elan Drug Technologies, an Elan Corporation plc division engaged in developing and manufacturing drug delivery technology-based pharmaceutical products. From September 2006 to July 2007, he was President and Chief Operating Officer of Circ Pharma Limited, a specialty pharmaceutical company, and from June 2004 to September 2006, he was Chief Financial Officer of Agenus Inc., a Nasdaq-listed biotechnology company. Mr. Thornton has previously served as a non-executive director of both public and private companies and currently is a non-executive director of Oculer Limited, a private company focused on rapid microbiology testing technology. Mr. Thornton worked for the international public accounting firm of KPMG for seven years in Ireland and France and is a fellow of Chartered Accountants Ireland. He holds a Bachelor of Commerce degree from University College Cork, Ireland.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe Mr. Thornton&#8217;s experience as a chief financial officer and his financial expertise make him well qualified to serve as a director. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Family Relationships</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no family relationship between any director or executive officer of the Company. There are no material proceedings to which any director, officer or affiliate, or any associate thereof, of the Company, any owner of record or beneficially of more than five percent of any class of voting securities of the Company, or security holder is a party adverse to the Company or any of its subsidiaries or has a material interest adverse to the Company or any of its subsidiaries. During the past ten years, none of our officers, directors, promoters or control persons have been involved in any legal proceedings as described in Item 401(f) of Regulation S-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Governance Guidelines</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has adopted corporate governance guidelines that set forth the practices of the Board with respect to the qualification, selection and election of directors, director orientation and continuing education, director responsibilities, Board composition and performance, director access to management and independent advisors, director compensation guidelines, management evaluation and succession, policies regarding the independent directors, meetings of the non-management directors, the policy on communicating with the non-management directors and various other issues. A copy of our corporate governance guidelines is available at https://investors.avadel.com/corporate-governance/highlights. A printed copy is available free of charge to any shareholder who requests it by contacting the Company Secretary in writing at 10 Earlsfort Terrace, Dublin 2, D02 T380 Ireland.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Audit Committee</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Composition, Qualifications and Governance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has an Audit Committee composed of Peter J. Thornton (Chair), Dr. Eric J. Ende, Geoffrey M. Glass and Dr. Mark A. McCamish. The Board has determined that all of the members of the Audit Committee are independent within the meaning of applicable SEC regulations and the listing standards of Nasdaq, and that each member is financially literate within the meaning of such listing standards. The Board has also determined that Mr. Thornton, as the Chair of the Committee, (i) is independent within the meaning of applicable SEC regulations and the listing standards of Nasdaq, (ii) is qualified as an audit committee financial expert within the meaning of SEC regulations, and (iii) has accounting and related financial management expertise within the meaning of the listing standards of Nasdaq and that he is financially literate within the meaning of such </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-106-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">listing standards. In addition, the Board has determined that the composition satisfies the requirements of the Irish Companies Act 2014.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has a written charter, which is available on our website at https://investors.avadel.com/corporate-governance/highlights. The Audit Committee reviews the charter annually and works with the Board to amend it as appropriate to reflect the evolving role of the Audit Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Responsibilities and Duties</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee recommends to the Board the selection of the Company&#8217;s independent registered public accounting firm and reviews the findings of the auditors and operates in accordance with the Audit Committee Charter. The Audit Committee Charter outlines the roles and responsibilities of the Audit Committee which includes appointment, compensation and oversight of the work of any registered public accounting firm employed by the Company and review of related party transactions pursuant to the Company&#8217;s policy. The Audit Committee also assists the Board in oversight of: (1) the integrity of the financial statements of the Company; (2) the adequacy of the Company&#8217;s system of internal controls; (3) compliance by the Company with legal and regulatory requirements; (4) the qualifications and independence of the Company&#8217;s independent auditors; and (5) the performance of the Company&#8217;s independent and internal auditors. The Audit Committee met four times during 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Changes to Procedures for Recommending Nominees to Board of Directors</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Code of Conduct and Financial Integrity Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a written Code of Conduct (the &#8220;Code of Conduct&#8221;) that applies to all of our employees, as well as a Financial Integrity Policy (the &#8220;Financial Integrity Policy&#8221;) that applies to our Chief Executive Officer, Chief Financial Officer, Chief Accounting Officer, Senior Tax Director and Controller (or persons performing similar functions). These documents cover a broad range of professional conduct, including employment policies, conflicts of interest, intellectual property and the protection of confidential information, as well as adherence to all laws and regulations applicable to the conduct of our business. A copy of the Code of Conduct and the Financial Integrity Policy is available at https://www.avadel.com/corporate-compliance. If we make any substantive amendments to, or grant any waivers from, the Code of Conduct or Financial Integrity Policy for any officer or director, we intend to satisfy the disclosure requirement under Item 5.05 of Form 8-K by disclosing the nature of such amendment or waiver on our website or in a current report on Form 8-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Insider Trading Policy</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have an insider trading policy governing the purchase, sale and other dispositions of our securities that applies to all of our directors, officers, employees and other covered persons. We believe that our insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and listing standards applicable to us. A copy of our insider trading policy is filed as Exhibit 19.1 to this Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_211"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;11. &#160;&#160;&#160;&#160;Executive Compensation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">EXECUTIVE COMPENSATION - COMPENSATION DISCUSSION AND ANALYSIS</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Discussion and Analysis</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In this Compensation Discussion and Analysis, we give an overview and analysis of our compensation philosophy, our compensation program, and the decisions we made in 2024 under those programs with respect to our named executive officers. Included in this discussion is specific information about the compensation earned or paid in 2024 to our named executive officers (the &#8220;Named Executive Officers&#8221;). Named Executive Officers for 2024 are:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.609%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Position</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Executive Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Former Chief Commercial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chief Financial Officer</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Counsel &amp; Corporate Secretary</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-107-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Mr. Kim resigned effective December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Philosophy and Objectives</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee&#8217;s executive compensation programs are designed to: (i) attract, retain and motivate executives with significant industry knowledge and the experience and leadership capability necessary for us to achieve success; (ii) align incentives for our named executive officers with our corporate strategies and business objectives and goals; and (iii) achieve key strategic performance measures aligned with the long-term interests of our shareholders.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Components</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive compensation program has three primary components: base salary, annual cash incentive awards and equity awards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Base Salary.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We fix the base salary of each of our executive officers at a level we believe enables us to hire and retain individuals in a competitive environment and rewards satisfactory individual performance and a satisfactory level of contribution to our overall business goals. We take into account the base salaries paid by similarly situated companies in our peer group and, to the extent practicable, we set base salary levels for similarly situated executives within the Company at comparable levels to avoid divisiveness and encourage teamwork, collaboration, and a cooperative working environment.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Cash Incentive Awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We provide annual cash incentive awards that are based upon the achievement of corporate and individual objectives established by the Compensation Committee and the Board of Directors. These cash incentive awards are designed to focus our executive officers on achieving key clinical, regulatory, commercial, operational, strategic and financial objectives.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Equity Awards.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We use stock options, restricted share units and performance share units to reward long-term performance. These equity awards are intended to provide significant incentive value for each executive officer if the Company performance is outstanding and the Company achieves its long-term goals to align executive compensation with long-term shareholder interests.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the primary components of compensation described above, we provide our Named Executive Officers with employee benefits that are generally available to our salaried employees. These benefits include health and medical benefits, flexible spending plans, matching 401(k) contributions and group life insurance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also entered into agreements with our Named Executive Officers under which they are provided certain benefits in the event their employment with the Company is terminated without cause or by the Named Executive Officer for good reason, following a change in control of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Policies and Process</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has oversight of our compensation philosophy and programs and annually reviews and recommends all compensation decisions relating to our Chief Executive Officer, our other Named Executive Officers and all other executive officers of the Company. The Chief Executive Officer provides specific information to the committee relative to the performance of the other members of the executive management team. However, the Chief Executive Officer is always excused from the Compensation Committee meetings when his compensation or employment is discussed. The Compensation Committee considers any recommendations by the Chief Executive Officer; however, the committee recommends final compensation for all executives. All compensation decisions are assessed within the framework of the Company&#8217;s financial position and general economic conditions. Our Board typically reviews and approves the compensation decisions made by the Compensation Committee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Compensation Committee has engaged Aon&#8217;s Human Capital Solutions Practices, a division of Aon plc (&#8220;Aon&#8221;) specializing in executive compensation, as its independent compensation consultant. In connection with the Compensation Committee&#8217;s executive compensation decisions for 2024, Aon reviewed and advised on principal aspects of our executive compensation program and performed the following services:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">conducted a competitive assessment of the Company&#8217;s then current executive compensation arrangements, including analyzing peer group Proxy Statements, compensation survey data, and other publicly available data;</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-108-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewed and provided compensation related data to support the Company&#8217;s disclosures;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provided recommendations on the composition of the Company&#8217;s peer group; and</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reviewed and advised on equity compensation and on industry best practices.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has determined that the work of Aon and the individual compensation advisors employed by Aon does not create any conflict of interest. In making that determination, the Compensation Committee took into consideration the following factors: (i) the provision of other services to the Company by the consultant; (ii) the amount of fees the Company paid the consultant as a percentage of the consultant&#8217;s total revenue; (iii) the consultant&#8217;s policies and procedures that are designed to prevent conflicts of interest; (iv) any business or personal relationship of the consultant or the individual compensation advisors employed by the consultant with any Company executive officer; (v) any business or personal relationship of the individual compensation advisors with any member of the Compensation Committee; and (vi) any Company stock owned by the consultant or the individual compensation advisors employed by the consultant.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Peer Group</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In an effort to provide competitive total compensation to our executive officers, the Compensation Committee approved a group of comparable companies as our peer group as recommended by Aon. The peer group was selected on the basis of similarity to the Company on the following criteria: business comparability, stage of product development and commercialization, number of employees, market capitalization and revenue. The following companies were identified as our &#8220;peer group&#8221; for 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:48.753%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:49.047%"/><td style="width:0.1%"/></tr><tr><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Peer Group</span></div></td></tr><tr><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amicus Therapeutics, Inc.</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dynavax Technologies Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Anika Therapeutics,&#160;Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Harmony Biosciences Holdings,&#160;Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Arcutis Biotherapeutics, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Harrow,&#160;Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ardelyx,&#160;Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liquidia Corporation</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Axsome Therapeutics,&#160;Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Mirum Pharmaceuticals,&#160;Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Catalyst Pharmaceuticals, Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Rhythm Pharmaceuticals,&#160;Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Collegium Pharmaceutical,&#160;Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sage Therapeutics, Inc.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deciphera Pharmaceuticals,&#160;Inc.</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">TG Therapeutics, Inc.</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Say-on-Pay and Say-on-Frequency</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have developed a compensation policy that is designed to attract and retain key executives responsible for our success and motivate management to enhance long-term shareholder value. We believe our compensation policy strikes an appropriate balance between the implementation of responsible, measured compensation practices and the effective provision of incentives for our named executive officers to exert their best efforts for our success.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As required by Section 14A(a)(1) of the Exchange Act, periodically we must provide our shareholders with an opportunity to provide an advisory vote related to the compensation of our named executive officers, commonly known as the &#8220;say-on-pay&#8221; proposal. The SEC say-on-pay vote generally covers the calendar year prior to the date of our proxy statement. As such vote is advisory, it is not binding upon our Board or our Compensation Committee and neither the Board nor the Compensation Committee is required to take any action as a result of the outcome of such vote. However, our Compensation Committee carefully considers the outcome of this vote when considering future executive compensation policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As reported in our report on Form 8-K, filed with the SEC on August 1, 2024, at our 2024 annual general meeting, approximately 90% of the votes cast on our SEC Say-on-Pay proposal supported the compensation paid to our named executive officers. At our 2022 annual general meeting, we held a separate non-binding advisory shareholder vote on the frequency of future shareholder advisory votes regarding the compensation program for our named executive officers, commonly referred to as a &#8220;say-on-frequency&#8221; vote. At the 2022 annual general meeting, our shareholders approved, on an advisory basis, a proposal to take the say-on-pay vote every two years until the next required say-on-frequency vote. Accordingly, our next say-on-pay vote will occur at the 2026 annual general meeting and our next say-on-frequency vote will occur at the 2028 annual general meeting.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Base Salary</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-109-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company provides base salaries to attract and retain executives with the proper experiences and skill sets required to assist us in achieving our specific business objectives, as well as our future growth and success. Base salaries provide a guaranteed base level of compensation that reflects a belief that base salary for executive officers should be targeted at market-competitive levels. Base salaries for a particular fiscal year are generally established at the end of the prior year. In establishing the base salaries for 2024, the Compensation Committee considered each Named Executive Officer&#8217;s role and level of responsibility at the Company, recent individual performance, perceived impact on Company results and overall Company performance. The base salaries of our Named Executive Officers during 2023 and 2024 were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:42.759%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.887%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023 Base</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary ($)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Base</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Salary ($)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Increase<br/>(%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><br/>(1) Mr. Kim resigned effective December 31, 2024. In connection with such resignation, the Company and Mr. Kim agreed to a form of separation and release agreement consistent with the terms of his employment agreement. Additionally, Mr. Kim remained eligible for 2024 incentive compensation.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Mr. Seurer was appointed as an executive officer in April 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Annual Cash Incentive</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The goal of the annual cash incentive program in 2024 was to align a meaningful portion of the total compensation potential for the Named Executive Officers to the achievement of specified quantitative and qualitative Company performance targets, as well as individual performance targets. The achievement of these targets advances the Company&#8217;s specific business objectives and results in long-term shareholder value. The target levels of the annual cash incentive awards were established as part of the Named Executive Officer&#8217;s individual employment agreements. Each of these employment agreements provides that the Named Executive Officer will receive an annual cash incentive award determined at the discretion of the Compensation Committee and the Board based on the Company&#8217;s performance against its objectives and individualized objective and subjective criteria, with a target award amount equal to a percentage of the Named Executive Officer&#8217;s base salary. The award criteria include specific objectives, relating to the achievement of clinical, regulatory, commercial, business and/or financial milestones. The table below sets forth each Named Executive Officer&#8217;s target incentive compensation for 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.981%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.882%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Target</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus (% of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Base Salary)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Target</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus ($)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024 Actual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Bonus ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">45&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">113,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)  Actual bonus paid to our Named Executive Officers based on the Company&#8217;s performance.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Mr. Kim resigned effective December 31, 2024. Mr. Kim remained eligible for 2024 year end incentive compensation, which at the discretion of the Compensation Company, was determined to be $0. In addition, Mr. Kim was eligible for a bonus based upon achievement of certain commercial milestones. Accordingly, Mr. Kim received $109,438 related to the achievement of certain commercial milestones which were met in 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) In addition to payment of an annual target bonus based upon corporate and individual performance, Mr. Seurer was eligible for an additional bonus based upon achievement of certain commercial milestones. Accordingly, in addition to the $113,400 paid to Mr. Seurer for 2024 performance, Mr. Seurer received an additional $87,500 related to the achievement of certain commercial milestones which were met in 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our approved 2024 corporate goals consisted of:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Achieving LUMRYZ launch revenue and patient demand targets</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execution of financial strategy and organizational plan</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Execution of portfolio and pipeline expansion</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-110-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee determined that the Company&#8217;s overall corporate performance score was 50% for 2024 based solely on the Compensation Committee&#8217;s assessment of the Company&#8217;s level of achievement against the approved 2024 corporate performance goals set forth above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mr. Divis&#8217; 2024 annual cash incentive bonus was based on the discretionary judgment of the Compensation Committee. The Compensation Committee determined to award no annual cash incentive with respect to 2024 for Mr. Divis. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process for determining the annual cash incentive for our other Named Executive Officers is generally similar to what is described above with respect to our Chief Executive Officer. For 2024, the Compensation Committee took into account the Company&#8217;s overall performance with respect to the corporate goals discussed above. The Compensation Committee assessed the individual performance of the other Named Executive Officers and also considered the recommendations of Mr. Divis. The other Named Executive Officers reported directly to Mr. Divis as Chief Executive Officer and so, the Compensation Committee believes Mr. Divis was in a position to provide a meaningful assessment of their capabilities and contributions to the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee determined 2024 annual cash incentives for the other Named Executive Officers based on its assessment of the Company&#8217;s achievement with respect to the corporate goals discussed above, in the following amounts: Richard J. Kim&#8201;-&#8201;$0, Thomas S. McHugh&#8201;-&#8201;$52,354, and Jerad G. Seurer - $113,400.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Equity Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee believes equity compensation awards help to align the interests of our executive officers with those of shareholders because the value of the equity awards to the recipient increases only with the appreciation of the price of our ordinary shares. Furthermore, the Compensation Committee believes granting equity awards that vest over time encourages executives to remain with the Company. The authority to grant equity awards to our executive officers lies with the Compensation Committee and Board. The Compensation Committee takes into consideration the peer group data provided by Aon and the recommendations of our Chief Executive Officer (other than for himself). Generally, the Compensation Committee has granted stock options to our executive officers upon commencement of their employment with the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to new hire stock options, at least annually, the Compensation Committee considers equity awards for our executive officers. These awards may consist of stock options, restricted share units (&#8220;RSUs&#8221;), restricted stock awards (&#8220;RSAs&#8221;) performance share units (&#8220;PSUs&#8221;) or performance stock options (&#8220;PSOs&#8221;). In February 2024, the Compensation Committee determined it would be appropriate to award time-based stock option awards to our Named Executive Officers as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:59.133%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:37.937%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Options</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining the number of stock options to grant to a particular Named Executive Officer, the Compensation Committee takes into account numerous factors, including: the executive&#8217;s role and level of responsibility within the Company, the Company&#8217;s performance with respect to the financial and strategic goals and objectives for that year, and comparative peer group data as presented by Aon.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Risk Assessment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company regularly reviews compensation plans and practices to ensure they are appropriately structured and aligned with business objectives, and not designed to encourage executives to take unwarranted risks. Specifically, the overall design of the compensation philosophy and plans mitigate risks because: (1) the financial performance objectives of the short and long-term incentive plans are reviewed and approved annually by the Board; (2) the plans consist of multiple performance objectives, thus lessening the focus on any one in particular; and (3) short and long-term incentive payouts are capped for all participants.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">General Employee Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel offers competitive health, dental and life insurance and vacation pay for all employees, including Named Executive Officers. In addition, the senior executives are eligible to receive matching 401(k) plan contributions on the same basis as other employees.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-111-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Severance and Change-in-Control Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to employment agreements, each of our Named Executive Officers has a provision in his or her employment agreement with the Company that entitles such Named Executive Officer to certain specified benefits in the event of termination of their employment under specified circumstances, including termination following a change in control of the Company. These benefits are described in the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Employment Agreement</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; section below, and certain estimates of these severance and change-in-control benefits are provided in &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Potential Payments Upon Termination or Change in Control</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; below.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Retirement Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company believes offering competitive retirement benefits is important to attract and retain top executives. The Company&#8217;s U.S.-based executives participate in a traditional defined contribution 401(k) plan. For our Company&#8217;s 401(k) plan, the Company generally contributed approximately $12,000 to $14,000 to each eligible executive&#8217;s 401(k) account during 2024, which was the maximum contribution match allowable under the Company&#8217;s 401(k) Plan, provided the participant contributed the maximum in order to receive the maximum match and contributed based off of $345,000 of wages, the maximum allowable under the IRS limits. Additional details regarding retirement benefits are provided in the tables below entitled &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary Compensation Table</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Deductibility of Executive Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generally, Section 162(m) of the Code disallows a federal income tax deduction for public corporations of remuneration in excess of $1 million paid for any fiscal year to &#8220;covered employees&#8221; of the Company. The Board and the Compensation Committee believe shareholder interests are best served if they retain maximum flexibility to design executive compensation programs that meet stated business objectives. For that reason, while our Board and Compensation Committee consider the potential effects of Section 162(m) of the Code on the compensation paid to our named executive officers, in light of the constraints imposed by Section 162(m) and our desire to maintain flexibility in compensation decisions, the Board and the Compensation Committee do not necessarily limit compensation to amounts deductible under Section 162(m).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Taxation of &#8220;Parachute&#8221; Payments</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sections 280G and 4999 of the Code provide that executive officers and directors who hold significant equity interests and certain other service providers may be subject to significant additional taxes if they receive payments or benefits in connection with a change in control of the Company that exceeds certain prescribed limits, and that the Company (or a successor) may forfeit a deduction on the amounts subject to this additional tax. Our compensation arrangements for executive officers, including our Named Executive Officers, do not provide tax gross-ups for any type of payments, including payments for severance or in connection with a change of control of the Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities Trading Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a policy that prohibits executive officers and directors from trading in the Company&#8217;s securities while aware of material non-public information or engaging in hedging transactions or short sales and trading in &#8220;puts&#8221; and &#8220;calls&#8221; involving the Company&#8217;s securities. This policy is described in our Code of Conduct, which may be viewed on our website at https://www.avadel.com/corporate-compliance. In addition, executive officers and directors are prohibited from pledging the Company&#8217;s securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Compensation Recovery Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2023, we adopted a compensation recovery policy (the &#8220;Clawback Policy&#8221;), in compliance with the requirements of the Dodd-Frank Act, final SEC rules and applicable Nasdaq listing standards, which covers our current and former executive officers, including all of our named executive officers. Under the Clawback Policy, if we are required to prepare a restatement of previously issued financial statements of the Company due to the material noncompliance of the Company with any financial reporting requirement under federal securities laws, the Company will recover any incentive-based compensation received by any current or former executive officer after the effective date of the policy and during the three-year period preceding the date on which the Company is required to prepare the restatement that is in excess of what would have been paid or earned by such executive officer had the financial results been properly reported.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2024 Compensation of Named Executive Officers</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-112-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary Compensation Table</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth the compensation paid or accrued during the fiscal years ended December 31, 2024, 2023 and 2022 to our Named Executive Officers:</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:21.268%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.818%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.204%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.213%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Principal Position</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Year</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Base Salary ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Equity</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Incentive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation ($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Compensation ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">651,600&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,722,205&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,800&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,399,605&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Chief Executive Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">360,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">985,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">561,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">168,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,200&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">753,687&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">472,328&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,646,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">109,438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525,595&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,754,301&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Former Chief Commercial Officer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">454,161&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">303,592&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">770,953&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,750&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,494&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,200&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">548,444&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,372&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764,579&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,354&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,393&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,294,698&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;Chief Financial Officer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">437,997&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,867&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,280&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">663,144&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,343&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">94,577&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,079&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">525,999&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,900&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,800&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,035,159&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Counsel &amp; Corporate Secretary</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents salaries before any employee contributions under our 401(k) Plan. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Represents the aggregate grant date fair value of share awards granted in 2024, 2023 and 2022, respectively, calculated in accordance with FASB ASC Topic 718. For a full description of the assumptions we use in calculating these amounts, see Note 15 to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. The actual value a Named Executive Officer may receive depends on market prices and there can be no assurance that the amounts reflected in the Stock Awards column will actually be realized. The amounts reported for 2023 do not reflect PSUs awarded in August 2023 as the grant date of such awards for accounting purposes did not occur in 2023. 1/3 of the PSUs that were tied to performance during the second half of 2023 were forfeited in February 2024. 2/3 of the PSUs that were tied to performance during 2024 were forfeited in February 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Amounts reported reflect the aggregate grant date fair value of options granted in 2024, 2023 and 2022, respectively, calculated in accordance with FASB ASC Topic 718. For a full description of the assumptions we use in calculating these amounts, see Note 15 to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. The actual value a Named Executive Officer may receive depends on market prices and there can be no assurance that the amounts reflected in the Option Awards column will actually be realized. No gain to a named executive officer is possible without an increase in share price after the date of grant. For 2022, the amounts reported in this table to Mr. Divis, Mr. McHugh and Mr. Kim do not include the grant date fair value of the PSOs, as achievement was not probable on the grant date. Assuming maximum achievement, the grant date fair value of the PSOs granted in 2022 to each of Mr. Divis, Mr. McHugh and Mr. Kim would have been $1,297,738, $648,869 and $648,869, respectively.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Non-equity incentive plan compensation represents cash bonuses for meeting Company and, if applicable, personal performance targets for the applicable year.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) For 2024, amounts include (i) for Mr. Divis, $13,800 in employer 401(k) contributions and $12,000 in auto allowance, (ii) for Mr. Kim, $13,800 in employer 401(k) contributions, $472,328 in cash severance payable in substantially equal installments in accordance with the Company&#8217;s normal payroll practices over 12 months and $39,467 of COBRA premiums, (iii) for Mr. McHugh, $12,393 in employer 401(k) contributions and (iv) for Mr. Seurer, $13,800 in employer 401(k) contributions.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Mr. Seurer was appointed as an executive officer in April 2024 and accordingly, compensation prior to 2024 is not included.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Grants of Plan-Based Awards 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information regarding grants of plan-based awards to the named executive officers during the year ended December 31, 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-113-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:14.104%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.695%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.005%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.034%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.043%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Future</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Payouts Under</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Non-Equity Incentive</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1) </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Estimated Future<br/>Payouts Under<br/>Equity Incentive<br/>Plan Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">All Other<br/>Option<br/>Awards:<br/>Number of<br/>Securities<br/>Underlying<br/>Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercise<br/>or Base<br/>Price of<br/>Option<br/>Awards<br/></span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Date Fair</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock and</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Target ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(Target (#)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(#)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">390,960&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,722,205&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">212,548&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">147,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,646,940&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">209,417&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,500&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,764,579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad Seurer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">189,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">--</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,400,459&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Represents the target amount that may be earned based on achievement of pre-determined performance criteria during fiscal year 2024. Our Compensation Committee has not set threshold or maximum amounts associated with non-equity incentive plan awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Amounts reported reflect the aggregate grant date fair value of options granted in 2024, respectively, calculated in accordance with FASB ASC Topic 718. For a full description of the assumptions we use in calculating these amounts, see Note 15 to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Outstanding Equity Awards at Fiscal Year-End 2024</span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth specified information concerning stock options and stock awards for each of the named executive officers outstanding as of December 31, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-114-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:14.126%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.784%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.581%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.637%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.345%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.532%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.644%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Grant Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options (#)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Exercisable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Underlying</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unexercised</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Options (#)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unexercisable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Equity<br/>Incentive<br/>Plan Awards:<br/>Number of<br/>Securities<br/>Underlying<br/>Unexercised<br/>Unearned<br/>Options (#)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option<br/>Exercise<br/>Price<br/>($)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option<br/>Expiration<br/>Date</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/14/2016</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150,000&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10.40</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/14/2026</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/12/2017</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.95</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/12/2027</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/22/2018</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.06</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/22/2028</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/7/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.85</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3/7/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">400,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1.71</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5/30/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">500,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">232,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">77,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;&#160;</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">350,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">600,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2034</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/15/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">262,500&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.99</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/31/2025</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2021</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">103,125&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/31/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/31/2025</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/31/2025</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/22/2019</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">250,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.45</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10/22/2029</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2020</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">200,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.79</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2030</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2021</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">112,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2031</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">175,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2032</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">157,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2034</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/7/2017</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.67</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11/7/2027</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/2/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.55</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1/2/2030</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2020</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.79</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/8/2030</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2021</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,875&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12/7/2031</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2022</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.69</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8/4/2032</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">125,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.57</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2/20/2034</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Unless otherwise noted, options to purchase shares become exercisable in four equal annual installments following the grant date.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Includes the unvested portion of the December 2021 option grant under the Avadel 2020 Omnibus Plan, 77,500 of which will vest on December 7, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Includes the unvested portion of the February 2024 option grant under the Avadel 2020 Omnibus Plan, 150,000 of which will vest on each of February 20, 2025, February 20, 2026, February 20, 2027, and February 20, 2028.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Mr. Kim resigned as Chief Commercial Officer effective as of December 31, 2024. In connection with such resignation, the unvested portion of his option grants were forfeited. Mr. Kim will have one year from resignation date to exercise the vested portion of his option grants.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Includes the unvested portion of the December 2021 option grant under the Avadel 2020 Omnibus Plan, 37,500 of which will vest on December 7, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) Includes the unvested portion of the February 2024 option grant under the Avadel 2020 Omnibus Plan, 39,375 of which will vest on each of February 20, 2025, February 20, 2026, February 20, 2027, and February 20, 2028.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Includes the unvested portion of the December 2021 option grant under the Avadel 2020 Omnibus Plan, 11,875 of which will vest on December 7, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Includes the unvested portion of the February 2024 option grant under the Avadel 2020 Omnibus Plan, 31,250 of which will vest on each of February 20, 2025, February 20, 2026, February 20, 2027, and February 20, 2028.</span></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-115-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Options Exercised and Shares Vested During Fiscal Year 2024</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth specified information concerning share options exercised and share awards vested for each of the named executive officers during fiscal year 2024:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:37.496%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.519%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.527%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option Awards</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share Awards</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>shares<br/>acquired on<br/>exercise (#)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value<br/>realized on<br/>exercise ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of<br/>shares<br/>acquired on<br/>vesting (#)</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Value<br/>realized on<br/>vesting ($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,627&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">268,784&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Employment Agreements</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have written employment agreements with each of our Named Executive Officers. Each employment agreement provides that the individual&#8217;s employment will continue until either we or the Named Executive Officer provides written notice of termination in accordance with the terms of the agreement. In addition, each of these agreements prohibit the Named Executive Officer from disclosing confidential information and competing with us during the term of their employment with the Company and for a specified time period thereafter. The agreements also contain customary non-solicitation and non-disparagement provisions. Under the terms of their respective employment agreements, each of the Named Executive Officers is entitled to receive an annual base salary, subject to annual review, an annual cash incentive and an annual equity award, each component of which is subject to the discretion of our Board.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to their employment agreements, each of our Named Executive Officers is entitled to certain severance benefits in the event he or she terminates his or her employment for &#8220;Good Reason&#8221; or if his or her employment is terminated by the Company for any reason other than for &#8220;Cause,&#8221; including non- renewal by the Company at the end of the employment term. Upon such a termination, each of the Named Executive Officers is entitled to receive all accrued but unpaid bonuses for any completed fiscal year and vacation pay, expense reimbursement and other benefits due under any Company-provided benefit plans, policies and arrangements. In addition, Mr. Divis is entitled to receive: (1) severance equal to 1.5 times his base salary, payable in substantially equal installments in accordance with the Company&#8217;s normal payroll practices; and (2) payment of monthly COBRA health insurance premiums for up to 18 months, and Mr. Kim, Mr. McHugh, and Mr. Seurer are entitled to receive (1) severance equal to 1.0 times their base salary, payable in substantially equal installments in accordance with the Company&#8217;s normal payroll practices; and (2) payment of monthly COBRA health insurance premiums for up to 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above, if such a termination occurs during a Change in Control Period (as defined below), Mr. Divis is entitled to receive (i) the highest of (x) his target bonus in effect for the fiscal year in which the applicable change in control occurs, (y) his target bonus in effect for the fiscal year in which the termination of employment occurs; or (z) his actual bonus for performance during the calendar year prior to the calendar year during which the termination of employment occurs. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, if such a termination occurs during a Change in Control Period (as defined below), each of the Named Executive Officers is entitled to receive (i) the immediate vesting of 100% of his outstanding and unvested share options and any other equity awards under the Company&#8217;s compensation plans and (ii) outstanding and vested stock options held by each of the Named Executive Officers as of his termination of employment date will remain exercisable until the eighteen (18) month anniversary of the termination of employment date (not to extend beyond the original maximum term as of the original date of grant).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of each of the Named Executive Officer&#8217;s agreements:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"> &#8220;Good Reason&#8221; is defined as</span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">For Mr. Divis: (i) the failure of the Company to timely pay to the employee any compensation owed under the agreement; (ii) the Company&#8217;s diminution in the employee&#8217;s authority, duties or responsibilities in any material respect or the Company&#8217;s assignment to the employee of duties that are materially inconsistent with the duties stated in the agreement; (iii) the relocation of the place of the employee&#8217;s employment more than sixty (60) miles outside the greater St. Louis metropolitan area; (iv) a material breach by the Company of the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-116-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="padding-left:72pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">agreement; or (v) the failure of the Company to have the agreement assumed in full by any successor in the case of any merger, consolidation, or sale of all or substantially all of the assets of the Company.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:72pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">For Mr. Kim, Mr. McHugh, and Mr. Seurer: (i) the Company&#8217;s diminution in the employee&#8217;s authority, duties or responsibilities in any material respect or the Company&#8217;s assignment to the employee of duties that are materially inconsistent with the duties stated in the agreement; (ii) the relocation of the place of the employee&#8217;s employment which increases such employee&#8217;s one-way commute by more than sixty (60) miles for such employee; or (iii) a material breach by the Company of the agreement.</span></div><div style="padding-left:36pt;text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Cause&#8221; means: (i) conviction of or plea of nolo contendere to a felony or crime involving moral turpitude; (ii) fraud, theft, or misappropriation of any asset or property of the Company, including, without limitation, any theft or embezzlement or any diversion of any corporate opportunity; (iii) breach of any of the material obligations contained in the agreement; (iv) conduct materially contrary to the material policies of the Company; (v) material failure to meet the goals and objectives established by the Company without cure within a reasonable period of time after written notice thereof; or (vi) conduct that results in a material detriment to the Company, its program, or goals or is inimical to the Company&#8217;s reputation and interests without cure within a reasonable period of time after written notice thereof.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Change of Control Period&#8221; means the period beginning six (6) months prior to, and ending eighteen (18) months following, a Change of Control for Mr. Divis, the period ending eighteen (18) months following, a Change of Control for Mr. Kim and Mr. McHugh and the period ending twelve (12) months following, a Change of Control for Mr. Seurer.</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">&#8220;Change of Control&#8221; means the occurrence of any of the following events: (i) A change in the ownership of the Company which occurs on the date that any one person, or more than one person acting as a group (&#8216;Person&#8217;), acquires ownership of the equity interests of the Company that, together with the shares held by such Person, constitutes more than fifty percent (50%) of the total voting power of the shares of the Company; provided, however, that for purposes of this subsection, the acquisition of additional shares by any one Person, who is considered to own more than fifty percent (50%) of the total voting power of the shares of the Company will not be considered a Change or Control; or (ii) A change in the effective control of the Company which occurs on the date that a majority of the members of the Board is replaced during any twelve (12) month period by Directors whose appointment or election is not endorsed by a majority of the members of the Board prior to the date of the appointment or election. For purposes of such definition, if any Person is considered to be in effective control of the Company, the acquisition of additional control of the Company by the same Person will not be considered a Change of Control; or (iii) A change in the ownership of a substantial portion of the Company&#8217;s assets which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from the Company that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of the Company immediately prior to such acquisition or acquisitions.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The benefits provided are designed to protect earned benefits in the case that one or more of such Named Executive Officers is terminated without cause or as a result of a Change in Control of the Company, in order to encourage such Named Executive Officers to act in the best interests of the shareholders at all times during the course of a Change in Control transaction or other significant event involving our Company.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Separation Agreement</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As disclosed above, Mr. Kim resigned as Chief Commercial Officer effective as of December 31, 2024. In connection with his departure, Mr. Kim executed a separation agreement pursuant to which he was entitled to receive (i) severance equal to 1.0 times his base salary, payable in substantially equal installments in accordance with the Company&#8217;s normal payroll practices; and (ii) payment of monthly COBRA health insurance premiums for up to 12 months.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Potential Payments upon Termination or Change of Control</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth information regarding potential payments that Mr. Divis, Mr. McHugh and Mr. Seurer would have received if the Named Executive Officer&#8217;s employment had terminated as of December 31, 2024 under the circumstances set forth above. </span></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-117-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:54.747%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.577%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.467%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.582%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Termination without Cause or Resignation for Good Reason Not in Connection with a Change in Control<br/>($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Termination without Cause or Resignation for Good Reason in Connection with a Change in Control ($)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Severance Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">977,400&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368,360&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">59,202&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Acceleration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Severance Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">465,372&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,116&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Acceleration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">86,625&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Jerad G. Seurer</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cash Severance Payment</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">420,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Value of Benefits</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,239&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity Acceleration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,431&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes 18 months base salary continuation for Mr. Divis and 12 months&#8217; base salary for Mr. McHugh and Mr. Seurer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Includes 18 months&#8217; COBRA continuation for Mr. Divis and 12 months&#8217; COBRA continuation for Mr. McHugh and Mr. Seurer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Includes 18 months base salary and target annual bonus for Mr. Divis and 12 months base salary for Mr. McHugh and Mr. Seurer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) Amounts reflect intrinsic value of unvested stock options whose vesting will be accelerated based on the closing price of one ordinary share on December 31, 2024, the last trading day of 2024 ($10.51).</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(5) Mr. Kim resigned effective December 31, 2024. As described above, Mr. Kim was eligible to receive (i) salary continuation for 12 months in an amount equal to $472,328 and (ii) 12 months&#8217; COBRA premiums with an estimated value of $39,467.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Award Grant Practices</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During 2024, the Compensation Committee did not take into account any material nonpublic information when determining the timing and terms of equity incentive awards, and we did not time the disclosure of material nonpublic information for the purpose of affecting the value of executive compensation. During 2024, we did not grant any stock options to our Named Executive Officers during any period beginning four business days before and ending one business day after the filing or furnishing of a Form 10-Q, 10-K or 8-K that discloses material nonpublic information.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">COMPENSATION COMMITTEE REPORT</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Compensation Committee has reviewed and discussed the Compensation Discussion and Analysis required by Item 402(b) of Regulation S-K with management and, based on such review and discussion, the Compensation Committee recommended to the Board that it be included in this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">THE COMPENSATION COMMITTEE</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Linda S. Palczuk, Chair</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dr. Mark A. McCamish</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peter J. Thornton</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The &#8220;Compensation Committee Report&#8221; above shall not be deemed incorporated by reference by any general statement incorporating this Annual Report on Form 10-K into any filing under the Securities Act of 1933 or under the Securities Exchange Act of 1934, as amended, except to the extent that we specifically incorporate this information by reference and shall not otherwise be deemed filed under such Acts.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Compensation Risk Assessment</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of its oversight of our executive compensation program, the Compensation Committee considers the impact of our executive compensation program, and the incentives created by the compensation awards that it administers, on our risk profile. In addition, we review all our compensation policies and procedures, including the incentives that they create and factors that </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-118-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">may reduce the likelihood of excessive risk-taking, to determine whether they present a significant risk to us. The Compensation Committee concluded that our compensation programs are designed with the appropriate balance of risk and reward in relation to our overall business strategy and that the balance of compensation elements discourages excessive risk-taking. The Compensation Committee, therefore, determined that the risks arising from our compensation policies and practices for employees are not reasonably likely to have a material adverse effect on us. The Compensation Committee will continue to consider compensation risk implications while deliberating the design of our executive compensation programs. In its discussions, the Compensation Committee considered the attributes of our programs, including:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Appropriate pay philosophy in light of our business model;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Balance with respect to the mix of cash and equity compensation, and measures of performance against both annual and multi-year standards;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Short and long-term incentives linked to share price performance;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Performance goals are set at levels that are sufficiently high to encourage strong performance and support the resulting compensation expense, but within reasonably attainable parameters to discourage pursuit of excessively risky business strategies;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Long-term incentives generally have multi-year vesting to ensure a long-term focus and appropriate balance against short-term goals;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Independent Compensation Committee oversight, with Compensation Committee discretion to reduce incentives based on subjective evaluation of individual performance; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-hedging/pledging policies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PAY RATIO DISCLOSURE</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under Section 953(b) of the Dodd-Frank Wall Street Reform and Consumer Protection Act and Item 402(u) of Regulation S-K, the Company is required to provide the ratio of the annual total compensation of Mr. Divis, who is the Company&#8217;s Chief Executive Officer, to the annual total compensation of the median employee of the Company (the &#8220;Pay Ratio Disclosure&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For fiscal year 2024, the median annual total compensation of all employees of the Company and its consolidated subsidiaries (other than the Chief Executive Officer) was $271,964. Mr. Divis&#8217; annual total compensation for fiscal year 2024 was $7,399,605. Based on this information, for fiscal year 2024, the ratio of the compensation of the Chief Executive Officer to the median annual total compensation of all other employees was estimated to be 27 to 1.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To identify, and to determine the annual total compensation of, the median employee, we used the following methodology:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We collected the payroll data of all employees globally, whether employed on a full-time, part-time, temporary or seasonal basis as of December&#160;31, 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We annualized the compensation of all permanent full-time and part-time employees who were hired by the Company and its consolidated subsidiaries between January 1, 2024, and December&#160;31, 2024.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We then identified our median employee from our employee population based on this compensation measure.</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">This process resulted in the identification of an employee whose compensation was anomalous, as that individual was newly hired in 2024. As a result, we substituted an employee near the median whose compensation was viewed as more representative of our median employee.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The median employee&#8217;s annual total compensation represents the amount of such employee&#8217;s compensation for fiscal year 2024 that would have been reported in the Summary Compensation Table in accordance with the requirements of Item 402(c)(2)(x) of Regulation S-K if the employee was a Named Executive Officer, and the annual total compensation of the Chief Executive Officer represents the amount reported in the &#8220;Total&#8221; column of our &#8220;Summary Compensation Table&#8221; on page 113 of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Pay Ratio Disclosure presented above is a reasonable estimate. Because the SEC rules for identifying the median employee and calculating the pay ratio allow companies to use different methodologies, exemptions, estimates and assumptions, the Pay Ratio Disclosure may not be directly comparable to the pay ratio reported by other companies.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DIRECTOR COMPENSATION</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-Employee Director Compensation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We compensate our non-executive directors with a basic cash fee plus supplementary fees to chairpersons and for meeting attendance. The amount of each component of such director cash compensation may change from year to year and is generally </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-119-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">established by the Board in conjunction with our annual general meeting of shareholders for the period until the next annual general meeting. The fees paid to non-employee directors for service on the Board of Directors and for service on each committee of the Board of Directors on which the director is a member are as follows: </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The annual retainers in effect for service in 2024 were as follows:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:75.508%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.292%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Annual Cash Retainers<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Board of Directors:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All non-employee members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,100&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additional retainer for Non-Executive Chair of the Board</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Audit Committee:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Chair members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Compensation Committee:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Chair members</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Nominating and Corporate Governance Committee:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Chair</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,000&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-Chair members</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, during 2024, our non-employee directors were awarded stock options and restricted stock awards, as described in footnote 3 to the &#8220;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Director Compensation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; table below.</span></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Director&#8217;s Compensation Table</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table presents information relating to total compensation of each person who served as a director for the year ended December 31, 2024.</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:23.461%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.859%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.723%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.719%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fees Earned or</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Paid in Cash</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Option</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Awards</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">($)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)(3)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total<br/>Compensation<br/>($)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Geoffrey M. Glass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">102,100&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,357&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">426,977&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr. Naseem S. Amin</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,207&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">797,548&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,011,275&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr.&#160;Eric J. Ende</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,100&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,357&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">396,977&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr.&#160;Mark A. McCamish</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">69,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">394,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linda S. Palczuk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">370,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634,500&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peter J. Thornton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,600&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">145,357&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">179,520&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">404,477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Fees earned or paid in cash for Mr. Thornton were earned in U.S. Dollars but were paid in Euro at the applicable exchange rate on the date of payment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Amounts reported reflect the aggregate grant date fair value of options granted in 2024 calculated in accordance with FASB ASC Topic 718. For a full description of the assumptions we use in calculating these amounts, see Note 15 to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K. The actual value a director may receive depends on market prices, and there can be no assurance that the amounts reflected in these columns will actually be realized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) On July 30, 2024, non-employee directors Peter J. Thornton, Geoffrey M. Glass, Eric J. Ende, Mark A. McCamish, Linda S. Palczuk, and Naseem S. Amin were each awarded an option to purchase 11,000 shares and restricted stock awards of 11,000 shares under the Company&#8217;s 2020 Plan. Each award vests 100% on the one-year anniversary of the award. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(4) As of December&#160;31, 2024, Mr. Glass held 230,000 unexercised share options and 11,000 unvested stock awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) As of December&#160;31, 2024, Dr. Amin held 60,500 unexercised share options and 11,000 unvested stock awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(6) On May 17, 2024, Dr. Amin was appointed to the Board of Directors as a non-employee director. As part of his appointment, Dr. Amin was awarded an option to purchase 49,500 shares under the Company&#8217;s 2020 Plan. The award vests 1/3 each year on the anniversary of the award.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) As of December&#160;31, 2024, Dr. Ende held 238,057 unexercised share options and 11,000 unvested stock awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) As of December&#160;31, 2024, Dr. McCamish held 280,000 unexercised share options and 11,000 unvested stock awards.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-120-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) As of December&#160;31, 2024, Ms. Palczuk held 255,000 unexercised share options and 11,000 unvested stock awards.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) On December 17, 2024, Ms. Palczuk earned additional cash compensation and was granted an additional share option to purchase 25,000 shares in connection with her participation on the Board&#8217;s Commercial Oversight Committee.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) As of December&#160;31, 2024, Mr. Thornton held 230,000 unexercised share options and 11,000 unvested stock awards.</span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_214"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;12. &#160;&#160;&#160;&#160;Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Compensation Plan Information</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information as of December&#160;31, 2024, regarding ordinary shares that may be issued under our equity compensation plans, consisting of our 2017 Omnibus Incentive Compensation Plan (the &#8220;2017 Omnibus Plan&#8221;) our 2020 Omnibus Incentive Compensation Plan, our 2017 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;) and our 2021 Inducement Plan (the &#8220;Inducement Plan&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:41.443%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:15.712%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.689%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.583%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Plan category</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of securities</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">to be issued upon</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted-average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">exercise price of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">outstanding options</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">and rights</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2) </span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of securities<br/>remaining available<br/>for future issuance<br/>under equity<br/>compensation plans<br/>(excluding securities<br/>reflected in column (a))</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(a)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(b)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">(c)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans approved by security holders</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,857,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.40&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,879,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Equity compensation plans not approved by security holders</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,085,325&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9.86&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">340,925&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:2pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,942,476&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,220,440&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Includes 83,882 ordinary shares that have previously been granted as RSUs but are pending issuance upon vesting date and 66,000 ordinary shares that have previously been granted and issued as RSAs but are pending vesting; the beneficiary is not required to pay any exercise price upon issuance of such 83,882 shares of RSUs or 66,000 shares or RSAs. The remaining 11,792,594 ordinary shares are issuable pursuant to the exercise of outstanding options upon payment of the weighted-average exercise price shown in column (b) of this table.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) The weighted-average exercise price shown in column (b) applies to 11,792,594 ordinary shares issuable pursuant to the exercise of outstanding options included in the total number shown in column (a) of this table. As to the 83,882 and 66,000 shares attributable to free shares awards, the beneficiary is not required to pay any exercise price upon issuance of such shares.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Represents shares reserved for issuance pursuant to our Inducement Plan. Please see Note 15 to our audited consolidated financial statements included in Part II, Item 8 of this Annual Report on Form 10-K for additional information regarding the Inducement Plan.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Beneficial Ownership Table</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table sets forth certain information regarding the beneficial ownership of our issued and outstanding ordinary shares by (i) each person who is known by the Company to own beneficially more than five percent of the outstanding ordinary shares, (ii) each Named Executive Officer of the Company, (iii) each director and director nominee of the Company and (iv) all directors and executive officers as a group. Except as otherwise indicated in the footnotes below, such information is provided as of February 14, 2025. On April 15, 2024, the Company&#8217;s ordinary shares became directly listed on the Nasdaq Stock Market (&#8220;Nasdaq&#8221;). According to SEC rules, a person is the &#8220;beneficial owner&#8221; of securities if he, she or it has or shares the power to vote them or to direct their investment or has the right to acquire beneficial ownership of such securities within 60 days through the exercise of an option, warrant or right, the conversion of a security or otherwise.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-121-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.116%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.560%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:21.564%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Name and Address of Beneficial Ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Beneficial Ownership</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Percentage of Class</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:700;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(2)</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&gt; 5% Stockholders:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Entities Affiliated with Janus Henderson Group plc</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(3)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">201 Bishopsgate</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">EC2M 3AE, United Kingdom</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,080,219&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Entities Affiliated with Tontine Asset Associates, LLC</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(4)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1 Sound Shore Drive, Suite 304</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Greenwich, CT 06830-7251</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,685,350&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Entities Affiliated with BlackRock, Inc.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(5)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">50 Hudson Yards, </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">New York, NY 10001</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,257,004&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Named Executive Officers and Directors:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gregory J. Divis</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(6)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,201,600&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thomas S. McHugh</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(7)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">864,675&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Richard J. Kim</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(8)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">540,625&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Jerad G. Seurer </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(9)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">310,670&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Geoffrey M. Glass</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(10)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">374,979&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Naseem S. Amin</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr.&#160;Eric J. Ende</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(11)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">435,957&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Dr.&#160;Mark A. McCamish</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(12)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">347,025&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Linda S. Palczuk</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(13)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">286,900&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Peter J. Thornton</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:5.85pt;font-weight:400;line-height:100%;position:relative;top:-3.15pt;vertical-align:baseline">(14)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">323,055&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">*</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All executive officers and directors as a group (9 persons)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,155,861&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">* Represents beneficial ownership of less than 1% of our outstanding ordinary shares.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) Except as stated in the table above or the footnotes below, the address of the named person is c/o Avadel Pharmaceuticals plc, 10 Earlsfort Terrace, Dublin 2, D02 T380 Ireland.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2) Unless otherwise stated in the footnotes to this table, we believe each of the shareholders named in this table has sole voting and dispositive with respect to the ordinary shares indicated as beneficially owned. Ownership percentages are based on 96,594,935 ordinary shares outstanding on February 14, 2025. On April 15, 2024, the Company&#8217;s ordinary shares became directly listed on Nasdaq. Accordingly, some of the Schedule 13Gs filed by investors prior to April 15, 2024 still reference ADSs, which were exchanged for ordinary shares on the April 15, 2024. The number of shares beneficially owned includes ordinary shares issuable pursuant to the exercise of stock options or warrants that are exercisable and &#8220;free shares,&#8221; if any, that will vest within 60 days of February 14, 2025. Ordinary shares issuable pursuant to the exercise of stock options or warrants that are exercisable and &#8220;free shares,&#8221; if any, that will vest within 60 days of February 14, 2025 are deemed to be outstanding and beneficially owned by the person to whom such shares are issuable for the purpose of computing the percentage ownership of that person, but they are not deemed to be outstanding for the purpose of computing the percentage ownership of any other person.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(3) Information herein is solely based on a Schedule 13G/A filed with the SEC by Janus Henderson Group plc (&#8220;JHG&#8221;) on February 14, 2025. JHG reports that it has shared voting power and shared dispositive power over 14,022,184 shares which are held directly by one or more funds or portfolios managed by JHG. The principal business address of JHG is 201 Bishopsgate, EC2M 3AE, United Kingdom.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(4) Information herein is solely based on a Schedule 13G/A filed by Tontine Capital Overseas Master Fund II, L.P. (&#8220;TCOM II&#8221;), Tontine Asset Associates, LLC (&#8220;TAA&#8221;) and Mr. Jeffrey L. Gendell on February 13, 2024. Consists of (i) 3,539,782 ADSs held by TCOM II, (ii) 2,075,568 ADSs held by Tontine Financial Partners, L.P. (&#8220;TFP&#8221;) and (iii) 70,000 ADSs, held by Mr. Gendell, which were automatically exchanged for ordinary shares on April 15, 2024 when the Company&#8217;s ordinary shares became directly listed on Nasdaq. Mr. Gendell serves as the Managing Member of TAA and also serves as the Managing Member of Tontine Management, L.L.C., a limited liability company organized under the laws of the State of Delaware (&#8220;TM&#8221;), which serves as general partner of TFP.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(5) Information herein is solely based on a Schedule 13G filed with the SEC by Black Rock, Inc. (&#8220;BRI&#8221;) on November 8, 2024. BRI reports that it has sole voting power and sole dispositive power over 5,257,004 shares. The principal business address of BRI is 50 Hudson Yards, New York, NY 10001.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(6) Includes options to purchase (i) 2,032,500 ordinary shares that are exercisable within 60 days of February 14, 2025 and (ii) 10,000 ordinary shares held by the Gregory J. Divis Jr. Revocable Trust, of which Mr. Divis is trustee and beneficiary.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(7) Includes options to purchase 776,875 ordinary shares that are exercisable within 60 days of February 14, 2025.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-122-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(8) Mr. Kim resigned effective December 31, 2024 and has 12 months to exercise options that were vested as of that date. The amount shown includes remaining vested options to purchase 540,625 ordinary shares that are exercisable as of February 14, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(9) Includes (i) options to purchase 301,875 ordinary shares that are exercisable within 60 days of February 14, 2025 and (ii) 8,795 ordinary shares held by Mr. Seurer.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(10) Includes (i) options to purchase 219,000 ordinary shares that are exercisable within 60 days February 14, 2025, (ii) 75,904 ordinary shares held by Geoffrey M. Glass Revokable u/t/d August 26, 2020, of which Mr. Glass and members of his immediate family are the sole beneficiaries and Mr. Glass serves as its trustee and (iii) 69,075 ordinary shares held by The Geoffrey Glass Trust of which Mr. Glass is a co-trustee and sole beneficiary.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(11) Includes options to purchase 227,057 ordinary shares that are exercisable within 60 days of February 14, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(12) Includes (i) options to purchase 269,000 ordinary shares that are exercisable within 60 days of February 14, 2025, and (ii) 67,025 ordinary shares held by Matthew 5 LLC. The Mark &amp; Barbara McCamish Family Trust is the sole owner of Matthew 5 LLC, and Dr. McCamish serves as its manager.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(13) Includes options to purchase 219,000 ordinary shares that are exercisable within 60 days of February 14, 2025.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(14) Includes options to purchase 219,000 ordinary shares that are exercisable within 60 days of February 14, 2025.</span></div><div><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_217"></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;13. &#160;&#160;&#160;&#160;Certain Relationships and Related Transactions, and Director Independence.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Policies and Procedures for Related Person Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee reviews all related party transactions and similar matters to the extent required by listing standards. The Nominating and Corporate Governance Committee further assists to ensure that all such related party transactions are thoroughly reviewed on a regular basis so that such transactions are and remain at arms&#8217; length terms, thus promoting long term shareholder value.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of related person transactions as managed by our Audit and Nominating and Corporate Governance Committees, a &#8220;related person transaction&#8221; is a transaction, arrangement or relationship (or any series of similar transactions, arrangements or relationships) in which we (or any of our subsidiaries) were, are or will be a participant, and the amount involved exceeds $120,000 and in which any related person had, has or will have a direct or indirect interest. For purposes of determining whether a transaction is a related person transaction, the Committees rely upon Item 404 of Regulation S-K, promulgated under the Securities Exchange Act of 1934, as amended.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A &#8220;related person&#8221; is defined as:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any person who is, or at any time since the beginning of our last fiscal year was, one of our directors or executive officers or a nominee to become one of our directors;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any person who is known to be the beneficial owner of more than five percent of any class of our voting securities;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any immediate family member of any of the foregoing persons, which means any child, stepchild, parent, stepparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother- in-law or sister-in-law of the director, executive officer, nominee or more than five percent beneficial owner, and any person (other than a tenant or employee) sharing the household of such director, executive officer, nominee or more than five percent beneficial owner; and</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Any firm, corporation, or other entity in which any of the foregoing persons is employed or is a general partner or principal or in a similar position or in which such person has a ten percent or greater beneficial ownership interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Related Party Transactions</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than the compensation agreements and other arrangements described under Item 11 of this Annual Report on Form 10-K, since January 1, 2024, there has not been and there is not currently proposed, any transaction or series of similar transactions to which we were, or will be, a party in which the amount involved exceeded, or will exceed, $120,000 and in which any director, executive officer, holder of five percent or more of any class of any class of our voting securities or any member of the immediate family of, or entities affiliated with, any of the foregoing persons, had, or will have, a direct or indirect material interest.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board Standards of Independence</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board sets our independence standards in our corporate governance guidelines. The director independence standards provide that a majority of the Board must be independent under the independence standards established by the corporate governance guidelines, Nasdaq, and the SEC as in effect from time to time. For a Board member or candidate for election to the </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-123-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Board to qualify as independent, the Board must determine that the person and his or her immediate family members do not have a material relationship with us (either directly or as a partner, shareholder or officer of an organization that has a relationship with us) or any of our affiliates. Under the categorical standards adopted by the Board, a member of the Board is not independent if:</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The director is, or has been within the last three years, our employee, or an immediate family member is, or has been within the last three years, an executive officer of the Company;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The director has received, or has an immediate family member who has received, during any twelve-month period within the last three years, more than $120,000 in direct compensation from us, other than director and committee fees and pension or other forms of deferred compensation for prior service (provided such compensation is not contingent in any way on continued service);</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">(i) The director is a current partner or employee of a firm that is our internal or external auditor; (ii) the director has an immediate family member who is a current partner of such a firm; (iii) the director has an immediate family member who is a current employee of such a firm and personally works on our audit; or (iv) the director or an immediate family member was within the last three years a partner or employee of such a firm and personally worked on our audit within that time;</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The director or an immediate family member is, or has been within the last three years, employed as an executive officer of another company where any of our present executive officers at the same time serves or served on that company&#8217;s compensation committee; or</span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The director is a current employee, or an immediate family member is a current executive officer, of a company that has made payments to, or received payments from, us for property or services in an amount which, in any of the last three fiscal years, exceeds the greater of $1&#160;million, or two percent, of such other company&#8217;s consolidated gross revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board will also consider a director&#8217;s charitable relationships. Contributions to tax-exempt organizations are not considered payments for purposes of the test in the final bullet point above, provided that we are required to disclose in our annual Proxy Statement any such contributions made by us to any tax-exempt organization in which any independent director serves as an executive officer if, within the preceding three years, contributions in any single fiscal year from us to the organization exceeded the greater of $1&#160;million, or two percent, of such tax-exempt organization&#8217;s consolidated gross revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For purposes of the above independence standards, an &#8220;immediate family member&#8221; includes a person&#8217;s spouse, parents, children, siblings, mothers- and fathers-in-law, sons- and daughters-in-law, brothers- and sisters-in-law and anyone (other than domestic employees) who shares such person&#8217;s home. When applying the look-back provisions set forth above, the Board need not consider individuals who are no longer immediate family members as a result of legal separation or divorce, or those who have died or become incapacitated.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board has affirmatively determined that each member of the Board (besides Gregory J. Divis, our Chief Executive Officer) is independent in accordance with the above standards. Additionally, we made no contributions during fiscal year 2024 to any charitable organization in which an independent director serves as an executive officer in any single fiscal year within the preceding three fiscal years in an amount in excess of the greater of $1&#160;million, or two percent, of the charitable organization&#8217;s consolidated gross revenues.</span></div><div style="text-align:justify"><span><br/></span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_220"></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;14. &#160;&#160;&#160;&#160;Principal Accountant Fees and Services.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our independent public accounting firm is <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-1012">Deloitte &amp; Touche LLP</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-1013">St. Louis, Missouri</ix:nonNumeric> (PCAOB Auditor ID: <ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-1014">34</ix:nonNumeric>). </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the aggregate fees of our independent registered public accounting firms, billed to us for audit and other services for the fiscal years ended </span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.402%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.783%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.530%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.785%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Audit Fees</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292,994&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178,158&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Audit-related Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax Fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">All Other Fees</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total Fees</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,292,994&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,178,158&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-124-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Audit fees include professional services rendered by public accounting firms for the audit of our annual financial statements in 2024 and 2023, including the reviews of the financial statements included in our quarterly reports on Form 10-Q. This category also includes fees for assistance with complex accounting and transactions, fees for audits provided in connection with statutory filings or services that generally only the principal auditor can reasonably provide to a client, and consents and assistance with and review of documents filed with the SEC.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Audit-Related Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Audit-related fees consist of amounts for assurance and related services that are reasonably related to the performance of the audit or review of our financial statements that are not reported under &#8220;Audit Fees.&#8221;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Tax Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Tax fees include original and amended tax returns, studies supporting tax return amounts as may be required by Internal Revenue Service regulations, claims for refunds, assistance with tax audits and other work directly affecting or supporting the payment of taxes, planning, research and advice supporting our efforts to maximize the tax efficiency of our operations for fiscal years 2024 and 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">All Other Fees.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> All other fees are fees for products or services other than those in the above three categories.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pre-Approval Policy</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Audit Committee has adopted a policy for the provision of audit services and permitted non-audit services by our independent registered public accounting firm and all fees described above were pre-approved by our Audit Committee. Our Chief Financial Officer has primary responsibility to the Audit Committee for administration and enforcement of this policy and for reporting non-compliance. Under the policy, our Audit Committee receives a presentation of an annual budget and plan for audit services and for any proposed audit-related, tax or other non-audit services to be performed by the independent registered public accounting firm.</span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-125-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_223"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">PART IV</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_226"></div><div style="-sec-extract:summary;margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;15. &#160;&#160;&#160;&#160;Exhibits and Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(a)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:6.34pt">Documents filed as part of this report:</span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">1.&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financial Statements</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See Item 8 - Financial Statements and Supplementary Data of Part II of this Report. </span></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">2</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">.&#160;&#160;&#160;&#160;Financial Statement Schedules</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See below for Schedule II: Valuation and Qualifying Accounts. All other schedules are omitted as they are not applicable, not required or the information is included in the consolidated financial statements or related notes to the consolidated financial statements. </span></div><ix:nonNumeric contextRef="c-1" name="srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" id="f-1015" escape="true"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"/><td style="width:26.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.961%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.472%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:10.206%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.024%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.534%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.561%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred Tax Asset Valuation Allowance:</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, <br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Changes<br/>(c)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, <br/>End of Period</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1016">96,428</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1017">12,587</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1018">7,457</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="f-1019">7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1020">101,565</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1021">71,341</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1022">30,918</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:num-dot-decimal" scale="3" id="f-1023">6,586</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" scale="3" id="f-1024">755</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-206" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1025">96,428</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1026">24,025</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense" format="ixt:num-dot-decimal" scale="3" id="f-1027">48,734</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesDeductions" format="ixt:fixed-zero" scale="3" id="f-1028">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-3" sign="-" name="us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease" format="ixt:num-dot-decimal" scale="3" id="f-1029">1,418</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-3" name="us-gaap:ValuationAllowancesAndReservesBalance" format="ixt:num-dot-decimal" scale="3" id="f-1030">71,341</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Additions to the deferred tax asset valuation allowance relate to movements on certain French, Irish and U.S. deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Deductions to the deferred tax asset valuation allowance include movements relating to utilization of net operating losses and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Other changes to the deferred tax asset valuation allowance including currency translation adjustments recorded directly in equity, account method changes and the impact of corporate restructuring.</span></div></ix:nonNumeric><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3.     Exhibits required by Item&#160;601 of Regulation S-K</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The exhibits required by Item 601 of Regulation S-K and Item 15(b) of this Annual Report on Form 10-K are listed in the Exhibit Index immediately preceding the signature page of this Annual Report on Form 10-K. The exhibits listed in the Exhibit Index are incorporated by reference herein.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item&#160;16. &#160;&#160;&#160;&#160;Form 10-K Summary</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:174%">Index to Exhibits</span></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Number</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Exhibit Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000114420416111245/v443435_ex2-1.htm">Constitution (containing the Memorandum and Articles of Association) of Avadel Pharmaceuticals plc (incorporated by reference to Appendix 15 of Exhibit 2.1 to the registrant&#8217;s current report on Form 8-K, filed on July 1, 2016)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000110465920024077/tm209736d1_ex3-1.htm">Certificate of Designation of Series A Non-Voting Convertible Preferred Shares of Avadel Pharmaceuticals plc, dated February 20, 2020 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K, filed on February 24, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-126-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">3.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000110465923039263/tm2310752d3_ex3-1.htm">Certificate of Designation of Series B Non-Voting Convertible Preferred Shares of Avadel Pharmaceuticals plc, dated March 29, 2023 (incorporated by reference to Exhibit 3.1 to the registrant&#8217;s current report on Form 8-K, filed on March 30, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-41.htm">Description of Securities (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001012477/000101247721000004/a123120ex-102.htm">Office Lease Agreement by and between Grove II LLC and Eclat Pharmaceuticals LLC dated October 5, 2015, as amended (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 9, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-102.htm">Fourth Amendment to Office Lease Agreement by and between Grove II LLC and Avadel Management, LLC dated February 1, 2025 (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.3&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000091068019000040/ex10_1-f8k05302019.htm">Amended Employment Agreement dated as of June 3, 2019 between Avadel Management Corporation and Gregory J. Divis (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K, filed on June 5, 2019)</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"> </span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.4&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247722000014/exhibit101-divisemployment.htm">First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Gregory J. Divis (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Quarterly Report on From 10-Q, for the quarter ended September 30, 2022, filed on November 9, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.5&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247720000013/exhibit102q22020.htm">Employment Agreement dated as of May 15, 2020 between Avadel Management Corporation and Thomas S. McHugh (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 10-Q, filed on August 10, 2020)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.6&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247722000014/exhibit102-mchughemploymen.htm">First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Thomas S. McHugh (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s Quarterly Report on From 10-Q, for the quarter ended September 30, 2022, filed on November 9, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.7&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001012477/000101247721000004/a123120ex-1018.htm">Avadel Pharmaceuticals plc 2017 Omnibus Incentive Compensation Plan and related equity award agreements (incorporated by reference to Exhibit 10.18 to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2020, filed on March 9, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.8&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a123124ex-108.htm">Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a123124ex-108.htm"> and related equity award agreements</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="a123124ex-108.htm"> (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.9&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000110465923087044/tm2322686d1_ex10-1.htm">Amendment to the Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s current report on Form 8-K, filed August 3, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.10&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247721000008/exhibit101q12021.htm">Employment Agreement dated as of February 15, 2021 between Avadel Management Corporation and Richard Kim (incorporated by reference to Exhibit 10.1 to the registrant&#8217;s Quarterly report on Form 10-Q, for the quarter ended March 31, 2021, filed on May 10, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.11&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247722000014/exhibit103-kimemploymentag.htm">First Amendment to Employment Agreement, dated as of September 28, 2022, between Avadel Management Corporation and Richard Kim (incorporated by reference to Exhibit 10.3 to the registrant&#8217;s Quarterly Report on From 10-Q, for the quarter ended September 30, 2022, filed on November 9, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.12&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247722000004/a123121ex-1020.htm">Avadel Pharmaceuticals plc 2021 Inducement Plan and related equity award agreements (incorporated by reference to Exhibit 10.20 to the registrant&#8217;s Annual Report on Form 10-K, for the year ended December 31, 2021, filed on March 16, 2022)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.13&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a123124ex-1013.htm">Amendment to Avadel Pharmaceuticals plc 2021 Inducement Plan (filed herewith) </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-127-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.673%"/><td style="width:0.1%"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.14+&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247723000009/a123122ex-1021.htm">Manufacturing Agreement by and between Flamel Ireland Limited and Recipharm Pessac, dated as of October 1, 2022 (incorporated by reference to Exhibit 10.21 to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 29, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.15+&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247723000009/a123122ex-1022.htm">Generic API Supply Agreement by and between Euticals Inc. and Avadel CNS Pharmaceuticals, LLC, dated as of January 2, 2020 (incorporated by reference to Exhibit 10.22 to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2022, filed on March 29, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.16+&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000110465923038584/tm2310752d2_ex10-2.htm">Purchase and Sale Agreement, dated March 29, 2023, between Avadel CNS Pharmaceuticals, LLC, the Company, Flamel Ireland Ltd., and RTW Royalty II DAC (incorporated by reference to Exhibit 10.2 to the registrant&#8217;s current report on Form 8-K, filed on March 30, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.17+&#x5E;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-1025.htm">Generic API Supply Agreement and Manufacturing Agreement by and between Catalent Pharma Solutions LLC and Flamel Ireland Limited, dated as of March 29, 2018 (incorporated by reference to Exhibit 10.25 to the registrant's Annual Report of Form 10-K for the year ended December 31, 2023, filed on February 29, 2024)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.18&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;text-decoration:underline" href="a123124ex-1018.htm">Employment Agreement dated as of August 30, 2022 between Avadel Management Corporation and Jerad G. Seurer (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.19&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-1019.htm"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-1031">Form of Restricted Stock Award Agreement (filed herewith)</ix:nonNumeric></a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.20&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-1020.htm">Non-Employee Director Compensation Policy, dated July 30, 2024 (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-1021.htm">Form of Indemnification Agreement between Avadel Pharmaceuticals plc and Directors and Officers (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-1022.htm">Form of Indemnification Agreement between Avadel US Holdings, Inc. and Directors and Officers (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-141.htm">Code of Business Conduct and Ethics (</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm">incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm">14</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm">.</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm">1</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm"> to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 29, 2024)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">14.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000091068017000027/ex14_2.htm">Financial Integrity Policy (incorporated by reference to Exhibit 14.2 to the registrant&#8217;s current report on Form 8-K, filed on March 7, 2017)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-191.htm">Insider Trading Policy dated August 1, 2023 (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">21.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-211.htm">List of Subsidiaries (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">23.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-231.htm">Consent of Deloitte &amp; Touche LLP (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-311.htm">Certification of the Chief Executive Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">31.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-312.htm">Certification of the Principal Financial Officer pursuant to Rule 13a-14(a)/15d-14(a) of the Securities Exchange Act, as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-321.htm">Certification of the Chief Executive Officer pursuant to USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-128-</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:5pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:12.054%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:1.332%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:71.441%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.673%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">32.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="a123124ex-322.htm">Certification of the Principal Financial Officer pursuant to USC Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (furnished herewith)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">97.1&#8225;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:middle"><div style="text-align:justify"><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1012477/000101247724000008/a123123ex-971.htm">Avadel Pharmaceuticals plc Compensation Recovery Policy (incorporated by reference to Exhibit 97.1 to the registrant&#8217;s Annual Report on Form 10-K for the year ended December 31, 2023, filed on February 29, 2024) </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.INS</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Instant Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.SCH</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.CAL</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.DEF</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.LAB</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Labels Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">101.PRE</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:14pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:middle"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101.*) </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(filed herewith)</span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">*  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Confidential treatment has been requested for the redacted portions of this agreement. A complete copy of the agreement, including the redacted portions, has been filed separately with the Securities and Exchange Commission.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%"># The representations and warranties contained in this agreement were made only for purposes of the transactions contemplated by the agreement as of specific dates and may have been qualified by certain disclosures between the parties and a contractual standard of materiality different from those generally applicable under securities laws, among other limitations. The representations and warranties were made for purposes of allocating contractual risk between the parties to the agreement and should not be relied upon as a disclosure of factual information relating to the Company, the Investors or the transaction described in the Current Report on Form 8-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:120%">&#8225; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">Management contract or compensatory plan or arrangement filed pursuant to Item 15(b) of Form 10-K.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">+ Certain exhibits and schedules to these agreements have been omitted pursuant to Item 601 of Regulation S-K. The registrant will furnish copies of any of the exhibits and schedules to the Securities and Exchange Commission upon request.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">&#x5E; Certain portions of this exhibit have been omitted because they are not material and the registrant customarily and actually treats that information as private or confidential.</span></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:120%">(1) This certification accompanies the Form 10-K to which it relates, is not deemed filed with the Securities and Exchange Commission and is not to be incorporated by reference into any filing of the registrant under the Securities Act of 1933 or the Securities Exchange Act of 1934 (whether made before or after the date of the Form 10-K), irrespective of any general incorporation language contained in such filing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-129-</span></div></div></div><div id="id52fa9b3dc2341649ffd3f8e14993a22_229"></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:43.995%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:4.610%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.095%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avadel Pharmaceuticals plc</span></td></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dated: March&#160;3, 2025</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory J. Divis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Name:&#160;&#160;&#160;Gregory J. Divis</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title:&#160;&#160;&#160;&#160;Chief Executive Officer</span></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, this Report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">POWER OF ATTORNEY</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">KNOW ALL PERSONS BY THESE PRESENTS</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, that each of Geoffrey M. Glass, Naseem S. Amin, MD, Eric J. Ende, Mark A. McCamish, MD, Ph.D., Linda S. Palczuk, and Peter J. Thornton, by their respective signatures below, irrevocably constitutes and appoints Gregory J. Divis and Thomas S. McHugh, and each of them individually acting alone without the other, his true and lawful attorneys-in-fact and agents, with full power of substitution and resubstitution, for him and in his name, place and stead, in any and all capacities, to sign any and all amendments to this report, and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done in connection therewith, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that said attorneys-in-fact and agents, or either of them, or their or his substitutes or substitute, may lawfully do or cause to be done by virtue hereof.</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"/><td style="width:29.398%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.565%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:41.128%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.419%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:18.990%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Signature</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Title</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Gregory J. Divis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director, Chief Executive Officer and Principal Executive Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Divis</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Thomas S. McHugh</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Financial Officer and Principal Financial and Accounting Officer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas S. McHugh</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Geoffrey M. Glass</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Non-Executive Chairman of the Board and Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Geoffrey M. Glass</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Naseem S. Amin, MD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Naseem S. Amin, MD</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Dr. Eric J. Ende</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Dr. Eric J. Ende</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Mark A. McCamish, MD, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Mark A. McCamish, MD, Ph.D.</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Linda S. Palczuk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Linda S. Palczuk</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr style="height:12pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/&#160;Peter J. Thornton</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Director</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March 3, 2025</span></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:justify;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Peter J. Thornton</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr></table></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-130-</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-4.1
<SEQUENCE>2
<FILENAME>a123124ex-41.htm
<DESCRIPTION>EX-4.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i030755d544e54a71824cd98930fb7d8e_1"></div><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%;text-decoration:underline">Description of the Registrant&#8217;s Securities Registered Pursuant to<br>Section 12 of the Securities Exchange Act of 1934, as amended</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">The following description of the registered securities of Avadel Pharmaceuticals plc (&#8220;Avadel,&#8221; &#8220;we&#8221; or &#8220;our&#8221;) summarizes the material terms and provisions of our ordinary shares and preferred shares. The following description of our share capital does not purport to be complete and is subject to, and qualified in its entirety by, our memorandum and articles of association (the &#8220;Avadel Constitution&#8221;), which is incorporated by reference as Exhibit 4.2 to this Form 10-K, and by applicable law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">The following description includes comparisons of certain provisions of the Avadel Constitution and Irish law applicable to us and the Delaware General Corporation Law, or the DGCL, the law under which many publicly listed companies in the United States are incorporated.  Because such statements are summaries, they do not address all aspects of Irish law that may be relevant to us and our shareholders or all aspects of Delaware law which may differ from Irish law, and they are not intended to be a complete discussion of the respective rights.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">General</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Our authorized share capital is $5,500,000 divided into 500,000,000 ordinary shares with a nominal value of $0.01 each and 50,000,000 preferred shares with a nominal value of $0.01 each, plus &#8364;25,000 divided into 25,000 deferred non-voting ordinary shares with a nominal value of &#8364;1.00 each.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ordinary Shares</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The holders of ordinary shares are entitled to one vote for each share held of record on all matters submitted to a vote of the shareholders. The holders of our ordinary shares do not have any cumulative voting rights. Holders of our ordinary shares are entitled to receive ratably any dividends declared by our board of directors out of funds legally available for that purpose, subject to any preferential dividend rights of any outstanding convertible preferred shares. Our ordinary shares have no preemptive rights, conversion rights or other subscription rights or redemption or sinking fund provisions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Our ordinary shares are listed on the Nasdaq Global Market under the trading symbol &#8220;AVDL.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The transfer agent and registrar for our ordinary shares is Computershare Trust Company, N.A.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Preferred Shares</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Avadel Constitution empowers our Board of Directors, without action by our shareholders, to issue up to 50,000,000 preferred shares from time to time in one or more classes or series.  Our Board of Directors is authorized, without obtaining any vote or consent of the holders of any class or series of shares, unless expressly provided by the terms of that class or series of shares, to provide from time to time for the issuance of other classes or series of shares and to establish the characteristics of each class or series, including the number of shares, designations, relative voting rights, dividend rights, liquidation and other rights, redemption, repurchase or exchange rights and any other preferences and relative, participating, optional or other rights and limitations not inconsistent with applicable law. Our Board of Directors has designated 487,614 of the 50,000,000 authorized preferred shares as Series A Non-Voting Convertible Preferred Shares (the &#8220;Series A Preferred&#8221;) and 4,705,882 of the 50,000,000 authorized preferred shares as Series B Non-Voting Convertible Preferred Shares (the &#8220;Series B Preferred&#8221; and together with the Series A Preferred, the &#8220;Designated Preferred Shares&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Conversion</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. Our Designated Preferred Shares have a nominal value of $0.01 per share and are convertible, from time to time at the option of the holder thereof, into one ordinary share, except that a holder will be prohibited from converting shares of Designated Preferred Shares into ordinary shares if, as a result of such conversion, such holder, together with its affiliates, would beneficially own more than 9.99% of the total number of ordinary shares then issued and outstanding.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Liquidation Preference</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. In the event of our liquidation, dissolution or winding up, our assets available for distribution shall be distributed among the holders of the Series A Preferred Shares, Series B Preferred Shares and ordinary shares, pro rata based on the number of shares held by each such holder, treating for this purpose all such securities as if they had been converted to ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Voting</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. Designated Preferred Shares prior to their conversion to ordinary shares will generally have no voting rights, provided that, except as required by law, the consent of the holders of a majority of the outstanding shares of Series A Preferred Shares will be required to amend the terms of the Series A Preferred Shares if such amendment would adversely affect the Series A Preferred Shares and the consent of the holders of a majority of the outstanding shares of Series B Preferred Shares will be required to amend the terms of the Series B Preferred Shares if such amendment would adversely affect the Series B Preferred Shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. Designated Preferred Shares will be entitled to receive dividends at a rate equal to (on an as-if-converted-to-ordinary share basis), and in the same form and manner as, dividends actually paid on ordinary shares.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Redemption</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. Designated Preferred Shares are not entitled to any redemption rights or mandatory sinking fund or analogous fund provisions.</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Listing</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">. There is no established public trading market for the Designated Preferred Shares, and we do not expect a market to develop. In addition, we do not intend to apply for listing of the Designated Preferred Shares on The Nasdaq Global Market or on any national securities or other nationally recognized trading system.</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Warrants</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We may issue warrants for the purchase of our ordinary shares, preferred shares or debt securities or any combination thereof.  Warrants may be issued independently or together with our ordinary shares, preferred shares or debt securities and may be attached to or separate from any offered securities.  To the extent warrants that we issue are to be publicly-traded, each series of such warrants will be issued under a separate warrant agreement to be entered into between us and a bank or trust company, as warrant agent.  The warrant agent will act solely as our agent in connection with such warrants.  The warrant agent will not have any obligation or relationship of agency or trust for or with any holders or beneficial owners of warrants.  This summary of certain provisions of the warrants is not complete.  For the terms of a particular series of warrants, you should refer to the prospectus supplement for that series of warrants and the warrant agreement for that particular series.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Anti-Takeover Provisions of Irish Law</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Business Combinations with Interested Shareholders</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Avadel Constitution includes a provision similar to Section 203 of the Delaware General Corporation Law, which generally prohibits us from engaging in a business combination with an interested shareholder for a period of three years following the date the person became an interested shareholder, unless, in general&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">our Board of Directors approved the transaction which resulted in the shareholder becoming an interested shareholder&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">upon consummation of the transaction which resulted in the shareholder becoming an interested shareholder, the shareholder owned at least 85% of the voting shares outstanding at the time of commencement of such transaction, excluding for purposes of determining the number of voting shares outstanding (but not the outstanding voting shares owned by the interested shareholder), voting shares owned by persons who are directors and also officers and by certain employee share plans&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">the business combination is approved by our Board of Directors and authorized at an annual or extraordinary general meeting of shareholders by the affirmative vote of the holders of at least 75% of the outstanding voting shares that are not owned by the interested shareholder.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A &#8220;business combination&#8221; is generally defined as a merger, asset or stock sale or other transaction resulting in a financial benefit to the interested shareholder.  An &#8220;interested shareholder&#8221; is generally defined as a person who, together with affiliates and associates, owns or, within three years prior to the date in question, owned 15% or more of our outstanding voting shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Irish Takeover Rules and Substantial Acquisition Rules</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">A transaction in which a third party seeks to acquire 30% or more of our voting rights will be governed by the Irish Takeover Panel Act 1997 and the Irish Takeover Rules made thereunder, the Irish Takeover Panel Act, 1997, Takeover Rules, 2022 (the &#8220;Irish Takeover Rules&#8221;), and will be regulated by the Irish Takeover Panel.  The &#8220;General Principles&#8221; of the Irish Takeover Rules and certain important aspects of the Irish Takeover Rules are described below.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">General Principles</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Irish Takeover Rules are built on the following General Principles which will apply to any transaction regulated by the Irish Takeover Panel&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">in the event of an offer, all holders of securities of the target company must be afforded equivalent treatment and, if a person acquires control of a company, the other holders of securities must be protected&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">the holders of securities in the target company must have sufficient time and information to enable them to reach a properly informed decision on the offer&#59; where it advises the holders of securities, the Board of Directors of the target company must give its views on the effects of the implementation of the offer on employment, employment conditions and the locations of the target company&#8217;s place of business&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">a target company&#8217;s Board of Directors must act in the interests of that company as a whole and must not deny the holders of securities the opportunity to decide on the merits of the offer&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">false markets must not be created in the securities of the target company, the bidder or any other company concerned by the offer in such a way that the rise or fall of the prices of the securities becomes artificial and the normal functioning of the markets is distorted&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">a bidder can only announce an offer after ensuring that he or she can fulfill in full any cash consideration offered, if such is offered, and after taking all reasonable measures to secure the implementation of any other type of consideration&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">a target company may not be hindered in the conduct of its affairs longer than is reasonable by an offer for its securities&#59; and</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">a &#8220;substantial acquisition&#8221; of securities, whether such acquisition is to be effected by one transaction or a series of transactions, shall take place only at an acceptable speed and shall be subject to adequate and timely disclosure.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Mandatory Bid</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under certain circumstances, a person who acquires shares, or other voting securities, of a company may be required under the Irish Takeover Rules to make a mandatory cash offer for the remaining outstanding voting securities in that company at a price not less than the highest price paid for the securities by the acquiror, or any parties acting in concert with the acquiror, during the previous 12 months.  This mandatory bid requirement is triggered if an acquisition of securities would increase the aggregate holding of an acquiror, including the holdings of any parties acting in concert with the acquiror, to securities representing 30% or more of the voting rights in a company, unless the Irish Takeover Panel otherwise consents.  An acquisition of securities by a person holding, together with its concert parties, securities representing between 30% and 50% of the voting rights in a company would also trigger the mandatory bid requirement if, after giving effect to the acquisition, the percentage of the voting rights held by that person, together with its concert parties, would increase by 0.05% within a 12-month period.  Any person, excluding any parties acting in concert with the holder, holding securities representing more than 50% of the voting rights of a company is not subject to these mandatory offer requirements in purchasing additional securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Voluntary Bid&#59; Requirements to Make a Cash Offer and Minimum Price Requirement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If a person makes a voluntary offer to acquire our outstanding ordinary shares, the offer price must not be less than the highest price paid for our ordinary shares by the bidder or its concert parties during the three-month period prior to the commencement of the offer period.  The Irish Takeover Panel has the power to extend the &#8220;look back&#8221; period to 12 months if the Irish Takeover Panel, taking into account the General Principles, believes it is appropriate to do so.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If the bidder or any of its concert parties has acquired our ordinary shares (1) during the 12-month period prior to the commencement of the offer period that represent more than 10% of our total ordinary shares or (2) at any time after the commencement of the offer period, the offer must be in cash or accompanied by a full cash alternative and the price per ordinary share must not be less than the highest price paid by the bidder or its concert parties during, in the case of clause (1), the 12-month period prior to the commencement of the offer period or, in the case of (2), the offer period.  The Irish Takeover Panel may apply this Rule to a bidder who, together with its concert parties, has acquired less than 10% of our total ordinary shares in the 12-month period prior to the commencement of the offer period if the Irish Takeover Panel, taking into account the General Principles, considers it just and proper to do so.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">An offer period will generally commence from the date of the first announcement of the offer or proposed offer.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Substantial Acquisition Rules</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Irish Takeover Rules also contain rules governing substantial acquisitions of shares and other voting securities which restrict the speed at which a person may increase his or her holding of shares and rights over shares to an aggregate of between 15% and 30% of the voting rights of the company.  Except in certain circumstances, an acquisition or series of acquisitions of shares or rights over shares representing 10% or more of the voting rights of the company is prohibited, if such acquisition(s), when aggregated with shares or rights already held, would result in the acquirer holding 15% or more but less than 30% of the voting rights of the company and such acquisitions are made within a period of seven days.  These rules also require accelerated disclosure of acquisitions of shares or rights over shares relating to such holdings.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Frustrating Action</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Irish Takeover Rules, our Board of Directors is not permitted to take any action that might frustrate an offer for our shares during the course of an offer or at any earlier time during which our Board of Directors has reason to believe that such an offer is or may be imminent, subject to certain exceptions.  Potentially frustrating actions such as (1) the issue of shares, options, restricted share units or convertible securities or the redemption or purchase of own securities, (2) material acquisitions or disposals, (3) entering into contracts other than in the ordinary course of business or (4) any action, other than seeking alternative offers, which may result in frustration of an offer, are prohibited during the course of an offer or at any earlier time during which our Board of Directors has reason to believe an offer is or may be imminent.  Exceptions to this prohibition are available where&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">the action is approved by our shareholders at a general meeting&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(b)&#160;&#160;&#160;&#160;the Irish Takeover Panel has given its consent, where&#58;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(i)&#160;&#160;&#160;&#160;it is satisfied the action would not constitute frustrating action&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(ii)&#160;&#160;&#160;&#160;our shareholders holding more than 50% of the voting rights state in writing that they approve the proposed action and would vote in favor of it at a general meeting&#59;</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iii)&#160;&#160;&#160;&#160;the action is taken in accordance with a contract entered into prior to the announcement of the offer, or any earlier time at which our Board of Directors considered the offer to be imminent&#59; or</font></div><div style="margin-bottom:12pt;padding-left:108pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(iv)&#160;&#160;&#160;&#160;the decision to take such action was made before the announcement of the offer and either has been at least partially implemented or is in the ordinary course of business.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Shareholders&#8217; Rights Plan</font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Irish law does not expressly authorize or prohibit companies from issuing share purchase rights or adopting a shareholder rights plan as an anti-takeover measure.  However, there is no directly relevant case law on the validity of such plans under Irish law.  In addition, such a plan would be subject to the Irish Takeover Rules and the General Principles underlying the Irish Takeover Rules.  The Avadel Constitution allows our Board of Directors to adopt a shareholder rights plan upon such terms and conditions as our Board of Directors deems expedient and in the best interests of us, subject to applicable law.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Subject to the Irish Takeover Rules, our Board of Directors also has power to issue any of our authorized and unissued shares on such terms and conditions as it may determine and any such action should be taken in our best interests.  It is possible, however, that the terms and conditions of any issue of preference shares could discourage a takeover or other transaction that holders of some or a majority of the ordinary shares believe to be in their best interests or in which holders might receive a premium for their shares over the then-market price of the shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:700;line-height:100%">Disclosure of Interests in Shares</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Irish Companies Act, our shareholders must notify us if, as a result of a transaction, the shareholder will become interested in three percent or more of our voting shares, or if as a result of a transaction a shareholder who was interested in three percent or more of our voting shares ceases to be so interested.  Where a shareholder is interested in three percent or more of our voting shares, the shareholder must notify us of any alteration of his or her interest that brings his or her total holding through the nearest whole percentage number, whether an increase or a reduction.  The relevant percentage figure is calculated by reference to the aggregate nominal value of the voting shares in which the shareholder is interested as a proportion of the entire nominal value of our issued share capital (or any such class of share capital in issue).  Where the percentage level of the shareholder&#8217;s interest does not amount to a whole percentage, this figure may be rounded down to the next whole number.  We must be notified within five business days of the transaction or alteration of the shareholder&#8217;s interests that gave rise to the notification requirement.  If a shareholder fails to comply with these notification requirements, the shareholder&#8217;s rights in respect of any of our shares it holds will not be enforceable, either directly or indirectly.  However, such person may apply to the court to have the rights attaching to such shares reinstated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In addition to these disclosure requirements, we, under the Irish Companies Act, may, by notice in writing, require a person whom we know or have reasonable cause to believe to be, or at any time during the three years immediately preceding the date on which such notice is issued to have been, interested in shares comprised in our relevant share capital to (i) indicate whether or not it is the case and (ii) where such person holds or has during that time held an interest in our shares, to provide additional information, including the person&#8217;s own past or present interests in our shares.  If the recipient of the notice fails to respond within the reasonable time period specified in the notice, we may apply to the Irish court for an order directing that the affected shares be subject to certain restrictions, as prescribed by the Irish Companies Act, as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">any transfer of those shares or, in the case of unissued shares, any transfer of the right to be issued with shares and any issue of shares, shall be void&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">no voting rights shall be exercisable in respect of those shares&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">no further shares shall be issued in right of those shares or in pursuance of any offer made to the holder of those shares&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">no payment shall be made of any sums due from us on those shares, whether in respect of capital or otherwise.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The court may also order that shares subject to any of these restrictions be sold with the restrictions terminating upon the completion of the sale.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In the event we are in an offer period pursuant to the Irish Takeover Rules, accelerated disclosure provisions apply for persons holding an interest in our securities of one percent or more.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Differences in Corporate Law</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As a public limited company incorporated under the laws of Ireland, the rights of our shareholders are governed by applicable Irish law, including the Irish Companies Act, and not by the law of any U.S. state.  As a result, our directors and shareholders are subject to different responsibilities, rights and privileges than are applicable to directors and shareholders of U.S. corporations.  The applicable provisions of the Irish Companies Act differ from laws applicable to U.S. corporations and their shareholders.  Set forth below is a summary of certain differences between the provisions of the Irish Companies Act applicable to us and the General Corporation Law of the State of Delaware relating to shareholders&#8217; rights and protections.  The applicable provisions in respect of the Company under the Avadel Constitution is also set out where relevant.  This summary is not intended to be a complete discussion of the respective rights and it is qualified in its entirety by reference to Delaware law and Irish law.  You are also urged to carefully read the relevant provisions of the Delaware General Corporation Law and the Irish Companies Act for a more complete understanding of the differences between Delaware and Irish law.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Ireland</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Delaware</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Number of Directors</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Irish Companies Act provides for a minimum of two directors.  The Avadel Constitution provides for a minimum of two directors and a maximum of 13.  Our shareholders may from time to time increase or reduce the maximum number, or increase the minimum number, of directors by ordinary resolution.  Our Board of Directors determines the number of directors within the range of two to 13.</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, a corporation must have at least one director and the number of directors shall be fixed by or in the manner provided in the bylaws.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Removal of Directors</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Irish Companies Act, the shareholders may, by ordinary resolution, remove a director from office before the expiration of his or her term, at a meeting held on no less than 28 days&#8217; notice and at which the director is entitled to be heard.  Because of this provision of the Irish Companies Act, a director may be so removed before the expiration of his or her period of office.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The power of removal is without prejudice to any claim for damages for breach of contract (e.g., employment contract) that the director may have against the Company in respect of his or her removal.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The Avadel Constitution also provides that the office of a director will also be vacated if the director is restricted or disqualified to act as a director under the Irish Companies Act&#59; resigns his or her office by notice in writing to us or in writing offers to resign and the directors resolve to accept such offer&#59; or is requested to resign in writing by not less than 75% of the other directors.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, any director or the entire board of directors may be removed, with or without cause, by the holders of a majority of the shares then entitled to vote at an election of directors, except (i) unless the certificate of incorporation provides otherwise, in the case of a corporation whose board of directors is classified, stockholders may effect such removal only for cause, or (ii) in the case of a corporation having cumulative voting, if less than the entire board of directors is to be removed, no director may be removed without cause if the votes cast against his removal would be sufficient to elect him if then cumulatively voted at an election of the entire board of directors, or, if there are classes of directors, at an election of the class of directors of which he is a part.</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vacancies on the Board of Directors</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Any vacancy on our Board of Directors, including a vacancy resulting from an increase in the number of directors or from the death, resignation, retirement, disqualification or removal of a director, shall be deemed a casual vacancy.  Subject to the terms of any one or more classes or series of preferred shares, any casual vacancy shall only be filled by the decision of a majority of our Board of Directors then in office, provided that a quorum is present and provided that the appointment does not cause the number of directors to exceed any number fixed by or in accordance with the Avadel Constitution as the maximum number of directors.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Any director of a class of directors elected to fill a vacancy resulting from an increase in the number of directors of such class shall hold office for the remaining term of that class.  Any director elected to fill a vacancy not resulting from an increase in the number of directors shall have the same remaining term as that of his predecessor.  A director retiring at a meeting shall retain office until the close or adjournment of the meeting.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, vacancies and newly created directorships may be filled by a majority of the directors then in office (even though less than a quorum) or by a sole remaining director unless (i) otherwise provided in the certificate of incorporation or bylaws of the corporation or (ii) the certificate of incorporation directs that a particular class of stock is to elect such director, in which case a majority of the other directors elected by such class, or a sole remaining director elected by such class, will fill such vacancy.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Annual General Meeting</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We are required to hold annual general meetings at intervals of no more than fifteen months after the previous annual general meeting, provided that an annual general meeting is held in each calendar year following our first annual general meeting, no more than nine months after our fiscal year-end.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The only matters which must, as a matter of Irish company law, be transacted at an annual general meeting are the consideration of the Irish statutory financial statements, the report of the directors, the report of the auditors on those statements and that report and a review by the members of our affairs.  If no resolution is made in respect of the reappointment of an auditor at an annual general meeting, the previous auditor will be deemed to have continued in office.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, the annual meeting of stockholders shall be held at such place, on such date and at such time as may be designated from time to time by the board of directors or as provided in the certificate of incorporation or by the bylaws.</font></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General Meeting</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Our extraordinary general meetings may be convened by (i) our Board of Directors, (ii) on requisition of shareholders holding not less than 10% of our paid up share capital carrying voting rights or (iii) on requisition of our auditors.  Extraordinary general meetings are generally held for the purposes of approving shareholder resolutions as may be required from time to time.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">If our directors become aware that our net assets are half or less of the amount of our called-up share capital, our directors must convene an extraordinary general meeting of our shareholders not later than 28 days from the date that they learn of this fact.  This meeting must be convened for the purposes of considering whether any, and if so what, measures should be taken to address the situation.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notice of General Meetings</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notice of a general meeting must be given to all our shareholders and to our auditors. The articles of association provide that the maximum notice period is 60 clear days. The minimum notice periods are 21 clear days&#8217; notice in writing for an annual general meeting or an extraordinary general meeting to approve a special resolution and 14 clear days&#8217; notice in writing for any other extraordinary general meeting. General meetings may be called by shorter notice, but only with the consent of our auditors and all of our shareholders entitled to attend and vote thereat. Because of the 21-day and 14-day requirements described in this paragraph, the articles of association include provisions reflecting these requirements of Irish law.</font></div><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font><br></font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In the case of an extraordinary general meeting convened by our shareholders, the proposed purpose of the meeting must be set out in the requisition notice. Upon receipt of this requisition notice, our Board of Directors has 21 days to convene a meeting of our shareholders to vote on the matters set out in the requisition notice. This meeting must be held within two months of the receipt of the requisition notice. If our Board of Directors does not convene the meeting within such 21-day period, the requisitioning shareholders, or any of them representing more than one-half of the total voting rights of all of them, may themselves convene a meeting, which meeting must be held within three months of the receipt of the requisition notice.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, special meetings of the stockholders may be called by the board of directors or by such person or persons as may be authorized by the certificate of incorporation or by the bylaws.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Quorum</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The presence, in person or by proxy, of five or more persons holding or representing by proxy at least a majority in nominal value of the class or, at any adjourned meeting of such holders, one holder holding or representing by proxy at least a majority in nominal value of the issued shares of the class constitutes a quorum for the conduct of business.  No business may take place at a general meeting if a quorum is not present in person or by proxy.  Our Board of Directors has no authority to waive quorum requirements stipulated in the Avadel Constitution.  Abstentions and broker non-votes will be counted as present for purposes of determining whether there is a quorum in respect of the proposals.</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The certificate of incorporation or bylaws may specify the number of shares, the holders of which shall be present or represented by proxy at any meeting in order to constitute a quorum, but in no event shall a quorum consist of less than one third of the shares entitled to vote at the meeting.  In the absence of such specification in the certificate of incorporation or bylaws, a majority of the shares entitled to vote, present in person or represented by proxy, shall constitute a quorum at a meeting of stockholders.</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Proxy</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Irish law, a shareholder may designate another person to attend, speak and vote at a general meeting of the company on their behalf by proxy, which proxy need not be a shareholder.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Where interests in shares are held by a nominee trust company, this company may exercise the rights of the beneficial holders on their behalf as their proxy.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voting rights may be exercised by shareholders registered in the share register as of the record date for the meeting or by a duly appointed proxy of such a registered shareholder, which proxy need not be a shareholder.  Where interests in shares are held by a nominee trust company, this company may exercise the rights of the beneficial holders on their behalf as their proxy.  All proxies must be appointed in accordance with the Avadel Constitution.  The Avadel Constitution permits the appointment of proxies by our shareholders to be notified to us electronically, when permitted by our directors.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, at any meeting of stockholders, a stockholder may designate another person to act for such stockholder by proxy, but no such proxy shall be voted or acted upon after three years from its date, unless the proxy provides for a longer period.  A director of a Delaware corporation may not issue a proxy representing the director&#8217;s voting rights as a director.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Issue of New Shares</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">As a matter of Irish law, the directors of a company may issue new shares without shareholder approval once authorized to do so by its constitution or by a simple majority of the votes cast at a general meeting of shareholders, referred to under Irish law as an &#8220;ordinary resolution.&#8221; Accordingly, upon incorporation, the Avadel Constitution authorized the Board to issue new ordinary and preferred shares without shareholder approval, subject to the maximum authorized share capital contained in the Avadel Constitution, for an initial period of five years from the date of adoption of the Avadel Constitution, expiring on December 20, 2021.  At the annual general meeting of shareholders held on August 3, 2021, this authorization was renewed by shareholders for a further period of five years expiring December 20, 2026.  The authorized share capital may be increased or reduced by a resolution approved by an ordinary resolution adopted by our shareholders at a general meeting.  Similarly, the authorization renewed at the 2021 annual general meeting may be further renewed by shareholders by way of subsequent ordinary resolution.  The authority to issue new ordinary and preferred shares provides us with the flexibility to consider and respond to future business needs and opportunities as they arise from time to time, including in connection with capital raising, financing and acquisition transactions or opportunities.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Avadel Constitution, our Board of Directors has discretion as to the terms attaching to any preferred shares, including as to voting, dividend and conversion rights and priority relative to other classes of shares with respect to dividends and upon a liquidation.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Notwithstanding this authority, under the Irish Takeover Rules our Board of Directors would not be permitted to issue any of our shares, including preferred shares, during a period when an offer has been made for us or is believed to be imminent unless the issue is (i) approved by our shareholders at a general meeting&#59; (ii) consented to by the Irish Takeover Panel on the basis it would not constitute action frustrating the offer&#59; (iii) consented to by the Irish Takeover Panel and approved by the holders of more than 50% of our shares carrying voting rights&#59; (iv) consented to by the Irish Takeover Panel in circumstances where a contract for the issue of the shares had been entered into prior to that period&#59; or (v) consented to by the Irish Takeover Panel in circumstances where the issue of the shares was decided by our directors prior to that period and either action has been taken to implement the issuance (whether in part or in full) prior to such period or the issuance was otherwise in the ordinary course of business.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, if the company&#8217;s certificate of incorporation so provides, the directors have the power to authorize the issuance of additional stock.  The directors may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the company or any combination thereof.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Preemptive Rights</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Irish law, unless otherwise authorized, when an Irish public limited company issues shares for cash, it is required first to offer those shares on the same or more favorable terms to existing shareholders of the company on a pro rata basis, commonly referred to as the statutory preemption right.  Upon incorporation, as permitted under Irish law, the Avadel Constitution opted out of these preemption rights for an initial period of five years from the date of adoption of the Avadel Constitution, expiring on December 20, 2021.  At the annual general meeting of shareholders held on August 3, 2021, this opt-out was renewed by shareholders for a further period of five years expiring December 20, 2026.  This opt-out may be further renewed by shareholders by way of a subsequent resolution approved by at least 75% of the votes cast at a general meeting of shareholders, referred to under Irish law as a &#8220;special resolution.&#8221; If the opt-out is not renewed, shares issued for cash must be offered to pre-existing shareholders of Avadel plc pro rata to their existing shareholding before the shares can be issued (subject to limited exceptions).  The statutory preemption rights do not apply where shares are issued for non-cash consideration and do not apply to the issue of non-equity shares (that is, shares that have the right to participate only up to a specified amount in any income or capital distribution).</font></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, shareholders have no preemptive rights to subscribe to additional issues of stock or to any security convertible into such stock unless, and except to the extent that, such rights are expressly provided for in the certificate of incorporation.</font></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Authority to Allot</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Avadel Constitution, we may issue shares subject to the maximum authorized share capital contained in the Avadel Constitution.  The authorized share capital may be increased or reduced by a resolution approved by a simple majority of the votes cast at a general meeting of our shareholders, referred to under Irish law as an &#8220;ordinary resolution.&#8221; Our authorized share capital may be divided into shares of such nominal value as the resolution shall prescribe.  As a matter of Irish law, the directors of a company may issue new ordinary or preferred shares without shareholder approval once authorized to do so by its constitution or by an ordinary resolution adopted by shareholders at a general meeting.  The authorization may be granted for a maximum period of five years, at which point it may be renewed by shareholders by an ordinary resolution.  Accordingly, upon incorporation, the Avadel Constitution authorized the Board to issue new ordinary and preferred shares without shareholder approval, subject to the maximum authorized share capital contained in the Avadel Constitution, for an initial period of five years from the date of adoption of the Avadel Constitution, expiring on December 20, 2021.  At the annual general meeting of shareholders held on August 3, 2021, this authorization was renewed by shareholders for a further period of five years expiring December 20, 2026.  The authority to issue new ordinary and preferred shares provides us with the flexibility to consider and respond to future business needs and opportunities as they arise from time to time, including in connection with capital raising, financing and acquisition transactions or opportunities.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, if the corporation&#8217;s charter or certificate of incorporation so provides, the board of directors has the power to authorize the issuance of stock.  The board may authorize capital stock to be issued for consideration consisting of cash, any tangible or intangible property or any benefit to the corporation or any combination thereof.  It may determine the amount of such consideration by approving a formula.  In the absence of actual fraud in the transaction, the judgment of the directors as to the value of such consideration is conclusive.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Liability of Directors and Officers</font></td><td colspan="3" style="border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">To the fullest extent permitted by Irish law, the Avadel Constitution contains indemnification for the benefit of our directors, company secretary and executive officers.  However, as to our directors and company secretary, this indemnity is limited by the Irish Companies Act, which prescribes that an advance commitment to indemnify only permits a company to pay the costs or discharge the liability of a director or company secretary where judgment is given in favor of the director or company secretary in any civil or criminal action in respect of such costs or liability, or where an Irish court grants relief because the director or company secretary acted honestly and reasonably and ought fairly to be excused.  Any provision whereby an Irish company seeks to commit in advance to indemnify its directors or company secretary over and above the limitations imposed by the Irish Companies Act will be void, whether contained in its articles of association or any contract between the company and the director or company secretary.  This restriction does not apply to our executive officers who are not directors, our company secretary or other persons who would be considered &#8220;officers&#8221; within the meaning of the Irish Companies Act.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">We are permitted under the Avadel Constitution and the Irish Companies Act to take out directors&#8217; and officers&#8217; liability insurance, as well as other types of insurance, for our directors, officers, employees and agents.  In order to attract and retain qualified directors and officers, we expect to purchase and maintain customary directors&#8217; and officers&#8217; liability insurance and other types of comparable insurance.</font></div></td><td colspan="3" style="border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Under Delaware law, a corporation&#8217;s certificate of incorporation may include a provision eliminating or limiting the personal liability of a director to the corporation and its stockholders for damages arising from a breach of fiduciary duty as a director.  However, no provision can limit the liability of a director for&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any breach of the director&#8217;s duty of loyalty to the corporation or its stockholders&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law&#59;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">intentional or negligent payment of unlawful dividends or stock purchases or redemptions&#59; or</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;padding-left:14.5pt">any transaction from which the director derives an improper personal benefit.</font></div></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Voting Rights</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under the Avadel Constitution, each holder of our ordinary shares is entitled to one vote for each ordinary share that he or she holds as of the record date for the meeting.  The holder of our deferred ordinary shares is not entitled to a vote.  We may not exercise any voting rights in respect of any shares held as treasury shares.  Any shares held by our subsidiaries will count as treasury shares for this purpose, and such subsidiaries cannot therefore exercise any voting rights in respect of those shares.</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware law provides that, unless otherwise provided in the certificate of incorporation, each stockholder is entitled to one vote for each share of capital stock held by such stockholder.</font></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholder Vote on Certain Transactions</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Pursuant to Irish law, shareholder approval in connection with a transaction involving the Company would be required under the following circumstances&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">in connection with a scheme of arrangement, both a court order from the Irish High Court and the approval of a majority in number representing 75% in value of the shareholders present and voting in person or by proxy at a meeting called to approve such a scheme would be required&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">in connection with an acquisition of the Company by way of a merger with an EU company under the EU Cross-Border Mergers Directive 2005&#47;56&#47;EC, (as replaced by Directive (EU) 2017&#47;1132 of 14 June 2017), approval by a special resolution of the shareholders would be required&#894; and</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">in connection with a merger with an Irish company under the Irish Companies Act, approval by a special resolution of shareholders would be required.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Generally, under Delaware law, unless the certificate of incorporation provides for the vote of a larger portion of the stock, completion of a merger, consolidation, sale, lease or exchange of all or substantially all of a corporation&#8217;s assets or dissolution requires&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">the approval of the board of directors&#59; and</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">the approval by the vote of the holders of a majority of the outstanding stock or, if the certificate of incorporation provides for more or less than one vote per share, a majority of the votes of the outstanding stock of the corporation entitled to vote on the matter.</font></div></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Standard of Conduct for Directors</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The directors of the Company have certain statutory and fiduciary duties as a matter of Irish law.  All of the directors have equal and overall responsibility for the management of the Company (although directors who also serve as employees may have additional responsibilities and duties arising under their employment agreements (if applicable), and it is likely that more will be expected of them in compliance with their duties than non-executive directors).  The Irish Companies Act provides specifically for certain fiduciary duties of the directors of Irish companies, including duties&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to act in good faith and in the best interests of the company&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to act honestly and responsibly in relation to the company&#8217;s affairs&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to act in accordance with the company&#8217;s constitution and to exercise powers only for lawful purposes&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">not to misuse the company&#8217;s property, information and&#47;or opportunity&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">not to fetter their independent judgment&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to avoid conflicts of interest&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to exercise care, skill and diligence&#894; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">to have regard for the interests of the company&#8217;s shareholders.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other statutory duties of directors include ensuring the maintenance of proper books of account, having annual accounts prepared, having an annual audit performed, maintaining certain registers, making certain filings and disclosing personal interests.  Directors of public limited companies such as Avadel will have a specific duty to ensure that the company secretary is a person with the requisite knowledge and experience to discharge the role.  Directors may rely on information, opinions, reports or statements, including financial statements and other financial data, prepared or presented by (1) other directors, officers or employees of the company whom the director reasonably believes to be reliable and competent in the matters prepared or presented, (2) legal counsel, public accountants or other persons as to matters the director reasonably believes to be within their professional or expert competence, or (3) a committee of the board of which the director does not serve as to matters within its designated authority, which committee the director reasonably believed to merit confidence.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Delaware law does not contain specific provisions setting forth the standard of conduct of a director.  The scope of the fiduciary duties of directors is generally determined by the courts of the State of Delaware.  In general, directors have a duty to act without self-interest, on a well-informed basis and in a manner they reasonably believe to be in the best interest of the stockholders.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Directors of a Delaware corporation owe fiduciary duties of care and loyalty to the corporation and to its shareholders.  The duty of care generally requires that a director act in good faith, with the care that an ordinarily prudent person would exercise under similar circumstances.  Under this duty, a director must inform himself of all material information reasonably available regarding a significant transaction.  The duty of loyalty requires that a director act in a manner he reasonably believes to be in the best interests of the corporation.  He must not use his corporate position for personal gain or advantage.  In general, but subject to certain exceptions, actions of a director are presumed to have been made on an informed basis, in good faith and in the honest belief that the action taken was in the best interests of the corporation.  However, this presumption may be rebutted by evidence of a breach of one of the fiduciary duties.  Delaware courts have also imposed a heightened standard of conduct upon directors of a Delaware corporation who take any action designed to defeat a threatened change in control of the corporation.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In addition, under Delaware law, when the board of directors of a Delaware corporation approves the sale or break-up of a corporation, the board of directors may, in certain circumstances, have a duty to obtain the highest value reasonably available to the shareholders.</font></div></td></tr></table></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:36pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:23.860%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.500%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:36.340%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholder Suits</font></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">In Ireland, the decision to institute proceedings is generally taken by a company&#8217;s board of directors, who will usually be empowered to manage the company&#8217;s business.  In certain limited circumstances, a shareholder may be entitled to bring a derivative action on behalf of the company.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">The central question at issue in deciding whether a minority shareholder may be permitted to bring a derivative action is whether, unless the action is brought, a wrong committed against the company would otherwise go un-redressed.  The principal case law in Ireland indicates that to bring a derivative action a person must first establish a prima facie case (i) that the company is entitled to the relief claimed and (ii) that the action falls within one of the five exceptions derived from case law, as follows&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.8pt;padding-right:2.75pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1)&#160;&#160;&#160;&#160;where an ultra vires or illegal act is perpetrated&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.8pt;padding-right:2.75pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2)&#160;&#160;&#160;&#160;where more than a bare majority is required to ratify the &#8220;wrong&#8221; complained of&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.8pt;padding-right:2.75pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3)&#160;&#160;&#160;&#160;where the shareholders&#8217; personal rights are infringed&#894;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.8pt;padding-right:2.75pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)&#160;&#160;&#160;&#160;where a fraud has been perpetrated upon a minority by those in control&#894; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:19.8pt;padding-right:2.75pt;text-indent:-17.05pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5)&#160;&#160;&#160;&#160;where the justice of the case requires a minority to be permitted to institute proceedings.</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Shareholders may also bring proceedings against the company where the affairs of the company are being conducted, or the powers of the directors are being exercised, in a manner oppressive to the shareholders or in disregard of their interests.  Oppression connotes conduct that is burdensome, harsh or wrong.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Conduct must relate to the internal management of the company.  This is an Irish statutory remedy and the court can grant any order it sees fit, usually providing for the purchase or transfer of the shares of any shareholder.</font></div></td><td colspan="3" style="border-bottom:1pt solid #000;border-left:1pt solid #000;border-right:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;margin-top:2.15pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Under Delaware law, a stockholder may initiate a derivative action to enforce a right of a corporation if the corporation fails to enforce the right itself.  The complaint must&#58;</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">state that the plaintiff was a stockholder at the time of the transaction of which the plaintiff complains or that the plaintiffs shares thereafter devolved on the plaintiff by operation of law&#59; and</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">allege with particularity the efforts made by the plaintiff to obtain the action the plaintiff desires from the directors and the reasons for the plaintiff&#8217;s failure to obtain the action&#59; or</font></div><div style="margin-bottom:6pt;margin-top:6pt;padding-left:20.75pt;padding-right:2.75pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%;padding-left:14.85pt">state the reasons for not making the effort.</font></div><div style="margin-bottom:1pt;margin-top:6pt;padding-left:2.75pt;padding-right:2.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Additionally, the plaintiff must remain a stockholder through the duration of the derivative suit.  The action will not be dismissed or compromised without the approval of the Delaware Court of Chancery.</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:61.92pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.2
<SEQUENCE>3
<FILENAME>a123124ex-102.htm
<DESCRIPTION>EX-10.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i83bd22d4c26f4fd89586a7b4fdbbe0a5_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">FOURTH AMENDMENT TO OFFICE LEASE</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">THIS FOURTH AMENDMENT TO OFFICE LEASE (this &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Fourth Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made and entered into as of February 1, 2025 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Effective Date</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) by and between GROVE II LLC, a Missouri limited liability company (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Landlord</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and AVADEL MANAGEMENT, LLC, a Delaware limited liability company.</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord and Eclat Pharmaceuticals, LLC entered into that certain Office Lease (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Office Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) dated October 5, 2015 and that certain First Amendment to Office Lease dated March 8, 2016 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">First Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, On February 2, 2017, Eclat Pharmaceuticals LLC changed its name from Eclat Pharmaceuticals LLC to Avadel Legacy Pharmaceuticals, LLC&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on May 5, 2017, Landlord and Avadel Legacy Pharmaceuticals, LLC entered into that Second Amendment to Office Lease dated May 5, 2017 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Second Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Avadel Legacy Pharmaceuticals, LLC requested that it be permitted to assign the Lease to a related entity, Avadel Management Corporation, and Landlord consented to such assignment&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord and Avadel Management Corporation entered into that Third Amendment to Office Lease dated March 22, 2018 (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Third Amendment</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (The Office Lease, First Amendment, Second Amendment, and the Third Amendment are, collectively, the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, on or about December 30, 2024, Avadel Management Corporation underwent a conversion from a Delaware corporation to a Delaware limited liability company, Avadel Management, LLC (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tenant</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, Landlord and Tenant desire to amend certain provisions of the Lease&#59; and,</font></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">NOW, THEREFORE, in consideration of the foregoing premises, the mutual covenants herein contained and each act performed hereunder by the parties, Landlord and Tenant hereby agree and the Lease is hereby further amended by entering into this Fourth Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Amendment to the Lease</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt">Subsections (a) through (d) and subsection (f) of Section 1.01 are hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Leased Premises&#58; Suite 200 of the building located at 16640 Chesterfield Grove Road, Chesterfield, Missouri 63005 (the &#8220;Building&#8221;).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;Rentable Area&#58; 17,065 rentable square feet.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;Tenant&#8217;s Proportionate Share&#58; 50.32%</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;Lease Term&#58; The period from the Commencement Date (as applicable) to and including January 31, 2029, unless sooner terminated or otherwise extended, in each event, pursuant to the terms and conditions of this Lease.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Minimum Annual Rent &#38; Monthly Rental Installment beginning February 1, 2025&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.233%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:32.234%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Period</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Minimum Annual Rent&#47;RSF</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Monthly Rental Installment</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year 1</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2&#47;1&#47;2025 &#8211; 1&#47;31&#47;2026)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$25.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$35,907.60</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year 2</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2&#47;1&#47;2026 &#8211; 1&#47;31&#47;2027)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$25.75</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$36,618.64</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year 3</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2&#47;1&#47;2027 &#8211; 1&#47;31&#47;2028)</font></div></td><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$26.25</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$37,329.68</font></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Year 4</font></div><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2&#47;1&#47;2028 &#8211; 1&#47;31&#47;2029)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$26.75</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">$38,040.73</font></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">Provided that Tenant is not in default under the terms and conditions of this Lease, Tenant is hereby granted an option to extend the term of the Lease for one (1) additional period of three (3) years (the &#8220;Renewal Term&#8221;) on the same terms and conditions provided the rental rate shall be the then prevailing market rate for comparable office buildings in the Chesterfield&#47;Highway 40 submarket as negotiated and agreed between Landlord and Tenant. In order to exercise this option, Tenant shall provide written notice to Landlord no later than April 30, 2028.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Lease is hereby deleted and replaced with </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit A</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> attached hereto.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">d.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt">Section 2 of </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit B</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> to the Lease is hereby amended and restated as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Scope of Work</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Landlord or its agent will perform the work listed on the attached Schedule 1. All such work shall be performed from Monday through Friday during normal business hours.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:27pt;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">a.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Brokerage Commissions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Landlord and Tenant hereby represent and warrant to each other that it has not dealt with any broker or agent in connection with the negotiation of this transaction and that no brokerage commissions would be due as a result of the execution of this Fourth Amendment. Landlord and Tenant shall indemnify, defend, and hold the other from any and all liability for the breach of this representation and warranty </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">on its part and shall pay any compensation to any broker or person who may be entitled thereto in connection with this Fourth Amendment.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">b.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:26.33pt;text-decoration:underline">Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. This Amendment may be executed in any number of counterparts, each of which shall be deemed to be an original instrument, but all such counterparts together shall constitute one and the same instrument.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%">c.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27.68pt;text-decoration:underline">Full Force and Effect</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Except as specifically amended hereby, all of the terms and conditions of the Lease shall remain in full force and effect, and the same are hereby ratified and confirmed.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">SIGNATURE PAGE FOLLOWS</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Fourth Amendment to be executed on the day and year first written above.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">LANDLORD&#58;</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">TENANT&#58;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">GROVE II LLC,<br>a Missouri limited liability company</font></td><td colspan="3" style="padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Avadel Management, LLC<br>a Delaware limited liability company</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.02pt;padding-right:2.77pt;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Christopher W. Pelligreen&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.77pt;padding-right:2.77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Thomas S. McHugh&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.02pt;padding-right:2.77pt;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Christopher W. Pelligreen&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.77pt;padding-right:2.77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;Thomas S. McHugh</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.02pt;padding-right:2.77pt;text-indent:-35.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Authorized Signatory&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:38.77pt;padding-right:2.77pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;Director</font></div></td></tr></table></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">EXHIBIT A</font></div><div style="margin-bottom:24pt"><img alt="image_02.jpg" src="image_02.jpg" style="height:374px;margin-bottom:5pt;vertical-align:text-bottom;width:624px"></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 200</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">17,065 RSF</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Attachment 1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grove II<br>16640 Chesterfield Grove Road, Suite<br>200 Chesterfield, MO 63005</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Avadel TI Scope of Work<br>1&#47;9&#47;2025</font></div><div style="padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">a)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CARPET</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furnish and install new carpet tile to replace existing carpet</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Carpet tile supplied by Landlord&#59; Minimal patching as required</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No flooring in Executive Bath &#38; IT Room&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No border and accent in Reception Area</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">b)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">PAINTING</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remove wall covering &#64; Reception area</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Skim drywall surfaces where VWC was removed Paint&#58;</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Drywall surfaces and hollow metal frames</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1) Accent wall per office</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Refresh existing doors</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No painting in Executive Conference Room (wood) and (2) small rooms and Executive Bath</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No work on existing paneled wall surfaces</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">c)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">KITCHEN REPAIR</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Drywall&#47;Carpentry</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furnish and Install&#58;</font></div><div style="padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Drywall</font></div><div style="margin-bottom:12pt;padding-left:27pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Remove, furnish &#38; install casework throughout</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Painting</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Painting drywall surfaces</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Flooring</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Furnish and install&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Vinyl Base</font></div><div style="padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Plumbing&#47;Electrical</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Install sink and dishwasher</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">d)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CLEAN UP AND SUPERVISION</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">6</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>4
<FILENAME>a123124ex-108.htm
<DESCRIPTION>EX-10.8
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i5ed0eeae80f84e3f8261b58525c2f7d6_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</font></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">2020 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">GENERAL PURPOSE OF THE PLAN&#59; DEFINITIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The name of the plan is the Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan (the &#8220;Plan&#8221;).  The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Consultants of Avadel Pharmaceuticals PLC, an Irish public limited company (the &#8220;Company&#8221;) and its Affiliates upon whose judgment, initiative and efforts the Company largely depends for the successful conduct of its business to acquire a proprietary interest in the Company.  It is anticipated that providing such persons with a direct stake in the Company&#8217;s welfare will assure a closer identification of their interests with those of the Company and its shareholders, thereby stimulating their efforts on the Company&#8217;s behalf and strengthening their desire to remain with the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following terms shall be defined as set forth below&#58;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the United States Securities Act of 1933, as amended, and the rules and regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Administrator&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means either the Board or the compensation committee of the Board or a similar committee performing the functions of the compensation committee and which is comprised of not less than two Non-Employee Directors who are independent.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;ADS&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an American Depositary Share representing one Ordinary Share, registered with the SEC and listed for trading on the Nasdaq Global Market under the trading symbol &#8220;AVDL&#8221;&#59; an ADS may be represented by a physical certificate referred to as an American Depositary Receipt, or &#8220;ADR.&#8221;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Affiliate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means, at the time of determination, any &#8220;parent&#8221; or &#8220;subsidiary&#8221; of the Company as such terms are defined in Rule 405 of the Act. The Board will have the authority to determine the time or times at which &#8220;parent&#8221; or &#8220;subsidiary&#8221; status is determined within the foregoing definition. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Awards,&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> except where referring to a particular category of grant under the Plan, shall include Incentive Stock Options, Non-Qualified Options, Share Appreciation Rights, Restricted Share Units, Restricted Share Awards, Unrestricted Share Awards, Cash-Based Awards, and Dividend Equivalent Rights.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Award Certificate&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a written or electronic document setting forth the terms and provisions applicable to an Award granted under the Plan.  Each Award Certificate is subject to the terms and conditions of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Board&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Board of Directors of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:28.044%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Cash-Based Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award entitling the recipient to receive a cash-denominated payment.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Code&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the United States Internal Revenue Code of 1986, as amended, and any successor Code, and related rules, regulations and interpretations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Companies Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Ireland Companies Act 2014.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Consultant&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a consultant or adviser who provides </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">bona fide</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> services to the Company or an Affiliate as an independent contractor and who qualifies as a consultant or advisor under Instruction A.1.(a)(1) of Form S-8 under the Act. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Dividend Equivalent Right&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the Shares specified in the Dividend Equivalent Right (or other award to which it relates) if such shares had been issued to and held by the grantee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Effective Date&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the date on which the Plan becomes effective as set forth in Section&#160;19.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Exchange Act&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the United States Securities Exchange Act of 1934, as amended, and the rules and regulations thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Fair Market Value&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of a Share (represented by ADSs) on any given date means the fair market value of a Share determined in good faith by the Administrator&#59; provided, however, that if the Shares or ADSs are listed on the NASDAQ, The NASDAQ Global Market, The NASDAQ Global Select Market, The New York Stock Exchange or another foreign or national securities exchange or traded on any established market, the determination shall be made by reference to market quotations.  If there are no market quotations for such date, the determination shall be made by reference to the last date preceding such date for which there are market quotations.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Incentive Stock Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any Option designated and qualified as an &#8220;incentive stock option&#8221; as defined in Section&#160;422 of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Minimum Vesting Period&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means the one-year period following the date of grant of an Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Non-Employee Director&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means a member of the Board who is not also an employee of the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Non-Qualified Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any Option that is not an Incentive Stock Option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Option&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any option to purchase Shares granted pursuant to Section&#160;5.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Ordinary Share&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an Ordinary Share, par value $0.01, in the capital of the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Restricted Shares&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means the Shares underlying a Restricted Share Award that remain subject to a risk of forfeiture or the Company&#8217;s right of repurchase.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Restricted Share Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Restricted Share Units&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award of share units subject to such restrictions and conditions as the Administrator may determine at the time of grant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Sale Event&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> shall mean (i) the sale of all or substantially all of the assets of the Company on a consolidated basis to an unrelated person or entity, (ii) the following individuals cease for any reason to constitute a majority of the number of directors then serving on the Board&#58; individuals who, on the Effective Date, constitute the Board and any new director (other than a director whose initial assumption of office is in connection with an actual or threatened election contest, including, but not limited to, a consent solicitation relating to the election of directors of the Company) whose appointment or election by the Board or nomination for election by the Company&#8217;s shareholders was approved or recommended by a vote of at least a majority of the directors then still in office who either were members of the Board on the Effective Date or whose appointment, election or nomination for election was previously so approved (the &#8220;Incumbent Directors&#8221;)&#59;  (iii) a merger, reorganization or consolidation with any other corporation or other entity, other than (A) a merger, reorganization or consolidation pursuant to which the holders of the Company&#8217;s outstanding voting power and outstanding Shares immediately prior to such transaction continue to own a majority of the outstanding voting power and outstanding Shares or other equity interests of the resulting or successor entity (or its ultimate parent, if applicable) immediately upon completion of such transaction and (B) the Incumbent Directors continuing immediately thereafter to represent at least a majority of the board of directors of the resulting or successor entity (or its ultimate parent, if applicable), (iv) the sale of all of the Shares of the Company to an unrelated person, entity or group thereof acting in concert, or (v) any other transaction in which the owners of the Company&#8217;s outstanding voting power immediately prior to such transaction do not own at least a majority of the outstanding voting power of the Company or any successor entity immediately upon completion of the transaction other than as a result of the acquisition of securities directly from the Company.  For the avoidance of doubt, any one or more of the above events may be effective pursuant to (a) a compromise or arrangement sanctioned by the court under Chapter 1 of Part 9 of the Companies Act, (b) an acquisition pursuant to Chapter 2 of Part 9 of the Companies Act, or (c) a merger pursuant to the European Communities (Cross-Border Mergers) Regulations 2008.   Notwithstanding the foregoing, in the case of any Award that constitutes deferred compensation within the meaning of Section 409A of the Code, there shall not be a Change in Control unless there is a change in the ownership or effective control of the Company, or in a substantial portion of the assets of the Company, within the meaning of Section 409A of the Code where necessary for such Award to comply with Section 409A of the Code.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Sale Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; means the value as determined by the Administrator of the consideration payable, or otherwise to be received by shareholders, per Share pursuant to a Sale Event.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Section 409A&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means Section 409A of the Code and the regulations and other guidance promulgated thereunder.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Service Relationship&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means any relationship as an employee, director or Consultant of the Company or any Affiliate (e.g., a Service Relationship shall be deemed to continue without interruption in the event an individual&#8217;s status changes from full-time employee to part-time employee or Consultant).</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Share&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means an Ordinary Shares, subject to adjustment pursuant to Section 3&#59; unless the context otherwise requires, references herein to &#8220;Shares&#8221; shall include references to ADSs.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> &#8220;Share Appreciation Right&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award entitling the recipient to receive Shares (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of the Stock on the date of exercise over the exercise price of the Share Appreciation Right multiplied by the number of Shares with respect to which the Share Appreciation Right shall have been exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Subsidiary&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means any corporation or other entity (other than the Company) in which the Company has at least a 50 percent interest, either directly or indirectly.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Ten Percent Owner&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an employee who owns or is deemed to own (by reason of the attribution rules of Section 424(d) of the Code) more than 10 percent of the combined voting power of all classes of stock of the Company or any parent or subsidiary corporation. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">&#8220;Unrestricted Share Award&#8221;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> means an Award of Shares free of any restrictions.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">ADMINISTRATION OF PLAN&#59; ADMINISTRATOR AUTHORITY TO SELECT GRANTEES AND DETERMINE AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Administration of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Plan shall be administered by the Administrator.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Powers of Administrator</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator shall have the power and authority to grant Awards consistent with the terms of the Plan, including the power and authority&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">to select the individuals to whom Awards may from time to time be granted&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">to determine the time or times of grant, and the extent, if any, of Incentive Stock Options, Non-Qualified Options, Share Appreciation Rights, Restricted Share Awards, Restricted Share Units, Unrestricted Share Awards, Cash-Based Awards, and Dividend Equivalent Rights, or any combination of the foregoing, granted to any one or more grantees&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">to determine the number of Shares to be covered by any Award and to determine whether any Award shall pertain to Shares or ADSs&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">to determine and modify from time to time the terms and conditions, including restrictions, not inconsistent with the terms of the Plan, of any Award, which terms and conditions may differ among individual Awards and grantees, and to approve the forms of Award Certificates&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;4</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(v)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">to accelerate at any time the exercisability or vesting of all or any portion of any Award&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vi)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">subject to the provisions of Section&#160;5(c), to extend at any time the period in which Options may be exercised&#59; and</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(vii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:15.36pt">at any time to adopt, alter and repeal such rules, guidelines and practices for administration of the Plan and for its own acts and proceedings as it shall deem advisable&#59; to interpret the terms and provisions of the Plan and any Award (including related written instruments)&#59; to make all determinations it deems advisable for the administration of the Plan&#59; to decide all disputes arising in connection with the Plan&#59; and to otherwise supervise the administration of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All decisions and interpretations of the Administrator shall be binding on all persons, including the Company and Plan grantees.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Delegation of Authority to Grant Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Subject to applicable law, the Administrator, in its discretion, may delegate to a committee consisting of one or more officers of the Company, including the Chief Executive Officer of the Company, all or part of the Administrator&#8217;s authority and duties with respect to the granting of Awards to individuals who are (i) not subject to the reporting and other provisions of Section&#160;16 of the Exchange Act and (ii) not members of the delegated committee.  Any such delegation by the Administrator shall include a limitation as to the amount of Stock underlying Awards that may be granted during the period of the delegation and shall contain guidelines as to the determination of the exercise price and the vesting criteria.  The Administrator may revoke or amend the terms of a delegation at any time but such action shall not invalidate any prior actions of the Administrator&#8217;s delegate or delegates that were consistent with the terms of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Award Certificate</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Awards under the Plan shall be evidenced by Award Certificates that set forth the terms, conditions and limitations for each Award which may include, without limitation, the term of an Award and the provisions applicable in the event employment or service terminates.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Board nor the Administrator, nor any member of either or any delegate thereof, shall be liable for any act, omission, interpretation, construction or determination made in good faith in connection with the Plan, and the members of the Board and the Administrator (and any delegate thereof) shall be entitled in all cases to indemnification and reimbursement by the Company in respect of any claim, loss, damage or expense (including, without limitation, reasonable attorneys&#8217; fees) arising or resulting therefrom to the fullest extent permitted by law and&#47;or under the Company&#8217;s articles or bylaws or any directors&#8217; and officers&#8217; liability insurance coverage which may be in effect from time to time and&#47;or any indemnification agreement between such individual and the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Foreign Award Recipients</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. Notwithstanding any provision of the Plan to the contrary, in order to comply with the laws in other countries in which the Company and its Subsidiaries operate or have employees or other individuals eligible for Awards, the Administrator, in its sole discretion, shall have the power and authority to&#58;  (i) determine which Subsidiaries shall be covered by the Plan&#59; (ii) determine which individuals outside the United States are eligible to participate in the Plan&#59; (iii) modify the terms and conditions of any Award granted to individuals outside the United States to comply with applicable foreign laws&#59; (iv) establish subplans and modify exercise procedures and other terms and procedures, to the extent the Administrator determines such actions to be necessary or advisable (and such subplans and&#47;or modifications shall be attached to this Plan as appendices)&#59; provided, however, that no such </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;5</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">subplans and&#47;or modifications shall increase the share limitations contained in Section 3(a) hereof&#59; and (v) take any action, before or after</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:100%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">an Award is made, that the Administrator determines to be necessary or advisable to obtain approval or comply with any local governmental regulatory exemptions or approvals.  Notwithstanding the foregoing, the Administrator may not take any actions hereunder, and no Awards shall be granted, that would violate the Exchange Act or any other applicable United States securities law, the Code, or any other applicable United States governing statute or law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Minimum Vesting Period</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The vesting period for each Award granted under the Plan must be at least equal to the Minimum Vesting Period&#59; provided, however, nothing in this Section 2(g) shall limit the Administrator&#8217;s authority to accelerate the vesting of Awards as set forth in Section 2(b)(v) above&#59; and, provided further, notwithstanding the foregoing, up to 5% of the Shares authorized for issuance under the Plan may be utilized for Unrestricted Share Awards or other Awards with a vesting period that is less than the Minimum Vesting Period (each such Award, an &#8220;Excepted Award&#8221;).  Notwithstanding the foregoing, in addition to Excepted Awards, the Administrator may grant Awards that vest (or permit previously granted Awards to vest) within the Minimum Vesting Period (i) if such Awards are granted as substitute Awards in replacement of other Awards (or awards previously granted by an entity being acquired (or assets of which are being acquired)) that were scheduled to vest within the Minimum Vesting Period or (ii) if such Awards are being granted in connection with an elective deferral of cash compensation that, absent a deferral election, otherwise would have been paid to the grantee within the Minimum Vesting Period.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 3.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">STOCK ISSUABLE UNDER THE PLAN&#59; MERGERS&#59; SUBSTITUTION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Stock Issuable</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The maximum number of Shares reserved and available for issuance under the Plan shall be 6,000,000 Shares, subject to adjustment as provided in this Section&#160;3.  For purposes of this limitation, the Shares underlying any awards under the Plan and under the Company&#8217;s 2017 Omnibus Incentive Compensation Plan that are forfeited, canceled or otherwise terminated (other than by exercise) shall be added back to the Shares available for issuance under the Plan and, to the extent permitted under Section 422 of the Code and the regulations promulgated thereunder, the Shares that may be issued as Incentive Stock Options.  Notwithstanding the foregoing, the following shares shall not be added to the shares authorized for grant under the Plan&#58;  (i) Shares tendered or held back upon exercise of an Option or settlement of an Award to cover the exercise price or tax withholding, and (ii) Shares subject to a Share Appreciation Right that are not issued in connection with the share settlement of the Share Appreciation Right upon exercise thereof. In the event the Company repurchases Shares on the open market, such Shares shall not be added to the Shares available for issuance under the Plan.  Subject to such overall limitations, Shares may be issued up to such maximum number pursuant to any type or types of Award&#59; provided, however, that no more than 6,000,000 Shares may be issued in the form of Incentive Stock Options.  The Shares available for issuance under the Plan may be authorized but unissued Shares or Shares reacquired by the Company.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Changes in Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Subject to Section&#160;3(c) hereof, if, as a result of any reorganization, recapitalization, reclassification, share dividend, share split, reverse share split or other similar change in the Company&#8217;s capital, the outstanding Shares are increased or decreased or are exchanged for a different number or kind of shares or other securities of the Company, or additional shares or new or different shares or other securities of the Company or other non-cash assets are distributed with respect to such Shares or other securities, or, if, as a result of any merger or consolidation, sale of all or substantially all of the assets of the Company, the outstanding Shares are converted into or exchanged for securities of the Company or any successor entity (or a parent or subsidiary thereof), the Administrator shall make an appropriate or proportionate adjustment in (i) the maximum number of Shares reserved for issuance under the Plan, including the maximum number of Shares that may be issued in the form of Incentive </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;6</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Stock Options, (ii) the number and kind of Shares or other securities subject to any then outstanding Awards under the Plan, (iii) the repurchase price, if any, per Share subject to each outstanding Restricted Share Award, and (iv)&#160;the exercise price for each Share subject to any then outstanding Options and Share Appreciation Rights under the Plan, without changing the aggregate exercise price (i.e., the exercise price multiplied by the number of shares subject to Options and Share Appreciation Rights) as to which such Options and Share Appreciation Rights remain exercisable.  The Administrator shall also make equitable or proportionate adjustments in the number of shares subject to outstanding Awards and the exercise price and the terms of outstanding Awards to take into consideration cash dividends paid other than in the ordinary course or any other extraordinary corporate event.  The adjustment by the Administrator shall be final, binding and conclusive.  No fractional Shares shall be issued under the Plan resulting from any such adjustment, but the Administrator in its discretion may make a cash payment in lieu of fractional Shares.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Mergers and Other Transactions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the case of and subject to the consummation of a Sale Event, the parties thereto may cause the assumption or continuation of Awards theretofore granted by the successor entity, or the substitution of such Awards with new Awards of the successor entity or parent thereof, with appropriate adjustment as to the number and kind of shares and, if appropriate, the per share exercise prices, as such parties shall agree.  To the extent the parties to such Sale Event do not provide for the assumption, continuation or substitution of Awards, upon the effective time of the Sale Event, the Plan and all outstanding Awards granted hereunder shall terminate.  In the event of such termination, (i) the Company shall have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding Options and Share Appreciation Rights, in exchange for the cancellation thereof, in an amount equal to the difference between (A) the Sale Price multiplied by the number of Shares subject to outstanding Options and Share Appreciation Rights (to the extent then vested and exercisable at prices not in excess of the Sale Price) and (B) the aggregate exercise price of all such outstanding Options and Share Appreciation Rights (provided that, in the case of an Option or Share Appreciation Right with an exercise price equal to or greater than the Sale Price, such Option or Share Appreciation Right shall be cancelled for no consideration)&#59; or (ii) each grantee shall be permitted, within a specified period of time prior to the consummation of the Sale Event as determined by the Administrator, to exercise all outstanding Options and Share Appreciation Rights (to the extent then vested and exercisable) held by such grantee.  The Company shall also have the option (in its sole discretion) to make or provide for a payment, in cash or in kind, to the grantees holding other Awards in an amount equal to the Sale Price multiplied by the number of vested Shares under such Awards.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Maximum Awards to Non-Employee Directors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything to the contrary in this Plan, the value of all Awards awarded under this Plan and all other cash compensation paid by the Company to any Non-Employee Director in any calendar year shall not exceed $675,000.  For the purpose of this limitation, the value of any Award shall be its grant date fair value, as determined in accordance with ASC 718 or successor provision but excluding the impact of estimated forfeitures related to service-based vesting provisions.  Notwithstanding the foregoing, the Board may make exceptions to the foregoing limit (up to twice such limit) for a non-executive chair of the Board or, in extraordinary circumstances, for other individual Non-Employee Directors, as the Administrator may determine, provided that the Non-Employee Director receiving such Awards may not participate in the decision to make such Awards.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 4.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">ELIGIBILITY</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantees under the Plan will be such employees, Non-Employee Directors or Consultants of the Company and its Affiliates as are selected from time to time by the Administrator in its sole discretion&#59; provided that Awards may not be granted to employees, Directors or Consultants </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;7</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">who are providing services only to any &#8220;parent&#8221; of the Company, as such term is defined in Rule 405 of the Act, unless (i) the stock underlying the Awards is treated as &#8220;service recipient stock&#8221; under Section 409A or (ii) the Company has determined that such Awards are exempt from or otherwise comply with Section 409A.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 5.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">OPTIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Award of Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may grant Options under the Plan.  Any Option granted under the Plan shall be in such form as the Administrator may from time to time approve.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options granted under the Plan may be either Incentive Stock Options or Non-Qualified Options.  Incentive Stock Options may be granted only to employees of the Company or any Subsidiary that is a &#8220;subsidiary corporation&#8221; within the meaning of Section&#160;424(f) of the Code.  To the extent that any Option does not qualify as an Incentive Stock Option, it shall be deemed a Non-Qualified Option.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Options granted pursuant to this Section&#160;5 shall be subject to the following terms and conditions and shall contain such additional terms and conditions, not inconsistent with the terms of the Plan, as the Administrator shall deem desirable.  If the Administrator so determines, Options may be granted in lieu of cash compensation at the optionee&#8217;s election, subject to such terms and conditions as the Administrator may establish.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exercise Price</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The exercise price per Share covered by an Option granted pursuant to this Section&#160;5 shall be determined by the Administrator at the time of grant but shall not be less than 100 percent of the Fair Market Value on the date of grant.  In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the exercise price of such Incentive Stock Option shall be not less than 110 percent of the Fair Market Value on the grant date.  Notwithstanding the foregoing, Options may be granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant (i) pursuant to a transaction described in, and in a manner consistent with, Section 424(a) of the Code, (ii) to individuals who are not subject to U.S. income tax on the date of grant or (iii) the Option is otherwise compliant with Section 409A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Option Term</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The term of each Option shall be fixed by the Administrator, but no Option shall be exercisable more than ten years after the date the Option is granted.  In the case of an Incentive Stock Option that is granted to a Ten Percent Owner, the term of such Option shall be no more than five years from the date of grant.  Where an Option is granted with an exercise price per share that is less than 100 percent of the Fair Market Value on the date of grant to an individual who is tax resident in Ireland, the Option shall lapse if not exercised within 7 years of the date of grant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exercisability&#59; Rights of a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Options shall become exercisable at such time or times, whether or not in installments, as shall be determined by the Administrator at or after the grant date.  The Administrator may at any time accelerate the exercisability of all or any portion of any Option.  An optionee shall have the rights of a shareholder only as to Shares acquired upon the exercise of an Option and not as to unexercised Options.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Method of Exercise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Options may be exercised in whole or in part, by giving written or electronic notice of exercise to the Company, specifying the number of shares to be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;8</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">purchased.  Payment of the purchase price may be made by one or more of the following methods except to the extent otherwise provided in the Award Certificate&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">In cash, by certified or bank check or other instrument acceptable to the Administrator&#59;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">Through the delivery (or attestation to the ownership following such procedures as the Company may prescribe) of Shares that are not then subject to restrictions under any Company plan.  Such surrendered Shares shall be valued at Fair Market Value on the exercise date&#59; </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.03pt">By the optionee delivering to the Company a properly executed exercise notice together with irrevocable instructions to a broker to promptly deliver to the Company cash or a check payable and acceptable to the Company for the purchase price&#59; provided that in the event the optionee chooses to pay the purchase price as so provided, the optionee and the broker shall comply with such procedures and enter into such agreements of indemnity and other agreements as the Company shall prescribe as a condition of such payment procedure&#59; or </font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(iv)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:18.69pt">With respect to Options that are not Incentive Stock Options, by a &#8220;net exercise&#8221; arrangement pursuant to which the Company will reduce the number of Shares issuable upon exercise by the largest whole number of Shares with a Fair Market Value that does not exceed the aggregate exercise price. Where newly issued Shares are to be delivered in this way, the Affiliate which employs the grantee, if so agreed with the Company, shall pay to the Company such price as is at least equal to the aggregate nominal value of the Shares issued.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Payment instruments will be received subject to collection.  The transfer to the optionee on the records of the Company or of the transfer agent of the Shares to be purchased pursuant to the exercise of an Option will be contingent upon receipt from the optionee (or a purchaser acting in his stead in accordance with the provisions of the Option) by the Company of the full purchase price for such shares and the fulfillment of any other requirements contained in the Award Certificate or applicable provisions of laws (including the satisfaction of any withholding taxes that the Company is obligated to withhold with respect to the optionee).  In the event an optionee chooses to pay the purchase price by previously-owned Shares through the attestation method, the number of Shares transferred to the optionee upon the exercise of the Option shall be net of the number of attested Shares.  In the event that the Company establishes, for itself or using the services of a third party, an automated system for the exercise of Stock Options, such as a system using an internet website or interactive voice response, then the paperless exercise of Stock Options may be permitted through the use of such an automated system.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Annual Limit on Incentive Stock Options</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent required for &#8220;incentive stock option&#8221; treatment under Section&#160;422 of the Code, the aggregate Fair Market Value (determined as of the time of grant) of the Shares with respect to which Incentive Stock Options granted under this Plan and any other plan of the Company or its parent and subsidiary corporations become exercisable for the first time by an optionee during any calendar year shall not exceed $100,000.  To the extent that any Incentive Stock Option exceeds this limit, it shall constitute a Non-Qualified Option.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 6.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">SHARE APPRECIATION RIGHTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Award of Share Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may grant Share Appreciation Rights under the Plan.  A Share Appreciation Right is an Award entitling the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;9</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">recipient to receive Shares (or cash, to the extent explicitly provided for in the applicable Award Certificate) having a value equal to the excess of the Fair Market Value of a Share on the date of exercise over the exercise price of the Share Appreciation Right multiplied by the number of Shares with respect to which the Share Appreciation Right shall have been exercised.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Exercise Price of Share Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The exercise price of a Share Appreciation Right shall not be less than 100 percent of the Fair Market Value of a Share on the date of grant.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Grant and Exercise of Share Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Share Appreciation Rights may be granted by the Administrator independently of any Stock Option granted pursuant to Section&#160;5 of the Plan.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Terms and Conditions of Share Appreciation Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Share Appreciation Rights shall be subject to such terms and conditions as shall be determined on the date of grant by the Administrator.  The term of a Share Appreciation Right may not exceed ten years.  The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 7.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">RESTRICTED SHARE AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Nature of Restricted Share Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may grant Restricted Share Awards under the Plan.  A Restricted Share Award is any Award of Restricted Shares subject to such restrictions and conditions as the Administrator may determine at the time of grant.  Conditions may be based on continuing employment (or other Service Relationship) and&#47;or achievement of pre-established performance goals and objectives.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Rights as a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Upon the grant of the Restricted Share Award and payment of any applicable purchase price, a grantee shall have the rights of a shareholder with respect to the voting of the Restricted Shares and receipt of dividends&#59; provided that any dividends paid by the Company during the vesting period shall accrue and shall not be paid to the grantee until and to the extent the Restricted Shares vest.  Unless the Administrator shall otherwise determine, (i) uncertificated Restricted Shares shall be accompanied by a notation on the records of the Company or the transfer agent to the effect that they are subject to forfeiture until such Restricted Shares are vested as provided in Section 7(d) below, and (ii) certificated Restricted Shares shall remain in the possession of the Company until such Restricted Shares are vested as provided in Section&#160;7(d) below, and the grantee shall be required, as a condition of the grant, to deliver to the Company such instruments of transfer as the Administrator may prescribe.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Restricted Shares may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of except as specifically provided herein or in the Restricted Share Award Certificate.  Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section 16 below, in writing after the Award is issued, if a grantee&#8217;s employment (or other Service Relationship) with the Company and its Subsidiaries terminates for any reason, any Restricted Shares that have not vested at the time of termination shall automatically and without any requirement of notice to such grantee from or other action by or on behalf of, the Company be deemed to have been reacquired by the Company at its original purchase price (if any) from such grantee or such grantee&#8217;s legal representative simultaneously with such termination of employment (or other Service Relationship), and thereafter shall cease to represent any ownership of the Company by the grantee or rights of the grantee as a shareholder.  Following such deemed reacquisition of Restricted Shares that are represented by physical certificates, a grantee shall surrender such certificates to the Company upon request without consideration.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;10</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Vesting and payment of Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator at the time of grant shall specify the date or dates and&#47;or the attainment of pre-established performance goals, objectives and other conditions on which the non-transferability of the Restricted Shares and the Company&#8217;s right of repurchase or forfeiture shall lapse.  Subsequent to such date or dates and&#47;or the attainment of such pre-established performance goals, objectives and other conditions, the shares on which all restrictions have lapsed shall no longer be Restricted Shares and shall be deemed &#8220;vested.&#8221; Where newly issued Shares are to be delivered on the vesting of a Restricted Share Award, the Affiliate which employs the grantee, if so agreed with the Company, shall pay to the Company such price as is at least equal to the aggregate nominal value of the Shares the subject of the Restricted Share Award.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 8.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">RESTRICTED SHARE UNITS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Nature of Restricted Share Units</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may grant Restricted Share Units under the Plan.  A Restricted Share Unit is an Award of stock units that may be settled in Shares (or cash, to the extent explicitly provided for in the Award Certificate) upon the satisfaction of such restrictions and conditions at the time of grant.  Conditions may be based on continuing employment (or other Service Relationship) and&#47;or achievement of pre-established performance goals and objectives.  The terms and conditions of each such Award shall be determined by the Administrator, and such terms and conditions may differ among individual Awards and grantees.  Except in the case of Restricted Share Units with a deferred settlement date that complies with Section 409A, at the end of the vesting period, the Restricted Share Units, to the extent vested, shall be settled in the form of Shares.  Restricted Share Units with deferred settlement dates are subject to Section 409A and shall contain such additional terms and conditions as the Administrator shall determine in its sole discretion in order to comply with the requirements of Section 409A.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Election to Receive Restricted Share Units in Lieu of Compensation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may, in its sole discretion, permit a grantee to elect to receive a portion of future cash compensation otherwise due to such grantee in the form of an award of Restricted Share Units.  Any such election shall be made in writing and shall be delivered to the Company no later than the date specified by the Administrator and in accordance with Section 409A and such other rules and procedures established by the Administrator.  Any such future cash compensation that the grantee elects to defer shall be converted to a fixed number of Restricted Share Units based on the Fair Market Value of Stock on the date the compensation would otherwise have been paid to the grantee if such payment had not been deferred as provided herein.  The Administrator shall have the sole right to determine whether and under what circumstances to permit such elections and to impose such limitations and other terms and conditions thereon as the Administrator deems appropriate.  Any Restricted Share Units that are elected to be received in lieu of cash compensation shall be fully vested, unless otherwise provided in the Award Certificate.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Rights as a Shareholder</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  A grantee shall have the rights as a shareholder only as to Shares acquired by the grantee upon settlement of Restricted Share Units&#59; provided, however, that the grantee may be credited with Dividend Equivalent Rights with respect to the stock units underlying his Restricted Share Units, subject to the provisions of Section 11 and such terms and conditions as the Administrator may determine.  Where newly issued Shares are to be delivered on the vesting of a Restricted Share Unit, the Affiliate which employs the grantee, if so agreed with the Company, shall pay to the Company such price as is at least equal to the aggregate nominal value of the Shares the subject of the Restricted Share Unit.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&#160;16 below, in writing after the Award is issued, a grantee&#8217;s right in all Restricted Share Units that have not vested shall automatically terminate </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;11</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 9.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:3.36pt;text-decoration:underline">UNRESTRICTED SHARE AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant or Sale of Unrestricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrator may grant (or sell at par value or such higher purchase price determined by the Administrator) an Unrestricted Share Award under the Plan.  An Unrestricted Share Award is an Award pursuant to which the grantee may receive Shares free of any restrictions under the Plan.  Unrestricted Share Awards may be granted in respect of past services or other valid consideration, or in lieu of cash compensation due to such grantee.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 10.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">CASH-BASED AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Grant of Cash-Based Awards</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Administrator may grant Cash-Based Awards under the Plan.  A Cash-Based Award is an Award that entitles the grantee to a payment in cash upon the attainment of specified performance goals.  The Administrator shall determine the maximum duration of the Cash-Based Award, the amount of cash to which the Cash-Based Award pertains, the conditions upon which the Cash-Based Award shall become vested or payable, and such other provisions as the Administrator shall determine.  Each Cash-Based Award shall specify a cash-denominated payment amount, formula or payment ranges as determined by the Administrator.  Payment, if any, with respect to a Cash-Based Award shall be made in accordance with the terms of the Award and may be made in cash.  </font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 11.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">DIVIDEND EQUIVALENT RIGHTS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Dividend Equivalent Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may grant Dividend Equivalent Rights under the Plan.  A Dividend Equivalent Right is an Award entitling the grantee to receive credits based on cash dividends that would have been paid on the Shares specified in the Dividend Equivalent Right (or other Award to which it relates) if such shares had been issued to the grantee.  A Dividend Equivalent Right may be granted hereunder to any grantee as a component of an award of Restricted Share Units or as a freestanding award.  The terms and conditions of Dividend Equivalent Rights shall be specified in the Award Certificate.  Dividend equivalents credited to the holder of a Dividend Equivalent Right may be paid currently or may be deemed to be reinvested in additional Shares, which may thereafter accrue additional equivalents.  Any such reinvestment shall be at Fair Market Value on the date of reinvestment or such other price as may then apply under a dividend reinvestment plan sponsored by the Company, if any.  Dividend Equivalent Rights may be settled in cash or Shares or a combination thereof, in a single installment or installments.  A Dividend Equivalent Right granted as a component of an Award of Restricted Share Units shall provide that such Dividend Equivalent Right shall be settled only upon settlement or payment of, or lapse of restrictions on, such other Award, and that such Dividend Equivalent Right shall expire or be forfeited or annulled under the same conditions as such other Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Termination</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as may otherwise be provided by the Administrator either in the Award Certificate or, subject to Section&#160;16 below, in writing after the Award is issued, a grantee&#8217;s rights in all Dividend Equivalent Rights shall automatically terminate upon the grantee&#8217;s termination of employment (or cessation of Service Relationship) with the Company and its Subsidiaries for any reason.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;12</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 12.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">TRANSFERABILITY OF AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Except as provided in Section&#160;12(b) below, during a grantee&#8217;s lifetime, his or her Awards shall be exercisable only by the grantee, or by the grantee&#8217;s legal representative or guardian in the event of the grantee&#8217;s incapacity.  No Awards shall be sold, assigned, transferred or otherwise encumbered or disposed of by a grantee other than by will or by the laws of descent and distribution or pursuant to a domestic relations order.  No Awards shall be subject, in whole or in part, to attachment, execution, or levy of any kind, and any purported transfer in violation hereof shall be null and void.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Administrator Action</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding Section&#160;12(a), the Administrator, in its discretion, may provide either in the Award Certificate regarding a given Award or by subsequent written approval that the grantee (who is an employee or director) may transfer his or her Non-Qualified Options to his or her immediate family members, to trusts for the benefit of such family members, or to partnerships in which such family members are the only partners, provided that the transferee agrees in writing with the Company to be bound by all of the terms and conditions of this Plan and the applicable Award.  In no event may an Award be transferred by a grantee for value.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Family Member</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  For purposes of Section&#160;12(b), &#8220;family member&#8221; shall mean a grantee&#8217;s child, stepchild, grandchild, parent, stepparent, grandparent, spouse, former spouse, sibling, niece, nephew, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law, or sister-in-law, including adoptive relationships, any person sharing the grantee&#8217;s household (other than a tenant of the grantee), a trust in which these persons (or the grantee) have more than 50 percent of the beneficial interest, a foundation in which these persons (or the grantee) control the management of assets, and any other entity in which these persons (or the grantee) own more than 50 percent of the voting interests.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Designation of Beneficiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent permitted by the Company, each grantee to whom an Award has been made under the Plan may designate a beneficiary or beneficiaries to exercise any Award or receive any payment under any Award payable on or after the grantee&#8217;s death.  Any such designation shall be on a form provided for that purpose by the Administrator and shall not be effective until received by the Administrator.  If no beneficiary has been designated by a deceased grantee, or if the designated beneficiaries have predeceased the grantee, the beneficiary shall be the grantee&#8217;s estate.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 13.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">TAX WITHHOLDING</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Payment by Grantee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Each grantee shall, no later than the date as of which the value of an Award or of any Stock or other amounts received thereunder first becomes includable in the gross income of the grantee for Federal income tax purposes, pay to the Company, or make arrangements satisfactory to the Administrator regarding payment of, any Federal, state, or local taxes of any kind required by law to be withheld by the Company with respect to such income.  The Company and its Subsidiaries shall, to the extent permitted by law, have the right to deduct any such taxes from any payment of any kind otherwise due to the grantee.  The Company&#8217;s obligation to deliver evidence of book entry (or stock certificates) to any grantee is subject to and conditioned on tax withholding obligations being satisfied by the grantee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Payment in Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may require the Company&#8217;s tax withholding obligation to be satisfied, in whole or in part, by the Company withholding from Shares to be issued pursuant to any Award a number of Shares with an aggregate Fair Market Value (as of the date the withholding is effected) that would satisfy the withholding amount due&#59; provided, however, that the amount withheld does not exceed the maximum statutory tax rate or such lesser amount as is necessary to avoid liability accounting treatment.    For purposes of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;13</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">share withholding, the Fair Market Value of withheld shares shall be determined in the same manner as the value of Shares includible in income of the grantees.  The Administrator may also require the Company&#8217;s tax withholding obligation to be satisfied, in whole or in part, by an arrangement whereby a certain number of Shares issued pursuant to any Award are immediately sold and proceeds from such sale are remitted to the Company in an amount that would satisfy the withholding amount due.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 14.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">SECTION 409A AWARDS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Awards are intended to be exempt from Section 409A to the greatest extent possible and to otherwise comply with Section 409A.  The Plan and all Awards shall be interpreted in accordance with such intent.  To the extent that any Award is determined to constitute &#8220;nonqualified deferred compensation&#8221; within the meaning of Section 409A (a &#8220;409A Award&#8221;), the Award shall be subject to such additional rules and requirements as specified by the Administrator from time to time in order to comply with Section 409A.  In this regard, if any amount under a 409A Award is payable upon a &#8220;separation from service&#8221; (within the meaning of Section 409A) to a grantee who is then considered a &#8220;specified employee&#8221; (within the meaning of Section 409A), then no such payment shall be made prior to the date that is the earlier of (i) six months and one day after the grantee&#8217;s separation from service, or (ii) the grantee&#8217;s death, but only to the extent such delay is necessary to prevent such payment from being subject to interest, penalties and&#47;or additional tax imposed pursuant to Section 409A.  Further, the settlement of any 409A Award may not be accelerated except to the extent permitted by Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 15.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">TERMINATION OF SERVICE RELATIONSHIP, TRANSFER, LEAVE OF ABSENCE, ETC.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Termination of Service Relationship</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If the grantee&#8217;s Service Relationship is with an Affiliate and such Affiliate  ceases to be an Affiliate, the grantee shall be deemed to have terminated his or her Service Relationship for purposes of the Plan.  </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">For purposes of the Plan, the following events shall not be deemed a termination of a Service Relationship&#58;</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(i)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.69pt">a transfer to the employment of the Company from an Affiliate or from the Company to an Affiliate, or from one Affiliate to another&#59; or</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(ii)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21.36pt">an approved leave of absence for military service or sickness, or for any other purpose approved by the Company, if the employee&#8217;s right to re-employment is guaranteed either by a statute or by contract or under the policy pursuant to which the leave of absence was granted or if the Administrator otherwise so provides in writing.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 16.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">AMENDMENTS AND TERMINATION</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Board may, at any time, amend or discontinue the Plan and the Administrator may, at any time, amend or cancel any outstanding Award for the purpose of satisfying changes in law or for any other lawful purpose, but no such action shall materially and adversely affect rights under any outstanding Award without the holder&#8217;s consent.  Except as provided in Section 3(b) or 3(c), without prior shareholder approval, in no event may the Administrator exercise its discretion to reduce the exercise price of outstanding Stock Options or Share Appreciation Rights or effect repricing through cancellation and re-grants or cancellation of Stock Options or Share </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;14</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Appreciation Rights in exchange for cash or other Awards.  To the extent required under the rules of any securities exchange or market system on which the Shares are listed, to the extent determined by the Administrator to be required by the Code to ensure that Incentive Stock Options granted under the Plan are qualified under Section&#160;422 of the Code, Plan amendments shall be subject to approval by Company shareholders.  Nothing in this Section&#160;16 shall limit the Administrator&#8217;s authority to take any action permitted pursuant to Section&#160;3(b) or 3(c).</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 17.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">STATUS OF PLAN</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">With respect to the portion of any Award that has not been exercised and any payments in cash, Stock or other consideration not received by a grantee, a grantee shall have no rights greater than those of a general creditor of the Company unless the Administrator shall otherwise expressly determine in connection with any Award or Awards.  In its sole discretion, the Administrator may authorize the creation of trusts or other arrangements to meet the Company&#8217;s obligations to deliver Stock or make payments with respect to Awards hereunder, provided that the existence of such trusts or other arrangements is consistent with the foregoing sentence.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 18.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">GENERAL PROVISIONS</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">No Distribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Administrator may require each person acquiring Stock pursuant to an Award to represent to and agree with the Company in writing that such person is acquiring the shares without a view to distribution thereof.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Issuance of Stock</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  To the extent certificated, stock certificates to grantees under this Plan shall be deemed delivered for all purposes when the Company or a stock transfer agent of the Company shall have mailed such certificates in the United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company.  Uncertificated Stock shall be deemed delivered for all purposes when the Company or a Stock transfer agent of the Company shall have given to the grantee by electronic mail (with proof of receipt) or by United States mail, addressed to the grantee, at the grantee&#8217;s last known address on file with the Company, notice of issuance and recorded the issuance in its records (which may include electronic &#8220;book entry&#8221; records).  Notwithstanding anything herein to the contrary, the Company shall not be required to issue or deliver any evidence of book entry or certificates evidencing Shares pursuant to the exercise or settlement of any Award, unless and until the Administrator has determined, with advice of counsel (to the extent the Administrator deems such advice necessary or advisable), that the issuance and delivery is in compliance with all applicable laws, regulations of governmental authorities and, if applicable, the requirements of any exchange on which the Shares are listed, quoted or traded.  Any Stock issued pursuant to the Plan shall be subject to any stop-transfer orders and other restrictions as the Administrator deems necessary or advisable to comply with federal, state or foreign jurisdiction, securities or other laws, rules and quotation system on which the Shares are listed, quoted or traded.  The Administrator may place legends on any Share certificate or notations on any book entry to reference restrictions applicable to the Shares.  In addition to the terms and conditions provided herein, the Administrator may require that an individual make such reasonable covenants, agreements, and representations as the Administrator, in its discretion, deems necessary or advisable in order to comply with any such laws, regulations, or requirements.  The Administrator shall have the right to require any individual to comply with any timing or other restrictions with respect to the settlement or exercise of any Award, including a window-period limitation, as may be imposed in the discretion of the Administrator.  </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;15</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Shareholder Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Until Shares are deemed delivered in accordance with Section 18(b), no right to vote or receive dividends or any other rights of a shareholder will exist with respect to Shares to be issued in connection with an Award, notwithstanding the exercise of an Option or any other action by the grantee with respect to an Award.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Other Compensation Arrangements&#59; No Employment Rights</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Nothing contained in this Plan shall prevent the Board from adopting other or additional compensation arrangements, including trusts, and such arrangements may be either generally applicable or applicable only in specific cases.  The adoption of this Plan and the grant of Awards do not confer upon any employee any right to continued employment with the Company or any Subsidiary.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt;text-decoration:underline">Trading Policy Restrictions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Option exercises and other Awards under the Plan shall be subject to the Company&#8217;s insider trading policies and procedures, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(f)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:24.03pt;text-decoration:underline">Clawback Policy</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Awards under the Plan shall be subject to the Company&#8217;s clawback policy, as in effect from time to time.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(g)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt;text-decoration:underline">Concert-Party Restrictions under the Irish Takeover Rules</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">. In the event that any individual who is eligible to receive an Award is, or is presumed to be, a &#8220;person acting in concert&#8221; for the purposes of the Irish Takeover Rules, and the grant, exercise, vesting, settlement or any other action in relation to an Award to such individual may, in the reasonable opinion of the Administrator, result in the individual and&#47;or any person acting, or presumed to be acting, in concert with such individual becoming obliged under the Irish Takeover Rules to make an offer for the Company under Rule 9 of the Irish Takeover Rules (&#8220;a Concert-Party Offer&#8221;), the Administrator may decide that either (i) such grant, exercise, vesting, settlement or other action in relation to such individual or Participant shall not take effect unless the Company is in receipt of a confirmation, direction or ruling from the Irish Takeover Panel that satisfies the Board that such grant, exercise, vesting, settlement or other action would not result in an obligation to make a Concert-Party Offer&#59; or the Shares which are to be delivered on the vesting or settlement of the relevant Award shall not have any voting rights. If the Administrator determines that the exercise or settlement of any such Award by way of the issuance of Shares is not possible or desirable, it may determine that such Award shall be settled in cash, on such conditions as the Administrator may determine.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 19.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">EFFECTIVE DATE OF PLAN</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Plan shall become effective upon shareholder approval in accordance with applicable law, the Company&#8217;s Constitution, and applicable stock exchange rules. No grants of Options and other Awards may be made hereunder after the tenth anniversary of the Effective Date and no grants of Incentive Stock Options may be made hereunder after the tenth anniversary of the date the Plan is approved by the Board.</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">SECTION 20.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:33.36pt;text-decoration:underline">GOVERNING LAW</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Plan and all Awards and actions taken thereunder shall be governed by, and construed in accordance with, the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;16</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in accordance with the internal laws of the State of Delaware, applied without regard to conflict of law principles.</font></div><div style="margin-bottom:12pt;margin-top:30pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DATE APPROVED BY BOARD OF DIRECTORS&#58; April 13, 2020</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">DATE APPROVED BY SHAREHOLDERS&#58; August 5, 2020</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;17</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:43.108%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;102142181.5 </font></div><div><font><br></font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.13
<SEQUENCE>5
<FILENAME>a123124ex-1013.htm
<DESCRIPTION>EX-10.13
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ie9a7f83f457444e5a8f258d2908f3e9f_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AMENDMENT<br>TO<br>AVADEL PHARMACEUTICALS PLC<br>2021 INDUCEMENT PLAN</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">A.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:24.34pt">The Avadel Pharmaceuticals plc 2021 Inducement Plan (the &#8220;Plan&#8221;) is hereby amended by deleting the first sentence of Section 3(a) and substituting therefore the following&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8220;The maximum number of Shares reserved and available for issuance under the Plan shall be 2,000,000 Shares, subject to adjustment as provided in this Section 3.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">B.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:25pt">The effective date of this Amendment shall be November 7, 2024.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%">C.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:125%;padding-left:25pt">Except as amended herein, the Plan is confirmed in all other respects.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>6
<FILENAME>a123124ex-1018.htm
<DESCRIPTION>EX-10.18
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i2b10061089b348ecb3dfbe41012967c3_1"></div><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><img alt="image_0.jpg" src="image_0.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:700;line-height:120%"><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_1.jpg" src="image_1.jpg" style="height:134px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jerad Seurer<br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">August 30, 2022</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Re&#58;&#160;&#160;&#160;&#160;Employment Letter Agreement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dear Jerad,</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On behalf of Avadel Pharmaceuticals plc (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Avadel plc</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and its U.S. subsidiary, Avadel Management Corporation (&#8220;Avadel&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), I am pleased to present to you the updated terms and conditions of your employment, effective as of August 30, 2022. The terms and conditions of your employment as of the Effective Date are set forth below in this letter agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;). This Agreement shall supersede and replace any prior employment agreement or offer letter between you and the Company&#59; provided, however, this Agreement supplements and does not supersede any other confidentiality, assignment of inventions or restrictive covenant agreement between the Company and you.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Position</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will continue in your role as General Counsel &#38; Corporate Secretary. This is a full-time employment position. It is understood and agreed that, while you render services to the Company, you will not engage in any other employment, consulting or other business activities (whether full-time or part-time), except as expressly authorized in writing by the Company&#8217;s Chief Executive Officer (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">CEO</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). Notwithstanding the foregoing, you may engage in religious, charitable and other community activities so long as such activities do not interfere or conflict with your obligations to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Compensation and Related Matters</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23pt">Base Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As of the Effective Date, the Company will pay you a base salary at the rate of three hundred fifty thousand dollars ($350,000) per year, payable in accordance with the Company&#8217;s standard payroll schedule and subject to applicable deductions and withholdings. Your base salary will be subject to periodic review and adjustments at the Company&#8217;s discretion. Your base salary in effect at any given time is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Base Salary</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.44pt">Annual Bonus</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You will remain eligible to receive an annual performance bonus having a target payout of 40% of your Base Salary. The actual bonus amount is discretionary. To earn an annual bonus, you must be employed by the Company as of the payment date of such bonus. Any annual bonus will be paid no later than March 15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:100%;position:relative;top:-4.2pt;vertical-align:baseline">th</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> of the calendar year following the calendar year to which such bonus relates.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.67pt">Expenses</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Company will promptly reimburse you for all reasonable expenses incurred by you in performing services hereunder, in accordance with the policies and procedures then in effect and established by the Company for its executives.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.44pt">Benefits&#47;Paid Time Off</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You remain eligible, subject to the terms of the applicable plans and programs, to participate in the employee benefits and insurance programs generally made available to the Company&#8217;s full-time employees. You will be entitled to paid time off consistent with the terms of the Company&#8217;s paid time off policy, as in effect from time to time. The Company reserves the right to modify, amend or cancel any of its benefits plans or programs at any time.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Equity Award</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You previously received an option agreement and&#47;or stock-based award, as applicable, which shall continue to be governed by any applicable option agreement or other stock-based award agreements and the corresponding Avadel plc Omnibus Incentive Compensation Plan (together, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Documents</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). You will also be eligible to participate in future equity awards which may be granted by the Board, based upon Company and individual performance, at the sole discretion of the Board.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">4.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Location</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Your primary work location will continue to be at the Company&#8217;s office which is currently in Chesterfield, MO, provided that you may be required to travel for business from time to time, consistent with the Company&#8217;s business needs.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">5.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">At-Will Employment&#59; Date of Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  At all times your employment is &#8220;at will,&#8221; meaning you or the Company may terminate it at any time for any or no reason, subject to the terms of this Agreement. Although your job duties, title, reporting structure, compensation and benefits, as well as the Company&#8217;s benefit plans and personnel policies and procedures, may change from time to time, the &#8220;at will&#8221; nature of your employment may only be changed in an express written agreement signed by you and the Chairman of the Board of Avadel plc. Your last day of employment for any reason is referred to herein as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Date of Termination</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> &#8220; In the event that you elect to end your employment, the Company requests that you provide at least 30 days&#8217; advance written notice to the Company. Notwithstanding the foregoing, the Company may unilaterally accelerate the Date of Termination, and such acceleration shall not result in a termination by the Company for purposes of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To the extent applicable, you shall be deemed to have resigned from all officer and board member positions that you hold with the Company or any of its respective subsidiaries and affiliates upon the termination of your employment for any reason. You shall execute any documents in reasonable form as may be requested to confirm or effectuate any such resignations.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">6.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Accrued Obligations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event of the ending of your employment for any reason, the Company shall pay you (i) your Base Salary through the Date of Termination, (ii) any accrued but unused vacation, and (iii) the amount of any documented expenses properly incurred by you on behalf of the Company prior to any such termination and not yet reimbursed (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accrued Obligations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">7.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Severance Pay and Benefits Outside of the Change in Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause outside of the Change in Control Period (as such capitalized terms are defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), then, in addition to you being entitled to the Accrued Obligations, and subject to (i) you signing a separation agreement and release in a form and manner reasonably satisfactory to the Company, which shall include, without limitation, a general release of claims against the Company and all related persons and entities, a reaffirmation of the Continuing Obligations (as defined below) and shall provide that if you breach the Continuing Obligations, all payments of the Severance Amount (as defined below) shall immediately cease (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Separation Agreement and Release</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), and (ii) the Separation Agreement and Release becoming irrevocable, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release)&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23pt">The Company shall pay you an amount equal to 1.0 times the Executive&#8217;s then current annual base salary (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Severance Amount</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), which shall be paid in substantially equal installments in accordance with the Company&#8217;s normal payroll practices&#59; provided that, solely to the extent such Severance Amount is exempt from Section 409A of the Internal Revenue Code of 1986, as amended (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Code</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) and does not constitute &#8220;non-qualified deferred compensation&#8221; within the meaning of Section 409A of the Code, the Company may, in its sole discretion, elect to pay such Severance Amount in a lump sum within 60 days following the Date of Termination&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.44pt">subject to your proper election to receive benefits under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">COBRA</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;), the Company shall pay to the group health plan provider(s), the COBRA provider or you, a monthly payment equal to the monthly Executive&#8217;s COBRA premiums for such coverage (at coverage levels in effect immediately prior to the Executive&#8217;s termination) until the earliest of (A) the 12&#160;month anniversary of the Date of Termination&#59; (B) your eligibility for group health plan benefits under any other employer&#8217;s group health plan&#59; or (C) the cessation of your continuation rights under COBRA&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if the Company reasonably determines that it cannot pay such amounts to the group health plan provider(s) or the COBRA provider (if applicable) without potentially violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then the Company shall convert such payments to payments directly to you for the time period specified above contingent upon making timely monthly payments directly to the COBRA administrator. Such payments, if to you, shall be subject to tax-related deductions and withholdings and paid on the Company&#8217;s regular payroll dates.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The amounts payable under this Section 7 (to the extent payable in installments) shall be paid in substantially equal installments in accordance with the Company&#8217;s payroll practice over 12 months commencing within 60 days after the Date of Termination&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that if the 60-day period begins in one calendar year and ends in a second calendar year, the Severance Amount, to the extent it qualifies as &#8220;non-qualified deferred compensation&#8221; within the meaning of Section&#160;409A of the Code, shall begin to be paid in the second calendar year by the last day of such 60-day period&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">provided, further,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> that the initial payment shall include a catch-up payment to cover amounts retroactive to the day immediately following the Date of Termination. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If your employment ends for any reason other than a termination by the Company without Cause you will be entitled to the Accrued Obligations and will not be entitled to any further compensation from the Company. For the avoidance of doubt, if your employment ends due to your death or disability, you will receive the Accrued Obligations but will not be eligible for severance pay and benefits, whether pursuant to Section 7, Section 8 or otherwise.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">8.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Severance Pay and Benefits Within the Change in Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In the event that the Company terminates your employment without Cause or you terminate your employment for Good Reason after following the Good Reason Process (as such capitalized terms are defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Exhibit&#160;A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">), in each case, within the Change in Control Period, then, in addition to you being entitled to the Accrued Obligations, and subject to you signing the Separation Agreement and Release and it becoming fully effective, all within 60 days after the Date of Termination (or such shorter period as set forth in the Separation Agreement and Release), the Company shall (i) provide you the severance pay and benefits set forth in Section 7, subject to the terms and conditions set forth in Section 7, (ii) notwithstanding any other provision in the Equity Documents, any of your outstanding and vested stock options as of the Date of Termination will remain exercisable until the twelve (12) month anniversary of the Date of Termination&#59; provided, however, that the post-termination exercise period for any individual stock option right will not extend beyond its original maximum term as of the original date of the grant&#59; and (iii) notwithstanding anything to the contrary in any applicable option agreement or other stock-based award agreement, all of your stock options and other stock-based awards (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Equity Awards</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) shall immediately accelerate and become fully exercisable or nonforfeitable as of the later of (i) the Date of Termination or (ii)&#160;the effective date of the Separation Agreement and Release (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Accelerated Vesting Date</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;)&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%"> that any termination or forfeiture of the unvested portion of such Equity Awards that would otherwise occur on the Date of Termination in the absence of this Agreement will be delayed until the effective date of the Separation Agreement and Release and will only occur if the vesting pursuant to this subsection does not occur due to the absence of the Separation Agreement and Release becoming fully effective within the time period set forth therein. Notwithstanding the foregoing, no additional vesting of the Equity Awards shall occur during the period between the Date of Termination and the Accelerated Vesting Date.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the avoidance of doubt, Section 7 and Section 8 of this Agreement are mutually exclusive and in no event shall you be entitled to payments or benefits pursuant to both Section 7 and Section 8 of this Agreement.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">9.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:26.72pt">Continuing Obligations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23pt">Restrictive Covenants Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  As a condition of your continued employment, and in consideration for the enhanced payments and benefits under this Agreement you are required to enter into the Employee Confidentiality, Non-Solicitation, Non-Competition and Assignment Agreement enclosed with this Agreement (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Restrictive Covenants Agreement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;). The Restrictive Covenants Agreement supplements and does not supersede any other prior confidentiality, assignment of inventions or restrictive covenant agreement between the Company and you. For purposes of this Agreement, the obligations in this Section 9 and those that arise in the Restrictive Covenants Agreement relating to confidentiality, assignment of inventions, or other restrictive covenants shall collectively be referred to as the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Continuing Obligations</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.44pt">Third Party Agreements and Rights</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You hereby affirm that you are not bound by the terms of any agreement with any previous employer or other party which restricts in any way your use or disclosure of information, other than confidentiality restrictions (if any) or your engagement in any business. You represent to the Company that your execution of this Agreement, your employment with the Company and the performance of your proposed duties for the Company will not violate any obligations you may have to any such previous employer or other party. In your work for the Company, you will not disclose or make use of any information in violation of any agreements with or rights of any such previous employer or other party, and you will not bring to the premises of the Company any copies or other tangible embodiments of </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">non-public information belonging to or obtained from any such previous employment or other party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:23.67pt">Litigation and Regulatory Cooperation</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  During and after your employment you shall cooperate fully with the Company in (1) the defense or prosecution of any claims or actions now in existence or which may be brought in the future against or on behalf of the Company which relate to events or occurrences that transpired while you were employed by the Company, and (ii) the investigation, whether internal or external, of any matters about which the Company believes you may have knowledge or information. Your full cooperation in connection with such claims, actions or investigations shall include, but not be limited to, being available to meet with counsel to answer questions or to prepare for discovery or trial and to act as a witness on behalf of the Company at mutually convenient times. During and after your employment, you also shall cooperate fully with the Company in connection with any investigation or review of any federal, state or local regulatory authority as any such investigation or review relates to events or occurrences that transpired while you were employed by the Company. The Company shall reimburse you for any reasonable out-of-pocket expenses incurred in connection with your performance of obligations pursuant to this Section 9(c).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:22.44pt">Relief</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  You agree that it would be difficult to measure any damages caused to the Company which might result from your breach of any of the Continuing Obligations, and that in any event money damages would be an inadequate remedy for any such breach. Accordingly, you agree that if you breach, or propose to breach, any portion of the Continuing Obligations, the Company shall be entitled, in addition to all other remedies that it may have, to an injunction or other appropriate equitable relief to restrain any such breach without showing or proving any actual damage to the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">10.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Section 409A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23pt">Anything in this Agreement to the contrary notwithstanding, if at the time of your separation from service within the meaning of Section 409Aof the Code, the Company determines that you are a &#8220;specified employee&#8221; within the meaning of Section&#160;409A(a)(2)(B)(i) of the Code, then to the extent any payment or benefit that you become entitled to under this Agreement or otherwise on account of your separation from service would be considered deferred compensation otherwise subject to the 20 percent additional tax imposed pursuant to Section 409A(a) of the Code as a result of the application of Section 409A(a)(2)(B)(i) of the Code, such payment shall not be payable and such benefit shall not be provided until the date that is the earlier of (A) six months and one day after your separation from service, or (B) your death. If any such delayed cash payment is otherwise payable on an installment basis, the first payment shall include a catch-up payment covering amounts that would otherwise have been paid during the six-month period but for the application of this provision, and the balance of the installments shall be payable in accordance with their original schedule.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.44pt">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by the Company or incurred by you during the time periods set forth in this Agreement. All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year (except for any lifetime or other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">aggregate limitation applicable to medical expenses). Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:23.67pt">To the extent that any payment or benefit described in this Agreement constitutes &#8220;non-qualified deferred compensation&#8221; under Section 409A of the Code, and to the extent that such payment or benefit is payable upon the termination of your employment, then such payments or benefits shall be payable only upon your &#8220;separation from service.&#8221; The determination of whether and when a separation from service has occurred shall be made in accordance with the presumptions set forth in Treasury Regulation Section 1.409A-l(h).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(d)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.44pt">The parties intend that this Agreement will be administered in accordance with Section 409A of the Code. To the extent that any provision of this Agreement is ambiguous as to its compliance with Section 409A of the Code, the provision shall be read in such a manner so that all payments hereunder comply with Section 409A of the Code. Each payment pursuant to this Agreement is intended to constitute a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2). The parties agree that this Agreement may be amended, as reasonably requested by either party, and as may be necessary to fully comply with Section 409A of the Code and all related rules and regulations in order to preserve the payments and benefits provided hereunder without additional cost to either party.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(e)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.77pt">The Company makes no representation or warranty and shall have no liability to you or any other person if any provisions of this Agreement are determined to constitute deferred compensation subject to Section 409A of the Code but do not satisfy an exemption from, or the conditions of, such Section.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">11.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Withholding&#59; Tax Effect</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  All forms of compensation referred to in this Agreement are subject to reduction to reflect applicable withholding and payroll taxes and other deductions required by law. You hereby acknowledge that the Company does not have a duty to design its compensation policies in a manner that minimizes your tax liabilities, and you will not make any claim against the Company or the Board related to tax liabilities arising from your compensation.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">12.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Interpretation and Enforcement</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement, together with </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, the Restrictive Covenants Agreement, the Continuing Obligations, and the Equity Documents, constitutes the complete agreement between you and the Company, contains all of the terms of your employment with the Company and supersedes any prior agreements, representations or understandings (whether written, oral or implied) between you and the Company. Except as expressly otherwise provided in the Equity Documents or the Restrictive Covenants Agreement, the terms of this Agreement and the resolution of any disputes as to the meaning, effect, performance or validity of this Agreement or arising out of, related to, or in any way connected with this Agreement, your employment with the Company or any other relationship between you and the Company (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Disputes</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#8221;) will be governed by Missouri law, excluding laws relating to conflicts or choice of law. You and the Company submit to the exclusive personal jurisdiction of the federal and state courts located in the State of Missouri in connection with any Dispute or any claim related to any Dispute.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">13.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Assignment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither you nor the Company may make any assignment of this Agreement or any interest in it, by operation of law or otherwise, without the prior written consent of the other&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">,</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%"> however</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that the Company may assign its rights and obligations under this Agreement without your consent to any affiliate or to any person or entity with whom the Company shall hereafter effect a reorganization, consolidate with, or merge into or to whom it transfers all or substantially all of its properties or assets&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:100%">provided further</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">, that if you remain employed or become employed by the Company, the purchaser or any of their </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">affiliates in connection with any such transaction, then you shall not be entitled to any payments, benefits or vesting pursuant to Section&#160;7 or pursuant to Section 8 of this Agreement solely as a result of such transaction. This Agreement shall inure to the benefit of and be binding upon you and the Company, and each of your and its respective successors, executors, administrators, heirs and permitted assigns.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">14.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Waiver&#59; Amendment</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  No waiver of any provision hereof shall be effective unless made in writing and signed by the waiving party. The failure of any party to require the performance of any term or obligation of this Agreement, or the waiver by any party of any breach of this Agreement, shall not prevent any subsequent enforcement of such term or obligation or be deemed a waiver of any subsequent breach. This Agreement may be amended or modified only by a written instrument signed by you and by a duly authorized representative of the Company.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">15.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Enforceability</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  If any portion or provision of this Agreement (including, without limitation, any portion or provision of any section of this Agreement) shall to any extent be declared illegal or unenforceable by a court of competent jurisdiction, then the remainder of this Agreement, or the application of such portion or provision in circumstances other than those as to which it is so declared illegal or unenforceable, shall not be affected thereby, and each portion and provision of this Agreement shall be valid and enforceable to the fullest extent permitted by law.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">16.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;padding-left:20.64pt">Other Terms</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The provisions of this Agreement shall survive the termination of this Agreement and&#47;or the termination of your employment to the extent necessary to effectuate the terms contained herein. The headings and other captions in this Agreement are for convenience and reference only and shall not be used in interpreting, construing or enforcing any of the provisions of this Agreement. This Agreement may be executed in separate counterparts. When both counterparts are signed, they shall be treated together as one and the same document. PDF copies of signed counterparts shall be equally effective as originals.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;Signature page follows.&#93;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">To accept the above terms and conditions of your employment, please sign and return this Agreement and the Restrictive Covenants Agreement to Angie Woods at </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">awoods&#64;avadel.com</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> by September 2, 2022.</font></div><div style="margin-bottom:30pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Very truly yours,</font></div><div style="margin-bottom:30pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Greg Divis&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Name&#58; Greg Divis<br>Title&#58; Chief Executive Officer</font></div><div style="margin-bottom:30pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Enclosure (Restrictive Covenants Agreement)</font></div><div style="margin-bottom:30pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I have read and accept this letter agreement&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#47;s&#47; Jerad Seurer&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Jerad Seurer</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">August 31, 2022&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Appendix A</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cause</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean (I) your dishonest statements or acts with respect to the Company or any affiliate of the Company, or any current or prospective customers, suppliers vendors or other third parties with which such entity does business that results in or is reasonably anticipated to result in harm to the Company&#59; (ii) your commission of (A) a felony or (B) any misdemeanor involving moral turpitude, deceit, dishonesty or fraud&#59; (iii) your failure to perform your assigned duties and responsibilities to the reasonable satisfaction of the Chief Executive Officer, which failure continues, in the reasonable judgment of the Chief Executive Officer, for thirty (30) days after written notice given to you describing such failure&#59; (iv) your gross negligence, willful misconduct or insubordination that results in or is reasonably anticipated to result in harm to the Company&#59; or (v) your violation of any material provision of any agreement(s) between you and the Company or any Company policies including, without limitation, agreements relating to noncompetition, nonsolicitation, nondisclosure and&#47;or assignment of inventions or policies related to ethics or workplace conduct.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the occurrence of any of the following events&#58; (i) a change in the ownership of Avadel plc which occurs on the date that any one person, or more than one person acting as a group (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Person</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) acquires ownership of equity interests of Avadel plc such that, together with the other equity interests held by such Person, constitute more than fifty percent (50%) of the total voting power of the equity interests of Avadel plc&#59; provided, however, that the acquisition of additional equity interests by any one Person who is considered to own more than fifty percent (50%) of the total voting power of the equity interests of Avadel plc at the time will not be considered a Change in Control&#59; (ii) a change in the effective control of Avadel plc which occurs on the date that a majority of the members of the Board of Directors of Avadel plc is replaced during any twelve (12) month period by directors whose appointment or election is not endorsed by a majority of the members of the Board of Avadel plc prior to the date of the appointment or election&#59; provided, however, if any Person is considered to be in effective control of Avadel plc, the acquisition of additional control of Avadel plc by the same Person will not be considered a Change in Control&#59; or (iii) a change in the ownership of a substantial portion of the assets of Avadel plc, which occurs on the date that any Person acquires (or has acquired during the twelve (12) month period ending on the date of the most recent acquisition by such person or persons) assets from Avadel plc that have a total gross fair market value equal to or more than fifty percent (50%) of the total gross fair market value of all of the assets of Avadel plc within the meaning of Section 409A.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean the twelve (12) month period that immediately follows the first event constituting a Change in Control.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, without your consent, any of the following&#58; (i) the material diminution in your authority, duties or responsibilities in connection with a Change in Control and only if such change occurs during the Change in Control Period&#59; provided, however, that a change in reporting structure shall not, in any respect, constitute Good Reason&#59; (ii) a change in the location of your primary work location such that your one-way commute increases by more than sixty (60) miles, however, a change to remote &#8220;work from </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div><hr style="page-break-after:always"><div style="min-height:50.4pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">home&#8221; status does not constitute a change in location&#59; or (iii) a material breach by the Company of this Agreement&#59; provided, however, before you may resign for Good Reason, you must follow the Good Reason Process.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">5)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Good Reason Process</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean&#58; (i) you reasonably determine in good faith that a condition giving rise to Good Reason has occurred&#59; (ii) you notify the Company in writing of the first occurrence of the condition giving rise to Good Reason within 60 days of the first occurrence of such condition&#59; (iii) you cooperate in good faith with the Company&#8217;s efforts, for a period of not less than 30 days following such notice (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cure Period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), to remedy the condition giving rise to Good Reason&#59; (iv) notwithstanding such efforts, the Good Reason condition continues to exist&#59; and (v) you terminate employment within 60 days after the end of the Cure Period. If the Company cures the condition giving rise to Good Reason during the Cure Period, Good Reason shall be deemed not to have occurred.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.19
<SEQUENCE>7
<FILENAME>a123124ex-1019.htm
<DESCRIPTION>EX-10.19
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i6e0f376783fd40e7972ed454a0a0389b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:24pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:14pt;font-weight:700;line-height:120%">RESTRICTED SHARE AWARD AGREEMENT<br>UNDER THE AVADEL PHARMACEUTICALS PLC<br>2020 OMNIBUS INCENTIVE COMPENSATION PLAN</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name of Grantee&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">No. of Shares&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grant Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to the Avadel Pharmaceuticals plc 2020 Omnibus Incentive Compensation Plan, as amended through the date hereof (the &#8220;Plan&#8221;), Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) hereby grants a Restricted Share Award (an &#8220;Award&#8221;) to the Grantee named above.  Upon acceptance of this Award, the Grantee shall receive the number of ordinary shares, nominal value $0.01 per share (the &#8220;Ordinary Shares&#8221;), of the Company specified above, subject to the restrictions and conditions set forth herein and in the Plan.  The Company acknowledges the receipt from the Grantee of consideration with respect to the nominal value of the Ordinary Shares in the form of cash, past or future services rendered to the Company by the Grantee or such other form of consideration as is acceptable to the Administrator.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Restricted Shares awarded hereunder shall be issued and held by the Company&#8217;s transfer agent in book entry form, and the Grantee&#8217;s name shall be entered as the shareholder of record on the books of the Company.  Thereupon, the Grantee shall have all the rights of a shareholder with respect to such shares, including voting and dividend rights, subject, however, to the restrictions and conditions specified in Paragraph&#160;2 below.  The Grantee shall sign and deliver to the Company a copy of this Award Agreement.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Restrictions and Conditions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">Any book entries for the shares of Restricted Shares granted herein shall bear an appropriate legend, as determined by the Administrator in its sole discretion, to the effect that such shares are subject to restrictions as set forth herein and in the Plan.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.02pt">Restricted Shares granted herein may not be sold, assigned, transferred, pledged or otherwise encumbered or disposed of by the Grantee prior to vesting.</font></div><div style="margin-bottom:12pt;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">(c)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:22.7pt">If the Grantee&#8217;s service as a member of the Board of Directors of the Company (the &#8220;Board&#8221;) is voluntarily or involuntarily terminated for any reason (including death) prior to vesting of Restricted Shares granted herein, all Restricted Shares shall immediately and automatically be forfeited and returned to the Company. </font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Vesting of Restricted Shares</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The restrictions and conditions in Paragraph&#160;2 of this Agreement shall lapse on the Vesting Date or Dates specified in the following schedule so long as the Grantee remains in service as a member of the Board on such Dates.  If a series of Vesting Dates is specified, then the restrictions and conditions in Paragraph&#160;2 shall lapse only with respect to the number of Restricted Shares specified as vested on such date.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;131379275.3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:41.4pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:83.333%"><tr><td style="width:1.0%"></td><td style="width:57.361%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.439%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:2.77pt;padding-right:2.77pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Incremental Number<br></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">of Shares Vested</font></div></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;text-decoration:underline">Vesting Date</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:3.07pt;padding-right:3.07pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#91;_&#93;</font></div></td><td colspan="3" style="padding:2px 2.38pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">&#91;_&#93;</font></td></tr></table></div><div style="margin-bottom:12pt;margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Subsequent to such Vesting Date or Dates, the Shares on which all restrictions and conditions have lapsed shall no longer be deemed Restricted Shares.  The Administrator may at any time accelerate the vesting schedule specified in this Paragraph&#160;3.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">4.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Dividends</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Dividends on Restricted Shares shall be paid currently to the Grantee.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">5.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Incorporation of Plan</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notwithstanding anything herein to the contrary, this Award shall be subject to and governed by all the terms and conditions of the Plan, including the powers of the Administrator set forth in Section 2(b) of the Plan.  Capitalized terms in this Agreement shall have the meaning specified in the Plan, unless a different meaning is specified herein.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">6.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Transferability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement is personal to the Grantee, is non-assignable and is not transferable in any manner, by operation of law or otherwise, other than by will or the laws of descent and distribution.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">7.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Tax Withholding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee shall, not later than the date as of which the receipt of this Award becomes a taxable event for Federal income tax purposes, pay to the Company or make arrangements satisfactory to the Administrator for payment of any Federal, state and local taxes required by law to be withheld on account of such taxable event.  Except in the case where an election is made pursuant to Paragraph 8 below, the Company shall have the authority to cause the required minimum tax withholding obligation to be satisfied, in whole or in part, by withholding from Shares to be issued or released by the transfer agent a number of Shares with an aggregate Fair Market Value that would satisfy the minimum withholding amount due.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">8.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">Election Under Section 83(b)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  The Grantee and the Company hereby agree that the Grantee may, within 30 days following the Grant Date of this Award, file with the Internal Revenue Service and the Company an election under Section 83(b) of the Internal Revenue Code.  In the event the Grantee makes such an election, he or she agrees to provide a copy of the election to the Company.  The Grantee acknowledges that he or she is responsible for obtaining the advice of his or her tax advisors with regard to the Section 83(b) election and that he or she is relying solely on such advisors and not on any statements or representations of the Company or any of its agents with regard to such election.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">9.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:27pt;text-decoration:underline">No Obligation to Continue as a Non-Employee Director</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Neither the Plan nor this Agreement confers upon the Grantee any rights with respect to continuance as a Non-Employee Director.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">10.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Integration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  This Agreement constitutes the entire agreement between the parties with respect to this Award and supersedes all prior agreements and discussions between the parties concerning such subject matter.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">11.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Data Privacy Consent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  In order to administer the Plan and this Agreement and to implement or structure future equity grants, the Company, its subsidiaries and affiliates and certain agents thereof (together, the &#8220;Relevant Companies&#8221;) may process any and all personal or professional data, including but not limited to, Social Security or other identification number, </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;2</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;131379275.3</font></div></td></tr></table></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">home address and telephone number, date of birth and other information that is necessary or desirable for the administration of the Plan and&#47;or this Agreement (the &#8220;Relevant Information&#8221;).  By entering into this Agreement, the Grantee (i) authorizes the Company to collect, process, register and transfer to the Relevant Companies all Relevant Information&#59; (ii) waives any privacy rights the Grantee may have with respect to the Relevant Information&#59; (iii) authorizes the Relevant Companies to store and transmit such information in electronic form&#59; and (iv) authorizes the transfer of the Relevant Information to any jurisdiction in which the Relevant Companies consider appropriate.  The Grantee shall have access to, and the right to change, the Relevant Information.  Relevant Information will only be used in accordance with applicable law.</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">12.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:21pt;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:100%">.  Notices hereunder shall be mailed or delivered to the Company at its principal place of business and shall be mailed or delivered to the Grantee at the address on file with the Company or, in either case, at such other address as one party may subsequently furnish to the other party in writing.</font></div><div style="margin-bottom:36pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</font></div><div style="padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:24pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Title&#58;</font></div><div style="margin-bottom:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The foregoing Agreement is hereby accepted and the terms and conditions thereof hereby agreed to by the undersigned.  Electronic acceptance of this Agreement pursuant to the Company&#8217;s instructions to the Grantee (including through an online acceptance process) is acceptable.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Dated&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s Signature</font></div><div><font><br></font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Grantee&#8217;s name and address&#58;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:12pt;padding-left:234pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;3</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:15.865%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;131379275.3</font></div></td></tr></table></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.20
<SEQUENCE>8
<FILENAME>a123124ex-1020.htm
<DESCRIPTION>EX-10.20
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i82d2be2144204cec87624186df52b720_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC<br>NON-EMPLOYEE DIRECTOR COMPENSATION POLICY</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The purpose of this Non-Employee Director Compensation Policy (the &#8220;Policy&#8221;) of Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) is to provide a total compensation package that enables the Company to attract and retain, on a long-term basis, high-caliber directors who are not employees or officers of the Company or its subsidiaries (&#8220;Outside Directors&#8221;). This Policy will become effective as of the date approved by the Board of Directors (the &#8220;Effective Date&#8221;). In furtherance of the purpose stated above, all Outside Directors shall be paid compensation for services provided to the Company as Outside Directors as set forth below&#58;</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Cash Retainers</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Retainer for Board Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; $52,100 for general availability and participation in meetings and conference calls of our Board of Directors, to be paid quarterly in arrears, pro-rated based on the number of actual days served by the director during such calendar quarter. No additional compensation will be paid for attending individual meetings of the Board of Directors.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Annual Retainer for Non-Executive Chair</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;&#160;&#160;&#160;&#160;$35,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Annual Retainers for Committee Membership</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Audit Committee Chair&#58;&#160;&#160;&#160;&#160;$20,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Audit Committee member&#58;&#160;&#160;&#160;&#160;$10,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Committee Chair&#58;&#160;&#160;&#160;&#160;$15,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Compensation Committee member&#58;&#160;&#160;&#160;&#160;$7,500</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee Chair&#58;&#160;&#160;&#160;&#160;$10,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Nominating and Corporate Governance Committee member&#58;&#160;&#160;&#160;&#160;$5,000</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chair and committee member retainers are in addition to retainers for members of the Board of Directors. No additional compensation will be paid for attending individual committee meetings of the Board of Directors.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Equity Retainers</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">All grants of equity retainer awards to Outside Directors pursuant to this Policy will be automatic and nondiscretionary and will be made in accordance with the following provisions&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Initial Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; Upon his or her initial election to the Board of Directors, each Outside Director will receive an initial, one-time stock option award (the &#8220;Initial Award&#8221;) to purchase </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">49,500 shares, which shall vest in equal annual installments over three years from the date of grant, provided, however, that all vesting shall cease if the director resigns from the Board of Directors or otherwise ceases to serve as on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. The Initial Award shall expire ten years from the date of grant and shall have a per share exercise price equal to the Fair Market Value (as defined in the Company&#8217;s 2020 Omnibus Incentive Compensation Plan) of the Company&#8217;s ordinary shares on the business day immediately preceding the date of grant. This Initial Award applies only to Outside Directors who are first elected to the Board of Directors subsequent to the Effective Date.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Annual Award</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; On each date of each Annual General Meeting of Shareholders of the Company following the Effective Date (the &#8220;Annual Meeting&#8221;), each continuing Outside Director will receive (x) an annual stock option award (the &#8220;Annual Option Award&#8221;) to purchase 11,000 shares, and (y) an annual restricted stock award (the &#8220;Annual Restricted Stock Award&#8221; and together with the Annual Option Award, the &#8220;Annual Awards&#8221;) of 11,000 shares, each of which shall vest in full upon the earlier of (i) the first anniversary of the date of grant or (ii)&#160;the date of the next Annual Meeting&#59; provided, however, that all vesting for the Annual Awards shall cease if the director resigns from the Board of Directors or otherwise ceases to serve on the Board of Directors of the Company, unless the Board of Directors determines that the circumstances warrant continuation of vesting. The Annual Option Award shall expire ten years from the date of grant and shall have a per share exercise price equal to the Fair Market Value of the Company&#8217;s ordinary shares on the business day immediately preceding the date of grant.</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Sale Event Acceleration</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#58; All outstanding Initial Awards and Annual Awards held by an Outside Director shall become fully vested and exercisable upon a Sale Event (as defined in the Company&#8217;s 2020 Omnibus Incentive Compensation Plan).</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will reimburse all reasonable out-of-pocket expenses incurred by Outside Directors in attending meetings of the Board of Directors or any committee thereof.</font></div><div style="margin-bottom:12pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Annual Compensation</font></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The aggregate amount of compensation, including both equity compensation and cash compensation, paid by the Company to any Outside Director in a calendar year for services as an Outside Director shall not exceed $675,000&#59; (or such other limits as may be set forth in Section 3(d) of the Company&#8217;s 2020 Omnibus Incentive Compensation Plan or any similar provision of a successor plan). For this purpose, the &#8220;amount&#8221; of equity compensation paid in a calendar year shall be determined based on the grant date fair value thereof, as determined in accordance with FASB ASC Topic 718 or its successor provision, but excluding the impact of estimated forfeitures related to service-based vesting conditions. Notwithstanding the foregoing, the Board may make exceptions to the foregoing limit (up to twice such limit) for a non-executive chair of the Board or, in extraordinary circumstances, for other individual Non-Employee Directors, as the Administrator may determine, provided that the Non-</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Employee Director receiving such Awards may not participate in the decision to make such Awards.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Adopted July 30, 2024.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.21
<SEQUENCE>9
<FILENAME>a123124ex-1021.htm
<DESCRIPTION>EX-10.21
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id85eb0d2fff04f7cacf457b0a1336aac_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PLC</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Deed of Indemnification (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Deed</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) is made as of&#160;&#160;__________________by and between Avadel Pharmaceuticals plc, a public limited company incorporated in Ireland (registered number 572535) having its registered office at 10 Earlsfort Terrace, Dublin 2, D02 T380, Ireland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) and &#91; </font><font style="font-family:'Wingdings',sans-serif;font-size:10pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> &#93; (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;).</font></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">RECITALS</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, the Company desires to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Company and its subsidiaries (each, a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiary</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; and together its &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Subsidiaries</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;)&#59;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, in order to induce Indemnitee to continue to provide services to the Company and its Subsidiaries, the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the Maximum Extent Permitted by Law&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, the articles of association of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Articles</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) provide that the indemnification provided therein shall not be exclusive and thereby contemplate that agreements may be made with members of the board of directors, secretaries, officers, executives and other persons with respect to indemnification&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, the Board of Directors of the Company (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) has determined that the increased difficulty in attracting and retaining highly qualified persons such as Indemnitee is detrimental to the best interests of the Company&#8217;s shareholders and that the Company should act to assure Indemnitee that there will be increased certainty of such protection in the future&#59;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, it is reasonable and prudent for the Company contractually to obligate itself to indemnify, and to advance expenses on behalf of, such persons to the Maximum Extent Permitted by Law, regardless of any amendment or revocation of the Company&#8217;s memorandum of association (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Memorandum</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;) or the Articles, so that they will serve or continue to serve the Company and its Subsidiaries free from undue concern that they will not be so indemnified&#59; and</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">WHEREAS, this Deed is a supplement to and in furtherance of the indemnification provided in the Articles or other governing documents of the Company and&#47;or its Subsidiaries and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NOW, THEREFORE, the Company and Indemnitee do hereby covenant and agree as follows&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 1. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Services to the Company and&#47;or any one or more of its Subsidiaries.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Indemnitee agrees to serve as a director, secretary, officer and&#47;or executive of the Company and&#47;or any one or more of its Subsidiaries. Indemnitee may at any time and for any reason resign from such position (subject to any other contractual obligation or any obligation imposed by law). This Deed shall not be deemed an employment contract between the Company (or any one or more of its Subsidiaries or any Enterprise) and Indemnitee. The foregoing notwithstanding, this Deed shall continue in force after Indemnitee has ceased to serve in such capacity at the Company and&#47;or any one or more of its Subsidiaries as the case may be.</font></div><div><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 2.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions.</font></div><div><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As used in this Deed&#58;</font></div><div style="text-align:justify;text-indent:79.2pt"><font><br></font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; describes the status of a person as a current or former Representative of the Company, its Subsidiaries or of any other Enterprise which such person is or was serving at the request of the Company or its Subsidiaries.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enforcement Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action, including, without limitation, the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean any domestic or foreign, for-profit or not-for-profit, corporation (other than the Company or its Subsidiaries), limited liability company, partnership, joint venture, trust, employee benefit plan or other legal entity of which Indemnitee is or was serving as a Representative at the request of the Company or its Subsidiaries. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.&#160;&#160;Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee. </font></div><div style="text-align:justify;text-indent:79.2pt"><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Indemnifiable Event&#8221; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">shall mean any event or occurrence that takes place either prior to or after the execution of this Deed, related to the fact that Indemnitee is or was a director,  secretary, officer and&#47;or executive of the Company or one of its Subsidiaries, or while a director, secretary, officer and&#47;or executive of the Company or one of its Subsidiaries is or was serving at the request of such entity as a director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or not done by Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a director, officer, secretary, employee, trustee, agent, or fiduciary.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of Irish law and neither presently is, nor in the past five years has been, retained to represent&#58; (i) the Company, its Subsidiaries, any Enterprise or any Indemnitee in any matter material to any such party (other than with respect to matters concerning Indemnitee under this Deed, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either the Company, its Subsidiaries or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Deed. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Deed or its engagement pursuant hereto.</font></div><div style="text-align:justify;text-indent:76.5pt"><font><br></font></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (g)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Maximum Extent Permitted by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include, but not be limited to, the maximum extent authorized or permitted by (i) the provisions of Irish law, (ii) the provisions of the Memorandum and Articles or other governing documents of the Company and its Subsidiaries that authorize, permit or contemplate indemnification by agreement, court action or the corresponding provision of any amendment to or replacement of such provisions, (iii) any amendments to or replacements of Irish law, and (iv) the Memorandum and Articles or other governing documents of the Company and its Subsidiaries adopted after the date of this Deed that either increase or decrease the extent to which a company may indemnify its directors, secretaries, officers and executives. </font></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall include any threatened, pending or completed action, suit, arbitration, alternative dispute resolution mechanism, investigation, inquiry, administrative hearing or any other </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">actual, threatened or completed proceeding, whether brought in the right of the Company, any of its Subsidiaries or otherwise and whether of a civil, criminal, administrative or investigative nature, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or secretary of the Company or any of its Subsidiaries or is or was serving at the request of the Company or any of its Subsidiaries as Representative of any Enterprise or by reason of any action taken by him or her or of any action taken on his or her part while acting as director or secretary of the Company or any of its Subsidiaries or while serving at the request of the Company or any of its Subsidiaries as a Representative of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Deed&#59; provided, however, that the term &#8220;Proceeding&#8221; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#8217;s rights under this Deed as provided for in Section 11(e) of this Deed. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:76.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; shall mean a person occupying the position or discharging the functions of a director, officer, employee, fiduciary, trustee or agent thereof, regardless of the name or title by which the person may be designated. The term does not imply that a director, secretary, officer or executive, as such, is an agent of a corporation.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div><div style="text-align:justify;text-indent:39.6pt"><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a) &#160;&#160;&#160;&#160;To the Maximum Extent Permitted by Law, the Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 in the event the Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding relating in whole or in part to an Indemnifiable Event.&#160;&#160;Pursuant to this Section 3, Indemnitee shall be indemnified to the Maximum Extent Permitted by Law against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Company or any of its Subsidiaries and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful&#59; provided, however, that the Company has no obligation to indemnify the Indemnitee for amounts paid in settlement without the Company&#8217;s prior written consent.</font></div><div style="text-align:justify;text-indent:39.6pt"><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company hereby agrees to take all reasonable actions to facilitate any application by Indemnitee under section 233 and 234 of the Irish Companies Act 2014 (as amended) (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Companies Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), including any successor provision, including without limitation the payment of any costs or expenses incurred by Indemnitee in making such application.</font></div><div style="text-align:justify;text-indent:39.6pt"><font><br></font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification for Expenses of a Party Who is Wholly or Partly Successful.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any other provisions of this Deed and except as provided in Section 8, to the extent that Indemnitee is a party to or a participant in any Proceeding or defense of any claim, issue or matter therein, relating in whole or in part to an Indemnifiable Event, and Indemnitee is successful (on the merits or otherwise) then the Company shall indemnify Indemnitee, to the Maximum Extent Permitted by Law, against all Expenses actually and reasonably incurred by him or her in connection therewith.&#160;&#160;If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee to the Maximum Extent Permitted by Law against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter.&#160;&#160;For the purposes of this Section, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification For Expenses of a Witness.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any other provision of this Deed, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, to The Maximum Extent Permitted by Law, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </font></div><div style="text-align:justify;text-indent:39.6pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusions.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Notwithstanding any provision in this Deed to the contrary, the Company shall not be obligated under this Deed&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to make any indemnity for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise, except with respect to any excess beyond the amount paid under any such insurance policy, contract, agreement or other indemnity provision&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to make any indemnity for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Company or its Subsidiaries within the meaning of Section 16(b) of the Securities Exchange Act of 1934, as amended, of the United States of America or similar provisions of U.S. state statutory law or common law&#59; </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to make any indemnity or advancement in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against the Company or any of its Subsidiaries or their directors, officers, employees or other indemnitees, unless (i) the Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) such Proceeding (or any part of any Proceeding) is initiated after a Change of Control has occurred after the date of this Deed or (iv) such Proceeding (or any part of any Proceeding) is brought to establish or enforce a right to indemnification under this Deed or any other law, statute or rule&#59; or </font></div><div style="text-align:justify"><font style="color:#ff0000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;to make any indemnity or advancement that is expressly prohibited by applicable law (including, with respect to any director or secretary, in respect of any liability expressly prohibited from being indemnified pursuant to section 235 of the Companies Act (including any successor provisions)), but (i) in no way limiting any rights under sections 233 and 234 of the Companies Act (including any successor provisions) or (ii) to the extent any such limitations or prescriptions are amended or determined by a court of competent jurisdiction to be void or inapplicable, or relief to the contrary is granted, then the Indemnitee shall receive the greatest rights then available under law. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Advances of Expenses.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The Company shall advance, to The Maximum Extent Permitted by Law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#8217;s ability to repay the expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Deed.&#160;&#160;Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Deed which shall constitute an undertaking providing that Indemnitee undertakes to the maximum extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company.&#160;&#160;The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein.&#160;&#160;Nothing in this Section 7 shall limit Indemnitee&#8217;s right to advancement pursuant to Section 11(e) of this Deed. </font></div><div><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure for Notification and Defense of Claim.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To obtain indemnification under this Deed, Indemnitee shall submit to the Company a written request therefor and, if Indemnitee so chooses pursuant to Section 9 of this Deed, such written request shall also include a request for Indemnitee to have the right to indemnification determined by Independent Counsel. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company will be entitled to participate in the Proceeding at its own expense. </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure Upon Application for Indemnification.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Upon written request by Indemnitee for indemnification pursuant to Section 8(a), a determination, if such determination is required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (i) by Independent Counsel in a written opinion to the Board if Indemnitee so requests in such written request for indemnification pursuant to Section 8(a), or (ii) by the Company in accordance with applicable law if Indemnitee does not so request such determination be made by Independent Counsel.&#160;&#160;In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#8217;s written opinion shall be delivered to Indemnitee and the Company and, if it is so determined that Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within twenty (20) days after such determination.&#160;&#160;Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. To the Maximum Extent Permitted by Law any costs or expenses (including reasonable attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that Indemnitee exercises his or her right to have his or her entitlement to indemnification determined by Independent Counsel pursuant to clause (i) of Section 9 (a), the Independent Counsel shall be selected by Indemnitee and notified in writing to the Company.&#160;&#160;The Company may, within ten (10) days after written notice of such selection, deliver to Indemnitee a written objection to such selection&#59; provided, however, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221; as defined in Section 2 of this Deed, and the objection shall set forth with particularity the factual basis of such assertion.&#160;&#160;Absent a proper and timely objection, the person so selected shall act as Independent Counsel.&#160;&#160;If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.&#160;&#160;If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification and Independent Counsel pursuant to Sections 8(a) and 9(a)(i) hereof, respectively, and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company to the selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate.&#160;&#160;&#160;The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 9(a) hereof.&#160;&#160;Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 11(a) of this Deed, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing). </font></div><div><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Presumptions and Effect of Certain Proceedings.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Deed if Indemnitee has submitted a request for indemnification in accordance with Section 8(a) of this Deed, and the Company shall have the burden of proof to overcome that presumption in connection with the making of any determination contrary to that presumption. Neither (i) the failure of the Company or of Independent Counsel to have made a determination prior to the commencement of any action pursuant to this Deed that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of guilty, nolo contendere or its equivalent, shall not </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(except as otherwise expressly provided in this Deed) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Company or any of its Subsidiaries or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The knowledge and&#47;or actions, or failure to act, of any Representative of the Company, its Subsidiaries or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Deed. </font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Remedies of Indemnitee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Subject to Section 11(f), in the event that (i) a determination is made pursuant to Section 9 of this Deed that Indemnitee is not entitled to indemnification under this Deed, (ii) advancement of Expenses is not timely made pursuant to Section 7 of this Deed, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 9(a) of this Deed within sixty (60) days after receipt by the Company of the request for indemnification that does not include a request for Independent Counsel, (iv)&#160;payment of indemnification is not made pursuant to Section 4 or 5 or the last sentence of Section 9(a) of this Deed within twenty (20) days after receipt by the Company of a written request therefor or (v) payment of indemnification pursuant to Section 3 of this Deed is not made within twenty (20) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by a court of his or her entitlement to such indemnification or advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 11(a)&#59; provided, however, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 4 of this Deed. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event that a determination shall have been made pursuant to Section 9(a) of this Deed that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 11 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 11, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If a determination shall have been made pursuant to Section 9(a) of this Deed that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 11, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 11 that the procedures and presumptions of this Deed are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Deed. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall indemnify Indemnitee against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within twenty (20) days after receipt by the Company of a written request therefor) advance, to the Maximum Extent Permitted by Law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Deed or under any liability insurance policies maintained by the Company or any of its Subsidiaries for coverage of any Representatives of the Company or any of its Subsidiaries, regardless of whether </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indemnitee ultimately is determined to be entitled to such indemnification, advancement or insurance recovery, as the case may be, in the suit for which indemnification or advancement is being sought. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;Notwithstanding anything in this Deed to the contrary, no determination as to entitlement to indemnification under this Deed shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.</font></div><div><font><br></font></div><div style="padding-left:49.5pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Non-exclusivity&#59; Survival of Rights&#59; Insurance&#59; Subrogation.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The rights of indemnification and to receive advancement as provided by this Deed shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the Memorandum, the Articles, any bylaws, any agreement, a vote of shareholders or a resolution of directors, or otherwise and rights of the Indemnitee under this deed shall supplement and be in furtherance of any other such rights.&#160;&#160;To the Maximum Extent Permitted by Law, no amendment, alteration or repeal of this Deed or of any provision hereof shall limit or restrict any right of Indemnitee under this Deed in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Irish law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the Memorandum, the Articles, any other governing documents of the Company or any of its Subsidiaries and this Deed, it is hereby agreed by the parties that Indemnitee shall enjoy by this Deed the greater benefits so afforded by such change.&#160;&#160;No right or remedy herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;To the extent that the Company or its Subsidiaries maintain an insurance policy or policies providing liability insurance for Representatives of the Company, of any of its Subsidiaries or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Representative under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, the Company or any of its Subsidiaries have liability insurance in effect covering Representatives of the Company or any of its Subsidiaries, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;In the event of any payment under this Deed, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="text-align:justify;text-indent:79.2pt"><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company shall not be liable under this Deed to make any payment of amounts otherwise indemnifiable hereunder or for which advancement of Expenses is provided hereunder if and to the extent that Indemnitee has otherwise actually received such payment under any insurance policy, contract, agreement. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company&#8217;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of the Company or its Subsidiaries as a Representative of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from such other Enterprise. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 13.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Duration of Deed.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;This Deed shall continue until and terminate upon the later of&#58; (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a Representative of the Company and&#47;or any of its Subsidiaries as the case may be or (b) one (1) year after the final termination of any Proceeding, including any </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 11 of this Deed relating thereto. </font></div><div style="text-align:justify;text-indent:39.6pt"><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 14. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  This Deed shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators.&#160;&#160;The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation, division or otherwise) to all, substantially all or a substantial part, of the business and&#47;or assets of the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Deed in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Severability.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;If any provision or provisions of this Deed is or becomes invalid, illegal or unenforceable for any reason whatsoever&#58; (a) the validity, legality and enforceability of the remaining provisions of this Deed (including without limitation, each portion of any section of this Deed containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to The Maximum Extent Permitted by Law&#59; (b) such provision or provisions shall be deemed reformed to the minimum extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (c) to the fullest extent possible, the provisions of this Deed (including, without limitation, each portion of any section of this Deed containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby. </font></div><div><font><br></font></div><div style="padding-left:39.6pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;The Company expressly confirms and agrees that it has entered into this Deed and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, secretary, officer and&#47;or executive of the Company and&#47;or its Subsidiaries, and the Company acknowledges that Indemnitee is relying upon this Deed in serving as a director, secretary, officer and&#47;or executive of the Company and&#47;or its Subsidiaries.</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;This Deed constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; provided, however, that this Deed is a supplement to and in furtherance of the Memorandum, the Articles, any other governing documents of the Company and&#47;or its Subsidiaries and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 17.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Modification and Waiver.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;No supplement, modification or amendment, or waiver of any provision, of this Deed shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Deed shall be deemed or shall constitute a waiver of any other provisions of this Deed nor shall any waiver constitute a continuing waiver. </font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 18.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notice by Indemnitee.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement as provided hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Deed or otherwise.</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 19.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Notices.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;All notices, requests, demands and other communications under this Deed shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed, or (d) sent by email, with receipt of oral or written confirmation that such email has been received&#58;</font></div><div><font><br></font></div><div style="text-align:justify;text-indent:79.2pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to Indemnitee, at such address as Indemnitee shall provide to the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="padding-left:79.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;If to the Company to&#58;</font></div><div><font><br></font></div><div style="padding-left:118.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Address&#58;&#160;&#160;&#160;&#160;Secretary</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10 Earlsfort Terrace</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Dublin 2</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">D02 T380</font></div><div style="padding-left:180pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></div><div style="padding-left:118.8pt"><font><br></font></div><div style="padding-left:118.8pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Email&#58; &#160;&#160;&#160;&#160;By email to the Secretary</font></div><div style="padding-left:118.8pt;padding-right:178.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or to any other address as may have been furnished to Indemnitee by the Company. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 20.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Contribution.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;To the Maximum Extent Permitted by Law, if the indemnification provided for in this Deed is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the Company and&#47;or its Subsidiaries and Indemnitee in connection with the event(s) and&#47;or transaction(s) giving rise to such Proceeding&#59; and&#47;or (ii) the relative fault of the Company and&#47;or its Subsidiaries (and its or their Representatives) and Indemnitee in connection with such event(s) and&#47;or transactions. </font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 21.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law and Consent to Jurisdiction.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> This Deed and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of Ireland, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 11(a) of this Deed, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Deed shall be brought only in a court of competent jurisdiction in Ireland (an &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Irish Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8221;), and not in any other court in any other country, (ii) consent to submit to the exclusive jurisdiction of Irish Court for purposes of any action or proceeding arising out of or in connection with this Deed, (iii) consent to service of process at the addresses set forth in or pursuant to Section 19 of this Deed, (iv) waive any objection to the laying of venue of any such action or proceeding in the Irish Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Irish Court has been brought in an improper or inconvenient forum. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 22.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Identical Counterparts.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;This Deed may be executed in one or more counterparts (including by facsimile or .pdf), each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Deed. Only one such counterpart signed by the party against whom enforceability is sought needs to be produced to evidence the existence of this Deed. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify;text-indent:39.6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 23.&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous.</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;The headings of the sections of this Deed are inserted for convenience only and shall not be deemed to constitute part of this Deed or to affect the construction thereof.</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Deed to be signed and delivered as of the day and year first above written.</font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">GIVEN </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the common seal of</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AVADEL PHARMACEUTICALS PUBLIC LIMITED COMPANY</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DELIVERED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">DEED</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Signed&#58;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; ___________________________</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNED AND DELIVERED</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> as a deed</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">by *&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="padding-left:216pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in the presence of&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Witness&#8217; Signature)</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Witness&#8217; Address)</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Witness&#8217; Occupation)</font></div><div><font><br></font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Current Indemnitee Address&#47;Phone</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">________________________________</font></div><div><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">*Print Name</font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="text-align:center"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;Signature Page &#8211; Deed of Indemnification&#93;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.22
<SEQUENCE>10
<FILENAME>a123124ex-1022.htm
<DESCRIPTION>EX-10.22
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="id058535abc814f6fa4f733c602de3051_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AVADEL US HOLDINGS, INC.</font></div><div style="margin-top:25.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Indemnification Agreement (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) is made as of _____, by and between Avadel US Holdings, Inc., a Delaware corporation (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and ________ (&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">RECITALS</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, the Company and Avadel Pharmaceuticals plc, a public limited company incorporated in Ireland (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), desire to attract and retain the services of highly qualified individuals, such as Indemnitee, to serve the Parent and its subsidiaries (</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">together, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Avadel Group</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and individually, an &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Avadel Company</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or, if more than one Avadel Company but less than the Avadel Group, the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Avadel Companies</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;),</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and it is beneficial to the Company for the Parent to be able to attract such professionals&#59;</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, in order to induce Indemnitee to continue to provide services to the Parent and&#47;or any other Avadel Company or any Enterprise (as defined below), the Company wishes to provide for the indemnification of, and advancement of expenses to, Indemnitee to the Maximum Extent Permitted by Law&#59;</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, because Indemnitee will make important decisions affecting the Company, including with respect to major corporate transactions and reorganizations as well as decisions affecting other Avadel Companies and&#47;or Enterprises in which an Avadel Company has an important interest, the board of directors of the Company (the &#8220;</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Board</font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has determined that it is in the best interests of the Company to ensure that Indemnitee obtain indemnification and expense advancement in connection with his or her service to the Avadel Group&#59; and</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">WHEREAS, this Agreement is a supplement to and in furtherance of the indemnification provided in the articles of association or other governing documents of any Avadel Company and any resolutions adopted pursuant thereto, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:13.80pt">NOW, THEREFORE, in consideration of the premises and the covenants contained herein, and for other good and valuable consideration, receipt of which is hereby acknowledged, the Company and Indemnitee do hereby agree as follows&#58;</font></div><div style="margin-top:25.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 1.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Services to the Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Indemnitee agrees to serve as a director, secretary, and&#47;or officer of the Parent and&#47;or other Avadel Companies and&#47;or any Enterprise. Indemnitee may at any time and for any reason resign from such position(s) (subject to any other contractual obligation or any obligation imposed by law). No Avadel Company shall have an obligation under this Agreement to continue Indemnitee in such position. This Agreement shall not be deemed an employment contract between the Company, any other Avadel Company or any Enterprise and Indemnitee. The foregoing notwithstanding, this Agreement shall continue in </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.589%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;103517515.2  </font></div><div style="text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.589%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;103517515.2  </font></div><div style="text-align:justify"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:25.2pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">force after Indemnitee has ceased to serve as a director, secretary and&#47;or officer of the Parent Company and&#47;or any other Avadel Company and&#47;or any Enterprise.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 2.  </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Definitions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As used in this Agreement&#58;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Change in Control</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall be deemed to have occurred if (i) any &#8220;person&#8221; (as such term is used in Sections 13(d) and 14(d) of the Securities Exchange Act of 1934, as amended (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exchange Act</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), other than an Avadel Company, or a trustee or other fiduciary holding securities under an employee benefit plan of the Avadel Group, is or becomes the &#8220;beneficial owner&#8221; (as defined in Rule 13d-3 under said Act), directly or indirectly, of securities of the Parent representing twenty-five percent (25%) or more of the total voting power represented by the Parent&#8217;s then outstanding Voting Securities, or (ii) during any period of two consecutive years, individuals who at the beginning of such period constitute the board of directors of the Parent (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Parent Board</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) and any new director whose election to the Parent Board or nomination for election by the Parent&#8217;s shareholders was approved by a vote of at least two-thirds (2&#47;3) of the directors then still in office who either were directors at the beginning of the period or whose election or nomination for election was previously so approved, cease for any reason to constitute a majority thereof, or (iii) the shareholders of the Parent approve a merger, scheme of arrangement or consolidation of the Parent with any other corporation, other than a merger, scheme of arrangement or consolidation which would result in the Voting Securities of the Parent outstanding immediately prior thereto continuing to represent (either by remaining outstanding or by being converted into Voting Securities of the surviving entity) at least fifty percent (50%) of the total voting power represented by the Voting Securities of the Parent or such surviving entity outstanding immediately after such merger, scheme of arrangement or consolidation, or (iv) the shareholders of the Parent approve a plan of complete liquidation of the Parent or an agreement for the sale or disposition by the Parent of (in one transaction or a series of transactions) all or substantially all of the assets of the Parent, except in the event of a sale of assets to an entity in which more than 50% of the Voting Securities of such entity is owned by shareholders of the Parent in substantially the same proportion as their ownership of Voting Securities immediately prior to the sale.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Corporate Status</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; describes the status of a person as a current or former Representative of an Avadel Company or of any other Enterprise which such person is or was serving at the request of an Avadel Company.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with an action to enforce indemnification or advancement rights, or an appeal from such action, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-2-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enterprise</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any domestic or foreign, for-profit or not-for-profit, corporation, limited liability company, partnership, joint venture, trust, employee benefit plan or other legal entity, in each case other than an Avadel Company, of which Indemnitee is or was serving as a Representative at the request of an Avadel Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include all reasonable attorneys&#8217; fees, retainers, court costs, transcript costs, fees of experts, witness fees, travel expenses, duplicating costs, printing and binding costs, telephone charges, postage, delivery service fees, and all other disbursements or expenses of the types customarily incurred in connection with prosecuting, defending, preparing to prosecute or defend, investigating, being or preparing to be a witness in, or otherwise participating in, a Proceeding or an appeal resulting from a Proceeding, including without limitation the premium, security for, and other costs relating to any cost bond, supersedeas bond, or other appeal bond or its equivalent.  Expenses, however, shall not include amounts paid in settlement by Indemnitee or the amount of judgments or fines against Indemnitee.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnifiable Event</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean any event or occurrence that takes place either prior to or after the execution of this Agreement, related to the fact that Indemnitee is or was a director, secretary, and&#47;or officer of the Company or one of its Subsidiaries, or is or was serving at the request of such entity as a director, officer, secretary, employee, trustee, agent, or fiduciary of another foreign or domestic corporation, partnership, limited liability company, joint venture, employee benefit plan, trust, or other Enterprise, or related to anything done or not done by Indemnitee in any such capacity, whether or not the basis of the Proceeding is alleged action in an official capacity as a director, officer, secretary, employee, trustee, agent, or fiduciary or in any other capacity while serving as a director, officer, secretary, employee, trustee, agent, or fiduciary.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(g)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Independent Counsel</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a law firm, or a partner (or, if applicable, member) of such a law firm, that is experienced in matters of Delaware corporation law and neither presently is, nor in the past five years has been, retained to represent&#58; (i) an Avadel Company, any Enterprise or Indemnitee in any matter material to any such party (other than with respect to matters concerning Indemnitee under this Agreement, or of other indemnitees under similar indemnification agreements), or (ii) any other party to the Proceeding giving rise to a claim for indemnification hereunder. Notwithstanding the foregoing, the term &#8220;Independent Counsel&#8221; shall not include any person who, under the applicable standards of professional conduct then prevailing, would have a conflict of interest in representing either an Avadel Company or Indemnitee in an action to determine Indemnitee&#8217;s rights under this Agreement. The Company agrees to pay the reasonable fees and expenses of the Independent Counsel referred to above and to fully indemnify such counsel against any and all expenses, claims, liabilities and damages arising out of or relating to this Agreement or its engagement pursuant hereto.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(h)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Maximum Extent Permitted by Law</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include, but not be limited to&#58; (i) to the maximum extent permitted by the provision of the Delaware General Corporation Law  (the &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">DGCL</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) that authorizes or contemplates additional indemnification by agreement, or the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-3-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">corresponding provision of any amendment to or replacement of the DGCL or such provision thereof&#59; and (ii) to the maximum extent authorized or permitted by any amendments to or replacements of the DGCL adopted after the date of this Agreement that increase the extent to which a corporation may indemnify its Representatives.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(i)&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Proceeding</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall include any threatened, pending or completed action, suit, arbitration, alternate dispute resolution mechanism, investigation, inquiry, administrative hearing or any other actual, threatened or completed proceeding, whether brought in the right of an Avadel Company, an Enterprise or otherwise and whether of a civil, criminal, administrative or investigative nature, in which Indemnitee was, is or will be involved as a party or otherwise by reason of the fact that Indemnitee is or was a director or officer of an Avadel Company or is or was serving at the request of an Avadel Company as a Representative of any Enterprise or by reason of any action taken by him or her or of any action taken on his or her part while acting as director or officer of an Avadel Company or while serving at the request of an Avadel Company as a Representative of any Enterprise, in each case whether or not serving in such capacity at the time any liability or expense is incurred for which indemnification, reimbursement or advancement of expenses can be provided under this Agreement&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the term &#8220;Proceeding&#8221; shall not include any action, suit or arbitration, or part thereof, initiated by Indemnitee to enforce Indemnitee&#8217;s rights under this Agreement as provided for in Section 13(e) of this Agreement.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(j)&#160;&#160;&#160;&#160; &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Representative</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean a person occupying the position or discharging the functions of a director, officer, employee, fiduciary, trustee or agent thereof, regardless of the name or title by which the person may be designated. The term does not imply that a director, secretary, and&#47;or officer, as such, is an agent of a corporation.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;(k)&#160;&#160;&#160;&#160;&#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Voting Securities</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; shall mean, with respect to any entity, any securities of such entity which vote generally in the election of directors.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 3.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity in Third-Party Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Notwithstanding any other provisions of this Agreement and except as provided in Section 8, to the Maximum Extent Permitted by Law, the Company shall indemnify Indemnitee in accordance with the provisions of this Section 3 in the event the Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding, other than a Proceeding by or in the right of an Avadel Company or any Enterprise to procure a judgment in its favor relating in whole or in part to an Indemnifiable Event.  Pursuant to this Section 3, Indemnitee shall be indemnified against all Expenses, judgments, fines, liabilities, losses, damages and amounts paid in settlement actually and reasonably incurred by Indemnitee or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Avadel Group or Enterprise, as applicable, and, in the case of a criminal proceeding, had no reasonable cause to believe that his or her conduct was unlawful&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the Company has no obligation to indemnify the Indemnitee for amounts paid in settlement without the Company&#8217;s prior written consent.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-4-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 4.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnity in Proceedings by or in the Right of an Avadel Company</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provisions of this Agreement and except as provided in Section 8, to the Maximum Extent Permitted by Law, the Company shall indemnify Indemnitee in accordance with the provisions of this Section 4 if Indemnitee is, or is threatened to be made, a party to or a participant in any Proceeding by or in the right of an Avadel Company or any Enterprise to procure a judgment in its favor relating in whole or in part to an Indemnifiable Event.  Pursuant to this Section 4, Indemnitee shall be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with such Proceeding or any claim, issue or matter therein, if Indemnitee acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the Avadel Group or Enterprise, as applicable.  No indemnification for Expenses shall be made under this Section 4 in respect of any claim, issue or matter as to which Indemnitee shall have been finally adjudged by a court to be liable to an Avadel Company or any Enterprise, unless and only to the extent that the court of common pleas of the judicial district embracing the county in which the registered office of such Avadel Company or Enterprise is located or any court in which the Proceeding was brought or any court in which a ruling or determination was made in relation thereto shall determine upon application that, despite the adjudication of liability but in view of all the circumstances of the case, Indemnitee is fairly and reasonably entitled to indemnification for such expenses as the court of common pleas or other court deems proper.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 5.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification for Expenses of a Party Who is Wholly or Partly Successful</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provisions of this Agreement and except as provided in Section 8, to the extent that Indemnitee is a party to or a participant in any Proceeding or defense of any claim, issue or matter therein, relating in whole or in part to an Indemnifiable Event, and Indemnitee is successful, on the merits or otherwise, then the Company shall indemnify Indemnitee, to the Maximum Extent Permitted by Law, against all Expenses actually and reasonably incurred by him or her in connection therewith.  If Indemnitee is not wholly successful in such Proceeding but is successful, on the merits or otherwise, as to one or more but less than all claims, issues or matters in such Proceeding, the Company shall indemnify Indemnitee, to the Maximum Extent Permitted by Law, against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection with each successfully resolved claim, issue or matter.  For purposes of this Section 5 and without limitation, the termination of any claim, issue or matter in such a Proceeding by dismissal, with or without prejudice, shall be deemed to be a successful result as to such claim, issue or matter.</font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 6.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Indemnification for Expenses of a Witness</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any other provision of this Agreement, to the extent that Indemnitee is, by reason of his or her Corporate Status, a witness in any Proceeding to which Indemnitee is not a party and is not threatened to be made a party, to the Maximum Extent Permitted by Law, he or she shall be indemnified against all Expenses actually and reasonably incurred by him or her or on his or her behalf in connection therewith. </font></div><div style="text-align:justify;text-indent:36pt"><font><br></font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 7.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Additional Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-5-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:9pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Except as provided in Section 8, notwithstanding any limitation in Sections 3, 4 or 5, the Company shall indemnify Indemnitee, to the Maximum Extent Permitted by Law, if Indemnitee is a party to or is threatened to be made a party to any Proceeding (including a Proceeding by or in the right of an Avadel Company or an Enterprise to procure a judgment in its favor) against all Expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by Indemnitee in connection with the Proceeding.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 8.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Exclusions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Notwithstanding any provision in this Agreement to the contrary, the Company shall not be obligated under this Agreement&#58; </font></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;to make any indemnity for amounts otherwise indemnifiable hereunder (or for which advancement is provided hereunder) if and to the extent that Indemnitee has otherwise actually received such amounts under any insurance policy, contract, agreement or otherwise, except with respect to any excess beyond the amount paid under any such insurance policy, contract, agreement or other indemnity provision&#59; provided, however, that Indemnitee acknowledges and agrees that to the extent Indemnitee has rights to indemnification, advancement of expenses and&#47;or insurance provided by or on behalf of an Enterprise, such Enterprise shall be the indemnitor of first resort (i.e., such Enterprise&#8217;s obligations to Indemnitee are primary and any obligation of the Company to advance expenses or to provide indemnification for the same expenses or liabilities incurred by Indemnitee are secondary)&#59;</font></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;to make any indemnity for an accounting of profits made from the purchase and sale (or sale and purchase) by Indemnitee of securities of the Parent or any Enterprise within the meaning of Section 16(b) of the Exchange Act or similar provisions of applicable statutory law or common law&#59; </font></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;to make any indemnity or advancement hereunder in connection with any Proceeding made on account of Indemnitee&#8217;s conduct which is determined by final judgment or other final adjudication to have constituted a breach of Indemnitee&#8217;s duty of loyalty or other fiduciary duty to an Avadel Company, an Enterprise, or their respective stockholders or an act or omission not in good faith or which involved intentional misconduct or a knowing violation of the law&#59; </font></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;to make any indemnity or advancement in connection with any Proceeding (or any part of any Proceeding) initiated by Indemnitee, including any Proceeding (or any part of any Proceeding) initiated by Indemnitee against an Avadel Company, an Enterprise or any director, officer, employee or other indemnitee of an Avadel Company or an Enterprise unless (i) the Board or the Parent Board authorized the Proceeding (or any part of any Proceeding) prior to its initiation, (ii) the Company provides the indemnification, in its sole discretion, pursuant to the powers vested in the Company under applicable law, (iii) such Proceeding (or any part of any Proceeding) is initiated after a Change of Control has occurred after the date of this Agreement or (iv) such Proceeding (or any part of any Proceeding) is brought to establish or enforce a right to indemnification under this Agreement or any other law, statute or rule&#59; or </font></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;to make any indemnity or advancement that is expressly prohibited by applicable law.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-6-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-bottom:5.4pt;margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company&#8217;s obligation to provide indemnification or advancement hereunder to Indemnitee who is or was serving at the request of an Avadel Company as a Representative of any other Enterprise shall be reduced by any amount Indemnitee has actually received as indemnification or advancement from, or on behalf of, such other Enterprise. </font></div><div style="padding-left:443.7pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 9.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Advances of Expenses</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The Company shall advance, to the Maximum Extent Permitted by Law, the Expenses incurred by Indemnitee in connection with any Proceeding, and such advancement shall be made within twenty (20) days after the receipt by the Company of a statement or statements requesting such advances (which shall include invoices received by Indemnitee in connection with such Expenses but, in the case of invoices in connection with legal services, any references to legal work performed or to expenditures made that would cause Indemnitee to waive any privilege accorded by applicable law shall not be included with the invoice) from time to time, whether prior to or after final disposition of any Proceeding. Advances shall be unsecured and interest free. Advances shall be made without regard to Indemnitee&#8217;s ability to repay the expenses and without regard to Indemnitee&#8217;s ultimate entitlement to indemnification under the other provisions of this Agreement.  Indemnitee shall qualify for advances upon the execution and delivery to the Company of this Agreement which shall constitute an undertaking providing that Indemnitee undertakes to the maximum extent required by law to repay the advance if and to the extent that it is ultimately determined by a court of competent jurisdiction in a final judgment, not subject to appeal, that Indemnitee is not entitled to be indemnified by the Company.  The right to advances under this paragraph shall in all events continue until final disposition of any Proceeding, including any appeal therein.  Nothing in this Section 9 shall limit Indemnitee&#8217;s right to advancement pursuant to Section 13(e) of this Agreement. </font></div><div style="padding-left:37.8pt;text-align:justify"><font><br></font></div><div style="padding-left:37.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 10.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure for Notification and Defense of Claim</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;To obtain indemnification under this Agreement, Indemnitee shall submit to the Company a written request therefor and, if Indemnitee so chooses pursuant to Section 11 of this Agreement, such written request shall also include a request for Indemnitee to have the right to indemnification determined by Independent Counsel.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The Company will be entitled to participate in the Proceeding at its own expense.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 11.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Procedure Upon Application for Indemnification</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Upon written request by Indemnitee for indemnification pursuant to Section 10(a), a determination, if such determination is required by applicable law, with respect to Indemnitee&#8217;s entitlement thereto shall be made in the specific case&#58; (i) by Independent Counsel in a written opinion to the Board if Indemnitee so requests in such written request for indemnification pursuant to Section 10(a), or (ii) by the Company in accordance with applicable law if Indemnitee does not so request such determination be made by Independent Counsel.  In the case that such determination is made by Independent Counsel, a copy of Independent Counsel&#8217;s written opinion shall be delivered to Indemnitee and, if it is so determined that </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-7-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Indemnitee is entitled to indemnification, payment to Indemnitee shall be made within ten (10) days after such determination.  Indemnitee shall cooperate with the Independent Counsel or the Company, as applicable, making such determination with respect to Indemnitee&#8217;s entitlement to indemnification, including providing to such counsel or the Company, upon reasonable advance request, any documentation or information which is not privileged or otherwise protected from disclosure and which is reasonably available to Indemnitee and reasonably necessary to such determination. Any costs or expenses (including attorneys&#8217; fees and disbursements) incurred by Indemnitee in so cooperating with the Independent Counsel or the Company shall be borne by the Company (irrespective of the determination as to Indemnitee&#8217;s entitlement to indemnification) and the Company hereby indemnifies and agrees to hold Indemnitee harmless therefrom.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event that Indemnitee exercises his or her right to have his or her entitlement to indemnification determined by Independent Counsel pursuant to clause (i) of Section 11(a), the Independent Counsel shall be selected by Indemnitee and notification shall be provided to the Company in writing.  The Company may, within ten (10) days after written notice of such selection, deliver to Indemnitee a written objection to such selection&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that such objection may be asserted only on the ground that the Independent Counsel so selected does not meet the requirements of &#8220;Independent Counsel&#8221; as defined in Section 2 of this Agreement, and the objection shall set forth with particularity the factual basis of such assertion.  Absent a proper and timely objection, the person so selected shall act as Independent Counsel.  If such written objection is so made and substantiated, the Independent Counsel so selected may not serve as Independent Counsel unless and until such objection is withdrawn or a court has determined that such objection is without merit.  If, within twenty (20) days after the later of (i) submission by Indemnitee of a written request for indemnification and Independent Counsel pursuant to Sections 10(a) and 11(a)(i) hereof, respectively, and (ii) the final disposition of the Proceeding, including any appeal therein, no Independent Counsel shall have been selected without objection, Indemnitee may petition a court of competent jurisdiction for resolution of any objection which shall have been made by the Company to the selection of Independent Counsel and&#47;or for the appointment as Independent Counsel of a person selected by the court or by such other person as the court shall designate.   The person with respect to whom all objections are so resolved or the person so appointed shall act as Independent Counsel under Section 11(a) hereof.  Upon the due commencement of any judicial proceeding or arbitration pursuant to Section 13(a) of this Agreement, Independent Counsel shall be discharged and relieved of any further responsibility in such capacity (subject to the applicable standards of professional conduct then prevailing).</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:37.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 12.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Presumptions and Effect of Certain Proceedings</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;In making a determination with respect to entitlement to indemnification hereunder, it shall be presumed that Indemnitee is entitled to indemnification under this Agreement if Indemnitee has submitted a request for indemnification in accordance with Section 10(a) of this Agreement, and the Company shall have the burden of proof to overcome that presumption in connection with the making of any determination contrary to that presumption. Neither (i) the failure of the Company or of Independent Counsel to have made a determination </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-8-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">prior to the commencement of any action pursuant to this Agreement that indemnification is proper in the circumstances because Indemnitee has met the applicable standard of conduct, nor (ii) an actual determination by the Company or by Independent Counsel that Indemnitee has not met such applicable standard of conduct, shall be a defense to the action or create a presumption that Indemnitee has not met the applicable standard of conduct.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;The termination of any Proceeding or of any claim, issue or matter therein, by judgment, order, settlement or conviction, or upon a plea of guilty, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">nolo</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">contendere</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or its equivalent, shall not (except as otherwise expressly provided in this Agreement) of itself adversely affect the right of Indemnitee to indemnification or create a presumption that Indemnitee did not act in good faith and in a manner which he or she reasonably believed to be in or not opposed to the best interests of the Avadel Group or Enterprise, as applicable, or, with respect to any criminal Proceeding, that Indemnitee had reasonable cause to believe that his or her conduct was unlawful.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;The knowledge and&#47;or actions, or failure to act, of any Representative of an Avadel Company or any Enterprise shall not be imputed to Indemnitee for purposes of determining the right to indemnification under this Agreement.</font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:244%">Section 13.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:244%;text-decoration:underline">Remedies of Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:244%">.</font></div><div style="margin-top:7.2pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;Subject to Section 13(f), in the event that (i) a determination is made pursuant to Section 11 of this Agreement that Indemnitee is not entitled to indemnification under this Agreement, (ii) advancement of Expenses is not timely made pursuant to Section 9 of this Agreement, (iii) no determination of entitlement to indemnification shall have been made pursuant to Section 11(a) of this Agreement within sixty (60) days after receipt by the Company of the request for indemnification that does not include a request for Independent Counsel, (iv)&#160;payment of indemnification is not made pursuant to Section 5 or 6 or the last sentence of Section 11(a) of this Agreement within ten (10) days after receipt by the Company of a written request therefor or (v) payment of indemnification pursuant to Section 3, 4 or 7 of this Agreement is not made within ten (10) days after a determination has been made that Indemnitee is entitled to indemnification, Indemnitee shall be entitled to an adjudication by a court of his or her entitlement to such indemnification or advancement. Alternatively, Indemnitee, at his or her option, may seek an award in arbitration to be conducted by a single arbitrator pursuant to the Commercial Arbitration Rules of the American Arbitration Association. Indemnitee shall commence such proceeding seeking an adjudication or an award in arbitration within one hundred and eighty (180) days following the date on which Indemnitee first has the right to commence such proceeding pursuant to this Section 13(a)&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that the foregoing time limitation shall not apply in respect of a proceeding brought by Indemnitee to enforce his or her rights under Section 5 of this Agreement. The Company shall not oppose Indemnitee&#8217;s right to seek any such adjudication or award in arbitration.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;In the event that a determination shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is not entitled to indemnification, any judicial proceeding or arbitration commenced pursuant to this Section 13 shall be conducted in all respects as a de novo trial, or arbitration, on the merits and Indemnitee shall not be prejudiced by </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-9-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">reason of that adverse determination. In any judicial proceeding or arbitration commenced pursuant to this Section 13, the Company shall have the burden of proving Indemnitee is not entitled to indemnification or advancement, as the case may be.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c) &#160;&#160;&#160;&#160;If a determination shall have been made pursuant to Section 11(a) of this Agreement that Indemnitee is entitled to indemnification, the Company shall be bound by such determination in any judicial proceeding or arbitration commenced pursuant to this Section 13, absent (i) a misstatement by Indemnitee of a material fact, or an omission of a material fact necessary to make Indemnitee&#8217;s statement not materially misleading, in connection with the request for indemnification, or (ii) a prohibition of such indemnification under applicable law.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(d)&#160;&#160;&#160;&#160;The Company shall be precluded from asserting in any judicial proceeding or arbitration commenced pursuant to this Section 13 that the procedures and presumptions of this Agreement are not valid, binding and enforceable and shall stipulate in any such court or before any such arbitrator that the Company is bound by all the provisions of this Agreement.  </font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(e)&#160;&#160;&#160;&#160;The Company shall indemnify Indemnitee against any and all Enforcement Expenses and, if requested by Indemnitee, shall (within ten (10) days after receipt by the Company of a written request therefor) advance, to the Maximum Extent Permitted by Law, such Enforcement Expenses to Indemnitee, which are incurred by Indemnitee in connection with any action brought by Indemnitee for indemnification or advancement from the Company under this Agreement or under any liability insurance policies maintained by any Avadel Company for coverage of any Representatives of the Avadel Group, regardless of whether Indemnitee ultimately is determined to be entitled to such indemnification, advancement or insurance recovery, as the case may be, in the suit for which indemnification or advancement is being sought.  </font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(f)&#160;&#160;&#160;&#160;Notwithstanding anything in this Agreement to the contrary, no determination as to entitlement to indemnification under this Agreement shall be required to be made prior to the final disposition of the Proceeding, including any appeal therein.</font></div><div style="text-align:justify;text-indent:72pt"><font><br></font></div><div style="padding-left:37.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 14.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Non-exclusivity&#59; Survival of Rights&#59; Insurance&#59; Subrogation</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The rights of indemnification and to receive advancement as provided by this Agreement shall not be deemed exclusive of any other rights to which Indemnitee may at any time be entitled under applicable law, the articles of association, bylaws or other governing documents of any Avadel Company or Enterprise, any agreement, a vote of shareholders or a resolution of directors, or otherwise.  No amendment, alteration or repeal of this Agreement or of any provision hereof shall limit or restrict any right of Indemnitee under this Agreement in respect of any action taken or omitted by such Indemnitee in his or her Corporate Status prior to such amendment, alteration or repeal. To the extent that a change in Delaware law, whether by statute or judicial decision, permits greater indemnification or advancement than would be afforded currently under the articles of association, bylaws or other governing documents of an Avadel Company and this Agreement, it is the intent of the parties hereto that Indemnitee shall enjoy by this Agreement the greater benefits so afforded by such change.  No right or remedy </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-10-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">herein conferred is intended to be exclusive of any other right or remedy, and every other right and remedy shall be cumulative and in addition to every other right and remedy given hereunder or now or hereafter existing at law or in equity or otherwise. The assertion or employment of any right or remedy hereunder, or otherwise, shall not prevent the concurrent assertion or employment of any other right or remedy.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;To the extent that any Avadel Company maintains an insurance policy or policies providing liability insurance for Representatives of the Avadel Group or of any other Enterprise, Indemnitee shall be covered by such policy or policies in accordance with its or their terms to the maximum extent of the coverage available for any such Representative under such policy or policies. If, at the time of the receipt of a notice of a claim pursuant to the terms hereof, an Avadel Company has liability insurance in effect covering Representatives of the Avadel Group, the Company shall give prompt notice of the commencement of such proceeding to the insurers in accordance with the procedures set forth in the respective policies. The Company shall thereafter take all necessary or desirable action to cause such insurers to pay, on behalf of Indemnitee, all amounts payable as a result of such proceeding in accordance with the terms of such policies.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(c)&#160;&#160;&#160;&#160;In the event of any payment under this Agreement, the Company shall be subrogated to the extent of such payment to all of the rights of recovery of Indemnitee, who shall execute all papers required and take all action necessary to secure such rights, including execution of such documents as are necessary to enable the Company to bring suit to enforce such rights.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 15.&#160;&#160;&#160;&#160; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Duration of Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement shall continue until and terminate upon the later of&#58; (a) ten (10) years after the date that Indemnitee shall have ceased to serve as a Representative of the Parent or one of its subsidiaries or (b) one (1) year after the final termination of any Proceeding, including any appeal, then pending in respect of which Indemnitee is granted rights of indemnification or advancement hereunder and of any proceeding commenced by Indemnitee pursuant to Section 13 of this Agreement relating thereto. </font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Successors and Assigns</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. This Agreement shall be binding upon the Company and its successors and assigns and shall inure to the benefit of Indemnitee and his or her heirs, executors and administrators.  The Company shall require and cause any successor (whether direct or indirect by purchase, merger, consolidation, division or otherwise) to all, substantially all or a substantial part, of the business and&#47;or assets of the Parent or the Company, by written agreement in form and substance satisfactory to Indemnitee, expressly to assume and agree to perform this Agreement in the same manner and to the same extent that the Company would be required to perform if no such succession had taken place.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 17.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Severability</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  If any provision or provisions of this Agreement shall be held to be invalid, illegal or unenforceable for any reason whatsoever&#58; (a) the validity, legality and enforceability of the remaining provisions of this Agreement (including without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall not in any way be affected or impaired thereby and shall remain enforceable to the Maximum Extent Permitted </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-11-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">by Law&#59; (b) such provision or provisions shall be deemed reformed to the extent necessary to conform to applicable law and to give the maximum effect to the intent of the parties hereto&#59; and (c) to the fullest extent possible, the provisions of this Agreement (including, without limitation, each portion of any section of this Agreement containing any such provision held to be invalid, illegal or unenforceable, that is not itself invalid, illegal or unenforceable) shall be construed so as to give effect to the intent manifested thereby.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 18.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Enforcement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</font></div><div style="padding-left:36pt;text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;The Company expressly confirms and agrees that it has entered into this Agreement and assumed the obligations imposed on it hereby in order to induce Indemnitee to serve as a director, secretary, and&#47;or officer of an Avadel Company or any other Enterprise, and the Company acknowledges that Indemnitee is relying upon this Agreement in serving as a director, secretary, and&#47;or officer of an Avadel Company or any other Enterprise.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(b)&#160;&#160;&#160;&#160;This Agreement constitutes the entire agreement between the parties hereto with respect to the subject matter hereof and supersedes all prior agreements and understandings, oral, written and implied, between the parties hereto with respect to the subject matter hereof&#59; </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">provided</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">however</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, that this Agreement is a supplement to and in furtherance of the charters, the bylaws, the articles of association and other governing documents of the applicable Avadel Companies, any indemnification agreement entered into by Indemnitee with the Parent and applicable law, and shall not be deemed a substitute therefor, nor to diminish or abrogate any rights of Indemnitee thereunder.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 19.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Modification and Waiver</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  No supplement, modification or amendment, or waiver of any provision, of this Agreement shall be binding unless executed in writing by the parties thereto. No waiver of any of the provisions of this Agreement shall be deemed or shall constitute a waiver of any other provisions of this Agreement nor shall any waiver constitute a continuing waiver.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 20.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notice by Indemnitee</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  Indemnitee agrees promptly to notify the Company in writing upon being served with any summons, citation, subpoena, complaint, indictment, information or other document relating to any Proceeding or matter which may be subject to indemnification or advancement as provided hereunder. The failure of Indemnitee to so notify the Company shall not relieve the Company of any obligation which it may have to Indemnitee under this Agreement or otherwise.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 21.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Notices</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  All notices, requests, demands and other communications under this Agreement shall be in writing and shall be deemed to have been duly given if (a) delivered by hand and receipted for by the party to whom said notice or other communication shall have been directed, (b) mailed by certified or registered mail with postage prepaid, on the third business day after the date on which it is so mailed, (c) mailed by reputable overnight courier and receipted for by the party to whom said notice or other communication shall have been directed or (d) sent by facsimile transmission, with receipt of oral confirmation that such transmission has been received&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-12-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify;text-indent:72pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(a)&#160;&#160;&#160;&#160;If to Indemnitee, at such address as Indemnitee shall provide to the Company.</font></div><div style="padding-left:72pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:244%">(b)&#160;&#160;&#160;&#160;If to the Company to&#58;</font></div><div style="padding-left:72pt;text-align:justify"><font><br></font></div><div style="padding-left:108pt;padding-right:162pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Avadel US Holdings, Inc. </font></div><div style="padding-left:108pt;padding-right:162pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">16640 Chesterfield Grove Road</font></div><div style="padding-left:108pt;padding-right:162pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Suite 200</font></div><div style="padding-left:108pt;padding-right:162pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Chesterfield, MO 63005</font></div><div style="padding-left:108pt;padding-right:162pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Attention&#58; Jerad G. Seurer</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:244%">or to any other address as may have been furnished to Indemnitee by the Company.</font></div><div style="margin-top:7.2pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 22.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Contribution</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  To the Maximum Extent Permitted by Law, if the indemnification provided for in this Agreement is unavailable to Indemnitee for any reason whatsoever, the Company, in lieu of indemnifying Indemnitee, shall contribute to the amount incurred by Indemnitee, whether for judgments, fines, penalties, excise taxes, amounts paid or to be paid in settlement and&#47;or for Expenses, in connection with any Proceeding in such proportion as is deemed fair and reasonable in light of all of the circumstances in order to reflect (i) the relative benefits received by the applicable Avadel Company or Companies and Indemnitee in connection with the event(s) and&#47;or transaction(s) giving rise to such Proceeding&#59; and&#47;or (ii) the relative fault of  the applicable Avadel Company or Companies (and its or their Representatives) and Indemnitee in connection with such event(s) and&#47;or transactions.</font></div><div style="margin-top:12.6pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 23.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Applicable Law and Consent to Jurisdiction</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement and the legal relations among the parties shall be governed by, and construed and enforced in accordance with, the laws of the State of Delaware, without regard to its conflict of laws rules. Except with respect to any arbitration commenced by Indemnitee pursuant to Section 13(a) of this Agreement, the Company and Indemnitee hereby irrevocably and unconditionally (i) agree that any action or proceeding arising out of or in connection with this Agreement shall be brought only in a court of competent jurisdiction in the State of Delaware (a &#8220;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Delaware Court</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), and not in any other state or federal court in the United States of America or any court in any other country, (ii) consent to submit to the exclusive jurisdiction of the Delaware Court for purposes of any action or proceeding arising out of or in connection with this Agreement, (iii) consent to service of process at the address set forth in Section 20 of this Agreement with the same legal force and validity as if served upon such party personally within the State of Delaware, (iv) waive any objection to the laying of venue of any such action or proceeding in the Delaware Court, and (v) waive, and agree not to plead or to make, any claim that any such action or proceeding brought in the Delaware Court has been brought in an improper or inconvenient forum.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 24.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Identical Counterparts</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  This Agreement may be executed in one or more counterparts, each of which shall for all purposes be deemed to be an original but all of which together shall constitute one and the same Agreement. Only one such counterpart signed by the </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-13-</font></div><div><font><br></font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10.8pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">party against whom enforceability is sought needs to be produced to evidence the existence of this Agreement.</font></div><div style="margin-top:10.8pt;text-align:justify;text-indent:32.4pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 25.&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Miscellaneous</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.  The headings of the sections of this Agreement are inserted for convenience only and shall not be deemed to constitute part of this Agreement or to affect the construction thereof.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-14-</font></div><div><font><br></font></div></div></div><div id="id058535abc814f6fa4f733c602de3051_4"></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10.8pt;text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">IN WITNESS WHEREOF, the parties have caused this Agreement to be signed as of the day and year first above written.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;AVADEL US HOLDINGS, INC. </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;By&#58;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     Indemnitee</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;    </font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;     __________________________________</font></div><div style="padding-left:180pt;text-align:justify;text-indent:36pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">     Name</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Current Indemnitee Address&#47;Phone </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">________________________________</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.589%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;103517515.2  </font></div><div style="text-align:justify"><font><br></font></div></td></tr></table><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:18.589%"><tr><td style="width:1.0%"></td><td style="width:98.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:8pt;font-weight:400;line-height:120%">ACTIVE&#47;103517515.2  </font></div><div style="text-align:justify"><font><br></font></div></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#91;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Signature Page &#8211; Avadel US Holdings, Inc. Indemnification Agreement</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#93;</font></div></div></div><hr style="page-break-after:always"><div style="min-height:72pt;width:100%"><div style="text-align:right"><font><br></font></div></div><div style="margin-top:10.8pt;text-align:center;text-indent:32.4pt"><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">-16-</font></div><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-19.1
<SEQUENCE>11
<FILENAME>a123124ex-191.htm
<DESCRIPTION>EX-19.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i54c4c999e4bf44dca004cdf25ae0fc6d_1"></div><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><img alt="image_01.jpg" src="image_01.jpg" style="height:86px;margin-bottom:5pt;vertical-align:text-bottom;width:164px"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:1pt;font-weight:700;line-height:120%"><br></font></div><div style="margin-bottom:12pt;text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font><img alt="image_11.jpg" src="image_11.jpg" style="height:134px;margin-bottom:5pt;vertical-align:text-bottom;width:251px"></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Avadel Pharmaceuticals plc<br>Insider Trading Policy</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Purpose</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Insider Trading Policy (this &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) provides requirements with respect to handling confidential information about and transacting in the securities of Avadel Pharmaceuticals plc (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Avadel</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; or the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Company</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) (Nasdaq&#58; AVDL). This Policy is intended to prevent the misuse of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Material Nonpublic Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> (as defined on page 6 of this Policy), insider trading in securities, and the severe consequences associated with violations of insider trading laws.  It is your obligation to review, understand, and comply with this Policy and applicable laws. Our Board of Directors has approved this Policy, and we have appointed Jerad G. Seurer as the Compliance Officer (with his designees, the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance Officer</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) to administer the policy and to be available to answer your questions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Federal and state laws prohibit those who are aware of Material Nonpublic Information about a company from&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Trading in shares of stock or other securities of that company.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Providing the Material Nonpublic Information to others who may trade based on that information.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Key components of our Code of Conduct (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Code of Conduct</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) are that we obey the law and we are loyal to our shareholders and customers. To promote those values and compliance with insider trading laws, we have adopted this Policy. Our reputation with our stakeholders is an important asset, and this Policy seeks to avoid even the appearance of impropriety.</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy Summary</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please read the entire Policy carefully. The Policy has many details that you are required to understand and with which you are required to comply.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to all directors, officers, employees, contractors and independent consultants of Avadel and its subsidiaries. It also applies to entities you control and to certain of your family members.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">1</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">If you are aware of Material Nonpublic Information relating to Avadel or its subsidiaries, you may not, directly or indirectly (1) disclose the information, (2) buy, sell, engage in any other transactions in or advise on a transaction in Avadel securities, (3) use the information for personal gain or (4) assist anyone with these activities. These prohibitions also apply to Material Nonpublic Information about other companies that you obtain in the course of your work for Avadel.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You may not engage in short sales of Avadel securities, transactions in derivative Avadel securities or transactions in hedging instruments involving Avadel securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Directors, officers and certain key employees (Tier 1 Insiders and Tier 2 Insiders</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(as defined in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">)) may not use Avadel securities as collateral and must comply with additional special procedures and, in some cases, special preclearance and reporting requirements (see </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Applicability</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whom Does This Policy Apply To&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to all directors, officers, employees, contractors and independent consultants of Avadel and its subsidiaries, as well as any other individuals whom the Compliance Officer may designate as insiders because they have access to Material Nonpublic Information about the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy also applies to Related Persons</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(as defined below). You are responsible for compliance by your Related Persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While certain additional rules and restrictions apply to both Tier 1 Insiders and Tier 2 Insiders, special preclearance and reporting procedures also apply to Tier 1 Insiders (see </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What Is Meant By &#8220;Related Persons&#8221;&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Policy, &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Related Persons</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; include&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">all investment funds, trusts, retirement plans, partnerships, corporations and other types of entities over which you have the ability to influence or direct investment decisions concerning securities&#59; provided, however, that, the Policy shall not apply to any such entity that engages in the investment of securities in the ordinary course of its business (e.g., an investment fund or partnership) if such entity has established its own insider trading controls and procedures in compliance with applicable securities laws and you have hereby represented to Avadel that your affiliated entities&#58; (a) engage in the investment of securities in the ordinary course of their respective businesses&#59; (b) have established insider trading controls and procedures in compliance with applicable securities laws&#59; and (c) are aware such securities laws prohibit any person or entity who has material, nonpublic information concerning Avadel from purchasing or selling securities of Avadel or from communicating such information to any other person under circumstances in which it is reasonably foreseeable that such person is likely to purchase or sell securities&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">your family members, which includes (a) your spouse or domestic partner, children, stepchildren, grandchildren, parents, stepparents, grandparents, siblings and in-laws who reside in the same household as you, (b) your children or your spouse&#8217;s children who do not reside in the same household as you but are financially dependent on you, (c) any of your other family members who do not reside in your household but whose transactions are directed by you, and (d) any other individual over whose account you have control and to whose financial support you materially contribute (materially contributing to financial support would include, for example, paying an individual&#8217;s rent but not just a phone bill)&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">all trusts, family partnerships and other types of entities formed for your benefit or for the benefit of a member of your family and over which you have the ability to influence or direct investment decisions concerning securities&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">all persons who execute trades on your behalf.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are responsible for the transactions of these persons and, therefore, should make them aware of the need to confer with you before they trade in Avadel securities, and you should treat all of these transactions for the purposes of this Policy and applicable securities laws as if the transactions were for your own account.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy does not, however, apply to personal securities transactions of individuals where the purchase or sale decision is made by a third party not controlled by, influenced by or related to you or the individual.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Does This Policy Still Apply To Me After I Leave Avadel&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy applies to you and your Related Persons so long as you are associated with the Company. If you leave the Company for any reason, this Policy, including, if applicable, the Special Procedures described in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, will continue to apply to you and your Related Persons until the later of&#58; (1) the end of the first full trading day following the public release of earnings for the fiscal quarter in which you leave the Company or (2) the end of the first full trading day after any material nonpublic information known to you has become public or is no longer material.</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Statement of Policy</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy has three components, each of which is addressed below&#58;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(1)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">You May Not Use or Disclose Material Nonpublic Information&#59;</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(2)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">You May Not Engage in Speculative Trading&#59; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">and</font></div><div style="margin-bottom:12pt;padding-left:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">(3)&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Tier 1 Insiders and Tier 2 Insiders May Not Use Avadel Securities as Collateral.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(1)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.46pt">You May Not Use or Disclose Material Nonpublic Information</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you are aware of Material Nonpublic Information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">relating to Avadel, neither you nor your Related Persons may&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">3</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Disclose that Material Nonpublic Information to anyone, with these limited exceptions&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">Avadel employees whose jobs require them to have that information&#59;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">third parties who are subject to a confidentiality agreement approved by Avadel that covers the information and whose engagement with Avadel requires them to have that information&#59; or</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-18pt"><font style="color:#000000;font-family:'Courier New',monospace;font-size:12pt;font-weight:400;line-height:120%">o</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:10.8pt">third party agents who are covered by statutory or regulatory confidentiality obligations to Avadel (such as attorneys) and whose engagement with Avadel requires them to have that information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Trade (whether for your account or for the account of another) in the Company&#8217;s securities, which includes ordinary shares, American Depositary Shares (&#8220;ADSs&#8221;), options to purchase ordinary shares, any other type of securities that the Company may issue (such as preferred shares, convertible debentures, warrants, exchange-traded options or other derivative securities), and any derivative securities that provide the economic equivalent of ownership of any of the Company&#8217;s securities or an opportunity, direct or indirect, to profit from any change in the value of the Company&#8217;s securities, except for trades made in compliance with the affirmative defense of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), such as when trades are made pursuant to a written plan that was adopted, or trading instructions that were given, before you knew or had possession of such material, nonpublic information and certain other conditions are satisfied.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Use the information for personal gain, such as sharing the information for a fee as part of an &#8220;expert network.&#8221;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Give trading advice of any kind about the Company, including recommending the purchase or sale of any Avadel securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Assist anyone engaged in the above activities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, if, in the course of working for Avadel, you learn of Material Nonpublic Information about any other company (for example, a current or potential customer, supplier or competitor of Avadel), you may not conduct any of the above actions with respect to that company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy does not apply to&#58; (1) an exercise of an employee stock option when payment of the exercise price is made </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">in cash</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> and shares received on exercise are </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">not sold</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> or (2) the withholding by the Company of shares upon vesting of restricted stock or upon settlement of restricted stock units to satisfy applicable tax withholding requirements if (a) such withholding is required by the applicable plan or award agreement or (b) the election to exercise such tax withholding right was made in compliance with the Special Procedures (set forth in </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">), if applicable, or (3) the surrender for cancellation of employee stock options in satisfaction of the exercise price or the surrender for cancellation of employee stock options or restricted stock units to satisfy applicable tax withholding requirements if such surrender is permitted by the applicable plan or award agreement and the election to surrender such awards was made by in compliance with the Special Procedures, if applicable.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">4</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy also does not apply to periodic wage withholding contributions by the Company or its employees that are used to purchase Company shares pursuant to the employees&#8217; advance instructions under the Company&#8217;s Employee Share Purchase Plan (the &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ESPP</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).  However, you may not&#58; (1) elect to participate in the ESPP or alter your instructions regarding the level of withholding or purchase of Company securities under the ESPP&#59; or (2) make cash contributions to the ESPP (other than through periodic wage withholding) without complying with this Policy.  Any sale of securities acquired under the ESPP is subject to the prohibitions and restrictions of this Policy.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Policy does apply, however, to&#58; (1) the use of outstanding Avadel securities to pay part or all of the exercise price of an option&#59; (2) any sale of shares as part of a broker-assisted cashless exercise of an option&#59; or (3) any other market sale for the purpose of generating the cash needed to pay the exercise price of an option or satisfy applicable tax withholding requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These prohibitions continue whenever and for as long as you know or are in possession of material, nonpublic information.  Remember, anyone scrutinizing your transactions will be doing so after the fact, with the benefit of hindsight.  As a practical matter, before engaging in any transaction, you should carefully consider how enforcement authorities and others might view the transaction in hindsight.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What is &#8220;Material Nonpublic Information&#8221;&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There is no &#8220;bright-line&#8221; definition. You should consider information to be &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">material</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; if there is a substantial likelihood that a reasonable shareholder would consider it important in making an investment decision. The information can be positive or negative and depends on the particular circumstances. Any information that could be expected to affect the particular company&#8217;s (e.g., Avadel&#8217;s) stock price, whether it is positive or negative, should be considered material. Because hindsight is often used to determine if information had an effect on the market, you should err on the side of caution in considering whether information is material.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While it is not possible to define all categories of &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">material information</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; some examples of information that ordinarily would be regarded as material are&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Financial results&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Projections of future earnings or losses or other earnings guidance&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Changes to previously announced earnings guidance or the decision to suspend earnings guidance&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Development of a significant new product or service&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Approval or disapproval of any product by government regulatory authorities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Developments regarding any programs in clinical development or subject to regulatory approval, including recent regulatory interaction and&#47;or data that have been recently generated from ongoing or recently completed clinical trials&#59;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">5</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A pending or proposed joint venture, merger or acquisition&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A disposition of a significant asset or subsidiary&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A change in senior management or the Board of Directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A change in dividend policy, declarations of stock splits, or proposed securities offerings or other financings&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">A restructuring&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Potential restatements of the particular company&#8217;s (e.g., Avadel&#8217;s) financial statements, changes in auditors or auditor notification that the company may no longer rely on an auditor&#8217;s audit report&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Cybersecurity risks and incidents, including the discovery of significant vulnerabilities or breaches&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Significant transactions with related parties or affiliates&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The imposition of a ban on trading in that particular company&#8217;s (e.g., Avadel&#8217;s) securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The establishment of a repurchase program for the particular company&#8217;s (e.g., Avadel&#8217;s) securities&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Operational disruptions&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Significant threatened or pending litigation or regulatory proceedings.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For purposes of this Policy, information is &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">nonpublic</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; unless&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">It has been widely disseminated to the investing public&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">One full trading day has passed since publication.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">By including the list above, the Company does not mean to imply that each of these items above is per se material.  The information and events on this list still require determinations as to their materiality (although some determinations will be reached more easily than others). For example, some new products or contracts may clearly be material to an issuer&#59; yet that does not mean that all product developments or contracts will be material.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The U.S. Securities and Exchange Commission (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SEC</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) has stated that there is no fixed quantitative threshold amount for determining materiality, and that even very small quantitative changes can be qualitatively material if they would result in a movement in the price of the Company&#8217;s securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Information that is disclosed through a newswire service, a broadcast on a widely-available radio or television program, a publication in a widely-available newspaper, a magazine or news website, our website or via social media if such posting is a regular way we communicate with </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">6</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">investors, or a public disclosure document filed with the SEC that is available on the SEC&#8217;s website is generally considered widely disseminated. Information that is only available to the particular company&#8217;s (e.g., Avadel&#8217;s) employees or to a select group of analysts, brokers and institutional investors would not be considered &#8220;public.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Once the information is published, it is still necessary to wait one full trading day after the release of the information so that the information can be fully absorbed by the marketplace. For example, if you have material, nonpublic information about Avadel, and that information is announced to the public on a Monday, you should not trade in Avadel securities until Wednesday. Depending on the particular circumstances, the Compliance Officer may determine that a longer or shorter period should apply to the release of specific Material Nonpublic Information.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Tipping&#8221; is prohibited. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Passing on Material Nonpublic Information (whether positive or negative) is known as &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">tipping</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221; You are prohibited from providing Material Nonpublic Information about the Company to a friend, relative, or anyone else who might buy or sell a security or other financial instrument or advise others to trade on the basis of that information, whether or not you intend to or actually do realize a profit (or any other benefit) from such tipping.  Additionally, you are prohibited from recommending to any person that such person engage in or refrain from engaging in any transaction involving the Company&#8217;s securities, or otherwise give trading advice concerning the Company&#8217;s securities, if you are in possession of Material Nonpublic Information about the Company. Not only may the &#8220;tipper&#8221; have liability for tipping, the &#8220;tippee&#8221; may have liability for trading on the information or passing it along to someone else.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Trading in securities of other companies based on Material Nonpublic Information learned during the course of your service to or employment by the Company is prohibited.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:7.8pt;font-weight:400;line-height:120%;position:relative;top:-4.2pt;vertical-align:baseline"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whenever, during the course of your service to or employment by the Company, you become aware of Material Nonpublic Information about another company, including any confidential information that is reasonably likely to affect the market price of that company&#8217;s securities (for example, discussions of licensing a product or acquiring that other company), neither you nor your Related Persons may trade in any securities of that company, give trading advice about that company, tip or disclose that information, pass it on to others, or engage in any other action to take advantage of that information. If your work regularly involves handling or discussing confidential information of one of our partners, suppliers or customers, you should consult with the Compliance Officer before trading in any of that company&#8217;s securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Confidential information should also be protected</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Confidential information is broader than Material Nonpublic Information. Generally, confidential information includes any nonpublic information obtained or created in connection with your activities with Avadel that might be of use to competitors or harmful to Avadel or its customers, suppliers, or other partners if disclosed. While this Policy restricts your use of Material Nonpublic Information, you are also required to safeguard Avadel&#8217;s confidential information. See the Code of Conduct for more information on your obligations to preserve confidential information.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">7</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(2)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.46pt">You May Not Engage in Speculative Trading</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whether or not you are in possession of Material Nonpublic Information, engaging in any of the following is prohibited by this Policy&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Short sales of Avadel securities (that is, the sale of a security that a seller does not own or a sale that is consummated by the delivery of a security borrowed by, or for the account of, the seller).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Transactions in put options, call options or similar derivative Avadel securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Transactions in financial instruments that are designed to hedge or offset any decrease in the market value of Avadel&#8217;s equity securities, such as prepaid variable forward contracts, equity swaps and collars.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Some of these transactions imply an expectation on the part of the transacting party that the securities will decline in value and may signal to the market that the party lacks confidence in Avadel&#8217;s prospects. In addition, since the value of these transactions is based on a decline in the value of Avadel&#8217;s securities, personal gains made in these types of transactions may conflict with the best interests of Avadel and its shareholders. Hedging transactions may permit the party to continue to own Avadel securities, but without the full risks and rewards of ownership, creating a misalignment between the party&#8217;s interests and best interests of Avadel and its shareholders. As importantly, even the most legitimate of these structures may appear to our investors, regulators and other important stakeholders as inappropriate and not in line with the stakeholders&#8217; best interests.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">(3)</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:700;line-height:100%;padding-left:22.46pt">Tier 1 Insiders and Tier 2 Insiders May Not Use Avadel Securities as Collateral</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Whether or not you are in possession of Material Nonpublic Information, all Tier 1 Insiders and Tier 2 Insiders and their Related Persons are prohibited from pledging Avadel securities as collateral for loans (including in margin accounts). In the event the collateral is called on and sold, it may adversely affect the market for Avadel securities, or may occur during a blackout period, in either event having a potential negative effect on our reputation.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What Are The Consequences Of Violating This Policy Or The Insider Trading Laws&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insider trading violations, including tipping, are pursued vigorously by the SEC, the national securities exchanges (through the Financial Industry Regulatory Authority), U.S. Attorneys and state enforcement authorities. Punishment for insider trading violations is severe and could include significant fines and imprisonment, including&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">disgorgement of the profit gained or loss avoided by the trading&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">payment of the loss suffered by the persons who, contemporaneously with the purchase or sale of securities that are subject of such violation, have purchased or sold, as applicable, securities of the same class&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">payment of criminal penalties of up to $5,000,000&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">payment of civil penalties of up to three times the profit made or loss avoided&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">8</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">imprisonment for up to 20 years.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company and&#47;or the supervisors of the person engaged in insider trading may also be required to pay civil penalties of fines starting from $2,000,000 or more, up to three times the profit made or loss avoided, as well as criminal penalties of up to $25,000,000, and could under certain circumstances be subject to private lawsuits.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, your failure to comply with this Policy may subject you to Avadel-imposed disciplinary action, including termination for cause, whether or not your failure to comply results in legal action.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Will I Be Held Individually Responsible For Compliance With This Policy And The Insider Trading Laws&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You have ethical and legal obligations to Avadel, its stakeholders and your colleagues to comply with this Policy. Each individual is responsible for making sure that he&#47;she complies with this Policy, and that any Related Persons also comply with this Policy. In all cases, the responsibility for determining whether you are in possession of Material Nonpublic Information rests with you, and any action on the part of Avadel or its representatives does not in any way constitute legal advice or insulate you from liability under applicable securities laws.</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Policy Administration</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer is responsible for the administration of this Policy. All determinations and interpretations by the Compliance Officer are final and not subject to further review.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Whom Should You Call If You Have Any Questions, Concerns or Something To Report&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer at +1 636-730-1420. Call the Compliance Officer when&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">You have any questions about this Policy&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">You have a question about your own compliance with this Policy&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">You believe there has been a violation of this Policy.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance Hotline. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you do not wish to talk with the Compliance Officer, or if you want to remain anonymous, you can always call the Compliance Hotline as detailed in the Code of Conduct. The Compliance Hotline is managed by an independent-third party and allows you to report incidents you believe to be non-compliant, unethical or criminal, confidentially and anonymously (where permitted under local law). In certain circumstances, however, you may remain anonymous provided that the severity of the facts is established and the factual elements are sufficiently detailed.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Compliance Hotline Contact Information. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">There are three ways in which you can make reports using the Compliance Hotline&#58;</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">1.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.9pt">Dial your country&#8217;s Toll-Free number</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">9</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These numbers operate 24 hours a day, 7 days a week. Write down the case number you are given and call back after a practicable period of time with your case number to receive Avadel&#8217;s response to your report.</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In the US, dial 1-844-264-2273</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In Ireland, dial +353-768-887197</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">2.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.9pt">Send an email to TellAvadel&#64;GetInTouch.com</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You will receive a response email from lnTouch, an independent-third party who manages the Compliance Hotline, on behalf of Avadel in response to your report.</font></div><div style="margin-bottom:12pt;text-indent:18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">3.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%;padding-left:8.9pt">Submit your issue or concern via the web</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For the US, visit </font><font style="color:#0562c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.intouchwebsite.com&#47;TellAvadelUS</font></div><div style="margin-bottom:12pt;padding-left:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">For Ireland, visit </font><font style="color:#0562c1;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">www.intouchwebsite.com&#47;TellAvadelIreland</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When you access the InTouch service via the web, you will be provided with a unique case number and password that you will need to write down so that you can later access the Company response via the web.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Unless you indicate otherwise for each of the three InTouch communication venues, and if you have provided, your name and email address will be removed from the message by InTouch before it is sent to the Company. If you would like a member of Company management or the Audit Committee to reach out to you directly regarding the concern or complaint, please leave your contact information and the contact information of the individual with whom you wish to speak in regard to the matter so InTouch can relay that information to the Company.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Use of the InTouch program is optional, and there is no consequence to employees for not using the hotline tool as their selected avenue to report concerns or potential violations. However, failure to report wrongdoing at all in any venue is basis for disciplinary action. Further, abusive use of the program can expose employees to disciplinary actions. Alternatively, good faith use of the program, even if facts subsequently turn out to be inaccurate or do not give rise to follow-up, do not expose employees to disciplinary actions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Your Supervisor. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Questions and concerns are best answered by the Compliance Officer, but you are always encouraged to talk to your supervisor(s). We value open and honest communication among our personnel.</font></div><div style="margin-bottom:12pt"><font style="color:#01569b;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Acknowledgement</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company will deliver a copy of this Policy to all current employees and directors and consultants and to future employees and directors and consultants at the start of their employment or relationship with the Company.  Each of these individuals must acknowledge that he&#47;she has received a copy and agrees to comply with the terms of this Policy, and, if applicable, the Special Procedures contained herein.  The attached acknowledgement must be completed and submitted to the Company within ten (10) days of receipt.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">10</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">At the Company&#8217;s request, directors and employees and consultants will be required to re-acknowledge and agree to comply with the Policy (including any amendments or modifications).  For that purpose, an individual will be deemed to have acknowledged and agreed to comply with the Policy, as amended from time to time, when copies of those items have been delivered by regular or electronic mail (or other delivery option used by the Company) to the Compliance Officer.</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;*&#160;&#160;&#160;&#160;*</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">ADOPTED&#58; &#160;&#160;&#160;&#160;December 7, 2022</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">EFFECTIVE&#58;&#160;&#160;&#160;&#160;December 7, 2022</font></div><div><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">AMENDED&#58;&#160;&#160;&#160;&#160;August 1, 2023</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">11</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">SPECIAL PROCEDURES APPLICABLE TO TIER 1 INSIDERS AND TIER 2 INSIDERS</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The additional procedures in this section apply to those who are more likely to have routine access to Material Nonpublic Information. These &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Special Procedures</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; are intended to better ensure compliance with insider trading laws by those who are more likely to have access to Material Nonpublic Information.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">These Special Procedures also provide guidance on reporting ownership of and permitted transactions in Avadel securities pursuant to federal securities laws and SEC regulations.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Please call the Compliance Officer if you have questions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">I.&#160;&#160;&#160;&#160;Identification of Tier 1 Insiders. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following persons are deemed to be &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tier 1 Insiders</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for purposes of the following Special Procedures&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Board of Directors&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Company Officers&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Certain other employees of Avadel that are more likely to have access to highly sensitive and&#47;or Material Nonpublic Information as identified by the Compliance Officer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Related Persons of the foregoing.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">II.&#160;&#160;&#160;&#160;Identification of Tier 2 Insiders. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The following persons are deemed to be &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Tier 2 Insiders</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">for purposes of the following Special Procedures listed in Section II below&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Certain employees of Avadel that are more likely to have routine access to Material Nonpublic Information as identified by the Compliance Officer&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Related Persons of the foregoing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer maintains a current list of Tier 1 Insiders and Tier 2 Insiders and notifies each such person that he&#47;she has been so designated. The Compliance Officer may determine that others should be subject to these additional Special Procedures from time to time.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">III.&#160;&#160;&#160;&#160;Trading Blackout Periods</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Quarterly Trading Restrictions</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. Tier 1 Insiders and Tier 2 Insiders may not conduct any transactions involving Avadel&#8217;s securities during a &#8216;&#8216;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">blackout period</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.&#8221;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">quarterly blackout</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> period is the period&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Beginning at the close of market on the third trading day prior to the last day of each fiscal quarter&#59; and</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">12</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Continuing through the end of the first full trading day after the public release of quarterly or annual financial results (not counting the day of the release itself, if released after the beginning of The Nasdaq Stock Market&#8217;s trading hours).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Event-Specific Trading Restriction Periods.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Tier 1 Insiders and Tier 2 Insiders may not conduct any transactions involving Avadel&#8217;s securities when directed by the Compliance Officer as a result of specific events.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">From time to time, an event may occur that is material to Avadel and is known by only certain directors, officers and&#47;or employees. So long as the event remains material and nonpublic, the Tier 1 Insiders and Tier 2 Insiders may not trade Avadel securities, even if such persons are not actually aware of the event.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In addition, Avadel&#8217;s financial results may be sufficiently material in a particular fiscal quarter that, in the judgment of the Compliance Officer, Tier 1 Insiders and Tier 2 Insiders should refrain from trading in Avadel securities even sooner than the quarterly blackout period described above. In that situation, the Compliance Officer may notify these persons that they should not trade in Avadel&#8217;s securities, without disclosing the reason for the restriction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a trading restriction outside the quarterly blackout period is imposed on you, do not disclose this to others, as this may inadvertently communicate that a material event has happened.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Gifts and Other Distributions in Kind.</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> No Insider may donate or make any other transfer of Company securities without consideration when the Insider is not permitted to trade unless the recipient agrees not to sell the shares until the Insider is permitted to sell. In addition to charitable donations or gifts to family members, friends, trusts or others, this prohibition applies to distributions to limited partners by limited partnerships that are subject to this Policy.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">Exceptions may be permitted in truly extraordinary circumstances, but only with the prior written approval of the Compliance Officer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">IV.&#160;&#160;&#160;&#160;Preclearance Procedures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Tier 1 Insiders may not engage in any transaction in Avadel securities at any time without first obtaining preclearance of the transaction from Avadel&#8217;s Compliance Officer. Preclearance is also required for transactions by any Tier 1 Insider&#8217;s Related Persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Preclearance Process. </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The process for requesting preclearance is as follows&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Submit a request for preclearance using the Stock Transaction Request form attached to this Policy to the Compliance Officer at least two business days in advance of the proposed transaction.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">When a request for preclearance is made, carefully consider whether you may be aware of any Material Nonpublic Information about the Company and certify in writing prior to the proposed trade(s) that you are not in possession of material, nonpublic information concerning the Company.</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">13</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">If the Compliance Officer or his or her designee is not obligated to approve any trade requested by a Covered Person and may reject any trading request at his or her sole discretion. If the Compliance Officer or his or her designee approves the preclearance request in writing (including via e-mail), the transaction must be consummated within three business days. Even if a Covered Person has received clearance, the Covered Person may not engage in a trade if (i) such clearance has been rescinded by the Compliance Officer, (ii) the Covered Person has otherwise received notice that the trading window has closed or (iii) the Covered Person has or acquires Material Nonpublic Information.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">The Compliance Officer or his or her designee is not obligated to approve any trade requested by a Covered Person and may reject any trading request at his or her sole discretion. If you seek preclearance and permission to engage in the transaction is denied, then you must refrain from initiating any transaction in Avadel securities, and may not inform any other person of the restriction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In all cases, the responsibility for determining whether you are in possession of Material Nonpublic Information rests with you, and any preclearance does not in any way constitute legal advice or insulate you from liability under applicable securities laws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">V.&#160;&#160;&#160;&#160;Exemptions for Trades Effected Pursuant to Pre-Approved Rule 10b5-1 Plans</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Transactions effected pursuant to a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 10b5-1 Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; (as defined below) will not be subject to the Company&#8217;s trading windows or preclearance procedures discussed above. Rule 10b5-1 of the Exchange Act provides an affirmative defense from insider trading liability under the federal securities laws for trading plans, arrangements or instructions that meet certain requirements.  A trading plan, arrangement or instruction that meets the requirements of Rule 10b5-1 (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Rule 10b5-1 Plan</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;) enables Tier 1 Insiders  and Tier 2 Insiders to establish arrangements to trade in Company securities outside of the Company&#8217;s trading windows, even when in possession of material, nonpublic information.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Company has adopted a separate Rule 10b5-1 Trading Plan Policy that sets forth the requirements for putting in place a Rule 10b5-1 Plan with respect to Company securities.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VI.&#160;&#160;&#160;&#160;Section 16 - Reporting Ownership and Trading of Company Ordinary Shares and American Depositary Shares (&#8220;ADSs&#8221;)</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This Section VI applies to members of the Board of Directors and Avadel&#8217;s executive officers, as determined by the Board of Directors (&#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Section 16 Insiders</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The Compliance Officer maintains a current list of Section 16 Insiders and notifies each such person that he&#47;she has been so designated.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16 of the Exchange Act, and related SEC regulations, require that ownership of and trading in Company ordinary shares and ADSs by Avadel&#8217;s Section 16 Insiders be reported to the SEC. These individuals also have Section 16 reporting obligations with respect to holdings and transactions by their Related Persons. Section 16 Insiders must&#58;</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">14</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">File reports with the SEC and furnish a copy to Avadel regarding the Section 16 Insider&#8217;s beneficial ownership of Avadel&#8217;s equity securities and changes in ownership&#59;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Refund to Avadel any profit from a purchase and sale, or sale and purchase, of the same class of securities within a six-month period (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">short-swing transaction</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221;), subject to certain exemptions&#59; and</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">Refrain from engaging in &#8220;short sales&#8221; or certain &#8220;sales against the box&#8221; with respect to Avadel&#8217;s securities.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Individual Section 16 Insiders, and not Avadel, are responsible for compliance with legal requirements and liability for noncompliance. Both civil remedies and criminal penalties (including severe monetary penalties) may be incurred for violations. The Legal Department has and will continue to prepare and file such SEC forms for Section 16 Insiders pursuant to a Power of Attorney executed by each Section 16 Insider.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Note&#58; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If a company other than Avadel maintains your EDGAR filing codes (CIK and CCC), please ensure that the Legal Department is promptly notified of all updates and changes to those codes.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">A.&#160;&#160;&#160;&#160;Reporting</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What transactions need to be reported&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pecuniary interest &#8211; A Section 16 Insider must report to the SEC all transactions in Avadel stock in which the Section 16 Insider has or shares a direct or indirect &#8220;pecuniary interest&#8221; through any contract, arrangement, understanding, relationship or otherwise. This includes transactions by Related Persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Basically, an Insider has a &#8220;pecuniary interest&#8221; if the Section 16 Insider has the opportunity, directly or indirectly, to profit or share in any profit derived from a transaction in Avadel&#8217;s shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">You are presumed to be the beneficial owner of shares of Avadel stock if you, your spouse, or any of the family members listed below living in your household owns such stock, whether directly or indirectly (that is, through Avadel plans, trusts, estates, holding companies, partnership, limited partnership or syndicates, or through any other groups of which you, your spouse, or any family member</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">in your household is a member that were formed for the purpose of acquiring, holding or disposing of such stock).</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">&#8220;Family member&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">means child, stepchild, grandchild, parent, stepparent, grandparent, spouse, sibling, mother-in-law, father-in-law, son-in-law, daughter-in-law, brother-in-law or sister-in-law, whether by blood, marriage or adoption.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Note that while you are not presumed to have beneficial ownership of shares owned by a non-family member living with you, or owned by a family member not living with you, you should consider yourself the beneficial owner if you exert control or influence over that person&#8217;s investments or if the person is financially dependent on you (such a child away at school).</font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">15</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Beneficial ownership may also arise if&#58;</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">You are the trustee of a trust owning Avadel shares whose beneficiary is a family member not living with you&#59; or</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;padding-left:13.8pt">You receive a fee for managing investments that include Avadel shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Change in form of ownership</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> - A change in the form of ownership (for example, transferring shares from sole to joint account, distribution to a beneficiary from a trust, or a distribution of Avadel shares to you from a partnership in which you have an interest) may need to be reported, so please inform the Legal Department before such changes are made by you or your Related Persons.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Gifts and Inheritances</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> &#8211; You must report the receipt of any shares by gift or inheritance in which you have a pecuniary interest. This may include a gift or inheritance received by a family member.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What is the deadline for reporting transactions&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16 Insiders must report the details of all transactions to the Legal Department on the trade date so that a Form 4 report can be timely filed. Details include trade date, account(s) in which the trade was made, price, and quantity.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As set forth above, all transactions in Avadel shares must be precleared. Once preclearance is obtained, the transaction must be consummated within three (3) business days, and the Legal Department must be notified immediately once the transaction has occurred, together with all material terms of the transaction, including trade date, accounts(s), price, and quantity.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">A Form 4 reporting a change in beneficial ownership is generally due within </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">two (2) business days </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">after execution of the transaction. The date of the transaction is considered to be the &#8220;trade date&#8221; of the transaction, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">not the &#8220;settlement date&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">which, in the case of market transactions, takes place three business days after the trade date.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">While inheritances of Avadel stock are reportable at the end of a fiscal year, it is Avadel&#8217;s practice to file the required forms as promptly as possible following the receipt of the inheritance.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The preclearance procedures outlined above usually provides the Legal Department with sufficient notice to analyze a transaction to determine whether a Section 16 filing is required, and if so, make a timely filing. However, you are encouraged to give as much advance notice as possible to ensure a timely filing.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Note that transactions under a 10b5-1 trading plan where the Section 16 Insider does not select the date of execution require the Section 16 Insider to be especially diligent about reporting the execution of the transaction to the Legal Department, since the particular transaction (as opposed to the plan itself) is not subject to preclearance.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In broker-executed transactions, the broker plays a key role in providing the Legal Department the necessary information to file a Form 4 on your behalf. As a result, Avadel requires that you </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">16</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">provide certain instructions to your broker (</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">Appendix A-2</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">). Section 16 Insiders must inform their broker-dealers that (a) they are subject to Section 16&#59; (b) the broker shall confirm that any trade by the Section 16 Insider or any of their Related Persons has been precleared by the Company&#59; and (c) the broker is to provide transaction information to the Section 16 Insider and&#47;or Compliance Officer on the day of any executed transaction.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This form imposes two requirements on the broker&#58;</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;Not to enter any order (except for orders under pre-approved Rule 10b5-1 plans) without first verifying with the Legal Department that your transaction was precleared and complying with the brokerage firm&#8217;s compliance procedures (for example, Rule 144)&#59; and</font></div><div style="margin-bottom:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;To report immediately to the Legal Department the details of every transaction involving Avadel shares, including gifts, transfers, pledges and all 10b5-1 transactions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Do I have any Section 16 reporting obligations after I cease being a Section 16 Insider&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Maybe. If you have had any transactions within six (6) months prior to ceasing to be a Section 16 Insider, then you are responsible for timely reporting any transactions that were non-exempt under the Short-Swing Profit Rule (as defined below) occurring within that six-month period, even after you cease being a Section 16 Insider in the case of opposite-way transactions (i.e., a purchase and sale or a sale and purchase). The subsection below titled &#8220;Short-Swing Profit Rule&#8221; provides an explanation of the rule, short-swing transactions and available exemptions. Please consult with the Legal Department to determine whether you will need to report any transactions after you cease being a Section 16 Insider.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">What are the penalties for failing to timely report a transaction under Section 16&#63;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Any late or delinquent Section 16 filings are required to be reported in Avadel&#8217;s proxy statement in a separate captioned section, identifying the delinquent reporting person and the type of transaction. In more egregious cases, the SEC may impose fines or other sanctions on the delinquent reporting person. The SEC has broad authority to seek &#8220;any equitable relief that may be appropriate or necessary for the benefit of investors&#8221; for violations of any provisions of the securities laws.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">B.&#160;&#160;&#160;&#160;Short-Swing Profit Rule</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">If you (or a Related Person) </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Avadel shares in a non-exempt transaction (exemptions are discussed below), then you (or your Related Persons) cannot </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">sell</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> any Avadel shares in a non-exempt transaction until six (6) months have elapsed. Similarly, if you </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">sell</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> Avadel shares in a non-exempt transaction, then you cannot </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">purchase</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> any Avadel shares in a non-exempt transaction until six (6) months have elapsed.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Under federal securities laws, </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">if you purchase Avadel shares and then sell Avadel shares within any six-month period (or sell and then purchase) in non-exempt transactions, and those two transactions generate a profit for you (a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">short-swing profit</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#8221;), then you must repay the short-swing profit to Avadel</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">. The &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Short-Swing Profit Rule</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; is absolute, and there is no requirement </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">17</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">that inside information actually be used in connection with the transaction in order for Avadel to be entitled to recover the profits of the transaction. The fact that you acted in good faith or that you had a legitimate reason for the transaction is no defense. It is irrelevant whether the sale or the purchase occurred first, and it makes no difference whether the same certificates or shares of stock are involved in both transactions or whether the proceeds of a sale are utilized to make a subsequent purchase. Furthermore, the terms &#8220;sale&#8221; and &#8220;purchase&#8221; are broadly construed to cover a wide variety of transactions.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The forms filed pursuant to Section 16 are public documents and are available to anyone. Certain attorneys make their living by reviewing these filings&#59; when they discover a violation, they purchase one share of stock to become a shareholder of a company. Thereafter, pursuant to Section 16 they make demand on the company to recover the short-swing profit. The courts repeatedly have upheld this practice. Thus, it is probable that any short-swing transaction will result in recovery by Avadel of any profit. For this reason, Avadel has decided to prohibit short-swing transactions. Section 16 Insiders must continue to monitor their transactions in Avadel stock for a period of six (6) months from the date of their last transaction as a Section 16 Insider to ensure compliance with this prohibition.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">The SEC has by rule created certain exemptions from the short-swing profit provisions for (a) certain employee benefit plans, including stock option, bonus, profit sharing, retirement, employee stock ownership plan or other similar plans, (b) the exercise or conversion of a derivative security, including an employee stock option, (c) the acquisition and&#47;or disposition of shares of stock pursuant to bona fide gifts and transfers of shares of stock by will or the laws of descent and distribution, and (d) the acquisition of shares of stock pursuant to a typical dividend reinvestment plan. Note that many of these transactions must still be reported on a Form 4.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">C.&#160;&#160;&#160;&#160;Short Sales and Sales Against the Box</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Section 16 prohibits Section 16 Insiders from engaging in any &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">short sales</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; and certain &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">sales against the box</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; of Avadel&#8217;s shares.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">In a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">short sale</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; the seller attempts to profit from an anticipated drop in market price by selling shares he&#47;she does not then own and covering with borrowed shares or shares bought after the decline in the market price. In a &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">sale against the box</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">,&#8221; the seller owns the shares in question but covers his&#47;her sale with borrowed shares or other shares bought after the sale while holding shares already owned &#8220;in the box.&#8221; A sale against the box is often used at year end to postpone the tax consequences of a sale into the following year. Sales against the box are prohibited unless the seller actually delivers his shares within twenty (20) days or deposits the shares in the mail within five (5) days.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">D.&#160;&#160;&#160;&#160;Rule 144 Requirements</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">When selling Avadel shares, you are responsible for ensuring compliance with Rule 144&#8217;s volume, manner of sale and notice requirements.</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Avadel securities held by its directors and executive officers are known as &#8220;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">control</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8221; securities. Rule 144 of the SEC&#8217;s regulations impose certain restrictions on the transfer of control securities. Generally, transfer is permitted as long as (a) the amounts of securities that may be </font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">18</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">sold during any three-month period does not exceed the greater of one percent (1%) of the total shares outstanding or the average weekly trading volume over the preceding four weeks, and (b) the securities are sold in unsolicited brokers&#8217; transactions or transactions directly with a market maker. In addition, notice to the SEC is required if the number of securities sold exceeds five thousand (5,000) shares or the aggregate sale price exceeds fifty thousand dollars ($50,000) in a three-month period.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VII.&#160;&#160;&#160;&#160;Amendments or Waivers to these Special Procedures</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Amendments or waivers to these Special Procedures (excluding any Appendices) affecting members of the Board of Directors, other than those involving administrative procedures, must be approved by the Board of Directors. All other amendments to these Special Procedures must be approved by the Compliance Officer and the Chief Executive Officer.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">VIII.&#160;&#160;&#160;&#160;Certification</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">On request of the Compliance Officer from time to time, Section 16 Insiders are required to certify that they have read, understand and will comply with this Policy, including the Special Procedures.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">19</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A-1</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">STOCK TRANSACTION REQUEST</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Pursuant to Avadel Pharmaceuticals plc&#8217;s Insider Trading Policy, I hereby notify Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) of my intent to trade the securities of the Company as indicated below&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">REQUESTER INFORMATION</font></td></tr><tr><td colspan="9" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Insider&#8217;s Name&#58;  </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INTENT TO PURCHASE</font></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares&#58;</font></td><td colspan="6" style="border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intended trade date&#58;</font></td><td colspan="6" style="border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Means of acquiring shares&#58;</font></td><td colspan="6" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Acquisition through employee benefit plan (please specify)&#58;</font></div><div style="margin-bottom:6pt;padding-left:37.82pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Purchase through a broker on the open market</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other (please specify)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">INTENT TO SELL</font></td><td colspan="6" style="border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Number of shares&#58;</font></td><td colspan="6" style="border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Intended trade date&#58;</font></td><td colspan="6" style="border-right:0.5pt solid #000000;padding:0 1pt"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Means of selling shares&#58;</font></td><td colspan="6" style="border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sale through employee benefit plan (please specify)&#58;</font></div><div style="margin-bottom:6pt;padding-left:37.82pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div><div style="margin-bottom:6pt;padding-left:2.77pt;padding-right:2.77pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Sale through a broker on the open market</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Other (please specify)&#58;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">SECTION 16</font></td><td colspan="3" style="border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%">RULE 144 (Not applicable if transaction requested involves a purchase)</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:24.12pt;padding-right:2.77pt;text-indent:-21.35pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;I am not subject to Section 16.</font></div><div style="margin-bottom:6pt;padding-left:24.12pt;padding-right:2.77pt;text-indent:-21.35pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the best of my knowledge, I have not (and am not deemed to have) engaged in an opposite way transaction within the previous 6 months that was not exempt from Section 16(b) of the Exchange Act.</font></div><div style="margin-bottom:6pt;padding-left:24.12pt;padding-right:2.77pt;text-indent:-21.35pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None of the above.</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:6pt;padding-left:24.62pt;padding-right:2.77pt;text-indent:-21.85pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;I am not an &#8220;affiliate&#8221; of the Company and the transaction requested above does not involve the sale of &#8220;restricted securities&#8221; (as such terms are defined under Rule 144 under the Securities Act of 1933, as amended).</font></div><div style="margin-bottom:6pt;padding-left:24.62pt;padding-right:2.77pt;text-indent:-21.85pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;To the best of my knowledge, the transaction requested above will meet all applicable conditions of Rule 144.</font></div><div style="margin-bottom:6pt;padding-left:24.62pt;padding-right:2.77pt;text-indent:-21.85pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;The transaction requested is being made pursuant to an effective registration statement covering such transaction.</font></div><div style="margin-bottom:6pt;padding-left:24.62pt;padding-right:2.77pt;text-indent:-21.85pt"><font style="font-family:'Wingdings',sans-serif;font-size:12pt;font-weight:400;line-height:120%"></font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;None of the above.</font></div></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">CERTIFICATION</font></td></tr></table></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">20</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:25.823%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:21.976%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.901%"></td><td style="width:0.1%"></td></tr><tr><td colspan="9" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">I hereby certify that I am not (1) in possession of any material, nonpublic information concerning the Company, as defined in the Company&#8217;s Statement of Company Policy on Insider Trading and Disclosure and (2) purchasing any securities of the Company on margin in contravention of the Company&#8217;s Insider Trading Policy.  I understand that, if I trade while possessing such information or in violation of such trading restrictions, I may be subject to severe civil and&#47;or criminal penalties, and may be subject to discipline by the Company including termination.</font></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Insider&#8217;s Signature</font></div></td><td colspan="3" style="border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Date</font></div></td></tr><tr><td colspan="6" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">AUTHORIZED APPROVAL</font></td><td colspan="3" style="border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="6" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Signature of Compliance Officer (or designee)</font></div></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-right:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><br>Date</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">*NOTE&#58; Multiple lots must be listed on separate forms or broken out herein.</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">21</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX A-2</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">INSTRUCTIONS TO BROKER</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">As a &#8220;Section 16 Insider&#8221; of Avadel Pharmaceuticals plc, I am sending these instructions to you in order to assure compliance with the two-day filing requirement for officers and directors and others (including family members) subject to Section 16 of the Securities Exchange Act of 1934, as amended. Please acknowledge receipt of these instructions.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">1.&#160;&#160;&#160;&#160;I authorize you, my securities broker, to implement procedures for reporting to Avadel all my transactions (including those of my family members and other entities attributable to me under Section 16 whose transactions you execute) involving Avadel stock, including transfers such as gifts, pledges, hedges, etc., and other changes in beneficial ownership.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">2.&#160;&#160;&#160;&#160;Prior to executing any instruction from me involving Avadel stock, you will verify with Avadel (via the contact persons set forth below) that my proposed order or instruction has been approved. You also agree to adhere to your brokerage firm&#8217;s Rule 144 procedures and all other relevant compliance procedures.</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">3.&#160;&#160;&#160;&#160;Immediately upon execution of any transaction or instruction involving Avadel stock (including Rule 10b5-1 or limit order transactions), you agree to provide all the details of the transaction to Avadel (via all the contact persons set forth below), both by telephone (primary contact) and by e-mail (primary and all secondary contacts).</font></div><div style="margin-bottom:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">4.&#160;&#160;&#160;&#160;Avadel contact persons&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:26.784%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:71.016%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Primary contact&#58;</font></td><td colspan="3" style="border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></div></td></tr><tr><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt 2px 3.77pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:100%">Secondary contact&#58;</font></td><td colspan="3" style="border-bottom:0.5pt solid #000000;border-left:0.5pt solid #000000;border-right:0.5pt solid #000000;border-top:0.5pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Telephone&#58;</font></div><div style="padding-left:2.77pt;padding-right:2.77pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Email&#58;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name of Section 16 Insider&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature of Section 16 Insider&#58;</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">22</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div><hr style="page-break-after:always"><div style="min-height:33.84pt;width:100%"><div style="margin-bottom:12pt"><font><br></font></div></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%;text-decoration:underline">APPENDIX B</font></div><div style="margin-bottom:12pt;text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">ACKNOWLEDGEMENT</font></div><div style="margin-bottom:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I hereby acknowledge that I have read, that I understand, and that I agree to comply with the Insider Trading Policy of Avadel Pharmaceuticals plc (the &#8220;Company&#8221;).  I further acknowledge and agree that I am responsible for ensuring compliance with the Insider Trading Policy by all my &#8220;Related Persons.&#8221; </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%"> </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">I also understand and agree that I will be subject to sanctions, including termination of employment, that may be imposed by the Company, in its sole discretion, for violation of the Insider Trading Policy, and that the Company may give stop-transfer and other instructions to the Company&#8217;s transfer agent or any brokerage firm managing the Company&#8217;s equity incentive plan(s) against the transfer of any Company securities the Company considers to be in contravention of the Insider Trading Policy.</font></div><div style="margin-bottom:30pt;text-indent:36pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">This acknowledgement constitutes consent for the Company to impose sanctions for violation of the Insider Trading Policy, including the Special Procedures, and to issue any stop-transfer orders to the Company&#8217;s transfer agent that the Company, in its sole discretion, deems appropriate to ensure compliance.</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:33.12pt;padding-right:2.77pt;text-indent:-30.35pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Date&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:60.57pt;padding-right:2.77pt;text-indent:-57.8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Signature&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:60.57pt;padding-right:2.77pt;text-indent:-57.8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Name&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:12pt;padding-left:60.57pt;padding-right:2.77pt;text-indent:-57.8pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Title&#58;&#160;&#160;&#160;&#160;</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%;text-decoration:underline">&#160;&#160;&#160;&#160;</font></div></td></tr></table></div><div><font><br></font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:120%">Please send signed Acknowledgement to&#58;</font></div><div style="margin-bottom:12pt"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Jerad G. Seurer<br>Compliance Officer, General Counsel and Corporate Secretary<br>Avadel Pharmaceuticals<br>16640 Chesterfield Grove Road, Suite 200<br>Chesterfield, MO 63005<br>jseurer&#64;avadel.com</font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">Page </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> of </font><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:700;line-height:120%">23</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>12
<FILENAME>a123124ex-211.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i75db9036496a4475a537c2012849437c_1"></div><div style="min-height:54pt;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 21.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:11pt;font-weight:700;line-height:120%">List of Subsidiaries</font></div><div style="margin-top:5pt;padding-left:4.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.958%"><tr><td style="width:1.0%"></td><td style="width:72.433%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.551%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:24.616%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Name</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Jurisdiction</font></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (the Registrant)&#58; </font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1) Avadel US Holdings, Inc. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(f&#47;k&#47;a Flamel US Holdings, Inc.)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Delaware)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Avadel Management, LLC</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Delaware)</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">B. Avadel CNS Pharmaceuticals, LLC</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">United States (Delaware)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2) Flamel Ireland Ltd. </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(d&#47;b&#47;a Avadel Ireland)</font></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3) Avadel Investment Company, Ltd. </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4) Avadel France Holding SAS</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Avadel Research SAS </font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">France</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5) Avadel Finance Ireland Designated Activity Company</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Ireland</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A. Avadel Finance Cayman Ltd.</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cayman Islands</font></td></tr></table></div><div><font><br></font></div><div style="height:54pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="margin-bottom:10pt"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>13
<FILENAME>a123124ex-231.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i8d03d4421e1445e39c2cdd90d1583138_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div><font><br></font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </font></div><div><font><br></font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We consent to the incorporation by reference in Registration Statement Nos. 333-213154, 333-212585, 333-177591, 333-219016, 333-252956 333-263620, and 333-279501 on Form S-8 and Registration Statement Nos. 333-183961, 333-236258, 333-237962 and 333-267198 on Form S-3 of our reports dated March&#160;3, 2025 relating to the financial statements of Avadel Pharmaceuticals plc and the effectiveness of Avadel Pharmaceuticals plc&#8217;s internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended December&#160;31, 2024. </font></div><div><font><br></font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte and Touche LLP</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">St. Louis, Missouri </font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">March&#160;3, 2025 </font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>14
<FILENAME>a123124ex-311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i64acfa9ca8364a70957a4f478acbf6ed_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.1</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Gregory J. Divis, certify that&#58;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Avadel Pharmaceuticals plc&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59;&#160;and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; March&#160;3, 2025</font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:63.175%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:34.625%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Gregory J. Divis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Divis</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>15
<FILENAME>a123124ex-312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i079d72b5b3ae42ccb216596adfbfc5bc_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-bottom:5pt;margin-top:5pt;text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CERTIFICATION </font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="margin-bottom:9pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Thomas S. McHugh, certify that&#58;&#160;</font></div><div style="margin-bottom:9pt;text-align:justify;text-indent:18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1. I have reviewed this Annual Report on Form 10-K of Avadel Pharmaceuticals plc&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4. The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c) Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d) Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting&#59; and&#160;</font></div><div style="margin-bottom:9pt;padding-left:18pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5. The registrant&#8217;s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions)&#58;&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information&#59; and&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.&#160;</font></div><div style="margin-bottom:9pt;padding-left:36pt;text-align:justify"><font><br></font></div><div style="margin-bottom:9pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:58.490%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:39.310%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date&#58; March&#160;3, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Thomas S. McHugh</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas S. McHugh</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>16
<FILENAME>a123124ex-321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="ia68bd6f4d147439ea353bc8c8fa0ef19_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report on Form 10-K of Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) for the period ended December&#160;31, 2024 (the &#8220;Report&#8221;), the undersigned hereby certifies in his capacity as Chief Executive Officer of the Company pursuant to 18&#160;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d))&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-36pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Gregory J. Divis</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Gregory J. Divis</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Chief Executive Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avadel Pharmaceuticals plc</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;3, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>17
<FILENAME>a123124ex-322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i3a4905838a494500a7e0fae12353fb2b_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.2</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the annual report of Form 10-K of Avadel Pharmaceuticals plc (the &#8220;Company&#8221;) for the period ended December&#160;31, 2024 (the &#34;Report&#34;), the undersigned hereby certifies in his capacity as Chief Financial Officer of the Company pursuant to 18&#160;U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge&#58;</font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:6.34pt">The Report fully complies with the requirements of Section&#160;13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C. 78m or 78</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">o</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(d))&#59; and</font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:6.34pt">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:43.995%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:53.805%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#47;s&#47;&#160;&#160;&#160;&#160;Thomas S. McHugh</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Thomas S. McHugh</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice President and Chief Financial Officer</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Avadel Pharmaceuticals plc</font></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">March&#160;3, 2025</font></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</font></td></tr></table></div><div style="text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>18
<FILENAME>avdl-20241231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:avdl="http://www.avadel.com/20241231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types1="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.avadel.com/20241231">
  <xs:import namespace="http://fasb.org/srt/2024" schemaLocation="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2024" schemaLocation="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/country/2024" schemaLocation="https://xbrl.sec.gov/country/2024/country-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2024" schemaLocation="https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2024" schemaLocation="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avdl-20241231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avdl-20241231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avdl-20241231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="avdl-20241231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.avadel.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.avadel.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofLoss" roleURI="http://www.avadel.com/role/ConsolidatedStatementsofLoss">
        <link:definition>9952151 - Statement - Consolidated Statements of Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLoss" roleURI="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss">
        <link:definition>9952152 - Statement - Consolidated Statements of Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofComprehensiveLossParenthetical" roleURI="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical">
        <link:definition>9952153 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.avadel.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952154 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952155 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofShareholdersEquity" roleURI="http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity">
        <link:definition>9952156 - Statement - Consolidated Statements of Shareholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952157 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NewlyIssuedAccountingStandards" roleURI="http://www.avadel.com/role/NewlyIssuedAccountingStandards">
        <link:definition>9952159 - Disclosure - Newly Issued Accounting Standards</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognition" roleURI="http://www.avadel.com/role/RevenueRecognition">
        <link:definition>9952160 - Disclosure - Revenue Recognition</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurements" roleURI="http://www.avadel.com/role/FairValueMeasurements">
        <link:definition>9952161 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecurities" roleURI="http://www.avadel.com/role/MarketableSecurities">
        <link:definition>9952162 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Inventories" roleURI="http://www.avadel.com/role/Inventories">
        <link:definition>9952163 - Disclosure - Inventories</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnet" roleURI="http://www.avadel.com/role/PropertyandEquipmentnet">
        <link:definition>9952164 - Disclosure - Property and Equipment, net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Goodwill" roleURI="http://www.avadel.com/role/Goodwill">
        <link:definition>9952165 - Disclosure - Goodwill</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Leases" roleURI="http://www.avadel.com/role/Leases">
        <link:definition>9952166 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligation" roleURI="http://www.avadel.com/role/RoyaltyFinancingObligation">
        <link:definition>9952167 - Disclosure - Royalty Financing Obligation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.avadel.com/role/IncomeTaxes">
        <link:definition>9952168 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilities" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilities">
        <link:definition>9952169 - Disclosure - Other Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentLiabilitiesandCommitments" roleURI="http://www.avadel.com/role/ContingentLiabilitiesandCommitments">
        <link:definition>9952170 - Disclosure - Contingent Liabilities and Commitments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInstrumentsandTransactions" roleURI="http://www.avadel.com/role/EquityInstrumentsandTransactions">
        <link:definition>9952171 - Disclosure - Equity Instruments and Transactions</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensation" roleURI="http://www.avadel.com/role/ShareBasedCompensation">
        <link:definition>9952172 - Disclosure - Share-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.avadel.com/role/NetLossPerShare">
        <link:definition>9952173 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComprehensiveLoss" roleURI="http://www.avadel.com/role/ComprehensiveLoss">
        <link:definition>9952174 - Disclosure - Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.avadel.com/role/SegmentInformation">
        <link:definition>9952175 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccounts" roleURI="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts">
        <link:definition>9952176 - Disclosure - Schedule II - Valuation and Qualifying Accounts</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionTables" roleURI="http://www.avadel.com/role/RevenueRecognitionTables">
        <link:definition>9955513 - Disclosure - Revenue Recognition (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementsTables" roleURI="http://www.avadel.com/role/FairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesTables" roleURI="http://www.avadel.com/role/MarketableSecuritiesTables">
        <link:definition>9955515 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesTables" roleURI="http://www.avadel.com/role/InventoriesTables">
        <link:definition>9955516 - Disclosure - Inventories (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetTables" roleURI="http://www.avadel.com/role/PropertyandEquipmentnetTables">
        <link:definition>9955517 - Disclosure - Property and Equipment, net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesTables" roleURI="http://www.avadel.com/role/LeasesTables">
        <link:definition>9955518 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationTables" roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationTables">
        <link:definition>9955519 - Disclosure - Royalty Financing Obligation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.avadel.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesTables" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesTables">
        <link:definition>9955521 - Disclosure - Other Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationTables" roleURI="http://www.avadel.com/role/ShareBasedCompensationTables">
        <link:definition>9955522 - Disclosure - Share-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.avadel.com/role/NetLossPerShareTables">
        <link:definition>9955523 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComprehensiveLossTables" roleURI="http://www.avadel.com/role/ComprehensiveLossTables">
        <link:definition>9955524 - Disclosure - Comprehensive Loss (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.avadel.com/role/SegmentInformationTables">
        <link:definition>9955525 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesNarrativeDetails" roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails">
        <link:definition>9955526 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails" roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails">
        <link:definition>9955527 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails" roleURI="http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails">
        <link:definition>9955528 - Disclosure - Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RevenueRecognitionNarrativeDetails" roleURI="http://www.avadel.com/role/RevenueRecognitionNarrativeDetails">
        <link:definition>9955529 - Disclosure - Revenue Recognition - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="FairValueMeasurementDetails" roleURI="http://www.avadel.com/role/FairValueMeasurementDetails">
        <link:definition>9955530 - Disclosure - Fair Value Measurement (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" roleURI="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails">
        <link:definition>9955531 - Disclosure - Marketable Securities - Summary of Available-for-sale Securities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesNarrativeDetails" roleURI="http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails">
        <link:definition>9955532 - Disclosure - Marketable Securities - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesScheduleofContractualMaturityDatesDetails" roleURI="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails">
        <link:definition>9955533 - Disclosure - Marketable Securities - Schedule of Contractual Maturity Dates (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="InventoriesDetails" roleURI="http://www.avadel.com/role/InventoriesDetails">
        <link:definition>9955534 - Disclosure - Inventories (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyandEquipmentnetDetails" roleURI="http://www.avadel.com/role/PropertyandEquipmentnetDetails">
        <link:definition>9955535 - Disclosure - Property and Equipment, net (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="GoodwillDetails" roleURI="http://www.avadel.com/role/GoodwillDetails">
        <link:definition>9955536 - Disclosure - Goodwill (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesNarrativeDetails" roleURI="http://www.avadel.com/role/LeasesNarrativeDetails">
        <link:definition>9955537 - Disclosure - Leases - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesComponentsofleasecostsDetails" roleURI="http://www.avadel.com/role/LeasesComponentsofleasecostsDetails">
        <link:definition>9955538 - Disclosure - Leases - Components of lease costs (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofoperatingleaseliabilitiesDetails" roleURI="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails">
        <link:definition>9955539 - Disclosure - Leases - Maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LeasesMaturitiesofoperatingleaseliabilitiesDetails_1" roleURI="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1">
        <link:definition>9955539 - Disclosure - Leases - Maturities of operating lease liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationNarrativeDetails" roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails">
        <link:definition>9955540 - Disclosure - Royalty Financing Obligation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RoyaltyFinancingObligationActivityDetails" roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails">
        <link:definition>9955541 - Disclosure - Royalty Financing Obligation - Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" roleURI="http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails">
        <link:definition>9955542 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesIncomeTaxBenefitDetails" roleURI="http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails">
        <link:definition>9955543 - Disclosure - Income Taxes - Income Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesReconciliationofTaxRateDetails" roleURI="http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails">
        <link:definition>9955544 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955545 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesUnrecognizedTaxBenefitDetails" roleURI="http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails">
        <link:definition>9955546 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesDeferredTaxesDetails" roleURI="http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Deferred Taxes (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails">
        <link:definition>9955548 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails">
        <link:definition>9955549 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesAccruedExpensesDetails" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails">
        <link:definition>9955550 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails" roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails">
        <link:definition>9955551 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ContingentLiabilitiesandCommitmentsDetails" roleURI="http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails">
        <link:definition>9955552 - Disclosure - Contingent Liabilities and Commitments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityInstrumentsandTransactionsDetails" roleURI="http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails">
        <link:definition>9955553 - Disclosure - Equity Instruments and Transactions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockbasedCompensationExpenseDetails" roleURI="http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails">
        <link:definition>9955554 - Disclosure - Share-Based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationNarrativeDetails" roleURI="http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails">
        <link:definition>9955555 - Disclosure - Share-Based Compensation - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationFairValueAssumptionsDetails" roleURI="http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails">
        <link:definition>9955556 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationStockOptionsDetails" roleURI="http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails">
        <link:definition>9955557 - Disclosure - Share-Based Compensation - Stock Options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ShareBasedCompensationRestrictedShareActivityDetails" roleURI="http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails">
        <link:definition>9955558 - Disclosure - Share-Based Compensation - Restricted Share Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails" roleURI="http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails">
        <link:definition>9955559 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareNarrativeDetails" roleURI="http://www.avadel.com/role/NetLossPerShareNarrativeDetails">
        <link:definition>9955560 - Disclosure - Net Loss Per Share - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ComprehensiveLossDetails" roleURI="http://www.avadel.com/role/ComprehensiveLossDetails">
        <link:definition>9955561 - Disclosure - Comprehensive Loss (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationNarrativeDetails" roleURI="http://www.avadel.com/role/SegmentInformationNarrativeDetails">
        <link:definition>9955562 - Disclosure - Segment Information - Narrative (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" roleURI="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails">
        <link:definition>9955563 - Disclosure - Segment Information - Segment Reporting Information, About the Company&#8217;s Significant Expenses (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationLongLivedAssetsbyGeographicRegionDetails" roleURI="http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails">
        <link:definition>9955564 - Disclosure - Segment Information - Long-Lived Assets by Geographic Region (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ScheduleIIValuationandQualifyingAccountsDetails" roleURI="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails">
        <link:definition>9955565 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="avdl_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="avdl_RoyaltyFinancingLiabilityNoncurrent" abstract="false" name="RoyaltyFinancingLiabilityNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_AtTheMarketOfferingProgramMember" abstract="true" name="AtTheMarketOfferingProgramMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_PublicOfferingMember" abstract="true" name="PublicOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_April2027NotesMember" abstract="true" name="April2027NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_October2023NotesMember" abstract="true" name="October2023NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" abstract="false" name="AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_February2023NotesMember" abstract="true" name="February2023NotesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_EquityTransactionsDisclosureTextBlock" abstract="false" name="EquityTransactionsDisclosureTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_NatureOfBusinessPolicyPolicyTextBlock" abstract="false" name="NatureOfBusinessPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_LiquidityAndGoingConcernPolicyTextBlock" abstract="false" name="LiquidityAndGoingConcernPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" abstract="false" name="ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" abstract="false" name="ScheduleOfIncomeTaxPaymentsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" abstract="false" name="ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" abstract="false" name="ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:textBlockItemType"/>
  <xs:element id="avdl_ThreeCustomersMember" abstract="true" name="ThreeCustomersMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_CaremarkLLCMember" abstract="true" name="CaremarkLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_AccredoHealthGroupInc.Member" abstract="true" name="AccredoHealthGroupInc.Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_OptumFrontierTherapiesLLCMember" abstract="true" name="OptumFrontierTherapiesLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" abstract="true" name="FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_NumberOfFinancialInstitutions" abstract="false" name="NumberOfFinancialInstitutions" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" abstract="true" name="SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" abstract="true" name="LeaseholdImprovementsFurnitureFixturesAndFittingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_CaremarkMember" abstract="true" name="CaremarkMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_AccredoMember" abstract="true" name="AccredoMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_OptumMember" abstract="true" name="OptumMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" abstract="false" name="OperatingLeaseLiabilityToBePaidAfterYearFour" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_RoyaltyFinancingMember" abstract="true" name="RoyaltyFinancingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_RoyaltyFinancingProceedsMaximum" abstract="false" name="RoyaltyFinancingProceedsMaximum" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_DebtInstrumentNumberOfTranches" abstract="false" name="DebtInstrumentNumberOfTranches" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" abstract="false" name="RoyaltyFinancingQuarterlyNetRevenueTarget" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_PaymentsForRoyaltyOneTimeCommitmentFee" abstract="false" name="PaymentsForRoyaltyOneTimeCommitmentFee" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" abstract="false" name="RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="avdl_DebtInstrumentIncreaseDecreaseNetRollForward" abstract="true" name="DebtInstrumentIncreaseDecreaseNetRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="avdl_RepaymentOfRoyaltyLiability" abstract="false" name="RepaymentOfRoyaltyLiability" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_IncomeTaxesTable" abstract="true" name="IncomeTaxesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="avdl_IncomeTaxesLineItems" abstract="true" name="IncomeTaxesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" abstract="false" name="EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" abstract="false" name="EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_FscHoldingsLlcMember" abstract="true" name="FscHoldingsLlcMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_U.S.HoldingsMember" abstract="true" name="U.S.HoldingsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_A163jCreditsMember" abstract="true" name="A163jCreditsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_OrphanDrugTaxCreditMember" abstract="true" name="OrphanDrugTaxCreditMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" abstract="false" name="IncreaseDecreaseInIncomeTaxExpenseBenefit" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_DeferredTaxAssetsRoyaltyIncome" abstract="false" name="DeferredTaxAssetsRoyaltyIncome" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" abstract="false" name="DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" abstract="false" name="DeferredTaxAssetsAmortizationOfIntangibleAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" abstract="false" name="OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_OtherNoncurrentReceivables" abstract="false" name="OtherNoncurrentReceivables" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_RemainingPerformanceObligationReserveCurrent" abstract="false" name="RemainingPerformanceObligationReserveCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_RoyaltyFinancingLiabilityCurrent" abstract="false" name="RoyaltyFinancingLiabilityCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" abstract="false" name="TaxLiabilitiesAndOtherNoncurrentLiabilities" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_FirstJazzComplaintMember" abstract="true" name="FirstJazzComplaintMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_ContractualObligationAnnualAmount" abstract="false" name="ContractualObligationAnnualAmount" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_ShelfRegistrationStatementOnFormS3Member" abstract="true" name="ShelfRegistrationStatementOnFormS3Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_AmericanDepositarySharesMember" abstract="true" name="AmericanDepositarySharesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_AmericanDepositorySharesConversionRatio" abstract="false" name="AmericanDepositorySharesConversionRatio" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:pureItemType"/>
  <xs:element id="avdl_SaleOfStockSalesAgentCommissionPercent" abstract="false" name="SaleOfStockSalesAgentCommissionPercent" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:percentItemType"/>
  <xs:element id="avdl_SaleOfStockMaximumAggregateOfferingPrice" abstract="false" name="SaleOfStockMaximumAggregateOfferingPrice" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="avdl_RestrictedShareAwardsGrantedToEmployeesMember" abstract="true" name="RestrictedShareAwardsGrantedToEmployeesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" abstract="true" name="VestUponTheAchievementOfCertainRegulatoryMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_VestOneYearFollowingAchievementOfMilestonesMember" abstract="true" name="VestOneYearFollowingAchievementOfMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_ShareBasedPaymentArrangementTrancheFourMember" abstract="true" name="ShareBasedPaymentArrangementTrancheFourMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="avdl_InducementPlanMember" abstract="true" name="InducementPlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_A2017AvadelEmployeeSharePurchasePlanMember" abstract="true" name="A2017AvadelEmployeeSharePurchasePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:domainItemType"/>
  <xs:element id="avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types1:perShareItemType"/>
  <xs:element id="avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="avdl_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>19
<FILENAME>avdl-20241231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofLoss" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofLoss"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_50931fd3-4ccf-4a63-b60b-108dbaea1d0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c73c744-d87f-4266-bd9b-0637a069b6f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_50931fd3-4ccf-4a63-b60b-108dbaea1d0e" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_7c73c744-d87f-4266-bd9b-0637a069b6f6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a834c8c8-42d8-4b0e-b5f8-783a9cc33279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_50931fd3-4ccf-4a63-b60b-108dbaea1d0e" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_a834c8c8-42d8-4b0e-b5f8-783a9cc33279" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_fc1986da-9fa2-4e6f-aa24-2ebef0d69f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_60636634-a1fe-40c9-9989-7d12aad2117e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fc1986da-9fa2-4e6f-aa24-2ebef0d69f8c" xlink:to="loc_us-gaap_GrossProfit_60636634-a1fe-40c9-9989-7d12aad2117e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_b7001c26-0666-4db2-8020-ce726db0715d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_fc1986da-9fa2-4e6f-aa24-2ebef0d69f8c" xlink:to="loc_us-gaap_OperatingExpenses_b7001c26-0666-4db2-8020-ce726db0715d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_263d2779-7349-4fd8-9511-bbc5620c3d76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_6a68ef0d-9716-4fd3-ab26-690de0516d81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_263d2779-7349-4fd8-9511-bbc5620c3d76" xlink:to="loc_us-gaap_InterestExpenseDebt_6a68ef0d-9716-4fd3-ab26-690de0516d81" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_7e9f8b58-9a74-44e1-9a9a-4caecec9c73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_263d2779-7349-4fd8-9511-bbc5620c3d76" xlink:to="loc_us-gaap_InvestmentIncomeNet_7e9f8b58-9a74-44e1-9a9a-4caecec9c73d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_1583d6ca-c9c2-4d36-84f1-440fa3d944be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_263d2779-7349-4fd8-9511-bbc5620c3d76" xlink:to="loc_us-gaap_OperatingIncomeLoss_1583d6ca-c9c2-4d36-84f1-440fa3d944be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_80a5c6d5-774f-481e-9ca6-27c8930e30c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_263d2779-7349-4fd8-9511-bbc5620c3d76" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_80a5c6d5-774f-481e-9ca6-27c8930e30c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_cc7cbdab-7291-4392-a571-28311ddf0df7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bcabfca-562d-4918-8522-b451d953bb8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cc7cbdab-7291-4392-a571-28311ddf0df7" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_4bcabfca-562d-4918-8522-b451d953bb8c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_929bdd00-a7f1-42c3-b567-22814c6f4303" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_GrossProfit_cc7cbdab-7291-4392-a571-28311ddf0df7" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_929bdd00-a7f1-42c3-b567-22814c6f4303" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_dc808a94-a74d-4be8-892f-fed592fcdcda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_4b039b4f-5817-42a5-af55-cc1c9bec7e47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dc808a94-a74d-4be8-892f-fed592fcdcda" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_4b039b4f-5817-42a5-af55-cc1c9bec7e47" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3c533be-c917-4b66-96fb-ab7a70b85e88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dc808a94-a74d-4be8-892f-fed592fcdcda" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_b3c533be-c917-4b66-96fb-ab7a70b85e88" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_0890b084-c155-4b35-bcce-d5862e455f97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_dc808a94-a74d-4be8-892f-fed592fcdcda" xlink:to="loc_us-gaap_RestructuringCharges_0890b084-c155-4b35-bcce-d5862e455f97" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_509561cd-f760-4972-8dc8-be06bb8530b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c6c8ae84-5fbd-4360-9f91-5d759bdb1325" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_509561cd-f760-4972-8dc8-be06bb8530b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_c6c8ae84-5fbd-4360-9f91-5d759bdb1325" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9cd0c66-4398-4701-be15-70d12f60d675" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_509561cd-f760-4972-8dc8-be06bb8530b2" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_f9cd0c66-4398-4701-be15-70d12f60d675" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_70ed4ba1-2cb3-461e-8e7a-b0e8863ca4b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6f1c41fc-9361-4637-91a8-60f764619a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_70ed4ba1-2cb3-461e-8e7a-b0e8863ca4b0" xlink:to="loc_us-gaap_NetIncomeLoss_6f1c41fc-9361-4637-91a8-60f764619a02" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8d10c5e3-061b-4d8c-80b7-42f346dce516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_70ed4ba1-2cb3-461e-8e7a-b0e8863ca4b0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_8d10c5e3-061b-4d8c-80b7-42f346dce516" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_775f4c76-fb81-457c-b38b-84fab7a6440c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:to="loc_us-gaap_PreferredStockValue_775f4c76-fb81-457c-b38b-84fab7a6440c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_1cc17888-a5d9-405c-9465-cad0120a5cd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:to="loc_us-gaap_CommonStockValue_1cc17888-a5d9-405c-9465-cad0120a5cd2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3d37177d-94e6-40b7-9afb-32a6fd319454" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_3d37177d-94e6-40b7-9afb-32a6fd319454" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_614e038a-d889-41c8-b203-28c3c4fb1b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_614e038a-d889-41c8-b203-28c3c4fb1b3b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_05192f11-8211-4ba6-bfb4-020fc0108a82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_6dc9d879-b557-421c-8690-31a2384ae7bd" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_05192f11-8211-4ba6-bfb4-020fc0108a82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_243c17d0-36d5-4698-a491-f67a8e5ac888" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a144c57e-fae5-4c9d-aa68-1135d41fab09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_243c17d0-36d5-4698-a491-f67a8e5ac888" xlink:to="loc_us-gaap_Liabilities_a144c57e-fae5-4c9d-aa68-1135d41fab09" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_45a52dea-5b4a-4c1c-9017-cc60b2506f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_243c17d0-36d5-4698-a491-f67a8e5ac888" xlink:to="loc_us-gaap_StockholdersEquity_45a52dea-5b4a-4c1c-9017-cc60b2506f24" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e0a41a6c-a2e8-4d65-982e-e7485f87b6a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:to="loc_us-gaap_AssetsCurrent_e0a41a6c-a2e8-4d65-982e-e7485f87b6a5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_33d1c4ff-e701-499c-953b-4d5091e3b6a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_33d1c4ff-e701-499c-953b-4d5091e3b6a0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_28d187bd-a440-4da9-915f-404e97d05c3e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_28d187bd-a440-4da9-915f-404e97d05c3e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ab1eda00-f59b-404e-8600-f13515c2cb80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:to="loc_us-gaap_Goodwill_ab1eda00-f59b-404e-8600-f13515c2cb80" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_6104769b-176f-4f36-b24b-9939cf4735ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_03a03a0f-94ec-4171-98b2-5eb081a8e8d9" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_6104769b-176f-4f36-b24b-9939cf4735ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_1051de0d-682d-47ea-83e9-6dc752b7c843" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_b13786a6-4f89-46b1-98b1-3ee43ee7523a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1051de0d-682d-47ea-83e9-6dc752b7c843" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_b13786a6-4f89-46b1-98b1-3ee43ee7523a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_5c025af2-12f3-42e4-8ac6-09e401318ca4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1051de0d-682d-47ea-83e9-6dc752b7c843" xlink:to="loc_us-gaap_AccountsPayableCurrent_5c025af2-12f3-42e4-8ac6-09e401318ca4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_4eca43f8-66f2-47d4-bf00-42871303291f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1051de0d-682d-47ea-83e9-6dc752b7c843" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_4eca43f8-66f2-47d4-bf00-42871303291f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_18d13910-7ea0-44a2-981d-169192182cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_1051de0d-682d-47ea-83e9-6dc752b7c843" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_18d13910-7ea0-44a2-981d-169192182cf8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_17d01fb7-4cea-44db-9493-e8272299695a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_17d01fb7-4cea-44db-9493-e8272299695a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_f4d01c7f-64c4-43c4-a9b9-53daa4fb1931" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_f4d01c7f-64c4-43c4-a9b9-53daa4fb1931" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0dad9b9-dd1d-4f52-9830-87449b1c40e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b0dad9b9-dd1d-4f52-9830-87449b1c40e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_20448ffd-b809-4a7c-b16a-25f00e014958" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_20448ffd-b809-4a7c-b16a-25f00e014958" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_67f82e7a-89cf-42f1-b8d6-979aa23a99da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_5241b021-177e-43db-a8ab-7ceefae86c52" xlink:to="loc_us-gaap_InventoryNet_67f82e7a-89cf-42f1-b8d6-979aa23a99da" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_009431d8-5c2a-4886-8557-d99623540dc8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_e23d8186-74ab-4b3f-8b80-b198b6c3378d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009431d8-5c2a-4886-8557-d99623540dc8" xlink:to="loc_us-gaap_LiabilitiesCurrent_e23d8186-74ab-4b3f-8b80-b198b6c3378d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityNoncurrent_fa123f12-17cd-4668-9844-7cf088b77f01" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009431d8-5c2a-4886-8557-d99623540dc8" xlink:to="loc_avdl_RoyaltyFinancingLiabilityNoncurrent_fa123f12-17cd-4668-9844-7cf088b77f01" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb7b6271-27b6-4d00-bb1c-29fd2886f998" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009431d8-5c2a-4886-8557-d99623540dc8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_eb7b6271-27b6-4d00-bb1c-29fd2886f998" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_fe02cd37-995f-4af7-ab2d-58a415aafe78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_009431d8-5c2a-4886-8557-d99623540dc8" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_fe02cd37-995f-4af7-ab2d-58a415aafe78" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_795dc839-21e4-4cbe-b728-fabd1f0b0b07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_NetIncomeLoss_795dc839-21e4-4cbe-b728-fabd1f0b0b07" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_802ecc5f-1481-47cf-a271-edf7bddeb910" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_DepreciationAndAmortization_802ecc5f-1481-47cf-a271-edf7bddeb910" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_083ec043-00d6-42f0-bbb3-cc7e81750955" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_083ec043-00d6-42f0-bbb3-cc7e81750955" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3661ebbb-6925-4b75-8f6f-af05772303e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_3661ebbb-6925-4b75-8f6f-af05772303e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_8c7792d0-fb5a-4964-80b9-71c7255cfec6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_ShareBasedCompensation_8c7792d0-fb5a-4964-80b9-71c7255cfec6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1fe38fb1-05a3-4bef-a90a-c90772ceeb94" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_1fe38fb1-05a3-4bef-a90a-c90772ceeb94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b908e286-5e90-4f7c-b6e9-d563309b4637" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_b908e286-5e90-4f7c-b6e9-d563309b4637" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_462077b1-d82c-449f-a2e6-723b49c25895" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_462077b1-d82c-449f-a2e6-723b49c25895" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_652a1630-de4f-4ae9-8b95-8402654f696e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_652a1630-de4f-4ae9-8b95-8402654f696e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_d8ce01ba-6fca-4b0e-b8e4-57212ace5e83" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_d8ce01ba-6fca-4b0e-b8e4-57212ace5e83" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aec71821-7756-406f-92e7-3d28bdef5231" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_aec71821-7756-406f-92e7-3d28bdef5231" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_f2a43759-eb6c-4186-98b5-8d6e21045669" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_f2a43759-eb6c-4186-98b5-8d6e21045669" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3db1e47-3c96-4e61-9f31-68afaa618452" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="13" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_3f8d5b42-697e-4cfe-9b18-b697cf5c56fe" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_a3db1e47-3c96-4e61-9f31-68afaa618452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bd7e3-144b-48c6-9472-0d75ac4bfc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_dc3bd7e3-144b-48c6-9472-0d75ac4bfc1e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_705a4465-d26c-4486-bdf3-f99386723182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_705a4465-d26c-4486-bdf3-f99386723182" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b450348c-815a-483d-9dc2-a5dbaefaf84d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_b450348c-815a-483d-9dc2-a5dbaefaf84d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_926550b9-82a5-4747-94ed-4e387bbf5973" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_926550b9-82a5-4747-94ed-4e387bbf5973" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5e66e301-9fdd-4946-9cde-702fb812dc04" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7c263463-46c6-4581-b26b-b36a59c079cf" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_5e66e301-9fdd-4946-9cde-702fb812dc04" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_732f2486-5a3f-48f5-9f6b-5483c41ae404" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24ac4694-cc45-488b-a090-840494294965" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_732f2486-5a3f-48f5-9f6b-5483c41ae404" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_24ac4694-cc45-488b-a090-840494294965" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4f629098-dcab-43d5-b650-fb36ac5ef9f9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_732f2486-5a3f-48f5-9f6b-5483c41ae404" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_4f629098-dcab-43d5-b650-fb36ac5ef9f9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7771e714-9ef7-4554-8d63-868b5ef34bd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_732f2486-5a3f-48f5-9f6b-5483c41ae404" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_7771e714-9ef7-4554-8d63-868b5ef34bd6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34db207d-a818-40e6-9460-4892cf7c5c1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_414da1a9-44fb-43b1-a313-0facd567ebfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34db207d-a818-40e6-9460-4892cf7c5c1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_414da1a9-44fb-43b1-a313-0facd567ebfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4127c70-664b-4127-9ca0-cc55f3a77e8a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34db207d-a818-40e6-9460-4892cf7c5c1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_e4127c70-664b-4127-9ca0-cc55f3a77e8a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55acc8db-02da-4cb0-8141-40b085fcec13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34db207d-a818-40e6-9460-4892cf7c5c1a" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_55acc8db-02da-4cb0-8141-40b085fcec13" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b9b4e87-517c-4360-9c42-8d02977a1470" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_34db207d-a818-40e6-9460-4892cf7c5c1a" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_2b9b4e87-517c-4360-9c42-8d02977a1470" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#FairValueMeasurementDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_44f10b2a-d72a-449e-b51a-e5f48da44b74" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8ccbfc8-372d-4007-904f-39d52bdb8738" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsFairValueDisclosure_44f10b2a-d72a-449e-b51a-e5f48da44b74" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c8ccbfc8-372d-4007-904f-39d52bdb8738" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b2bc4a6-0c61-4bc0-baaa-c64b658b18b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5a4013d-6ff9-427e-b7b4-aadb3e9ba628" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b2bc4a6-0c61-4bc0-baaa-c64b658b18b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b5a4013d-6ff9-427e-b7b4-aadb3e9ba628" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4904a6da-ddb4-46fe-a089-eb02e651397a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b2bc4a6-0c61-4bc0-baaa-c64b658b18b9" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4904a6da-ddb4-46fe-a089-eb02e651397a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dbdc0a3b-5ee9-47e2-8e40-7ef0f60a3df3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_2b2bc4a6-0c61-4bc0-baaa-c64b658b18b9" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dbdc0a3b-5ee9-47e2-8e40-7ef0f60a3df3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesScheduleofContractualMaturityDatesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80a83a7b-3d9f-4a85-bfd8-4b3d33603970" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6d6e7a3-0829-47b0-a367-bb9c2cb828b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80a83a7b-3d9f-4a85-bfd8-4b3d33603970" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_d6d6e7a3-0829-47b0-a367-bb9c2cb828b1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_56d747ef-314b-4f35-960b-6391a35fb1b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80a83a7b-3d9f-4a85-bfd8-4b3d33603970" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_56d747ef-314b-4f35-960b-6391a35fb1b4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_390e1d52-509c-458c-aa48-0afc27c0b923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80a83a7b-3d9f-4a85-bfd8-4b3d33603970" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_390e1d52-509c-458c-aa48-0afc27c0b923" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_195cafb7-cc3d-4027-a499-63478eeefcc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_80a83a7b-3d9f-4a85-bfd8-4b3d33603970" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_195cafb7-cc3d-4027-a499-63478eeefcc7" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/InventoriesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#InventoriesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_f5c35095-1e3e-4a13-babe-eceb47976081" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_efa3e2f8-7408-49f6-9646-e441ad832152" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5c35095-1e3e-4a13-babe-eceb47976081" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_efa3e2f8-7408-49f6-9646-e441ad832152" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fc8bf8ec-c0a6-4a14-9939-06ebbc77560c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5c35095-1e3e-4a13-babe-eceb47976081" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_fc8bf8ec-c0a6-4a14-9939-06ebbc77560c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f1444efd-d20e-408e-996d-657979fc59d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_InventoryNet_f5c35095-1e3e-4a13-babe-eceb47976081" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_f1444efd-d20e-408e-996d-657979fc59d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#PropertyandEquipmentnetDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_ba19733e-1448-475a-b785-dab0adb06bfd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_f3ec353d-dbf0-4f53-be28-03c574884121" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ba19733e-1448-475a-b785-dab0adb06bfd" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_f3ec353d-dbf0-4f53-be28-03c574884121" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2ac37f-fc5c-4e09-aaa0-bfa314da07b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_ba19733e-1448-475a-b785-dab0adb06bfd" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_dc2ac37f-fc5c-4e09-aaa0-bfa314da07b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesComponentsofleasecostsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesComponentsofleasecostsDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/LeasesComponentsofleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_6c8675bf-4544-4104-8024-f63a275b3591" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_3f9ea53d-bd7e-4630-ba1b-828093bd6905" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6c8675bf-4544-4104-8024-f63a275b3591" xlink:to="loc_us-gaap_OperatingLeaseCost_3f9ea53d-bd7e-4630-ba1b-828093bd6905" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_0f596724-61d9-4a05-9782-566418a603a8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LeaseCost_6c8675bf-4544-4104-8024-f63a275b3591" xlink:to="loc_us-gaap_SubleaseIncome_0f596724-61d9-4a05-9782-566418a603a8" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesMaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_99ace047-6c08-4839-9bbf-83ac57b6d64f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_aa8939e1-f26a-4dfc-b7d4-2af95059d160" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_99ace047-6c08-4839-9bbf-83ac57b6d64f" xlink:to="loc_us-gaap_OperatingLeaseLiability_aa8939e1-f26a-4dfc-b7d4-2af95059d160" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c98069ee-c02d-4e2c-8d3b-81311b791a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_99ace047-6c08-4839-9bbf-83ac57b6d64f" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_c98069ee-c02d-4e2c-8d3b-81311b791a6d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesMaturitiesofoperatingleaseliabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c1331042-3c64-45b5-8091-be5e94168a69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_c1331042-3c64-45b5-8091-be5e94168a69" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd12cad4-47c5-4699-baf0-9bd1de895758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_bd12cad4-47c5-4699-baf0-9bd1de895758" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1e9e2c01-3260-4951-8ac6-afbf79707b49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_1e9e2c01-3260-4951-8ac6-afbf79707b49" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_ae485686-9835-49b6-96a7-154392dc2d5d" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:to="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_ae485686-9835-49b6-96a7-154392dc2d5d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_663f6159-6913-4160-8d7f-7ce73c1ff2b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_aa48a40d-a4a3-450f-b1f9-0b6e9d7ec4fb" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_663f6159-6913-4160-8d7f-7ce73c1ff2b2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationActivityDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_cc102381-d084-4e89-b3c9-83a955de89d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_954e87c4-ac66-4f38-99e8-03a65627a309" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cc102381-d084-4e89-b3c9-83a955de89d1" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_954e87c4-ac66-4f38-99e8-03a65627a309" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_970c93ff-f50a-4cc1-adef-b6308e328df9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_cc102381-d084-4e89-b3c9-83a955de89d1" xlink:to="loc_us-gaap_LongTermDebtCurrent_970c93ff-f50a-4cc1-adef-b6308e328df9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_a1df6333-a37f-42ec-82ac-5c5f237f8d15" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2684a8ad-2299-4110-8b76-7f8a5bd59677" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a1df6333-a37f-42ec-82ac-5c5f237f8d15" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_2684a8ad-2299-4110-8b76-7f8a5bd59677" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d851ccd7-32b6-4f58-9434-e15b1ce2c3b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_a1df6333-a37f-42ec-82ac-5c5f237f8d15" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_d851ccd7-32b6-4f58-9434-e15b1ce2c3b2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bcc2ff8b-f9c3-4ac3-b094-ea0677c321d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b9b43e1f-a0e6-4adb-8c97-94bfc49ce08c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bcc2ff8b-f9c3-4ac3-b094-ea0677c321d1" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_b9b43e1f-a0e6-4adb-8c97-94bfc49ce08c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0eeae4ca-2ed3-4cf8-9e4e-18b01794b155" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_bcc2ff8b-f9c3-4ac3-b094-ea0677c321d1" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_0eeae4ca-2ed3-4cf8-9e4e-18b01794b155" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b622081-3dcd-449d-b37e-95fd8dc90b3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ff1aef72-bd45-4d72-85e6-ebb4d0c14dbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_3b622081-3dcd-449d-b37e-95fd8dc90b3d" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_ff1aef72-bd45-4d72-85e6-ebb4d0c14dbb" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesReconciliationofTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e267f5e9-6b41-4bb0-a6a1-cb04f78867c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_e267f5e9-6b41-4bb0-a6a1-cb04f78867c2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_f2884c52-260b-41b9-8516-d54ecdf5e990" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_f2884c52-260b-41b9-8516-d54ecdf5e990" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e5bc9b8e-9869-40fd-9c8b-a6119ec18fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_e5bc9b8e-9869-40fd-9c8b-a6119ec18fc4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8755e37d-e462-4839-8072-88f13e8cab21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8755e37d-e462-4839-8072-88f13e8cab21" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_84008740-8a1b-4ef1-99ee-02b22d37962f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_84008740-8a1b-4ef1-99ee-02b22d37962f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_62701f48-5578-4b7f-941a-73b0d80b6de7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_62701f48-5578-4b7f-941a-73b0d80b6de7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ce205bc-1b21-477a-8e2c-5981879c4f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_1ce205bc-1b21-477a-8e2c-5981879c4f1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e497bbb0-7948-4dfe-b7bf-ad6554a3f3e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_e497bbb0-7948-4dfe-b7bf-ad6554a3f3e0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d6bb28e8-4d32-4376-8cd0-e9f78c423277" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_d6bb28e8-4d32-4376-8cd0-e9f78c423277" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_fe1b23c4-87e1-49e1-b7bd-2480dab671e0" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_293f25e8-faf6-4342-adfb-5e900edd6f24" xlink:to="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_fe1b23c4-87e1-49e1-b7bd-2480dab671e0" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_00fc013c-5e0b-4880-8394-126cf8914e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_01f9c5b5-91c5-43f9-a1d5-0581a2761915" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_00fc013c-5e0b-4880-8394-126cf8914e3c" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_01f9c5b5-91c5-43f9-a1d5-0581a2761915" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4e5cd43a-c0c7-485e-83e1-628c5f0ef2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_e19825bc-368c-4620-b612-ee6b913e5cf1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4e5cd43a-c0c7-485e-83e1-628c5f0ef2a5" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_e19825bc-368c-4620-b612-ee6b913e5cf1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_02dcdadb-0d46-4958-909d-93968f846be9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4e5cd43a-c0c7-485e-83e1-628c5f0ef2a5" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_02dcdadb-0d46-4958-909d-93968f846be9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61a6a36e-13dc-47de-af92-5bda92bbc60f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_4e5cd43a-c0c7-485e-83e1-628c5f0ef2a5" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_61a6a36e-13dc-47de-af92-5bda92bbc60f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsRoyaltyIncome_b58b37ae-14ac-40af-a80e-618f336b736d" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsRoyaltyIncome"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_avdl_DeferredTaxAssetsRoyaltyIncome_b58b37ae-14ac-40af-a80e-618f336b736d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_38c92772-8c93-4904-949f-3da62dada7ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_38c92772-8c93-4904-949f-3da62dada7ea" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e0b12359-662f-41bd-9ee5-9983239549eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_e0b12359-662f-41bd-9ee5-9983239549eb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_6ec09da7-abe1-4cba-8928-43566b58e44b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_6ec09da7-abe1-4cba-8928-43566b58e44b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_7ce1e9af-1c94-4760-8b0f-12a250934a5e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_7ce1e9af-1c94-4760-8b0f-12a250934a5e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_dd7476f3-9154-46f3-8128-27d4881e56ba" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_dd7476f3-9154-46f3-8128-27d4881e56ba" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4d3ce39a-119d-4031-81c9-412296f726c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="7" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_4d3ce39a-119d-4031-81c9-412296f726c9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_d23bbd56-6f41-46cf-af7b-b5338e000aab" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_d23bbd56-6f41-46cf-af7b-b5338e000aab" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_6e7fe7b6-78d5-44cb-8cc1-6ba592040448" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:calculationArc order="9" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_322114b5-a433-4d5f-946e-46c0a240c02a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_6e7fe7b6-78d5-44cb-8cc1-6ba592040448" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_396d9e49-df2f-45cc-9333-6d7e11cd0d45" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_972df703-a073-40f6-b351-17d3e1f86095" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_396d9e49-df2f-45cc-9333-6d7e11cd0d45" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_972df703-a073-40f6-b351-17d3e1f86095" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_f8c818eb-af22-44a8-b29c-6a5d4ed9be63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_396d9e49-df2f-45cc-9333-6d7e11cd0d45" xlink:to="loc_us-gaap_OtherAssetsCurrent_f8c818eb-af22-44a8-b29c-6a5d4ed9be63" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_b2675a35-d5ca-4ccd-9dca-666f1357c26f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_b6fa61ab-9975-488c-bd33-b6abe3c67c9d" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b2675a35-d5ca-4ccd-9dca-666f1357c26f" xlink:to="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_b6fa61ab-9975-488c-bd33-b6abe3c67c9d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OtherNoncurrentReceivables_267b0f88-71e3-4d84-a1df-9c3889031901" xlink:href="avdl-20241231.xsd#avdl_OtherNoncurrentReceivables"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherAssetsNoncurrent_b2675a35-d5ca-4ccd-9dca-666f1357c26f" xlink:to="loc_avdl_OtherNoncurrentReceivables_267b0f88-71e3-4d84-a1df-9c3889031901" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesAccruedExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_f216649a-6d61-4a50-b097-ece1841b2ca2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RemainingPerformanceObligationReserveCurrent_c74cbdba-a954-4fa5-a11a-6d1c57c62318" xlink:href="avdl-20241231.xsd#avdl_RemainingPerformanceObligationReserveCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f216649a-6d61-4a50-b097-ece1841b2ca2" xlink:to="loc_avdl_RemainingPerformanceObligationReserveCurrent_c74cbdba-a954-4fa5-a11a-6d1c57c62318" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_5d6848ee-2583-4e06-b345-a1313fb808d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f216649a-6d61-4a50-b097-ece1841b2ca2" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_5d6848ee-2583-4e06-b345-a1313fb808d6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityCurrent_9582e2b6-4e34-4121-a417-a2ab63026452" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f216649a-6d61-4a50-b097-ece1841b2ca2" xlink:to="loc_avdl_RoyaltyFinancingLiabilityCurrent_9582e2b6-4e34-4121-a417-a2ab63026452" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_7acf21c1-c649-4944-8f6a-3ed252e7a18f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent_f216649a-6d61-4a50-b097-ece1841b2ca2" xlink:to="loc_us-gaap_AccruedSalariesCurrent_7acf21c1-c649-4944-8f6a-3ed252e7a18f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_bc6617fa-f82b-46eb-a528-b04b3f322278" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_08a07570-1884-48ed-9a14-1765c7f2548b" xlink:href="avdl-20241231.xsd#avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_bc6617fa-f82b-46eb-a528-b04b3f322278" xlink:to="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_08a07570-1884-48ed-9a14-1765c7f2548b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_acb1bf16-ad4d-484d-b225-86e5dd2b99fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantyLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent_bc6617fa-f82b-46eb-a528-b04b3f322278" xlink:to="loc_us-gaap_GuarantyLiabilities_acb1bf16-ad4d-484d-b225-86e5dd2b99fe" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63df6a4d-707d-49b3-b2da-a87441c9461e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aed527db-bc0f-4d4a-bde2-004f008ecf33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63df6a4d-707d-49b3-b2da-a87441c9461e" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_aed527db-bc0f-4d4a-bde2-004f008ecf33" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_efa66d5e-dd89-4164-8f9e-c93ffcdbcfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_63df6a4d-707d-49b3-b2da-a87441c9461e" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_efa66d5e-dd89-4164-8f9e-c93ffcdbcfc1" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"/>
  <link:calculationLink xlink:role="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_8a9ab8cc-824b-445b-8fed-c9ff6ce605ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_de708e7c-1c68-4f88-84e4-471bb3392e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8a9ab8cc-824b-445b-8fed-c9ff6ce605ae" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_de708e7c-1c68-4f88-84e4-471bb3392e3c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_4b8a6691-e9cb-46a0-bde9-5163765f800a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8a9ab8cc-824b-445b-8fed-c9ff6ce605ae" xlink:to="loc_us-gaap_SellingAndMarketingExpense_4b8a6691-e9cb-46a0-bde9-5163765f800a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_49b6f17d-6274-4290-b4fd-ae45e746d38b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8a9ab8cc-824b-445b-8fed-c9ff6ce605ae" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_49b6f17d-6274-4290-b4fd-ae45e746d38b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_d63c3285-e8b8-4748-b629-8d90142c12b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_8a9ab8cc-824b-445b-8fed-c9ff6ce605ae" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_d63c3285-e8b8-4748-b629-8d90142c12b6" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>20
<FILENAME>avdl-20241231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:to="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_6dafd95c-02ce-4bd9-ab45-171e59e9f778_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:to="loc_us-gaap_EquityComponentDomain_6dafd95c-02ce-4bd9-ab45-171e59e9f778_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:to="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b112fa49-3e0d-4de1-8179-63540d882c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_CommonStockMember_b112fa49-3e0d-4de1-8179-63540d882c43" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ad6345b7-932d-4457-848e-c745b96ef8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_PreferredStockMember_ad6345b7-932d-4457-848e-c745b96ef8cf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b489695e-7fd8-4664-ac7f-5f0e15bd3862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b489695e-7fd8-4664-ac7f-5f0e15bd3862" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e550c828-08f3-491d-87cf-ff1a3c741e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_RetainedEarningsMember_e550c828-08f3-491d-87cf-ff1a3c741e81" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5806970-536c-42cd-9e0f-c13a902aecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5806970-536c-42cd-9e0f-c13a902aecbd" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d611e476-5931-4673-a01a-a35b506cfdbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_d611e476-5931-4673-a01a-a35b506cfdbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AtTheMarketOfferingProgramMember_ff721a9b-6d7b-4c1b-a42e-d312c2273df6" xlink:href="avdl-20241231.xsd#avdl_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:to="loc_avdl_AtTheMarketOfferingProgramMember_ff721a9b-6d7b-4c1b-a42e-d312c2273df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PublicOfferingMember_f1c7e8d5-869e-45f1-88c5-dd9aa96167a2" xlink:href="avdl-20241231.xsd#avdl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:to="loc_avdl_PublicOfferingMember_f1c7e8d5-869e-45f1-88c5-dd9aa96167a2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_7965b826-60f5-4c80-8e61-6e1a54f19977_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_7965b826-60f5-4c80-8e61-6e1a54f19977_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_April2027NotesMember_a173782f-cdf8-4957-90ed-147f2d77f9b4" xlink:href="avdl-20241231.xsd#avdl_April2027NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:to="loc_avdl_April2027NotesMember_a173782f-cdf8-4957-90ed-147f2d77f9b4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_382e6342-31a4-430c-9d64-956ecead251e" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:to="loc_avdl_October2023NotesMember_382e6342-31a4-430c-9d64-956ecead251e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69cea04b-7fe8-4778-8485-0c6d9bc7ceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_SharesOutstanding_69cea04b-7fe8-4778-8485-0c6d9bc7ceed" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ba1eb2e1-2577-436a-91e5-6d47ee06c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockholdersEquity_ba1eb2e1-2577-436a-91e5-6d47ee06c7d0" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a853def2-e2e8-4b0c-a7e5-ce2a2d5ff88e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_NetIncomeLoss_a853def2-e2e8-4b0c-a7e5-ce2a2d5ff88e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f686d901-5924-446f-955e-1fe1995a68a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f686d901-5924-446f-955e-1fe1995a68a2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_ec6752f3-8ff8-41a1-aa71-a138ec30d97e" xlink:href="avdl-20241231.xsd#avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_ec6752f3-8ff8-41a1-aa71-a138ec30d97e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_220d9a68-c337-4e41-90bc-32184922b758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_220d9a68-c337-4e41-90bc-32184922b758" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4f83d2b2-1109-4658-80a3-d281c64bc418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4f83d2b2-1109-4658-80a3-d281c64bc418" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4baa10be-1014-4b2f-a5c7-1ab265f52b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4baa10be-1014-4b2f-a5c7-1ab265f52b0f" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_707a8d99-6077-43c7-a5c2-27c7f6ae07c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_707a8d99-6077-43c7-a5c2-27c7f6ae07c0" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1bf1d17a-3fde-45f7-ab1d-511ce0321c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1bf1d17a-3fde-45f7-ab1d-511ce0321c2c" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c67d060c-9b0b-42b4-96d0-41eb1c358896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c67d060c-9b0b-42b4-96d0-41eb1c358896" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21cc3fb1-2bad-4d15-b573-559712e5cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21cc3fb1-2bad-4d15-b573-559712e5cfdf" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_f6f0f493-ef35-4c71-879a-107288734200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_f6f0f493-ef35-4c71-879a-107288734200" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2b97e52b-3ac3-43bf-b92a-2adb488e420a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2b97e52b-3ac3-43bf-b92a-2adb488e420a" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_6bcd47a5-cade-4f2c-ac0d-d835689b2f08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_6bcd47a5-cade-4f2c-ac0d-d835689b2f08" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6baffa6b-5f37-4672-bb73-7ef3f35997c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6baffa6b-5f37-4672-bb73-7ef3f35997c6" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13aae24e-3a42-4207-b403-e135f3c406c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13aae24e-3a42-4207-b403-e135f3c406c9" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_52ef66fb-9968-47a6-ac0e-ce6d5ca171ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7163fc5-e69e-4612-9631-e3183548a592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_937131db-b0ce-4bf9-916e-5bf2623f045e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_937131db-b0ce-4bf9-916e-5bf2623f045e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PublicOfferingMember_a2c413cf-6674-4ede-8a00-e5b4d1ed12d7" xlink:href="avdl-20241231.xsd#avdl_PublicOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:to="loc_avdl_PublicOfferingMember_a2c413cf-6674-4ede-8a00-e5b4d1ed12d7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AtTheMarketOfferingProgramMember_205faf57-77e6-4bd2-a07a-c8c0fe4f5325" xlink:href="avdl-20241231.xsd#avdl_AtTheMarketOfferingProgramMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:to="loc_avdl_AtTheMarketOfferingProgramMember_205faf57-77e6-4bd2-a07a-c8c0fe4f5325" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:to="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_February2023NotesMember_5934c6a1-0659-4e56-945a-8c7d6bf6fe78" xlink:href="avdl-20241231.xsd#avdl_February2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:to="loc_avdl_February2023NotesMember_5934c6a1-0659-4e56-945a-8c7d6bf6fe78" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_8d5b7b70-5662-4b16-9d47-d32f0cc43227" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:to="loc_avdl_October2023NotesMember_8d5b7b70-5662-4b16-9d47-d32f0cc43227" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb00ead9-9056-4636-a436-2863582fb0df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_NetIncomeLoss_bb00ead9-9056-4636-a436-2863582fb0df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5029e33f-7895-4bea-b899-4aab506de24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_DepreciationAndAmortization_5029e33f-7895-4bea-b899-4aab506de24c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_481a753b-8e67-4341-9981-f78393b639a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_481a753b-8e67-4341-9981-f78393b639a3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2971548e-94d9-4533-952d-72f40d98d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2971548e-94d9-4533-952d-72f40d98d28f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10faed6a-370a-4fda-810c-01b749264c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_ShareBasedCompensation_10faed6a-370a-4fda-810c-01b749264c2b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f521315-f609-4b13-a844-cb80d6ad0930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f521315-f609-4b13-a844-cb80d6ad0930" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5c70765b-091c-43fd-9a2e-a42257aa34da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5c70765b-091c-43fd-9a2e-a42257aa34da" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8aca4e22-73d3-409a-8984-d4e09149bc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8aca4e22-73d3-409a-8984-d4e09149bc6f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_108048f2-4f91-4f8c-b0a8-d10104c8fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_108048f2-4f91-4f8c-b0a8-d10104c8fdef" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_311ecf10-df7e-41d3-9846-ef2cca416b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_311ecf10-df7e-41d3-9846-ef2cca416b65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503c8f2e-b259-4b1e-b284-4dfe278f1de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503c8f2e-b259-4b1e-b284-4dfe278f1de3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_584e69af-d1ab-41fe-bd1b-0af5ae06d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_584e69af-d1ab-41fe-bd1b-0af5ae06d7b9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_3aeaea60-d8d2-49a0-a873-97d8f3748d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_3aeaea60-d8d2-49a0-a873-97d8f3748d68" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be5a22af-d1d4-4c9a-a072-47318a24fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be5a22af-d1d4-4c9a-a072-47318a24fe97" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa9ca90e-380e-4468-85b7-d6f05233cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa9ca90e-380e-4468-85b7-d6f05233cd47" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e42c3ce3-e895-488a-8208-aa3f4cd89c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e42c3ce3-e895-488a-8208-aa3f4cd89c63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3521df12-36f4-4ddf-b51b-a64369136c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3521df12-36f4-4ddf-b51b-a64369136c00" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780bde19-63c8-44e4-b01b-ee86bc7ddcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780bde19-63c8-44e4-b01b-ee86bc7ddcd2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8be9aff-9bae-428d-b96f-5bae571e5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8be9aff-9bae-428d-b96f-5bae571e5e68" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74522e3a-4f55-406a-97cd-871f14e3a91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74522e3a-4f55-406a-97cd-871f14e3a91f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_91614c1b-0b9a-43c5-92ab-93d6b854da40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_91614c1b-0b9a-43c5-92ab-93d6b854da40" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_786b5baf-6797-44f0-a795-3c5d2069adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_786b5baf-6797-44f0-a795-3c5d2069adc6" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11078289-6704-4921-b9ba-3a908ae0460e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11078289-6704-4921-b9ba-3a908ae0460e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac5c4ffb-4459-405a-be79-991d86dea7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac5c4ffb-4459-405a-be79-991d86dea7fc" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc67365e-c73a-480a-b2ce-9b288b7f65b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc67365e-c73a-480a-b2ce-9b288b7f65b4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43a42a23-98c6-4fdc-88d8-343b86ace871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43a42a23-98c6-4fdc-88d8-343b86ace871" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3540ece7-0243-43fa-895d-da617985be00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3540ece7-0243-43fa-895d-da617985be00" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a198051-e9c9-494a-badc-74b9154c3239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fa8f26fd-0352-4637-9e2a-ad4ea1676ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:to="loc_us-gaap_InterestPaidNet_fa8f26fd-0352-4637-9e2a-ad4ea1676ad9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_6ee12c21-a3b0-4f1d-ba78-5dd161a3cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_6ee12c21-a3b0-4f1d-ba78-5dd161a3cdfc" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_38367b56-8848-49fa-a14c-67abc1b4501a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:to="loc_srt_NameOfMajorCustomerDomain_38367b56-8848-49fa-a14c-67abc1b4501a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:to="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_e0d95296-872a-4906-a74f-b1f41cac6564" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_ThreeCustomersMember_e0d95296-872a-4906-a74f-b1f41cac6564" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkLLCMember_c01b0ac7-da01-4de4-a194-54ada2402f5f" xlink:href="avdl-20241231.xsd#avdl_CaremarkLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_CaremarkLLCMember_c01b0ac7-da01-4de4-a194-54ada2402f5f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoHealthGroupInc.Member_dd9d339b-d19d-4f7c-9aa6-fe860b513fb8" xlink:href="avdl-20241231.xsd#avdl_AccredoHealthGroupInc.Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_AccredoHealthGroupInc.Member_dd9d339b-d19d-4f7c-9aa6-fe860b513fb8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumFrontierTherapiesLLCMember_f4dc7adc-2391-4edc-abf7-df0b511d4326" xlink:href="avdl-20241231.xsd#avdl_OptumFrontierTherapiesLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_OptumFrontierTherapiesLLCMember_f4dc7adc-2391-4edc-abf7-df0b511d4326" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e4df554-63c7-4171-ae78-3a5eb6b171cf_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_7e4df554-63c7-4171-ae78-3a5eb6b171cf_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a982ffba-ee1b-4ca1-bb85-0252715c48f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:to="loc_us-gaap_AccountsReceivableMember_a982ffba-ee1b-4ca1-bb85-0252715c48f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_be001464-01cb-4c96-8160-8f1f0518d9b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_be001464-01cb-4c96-8160-8f1f0518d9b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ca9e04f3-8ece-488e-99a7-47ef2a9a6432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ca9e04f3-8ece-488e-99a7-47ef2a9a6432" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_b839e4d4-76a3-4aa5-a461-cf22ef4d2a94" xlink:href="avdl-20241231.xsd#avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:to="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_b839e4d4-76a3-4aa5-a461-cf22ef4d2a94" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_NumberOfFinancialInstitutions_f17c2754-378b-4d94-85be-cd3683bd7e86" xlink:href="avdl-20241231.xsd#avdl_NumberOfFinancialInstitutions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_avdl_NumberOfFinancialInstitutions_f17c2754-378b-4d94-85be-cd3683bd7e86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fada1db4-3527-4d64-9108-7227eafda584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fada1db4-3527-4d64-9108-7227eafda584" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_0383bba9-5959-424d-8488-0413003f6a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_AdvertisingExpense_0383bba9-5959-424d-8488-0413003f6a29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4de90f02-d278-4b8f-ba8e-5419783a450d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4de90f02-d278-4b8f-ba8e-5419783a450d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8a100df6-4412-4787-bcc4-e711b76741d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8a100df6-4412-4787-bcc4-e711b76741d3" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6306e623-20eb-48b8-ba11-6b26e478c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6306e623-20eb-48b8-ba11-6b26e478c32a" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a8d7eec0-54ee-470c-9af6-704e7774a4f4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_a8d7eec0-54ee-470c-9af6-704e7774a4f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_80a2891b-74a5-4ea8-b503-8c97d53522eb" xlink:href="avdl-20241231.xsd#avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:to="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_80a2891b-74a5-4ea8-b503-8c97d53522eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_307bce90-7e57-4471-b251-c1110bb29164" xlink:href="avdl-20241231.xsd#avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:to="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_307bce90-7e57-4471-b251-c1110bb29164" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:to="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:to="loc_srt_RangeMember_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:to="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef284fdc-a380-4603-ace1-f81f890cb46c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:to="loc_srt_MinimumMember_ef284fdc-a380-4603-ace1-f81f890cb46c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4cc2eca-5ea7-41f3-a34c-1a595c963e04" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:to="loc_srt_MaximumMember_a4cc2eca-5ea7-41f3-a34c-1a595c963e04" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d7b733f0-e59a-4f4d-ae79-5eaea8b2158b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d7b733f0-e59a-4f4d-ae79-5eaea8b2158b" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:to="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a6016131-cee3-48fc-9438-bcd2ca0e1521_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_a6016131-cee3-48fc-9438-bcd2ca0e1521_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_efa0c1e8-f6ac-4355-83c0-cd84efff24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_efa0c1e8-f6ac-4355-83c0-cd84efff24a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_fde654e6-dbd4-4799-b053-d82a859743b1_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_fde654e6-dbd4-4799-b053-d82a859743b1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a4b637fe-cfbc-49eb-94d1-e1c0870c22ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a4b637fe-cfbc-49eb-94d1-e1c0870c22ef" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_2505fe5d-95dc-4be2-94a1-7e74bf792b26_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_2505fe5d-95dc-4be2-94a1-7e74bf792b26_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:to="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkMember_6ffa8c2d-1299-4649-bba8-4e36c7625729" xlink:href="avdl-20241231.xsd#avdl_CaremarkMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_CaremarkMember_6ffa8c2d-1299-4649-bba8-4e36c7625729" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoMember_bdb70b8a-a289-45a8-9df0-f301bf34d2ca" xlink:href="avdl-20241231.xsd#avdl_AccredoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_AccredoMember_bdb70b8a-a289-45a8-9df0-f301bf34d2ca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumMember_b4534940-8b06-4409-945f-a16bf92d5de5" xlink:href="avdl-20241231.xsd#avdl_OptumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_OptumMember_b4534940-8b06-4409-945f-a16bf92d5de5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f781a764-f6a9-4c96-b289-93f25c9911f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f781a764-f6a9-4c96-b289-93f25c9911f5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66fce3fc-01a7-4072-9bd6-410a8376bf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66fce3fc-01a7-4072-9bd6-410a8376bf9f" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:to="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_4c3dc192-4c61-483b-a61d-48936368317e_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:to="loc_srt_NameOfMajorCustomerDomain_4c3dc192-4c61-483b-a61d-48936368317e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:to="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_ba9b29d5-2701-420c-820c-638cd9f1051a" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:to="loc_avdl_ThreeCustomersMember_ba9b29d5-2701-420c-820c-638cd9f1051a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b70de794-91b9-4c58-b6b5-ec6717da3f02_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b70de794-91b9-4c58-b6b5-ec6717da3f02_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_fe6d7ebe-9f43-4c0d-bab1-d19dae108418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_fe6d7ebe-9f43-4c0d-bab1-d19dae108418" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_24d8a045-e283-43e6-88cb-97de232e8d1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_24d8a045-e283-43e6-88cb-97de232e8d1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_12e069d8-650c-4880-81a3-84ef345f71eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_12e069d8-650c-4880-81a3-84ef345f71eb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0c11ebb-12b6-465b-a542-e29269c9f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0c11ebb-12b6-465b-a542-e29269c9f1b0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db3491b2-86e9-48ab-9f0c-eab828274194" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db3491b2-86e9-48ab-9f0c-eab828274194" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#FairValueMeasurementDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_689c0e3a-d9e1-4cc9-9663-af159f5373c7_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_689c0e3a-d9e1-4cc9-9663-af159f5373c7_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b2de00ad-2d7f-4d95-95f6-fd172d2ba47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b2de00ad-2d7f-4d95-95f6-fd172d2ba47a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5df3862c-24f3-43ee-aba8-40950bad3c60_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_5df3862c-24f3-43ee-aba8-40950bad3c60_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f44f9174-c202-43d6-9311-2dd98be032f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f44f9174-c202-43d6-9311-2dd98be032f1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_32957544-6570-48c1-9408-522bde0a0ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_32957544-6570-48c1-9408-522bde0a0ae2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_044a0fb2-16f1-4785-b4b5-b4b3c34e299c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_044a0fb2-16f1-4785-b4b5-b4b3c34e299c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db7611e0-b946-4c56-a9e6-f56ad8164621_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_db7611e0-b946-4c56-a9e6-f56ad8164621_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e89cf3a2-151b-4127-9d15-8a80d4e89d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e89cf3a2-151b-4127-9d15-8a80d4e89d4a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9f9d1c-2489-4002-b69d-0883fc1d6976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9f9d1c-2489-4002-b69d-0883fc1d6976" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_70e429f3-8fb4-4112-9c24-3fdee1682851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_70e429f3-8fb4-4112-9c24-3fdee1682851" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32118559-3f7b-4d46-86e2-cdddfadf7829_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_32118559-3f7b-4d46-86e2-cdddfadf7829_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bcd75df3-1cb3-4e7a-8170-5adc27d8a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bcd75df3-1cb3-4e7a-8170-5adc27d8a7a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_269ba92f-a7c1-4e2d-aae5-657131bc049a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_269ba92f-a7c1-4e2d-aae5-657131bc049a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4e80af4-c72f-4de6-af1e-9f4d899edd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4e80af4-c72f-4de6-af1e-9f4d899edd3a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ed84a19-99a6-412a-9745-ee7a2889512f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ed84a19-99a6-412a-9745-ee7a2889512f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ee6e6f2-cf35-4986-b84c-98b1f5831773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ee6e6f2-cf35-4986-b84c-98b1f5831773" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesScheduleofContractualMaturityDatesDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3c6bf0f-dd70-4daf-baba-db1f1101bffb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c3c6bf0f-dd70-4daf-baba-db1f1101bffb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_11db230f-624e-4f4c-a2ee-69284849fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_11db230f-624e-4f4c-a2ee-69284849fccf" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51702681-3f15-4f86-bfaa-830681c336a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51702681-3f15-4f86-bfaa-830681c336a9" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_836b15b7-7d2c-42dc-a1a5-45a7c3516721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_836b15b7-7d2c-42dc-a1a5-45a7c3516721" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5299151-2a1f-41d5-b1d3-bb60e8f32908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5299151-2a1f-41d5-b1d3-bb60e8f32908" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_33faadfc-6bfa-4880-a457-ae971ffff05d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_33faadfc-6bfa-4880-a457-ae971ffff05d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4171c4c8-35c9-4b2e-be02-04a9b59af1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4171c4c8-35c9-4b2e-be02-04a9b59af1e6" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#PropertyandEquipmentnetDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b91ecadd-db0f-462d-b08e-70e46dcaffd4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_b91ecadd-db0f-462d-b08e-70e46dcaffd4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_42dbe045-82b6-4128-a46e-292c98d7518d" xlink:href="avdl-20241231.xsd#avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:to="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_42dbe045-82b6-4128-a46e-292c98d7518d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_624aedae-cdb8-487c-9c73-a6ab8f38f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_624aedae-cdb8-487c-9c73-a6ab8f38f38f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6ad20159-87c5-45b2-be25-951bfe143e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6ad20159-87c5-45b2-be25-951bfe143e0a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755cd353-b4ed-4d88-bc65-5700a0548972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755cd353-b4ed-4d88-bc65-5700a0548972" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92cbff92-8e5c-4c8e-9980-fab66db8d964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_92cbff92-8e5c-4c8e-9980-fab66db8d964" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d3dd0693-973d-4ad8-9e39-bf182d3d15d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_Depreciation_d3dd0693-973d-4ad8-9e39-bf182d3d15d1" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:to="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_d759a75f-f66b-4226-bdce-c0e5e2f03eeb_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:to="loc_srt_RangeMember_d759a75f-f66b-4226-bdce-c0e5e2f03eeb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:to="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bd1f9d6-eb67-4781-870c-15a2ef7d3591" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:to="loc_srt_MinimumMember_3bd1f9d6-eb67-4781-870c-15a2ef7d3591" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcb483eb-d337-4325-8d7c-cae6f434ea4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:to="loc_srt_MaximumMember_bcb483eb-d337-4325-8d7c-cae6f434ea4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7349900c-9397-4391-a0ef-b052d0f17767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7349900c-9397-4391-a0ef-b052d0f17767" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6fe3cb74-6a72-4c15-ad48-3da76785b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeasePayments_6fe3cb74-6a72-4c15-ad48-3da76785b40c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f440f95-1c30-4e30-8e89-070bce24cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f440f95-1c30-4e30-8e89-070bce24cf78" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81a80169-9860-4518-9387-ca32e9fb3279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81a80169-9860-4518-9387-ca32e9fb3279" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dcea926-084a-459f-a5fe-378fb1c6fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dcea926-084a-459f-a5fe-378fb1c6fd18" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_89f3a65d-00c8-4c45-a2eb-f1c988ca2063_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_89f3a65d-00c8-4c45-a2eb-f1c988ca2063_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingMember_8f5c9c59-4f45-450d-9410-758cec755248" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:to="loc_avdl_RoyaltyFinancingMember_8f5c9c59-4f45-450d-9410-758cec755248" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_141ed7df-eb37-4c8b-846f-811c7ef6e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:to="loc_us-gaap_SeniorNotesMember_141ed7df-eb37-4c8b-846f-811c7ef6e88d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:to="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_bb66443e-c97a-433b-821e-45fd24b8269f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_bb66443e-c97a-433b-821e-45fd24b8269f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_February2023NotesMember_a2ed2926-9051-408f-97c6-705832393610" xlink:href="avdl-20241231.xsd#avdl_February2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:to="loc_avdl_February2023NotesMember_a2ed2926-9051-408f-97c6-705832393610" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_70fa4134-6ab1-4184-89b3-c8cf26a550e1" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:to="loc_avdl_October2023NotesMember_70fa4134-6ab1-4184-89b3-c8cf26a550e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingProceedsMaximum_a4c9637b-20ff-4811-86cc-8a1e27cbf88a" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingProceedsMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingProceedsMaximum_a4c9637b-20ff-4811-86cc-8a1e27cbf88a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentNumberOfTranches_5596f837-7d32-47d2-8cec-3d8601e46cbc" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentNumberOfTranches"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_DebtInstrumentNumberOfTranches_5596f837-7d32-47d2-8cec-3d8601e46cbc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e942976a-71bd-48e1-b84a-be45637cecce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e942976a-71bd-48e1-b84a-be45637cecce" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_76b458bc-3769-481f-bc13-2368673f2d60" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyNetRevenueTarget"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_76b458bc-3769-481f-bc13-2368673f2d60" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_53401f9c-ce8f-4e06-9992-87f22ac3a894" xlink:href="avdl-20241231.xsd#avdl_PaymentsForRoyaltyOneTimeCommitmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_53401f9c-ce8f-4e06-9992-87f22ac3a894" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_15c51e3c-d546-4686-bc38-a14886e42d3e" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_15c51e3c-d546-4686-bc38-a14886e42d3e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b39a82f2-8e49-44ec-865e-0831b2e49f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b39a82f2-8e49-44ec-865e-0831b2e49f28" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_422b91dd-bfaf-4db5-8dff-0c170c73af27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_InterestExpenseDebt_422b91dd-bfaf-4db5-8dff-0c170c73af27" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae883a9b-3063-4822-8494-d2dcd9c58763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae883a9b-3063-4822-8494-d2dcd9c58763" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationActivityDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_86b69cfc-b2bc-40ec-8aa8-514b673364f6_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_86b69cfc-b2bc-40ec-8aa8-514b673364f6_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingMember_1af17a83-4307-4047-9316-43161fa31065" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:to="loc_avdl_RoyaltyFinancingMember_1af17a83-4307-4047-9316-43161fa31065" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentIncreaseDecreaseNetRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d631ebba-04d3-4560-b0c1-02d594625559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_LongTermDebt_d631ebba-04d3-4560-b0c1-02d594625559" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_82185c0d-4a02-44ae-b8f7-3c7c170fc49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_82185c0d-4a02-44ae-b8f7-3c7c170fc49f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_36050ac7-690d-4f83-a62c-663ed81eec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_InterestExpenseDebt_36050ac7-690d-4f83-a62c-663ed81eec0e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RepaymentOfRoyaltyLiability_454249fc-29e0-4757-a84b-97c83b2682d4" xlink:href="avdl-20241231.xsd#avdl_RepaymentOfRoyaltyLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_avdl_RepaymentOfRoyaltyLiability_454249fc-29e0-4757-a84b-97c83b2682d4" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_fcc3e9d9-bbe8-4fd8-ab38-5f685f361870" xlink:href="avdl-20241231.xsd#avdl_PaymentsForRoyaltyOneTimeCommitmentFee"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_fcc3e9d9-bbe8-4fd8-ab38-5f685f361870" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2e6d4dbe-88f1-48a5-a419-1730baff603e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_132e245c-9333-458f-b81a-38d05e26ceba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_us-gaap_LongTermDebtCurrent_132e245c-9333-458f-b81a-38d05e26ceba" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4e2b9f71-8391-4f0f-a3d1-de502ae8e9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4e2b9f71-8391-4f0f-a3d1-de502ae8e9bf" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:to="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:to="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_b4561c76-83df-4cf3-a81a-6072ea69e201_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:to="loc_srt_SegmentGeographicalDomain_b4561c76-83df-4cf3-a81a-6072ea69e201_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:to="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_a9c0959a-a5cc-48dd-8357-57b87327292d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:to="loc_srt_EuropeMember_a9c0959a-a5cc-48dd-8357-57b87327292d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f45bcb46-f45d-4628-9e7b-7ed16b5cbc83" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:to="loc_country_US_f45bcb46-f45d-4628-9e7b-7ed16b5cbc83" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d40ac57-d728-41b4-bcca-996abcddfd30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d40ac57-d728-41b4-bcca-996abcddfd30" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FscHoldingsLlcMember_53f99efb-2843-4b41-a7e6-34ce083aac37" xlink:href="avdl-20241231.xsd#avdl_FscHoldingsLlcMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:to="loc_avdl_FscHoldingsLlcMember_53f99efb-2843-4b41-a7e6-34ce083aac37" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_U.S.HoldingsMember_55b54720-a605-4965-b390-26af6c6c631c" xlink:href="avdl-20241231.xsd#avdl_U.S.HoldingsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:to="loc_avdl_U.S.HoldingsMember_55b54720-a605-4965-b390-26af6c6c631c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_a65f0779-6d81-4f6f-8ac0-008c88a97f29_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:to="loc_srt_SegmentGeographicalDomain_a65f0779-6d81-4f6f-8ac0-008c88a97f29_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:to="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_21f89d12-a7d7-4562-be21-0ca55a34998f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_IE_21f89d12-a7d7-4562-be21-0ca55a34998f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7ad4d1f0-a809-40ca-a978-d78ce1625375" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_US_7ad4d1f0-a809-40ca-a978-d78ce1625375" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ca93a792-bf6f-4a04-863b-5ee14c833fac" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_FR_ca93a792-bf6f-4a04-863b-5ee14c833fac" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_fe183089-1229-40d6-b002-13617c69ccbb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_fe183089-1229-40d6-b002-13617c69ccbb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5519ab01-35d3-4eaf-b812-d6f938f41285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5519ab01-35d3-4eaf-b812-d6f938f41285" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_92d54d10-570a-4161-b47c-868a70756389_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_92d54d10-570a-4161-b47c-868a70756389_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A163jCreditsMember_1ff55e7f-1bee-4694-8e35-32f3322da2ec" xlink:href="avdl-20241231.xsd#avdl_A163jCreditsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_avdl_A163jCreditsMember_1ff55e7f-1bee-4694-8e35-32f3322da2ec" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OrphanDrugTaxCreditMember_f02b8483-76bb-4aa8-abc4-a1f99b41f127" xlink:href="avdl-20241231.xsd#avdl_OrphanDrugTaxCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_avdl_OrphanDrugTaxCreditMember_f02b8483-76bb-4aa8-abc4-a1f99b41f127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5b76b672-1ad3-46f1-83d0-775c9c10abca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_us-gaap_ResearchMember_5b76b672-1ad3-46f1-83d0-775c9c10abca" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bdc77321-c679-4d97-bfdd-34ed10d8b2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bdc77321-c679-4d97-bfdd-34ed10d8b2a5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_c66c26fb-3c71-4ca2-9197-6663e955f6f1" xlink:href="avdl-20241231.xsd#avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_c66c26fb-3c71-4ca2-9197-6663e955f6f1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4f96d937-2727-4a76-8edd-65ab5208d805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4f96d937-2727-4a76-8edd-65ab5208d805" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8fbb3f0d-d07a-4054-aa1f-af171f496ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8fbb3f0d-d07a-4054-aa1f-af171f496ab8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ab072f87-df99-4d00-988f-a73ea99a0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ab072f87-df99-4d00-988f-a73ea99a0c96" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c139d08-c028-4a89-97b7-b0ea21ccf3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c139d08-c028-4a89-97b7-b0ea21ccf3d7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_442da282-fea2-4d82-af14-22a167d7f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_442da282-fea2-4d82-af14-22a167d7f5f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ec42a88e-be78-4a25-91ec-72f5156aa661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ec42a88e-be78-4a25-91ec-72f5156aa661" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_bdb68aec-8bdb-48a4-999e-e5527a91a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_bdb68aec-8bdb-48a4-999e-e5527a91a9fb" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_3f0dcee9-6f56-4ed0-a7bd-c7a0606686ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarnings"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UndistributedEarnings_3f0dcee9-6f56-4ed0-a7bd-c7a0606686ae" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d4d8625-b602-4486-99bf-804b8911feac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d4d8625-b602-4486-99bf-804b8911feac" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dc4b0ac3-1e56-411c-9870-46b90daabc35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dc4b0ac3-1e56-411c-9870-46b90daabc35" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ContingentLiabilitiesandCommitmentsDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:to="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_02f291f1-2008-43f8-a058-462318e517f4_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:to="loc_srt_LitigationCaseTypeDomain_02f291f1-2008-43f8-a058-462318e517f4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:to="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FirstJazzComplaintMember_d6617634-4334-4e35-a0f6-f43d258d09e4" xlink:href="avdl-20241231.xsd#avdl_FirstJazzComplaintMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:to="loc_avdl_FirstJazzComplaintMember_d6617634-4334-4e35-a0f6-f43d258d09e4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:to="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_c4f864e8-43f6-4dfb-8223-41a84267e5c5_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:to="loc_srt_RangeMember_c4f864e8-43f6-4dfb-8223-41a84267e5c5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:to="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_794e351c-5d42-476d-aff1-e6d472b8eac7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:to="loc_srt_MinimumMember_794e351c-5d42-476d-aff1-e6d472b8eac7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34ddb931-8925-4465-a5c5-440b6bc35440" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:to="loc_srt_MaximumMember_34ddb931-8925-4465-a5c5-440b6bc35440" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2ef42498-675d-4f3f-8ce3-1efc41610387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2ef42498-675d-4f3f-8ce3-1efc41610387" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_52dfe869-2560-4b1d-b706-13fcf43feb20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_52dfe869-2560-4b1d-b706-13fcf43feb20" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ContractualObligationAnnualAmount_2551040d-f303-4889-86b1-0368eacd3c64" xlink:href="avdl-20241231.xsd#avdl_ContractualObligationAnnualAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_avdl_ContractualObligationAnnualAmount_2551040d-f303-4889-86b1-0368eacd3c64" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#EquityInstrumentsandTransactionsDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_51f0e4b9-ebb8-4eea-b466-a298383ce65f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:to="loc_us-gaap_EquityComponentDomain_51f0e4b9-ebb8-4eea-b466-a298383ce65f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:to="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4917aa06-3909-4b72-bdb3-498a5d4edaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:to="loc_us-gaap_PreferredStockMember_4917aa06-3909-4b72-bdb3-498a5d4edaa2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0959e67e-039b-4814-989b-97630cb32217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:to="loc_us-gaap_CommonStockMember_0959e67e-039b-4814-989b-97630cb32217" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9b5f3248-a414-46db-a26b-235b5c234c14_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_9b5f3248-a414-46db-a26b-235b5c234c14_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShelfRegistrationStatementOnFormS3Member_857b12a6-4f2a-4a74-a8b5-73b706374aae" xlink:href="avdl-20241231.xsd#avdl_ShelfRegistrationStatementOnFormS3Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:to="loc_avdl_ShelfRegistrationStatementOnFormS3Member_857b12a6-4f2a-4a74-a8b5-73b706374aae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_86cc8533-f930-4890-b08f-dbeda3d9f2d3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_86cc8533-f930-4890-b08f-dbeda3d9f2d3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositarySharesMember_1465dac9-eeb6-4c8a-9282-8fec752e2643" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositarySharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:to="loc_avdl_AmericanDepositarySharesMember_1465dac9-eeb6-4c8a-9282-8fec752e2643" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fc4643f8-13a6-40e8-8165-eebfaf7e7190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fc4643f8-13a6-40e8-8165-eebfaf7e7190" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2feb55d-cd7e-4c7f-b6c1-33693e78d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2feb55d-cd7e-4c7f-b6c1-33693e78d4df" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositorySharesConversionRatio_ba8ddb10-48df-43cd-ad60-7b65a81e6c6b" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositorySharesConversionRatio"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_AmericanDepositorySharesConversionRatio_ba8ddb10-48df-43cd-ad60-7b65a81e6c6b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a12c132-b6d0-4370-be95-91ad3458f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a12c132-b6d0-4370-be95-91ad3458f4ab" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dee6e43f-fe2a-4850-89a8-64a08e1b5946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dee6e43f-fe2a-4850-89a8-64a08e1b5946" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6f99b6ac-9174-49da-a132-755d53de41ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6f99b6ac-9174-49da-a132-755d53de41ac" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5a1046f1-6538-442e-b57c-8e5374732133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5a1046f1-6538-442e-b57c-8e5374732133" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d3617a1d-e2aa-4757-b896-f8f6ce691595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d3617a1d-e2aa-4757-b896-f8f6ce691595" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockSalesAgentCommissionPercent_b7e9bd3a-fb11-4dc5-afcb-b2216c181388" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockSalesAgentCommissionPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_SaleOfStockSalesAgentCommissionPercent_b7e9bd3a-fb11-4dc5-afcb-b2216c181388" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice_92020e0c-2635-4ac9-a2d5-50af53dc032f" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice_92020e0c-2635-4ac9-a2d5-50af53dc032f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ecc15ba-93f7-4fe9-8d24-50d08b70ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ecc15ba-93f7-4fe9-8d24-50d08b70ac40" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06dd123b-e578-4ed8-b259-580f59d229c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06dd123b-e578-4ed8-b259-580f59d229c4" xlink:type="arc" order="11"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_af879c2b-e5d2-4aea-add4-cbe04a92dfda_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_af879c2b-e5d2-4aea-add4-cbe04a92dfda_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6543ae96-6f80-41be-8d59-d3af237b2d00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6543ae96-6f80-41be-8d59-d3af237b2d00" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3199e5bf-07dc-46eb-b671-b32582b8370a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3199e5bf-07dc-46eb-b671-b32582b8370a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7451a71f-aa3b-4ca0-af5d-f5c63be0eebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7451a71f-aa3b-4ca0-af5d-f5c63be0eebe" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fc4b099f-7458-4c6a-a07b-68bbf9362ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_PerformanceSharesMember_fc4b099f-7458-4c6a-a07b-68bbf9362ebc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50d8d384-aba6-459b-a2f4-21c9ddb105c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50d8d384-aba6-459b-a2f4-21c9ddb105c6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember_7474548d-76bf-4e82-84ee-89559550d904" xlink:href="avdl-20241231.xsd#avdl_RestrictedShareAwardsGrantedToEmployeesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:to="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember_7474548d-76bf-4e82-84ee-89559550d904" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_86e73d4e-e237-4649-a83b-8176aef2834d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:to="loc_us-gaap_VestingDomain_86e73d4e-e237-4649-a83b-8176aef2834d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:to="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_a6bd5d1a-6562-4bce-93ef-ecfbbfffee2e" xlink:href="avdl-20241231.xsd#avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_a6bd5d1a-6562-4bce-93ef-ecfbbfffee2e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember_c7d8cdfb-b70e-45e0-af87-7c4090498070" xlink:href="avdl-20241231.xsd#avdl_VestOneYearFollowingAchievementOfMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember_c7d8cdfb-b70e-45e0-af87-7c4090498070" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_55bbc07e-1e3c-4e92-b12d-0ab28a05b2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_55bbc07e-1e3c-4e92-b12d-0ab28a05b2e8" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_584a7548-c717-4d8f-80a3-e0f178131c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_584a7548-c717-4d8f-80a3-e0f178131c70" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_783ea437-0278-4c1a-b773-0e2d75c9578c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_783ea437-0278-4c1a-b773-0e2d75c9578c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember_86d46256-1074-4cab-b016-6667d60ff965" xlink:href="avdl-20241231.xsd#avdl_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember_86d46256-1074-4cab-b016-6667d60ff965" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_058c57f8-5b3d-42d8-bfba-81aa19dabe65_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:to="loc_us-gaap_PlanNameDomain_058c57f8-5b3d-42d8-bfba-81aa19dabe65_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:to="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_InducementPlanMember_25a35438-2464-4f96-814c-fcfacb98b56a" xlink:href="avdl-20241231.xsd#avdl_InducementPlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:to="loc_avdl_InducementPlanMember_25a35438-2464-4f96-814c-fcfacb98b56a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember_7b78ea44-ab6a-445f-bda3-c07213afed15" xlink:href="avdl-20241231.xsd#avdl_A2017AvadelEmployeeSharePurchasePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:to="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember_7b78ea44-ab6a-445f-bda3-c07213afed15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_efe4072e-ba14-4aa6-9480-3a2020d94a4f_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_efe4072e-ba14-4aa6-9480-3a2020d94a4f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_13b35722-86c6-442f-8b3d-3ef7616cba1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:to="loc_srt_DirectorMember_13b35722-86c6-442f-8b3d-3ef7616cba1d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_6123d551-2393-4e16-8169-3e5d5a47d706_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:to="loc_us-gaap_GranteeStatusDomain_6123d551-2393-4e16-8169-3e5d5a47d706_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:to="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_31ff8a7c-a321-4045-8b90-46fc84ab643a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_31ff8a7c-a321-4045-8b90-46fc84ab643a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_dd63221b-6c60-48ac-aa88-ba2691df00f1_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:to="loc_srt_RangeMember_dd63221b-6c60-48ac-aa88-ba2691df00f1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:to="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b16e5ba-091f-45c6-9560-140205245596" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:to="loc_srt_MinimumMember_5b16e5ba-091f-45c6-9560-140205245596" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7227004-4230-49a8-8de0-034c8fb31428" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:to="loc_srt_MaximumMember_f7227004-4230-49a8-8de0-034c8fb31428" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77b88d18-b31d-4337-9535-08774d1944a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77b88d18-b31d-4337-9535-08774d1944a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6974bd3-5d6d-4051-9494-f4949e8e46c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6974bd3-5d6d-4051-9494-f4949e8e46c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2963c0b6-cf70-4ef4-aaab-3239667e0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2963c0b6-cf70-4ef4-aaab-3239667e0d90" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6487acd-61ec-45ef-bc10-9c1023583ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6487acd-61ec-45ef-bc10-9c1023583ca9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79bd1af9-1e7d-4717-83c9-2c035ddf7937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79bd1af9-1e7d-4717-83c9-2c035ddf7937" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_025ef83f-fed2-4f2c-ade9-c00a210ad600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_025ef83f-fed2-4f2c-ade9-c00a210ad600" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_76e906d2-719b-41f9-9e78-6276fe1cdec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_76e906d2-719b-41f9-9e78-6276fe1cdec5" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3294c80c-1737-43ea-a837-7111c37436ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3294c80c-1737-43ea-a837-7111c37436ff" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8f8b133f-56a3-4e9d-8f09-2c74b1da570c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8f8b133f-56a3-4e9d-8f09-2c74b1da570c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b8bc8393-1a5a-4496-8f0a-19a8010eec96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b8bc8393-1a5a-4496-8f0a-19a8010eec96" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65c75635-382b-4ab3-bcf7-383269c5027a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65c75635-382b-4ab3-bcf7-383269c5027a" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_866eee0d-a222-4fde-9079-4ac80d05b728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_866eee0d-a222-4fde-9079-4ac80d05b728" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_175957e0-09f5-4c8b-9c01-34368a06d742" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_175957e0-09f5-4c8b-9c01-34368a06d742" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_607e3811-bc11-4e17-af34-9888a78329c1" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_607e3811-bc11-4e17-af34-9888a78329c1" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_425241f6-b1e8-4b70-a240-1036b86a5ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_425241f6-b1e8-4b70-a240-1036b86a5ef1" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_249d6a7f-1c24-4c85-a241-fb17fa8fa060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_249d6a7f-1c24-4c85-a241-fb17fa8fa060" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e04be747-a09a-4535-873b-aa9e27ee87eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e04be747-a09a-4535-873b-aa9e27ee87eb" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4493a4f8-b4f8-4232-b80b-6341de777ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4493a4f8-b4f8-4232-b80b-6341de777ff6" xlink:type="arc" order="17"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationFairValueAssumptionsDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_a8b76c82-6f6f-4132-9754-458171c698b5_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_a8b76c82-6f6f-4132-9754-458171c698b5_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8416678f-240c-490d-8bc6-7957cad81af0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8416678f-240c-490d-8bc6-7957cad81af0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc1d205-f6c4-40c5-af4d-70cb4715a4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc1d205-f6c4-40c5-af4d-70cb4715a4a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_62355ff3-7eeb-44c9-9e54-4139507c7d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_62355ff3-7eeb-44c9-9e54-4139507c7d77" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f428c8c8-daa4-4a3f-ab22-024c572ee287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f428c8c8-daa4-4a3f-ab22-024c572ee287" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73730b5a-cfc9-4c63-b8d1-073fdf5fe1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73730b5a-cfc9-4c63-b8d1-073fdf5fe1dc" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationRestrictedShareActivityDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:to="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d036e12b-fd62-4df0-9bdc-561078f34516_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_d036e12b-fd62-4df0-9bdc-561078f34516_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_48e117f4-2336-45ec-b61f-33106bfbdacc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:to="loc_us-gaap_RestrictedStockMember_48e117f4-2336-45ec-b61f-33106bfbdacc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_147b27d4-8d47-4521-b5db-1f021eed2182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_147b27d4-8d47-4521-b5db-1f021eed2182" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ed185d-afe5-4e36-ad70-0983c412a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ed185d-afe5-4e36-ad70-0983c412a9a2" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26532ae9-c1a0-4cdf-9bb7-ba51f0b1053d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26532ae9-c1a0-4cdf-9bb7-ba51f0b1053d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44434183-c10b-4508-be26-68ac2e3f4529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44434183-c10b-4508-be26-68ac2e3f4529" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c03e9b7-7d29-4dc3-90dd-8015fb88a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a59f1dbc-ff44-4ef8-b994-56717d90fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a59f1dbc-ff44-4ef8-b994-56717d90fc88" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8224f6a5-5d2c-4065-a3fd-31fd01d4476f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8224f6a5-5d2c-4065-a3fd-31fd01d4476f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_675b48a4-bdce-4437-bfd9-801b1cf73cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_675b48a4-bdce-4437-bfd9-801b1cf73cde" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_01462a84-6bd2-4277-b56a-58853f980335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_01462a84-6bd2-4277-b56a-58853f980335" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c88b041d-4bbd-44c4-a0d8-f93082ca7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ComprehensiveLossDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ComprehensiveLossDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_34778c49-4f60-4e51-91d4-7cb97f90f493_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:to="loc_us-gaap_EquityComponentDomain_34778c49-4f60-4e51-91d4-7cb97f90f493_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:to="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_77c37660-e976-450c-b841-f2d4c8802906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_77c37660-e976-450c-b841-f2d4c8802906" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_be85f7b9-c3f0-4000-a8a4-0bc7c3c792e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_be85f7b9-c3f0-4000-a8a4-0bc7c3c792e9" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33f20315-7519-4533-a52d-f28eb55892da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:to="loc_us-gaap_StockholdersEquity_33f20315-7519-4533-a52d-f28eb55892da" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0bdbecad-5da5-4920-b359-3018de6d33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0bdbecad-5da5-4920-b359-3018de6d33c3" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a54fc53-94e0-4111-b590-24731fff9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_406ac076-dd55-4f10-8e5e-8802cc1cc29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_406ac076-dd55-4f10-8e5e-8802cc1cc29b" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_2ebad4e3-c284-418f-87d3-ef8bf058d1ae_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:to="loc_us-gaap_SegmentDomain_2ebad4e3-c284-418f-87d3-ef8bf058d1ae_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:to="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ReportableSegmentMember_c284089b-cb92-493f-96aa-0a8153e71689" xlink:href="avdl-20241231.xsd#avdl_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:to="loc_avdl_ReportableSegmentMember_c284089b-cb92-493f-96aa-0a8153e71689" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8ac5f9d0-7795-424e-86dd-b994a4a706a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8ac5f9d0-7795-424e-86dd-b994a4a706a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_94f729bf-954e-435f-92c8-da4896a78b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_94f729bf-954e-435f-92c8-da4896a78b97" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8f01dcb3-9249-4fa1-80b1-119ad3bf3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_GrossProfit_8f01dcb3-9249-4fa1-80b1-119ad3bf3cc5" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_976191dd-efe6-45cb-a2a5-54ad6e498d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_976191dd-efe6-45cb-a2a5-54ad6e498d53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5bfe4098-29d1-4e04-8094-b30ad538d650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5bfe4098-29d1-4e04-8094-b30ad538d650" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cb0e3e1d-9a41-44de-a3b0-3bda6115a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cb0e3e1d-9a41-44de-a3b0-3bda6115a30c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0cb1095c-2d12-408d-ba07-51d010dbb54c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0cb1095c-2d12-408d-ba07-51d010dbb54c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ce7912c8-a518-4cea-a43b-cf4e9bb8e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_OperatingExpenses_ce7912c8-a518-4cea-a43b-cf4e9bb8e9a6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf944735-3d1b-4f8e-b687-647aba5c82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_bf944735-3d1b-4f8e-b687-647aba5c82b1" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_ec2dfd66-e7d6-43b0-9098-389a71a8e49e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_InvestmentIncomeNet_ec2dfd66-e7d6-43b0-9098-389a71a8e49e" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4830aa1b-3f03-4344-a724-b47a992f29cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_InterestExpenseDebt_4830aa1b-3f03-4344-a724-b47a992f29cf" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e34199a9-8710-403c-86b9-4ff4356251e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e34199a9-8710-403c-86b9-4ff4356251e3" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfac80d9-b3cd-4dc0-ae1d-181fd8429ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfac80d9-b3cd-4dc0-ae1d-181fd8429ed5" xlink:type="arc" order="8"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationLongLivedAssetsbyGeographicRegionDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:to="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a_default" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:to="loc_srt_SegmentGeographicalDomain_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:to="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_60bf82ef-7e26-42a9-8d66-7a9f6bb287e5" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:to="loc_country_US_60bf82ef-7e26-42a9-8d66-7a9f6bb287e5" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8c311629-1bd0-4a28-88b7-2b3d0e1e1513" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:to="loc_country_IE_8c311629-1bd0-4a28-88b7-2b3d0e1e1513" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:to="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_b06eec76-5e21-41fd-bbb9-455a53177437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:to="loc_us-gaap_NoncurrentAssets_b06eec76-5e21-41fd-bbb9-455a53177437" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:definitionLink xlink:role="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_a6bb30d8-085b-4e37-9ccd-1c24336ca04b_default" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_a6bb30d8-085b-4e37-9ccd-1c24336ca04b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9d99cbe0-49af-4964-bdbc-7ebacde8c6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9d99cbe0-49af-4964-bdbc-7ebacde8c6ee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_90fe638c-7efe-4ea5-b96d-8db59a82b406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_90fe638c-7efe-4ea5-b96d-8db59a82b406" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_07283ec4-d1f0-4484-94f2-78dbec0fe6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_07283ec4-d1f0-4484-94f2-78dbec0fe6cf" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_11b93697-533c-4fd9-ba4f-0e5294288fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_11b93697-533c-4fd9-ba4f-0e5294288fec" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_11c0be5f-9f62-4f5d-9d9b-369e6f7f1cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_11c0be5f-9f62-4f5d-9d9b-369e6f7f1cfa" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48cb87b0-559d-4e67-966e-b9e689d17d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>21
<FILENAME>avdl-20241231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_05d85d5b-e53f-4d12-a48a-54112df0ffc6_terseLabel_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price</link:label>
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_documentation_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The weighted average exercise price of equity instruments other than options granted in period.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_753cd530-ea5b-4f3b-8a71-29e2ec6ea5c9_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_4ab1e4d7-9a88-42c5-a21e-2b1118f99517_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract_51e1fb1b-af7d-41e8-8e7b-32bb739536d4_verboseLabel_en-US" xlink:label="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Long-lived Assets by Geographic Region:</link:label>
    <link:label id="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract_label_en-US" xlink:label="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographic Areas, Long-Lived Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:to="lab_us-gaap_GeographicAreasLongLivedAssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_9c2dd70c-310c-4aff-b725-25f716a2981f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest expense carryforward</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetInterestCarryforward_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, Interest Carryforward</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:to="lab_us-gaap_DeferredTaxAssetInterestCarryforward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_576e593a-26c0-4034-a737-806d58629048_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_ae6ef4a8-5910-4443-80df-92067eebc5cd_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_c950cb32-de3a-4bf6-9b92-c5f3a34cab5b_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Costs</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_ef6d8260-eeaf-44a5-a3fa-6b6119198ef5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) provision - at statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_c3429dff-10ef-42dc-921f-19708c365de1_negatedLabel_en-US" xlink:label="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Decrease in income tax benefit</link:label>
    <link:label id="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Income Tax Expense (Benefit)</link:label>
    <link:label id="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_documentation_en-US" xlink:label="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase (Decrease) In Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:href="avdl-20241231.xsd#avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:to="lab_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AmericanDepositorySharesConversionRatio_e7b35352-3e55-40a1-906e-629d1ede49e9_terseLabel_en-US" xlink:label="lab_avdl_AmericanDepositorySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ADSs, conversion ratio</link:label>
    <link:label id="lab_avdl_AmericanDepositorySharesConversionRatio_label_en-US" xlink:label="lab_avdl_AmericanDepositorySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depository Shares, Conversion Ratio</link:label>
    <link:label id="lab_avdl_AmericanDepositorySharesConversionRatio_documentation_en-US" xlink:label="lab_avdl_AmericanDepositorySharesConversionRatio" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depository Shares, Conversion Ratio</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositorySharesConversionRatio" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositorySharesConversionRatio"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AmericanDepositorySharesConversionRatio" xlink:to="lab_avdl_AmericanDepositorySharesConversionRatio" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_e208cf51-84a4-4113-bbb4-63e17f58f67d_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net change in cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_February2023NotesMember_c2b61cc3-9318-4f31-9a8b-c87d307ce33a_terseLabel_en-US" xlink:label="lab_avdl_February2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">February 2023 Notes</link:label>
    <link:label id="lab_avdl_February2023NotesMember_label_en-US" xlink:label="lab_avdl_February2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">February 2023 Notes [Member]</link:label>
    <link:label id="lab_avdl_February2023NotesMember_documentation_en-US" xlink:label="lab_avdl_February2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_February2023NotesMember" xlink:href="avdl-20241231.xsd#avdl_February2023NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_February2023NotesMember" xlink:to="lab_avdl_February2023NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_DirectorMember_e1240d2d-190d-40fd-a55d-6194f6bbf74d_terseLabel_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Board of Directors</link:label>
    <link:label id="lab_srt_DirectorMember_label_en-US" xlink:label="lab_srt_DirectorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_DirectorMember" xlink:to="lab_srt_DirectorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9aa5db6b-88bf-4422-be22-d808a5f108ba_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_0aaf537c-1ebf-4a65-8575-138b0d5b414c_terseLabel_en-US" xlink:label="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax liabilities</link:label>
    <link:label id="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_label_en-US" xlink:label="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Liabilities And Other Noncurrent Liabilities</link:label>
    <link:label id="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_documentation_en-US" xlink:label="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tax Liabilities And Other Noncurrent Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:href="avdl-20241231.xsd#avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:to="lab_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_4a625316-6708-4854-b4d1-3e1150cab050_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesCurrent" xlink:to="lab_us-gaap_OtherLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_f9999b5c-550b-4d3f-ba38-b75a3bc575e7_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits that Would Impact Effective Tax Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_dd9393cd-b4a1-41df-aa29-78a6fd6d7b79_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_cfa17181-0689-47e9-884f-624f3d490146_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_c79ed9a0-2f01-4ae0-89c8-3baeeca753a6_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_a1632068-d1f4-466d-a225-b9e5fce7626d_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_abe5ca12-20d1-4bb9-b655-e7862fae7fef_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting period (in years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityNoncurrent_fffd4e57-9940-4fec-8dba-4f7bd6b3afe4_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligation</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityNoncurrent_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liability, Noncurrent</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityNoncurrent_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:to="lab_avdl_RoyaltyFinancingLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_0bfa7488-e26e-46af-93dd-56d7dc5bc6d0_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_0ac29847-0577-4ff0-9727-44d5f381be03_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_c73e5a38-bc77-4fa6-961a-bcfc678a6cb7_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income taxes refunded, net</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_3bca049c-8bf8-4fde-b191-91c9eb492140_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange/Settlement of Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RepaymentOfRoyaltyLiability_84b7c579-1490-4fb6-95b4-eb9c78d6761f_negatedTerseLabel_en-US" xlink:label="lab_avdl_RepaymentOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: royalty payments made to RTW</link:label>
    <link:label id="lab_avdl_RepaymentOfRoyaltyLiability_label_en-US" xlink:label="lab_avdl_RepaymentOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayment Of Royalty Liability</link:label>
    <link:label id="lab_avdl_RepaymentOfRoyaltyLiability_documentation_en-US" xlink:label="lab_avdl_RepaymentOfRoyaltyLiability" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Repayment Of Royalty Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RepaymentOfRoyaltyLiability" xlink:href="avdl-20241231.xsd#avdl_RepaymentOfRoyaltyLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RepaymentOfRoyaltyLiability" xlink:to="lab_avdl_RepaymentOfRoyaltyLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_2ff394da-9b67-4c18-a154-566bb59ac6d2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_5bbe16f1-16b1-425e-afd3-3db1c1898edb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Employee</link:label>
    <link:label id="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Employee [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:to="lab_us-gaap_ShareBasedPaymentArrangementEmployeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_e886c1f8-f356-4a1a-ac4a-ff31d8889411_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryPolicyTextBlock" xlink:to="lab_us-gaap_InventoryPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_30be7af3-b44a-4e03-8308-444e7dc23836_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_ac76fcb3-6109-47df-9015-749ca00545de_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_91297632-ebfb-4ae8-ac75-d21e08fefbea_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development tax credits</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_cda765a2-04b1-4423-bbe3-00b4cdefdde1_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_20f86af4-1073-4958-bf7a-ffdaf20d61ed_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_6806d844-a0dc-48bf-8176-d543047421cc_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease costs</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UndistributedEarnings_14d39b4e-0bef-4c9e-bf06-3f6f5118ca62_terseLabel_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unremitted earnings</link:label>
    <link:label id="lab_us-gaap_UndistributedEarnings_label_en-US" xlink:label="lab_us-gaap_UndistributedEarnings" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Undistributed Earnings, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarnings"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UndistributedEarnings" xlink:to="lab_us-gaap_UndistributedEarnings" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_83944e63-4d42-4d17-ac0f-c98e22a0a2e6_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_57e9bf0f-3323-467d-80b2-627a489c4dae_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_7853b633-7c80-4f3c-bf99-3c76df2bbf1d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross realized losses</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_715278a9-cb1d-4c8b-a6fa-1c092d7ca662_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_b5a2d187-c68e-4bcb-a79f-d34151326800_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_8264010d-6d28-475f-86e8-44c6ba31d03f_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_country_US_27f3995a-2549-4f8f-8046-5b118553c283_terseLabel_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S.</link:label>
    <link:label id="lab_country_US_label_en-US" xlink:label="lab_country_US" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">UNITED STATES</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_US" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_US" xlink:to="lab_country_US" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_728f413c-11dd-4923-af60-7ab8d6f379ee_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Changes</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_b891931d-ef0b-4aa1-a88d-7285e725ad25_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effect of dilutive securities&#8212;employee and director equity awards outstanding, preferred shares and 2023 Notes (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted, Adjustment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:to="lab_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_81048bc0-a375-462d-a34e-cc204b10fa47_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other non-current assets</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_7a4a338d-5962-42a0-9069-fe7ab493a07b_totalLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total &#160;</link:label>
    <link:label id="lab_us-gaap_OtherAssetsNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsNoncurrent" xlink:to="lab_us-gaap_OtherAssetsNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_0c59dd83-f4c9-414b-bce2-8e3219cf15ad_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_7164ad29-63c2-4afc-a07f-9b59d2cf8fe8_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_f5465d33-330a-463a-8959-affc01623dcd_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Royalty Financing Obligation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_50277547-3891-42a4-b17f-2a4923022e9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_cddad926-2de2-4882-a435-c7bb8c063e89_terseLabel_en-US" xlink:label="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net [Roll Forward]</link:label>
    <link:label id="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_label_en-US" xlink:label="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net [Roll Forward]</link:label>
    <link:label id="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_documentation_en-US" xlink:label="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Increase (Decrease), Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentIncreaseDecreaseNetRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:to="lab_avdl_DebtInstrumentIncreaseDecreaseNetRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_077b148f-df06-40f5-9cea-595db8013da7_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research tax credit receivable</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_a2e58016-7d44-46af-9cc2-f3371197fb33_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Return to Provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_5cd98a92-057b-4cfd-8690-05e280f6cb6c_terseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expenses [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpensesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_82493944-78dc-42fa-8fab-21c0abe17973_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_5845f523-0017-42b7-87fb-730fff347692_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net proceeds from shares issued</link:label>
    <link:label id="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Consideration Received on Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:to="lab_us-gaap_SaleOfStockConsiderationReceivedOnTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_56a23d01-65ac-4c05-9d27-b23adc16b5e3_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Operating Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_85341b9f-b19e-4233-a918-e0988bf828b5_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_29650c35-ae73-424b-b49c-b22b75696013_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Accumulated Other Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_17660f31-c05f-4841-86f4-6fa851bc12c0_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember_ef4afea0-f127-48ca-a21e-fbd3f22f8d7f_terseLabel_en-US" xlink:label="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Four</link:label>
    <link:label id="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember_label_en-US" xlink:label="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four [Member]</link:label>
    <link:label id="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember_documentation_en-US" xlink:label="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:href="avdl-20241231.xsd#avdl_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:to="lab_avdl_ShareBasedPaymentArrangementTrancheFourMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_9262e3ca-910f-4112-b911-9c744350a49b_verboseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Prepaid and other expenses</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseCurrent" xlink:to="lab_us-gaap_PrepaidExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_c2fa68de-f3e4-4978-aeca-fe6c8aa94fa2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_d91eb4b2-3cdd-4dd6-bfaf-0b2b165ee583_terseLabel_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_OtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_OtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherAssetsCurrent" xlink:to="lab_us-gaap_OtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_f587ab1e-7060-450e-a710-15128566cad9_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development (&#8220;R&amp;D&#8221;)</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_4a8b064a-9ac6-460f-8406-c16bf9c3e719_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_98c7838e-ac5a-4b03-a3e0-9c8f4a85b7e5_verboseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_0cc86a97-abbe-4f0b-bed7-eae6e7b6e23b_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_d1f664bc-dad2-40b3-8a8c-007b54ae246d_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ContractualObligationAnnualAmount_ab12fb3e-e088-48ab-9016-2dac578755a1_terseLabel_en-US" xlink:label="lab_avdl_ContractualObligationAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contractual obligation, annual amount</link:label>
    <link:label id="lab_avdl_ContractualObligationAnnualAmount_label_en-US" xlink:label="lab_avdl_ContractualObligationAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Annual Amount</link:label>
    <link:label id="lab_avdl_ContractualObligationAnnualAmount_documentation_en-US" xlink:label="lab_avdl_ContractualObligationAnnualAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contractual Obligation, Annual Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ContractualObligationAnnualAmount" xlink:href="avdl-20241231.xsd#avdl_ContractualObligationAnnualAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ContractualObligationAnnualAmount" xlink:to="lab_avdl_ContractualObligationAnnualAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_8ed58c07-af05-44bb-b109-1fd2262855cf_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Deferred Revenue [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:to="lab_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_bdb5e0ec-6bea-4796-bd66-db9b17e54ba9_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_22a679f0-cd5e-4089-8a82-efa4e6adc4f9_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_4ba6d62b-6322-41b1-9a39-526a2d4053a1_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_865c0171-b5e1-4692-9e0c-d2f1f9016d26_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAcquireeDomain_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition, Acquiree [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:to="lab_us-gaap_BusinessAcquisitionAcquireeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_d7b85885-d514-42aa-9a9d-aaedcf75ea7d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_b47705f0-4a76-4e40-8d10-264540706691_verboseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalCommonStock_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital, Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="lab_us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_72d6c8e5-3f10-495c-adb8-4d26047fc7c1_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_fa47c788-11e3-40e0-9371-3e2f9dabc285_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_bb5ec453-ca08-4e9b-a6df-0ed10a65762b_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for debt issuance costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfDebtIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Debt Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfDebtIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_6cc3a5a5-7cfb-407b-a015-52e6f9dd8fec_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="lab_us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_5a7c68f4-7c14-4ee8-bb45-714e5ccebf10_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency accrued</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency, Accrual, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:to="lab_us-gaap_LossContingencyAccrualCarryingValueCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_992b066c-dfb2-4565-a9a0-d4242c18c6fa_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 3</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel3Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 3 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel3Member" xlink:to="lab_us-gaap_FairValueInputsLevel3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_144c0c3c-1733-4cc3-95d0-fa3c44a90932_negatedLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deductions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDeductions_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDeductions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_7418bbf2-fb28-40d2-b184-3b534b78186a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_84cd8e35-9ca7-4f63-bb5b-1f9aab80a17c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible share-based compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_cfbca3fe-f39e-4af1-968a-28592684f229_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Non-Current Assets</link:label>
    <link:label id="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Other Assets, Noncurrent [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:to="lab_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_9ed7676c-00d6-4483-8ea6-0abca37068ac_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_f2d670ca-67a4-4f01-ac12-48731e0f39f1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="lab_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_f25c667e-b1e4-44e3-ba9b-646dececa7ae_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_d8a55440-4348-4209-b3ad-69a1921415ab_totalLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_3353e5b5-7494-426f-8db8-fecada858dc7_verboseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Potential ordinary shares excluded from the computation of weighted average shares (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_4e7aa1ba-371d-422d-a2e5-c52b320bc71d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche One</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche One [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OrphanDrugTaxCreditMember_64ff4514-ff2c-4732-bd98-401b42dd213f_terseLabel_en-US" xlink:label="lab_avdl_OrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan Drug tax credit</link:label>
    <link:label id="lab_avdl_OrphanDrugTaxCreditMember_label_en-US" xlink:label="lab_avdl_OrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan Drug Tax Credit [Member]</link:label>
    <link:label id="lab_avdl_OrphanDrugTaxCreditMember_documentation_en-US" xlink:label="lab_avdl_OrphanDrugTaxCreditMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Orphan Drug Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OrphanDrugTaxCreditMember" xlink:href="avdl-20241231.xsd#avdl_OrphanDrugTaxCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OrphanDrugTaxCreditMember" xlink:to="lab_avdl_OrphanDrugTaxCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_b7fa8106-4db5-4da6-9c73-6b70a06aa238_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_b5a8cf8a-305c-4863-a57c-c4248696582e_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at January 1</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_903f67fb-a169-4feb-9656-e0dafd1fbe31_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at December 31</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AccredoMember_4583b7e2-3d2a-4a7a-a140-d93d74a8d169_terseLabel_en-US" xlink:label="lab_avdl_AccredoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo</link:label>
    <link:label id="lab_avdl_AccredoMember_label_en-US" xlink:label="lab_avdl_AccredoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo [Member]</link:label>
    <link:label id="lab_avdl_AccredoMember_documentation_en-US" xlink:label="lab_avdl_AccredoMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoMember" xlink:href="avdl-20241231.xsd#avdl_AccredoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AccredoMember" xlink:to="lab_avdl_AccredoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ThreeCustomersMember_5e692126-b232-4e06-be82-c10a16ea050e_terseLabel_en-US" xlink:label="lab_avdl_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Three customers</link:label>
    <link:label id="lab_avdl_ThreeCustomersMember_label_en-US" xlink:label="lab_avdl_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Three Customers [Member]</link:label>
    <link:label id="lab_avdl_ThreeCustomersMember_documentation_en-US" xlink:label="lab_avdl_ThreeCustomersMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Three Customers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ThreeCustomersMember" xlink:to="lab_avdl_ThreeCustomersMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_d8998312-be07-4a0b-b9b7-ebb8b4c9995c_verboseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized compensation expense</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_54df0f29-a5b2-41f5-b192-63a6909094af_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Goodwill_07c15330-c823-4cac-a7ee-7eda548e27ed_verboseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_eebc0972-aef8-4bd4-a73c-c76e96c41f74_terseLabel_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_Goodwill_label_en-US" xlink:label="lab_us-gaap_Goodwill" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Goodwill" xlink:to="lab_us-gaap_Goodwill" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_69cc7d28-98b3-452f-b998-8bde3c3388e3_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureTextBlock" xlink:to="lab_us-gaap_InventoryDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_da89aee5-2079-466e-9e3e-efdd331fdafe_terseLabel_en-US" xlink:label="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug and R&amp;D tax credit</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_label_en-US" xlink:label="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug And Research</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_documentation_en-US" xlink:label="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug And Research</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:to="lab_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_18e1327a-094f-4b9f-939b-cae162710c0c_terseLabel_en-US" xlink:label="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Software, office and computer equipment</link:label>
    <link:label id="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_label_en-US" xlink:label="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs, Office Equipment, and Computer Equipment [Member]</link:label>
    <link:label id="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_documentation_en-US" xlink:label="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Software and Software Development Costs, Office Equipment, and Computer Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:href="avdl-20241231.xsd#avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:to="lab_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_990ceb1e-f662-4caa-95cb-4f17326a7ad2_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Option</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_9b963d0d-743b-494f-aea0-1365e3adc8b6_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal, State and Local, Tax Expense (Benefit) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:to="lab_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_ae11225d-63d8-410f-90b1-7269f00db574_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-sale [Table]</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTable_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_678eaacc-172e-45b7-a5e9-fdc46960ec1b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vested (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_FscHoldingsLlcMember_1749468c-b081-4bae-91de-83fdd46a593b_terseLabel_en-US" xlink:label="lab_avdl_FscHoldingsLlcMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">FSC</link:label>
    <link:label id="lab_avdl_FscHoldingsLlcMember_label_en-US" xlink:label="lab_avdl_FscHoldingsLlcMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FSC Holdings, LLC [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FscHoldingsLlcMember" xlink:href="avdl-20241231.xsd#avdl_FscHoldingsLlcMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_FscHoldingsLlcMember" xlink:to="lab_avdl_FscHoldingsLlcMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Depreciation_4cb7ce84-e7a8-4d05-a83b-6eba02daaba9_verboseLabel_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:label id="lab_us-gaap_Depreciation_label_en-US" xlink:label="lab_us-gaap_Depreciation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Depreciation" xlink:to="lab_us-gaap_Depreciation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_2f4f5612-ea58-4963-8c91-4eaed3b82a23_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_a9c1668e-0f1c-48be-9dab-552a2216df31_verboseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_97043999-49b6-4e77-967c-58d5d0d76072_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2025</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_FirstJazzComplaintMember_f3b69090-e09d-4b81-92ef-6bf663dedf30_terseLabel_en-US" xlink:label="lab_avdl_FirstJazzComplaintMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">First Jazz Complaint</link:label>
    <link:label id="lab_avdl_FirstJazzComplaintMember_label_en-US" xlink:label="lab_avdl_FirstJazzComplaintMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">First Jazz Complaint [Member]</link:label>
    <link:label id="lab_avdl_FirstJazzComplaintMember_documentation_en-US" xlink:label="lab_avdl_FirstJazzComplaintMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">First Jazz Complaint</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FirstJazzComplaintMember" xlink:href="avdl-20241231.xsd#avdl_FirstJazzComplaintMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_FirstJazzComplaintMember" xlink:to="lab_avdl_FirstJazzComplaintMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_40cb51ae-659b-49a7-803f-fbff8732d3d9_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_2b76cb7f-6644-45f1-a547-333d30ae0e17_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_10ea39d2-9180-49d1-b045-2d95fe1533f2_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Raw materials and supplies</link:label>
    <link:label id="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Raw Materials and Supplies, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:to="lab_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_7770ab65-ee20-4ee5-9de3-ae44bd84df6e_terseLabel_en-US" xlink:label="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements, furniture, fixtures and fittings</link:label>
    <link:label id="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_label_en-US" xlink:label="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Furniture, Fixtures And Fittings [Member]</link:label>
    <link:label id="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_documentation_en-US" xlink:label="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Leasehold Improvements, Furniture, Fixtures And Fittings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:href="avdl-20241231.xsd#avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:to="lab_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_1a322244-3f64-4260-bee8-4d8123bf447f_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_74ab583f-d15a-4a51-8937-2320525be7d8_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contractual Maturity Dates</link:label>
    <link:label id="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_label_en-US" xlink:label="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments Classified by Contractual Maturity Date [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:to="lab_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_161f2e9f-3a28-4c6f-9ced-896b881b5f45_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_1bc29093-3350-4aaf-b408-3780902f9738_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_DeferredTaxAssetsRoyaltyIncome_b4bb6181-3247-4039-b177-0c107fd0f352_terseLabel_en-US" xlink:label="lab_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty income</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsRoyaltyIncome_label_en-US" xlink:label="lab_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Royalty Income</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsRoyaltyIncome_documentation_en-US" xlink:label="lab_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Royalty Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsRoyaltyIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:to="lab_avdl_DeferredTaxAssetsRoyaltyIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_a6012202-3ddd-4b3f-91da-9e789b0f5f14_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Free Share Activity and Other Data, Nonvested [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_2ec19c3e-4b6c-4ef5-8fa3-4749245ae5c8_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Work in process</link:label>
    <link:label id="lab_us-gaap_InventoryWorkInProcessNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Work in Process, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:to="lab_us-gaap_InventoryWorkInProcessNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_5b030ff3-7a31-42b0-a33a-537c6b94c9fe_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_19958f34-59aa-4f77-aa47-bdbef83f79b6_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_2351b443-6315-4c26-86b1-a6227e25df25_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_e0b2603b-7530-45f7-a09b-e7a5d44e850a_verboseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">U.S. - State</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_0b30d24f-e8e9-4151-8d9d-449fde4deb85_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NoncurrentAssets_5bab3e9e-5077-4781-953c-97638a3b3d08_terseLabel_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived assets</link:label>
    <link:label id="lab_us-gaap_NoncurrentAssets_label_en-US" xlink:label="lab_us-gaap_NoncurrentAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NoncurrentAssets" xlink:to="lab_us-gaap_NoncurrentAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_858aedc9-bb62-4c08-89ca-0beddc2a5a9d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_96c4bdfe-fd08-40b2-95b6-d5876ae69f52_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-sale Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_569c3823-e1b6-4be6-906c-62e4769bfaee_verboseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_1ef93208-5ebc-46ca-84f7-1e080d941cb3_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_70462a56-be9a-4bd2-a914-134877c928e4_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_8c435f5f-843a-4549-a112-df747038e9aa_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_a4a3f299-ab4e-43c5-80bd-1797c1dcddb5_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock_74365f00-66fd-4dbe-a133-1c9b52394c73_terseLabel_en-US" xlink:label="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Income Tax Provision (Benefit)</link:label>
    <link:label id="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock_label_en-US" xlink:label="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Income Tax Payments [Table Text Block]</link:label>
    <link:label id="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock_documentation_en-US" xlink:label="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of scheduled payments of income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:to="lab_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_75fe6d4f-e307-4828-8268-ece00e36507e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_1c927dc5-3454-4bec-8d6d-aed779a32953_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_4a353c89-b38d-4122-9d6b-7b6a8af258be_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_a4187e1b-39f1-4721-b0b7-3df25cb18e73_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Greater than 10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_72de5d40-7d60-4a1e-82fb-c53c59ef9aac_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_e99729bb-de83-4a6b-af5f-7cad44bac9e0_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase commitment, period (in years)</link:label>
    <link:label id="lab_us-gaap_LongtermPurchaseCommitmentPeriod_label_en-US" xlink:label="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Purchase Commitment, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:to="lab_us-gaap_LongtermPurchaseCommitmentPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0d4fd8d6-0273-434a-b7c2-b205b8e243de_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_f8ea5d75-e0e7-474f-b8b4-634f06aeb1fb_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross realized gains</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_e0a12d4c-310b-4ee4-a7cc-92b6efcbc225_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:to="lab_us-gaap_IncomeTaxReconciliationOtherReconcilingItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_30609f47-0518-46c0-8d2f-53202ade9cb7_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less - accumulated depreciation</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_a6cf02c3-4d44-4b18-9b19-a930ba8c0e06_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total property and equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_177e2a56-70e5-48a3-a8e3-cbbf5eeea492_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share purchase plan share issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Ownership Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_aa6a2830-7ca9-457b-a46d-b9e5e8849168_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_7fe35833-0f3f-4ade-ab0e-b492b056a3df_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Exercised (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_5b05af72-7c54-4fd6-ba67-74a3cc5f81f7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_72ec76d4-a29d-4751-9018-9cdf4784220f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_8321207f-8bd6-4189-a3c3-1526e7d5a071_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_5e3dbbbe-33fb-4a97-afc4-60fb2fe87623_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_65afd911-00b3-432e-8bac-add85b6ab1cc_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Statute of limitations expiration</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EuropeMember_2641e7c7-2181-44f9-8413-ce64f15ab41d_terseLabel_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_srt_EuropeMember_label_en-US" xlink:label="lab_srt_EuropeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Europe [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EuropeMember" xlink:to="lab_srt_EuropeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_c2f40cd5-a261-4a7b-b5b1-d03346114093_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_9034db6c-71e5-4a8d-b294-634a30bce375_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_a1631d8d-18aa-4e0e-a204-dde10f275672_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_8c16a247-ca01-4507-b222-fb507d6d5319_totalLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Diluted shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_3072359d-f235-4f43-983b-74ef32669995_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive (loss) income, net of tax:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_c5a74a05-7043-4743-8e8f-152db1a15ef5_terseLabel_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss:</link:label>
    <link:label id="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_label_en-US" xlink:label="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent, Net of Tax [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:to="lab_us-gaap_AOCIAttributableToParentNetOfTaxRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_a3c792fd-ac9e-4483-beea-edfd33cd9944_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeAxis_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeAxis" xlink:to="lab_us-gaap_LongtermDebtTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_1c080f2a-b59c-4a5f-8a9e-62348e477b7a_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_df70097e-0859-4b24-b727-5966a9331d3f_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_b063c11e-ec0e-4cf7-a01d-1b1e69c60bb3_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_d6e693ef-ccf5-4a50-ab7c-2099e00b2537_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_9436cbca-41a1-46d3-a652-f391a997659b_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_2ae450eb-a324-43b0-9186-bfd013a80a36_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less than 1 Year</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseAxis_0a2766f2-97fd-4d4f-aba5-7c6acf20f0b7_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:label id="lab_srt_LitigationCaseAxis_label_en-US" xlink:label="lab_srt_LitigationCaseAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseAxis" xlink:to="lab_srt_LitigationCaseAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_af19d796-2449-49ad-b976-8d82c03cf2b6_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_7ecaa62c-fc95-4c97-87dd-6487cc33c50b_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued compensation</link:label>
    <link:label id="lab_us-gaap_AccruedSalariesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedSalariesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Salaries, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedSalariesCurrent" xlink:to="lab_us-gaap_AccruedSalariesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_dee0f82f-c8b5-4f57-abc8-ab57ff64378e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_567c7500-3a97-4249-a877-3a0e5afae724_terseLabel_en-US" xlink:label="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of use assets at contract manufacturing organizations</link:label>
    <link:label id="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_label_en-US" xlink:label="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent</link:label>
    <link:label id="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_documentation_en-US" xlink:label="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:to="lab_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_cd07c7ad-0eb8-4d00-8131-f5edfc1545e5_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_11e5d9a8-bcea-4461-af61-85fa7ee33672_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment and other income (expense), net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeNet_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeNet" xlink:to="lab_us-gaap_InvestmentIncomeNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_6f3c9d00-c5b4-457c-979e-5f09dc6f413e_verboseLabel_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Selling, general and administrative expenses</link:label>
    <link:label id="lab_us-gaap_SellingGeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling, General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_SellingGeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCountry_ce2bbc25-45da-4355-af98-7d1e1d30c9c4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:label id="lab_dei_EntityAddressCountry_label_en-US" xlink:label="lab_dei_EntityAddressCountry" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Country</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCountry" xlink:to="lab_dei_EntityAddressCountry" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_27caf021-f902-4fb5-8a62-bb8ac54c3ac3_totalLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other comprehensive (loss) income, net of tax</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_ffea98cf-d05a-4973-9a0e-f227a1c54222_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_f9ddc23b-896a-4a86-bb02-652fbff80cec_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_91bfb7a8-4b94-46cc-ac9a-23e004aacb71_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable, net</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_fe560f70-a796-43e4-89e9-72b688a6214d_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_3b6dca3f-e1e1-4d3f-928c-efc132d9bd72_terseLabel_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_label_en-US" xlink:label="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues from External Customers and Long-Lived Assets [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:to="lab_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_157acde6-8190-4862-8dc7-d53a2665e36e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_1bab804e-ceb9-4cf0-9801-b0c7f4c22753_terseLabel_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment loss related to goodwill</link:label>
    <link:label id="lab_us-gaap_AssetImpairmentCharges_label_en-US" xlink:label="lab_us-gaap_AssetImpairmentCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Impairment Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetImpairmentCharges" xlink:to="lab_us-gaap_AssetImpairmentCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_b23f540b-ca90-47d1-82d4-96463284d7ff_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AmericanDepositarySharesMember_416c11db-a465-4f5f-947f-810cc7815483_terseLabel_en-US" xlink:label="lab_avdl_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">American Depositary Shares</link:label>
    <link:label id="lab_avdl_AmericanDepositarySharesMember_label_en-US" xlink:label="lab_avdl_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:label id="lab_avdl_AmericanDepositarySharesMember_documentation_en-US" xlink:label="lab_avdl_AmericanDepositarySharesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">American Depositary Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositarySharesMember" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositarySharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AmericanDepositarySharesMember" xlink:to="lab_avdl_AmericanDepositarySharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_ef3fa009-9eb7-4861-8598-8f1a5e0da09f_periodStartLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligation &#8211; beginning balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_35ec2a39-6609-4ea0-bfe4-b8454a4049c8_periodEndLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligation &#8211; ending balance</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_faf17be7-e6cc-4660-83e1-9190c1f3e2b3_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_533c5dbe-8ef7-4ae9-8241-d18c8bfb4826_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted shares</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueOther_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueOther" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueOther" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_2d0aedb3-34c6-4449-8ceb-234f10075499_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain (loss) on marketable debt securities, net</link:label>
    <link:label id="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:to="lab_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_800d7b4e-6f2b-4fdb-881a-50db70d11d71_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">ASSETS</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_161adaf0-2daa-4fc1-8fde-a968473fdb7e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_afe918a2-fc80-44af-81f2-5e7fcdbc6b3c_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_2f341c7a-af76-4074-b1b1-26b221d7fbc3_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Effective interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Effective Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateEffectivePercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_f4002a05-c3a8-427f-86b1-513b1cbc403f_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, About The Company&#8217;s Significant Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_07bdfc16-f111-4a04-b35d-8f5245e2d819_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_6cc6b8c6-ce27-44d5-aa66-d75be78dd558_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_51614cb0-68c4-4c84-b6ff-14ec1227f531_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable, Weighted Average Remaining Contractual Life (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_bb17ebcb-5a56-4746-a10d-cd11afb590b3_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Vested (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_8c2cfa1e-98e3-499f-a429-0bf060d06797_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Adjusted Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f83986ea-9bf3-4dd6-adf1-7ef64ac5a3da_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_8f054397-fe58-4de1-9648-8c5e42d55939_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_f9250dd9-7ae3-425b-af9e-eecb6fffdd84_terseLabel_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward_label_en-US" xlink:label="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:to="lab_us-gaap_MovementInValuationAllowancesAndReservesRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_c0992fcd-3ddb-4790-a7ad-a8337810466b_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized tax benefits</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxContingencies_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Contingency, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_cfa3f0a6-3ac9-4568-bad0-d25d09e1c09c_terseLabel_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Furniture, fixtures and fittings</link:label>
    <link:label id="lab_us-gaap_FurnitureAndFixturesMember_label_en-US" xlink:label="lab_us-gaap_FurnitureAndFixturesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Furniture and Fixtures [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FurnitureAndFixturesMember" xlink:to="lab_us-gaap_FurnitureAndFixturesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_d446a276-a1cf-495d-a1e3-364089d1d312_verboseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_68efcecf-d85b-41d1-9501-bb3daaa5a7cf_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_4186c5cd-0ee7-4a38-abd2-0579d5ab822e_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_a7906875-4119-4676-8b86-9ead21d3de35_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expired (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_0e8df8fe-a21f-4338-bb49-eb892e6bf88f_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_5a7c2c22-7e59-422f-a0d5-7dda93ea24ac_periodStartLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance at beginning of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_2623d2be-cb3d-4dc3-8b00-50d5e85579e9_periodEndLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance at end of period</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesBalance_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesBalance" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesBalance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_13ee6d38-e137-45b6-a391-3ddbdae26594_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCost_b715f38e-2215-4523-9751-0ab90a5c910f_totalLabel_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease cost</link:label>
    <link:label id="lab_us-gaap_LeaseCost_label_en-US" xlink:label="lab_us-gaap_LeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCost" xlink:to="lab_us-gaap_LeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_15e65ffe-8da2-40df-998b-636a6ecdab80_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Range [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember_9e067882-1301-4a3f-8eb4-207733cacdf4_terseLabel_en-US" xlink:label="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2017 Avadel Employee Share Purchase Plan</link:label>
    <link:label id="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember_label_en-US" xlink:label="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">2017 Avadel Employee Share Purchase Plan [Member]</link:label>
    <link:label id="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember_documentation_en-US" xlink:label="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">2017 Avadel Employee Share Purchase Plan [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:href="avdl-20241231.xsd#avdl_A2017AvadelEmployeeSharePurchasePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:to="lab_avdl_A2017AvadelEmployeeSharePurchasePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_c490642c-0fbe-4b7a-98b5-79a06dcb9703_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusDomain_cc9f6475-4f9e-4b0b-84ea-e01c76a9ff8d_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusDomain_label_en-US" xlink:label="lab_us-gaap_GranteeStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusDomain" xlink:to="lab_us-gaap_GranteeStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingAxis_c4f30d6f-593f-49bf-9108-2aecc11509ac_terseLabel_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:label id="lab_us-gaap_VestingAxis_label_en-US" xlink:label="lab_us-gaap_VestingAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingAxis" xlink:to="lab_us-gaap_VestingAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_86c4d7c1-71d7-4661-be16-748c2e6e8adb_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Award [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_2da496d4-a795-4632-ae26-17c7eb66cd56_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CountryRegion_a1962ec3-41cd-4240-9304-8006b1ae1c5a_terseLabel_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:label id="lab_dei_CountryRegion_label_en-US" xlink:label="lab_dei_CountryRegion" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Country Region</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CountryRegion" xlink:to="lab_dei_CountryRegion" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_280d72eb-fdbc-449c-b8f2-3511cb2bcd68_terseLabel_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Goodwill impairment loss</link:label>
    <link:label id="lab_us-gaap_GoodwillImpairmentLoss_label_en-US" xlink:label="lab_us-gaap_GoodwillImpairmentLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill, Impairment Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillImpairmentLoss" xlink:to="lab_us-gaap_GoodwillImpairmentLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualAxis_adfc7a2d-447f-485e-b7e3-386cd3b2a8f9_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:label id="lab_srt_TitleOfIndividualAxis_label_en-US" xlink:label="lab_srt_TitleOfIndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualAxis" xlink:to="lab_srt_TitleOfIndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_dcd9ee3a-fad8-4c2e-9f5c-168a7d477a02_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock_198d479c-be48-494e-99f2-d92997995784_terseLabel_en-US" xlink:label="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Weighted-Average Assumptions</link:label>
    <link:label id="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Payment Award Stock Options And Warrant Grants Valuation Assumptions [Table Text Block]</link:label>
    <link:label id="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock_documentation_en-US" xlink:label="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and Warrants grants.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:to="lab_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_A163jCreditsMember_b06adc54-5979-4a1d-a89d-9f01ced4897c_terseLabel_en-US" xlink:label="lab_avdl_A163jCreditsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">163(j) Credits</link:label>
    <link:label id="lab_avdl_A163jCreditsMember_label_en-US" xlink:label="lab_avdl_A163jCreditsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">163(j) Credits [Member]</link:label>
    <link:label id="lab_avdl_A163jCreditsMember_documentation_en-US" xlink:label="lab_avdl_A163jCreditsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">163(j) Credits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A163jCreditsMember" xlink:href="avdl-20241231.xsd#avdl_A163jCreditsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_A163jCreditsMember" xlink:to="lab_avdl_A163jCreditsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_6d1a642c-d622-4eb4-96e6-2b0871e3a902_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockLineItems_label_en-US" xlink:label="lab_us-gaap_ClassOfStockLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockLineItems" xlink:to="lab_us-gaap_ClassOfStockLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_dbcfaa19-2528-4494-8fcd-b5dcd688ca7d_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Recently Adopted Accounting Guidance, Recent Accounting Guidance Not Yet Adopted, Newly Issued Climate-Related Disclosure Rule</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_40af846c-096a-4321-998f-69c5ea1b4dec_terseLabel_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementClassOfStockAxis_label_en-US" xlink:label="lab_us-gaap_StatementClassOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementClassOfStockAxis" xlink:to="lab_us-gaap_StatementClassOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_6a991ed6-d355-4682-8435-365179583132_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_21bb364f-388e-4da3-bf2c-b729cacfeba4_terseLabel_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Relationship to Entity [Domain]</link:label>
    <link:label id="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain_label_en-US" xlink:label="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title and Position [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="lab_srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_01693793-1621-4dcf-96f4-fa156964c21b_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_f2061216-49fc-4905-a064-3ff2c09f6625_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_76a5badc-42ee-49b2-9856-448b6bc82dc2_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_12bb2766-a820-410f-bcf5-215f1f1414fb_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from sales of marketable securities</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:to="lab_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_a67ceaaf-4c99-4555-86a5-23ae0e8683ae_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_50f1990e-f5de-47be-b381-2e7c82721a92_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_002985f2-292a-4293-b61e-938d18415ea5_terseLabel_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nondeductible interest expense</link:label>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_label_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount</link:label>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_documentation_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:to="lab_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_c3cfabb5-0951-4333-aca8-65671a7440b9_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MajorCustomersAxis_b3168c64-c946-4ac6-a673-f809816ddc04_terseLabel_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:label id="lab_srt_MajorCustomersAxis_label_en-US" xlink:label="lab_srt_MajorCustomersAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MajorCustomersAxis" xlink:to="lab_srt_MajorCustomersAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_c2fe54f2-b550-4640-ba82-244ba117a7a0_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</link:label>
    <link:label id="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingProceedsMaximum_1e85e1a6-6d43-492e-8f29-e57715e05de9_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingProceedsMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum proceeds from royalty financing</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingProceedsMaximum_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingProceedsMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing, Proceeds, Maximum</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingProceedsMaximum_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingProceedsMaximum" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing, Proceeds, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingProceedsMaximum" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingProceedsMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingProceedsMaximum" xlink:to="lab_avdl_RoyaltyFinancingProceedsMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_c40065bd-ff3d-4e7e-8808-99956d8945c2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_b828d066-c130-4443-b669-819b185f9c60_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Percentage of Total Sales to Customers</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_a3c1678c-50ed-4934-b961-cd45bacb4b22_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_c0acd3a1-d5c4-41c7-ba68-094c21969e32_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross research tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_8ecafd52-4e5c-4cf9-9942-e985f93d36ff_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for tax positions of prior years</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Period Increase (Decrease)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_540356b7-db87-4f18-99b1-ec7ddc2b1984_terseLabel_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Selling and marketing expenses</link:label>
    <link:label id="lab_us-gaap_SellingAndMarketingExpense_label_en-US" xlink:label="lab_us-gaap_SellingAndMarketingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Selling and Marketing Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SellingAndMarketingExpense" xlink:to="lab_us-gaap_SellingAndMarketingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingMember_dca46ba2-3ead-4d0c-b1a3-0ca85ff88669_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty Financing</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingMember_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing [Member]</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingMember_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingMember" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingMember" xlink:to="lab_avdl_RoyaltyFinancingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_19734ac7-ca27-4b1f-a220-b3673fdd6b62_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Two</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Two [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheTwoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_IncomeTaxesTable_4eccf5f9-d860-40bb-82ac-0c3b85b573e2_terseLabel_en-US" xlink:label="lab_avdl_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:label id="lab_avdl_IncomeTaxesTable_label_en-US" xlink:label="lab_avdl_IncomeTaxesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesTable" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_IncomeTaxesTable" xlink:to="lab_avdl_IncomeTaxesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock_5d70407e-5032-4f00-8908-152a00e6d0fd_terseLabel_en-US" xlink:label="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Operations</link:label>
    <link:label id="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock_label_en-US" xlink:label="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature Of Business Policy [Policy Text Block]</link:label>
    <link:label id="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Disclosure of accounting policy for nature of business.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:href="avdl-20241231.xsd#avdl_NatureOfBusinessPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:to="lab_avdl_NatureOfBusinessPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_994632c6-c4dc-460c-a6bf-9ca7c6f95d20_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_d4e4e62b-9971-4a21-be64-1d49c489bc0a_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax (benefit) provision</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_4e0f13d9-1825-4402-8db7-11fc28ceb17f_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_c38d35f8-dcf7-460e-8fbf-b99989b1f372_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_6bb7ac64-48fd-48c3-ab85-036fde77b93d_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments for Notes</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfSeniorDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Senior Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfSeniorDebt" xlink:to="lab_us-gaap_RepaymentsOfSeniorDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_NumberOfFinancialInstitutions_6c93a885-414b-4d3f-9f0d-fc9705253691_terseLabel_en-US" xlink:label="lab_avdl_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of financial institutions</link:label>
    <link:label id="lab_avdl_NumberOfFinancialInstitutions_label_en-US" xlink:label="lab_avdl_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions</link:label>
    <link:label id="lab_avdl_NumberOfFinancialInstitutions_documentation_en-US" xlink:label="lab_avdl_NumberOfFinancialInstitutions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number Of Financial Institutions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_NumberOfFinancialInstitutions" xlink:href="avdl-20241231.xsd#avdl_NumberOfFinancialInstitutions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_NumberOfFinancialInstitutions" xlink:to="lab_avdl_NumberOfFinancialInstitutions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_ec256f6d-c742-403e-b1bb-8cc4f8701c95_verboseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosures of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_6b89ff0e-8cb8-40f3-b4bc-ade07221610d_terseLabel_en-US" xlink:label="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Thereafter</link:label>
    <link:label id="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_label_en-US" xlink:label="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:label id="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_documentation_en-US" xlink:label="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, to be Paid, after Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:to="lab_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_1865e81f-b7dc-4f44-a34e-e4fc176407b0_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Settlements</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_f6719864-4e58-4c78-808d-cac91e8515ca_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net product revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_3d4cc3df-a46f-4e76-ab79-e3be59379d9f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research costs</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_6376c227-8669-46c7-8e82-f9adb52c1d1b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_1a68c75f-85dc-4c1a-bc20-bcf7b7c7e04c_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_19c75de9-8739-426a-96de-b1b5668f904b_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule II Valuation and Qualifying Accounts</link:label>
    <link:label id="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_label_en-US" xlink:label="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:to="lab_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_b8dd029f-331d-4496-a2a2-6b38f6285663_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4ee7002-de37-4fad-ae71-294f4b187d76_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by (used in) investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Investing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_3170be72-1e83-409a-a132-cd59f60d1323_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Operating loss</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_48bbff6e-a0c0-48cc-878d-c58a24108784_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_da35d7ba-fb23-4bed-8170-2b9de17ec4f1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowances</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_cf5658bb-55cf-4180-b57d-7ed4be38c37c_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_9ea2c276-173f-4734-a55b-0a4e5b851a5f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and shareholders&#8217; equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_57c73df4-a2e4-487a-8e92-33b627dc43ef_terseLabel_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other adjustments</link:label>
    <link:label id="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement_label_en-US" xlink:label="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Operating Activities, Cash Flow Statement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:to="lab_us-gaap_OtherOperatingActivitiesCashFlowStatement" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_ea28a0a1-afeb-4538-8a4a-c1bf8e15464b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_2409b448-59af-4515-b120-ad579e4a80e0_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_277588bf-c433-4d13-8bcb-30317de21504_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_0b4f4bf9-3c97-43dc-920a-545e2f411394_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring expense</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_dae7e093-fa64-46f3-8ffa-43e3fc01af17_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_ace7e59a-cb9e-4f77-b87c-bec1704fd45c_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_48f90a13-4407-41fc-a90a-00eda404f09b_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OptumFrontierTherapiesLLCMember_17fbdfc5-f953-4f9e-802e-e0f4222edc98_terseLabel_en-US" xlink:label="lab_avdl_OptumFrontierTherapiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optum</link:label>
    <link:label id="lab_avdl_OptumFrontierTherapiesLLCMember_label_en-US" xlink:label="lab_avdl_OptumFrontierTherapiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optum Frontier Therapies LLC [Member]</link:label>
    <link:label id="lab_avdl_OptumFrontierTherapiesLLCMember_documentation_en-US" xlink:label="lab_avdl_OptumFrontierTherapiesLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Optum Frontier Therapies LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumFrontierTherapiesLLCMember" xlink:href="avdl-20241231.xsd#avdl_OptumFrontierTherapiesLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OptumFrontierTherapiesLLCMember" xlink:to="lab_avdl_OptumFrontierTherapiesLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_6f081e49-71f8-47ce-acc4-b868ddd986a1_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase in operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_InducementPlanMember_1ced4466-8e35-41bf-b551-2c62dd8d5b7e_terseLabel_en-US" xlink:label="lab_avdl_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:label id="lab_avdl_InducementPlanMember_label_en-US" xlink:label="lab_avdl_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inducement Plan [Member]</link:label>
    <link:label id="lab_avdl_InducementPlanMember_documentation_en-US" xlink:label="lab_avdl_InducementPlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Inducement Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_InducementPlanMember" xlink:href="avdl-20241231.xsd#avdl_InducementPlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_InducementPlanMember" xlink:to="lab_avdl_InducementPlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice_c6e6c2ed-dd4f-43bf-b248-f9811fc044c9_terseLabel_en-US" xlink:label="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, maximum aggregate offering price</link:label>
    <link:label id="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice_label_en-US" xlink:label="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:label id="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice_documentation_en-US" xlink:label="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Maximum Aggregate Offering Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:to="lab_avdl_SaleOfStockMaximumAggregateOfferingPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_ce462cba-294c-42f2-ad8b-65d139e5cbd7_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock_785a0190-2df4-48a9-8196-9d43e7705a46_terseLabel_en-US" xlink:label="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Liquidity</link:label>
    <link:label id="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock_label_en-US" xlink:label="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern [Policy Text Block]</link:label>
    <link:label id="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock_documentation_en-US" xlink:label="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Liquidity and Going Concern</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:href="avdl-20241231.xsd#avdl_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:to="lab_avdl_LiquidityAndGoingConcernPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6d72fedb-ae34-44ca-aef0-b9a50a5bbb68_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_6927efbd-8f80-4378-9cb7-c86c34011087_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember_67cbe7f1-4fd9-4da8-a2e6-c408a285afa6_terseLabel_en-US" xlink:label="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest One Year Following Achievement of Milestones</link:label>
    <link:label id="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember_label_en-US" xlink:label="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest One Year Following Achievement Of Milestones [Member]</link:label>
    <link:label id="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember_documentation_en-US" xlink:label="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vest One Year Following Achievement Of Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:href="avdl-20241231.xsd#avdl_VestOneYearFollowingAchievementOfMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:to="lab_avdl_VestOneYearFollowingAchievementOfMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_85cd9994-dd17-4abc-a24d-514186630430_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_59c3f9cc-44f2-453a-9b26-25d3109de908_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average period for unrecognized expense (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_cc1cc4ec-bbf8-4596-acc2-58b08cf9add9_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected term (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryNet_4d8fbbbe-5a16-47ad-ab88-45a930c817c0_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_dbf6e31e-61e9-4a15-a4fc-7d20368f1376_totalLabel_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_InventoryNet_label_en-US" xlink:label="lab_us-gaap_InventoryNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryNet" xlink:to="lab_us-gaap_InventoryNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_18dd0a65-ff45-48dd-9b2b-4b0e21a02b4f_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government securities - U.S.</link:label>
    <link:label id="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Agencies Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_ead48593-4e59-4dbe-a41b-da661a5556d5_terseLabel_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-term Debt, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_LongtermDebtTypeDomain_label_en-US" xlink:label="lab_us-gaap_LongtermDebtTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongtermDebtTypeDomain" xlink:to="lab_us-gaap_LongtermDebtTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_f3afd6a7-9031-46da-a87d-d6dee438f2bb_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_74298e7b-0dca-4518-9227-52dadce12c97_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_EquityTransactionsDisclosureTextBlock_5b1d003d-0b79-47cb-b53a-1b6aad90672a_terseLabel_en-US" xlink:label="lab_avdl_EquityTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Instruments and Transactions</link:label>
    <link:label id="lab_avdl_EquityTransactionsDisclosureTextBlock_label_en-US" xlink:label="lab_avdl_EquityTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Transactions Disclosure [Text Block]</link:label>
    <link:label id="lab_avdl_EquityTransactionsDisclosureTextBlock_documentation_en-US" xlink:label="lab_avdl_EquityTransactionsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Transactions Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EquityTransactionsDisclosureTextBlock" xlink:href="avdl-20241231.xsd#avdl_EquityTransactionsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_EquityTransactionsDisclosureTextBlock" xlink:to="lab_avdl_EquityTransactionsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_ffc2a2e7-9b1f-4503-9314-3898eb4aed81_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_72aba9f8-3e31-4a2e-8ea4-2dfdac635a0e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_0737eb80-8197-450d-80f4-e3fdb02bf1a0_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment Useful Life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_604c6f9d-c6ff-4a84-9381-977b74b2020d_verboseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_c0aec9f2-ce4c-4487-b6bd-5d9b7946cd9c_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ShelfRegistrationStatementOnFormS3Member_7540c00a-3f04-42f2-8ae0-50ac7ce8f4ca_terseLabel_en-US" xlink:label="lab_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement On Form S-3</link:label>
    <link:label id="lab_avdl_ShelfRegistrationStatementOnFormS3Member_label_en-US" xlink:label="lab_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement On Form S-3 [Member]</link:label>
    <link:label id="lab_avdl_ShelfRegistrationStatementOnFormS3Member_documentation_en-US" xlink:label="lab_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Shelf Registration Statement On Form S-3</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:href="avdl-20241231.xsd#avdl_ShelfRegistrationStatementOnFormS3Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:to="lab_avdl_ShelfRegistrationStatementOnFormS3Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubleaseIncome_ddbc5a3b-adf7-40d7-8906-d90cb99aae98_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Sublease income</link:label>
    <link:label id="lab_us-gaap_SubleaseIncome_label_en-US" xlink:label="lab_us-gaap_SubleaseIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sublease Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubleaseIncome" xlink:to="lab_us-gaap_SubleaseIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_VestingDomain_8dc0f879-6948-493b-9785-ee7d5c000888_terseLabel_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:label id="lab_us-gaap_VestingDomain_label_en-US" xlink:label="lab_us-gaap_VestingDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_VestingDomain" xlink:to="lab_us-gaap_VestingDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_9fa6edd0-76f0-4d3f-92e4-66dab24734c8_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Nonvested free share award, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_b2d34b3c-a6f0-4f65-8e89-2c8f74615db8_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Nonvested free share award, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_65ea99ec-7e05-449e-adec-1da2360e8079_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">LIABILITIES AND SHAREHOLDERS&#8217; EQUITY</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_4bd8359b-3bbb-42ef-9408-4b8b268d8959_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_baeac6ce-414b-435e-9ce4-b0bffa2f16fd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_1c84dfcd-6a28-48d9-8d02-20571e5fea8e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_0ff235d0-08a2-482f-8e62-9f33ffe36748_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_f1284452-001a-4f2d-9400-01dcf717873f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_81e13418-b032-44ea-a5db-f7e4966e7431_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">5-10 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_4000e872-79cc-4008-90f8-0f66fb8219bd_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTable_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTable" xlink:to="lab_us-gaap_ConcentrationRiskTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_70ca08ff-7ff7-444f-9ba8-b43e498dca55_verboseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0b53e949-389d-4bb7-a883-1f47f46651c6_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_0c6c0452-e44e-48fc-9939-674c90ae3b48_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Stock options outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_f3044c92-5b52-4f32-b152-6e8d4825fc5d_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_83c3ce00-d1b0-4dbf-b4d4-71698babaf34_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Restricted Share Awards</link:label>
    <link:label id="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:to="lab_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_ef7e6fe8-6199-4371-9cd6-9de968fecb3c_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_8c4091aa-e394-46c0-a8c8-1973570cb8cc_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_636dfd05-aee1-4fdc-8861-bc98192636bf_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_62b5ccce-c32b-48c6-b8c8-d9226a43f48a_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee share purchase plan share issuance</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Employee Stock Purchase Plan</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_5d9ebe55-411f-4387-aa73-64fa0bbc0110_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_8ea4ef71-fefb-4f45-9d8d-6e73e0cafd47_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise of stock options</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Stock Options Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_42fb45b5-aaa2-467a-84f8-e93e612ab5f0_verboseLabel_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Goodwill</link:label>
    <link:label id="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:to="lab_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_9c1a988a-cbb1-4caa-b568-945c33272435_verboseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Shareholders&#8217; equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_6e46063d-cf25-401e-a3b6-612ae31049fe_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant fair value of free share awards (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8606ead8-e7c3-4df0-8458-23cfe373793a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_a07c6056-76ed-491d-b0d0-64f8cd992b98_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_b9ebb7b3-fbc4-4710-8a2c-63c9ccb1f6bb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_U.S.HoldingsMember_3fab362d-95c9-4a5c-b791-2895ae1cdc4b_terseLabel_en-US" xlink:label="lab_avdl_U.S.HoldingsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Holdings</link:label>
    <link:label id="lab_avdl_U.S.HoldingsMember_label_en-US" xlink:label="lab_avdl_U.S.HoldingsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">U.S. Holdings [Member]</link:label>
    <link:label id="lab_avdl_U.S.HoldingsMember_documentation_en-US" xlink:label="lab_avdl_U.S.HoldingsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">U.S. Holdings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_U.S.HoldingsMember" xlink:href="avdl-20241231.xsd#avdl_U.S.HoldingsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_U.S.HoldingsMember" xlink:to="lab_avdl_U.S.HoldingsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_5fb03ce7-297e-410d-9bed-6c98111f44b3_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefit Activity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_country_FR_af9d800c-7c51-4ef5-8277-eed5be451379_terseLabel_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">France</link:label>
    <link:label id="lab_country_FR_label_en-US" xlink:label="lab_country_FR" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">FRANCE</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_FR" xlink:to="lab_country_FR" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_816e4ce8-1c1c-4a26-844e-4cd3581adabb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_415c4175-bafe-4d7b-8cdc-74187764004f_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a4947a6a-9707-4214-89e5-71abbf0918b6_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_abd1ad92-fbf5-47bf-9694-9bb4201ce01a_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_98e80c19-af47-483e-a5e9-569a20848052_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_486b5627-f3a5-4085-8aa4-b584ff97c8d1_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from stock option exercises and employee share purchase plan</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_4765c042-0968-461d-b3ce-9f55e13bd1ad_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_d98a8065-5314-4479-bef2-00c88e553646_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_45046936-57a6-47f3-8171-d2bfc96d9eb4_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tranche Three</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Tranche Three [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:to="lab_us-gaap_ShareBasedCompensationAwardTrancheThreeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_f154d665-84ba-46ed-a0c7-97d9c6af1aa8_terseLabel_en-US" xlink:label="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in fair value of October 2023 Notes conversion feature</link:label>
    <link:label id="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_label_en-US" xlink:label="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Adjustments In Fair Value Of Convertible Debt Conversion Feature</link:label>
    <link:label id="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_documentation_en-US" xlink:label="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Adjustments In Fair Value Of Convertible Debt Conversion Feature</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:href="avdl-20241231.xsd#avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:to="lab_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_ffdba0c6-326f-42e7-aa14-7b7ca0d34905_terseLabel_en-US" xlink:label="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_label_en-US" xlink:label="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortization Of Intangible Assets</link:label>
    <link:label id="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_documentation_en-US" xlink:label="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Amortization Of Intangible Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:to="lab_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_a87399ed-a02e-448e-9f40-f74e7d47c0f6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum number of shares reserved and available for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_19ee62cb-3a7e-4005-8fb7-5554163dfcdd_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_label_en-US" xlink:label="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Disposal Groups, Including Discontinued Operations [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:to="lab_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_76b4388a-27d2-4ae9-8043-2ef5f60fdfc5_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsAbstract_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract" xlink:to="lab_srt_ValuationAndQualifyingAccountsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesOutstanding_2ed1e7dc-0a6a-4e99-8726-f6aea1be9044_periodStartLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_2bf2e278-b214-4df6-b052-d1dd9a4f6fda_periodEndLabel_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_SharesOutstanding_label_en-US" xlink:label="lab_us-gaap_SharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesOutstanding" xlink:to="lab_us-gaap_SharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_52fcece9-50b2-4937-951d-03d803589361_terseLabel_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in unrecognized tax benefits is reasonably possible</link:label>
    <link:label id="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_label_en-US" xlink:label="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Decrease in Unrecognized Tax Benefits is Reasonably Possible</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:to="lab_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_048c2573-7655-4582-a5c1-344f6778b6b0_verboseLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, and Marketable Securities [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:to="lab_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_dadfdb20-e225-4e1d-9bdd-1d8e21162d9b_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AccredoHealthGroupInc.Member_2c1c7dbc-36c0-4eb9-bebf-dc84080e91be_terseLabel_en-US" xlink:label="lab_avdl_AccredoHealthGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accredo</link:label>
    <link:label id="lab_avdl_AccredoHealthGroupInc.Member_label_en-US" xlink:label="lab_avdl_AccredoHealthGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accredo Health Group, Inc. [Member]</link:label>
    <link:label id="lab_avdl_AccredoHealthGroupInc.Member_documentation_en-US" xlink:label="lab_avdl_AccredoHealthGroupInc.Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accredo Health Group, Inc.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoHealthGroupInc.Member" xlink:href="avdl-20241231.xsd#avdl_AccredoHealthGroupInc.Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AccredoHealthGroupInc.Member" xlink:to="lab_avdl_AccredoHealthGroupInc.Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_2304b64f-98dd-427f-8f22-266a52731a04_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: valuation allowances</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_fa1a88f3-4211-4285-b1f6-96a453b62e61_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_ad89dfd7-c29e-4a4d-8382-5ab2e906b93b_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_1aed895a-c7ec-4912-8ca6-59adb13102b4_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net changes in assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember_be291163-347d-4d6d-842b-95aa5d2ac6fa_terseLabel_en-US" xlink:label="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Share Awards Granted to Employees</link:label>
    <link:label id="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember_label_en-US" xlink:label="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Share Awards Granted To Employees [Member]</link:label>
    <link:label id="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember_documentation_en-US" xlink:label="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Restricted Share Awards Granted To Employees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:href="avdl-20241231.xsd#avdl_RestrictedShareAwardsGrantedToEmployeesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:to="lab_avdl_RestrictedShareAwardsGrantedToEmployeesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_892773dc-357e-4d34-be65-b5d51298de5d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchase price of common stock, percentage</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AtTheMarketOfferingProgramMember_16726bfc-6d58-41b9-9d2d-4a60c98de3cf_terseLabel_en-US" xlink:label="lab_avdl_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-market offering program</link:label>
    <link:label id="lab_avdl_AtTheMarketOfferingProgramMember_label_en-US" xlink:label="lab_avdl_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Program [Member]</link:label>
    <link:label id="lab_avdl_AtTheMarketOfferingProgramMember_documentation_en-US" xlink:label="lab_avdl_AtTheMarketOfferingProgramMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At-The-Market Offering Program</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AtTheMarketOfferingProgramMember" xlink:href="avdl-20241231.xsd#avdl_AtTheMarketOfferingProgramMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AtTheMarketOfferingProgramMember" xlink:to="lab_avdl_AtTheMarketOfferingProgramMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_PublicOfferingMember_c76f8027-fb64-443d-b740-46fde06ce3f7_terseLabel_en-US" xlink:label="lab_avdl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Public offering</link:label>
    <link:label id="lab_avdl_PublicOfferingMember_label_en-US" xlink:label="lab_avdl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:label id="lab_avdl_PublicOfferingMember_documentation_en-US" xlink:label="lab_avdl_PublicOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Public Offering [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PublicOfferingMember" xlink:href="avdl-20241231.xsd#avdl_PublicOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_PublicOfferingMember" xlink:to="lab_avdl_PublicOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_85f1db63-40d2-482c-8832-182b4e8b5496_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_dd5e206a-5dae-491d-977c-fe2344a301f7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_ac9cbdc9-641b-4ec2-882d-0045a698d0d8_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Expenses</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_b06706f0-ee6d-4497-9816-e0150c001bc5_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_0f922bb5-bc1d-476d-a489-9ec5d24b72db_negatedTerseLabel_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Orphan drug and R&amp;D tax credit</link:label>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_label_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount, Orphan Drug and Research And Development Tax Credit</link:label>
    <link:label id="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_documentation_en-US" xlink:label="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Amount, Orphan Drug and Research And Development Tax Credit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:to="lab_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_dad8e4f7-f9bb-4893-8470-8283920c81b8_terseLabel_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-lived Assets by Geographic Areas</link:label>
    <link:label id="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Assets by Geographic Areas [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:to="lab_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_5218d148-ce3c-4acb-ac00-debcde12c1b7_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_69c7d7b2-04f2-40dd-8a19-83649b4384a4_verboseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Contingent Liabilities and Commitments</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cc84e622-bd51-44cb-b064-5f1e3b64b85f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityCurrent_3fdae69a-9f75-47f0-ac14-60355fa0e7c5_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payable to RTW</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityCurrent_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing Liability, Current</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingLiabilityCurrent_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityCurrent" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingLiabilityCurrent" xlink:to="lab_avdl_RoyaltyFinancingLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_160dce63-28e8-4dda-87c1-a71313ca54eb_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Prepaid Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ReportableSegmentMember_00c2e95f-2f0a-401b-8031-82fcf45c17b5_terseLabel_en-US" xlink:label="lab_avdl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_avdl_ReportableSegmentMember_label_en-US" xlink:label="lab_avdl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_avdl_ReportableSegmentMember_documentation_en-US" xlink:label="lab_avdl_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ReportableSegmentMember" xlink:href="avdl-20241231.xsd#avdl_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ReportableSegmentMember" xlink:to="lab_avdl_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_49856c0d-ce91-4e6a-b1fc-127b2a97218c_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-lived asset impairment</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment, Long-Lived Asset, Held-for-Use</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_b964ea27-a245-4813-aad8-3cbce6341904_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_445493d5-692d-4a4a-89ce-2deb1dbe6369_terseLabel_en-US" xlink:label="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vest Upon the Achievement of Certain Regulatory Milestones</link:label>
    <link:label id="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_label_en-US" xlink:label="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vest Upon The Achievement Of Certain Regulatory Milestones [Member]</link:label>
    <link:label id="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_documentation_en-US" xlink:label="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Vest Upon The Achievement Of Certain Regulatory Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:href="avdl-20241231.xsd#avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:to="lab_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_SaleOfStockSalesAgentCommissionPercent_d672e279-dcf9-4cc2-a4f7-3336904e5dde_terseLabel_en-US" xlink:label="lab_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales agent commission, as a percent of aggregate gross sales proceeds</link:label>
    <link:label id="lab_avdl_SaleOfStockSalesAgentCommissionPercent_label_en-US" xlink:label="lab_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Sales Agent Commission, Percent</link:label>
    <link:label id="lab_avdl_SaleOfStockSalesAgentCommissionPercent_documentation_en-US" xlink:label="lab_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale Of Stock, Sales Agent Commission, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockSalesAgentCommissionPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:to="lab_avdl_SaleOfStockSalesAgentCommissionPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_DebtInstrumentNumberOfTranches_dd59593e-abbc-4d68-abd9-f72cad9d5869_terseLabel_en-US" xlink:label="lab_avdl_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of tranches</link:label>
    <link:label id="lab_avdl_DebtInstrumentNumberOfTranches_label_en-US" xlink:label="lab_avdl_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:label id="lab_avdl_DebtInstrumentNumberOfTranches_documentation_en-US" xlink:label="lab_avdl_DebtInstrumentNumberOfTranches" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument, Number Of Tranches</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentNumberOfTranches" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentNumberOfTranches"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_DebtInstrumentNumberOfTranches" xlink:to="lab_avdl_DebtInstrumentNumberOfTranches" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_75b24511-c305-4bf4-86d0-3fd6c6bf1629_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_c0863ecf-9ebb-4145-91d4-738779829e4d_verboseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_14aa50ae-d3ba-40c7-8eab-4e5ff47b9e75_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_d8728032-faa2-4c4e-9b83-c884e047b75b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_c6549780-5762-41bd-9944-abc7cf4d42c1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Amortization of deferred issuance costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_8671413d-3f1e-4526-853a-3f8d9f8c6a94_terseLabel_en-US" xlink:label="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Prepaid Expenses and Other Current Assets</link:label>
    <link:label id="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_label_en-US" xlink:label="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]</link:label>
    <link:label id="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_documentation_en-US" xlink:label="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:to="lab_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_7da929d5-5611-41a9-803d-625965a783fb_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_c98e7e97-916f-465b-b335-af60c489cbfb_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment items</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_e095e1ac-c664-43d2-ba66-43a27b39fc65_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Principal Categories of Inventories</link:label>
    <link:label id="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Inventory, Current [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfInventoryCurrentTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_1c0118f6-1291-4836-8488-762379ce6d45_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_b72c5677-2775-4467-8149-021c9846d277_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_9d8b9878-f457-4f29-9a77-26337b8bbecf_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation adjustment:</link:label>
    <link:label id="lab_us-gaap_AccumulatedTranslationAdjustmentMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Foreign Currency Adjustment Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:to="lab_us-gaap_AccumulatedTranslationAdjustmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock_1429fa3b-f575-4b49-9b31-6c55f1f208e6_verboseLabel_en-US" xlink:label="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of (Loss) Income Before Income Tax</link:label>
    <link:label id="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock_label_en-US" xlink:label="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Components Of Income Before Income Tax [Table Text Block]</link:label>
    <link:label id="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock_documentation_en-US" xlink:label="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Tabular disclosure of components of income before income tax.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:to="lab_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_34953198-5969-46b6-af6b-3d330bc23ec2_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_86fab930-3cc1-46ad-831c-b882e17a838c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, nominal value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_0290d33c-864e-40a6-ae20-09a704e2b805_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_affc83fd-bdb4-4c6d-adc1-60458e65317b_negatedNetLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="resource" xml:lang="en-US">Less: royalty payable to RTW classified within accrued expenses</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_e792ddda-2f28-4087-b93e-220aec0e7b23_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_41fb3e4e-d2c4-462d-b70b-36805af00a03_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Newly Issued Accounting Standards</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Standards Update and Change in Accounting Principle [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1f7e17bc-476c-44fa-8cdb-f1afcdd21cd9_verboseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockMember_b3a81c8e-fac5-4baa-8909-2a4a2fd27492_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Shares</link:label>
    <link:label id="lab_us-gaap_RestrictedStockMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockMember" xlink:to="lab_us-gaap_RestrictedStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_CaremarkMember_bbbf3fef-fb55-41e3-993b-cb3bcf629a3b_terseLabel_en-US" xlink:label="lab_avdl_CaremarkMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark</link:label>
    <link:label id="lab_avdl_CaremarkMember_label_en-US" xlink:label="lab_avdl_CaremarkMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark [Member]</link:label>
    <link:label id="lab_avdl_CaremarkMember_documentation_en-US" xlink:label="lab_avdl_CaremarkMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkMember" xlink:href="avdl-20241231.xsd#avdl_CaremarkMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_CaremarkMember" xlink:to="lab_avdl_CaremarkMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_86991579-7083-411b-84f4-b286199fbbb5_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_2406c6b2-4939-4998-a1b0-c27c0d91ee97_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_f71016e3-054d-4268-887e-67484f68ccd2_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_ccff766d-6a07-403e-bf42-fffd9f88c3a9_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:label id="lab_us-gaap_ValuationAllowancesAndReservesDomain_label_en-US" xlink:label="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain" xlink:to="lab_us-gaap_ValuationAllowancesAndReservesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_c9ed5665-6b37-46c8-a625-77631af81820_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_country_IE_8fb393d9-0018-4d02-8550-903ddcd1a8ff_terseLabel_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Europe</link:label>
    <link:label id="lab_country_IE_label_en-US" xlink:label="lab_country_IE" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">IRELAND</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_country_IE" xlink:to="lab_country_IE" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a3ee329d-80b9-4d6d-866a-28925c6ae9fe_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_d92c7605-3631-4e53-8f8b-97a4ee9505ce_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest expense</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_a06fb7b5-e3bb-4068-9a69-5277a3ec585b_terseLabel_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accretion of imputed interest expense on royalty financing obligation</link:label>
    <link:label id="lab_us-gaap_InterestExpenseDebt_label_en-US" xlink:label="lab_us-gaap_InterestExpenseDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Expense, Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestExpenseDebt" xlink:to="lab_us-gaap_InterestExpenseDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_dcdc168e-c002-49f7-bb10-bd1f920616ff_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_163c85fd-be19-4fb4-89a6-f034e1cfd839_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_56238cd8-f972-48ca-a873-1982d761226e_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_f1d2887b-b224-464c-8ecc-eeb174cfb5cc_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OptumMember_9581972d-d018-4980-903c-8face5d4ef58_terseLabel_en-US" xlink:label="lab_avdl_OptumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Optum</link:label>
    <link:label id="lab_avdl_OptumMember_label_en-US" xlink:label="lab_avdl_OptumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Optum [Member]</link:label>
    <link:label id="lab_avdl_OptumMember_documentation_en-US" xlink:label="lab_avdl_OptumMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Optum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumMember" xlink:href="avdl-20241231.xsd#avdl_OptumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OptumMember" xlink:to="lab_avdl_OptumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_f27cbd49-c1f1-434a-b550-29632f21cb8b_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_71e71dff-d001-41e4-b9d9-381566c62ebb_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_d58d72ea-82bb-41f2-b8e6-8eed72d08139_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InterestPaidNet_1e1dcd84-1d82-4a58-8ce2-7012035ec253_verboseLabel_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest paid</link:label>
    <link:label id="lab_us-gaap_InterestPaidNet_label_en-US" xlink:label="lab_us-gaap_InterestPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest Paid, Excluding Capitalized Interest, Operating Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InterestPaidNet" xlink:to="lab_us-gaap_InterestPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_eb3ecffc-cbdd-4fae-a842-420dd476132e_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue and Cost of Products Sold</link:label>
    <link:label id="lab_us-gaap_RevenueRecognitionPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:to="lab_us-gaap_RevenueRecognitionPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_9410f1dd-af36-4ebb-9961-141493460159_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_56001c98-5b6a-47a2-9add-0c20ef04304d_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 1</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel1Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel1Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 1 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel1Member" xlink:to="lab_us-gaap_FairValueInputsLevel1Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_1036d9b9-8ce0-49ce-aaa1-940bb40e77ae_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_58e8f078-9e15-4c9b-825f-eaad26c555b1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityNoteAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract" xlink:to="lab_us-gaap_StockholdersEquityNoteAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_8a5301c0-bd88-4363-950e-a7a7224d45a9_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_c4d5bb61-09a0-4dbb-8342-be6ae2647eb2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SeniorNotesMember_5bffd0f3-9a3e-47f4-a2a5-62398f90d7a1_terseLabel_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Senior Notes</link:label>
    <link:label id="lab_us-gaap_SeniorNotesMember_label_en-US" xlink:label="lab_us-gaap_SeniorNotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Senior Notes [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SeniorNotesMember" xlink:to="lab_us-gaap_SeniorNotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockMember_e02f9a90-033d-4973-ba9c-09d6f2c47bd6_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares</link:label>
    <link:label id="lab_us-gaap_PreferredStockMember_label_en-US" xlink:label="lab_us-gaap_PreferredStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockMember" xlink:to="lab_us-gaap_PreferredStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_363071cd-dd25-4cfc-9870-afae45208f19_verboseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued expenses</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_f8e7a2b5-5d91-4ae7-8b09-ed56e2ce44cf_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Valuation Allowance of Deferred Tax Assets</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:to="lab_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_4db5608e-f55f-4118-b70c-bdd565dc403d_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-term Debt Instruments [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_OtherNoncurrentReceivables_54d36766-f2cd-4b53-8a3c-bb2287911ce7_terseLabel_en-US" xlink:label="lab_avdl_OtherNoncurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_avdl_OtherNoncurrentReceivables_label_en-US" xlink:label="lab_avdl_OtherNoncurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Receivables</link:label>
    <link:label id="lab_avdl_OtherNoncurrentReceivables_documentation_en-US" xlink:label="lab_avdl_OtherNoncurrentReceivables" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The carrying amount of other noncurrent receivables.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OtherNoncurrentReceivables" xlink:href="avdl-20241231.xsd#avdl_OtherNoncurrentReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_OtherNoncurrentReceivables" xlink:to="lab_avdl_OtherNoncurrentReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_800c66f0-d9db-4beb-9562-d0c671b10742_netLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Royalty financing obligation, non-current</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_e3aeeb96-3f32-4b00-9587-93d381514e4b_terseLabel_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:label id="lab_srt_ValuationAndQualifyingAccountsDisclosureTable_label_en-US" xlink:label="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:to="lab_srt_ValuationAndQualifyingAccountsDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_02524d6b-644d-42fb-b711-815147fc0829_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_48fee094-0b1c-4952-8d50-06fd561c3201_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Free Share Activity and Other Data, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_dbb11a24-fba8-4eaf-b6dd-3147afb05d9a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grant date fair value of options granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_09341fe4-564e-4558-a1f4-c294df049a4d_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss) [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_b962a5d3-79c9-46ea-a012-a9461359adb5_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_95532d32-6401-4687-98e0-41dab31ee675_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fd319b9d-3239-457e-8d39-a887fe6209a2_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_bda33e9e-a42b-47e1-b54b-faa8e4301323_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityAbstract_label_en-US" xlink:label="lab_us-gaap_EquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityAbstract" xlink:to="lab_us-gaap_EquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_74c96826-e016-4ce9-a8f8-560a3c2b0195_verboseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfStockDomain_1bb8edb2-9917-4044-a5e2-b5030a86c4d4_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfStockDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfStockDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfStockDomain" xlink:to="lab_us-gaap_ClassOfStockDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_ec0db4c9-772d-4972-921f-d09a762be98a_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerMember_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerMember" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_adfd7d70-3a8c-4844-be4a-2182c662b7a4_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Inventories</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInInventories_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInInventories" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Inventories</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInInventories" xlink:to="lab_us-gaap_IncreaseDecreaseInInventories" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_71140b28-ed6b-4a38-a1a3-cefbdd139598_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expenses</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_d656c707-5361-4793-866a-51b509b8b242_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_424d2551-a5ac-45f2-82fd-816188c74ab1_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Present value of lease liabilities</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_69c91d85-06c5-4d26-999d-2f48f29eed9d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_9a6579d3-fbce-439d-b74d-a88b2753c89f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserves and Other Accruals</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PerformanceSharesMember_aa1e582f-63b8-48fd-bb1e-e5b0aa065621_terseLabel_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Performance Shares</link:label>
    <link:label id="lab_us-gaap_PerformanceSharesMember_label_en-US" xlink:label="lab_us-gaap_PerformanceSharesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PerformanceSharesMember" xlink:to="lab_us-gaap_PerformanceSharesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_7bb89baa-75a2-46af-97e8-d4eed01fbdea_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Changes and Error Corrections [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:to="lab_us-gaap_AccountingChangesAndErrorCorrectionsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_4278646a-fd6a-4a50-9362-398be3f8ad3f_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_c5abc8c6-69db-4e8a-af6d-cc6e93d922b6_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GrossProfit_daedc829-6bb6-4446-a395-96400bad20f9_totalLabel_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Gross profit</link:label>
    <link:label id="lab_us-gaap_GrossProfit_label_en-US" xlink:label="lab_us-gaap_GrossProfit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gross Profit</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GrossProfit" xlink:to="lab_us-gaap_GrossProfit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GuarantyLiabilities_92da0520-1777-4a09-a583-38dd184a0986_terseLabel_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_GuarantyLiabilities_label_en-US" xlink:label="lab_us-gaap_GuarantyLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Guaranty Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantyLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GuarantyLiabilities" xlink:to="lab_us-gaap_GuarantyLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_b1a592ee-6a7d-4ee0-b952-2faba398a680_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Foreign currency translation (loss) income</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_131339c6-d087-4a68-b6c5-5d1986719e8b_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. - State</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_8f971a1b-334b-4c9c-99f2-81f0b2ad052a_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Differences in international tax rates</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:to="lab_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_25bc7e2e-1198-4059-b8cf-d13d15c730f4_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_414af763-94fe-4622-9085-d482bc5710b4_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_e3d7df5b-b488-4f8e-8e15-b1abc6eccb54_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_e6a3e83c-e06b-41b5-8ed5-70d2debc1c4f_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Royalty Financing Obligation</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_c51976cb-06f5-41e0-9b8a-1eab34b68988_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_3d646a85-086e-40a2-bca8-671417c23fb7_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_71884c16-5fb2-4b74-8e47-9ab6c77f8676_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_00b5dec1-e4a8-499e-bae6-79c8f17d79bd_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingExpense_f33e65fa-e6c1-4f05-a4ed-81ad84b65d73_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingExpense_label_en-US" xlink:label="lab_us-gaap_AdvertisingExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingExpense" xlink:to="lab_us-gaap_AdvertisingExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_c89540de-4747-4707-b761-78ff1e8f9662_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Compensation Expense for Share-Based Compensation Arrangements</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="lab_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_e025a9b8-5204-4878-a9d2-3e018f70d209_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_51f60e94-03ac-48da-8614-ea18b4219def_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_6433cd6b-ab84-4311-ae12-b59ee67b9dc9_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized;&#160;96,518 issued and outstanding at December&#160;31, 2024 and 89,825 issued and outstanding at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_7babfa9a-0b3e-4823-bbf8-838d17ae0d92_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_43eb3a45-fbdc-4264-8966-3f0b84a69b0a_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Disclosure of Compensation Related Costs, Share-based Payments [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_b183c020-e016-4d82-a3ff-fb3337e92dd1_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, at Carrying Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GranteeStatusAxis_208c2a2e-d1bf-4e6a-97dc-9f970d6cadd0_terseLabel_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:label id="lab_us-gaap_GranteeStatusAxis_label_en-US" xlink:label="lab_us-gaap_GranteeStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Grantee Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GranteeStatusAxis" xlink:to="lab_us-gaap_GranteeStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_aed5a7c4-de61-41b7-8dfa-45ddc12d095c_terseLabel_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:label id="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis_label_en-US" xlink:label="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Indexed to Issuer's Equity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:to="lab_us-gaap_OptionIndexedToIssuersEquityEquityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_120dfbb7-da78-459c-a2eb-7131f12cc9d5_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_cd94cb78-4b7e-4604-87b7-f558dbd16305_verboseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_c6dff396-b44d-46d4-8b91-2dab2c9a943a_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_4a3386c5-4d81-451d-aec6-cdd109f7bd94_verboseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_a52c1074-bdb3-4939-8b37-c81bd95ef369_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Loss on extinguishment of debt</link:label>
    <link:label id="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt_label_en-US" xlink:label="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Extinguishment of Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:to="lab_us-gaap_GainsLossesOnExtinguishmentOfDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_c19ade21-6df1-4d6b-946f-bf6a90a36888_verboseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Cash Provided by (Used in) Financing Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_f7addfe9-15c4-4b04-a99c-97edc1421f47_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskLineItems_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskLineItems" xlink:to="lab_us-gaap_ConcentrationRiskLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_b7dffc41-6161-4f55-b875-1dd2261cd1af_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at December&#160;31, 2024 and 5,194 issued and outstanding at December&#160;31, 2023</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_21252875-a7be-4dc9-8bb7-1b33b72f31ae_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local taxes (net of federal)</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_076c0c84-aa2d-454c-9dfe-fb6ecfda6308_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, plant and equipment, useful life (in years)</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_d6d4d5b0-fa85-46b6-8808-b5ec69a40147_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Options, Outstanding [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_a2863979-1eda-4be7-91be-1f41f18b11cd_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Gross deferred tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0abf026e-e456-49f3-9421-7a1768c7229c_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_19606a39-d51d-4d25-b837-afac27f0c07a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_c10074b0-628b-4c7c-9521-1b4e35645a40_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable &amp; other current liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_cd058a0d-238a-4611-a7ac-36176a2c2722_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of shares, net of issue costs</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfCommonStock_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_f8e6cc31-34e1-4492-b23a-e9658fdc5845_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, payments</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_4fef78eb-7f34-4cfe-ba5e-422937b5e148_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration period (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_da50c2f1-d9e0-4ed6-ba7a-6964b90054da_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_0f489012-3b31-45b5-9b7d-2727cec63768_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and Equipment</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_7acba9f9-7d67-4385-b206-2131124c7d19_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfStockByClassTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfStockByClassTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock, Class of Stock [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable" xlink:to="lab_us-gaap_ScheduleOfStockByClassTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_170575d4-bab6-4a95-ad6e-2e40d20da83f_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_0fbae162-eb43-4340-9936-5370a0d0002f_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average shares:</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_a8c05d89-0881-46c7-8304-237ddf41c458_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Other Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_OtherLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_bbbdad1e-cf81-4f79-be49-dde85d7f8e0c_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_df9d8b0b-9ba1-4075-8cff-eb793c31b363_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentrations of Risk</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_CaremarkLLCMember_bbac48b6-43d5-42d6-903c-e44c04c1e530_terseLabel_en-US" xlink:label="lab_avdl_CaremarkLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Caremark</link:label>
    <link:label id="lab_avdl_CaremarkLLCMember_label_en-US" xlink:label="lab_avdl_CaremarkLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Caremark LLC [Member]</link:label>
    <link:label id="lab_avdl_CaremarkLLCMember_documentation_en-US" xlink:label="lab_avdl_CaremarkLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Caremark LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkLLCMember" xlink:href="avdl-20241231.xsd#avdl_CaremarkLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_CaremarkLLCMember" xlink:to="lab_avdl_CaremarkLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_9792ab00-e5ed-4a64-8c58-45055804a615_terseLabel_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cost of products sold</link:label>
    <link:label id="lab_us-gaap_CostOfGoodsAndServicesSold_label_en-US" xlink:label="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cost of Goods and Services Sold</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CostOfGoodsAndServicesSold" xlink:to="lab_us-gaap_CostOfGoodsAndServicesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_62f344b6-70d2-4f3c-8861-6a196a14b37b_terseLabel_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Advertising Expenses</link:label>
    <link:label id="lab_us-gaap_AdvertisingCostsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Advertising Cost [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:to="lab_us-gaap_AdvertisingCostsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c183ecb5-7e8b-4bdd-86ad-e6ba67e8d30a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_f8808e47-3ce6-496b-96df-8737ab18b682_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards, valuation allowance (decrease)</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:to="lab_us-gaap_OperatingLossCarryforwardsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_d458b929-1345-4069-9d22-514b6dd818bc_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchases of property and equipment</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_April2027NotesMember_98fad3dd-d2ec-4113-ad38-2dbbfea893c7_terseLabel_en-US" xlink:label="lab_avdl_April2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">April 2027 Notes</link:label>
    <link:label id="lab_avdl_April2027NotesMember_label_en-US" xlink:label="lab_avdl_April2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">April 2027 Notes [Member]</link:label>
    <link:label id="lab_avdl_April2027NotesMember_documentation_en-US" xlink:label="lab_avdl_April2027NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">April 2027 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_April2027NotesMember" xlink:href="avdl-20241231.xsd#avdl_April2027NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_April2027NotesMember" xlink:to="lab_avdl_April2027NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_ce94c350-0665-44ea-a83f-f8ccecead202_terseLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other non-current liabilities</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_0cfdba15-c791-41e8-a40d-d1964d7af411_totalLabel_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OtherLiabilitiesNoncurrent_label_en-US" xlink:label="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Liabilities, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherLiabilitiesNoncurrent" xlink:to="lab_us-gaap_OtherLiabilitiesNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_acea408c-fca4-426d-aca9-eaa7303e9933_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_efa4a5d9-6681-44f9-8990-5850d6a83f31_verboseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_2df26b55-3318-4ccd-975b-ec89f148039e_terseLabel_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards that did not have an accounting grant date (in shares)</link:label>
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_label_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards With No Grant Date</link:label>
    <link:label id="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_documentation_en-US" xlink:label="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award, Awards With No Grant Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:to="lab_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_IncomeTaxesLineItems_fcc34593-b335-4766-9c47-4d9a766457de_terseLabel_en-US" xlink:label="lab_avdl_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:label id="lab_avdl_IncomeTaxesLineItems_label_en-US" xlink:label="lab_avdl_IncomeTaxesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesLineItems" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_IncomeTaxesLineItems" xlink:to="lab_avdl_IncomeTaxesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_41ce157c-7a4f-4888-b8ef-ac331636ba2a_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other assets and liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_fd49be7c-9f70-408d-aae6-1cbcbe3f9b8c_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_30c947b0-28df-467d-b7f7-e89a04b59462_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_d62e1d14-b787-4fc3-8ff0-513dd959a5ac_verboseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Share-Based Compensation</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_039f091c-89db-40d7-bb24-0953902ed6af_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_179d4ddb-96a8-4681-9c3f-b1b4c1260126_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from royalty purchase agreement</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_aa083c64-161b-400c-ac5d-102e6091fd79_verboseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of long-term debt</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_c4d26e0e-1672-465b-8f25-0ca86bf296bf_netLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/netLabel" xlink:type="resource" xml:lang="en-US">Receipt of the first tranche of the royalty financing obligation</link:label>
    <link:label id="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:to="lab_us-gaap_ProceedsFromIssuanceOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_7f8b5688-1dd3-4a6d-a8cc-a0332ddd932d_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">1-5 Years</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_9d08bc02-230b-415a-98a0-8bd27ab58fbf_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease Obligations</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_1ef4bbb6-0053-4800-a749-761d9f2863ca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_e82085be-ef36-4972-926a-cda937e9cda6_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_97d82676-c4c4-4adc-85a7-6a8ddc75de32_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_7f0d8529-c012-40af-8756-20d2fe1bc247_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_934f448d-6060-4486-b3d5-7f4fbcbba7cf_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_17341b21-d812-4333-aead-bfad9249d23c_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_de22357e-48c2-45fd-af86-153d47b8cabd_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_8f4f5e7d-130f-4c08-9aa6-caabba75633d_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:label id="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_label_en-US" xlink:label="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investments, Debt and Equity Securities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="lab_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_3bd79f19-e7a7-49e3-98c3-c6a251b57c52_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax penalties and interest expense</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_8622a7e5-03ca-46c8-ae7c-c774ab66248f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exchange/Settlement of Notes</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, Conversion of Convertible Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_c4791d28-99fb-468d-959d-8331b8d3fb69_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_84abbe66-9f62-4bf9-9697-046cad898145_terseLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNoteTextBlock_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss) Note [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:to="lab_us-gaap_ComprehensiveIncomeNoteTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_089028c2-db54-4774-8209-ac5886c6f399_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_9a6f3c58-15a9-47da-bfb3-51a3f2dc4e71_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_4ae7ce17-c5b8-45f3-b5ea-2d74f30b510e_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:label id="lab_us-gaap_BusinessAcquisitionAxis_label_en-US" xlink:label="lab_us-gaap_BusinessAcquisitionAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Acquisition [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessAcquisitionAxis" xlink:to="lab_us-gaap_BusinessAcquisitionAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_4d3a341c-2d40-45c5-9d35-4fcbccbc84cc_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_bd931e22-822e-4a5b-9ddd-8cab76b1ccb0_terseLabel_en-US" xlink:label="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fixed Assets and Right Of Use Assets, Contract Manufacturing Organizations</link:label>
    <link:label id="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_label_en-US" xlink:label="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fixed Assets And Right Of Use Assets, Contract Manufacturing Organizations [Member]</link:label>
    <link:label id="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_documentation_en-US" xlink:label="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Fixed Assets And Right Of Use Assets, Contract Manufacturing Organizations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:href="avdl-20241231.xsd#avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:to="lab_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_6dad01de-ff0b-4750-ba89-a95f4274b6cb_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_eaa17741-81b2-44f2-b705-25acc6bb5837_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_b5a7008a-8f6d-42e4-8431-0ae25776b924_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_3ddd97c4-011d-406e-a071-0d6b162fe4c1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_21e4995f-10e5-45f6-8b56-2fd54469eccb_terseLabel_en-US" xlink:label="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for royalty, one-time commitment fee</link:label>
    <link:label id="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_e66d0ce7-ccb7-4fa8-a287-837e8b4fd2be_negatedTerseLabel_en-US" xlink:label="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Less: one-time payment for expiration of second tranche</link:label>
    <link:label id="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_label_en-US" xlink:label="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Royalty, One-Time Commitment Fee</link:label>
    <link:label id="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_documentation_en-US" xlink:label="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Royalty, One-Time Commitment Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:href="avdl-20241231.xsd#avdl_PaymentsForRoyaltyOneTimeCommitmentFee"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:to="lab_avdl_PaymentsForRoyaltyOneTimeCommitmentFee" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_7cc9097d-07d3-4b5f-9fda-02058a65b7b0_verboseLabel_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Effect of foreign currency exchange rate changes on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_fa104664-3753-4482-82e7-b7e46d549bbc_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_57a5235e-43ce-466e-965a-ae9f9529debc_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, term of contract</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseTermOfContract_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Term of Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:to="lab_us-gaap_LesseeOperatingLeaseTermOfContract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_ea181fc2-1595-40fc-8e85-edb1dd80b136_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_AssetsFairValueDisclosure_label_en-US" xlink:label="lab_us-gaap_AssetsFairValueDisclosure" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Fair Value Disclosure</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsFairValueDisclosure" xlink:to="lab_us-gaap_AssetsFairValueDisclosure" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7468e238-8c8b-43a0-b843-00092bb23d2e_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock options exercisable, Aggregate Intrinsic Value</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_1032aa07-1107-4cd0-8d15-6d64e0a37260_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_5b5215a4-e9c6-47d9-b906-93876e2afd1a_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_228a5084-eac3-4043-8196-46932229f534_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_a8af86a2-11cc-4064-bc5b-4a5472d96f28_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Changes in deferred taxes</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Deferred Income Taxes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:to="lab_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_1c3934b0-d82b-494c-b7d8-cb25a0201ebe_verboseLabel_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Finished goods</link:label>
    <link:label id="lab_us-gaap_InventoryFinishedGoodsNetOfReserves_label_en-US" xlink:label="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory, Finished Goods, Net of Reserves</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:to="lab_us-gaap_InventoryFinishedGoodsNetOfReserves" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_839d1d47-0d4c-450c-b44e-837aafd6fbaf_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_d8ed72e0-7c97-4edf-86a9-33b24f86512a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Outstanding, beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_e759395b-97a9-4c3f-94b5-46c14e7f6a9b_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Outstanding, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_0137be60-766c-43a6-9c61-b6549c6cfb4a_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_d37fdf73-1833-46a9-8337-33344302d650_terseLabel_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_InventoryDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_InventoryDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Inventory Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InventoryDisclosureAbstract" xlink:to="lab_us-gaap_InventoryDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_AuditInformationAbstract_label_en-US" xlink:label="lab_avdl_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_avdl_AuditInformationAbstract_documentation_en-US" xlink:label="lab_avdl_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AuditInformationAbstract" xlink:href="avdl-20241231.xsd#avdl_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_AuditInformationAbstract" xlink:to="lab_avdl_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_93859467-e0b1-4218-8dfc-0b85ed2af646_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_October2023NotesMember_5cbc0006-c3d0-406f-a6fa-eb9362709850_terseLabel_en-US" xlink:label="lab_avdl_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">October 2023 Notes</link:label>
    <link:label id="lab_avdl_October2023NotesMember_label_en-US" xlink:label="lab_avdl_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">October 2023 Notes [Member]</link:label>
    <link:label id="lab_avdl_October2023NotesMember_documentation_en-US" xlink:label="lab_avdl_October2023NotesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">October 2023 Notes</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_October2023NotesMember" xlink:to="lab_avdl_October2023NotesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_426922b2-bc3c-4b12-9664-7f78eba31eee_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_ed4262b0-bfb3-482c-a91d-9285bf854925_totalLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total &#160;</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableMember_ab005c28-8a22-47a7-ae86-db0f030f8c59_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableMember_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableMember" xlink:to="lab_us-gaap_AccountsReceivableMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_2f6c9d22-95a6-4488-a0ae-117c505d96fe_terseLabel_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reclassifications</link:label>
    <link:label id="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription_label_en-US" xlink:label="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reclassification, Comparability Adjustment [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:to="lab_us-gaap_PriorPeriodReclassificationAdjustmentDescription" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_9040c943-0f33-4cc4-8f5e-02de910e9307_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_e1ffccd4-356c-45ad-ae15-dc89f8bed82d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_3855ce60-d320-4f10-9fd6-f4872431e6cc_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly royalty payments for royalty financing, percentage</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing, Quarterly Royalty Payment, Percentage</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing, Quarterly Royalty Payment, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:to="lab_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_LitigationCaseTypeDomain_6af6913f-0d4f-4c75-bb64-d197406b5add_terseLabel_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:label id="lab_srt_LitigationCaseTypeDomain_label_en-US" xlink:label="lab_srt_LitigationCaseTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Litigation Case [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_LitigationCaseTypeDomain" xlink:to="lab_srt_LitigationCaseTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_b8326b54-38d7-45dc-b407-90f2a88b2388_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_aa57cc8f-241b-40a8-bf9a-4cad7257c02b_terseLabel_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:label id="lab_srt_NameOfMajorCustomerDomain_label_en-US" xlink:label="lab_srt_NameOfMajorCustomerDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_NameOfMajorCustomerDomain" xlink:to="lab_srt_NameOfMajorCustomerDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_ec56505e-43aa-4ca1-83ea-7723782aadf4_verboseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive loss</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_0509ad09-66ba-46a8-b321-1f1371ecf534_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_48a5fcda-bcd3-4c82-956d-510283f86f66_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_321d4155-ba3a-473e-9db3-bcfc0133982b_verboseLabel_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Other Non-Current Liabilities</link:label>
    <link:label id="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Noncurrent Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_0309c65e-18e6-40aa-b455-c6597f9496ed_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average number of shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_24225fa3-9089-46f8-943a-ff730bc449a6_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basic shares (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_87a90065-5e3d-47a1-aca2-00b275496073_negatedLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net other comprehensive (loss) income, tax benefit</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="lab_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RemainingPerformanceObligationReserveCurrent_cd75ea8f-f404-48b0-b315-9ea3250c9b7d_terseLabel_en-US" xlink:label="lab_avdl_RemainingPerformanceObligationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reserve for variable consideration</link:label>
    <link:label id="lab_avdl_RemainingPerformanceObligationReserveCurrent_label_en-US" xlink:label="lab_avdl_RemainingPerformanceObligationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Remaining Performance Obligation Reserve, Current</link:label>
    <link:label id="lab_avdl_RemainingPerformanceObligationReserveCurrent_documentation_en-US" xlink:label="lab_avdl_RemainingPerformanceObligationReserveCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Remaining Performance Obligation Reserve, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RemainingPerformanceObligationReserveCurrent" xlink:href="avdl-20241231.xsd#avdl_RemainingPerformanceObligationReserveCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RemainingPerformanceObligationReserveCurrent" xlink:to="lab_avdl_RemainingPerformanceObligationReserveCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_ca722534-2f71-4b63-a724-da1a3d46cadf_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Revenues from External Customers and Long-Lived Assets [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:to="lab_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_34638d08-0fe6-4612-a1fe-8a5c1133c231_terseLabel_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of debt discount and debt issuance costs</link:label>
    <link:label id="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts_label_en-US" xlink:label="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amortization of Debt Issuance Costs and Discounts</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:to="lab_us-gaap_AmortizationOfFinancingCostsAndDiscounts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_6e2d017c-9ae9-4070-8f0d-d24edf46ace8_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_27a04770-b7b2-4e29-9811-2a97fbae0e48_verboseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_6264db18-482b-4531-ab9f-2ba004dee714_terseLabel_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Quarterly net revenue target for royalty financing</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_label_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Royalty Financing, Quarterly Net Revenue Target</link:label>
    <link:label id="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_documentation_en-US" xlink:label="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Royalty Financing, Quarterly Net Revenue Target</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyNetRevenueTarget"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:to="lab_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_67b883d5-884e-4895-9c13-243a49b02b62_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_7aa6ed44-ef8c-44bb-a68c-248e699839bc_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_2c8f5961-c5c8-4a76-8d4d-56a34789773d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>22
<FILENAME>avdl-20241231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:8b58f3b4-1327-4d69-92fa-78c232307a24,g:a42ae727-1f8d-471b-9438-1e77c171d253-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.avadel.com/role/CoverPage" xlink:type="simple" xlink:href="avdl-20241231.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_fa0fd36a-3d21-4cb8-a29e-6140c204d01b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentType_fa0fd36a-3d21-4cb8-a29e-6140c204d01b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_1d9b6ca4-ea53-4c00-9cef-9e7d68336373" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentAnnualReport_1d9b6ca4-ea53-4c00-9cef-9e7d68336373" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_93a6274e-25da-40ce-adf2-f2f7374960a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentPeriodEndDate_93a6274e-25da-40ce-adf2-f2f7374960a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_74e8468f-769a-4b49-b91e-a18f785b80ae" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_CurrentFiscalYearEndDate_74e8468f-769a-4b49-b91e-a18f785b80ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_5fed3c50-93db-43dd-bb41-0e57bc8e3bcf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentTransitionReport_5fed3c50-93db-43dd-bb41-0e57bc8e3bcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_53d3b024-d69c-4e44-8bb1-17653f42dc4b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityFileNumber_53d3b024-d69c-4e44-8bb1-17653f42dc4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_17d26bc6-ea7f-4abc-b78c-9eeac5a08db8" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityRegistrantName_17d26bc6-ea7f-4abc-b78c-9eeac5a08db8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_59f36374-91f5-4502-81fb-70436664241b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityIncorporationStateCountryCode_59f36374-91f5-4502-81fb-70436664241b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_1d7ae592-8020-4e03-b5ee-3ac3e6dfa544" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityTaxIdentificationNumber_1d7ae592-8020-4e03-b5ee-3ac3e6dfa544" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_a3e40a30-d0e1-41fc-9cda-5df8e8ab3f9b" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityAddressAddressLine1_a3e40a30-d0e1-41fc-9cda-5df8e8ab3f9b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_eca85e12-8dd2-4288-8123-5c11c27ccf0a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityAddressCityOrTown_eca85e12-8dd2-4288-8123-5c11c27ccf0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCountry_a124752d-de2f-4058-93cb-c074795dd7b5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCountry"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityAddressCountry_a124752d-de2f-4058-93cb-c074795dd7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_bd17a2b5-f18d-4a12-97c8-bf7fe2223eb4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityAddressPostalZipCode_bd17a2b5-f18d-4a12-97c8-bf7fe2223eb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CountryRegion_3f5d9a22-2d34-49d7-92f2-d0a60e585602" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CountryRegion"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_CountryRegion_3f5d9a22-2d34-49d7-92f2-d0a60e585602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_8e4d74a2-4842-4b80-a47e-e7e4d7b1f9d5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_CityAreaCode_8e4d74a2-4842-4b80-a47e-e7e4d7b1f9d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_feabdf91-9f1e-4904-a898-89d98a4cd0af" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_LocalPhoneNumber_feabdf91-9f1e-4904-a898-89d98a4cd0af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_c7e6e532-620a-4c01-9ccb-2878ae1ba6a4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_Security12bTitle_c7e6e532-620a-4c01-9ccb-2878ae1ba6a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_1b0b1bc3-f5b9-4942-abf5-7a0411d59b02" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_TradingSymbol_1b0b1bc3-f5b9-4942-abf5-7a0411d59b02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_6da88592-2d16-4a2b-a00b-f012711879a5" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_SecurityExchangeName_6da88592-2d16-4a2b-a00b-f012711879a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_7e4da8b1-2850-4575-b751-0cdbf6786c5a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_7e4da8b1-2850-4575-b751-0cdbf6786c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f67f34ea-7855-43ee-923b-3dc6617311dc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityVoluntaryFilers_f67f34ea-7855-43ee-923b-3dc6617311dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_74379b52-d78e-4b60-8613-908fca07256c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityCurrentReportingStatus_74379b52-d78e-4b60-8613-908fca07256c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_5102d9fa-925f-45e5-8432-7be43327b9cb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityInteractiveDataCurrent_5102d9fa-925f-45e5-8432-7be43327b9cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_fa82233e-68ce-4348-9ed5-27269c57c236" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityFilerCategory_fa82233e-68ce-4348-9ed5-27269c57c236" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_e41ee55f-18a2-4890-93b8-ea1b0b67a4b2" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntitySmallBusiness_e41ee55f-18a2-4890-93b8-ea1b0b67a4b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_2ee53f04-37da-48f1-a1a7-b94192ec784a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityEmergingGrowthCompany_2ee53f04-37da-48f1-a1a7-b94192ec784a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_4782f363-ce51-40ff-b711-de1b51a3006e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_IcfrAuditorAttestationFlag_4782f363-ce51-40ff-b711-de1b51a3006e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_fceff817-7ff7-455d-a921-3dae02df002d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_fceff817-7ff7-455d-a921-3dae02df002d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_01766eb1-1eba-4c59-8333-723c043480cc" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityShellCompany_01766eb1-1eba-4c59-8333-723c043480cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_40c63f7c-0652-41fa-9cf0-a078520e3981" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityPublicFloat_40c63f7c-0652-41fa-9cf0-a078520e3981" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_302f93eb-c3d4-4b42-92d9-913cd025a7c4" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_302f93eb-c3d4-4b42-92d9-913cd025a7c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_0aa86296-9db8-4f39-ba5c-8a46e64b342d" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_EntityCentralIndexKey_0aa86296-9db8-4f39-ba5c-8a46e64b342d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_d8769af6-decf-4871-9068-b4384b3ff4db" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_AmendmentFlag_d8769af6-decf-4871-9068-b4384b3ff4db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_4ba7093c-f80c-4b34-aa76-66e39a81afcf" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentFiscalPeriodFocus_4ba7093c-f80c-4b34-aa76-66e39a81afcf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_5a19d8c1-1530-49bd-a823-622c06f3bd49" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_97654116-cbe0-45a9-bfc5-c9cec73566e6" xlink:to="loc_dei_DocumentFiscalYearFocus_5a19d8c1-1530-49bd-a823-622c06f3bd49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/AuditInformation" xlink:type="simple" xlink:href="avdl-20241231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AuditInformationAbstract_a0c4abea-e946-48bf-b697-607a0231735c" xlink:href="avdl-20241231.xsd#avdl_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_5cba26b9-b7cd-4d6e-9043-f409cb7058b1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_AuditInformationAbstract_a0c4abea-e946-48bf-b697-607a0231735c" xlink:to="loc_dei_AuditorName_5cba26b9-b7cd-4d6e-9043-f409cb7058b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_57de4a46-ca2d-4881-9e12-6a27ab08e20f" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_AuditInformationAbstract_a0c4abea-e946-48bf-b697-607a0231735c" xlink:to="loc_dei_AuditorLocation_57de4a46-ca2d-4881-9e12-6a27ab08e20f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_c3c1b369-c6fe-4e7f-b474-6b25fe32084a" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_AuditInformationAbstract_a0c4abea-e946-48bf-b697-607a0231735c" xlink:to="loc_dei_AuditorFirmId_c3c1b369-c6fe-4e7f-b474-6b25fe32084a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofLoss" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofLoss"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9afa2ec-4af3-4e4e-97ed-0442893c279d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_b9afa2ec-4af3-4e4e-97ed-0442893c279d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_86ca36e0-ba06-4eee-9f34-c4bb621a1344" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_86ca36e0-ba06-4eee-9f34-c4bb621a1344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_506a7d27-892b-428f-8e72-5038d99e98d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_GrossProfit_506a7d27-892b-428f-8e72-5038d99e98d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_6d985277-0a65-4b3c-8921-b48bf4052573" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_6d985277-0a65-4b3c-8921-b48bf4052573" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7fdd7090-a179-4b44-8b9b-bc54f3f01983" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpense_7fdd7090-a179-4b44-8b9b-bc54f3f01983" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_630048ae-b214-4163-bfbf-5ea7f9b094e4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:to="loc_us-gaap_RestructuringCharges_630048ae-b214-4163-bfbf-5ea7f9b094e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_5eff5d32-3873-4f5d-a809-fbeee0407487" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_822f5345-bb16-4434-a029-1f5309534f9d" xlink:to="loc_us-gaap_OperatingExpenses_5eff5d32-3873-4f5d-a809-fbeee0407487" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_7568d7bb-f5b4-425d-a46c-e886d69642a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_OperatingIncomeLoss_7568d7bb-f5b4-425d-a46c-e886d69642a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_d57818cb-951e-405d-adec-d7c524111896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_InvestmentIncomeNet_d57818cb-951e-405d-adec-d7c524111896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_cfc070de-5c75-410d-b1ec-b450b6e863ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_InterestExpenseDebt_cfc070de-5c75-410d-b1ec-b450b6e863ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d3e9af02-64b7-48ae-a74f-f23e05fdf672" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_d3e9af02-64b7-48ae-a74f-f23e05fdf672" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00154abe-991f-45b6-b7da-afbff871c191" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_00154abe-991f-45b6-b7da-afbff871c191" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5165387f-737a-4315-b7c2-83dd1ef29bb2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5165387f-737a-4315-b7c2-83dd1ef29bb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_ea4a09f2-515a-4c87-98ce-e3382387bbbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_NetIncomeLoss_ea4a09f2-515a-4c87-98ce-e3382387bbbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_9082e2c4-387c-4614-ad52-2a1ac03bb8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_EarningsPerShareBasic_9082e2c4-387c-4614-ad52-2a1ac03bb8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_3e19511d-3b3f-4689-9177-2169bb911b6a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_EarningsPerShareDiluted_3e19511d-3b3f-4689-9177-2169bb911b6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_240df836-759a-42a4-a2da-4e21751a4c1c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_240df836-759a-42a4-a2da-4e21751a4c1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f035b42-2f1e-4918-a119-1c20f1915b2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_8b7fe8fb-0fb8-4305-b775-74cd1d363dbd" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_1f035b42-2f1e-4918-a119-1c20f1915b2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9206aaf5-9e3a-4f5a-9815-3f09641b34c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a8730b11-60d9-41b6-95ab-9c237f83ead1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9206aaf5-9e3a-4f5a-9815-3f09641b34c7" xlink:to="loc_us-gaap_NetIncomeLoss_a8730b11-60d9-41b6-95ab-9c237f83ead1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a8b1a59c-db34-45f7-9f68-eb532da2c2e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9206aaf5-9e3a-4f5a-9815-3f09641b34c7" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a8b1a59c-db34-45f7-9f68-eb532da2c2e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d4eaf9db-fa43-44a7-975d-285296b5f697" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a8b1a59c-db34-45f7-9f68-eb532da2c2e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent_d4eaf9db-fa43-44a7-975d-285296b5f697" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a885b401-acbb-4db2-a9ef-b32a5340f951" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a8b1a59c-db34-45f7-9f68-eb532da2c2e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_a885b401-acbb-4db2-a9ef-b32a5340f951" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_15727f07-69bc-4831-b40f-601368f20941" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_a8b1a59c-db34-45f7-9f68-eb532da2c2e0" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_15727f07-69bc-4831-b40f-601368f20941" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_3f3b3db5-5350-4de5-9b78-b295daceab89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9206aaf5-9e3a-4f5a-9815-3f09641b34c7" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_3f3b3db5-5350-4de5-9b78-b295daceab89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofComprehensiveLossParenthetical"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ddbd6208-a401-4abe-8e94-bebb338770c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_67a6204f-874d-4c65-bc76-575cc0eb52d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_ddbd6208-a401-4abe-8e94-bebb338770c3" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_67a6204f-874d-4c65-bc76-575cc0eb52d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e2e075b6-f0a6-482d-bec4-be960d78de26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e2e075b6-f0a6-482d-bec4-be960d78de26" xlink:to="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ccf68d9-c5b8-4050-9f93-78c0b2764486" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_8ccf68d9-c5b8-4050-9f93-78c0b2764486" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_72085142-a218-44e6-aeb1-d1e5ee7132c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_72085142-a218-44e6-aeb1-d1e5ee7132c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_e8e309c8-9402-42ac-a076-eccb1aaac919" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_e8e309c8-9402-42ac-a076-eccb1aaac919" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_9cf5017a-0704-40ea-ad3c-3694346f815f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_InventoryNet_9cf5017a-0704-40ea-ad3c-3694346f815f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d38fab7a-bec8-4cb7-8225-685736359267" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_d38fab7a-bec8-4cb7-8225-685736359267" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_e4693737-39fb-4053-bc55-586229accf91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_bc6b41e1-75b5-41b0-a31f-fb15220c18d0" xlink:to="loc_us-gaap_AssetsCurrent_e4693737-39fb-4053-bc55-586229accf91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_1e4cdcf9-a1ed-4508-9bbc-9aec35bd2149" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_1e4cdcf9-a1ed-4508-9bbc-9aec35bd2149" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_cf9ff1b7-cba5-496e-b079-f8148a0d25b6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_cf9ff1b7-cba5-496e-b079-f8148a0d25b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_9d5175bb-6a9a-4a4e-9d5f-7966caa90587" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_Goodwill_9d5175bb-6a9a-4a4e-9d5f-7966caa90587" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_90437570-5d02-42f8-8349-22812a1e0cd8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_90437570-5d02-42f8-8349-22812a1e0cd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_11152f1b-d3aa-47ab-941e-488d46101a0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Assets"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_b95bc5d1-d01f-4b0f-9a13-58094156a29e" xlink:to="loc_us-gaap_Assets_11152f1b-d3aa-47ab-941e-488d46101a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e2e075b6-f0a6-482d-bec4-be960d78de26" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_aecf6575-d333-4afd-9cb2-03fdb352a512" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_aecf6575-d333-4afd-9cb2-03fdb352a512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_10da8d25-81c4-4eb8-8c44-45d0fe8a3f6c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:to="loc_us-gaap_AccountsPayableCurrent_10da8d25-81c4-4eb8-8c44-45d0fe8a3f6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_22e93a5b-c3d1-4666-88d1-66a7274cc547" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_22e93a5b-c3d1-4666-88d1-66a7274cc547" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesCurrent_521ec803-09cc-4d60-98c9-c623bd7a5630" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:to="loc_us-gaap_OtherLiabilitiesCurrent_521ec803-09cc-4d60-98c9-c623bd7a5630" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6ad2b8e6-3cce-4359-bb3a-20dccd1b7eb6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_6f6921cc-d694-47d0-b3cb-2622e171f485" xlink:to="loc_us-gaap_LiabilitiesCurrent_6ad2b8e6-3cce-4359-bb3a-20dccd1b7eb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32867c70-374e-46cc-9294-3d45c76cb134" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_32867c70-374e-46cc-9294-3d45c76cb134" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityNoncurrent_7672e879-88dc-4b21-8e60-9e47108560ad" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_avdl_RoyaltyFinancingLiabilityNoncurrent_7672e879-88dc-4b21-8e60-9e47108560ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_f11f9024-ec46-4ec8-b933-97ca82ce2778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_f11f9024-ec46-4ec8-b933-97ca82ce2778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_a71c3704-995c-4e3b-b11e-0df4438711bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_Liabilities_a71c3704-995c-4e3b-b11e-0df4438711bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_86273a54-69f4-4d3b-987b-bc37543b60c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_PreferredStockValue_86273a54-69f4-4d3b-987b-bc37543b60c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_925d145c-2597-435a-9028-b8d2c2f434a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_CommonStockValue_925d145c-2597-435a-9028-b8d2c2f434a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2d744a04-07d7-4600-82dc-3461c2d3aa95" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalCommonStock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_AdditionalPaidInCapitalCommonStock_2d744a04-07d7-4600-82dc-3461c2d3aa95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_585e8841-c3ca-469c-90d0-f1a6a4dcdf64" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_585e8841-c3ca-469c-90d0-f1a6a4dcdf64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b099538c-c870-4b6c-ac92-cebae45eeb09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_b099538c-c870-4b6c-ac92-cebae45eeb09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7e4c4b18-1e9c-4dc1-845f-f5f826f80761" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_351b0595-8904-4504-83e8-207f7d1bb4f5" xlink:to="loc_us-gaap_StockholdersEquity_7e4c4b18-1e9c-4dc1-845f-f5f826f80761" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a2ad0c6-c459-4c33-b662-2cfefc035f8b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_7a16cd81-1094-47c9-9c00-da123fc096fb" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_2a2ad0c6-c459-4c33-b662-2cfefc035f8b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f04faeb6-41bd-4262-a45e-2b246231a7ed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_f04faeb6-41bd-4262-a45e-2b246231a7ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_37902062-92cb-4d11-99f2-43ef24fdf350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_37902062-92cb-4d11-99f2-43ef24fdf350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_53fc4396-db55-48fb-8e0a-7ded877b3dad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_PreferredStockSharesIssued_53fc4396-db55-48fb-8e0a-7ded877b3dad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_f1752b4b-fcd7-4e20-99fe-8c92edc5e289" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_f1752b4b-fcd7-4e20-99fe-8c92edc5e289" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_95ca2ba3-0ad0-4d12-965a-0dc4582f0184" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_95ca2ba3-0ad0-4d12-965a-0dc4582f0184" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_a68efaf6-2a51-4343-8e4b-c9b762d6e208" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_a68efaf6-2a51-4343-8e4b-c9b762d6e208" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f375fe35-ee3e-4cac-ad90-a4d87076edf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_CommonStockSharesIssued_f375fe35-ee3e-4cac-ad90-a4d87076edf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_5b15c606-4156-4f31-8782-61638293a0d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_e5e6740a-85d1-466d-9df9-254327f6e3c4" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_5b15c606-4156-4f31-8782-61638293a0d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofShareholdersEquity"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_b7d49083-06ca-45d8-a896-3c59cb020e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_b7d49083-06ca-45d8-a896-3c59cb020e6b" xlink:to="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_6dafd95c-02ce-4bd9-ab45-171e59e9f778" xlink:to="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_b112fa49-3e0d-4de1-8179-63540d882c43" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_CommonStockMember_b112fa49-3e0d-4de1-8179-63540d882c43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_ad6345b7-932d-4457-848e-c745b96ef8cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_PreferredStockMember_ad6345b7-932d-4457-848e-c745b96ef8cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_b489695e-7fd8-4664-ac7f-5f0e15bd3862" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_b489695e-7fd8-4664-ac7f-5f0e15bd3862" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_e550c828-08f3-491d-87cf-ff1a3c741e81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_RetainedEarningsMember_e550c828-08f3-491d-87cf-ff1a3c741e81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5806970-536c-42cd-9e0f-c13a902aecbd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_b1745d47-0a36-4608-82f8-5849999b859c" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_f5806970-536c-42cd-9e0f-c13a902aecbd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_d611e476-5931-4673-a01a-a35b506cfdbb" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AtTheMarketOfferingProgramMember_ff721a9b-6d7b-4c1b-a42e-d312c2273df6" xlink:href="avdl-20241231.xsd#avdl_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:to="loc_avdl_AtTheMarketOfferingProgramMember_ff721a9b-6d7b-4c1b-a42e-d312c2273df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PublicOfferingMember_f1c7e8d5-869e-45f1-88c5-dd9aa96167a2" xlink:href="avdl-20241231.xsd#avdl_PublicOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_2ed51a40-ded3-468c-92cf-6f265c8eb28a" xlink:to="loc_avdl_PublicOfferingMember_f1c7e8d5-869e-45f1-88c5-dd9aa96167a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_7965b826-60f5-4c80-8e61-6e1a54f19977" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_April2027NotesMember_a173782f-cdf8-4957-90ed-147f2d77f9b4" xlink:href="avdl-20241231.xsd#avdl_April2027NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:to="loc_avdl_April2027NotesMember_a173782f-cdf8-4957-90ed-147f2d77f9b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_382e6342-31a4-430c-9d64-956ecead251e" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e418f193-c1f2-44ac-b471-a09d7f19a8a4" xlink:to="loc_avdl_October2023NotesMember_382e6342-31a4-430c-9d64-956ecead251e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_203f9076-4d9b-4fd7-bb67-b51cac373fd6" xlink:to="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_49fe43da-fe06-4952-9ccc-9b5197332e82" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_69cea04b-7fe8-4778-8485-0c6d9bc7ceed" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_SharesOutstanding_69cea04b-7fe8-4778-8485-0c6d9bc7ceed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_ba1eb2e1-2577-436a-91e5-6d47ee06c7d0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockholdersEquity_ba1eb2e1-2577-436a-91e5-6d47ee06c7d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a853def2-e2e8-4b0c-a7e5-ce2a2d5ff88e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_NetIncomeLoss_a853def2-e2e8-4b0c-a7e5-ce2a2d5ff88e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f686d901-5924-446f-955e-1fe1995a68a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_f686d901-5924-446f-955e-1fe1995a68a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_ec6752f3-8ff8-41a1-aa71-a138ec30d97e" xlink:href="avdl-20241231.xsd#avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature_ec6752f3-8ff8-41a1-aa71-a138ec30d97e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_220d9a68-c337-4e41-90bc-32184922b758" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_220d9a68-c337-4e41-90bc-32184922b758" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4f83d2b2-1109-4658-80a3-d281c64bc418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4f83d2b2-1109-4658-80a3-d281c64bc418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4baa10be-1014-4b2f-a5c7-1ab265f52b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_4baa10be-1014-4b2f-a5c7-1ab265f52b0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_707a8d99-6077-43c7-a5c2-27c7f6ae07c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_707a8d99-6077-43c7-a5c2-27c7f6ae07c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1bf1d17a-3fde-45f7-ab1d-511ce0321c2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_1bf1d17a-3fde-45f7-ab1d-511ce0321c2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c67d060c-9b0b-42b4-96d0-41eb1c358896" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_c67d060c-9b0b-42b4-96d0-41eb1c358896" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21cc3fb1-2bad-4d15-b573-559712e5cfdf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_21cc3fb1-2bad-4d15-b573-559712e5cfdf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesOther_f6f0f493-ef35-4c71-879a-107288734200" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesOther"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesOther_f6f0f493-ef35-4c71-879a-107288734200" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueOther_2b97e52b-3ac3-43bf-b92a-2adb488e420a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueOther"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueOther_2b97e52b-3ac3-43bf-b92a-2adb488e420a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_6bcd47a5-cade-4f2c-ac0d-d835689b2f08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan_6bcd47a5-cade-4f2c-ac0d-d835689b2f08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6baffa6b-5f37-4672-bb73-7ef3f35997c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_6baffa6b-5f37-4672-bb73-7ef3f35997c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13aae24e-3a42-4207-b403-e135f3c406c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_13aae24e-3a42-4207-b403-e135f3c406c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesOutstanding_52ef66fb-9968-47a6-ac0e-ce6d5ca171ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharesOutstanding"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_SharesOutstanding_52ef66fb-9968-47a6-ac0e-ce6d5ca171ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_b7163fc5-e69e-4612-9631-e3183548a592" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_d98aea69-b9aa-4d64-91b9-ca3df233b038" xlink:to="loc_us-gaap_StockholdersEquity_b7163fc5-e69e-4612-9631-e3183548a592" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="avdl-20241231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_fab2f48a-0ff3-4c5f-ae09-59d8000038fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_fab2f48a-0ff3-4c5f-ae09-59d8000038fa" xlink:to="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_937131db-b0ce-4bf9-916e-5bf2623f045e" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PublicOfferingMember_a2c413cf-6674-4ede-8a00-e5b4d1ed12d7" xlink:href="avdl-20241231.xsd#avdl_PublicOfferingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:to="loc_avdl_PublicOfferingMember_a2c413cf-6674-4ede-8a00-e5b4d1ed12d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AtTheMarketOfferingProgramMember_205faf57-77e6-4bd2-a07a-c8c0fe4f5325" xlink:href="avdl-20241231.xsd#avdl_AtTheMarketOfferingProgramMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_42dc3a9a-475f-4a1b-b758-5346e1bc5fb8" xlink:to="loc_avdl_AtTheMarketOfferingProgramMember_205faf57-77e6-4bd2-a07a-c8c0fe4f5325" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:to="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_353c54dc-2d16-4fe5-ae62-ecf8ac91a7b5" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_February2023NotesMember_5934c6a1-0659-4e56-945a-8c7d6bf6fe78" xlink:href="avdl-20241231.xsd#avdl_February2023NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:to="loc_avdl_February2023NotesMember_5934c6a1-0659-4e56-945a-8c7d6bf6fe78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_8d5b7b70-5662-4b16-9d47-d32f0cc43227" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_e4c1703d-a933-47ae-bfcc-192cb7759021" xlink:to="loc_avdl_October2023NotesMember_8d5b7b70-5662-4b16-9d47-d32f0cc43227" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_c93da5ca-fa6c-4b33-b0ee-7592f105227e" xlink:to="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_bb00ead9-9056-4636-a436-2863582fb0df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_NetIncomeLoss_bb00ead9-9056-4636-a436-2863582fb0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_5029e33f-7895-4bea-b899-4aab506de24c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_DepreciationAndAmortization_5029e33f-7895-4bea-b899-4aab506de24c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_481a753b-8e67-4341-9981-f78393b639a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AmortizationOfFinancingCostsAndDiscounts"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_AmortizationOfFinancingCostsAndDiscounts_481a753b-8e67-4341-9981-f78393b639a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2971548e-94d9-4533-952d-72f40d98d28f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInDeferredIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes_2971548e-94d9-4533-952d-72f40d98d28f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_10faed6a-370a-4fda-810c-01b749264c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_ShareBasedCompensation_10faed6a-370a-4fda-810c-01b749264c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f521315-f609-4b13-a844-cb80d6ad0930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_2f521315-f609-4b13-a844-cb80d6ad0930" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5c70765b-091c-43fd-9a2e-a42257aa34da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherOperatingActivitiesCashFlowStatement"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_OtherOperatingActivitiesCashFlowStatement_5c70765b-091c-43fd-9a2e-a42257aa34da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_ef2fd6e5-57f4-4e29-b204-6b1fa0144a76" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8aca4e22-73d3-409a-8984-d4e09149bc6f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_8aca4e22-73d3-409a-8984-d4e09149bc6f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInInventories_108048f2-4f91-4f8c-b0a8-d10104c8fdef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInInventories"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInInventories_108048f2-4f91-4f8c-b0a8-d10104c8fdef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_311ecf10-df7e-41d3-9846-ef2cca416b65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_311ecf10-df7e-41d3-9846-ef2cca416b65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503c8f2e-b259-4b1e-b284-4dfe278f1de3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccountsPayable"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayable_503c8f2e-b259-4b1e-b284-4dfe278f1de3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_584e69af-d1ab-41fe-bd1b-0af5ae06d7b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInAccruedLiabilities_584e69af-d1ab-41fe-bd1b-0af5ae06d7b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_3aeaea60-d8d2-49a0-a873-97d8f3748d68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_421f5bd3-3302-409c-9b4f-168029f161ac" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet_3aeaea60-d8d2-49a0-a873-97d8f3748d68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be5a22af-d1d4-4c9a-a072-47318a24fe97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_b449a6b7-c765-49c1-8b09-66bc6a34e204" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_be5a22af-d1d4-4c9a-a072-47318a24fe97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa9ca90e-380e-4468-85b7-d6f05233cd47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_fa9ca90e-380e-4468-85b7-d6f05233cd47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e42c3ce3-e895-488a-8208-aa3f4cd89c63" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt_e42c3ce3-e895-488a-8208-aa3f4cd89c63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3521df12-36f4-4ddf-b51b-a64369136c00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_3521df12-36f4-4ddf-b51b-a64369136c00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780bde19-63c8-44e4-b01b-ee86bc7ddcd2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_b457557a-84f5-4855-bd4d-b59d233b3917" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_780bde19-63c8-44e4-b01b-ee86bc7ddcd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8be9aff-9bae-428d-b96f-5bae571e5e68" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfCommonStock_f8be9aff-9bae-428d-b96f-5bae571e5e68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74522e3a-4f55-406a-97cd-871f14e3a91f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions_74522e3a-4f55-406a-97cd-871f14e3a91f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfSeniorDebt_91614c1b-0b9a-43c5-92ab-93d6b854da40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RepaymentsOfSeniorDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_RepaymentsOfSeniorDebt_91614c1b-0b9a-43c5-92ab-93d6b854da40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfDebtIssuanceCosts_786b5baf-6797-44f0-a795-3c5d2069adc6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PaymentsOfDebtIssuanceCosts"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_PaymentsOfDebtIssuanceCosts_786b5baf-6797-44f0-a795-3c5d2069adc6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11078289-6704-4921-b9ba-3a908ae0460e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_11078289-6704-4921-b9ba-3a908ae0460e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac5c4ffb-4459-405a-be79-991d86dea7fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_5d7f5fb7-14a2-4f4b-8bbd-73069912c842" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_ac5c4ffb-4459-405a-be79-991d86dea7fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc67365e-c73a-480a-b2ce-9b288b7f65b4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_cc67365e-c73a-480a-b2ce-9b288b7f65b4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43a42a23-98c6-4fdc-88d8-343b86ace871" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_43a42a23-98c6-4fdc-88d8-343b86ace871" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3540ece7-0243-43fa-895d-da617985be00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_3540ece7-0243-43fa-895d-da617985be00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a198051-e9c9-494a-badc-74b9154c3239" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_5a198051-e9c9-494a-badc-74b9154c3239" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_f986d269-d422-4df5-aba5-61d870f16e3b" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestPaidNet_fa8f26fd-0352-4637-9e2a-ad4ea1676ad9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestPaidNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:to="loc_us-gaap_InterestPaidNet_fa8f26fd-0352-4637-9e2a-ad4ea1676ad9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_6ee12c21-a3b0-4f1d-ba78-5dd161a3cdfc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_7f0c1cde-39ce-4619-80b3-b257725750d3" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_6ee12c21-a3b0-4f1d-ba78-5dd161a3cdfc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_baade06d-3181-4353-8c30-de1265e02361" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f9ed888-b57c-4df2-bd31-053215d4a410" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_baade06d-3181-4353-8c30-de1265e02361" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_8f9ed888-b57c-4df2-bd31-053215d4a410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NewlyIssuedAccountingStandards" xlink:type="simple" xlink:href="avdl-20241231.xsd#NewlyIssuedAccountingStandards"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/NewlyIssuedAccountingStandards" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1431cb10-4253-41d9-9616-11a8561ca092" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingChangesAndErrorCorrectionsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1a49be41-41a1-41f7-9e9c-c1ece9ffe1b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingChangesAndErrorCorrectionsAbstract_1431cb10-4253-41d9-9616-11a8561ca092" xlink:to="loc_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock_1a49be41-41a1-41f7-9e9c-c1ece9ffe1b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognition" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognition"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RevenueRecognition" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b7e2654-8c9a-4952-9e16-ec5722a1f8b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dfb6514-44fa-4cbd-abfc-6ac274960d91" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9b7e2654-8c9a-4952-9e16-ec5722a1f8b9" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerTextBlock_7dfb6514-44fa-4cbd-abfc-6ac274960d91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/FairValueMeasurements" xlink:type="simple" xlink:href="avdl-20241231.xsd#FairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/FairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9cb53078-386b-441f-8aed-82a43e3badad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_8a09fcb0-d820-4655-8e6e-fcb35e258e05" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9cb53078-386b-441f-8aed-82a43e3badad" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_8a09fcb0-d820-4655-8e6e-fcb35e258e05" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecurities" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecurities"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/MarketableSecurities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3febbc7c-8173-45c4-b271-4c9491754b7a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_97986f4f-614d-42f4-85c6-2234e144bc21" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3febbc7c-8173-45c4-b271-4c9491754b7a" xlink:to="loc_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock_97986f4f-614d-42f4-85c6-2234e144bc21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/Inventories" xlink:type="simple" xlink:href="avdl-20241231.xsd#Inventories"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/Inventories" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_8bdaaaff-5158-41fe-871c-07f63eb84b54" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureTextBlock_90750f23-2a4f-4e97-a686-e4560c145a35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_8bdaaaff-5158-41fe-871c-07f63eb84b54" xlink:to="loc_us-gaap_InventoryDisclosureTextBlock_90750f23-2a4f-4e97-a686-e4560c145a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/PropertyandEquipmentnet" xlink:type="simple" xlink:href="avdl-20241231.xsd#PropertyandEquipmentnet"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/PropertyandEquipmentnet" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_868146df-c8ac-415d-993c-ca82da635360" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6da04192-4305-418e-ac92-e47f4034a139" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_868146df-c8ac-415d-993c-ca82da635360" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_6da04192-4305-418e-ac92-e47f4034a139" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/Goodwill" xlink:type="simple" xlink:href="avdl-20241231.xsd#Goodwill"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/Goodwill" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ec1ffde-0746-45c4-9170-6bd72a144190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_9313a8ed-9e81-498d-ab9a-47b73e938b38" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_3ec1ffde-0746-45c4-9170-6bd72a144190" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock_9313a8ed-9e81-498d-ab9a-47b73e938b38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/Leases" xlink:type="simple" xlink:href="avdl-20241231.xsd#Leases"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/Leases" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_6a492ee6-4025-432b-812f-6fcc60093703" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7af81e38-5890-4bc6-858f-8328b6ae0ca8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_6a492ee6-4025-432b-812f-6fcc60093703" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7af81e38-5890-4bc6-858f-8328b6ae0ca8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligation" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligation"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_b37ad20e-503b-439b-b447-be76bb9d4577" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_fb993a0b-2de5-4319-8f3e-b8121b8aed26" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_b37ad20e-503b-439b-b447-be76bb9d4577" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_fb993a0b-2de5-4319-8f3e-b8121b8aed26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxes" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ea8634-cdde-441f-becc-3532d4b97686" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_2e4aafe8-61ca-400b-8005-70dc41a0aee0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b1ea8634-cdde-441f-becc-3532d4b97686" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_2e4aafe8-61ca-400b-8005-70dc41a0aee0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilities" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e3fdc73d-3204-4d7d-adc4-ccaeeadc1a14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4fd9147e-731f-46c7-b2e4-d08052e399a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_e3fdc73d-3204-4d7d-adc4-ccaeeadc1a14" xlink:to="loc_us-gaap_OtherLiabilitiesDisclosureTextBlock_4fd9147e-731f-46c7-b2e4-d08052e399a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ContingentLiabilitiesandCommitments" xlink:type="simple" xlink:href="avdl-20241231.xsd#ContingentLiabilitiesandCommitments"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ContingentLiabilitiesandCommitments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9e122bc4-d7c3-4639-95b4-d73d0198c3be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_39979ea0-def9-4808-a845-38c3cc10477e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_9e122bc4-d7c3-4639-95b4-d73d0198c3be" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_39979ea0-def9-4808-a845-38c3cc10477e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/EquityInstrumentsandTransactions" xlink:type="simple" xlink:href="avdl-20241231.xsd#EquityInstrumentsandTransactions"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/EquityInstrumentsandTransactions" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_10c35c4a-2ee4-4663-9d0a-19df673fae08" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EquityTransactionsDisclosureTextBlock_4ba2efea-12c4-4743-862e-c2ddd0a3d0d0" xlink:href="avdl-20241231.xsd#avdl_EquityTransactionsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_10c35c4a-2ee4-4663-9d0a-19df673fae08" xlink:to="loc_avdl_EquityTransactionsDisclosureTextBlock_4ba2efea-12c4-4743-862e-c2ddd0a3d0d0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensation" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensation"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b19fcff9-49cb-43f4-b18b-bf7c3cd61990" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35e46e7e-a0b8-44cd-bf9c-16ac4d140d5a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_b19fcff9-49cb-43f4-b18b-bf7c3cd61990" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_35e46e7e-a0b8-44cd-bf9c-16ac4d140d5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NetLossPerShare" xlink:type="simple" xlink:href="avdl-20241231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_aa2230ba-faa7-48a4-bbd3-5a4eb7abb0da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_737e13ef-8912-43f8-8dfd-ac1ca1196fa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_aa2230ba-faa7-48a4-bbd3-5a4eb7abb0da" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_737e13ef-8912-43f8-8dfd-ac1ca1196fa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ComprehensiveLoss" xlink:type="simple" xlink:href="avdl-20241231.xsd#ComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_c2c72e71-81ad-4d41-b044-b60e5aad8e44" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0335b400-7f47-446c-9d54-b67586a56861" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ComprehensiveIncomeNoteTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_c2c72e71-81ad-4d41-b044-b60e5aad8e44" xlink:to="loc_us-gaap_ComprehensiveIncomeNoteTextBlock_0335b400-7f47-446c-9d54-b67586a56861" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformation" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7c053695-3020-4a72-ac44-a5a5495b0059" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_fb55b89a-f60d-4782-8643-b6463b3b5467" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7c053695-3020-4a72-ac44-a5a5495b0059" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_fb55b89a-f60d-4782-8643-b6463b3b5467" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="simple" xlink:href="avdl-20241231.xsd#ScheduleIIValuationandQualifyingAccounts"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_0eb0fb63-deec-4529-9710-03a3ec6f52ad" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_01228e55-1e61-40b0-a62e-ea09d1ba5186" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_0eb0fb63-deec-4529-9710-03a3ec6f52ad" xlink:to="loc_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock_01228e55-1e61-40b0-a62e-ea09d1ba5186" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_NatureOfBusinessPolicyPolicyTextBlock_b2e48a5e-6456-482e-9d4b-25f030b91c44" xlink:href="avdl-20241231.xsd#avdl_NatureOfBusinessPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_avdl_NatureOfBusinessPolicyPolicyTextBlock_b2e48a5e-6456-482e-9d4b-25f030b91c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_LiquidityAndGoingConcernPolicyTextBlock_254a74d0-9c27-43d2-a6f5-afa89a78740f" xlink:href="avdl-20241231.xsd#avdl_LiquidityAndGoingConcernPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_avdl_LiquidityAndGoingConcernPolicyTextBlock_254a74d0-9c27-43d2-a6f5-afa89a78740f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a731032b-7436-4e40-847f-7745974505d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_a731032b-7436-4e40-847f-7745974505d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4017643b-ffdc-4f3d-8751-cc179c13d9ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PriorPeriodReclassificationAdjustmentDescription"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_PriorPeriodReclassificationAdjustmentDescription_4017643b-ffdc-4f3d-8751-cc179c13d9ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_809115e5-9b72-49d0-a539-fd4193bfcdf6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_809115e5-9b72-49d0-a539-fd4193bfcdf6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5fa1a664-e0d2-49dc-87ae-54954be06c3f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionPolicyTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_RevenueRecognitionPolicyTextBlock_5fa1a664-e0d2-49dc-87ae-54954be06c3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryPolicyTextBlock_73db9e36-cee4-4ecb-b163-4e20b9b128f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryPolicyTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_InventoryPolicyTextBlock_73db9e36-cee4-4ecb-b163-4e20b9b128f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7be39627-2b84-4a55-b11c-b7a84c79c95b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_7be39627-2b84-4a55-b11c-b7a84c79c95b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingCostsPolicyTextBlock_e878df51-3344-4847-88aa-485337410ece" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingCostsPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_AdvertisingCostsPolicyTextBlock_e878df51-3344-4847-88aa-485337410ece" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2a51eb6c-8b74-4817-a2d8-d0154aa2fb22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_CommitmentsAndContingenciesPolicyTextBlock_2a51eb6c-8b74-4817-a2d8-d0154aa2fb22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6571706b-08ce-4664-9718-905357a0563a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_6571706b-08ce-4664-9718-905357a0563a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_03196c01-2877-4322-bfd0-d4c91fc8bafb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_03196c01-2877-4322-bfd0-d4c91fc8bafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_04c36fad-6b3e-4469-98df-04f5567564de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_04c36fad-6b3e-4469-98df-04f5567564de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_1a4947b3-2a3e-4501-bb8b-6950a2a6d946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_1a4947b3-2a3e-4501-bb8b-6950a2a6d946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8b4ce2a-5c99-434a-a497-45a8511e6e3c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_e8b4ce2a-5c99-434a-a497-45a8511e6e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_fc2650f3-68f0-4a87-87f7-0f5ac96d92ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock_fc2650f3-68f0-4a87-87f7-0f5ac96d92ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0c8ee3d1-99e8-4fce-8daa-48b73b7cd2c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_0c8ee3d1-99e8-4fce-8daa-48b73b7cd2c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_bb83feeb-738a-42ea-bf6c-c5e11b3d6f16" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_bb83feeb-738a-42ea-bf6c-c5e11b3d6f16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_b9e8ee20-60a6-4da8-9fff-b6dfa88b0d4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_UseOfEstimates_b9e8ee20-60a6-4da8-9fff-b6dfa88b0d4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1d637acc-b6d0-4857-9eda-52fa8b6445f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_cbc84a85-48ca-4f15-a3c1-288972506409" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_1d637acc-b6d0-4857-9eda-52fa8b6445f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_85b364db-09ce-4392-985a-a8f25c9fb08e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_368a8658-d798-4c2b-a1ff-139649fc319f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_85b364db-09ce-4392-985a-a8f25c9fb08e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_368a8658-d798-4c2b-a1ff-139649fc319f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognitionTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognitionTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RevenueRecognitionTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ae47856-f525-444b-9db7-6aacba178dba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_df80aa28-bb96-4651-8ace-916dbb643ba6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_9ae47856-f525-444b-9db7-6aacba178dba" xlink:to="loc_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock_df80aa28-bb96-4651-8ace-916dbb643ba6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/FairValueMeasurementsTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#FairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/FairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_42a0eb79-f050-49b7-a6b0-15df1ee5945e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3dcb5fa2-4c77-47e9-8dca-4499373e71e5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_42a0eb79-f050-49b7-a6b0-15df1ee5945e" xlink:to="loc_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock_3dcb5fa2-4c77-47e9-8dca-4499373e71e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3a5accd2-8ac4-4a89-8d00-bd2d06aa6b81" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ad4fcb4a-26c1-4efe-aafb-b9d96b12ec71" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3a5accd2-8ac4-4a89-8d00-bd2d06aa6b81" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_ad4fcb4a-26c1-4efe-aafb-b9d96b12ec71" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7b6c8cfa-f63a-4fec-915b-b6c661e5d040" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_3a5accd2-8ac4-4a89-8d00-bd2d06aa6b81" xlink:to="loc_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock_7b6c8cfa-f63a-4fec-915b-b6c661e5d040" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/InventoriesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#InventoriesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/InventoriesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_43de2b54-3639-47b0-96a5-3696c1e9f5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2f70b09f-980f-4e12-8d13-6f14b43b8cac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfInventoryCurrentTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_43de2b54-3639-47b0-96a5-3696c1e9f5ab" xlink:to="loc_us-gaap_ScheduleOfInventoryCurrentTableTextBlock_2f70b09f-980f-4e12-8d13-6f14b43b8cac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/PropertyandEquipmentnetTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#PropertyandEquipmentnetTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/PropertyandEquipmentnetTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cd6b6b8d-26fb-4872-9e7a-98338c1bf36e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6e28a748-a8ed-4851-899b-16b3338c7cf8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_cd6b6b8d-26fb-4872-9e7a-98338c1bf36e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_6e28a748-a8ed-4851-899b-16b3338c7cf8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/LeasesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_0e1a56cd-c9a0-4cfb-ab31-62debeac4939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_99438198-6b54-4d70-88d4-442b10012d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e1a56cd-c9a0-4cfb-ab31-62debeac4939" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_99438198-6b54-4d70-88d4-442b10012d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9b90d0fa-20f7-46b3-ae4f-d113d0a6de18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_0e1a56cd-c9a0-4cfb-ab31-62debeac4939" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_9b90d0fa-20f7-46b3-ae4f-d113d0a6de18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_17d478c1-9f59-49b5-b767-2c52cb51e8ec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_09d4803a-bd13-435e-921e-1a284e35c69a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_17d478c1-9f59-49b5-b767-2c52cb51e8ec" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_09d4803a-bd13-435e-921e-1a284e35c69a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock_a3a66152-52db-43ab-bfbb-6a2b7cf165b8" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:to="loc_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock_a3a66152-52db-43ab-bfbb-6a2b7cf165b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock_18525b02-c9e0-4241-8e2d-03373517f36c" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:to="loc_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock_18525b02-c9e0-4241-8e2d-03373517f36c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cac93cc9-39a1-40bc-ba5e-a231b4f43f2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_cac93cc9-39a1-40bc-ba5e-a231b4f43f2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a20d9e35-ce1f-4d44-9b21-7224a06267c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_a20d9e35-ce1f-4d44-9b21-7224a06267c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_40d9972c-c6f8-4112-8121-a4291f811b8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_ddf8610a-c909-43a9-ab27-e98aecad8a2d" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_40d9972c-c6f8-4112-8121-a4291f811b8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_50eeefd3-58a9-45ef-9fc1-0c1aff177f20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_01bdb3ad-6227-45bf-b8e0-4cbdfb163380" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_50eeefd3-58a9-45ef-9fc1-0c1aff177f20" xlink:to="loc_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock_01bdb3ad-6227-45bf-b8e0-4cbdfb163380" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_64c04acd-d785-45b0-8b9e-05da9c14ff7b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_50eeefd3-58a9-45ef-9fc1-0c1aff177f20" xlink:to="loc_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock_64c04acd-d785-45b0-8b9e-05da9c14ff7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2ef2e3a4-cd9e-4104-956b-c9c1c9d2861c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_50eeefd3-58a9-45ef-9fc1-0c1aff177f20" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_2ef2e3a4-cd9e-4104-956b-c9c1c9d2861c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_9c4f9cf4-1b0c-4032-acde-0cf0bad04237" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherNoncurrentLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_50eeefd3-58a9-45ef-9fc1-0c1aff177f20" xlink:to="loc_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock_9c4f9cf4-1b0c-4032-acde-0cf0bad04237" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae117420-119b-42ce-9f0d-d1f99834e8e1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3a8cff02-f871-4d9a-b095-b7e2f5e9bd33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae117420-119b-42ce-9f0d-d1f99834e8e1" xlink:to="loc_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_3a8cff02-f871-4d9a-b095-b7e2f5e9bd33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock_fe95800b-0f47-4b98-801b-b234d7ddb531" xlink:href="avdl-20241231.xsd#avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae117420-119b-42ce-9f0d-d1f99834e8e1" xlink:to="loc_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock_fe95800b-0f47-4b98-801b-b234d7ddb531" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dec81def-e637-454f-89c1-f22a02fe3720" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae117420-119b-42ce-9f0d-d1f99834e8e1" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_dec81def-e637-454f-89c1-f22a02fe3720" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_bc8a5848-cda3-4b83-b9cc-aef0384659fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ae117420-119b-42ce-9f0d-d1f99834e8e1" xlink:to="loc_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_bc8a5848-cda3-4b83-b9cc-aef0384659fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b7cbefc1-7fca-4621-946b-5ff00c0c947b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_891ab793-8744-487a-a2fe-7a0c369f67c2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b7cbefc1-7fca-4621-946b-5ff00c0c947b" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_891ab793-8744-487a-a2fe-7a0c369f67c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ComprehensiveLossTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#ComprehensiveLossTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ComprehensiveLossTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_89fce6cf-e56b-4ce5-b612-ac90c95a99d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_24145a64-6251-45d9-a1a8-63bfbd35097e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_89fce6cf-e56b-4ce5-b612-ac90c95a99d6" xlink:to="loc_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock_24145a64-6251-45d9-a1a8-63bfbd35097e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_28e3a7e7-199b-421f-aa58-499eede10e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6a9e41fd-df1b-4d24-9f9c-6bbb3cc40df6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28e3a7e7-199b-421f-aa58-499eede10e1a" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_6a9e41fd-df1b-4d24-9f9c-6bbb3cc40df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_9ccaf0db-49d6-4b94-aac7-e46014a26dbc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_28e3a7e7-199b-421f-aa58-499eede10e1a" xlink:to="loc_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock_9ccaf0db-49d6-4b94-aac7-e46014a26dbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_823e72ab-fc90-41ff-9f8d-deaad4bc21df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_823e72ab-fc90-41ff-9f8d-deaad4bc21df" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_38367b56-8848-49fa-a14c-67abc1b4501a" xlink:to="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_e0d95296-872a-4906-a74f-b1f41cac6564" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_ThreeCustomersMember_e0d95296-872a-4906-a74f-b1f41cac6564" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkLLCMember_c01b0ac7-da01-4de4-a194-54ada2402f5f" xlink:href="avdl-20241231.xsd#avdl_CaremarkLLCMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_CaremarkLLCMember_c01b0ac7-da01-4de4-a194-54ada2402f5f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoHealthGroupInc.Member_dd9d339b-d19d-4f7c-9aa6-fe860b513fb8" xlink:href="avdl-20241231.xsd#avdl_AccredoHealthGroupInc.Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_AccredoHealthGroupInc.Member_dd9d339b-d19d-4f7c-9aa6-fe860b513fb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumFrontierTherapiesLLCMember_f4dc7adc-2391-4edc-abf7-df0b511d4326" xlink:href="avdl-20241231.xsd#avdl_OptumFrontierTherapiesLLCMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_96909f37-e11a-4894-891d-40655b6dd1f9" xlink:to="loc_avdl_OptumFrontierTherapiesLLCMember_f4dc7adc-2391-4edc-abf7-df0b511d4326" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_7e4df554-63c7-4171-ae78-3a5eb6b171cf" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableMember_a982ffba-ee1b-4ca1-bb85-0252715c48f8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountsReceivableMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_2e4a2277-fedf-48eb-84c0-844f672979b9" xlink:to="loc_us-gaap_AccountsReceivableMember_a982ffba-ee1b-4ca1-bb85-0252715c48f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_be001464-01cb-4c96-8160-8f1f0518d9b5" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_ca9e04f3-8ece-488e-99a7-47ef2a9a6432" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_ecf73e78-289e-4be5-882d-c17020ca2dc7" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_ca9e04f3-8ece-488e-99a7-47ef2a9a6432" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_5fcaa0a3-a0f4-4ed7-9be7-5f02eeccc19e" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_b839e4d4-76a3-4aa5-a461-cf22ef4d2a94" xlink:href="avdl-20241231.xsd#avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_325723db-1e59-4b07-87f5-50211154e682" xlink:to="loc_avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember_b839e4d4-76a3-4aa5-a461-cf22ef4d2a94" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_d7e4e26a-13c9-481e-86cc-298b971fb73d" xlink:to="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_NumberOfFinancialInstitutions_f17c2754-378b-4d94-85be-cd3683bd7e86" xlink:href="avdl-20241231.xsd#avdl_NumberOfFinancialInstitutions"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_avdl_NumberOfFinancialInstitutions_f17c2754-378b-4d94-85be-cd3683bd7e86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_fada1db4-3527-4d64-9108-7227eafda584" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_fada1db4-3527-4d64-9108-7227eafda584" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdvertisingExpense_0383bba9-5959-424d-8488-0413003f6a29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AdvertisingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_AdvertisingExpense_0383bba9-5959-424d-8488-0413003f6a29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillImpairmentLoss_4de90f02-d278-4b8f-ba8e-5419783a450d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillImpairmentLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_GoodwillImpairmentLoss_4de90f02-d278-4b8f-ba8e-5419783a450d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8a100df6-4412-4787-bcc4-e711b76741d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ImpairmentOfLongLivedAssetsHeldForUse"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse_8a100df6-4412-4787-bcc4-e711b76741d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6306e623-20eb-48b8-ba11-6b26e478c32a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_3f4c2655-0545-47e2-8811-071795a9c42d" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_6306e623-20eb-48b8-ba11-6b26e478c32a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_bd0e395d-8b64-4594-93cd-6251d6b6bc1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_bd0e395d-8b64-4594-93cd-6251d6b6bc1e" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_a8d7eec0-54ee-470c-9af6-704e7774a4f4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_80a2891b-74a5-4ea8-b503-8c97d53522eb" xlink:href="avdl-20241231.xsd#avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:to="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_80a2891b-74a5-4ea8-b503-8c97d53522eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_307bce90-7e57-4471-b251-c1110bb29164" xlink:href="avdl-20241231.xsd#avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_658f64ca-ae64-4e85-b9db-ae46beb95eb8" xlink:to="loc_avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember_307bce90-7e57-4471-b251-c1110bb29164" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:to="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0439c26d-3b14-4b82-b2e6-5cc2a2da0e21" xlink:to="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_ef284fdc-a380-4603-ace1-f81f890cb46c" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:to="loc_srt_MinimumMember_ef284fdc-a380-4603-ace1-f81f890cb46c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a4cc2eca-5ea7-41f3-a34c-1a595c963e04" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ef011a56-60a2-4568-9a73-12d96c70f2bb" xlink:to="loc_srt_MaximumMember_a4cc2eca-5ea7-41f3-a34c-1a595c963e04" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_d3c34048-8d41-4b17-ad04-0bb37a7064aa" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d7b733f0-e59a-4f4d-ae79-5eaea8b2158b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_5adeb6f2-325e-4f89-8bde-4bc69a4dfad6" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_d7b733f0-e59a-4f4d-ae79-5eaea8b2158b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dc8664ef-5038-42c7-b7f8-1e570aa17ab3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_dc8664ef-5038-42c7-b7f8-1e570aa17ab3" xlink:to="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_a6016131-cee3-48fc-9438-bcd2ca0e1521" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_efa0c1e8-f6ac-4355-83c0-cd84efff24a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_1e1e018c-ac8d-4385-959d-a19ace5d142a" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_efa0c1e8-f6ac-4355-83c0-cd84efff24a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_fde654e6-dbd4-4799-b053-d82a859743b1" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_a4b637fe-cfbc-49eb-94d1-e1c0870c22ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_9571521b-4728-4f74-a229-d7bfe0c07471" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_a4b637fe-cfbc-49eb-94d1-e1c0870c22ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_2505fe5d-95dc-4be2-94a1-7e74bf792b26" xlink:to="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_01778d42-189e-42e4-a3e4-46dfe4d8cff7" xlink:to="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_CaremarkMember_6ffa8c2d-1299-4649-bba8-4e36c7625729" xlink:href="avdl-20241231.xsd#avdl_CaremarkMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_CaremarkMember_6ffa8c2d-1299-4649-bba8-4e36c7625729" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AccredoMember_bdb70b8a-a289-45a8-9df0-f301bf34d2ca" xlink:href="avdl-20241231.xsd#avdl_AccredoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_AccredoMember_bdb70b8a-a289-45a8-9df0-f301bf34d2ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OptumMember_b4534940-8b06-4409-945f-a16bf92d5de5" xlink:href="avdl-20241231.xsd#avdl_OptumMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_ThreeCustomersMember_0ffee29d-85a4-43c8-95ca-0ebae66973dd" xlink:to="loc_avdl_OptumMember_b4534940-8b06-4409-945f-a16bf92d5de5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_a254cfa7-0068-4402-ba1a-336bb092e472" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_f781a764-f6a9-4c96-b289-93f25c9911f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_f781a764-f6a9-4c96-b289-93f25c9911f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66fce3fc-01a7-4072-9bd6-410a8376bf9f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_362cdc71-6ded-491a-877f-3c9556336607" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_66fce3fc-01a7-4072-9bd6-410a8376bf9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RevenueRecognitionNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RevenueRecognitionNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RevenueRecognitionNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_b767c613-b035-4f9b-88cd-0bc06beb71b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueRecognitionAndDeferredRevenueAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRecognitionAndDeferredRevenueAbstract_b767c613-b035-4f9b-88cd-0bc06beb71b8" xlink:to="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MajorCustomersAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_NameOfMajorCustomerDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_MajorCustomersAxis_4c3dc192-4c61-483b-a61d-48936368317e" xlink:to="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ThreeCustomersMember_ba9b29d5-2701-420c-820c-638cd9f1051a" xlink:href="avdl-20241231.xsd#avdl_ThreeCustomersMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_NameOfMajorCustomerDomain_98179c85-9065-4e2b-a55f-2e05c9599ab5" xlink:to="loc_avdl_ThreeCustomersMember_ba9b29d5-2701-420c-820c-638cd9f1051a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b70de794-91b9-4c58-b6b5-ec6717da3f02" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerMember_fe6d7ebe-9f43-4c0d-bab1-d19dae108418" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_86edec19-6e3f-48bf-a8e1-3f877b27c5ea" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerMember_fe6d7ebe-9f43-4c0d-bab1-d19dae108418" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_24d8a045-e283-43e6-88cb-97de232e8d1e" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_12e069d8-650c-4880-81a3-84ef345f71eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_0499ab36-c663-4b5d-9a8d-e74ecf9c32c8" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_12e069d8-650c-4880-81a3-84ef345f71eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTable_d4a36e77-d7a3-452b-bf2a-ae268ca0ce1e" xlink:to="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_e0c11ebb-12b6-465b-a542-e29269c9f1b0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_e0c11ebb-12b6-465b-a542-e29269c9f1b0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db3491b2-86e9-48ab-9f0c-eab828274194" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskLineItems_875e38fe-c92c-4eae-ab4e-4c620ee5998f" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_db3491b2-86e9-48ab-9f0c-eab828274194" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#FairValueMeasurementDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/FairValueMeasurementDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_9fe1483a-1a1e-4453-ae36-165f87ffced5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_9fe1483a-1a1e-4453-ae36-165f87ffced5" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_689c0e3a-d9e1-4cc9-9663-af159f5373c7" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_b2de00ad-2d7f-4d95-95f6-fd172d2ba47a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_aeb5ca85-8f0c-4cee-8df8-ec4e992360d4" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_b2de00ad-2d7f-4d95-95f6-fd172d2ba47a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_5df3862c-24f3-43ee-aba8-40950bad3c60" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel1Member_f44f9174-c202-43d6-9311-2dd98be032f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel1Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel1Member_f44f9174-c202-43d6-9311-2dd98be032f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_32957544-6570-48c1-9408-522bde0a0ae2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_32957544-6570-48c1-9408-522bde0a0ae2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel3Member_044a0fb2-16f1-4785-b4b5-b4b3c34e299c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueInputsLevel3Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_3af119c3-d5c0-4919-8584-eb1743efcdd4" xlink:to="loc_us-gaap_FairValueInputsLevel3Member_044a0fb2-16f1-4785-b4b5-b4b3c34e299c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_db7611e0-b946-4c56-a9e6-f56ad8164621" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e89cf3a2-151b-4127-9d15-8a80d4e89d4a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dc54600b-b0c5-4e94-b99d-8917016b7fca" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_e89cf3a2-151b-4127-9d15-8a80d4e89d4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_37d4abeb-c2c9-495d-aa76-f6f215594249" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9f9d1c-2489-4002-b69d-0883fc1d6976" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_dc9f9d1c-2489-4002-b69d-0883fc1d6976" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsFairValueDisclosure_70e429f3-8fb4-4112-9c24-3fdee1682851" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetsFairValueDisclosure"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_8805e5b4-e38d-4bc2-9862-a94fa0aad35a" xlink:to="loc_us-gaap_AssetsFairValueDisclosure_70e429f3-8fb4-4112-9c24-3fdee1682851" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e56054c9-e788-4d98-a8ab-85da3692d170" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_e56054c9-e788-4d98-a8ab-85da3692d170" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:to="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_32118559-3f7b-4d46-86e2-cdddfadf7829" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bcd75df3-1cb3-4e7a-8170-5adc27d8a7a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_7eb73a91-1188-4b05-b1b9-cb2cf1c87eea" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_bcd75df3-1cb3-4e7a-8170-5adc27d8a7a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_90c029c9-cda6-417e-a033-753e46143e2c" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_269ba92f-a7c1-4e2d-aae5-657131bc049a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_269ba92f-a7c1-4e2d-aae5-657131bc049a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4e80af4-c72f-4de6-af1e-9f4d899edd3a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_e4e80af4-c72f-4de6-af1e-9f4d899edd3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ed84a19-99a6-412a-9745-ee7a2889512f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_3ed84a19-99a6-412a-9745-ee7a2889512f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ee6e6f2-cf35-4986-b84c-98b1f5831773" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_a5c098ce-54f5-4810-95f7-d1a1a1b41957" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_1ee6e6f2-cf35-4986-b84c-98b1f5831773" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48508b37-91ec-442a-9e5a-057585d46874" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ed0046d2-4dc6-4437-b833-62ab43327a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48508b37-91ec-442a-9e5a-057585d46874" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_ed0046d2-4dc6-4437-b833-62ab43327a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_0945bd78-0176-4aae-8e9e-91b4aac08f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_48508b37-91ec-442a-9e5a-057585d46874" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss_0945bd78-0176-4aae-8e9e-91b4aac08f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#MarketableSecuritiesScheduleofContractualMaturityDatesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0bdc0a16-3cd6-4b33-8500-c6830b969e4b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_0bdc0a16-3cd6-4b33-8500-c6830b969e4b" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:to="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_c3c6bf0f-dd70-4daf-baba-db1f1101bffb" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_11db230f-624e-4f4c-a2ee-69284849fccf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_dadc1516-3c93-4e1a-a397-c64df397626a" xlink:to="loc_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_11db230f-624e-4f4c-a2ee-69284849fccf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTable_815c50bf-7897-4e44-8f4c-074a24f37d07" xlink:to="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51702681-3f15-4f86-bfaa-830681c336a9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_51702681-3f15-4f86-bfaa-830681c336a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_836b15b7-7d2c-42dc-a1a5-45a7c3516721" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue_836b15b7-7d2c-42dc-a1a5-45a7c3516721" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5299151-2a1f-41d5-b1d3-bb60e8f32908" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue_c5299151-2a1f-41d5-b1d3-bb60e8f32908" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_33faadfc-6bfa-4880-a457-ae971ffff05d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue_33faadfc-6bfa-4880-a457-ae971ffff05d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4171c4c8-35c9-4b2e-be02-04a9b59af1e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_da0d52f9-89d8-4de8-8207-15127e9975cc" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_4171c4c8-35c9-4b2e-be02-04a9b59af1e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/InventoriesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#InventoriesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/InventoriesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryDisclosureAbstract_a24d1226-b501-4cdb-a63a-538d2d63ed69" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_bc4881cb-85e2-428d-a3cf-c12ae98f1225" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a24d1226-b501-4cdb-a63a-538d2d63ed69" xlink:to="loc_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves_bc4881cb-85e2-428d-a3cf-c12ae98f1225" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryWorkInProcessNetOfReserves_65fcb74c-ff34-41f5-aaba-1abb2fe01b80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryWorkInProcessNetOfReserves"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a24d1226-b501-4cdb-a63a-538d2d63ed69" xlink:to="loc_us-gaap_InventoryWorkInProcessNetOfReserves_65fcb74c-ff34-41f5-aaba-1abb2fe01b80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e80d0c18-c36d-45ee-9997-cedd8b9be1d4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryFinishedGoodsNetOfReserves"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a24d1226-b501-4cdb-a63a-538d2d63ed69" xlink:to="loc_us-gaap_InventoryFinishedGoodsNetOfReserves_e80d0c18-c36d-45ee-9997-cedd8b9be1d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InventoryNet_820e3b3a-1e0d-422b-8d45-519335293a02" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InventoryNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_InventoryDisclosureAbstract_a24d1226-b501-4cdb-a63a-538d2d63ed69" xlink:to="loc_us-gaap_InventoryNet_820e3b3a-1e0d-422b-8d45-519335293a02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#PropertyandEquipmentnetDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/PropertyandEquipmentnetDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23b35663-ad7e-4598-9403-58e745dc28ca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_23b35663-ad7e-4598-9403-58e745dc28ca" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_b91ecadd-db0f-462d-b08e-70e46dcaffd4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_42dbe045-82b6-4128-a46e-292c98d7518d" xlink:href="avdl-20241231.xsd#avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:to="loc_avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember_42dbe045-82b6-4128-a46e-292c98d7518d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FurnitureAndFixturesMember_624aedae-cdb8-487c-9c73-a6ab8f38f38f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_FurnitureAndFixturesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ace5436e-76d7-41a0-a2ad-351248f8257d" xlink:to="loc_us-gaap_FurnitureAndFixturesMember_624aedae-cdb8-487c-9c73-a6ab8f38f38f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_28aa2db7-7fde-4dfb-888a-1e0f0df7755f" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_6ad20159-87c5-45b2-be25-951bfe143e0a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_6ad20159-87c5-45b2-be25-951bfe143e0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755cd353-b4ed-4d88-bc65-5700a0548972" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_755cd353-b4ed-4d88-bc65-5700a0548972" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_92cbff92-8e5c-4c8e-9980-fab66db8d964" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_92cbff92-8e5c-4c8e-9980-fab66db8d964" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Depreciation_d3dd0693-973d-4ad8-9e39-bf182d3d15d1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Depreciation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_09ae2af7-371c-4416-8788-38193b10a574" xlink:to="loc_us-gaap_Depreciation_d3dd0693-973d-4ad8-9e39-bf182d3d15d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/GoodwillDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#GoodwillDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/GoodwillDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e24bee3d-85e7-447b-a843-3f1c09d0cfc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Goodwill_ed3d4e18-5166-4212-b674-9cabb95bb563" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_Goodwill"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e24bee3d-85e7-447b-a843-3f1c09d0cfc1" xlink:to="loc_us-gaap_Goodwill_ed3d4e18-5166-4212-b674-9cabb95bb563" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetImpairmentCharges_b928a09f-6b47-4f23-9897-9ece5e13659a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AssetImpairmentCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract_e24bee3d-85e7-447b-a843-3f1c09d0cfc1" xlink:to="loc_us-gaap_AssetImpairmentCharges_b928a09f-6b47-4f23-9897-9ece5e13659a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/LeasesNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_d7065a97-0828-4df7-982d-4227f9b6580c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_d7065a97-0828-4df7-982d-4227f9b6580c" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:to="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_d759a75f-f66b-4226-bdce-c0e5e2f03eeb" xlink:to="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_3bd1f9d6-eb67-4781-870c-15a2ef7d3591" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:to="loc_srt_MinimumMember_3bd1f9d6-eb67-4781-870c-15a2ef7d3591" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_bcb483eb-d337-4325-8d7c-cae6f434ea4a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4fb4537a-4e40-43fc-a54e-3bb22e3acdb3" xlink:to="loc_srt_MaximumMember_bcb483eb-d337-4325-8d7c-cae6f434ea4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_6f7a2477-18ea-467a-8677-6633c310c805" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7349900c-9397-4391-a0ef-b052d0f17767" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseTermOfContract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_LesseeOperatingLeaseTermOfContract_7349900c-9397-4391-a0ef-b052d0f17767" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_6fe3cb74-6a72-4c15-ad48-3da76785b40c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeasePayments_6fe3cb74-6a72-4c15-ad48-3da76785b40c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f440f95-1c30-4e30-8e89-070bce24cf78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_0f440f95-1c30-4e30-8e89-070bce24cf78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81a80169-9860-4518-9387-ca32e9fb3279" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81a80169-9860-4518-9387-ca32e9fb3279" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dcea926-084a-459f-a5fe-378fb1c6fd18" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_cd5d9963-9838-4b0c-ad19-394f786311b9" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6dcea926-084a-459f-a5fe-378fb1c6fd18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesComponentsofleasecostsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesComponentsofleasecostsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/LeasesComponentsofleasecostsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_5669f5c1-b621-4d08-b2dc-554f8fc4e283" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_e7efabb6-6530-46c7-b9bb-e23a44cc645e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5669f5c1-b621-4d08-b2dc-554f8fc4e283" xlink:to="loc_us-gaap_OperatingLeaseCost_e7efabb6-6530-46c7-b9bb-e23a44cc645e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubleaseIncome_a6ebbf54-ca46-4f77-b2e0-70b3d6476dc9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubleaseIncome"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5669f5c1-b621-4d08-b2dc-554f8fc4e283" xlink:to="loc_us-gaap_SubleaseIncome_a6ebbf54-ca46-4f77-b2e0-70b3d6476dc9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCost_892bb348-1049-4eaa-a7aa-866526b2a350" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeaseCost"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_5669f5c1-b621-4d08-b2dc-554f8fc4e283" xlink:to="loc_us-gaap_LeaseCost_892bb348-1049-4eaa-a7aa-866526b2a350" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#LeasesMaturitiesofoperatingleaseliabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_323eb1bb-6dac-4ca7-8fa8-87362d1e3eb7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_323eb1bb-6dac-4ca7-8fa8-87362d1e3eb7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b60653ec-466b-40e0-8011-bd1ed2bd6dda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_b60653ec-466b-40e0-8011-bd1ed2bd6dda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef5ff97f-aec7-4199-9d6d-4dbaa4e016d6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_ef5ff97f-aec7-4199-9d6d-4dbaa4e016d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_611c8a4f-d515-4c1b-be7c-1ce744e4ecc1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_611c8a4f-d515-4c1b-be7c-1ce744e4ecc1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_e6f90df7-eaa1-4ae7-9711-412792f0ed70" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseLiabilityToBePaidAfterYearFour"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour_e6f90df7-eaa1-4ae7-9711-412792f0ed70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_782d748c-4565-40bb-ab1b-979f35eaa97c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_782d748c-4565-40bb-ab1b-979f35eaa97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_acd41558-44d0-40bd-bd73-64ed8a640f5c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_acd41558-44d0-40bd-bd73-64ed8a640f5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_964dff31-9ded-46fe-abdd-875f5887af14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_992dd041-b2a1-4a23-a2b9-aabeb7cda930" xlink:to="loc_us-gaap_OperatingLeaseLiability_964dff31-9ded-46fe-abdd-875f5887af14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_8616e44b-4f57-451f-bf7a-98050b8150de" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_8616e44b-4f57-451f-bf7a-98050b8150de" xlink:to="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_89f3a65d-00c8-4c45-a2eb-f1c988ca2063" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingMember_8f5c9c59-4f45-450d-9410-758cec755248" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:to="loc_avdl_RoyaltyFinancingMember_8f5c9c59-4f45-450d-9410-758cec755248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SeniorNotesMember_141ed7df-eb37-4c8b-846f-811c7ef6e88d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SeniorNotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_2043adb4-e7e7-4df0-8599-25284a207371" xlink:to="loc_us-gaap_SeniorNotesMember_141ed7df-eb37-4c8b-846f-811c7ef6e88d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:to="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_bb66443e-c97a-433b-821e-45fd24b8269f" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_February2023NotesMember_a2ed2926-9051-408f-97c6-705832393610" xlink:href="avdl-20241231.xsd#avdl_February2023NotesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:to="loc_avdl_February2023NotesMember_a2ed2926-9051-408f-97c6-705832393610" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_October2023NotesMember_70fa4134-6ab1-4184-89b3-c8cf26a550e1" xlink:href="avdl-20241231.xsd#avdl_October2023NotesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_531d6985-c496-457b-9d99-8cd09455900c" xlink:to="loc_avdl_October2023NotesMember_70fa4134-6ab1-4184-89b3-c8cf26a550e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_a67d387d-08d9-4d84-b69e-d6c7b0d2c537" xlink:to="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingProceedsMaximum_a4c9637b-20ff-4811-86cc-8a1e27cbf88a" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingProceedsMaximum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingProceedsMaximum_a4c9637b-20ff-4811-86cc-8a1e27cbf88a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentNumberOfTranches_5596f837-7d32-47d2-8cec-3d8601e46cbc" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentNumberOfTranches"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_DebtInstrumentNumberOfTranches_5596f837-7d32-47d2-8cec-3d8601e46cbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e942976a-71bd-48e1-b84a-be45637cecce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_e942976a-71bd-48e1-b84a-be45637cecce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_76b458bc-3769-481f-bc13-2368673f2d60" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyNetRevenueTarget"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget_76b458bc-3769-481f-bc13-2368673f2d60" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_53401f9c-ce8f-4e06-9992-87f22ac3a894" xlink:href="avdl-20241231.xsd#avdl_PaymentsForRoyaltyOneTimeCommitmentFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_53401f9c-ce8f-4e06-9992-87f22ac3a894" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_15c51e3c-d546-4686-bc38-a14886e42d3e" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage_15c51e3c-d546-4686-bc38-a14886e42d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b39a82f2-8e49-44ec-865e-0831b2e49f28" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateEffectivePercentage"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_DebtInstrumentInterestRateEffectivePercentage_b39a82f2-8e49-44ec-865e-0831b2e49f28" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_422b91dd-bfaf-4db5-8dff-0c170c73af27" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_InterestExpenseDebt_422b91dd-bfaf-4db5-8dff-0c170c73af27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae883a9b-3063-4822-8494-d2dcd9c58763" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_9759a5e1-976b-411f-bd18-bdb8df832305" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ae883a9b-3063-4822-8494-d2dcd9c58763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#RoyaltyFinancingObligationActivityDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f7028b07-5d1e-4bb8-bfd2-6c36e9f154e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f7028b07-5d1e-4bb8-bfd2-6c36e9f154e6" xlink:to="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:to="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermDebtTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeAxis_86b69cfc-b2bc-40ec-8aa8-514b673364f6" xlink:to="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingMember_1af17a83-4307-4047-9316-43161fa31065" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LongtermDebtTypeDomain_bd08d272-6eec-4506-b902-7cdfae3673f1" xlink:to="loc_avdl_RoyaltyFinancingMember_1af17a83-4307-4047-9316-43161fa31065" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_ad430085-19ca-4872-9e75-59368f5f4efe" xlink:to="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:href="avdl-20241231.xsd#avdl_DebtInstrumentIncreaseDecreaseNetRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d631ebba-04d3-4560-b0c1-02d594625559" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_LongTermDebt_d631ebba-04d3-4560-b0c1-02d594625559" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_82185c0d-4a02-44ae-b8f7-3c7c170fc49f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ProceedsFromIssuanceOfLongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_ProceedsFromIssuanceOfLongTermDebt_82185c0d-4a02-44ae-b8f7-3c7c170fc49f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_36050ac7-690d-4f83-a62c-663ed81eec0e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_InterestExpenseDebt_36050ac7-690d-4f83-a62c-663ed81eec0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RepaymentOfRoyaltyLiability_454249fc-29e0-4757-a84b-97c83b2682d4" xlink:href="avdl-20241231.xsd#avdl_RepaymentOfRoyaltyLiability"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_avdl_RepaymentOfRoyaltyLiability_454249fc-29e0-4757-a84b-97c83b2682d4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_fcc3e9d9-bbe8-4fd8-ab38-5f685f361870" xlink:href="avdl-20241231.xsd#avdl_PaymentsForRoyaltyOneTimeCommitmentFee"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_avdl_PaymentsForRoyaltyOneTimeCommitmentFee_fcc3e9d9-bbe8-4fd8-ab38-5f685f361870" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_2e6d4dbe-88f1-48a5-a419-1730baff603e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_DebtInstrumentIncreaseDecreaseNetRollForward_6c59e9d9-cb6f-4e3d-bb58-ea0d2c883574" xlink:to="loc_us-gaap_LongTermDebt_2e6d4dbe-88f1-48a5-a419-1730baff603e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_132e245c-9333-458f-b81a-38d05e26ceba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_us-gaap_LongTermDebtCurrent_132e245c-9333-458f-b81a-38d05e26ceba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedNetLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_4e2b9f71-8391-4f0f-a3d1-de502ae8e9bf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_aef3ffe0-d07d-4180-b6f7-9a0cd8b33d19" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_4e2b9f71-8391-4f0f-a3d1-de502ae8e9bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/netLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_beec8a31-bac7-492c-861c-77844532261d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_beec8a31-bac7-492c-861c-77844532261d" xlink:to="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:to="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_b4561c76-83df-4cf3-a81a-6072ea69e201" xlink:to="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EuropeMember_a9c0959a-a5cc-48dd-8357-57b87327292d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_EuropeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:to="loc_srt_EuropeMember_a9c0959a-a5cc-48dd-8357-57b87327292d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_f45bcb46-f45d-4628-9e7b-7ed16b5cbc83" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_175ae904-4f66-41f7-8822-c25d4347a5e0" xlink:to="loc_country_US_f45bcb46-f45d-4628-9e7b-7ed16b5cbc83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_fff7a726-6897-4672-ba1f-a0d80a45dde6" xlink:to="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d40ac57-d728-41b4-bcca-996abcddfd30" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_719ebeac-d674-4cd7-b1f3-fb34e9c958ff" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_9d40ac57-d728-41b4-bcca-996abcddfd30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesIncomeTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_c48803b2-0238-494b-b43f-f4e9e7353ae5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_abdec4be-d28e-41f5-8dd7-7a0eaa146e8e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c48803b2-0238-494b-b43f-f4e9e7353ae5" xlink:to="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_abdec4be-d28e-41f5-8dd7-7a0eaa146e8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_aa1dec04-1b0c-4326-b1c1-d921f3eeb7f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_abdec4be-d28e-41f5-8dd7-7a0eaa146e8e" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_aa1dec04-1b0c-4326-b1c1-d921f3eeb7f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ecd905e1-c745-4d78-8bb7-8c338077472a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract_abdec4be-d28e-41f5-8dd7-7a0eaa146e8e" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_ecd905e1-c745-4d78-8bb7-8c338077472a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3f196d5a-02a0-414c-97fd-e5372da126df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c48803b2-0238-494b-b43f-f4e9e7353ae5" xlink:to="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3f196d5a-02a0-414c-97fd-e5372da126df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7683e505-f966-419e-b4c2-4e209fc6f793" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3f196d5a-02a0-414c-97fd-e5372da126df" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_7683e505-f966-419e-b4c2-4e209fc6f793" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_09103d8c-8473-400e-9e32-387050a47f17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3f196d5a-02a0-414c-97fd-e5372da126df" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_09103d8c-8473-400e-9e32-387050a47f17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_07f523b6-474d-40f8-a536-8ae277714740" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract_3f196d5a-02a0-414c-97fd-e5372da126df" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_07f523b6-474d-40f8-a536-8ae277714740" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_3d9a1e9a-4ca4-4de2-b819-1caa64e3d4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_c48803b2-0238-494b-b43f-f4e9e7353ae5" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_3d9a1e9a-4ca4-4de2-b819-1caa64e3d4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesReconciliationofTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_e0f737bf-ee13-412b-8cf5-0117825dc7b8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_e0f737bf-ee13-412b-8cf5-0117825dc7b8" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a121ebcc-40b8-464f-8db1-fc0b701262e0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_a121ebcc-40b8-464f-8db1-fc0b701262e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e169c3d8-769d-4971-b448-cb5600460d96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential_e169c3d8-769d-4971-b448-cb5600460d96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_d2c216db-9c51-40b4-a12a-1b56105cc406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes_d2c216db-9c51-40b4-a12a-1b56105cc406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_12dc0fcf-8e2e-4fd5-bceb-127d9d88c07b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_12dc0fcf-8e2e-4fd5-bceb-127d9d88c07b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fec911a0-3bf2-4d22-8723-062e3f0cc8a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_fec911a0-3bf2-4d22-8723-062e3f0cc8a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_ae3e33ab-7faa-4310-880b-1329d4f95240" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxContingencies_ae3e33ab-7faa-4310-880b-1329d4f95240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2f19a76a-b413-43be-b5f7-035190a3af2e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_2f19a76a-b413-43be-b5f7-035190a3af2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_bc0c6fc0-8176-4220-850d-03a1ea4c87f1" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount_bc0c6fc0-8176-4220-850d-03a1ea4c87f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_9b6eb023-c693-4a05-92c1-3f2ce28a558d" xlink:href="avdl-20241231.xsd#avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit_9b6eb023-c693-4a05-92c1-3f2ce28a558d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_0df7674a-1a35-4775-801c-6a695e5e1f8c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationOtherReconcilingItems"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxReconciliationOtherReconcilingItems_0df7674a-1a35-4775-801c-6a695e5e1f8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_491053d0-d189-44c1-a8c3-627746326451" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_b9ffb6f8-dcd0-4a67-a08f-a7631d0cff17" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_491053d0-d189-44c1-a8c3-627746326451" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0ea7e8b2-a7d6-41dd-b883-08fb62e50913" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0ea7e8b2-a7d6-41dd-b883-08fb62e50913" xlink:to="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_BusinessAcquisitionAcquireeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAxis_5c15f6a6-aca7-4c2a-9556-9b015b7cb9c0" xlink:to="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FscHoldingsLlcMember_53f99efb-2843-4b41-a7e6-34ce083aac37" xlink:href="avdl-20241231.xsd#avdl_FscHoldingsLlcMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:to="loc_avdl_FscHoldingsLlcMember_53f99efb-2843-4b41-a7e6-34ce083aac37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_U.S.HoldingsMember_55b54720-a605-4965-b390-26af6c6c631c" xlink:href="avdl-20241231.xsd#avdl_U.S.HoldingsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_BusinessAcquisitionAcquireeDomain_6223ac30-9b76-4043-8dc4-e0afd1fa4f4e" xlink:to="loc_avdl_U.S.HoldingsMember_55b54720-a605-4965-b390-26af6c6c631c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_a65f0779-6d81-4f6f-8ac0-008c88a97f29" xlink:to="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_21f89d12-a7d7-4562-be21-0ca55a34998f" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_IE_21f89d12-a7d7-4562-be21-0ca55a34998f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_7ad4d1f0-a809-40ca-a978-d78ce1625375" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_US_7ad4d1f0-a809-40ca-a978-d78ce1625375" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_FR_ca93a792-bf6f-4a04-863b-5ee14c833fac" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_FR"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_99245390-88f2-429f-8eed-3eb8537425b6" xlink:to="loc_country_FR_ca93a792-bf6f-4a04-863b-5ee14c833fac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_fe183089-1229-40d6-b002-13617c69ccbb" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_5519ab01-35d3-4eaf-b812-d6f938f41285" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_913b916f-abbf-4676-8420-69653117a1fc" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_5519ab01-35d3-4eaf-b812-d6f938f41285" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_92d54d10-570a-4161-b47c-868a70756389" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A163jCreditsMember_1ff55e7f-1bee-4694-8e35-32f3322da2ec" xlink:href="avdl-20241231.xsd#avdl_A163jCreditsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_avdl_A163jCreditsMember_1ff55e7f-1bee-4694-8e35-32f3322da2ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OrphanDrugTaxCreditMember_f02b8483-76bb-4aa8-abc4-a1f99b41f127" xlink:href="avdl-20241231.xsd#avdl_OrphanDrugTaxCreditMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_avdl_OrphanDrugTaxCreditMember_f02b8483-76bb-4aa8-abc4-a1f99b41f127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_5b76b672-1ad3-46f1-83d0-775c9c10abca" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_6b1b4d5b-b9e9-4907-8a47-aca080fb67e6" xlink:to="loc_us-gaap_ResearchMember_5b76b672-1ad3-46f1-83d0-775c9c10abca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:href="avdl-20241231.xsd#avdl_IncomeTaxesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesTable_1d23b6db-54c4-4ed4-8efc-a8d6cbe175d7" xlink:to="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_bdc77321-c679-4d97-bfdd-34ed10d8b2a5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_bdc77321-c679-4d97-bfdd-34ed10d8b2a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_c66c26fb-3c71-4ca2-9197-6663e955f6f1" xlink:href="avdl-20241231.xsd#avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit_c66c26fb-3c71-4ca2-9197-6663e955f6f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4f96d937-2727-4a76-8edd-65ab5208d805" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible_4f96d937-2727-4a76-8edd-65ab5208d805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8fbb3f0d-d07a-4054-aa1f-af171f496ab8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate_8fbb3f0d-d07a-4054-aa1f-af171f496ab8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ab072f87-df99-4d00-988f-a73ea99a0c96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_ab072f87-df99-4d00-988f-a73ea99a0c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c139d08-c028-4a89-97b7-b0ea21ccf3d7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_7c139d08-c028-4a89-97b7-b0ea21ccf3d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_442da282-fea2-4d82-af14-22a167d7f5f1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_OperatingLossCarryforwards_442da282-fea2-4d82-af14-22a167d7f5f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_ec42a88e-be78-4a25-91ec-72f5156aa661" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_ec42a88e-be78-4a25-91ec-72f5156aa661" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_bdb68aec-8bdb-48a4-999e-e5527a91a9fb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingLossCarryforwardsValuationAllowance"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_OperatingLossCarryforwardsValuationAllowance_bdb68aec-8bdb-48a4-999e-e5527a91a9fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UndistributedEarnings_3f0dcee9-6f56-4ed0-a7bd-c7a0606686ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UndistributedEarnings"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_UndistributedEarnings_3f0dcee9-6f56-4ed0-a7bd-c7a0606686ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d4d8625-b602-4486-99bf-804b8911feac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_7d4d8625-b602-4486-99bf-804b8911feac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dc4b0ac3-1e56-411c-9870-46b90daabc35" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_avdl_IncomeTaxesLineItems_67b9c50a-bff6-44e4-9dcb-979f27ad142a" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_dc4b0ac3-1e56-411c-9870-46b90daabc35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesUnrecognizedTaxBenefitDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_d82092fa-e728-419a-be3a-798359bb8c09" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_d82092fa-e728-419a-be3a-798359bb8c09" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2736dde0-08b2-4c41-af39-ff5bb0ae9d75" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2736dde0-08b2-4c41-af39-ff5bb0ae9d75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_247cfd4f-41cc-4bd7-a0c7-96f47fd7a5c1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease_247cfd4f-41cc-4bd7-a0c7-96f47fd7a5c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_31aaf941-2e42-4eeb-bdd8-5fd321dde06c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations_31aaf941-2e42-4eeb-bdd8-5fd321dde06c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f8e64d2a-a580-4f5d-8b31-efa2fff91e3b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities_f8e64d2a-a580-4f5d-8b31-efa2fff91e3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_91c634b6-bca5-4ef9-8437-1e6926c301a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_00877904-fecb-4ee9-ab91-7a01aa115b47" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_91c634b6-bca5-4ef9-8437-1e6926c301a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#IncomeTaxesDeferredTaxesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_38166052-bc34-408e-9ee9-38128420fd00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38166052-bc34-408e-9ee9-38128420fd00" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0e81dad0-d427-46bd-bed4-c44bccb08003" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_0e81dad0-d427-46bd-bed4-c44bccb08003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1073a741-3129-4cb1-8b55-e4558ba9d7a1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_1073a741-3129-4cb1-8b55-e4558ba9d7a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsRoyaltyIncome_a930781d-465b-4c50-8719-c69cb618699c" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsRoyaltyIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_avdl_DeferredTaxAssetsRoyaltyIncome_a930781d-465b-4c50-8719-c69cb618699c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7145287e-41d6-46bb-a783-90dab68f8659" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals_7145287e-41d6-46bb-a783-90dab68f8659" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_8e05f6b6-cf0f-4a9b-bfe1-8f17c5929a14" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch_8e05f6b6-cf0f-4a9b-bfe1-8f17c5929a14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a08e5a0b-d23a-42a3-8525-ab3f138f63af" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_a08e5a0b-d23a-42a3-8525-ab3f138f63af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetInterestCarryforward_a4727793-e665-40dd-a272-fd192608f597" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetInterestCarryforward"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetInterestCarryforward_a4727793-e665-40dd-a272-fd192608f597" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_1f3589ca-fd3a-49df-aa87-ea4f10b7129c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_1f3589ca-fd3a-49df-aa87-ea4f10b7129c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_9c795655-056d-4cdc-8cf5-faed0e94ee4a" xlink:href="avdl-20241231.xsd#avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets_9c795655-056d-4cdc-8cf5-faed0e94ee4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_1e62db38-778a-4115-a916-f89628b2bb4e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_c52580ad-3948-4f04-9154-69e5066d1e0d" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_1e62db38-778a-4115-a916-f89628b2bb4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8d1e437b-ccfa-4633-a216-d907581f450f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38166052-bc34-408e-9ee9-38128420fd00" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8d1e437b-ccfa-4633-a216-d907581f450f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2e72b73c-97e2-4ca7-9fdc-85966d74a248" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxLiabilitiesPrepaidExpenses"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8d1e437b-ccfa-4633-a216-d907581f450f" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses_2e72b73c-97e2-4ca7-9fdc-85966d74a248" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_2b71e016-1c40-43e8-975a-aff4d7c015fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_8d1e437b-ccfa-4633-a216-d907581f450f" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_2b71e016-1c40-43e8-975a-aff4d7c015fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_697755f0-10b5-4836-b0e8-af39897f5066" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38166052-bc34-408e-9ee9-38128420fd00" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_697755f0-10b5-4836-b0e8-af39897f5066" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_44eb5743-4368-418b-bb06-7ab272ec61ba" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_38166052-bc34-408e-9ee9-38128420fd00" xlink:to="loc_us-gaap_DeferredTaxAssetsLiabilitiesNet_44eb5743-4368-418b-bb06-7ab272ec61ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_83c7394e-cdc8-4407-b2ed-8c167e52d927" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseCurrent_f692bc42-6b04-4dbd-b26f-ff0e23a9cbf5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_83c7394e-cdc8-4407-b2ed-8c167e52d927" xlink:to="loc_us-gaap_PrepaidExpenseCurrent_f692bc42-6b04-4dbd-b26f-ff0e23a9cbf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsCurrent_569011ab-0985-437d-ba45-1e1340a5a802" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_83c7394e-cdc8-4407-b2ed-8c167e52d927" xlink:to="loc_us-gaap_OtherAssetsCurrent_569011ab-0985-437d-ba45-1e1340a5a802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_561f6313-78bd-4b5d-8237-930a6937997d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_83c7394e-cdc8-4407-b2ed-8c167e52d927" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_561f6313-78bd-4b5d-8237-930a6937997d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1e0323c2-435a-428a-be72-12f53ba67cda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_50f88d23-4d18-4cfb-ae9c-7349813553aa" xlink:href="avdl-20241231.xsd#avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1e0323c2-435a-428a-be72-12f53ba67cda" xlink:to="loc_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent_50f88d23-4d18-4cfb-ae9c-7349813553aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_OtherNoncurrentReceivables_dea4d6af-1c0e-4c0a-8b3f-9703715cef02" xlink:href="avdl-20241231.xsd#avdl_OtherNoncurrentReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1e0323c2-435a-428a-be72-12f53ba67cda" xlink:to="loc_avdl_OtherNoncurrentReceivables_dea4d6af-1c0e-4c0a-8b3f-9703715cef02" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherAssetsNoncurrent_af435076-f8bd-41a8-b013-870110c66769" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherAssetsNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_1e0323c2-435a-428a-be72-12f53ba67cda" xlink:to="loc_us-gaap_OtherAssetsNoncurrent_af435076-f8bd-41a8-b013-870110c66769" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesAccruedExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_e140f456-f453-45f0-bcef-f4add4e1317b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_e140f456-f453-45f0-bcef-f4add4e1317b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RemainingPerformanceObligationReserveCurrent_06d049d4-9aed-4cc7-97e8-4104299f3c85" xlink:href="avdl-20241231.xsd#avdl_RemainingPerformanceObligationReserveCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:to="loc_avdl_RemainingPerformanceObligationReserveCurrent_06d049d4-9aed-4cc7-97e8-4104299f3c85" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedSalariesCurrent_9debaec3-dcdf-4684-bfb6-919563a6b33a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedSalariesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:to="loc_us-gaap_AccruedSalariesCurrent_9debaec3-dcdf-4684-bfb6-919563a6b33a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RoyaltyFinancingLiabilityCurrent_2769eb78-a715-4613-ba82-7c3d91a4301d" xlink:href="avdl-20241231.xsd#avdl_RoyaltyFinancingLiabilityCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:to="loc_avdl_RoyaltyFinancingLiabilityCurrent_2769eb78-a715-4613-ba82-7c3d91a4301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrent_c50e1df8-d1c1-4c6e-a4ad-70b906daec13" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccruedLiabilitiesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b283660c-0ebe-4dcc-acb2-ffdc2415f37a" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrent_c50e1df8-d1c1-4c6e-a4ad-70b906daec13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b9109e20-903e-4723-a49c-1936eeb84411" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_04fe30db-e17c-4f07-a881-82dd421d2eab" xlink:href="avdl-20241231.xsd#avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b9109e20-903e-4723-a49c-1936eeb84411" xlink:to="loc_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities_04fe30db-e17c-4f07-a881-82dd421d2eab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GuarantyLiabilities_df836b74-7c4b-4b13-9859-605899910e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GuarantyLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b9109e20-903e-4723-a49c-1936eeb84411" xlink:to="loc_us-gaap_GuarantyLiabilities_df836b74-7c4b-4b13-9859-605899910e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherLiabilitiesNoncurrent_70ff5fc6-d473-48e4-b08e-e2c940ec17c9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherLiabilitiesNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherLiabilitiesDisclosureAbstract_b9109e20-903e-4723-a49c-1936eeb84411" xlink:to="loc_us-gaap_OtherLiabilitiesNoncurrent_70ff5fc6-d473-48e4-b08e-e2c940ec17c9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ContingentLiabilitiesandCommitmentsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_417c2413-7e79-45bb-8b50-dfe50bdfc940" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_417c2413-7e79-45bb-8b50-dfe50bdfc940" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:to="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_LitigationCaseTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseAxis_02f291f1-2008-43f8-a058-462318e517f4" xlink:to="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_FirstJazzComplaintMember_d6617634-4334-4e35-a0f6-f43d258d09e4" xlink:href="avdl-20241231.xsd#avdl_FirstJazzComplaintMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_LitigationCaseTypeDomain_2d0c1868-b4e6-4d25-b837-9ad627d4a6bb" xlink:to="loc_avdl_FirstJazzComplaintMember_d6617634-4334-4e35-a0f6-f43d258d09e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:to="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_c4f864e8-43f6-4dfb-8223-41a84267e5c5" xlink:to="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_794e351c-5d42-476d-aff1-e6d472b8eac7" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:to="loc_srt_MinimumMember_794e351c-5d42-476d-aff1-e6d472b8eac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_34ddb931-8925-4465-a5c5-440b6bc35440" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4b9ee106-7865-409a-a6e8-60e4e6f35f74" xlink:to="loc_srt_MaximumMember_34ddb931-8925-4465-a5c5-440b6bc35440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable_d780e59c-bfde-478b-a054-8aa6a3df9f3d" xlink:to="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2ef42498-675d-4f3f-8ce3-1efc41610387" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LossContingencyAccrualCarryingValueCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_us-gaap_LossContingencyAccrualCarryingValueCurrent_2ef42498-675d-4f3f-8ce3-1efc41610387" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongtermPurchaseCommitmentPeriod_52dfe869-2560-4b1d-b706-13fcf43feb20" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_LongtermPurchaseCommitmentPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_us-gaap_LongtermPurchaseCommitmentPeriod_52dfe869-2560-4b1d-b706-13fcf43feb20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ContractualObligationAnnualAmount_2551040d-f303-4889-86b1-0368eacd3c64" xlink:href="avdl-20241231.xsd#avdl_ContractualObligationAnnualAmount"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems_019dae36-70d3-416f-a02a-c17ee772058b" xlink:to="loc_avdl_ContractualObligationAnnualAmount_2551040d-f303-4889-86b1-0368eacd3c64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#EquityInstrumentsandTransactionsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityAbstract_9ec11a31-dfd9-43fb-b3a2-ea9138e07c3d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfStockByClassTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityAbstract_9ec11a31-dfd9-43fb-b3a2-ea9138e07c3d" xlink:to="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_51f0e4b9-ebb8-4eea-b466-a298383ce65f" xlink:to="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockMember_4917aa06-3909-4b72-bdb3-498a5d4edaa2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:to="loc_us-gaap_PreferredStockMember_4917aa06-3909-4b72-bdb3-498a5d4edaa2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_0959e67e-039b-4814-989b-97630cb32217" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_bb9b483c-db76-4ea8-83f9-2570b4e9d205" xlink:to="loc_us-gaap_CommonStockMember_0959e67e-039b-4814-989b-97630cb32217" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_9b5f3248-a414-46db-a26b-235b5c234c14" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShelfRegistrationStatementOnFormS3Member_857b12a6-4f2a-4a74-a8b5-73b706374aae" xlink:href="avdl-20241231.xsd#avdl_ShelfRegistrationStatementOnFormS3Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_1e04b63d-4f81-4718-8e0d-37514c965e1a" xlink:to="loc_avdl_ShelfRegistrationStatementOnFormS3Member_857b12a6-4f2a-4a74-a8b5-73b706374aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementClassOfStockAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementClassOfStockAxis_86cc8533-f930-4890-b08f-dbeda3d9f2d3" xlink:to="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositarySharesMember_1465dac9-eeb6-4c8a-9282-8fec752e2643" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositarySharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockDomain_af855301-05fc-4785-9db9-3b5f38a95640" xlink:to="loc_avdl_AmericanDepositarySharesMember_1465dac9-eeb6-4c8a-9282-8fec752e2643" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ClassOfStockLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfStockByClassTable_06037455-b8ad-4daf-83c2-fd63f7219569" xlink:to="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_fc4643f8-13a6-40e8-8165-eebfaf7e7190" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_fc4643f8-13a6-40e8-8165-eebfaf7e7190" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2feb55d-cd7e-4c7f-b6c1-33693e78d4df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e2feb55d-cd7e-4c7f-b6c1-33693e78d4df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_AmericanDepositorySharesConversionRatio_ba8ddb10-48df-43cd-ad60-7b65a81e6c6b" xlink:href="avdl-20241231.xsd#avdl_AmericanDepositorySharesConversionRatio"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_AmericanDepositorySharesConversionRatio_ba8ddb10-48df-43cd-ad60-7b65a81e6c6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_2a12c132-b6d0-4370-be95-91ad3458f4ab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesIssued_2a12c132-b6d0-4370-be95-91ad3458f4ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_dee6e43f-fe2a-4850-89a8-64a08e1b5946" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_dee6e43f-fe2a-4850-89a8-64a08e1b5946" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_6f99b6ac-9174-49da-a132-755d53de41ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_6f99b6ac-9174-49da-a132-755d53de41ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5a1046f1-6538-442e-b57c-8e5374732133" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_5a1046f1-6538-442e-b57c-8e5374732133" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d3617a1d-e2aa-4757-b896-f8f6ce691595" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities_d3617a1d-e2aa-4757-b896-f8f6ce691595" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockSalesAgentCommissionPercent_b7e9bd3a-fb11-4dc5-afcb-b2216c181388" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockSalesAgentCommissionPercent"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_SaleOfStockSalesAgentCommissionPercent_b7e9bd3a-fb11-4dc5-afcb-b2216c181388" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice_92020e0c-2635-4ac9-a2d5-50af53dc032f" xlink:href="avdl-20241231.xsd#avdl_SaleOfStockMaximumAggregateOfferingPrice"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_avdl_SaleOfStockMaximumAggregateOfferingPrice_92020e0c-2635-4ac9-a2d5-50af53dc032f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ecc15ba-93f7-4fe9-8d24-50d08b70ac40" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_2ecc15ba-93f7-4fe9-8d24-50d08b70ac40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06dd123b-e578-4ed8-b259-580f59d229c4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SaleOfStockConsiderationReceivedOnTransaction"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfStockLineItems_d207f07d-2e37-40ec-801c-1f496dbd51fa" xlink:to="loc_us-gaap_SaleOfStockConsiderationReceivedOnTransaction_06dd123b-e578-4ed8-b259-580f59d229c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationStockbasedCompensationExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6860fd3d-8936-4312-a621-b17b4a63205f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6860fd3d-8936-4312-a621-b17b4a63205f" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_af879c2b-e5d2-4aea-add4-cbe04a92dfda" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6543ae96-6f80-41be-8d59-d3af237b2d00" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingGeneralAndAdministrativeExpensesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:to="loc_us-gaap_SellingGeneralAndAdministrativeExpensesMember_6543ae96-6f80-41be-8d59-d3af237b2d00" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3199e5bf-07dc-46eb-b671-b32582b8370a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_c2d655fc-0976-41dd-91d4-dddd70c4a904" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_3199e5bf-07dc-46eb-b671-b32582b8370a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_34f85f24-4fa5-4046-9f85-8cdc3b5839be" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_7451a71f-aa3b-4ca0-af5d-f5c63be0eebe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_06586db9-750d-49a1-99a3-397d41e5cacb" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_7451a71f-aa3b-4ca0-af5d-f5c63be0eebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8eab1a1-64b2-4fd3-93c6-6bf285556fe3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_c8eab1a1-64b2-4fd3-93c6-6bf285556fe3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_6e2ef6ff-cf05-449b-8715-b8f8d7ab9621" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PerformanceSharesMember_fc4b099f-7458-4c6a-a07b-68bbf9362ebc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PerformanceSharesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_PerformanceSharesMember_fc4b099f-7458-4c6a-a07b-68bbf9362ebc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_50d8d384-aba6-459b-a2f4-21c9ddb105c6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_50d8d384-aba6-459b-a2f4-21c9ddb105c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_f3ba8e9a-3b19-4c5c-aba3-b6d4d5fb03b2" xlink:to="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember_7474548d-76bf-4e82-84ee-89559550d904" xlink:href="avdl-20241231.xsd#avdl_RestrictedShareAwardsGrantedToEmployeesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestrictedStockMember_8297a4fa-a404-4be4-b658-8c6ba253c6ad" xlink:to="loc_avdl_RestrictedShareAwardsGrantedToEmployeesMember_7474548d-76bf-4e82-84ee-89559550d904" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_VestingDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingAxis_86e73d4e-e237-4649-a83b-8176aef2834d" xlink:to="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_a6bd5d1a-6562-4bce-93ef-ecfbbfffee2e" xlink:href="avdl-20241231.xsd#avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember_a6bd5d1a-6562-4bce-93ef-ecfbbfffee2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember_c7d8cdfb-b70e-45e0-af87-7c4090498070" xlink:href="avdl-20241231.xsd#avdl_VestOneYearFollowingAchievementOfMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_VestOneYearFollowingAchievementOfMilestonesMember_c7d8cdfb-b70e-45e0-af87-7c4090498070" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_55bbc07e-1e3c-4e92-b12d-0ab28a05b2e8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheOneMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheOneMember_55bbc07e-1e3c-4e92-b12d-0ab28a05b2e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_584a7548-c717-4d8f-80a3-e0f178131c70" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheTwoMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheTwoMember_584a7548-c717-4d8f-80a3-e0f178131c70" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_783ea437-0278-4c1a-b773-0e2d75c9578c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationAwardTrancheThreeMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_us-gaap_ShareBasedCompensationAwardTrancheThreeMember_783ea437-0278-4c1a-b773-0e2d75c9578c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember_86d46256-1074-4cab-b016-6667d60ff965" xlink:href="avdl-20241231.xsd#avdl_ShareBasedPaymentArrangementTrancheFourMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_VestingDomain_d6980ee1-7eb9-497e-9392-7561fd318b82" xlink:to="loc_avdl_ShareBasedPaymentArrangementTrancheFourMember_86d46256-1074-4cab-b016-6667d60ff965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_058c57f8-5b3d-42d8-bfba-81aa19dabe65" xlink:to="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_InducementPlanMember_25a35438-2464-4f96-814c-fcfacb98b56a" xlink:href="avdl-20241231.xsd#avdl_InducementPlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:to="loc_avdl_InducementPlanMember_25a35438-2464-4f96-814c-fcfacb98b56a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember_7b78ea44-ab6a-445f-bda3-c07213afed15" xlink:href="avdl-20241231.xsd#avdl_A2017AvadelEmployeeSharePurchasePlanMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_79c7f058-a0be-48aa-8d34-888980e50ca0" xlink:to="loc_avdl_A2017AvadelEmployeeSharePurchasePlanMember_7b78ea44-ab6a-445f-bda3-c07213afed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualAxis_efe4072e-ba14-4aa6-9480-3a2020d94a4f" xlink:to="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_DirectorMember_13b35722-86c6-442f-8b3d-3ef7616cba1d" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_DirectorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_TitleOfIndividualWithRelationshipToEntityDomain_9f1973f5-f3c9-4c8d-9af7-f52f13487879" xlink:to="loc_srt_DirectorMember_13b35722-86c6-442f-8b3d-3ef7616cba1d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GranteeStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusAxis_6123d551-2393-4e16-8169-3e5d5a47d706" xlink:to="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_31ff8a7c-a321-4045-8b90-46fc84ab643a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedPaymentArrangementEmployeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GranteeStatusDomain_7bedb8b5-a6ea-462a-8417-876432dfcfa1" xlink:to="loc_us-gaap_ShareBasedPaymentArrangementEmployeeMember_31ff8a7c-a321-4045-8b90-46fc84ab643a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_dd63221b-6c60-48ac-aa88-ba2691df00f1" xlink:to="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5b16e5ba-091f-45c6-9560-140205245596" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:to="loc_srt_MinimumMember_5b16e5ba-091f-45c6-9560-140205245596" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f7227004-4230-49a8-8de0-034c8fb31428" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_6ca71f76-f14a-4a57-a226-590e5d8ee768" xlink:to="loc_srt_MaximumMember_f7227004-4230-49a8-8de0-034c8fb31428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_98406c03-e74a-48c8-bab8-ead4381b4fc4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77b88d18-b31d-4337-9535-08774d1944a7" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_77b88d18-b31d-4337-9535-08774d1944a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6974bd3-5d6d-4051-9494-f4949e8e46c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_e6974bd3-5d6d-4051-9494-f4949e8e46c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2963c0b6-cf70-4ef4-aaab-3239667e0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage_2963c0b6-cf70-4ef4-aaab-3239667e0d90" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6487acd-61ec-45ef-bc10-9c1023583ca9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_b6487acd-61ec-45ef-bc10-9c1023583ca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_79bd1af9-1e7d-4717-83c9-2c035ddf7937" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_79bd1af9-1e7d-4717-83c9-2c035ddf7937" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_025ef83f-fed2-4f2c-ade9-c00a210ad600" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized_025ef83f-fed2-4f2c-ade9-c00a210ad600" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_76e906d2-719b-41f9-9e78-6276fe1cdec5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_76e906d2-719b-41f9-9e78-6276fe1cdec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3294c80c-1737-43ea-a837-7111c37436ff" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3294c80c-1737-43ea-a837-7111c37436ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8f8b133f-56a3-4e9d-8f09-2c74b1da570c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_8f8b133f-56a3-4e9d-8f09-2c74b1da570c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b8bc8393-1a5a-4496-8f0a-19a8010eec96" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_b8bc8393-1a5a-4496-8f0a-19a8010eec96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65c75635-382b-4ab3-bcf7-383269c5027a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_65c75635-382b-4ab3-bcf7-383269c5027a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_866eee0d-a222-4fde-9079-4ac80d05b728" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_866eee0d-a222-4fde-9079-4ac80d05b728" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_175957e0-09f5-4c8b-9c01-34368a06d742" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice_175957e0-09f5-4c8b-9c01-34368a06d742" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_607e3811-bc11-4e17-af34-9888a78329c1" xlink:href="avdl-20241231.xsd#avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate_607e3811-bc11-4e17-af34-9888a78329c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_425241f6-b1e8-4b70-a240-1036b86a5ef1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_425241f6-b1e8-4b70-a240-1036b86a5ef1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_249d6a7f-1c24-4c85-a241-fb17fa8fa060" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent_249d6a7f-1c24-4c85-a241-fb17fa8fa060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e04be747-a09a-4535-873b-aa9e27ee87eb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e04be747-a09a-4535-873b-aa9e27ee87eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4493a4f8-b4f8-4232-b80b-6341de777ff6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_05bd5698-b2d2-4514-8ed2-94a8153a5fab" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_4493a4f8-b4f8-4232-b80b-6341de777ff6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationFairValueAssumptionsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ca128-2c34-4103-9fa2-86a717c06de6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_4a3ca128-2c34-4103-9fa2-86a717c06de6" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityEquityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OptionIndexedToIssuersEquityTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityEquityAxis_a8b76c82-6f6f-4132-9754-458171c698b5" xlink:to="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_8416678f-240c-490d-8bc6-7957cad81af0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OptionIndexedToIssuersEquityTypeDomain_99d3e357-1f29-4760-b6d0-fd34a700f222" xlink:to="loc_us-gaap_EmployeeStockOptionMember_8416678f-240c-490d-8bc6-7957cad81af0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_c588aa98-21bc-422e-aae2-c2595f419771" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc1d205-f6c4-40c5-af4d-70cb4715a4a3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_7fc1d205-f6c4-40c5-af4d-70cb4715a4a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_62355ff3-7eeb-44c9-9e54-4139507c7d77" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_62355ff3-7eeb-44c9-9e54-4139507c7d77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f428c8c8-daa4-4a3f-ab22-024c572ee287" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_f428c8c8-daa4-4a3f-ab22-024c572ee287" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73730b5a-cfc9-4c63-b8d1-073fdf5fe1dc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_e0d86bac-87fc-442a-86ce-4e508b1610c8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_73730b5a-cfc9-4c63-b8d1-073fdf5fe1dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationStockOptionsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8bb311a2-32c2-4950-aa70-3b505fa28a22" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_8bb311a2-32c2-4950-aa70-3b505fa28a22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be126326-417b-44a9-9502-cce79f0f663e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_be126326-417b-44a9-9502-cce79f0f663e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39e4fee1-789a-449d-9649-387cbf893652" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_39e4fee1-789a-449d-9649-387cbf893652" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e1d5fc-4e91-4199-ba64-3b33e0a1b51f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_c3e1d5fc-4e91-4199-ba64-3b33e0a1b51f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c855caf9-6027-49ee-aab7-f56a0c30d114" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod_c855caf9-6027-49ee-aab7-f56a0c30d114" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44329d04-0ed4-4565-8686-5fd82fcf6655" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_ccfaa68f-f2cc-4c59-92c3-d3695d4fafa1" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_44329d04-0ed4-4565-8686-5fd82fcf6655" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25bc65d5-891d-46a6-849f-dfb6b7fabe89" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_25bc65d5-891d-46a6-849f-dfb6b7fabe89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34c49f7f-88d7-47aa-9879-486755798a6b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_34c49f7f-88d7-47aa-9879-486755798a6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_204fb2c3-4fd3-4fc9-a6f8-10eafe42d276" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_204fb2c3-4fd3-4fc9-a6f8-10eafe42d276" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecbed112-725c-4d6b-8f90-1120b519dbfe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_ecbed112-725c-4d6b-8f90-1120b519dbfe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1b80c24a-4513-4eab-ac3c-aa56198567f5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1b80c24a-4513-4eab-ac3c-aa56198567f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_091fda8e-f1de-45ce-bf31-8a540071564b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice_091fda8e-f1de-45ce-bf31-8a540071564b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7190bca4-5f0d-40a9-8d70-7603e02d1be4" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_1e2016f1-e375-444c-9878-3a979f778cc3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_7190bca4-5f0d-40a9-8d70-7603e02d1be4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_120bcf0c-f54f-4fb1-9df4-76f6855ba1f3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_120bcf0c-f54f-4fb1-9df4-76f6855ba1f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1fa1b5e5-e2f6-44ec-a85d-348ebfffc8d8" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_1fa1b5e5-e2f6-44ec-a85d-348ebfffc8d8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77ab8cd8-ad0c-4480-a96b-555a08643abe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_77ab8cd8-ad0c-4480-a96b-555a08643abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f708346-0035-40da-a713-2ce1277a8e33" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6f708346-0035-40da-a713-2ce1277a8e33" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b438c8b9-bce4-401a-a71b-c12e4eaa3939" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_32dde17d-3442-4f10-ab6d-0f86e18e3b87" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_b438c8b9-bce4-401a-a71b-c12e4eaa3939" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ShareBasedCompensationRestrictedShareActivityDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d777c31-3231-4eac-a402-d9f7ab9f29fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_8d777c31-3231-4eac-a402-d9f7ab9f29fd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:to="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_d036e12b-fd62-4df0-9bdc-561078f34516" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockMember_48e117f4-2336-45ec-b61f-33106bfbdacc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RestrictedStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_fdf5095e-03bf-4600-b0c1-f80ab2d55afb" xlink:to="loc_us-gaap_RestrictedStockMember_48e117f4-2336-45ec-b61f-33106bfbdacc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_dad4d179-df2c-4c28-9266-80ee0bb66e80" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_147b27d4-8d47-4521-b5db-1f021eed2182" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_147b27d4-8d47-4521-b5db-1f021eed2182" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ed185d-afe5-4e36-ad70-0983c412a9a2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_77ed185d-afe5-4e36-ad70-0983c412a9a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26532ae9-c1a0-4cdf-9bb7-ba51f0b1053d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_26532ae9-c1a0-4cdf-9bb7-ba51f0b1053d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44434183-c10b-4508-be26-68ac2e3f4529" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_44434183-c10b-4508-be26-68ac2e3f4529" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c03e9b7-7d29-4dc3-90dd-8015fb88a84a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_ff673339-474d-4eec-b126-47e2956e82fc" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_1c03e9b7-7d29-4dc3-90dd-8015fb88a84a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_21b94a35-e713-4e3b-8371-f43d472330e6" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a59f1dbc-ff44-4ef8-b994-56717d90fc88" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_a59f1dbc-ff44-4ef8-b994-56717d90fc88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8224f6a5-5d2c-4065-a3fd-31fd01d4476f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_8224f6a5-5d2c-4065-a3fd-31fd01d4476f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_675b48a4-bdce-4437-bfd9-801b1cf73cde" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_675b48a4-bdce-4437-bfd9-801b1cf73cde" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_01462a84-6bd2-4277-b56a-58853f980335" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_01462a84-6bd2-4277-b56a-58853f980335" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c88b041d-4bbd-44c4-a0d8-f93082ca7bec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_63c0ce3f-f581-4272-afc6-6ab4cbc385ea" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_c88b041d-4bbd-44c4-a0d8-f93082ca7bec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_b75c9aef-9fee-45e2-842b-394c3fa10f78" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_8f9dda31-7365-42d5-9f16-ff283097cc14" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b75c9aef-9fee-45e2-842b-394c3fa10f78" xlink:to="loc_us-gaap_NetIncomeLoss_8f9dda31-7365-42d5-9f16-ff283097cc14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fc175af1-3045-415f-970a-67ba968a1386" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b75c9aef-9fee-45e2-842b-394c3fa10f78" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fc175af1-3045-415f-970a-67ba968a1386" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c87348c-2896-4dc1-a834-7e2aaee7b064" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fc175af1-3045-415f-970a-67ba968a1386" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_5c87348c-2896-4dc1-a834-7e2aaee7b064" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c96020e-6f74-44d3-8651-82b58d9111ef" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fc175af1-3045-415f-970a-67ba968a1386" xlink:to="loc_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment_7c96020e-6f74-44d3-8651-82b58d9111ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b6d57be-0234-4344-8e7c-6e28dfacf57a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract_fc175af1-3045-415f-970a-67ba968a1386" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_9b6d57be-0234-4344-8e7c-6e28dfacf57a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_b1b8e72e-1949-42af-ac84-4a9591baf2e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b75c9aef-9fee-45e2-842b-394c3fa10f78" xlink:to="loc_us-gaap_EarningsPerShareBasic_b1b8e72e-1949-42af-ac84-4a9591baf2e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_eee0851f-7382-41b8-b356-692ad8739c17" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_b75c9aef-9fee-45e2-842b-394c3fa10f78" xlink:to="loc_us-gaap_EarningsPerShareDiluted_eee0851f-7382-41b8-b356-692ad8739c17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/NetLossPerShareNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#NetLossPerShareNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/NetLossPerShareNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_76878a6a-af36-40cc-bb92-6191f16c586d" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_761378be-d889-4b7e-90f3-44055ad64923" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_76878a6a-af36-40cc-bb92-6191f16c586d" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_761378be-d889-4b7e-90f3-44055ad64923" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ComprehensiveLossDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ComprehensiveLossDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ComprehensiveLossDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityNoteAbstract_e8138322-4659-4a96-ab4f-fb222669575b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquityNoteAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityNoteAbstract_e8138322-4659-4a96-ab4f-fb222669575b" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_34778c49-4f60-4e51-91d4-7cb97f90f493" xlink:to="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_5cd628da-0e34-4366-ba3a-df3fac2548c3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedTranslationAdjustmentMember_77c37660-e976-450c-b841-f2d4c8802906" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedTranslationAdjustmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:to="loc_us-gaap_AccumulatedTranslationAdjustmentMember_77c37660-e976-450c-b841-f2d4c8802906" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_be85f7b9-c3f0-4000-a8a4-0bc7c3c792e9" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_442955b3-98d2-4932-900b-807e14119693" xlink:to="loc_us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember_be85f7b9-c3f0-4000-a8a4-0bc7c3c792e9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossTable_c0a55aa4-5ef5-46cc-acec-5bd5426662cc" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AOCIAttributableToParentNetOfTaxRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:to="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_33f20315-7519-4533-a52d-f28eb55892da" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:to="loc_us-gaap_StockholdersEquity_33f20315-7519-4533-a52d-f28eb55892da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0bdbecad-5da5-4920-b359-3018de6d33c3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent_0bdbecad-5da5-4920-b359-3018de6d33c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_8a54fc53-94e0-4111-b590-24731fff9df1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AOCIAttributableToParentNetOfTaxRollForward_1c1978bd-df0c-4f74-a81b-9f6ef7622c2b" xlink:to="loc_us-gaap_StockholdersEquity_8a54fc53-94e0-4111-b590-24731fff9df1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_406ac076-dd55-4f10-8e5e-8802cc1cc29b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems_96540317-4a30-4aed-8822-60951d7849cf" xlink:to="loc_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_406ac076-dd55-4f10-8e5e-8802cc1cc29b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationNarrativeDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationNarrativeDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SegmentInformationNarrativeDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_6352721f-bb66-4e5f-b7f8-8003b07d004f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_08dd2cb9-2677-4833-8e82-53f7b349be0f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6352721f-bb66-4e5f-b7f8-8003b07d004f" xlink:to="loc_us-gaap_NumberOfOperatingSegments_08dd2cb9-2677-4833-8e82-53f7b349be0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_5e4cd48d-088b-4316-9c2e-fb2f43be86ce" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_6352721f-bb66-4e5f-b7f8-8003b07d004f" xlink:to="loc_us-gaap_NumberOfReportableSegments_5e4cd48d-088b-4316-9c2e-fb2f43be86ce" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_cbe62bba-0a97-4c07-9570-774ce6c51072" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_cbe62bba-0a97-4c07-9570-774ce6c51072" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_2ebad4e3-c284-418f-87d3-ef8bf058d1ae" xlink:to="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_avdl_ReportableSegmentMember_c284089b-cb92-493f-96aa-0a8153e71689" xlink:href="avdl-20241231.xsd#avdl_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_08579693-9a87-47bf-a89a-a075170e0d49" xlink:to="loc_avdl_ReportableSegmentMember_c284089b-cb92-493f-96aa-0a8153e71689" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_99b4860c-488c-4497-a7bd-a0bd4b16dc29" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8ac5f9d0-7795-424e-86dd-b994a4a706a0" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_8ac5f9d0-7795-424e-86dd-b994a4a706a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CostOfGoodsAndServicesSold_94f729bf-954e-435f-92c8-da4896a78b97" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_CostOfGoodsAndServicesSold"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_CostOfGoodsAndServicesSold_94f729bf-954e-435f-92c8-da4896a78b97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GrossProfit_8f01dcb3-9249-4fa1-80b1-119ad3bf3cc5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GrossProfit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_GrossProfit_8f01dcb3-9249-4fa1-80b1-119ad3bf3cc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_976191dd-efe6-45cb-a2a5-54ad6e498d53" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_976191dd-efe6-45cb-a2a5-54ad6e498d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_5bfe4098-29d1-4e04-8094-b30ad538d650" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_5bfe4098-29d1-4e04-8094-b30ad538d650" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SellingAndMarketingExpense_cb0e3e1d-9a41-44de-a3b0-3bda6115a30c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SellingAndMarketingExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_SellingAndMarketingExpense_cb0e3e1d-9a41-44de-a3b0-3bda6115a30c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_0cb1095c-2d12-408d-ba07-51d010dbb54c" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_0cb1095c-2d12-408d-ba07-51d010dbb54c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ce7912c8-a518-4cea-a43b-cf4e9bb8e9a6" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_b7bbe718-fe94-41b7-ae47-4bd2fb20c0fd" xlink:to="loc_us-gaap_OperatingExpenses_ce7912c8-a518-4cea-a43b-cf4e9bb8e9a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_bf944735-3d1b-4f8e-b687-647aba5c82b1" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_OperatingIncomeLoss_bf944735-3d1b-4f8e-b687-647aba5c82b1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeNet_ec2dfd66-e7d6-43b0-9098-389a71a8e49e" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InvestmentIncomeNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_InvestmentIncomeNet_ec2dfd66-e7d6-43b0-9098-389a71a8e49e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InterestExpenseDebt_4830aa1b-3f03-4344-a724-b47a992f29cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_InterestExpenseDebt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_InterestExpenseDebt_4830aa1b-3f03-4344-a724-b47a992f29cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e34199a9-8710-403c-86b9-4ff4356251e3" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GainsLossesOnExtinguishmentOfDebt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_GainsLossesOnExtinguishmentOfDebt_e34199a9-8710-403c-86b9-4ff4356251e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfac80d9-b3cd-4dc0-ae1d-181fd8429ed5" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_c3d59df0-1935-42b3-87f9-e8d0b062a2ac" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_bfac80d9-b3cd-4dc0-ae1d-181fd8429ed5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#SegmentInformationLongLivedAssetsbyGeographicRegionDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_f6cb3c33-7e46-4ed8-9085-4fca4a275b32" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_f6cb3c33-7e46-4ed8-9085-4fca4a275b32" xlink:to="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:to="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_9dd8f864-87ab-4727-b4a3-9bb91fde6b7a" xlink:to="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_US_60bf82ef-7e26-42a9-8d66-7a9f6bb287e5" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_US"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:to="loc_country_US_60bf82ef-7e26-42a9-8d66-7a9f6bb287e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_country_IE_8c311629-1bd0-4a28-88b7-2b3d0e1e1513" xlink:href="https://xbrl.sec.gov/country/2024/country-2024.xsd#country_IE"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_c71da15c-f71a-4931-a3d0-342cbc330ebf" xlink:to="loc_country_IE_8c311629-1bd0-4a28-88b7-2b3d0e1e1513" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable_371b49b1-10b2-46d2-804c-966e540b10d2" xlink:to="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_GeographicAreasLongLivedAssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems_387a4ed3-0836-40e8-b059-8fbd416557fe" xlink:to="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NoncurrentAssets_b06eec76-5e21-41fd-bbb9-455a53177437" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NoncurrentAssets"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_GeographicAreasLongLivedAssetsAbstract_5ce1a211-8040-42a2-8e95-8926d5ba31df" xlink:to="loc_us-gaap_NoncurrentAssets_b06eec76-5e21-41fd-bbb9-455a53177437" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="simple" xlink:href="avdl-20241231.xsd#ScheduleIIValuationandQualifyingAccountsDetails"/>
  <link:presentationLink xlink:role="http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsAbstract_81613aeb-d720-4da9-9374-5052feb4144f" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsAbstract_81613aeb-d720-4da9-9374-5052feb4144f" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesTypeAxis_a6bb30d8-085b-4e37-9ccd-1c24336ca04b" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9d99cbe0-49af-4964-bdbc-7ebacde8c6ee" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ValuationAllowancesAndReservesDomain_076fa24e-dbf0-4dfb-8335-3624c4f4d97f" xlink:to="loc_us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember_9d99cbe0-49af-4964-bdbc-7ebacde8c6ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:href="https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd#srt_ValuationAndQualifyingAccountsDisclosureLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureTable_41558c94-2ef6-4d58-ab12-c3f8d1778558" xlink:to="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_MovementInValuationAllowancesAndReservesRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ValuationAndQualifyingAccountsDisclosureLineItems_aee0deb5-5afb-48dc-983d-ddcc948500dc" xlink:to="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_90fe638c-7efe-4ea5-b96d-8db59a82b406" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_90fe638c-7efe-4ea5-b96d-8db59a82b406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_07283ec4-d1f0-4484-94f2-78dbec0fe6cf" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense_07283ec4-d1f0-4484-94f2-78dbec0fe6cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesDeductions_11b93697-533c-4fd9-ba4f-0e5294288fec" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesDeductions"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesDeductions_11b93697-533c-4fd9-ba4f-0e5294288fec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_11c0be5f-9f62-4f5d-9d9b-369e6f7f1cfa" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease_11c0be5f-9f62-4f5d-9d9b-369e6f7f1cfa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowancesAndReservesBalance_48cb87b0-559d-4e67-966e-b9e689d17d2a" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ValuationAllowancesAndReservesBalance"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_MovementInValuationAllowancesAndReservesRollForward_fb96bf5a-9af2-49e3-87b1-cbbeaa166036" xlink:to="loc_us-gaap_ValuationAllowancesAndReservesBalance_48cb87b0-559d-4e67-966e-b9e689d17d2a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_us-gaap_NetIncomeLoss" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>avdl-20241231_g1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 avdl-20241231_g1.jpg
M_]C_X  02D9)1@ ! 0$!2@%*  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" 4+"/P# 2(  A$! Q$!_\0
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M_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\
M^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@Q
MOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_
M .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D
M.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]
MJ:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB
M@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _
M%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_
MX<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*
MGQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;
M_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\
MZ&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI
M^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A_
M_P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\
M@QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;
M[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^
M0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C
M_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<
MJ?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQ
MO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^
MAI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?
MA_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_
M /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X
M,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^
M_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\
MY#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z
M_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVI
MHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:*
M/Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5
MO^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_A
MRI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?
M&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_
M .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H
M:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX
M?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__
M (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#
M&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO
M_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#
MH_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^
M'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI
M\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&_
M_H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&
MGX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'
M_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\
M^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@Q
MOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_
M .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D
M.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]
MJ:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB
M@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _
M%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_
MX<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*
MGQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;
M_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\
MZ&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI
M^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A_
M_P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\
M@QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;
M[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^
M0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C
M_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<
MJ?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQ
MO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^
MAI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?
MA_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_
M /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X
M,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^
M_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\
MY#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z
M_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVI
MHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:*
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M_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\
M^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@Q
MOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_
M .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D
M.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]
MJ:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB
M@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _
M%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_
MX<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*
MGQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;
M_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\
MZ&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI
M^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A_
M_P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\
M@QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;
M[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^
M0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C
M_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<
MJ?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQ
MO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^
MAI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?
MA_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_
M /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X
M,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^
M_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\
MY#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z
M_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVI
MHH _%;_ARI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:*
M/Q6_X<J?&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5
MO^'*GQO_ .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_A
MRI\;_P#H:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?
M&_\ Z&GX?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_
M .AI^'__ (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H
M:?A__P"#&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX
M?_\ @QOO_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__
M (,;[_Y#H_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _%;_ARI\;_P#H:?A__P"#
M&^_^0Z/^'*GQO_Z&GX?_ /@QOO\ Y#K]J:* /Q6_X<J?&_\ Z&GX?_\ @QOO
M_D.C_ARI\;_^AI^'_P#X,;[_ .0Z_:FB@#\5O^'*GQO_ .AI^'__ (,;[_Y#
MH_X<J?&__H:?A_\ ^#&^_P#D.OVIHH _#;XA?\$B?C#\-? 'B7Q?J?B3P//I
MN@:9<ZK=16E_>-,\4$32NJ!K106*H0 2!G&2.M?,7@C]H;XF_#713I'A;QWK
MV@Z7YAF^R6-\\<8<@ D*#@<*/RK^A']K'_DUCXR?]B9K/_I#-7\UE 'W_P#\
M$5/^3I_%/_8F77_I=8U^U-?BM_P14_Y.G\4_]B9=?^EUC7[4T %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% 'E7[6/_)K'QD_[$S6?_2&:OYK*_I3_:Q_
MY-8^,G_8F:S_ .D,U?S64 ??_P#P14_Y.G\4_P#8F77_ *76-?M37XK?\$5/
M^3I_%/\ V)EU_P"EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M'E7[6/\ R:Q\9/\ L3-9_P#2&:OYK*_I3_:Q_P"36/C)_P!B9K/_ *0S5_-9
M0!]__P#!%3_DZ?Q3_P!B9=?^EUC7[4U^*W_!%3_DZ?Q3_P!B9=?^EUC7[4T
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M#P0 #Z-HKF_B5K%WX>^'/BK5;"00WUCI5W=02%0VR1(693@\'! X-?FY\/\
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M;B"?8$]J_/;X?_'3XT?$GQYH_A_3?&^I&^U.Z6,$!-D8)R[E0N-JJ&8CT!H
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MG]M3XM>&YU=_$2:Q".MOJ=K'(K?5E"O^34 ?J317BW[-O[2^E_'[2;J(VO\
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MQU_:.^)^@_&/QCIEEXKU#3;*SU.:WM[6':B)$K$)@8[J <]\YKA?^&I/BO\
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M_P!*H:^1/^"?/_)>+C_L#7'_ *,BKZ[_ &R/^3:_&G_7.V_]*H: /@;]D_\
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M"X#$CC<P)QWK\J_AE\<O&OPBN@_AK7)[6V+;I+"7][;2>N8VXR?48/O7WO\
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M5\&5UN"/?>>'KI;G(&3Y$F(Y!^9C8^R5\L_L0_$+_A!_CGI]E-)LL=?C;3)
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M?1%"(NH7 55& !YC<"OV3T+_ ) FG?\ 7O'_ .@BOQN\=?\ ([>(?^PC<?\
MHUJ_9'0O^0)IW_7O'_Z"* /R0_: _P"2Y>/_ /L.WO\ Z.:OTP_9G_Y(#X$_
M[!47\J_,_P#: _Y+EX__ .P[>_\ HYJ_3#]F?_D@/@3_ +!47\J /3:_+/\
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M4DFXLNIR1#=UP@"C\,** /;?V&/V>-)\<_;?''B:S34+"RN/LVGV4Z[HI)E
M9Y'4_>"[E !R"2V>@K[[AACMH4BBC6*) %5$ "J!T  Z5X=^Q-9QVO[-?A5T
M(+3O=RN1Z_:I5_DH%>Z4 ?&W[=GP T9?"!\?Z!ID5AJ5E,B:FMH@1)X7.T2,
MH&-ZN5&1U#'.<#'SU^QU\0)_ ?QWT!!)ML=9?^RKF,G 82D",_42!#],CO7Z
M#_M'6J7?P&\>QR-M4:/<2 GU5"P_4"ORL^'<SV_Q \,RQ?ZR/5+5EQZB52*
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M  60?_$UX)^VK\$]#G^"MUK.@:#I^F7^BW$=V[6%I'"TD!^213M R!N#_P#
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MC@ 9)T*^_P#2=Z /R5^'2A_B#X85@&4ZI:@@C@CS5K]C/["TW_H'VG_?A?\
M"OQAT#5GT#7M-U2.-99+*YCN5C8X#%&# 'ZXKZS_ .'D/B3_ *$[2O\ P)DH
M ^\K:QMK(,+>WB@#=1$@7/UQ4]?$WP]_X*!:UXL\=^'M#O?"=A!:ZG?P63RP
M7#EX_,<)N (P<%@<=\5]LT %%%% 'Q[_ ,%(?^1)\'?]A&7_ -%5YU_P3C_Y
M*CXF_P"P,?\ T?'7HO\ P4A_Y$GP=_V$9?\ T57G7_!./_DJ/B;_ + Q_P#1
M\= 'Z#U^57[86@2^'_VB?%J.,1W<L=Y$V,;EDB5C^3;A^%?JK7RO^W!^SUJ'
MQ+T>R\7>'+5[W7=)B,%Q91+F2YMLE@4'4LA+';U(8XY ! -#]@'Q?;:Y\$FT
M5&Q=Z)?2Q21YYV2L94;Z$LX_X :^F*_'SX3_ !?\3?!/Q0=7\/7(AE8>5<V=
MPI:&X0'.R1<@\'H001S@C)KZ53_@I-JHLMK^!;-KO _>KJ+B/..?D\LGKC^+
M_&@#W[]LWQC;>$OV?_$4<LBK=:J$TZVC)P79V!?'TC5S^'O7Y\_L[^%9?&7Q
MO\&:;&C.O]I17$NT9Q%$?-?_ ,=0U'\7?C5XK^.OB*"^U^97\K]W9Z=9H5@@
M#$9"+DDDG&222>!G  'VC^Q3^S9>_#.QN/&'B>U-MXAU"'R;6RD'SVEN<$EQ
MVD<@<=5 P>20 #ZIKX]_X*0_\B3X._[",O\ Z*K["KX]_P""D/\ R)/@[_L(
MR_\ HJ@#SK_@G'_R5'Q-_P!@8_\ H^.OT$FFCMH9)976.*-2SNQP% Y))K\^
M_P#@G'_R5'Q-_P!@8_\ H^.OIO\ ;#^(/_"OO@1KKQ2>7?:L!I5M@X.90?,(
M^D8D.?7% 'YP_&'QW)\3/B?XD\2NQ,=_>.\ ;JL*_+$I^B*H_"O0?!W[9/Q%
M\">%]-\/Z/-I<&FZ?"(($:Q5C@=R<\DG))]2:H?LD_#J/XD_'+0K.[MDNM,L
M"VI7D<B[D:.+&T,#P09#&I!XPQK]+O\ A5/@G_H3M _\%D'_ ,30!^6GQ=^/
M?BGXVC3/^$G:RE?3O,^SR6UL(F ?;N!(/(^45Z+^PI\0O^$-^-L&E3R[+'Q#
M UBP)^43#YXC]<@H/^NE?=7COX$^#_%?@S6]'MO#.BV%U>V<L,-U!I\4;PR%
M3L<,%R"&P?PK\G+*[U#P?XC@N8MUGJNEW:R+N'S131OD9]PR_I0!^O'QE_Y)
M!XY_[ 5]_P"D[U^2_P ./^2A^%_^PK:_^CEK]3?%?BJW\=?LWZ]X@LQ^XU/P
MO<W2(.2N^U8E3[@DCZBOR>T+5I- UO3]3A19);*XCN41\[69&# '';B@#]K:
M*_/C_AXYXV_Z%G0/RG_^.5ZW^S)^V!KWQL^(LGAO6-$TZQA-E)<QSV)D#!T9
M>"&8Y!#'IWQ0!]64444 ?B7?_P#']<?]=&_G7Z8ZG^QY\-/&OP^M88-!BT35
M9[&-XM3L697CE* [BN=KC/4$=,X(/(_,Z_\ ^/ZX_P"NC?SK]G_"?_(K:-_U
MY0_^@"@#\A+A?$7P5^)$\4-Q)IGB+0;UHQ-"2,.A(R/[R,/7AE;T-?JU\&?B
M7:_%SX;:+XHM@L;W<.+F!3Q#.IVR)ZX# XSU!![U\:_\%#OAG_8WC32/&MK#
MBVUB+[)=LHX%Q$/E)]VCP!_UR-7_ /@G;\3C8:]K?@2[EQ!?H=1L0QX$R +*
MH]V0*W_;(T ;7_!2K_CQ^'W_ %TO_P"5O7._\$Y+*WO?%'C07$$4X6SMR!*@
M;'SOZUT?_!2H'[!\/CCCS+[^4%?.7[/_ .T'J'P U+6+S3])MM5;4H8X76YD
M9 @4DY&WZT ?JK_86F_] ^T_[\+_ (5<1%C1550JJ,!0, "O@C_AY#XD_P"A
M.TK_ ,"9*]]_98_:5O/V@E\1QW^BP:3<:28&4VTK.LBR>9USR"#'^.?:@#WR
MOS._;U_Y.#N_^P=:_P#H)K],:_,[]O7_ ).#N_\ L'6O_H)H ^F?^"?/_)![
MC_L,W'_HN*OIBOF?_@GS_P D'N/^PS<?^BXJ^F* /SX_X*.6CI\4?#-T0?+D
MT81@X[K/(3_Z&*[S_@FYK$,GAOQII6]1<17<%ULS\Q5T9<X] 4_45Z#^VK\#
M[[XM?#^TU'1(#=:]H#R3QVR#+W$#@>:BCN_R(P'?:0.2*_/[X9_$_P 1_!GQ
M>NN:!.+34(U:":"XCW1RH2-T<B\'&5'H00,$$4 ?L77PG_P4GU>"?6_ FEJP
M-S;6]Y<NN>0LC1*IQ]87_*H9?^"DNM'32D7@BP34/^>[WSM%_P!^]@/_ (_7
MS'XJ\4^*?C9X\?4;\SZUXAU*18HX+:+).!A(XT4< #L/<G))- 'U?_P35M9-
M_P 0;DJ1#BPC#$<%O]() ^G'YBO0/^"AW_)#=._[#L'_ *)GKT+]E_X,M\$_
MA;::5>!#KE[(;W460[@LK  1@^B*%7C@D,1UKSW_ (*'?\D-T[_L.P?^B9Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#RK]K'_DUCXR?]B9K/_I#-7\UE?TI_M8_\FL?&3_L3-9_](9J_
MFLH ^_\ _@BI_P G3^*?^Q,NO_2ZQK]J:_%;_@BI_P G3^*?^Q,NO_2ZQK]J
M: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M22>YK7U"PM]5L+FRO(4N+2YB:&:&0961&!#*1Z$$BK%% 'A*?L1_!Y+L3?\
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MP<#C@5V=% 'G?PO^ '@;X.W5W=^%M&^Q7MU'Y4MS+/)-(R9!V@NQP,@' QG
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M,$JZ,K#/?!YKSS_ABKX,_P#0F_\ E4O?_CU>WT4 >(?\,5?!G_H3?_*I>_\
MQZNZ^&OP9\&_""*_C\(Z*ND+?E&N3]HEF,FS=MYD=B -S<#U-=K10 5YA\2?
MV:_A[\6=<76/$FB-=:H(UA-S#=2PED7. 0K '&>N,^]>GT4 <W\/_AUX>^%W
MAU-#\,Z<NF:8LC2^4)'D+.V-S%G)8DX'4]@*Z2BB@ KS'XA_LU_#GXH7<E[K
MOAJW;49.6OK1FMYF/JQ0C>?]X&O3J* /FY/V _A6ER92FLNA_P"6+7WR#\ES
M^M>K_#OX'^!OA4"WACPY::=<,-K79W2W!'<>:Y9@#Z X]J[JB@ KF?B'\-O#
MOQ4\.G0_$^G#4M-\U9UC\QXRDB@A65D(((R>_<@\5TU% 'F/PT_9N^'_ ,)-
M9DU?PUHK6NIO$T/VF:ZEF8(<$J S$#.!SC/O7IU%% 'EGQ&_9D^'7Q4U]M;\
M0Z$UQJSHL<EU!=2PF15&%W!6 ) XSC. !G@5T_PW^%OAGX2:#)H_A;3CIMA+
M,;F1#/)*7E*JI<EV)R0B\# XZ5UE% 'CGB?]D;X6>,/$]YKVI^''EU"]F-Q<
MF.^GC2:0G+,55P 2>N,5Z[:6L5C:PVUO&(H(46..->BJ!@ ?0"IJ* $(!!!&
M0:\;U3]CWX/ZQJ-Q>W'@R%9YW+N+>]N8(\GT1)551[  5[+10!C^$O".C^!?
M#]IH>@V$6FZ5:*5AMHLD+DDDDDDDDDDDDDD\UL444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!Y5^UC_R:Q\9/^Q,
MUG_TAFK^:ROZ4_VL?^36/C)_V)FL_P#I#-7\UE 'W_\ \$5/^3I_%/\ V)EU
M_P"EUC7[4U^*W_!%3_DZ?Q3_ -B9=?\ I=8U^U- !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110!Y5^UC_ ,FL?&3_ +$S6?\ TAFK^:ROZ4_VL?\ DUCX
MR?\ 8F:S_P"D,U?S64 ??_\ P14_Y.G\4_\ 8F77_I=8U^U-?BM_P14_Y.G\
M4_\ 8F77_I=8U^U- !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \J_:Q_P"3
M6/C)_P!B9K/_ *0S5_-97]*?[6/_ ":Q\9/^Q,UG_P!(9J_FLH ^_P#_ ((J
M?\G3^*?^Q,NO_2ZQK]J:_%;_ ((J?\G3^*?^Q,NO_2ZQK]J: "BBB@ HHHH
M*^$?^"A?Q2UNW\4:7X'L[N:ST4V"WUW'$Q3[4[R.H5_[R*(P0.F6.>@Q]W5\
M_?M4?LMK\>;>RU72KZ'3?$^GPF"-[D'R;F+<6$;D9*X)8A@#]X@CD$ 'FFF?
M\$Z_#&I^%[.XC\9ZB]_<6Z2K=PPQO;,6 .Y4X8KSQ\]?1OP/^'FI?"SX6:5X
M5U'5%U6\L/.1;Q0VTHTKM& &Y&U648Z#&!Q7P7#XJ^.O[),UO:7HN[710^R&
MWO@+O3I>^U'!(3."<*RMU]Z^Y/V>OC?9_'CP$NN16O\ 9]_;S&UOK/<66.4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OVL?^36/C)_V
M)FL_^D,U?S65_2G^UC_R:Q\9/^Q,UG_TAFK^:R@#[_\ ^"*G_)T_BG_L3+K_
M -+K&OVIK\5O^"*G_)T_BG_L3+K_ -+K&OVIH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** /*OVL?^36/C)_V)FL_P#I#-7\UE?TI_M8_P#)K'QD_P"Q
M,UG_ -(9J_FLH ^__P#@BI_R=/XI_P"Q,NO_ $NL:_:FOQ6_X(J?\G3^*?\
ML3+K_P!+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /*OVL?\
MDUCXR?\ 8F:S_P"D,U?S65_2G^UC_P FL?&3_L3-9_\ 2&:OYK* /O\ _P""
M*G_)T_BG_L3+K_TNL:_:FOQ6_P""*G_)T_BG_L3+K_TNL:_:F@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH \J_:Q_Y-8^,G_8F:S_Z0S5_-97]*?[6/
M_)K'QD_[$S6?_2&:OYK* /O_ /X(J?\ )T_BG_L3+K_TNL:_:FOQ6_X(J?\
M)T_BG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXI_[$RZ_]+K&OVIH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXO\ C0!:HJK_ &G9_P#/W!_W\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\
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M\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\ ?Q?\:/[3L_\ G[@_[^+_ (T
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M.S_Y^X/^_B_XT 6J*J_VG9_\_<'_ '\7_&C^T[/_ )^X/^_B_P"- %JBJO\
M:=G_ ,_<'_?Q?\:/[3L_^?N#_OXO^- %JBJO]IV?_/W!_P!_%_QH_M.S_P"?
MN#_OXO\ C0!:HJK_ &G9_P#/W!_W\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]
MP?\ ?Q?\:/[3L_\ G[@_[^+_ (T 6J*J_P!IV?\ S]P?]_%_QH_M.S_Y^X/^
M_B_XT 6J*J_VG9_\_<'_ '\7_&C^T[/_ )^X/^_B_P"- %JBJO\ :=G_ ,_<
M'_?Q?\:/[3L_^?N#_OXO^- %JBJO]IV?_/W!_P!_%_QH_M.S_P"?N#_OXO\
MC0!:HJK_ &G9_P#/W!_W\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\ ?Q?\
M:/[3L_\ G[@_[^+_ (T 6J*J_P!IV?\ S]P?]_%_QH_M.S_Y^X/^_B_XT 6J
M*J_VG9_\_<'_ '\7_&C^T[/_ )^X/^_B_P"- %JBJO\ :=G_ ,_<'_?Q?\:/
M[3L_^?N#_OXO^- %JBJO]IV?_/W!_P!_%_QH_M.S_P"?N#_OXO\ C0!:HJK_
M &G9_P#/W!_W\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\ ?Q?\:/[3L_\
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M@_[^+_C0!:HJK_:=G_S]P?\ ?Q?\:/[3L_\ G[@_[^+_ (T 6J*J_P!IV?\
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MXO\ C0!:HJK_ &G9_P#/W!_W\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\
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M\7_&C^T[/_G[@_[^+_C0!:HJK_:=G_S]P?\ ?Q?\:/[3L_\ G[@_[^+_ (T
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MMXAA8T48 'X4 7:*** "BBB@#+U#PW8:G<F>XB9Y" ,AR.!5;_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
M]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@
M_P#W\;_&C_A"M)_YX/\ ]_&_QK=HH PO^$*TG_G@_P#W\;_&C_A"M)_YX/\
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M?^>#_P#?QO\ &N*^,/C#X=_ ;P)>^+_&VH#1]$M2$\PL[O+(V=L4:+DN[8.
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M HH PO\ A"M)_P">#_\ ?QO\:/\ A"M)_P">#_\ ?QO\:W:* ,+_ (0K2?\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M(5)!]<$U^'&O?\$E?C]8_$F;P]INBV&I:";@K!XG.HP16A@R,2O&6\U2 1E
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M?_!(3X>?%CXHZAXOTSQ3JGA&WU2Y:[U#2;2VCFC:5VW2-"S$>5N))P0X!/
MPM 'TM^R1\=Y/VD_V?O"GQ N;!-,O]2BEBO+6+/EI/%*\4A3))V,R%E!)(#
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH \J_:Q_Y-8^,G_8F:S_Z0S5_-97]*
M?[6/_)K'QD_[$S6?_2&:OYK* /O_ /X(J?\ )T_BG_L3+K_TNL:_:FOQ6_X(
MJ?\ )T_BG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/LT=M;7^XP%Y;B.'+A2K$ 2$X!&<8R*]IKY*_P""J?\ R8YX^_Z[:;_Z7V]
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M))))KJ:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ^,OVLO\
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M/5T)72[QN@W%B3;L?]LE.#\RY"U^@L4J3Q))&ZR1N RNIR&!Z$'N* 'T444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 >5?M8_\ )K'QD_[$S6?_ $AFK^:ROZ4_VL?^36/C
M)_V)FL_^D,U?S64 ??\ _P $5/\ DZ?Q3_V)EU_Z76-?M37XK?\ !%3_ ).G
M\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M75]-UN+4RNJ2O%%+&(9HF4,JMALRJ>1C /.<5]444 ?B!_PYM^/?_/YX/_\
M!I+_ /&*/^'-OQ[_ .?SP?\ ^#27_P",5^W]% 'X@?\ #FWX]_\ /YX/_P#!
MI+_\8H_X<V_'O_G\\'_^#27_ .,5^W]% 'XB0?\ !&KX\23QI)J'@Z%&8!I#
MJ<Q"C/)P(,\>U?MAI%C_ &7I-E9%_,-O D._&-VU0,X[=*MT4 %%%% 'RO\
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M_.#]KK_@D1HGC'[;XG^"[V_AO6FW2R^%[E]MA<'KBW?_ )8,3T4YCY 'E@4
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M?Q3_ -B9=?\ I=8U^U-?BM_P14_Y.G\4_P#8F77_ *76-?M30 4444 %%%%
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M%&<?4GQ^^%[?&KX+>,_ R7O]FS:[IDUG%=XR(I&7Y&8=UW 9 Y(S7XG^$O\
M@EM\?M=^)</AC5/"?]AZ:MP%NO$,]S$]E'"&YE1E8F0D<A -W(R%YP ?O<#D
M9'(I:J:3IL>C:596$+.T-K"D",YRQ55"C)]<"LVX\=^&K3Q+%X=G\0Z5#X@E
M4-'I,E[$MVX(R"(BV\C'M0!NT444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7D_[2W[2?A+]ESX:7?BWQ3/YC\Q:?I4+@7&H7&.(HP>W=
MFZ*N2<\ W_V@OV@/"7[-?PVO_&7B^\,-G!^[MK2+!N+V<@E(8E/5C@^P ))
M!-?S]?M)_M(>,/VJ?B=<^*O$TIRQ\C3=(MV9H+"#/RQ1CN3U9L99N?0  K_M
M _'_ ,9_M3?%&X\4^)YFN;ZY86]AIEJ"8;.'=\D$*=>IZ]6)).2:_5'_ ()S
M?\$Z8/@K9V'Q)^)%C'<>/YXQ+IVE3*&3148<,PZ&X(/)_@Z#G)JC_P $W?\
M@G5'\);:P^*'Q-TU)?&TRB;2-&N%W#2$(XED'3[00>!_RS'^W]W]$Z "BBB@
M HHHH **** "BBB@ HHHH **^.?^"BO[<6I_LB>'?#FG^%M+L]2\6^(3,\,V
MHAFM[."+8&<HI4NS%P%&X 8).<8/G?\ P3I_X*+>)_VE/'>H?#_X@:?IZZV+
M)[_3]5TR(PK,L94212QEB-V&W!EP,*P(S@D ^A?V\_CWKO[.'[-?B#Q?X9AC
M?7S-!86<\T?F1VSROM,S+T.U=V >-Q7.1P?Q$\9?MD_&/XC>"_$'A/Q7XYU#
MQ)H&N&)KJTU$)(%:.9)4:(XS'AHQPN%P3QTQ_0Q\3/AKX=^,'@76/!_BS3DU
M70-5A\FYMG)&>0596'*LK!65AR"H(Z5^>'QS_P""/WA'PI\'O&5]\,!XA\6>
M.V6!M(L=7U"!8XE%Q$9@FU(@S^4)0-[$8. -V#0!^1U%?2G_  [>_:2_Z);J
M'_@;:?\ QZC_ (=O?M)?]$MU#_P-M/\ X]0!\UT5]*?\.WOVDO\ HENH?^!M
MI_\ 'J/^';W[27_1+=0_\#;3_P"/4 ?-=?T>_L4?\FC_  A_[%FQ_P#12U^*
MW_#M[]I+_HENH?\ @;:?_'J_<?\ 9D\$ZO\ #;]GCX<^%M?@6TUO2-!M+2]M
MTD6013+$H=-RD@X.1D$CC@D<T >FT444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M80:Y:><UH[;C!*KM'+'NP-P61' ; R #CFO0Z "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH *X;XU?&?PM\ ?AUJGC3QA?BQTBQ7A5P9KF4@[(8E)&Z1B,
M?4D@ D:OQ%^(GA[X3^"M6\6>*M2BTG0=+A,]S=2]AT"J!RS,2 JC))( Y-?@
M'^VG^V-XA_:Y^(K:A<>;IG@_37>/1-$+<0QGK++@X:9\#)Z 84<#) ,+]K#]
MJOQ5^UC\2IO$>O.;/2;8O#H^B1ONAL(">G;=(V 7?&6('10JC]"O^"9W_!._
M_A$(M,^+OQ/TS&O.%N/#^@W2?\>*GE;J93_RU/!1#]P?,?G(V<G_ ,$R?^">
M(OSI7QB^)^F?Z,"MUX<T&[3_ %IX*7DRG^'O&AZ\.>-N?U?H **** "BBB@
MHHHH **** "BO%OBO^V9\%_@AXNA\+^-?'MAHVO2!";(0SW#0A_NF4Q(XBR,
M']X5X(/0YKUS1=;T_P 2:19ZKI-];ZGIE[$L]M>6DJRQ31L,JZ.I(8$'((H
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M%:_9[:SA9E9PBEF9G;8N7.,#( Y)/V710 4444 %%%% !1110 4444 %%%%
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M* /*OVL?^36/C)_V)FL_^D,U?S65_2G^UC_R:Q\9/^Q,UG_TAFK^:R@#[_\
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M /0;E_(_XUTU% ',_P#".:O_ -!N7\C_ (T?\(YJ_P#T&Y?R/^-=-10!S/\
MPCFK_P#0;E_(_P"-'_".:O\ ]!N7\C_C7344 <S_ ,(YJ_\ T&Y?R/\ C1_P
MCFK_ /0;E_(_XUTU% ',_P#".:O_ -!N7\C_ (T?\(YJ_P#T&Y?R/^-=-10!
MS/\ PCFK_P#0;E_(_P"-'_".:O\ ]!N7\C_C7344 <S_ ,(YJ_\ T&Y?R/\
MC1_PCFK_ /0;E_(_XUTU% ',_P#".:O_ -!N7\C_ (T?\(YJ_P#T&Y?R/^-=
M-10!S/\ PCFK_P#0;E_(_P"-'_".:O\ ]!N7\C_C7344 <S_ ,(YJ_\ T&Y?
MR/\ C1_PCFK_ /0;E_(_XUTU% ',_P#".:O_ -!N7\C_ (T?\(YJ_P#T&Y?R
M/^-=-10!S/\ PCFK_P#0;E_(_P"-'_".:O\ ]!N7\C_C7344 <S_ ,(YJ_\
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M .@W+^1_QH_X1S5_^@W+^1_QKIJKZCJ%OI.GW-]=RK!:VT3332MT1%!+$_0
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M6MM:\7>()HI=1GL0WV:%(@XBBB+@,P!DD8L57);&T;<D ;^V_P#L>ZS^U/\
M!Y= L?$45OK^F7BZEIIO0P@DD".C12,,E597/S '!"]LU\F_L5?\$MOB3\.?
MC/I7CGX@W>FZ%:^'Y6N+*TLKH7,UU/AE1B5^5$&=V2=QP!@9)'ZNT4 <S_PC
MFK_]!N7\C_C1_P (YJ__ $&Y?R/^-=-10!S/_".:O_T&Y?R/^-'_  CFK_\
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M_P (YJ__ $&Y?R/^-=-10!S/_".:O_T&Y?R/^-'_  CFK_\ 0;E_(_XUTU%
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M0!S/_".:O_T&Y?R/^-'_  CFK_\ 0;E_(_XUTU% ',_\(YJ__0;E_(_XT?\
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M_0;E_(_XUTU% ',_\(YJ_P#T&Y?R/^-'_".:O_T&Y?R/^-=-10!S/_".:O\
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M_P (YJ__ $&Y?R/^-=-10!S/_".:O_T&Y?R/^-'_  CFK_\ 0;E_(_XUTU%
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M0!S/_".:O_T&Y?R/^-'_  CFK_\ 0;E_(_XUTU% ',_\(YJ__0;E_(_XT?\
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MNCNK4G^&:%B'0]1DC!QP2.:^!OVH?^"-]_IIN]>^"6I'4K89D;PKJ\P6=?\
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MX%TGX8^!M!\):#"UOHVBV45A:1NVYA'&H4%CW8XR3W))KH:* "BBB@ HHHH
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MZQ;ZG?:GK5H]HK"WE63RX=X!E+E0H*94 DDX%?NG110 4444 %%%% !1110
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MT_[&;3/_ $JCK^FFOYEOV>O^2^_#3_L9M,_]*HZ_IIH **** "BBB@ HHHH
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MAHOA6.[8-<?V38QVYF(^[O*@%L9.,],G%=C110 4444 %%%% !1110 4444
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M^EUC7[4U^*W_  14_P"3I_%/_8F77_I=8U^U- !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MHH **** /*OVL?\ DUCXR?\ 8F:S_P"D,U?S65_2G^UC_P FL?&3_L3-9_\
M2&:OYK* /O\ _P""*G_)T_BG_L3+K_TNL:_:FOQ6_P""*G_)T_BG_L3+K_TN
ML:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MXW ]<DXQ7KOPS_:W^#GQAUJ'1_"'Q$T36-7G4M#IZSF*XE !)V1R!68@ D@
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M#SQOXETK1O%/@[5_!OV^9+?^T%NH[VUMW8@!I&Q&P0$\L%..N.N #]#****
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M_P""H?@S]IKXA1^"+SPW>>"O$-X)&TQ9[M;J"\V*69/,"(4DVJ6"E2#@@-G
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M;RRT>ZMHX8S(C;H_/=2?-"D E0$#$<\$J?OZB@ HHHH **** "BBB@ HHHH
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MZTK6[RYUS_A)O%NMK'%=7L<)A@@A0DB*)223ECEF)YPN ,<_5E 'Y%_LT?\
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MBO\ :W\6^%_$_@[Q'I.FW^FV+:;<6.NR31P-'YC2+)&T4<AW9=@05Y 7GC%
M'-_$/_@M1\+M!\V+PAX1\0^+;A/NR71CTZV?TPY,DGYQBOF+XA?\%FOC%XD,
MD7A?1/#G@^V;.R00/>W*_P# Y&\L_P#?NO6?A[_P1!'[J;QU\3B?^>EEX>T_
M^4\S?^TJ^G/AW_P2R_9X\ ".2;PG<^++N/&+GQ%?R3Y^L2;(C^*4 ?%'[ O[
M<'Q]^*/[5/A_P]KOB*[\::'K)E&J6<UI$L=K"L;'[0AC11#L8+TPK;MI&2I'
M['5S?@OX:^$OAO9-:>$_"^C>&;5@ T.D6$5JK8Z9$:C/XUTE !7@O[2_[%'P
MR_:NNM(O?&MI?Q:II<;0P:CI5R()C$3N,3DJP90Q)&1D$G!&3GWJB@#Y<\%?
M\$R_V<_!1CD3X?1:U<J0?/UJ]GN]V/6-G\O_ ,<KWOP?\+/!?P\C$?A;PCH7
MAM!QMTC38;7MC_EFHKJ** "BBB@ I",C!Y%+10!^2O[>7_!++6+?7M2^('P6
MTPZEIUY(UQJ'A&U4":U<\L]HO\:$Y/E#YE)P@8$*OYE:EIEYHU_<6.H6D]C>
MV[F.:VN8S')&PZJRL 01Z&OZGZX[QY\&O /Q2"?\)CX*\/\ BAHUVQR:OID-
MR\8_V6=25_ B@#^8BOH+]E[]B#XE_M2ZU;?V'I4ND^%/-"W?B?4(BEI"F?F\
MO.#,^.B)GDC<5!S7[EZ)^R/\$O#E\EYIWPF\&V]W&0R3?V);NT9'0J60[3[C
M!KUF.-(8UCC5410%55&  .@ H \W_9Z^ 'A7]FKX8Z;X*\)VQ2TM_P!Y<WDH
M'GWUP0-\\I'5C@<=  JC@"O2J** "BBB@ HHHH **** "BBB@ HHHH ****
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M6"1#N]<>8.G4T ?JM15/1]6M-?TBQU2PF%Q8WL"7-O,H($D;J&5AGGD$&KE
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&:OYK* /O_\ X(J?\G3^*?\ L3+K_P!+K&OVIK\5O^"*G_)T_BG_ +$RZ_\
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M\O5;&*Y7'IAU/%;]% 'SCXQ_X)V?LZ^-C(U[\+M*L9&R0^CR3:?M/J%@=%_
MC'M7DLG_  1O^ CZ];Z@MUXOCM8I%=M+75(C;R@')5B8#+@]#MD!QT(/-?=%
M% %?3M/MM)T^VL;.%+:SMHEAAAC&%C10 J@=@  *L444 ?.W[?NK_$O0OV8/
M%%[\*C?)XEC:'S9=*4M>Q6A<"9X H+;P,<KRJ[B,$ U^)WAK]LSX^?#VX,-C
M\4_%D#PD@VVI7\EVJ'N/+GW@?3'K7]'58'BGX?\ A?QS 8?$GAO2/$$)7;Y>
MJV,5RN/3#J>* /Q.\(?\%?/V@_#93^TKWP]XK //]K:2L9;C_IV:'Z_YQ7N?
M@7_@N!=K<V\/C+X7026[,!->:'J;(R#N5AE0[OH9%^M?:7C#_@GC^SMXV\PW
MOPMTBRD?)#Z.TNG[2>X$#HO'H1CVKR&]_P""-_P$NM9BO8KKQ?9VR.';3H-4
MB,$@!&5)>%I,'V<'G@B@#[3\(^*-.\<>%-%\1Z/,;G2=8LH=0LYBI7S(98UD
MC;!Y&58'%:U4-!T.P\,:'IVC:5:QV.EZ=;1VEI:Q#"0PQJ$1%]@H 'TJ_0 4
M5X?^VM=?$6R_9D\;S?"M;L^,UMH_LYTX$W:Q>:GGF #GS!%YFW;\W]WYL5^%
M-A^T[\>/AQJLL*?$KQQI-XA(DM+[5;D@'./FBE8C/&.10!_2-17X*>$O^"K?
M[1OA@JMSXLL?$4*\"+5M(MS^;1+&Y_%N_P!*]H\'_P#!;GQY9S0CQ3\._#NK
M0AAYITBXGLF*YYQYC3#./\^@!^P=%<M\+?B)IGQ;^'/AOQIHRS)I>NV$5_!'
M<+MD174'8X&1N4Y!P2,C@D<UU- !115#3M?TS5Y9HK#4;2]EA8K*EO.LC1D<
M$, 3@_6@"_1110!^#G[8'[#/QGT+]HGQE=Z5X'\0>,M'U_6;G4[#5M&L9+Q'
MCGE:0"4Q@^6ZE]K;PHRI(^4@U^JO_!/SX&^)/V>_V8_#WA;Q:1'KSSSW]Q9+
M('%EYK[A#N!() P6QQN9L9ZGZ.HH ^;OVUOVUM"_8X\(Z3=W6DR>)/$>M221
MZ;I$=P(%98]OF2R2;6VHN]1PI+%@!@9(XK]B'_@HQHO[7.OZGX6O_#K>$?%M
MI;M>PVRW7VF"\@#!6*.44JZEERI'(.03@@,_X*-_L0:M^UOX;\.:EX4U&ULO
M%OAWSUAMK]RD%[!+L+(7 .QPT8*G&#N8''!'G?\ P3I_X)S^*?V;O'U]\0?B
M!J%@-9^QR6&G:5IDQF6)9"/,EED*@;L+M55R,,23G H _0VODK_@JG_R8YX^
M_P"NVF_^E]O7T=\4?$M]X,^&?B[Q!I=I_:&I:3I%W?VMI@GSY8H7=$P.3N90
M..>:_FW^(?QT^(/Q7U35+_Q9XQUG6I-3DWW,-Q>R&!OF#*HBSL5%(!50 %P,
M 8% '#4444 %%%% !7]'O[%'_)H_PA_[%FQ_]%+7\X5?T>_L4?\ )H_PA_[%
MFQ_]%+0![717YC_\%8OVQ_B)\'_'/ASX=>!-8N?"L-SI2ZO?:K982YGWRRQI
M$DF,HJ^26)7!)8#. 0=[_@DW^UWX_P#CC<>+?!'CS4YO$KZ-:17]CK%TH-PJ
M%]CPRN,&3DJRLV6^^"2-H !^BUQ<16=O+//*D$$2EY)9&"JB@9))/  '>OG?
MPM_P4*^ 'C+XAQ^"]*^(5I-K$T_V:WDDMIHK6XER $CN&01L23@'=AC]TG(S
MZ%^TKX#UKXH? #X@>$_#MR+77-8T6YL[1BVT/(R$",MD;0_W"3T#$U_/_P"$
M/V3?C!XL^)%MX+LO 'B"SU\W(AD^V6$L$5K@C,DLK+M1!P=V<$8QG(R ?TE5
M^.G_  5$_;$^*GA_]H[5/AYX6\5:OX+T#P]!:E3H=W)9S7LLUND[2/+&0[ >
M:$"YV_(3C/-?K_H]I-I^DV5K<W+7EQ! D4ER_P!Z5@H!<^Y(S^->%_M(?L-?
M"G]J75+'5O&.F7=OKEG%Y":KI%Q]GN'BSD1R$JRN 2<;E)&3@C)H \:_X)1?
MM*^-OC_\*O%&G^.+R?6[_P ,WL,-OK=R/WMS#*C,(Y&Q\[H8S\QY(=<],GZ%
M_:L_9LT3]JOX/W_@?6;N73)#,E[I^I0IO:SND#!)-F0'&UW5ER,JYP0<$=!\
M#_@/X*_9V\#0^$_ VD+I6E)(9Y69S)-<S$ -++(>68@ >@      [;5=5LM#
MTR[U'4;N&PT^TB:>XNKF01Q0QJ"6=V/"J "23TQ0!^=?[*7_  2=7X$_%?3_
M (@>//&5CK:>'Y3>:=8Z?"\47FKDI-/(Y& G#;0,;@,M@8;Q'_@HO_P4CD^)
MSZG\+_A;?M#X/5FM]7U^W<AM5QPT,)'2W[%O^6G3[GW\3_@H3_P4EN_C?)J'
MP[^&MS-I_P /U8PW^J+E)M:P>5'=+?/\/5_XL#Y:\<_8B_8<\2?M<^+C/(9M
M$\ :;,HU36]G+G@FWM\\-*0>3R$!!;.55@"K^Q5^Q+XG_:Y\: ()M'\":?*!
MJ^OE.!T/D09X>9@1ZA 0S?PAOWK^&7PR\-?![P1I?A'PCI<.CZ%IL7EP6T0Y
M/=G=NK.QR68\DDDU)\.?ASX<^$O@O2O"?A/2H=&T'3(A%;VL X ZEF)Y9F.2
MS'))))))KI: "BBB@ HHHH **** "BBB@ HHHH ***KWM_:Z;#YMW<PVL6=N
M^9PBY],F@"Q16%I7COPUKFH?8=-\0Z5J%]@G[-:WL4LG'7Y58GBMV@ HHKS/
M]H#]HGP3^S-X%_X2OQQJ$EI8/.MK;6]K%YMQ=3$$A(TXR<*Q))  ')Z4 >F4
M5^>NJ?\ !:[X/P<:?X.\;7A&[)GM[2$>V,7#'!YZ@8]ZX[5?^"XGAZ$-_9OP
MGU.[.W(^UZU'!EL]/EA?CIS^E 'Z=T5^5>D?\%Q#<>([1=2^$JV.A/*JW#V^
MN&>YBC/#,H,"*Y')"G;GID=:_4ZSNXM0LX+J!M\$\:RQMC&5(R#^1H FHHKY
MV_;[^,'C3X&?LR>)/%?@* G7H)8(/MOD"86$3R!7N"C @XX4;@0"X)! Q0!]
M$T5_.?J'[>'[06IIMF^+7B5!NW_Z/=>2<\]T XYZ=*Y^?]J#XX^)IGMW^*WC
MV_:<[C;1^(+QE;'/$8DQQC/ [4 ?TH45_-SH.I_'_P 4ZU9W&D7GQ&U75'F4
M6\UK-?RRF0'Y=K DY&!],5_0M\'4\4)\)?!B^-F5_& T>T&L,N.;OR5\[..,
M[]V<<9SCB@#L*9--';0R2RR+%%&I=W<X50.223T%/KS3]I3X8:G\:?@-XX\#
MZ-J:Z/JFN:;):6]W(2(PQP=CD9(1\;&(!.UCP>E &'??MH? ?3IIHI_B[X.W
MPDAQ'K$,G(Z@;6.?PKG[S_@H1^SK8P^;)\5M$9<XQ")I6_[Y5":_*./_ (),
M?M'/=")O#&EQINQY[:U;; /7ABV/PS6O9?\ !'W]H*[E*2P>&;-0N?,GU;()
M]/D1CG\,<4 ?I;=?\%,_V:+.>**3XH6S-)]TQ:5?R*.<<LL!"_B12_MQ_%ZP
M@_81^(/C'PKJ]OJ.GZMI$=K9ZA9R!XYHKN:.W8HP[[96]P0?2OSLTW_@B_\
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M/Q \!O8Z[:7MC!:S:;=WBVTUH\0V_(7PC(P^;[P(8MQT)^3_ /AT_P#M)?\
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MF:S_ .D,U?S64 ??_P#P14_Y.G\4_P#8F77_ *76-?M37XK?\$5/^3I_%/\
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M& .T9!P*?\-OA-\./V:O!4VF>$]'TSP9X=C;S[B1I2H9L8WS32L6<X &YV/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0.M<7/\  'X87,SRS?#CPE+*YW,[Z':EF/J28^:[VB@#RB;]DSX(3HZO\'/
M/S@@D>&;(-S[B+(/O2^&/V4?@UX+UVSUK0_A?X4TS5K-Q+;7MOI4(E@<='1M
MN58=B.17JU% !1110!RWQ,^&'A;XQ^"]0\)^,M&@UWP_?A1/9SEE!P0RLK*0
MR," 0RD$=C7S!??\$E?V<KN)5B\.:M9,#DO!K5P2?;YV88_"OLBB@#XBO?\
M@CY^S[=1*L4/B:S8')>#5LD^WSQL,?A5&#_@C9\!8M2M+IKWQA-!"VY[)]4A
M$4X_NN1 ' _W64^]?==% %'0]%L?#6BZ?I&EVL=CIFGV\=I:VL(PD,2*%1%'
MH%  ^E7J** .-^,7PIT/XX_#+Q#X%\2+,=&UNV^SSM;N%EC(8,DB$@@,KJK#
M((RHR".*_.C4?^"&MC+-FP^,EQ;1<_+<^&UF;VY%TG\J_4FB@#\GK[_@AMJ$
M;J+/XQ6TZ8^8S^'&B(/L!<MFL^X_X(>^)5DA$'Q6TJ2,MB5I-(E0J/50)3N/
M7@D?6OUQHH \[_9[^#&G?L\_!KPO\/=+O9M1M-$MVC^V3J%>>1Y'ED?:"=H+
MR.0N3@$#)QFK/QY\(S^/O@?\0O#-I$9[O6/#VH6$$8ZM)+;R(@_[Z85W=% '
M\JY!4D$$$<$&BOL7_@I7^R-?_L\?&6^\2Z38M_PK_P 4W+W5A/&"4M+ELO+:
MN?X2&W,GJAP,E&Q\=4 %%%% !7] _P#P3-\*77A']B?X<07L30W-[#=:B5;_
M )YSW4LD3#V,;1G\:_&?]D']F#7?VJOC!IWAC3XI8="MW2YUS5$&%L[3=\Q!
M((\QL%47NW/16(_HKT+1+'PSHFGZ/I=LEGINGV\=I:VT?W8HHU"H@]@H _"@
M"]1110 4444 %%%% !1110 4444 >5?M8_\ )K'QD_[$S6?_ $AFK^:ROZ4_
MVL?^36/C)_V)FL_^D,U?S64 ??\ _P $5/\ DZ?Q3_V)EU_Z76-?M37XK?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** .<^(/P\\-_%7PAJ/A?Q9H]MKF@ZA
M'Y=Q9W295O1@>JL#R&4@J0"""*_*OX__ /!&#Q+I>HW.H_"'Q#:ZWI39==%U
MZ7R+R+_828+Y<@]V\O'OUK]=Z* /Y\9O^":?[2L%T8&^%UX7! RFI6+IS_M"
M<K^.:]M^"?\ P1L^*'BS4+:Y^(^IZ=X%T<-F>UMITOM08#LHC)A7/3<9#CKM
M/2OVAHH \[^!7P!\$_LY>!;?PIX'TE=.L$.^>XD(>YO)<<RS28!=C^  X4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 >5?M8_\FL?&3_L3-9_](9J_FLK^E/\ :Q_Y-8^,G_8F
M:S_Z0S5_-90!]_\ _!%3_DZ?Q3_V)EU_Z76-?M37XK?\$5/^3I_%/_8F77_I
M=8U^U- !1110 4444 %?.?[67[+<WQSCL=;T*[AM/$VGP&W$=T2(KJ'<6"%A
MG:REF(.,'<0<<$?1E?.7Q3_;'T_X-_%J]\*>(/#MY-ID=O#-#J%@ZM*V]<G,
M;;00#D9#?PG@T ?+NE?%;XX?LJ7-II.LP7::0AV0V&L1_:+1U'\,,RG@ =D?
M SR*^Z/@-\:]-^.W@9->L;=K&YBE-M>6+MN,$H . V!N4@@@X'7U!KY7_:8_
M;'\&?%+X6WWA;0-)U"YNKZ2(FYU"%(DM@DBON7#,2QVE>W#'GL?6/V#OAKJ_
M@3X67^H:S;RV4VMW8N8+68%76%5"JS*?NECN/TVGO0!VW[7G_)N/C;_KWB_]
M'QUX]_P3>_Y$GQC_ -A&+_T54'[3?[6G@;Q1\/\ QIX$L%U1]99S9"1[95@+
MQSKN.[?G'R''%>8_L@?M)^$O@=X<U^P\1QZBTU_=QS1&R@610H3:<Y88YH [
M;_@I5-+YWP^B(Q!MOV!]6S;@_D,?G7U!^SXJI\"_  7I_8=F>/7RES^M>'?M
M[>";KQ[\*_#OBS1H)+V#29&GE$:$LMM.BDR$=< HF?0$GH#7,? O]MKPEX'^
M#&FZ)K]O?G7=&MVMH8;>+>ETJY\K#YPG!"G/3;GOB@#S?X1QM;?M\7,=J.$\
M2:P@Q_<Q<@_^.YH^$TCW7[>T[W(Q*?$>K%E)Z,%N,#\"!6]^PYX.U7Q]\;-8
M^(U] R6=F;F4W&,))=W&047UPDCD^F5]:Y[XSVVI?L\?M<'QA-82SZ;/JAUB
MW<?*MS%)S.BMTW NZX[<$\$9 /K']MF))/V:?%C-]Z-K-E^OVN$?R)KA/^"<
MQE_X5%XA!_U(UQRO^]]GAW?IMKS?]J_]K?PO\5/AQ%X6\)K>SM>W$<UY+<P>
M4(T0[@@!.2Q;:>. %Z\U]%?L>_#:]^&7P0TRTU.%[74]1FDU.XMY!AHC(%"*
M1V/EHF1V)([4 >V5^3W_  7)+?VS\'05&S[/JV#GDG=:9_I^=?K#7Y0?\%RO
M^0K\&_\ KCJW_H5G0!^6U%%% !1110 5^EW[+'_!4;X9_LY?"+0_ $'PY\2&
MST_S'EO4U&"XEN)I'+R2$%8PN68@*.@"C).37YX?#WPI_P )YX^\->&?M7V'
M^V=3MM.^U>7YGD^=*L>_;D;L;LXR,XZBOT(U[_@B'XZMU/\ 8OQ)\/:@V.!?
MV<]J,\_W?-]OS/IR ?2.B?\ !9'X'ZKM^U6/B;1LGG[;8JV.3U\IY/K^-=]H
MO_!3_P#9_P!="^3XUM[=B.5O;>YM]IQG!,D('Y'%?G1X@_X(\_M :-N^QKX7
MU[&<?V?JQ3/3IYT<?K^A]L^;>(/^";?[2'ALM]H^%]]<J.C:?>VMWN&3R!%*
MQ[=",]..: /VAT']LGX5>)W5-*\<>&+Z5C@0PZY;F3KC[F[=^E>@Z=\0X]7M
MA<6-B][;MTEMY!(AXSU (Z$?G7\Z?B']F/XO^$PS:O\ "WQCI\:]9IM"N1'T
M'1]FT]1T-<*DFL>$=2RC7VBZ@G=2\$J\Y]B.0/Q% '].'_"87'_0'NOU_P#B
M:/\ A,+C_H#W7Z__ !-?SF^'?VI?C'X2"+I'Q3\8V,2\"%-<N3%_WP7*_I7J
M/AW_ (*:?M)>&PJ1?$F>^A'6/4=-L[C/7^)XBW?LWI0!^\/_  F%Q_T![K]?
M_B:/^$PN/^@/=?K_ /$U^-_A[_@LS\<])*KJ&E>#];C_ (C<:?-%)WZ&.=0.
MW\)Z5ZAX<_X+B:O"477OA-97@. TFG:T]OCIDA7A?/?C(^M 'Z@?\)A<?] >
MZ_7_ .)H_P"$PN/^@/=?K_\ $U\'^&_^"V?POO @UWP+XLTIVP&-C]FNT4\=
MVDC..O;/ XYP/5?#/_!6#]G'Q!L%UXJU'P^[X 34]&N3@\<$PI(HZ]2<<'F@
M#Z;_ .$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:\Z\,_MK? ;Q=Y8T[XM>$U
M>3 2.^U..S=B<8 68H<_,.,9Z^AKU30/&&@^*XO-T36].UF+&[?I]W'.N..<
MH3ZC\Q0!0_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_
M /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?
M_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^
MO_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\
MB:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W
M7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B
M:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7
MZ_\ Q-'_  F%Q_T![K]?_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_
M^)KIJ* .9_X3"X_Z ]U^O_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_
M /$T?\)A<?\ 0'NOU_\ B:Z:B@#F?^$PN/\ H#W7Z_\ Q-'_  F%Q_T![K]?
M_B:Z:B@#F?\ A,+C_H#W7Z__ !-'_"87'_0'NOU_^)KIJ* .9_X3"X_Z ]U^
MO_Q-'_"87'_0'NOU_P#B:Z:B@#F?^$PN/^@/=?K_ /$T?\)A<?\ 0'NOU_\
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M3"X_Z ]U^O\ \31_PF%Q_P! >Z_7_P")KIJ* .9_X3"X_P"@/=?K_P#$T?\
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M^F88D'_HROE_X??\$N_VB?'PBE?P9'X8LY.EQX@OHK?'UB4M*/Q2OI;X??\
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M^KZ* /R?^)/_  1VT:\:6?P#XNUK2SR4LO$%FMVI/IYL0C*C_@#&OE[XA?\
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M ,37344 <S_PF%Q_T![K]?\ XFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\
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MH_X3"X_Z ]U^O_Q-=-10!S/_  F%Q_T![K]?_B:/^$PN/^@/=?K_ /$UTU%
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MTU% ',_\)A<?] >Z_7_XFC_A,+C_ * ]U^O_ ,37344 <S_PF%Q_T![K]?\
MXFC_ (3"X_Z ]U^O_P 37344 <S_ ,)A<?\ 0'NOU_\ B:/^$PN/^@/=?K_\
M37344 <S_P )A<?] >Z_7_XFC_A,+C_H#W7Z_P#Q-=-10!S/_"87'_0'NOU_
M^)H_X3"X_P"@/=?K_P#$UTU% ',_\)A<?] >Z_7_ .)H_P"$PN/^@/=?K_\
M$UTU% ',_P#"87'_ $![K]?_ (FC_A,+C_H#W7Z__$UTU% ',_\ "87'_0'N
MOU_^)H_X3"X_Z ]U^O\ \37344 <S_PF%Q_T![K]?_B:/^$PN/\ H#W7Z_\
MQ-=-10!S/_"87'_0'NOU_P#B:/\ A,+C_H#W7Z__ !-=-10!S/\ PF%Q_P!
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MHHH ***QO$7C+P_X1A\[7==TW18<9\S4;N.W7'/.7(]#^1H V:*\-\4?MQ_
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M3>+)@/W;V=@MO Q]VG=' _X ?I7Y3^"/V./C?\1-C:%\+?$\\,@RES=:>]I
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M$$4GBWQEXC\43I]Z.S6+3[=S[KB1P/I(/K7Z)44 >!_#_P#8-^ /PT$3:/\
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MQX3\ 0>1X7\+Z-X;AV[?+TC3X;5<>F(U'%=%10 4444 %%%% !1110 4444
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MR6^H2R.UJ3MN(PODC=OB:1,9'WNHZT ?KM1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110!Y5^UC_P FL?&3_L3-9_\ 2&:OYK*_I3_:
MQ_Y-8^,G_8F:S_Z0S5_-90!]_P#_  14_P"3I_%/_8F77_I=8U^U-?BM_P $
M5/\ DZ?Q3_V)EU_Z76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5XW^UU\?[3]FGX!^)O&TK1MJ4,/V72;>3D3WT@*P
MKCN <NP_NQM7LE?BA_P5X_:1_P"%G?&JV^'.D77F>'_!>Y+KRV^6;4G \TGU
M\I=L?LWF^M 'P?J>IW>M:E=ZA?W$EW?7<SSSW$S;GED9BS,Q[DDDD^]5J**
M"BBB@#Z:_P"">7[2/_#-W[1VC7^H77D>%-=QH^M;FPD<4C#RYSZ>5)M8GKMW
M@=:_H-!R,CD5_*Q7[W?\$R/VD?\ A?W[.5AI^IW7G^*_"&S2-1WMEY8@O^C3
MGO\ -&NTD\EHG/>@#ZZHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RK]K'_DUCXR?]B9K/_I#-
M7\UE?TI_M8_\FL?&3_L3-9_](9J_FLH ^_\ _@BI_P G3^*?^Q,NO_2ZQK]J
M:_%;_@BI_P G3^*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** $(R" 2/<=J_*/6O^")GB+6M9O]0N?C':W=
MQ=W$D\EQ<Z([2RLS%BSGS^6).2?4U^KM% 'Y*_\ #CK7/^BMZ?\ ^"-__C]'
M_#CK7/\ HK>G_P#@C?\ ^/U^M5% 'Y*_\..M<_Z*WI__ ((W_P#C]'_#CK7/
M^BMZ?_X(W_\ C]?K510!^2O_  XZUS_HK>G_ /@C?_X_7T;^P[_P3NUK]D#X
ME:QXGN/B+'XALM1TMM/DTNVTYK='<R(ZR,3(V2NQ@,#/SGGJ#]NT4 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 >5?M8_\FL?&3_L3-9_](9J_FLK^E/]K'_DUCXR?]B9K/\
MZ0S5_-90!]__ /!%3_DZ?Q3_ -B9=?\ I=8U^U-?BM_P14_Y.G\4_P#8F77_
M *76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >5?M8_P#)K'QD
M_P"Q,UG_ -(9J_FLK^E/]K'_ )-8^,G_ &)FL_\ I#-7\UE 'W__ ,$5/^3I
M_%/_ &)EU_Z76-?M37XK?\$5/^3I_%/_ &)EU_Z76-?M30 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 >5?M8_\ )K'QD_[$S6?_ $AFK^:ROZ4_VL?^
M36/C)_V)FL_^D,U?S64 ??\ _P $5/\ DZ?Q3_V)EU_Z76-?M37XK?\ !%3_
M ).G\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E
M7[6/_)K'QD_[$S6?_2&:OYK*_I3_ &L?^36/C)_V)FL_^D,U?S64 ??_ /P1
M4_Y.G\4_]B9=?^EUC7[4U^*W_!%3_DZ?Q3_V)EU_Z76-?M30 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 >5?M8_\FL?&3_L3-9_](9J_FLK^E/]K'_D
MUCXR?]B9K/\ Z0S5_-90!]__ /!%3_DZ?Q3_ -B9=?\ I=8U^U-?BM_P14_Y
M.G\4_P#8F77_ *76-?M30 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 >
M5?M8_P#)K'QD_P"Q,UG_ -(9J_FLK^E/]K'_ )-8^,G_ &)FL_\ I#-7\UE
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?\:S/^$*TG_G@_\ W\;_ !H_X0K2?^>#_P#?QO\ &@#3_M.S_P"?N#_OXO\
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ML_\ G[@_[^+_ (T?VG9_\_<'_?Q?\:S/^$*TG_G@_P#W\;_&C_A"M)_YX/\
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M^>#_ /?QO\:/^$*TG_G@_P#W\;_&@#3_ +3L_P#G[@_[^+_C1_:=G_S]P?\
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MB_XT?VG9_P#/W!_W\7_&LS_A"M)_YX/_ -_&_P :/^$*TG_G@_\ W\;_ !H
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MH T_[3L_^?N#_OXO^-']IV?_ #]P?]_%_P :S/\ A"M)_P">#_\ ?QO\:/\
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MYX/_ -_&_P : -/^T[/_ )^X/^_B_P"-']IV?_/W!_W\7_&LS_A"M)_YX/\
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M$*TG_G@__?QO\: -/^T[/_G[@_[^+_C1_:=G_P _<'_?Q?\ &LS_ (0K2?\
MG@__ '\;_&C_ (0K2?\ G@__ '\;_&@#3_M.S_Y^X/\ OXO^-']IV?\ S]P?
M]_%_QK,_X0K2?^>#_P#?QO\ &C_A"M)_YX/_ -_&_P : -/^T[/_ )^X/^_B
M_P"-']IV?_/W!_W\7_&LS_A"M)_YX/\ ]_&_QH_X0K2?^>#_ /?QO\: -/\
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M )X/_P!_&_QH T_[3L_^?N#_ +^+_C1_:=G_ ,_<'_?Q?\:S/^$*TG_G@_\
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M_G[@_P"_B_XT?VG9_P#/W!_W\7_&LS_A"M)_YX/_ -_&_P :/^$*TG_G@_\
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M2?\ G@__ '\;_&C_ (0K2?\ G@__ '\;_&@#3_M.S_Y^X/\ OXO^-']IV?\
MS]P?]_%_QK,_X0K2?^>#_P#?QO\ &C_A"M)_YX/_ -_&_P : -/^T[/_ )^X
M/^_B_P"-']IV?_/W!_W\7_&LS_A"M)_YX/\ ]_&_QH_X0K2?^>#_ /?QO\:
M-/\ M.S_ .?N#_OXO^-']IV?_/W!_P!_%_QK,_X0K2?^>#_]_&_QH_X0K2?^
M>#_]_&_QH T_[3L_^?N#_OXO^-']IV?_ #]P?]_%_P :S/\ A"M)_P">#_\
M?QO\:/\ A"M)_P">#_\ ?QO\: -/^T[/_G[@_P"_B_XT?VG9_P#/W!_W\7_&
MLS_A"M)_YX/_ -_&_P :/^$*TG_G@_\ W\;_ !H T_[3L_\ G[@_[^+_ (T?
MVG9_\_<'_?Q?\:S/^$*TG_G@_P#W\;_&C_A"M)_YX/\ ]_&_QH T_P"T[/\
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M '\;_&@#3_M.S_Y^X/\ OXO^-']IV?\ S]P?]_%_QK,_X0K2?^>#_P#?QO\
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M +^+_C1_:=G_ ,_<'_?Q?\:S/^$*TG_G@_\ W\;_ !H_X0K2?^>#_P#?QO\
M&@#3_M.S_P"?N#_OXO\ C1_:=G_S]P?]_%_QK,_X0K2?^>#_ /?QO\:/^$*T
MG_G@_P#W\;_&@#6BO;>=]D=Q%(W]U'!-3UEZ?X;L-,N1/;Q,D@!&2Y/!K4H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** /*OVL?\ DUCXR?\ 8F:S_P"D,U?S65_2
MG^UC_P FL?&3_L3-9_\ 2&:OYK* /O\ _P""*G_)T_BG_L3+K_TNL:_:FOQ6
M_P""*G_)T_BG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH \J_:Q_Y-8^,G_8F:S_Z0S5_-97]*?[6/_)K'QD_[$S6?_2&:OYK* /O_
M /X(J?\ )T_BG_L3+K_TNL:_:FOQ6_X(J?\ )T_BG_L3+K_TNL:_:F@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH \J_:Q_P"36/C)_P!B9K/_
M *0S5_-97]*?[6/_ ":Q\9/^Q,UG_P!(9J_FLH ^_P#_ ((J?\G3^*?^Q,NO
M_2ZQK]J:_%;_ ((J?\G3^*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@#RK]K'_DUCXR?]B9K/_I#-7\UE?TI_M8_\FL?&3_L3-9_]
M(9J_FLH ^_\ _@BI_P G3^*?^Q,NO_2ZQK]J:_%;_@BI_P G3^*?^Q,NO_2Z
MQK]J: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RK]K'_DUCXR?]B9K
M/_I#-7\UE?TI_M8_\FL?&3_L3-9_](9J_FLH ^__ /@BI_R=/XI_[$RZ_P#2
MZQK]J:_%;_@BI_R=/XI_[$RZ_P#2ZQK]J: "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@#RK]K'_DUCXR?]B9K/\ Z0S5_-97]*?[6/\ R:Q\9/\ L3-9
M_P#2&:OYK* /O_\ X(J?\G3^*?\ L3+K_P!+K&OVIK\5O^"*G_)T_BG_ +$R
MZ_\ 2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH **I:UK5AX<TJYU/5+R#3]
M/MD,DUS<R!(XU]23P*^!?VM/VGM#^(^J>%+3P7K>JPV.FSS27]U;"2V\S<8@
MA3E6) 63J!U&* /T'HKA/A-\;/"?QKTNZO?"]\]Q]D94NK>>(QRP%LE=P/&#
MM.""1P>>#5+XQ_'_ ,(? ZQ@E\17<K7ERI:WTZS3S+B8#J0"0%&>,L0* /2*
M*^7O#G_!0CX=ZQJD-I?Z?K.BPR$+]LN(8Y(DYZML<L![@&OINSO(-0M(+JUF
MCN+:=%EBFB8,DB,,JRD<$$$$&@":BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH \J_:Q_Y-8^,G_8F:S_ .D,U?S65_2G^UC_ ,FL
M?&3_ +$S6?\ TAFK^:R@#[__ ."*G_)T_BG_ +$RZ_\ 2ZQK]J:_%;_@BI_R
M=/XI_P"Q,NO_ $NL:_:F@ HHHH **** "BBB@ HHHH **** /E?_ (*(W6I0
M?!_1XK5G73YM71;S82 V(I&16]5W#//=5]JY7]C;2O@OXJ^'5KI.K:7H-[XU
M:65;R'68HY)YLN=AA\P<KLVC"<@@YZY/UWXL\):1XY\/7NAZ[8Q:CI=XFR:W
MEZ$9R"".000"".00"*^+/BS_ ,$]+C3;6[U/P%K3WHB5I5TC4@!*<<[8Y5P&
M/8!E';YJ /K+X<_!?PC\)K_6[KPKIG]E?VN8C<PI*SQYCW[=H8G;_K&X''-?
M"FLP+^T+^V[+I&KYETL:M-8^2KD VMHKDJ#U <0L3CNYKT3]@OX[^(=<\27?
M@/7;^;5;(6;75A/=.9)8&1E#1;CR4*MD GY=F!UKSSX!XTC]N9X+ELNNLZO;
MEFZ[]EP/U/'XT >P?MQ_!'PIHGPCM?$&@>']/T2]TN\BB=].MD@$D#Y4JX4#
M=ABA!/(Y]:[_ /87\5W'B?X 6$-RV]](O)M.5\Y)1=LB@_02A?H!3OVZ[B.#
M]G76$=MK37=HB#U/FJV/R4_E7/\ _!/&R>V^!^I3,3MN=<GD4'I@0P+_ #4T
M ?4-%%% !1110 45R?V[6M8U2_BL+F&VCM9/+*NH.>2,_=/I4WV#Q1_T$K7_
M +Y'_P 10!TU%<S]@\4?]!*U_P"^1_\ $4?8/%'_ $$K7_OD?_$4 =-17,_8
M/%'_ $$K7_OD?_$4?8/%'_02M?\ OD?_ !% '345S/V#Q1_T$K7_ +Y'_P 1
M1]@\4?\ 02M?^^1_\10!TU%<S]@\4?\ 02M?^^1_\11]@\4?]!*U_P"^1_\
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MTU%<S]@\4?\ 02M?^^1_\11]@\4?]!*U_P"^1_\ $4 =-17,_8/%'_02M?\
MOD?_ !%'V#Q1_P!!*U_[Y'_Q% '345S/V#Q1_P!!*U_[Y'_Q%'V#Q1_T$K7_
M +Y'_P 10!TU%<S]@\4?]!*U_P"^1_\ $4?8/%'_ $$K7_OD?_$4 =-17,_8
M/%'_ $$K7_OD?_$4?8/%'_02M?\ OD?_ !% '345S/V#Q1_T$K7_ +Y'_P 1
M1]@\4?\ 02M?^^1_\10!TU%<S]@\4?\ 02M?^^1_\11]@\4?]!*U_P"^1_\
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M_P#$4?8/%'_02M?^^1_\10!TU%<S]@\4?]!*U_[Y'_Q%'V#Q1_T$K7_OD?\
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M'V#Q1_T$K7_OD?\ Q% '345S/V#Q1_T$K7_OD?\ Q%'V#Q1_T$K7_OD?_$4
M=-17,_8/%'_02M?^^1_\11]@\4?]!*U_[Y'_ ,10!TU%<S]@\4?]!*U_[Y'_
M ,11]@\4?]!*U_[Y'_Q% '345S/V#Q1_T$K7_OD?_$4?8/%'_02M?^^1_P#$
M4 =-17,_8/%'_02M?^^1_P#$4?8/%'_02M?^^1_\10!TU%<S]@\4?]!*U_[Y
M'_Q%'V#Q1_T$K7_OD?\ Q% '345S/V#Q1_T$K7_OD?\ Q%'V#Q1_T$K7_OD?
M_$4 =-17,_8/%'_02M?^^1_\11]@\4?]!*U_[Y'_ ,10!TU%<S]@\4?]!*U_
M[Y'_ ,11]@\4?]!*U_[Y'_Q% '345S/V#Q1_T$K7_OD?_$4?8/%'_02M?^^1
M_P#$4 =-17%3W/B*WU6"P:_A,TR[E8(NT#GK\GL:O_8/%'_02M?^^1_\10!T
MU%<S]@\4?]!*U_[Y'_Q%'V#Q1_T$K7_OD?\ Q% '345S/V#Q1_T$K7_OD?\
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M%'_02M?^^1_\10!TU%<G]NUK1]4L(K^YAN8[J3RPJ*!CD#/W1ZUUE !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH YFT_Y'R]_P"O<?R2NFJ!;&W2[>Z$2BX8;6D[D<?X"IZ
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** .9U/_D=],_ZXG_V>NFJ![&WENH[EHE:>,860]0.?\34] !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M ',^*_\ D,Z!_P!?'_LR5TU07%C;W<L,DT2R/"=T;'^$\=/R%3T %%%% !11
M10 4444 %%%% !1110 4444 >5?M8_\ )K'QD_[$S6?_ $AFK^:ROZ4_VL?^
M36/C)_V)FL_^D,U?S64 ??\ _P $5/\ DZ?Q3_V)EU_Z76-?M37XK?\ !%3_
M ).G\4_]B9=?^EUC7[4T %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#*P'0;6]: /MRBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M%GX]^($5Q9Z-=78M=/LY_P!RB%D9\Q0=57:GWVY;CENH^L?^">/_ "0W4?\
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MK]J:_%;_ ((J?\G3^*?^Q,NO_2ZQK]J: "BBB@ HHHH **** "BBB@ HHHH
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MV\;2S32L%2-%&69B>@ !)- %3Q'XCTWPCH5]K.KW<=CIME$9I[B4X"*/YD]
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MLJ0QO)(ZQQH"S.QP% ZDF@"OJFJ6>B:;=:AJ%S%9V-K&TT]Q,P5(T49+$GH
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M^PC:_P#H1KC_ /@G!_R3SQ7_ -A5/_1*UV'[>O\ R;Y=_P#81M?_ $(UQ_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MWZBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M? +X877P=^%VE>%;S4(]3N+1YG:>)2J?/*S@ 'GC=^>:]#HH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** /*OVL?\ DUCXR?\ 8F:S_P"D,U?S65_2G^UC
M_P FL?&3_L3-9_\ 2&:OYK* /O\ _P""*G_)T_BG_L3+K_TNL:_:FOQ6_P""
M*G_)T_BG_L3+K_TNL:_:F@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_P ./BQX4^+>F76H>$]5&K6EK-Y$TGV>6$H^T-C$BJ3P1R!BNNKY$_X)P?\
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M>:8*>A,<:LP![$CF@#O:*X_P#\7_  ;\4!-_PB_B&SU>2%0\L,1*RHI. 2C
M,![XJ?Q]\4/"WPOLK:[\4ZS!H\%RYCA:8,QD8#) "@DXSZ4 =315'1-;L/$F
MD6FJ:9=1WNGW<8F@N(3E9$/((KEO"OQL\#^-_$MUX?T/Q'::EK%L',EK$&R
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MA@D>-[$$<@+D59^'WQI\$?%1Y8_"WB*TU:>)/->W7=',J9QN,;A6QD@9QW%
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M/.9)Q+913N&)$C"1<DD]<L,\U\Q?L\?L@0_'KX?77B'_ (2E]#GAU"2R$/V
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MV)$",2%)&,\D$#'>@#OJ*Y?P%\3O"WQ/L+B]\+:S!K%O;N(YFA#*8V(R 58
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M<&RUETUK4(C.&RT%QY:7 50ZY7  &Z)\ #% 'RO_ ,/1_P!IW_HIO_E TO\
M^1J/^'H_[3O_ $4W_P H&E__ "-7ZJ?\.N/V8O\ HF7_ )7]4_\ DFC_ (=<
M?LQ?]$R_\K^J?_)- 'Y5_P##T?\ :=_Z*;_Y0-+_ /D:C_AZ/^T[_P!%-_\
M*!I?_P C5^JG_#KC]F+_ *)E_P"5_5/_ ))H_P"'7'[,7_1,O_*_JG_R30!^
M5?\ P]'_ &G?^BF_^4#2_P#Y&K[M_P""87[=7Q$_:2\8>)/!/Q"-MK%UI^E_
MVK;:W;VB6SX66.)XI5C 0D^:K*55<;7SGC'L_P#PZX_9B_Z)E_Y7]4_^2:]<
M^"7[-'PR_9SL]0M_AWX3MO#BZ@RM=2K-+<33;<[0TLSNY49.%W8&3QS0!Z=1
M12,P12S$*H&22< "@#X<_P""B?CN34-8\*^!+)C(R ZE<Q(<[I')CA7Z@>8?
M^!BNG_:3^$FEV/[)NBZ3875I/J/A"*"?]S*I:7(VW)'/0ES(?]RO [+PY/\
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M0 '^=?/?P8?PK\&OC'K&@_%O0+>\L8E>QF:YM?M"VLRN"LP7!+(0#RH)(8$
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M_7 ]!7UK\#O^3?\ P1_V+UI_Z(6OC?\ X)S?\E?\0?\ 8"D_]*(* /;?B/\
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M7YA_#*RTRP_:_P!#M_A=>WE]X?358O)N&#!VM2JFY!R 2@4RJ"1R ":_3R@
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MF4ID_P!W?C\*XFO6OVN;6"Q_:E^+=M;0QV]M#XJU*.*&)0J(HN7 50.  !@
M5Y+0 5^ZO_!.KQ0?!'_!.+1/$8M7OCI%GK>H?94.&F\J[NI-@X/)VXZ=Z_"J
MOWQ_X)81)/\ L,>!(Y$62-Y=35D89# W]QD$=Q0!^5%[_P %(OV@[KXB/XM3
MX@7MNQN/.718U7^S53.1#]G(VE<?+D_-WW9YK]X_A/XU?XE?"WP=XNDLSI\F
MO:/9ZHUH23Y)FA20ID\G&['X5\LW?_!)#X 7?Q!;Q.;'78K-I_M#>&XM05=,
M)SDJ%\OS0A/\(E  X&!Q7V9:VL%C:PVUM#';VT*".*&)0J(H& J@<  #  H
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MJ&.1TX&*]Z^+^O7?B?\ 8!75+Z0S7MQI6EM-*W5W%U;@L?<D9_&N?_X*2?\
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MZ=ZX3]CC]J3P?\,O =YX6\87DNE>5>/<VMVMM)-&Z.!E"(U9@P92<XP0P]*
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M](9J_FLK^E/]K'_DUCXR?]B9K/\ Z0S5_-90!]__ /!%3_DZ?Q3_ -B9=?\
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M,P=E +$ %E!P .@]*ZS4],M-:TZYL-0MHKVRN8VBFMYT#I(A&"K \$$5:HH
MX+P3\"/ /PYUF35O#GABSTO4I$,9N(R[,JGJ%W,=N?;%.UCX&>!/$'C:/Q=J
M/ANUN_$2213+?2,^=\8 C8KNVD@*O4=A7=T4 %<E\0/A/X2^*<%E#XJT2#6$
MLV9[?S6=3&6 #8*D'G R/8>E=;10!QUS\'O!=[X,M/"=SX<L;GP]9C%M93IY
M@AY)RC$EE.2>0<\FN+L/V//@]IMXMS%X*MWD4[@L]Y<S)USRCR%2/;%>RT4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'E7[6/_ ":Q\9/^Q,UG
M_P!(9J_FLK^E/]K'_DUCXR?]B9K/_I#-7\UE 'U__P $O_CWX$_9V^/NO^)/
MB%KO_"/Z+=>&;C3X;G['/<[IVNK214VPH[#*Q2')&/EZY(S^G_\ P]'_ &8O
M^BF_^4#5/_D:OQ%_:'\-:;X/^._Q T31[5;+2M/UR[MK6V5F811K*P5022<
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MS%_T4W_R@:I_\C4?\/1_V8O^BF_^4#5/_D:OP#P*,"@#]_/^'H_[,7_13?\
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MF+_HIO\ Y0-4_P#D:OP#P*,"@#]_/^'H_P"S%_T4W_R@:I_\C4?\/1_V8O\
MHIO_ )0-4_\ D:OP#P*,"@#]_/\ AZ/^S%_T4W_R@:I_\C4?\/1_V8O^BF_^
M4#5/_D:OP#P*,"@#]_/^'H_[,7_13?\ R@:I_P#(U'_#T?\ 9B_Z*;_Y0-4_
M^1J_ / HP* /W\_X>C_LQ?\ 13?_ "@:I_\ (U'_  ]'_9B_Z*;_ .4#5/\
MY&K\ \"C H _?S_AZ/\ LQ?]%-_\H&J?_(U'_#T?]F+_ **;_P"4#5/_ )&K
M\ \"C H _?S_ (>C_LQ?]%-_\H&J?_(U'_#T?]F+_HIO_E U3_Y&K\ \"C H
M _?S_AZ/^S%_T4W_ ,H&J?\ R-1_P]'_ &8O^BF_^4#5/_D:OP#P*,"@#]_/
M^'H_[,7_ $4W_P H&J?_ "-1_P /1_V8O^BF_P#E U3_ .1J_ / HP* /W\_
MX>C_ +,7_13?_*!JG_R-1_P]'_9B_P"BF_\ E U3_P"1J_ / HP* /W\_P"'
MH_[,7_13?_*!JG_R-1_P]'_9B_Z*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?]%-
M_P#*!JG_ ,C4?\/1_P!F+_HIO_E U3_Y&K\ \"C H _?S_AZ/^S%_P!%-_\
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M/^'H_P"S%_T4W_R@:I_\C4?\/1_V8O\ HIO_ )0-4_\ D:OP#P*,"@#]_/\
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M;_Y0-4_^1J_ / HP* /W\_X>C_LQ?]%-_P#*!JG_ ,C4?\/1_P!F+_HIO_E
MU3_Y&K\ \"C H _?S_AZ/^S%_P!%-_\ *!JG_P C4?\ #T?]F+_HIO\ Y0-4
M_P#D:OP#P*,"@#]_/^'H_P"S%_T4W_R@:I_\C4?\/1_V8O\ HIO_ )0-4_\
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M?\/1_P!F+_HIO_E U3_Y&K\ \"C H _?S_AZ/^S%_P!%-_\ *!JG_P C4?\
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M#]_/^'H_[,7_ $4W_P H&J?_ "-1_P /1_V8O^BF_P#E U3_ .1J_ / HP*
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M_P"1J_ / HP* /W\_P"'H_[,7_13?_*!JG_R-1_P]'_9B_Z*;_Y0-4_^1J_
M/ HP* /W\_X>C_LQ?]%-_P#*!JG_ ,C4?\/1_P!F+_HIO_E U3_Y&K\ \"C
MH _?S_AZ/^S%_P!%-_\ *!JG_P C4?\ #T?]F+_HIO\ Y0-4_P#D:OP#P*,"
M@#]_/^'H_P"S%_T4W_R@:I_\C4?\/1_V8O\ HIO_ )0-4_\ D:OP#P*,"@#]
M_/\ AZ/^S%_T4W_R@:I_\C4?\/1_V8O^BF_^4#5/_D:OP#P*,"@#]_/^'H_[
M,7_13?\ R@:I_P#(U'_#T?\ 9B_Z*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?\
M13?_ "@:I_\ (U'_  ]'_9B_Z*;_ .4#5/\ Y&K\ \"C H _?S_AZ/\ LQ?]
M%-_\H&J?_(U'_#T?]F+_ **;_P"4#5/_ )&K\ \"C H _?S_ (>C_LQ?]%-_
M\H&J?_(U'_#T?]F+_HIO_E U3_Y&K\ \"C H _?S_AZ/^S%_T4W_ ,H&J?\
MR-1_P]'_ &8O^BF_^4#5/_D:OP#P*,"@#]_/^'H_[,7_ $4W_P H&J?_ "-1
M_P /1_V8O^BF_P#E U3_ .1J_ / HP* /W\_X>C_ +,7_13?_*!JG_R-1_P]
M'_9B_P"BF_\ E U3_P"1J_ / HP* /W\_P"'H_[,7_13?_*!JG_R-1_P]'_9
MB_Z*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?]%-_P#*!JG_ ,C4?\/1_P!F+_HI
MO_E U3_Y&K\ \"C H _?S_AZ/^S%_P!%-_\ *!JG_P C4?\ #T?]F+_HIO\
MY0-4_P#D:OP#P*,"@#]_/^'H_P"S%_T4W_R@:I_\C4?\/1_V8O\ HIO_ )0-
M4_\ D:OP#P*,"@#]_/\ AZ/^S%_T4W_R@:I_\C4?\/1_V8O^BF_^4#5/_D:O
MP#P*,"@#]_/^'H_[,7_13?\ R@:I_P#(U'_#T?\ 9B_Z*;_Y0-4_^1J_ / H
MP* /W\_X>C_LQ?\ 13?_ "@:I_\ (U'_  ]'_9B_Z*;_ .4#5/\ Y&K\ \"C
M H _?S_AZ/\ LQ?]%-_\H&J?_(U'_#T?]F+_ **;_P"4#5/_ )&K\ \"C H
M_?S_ (>C_LQ?]%-_\H&J?_(U'_#T?]F+_HIO_E U3_Y&K\ \"C H _?S_AZ/
M^S%_T4W_ ,H&J?\ R-1_P]'_ &8O^BF_^4#5/_D:OP#P*,"@#]_/^'H_[,7_
M $4W_P H&J?_ "-1_P /1_V8O^BF_P#E U3_ .1J_ / HP* /W\_X>C_ +,7
M_13?_*!JG_R-1_P]'_9B_P"BF_\ E U3_P"1J_ / HP* /W\_P"'H_[,7_13
M?_*!JG_R-1_P]'_9B_Z*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?]%-_P#*!JG_
M ,C4?\/1_P!F+_HIO_E U3_Y&K\ \"C H _?S_AZ/^S%_P!%-_\ *!JG_P C
M4?\ #T?]F+_HIO\ Y0-4_P#D:OP#P*,"@#]_/^'H_P"S%_T4W_R@:I_\C4?\
M/1_V8O\ HIO_ )0-4_\ D:OP#P*,"@#]_/\ AZ/^S%_T4W_R@:I_\C4?\/1_
MV8O^BF_^4#5/_D:OP#P*,"@#]_/^'H_[,7_13?\ R@:I_P#(U'_#T?\ 9B_Z
M*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?\ 13?_ "@:I_\ (U'_  ]'_9B_Z*;_
M .4#5/\ Y&K\ \"C H _?S_AZ/\ LQ?]%-_\H&J?_(U'_#T?]F+_ **;_P"4
M#5/_ )&K\ \"C H _?S_ (>C_LQ?]%-_\H&J?_(U'_#T?]F+_HIO_E U3_Y&
MK\ \"C H _?S_AZ/^S%_T4W_ ,H&J?\ R-1_P]'_ &8O^BF_^4#5/_D:OP#P
M*,"@#]_/^'H_[,7_ $4W_P H&J?_ "-1_P /1_V8O^BF_P#E U3_ .1J_ /
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M_P#(U'_#T?\ 9B_Z*;_Y0-4_^1J_ / HP* /W\_X>C_LQ?\ 13?_ "@:I_\
M(U'_  ]'_9B_Z*;_ .4#5/\ Y&K\ \"C H _?S_AZ/\ LQ?]%-_\H&J?_(U'
M_#T?]F+_ **;_P"4#5/_ )&K\ \"C H _?S_ (>C_LQ?]%-_\H&J?_(U'_#T
M?]F+_HIO_E U3_Y&K\ \"C H _;S]H7_ (*/?L[>.?@%\2_#>B?$/[;K6L>&
M=3T^QMO[$U&/SIY;62.--SVX5<LP&6( SR0*_$&G8%?>'[#?[.GPZ^*_P>OM
?9\5^&HM7U*/69K99WN9HR(UBA8+A'4=68].] '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>image_0.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_0.jpg
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MDW7C$%SG/OKHHWS\\<>DIJ9JSVBWVW6'-.QV.R^\\ (??O@AHT>/;O5,!+\
M&1D9O/WVV_S^][_7/@N"60>KU8K#X<!FLVG9!X?#07)R,KV2>^'W^SERY$B;
M8U\L'3Y^5N<7//M- W^O4L\>L) DNEH"O)\6R2W=.I;V 1 !'^XU+V/Y:CFJ
MSX?=(D%L(HR;C>FZ<:'F$$RAM%Q+V6PV1HT:=4$_1#IPX ![]^[5?B"5D)#
M\.'#L5@LJ*K*%U]\06UM+;(L(X3 9#*1F9EYWJ0WP<3RCAT[*"TMI;&Q$9/)
M1&)B(IF9F?3ITP>/Q\.77WZ)VWTVA>5P.!@^?+AN6Y/@3'3@P &*BXNUTSK-
M AHT:!!VNYVBHB*JJZN191E554E/3V^5+">8%MNU:Q=??_VUEJNUV6ST[]^?
M(4.&M/D_'3MVC&W;MFGG1*^^^FHR,C*P6"Q45%9BELTH2H"33B=]>O>^H,_\
M?'18D #U <%K1QI9<ERE1C&!\#'05,<; ^/)3#RW7WJA!-PNW)O?1]KQ(8Y
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>:1!6&((T""O^'[:]Q=.\5E?E     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>image_01.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_01.jpg
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MDW7C$%SG/OKHHWS\\<>DIJ9JSVBWVW6'-.QV.R^\\ (??O@AHT>/;O5,!+\
M&1D9O/WVV_S^][_7/@N"60>KU8K#X<!FLVG9!X?#07)R,KV2>^'W^SERY$B;
M8U\L'3Y^5N<7//M- W^O4L\>L) DNEH"O)\6R2W=.I;V 1 !'^XU+V/Y:CFJ
MSX?=(D%L(HR;C>FZ<:'F$$RAM%Q+V6PV1HT:=4$_1#IPX ![]^[5?B"5D)#
M\.'#L5@LJ*K*%U]\06UM+;(L(X3 9#*1F9EYWJ0WP<3RCAT[*"TMI;&Q$9/)
M1&)B(IF9F?3ITP>/Q\.77WZ)VWTVA>5P.!@^?+AN6Y/@3'3@P &*BXNUTSK-
M AHT:!!VNYVBHB*JJZN191E554E/3V^5+">8%MNU:Q=??_VUEJNUV6ST[]^?
M(4.&M/D_'3MVC&W;MFGG1*^^^FHR,C*P6"Q45%9BELTH2H"33B=]>O>^H,_\
M?'18D #U <%K1QI9<ERE1C&!\#'05,<; ^/)3#RW7WJA!-PNW)O?1]KQ(8Y
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>:1!6&((T""O^'[:]Q=.\5E?E     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>image_02.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_02.jpg
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M15%E38[G^:RL+(52Z7*Y/-9+ ( @" 4%!800M]OMU10<PNSL;(B0V^WV>#,
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MSO.X" ! ")G,)@" 3JM#$-5LRF88YN+%BS_^\$-<7%S__OU;M6[M33E8K!9
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MU;-7K[(K+5K6L26CVD<CZ(<>-$Z7Z_SY\[DY.<'!P1 A+(K20E)H:&A\?#P
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MIE$C)<('8B;\K<D'5K@F+Y'UC$"BL+!PZ3M+/OUDS4LOOKA_W_[*-_A5@ZE
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MV+AAPXX=_WK]"P@A@ C!DH5*!$J&X-*%2WAUY;/D-U>'L:M%73H]*=U643J
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MEQVR#DJ_+CO>6/H'0(!*-5=05L80EJ@(Y4XQ+JE;)1L$2.E1[*4[G@C!& -
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MS\?5A?^-C$S-8%'$.%![SNJHG9[!<=R)X\<S,S/5JJO[]2F* A   @@A9:H
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M2 4"GN-.GSZ3FYO;OV\?E4I56%A8\@T$G3JT3TE)W;1Q,\]Q$ ! @-31(X0
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MM-2TXN)B &';-FTHJJ+EB::H9Y]_CA"R>=,FFJ%'C1E# .!YKKBXZ,*%"Q!
M"$%*2LJB-]_B..Z#CSX<.FR83J>KD$AH:"A"5.4=:Q#"GCU[OOG66V\N6/#.
MVXM=3M>H,6,PP1^^]_Z?O__!*EB$D&3/,YN,-]UR"U>JBU= J5)V[M*E,P#]
M!PR8,G6JW6'/RLC8N6-G>GIZ07Z^S6YW.9T.AR,[.SLU-552.Q0*A4:C4:O5
M6JU6K=%0"/7IU^_Y:\TPM840LF?W[D]7K[;9[&ZWVVZW6RT6N]WN<#HXEQL3
M0C,,RS!*I3(T+%2I5.GU^I:M6G;LV*E[C^YZ@\%@,(1'A%.H>F=/",UFTYE3
MIQ8O6I23G2TI7H(@((2Z=.D\<O3HZY;<&Y1*Y:R77T:(^GWKUN>>>OJ-^?.Z
M=NO6\)8ACXBB>.# @94K5B1=NB2))PA"<$C(]S_]Z,^Z48-AL]L7+UJT=_<>
MGN>E\SLQQIE9F?][]-%6OO;S)00(@I"<E)23G8U+3ORHU!.6ZR6]YFK'6$4_
M#FOX0?E+,#4E9=?.G6ZWFV$80@C#,"J5"F-<\X*#9SW#;K,IE<JRMJ10*(X?
M.W;3^/'2GP@ABJ(D\\.FC1M)N;,E15$$ /SS]]\  $$0(01[_]N%* I!6+9M
M%4C>@J5_4#0- #AYXN31(T>EG],T#2'\Y^]_:(I:LGCQ!^^]I]5JWY@W]^9;
M;ZVK]UI/2+%6)"NW5(\)(2JU^KMOOOGQN^](^;=86JVE^EW^7W#M ECI9^F.
MJ\^"Y1(ISS6/(*3D7P! E36T4DTINU#!8^;J?TJ_N'J#%"H$(9[G15'\XK//
MOUG[5=F7TO,%4=#I=-+6:%$4Q=*A=]6''WVRZF- "$2HI @0A !""*7BJK),
MRLE64;3R "FX2Y6E!*$4?2XK,[.ZG1JAH:%O+GI+Q.*:3]9\LNICG4Y'4=07
MGW[^^9K/)$N^Q6S1&_0KWEUYT\TW5YF"5J=-;-\N.B:FRF^;-6\VYXW7S1;+
MVXL6??3AAS1-NUPN1*'RY?/]=]]M6+>^K(575_$T&DV;MFT  -VZ=9MX\\T
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M'1I8&/^A;#%:%,6MOVU=LWHUA9!.IX,0L@S+B[PHB 1C1%,LS8B2M1^61!&
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MB(B,_'3UFM4??VPRF4:.&MFO?W_I!JO%$A;N7YMK*(I*:-$20IB3D]VQ4R<
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MK;>2+B?->?VU^V?,:*JSN&O*A!!25@H,P\A!CYLB37D"30A-^T6OA1"B&1H
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MW?K??OV-$*Q2JR $%$7_LWU[6'A80D*"4J52J]5=NW8M[\QX\<)%D]DT8.#
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M*%Z\<''.[-G%1N,;\^9-O.5F""'&6'+(O8[.@V79KMVZ;OEY2W9V=O/H:
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MT\9-?_RV-28FIO*1]!*[=NSLT;/'F''C*K1\"&'KUJW'C1^7G9UE*C92%$4
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M]L4.81"S+2%AT:^_AGK@*"<YG5GZPEG#T*!Z1N3A<KG6KUNG-; ]K -X@-<
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M]^IKK^G=IT]G9P$"L&7+EHAH'4*A= <^KQ?C0.68N]8S9%GV>#R2*(7Z6"@
M   A+"\M?>"^^UB."[BB$(C0M==>.V["A'8?E)>7O_;JJRZGLZ:Z1A"$J*@H
MCN<:;3:=3O?KS[^L6[-&LPKX-7S^)^;/'SUZS"6770H P)BHJJH5[3Y06)"7
MM_^_+[^2D)C0H=]$@^78JHI*CN/,9O.>W7L:&QN/;%I!""DH*&BM!0XA3$A(
MT,I4=(:J8EX0",8LPT (HRS1,3$Q =9CO5[/\SS1CB$(/</C\7C<;D)(D\UF
M:VPL*X,0[M)R:%N$!@  B"##,! A!"&""#%(JS,&(?3[_;(LRY)TH+"PZ.#!
MYC 9HATO(  33  AF!!,,,"  ((0TM(B,,:2)#E=+DD^JOL.PA-=2?.D 2($
M(=1*;Z6DI@:NGQ$5%84@8EE64V23DI/CXN(";)^0D!#A5B0*Y=CQ>+PXH)VX
M:SU#I]?'Q<<??PP=Y41A,IO/&#=.$ )-E 00!%%24M*1'QF-QC%CQXJBN'/[
MCMV[=@\<-&C P('??O.-)/H'#!RHQ=5# "59JJNK5S$>/F)D:TAF:Z(* " J
M*LIJL0X=-JQ7KUX!+C*$X)X]>_/S\_OEYI:4%-?7U1^I9\BR7%)<'!<71PB!
M"(FB^/%''RU=NK2S$N$,P]B;FLI*2RT6B]OE$D5QZ=]_-]F: OA-?%YO944%
M@E -SKZM!48HJC)Y\I318\=(DM3."M+21J2E/1II^0> PH+"W;MVQ2<D.!V.
MHJ*BP8,'CQHSYI PG;QJ_;_VMJPH@L"/''ETO9$9A"+=;](=0 AE411%<<.Z
M]0" IYYX0J?KV&^BU2#9M'&C*/J;FII\/M^.'3M>>^65V+BX %=C17DY[0#5
M'=#HVH@@-B8F<&!UUWH&RS \SQ^6B4 )'820N/CX&V;//H:\5HV8F)C++K\<
M &"Q6C_Y^&.3R31@X   B"1)(T>/&C)DJ*HJ&.,F6].B7WY-3$JZZ(+S6K^K
M9<1JK]/2,E+34J?-F#YB^/# O[ALZ;*??_QQX,"!=76UY>5E0X<-;;>!V^UV
M.IT#!@ZL*"]G&(9AF*RLK'ZYN9U;T$E3DWW+YLV  (9E&89)B$_H/Z!_YZD6
MQ.WQK%F]N@D$T<,8  ! 9F;F P\^>,[4:5NV;#88#5=<=:4I"$>5QJH5*RLJ
MR@T&@\_G555U[!FGS[[Q1H00Q_/=.F]V1V1#2#CAGA]-?T4(Q<3&  #Z]Q]@
M,.@#7%W%!P_6UE1K4Z?58NV;FYN0D!#@ZN)Y#B%J23IA?/CAAW___;=6=:K+
MC$UM@_GSYY>5E85:\%,4AF4">SMIODGDX??["PH+32;3\82>,8@I+2D!A/RY
M>/&RI4M5C!F&O6?.7(9E04O[4T&G$P2AHJ)2*XT!(72Y/0A!I\/!<7Q59:7+
MY98EL<O?4A0%0)#3-Z>@H&#_OGWG7W!!NPT*\O)X@<_-S2TN+D8(<1PW><J4
M,0'C'_/VYWWSU5?1EFB#P<!QW. A0V9>?''@NN,_?/=]965EL./#, ,&#.C?
MO_^ 00/>?>L=K\<[^Z8;.\SFD"3)[_>KJLH@1 !05;6AH4'SL*@JQAAOWK29
MY5A9DJ=.G=JK<S?_"0#"8]8^PXMNB*ED69;CN)Q^_0  EUQV:6"_24EQ25Y>
M7K3%HM?KC6;3N/'C!PX<&.#$[=B^_8/W/@CUJ)TD''/G^HR,C.";*E-Z$JIG
M1!@0P>*BHCMNN_TX,Q@A! Z'TV T*HK2&IMIM]L)QJ E2")1K[<W-3WTX(/E
M964LRTJ2.'[")*_7NW?/+D* (LM-34W!/GL2P M"9E9F75U=NT]\/E_>_CR3
MR9R8E*BJJE97P^?SM>UM#5I"FK77E965WW[SM=Y@^/?##_WUYU^$$%F6 VM=
M'H^GV:MR--H9A'#(D*'_O/..M]Y\:]#@0:/;N#\T7"[7KS__O'+EJKJ:FBB+
M1:_3 0 JJZK<3J<EVD(P)H0XG<[-FS;OVKDS/CX^(ROKJ/)4CQ84^?4S2+>H
M&4"S8BFR# #P>#P=!B.W(LNR),MIJ6FS;[SQO??>^W/QXEZ]>FF^X]8HHK;7
MD<_G"_6PG3P<;<FIUNVU\Z(5QP014ECB%('J&1$&QC@^/N'Z&ZX/_$ 6#%H
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M%&7%\F5E)<7UC8TZ09>1F4$(":0=M@C<3G(" (*HO*RTMJ;&[79AC*/-40"
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M#A3"^H:& P6%I24E+,<10#0#P(Z=.\^_X((NE8Q6TM+29IQ_WK=??9/;/Q<
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M.(YKZQF9.7/F.>><(PA"-Z5]$4(@PUBM5D'@ 0%::7>7TUE=5>WW^X_6S$D
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M+O[TXX\__>03"*$@\'?=<_=WWWXGBF)4E-EL-A^M/&:S.=H275]?EYF5"0@
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M46:OU\OS?'%QR<@1(QY^Y)'TC'1551]^Y#_OO_NN),D<QVG>1HRQIG.HBDH
M@00</'# X_7<^H]_C!XSFF&8)YY^ZOIKKZNLJ-"L_>>>._W33S]YXW__&WOZ
MZ<-'C-!U<E NIW/SEBT;UV^X[OKK1XT>TVK;(\UQH"<;+,MZO=[??EU445X^
M/&@GUQ' X TAU\Z:==GEEVN%=WF>#WPI @#T!GWX1,;,FS=O_OSY1[ZF4+H/
ME@U4=:)K/8-A&(/!,./\\R9-GAS:(WE\WGQ%408-'I29F74J^TTB-$ #0H@0
M4YA?,'#0H)345.TPHBW1 P<.VKIEB\?C 0!J%9F\7J\D2EWN\*BJ9RJ*XG*Y
M)$E2"6F; ).4G#3[IAN__NJK]]]]=\# @=//.\]B.<SW7U96MFGCIFU;MF1F
M9UUQQ17FEOXC$$)9DN+BX[3M&8;)RLZ6)5F6) A A]X+C+'H%ZU6:U96EJ9F
MQ<3$FJ/,K9U96(Z]YMIK?_[IIQ^^_W[_OOVC1H\:,K3]X_L?O_V^=>L6A\-Q
MW?77M_L4GJ3Q&5K1<4 (PR"&88[A\M>"?_U^?Y/=#@#H,@=5K]<'#N!HAR++
M7J\O^.V[B?GSYR]8L"#44E"ZBY4K5VK&@R[I,?UR_OSYFDB!S<E!96V0KMH.
M=2L8XZ(#![]<^&5^?OZ''W^<U2L[*2F)^DTB$4F6*BLK+YHYL_7T&8W&L:>/
M7;UJ555E)<>Q  !!$*ZY]MI^N?U.[$]'145=<.$%/_WP8VE9V9&.]IDS9PX9
M,F3CAHUOO?&ZT^%,2$S4Z70&HZ&FNCH^(5Y5R<R++QX]]K#ZI!AC<Y2YHJ*B
MH+"P?__^BJ*L6KG2'!4E^OU.EXME.KBS%$6)CT^HJZM=MW;=J#%C&(8I+"AH
MJ&^(ULJ'$ ( T.ETEU]QQ;CQXW=NW[%VS9H_?O]=Q3@I*<GM<DN2)(IB9E;6
M.5.G9F=G)R0FMML_"6(%C12TF$V-YK<@K*JLJJBH.+9CE!5Y\)#!,\Z; 8Y2
M0PV&K%Z])DZ<^/E7"T,\:EV9K^FT&=$$Z30)0UTS K)##QPX</\]]SKLCI=>
M?7G4Z-&A%B<,")M'5D51ZFIK369SEUU&M2">POP"O]\_9NPA4S_#,$.&#8N)
MB2DL+-1:FNGTNMON^&=KN<P3A<%@F'GQQ9LW;BHJ*CKR4T&GZS]@0/\! R1)
M6K9TZ?:MV\:-.R,N(2$N-LYL-L$.C&?$[_/U[]\_.27EWCESSYDV39*DK[_Z
M\I]WSMFU<T=149')>$3." %^O[__P/[]!_3_<N%"O]\7%16]Z-=%,7&QT5'1
M#J>C]:PBA-+2TM+2T@@ADB0Y'(ZB@P=U>OW2O_X:-FS8]/-F=&[,(UA52?A<
M'\>'PVZOKZMKJ&^ $&HF*%X0C$8C<PPY[02HJCILV+!SIDX%W1!%GI*2<N;9
M9X6#GD$YB0G21!&&>D:X>Q\PQE]_^:7=;K_E'[<.._JN5Y1NI;BHZ([;;G_S
MC3<DJ0LWA[94'#QX$"&4F)34]B.SR935*[NFJIIIM@' [G**M2Q7 =BV=>L'
M[[W_ZR^_Z(V&7KUZ145'P<Z*:RF*R6RZ\**9$*&OO_IJT2^_3)PT>>JTJ8JB
M:EW%VVU/ ) 5)2XN_MKK9ITV?/BOO_RZ<.%"41)GS9J%,>ZLIY<@" D)":/'
MC,G(R/CEEU^_^O++VIJ:SH0GY.2Q9R"$LK.S3293<DH*;HFJT=)&CG&/I'N?
MYN&I[,FE4 (2UO:,HJ*BA9]_OG?/WA=??OFTX:?1_B9AA22*?_SQA]/I_/;+
MKPQZPQUS[@Q0/ U"" C9O&E3<DI*N^G>8K6.&3MVS^[=+86V2#<ME@1CC ,5
MYE[\^Q^//?*(S^>+BX]?^/D7M_\S.D!D* ! EN1QX\>-'#6RJK*289@^??I@
MC%5595D6(<AQ7.N1<CROC1C&>,B0(:^]\7IQ49&JJLG)R0BA3S_^&'0N%2&D
MKJ[NU9=?%GA^V[9M\QY];-[C"U)34SO<5E75D\.< 2&,B8TUF<UFL[GMX!Q;
MN*5V'@*?_>,$XY-$PZ-$-)K-8W*H@RG;$;YZQL$#!^Z>>Y>]R?[2JR^/&3OF
M^'=(.;'LV+&C8'_>V^^_MVO'SGF//LIQ[ TWWA@@,M_A<.S=NW?:M'/;O:_7
MZ\>-&[=RQ0I9DKM=E>Q\G5FW=NVCCSRBJNJ##SW4MU_?VVZYA1#PZ+S'.NQ^
MSK L8ABBR"S+QL7%M:[Z+I<+(H0)\?O\O_S\<UE9&4(((51XX(#3X5!5%4((
M$;):K5:M7@@ =;5UF! ((==)P+8HBJ^]^NK??RUY^;^OEI66+9@WS^UVWW/?
MO1WVLU55-4+#A-N/,,/8[799ED^($8( <#(&R%(H[=&<)E3/" I55;_\8J'F
M+CEM^#%GLE&Z"Z_7NWS9\H&#!O7MVS<]/7W%LF6OOOP*0LR--]^DA5FT@Q!2
M45YN;VI*;VUMVH:$Q$2"L685Z%:Q.UMKRLO+7WOU59O-]O CCUQ^Y96$X#&G
MG[YZU:JRTM+^ PXKX27+<GY>WJ:-F^KJZF1)^N[K;Z(MEE:KOMOMKJFI(1A+
MJOK++[^L6+$"0001\OO]7H\' +!G]^Y??_[%Y_,! #53OM/A:&QL5!7E^^^^
M.V/<N*SLK"-E6[%L^>@QHX<.&S;LM&$;-JS_\HN% ( 77GHQ-6 Q[(BFHJ)\
M_[Y]/I\/H68]0QMD36\+9@_M%!1"-0W*R8YFS B?%.M6PD[/((3DY^5]_=77
MA04%K_SWU:'#AG6X;IW2A,%E5)"?OV']^I=>>1D H-?K'WSX88C0FZ^_KBC*
M;?^\_4@'"L9X[]Y]"*(.ET:=3F>Q6#9OVLQQ7+>F[;:KGP$ P)A45)0]/F_!
MUBU;__7@@S?,OD$3_LXY<_[ST$,;-VQHIV>(HKCDKR5OOOZZ9H2?/V^>5FA2
M"QUH]?@8C :#P:BJ6 5:= %!#"-+TJH5*U:N6 $1TD0!$!*,.8Y#"/WK_ON?
M?_&%S*S,=@ODZI4KX^+B;K[UUJBH* CAOQY\$ "XY*\_YS_VV+S''T]-36V_
MH(;^ZCC><U1>5O;Z:_\K+2W5]$Y""$)(K]<3 !H;;?OV[C6;S0$G4\ARK-OC
M:1OU0D[&"F842BM:5G.X%?+2"#L]P^UVO_7F6S__^..;;[]-LTO"EGW[]N7V
MS\W(; Y?2,](?^:YYW[^Z:?GGWO.H-=?/_N&=DD!A)#]^_8-'SE2:VO2#D$0
M,K.R&^KK32<ZX?!PX)%ZQKJU:__WW_]NV[;MX4<>N?:Z6:T:TN A0\:-'[]]
MV_8;;CRLT1J$,"HJ*CDEN:JRBA"2E)24FIJJ+8<(H8:&AJJJ*H10K^Q>>H->
M451)DGB.8QE&4I3RLC*&8=+2TA!"K4_G%145#0T-#,-8K=8.G]3W[MT[:<KD
MG)R^FAB9F9G/O?#\\!'#GWOZF0<?^->]]]\W<M2H[C_A/4=Y>?E33SY95E+:
MK#%!*(IB3$S,#3?.KJJNWKE]1V5%!:,-%(1 "XPX0H% #&JHKY=E&0   =2*
M"A-R$A9EIU! B_4N;,NRA9V>H=/IA@X=LG;UZ@WKUT^;?NZI6_2S<P@)O0N^
MO+Q\Y.C13)MUT60V77S)Q>O6KGWA^1<(!#?>=%/;Y1D3[/%XTM/3HZ(ZUB32
MTE)[(%>"$,U\WEPIO[2DY(W__6_%\N4S+[GDBBNO;&<YZ]>OW]X]>SO<C]%H
M$OW^@8,'_]^_'TQ,/%3R7!1%K]>KZ2+5556??/S)KIT[1X\=<]GEEZ>GI[O=
M;@BAT6ALW1Y"6%Y6_MJKKQXX>%!O,!R9#N-VN9ML33/..\]D,K;Y=>.EEUVV
M=?.6;[_Y!D#X_(LO=!(6&I'\\M//!PL/N-SNZ.AHA!!6,2&$Y_DA0X=.GC2I
MR=:D-^@) 0 0S8PDBF*'V3J)B4G]<OMIO5% &"6#4R@GF%;=(CR5#!"&>@;'
M<5==<\UIIPU_X_779UUSS<2)$R=,G)B0F&@P&+1RSBS+GM)-X0% "(7<EV2W
M-0T8,*!=+I_!:/SWPP\3C%]]Z65%46^\<;:69\'SO*JH+,N.&#G2T%%8)0 @
M/3,S)27%X70"0F1)ZFSQ.&8@A)(DJHI*"%&)ZG*Y:FIJGGGRJ8T;-LR\^.+_
M//J(T=1>L-Y]^HBB:&]JTK4I#2F*HJ(HBBRK&%NMUI&C1G58.Z2NKNZS3S\=
M/6;,?0_<_\O//V_>N''<^/$=EH>*C8NS6JU:=S=%47P^GZ:%:,Z"RLH*M]O=
M+S<7':YP1T='_^O?_T< ^?NO)?,?>^S^!_Z5DIJBJA'_O)Z?E_?;HE\K*BJF
MG'DF+PBK5JYD.;:AOOZEYU_HEYO+L2P!1"N?BA J*BI25.7A__RG7[_<(_9$
M" $\ST$($8*$ (RQHJK:=X^M&5L $$)R5ZG=%,H)1U,L-'=)V"H9( SU# "
MP6 X;<3P%UYZZ8/WW_OYIY^_7/AE9E9F8F)B7%R\3A",)M.8L6,&#QER"M:V
MTQ[@'$['\F7+]'I#IQ69@FH8T_%;00YJ;6V-]5#[KD.D9Z2_^.HKWW_[W:NO
MO"+Y_8.'# $0;-^VG1 2%Q<G^GSY>?G@B/(2$ "7PYF4G&QW.%2,O_C\B[CX
M.$D4FT]QRYDFS=UPM&^W;[?7JI>T6T&T+S,,8VMLM-EL1J-Q]\Y=;_SO]5]^
M^JFFIN:1Q^;-NFX6+W2@M\7%Q\NR_,;__F>-B2&$  !9EO&+XIY=NQ1510AI
M6:P=CH^ML;&PH.#V.^[(SLZNK:M;LOC/ZJHJ<[\.BIRJJDH(P:KJ\_O7K5GK
M=#BT'F]:\8P#!PYX/.X.LWBRLK*?>^&%[T9]\\)SS^_>N>O<&3,*\O,C_J:
M0*_7Q\?'&4W&ZNH:C]O=4-\@26)I:6EQ<;'VI %:+EZ?WQ\;%U=<5,1S/( 0
MDR-C/P$@I*#@(&18AN5W[=K[UIMO P 8ANTH#?50O^F6R^[(UI#PL'V#YJN-
M%_B5RU>%>NP H!4_3VHZ.[EA&/C9CJ[UC.8B0CU^(-88Z_W_^M>ULV;MW;NW
MI+C8[7;OW;-W^?+ELB1=,VO6H,&#3[4[BA @2Y(LR\5%17/NN!- B#KOG0M
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M(UCM@81-]"6]#"C'C*JJ+,N^\]9;7WSV^3%,*%IP!PG\S=8/(800$D*.RMY
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M6L_ &$N2U-#0H,V]+I>+X_G,K,QV,[$V[9)#L^^A#X)\;(3@4)'TUM>M_R$
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M;$TE;+[N#[O^"0$ $$T7(41[(&QY0L0J)@00HF+<^M#(\7Q*<G)DW$(0"H+
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M6$FA4(Z3X[5G4"B45IK#)L/)E4@@X_5)UUYWW4VWW!)D^ ABF#V[=UU^Q74
M,30^@T*A="M4SZ!0C@((4=B%-4 ((=3:N ?ODN<XS<[90\=RM+$"D':!/VX(
M(3?==!---J&$'*IG4"A'02BC0#N#$(A =75U04%!:[_6P/ \5UA8" CNB4,A
MA&#%Y73FY^<30H+QP$( G$ZG)(H08AI!0J%$.E3/H% B'*)R#).7E_?'HM^4
MX/0,CN,J*LH)5KM[%2<$^'T^49+JZM3?%_T6K)X!@<_G=WL\+) !;NET'VYF
M) J%$AQ4SZ!0CH8P7.T0*\GJY,F3;[GMMN 7X]V[=O[TRV*MOTDWR@8!A(A
M-KM7[WOOOR]X\6PVVXKERTM+*UH'/$A3#85""3>H$Y1".0K"3\MH$>PH%2#4
MLP$01SMN[0X'0NAVNWM28 J%<A0$?%JA]@P*)<(A*L\Q*U>L='L\0>:?(\14
M5U>2YOXFW:L[$8(A48J+BUY]^17MC6"^Y?/YFVPVGN.TS0D@>KT^F"]2*)1P
M@^H9%,K1$'Y^$T@  $"4)+]?E&4YF*_H=(+/Z^^A&NH0 @)45?7Y?(3@8'K0
M0PA$4208 PA!BZ+!\T)/2$NA4$XT5,^@4(Z&\"M81R"29'7\^''7WWACD/8,
MAF'V[MG]^Y_+>J"_"0200"8C,_.?=]X!@_XQA]V^=LW:TO*J5L6.T,03"B4R
MH7H&A1+A0 @ T.ETT='103I!( 1&@]9)H$?,,Q *O&"Q6((/(D$0,@P3Y,84
M"B6T!+ZQJ9Y!H40Z!$)045&Q9_>>(/TF>KTN+R^/X!ZIGP$  <3G]SOL=HQQ
M,&DC"*&FIB9%42 ,.^L1A4(Y6KK6,S#&[?HI4"BG+"&_#5J6ZC:"$,RQ3%%1
MT=*_EP03_0  8!BFJJJ2$+6E5%<W0@A&6"DK*7GQ^1= T(X3O^AO:FSD.#X,
M'561POSY\[=OWSY__GQ:$O3D8.7*E>#P5*QY\^8! ,+A_)* -W;7>H;7ZZVI
MJ?%Z?:$^$ KE5,?K]9:5ES<VVAQV1U1,?/.[D!$E=>K4J=?-GAV\8^+@P<(?
M?_X#P&[W34"(".('#.S_Q--/!2^>Q^/9M6MW645U& ;>1@H+%BR8-&E2J*6@
MG#".?-K7;J@%"Q:$W!"@J$J 3[O.H<<8RY*$,2V20Z&$. Y4412_WZ\HBBS+
MATD"C[J,E:KTY!U-5/7HHC@56288TQJ@%$H 6@OLAOY.(<=GSS :C2FIJ2:C
M*<2'0:&$ 800"&&H[FJ3R9R=G0T(CHF-99B6FY=@ED&[=^_^<_%BC(-:SAF&
M*3IX$#?7S^B!4<,V6^/F39M(1\]D1Z+U-_%YO3U<3(Q"B426+U\^9<H4".'R
MY<LG3YX<$AE8E@OT:9??9QB&YWF(0JTN42AA  $ D)!5!44(Z@2!Y[EV"S""
MT&:S5927!UT_0U==7=WR"-+=1T,@4>OKZ__\8W'0_4V@W^_W>#PL1]O64RA=
M,'GR9.WY9\J4*:%RH 1^] HJWR3DOA\*)1Q@&,;>U/3N.^_LV;U[\Y8M\?'Q
M#_[[P83$Q)Z4H:.5&LJ*.FK4J"NOOCK(G4 (]^_;^^77/W9[?Q,  ( $LEG9
MV;??<4?P9B"'P[E^_?JR\JHP+O5.H801A)#)DR>'9]@OS6NE4((%0B2*XNY=
MNVIK:SB6*RDJJJFIZ6$]HT.Q""%145$FDREXATY<7%S/>7\@TNOU<?%'\8MZ
MO9[C./J$0Z$$SXH5*R"$X1 6V@ZJ9U HP>)V.KT^7Y3)%!L;FY24 @#.SLX.
MM5#->:U[=N]9OFQ9D LY(:2DN+@'^L)KOP:(6E=;NVSI,@1AD.8)E]/E=KE8
MEI;JHE B'JIG4"A!H=/K+KWB\GZYN1Z/V^/Q-C8V8((7S)M_UCEG#Q\Q(B$A
M(60AWX0@!*NKJ_?OVZ\J2C#?X 6AK*R48+4'HA\( 8!@E\N9MV\?)I@$U=\$
M>GT^41010K1^!H42/%J@1KAY3ZB>0:$$!<_S5UU]-;CZ:E$4)4ER.!Q--MMO
MORYZ].'_6&-CGGKZZ=%CQH1&,L2(DC)YRN0;;[DE>%TG+V__MS\LZI'Z&1 @
M-CN[]QUSYP0OGL/A^'O)DI+2\N;Z&1"H:E J%(5""3>HGD&A'!V"( B"8#:;
MT]+24E)3$Y(2O__VN^>???;J:ZZ]Y+)+0V+5@! >K4>68-R3F1SD*'^,')X+
M R&TV^T])RZ%0CEQ4#V#0CEV8F-C9\^>G9:6=L_<N]Y^\\W!0P;W[=>OIX4@
MF$%P__[]*Y8O5X+SFP@"GY^?3[ "0 _%9]37U2U?NHP $DR%#PBAV^WVN-UL
M2RLU0HA>K^]^42F4\"7TQ;B.%:IG4"C'CJJJO__VVRLOO0PAO'K6M;W[].EY
M&2#!+(O*2LO6K%H=;)TNEJFMJ0$$ ]+M?=0((9!@N[UI]>K5,.@D>;\H^GP^
MQ##-\1D$&&FI0,JIS;QY\\(JZB)XJ)Y!H1P[A04%+[_TTKX]>ZZ?/7O6==>%
MI)4Y08PDJQ,G39Q]\\W!/_'LV;UK\9*5/5 _ T)$$)>=W>O^?ST0O'A--MO&
M#1O**ZI:^YN$6ZH>A=+#+%BP8,&"!:&6HC..K^ZX1D@F4 HE;"&$%!04//+P
M?QKJZF??=//=]][#\WR(9(&$ (/!8#0:@U_(+19+3YIA.8X_*O$416$8)KCN
MLQ3**4%F9F965E:HI3B,DI*2TM+2+C<+2L_ &.?MS[-8+!TU0VK[F$' T?29
M:C/G:*^(Q^--3$H<.'!@@&_MV[^_LKQ";] +O#!X\" =]=I20L&?B_]X\;D7
MJVNJGWKFF>DSI@N"$#)1".989LN6+4:3*<B'?H28LK)2HLJ X![QFRB5%>5?
M?_DE"+8Q//1XW Z'@V<96G:<0M&8/7MVN/E-YL^?'XR)):C^)H20WQ8MVKA^
M@WI$UU8((4)(ZRS5^@)""%IZ3;6;P[1YD+3T.2"$$(RUOU15=3@<4\X\,[">
M\>7G7^S:N3,F)B8F)B;IWGO2,S-#/=244X["PL*7GG]QR^;-<^Z>>\&%%_28
MM0]"R+ L0@C"-OU-"$$(U%17[]VS5U:"ZF\B"+KJJBJ,<4_$@4( "'&Y77MW
M[\&$X" J@T$(15&2) DAVM^$0FDF>+])]T5R=&:2#%R KVL]P^5R-=37JZI:
M7E[>X:^V52\.Z1F="=3RP$4( 81@ %KU#*_'X_%X,CO7&_Q^_[=??_/3]]_+
ML@P@[#]@@%\4NV,H*93.P!@7%Q?_YZ&'"NUM%@  'SU)1$%4:VMKY]YS]UWW
MW-V3+D6?SU=66EI75^=R.:)C8IO?A4B2U3/&C;OV^NN#C -E&6;/GMW+5JSM
MB?@,  ED,S(R_SEW#@BZ7ZO=;M^Z>7-%136(V!A["N7$,F_>O& V"TD,AQ*P
MO$W7>H8HBEZ/Y['Y\V=<<'[S6^TG"@*.;Z[2)I*'__W0BN7+ SSN_/#]]POF
MS1LT:-#5UU[[^/SY""&&I7&LE)X#8[QZU:IGGGRJIK;VZ>>>G39M&M>S,1F*
MHC@<#J_7)TG2H04;0D* Q6))2DH*/@"BH:$>0-A#7<H@U!OTR<G)P8MG-!HY
MGJ>QGQ1**T&:*$*B9Y" =LJNU^GHZ.B,K*S4]+3X^/AN%32W?^[&#1N<=J??
M[]?I=&T_LC4V+O[CCY=>?+%WGS[S'E] ,#F&PD04RO$@2=)GGW[ZRDLO8U5]
M\NFGSYT^G>UQ-3<Z.CHW-Y=E68O%BE"+'85@ED';MFVS:J:^(- )N@,'"K$J
M Z+V0'P&P4IM3<VO/_\"@BO8!0%P>SS-_4WH;4ZAA WM;"HK5JQ8N7(E (!C
MN #?ZGJB1 @Q#!.D/?9X<#E=-INMNJ;Z0&'!H,%#6M]O;&A\8L'\;[_Y=MBP
M86^\\W965M:FC1NIDD'I8=QN]Z)??E5D>>3H43&Q,1O6KP^P<;OKDQQ5/<QV
M3_VPQ?<)865YN=OM9AB$$&J[>X2@S^>KJZT+^B> R^5$/>620("XG(ZM6[<T
M_W;7$+_?[_?[&433W"B4HT";/+HO7+3=GN?/GZ_I&8%OZS#R._3JW7O"Q D.
MA[.@H+"MGK%X\1]?+?S*'&6^Z99;PBVKAW+JP+*<V61&"#4V-/[WE5<[LQ-J
M(=$00BUL";0$18/F?T#' 0>:)G)8F'0S&)/FCPCQ>KVR)',\=]@^("-*ZN3)
MDZ^_\<;@'1,'"@N^_/JG'JF? 0GB^_7O/__QQX,7S^UV;]^VO;2LDL9G4"B1
M3ACI&5=<=>5YYY_W\4<?__3#CP,&#,CMW]]AMR_Z==%++[PP9NSH&V^^>?IY
MYX5:1LJI#)$569*DLM(RCF,[6)P) 0"TQD4?EG[5K'^TB8]N3<9JL7P00EJ5
M#0((P2W_)40KUDT(420YVFHY,B@$0N#W^X-TFF@R>-R>'C0*$B5HV30D4<08
M1VZA90JEYYD\>7)XU@P-(SU#I]/I=+IIYT[[]INOWWWGG4<>??311QY=_,<?
M _KW?_>##Q*3DD(M(.641E4419955>W=I_>3SSQMM5@ZBH=NK1!!VK[7P6;M
M@('?:/:<E!87?_C^!Q45Y8=I" 1S++-QPT:&Y515!4' <5Q9N58_H]OC,R@4
M2@^@*>4K5JP(M2 =$$9ZAD:?/GU&CAJU;MVZ9YYZ^N^_EDB2=,MM_Z!*!B7D
MF$RF08,'KUZ]NKRL# "0GI'1\S)P+&LP&(YXFT (O#Z?PVZ7@HP#U0E.A[/G
MY:=0*-V!IF0$F?C:\X2=GJ'3Z__UX(-O_N_U3S_Y9.SI8V^ZY=:ITZ9VN"5"
M,)1%&"FG&!S/_W/.G3&QL5]_^>6#]S\P_XG'APX;UBXQJKOQ>#P=62R0K*AC
MQXZY]KKK@G2$( CS\O;_^MM? *)(*83543%B"H4")D^>#,*[RUK8Z1D @,S,
MS$LNN]3C]3SZV&.=6#(@A-!A=ZQ8MGS"Q D9 4N"-C4U[=ZU"V/2Z7S:>2H
M/.R?CC_OTH.,,8$0].[=)STC/30#2CE!)"0DS+W[KM%CQ]PS]ZZY=]YYYYRY
M5UUS=>B570@Q!E:K-2X^/OB AB1[$X0H4IPF$$&7BQI@*)3#@!'293 <]0P
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M#2& 5BHZ25 5U6*QW'/?O>,G3& 81I*DY.3D4 E#".$YWGB4<0\1![UU*.&
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M$U$H80H;L.9U4'$#D;&BAR^03I$G"02$W(H $:W&0J%0PHO 4Q*-3^P)Z,)
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M[VR-MMOON..TX:>%>N3"@I]^_/'Q>?--9C/4KC%)>N#!_[OYEEM"+5= " "
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MB+'J<#@()G'Q<<&L6UC%MB8;SPM145T^'T,(@:(H=77U/,_%Q,1 B (O11!
M%6.;K5&GTP5EGP 0 %!;5VLV1^GUNBZW!P#*DN1P.#B>MT1'!S.>DB0WV1J-
M1I,Y*HJ0+L8' BB*8D-C@\%@L%JL7>X?0N3QN)U.E\42K=-IS_<D\/:*(C<T
M-%HLT7J]/ICS)?I%I].A-QA-IJZ=&A!"C\?C<#BBHRU&H['KXX7(X_$X'/;H
M:(O!8 A&S]#47XO%$H0?!R($O5Z?T^&(C8OC.+;U>//V[U_V][)??OKYQIMO
M0LPQAEA%"IJ5J**B\K=%BU:O7AUJ<2@42GO^7O3E9Y]^_I]''^W,3-OQ)$4
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G0J%0*)3N@NH9% J%0J%0NHO_!]3!NQ\8?G6>     $E%3D2N0F""

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>image_1.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_1.jpg
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M#]P\G JQL=R.S:3G=R^.\/YC#Q]USW.FSX^J*/S>I5$&YJ+\Z_,C_%7[#*(
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M@]%$D:N0_OXAUK8V8S89"87## P.LV%]*XE$@I'1"5[9N(YL.D-'=P\.NYU
M(,3U&[<I+2E&I],S/C[-YDWK2:52M#_JP& P,#XQ24=G#]55Y=365,-B"V6W
MV;C_X#$S,QY2J11S\PNTMS]B>'2"_'PGK:U-='3V4%Q<1'E9"2:3D8[.'D*A
M,)E,EK;V1V0S6?;L?A6]3D=6EKEY^Q[KUC;3M*81L\G$T/ XX7 $O4%'=^\
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M6*T6#N[?L]SOMUJM6,PFUK8V8;58T.OUE)>7X/',,3$UC<EHY,#>W2N&/T%
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MW^?GR,&]2)+$\6.'>&7#6A*))-/N660Y2WE%&:%0!)O-O)RCK:RL! $!KR^
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ME>2BU9/-RJ3324118&AXE#/G+I)8S(H33R109!FKQ4Q)L8N1D;%<^4)AO($
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M<N41" 011(&RTB),1B.*HF VF2A=7/I9$ 0,1BWH1.-G@Y<F=EF6.77F(KY
MD/W[=G)@WRZL5C,(H-?K:6ILH*N[CZ&1,=:N;2:13/+AZ;-8S&:.'-K'SIU;
M$4601 &#7K\BNXV<E5%4%4DG8;:8V+US.X?V[^'0@3ULW[89B\6$RB<5+TD2
MLB*C+J:9BL9B=/<.((IB+HW4DL-/A70RE?,I+,:?LYQ51UUQ;<W;K_&SPLL3
MNZ(0#H>QF(R@PO#(.-%HG& PA*JJ-#>M87ALE'0Z3755!>ETFE@TBM-I(Y/.
M,#(R3BJ5)A@*4U55B=L]1V=W+]/3;@:'1Q" XJ)")$EB<FH&08")B6D>/>I\
MDO))S8FQN[>?X9%QBHI<F$UF'CSJ8G[!RZW;;71V]U!>5HJ*RMW[#UCP^FAK
M?T@H'*:VIHJLG*M8EE 49?EOX:F*0$/CR\Y+<]!)DH338:.W?XBAX5&*BPHI
M+BEF;FZ!AOI:' X[\422NMHJ:JHJ,1H,Z/5ZVA]U,..>I::Z$DFO(QY+L'']
M6O0&'6WM#YGU>&ALJ,-56$!M336E)<5T=O?2V=U+(I'@P-[=N%R%)!()]'H]
MY64E]/0.DI6SU-564U)23%_? )W=O8B"P*$#>RER%5+L<M'3.TA7=R^A<(2#
M^_=07EY"-!K+Q<%7E*&J*N%(E/*R4IP.!YE,AE0J37U]+?JG4EMI:'P9T:+>
M-#16"2_-C-?0T/ARH8E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=
M0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5
MH(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5\/\#D#:4834;I,0
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>image_11.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 image_11.jpg
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M#]P\G JQL=R.S:3G=R^.\/YC#Q]USW.FSX^J*/S>I5$&YJ+\Z_,C_%7[#*(
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M@]%$D:N0_OXAUK8V8S89"87## P.LV%]*XE$@I'1"5[9N(YL.D-'=P\.NYU
M(,3U&[<I+2E&I],S/C[-YDWK2:52M#_JP& P,#XQ24=G#]55Y=365,-B"V6W
MV;C_X#$S,QY2J11S\PNTMS]B>'2"_'PGK:U-='3V4%Q<1'E9"2:3D8[.'D*A
M,)E,EK;V1V0S6?;L?A6]3D=6EKEY^Q[KUC;3M*81L\G$T/ XX7 $O4%'=^\
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M6*T6#N[?L]SOMUJM6,PFUK8V8;58T.OUE)>7X/',,3$UC<EHY,#>W2N&/T%
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MW^?GR,&]2)+$\6.'>&7#6A*))-/N660Y2WE%&:%0!)O-O)RCK:RL! $!KR^
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ME>2BU9/-RJ3324118&AXE#/G+I)8S(H33R109!FKQ4Q)L8N1D;%<^4)AO($
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M<N41" 011(&RTB),1B.*HF VF2A=7/I9$ 0,1BWH1.-G@Y<F=EF6.77F(KY
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MH(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5H(E=0V.5\/\#D#:4834;I,0
(245.1*Y"8((!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639792037328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover Page - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Feb. 26, 2025</div></th>
<th class="th"><div>Jun. 28, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37977<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">AVADEL PHARMACEUTICALS PLC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">L2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">98-1341933<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">10 Earlsfort Terrace<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Dublin 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCountry', window );">Entity Address, Country</a></td>
<td class="text">IE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">D02 T380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CountryRegion', window );">Country Region</a></td>
<td class="text">353<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">901-5201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Ordinary Shares, nominal value $0.01 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">AVDL<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Large Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,342,171,790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,629,435<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001012477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CountryRegion">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Region code of country</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CountryRegion</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCountry">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>ISO 3166-1 alpha-2 country code.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCountry</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:countryCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791984000">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">St. Louis, Missouri<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information [Abstract]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639794753872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Loss - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Income Statement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 169,117<span></span>
</td>
<td class="nump">$ 27,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">15,277<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">153,840<span></span>
</td>
<td class="nump">27,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">15,196<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
<td class="nump">20,700<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingGeneralAndAdministrativeExpense', window );">Selling, general and administrative expenses</a></td>
<td class="nump">181,043<span></span>
</td>
<td class="nump">151,705<span></span>
</td>
<td class="nump">74,516<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">3,345<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">196,239<span></span>
</td>
<td class="nump">164,966<span></span>
</td>
<td class="nump">98,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,399)<span></span>
</td>
<td class="num">(137,849)<span></span>
</td>
<td class="num">(98,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income (expense), net</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(10,830)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="num">(12,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(13,129)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(49,079)<span></span>
</td>
<td class="num">(160,777)<span></span>
</td>
<td class="num">(111,439)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="num">(247)<span></span>
</td>
<td class="num">(501)<span></span>
</td>
<td class="nump">26,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,832)<span></span>
</td>
<td class="num">$ (160,276)<span></span>
</td>
<td class="num">$ (137,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average number of shares outstanding - basic (in shares)</a></td>
<td class="nump">95,141<span></span>
</td>
<td class="nump">80,174<span></span>
</td>
<td class="nump">60,094<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted average number of shares outstanding - diluted (in shares)</a></td>
<td class="nump">95,141<span></span>
</td>
<td class="nump">80,174<span></span>
</td>
<td class="nump">60,094<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789479552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,832)<span></span>
</td>
<td class="num">$ (160,276)<span></span>
</td>
<td class="num">$ (137,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive (loss) income, net of tax:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent', window );">Foreign currency translation (loss) income</a></td>
<td class="num">(623)<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively</a></td>
<td class="num">(790)<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Total other comprehensive (loss) income, net of tax</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (50,245)<span></span>
</td>
<td class="num">$ (157,102)<span></span>
</td>
<td class="num">$ (139,865)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789466480">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Comprehensive Loss (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Statement of Comprehensive Income [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net other comprehensive (loss) income, tax benefit</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791135456">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 51,371<span></span>
</td>
<td class="nump">$ 31,167<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">73,944<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable, net</a></td>
<td class="nump">34,097<span></span>
</td>
<td class="nump">12,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">20,298<span></span>
</td>
<td class="nump">10,380<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">6,036<span></span>
</td>
<td class="nump">6,608<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">134,208<span></span>
</td>
<td class="nump">134,202<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">585<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right-of-use assets</a></td>
<td class="nump">1,702<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">16,836<span></span>
</td>
<td class="nump">16,836<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other non-current assets</a></td>
<td class="nump">11,037<span></span>
</td>
<td class="nump">10,484<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">164,236<span></span>
</td>
<td class="nump">164,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">582<span></span>
</td>
<td class="nump">934<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">7,328<span></span>
</td>
<td class="nump">11,433<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Accrued expenses</a></td>
<td class="nump">40,651<span></span>
</td>
<td class="nump">24,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other current liabilities</a></td>
<td class="nump">273<span></span>
</td>
<td class="nump">261<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">48,834<span></span>
</td>
<td class="nump">36,855<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Long-term operating lease liability</a></td>
<td class="nump">1,122<span></span>
</td>
<td class="nump">1,690<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RoyaltyFinancingLiabilityNoncurrent', window );">Royalty financing obligation</a></td>
<td class="nump">35,249<span></span>
</td>
<td class="nump">32,760<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other non-current liabilities</a></td>
<td class="nump">5,183<span></span>
</td>
<td class="nump">5,654<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">90,388<span></span>
</td>
<td class="nump">76,959<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Shareholders&#8217; equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at December&#160;31, 2024 and 5,194 issued and outstanding at December&#160;31, 2023</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">52<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized;&#160;96,518 issued and outstanding at December&#160;31, 2024 and 89,825 issued and outstanding at December&#160;31, 2023</a></td>
<td class="nump">965<span></span>
</td>
<td class="nump">898<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">891,791<span></span>
</td>
<td class="nump">855,452<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(794,328)<span></span>
</td>
<td class="num">(745,496)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(24,580)<span></span>
</td>
<td class="num">(23,167)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total shareholders&#8217; equity</a></td>
<td class="nump">73,848<span></span>
</td>
<td class="nump">87,739<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and shareholders&#8217; equity</a></td>
<td class="nump">$ 164,236<span></span>
</td>
<td class="nump">$ 164,698<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RoyaltyFinancingLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Liability, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RoyaltyFinancingLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 30: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 29: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639906879248">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, nominal value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred shares, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred shares, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in dollars per share)</a></td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in shares)</a></td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued (in shares)</a></td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">89,825,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding (in shares)</a></td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">89,825,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639784634320">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Shareholders' Equity - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>April 2027 Notes</div></th>
<th class="th"><div>October 2023 Notes</div></th>
<th class="th"><div>At-the-market offering program</div></th>
<th class="th"><div>Public offering</div></th>
<th class="th"><div>Ordinary shares</div></th>
<th class="th">
<div>Ordinary shares </div>
<div>April 2027 Notes</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>October 2023 Notes</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>At-the-market offering program</div>
</th>
<th class="th">
<div>Ordinary shares </div>
<div>Public offering</div>
</th>
<th class="th"><div>Preferred shares</div></th>
<th class="th">
<div>Preferred shares </div>
<div>Public offering</div>
</th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th">
<div>Additional paid-in capital </div>
<div>April 2027 Notes</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>October 2023 Notes</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>At-the-market offering program</div>
</th>
<th class="th">
<div>Additional paid-in capital </div>
<div>Public offering</div>
</th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Accumulated other comprehensive loss</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2021</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">58,620<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2021</a></td>
<td class="nump">$ 78,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 586<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 549,349<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (447,756)<span></span>
</td>
<td class="num">$ (23,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(137,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(137,464)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(2,401)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature', window );">Change in fair value of October 2023 Notes conversion feature</a></td>
<td class="nump">5,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">25,318<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25,282<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Amortization of deferred issuance costs</a></td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(45)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">451<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,460<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">144<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueOther', window );">Vesting of restricted shares</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Employee share purchase plan share issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee share purchase plan share issuance</a></td>
<td class="nump">222<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">221<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">7,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">62,878<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">488<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2022</a></td>
<td class="num">(21,145)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 628<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">589,783<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(585,220)<span></span>
</td>
<td class="num">(26,341)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(160,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(160,276)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="nump">3,174<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,564<span></span>
</td>
<td class="nump">12,205<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,706<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,913<span></span>
</td>
<td class="nump">$ 134,151<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 16<span></span>
</td>
<td class="nump">$ 122<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,897<span></span>
</td>
<td class="nump">$ 133,982<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Amortization of deferred issuance costs</a></td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(16)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12,347<span></span>
</td>
<td class="nump">408<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,812<span></span>
</td>
<td class="nump">$ 22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 123<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 101,689<span></span>
</td>
<td class="nump">$ 18<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">343<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">2,062<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,058<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Employee share purchase plan share issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee share purchase plan share issuance</a></td>
<td class="nump">231<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">230<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">15,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,811<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">89,825<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">87,739<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 898<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">855,452<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(745,496)<span></span>
</td>
<td class="num">(23,167)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(48,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(48,832)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,413)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Issuance of common stock, net of issuance costs</a></td>
<td class="nump">9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,244<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Amortization of deferred issuance costs</a></td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,194)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 52<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (52)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">734<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">735<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="nump">$ 5,359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,351<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesOther', window );">Vesting of restricted shares (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan', window );">Employee share purchase plan share issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Employee share purchase plan share issuance</a></td>
<td class="nump">1,361<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,360<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Share-based compensation expense</a></td>
<td class="nump">20,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20,387<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 73,848<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 965<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 891,791<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (794,328)<span></span>
</td>
<td class="num">$ (24,580)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments to Additional Paid in Capital, Adjustments In Fair Value Of Convertible Debt Conversion Feature</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-13<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481089/718-20-55-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 40<br> -Section 25<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480637/718-40-25-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of shares of stock issued attributable to transactions classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639784294160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,832)<span></span>
</td>
<td class="num">$ (160,276)<span></span>
</td>
<td class="num">$ (137,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">2,681<span></span>
</td>
<td class="nump">1,766<span></span>
</td>
<td class="nump">1,493<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts', window );">Amortization of debt discount and debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,796<span></span>
</td>
<td class="nump">6,052<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes', window );">Changes in deferred taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">26,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Share-based compensation expense</a></td>
<td class="nump">20,387<span></span>
</td>
<td class="nump">15,811<span></span>
</td>
<td class="nump">7,013<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherOperatingActivitiesCashFlowStatement', window );">Other adjustments</a></td>
<td class="num">(828)<span></span>
</td>
<td class="nump">1,262<span></span>
</td>
<td class="nump">2,042<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Net changes in assets and liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="num">(21,994)<span></span>
</td>
<td class="num">(12,103)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInInventories', window );">Inventories</a></td>
<td class="num">(9,219)<span></span>
</td>
<td class="num">(9,532)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">416<span></span>
</td>
<td class="num">(2,155)<span></span>
</td>
<td class="nump">30,950<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable &amp; other current liabilities</a></td>
<td class="num">(4,093)<span></span>
</td>
<td class="nump">1,545<span></span>
</td>
<td class="num">(3,108)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccruedLiabilities', window );">Accrued expenses</a></td>
<td class="nump">16,424<span></span>
</td>
<td class="nump">16,892<span></span>
</td>
<td class="nump">227<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet', window );">Other assets and liabilities</a></td>
<td class="num">(1,849)<span></span>
</td>
<td class="nump">2,354<span></span>
</td>
<td class="num">(3,534)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(46,907)<span></span>
</td>
<td class="num">(128,511)<span></span>
</td>
<td class="num">(70,304)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(716)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt', window );">Proceeds from sales of marketable securities</a></td>
<td class="nump">327,781<span></span>
</td>
<td class="nump">187,136<span></span>
</td>
<td class="nump">83,828<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(276,001)<span></span>
</td>
<td class="num">(237,229)<span></span>
</td>
<td class="num">(3,414)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by (used in) investing activities</a></td>
<td class="nump">51,780<span></span>
</td>
<td class="num">(50,093)<span></span>
</td>
<td class="nump">79,698<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions', window );">Proceeds from stock option exercises and employee share purchase plan</a></td>
<td class="nump">6,720<span></span>
</td>
<td class="nump">2,293<span></span>
</td>
<td class="nump">2,682<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfDebtIssuanceCosts', window );">Payments for debt issuance costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(4,357)<span></span>
</td>
<td class="num">(4,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from royalty purchase agreement</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">15,970<span></span>
</td>
<td class="nump">135,335<span></span>
</td>
<td class="nump">14,543<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Effect of foreign currency exchange rate changes on cash and cash equivalents</a></td>
<td class="num">(639)<span></span>
</td>
<td class="nump">455<span></span>
</td>
<td class="num">(664)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net change in cash and cash equivalents</a></td>
<td class="nump">20,204<span></span>
</td>
<td class="num">(42,814)<span></span>
</td>
<td class="nump">23,273<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at January 1</a></td>
<td class="nump">31,167<span></span>
</td>
<td class="nump">73,981<span></span>
</td>
<td class="nump">50,708<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at December 31</a></td>
<td class="nump">51,371<span></span>
</td>
<td class="nump">31,167<span></span>
</td>
<td class="nump">73,981<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Interest paid</a></td>
<td class="nump">7,181<span></span>
</td>
<td class="nump">5,250<span></span>
</td>
<td class="nump">9,660<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Income taxes refunded, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(29,058)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avdl_February2023NotesMember', window );">February 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payments for Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(17,500)<span></span>
</td>
<td class="num">(8,653)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=avdl_October2023NotesMember', window );">October 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfSeniorDebt', window );">Payments for Notes</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(21,165)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_PublicOfferingMember', window );">Public offering</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares, net of issue costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">134,151<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_AtTheMarketOfferingProgramMember', window );">At-the-market offering program</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from issuance of shares, net of issue costs</a></td>
<td class="nump">$ 9,250<span></span>
</td>
<td class="nump">$ 11,913<span></span>
</td>
<td class="nump">$ 25,318<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AmortizationOfFinancingCostsAndDiscounts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense attributable to debt discount (premium) and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AmortizationOfFinancingCostsAndDiscounts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 830<br> -SubTopic 230<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInDeferredIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInDeferredIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherOperatingActivitiesCashFlowStatement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherOperatingActivitiesCashFlowStatement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfDebtIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfDebtIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfSeniorDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfSeniorDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avdl_February2023NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avdl_February2023NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avdl_October2023NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avdl_October2023NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avdl_PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_AtTheMarketOfferingProgramMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avdl_AtTheMarketOfferingProgramMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798282992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Summary of Significant Accounting Policies</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is registered as an Irish public limited company. The Company&#8217;s headquarters are in Dublin, Ireland with operations in Dublin, Ireland and St. Louis, Missouri, United States (&#8220;U.S.&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (&#8220;EDS&#8221;) in patients seven years of age and older with narcolepsy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted Orphan Drug Exclusivity (&#8220;ODE&#8221;) to LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy for a period of seven years until May 1, 2030. In June 2023, the Company commercially launched LUMRYZ in the U.S for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has required implementation of a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, the Company&#8217;s only commercialized product is LUMRYZ. The Company continues to evaluate opportunities to expand its product portfolio.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adequacy of the Company&#8217;s cash resources depends on the outcome of certain business conditions including the cost of the Company&#8217;s ongoing LUMRYZ commercialization activities, the Company&#8217;s cost structure, and other factors set forth in &#8220;Risk Factors&#8221; within Part I, Item 1A of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. and the requirements of Form 10-K. The consolidated financial statements include the accounts of the Company and all subsidiaries. All intercompany accounts and transactions have been eliminated.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified within the notes to the consolidated financial statements to condense line items of the same nature to conform with the current year presentation.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and marketable securities are held at three financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. The Company has not experienced any losses on its cash, cash equivalents, or marketable securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to the sale of LUMRYZ. The Company extends credit to its customers, specialty pharmacies. Customer creditworthiness is monitored, and collateral is not required. Amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible. As of December&#160;31, 2024, the Company did not recognize any allowances for credit </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses. As of December&#160;31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;Caremark&#8221;), which accounted for 53% of gross accounts receivable; Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (&#8220;Optum&#8221;), which accounted for 22% of gross accounts receivable. As of December&#160;31, 2023, three customers accounted for 100% of gross accounts receivable, Caremark, which accounted for 52% of gross accounts receivable; Accredo, which accounted for 28% of gross accounts receivable; and Optum, which accounted for 20% of gross accounts receivable. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company attempts to maintain multiple suppliers for its active pharmaceutical ingredient (&#8220;API&#8221;) and manufacturing in order to mitigate the risk of shortfall and inability to supply market demand, but is subject to risk due to a limited number of providers. The API is currently manufactured by two outsourced contract development and manufacturing organizations (&#8220;CDMOs&#8221;) in the U.S. The drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue includes sales of LUMRYZ. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer&#894; (ii) identify the performance obligations in the contract; (iii) determine the transaction price&#894; (iv) allocate the transaction price to the performance obligations in the contract&#894; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#8217;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells LUMRYZ to specialty pharmacies and considers those specialty pharmacies to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. The Company&#8217;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes the cost of the API, manufacturing and distribution costs, packaging costs and freight. LUMRYZ was approved by the FDA on May 1, 2023 and the Company began shipping product to its customers in June 2023. Cost of products sold includes inventory purchased or produced that was expensed as research and development costs prior to FDA approval.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories consist of raw materials, work in process and finished products, which are stated at lower of cost or net realizable value, using the first-in, first- out method. Raw materials used in the production of pre-clinical and clinical products are expensed as research and development costs. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (&#8220;R&amp;D&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of costs related to outside services, personnel expenses, clinical studies and other R&amp;D expenses. Outside services and clinical studies costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third-party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other R&amp;D expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&amp;D expenditures are charged to operations as incurred. Raw materials used in the production of pre-clinical and clinical products are expensed as R&amp;D costs.  &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes refundable R&amp;D tax credits received for spending on innovative R&amp;D as an offset of R&amp;D expenses.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expenses. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses the costs of advertising as incurred. Branded advertising expenses were $12,186 and $6,452 for the years ended December&#160;31, 2024 and 2023. Branded advertising expenses were immaterial for the year ended December 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations, cash flows or liquidity.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for share-based compensation based on the estimated grant-date fair value. The fair value of stock options is estimated using Black-Scholes option-pricing valuation models (&#8220;Black-Scholes model&#8221;). As required by the Black-Scholes model, estimates are made of the underlying volatility of Avadel stock, a risk-free rate and an expected term of the option or warrant. The Company estimates the expected term using a simplified method, as the Company does not have enough historical exercise data for a majority of such options upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of December&#160;31, 2024, the Company's cumulative loss position was significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax expense line in the consolidated statements of loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are considered to be available for sale and are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in shareholders&#8217; equity, with the exception of unrealized gains and losses on equity instruments and allowances for expected credit losses, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements, furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years</span></div></td></tr></table></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company determined that no impairment of goodwill existed at December&#160;31, 2024 and 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Long-lived assets include fixed assets and right of use assets at contract manufacturing organizations. Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset or other market-based value approaches. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. Certain long-lived assets are amortized using the straight-line method over a five year useful life. Amortization on long-lived assets is considered to be manufacturing overhead costs and is either capitalized into inventory or expensed in the period incurred. The Company determined that no impairment of long-lived assets existed at December&#160;31, 2024 and 2023. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract is a lease at the inception of the arrangement. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. Short term leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease payments are recognized in the consolidated statements of loss on a straight-line basis over the lease term. The Company&#8217;s lease contracts do not provide a readily determinable implicit rate. The Company&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease. The Company&#8217;s lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the consolidated statements of loss.</span></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span>The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. These estimates and assumptions are based on the best information available to management and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company&#8217;s consolidated financial statements. Actual results could differ from those estimates under different assumptions or&#160;conditions.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798310544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Newly Issued Accounting Standards<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract', window );"><strong>Accounting Changes and Error Corrections [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock', window );">Newly Issued Accounting Standards</a></td>
<td class="text">Newly Issued Accounting Standards<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the provisions of ASU 2023-07 for the annual period beginning on January 1, 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18: Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding segment disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for annual periods beginning after December 15, 2024. Adoption of ASU 2023-09 will not have a material effect on the Company&#8217;s financial position or results of operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 220-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact adopting ASU 2024-03 will have on its financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Issued Climate-Related Disclosure Rule</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) issued a final rule requiring public companies to disclose climate-related information in their registration statements and annual reports. For large accelerated filers, the initial disclosure rules are effective for annual periods for the year ending December 31, 2025. In April 2024, the SEC voluntarily stayed the final rule pending the completion of judicial review by the Court of Appeals for the Eighth Circuit. The Company is monitoring the development of litigation related to the SEC&#8217;s rule, and is currently evaluating the effects of the final rule on its disclosures, processes and procedures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingChangesAndErrorCorrectionsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingChangesAndErrorCorrectionsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476173/280-10-65-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-7<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483550/848-10-65-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 5<br> -Subparagraph (SAB Topic 11.M.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-5<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (i)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480528/815-20-65-6<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479654/326-10-65-4<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 926<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483194/926-20-65-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480530/250-10-S99-6<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 250<br> -Publisher FASB<br> -URI https://asc.fasb.org/250/tableOfContent<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789577520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerTextBlock', window );">Revenue Recognition</a></td>
<td class="text">Revenue Recognition<div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s source of net product revenue during the years</span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ended </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> consists solely of sales of LUMRYZ in the U.S.</span></div><div style="margin-bottom:12pt;text-align:justify"><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2024 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2023</span><span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, three customers accounted for 100% of sales. The following table presents a summary of the percentage of total gross sales to customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales by Customer:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caremark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accredo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had no net product revenue during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-9<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-15<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789579728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text">Fair Value Measurements<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, the Company uses fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ASC 820, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fair Value Measurements and Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">,&#160;defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may generally use one or each of the following techniques: &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Income approach, which is based on the present value of a future stream of net cash flows. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: &#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 1 - Quoted prices for identical assets or liabilities in active markets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. </span></div><div style="text-align:justify"><span><br/></span></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Level 3 - Unobservable inputs that reflect estimates and assumptions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A review of fair value hierarchy classifications is conducted on a quarterly basis.&#160;Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the year ended December&#160;31, 2024, there were no transfers in and out of&#160;Level&#160;1, 2, or 3. During the&#160;years ended December&#160;31, 2024, 2023, and 2022, the Company did not recognize any allowances for credit losses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some of the Company&#8217;s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the consolidated balance sheets at carrying value, which approximates fair value due to their short-term nature. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Royalty Financing Obligation</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024 and 2023, the carrying value of the royalty financing obligation under the Royalty Purchase Agreement (&#8220;RPA&#8221;) approximated its fair value and was measured using the estimates of forecasted net product revenue based on current contractual and statutory requirements, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns (Level 3 inputs). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 10: Royalty Financing Obligation</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding the Company&#8217;s royalty financing obligation.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798265312">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock', window );">Marketable Securities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities&#160;</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has investments in available-for-sale debt securities that are recorded at fair market value. The change in the fair value of available-for-sale debt investments is recorded as accumulated other comprehensive loss in shareholders&#8217; equity, net of </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">income tax effects. As of December&#160;31, 2024 and 2023, the Company considered any decreases in fair value on its marketable securities to be driven by factors other than credit risk, including market risk.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s available-for-sale securities&#8217; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines realized gains or losses on the sale of marketable securities on a specific identification method. The Company reflects these gains and losses as a component of investment and other income (expense), net in the accompanying consolidated statements of loss.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognized gross realized gains of&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1,625,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $988 and $584 for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. These realized gains were offset by no gross realized losses for the year ended December&#160;31, 2024 and gross realized losses of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$2,791 and $2,338 for the years ended December&#160;31, 2023 and 2022, respectively. </span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of the Company&#8217;s investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Debt Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5-10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has classified its investment in available-for-sale marketable debt securities as current assets in the consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in the Company&#8217;s investment portfolio.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/320/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790289344">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureTextBlock', window );">Inventories</a></td>
<td class="text">Inventories<div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of inventories at December&#160;31, 2024 and 2023 were comprised of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inventory:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,298&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,380&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790269120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, net</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property and Equipment, net</span><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Property and Equipment, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div>Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was $132, $254 and $162, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798117472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Goodwill </span><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s goodwill is $16,836 at December&#160;31, 2024 and 2023.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No impairment loss related to goodwill was recognized during the years ended December&#160;31, 2024 or 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798265808">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text">Leases<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company leases office space and a production suite. All leased facilities are classified as operating leases with remaining lease terms between&#160;<span style="-sec-ix-hidden:f-539">one</span>&#160;and&#160;four years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. The Company&#8217;s lease agreements do not contain any material residual value guarantees or material variable lease payments. For the Company&#8217;s leased production suite, contract consideration was allocated to lease and non-lease components on the basis of relative standalone price. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs, which are included in selling, general and administrative expenses in the consolidated statements of loss for the years ended December&#160;31, 2024, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2024, the Company reduced its operating lease liabilities by $1,091 for cash paid. During the year ended December&#160;31, 2023, the Company increased its operating lease liabilities by $1,803 due to an increase in the lease term for the production suite, offset by $1,036 for cash paid. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company&#8217;s operating leases have a weighted-average remaining lease term of</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> 3.3 years</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and a weighted-average discount rate of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8.4%</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company&#8217;s lease contracts do not provide a readily determinable implicit rate. The Company&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790171152">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Royalty Financing Obligation</a></td>
<td class="text">Royalty Financing Obligation<div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 29, 2023, the Company and Avadel CNS Pharmaceuticals, LLC entered into the RPA with RTW Investments, L.P. (&#8220;RTW&#8221;) for up to $75,000 of royalty financing in two tranches. The first tranche of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$30,000</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> became available upon satisfaction of certain conditions which included the Company&#8217;s first shipment of LUMRYZ. The second tranche became available to use, at the Company&#8217;s election, when the Company achieved quarterly net revenue of $25,000 prior to the quarter ending June 30, 2024. The Company allowed the second tranche to expire on August 31, 2024 and paid a one-time commitment fee of $2,000 to RTW in accordance with the terms of the RPA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 1, 2023, the Company received the first tranche of $30,000. The Company is required to make quarterly royalty payments calculated as 3.75% of worldwide net product revenue of LUMRYZ, up to a total payback of $75,000. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The RPA is recorded as a royalty financing obligation on the consolidated balance sheets based on the Company&#8217;s evaluation of the terms of the RPA. The accounts receivable and inventory balances of LUMRYZ are pledged as collateral for the RPA. There are no subjective acceleration clauses or provisions, and there are no covenants in violation or other clauses that would cause the full amount of the royalty financing obligation to be callable. As such, the RPA is recorded as a long-term obligation on the consolidated balance sheets. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company imputes interest using the effective interest method and records interest expense based on the unamortized royalty financing obligation. The Company&#8217;s estimate of the interest rate under the RPA is based primarily on forecasted net revenue and the calculated amounts and timing of net royalty payments to reach the total payback of $75,000. As of December&#160;31, 2024 and December&#160;31, 2023 the effective interest rate is estimated as 25.2% and 30.4%, respectively. The Company accounts for changes in the imputed interest rate resulting from changes in forecasted net product revenue using the prospective method. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table shows the activity within the royalty financing obligation account:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Financing Obligation:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of the first tranche of the royalty financing obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of imputed interest expense on royalty financing obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payments made to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: one-time payment for expiration of second tranche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payable to RTW classified within accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The accretion of imputed interest expense is reflected as interest expense in the consolidated statements of loss. For the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, the total interest expense related to the royalty financing obligation was $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">10,830</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and $</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">3,743, </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">respectively. The remaining interest expense incurred for the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023 was related to </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">the 4.50% exchangeable senior notes due February 2023 (&#8220;February 2023 Notes&#8221;) and the 4.50%  exchangeable senior notes due October 2023 (&#8220;October 2023 Notes&#8221;, together, the &#8220;2023 Notes&#8221;). The Company had no interest expense related to the royalty financing obligation during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790297120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes</span><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the following years ended December 31, are as follows:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss Before Income Taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,439)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax (benefit) provision consists of the following for the years ended December 31:&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Income Tax (Benefit) Provision:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between income taxes at the statutory rate and the Company&#8217;s (benefit) provision for income taxes is as follows for the following years ended December 31:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Reconciliation to Effective Income Tax Rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences in international tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Return to Provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes (net of federal)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2024, the income tax benefit was $247, a decrease of $254 from income tax benefit of $501. The change in the effective tax rate for the year ended December 31, 2024 is primarily driven by the reversal of unrecognized tax benefits during the year. The effective tax rate for 2022 was impacted by the valuation allowance.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Unrecognized Tax Benefits</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company or one of its subsidiaries files income tax returns in Ireland, France, U.S. and various states. The Company is no longer subject to Irish, French, U.S. Federal, and state and local examinations for years before 2020. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Unrecognized Tax Benefit Activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statute of limitations expiration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expects that within the next twelve months the unrecognized tax benefits could decrease by approximately $1,637 and the interest could increase by an immaterial amount.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, 2023 and 2022, there are $2,724, $3,035,and $3,143 of unrecognized tax benefits that if recognized would affect the annual effective tax rate.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax provision. During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized approximately $56, $268 and $258 in interest and penalties, respectively. The Company had approximately $2,427 and $2,372 for the payment of interest and penalties accrued at December&#160;31, 2024 and 2023, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Deferred Tax Assets (Liabilities)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income tax provisions reflect the effect of temporary differences between consolidated financial statement and tax reporting of income and expense items. The net deferred tax assets (liabilities) at December&#160;31, 2024 and 2023 resulted from the following temporary differences:&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Liabilities: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and Other Accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense carryforward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company had </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$71,588</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of net operating losses in Ireland that do not have an expiration date and $227,344 of net operating losses and $5,809 163(j) carryforwards in the U.S. Of the $227,344 of net operating losses in the U.S., $10,365 were acquired due to the acquisition of FSC Therapeutics and FSC Laboratories, Inc., (collectively &#8220;FSC&#8221;) and $212,637 are due to the losses at US Holdings, of which $4,342 are state net operating losses. The portion due to the acquisition of FSC will expire in 2034 through 2035. The remaining U.S. net operating loss and 163(j) carryforwards do not have an expiration date. A valuation allowance is recorded if, based on the weight of available evidence, it is more likely than not that a deferred tax asset will not be realized. This assessment is based on an evaluation of the level of historical taxable income and projections for future taxable income. For the year ended December&#160;31, 2024, the Company recorded a net increase to the valuation allowance related primarily to current year net operating losses of $5,137. The U.S. net operating losses are subject to an annual limitation as a result of the FSC acquisition under Internal Revenue Code Section 382 and will not be fully utilized before they expire. In addition to net operating losses and 163(j) carryforwards, the Company has U.S. Orphan Drug tax credit carryforwards of $3,059 as well as U.S. Research and Development credits of $1,036. The Orphan Drug Credit and Research and Development credits will expire in 2040 through 2044. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's cumulative loss position is significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company has recorded a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recorded a valuation allowance against all of its net operating losses in Ireland, France and the U.S. as of December&#160;31, 2024 and 2023. The Company intends to continue maintaining a full valuation allowance on the Irish, French and U.S. net operating losses until there is sufficient evidence to support the reversal of all or some portion of these allowances.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, the Company has unremitted earnings of $3,755 outside of Ireland as measured on a U.S. GAAP basis.  Whereas the measure of earnings for purposes of taxation of a distribution may be different for tax purposes, these earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends or if the Company were to sell its stock in the subsidiaries, net of any prior income taxes paid. It is not practicable to estimate the amount of deferred tax liability on such earnings, if any.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">R&amp;D Tax Credits Receivable</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The French and Irish governments provide tax credits to companies for spending on innovative R&amp;D. These credits are recorded as an offset of R&amp;D expenses and are credited against income taxes payable in years after being incurred or, if not so utilized, are recoverable in cash after a specified period of time, which may differ depending on the tax credit regime. As of December&#160;31, 2024, the Company&#8217;s net research tax credit receivable amounts to $587 and represents an Irish gross research tax credit. As of December&#160;31, 2023, the Company&#8217;s net research tax credit receivable amounts to $1,654 and represents a French gross research tax credit of $837 and an Irish gross research tax credit of $817.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790116880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureTextBlock', window );">Other Assets and Liabilities</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Other Assets and Liabilities</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various other assets and liabilities are summarized for the years ended December 31, as follows:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaid Expenses and Other Current Assets: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use assets at contract manufacturing organizations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrued Expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for variable consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty payable to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-bottom:6pt;text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:61.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for other liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798299168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Contingent Liabilities and Commitments</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Contingent Liabilities and Commitments</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Litigation &#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations, cash flows or liquidity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">First Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 12, 2021, Jazz Pharmaceuticals, Inc. (&#8220;Jazz&#8221;) filed a formal complaint (the &#8220;First Complaint&#8221;) initiating a lawsuit in the United States District Court for the District of Delaware (the &#8220;Court&#8221;) against Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Management Corporation, Avadel Legacy Pharmaceuticals, LLC, Avadel Specialty Pharmaceuticals, LLC, and Avadel CNS Pharmaceuticals, LLC (collectively, the &#8220;Avadel Parties&#8221;). In the First Complaint, Jazz alleges the sodium oxybate product (&#8220;Proposed Product&#8221;) described in the NDA owned by Avadel CNS Pharmaceuticals, LLC (&#8220;Avadel CNS&#8221;) will infringe at least one claim of U.S. Patent No. 8731963, 10758488, 10813885, 10959956 and/or 10966931 (collectively, the &#8220;patents-in-suit&#8221;). The First Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 3, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#8220;Avadel Answer&#8221;) with the Court in response to the First Complaint. The Avadel Answer generally denies the allegations set forth in the First Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patents-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of each patent-in-suit, and ii) a declaratory judgment of invalidity of each patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 18, 2021, Jazz filed its Answer (&#8220;Jazz Answer&#8221;) with the Court in response to the Avadel Answer. The Jazz Answer generally denies the allegations set forth in the Avadel Answer and sets forth a single affirmative defense asserting that Avadel has failed to state a claim for which relief can be granted.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 21, 2021, the Court issued an oral order requiring the parties to i) confer regarding proposed dates to be included in the Court&#8217;s scheduling order for the case, and ii) submit a proposed order, including a proposal for the length and timing of trial, to the Court by no later than July 21, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 30, 2021, the Court issued a scheduling order establishing timing for litigation events including i) a claim construction hearing date of August 2, 2022, and ii) a trial date of October 30, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 18, 2021, consistent with the scheduling order, Jazz filed a status update with the Court indicating that Jazz did not intend to file a preliminary injunction with the Court at this time. Jazz further indicated that it would provide the Court with an </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">update regarding whether preliminary injunction proceedings may be necessary after receiving further information regarding the FDA&#8217;s action on Avadel CNS&#8217;s NDA.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 4, 2022, the Court entered an agreed order dismissing this case with respect to Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Specialty Pharmaceuticals, LLC, Avadel Legacy Pharmaceuticals, LLC, and Avadel Management Corporation. A corresponding order was entered in the two below cases on the same day.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2022, Jazz filed an amended Answer to the Avadel Parties&#8217; Counterclaims (&#8220;the Jazz First Amended Answer&#8221;). The Jazz First Amended Answer is substantially similar to the Jazz Answer except insofar as it adds an affirmative defense for judicial estoppel and unclean hands. Corresponding amended answers were filed in the two below cases on the same day.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2022, Avadel CNS filed a Renewed Motion for Judgment on the Pleadings, with respect to its counterclaim against Jazz seeking to have U.S. Patent No. 8731963 (the &#8220;REMS Patent&#8221;) delisted from the Orange Book and seeking to have the motion resolved concurrent with the parties&#8217; </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing on August 31, 2022. On July 7, 2022, Jazz filed a response styled as Objections to Avadel CNS&#8217; Motion for Judgment on the Pleadings. On July 14, 2022, Avadel CNS replied to Jazz&#8217;s response, and on July 21, 2022, Avadel CNS requested oral argument on its delisting motion simultaneous with the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing. On August 24, 2022, the Court ordered Jazz to respond substantively to Avadel CNS&#8217; motion, which Jazz did on August 26, 2022. Avadel CNS filed its reply on August 28, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 23, 2022, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing was postponed. On September 7, 2022, the case was reassigned to a new judge, and the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing was held on October 25, 2022. At the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing, Avadel CNS reiterated its request for an expedited hearing on the Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent. On October 28, 2022, the Court granted Avadel CNS&#8217; request and scheduled the hearing for November 15, 2022.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Court held the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> hearing on November 15, 2022 and issued a claim construction ruling on November 18, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also, on November 18, 2022 the Court granted Avadel&#8217;s Renewed Motion for Judgment on the Pleadings and ordered Jazz to request delisting of the REMS Patent from the Orange Book. On November 22, 2022, Jazz appealed that decision and on December 14, 2022, the Federal Circuit issued a stay of the delisting order until further notice. Oral argument was held February 14, 2023. On February 24, 2023, the United States Court of Appeals for the Federal Court affirmed the previous ruling from the Court, ordering the delisting of the REMS Patent from the Orange Book, which has since occurred. On March 7, 2023, in response to a joint stipulation filed by the parties, the Court issued an order dismissing Jazz&#8217;s infringement claims against the Avadel Parties relating to the REMS Patent as well as Avadel Parties&#8217; noninfringement and invalidity counterclaims relating to the REMS Patent.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 15, 2023, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule to accommodate additional claim construction proceedings. That stipulation remains pending before the Court. On April 26, 2023, the parties filed their Supplemental Joint Claim Construction Brief.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2023, the Court issued a modified scheduling order establishing a new trial date of February 26, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On July 21, 2023, in response to a Court order, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule with an updated proposed schedule to accommodate additional claim construction proceedings.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 4, 2023, the Court entered a modified version of the parties&#8217; proposed schedule, which was revised on August 28, 2023. The parties&#8217; Second Supplemental Joint Claim Construction Brief was filed on October 10, 2023, and a </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Markman</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> hearing regarding the disputed terms occurred on November 1, 2023. The Court issued its claim construction order on December 15, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On August 15, 2023, Avadel renewed its request to consolidate this litigation with the litigation described in the Avadel Complaint below. On November 3, 2023, the Court denied that request.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 30, 2023, the parties filed cross motions for summary judgment. The parties filed opposition briefs on December 15, 2023. The parties filed reply briefs on December 22, 2023.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 14, 2024, the Court denied the parties&#8217; summary judgment motions. On February 15, 2024, the Court held its Pretrial Conference. Trial was held from February 26, 2024 to March 1, 2024 (the &#8220;February Patent Trial&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 4, 2024, the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">jury returned a verdict of no infringement for U.S. Patent No. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10758488 and infringement of U.S. Patent No. 11147782, with</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> damages of $234,</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> which are included in the consolidated balance sheets in accrued expenses at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2024, the Court issued a Supplemental Scheduling Order setting a June 4, 2024 hearing on Jazz&#8217;s request for a permanent injunction or ongoing royalty. Briefing on Jazz&#8217;s request closed on May 20, 2024, and the hearing was held June 4, 2024. On August 27, 2024, the Court issued an opinion and order enjoining Avadel from infringing claim 24 of U.S. Patent No. </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11147782. That injunction excluded certain categories of conduct, including permitting Avadel to continue making, using and selling LUMRYZ for the treatment of narcolepsy and for use in ongoing clinical trials and studies. The August 27, 2024 opinion and order also granted Jazz&#8217;s motion for an ongoing royalty, pending additional briefing on the appropriate royalty rate. That briefing closed on September 23, 2024. While a future ongoing royalty is pending briefing and a decision by the Court, the Company recorded an estimated liability for a royalty based on information available as of December 31, 2024. It is reasonably possible that a change in the estimate may occur pending the Court&#8217;s decision. On August 28, 2024, Avadel filed a notice of appeal concerning the August 27, 2024 injunction (the &#8220;Patent Appeal&#8221;). On September 3, 2024, Avadel moved in District Court to stay the August 27, 2024 injunction pending appeal. Briefing on that motion closed on September 16, 2024. On September 24, 2024, the District Court denied Avadel&#8217;s motion to stay the injunction pending appeal.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, Avadel moved the U.S. Court of Appeals for the Federal Circuit to stay the injunction pending appeal. Briefing on that motion closed on September 27, 2024. On October 2, 2024, the Federal Circuit granted Avadel&#8217;s motion in part, staying the injunction with respect to Avadel&#8217;s initiating new clinical trials or studies.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 10, 2024, the Federal Circuit entered a briefing schedule concerning the Patent Appeal. On September 30, 2024, Avadel filed its opening brief. Jazz filed its response brief on November 7, 2024. Avadel filed its reply brief on November 18, 2024. On October 2, 2024, the Federal Circuit placed the Patent Appeal on the February 2025 oral argument calendar. On February 7, 2025, the Federal Circuit heard oral argument in the Patent Appeal. The Patent Appeal remains pending.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Jazz Complaint </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 4, 2021, Jazz filed another formal complaint (the &#8220;Second Complaint&#8221;) initiating a lawsuit in the Court against the Avadel Parties. In the Second Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11077079. The Second Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 9, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#8220;Second Avadel Answer&#8221;) with the Court in response to the Second Complaint. The Second Avadel Answer generally denies the allegations set forth in the Second Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity of the patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 22, 2021, the Court issued an oral order stating that this case should proceed on the same schedule as the case filed on May 12, 2021.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 10, 2021, Jazz filed another formal complaint (the &#8220;Third Complaint&#8221;) initiating a lawsuit in the Court against the Avadel Parties. In the Third Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11147782. The Third Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses. This case will proceed on the same schedule as the cases associated with the First and Second Complaints above.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 21, 2021, the Court entered a revised schedule for the First, Second and Third Complaints, setting a new claim construction date of August 31, 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 7, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#8220;Third Avadel Answer&#8221;) with the Court in response to the Third Complaint. The Third Avadel Answer generally denies the allegations set forth in the Third Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fourth Jazz Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 15, 2022, Jazz filed another formal complaint (the &#8220;Fourth Complaint&#8221;) initiating a lawsuit in the Court against Avadel CNS. In the Fourth Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">least one claim of the REMS Patent, which was asserted in the First Complaint. The FDA required Avadel CNS to file a Paragraph IV certification against the REMS Patent, which Avadel CNS did under protest, consistent with its Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent from the Orange Book, which was later ordered to be delisted in the above First Jazz Complaint action. Avadel CNS provided the required notice of its Paragraph IV certification to Jazz, and Jazz reasserted the REMS Patent in a separate action following receipt of that notice. The Fourth Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 21, 2022, Jazz served the Fourth Complaint. On October 21, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#8220;Fourth Avadel Answer&#8221;) with the Court in response to the Fourth Complaint. The Fourth Avadel Answer generally denies the allegations set forth in the Fourth Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims for i) a declaratory judgment of non-infringement of the patent-in-suit, ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit, iii) delisting of the patent-in-suit from the Orange Book; iv) monopolization under the Sherman Antitrust Act of 1890 (the &#8220;Sherman Act&#8221;); and v) attempted monopolization under the Sherman Act.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 9, 2022, Jazz filed a Motion to Dismiss Avadel&#8217;s Antitrust Counterclaims.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Avadel filed its opposition brief on December 27, 2022, and Jazz filed its reply brief on January 6, 2022.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On January 11, 2023, Avadel filed a request for oral argument on the motion. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Dismiss.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 7, 2024, Jazz filed its Answer to Avadel&#8217;s Counterclaims.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On March 6, 2023, the parties filed a stipulation of dismissal, dismissing Jazz&#8217;s claims with respect to the REMS Patent and Avadel CNS&#8217;s related non-infringement and invalidity counterclaims. The Court entered that stipulation on March 7, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 19, 2023, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by March 14, 2024, and ii) a deadline for case dispositive motions of September 20, 2024. On January 23, 2024, the parties submitted a stipulation to extend the case schedule. On January 24, 2024, the Court ordered an extension of the case schedule, including i) completion of fact discovery by June 20, 2024 and ii) a deadline for case dispositive motions by January 31, 2025. On January 24, 2024, the Court issued an order setting a pretrial conference for October 30, 2025 and a 5-day trial to begin on November 3, 2025. On April 22, 2024, the parties submitted a stipulation extending certain pretrial deadlines, including i) extending completion of fact discovery to September 27, 2024 and ii) extending the deadline for case dispositive motions to April 4, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 29, 2023, Jazz filed a Motion to Stay the case, pending resolution of its Motion to Dismiss. Briefing on that Motion to Stay closed on August 10, 2023. On March 13, 2024, Jazz filed a Supplemental Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Stay.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 7, 2024, Jazz filed a Motion for Reargument or in the Alternative to Certify an Appeal. Avadel filed its opposition brief on June 28, 2024. Jazz filed its reply brief on July 12, 2024. On September 25, 2024, Jazz sought leave to file a supplemental brief in support of its Motion to Stay.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">  </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On October 4, 2024, the Court granted leave to Jazz to file its supplemental brief, which Jazz filed on October 7, 2024. Avadel filed its response on October 21, 2024. Jazz filed its reply on October 28, 2024. Jazz&#8217;s motion remains pending.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Avadel Complaint</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 14, 2022, Avadel CNS and Avadel Pharmaceuticals plc (collectively the &#8220;Avadel Plaintiffs&#8221;) filed a formal complaint (the &#8220;Avadel Complaint&#8221;) initiating a lawsuit in the Court against Jazz and Jazz Pharmaceuticals Ireland Ltd. (collectively, the &#8220;Jazz Parties&#8221;). In the Avadel Complaint, the Avadel Plaintiffs allege that the Jazz Parties breached certain confidential disclosure agreements and misappropriated certain of the Avadel Plaintiffs&#8217; trade secrets. The Avadel Complaint further includes typical relief requests such as injunctive relief, monetary damages and attorneys&#8217; fees, costs and expenses, as well as seeking correction of inventorship of certain Jazz patents, for which the Jazz Parties claim ownership, to include former Avadel Plaintiffs&#8217; scientists.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 2, 2022, Jazz answered the Avadel Complaint. The Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 8, 2022, Jazz filed a Motion for Judgment on the Pleadings seeking to have all Counts dismissed for failure to state a claim upon which relief can be granted. The Avadel Plaintiffs&#8217; response to that Motion was filed with the Court on July 29, </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022. Jazz&#8217;s reply was filed with the Court on August 5, 2022. On February 2, 2023, the Court held a hearing on Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 7, 2022, the case was reassigned to a new judge.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 2, 2023, the Court held a hearing on Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 18, 2023, the Court denied Jazz&#8217;s Motion for Judgment on the Pleadings.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 15, 2023, the parties submitted competing proposed scheduling orders, and Avadel requested consolidation with the above First Jazz Complaint litigation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That request for consolidation was denied on November 3, 2023.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 17, 2023, the parties submitted an updated joint proposed scheduling order. On January 30, 2024, the parties agreed to a 6-week stay of discovery and submitted a proposed stipulation extending certain case deadlines to accommodate the same. On February 9, 2024, the parties submitted an updated proposed scheduling order consistent with that stipulation,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">setting the close of fact discovery for August 9, 2024 and a trial date of December 15, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That proposed scheduling order remains pending before the Court as of the date of this Annual Report on Form 10-K.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On March 19, 2024, Jazz filed a Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#8217;s Motions to Stay.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 10, 2024, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by August 9, 2024, ii) a deadline for case dispositive motions of May 30, 2025, and iii) a 5-day jury trial beginning December 15, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 11, 2024, the Court entered a stipulation by the parties extending certain case deadlines, including i) extending close of fact discovery to November 1, 2024 and ii) dispositive motions to July 18, 2025. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 3, 2024, Jazz filed an Amended Answer to the Avadel Complaint. The Amended Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 6, 2024, Avadel and Jazz stipulated to stay proceedings pending the resolution of the Patent Appeal above, which the Court entered on September 9, 2024.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Second Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 3, 2025, Avadel CNS and Flamel Ireland Limited (&#8220;Flamel&#8221;) filed a formal complaint (the &#8220;Second Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Second Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12167991 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Second Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jazz Parties&#8217; Answer is due on April 21, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Third Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 14, 2025, Avadel CNS and Flamel filed a formal complaint (the &#8220;Third Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Third Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12186298 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Third Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Jazz Parties&#8217; Answer is due on April 21, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Fourth Avadel Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On February 25, 2025, Avadel CNS and Flamel filed a formal complaint (the &#8220;Fourth Avadel Complaint&#8221;) initiating a lawsuit in the Court against the Jazz Parties. In the Fourth Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent Nos. 12226388 and 12226389 through, inter alia, the sale of XYWAV&#174; in conjunction with its FDA-approved labeling. The Fourth Avadel Complaint includes typical requests for monetary damages and attorneys&#8217; fees, as well as costs and expenses.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Jazz&#8217;s Administrative Procedure Act Complaint</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 22, 2023, Jazz filed an Administrative Procedure Act suit against the FDA, the U.S. Department of Health and Human Services, the Secretary of Health and Human Services and the Commissioner of Food and Drugs (the &#8220;Federal Defendants&#8221;) in the United States District Court for the District of Columbia (the &#8220;DC Court&#8221;) related to the NDA for LUMRYZ. This suit alleges that the FDA&#8217;s approval of LUMRYZ was an unlawful agency action and asks the DC Court to set aside FDA&#8217;s approval of LUMRYZ. On June 28, 2023, the DC Court granted Avadel CNS&#8217;s unopposed motion to intervene in the case to defend the FDA&#8217;s decision. On August 14, 2023, the Court entered a scheduling order establishing timing for litigation events including early summary judgment briefing closing December 22, 2023. On September 22, 2023, Jazz filed its Motion for Summary Judgment. On October 20, 2023, the FDA and Avadel filed their Cross Motions for Summary Judgment. Briefing on the parties&#8217; motions closed January 4, 2024. On February 14, 2024, the Court set hearing for oral argument on the parties&#8217; motions for February 27, 2024. On February 21, 2024, the Court rescheduled the oral argument to April 9, 2024. On April 2, 2024, the Court rescheduled the oral argument to May 10, 2024. On May 10, 2024, the Court heard oral argument on the parties&#8217; motions. On October 30, 2024, the Court granted FDA and Avadel&#8217;s Motions for Summary Judgment with respect to the sole count in Jazz&#8217;s complaint and denied Jazz&#8217;s Motion for Summary Judgment regarding the same. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On November 15, 2024, Jazz filed a notice of appeal concerning the Court&#8217;s October 30, 2024 ruling (the &#8220;APA Appeal&#8221;).</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2025, Jazz filed its opening brief in the APA Appeal.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel&#8217;s response brief is due March 17, 2025.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jazz&#8217;s reply brief is due April 7, 2025.</span></div><div style="text-align:justify"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Material Commitments </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div>The Company has a four year commitment with a CDMO to manufacture the LUMRYZ drug product of approximately $3,000 to $4,200 per year as determined by the terms of the agreement with the CDMO<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798277568">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments and Transactions<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_EquityTransactionsDisclosureTextBlock', window );">Equity Instruments and Transactions</a></td>
<td class="text">Equity Instruments and Transactions<div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Capital Shares</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has 500,000 authorized ordinary shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (&#8220;ordinary shares&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> with a nominal value of $0.01 per ordinary share. Effective April 15, 2024, the Company&#8217;s ordinary shares became directly listed on the Nasdaq Stock Market. The Company caused a mandatory exchange of its </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">American Depositary Shares (&#8220;ADSs&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for the underlying ordinary shares</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">on a one-for-one basis. Accordingly, the Bank of New York Mellon (&#8220;BNY Mellon&#8221;), as Depositary for the ADSs, issued a notice of termination of its American Depository Receipt program (&#8220;ADR Program&#8221;) of ADSs to the registered holders of ADSs according to the requirements under the deposit agreement dated January 3, 2017 (the &#8220;Deposit Agreement&#8221;) among the Company, BNY Mellon and holders of ADSs. The Deposit Agreement terminated on July 15, 2024. As of December&#160;31, 2024, the Company had 96,518 ordinary shares issued and outstanding. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Board of Directors is authorized to issue preferred shares in series, and with respect to each series, to fix its designation, relative rights (including voting, dividend, conversion, sinking fund, and redemption rights), preferences (including dividends and liquidation) and limitations. The Company has 50,000 authorized preferred shares, with a nominal value of $0.01 per preferred share. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Series A Non-Voting Convertible Preferred Shares and Series B Non-Voting Convertible Preferred Shares were converted to </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5,194</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ordinary shares at the option of the holders. Accordingly, there were no preferred shares issued and outstanding at </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%">Shelf Registration Statement on Form S-3</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 8, 2024, the Company entered into an Open Market Sale Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> (the &#8220;Sales Agreement&#8221;) with Jefferies LLC (&#8220;Jefferies&#8221;) pursuant to which the Company may offer and sell its ordinary shares, from time to time, with respect to an at-the-market offering program (&#8220;ATM Program&#8221;) under which Jefferies will act as sales agent. The Sales Agreement provides that Jefferies will be entitled to aggregate compensation for its services of an amount up to 3.0% of the gross proceeds of any ordinary shares sold through Jefferies under the Sales Agreement. The Sales Agreement replaces the Company&#8217;s previous Open Market Sale Agreement</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">SM </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with Jefferies, dated February 4, 2020 (the &#8220;ADS Sales Agreement&#8221;), which provided for the sale of ADSs by the Company. The Company terminated the ADS Sales Agreement upon effectiveness of the Sales Agreement following the mandatory exchange of the ADSs and the direct listing of the ordinary shares on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Nasdaq Stock Market on April 15, 2024.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The ordinary shares will be offered and sold pursuant to the Company&#8217;s shelf registration statement on Form S-3 </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(File No. 333-267198), filed with the SEC on August 31, 2022, as amended, and declared effective by the SEC on September 12, 2022, as supplemented by the prospectus supplement dated May 8, 2024 (the &#8220;Prospectus Supplement&#8221;). The Company may offer and sell ordinary shares having an aggregate offering price of up to $100,000 under the Prospectus Supplement. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Prior to termination, the Company issued and sold 640 ordinary shares pursuant to the ADS Sales Agreement during the three months ended March 31, 2024, resulting in net proceeds to the Company of approximately $9,250. The Company has not issued or sold ordinary shares under at-the-market offering programs subsequent to March 31, 2024.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_EquityTransactionsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity Transactions Disclosure</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_EquityTransactionsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790136528">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-Based Compensation</a></td>
<td class="text">Share-Based Compensation<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense included in the Company&#8217;s consolidated statements of loss for all share-based compensation arrangements was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-based Compensation Expense:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2024, the Company expects $22,513 of unrecognized expense related to granted, but non-vested share-based compensation arrangements to be incurred in future periods. This expense is expected to be recognized over a weighted average period of 2.0 years.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2022, the Company granted options with performance conditions to employees of which 50% vest upon the achievement of certain commercial milestones related to LUMRYZ and the other 50% vest one year following achievement of those milestones (&#8220;2022 Performance Options&#8221;). In May 2023, the achievement of the milestones related to the 2022 Performance Options became probable, and the Company recognized the compensation costs that would have been recognized had the performance factor been considered probable since the inception of the award. In June 2023, achievement of these milestones were met and 50% of the 2022 Performance Options vested. In June 2024, one year passed since achievement of these milestones were met and the remaining 50% of the 2022 Performance Options vested. As of December&#160;31, 2024, the Company has recognized $8,009 in share-based compensation for the 2022 Performance Options. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The excess tax benefit related to share-based compensation recorded by the Company was not material for the years ended December&#160;31, 2024, 2023, and 2022. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon exercise of stock options, or upon the issuance of restricted share awards or performance share unit awards, the Company issues new shares.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At December&#160;31, 2024, there were 4,259 shares authorized for stock option grants, restricted share award grants, and performance share unit award grants in subsequent periods.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inducement Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2021, the Board of Directors approved the Avadel Pharmaceuticals plc 2021 Inducement Plan (the &#8220;Inducement Plan&#8221;), which allows the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company to accept employment and provide them with a proprietary interest in the Company. The maximum number of shares reserved and available for issuance under the Plan is 2,000 shares. As of December&#160;31, 2024, the Company had 841 shares available for issuance under this Inducement Plan in subsequent periods.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Determining the Fair Value of Stock Options</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures the total fair value of stock options on the grant date using the Black-Scholes option-pricing model and recognizes each grant&#8217;s fair value as compensation expense over the period that the option vests. Other than the 2022 Performance Options described above, options are granted to employees of the Company and become exercisable ratably over four years following the grant date and expire ten years after the grant date. During the years ended December 31, 2022 and 2023, the Company issued stock options to its Board of Directors as compensation for services rendered that are exercisable one year following the grant date and expire ten years after the grant date. During the year ended December&#160;31, 2024, the Company </span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">issued stock options to its Board of Directors as compensation for services rendered that are exercisable over either a one year period or ratably over three years following the grant date and expire ten years after the grant date. </span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:14pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions under the Black-Scholes option-pricing model for stock option grants as of December&#160;31, 2024, 2023 and 2022 are as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Option Assumptions: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option grants:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected term</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected term of the options represents the period of time between the grant date and the time the options are either exercised or forfeited, including an estimate of future forfeitures for outstanding options. Given the limited historical data, the simplified method has been used to calculate the expected life.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected volatility</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The expected volatility is calculated based on an average of the historical volatility of the Company&#8217;s stock price for a period approximating the expected term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Risk-free interest rate</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Expected dividend yield</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: The Company has not distributed any dividends since its inception and have no plan to distribute dividends in the foreseeable future.</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the combined stock option activity and other data for the Company&#8217;s stock option plans for the year ended December&#160;31, 2024 is as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:34.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Stock Option Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(468)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $5,781, $2,612, and $877, respectively. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $11.34, $9.14, and $4.02 per share, respectively.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Share Awards</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted share awards represent Company shares issued free of charge to employees of the Company as compensation for services rendered. The Company measures the total fair value of restricted share awards on the grant date using the Company&#8217;s stock price at the time of the grant. Restricted share awards granted to employees vest ratably over a range of one year to four years on each anniversary of the grant date. Compensation expense for such awards granted is recognized over the applicable vesting period. Additionally, during the year ended December&#160;31, 2024, the Company issued restricted stock awards to its Board of Directors that vest on the </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">one-year anniversary of the award.</span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted share awards as of December&#160;31, 2024, and changes during the year then ended, is reflected in the table below.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Share Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Restricted Share Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted average grant date fair value of restricted share awards granted during the year ended December&#160;31, 2024 was $15.36 per share. No restricted share awards were granted during the years ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Performance Share Units Awards</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Performance share units awards (&#8220;PSUs&#8221;) represent Company shares issued free of charge to employees of the Company as compensation for achieving specified results. The Company measures the total fair value of performance share unit awards on the grant date using the Company&#8217;s stock price at the time of the grant. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">No performance share awards were granted during the year ended December&#160;31, 2022. As of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">, there were </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">555</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> performance share awards that did not have an accounting grant date due to the discretionary nature of the performance criteria. Accordingly, no grant date fair value was established and there were no performance share awards considered granted during the year ended </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. In February 2024, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">185 of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">performance share awards</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> that were tied to performance during the second half of 2023 were forfeited. No</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> performance share awards were granted during the year ended December&#160;31, 2024.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Employee Share Purchase Plan</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2017, the Board of Directors approved the Avadel Pharmaceuticals plc 2017 Avadel Employee Share Purchase Plan (&#8220;ESPP&#8221;). The total number of Company ordinary shares which may be issued under the ESPP is 1,000. The purchase price at which a share will be issued or sold for a given offering period will be established by the Compensation Committee of the Board (&#8220;Committee&#8221;) (and may differ among participants, as determined by the Committee in its sole discretion) but will in no event be less than 85% of the lesser of: (a) the fair market value of a Share on the offering date; or (b) the fair market value of a Share on the purchase date. During the years ended December&#160;31, 2024, 2023 and 2022 the Company issued 113, 47, and 75 ordinary shares to employees, respectively. Expense related to the ESPP for the years ended December&#160;31, 2024, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790317456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net loss per share is calculated by dividing net loss by the diluted number of shares outstanding during each period. Except where th</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">e result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the conversion of the  Company&#8217;s preferred shares, the exercise of outstandi</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ng equity compensation awards, and ordinary shares expected to be issued under the Company&#8217;s ESPP.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had a choice to settle the conversion obligations under the 2023 Notes in cash, shares or any combination of the two. The Company utilized the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result was anti-dilutive. This method assumed the conversion of the 2023 Notes into shares of the Company&#8217;s ordinary shares and reflected the elimination of the interest expense related to the 2023 Notes. The Company had no 2023 Notes remaining as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024 and 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The dilutive effect of the stock options, restricted share awards, preferred shares and ordinary shares expected to be issued under the Company&#8217;s ESPP has been calculated using the treasury stock method.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands for the years ended December&#160;31, 2024, 2023 and 2022, is as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Loss Per Share: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee and director equity awards outstanding, preferred shares and 2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,141&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Potential ordinary shares of </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,410</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, 513, and 17,941 were excluded from the calculation of weighted average shares for the years ended December&#160;31, 2024, 2023 and 2022, respectively, because their effect was considered to be anti-dilutive or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. For the years ended December&#160;31, 2024, 2023 and 2022, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in these periods.</span><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639903721632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comprehensive Loss<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNoteTextBlock', window );">Comprehensive Loss</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Comprehensive Loss</span><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of accumulated other comprehensive loss for the year ended December 31, net of tax effects:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable debt securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,341)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:5pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The effect on the Company&#8217;s consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNoteTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/220/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNoteTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790276032">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Segment Information</span><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. The Company&#8217;s Chief Operating Decision Maker is the Chief Executive Officer (&#8220;CEO&#8221;). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All products are included in one segment because the Company&#8217;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the Company&#8217;s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98,561)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,777)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,439)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/>*For the years ended December&#160;31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December&#160;31, 2022, the other segment items category also includes restructuring expense.</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-monetary long-lived assets primarily consist of property and equipment, goodwill, and operating right-of use-assets.&#160;The following table summarizes non-monetary long-lived assets by geographic region as of December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets by Geographic Region: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amortization expense on long-lived assets was immaterial for the years ended December&#160;31, 2024, 2023 and 2022.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790270512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ValuationAndQualifyingAccountsAbstract', window );"><strong>SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock', window );">Schedule II Valuation and Qualifying Accounts</a></td>
<td class="text"><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Schedule II</span></div><div style="margin-bottom:3pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Valuation and Qualifying Accounts</span></div><div style="margin-bottom:6pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(In thousands)&#160;</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:26.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.961%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.472%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.206%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.024%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.561%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deferred Tax Asset Valuation Allowance:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, <br/>Beginning of Period</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Additions<br/>(a)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Deductions<br/>(b)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Changes<br/>(c)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Balance, <br/>End of Period</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2024</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,428&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,587&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(7,457)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,565&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2023</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,341&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,918&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,586)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">755&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,428&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2022</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,025&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,734&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,418)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,341&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:center"><span><br/></span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Additions to the deferred tax asset valuation allowance relate to movements on certain French, Irish and U.S. deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">b.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt">Deductions to the deferred tax asset valuation allowance include movements relating to utilization of net operating losses and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.</span></div><div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">c.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt">Other changes to the deferred tax asset valuation allowance including currency translation adjustments recorded directly in equity, account method changes and the impact of corporate restructuring.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Regulation S-X (SX)<br> -Number 210<br> -Section 12<br> -Subsection 09<br> -Publisher SEC<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ValuationAndQualifyingAccountsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ValuationAndQualifyingAccountsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790124512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Pay vs Performance Disclosure - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_PvpTable', window );"><strong>Pay vs Performance Disclosure</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,832)<span></span>
</td>
<td class="num">$ (160,276)<span></span>
</td>
<td class="num">$ (137,464)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_PvpTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection v<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_PvpTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798254400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639906799536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791599184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Avadel, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cybersecurity policies and procedures as part of our overall risk management process. We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments which are designed to identify, assess, and manage cybersecurity risks. We perform cybersecurity risk analyses of select third-party service providers and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not experience any material cybersecurity threats or incidents for the year ended December&#160;31, 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At Avadel, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain cybersecurity policies and procedures as part of our overall risk management process. We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments which are designed to identify, assess, and manage cybersecurity risks. We perform cybersecurity risk analyses of select third-party service providers and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">The audit committee of our Board of Directors has responsibility for oversight of the Company&#8217;s cybersecurity risk management and receives cybersecurity updates from management at regularly scheduled meetings.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Director of Information Technology (&#8220;IT&#8221;), who reports to the Chief Financial Officer,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is responsible for the strategic leadership and direction of the Company&#8217;s cybersecurity program. The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management. The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our Senior Director of Information Technology (&#8220;IT&#8221;), who reports to the Chief Financial Officer,</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is responsible for the strategic leadership and direction of the Company&#8217;s cybersecurity program. The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the Company&#8217;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management. The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">As part of the Company&#8217;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639794789616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_NatureOfBusinessPolicyPolicyTextBlock', window );">Nature of Operations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Nature of Operations.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#8220;Avadel,&#8221; the &#8220;Company,&#8221; &#8220;we,&#8221; &#8220;our,&#8221; or &#8220;us&#8221;) is a biopharmaceutical company.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company is registered as an Irish public limited company. The Company&#8217;s headquarters are in Dublin, Ireland with operations in Dublin, Ireland and St. Louis, Missouri, United States (&#8220;U.S.&#8221;).</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%">LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (&#8220;EDS&#8221;) in patients seven years of age and older with narcolepsy. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LUMRYZ was approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted Orphan Drug Exclusivity (&#8220;ODE&#8221;) to LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy for a period of seven years until May 1, 2030. In June 2023, the Company commercially launched LUMRYZ in the U.S for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The FDA has required implementation of a </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Risk Evaluation and Mitigation Strategy (&#8220;REMS&#8221;)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of the date of this Annual Report, the Company&#8217;s only commercialized product is LUMRYZ. The Company continues to evaluate opportunities to expand its product portfolio.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_LiquidityAndGoingConcernPolicyTextBlock', window );">Liquidity</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Liquidity. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (&#8220;U.S. GAAP&#8221;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The adequacy of the Company&#8217;s cash resources depends on the outcome of certain business conditions including the cost of the Company&#8217;s ongoing LUMRYZ commercialization activities, the Company&#8217;s cost structure, and other factors set forth in &#8220;Risk Factors&#8221; within Part I, Item 1A of this Annual Report on Form 10-K.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Basis of Presentation.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. and the requirements of Form 10-K. The consolidated financial statements include the accounts of the Company and all subsidiaries. All intercompany accounts and transactions have been eliminated.</span><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription', window );">Reclassifications</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reclassifications </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Certain prior year amounts have been reclassified within the notes to the consolidated financial statements to condense line items of the same nature to conform with the current year presentation.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentrations of Risk</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Concentrations of Risk. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s cash, cash equivalents and marketable securities are held at three financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. The Company has not experienced any losses on its cash, cash equivalents, or marketable securities.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to credit risk from its accounts receivable related to the sale of LUMRYZ. The Company extends credit to its customers, specialty pharmacies. Customer creditworthiness is monitored, and collateral is not required. Amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible. As of December&#160;31, 2024, the Company did not recognize any allowances for credit </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">losses. As of December&#160;31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#8220;Caremark&#8221;), which accounted for 53% of gross accounts receivable; Accredo Health Group, Inc. (&#8220;Accredo&#8221;), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (&#8220;Optum&#8221;), which accounted for 22% of gross accounts receivable. As of December&#160;31, 2023, three customers accounted for 100% of gross accounts receivable, Caremark, which accounted for 52% of gross accounts receivable; Accredo, which accounted for 28% of gross accounts receivable; and Optum, which accounted for 20% of gross accounts receivable. </span></div>The Company attempts to maintain multiple suppliers for its active pharmaceutical ingredient (&#8220;API&#8221;) and manufacturing in order to mitigate the risk of shortfall and inability to supply market demand, but is subject to risk due to a limited number of providers. The API is currently manufactured by two outsourced contract development and manufacturing organizations (&#8220;CDMOs&#8221;) in the U.S. The drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRecognitionPolicyTextBlock', window );">Revenue and Cost of Products Sold</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Revenue includes sales of LUMRYZ. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer&#894; (ii) identify the performance obligations in the contract; (iii) determine the transaction price&#894; (iv) allocate the transaction price to the performance obligations in the contract&#894; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#8217;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.</span></div><div><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Product Sales</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company sells LUMRYZ to specialty pharmacies and considers those specialty pharmacies to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. The Company&#8217;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reserves for Variable Consideration</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#8217;s best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cost of Products Sold. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cost of products sold includes the cost of the API, manufacturing and distribution costs, packaging costs and freight. LUMRYZ was approved by the FDA on May 1, 2023 and the Company began shipping product to its customers in June 2023. Cost of products sold includes inventory purchased or produced that was expensed as research and development costs prior to FDA approval.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryPolicyTextBlock', window );">Inventories</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Inventories.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Inventories consist of raw materials, work in process and finished products, which are stated at lower of cost or net realizable value, using the first-in, first- out method. Raw materials used in the production of pre-clinical and clinical products are expensed as research and development costs. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. </span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development (&#8220;R&amp;D&#8221;)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development (&#8220;R&amp;D&#8221;). </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">R&amp;D expenses consist primarily of costs related to outside services, personnel expenses, clinical studies and other R&amp;D expenses. Outside services and clinical studies costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third-party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other R&amp;D expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&amp;D expenditures are charged to operations as incurred. Raw materials used in the production of pre-clinical and clinical products are expensed as R&amp;D costs.  &#160;</span></div>The Company recognizes refundable R&amp;D tax credits received for spending on innovative R&amp;D as an offset of R&amp;D expenses.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingCostsPolicyTextBlock', window );">Advertising Expenses</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Advertising Expenses. </span>The Company expenses the costs of advertising as incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock', window );">Contingencies</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Contingencies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#8217;s consolidated financial position, results of operations, cash flows or liquidity.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Compensation</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share-based Compensation. </span>The Company accounts for share-based compensation based on the estimated grant-date fair value. The fair value of stock options is estimated using Black-Scholes option-pricing valuation models (&#8220;Black-Scholes model&#8221;). As required by the Black-Scholes model, estimates are made of the underlying volatility of Avadel stock, a risk-free rate and an expected term of the option or warrant. The Company estimates the expected term using a simplified method, as the Company does not have enough historical exercise data for a majority of such options upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes.</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of December&#160;31, 2024, the Company's cumulative loss position was significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.</span></div><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company records uncertain tax positions on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.</span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax expense line in the consolidated statements of loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash and Cash Equivalents.</span> Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Marketable Securities. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s marketable securities are considered to be available for sale and are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in shareholders&#8217; equity, with the exception of unrealized gains and losses on equity instruments and allowances for expected credit losses, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.  </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">&#160;</span></div>For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#8217;s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Property and Equipment.</span> Property and equipment is stated at historical cost less accumulated depreciation.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Goodwill.</span> Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Long-Lived Assets</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Long-Lived Assets. </span>Long-lived assets include fixed assets and right of use assets at contract manufacturing organizations. Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset or other market-based value approaches. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. Certain long-lived assets are amortized using the straight-line method over a five year useful life. Amortization on long-lived assets is considered to be manufacturing overhead costs and is either capitalized into inventory or expensed in the period incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease Obligations</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Lease Obligations. </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines if a contract is a lease at the inception of the arrangement. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. Short term leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease payments are recognized in the consolidated statements of loss on a straight-line basis over the lease term. The Company&#8217;s lease contracts do not provide a readily determinable implicit rate. The Company&#8217;s estimated incremental borrowing rate is based on information available at the inception of the lease. The Company&#8217;s lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the consolidated statements of loss.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates. </span>The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. These estimates and assumptions are based on the best information available to management and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company&#8217;s consolidated financial statements. Actual results could differ from those estimates under different assumptions or&#160;conditions.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Adopted Accounting Guidance, Recent Accounting Guidance Not Yet Adopted, Newly Issued Climate-Related Disclosure Rule</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Guidance</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Financial Accounting Standards Board (&#8220;FASB&#8221;) issued Accounting Standards Update (&#8220;ASU&#8221;) 2023-07, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the provisions of ASU 2023-07 for the annual period beginning on January 1, 2024. See </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Note 18: Segment Information</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for additional information regarding segment disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recent Accounting Guidance Not Yet Adopted</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2023, the FASB issued ASU 2023-09, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Taxes (Topic 740): Improvements to Income Tax Disclosures, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for annual periods beginning after December 15, 2024. Adoption of ASU 2023-09 will not have a material effect on the Company&#8217;s financial position or results of operations.  </span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2024, the FASB issued ASU 2024-03, </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">(Subtopic 220-40)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact adopting ASU 2024-03 will have on its financial statement disclosures.</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Newly Issued Climate-Related Disclosure Rule</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2024, the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;) issued a final rule requiring public companies to disclose climate-related information in their registration statements and annual reports. For large accelerated filers, the initial disclosure rules are effective for annual periods for the year ending December 31, 2025. In April 2024, the SEC voluntarily stayed the final rule pending the completion of judicial review by the Court of Appeals for the Eighth Circuit. The Company is monitoring the development of litigation related to the SEC&#8217;s rule, and is currently evaluating the effects of the final rule on its disclosures, processes and procedures.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_LiquidityAndGoingConcernPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Liquidity and Going Concern</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_LiquidityAndGoingConcernPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_NatureOfBusinessPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for nature of business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_NatureOfBusinessPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for advertising cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -SubTopic 35<br> -Topic 720<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 450<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477850/954-450-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 460<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482425/460-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478898/942-825-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/350-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 330<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478411/912-330-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/330/tableOfContent<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483080/330-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 6<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 270<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482989/270-10-45-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PriorPeriodReclassificationAdjustmentDescription">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483504/205-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PriorPeriodReclassificationAdjustmentDescription</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRecognitionPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRecognitionPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798260368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment Useful Life</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements, furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years</span></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Property and Equipment, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790104800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerAbstract', window );"><strong>Revenue from Contract with Customer [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock', window );">Schedule of Percentage of Total Sales to Customers</a></td>
<td class="text">The following table presents a summary of the percentage of total gross sales to customers<span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:53.870%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.683%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.687%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Sales by Customer:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Caremark</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">44&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">39&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accredo</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Optum</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798225104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock', window );">Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:</span></div><div style="text-align:justify"><span><br/></span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:35.649%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.709%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:8.714%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2024</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">As of December&#160;31, 2023</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value Measurements:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 1</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 2</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Level 3</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Marketable securities (see </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%">Note 5)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639792400784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-sale Securities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following tables show the Company&#8217;s available-for-sale securities&#8217; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;December&#160;31, 2024 and 2023:</span></div><div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.73pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,242&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:44.861%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.675%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.678%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Adjusted Cost</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Gains</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Unrealized Losses</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,990&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">72,990&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">73,944&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock', window );">Schedule of Contractual Maturity Dates</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the estimated fair value of the Company&#8217;s investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">:</span></div><div style="margin-bottom:9pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:33.554%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.234%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.240%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Marketable Debt Securities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Less than 1 Year</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">1-5 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">5-10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Greater than 10 Years</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Total</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Government securities - U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">22,406&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789581968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Inventories (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock', window );">Schedule of Principal Categories of Inventories</a></td>
<td class="text"><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of inventories at December&#160;31, 2024 and 2023 were comprised of the following:</span></div><div><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"><tr><td style="width:1.0%"></td><td style="width:58.251%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.487%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.536%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.490%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Inventory:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Raw materials and supplies</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,199&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Work in process</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,963&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,037&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Finished goods</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,136&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,052&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,298&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,380&#160;</span></td><td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfInventoryCurrentTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483489/210-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfInventoryCurrentTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790290368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property and Equipment</a></td>
<td class="text">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  <div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:77.639%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:20.161%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3 years</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Leasehold improvements, furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2-10 years</span></div></td></tr></table></div><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:66.103%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.567%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Property and Equipment, net:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Software, office and computer equipment</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">832&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Furniture, fixtures and fittings</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">634&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less - accumulated depreciation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,013)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(881)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">453&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">585&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790376064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Costs</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease costs, which are included in selling, general and administrative expenses in the consolidated statements of loss for the years ended December&#160;31, 2024, 2023 and </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2022</span><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> were as follows:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"><tr><td style="width:1.0%"></td><td style="width:42.888%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.533%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.935%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.386%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.937%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Lease cost:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating lease costs</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,058&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,039&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Sublease income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(128)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(123)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(116)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease cost</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">930&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">916&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">912&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of the Company&#8217;s operating lease liabilities are as follows:</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:80.076%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.989%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Maturities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Operating Leases</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2025</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">683&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2026</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2027</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">477&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2028</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">316&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Thereafter</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total lease payments</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,953&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: interest</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(249)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Present value of lease liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,704&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798226416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Royalty Financing Obligation</a></td>
<td class="text"><div><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%">The following table shows the activity within the royalty financing obligation account:</span></div><div><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.549%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.344%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.347%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Royalty Financing Obligation:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,490&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Receipt of the first tranche of the royalty financing obligation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,000&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accretion of imputed interest expense on royalty financing obligation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,830&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,743&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payments made to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,181)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(253)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: one-time payment for expiration of second tranche</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,000)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation &#8211; ending balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">37,139&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">33,490&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: royalty payable to RTW classified within accrued expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,890)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(730)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty financing obligation, non-current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">35,249&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,760&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798121648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock', window );">Schedule Of Components Of (Loss) Income Before Income Tax</a></td>
<td class="text"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of loss before income taxes for the following years ended December 31, are as follows:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Loss Before Income Taxes:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Europe</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(3,708)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,835)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(53,684)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(45,371)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(114,942)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(57,755)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total loss before income taxes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,777)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,439)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock', window );">Schedule Of Income Tax Provision (Benefit)</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The income tax (benefit) provision consists of the following for the years ended December 31:&#160;&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Income Tax (Benefit) Provision:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Current:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total current</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(661)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - Federal</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">25,896&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S. - State</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">129&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total deferred</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation</a></td>
<td class="text"><div style="margin-bottom:9pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The reconciliation between income taxes at the statutory rate and the Company&#8217;s (benefit) provision for income taxes is as follows for the following years ended December 31:&#160;</span></div><div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Reconciliation to Effective Income Tax Rate:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at statutory tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,135)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(20,097)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,916)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Differences in international tax rates</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2,991)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(6,635)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,921)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Return to Provision</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,632&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Change in valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,982&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,332&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">48,734&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible share-based compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,444&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">798&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,424&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized tax benefits</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(218)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">160&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">258&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">State and local taxes (net of federal)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">778&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(5,614)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4,467)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Nondeductible interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(848)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,362&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,239&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(30)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">899&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">139&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">438&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(225)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Income tax (benefit) provision - at effective income tax rate</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(247)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(501)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">26,025&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Summary of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the activity related to the Company&#8217;s unrecognized tax benefits for the years ended December 31:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.826%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.859%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Unrecognized Tax Benefit Activity</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at January 1: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Increases for tax positions of prior years</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Statute of limitations expiration</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(311)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(108)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Settlements</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31: </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,724&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,035&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3,143&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities</a></td>
<td class="text">The net deferred tax assets (liabilities) at December&#160;31, 2024 and 2023 resulted from the following temporary differences:&#160;<div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Net Deferred Tax Assets and Liabilities: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net operating loss carryforwards</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">68,568&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">71,051&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Share-based compensation</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,791&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,347&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty income</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,334&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8,378&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserves and Other Accruals</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Orphan drug and R&amp;D tax credit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,095&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,065&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Capitalized research costs</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,568&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,738&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense carryforward</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,460&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,368&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,176&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,322&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Amortization</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">970&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,159&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax assets</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">101,565&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">96,428&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Deferred tax liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross deferred tax liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Less: valuation allowances</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(101,565)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(96,428)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:8pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net deferred tax assets </span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of components of income before income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of scheduled payments of income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798312624">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Other Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock', window );">Schedule of Prepaid Expenses and Other Current Assets</a></td>
<td class="text"><div style="margin-bottom:14pt;text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Various other assets and liabilities are summarized for the years ended December 31, as follows:&#160;</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Prepaid Expenses and Other Current Assets: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Prepaid and other expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,154&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,373&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">882&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,235&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,036&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,608&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock', window );">Schedule of Other Non-Current Assets</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Assets:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Right of use assets at contract manufacturing organizations</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,905&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">337&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">579&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:11.25pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,037&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,484&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Accrued Expenses</a></td>
<td class="text"><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:61.418%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.908%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.910%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accrued Expenses:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued professional fees</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,028&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,961&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Reserve for variable consideration</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14,218&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,044&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accrued compensation</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,515&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,492&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Royalty payable to RTW</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">1,890&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">730&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">40,651&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">24,227&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock', window );">Schedule of Other Non-Current Liabilities</a></td>
<td class="text"><div style="margin-bottom:4pt;margin-top:3pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"><tr><td style="width:1.0%"></td><td style="width:61.895%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.667%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.534%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.670%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Other Non-Current Liabilities:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Tax liabilities</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,151&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,407&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">247&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,183&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5,654&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the carrying amounts of prepaid expenses and other current assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNoncurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other noncurrent liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNoncurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of noncurrent assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639905684112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Schedule of Compensation Expense for Share-Based Compensation Arrangements</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Compensation expense included in the Company&#8217;s consolidated statements of loss for all share-based compensation arrangements was as follows for the years ended December&#160;31, 2024, 2023, and 2022:</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Share-based Compensation Expense:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling, general and administrative </span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,532&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,248&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6,844&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">856&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">563&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total share-based compensation expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,388&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,811&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,013&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock', window );">Schedule of Weighted-Average Assumptions</a></td>
<td class="text"><div style="margin-bottom:14pt;text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average assumptions under the Black-Scholes option-pricing model for stock option grants as of December&#160;31, 2024, 2023 and 2022 are as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:48.900%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Stock Option Assumptions: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock option grants:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.1</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">104.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">100.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">93.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Risk-free interest rate</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">3.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of Stock Option Activity</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the combined stock option activity and other data for the Company&#8217;s stock option plans for the year ended December&#160;31, 2024 is as follows: &#160;&#160;</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:34.782%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.194%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.535%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.196%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">&#160;Stock Option Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number&#160;of Stock<br/>Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Exercise Price per Share</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average<br/>Remaining<br/>Contractual Life</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">10,299&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.29&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,961&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13.75&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Exercised</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(734)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(468)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11.65&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Expired</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(266)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">16.30&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,792&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.53&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.8</span></td><td colspan="3" style="padding:0 1pt"></td><td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">34,411&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Stock options exercisable, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">7,799&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">6.53&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">5.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">32,380&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock', window );">Summary of Restricted Share Awards</a></td>
<td class="text"><div style="text-align:justify"><span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the Company&#8217;s restricted share awards as of December&#160;31, 2024, and changes during the year then ended, is reflected in the table below.&#160;</span></div><div style="text-align:justify"><span><br/></span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"></td><td style="width:48.533%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.350%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.532%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:23.353%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Restricted Share Activity and Other Data: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Number of Restricted Share Awards</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Weighted Average Grant Date<br/>Fair Value</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, January 1, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">23&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">142&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15.36&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Vested</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(11)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">8.20&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(4)</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12.60&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:6.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Non-vested restricted share awards outstanding, December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">150&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">14.88&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and Warrants grants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789518672">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Reconciliation of Basic and Diluted Net Loss Per Share</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands for the years ended December&#160;31, 2024, 2023 and 2022, is as follows: </span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.771%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.788%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.496%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.501%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Net Loss Per Share: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(48,832)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,276)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,464)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Weighted average shares:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Basic shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,141&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,174&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,094&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Effect of dilutive securities&#8212;employee and director equity awards outstanding, preferred shares and 2023 Notes</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Diluted shares</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">95,141&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">80,174&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">60,094&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - basic</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.00)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net loss per share - diluted</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(0.51)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.00)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(2.29)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790287616">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comprehensive Loss (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteAbstract', window );"><strong>Stockholders' Equity Note [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock', window );">Schedule of Components of Accumulated Other Comprehensive Loss</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table shows the components of accumulated other comprehensive loss for the year ended December 31, net of tax effects:</span></div><div style="margin-top:5pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:49.338%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.689%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.840%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Accumulated Other Comprehensive Loss:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Foreign currency translation adjustment:</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,452)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,855)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(623)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">331&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(597)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,744)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,121)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,452)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Unrealized gain (loss) on marketable debt securities, net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Beginning balance</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,889)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(85)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(790)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">2,843&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,804)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Balance at December 31,</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">954&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(1,889)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss at December 31,</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(24,580)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(23,167)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(26,341)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accumulated other comprehensive income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481674/830-30-50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 830<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481694/830-30-45-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639906047584">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Segment Reporting Information, About The Company&#8217;s Significant Expenses</a></td>
<td class="text"><div style="text-align:justify"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about the Company&#8217;s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.</span></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:61.180%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.742%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.746%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Years ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2022</span></td></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Net product revenue</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">169,117&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,963&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Cost of products sold</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,277&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">846&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Gross profit</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">153,840&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">27,117&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,196&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">13,261&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">20,700&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">84,962&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">79,596&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">52,655&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Selling and marketing expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">76,478&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">56,419&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,291&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Other segment items*</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">19,603&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">15,690&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">9,915&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total operating expenses</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">196,239&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">164,966&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">98,561&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Operating loss</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(42,399)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(137,849)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(98,561)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Investment and other income (expense), net</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">4,150&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">87&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(536)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Interest expense</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(10,830)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(9,886)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(12,342)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss on extinguishment of debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(13,129)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Loss before income taxes</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(49,079)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(160,777)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">(111,439)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"><br/>*For the years ended December&#160;31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December&#160;31, 2022, the other segment items category also includes restructuring expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock', window );">Schedule of Long-lived Assets by Geographic Areas</a></td>
<td class="text">The following table summarizes non-monetary long-lived assets by geographic region as of December&#160;31, 2024 and 2023:<div style="margin-bottom:4pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:65.566%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.835%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.530%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.839%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">Long-lived Assets by Geographic Region: </span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%">2023</span></td></tr><tr style="height:3pt"><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">U.S.</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">17,513&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">18,413&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Ireland</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">12,210&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">11,751&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">29,723&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%">30,164&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639794754128">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>institution</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_NumberOfFinancialInstitutions', window );">Number of financial institutions | institution</a></td>
<td class="nump">3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdvertisingExpense', window );">Advertising expenses</a></td>
<td class="nump">$ 12,186,000<span></span>
</td>
<td class="nump">$ 6,452,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillImpairmentLoss', window );">Goodwill impairment loss</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse', window );">Long-lived asset impairment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember', window );">Fixed Assets and Right Of Use Assets, Contract Manufacturing Organizations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avdl_ThreeCustomersMember', window );">Three customers | Accounts receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avdl_CaremarkLLCMember', window );">Caremark | Accounts receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">53.00%<span></span>
</td>
<td class="nump">52.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avdl_AccredoHealthGroupInc.Member', window );">Accredo | Accounts receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">25.00%<span></span>
</td>
<td class="nump">28.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avdl_OptumFrontierTherapiesLLCMember', window );">Optum | Accounts receivable | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">22.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_NumberOfFinancialInstitutions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number Of Financial Institutions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_NumberOfFinancialInstitutions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdvertisingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483385/720-35-55-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 720<br> -SubTopic 35<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483406/720-35-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdvertisingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillImpairmentLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillImpairmentLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsHeldForUse">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-2<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsHeldForUse</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_AccountsReceivableMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_CaremarkLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_CaremarkLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_AccredoHealthGroupInc.Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_AccredoHealthGroupInc.Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_OptumFrontierTherapiesLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_OptumFrontierTherapiesLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639794724672">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember', window );">Software, office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">3 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember', window );">Leasehold improvements, furniture, fixtures and fittings | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">2 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember', window );">Leasehold improvements, furniture, fixtures and fittings | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, plant and equipment, useful life (in years)</a></td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791972432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 169,117<span></span>
</td>
<td class="nump">$ 27,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Three customers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Caremark</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">44.00%<span></span>
</td>
<td class="nump">39.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Accredo</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">37.00%<span></span>
</td>
<td class="nump">41.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember', window );">Revenue from Contract with Customer Benchmark | Customer Concentration Risk | Optum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">19.00%<span></span>
</td>
<td class="nump">20.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_CaremarkMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_CaremarkMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_AccredoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_AccredoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_OptumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_OptumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790124512">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Revenue Recognition - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 169,117<span></span>
</td>
<td class="nump">$ 27,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_MajorCustomersAxis=avdl_ThreeCustomersMember', window );">Three customers | Revenue from Contract with Customer Benchmark | Customer Concentration Risk</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskLineItems', window );"><strong>Concentration Risk [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478785/954-310-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-20<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_MajorCustomersAxis=avdl_ThreeCustomersMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_MajorCustomersAxis=avdl_ThreeCustomersMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_RevenueFromContractWithCustomerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790754880">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Fair Value Measurement (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 22,406<span></span>
</td>
<td class="nump">$ 73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 1</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 1 | Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 2</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 2 | Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsFairValueDisclosure', window );">Total assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember', window );">Fair Value Measurements, Recurring | Level 3 | Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Marketable securities</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790890864">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Summary of Available-for-sale Securities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">$ 22,242<span></span>
</td>
<td class="nump">$ 72,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Adjusted Cost</a></td>
<td class="nump">22,242<span></span>
</td>
<td class="nump">72,990<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Unrealized Gains</a></td>
<td class="nump">164<span></span>
</td>
<td class="nump">954<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Unrealized Losses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 22,406<span></span>
</td>
<td class="nump">$ 73,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789877232">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Investments, Debt and Equity Securities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains</a></td>
<td class="nump">$ 1,625<span></span>
</td>
<td class="nump">$ 988<span></span>
</td>
<td class="nump">$ 584<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss', window );">Gross realized losses</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 2,791<span></span>
</td>
<td class="nump">$ 2,338<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791261840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities - Schedule of Contractual Maturity Dates (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 Year</a></td>
<td class="nump">$ 22,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">5-10 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Greater than 10 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="nump">$ 73,944<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Government securities - U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Debt Securities, Available-for-sale [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Less than 1 Year</a></td>
<td class="nump">22,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue', window );">1-5 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue', window );">5-10 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue', window );">Greater than 10 Years</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 22,406<span></span>
</td>
<td class="nump">$ 73,944<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 320<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-3A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639907039840">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Inventories (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryDisclosureAbstract', window );"><strong>Inventory Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves', window );">Raw materials and supplies</a></td>
<td class="nump">$ 5,199<span></span>
</td>
<td class="nump">$ 5,291<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryWorkInProcessNetOfReserves', window );">Work in process</a></td>
<td class="nump">4,963<span></span>
</td>
<td class="nump">2,037<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryFinishedGoodsNetOfReserves', window );">Finished goods</a></td>
<td class="nump">10,136<span></span>
</td>
<td class="nump">3,052<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InventoryNet', window );">Inventories</a></td>
<td class="nump">$ 20,298<span></span>
</td>
<td class="nump">$ 10,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryFinishedGoodsNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryFinishedGoodsNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InventoryWorkInProcessNetOfReserves">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 330<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.BB)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480581/330-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(6)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InventoryWorkInProcessNetOfReserves</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639795644912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, net (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less - accumulated depreciation</a></td>
<td class="num">$ (1,013)<span></span>
</td>
<td class="num">$ (881)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">453<span></span>
</td>
<td class="nump">585<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Depreciation', window );">Depreciation</a></td>
<td class="nump">132<span></span>
</td>
<td class="nump">254<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember', window );">Software, office and computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">832<span></span>
</td>
<td class="nump">832<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture, fixtures and fittings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, Plant and Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property and equipment</a></td>
<td class="nump">$ 634<span></span>
</td>
<td class="nump">$ 634<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Depreciation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Depreciation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798322544">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Goodwill (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract', window );"><strong>Goodwill and Intangible Assets Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Goodwill', window );">Goodwill</a></td>
<td class="nump">$ 16,836,000<span></span>
</td>
<td class="nump">$ 16,836,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentCharges', window );">Impairment loss related to goodwill</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Goodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482548/350-20-55-24<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482598/350-20-45-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 350<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482573/350-20-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(10)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Goodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790802496">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Narrative (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating lease, payments</a></td>
<td class="nump">$ 1,091<span></span>
</td>
<td class="nump">$ 1,036<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Increase in operating lease liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,803<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">3 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="nump">8.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee, Lease, Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseTermOfContract', window );">Operating lease, term of contract</a></td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseTermOfContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseTermOfContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798167440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Components of lease costs (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease costs</a></td>
<td class="nump">$ 1,058<span></span>
</td>
<td class="nump">$ 1,039<span></span>
</td>
<td class="nump">$ 1,028<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubleaseIncome', window );">Sublease income</a></td>
<td class="num">(128)<span></span>
</td>
<td class="num">(123)<span></span>
</td>
<td class="num">(116)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCost', window );">Total lease cost</a></td>
<td class="nump">$ 930<span></span>
</td>
<td class="nump">$ 916<span></span>
</td>
<td class="nump">$ 912<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lease cost recognized by lessee for lease contract.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubleaseIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of sublease income excluding finance and operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubleaseIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791776704">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities of operating lease liabilities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2025</a></td>
<td class="nump">$ 683<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2026</a></td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2027</a></td>
<td class="nump">477<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2028</a></td>
<td class="nump">316<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour', window );">Thereafter</a></td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">1,953<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: interest</a></td>
<td class="num">(249)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 1,704<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_OperatingLeaseLiabilityToBePaidAfterYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Liability, to be Paid, after Year Four</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_OperatingLeaseLiabilityToBePaidAfterYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798355136">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligation - Narrative (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Aug. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 01, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 29, 2023 </div>
<div>USD ($) </div>
<div>tranche</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RoyaltyFinancingProceedsMaximum', window );">Maximum proceeds from royalty financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget', window );">Quarterly net revenue target for royalty financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_PaymentsForRoyaltyOneTimeCommitmentFee', window );">Payments for royalty, one-time commitment fee</a></td>
<td class="nump">$ 2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage', window );">Quarterly royalty payments for royalty financing, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.75%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,830<span></span>
</td>
<td class="nump">9,886<span></span>
</td>
<td class="nump">12,342<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember', window );">Royalty Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DebtInstrumentNumberOfTranches', window );">Number of tranches | tranche</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Proceeds from issuance of long-term debt</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage', window );">Effective interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.20%<span></span>
</td>
<td class="nump">30.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,830<span></span>
</td>
<td class="nump">$ 3,743<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | February 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember', window );">Senior Notes | October 2023 Notes</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_DebtInstrumentNumberOfTranches">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Number Of Tranches</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_DebtInstrumentNumberOfTranches</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_PaymentsForRoyaltyOneTimeCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalty, One-Time Commitment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_PaymentsForRoyaltyOneTimeCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RoyaltyFinancingProceedsMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing, Proceeds, Maximum</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RoyaltyFinancingProceedsMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RoyaltyFinancingQuarterlyNetRevenueTarget">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing, Quarterly Net Revenue Target</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RoyaltyFinancingQuarterlyNetRevenueTarget</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing, Quarterly Royalty Payment, Percentage</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateEffectivePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateEffectivePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=us-gaap_SeniorNotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avdl_February2023NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avdl_February2023NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=avdl_October2023NotesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=avdl_October2023NotesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639795306368">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Royalty Financing Obligation - Activity (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2024</div></th>
<th class="th"><div>Aug. 01, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DebtInstrumentIncreaseDecreaseNetRollForward', window );"><strong>Debt Instrument, Increase (Decrease), Net [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Receipt of the first tranche of the royalty financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accretion of imputed interest expense on royalty financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,830<span></span>
</td>
<td class="nump">9,886<span></span>
</td>
<td class="nump">12,342<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_PaymentsForRoyaltyOneTimeCommitmentFee', window );">Less: one-time payment for expiration of second tranche</a></td>
<td class="num">$ (2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(2,000)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember', window );">Royalty Financing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DebtInstrumentIncreaseDecreaseNetRollForward', window );"><strong>Debt Instrument, Increase (Decrease), Net [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Royalty financing obligation &#8211; beginning balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">33,490<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt', window );">Receipt of the first tranche of the royalty financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">30,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Accretion of imputed interest expense on royalty financing obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,830<span></span>
</td>
<td class="nump">3,743<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RepaymentOfRoyaltyLiability', window );">Less: royalty payments made to RTW</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,181)<span></span>
</td>
<td class="num">(253)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Royalty financing obligation &#8211; ending balance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">37,139<span></span>
</td>
<td class="nump">33,490<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: royalty payable to RTW classified within accrued expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,890)<span></span>
</td>
<td class="num">(730)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Royalty financing obligation, non-current</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 35,249<span></span>
</td>
<td class="nump">$ 32,760<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_DebtInstrumentIncreaseDecreaseNetRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument, Increase (Decrease), Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_DebtInstrumentIncreaseDecreaseNetRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_PaymentsForRoyaltyOneTimeCommitmentFee">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Royalty, One-Time Commitment Fee</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_PaymentsForRoyaltyOneTimeCommitmentFee</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RepaymentOfRoyaltyLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment Of Royalty Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RepaymentOfRoyaltyLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermDebtTypeAxis=avdl_RoyaltyFinancingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790292320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income (Loss) Before Income Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (49,079)<span></span>
</td>
<td class="num">$ (160,777)<span></span>
</td>
<td class="num">$ (111,439)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=srt_EuropeMember', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(3,708)<span></span>
</td>
<td class="num">(45,835)<span></span>
</td>
<td class="num">(53,684)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (45,371)<span></span>
</td>
<td class="num">$ (114,942)<span></span>
</td>
<td class="num">$ (57,755)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=srt_EuropeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=srt_EuropeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791511440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Income Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">U.S. - State</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (661)<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(661)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">U.S. - Federal</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">25,896<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">U.S. - State</a></td>
<td class="num">(247)<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">129<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="num">(247)<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">26,025<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="num">$ (247)<span></span>
</td>
<td class="num">$ (501)<span></span>
</td>
<td class="nump">$ 26,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639792076912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation of Tax Rate (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Effective Income Tax Rate Reconciliation, Amount [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">Income tax (benefit) provision - at statutory tax rate</a></td>
<td class="num">$ (6,135)<span></span>
</td>
<td class="num">$ (20,097)<span></span>
</td>
<td class="num">$ (13,916)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential', window );">Differences in international tax rates</a></td>
<td class="num">(2,991)<span></span>
</td>
<td class="num">(6,635)<span></span>
</td>
<td class="num">(9,921)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes', window );">Return to Provision</a></td>
<td class="nump">2,632<span></span>
</td>
<td class="nump">856<span></span>
</td>
<td class="num">(101)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowances</a></td>
<td class="nump">4,982<span></span>
</td>
<td class="nump">24,332<span></span>
</td>
<td class="nump">48,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Nondeductible share-based compensation</a></td>
<td class="nump">1,444<span></span>
</td>
<td class="nump">798<span></span>
</td>
<td class="nump">1,424<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxContingencies', window );">Unrealized tax benefits</a></td>
<td class="num">(218)<span></span>
</td>
<td class="nump">160<span></span>
</td>
<td class="nump">258<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local taxes (net of federal)</a></td>
<td class="nump">778<span></span>
</td>
<td class="num">(5,614)<span></span>
</td>
<td class="num">(4,467)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount', window );">Nondeductible interest expense</a></td>
<td class="num">(848)<span></span>
</td>
<td class="nump">4,362<span></span>
</td>
<td class="nump">4,239<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit', window );">Orphan drug and R&amp;D tax credit</a></td>
<td class="num">(30)<span></span>
</td>
<td class="nump">899<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems', window );">Other</a></td>
<td class="nump">139<span></span>
</td>
<td class="nump">438<span></span>
</td>
<td class="num">(225)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax (benefit) provision</a></td>
<td class="num">$ (247)<span></span>
</td>
<td class="num">$ (501)<span></span>
</td>
<td class="nump">$ 26,025<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Amount, Orphan Drug and Research And Development Tax Credit</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationOtherReconcilingItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationOtherReconcilingItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(8)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639792139456">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">$ 247<span></span>
</td>
<td class="nump">$ 501<span></span>
</td>
<td class="num">$ (26,025)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit', window );">Decrease in income tax benefit</a></td>
<td class="nump">254<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible', window );">Decrease in unrecognized tax benefits is reasonably possible</a></td>
<td class="nump">1,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate', window );">Unrecognized tax benefits</a></td>
<td class="nump">2,724<span></span>
</td>
<td class="nump">3,035<span></span>
</td>
<td class="nump">3,143<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Income tax penalties and interest expense</a></td>
<td class="nump">56<span></span>
</td>
<td class="nump">268<span></span>
</td>
<td class="nump">$ 258<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Income tax penalties and interest accrued</a></td>
<td class="nump">2,427<span></span>
</td>
<td class="nump">2,372<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UndistributedEarnings', window );">Unremitted earnings</a></td>
<td class="nump">3,755<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research tax credit receivable</a></td>
<td class="nump">587<span></span>
</td>
<td class="nump">1,654<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=avdl_OrphanDrugTaxCreditMember', window );">Orphan Drug tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">3,059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development tax credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">1,036<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">71,588<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwardsValuationAllowance', window );">Operating loss carryforwards, valuation allowance (decrease)</a></td>
<td class="nump">5,137<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Gross research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">817<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">227,344<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S. | 163(j) Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Tax credit carryforwards</a></td>
<td class="nump">5,809<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_FR', window );">France</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Gross research tax credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 837<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avdl_FscHoldingsLlcMember', window );">FSC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">10,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avdl_U.S.HoldingsMember', window );">U.S. Holdings</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">212,637<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessAcquisitionAxis=avdl_U.S.HoldingsMember', window );">U.S. Holdings | State</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_IncomeTaxesLineItems', window );"><strong>Income Taxes [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 4,342<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_IncomeTaxesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_IncomeTaxesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase (Decrease) In Income Tax Expense (Benefit)</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (d)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwardsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwardsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UndistributedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 66<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-66<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UndistributedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=avdl_OrphanDrugTaxCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=avdl_OrphanDrugTaxCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=avdl_A163jCreditsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=avdl_A163jCreditsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_FR">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_FR</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=avdl_FscHoldingsLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=avdl_FscHoldingsLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessAcquisitionAxis=avdl_U.S.HoldingsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessAcquisitionAxis=avdl_U.S.HoldingsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639795007920">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Unrecognized Tax Benefit (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefit Activity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning balance</a></td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 3,143<span></span>
</td>
<td class="nump">$ 3,143<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease', window );">Increases for tax positions of prior years</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations', window );">Statute of limitations expiration</a></td>
<td class="num">(311)<span></span>
</td>
<td class="num">(108)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities', window );">Settlements</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Ending balance</a></td>
<td class="nump">$ 2,724<span></span>
</td>
<td class="nump">$ 3,035<span></span>
</td>
<td class="nump">$ 3,143<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798122432">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Deferred Taxes (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 68,568<span></span>
</td>
<td class="nump">$ 71,051<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">9,791<span></span>
</td>
<td class="nump">7,347<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DeferredTaxAssetsRoyaltyIncome', window );">Royalty income</a></td>
<td class="nump">9,334<span></span>
</td>
<td class="nump">8,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals', window );">Reserves and Other Accruals</a></td>
<td class="nump">4,603<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch', window );">Orphan drug and R&amp;D tax credit</a></td>
<td class="nump">4,095<span></span>
</td>
<td class="nump">4,065<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research costs</a></td>
<td class="nump">1,568<span></span>
</td>
<td class="nump">1,738<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetInterestCarryforward', window );">Interest expense carryforward</a></td>
<td class="nump">1,460<span></span>
</td>
<td class="nump">1,368<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,322<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets', window );">Amortization</a></td>
<td class="nump">970<span></span>
</td>
<td class="nump">1,159<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">101,565<span></span>
</td>
<td class="nump">96,428<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses', window );">Prepaid expenses</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowances</a></td>
<td class="num">(101,565)<span></span>
</td>
<td class="num">(96,428)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsLiabilitiesNet', window );">Net deferred tax assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Amortization Of Intangible Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_DeferredTaxAssetsRoyaltyIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Royalty Income</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_DeferredTaxAssetsRoyaltyIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug And Research</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetInterestCarryforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetInterestCarryforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPrepaidExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPrepaidExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798164592">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseCurrent', window );">Prepaid and other expenses</a></td>
<td class="nump">$ 5,154<span></span>
</td>
<td class="nump">$ 4,373<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsCurrent', window );">Other</a></td>
<td class="nump">882<span></span>
</td>
<td class="nump">2,235<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Total &#160;</a></td>
<td class="nump">$ 6,036<span></span>
</td>
<td class="nump">$ 6,608<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482955/340-10-05-5<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483032/340-10-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789562896">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities - Other Non-Current Assets (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent', window );">Right of use assets at contract manufacturing organizations</a></td>
<td class="nump">$ 10,700<span></span>
</td>
<td class="nump">$ 9,905<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_OtherNoncurrentReceivables', window );">Other</a></td>
<td class="nump">337<span></span>
</td>
<td class="nump">579<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Total &#160;</a></td>
<td class="nump">$ 11,037<span></span>
</td>
<td class="nump">$ 10,484<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_OtherNoncurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The carrying amount of other noncurrent receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_OtherNoncurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639792006048">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities - Accrued Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">$ 18,028<span></span>
</td>
<td class="nump">$ 11,961<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RemainingPerformanceObligationReserveCurrent', window );">Reserve for variable consideration</a></td>
<td class="nump">14,218<span></span>
</td>
<td class="nump">4,044<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued compensation</a></td>
<td class="nump">6,515<span></span>
</td>
<td class="nump">7,492<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_RoyaltyFinancingLiabilityCurrent', window );">Royalty payable to RTW</a></td>
<td class="nump">1,890<span></span>
</td>
<td class="nump">730<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 40,651<span></span>
</td>
<td class="nump">$ 24,227<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RemainingPerformanceObligationReserveCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Remaining Performance Obligation Reserve, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RemainingPerformanceObligationReserveCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_RoyaltyFinancingLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Royalty Financing Liability, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_RoyaltyFinancingLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 8<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798280768">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Other Assets and Liabilities - Other Non-Current Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesDisclosureAbstract', window );"><strong>Other Liabilities Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities', window );">Tax liabilities</a></td>
<td class="nump">$ 5,151<span></span>
</td>
<td class="nump">$ 5,407<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GuarantyLiabilities', window );">Other</a></td>
<td class="nump">32<span></span>
</td>
<td class="nump">247<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Total</a></td>
<td class="nump">$ 5,183<span></span>
</td>
<td class="nump">$ 5,654<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tax Liabilities And Other Noncurrent Liabilities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GuarantyLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 460<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482050/460-10-25-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GuarantyLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R74.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639798173648">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Contingent Liabilities and Commitments (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongtermPurchaseCommitmentPeriod', window );">Purchase commitment, period (in years)</a></td>
<td class="text">4 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ContractualObligationAnnualAmount', window );">Contractual obligation, annual amount</a></td>
<td class="nump">$ 3,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ContractualObligationAnnualAmount', window );">Contractual obligation, annual amount</a></td>
<td class="nump">4,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_LitigationCaseAxis=avdl_FirstJazzComplaintMember', window );">First Jazz Complaint</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems', window );"><strong>Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualCarryingValueCurrent', window );">Loss contingency accrued</a></td>
<td class="nump">$ 234<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ContractualObligationAnnualAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual Obligation, Annual Amount</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ContractualObligationAnnualAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongtermPurchaseCommitmentPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongtermPurchaseCommitmentPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualCarryingValueCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualCarryingValueCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_LitigationCaseAxis=avdl_FirstJazzComplaintMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_LitigationCaseAxis=avdl_FirstJazzComplaintMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R75.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639791618800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Instruments and Transactions (Details)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="1">9 Months Ended</th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>May 08, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th"><div>Apr. 15, 2024</div></th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>shares</div>
</th>
<th class="th">
<div>Mar. 31, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Ordinary shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
<td class="nump">500,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_AmericanDepositorySharesConversionRatio', window );">ADSs, conversion ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Ordinary shares, shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">89,825,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ordinary shares, shares outstanding (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">96,518,000<span></span>
</td>
<td class="nump">89,825,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred shares, shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
<td class="nump">50,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred shares, nominal value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_ShelfRegistrationStatementOnFormS3Member', window );">Shelf Registration Statement On Form S-3</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_SaleOfStockSalesAgentCommissionPercent', window );">Sales agent commission, as a percent of aggregate gross sales proceeds</a></td>
<td class="nump">3.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_SaleOfStockMaximumAggregateOfferingPrice', window );">Sale of stock, maximum aggregate offering price | $</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction', window );">Net proceeds from shares issued | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,250<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_ShelfRegistrationStatementOnFormS3Member', window );">Shelf Registration Statement On Form S-3 | American Depositary Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Shares issued (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">640,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember', window );">Preferred shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(5,194,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfStockLineItems', window );"><strong>Class of Stock [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Exchange/Settlement of Notes (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,194,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_AmericanDepositorySharesConversionRatio">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>American Depository Shares, Conversion Ratio</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_AmericanDepositorySharesConversionRatio</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_SaleOfStockMaximumAggregateOfferingPrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Maximum Aggregate Offering Price</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_SaleOfStockMaximumAggregateOfferingPrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_SaleOfStockSalesAgentCommissionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale Of Stock, Sales Agent Commission, Percent</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_SaleOfStockSalesAgentCommissionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfStockLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483014/272-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 272<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482987/272-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-14<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-18<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfStockLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockConsiderationReceivedOnTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received on stock transaction after deduction of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockConsiderationReceivedOnTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=avdl_ShelfRegistrationStatementOnFormS3Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=avdl_ShelfRegistrationStatementOnFormS3Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementClassOfStockAxis=avdl_AmericanDepositarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementClassOfStockAxis=avdl_AmericanDepositarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_PreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R76.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790253504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 20,388<span></span>
</td>
<td class="nump">$ 15,811<span></span>
</td>
<td class="nump">$ 7,013<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember', window );">Selling, general and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">19,532<span></span>
</td>
<td class="nump">15,248<span></span>
</td>
<td class="nump">6,844<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 856<span></span>
</td>
<td class="nump">$ 563<span></span>
</td>
<td class="nump">$ 169<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_SellingGeneralAndAdministrativeExpensesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R77.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639794880272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Narrative (Details) - USD ($)<br> $ / shares in Units, $ in Thousands</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Feb. 29, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 22,513<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Weighted average period for unrecognized expense (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20,388<span></span>
</td>
<td class="nump">$ 15,811<span></span>
</td>
<td class="nump">$ 7,013<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,781<span></span>
</td>
<td class="nump">$ 2,612<span></span>
</td>
<td class="nump">$ 877<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Grant date fair value of options granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11.34<span></span>
</td>
<td class="nump">$ 9.14<span></span>
</td>
<td class="nump">$ 4.02<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Ordinary shares, nominal value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="nump">$ 0.01<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avdl_InducementPlanMember', window );">Inducement Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Maximum number of shares reserved and available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">841,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=avdl_A2017AvadelEmployeeSharePurchasePlanMember', window );">2017 Avadel Employee Share Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Shares available for issuance (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent', window );">Purchase price of common stock, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8,009<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate', window );">Awards that did not have an accounting grant date (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">555,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">185,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Share-based Payment Arrangement, Employee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">113,000<span></span>
</td>
<td class="nump">47,000<span></span>
</td>
<td class="nump">75,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Vest Upon the Achievement of Certain Regulatory Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares | Vest One Year Following Achievement of Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized', window );">Number of shares authorized (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,259,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Expiration period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option | Board of Directors | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember', window );">Restricted Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant fair value of free share awards (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Tranche One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Tranche Two</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Tranche Three</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember', window );">Restricted Share Awards Granted to Employees | Tranche Four</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage', window );">Vesting percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">25.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award, Awards With No Grant Date</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average exercise price of equity instruments other than options granted in period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>avdl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types1:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of vesting of award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Purchase price of common stock expressed as a percentage of its fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avdl_InducementPlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avdl_InducementPlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=avdl_A2017AvadelEmployeeSharePurchasePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=avdl_A2017AvadelEmployeeSharePurchasePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GranteeStatusAxis=us-gaap_ShareBasedPaymentArrangementEmployeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=avdl_VestOneYearFollowingAchievementOfMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=avdl_VestOneYearFollowingAchievementOfMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=avdl_RestrictedShareAwardsGrantedToEmployeesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheTwoMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=us-gaap_ShareBasedCompensationAwardTrancheThreeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_VestingAxis=avdl_ShareBasedPaymentArrangementTrancheFourMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_VestingAxis=avdl_ShareBasedPaymentArrangementTrancheFourMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R78.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639789598880">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Fair Value Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember', window );">Stock Option</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (in years)</a></td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 2 months 12 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">104.10%<span></span>
</td>
<td class="nump">100.10%<span></span>
</td>
<td class="nump">93.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">4.30%<span></span>
</td>
<td class="nump">3.90%<span></span>
</td>
<td class="nump">2.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OptionIndexedToIssuersEquityEquityAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R79.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639781794176">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Stock Options (Details)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Stock Options, Outstanding [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, beginning balance (in shares) | shares</a></td>
<td class="nump">10,299<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares) | shares</a></td>
<td class="nump">2,961<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares) | shares</a></td>
<td class="num">(734)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares) | shares</a></td>
<td class="num">(468)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares) | shares</a></td>
<td class="num">(266)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Stock options outstanding, ending balance (in shares) | shares</a></td>
<td class="nump">11,792<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Stock options exercisable (in shares) | shares</a></td>
<td class="nump">7,799<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Stock Options, Outstanding, Weighted Average Exercise Price [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, beginning balance (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 7.29<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="nump">13.75<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share) | $ / shares</a></td>
<td class="nump">7.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share) | $ / shares</a></td>
<td class="nump">11.65<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired (in dollars per share) | $ / shares</a></td>
<td class="nump">16.30<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Stock options outstanding, ending balance (in dollars per share) | $ / shares</a></td>
<td class="nump">8.53<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Stock options exercisable (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 6.53<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Stock options outstanding, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">6 years 9 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Stock options exercisable, Weighted Average Remaining Contractual Life (in years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Stock options outstanding, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 34,411<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Stock options exercisable, Aggregate Intrinsic Value | $</a></td>
<td class="nump">$ 32,380<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R80.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639784280352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Share-Based Compensation - Restricted Share Activity (Details) - Restricted Shares - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Free Share Activity and Other Data, Nonvested [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, beginning balance (in shares)</a></td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">142,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested (in shares)</a></td>
<td class="num">(11,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(4,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Outstanding, ending balance (in shares)</a></td>
<td class="nump">150,000<span></span>
</td>
<td class="nump">23,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Free Share Activity and Other Data, Weighted Average Grant Date Fair Value [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested free share award, beginning balance (in dollars per share)</a></td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">15.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested (in dollars per share)</a></td>
<td class="nump">8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">12.60<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Nonvested free share award, ending balance (in dollars per share)</a></td>
<td class="nump">$ 14.88<span></span>
</td>
<td class="nump">$ 8.20<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R81.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639799789968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details) - USD ($)<br> $ / shares in Units, shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (48,832)<span></span>
</td>
<td class="num">$ (160,276)<span></span>
</td>
<td class="num">$ (137,464)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract', window );"><strong>Weighted average shares:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic shares (in shares)</a></td>
<td class="nump">95,141<span></span>
</td>
<td class="nump">80,174<span></span>
</td>
<td class="nump">60,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment', window );">Effect of dilutive securities&#8212;employee and director equity awards outstanding, preferred shares and 2023 Notes (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted shares (in shares)</a></td>
<td class="nump">95,141<span></span>
</td>
<td class="nump">80,174<span></span>
</td>
<td class="nump">60,094<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share - basic (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per share - diluted (in dollars per share)</a></td>
<td class="num">$ (0.51)<span></span>
</td>
<td class="num">$ (2.00)<span></span>
</td>
<td class="num">$ (2.29)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 34: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R82.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639904026416">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Narrative (Details) - shares<br> shares in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Potential ordinary shares excluded from the computation of weighted average shares (in shares)</a></td>
<td class="nump">1,410<span></span>
</td>
<td class="nump">513<span></span>
</td>
<td class="nump">17,941<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R83.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639795309968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Comprehensive Loss (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">$ 87,739<span></span>
</td>
<td class="num">$ (21,145)<span></span>
</td>
<td class="nump">$ 78,244<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">73,848<span></span>
</td>
<td class="nump">87,739<span></span>
</td>
<td class="num">(21,145)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Net other comprehensive (loss) income, tax benefit</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember', window );">Accumulated other comprehensive loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(23,167)<span></span>
</td>
<td class="num">(26,341)<span></span>
</td>
<td class="num">(23,940)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(1,413)<span></span>
</td>
<td class="nump">3,174<span></span>
</td>
<td class="num">(2,401)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(24,580)<span></span>
</td>
<td class="num">(23,167)<span></span>
</td>
<td class="num">(26,341)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember', window );">Foreign currency translation adjustment:</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="num">(24,121)<span></span>
</td>
<td class="num">(24,452)<span></span>
</td>
<td class="num">(23,855)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(623)<span></span>
</td>
<td class="nump">331<span></span>
</td>
<td class="num">(597)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="num">(24,744)<span></span>
</td>
<td class="num">(24,121)<span></span>
</td>
<td class="num">(24,452)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember', window );">Unrealized gain (loss) on marketable debt securities, net</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward', window );"><strong>Accumulated Other Comprehensive Loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance</a></td>
<td class="nump">954<span></span>
</td>
<td class="num">(1,889)<span></span>
</td>
<td class="num">(85)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent', window );">Net other comprehensive (loss) income</a></td>
<td class="num">(790)<span></span>
</td>
<td class="nump">2,843<span></span>
</td>
<td class="num">(1,804)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance</a></td>
<td class="nump">$ 164<span></span>
</td>
<td class="nump">$ 954<span></span>
</td>
<td class="num">$ (1,889)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AOCIAttributableToParentNetOfTaxRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AOCIAttributableToParentNetOfTaxRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of other comprehensive income (loss) attributable to parent entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -SubTopic 10<br> -Topic 220<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-12<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-10A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedOtherComprehensiveIncomeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedTranslationAdjustmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R84.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639795648208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Narrative (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2024 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R85.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639790646896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Segment Reporting Information, About the Company&#8217;s Significant Expenses (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">$ 169,117<span></span>
</td>
<td class="nump">$ 27,963<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">15,277<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">153,840<span></span>
</td>
<td class="nump">27,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">15,196<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
<td class="nump">20,700<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">196,239<span></span>
</td>
<td class="nump">164,966<span></span>
</td>
<td class="nump">98,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,399)<span></span>
</td>
<td class="num">(137,849)<span></span>
</td>
<td class="num">(98,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income (expense), net</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(10,830)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="num">(12,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(49,079)<span></span>
</td>
<td class="num">(160,777)<span></span>
</td>
<td class="num">(111,439)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=avdl_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Net product revenue</a></td>
<td class="nump">169,117<span></span>
</td>
<td class="nump">27,963<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CostOfGoodsAndServicesSold', window );">Cost of products sold</a></td>
<td class="nump">15,277<span></span>
</td>
<td class="nump">846<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GrossProfit', window );">Gross profit</a></td>
<td class="nump">153,840<span></span>
</td>
<td class="nump">27,117<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating Expenses [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development expenses</a></td>
<td class="nump">15,196<span></span>
</td>
<td class="nump">13,261<span></span>
</td>
<td class="nump">20,700<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expenses</a></td>
<td class="nump">84,962<span></span>
</td>
<td class="nump">79,596<span></span>
</td>
<td class="nump">52,655<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SellingAndMarketingExpense', window );">Selling and marketing expenses</a></td>
<td class="nump">76,478<span></span>
</td>
<td class="nump">56,419<span></span>
</td>
<td class="nump">15,291<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment items</a></td>
<td class="nump">19,603<span></span>
</td>
<td class="nump">15,690<span></span>
</td>
<td class="nump">9,915<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">196,239<span></span>
</td>
<td class="nump">164,966<span></span>
</td>
<td class="nump">98,561<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Operating loss</a></td>
<td class="num">(42,399)<span></span>
</td>
<td class="num">(137,849)<span></span>
</td>
<td class="num">(98,561)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeNet', window );">Investment and other income (expense), net</a></td>
<td class="nump">4,150<span></span>
</td>
<td class="nump">87<span></span>
</td>
<td class="num">(536)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestExpenseDebt', window );">Interest expense</a></td>
<td class="num">(10,830)<span></span>
</td>
<td class="num">(9,886)<span></span>
</td>
<td class="num">(12,342)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainsLossesOnExtinguishmentOfDebt', window );">Loss on extinguishment of debt</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">13,129<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">$ (49,079)<span></span>
</td>
<td class="num">$ (160,777)<span></span>
</td>
<td class="num">$ (111,439)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CostOfGoodsAndServicesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CostOfGoodsAndServicesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainsLossesOnExtinguishmentOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 50<br> -Section 40<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481303/470-50-40-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainsLossesOnExtinguishmentOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestExpenseDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the cost of borrowed funds accounted for as interest expense for debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestExpenseDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SellingAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total amount of expenses directly related to the marketing or selling of products or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SellingAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=avdl_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=avdl_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R86.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639782035264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Segment Information - Long-Lived Assets by Geographic Region (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasLongLivedAssetsAbstract', window );"><strong>Long-lived Assets by Geographic Region:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 29,723<span></span>
</td>
<td class="nump">$ 30,164<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_US', window );">U.S.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasLongLivedAssetsAbstract', window );"><strong>Long-lived Assets by Geographic Region:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">17,513<span></span>
</td>
<td class="nump">18,413<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StatementGeographicalAxis=country_IE', window );">Europe</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeographicAreasLongLivedAssetsAbstract', window );"><strong>Long-lived Assets by Geographic Region:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncurrentAssets', window );">Long-lived assets</a></td>
<td class="nump">$ 12,210<span></span>
</td>
<td class="nump">$ 11,751<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeographicAreasLongLivedAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeographicAreasLongLivedAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_US">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_US</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=country_IE">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=country_IE</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R87.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.0.1</span><table class="report" border="0" cellspacing="2" id="idm45639906358256">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Schedule II - Valuation and Qualifying Accounts (Details) - Valuation Allowance of Deferred Tax Assets - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward', window );"><strong>SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at beginning of period</a></td>
<td class="nump">$ 96,428<span></span>
</td>
<td class="nump">$ 71,341<span></span>
</td>
<td class="nump">$ 24,025<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense', window );">Additions</a></td>
<td class="nump">12,587<span></span>
</td>
<td class="nump">30,918<span></span>
</td>
<td class="nump">48,734<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesDeductions', window );">Deductions</a></td>
<td class="num">(7,457)<span></span>
</td>
<td class="num">(6,586)<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease', window );">Other Changes</a></td>
<td class="nump">7<span></span>
</td>
<td class="nump">755<span></span>
</td>
<td class="num">(1,418)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowancesAndReservesBalance', window );">Balance at end of period</a></td>
<td class="nump">$ 101,565<span></span>
</td>
<td class="nump">$ 96,428<span></span>
</td>
<td class="nump">$ 71,341<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MovementInValuationAllowancesAndReservesRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MovementInValuationAllowancesAndReservesRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesBalance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column E))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesBalance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column C)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesDeductions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09(Column D))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesDeductions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in valuation and qualifying accounts and reserves.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SX 210.12-09)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowancesAndReservesTypeAxis=us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>117
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
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MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MGDN#./V+GK)SV]T&<I.8TW 7#%<0^E'VB9]W((X#>B4!UB[ >A5@MDL"[%V
M_3J@4Q+0W@6T4S+94%(.(\SQX)+1)\3$V: FOJ0PTV@8OA^)__N",SCJ0QP?
M#.DC86@._V+41-\7(_3^W8?+%@=E<;SE[E2N,Q6K1,6TT%<:\4V,QI%'O*)
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MXVS2.9O<Y&PMTZM_2C]AAP.CKIB^)QNFM:P4Z_$U[7Q-;_+UQ!0GJ^4E6_V
MT<5_S#\K*@[JZ%J')JFL!#;UU:UVW6G>%.6_\*:U;:@Z,J%) 0<C#0;OS36I
MIETT$Y2E*]&]1%/P;IB;#@O*!IC]@Y1XFM@#NIZ=_ 502P,$%     @ &$IC
M6FL4$)=]!0  ,A8  !@   !X;"]W;W)K<VAE971S+W-H965T,RYX;6RMF%UO
MVS84AO\*X15# B2Q2'UGCH'&WD>!=0N2=KT8=B%;M"U4$EV2=K)_OT-)EF21
M8C,@-XDEO3SB0QX>ON+LF?&O8D>I1"]%7HJ[R4[*_>UT*M8[6B3BANUI"4\V
MC!>)A$N^G8H]ITE:-2KR*7&<8%HD63F9SZI[#WP^8P>99R5]X$@<BB+A_][3
MG#W?3?#D=.,QV^ZDNC&=S_;)ECY1^7G_P.%JVD9)LX*6(F,EXG1S-WF/;Y>$
MJ :5XJ^,/HO>;Z105HQ]51<?TKN)HWI$<[J6*D0"_XYT0?-<18)^?&N"3MIW
MJH;]WZ?HOU3P +-*!%VP_$N6RMW=))J@E&Z20RX?V?-OM 'R5;PURT7U%SW7
MVA#$ZX.0K&@:0P^*K*S_)R_-0/0:X&"D 6D:D&$#;Z2!VS1P7]O :QIXU<C4
M*-4X+!.9S&></2.NU!!-_:@&LVH-^%FIYOU)<GB:03LY7[!2L#Q+$TE3]"3A
M'TRJ%(AMT.],"'2-/C\MT<6[2R1V":<"927ZM&,'D92IN$+OSJYG4PE=4H&G
MZ^;U]_7KR<CK,4$?62EW OU<IC0]#S %EA:(G(#NB37BDJYOD(NO$'&(9^C0
MXO7-74/SY>N;$PN-VTZ/6\5S1^)]*->LH-W$H+_?KX3DL%K^,0UV'<PS!U,E
MY%;LDS6]FT"-$)0?Z63^XP\X<'XR#=1;!EN^4;"S0?3:0?1LT>=_0/G<<Y8>
MUA)*U9&6!VH:O#J(7P51Y?(XQT&,<3B;'OO#HLM(& ?NN6JIJYQ6<0;AMQ"^
M%6+!A%2KL@$1")9M:L*HPP1]#)^$0PI=%7G!@$'7C# $+4-@9?B5JY("!)M,
MFKH>&+KN1IXSZ+LN(Z$V3TM=-=+[L.U]:%V+?^XI3V16;A%]@6U74'%K@@C?
M<@V^9;#E&P4[&[RH';S(.O6/$#'AZQV"?0+VY2,8CGU5T$YC:1K*R) /.!ZD
MZ<*@<DF !^F@JX@3.B,I$;=4L97J"?P*),05VM(2DB.OZ)(4]NE,56EE::R
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M^%K5%8,'0>2Z::AXN8>:;Z>.[[Q.?*R6I=(3[FRRHDMX!/5Y]2!PY/8H1=4
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MN!>-Z.;=NO?MNL&1=?V ?.!,E9+\R@HH]@%<)-$S"5Z9W <G$3/(;TCH7Y/
M"R++AN;GNX<6]^Q\]^ $F["/2VCPPB-X?2@.(_&>Y;P!\L_=DU0"S\V_-O5;
M],B.KFO)K5S1'*8. DL0&W!F/__D)]XO-N4N"99="&Q/U:A7-3J%/OL3ZVB-
MB6Q3K/6,C:<NEIO9NV@T"C&8FUTM+&:XN2!-]NTRFUV81DG4V^TQB'L&\<F\
M^$N5($B^EQ!O-*6W>"!U7EP3!B9I%'V^M?&,+YD9EP3++@2VIVO2ZYJ<S R\
M1/"*8%ARA0"6OQ \6DS6U%Q.>P+;-&VQD]U@)[J*[&7.H5$8^H.LL0#%X]2>
M,FE/+?UNTO.STZ8=ZNPA\(S-A00]>^5=FQ\6>_/$ *S 7-GUBTV0])!'.O8&
M@AP:!:-HH%IF0?)'WI%3-.HE&9V4Y!-7M/X!45 -&\N196^1/XS[H57HI]&
MI@4JB#S?3G/<TQR?07.?X+'R-SZL5S%>I/& C,7,CU/?&Y3)S&87CD=)/&#D
M[K0N#8BE:0$E[GG-5'OW][-]EWEGFJO!_#UVGVVS^ VF;5T_4+&LF"0U+!#2
MNTEQ5Z)M!]N!XBO3(#UQA>V6>2VQ@P:A#?#[@G/U.M +]#WY[']02P,$%
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MI2%C<MV2_C6H; "M%U*:S<!NT/^]DC]02P,$%     @ &$IC6HLY1J,2!@
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MZJ<9[VC&HS0_UVMXP5(-)#!V$QB0+.TQ<U' *PW\S)(=LV24V;7B*R8*Q!]
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M1=SO_=&Q15YVO"+N>?WHVW_9]8JX[]6CQ^#+SE?$O:\=VV+JR]Y7]WO_ZOF
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M,6?4:&Q:7[R-Q"4K>B3FDUA 8B&)1206DUA"8BF)91!6&PS&KX/!F!P,9 /
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M>%'BG]=%L7[8?WF?SV[SS>X%Y?_?K=?%RS=7I?]MO?ES7^/3_P-02P,$%
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M\(5H%9*(EVKK^U/3V4[8$H2]E"F5HS=>X+PH\N#DOTE2R'")^EEZT%5@DW6
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MS3R_*$)B[.A6Y3(E%RA:#L-O+7KE.<^!O+R<,.)5D?QP$?ALA8(_9]$EK"_
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M',['T+BK0$G;58YD^/00$LCE*(M1U&6#M!=D&5_8JC&S%@Q[),Q, 5R /_&
M9]KR [),<D\A47Z06"6F%HL#8U$9."$^/508Q@M[,%IU^MQ*S#6/V,>A5UAN
MS)VG[%Z1@IP4@$.S;=R2T9K$U&[ER'$@<%:<)LQ( G1$!TO5/6@9;<JI:1>S
M'(BYO2^<14S16DQ*%$\LTBF1D)4,@"A9@U/B<TRICUK^(505F#PX<:YC3J[K
M>)VK*JDGHPAT>/4\8>EU&IRO1;F;D\?7Q2_AAI 4#T/(I@XYM<M[1S$VXJTS
MUMQI#B^W^)=I84W!$[[#HOTWU8U=]7N%(_8$^TTHD(1Y7+&PIZ&,]1:'-C;L
M+;;<TA-ZNU8#^1TYJT^P)-0F&:/T/?NCR[.+)V&,'ZUM8)#/TU_YI'%,SQ9Q
M.K%,,I&2YBQ;T_)"1TGQF("I@[&?II'H/OG=28B2SF:&WO&0=)#(*3BQV&SM
M]3JEV4)1(MP17PR.X_,71_T,8F;'!XZ.VT101AN?T(K5UTD_MX:DKB,3.8=
M=XP+8^/3!JV(*(>O(;\)O0K&D195&T<2*3V7/MFJK#0 8H=8+-#<@0:?LDQ^
M\OA4VI2-G2WIPNFV2#+KOFC+7:71M^0?SMYR@?@JQ/)\J>5+*=LCA7>!Q44&
MT<6$Q% DYW+;XETGON;F$<B%L\S!#!5K YN12!A_-N,++(UB+L,7#$:2XS!F
M\PTRA,6$(@*CIE<5C+_Q^;@T:1?"F*&+7;FZN<.@QU1&-J2<V4K=_L$$'U.?
MP8 $ :'B)0]R>XZJ-UK 4[$(DYD4(MV<2M-SH,?T,<R(SR"EJ!KT7Z3D:>C[
MPK-%,20;BL2P69[@8/QAE$ K="85O].'"\H-YWV^1?(TG)<6""Y,3HT@2 7.
M9W3&QFR<4^[DLPJYVEQ8F,S1\_0MC796?+.SNX\G47) C-/_R7NL-'^O(#LH
M.S?9N.%-I&NB;K%-)C>0HHHIR#JWX#72F9S[P4*$U)6M+)+^SVT;O\LF'1-_
M7^/$7]Q[GP_UG)C8<^B6S0Y_MU ^UQ?L E&>@TA6@WQ,X;SB+ZR>V=79,):'
M(K?'@XT\G=-5D5EAJT?>AN9)U9!Q"?H(^N&LM.GRZ*%EVF??*]>E4OE#^AC:
MX"B^TZ>*%WS.+0V5JO[!='.37J'%,6-GPC>*BB5,<TXPRU(;B556_OP4XL=%
M%:LJFK\X$CL*V4*X.>:>V)6P9_R11_X*3OJ&CM>Y%-]-F),.!AVF#0XQ)8H^
M$RU=/U)%;M!K@,8P?E_.RX8SF"A]&38 L09^<1F2-=RM()TY.GT%P16)K5&F
M*C6?%H9DLM,3(;I?RDT\T=BHA*AC3G#F$DER/Q_Q:RPO)QS\1MPV9_*YAE_C
MRS#34E\:.+L#VCL)RHF12^N<@&5.XYOBRQNFD^\E,Q!/.:L[Y>.N):FUTX%;
M\/98(?:_.)0#4YB.69"X2P"@Y(R_[E2HZ:6#T\BL<+MT'VOLR1.'OKQT]BAR
M->*&LI<O]179>Z95?Y;VJ-?Y",+<AW$?%Q\T)JB[YL\VLP_L>OFV<;I:Q2]#
M7\D'D?/C\EGI=\JMD5%K]8I>?7+^EZ\>B.[&'[W=\>>1E[;O[9;_A'O1#@_0
M_94EUQE^8(+TO>R7_PU02P,$%     @ &$IC6N=Z1*'9!0  NPX  !D   !X
M;"]W;W)K<VAE971S+W-H965T,3$N>&ULK5=K;]LV%/TKA L4+>#$CSA-FA?@
MN.F6 2V*N-DP#/M 2]<65XE422J.__W.)259;IT4V/K%UN/>P_LX/%>\6!O[
MQ65$7CP6N7:7O<S[\FPP<$E&A72'IB2--TMC"^EQ:U<#5UJ2:7 J\L%X.'PS
M**32O:N+\.R3O;HPE<^5ID]6N*HHI-U<4V[6E[U1KWEPIU:9YP>#JXM2KFA.
M_K[\9'$W:%%259!VRFAA:7G9FX[.KB=L'PQ^5[1VG6O!F2R,^<(WM^EE;\@!
M44Z)9P2)OP>:49XS$,+X6F/VVB79L7O=H+\/N2.7A70T,_D?*O799>^T)U):
MRBKW=V;]*]7Y'#->8G(7?L4ZVAZ/>R*IG#=%[8P("J7COWRLZ]!Q.!T^X3"N
M'<8A[KA0B/*=]/+JPIJUL&P--+X(J09O!*<T-V7N+=XJ^/FKC[3.-^+6N8I2
M,4T24VFO]$K,O=2IM*F[&'@LP\:#I(:\CI#C)R!'8_'!:)\Y<:-32G<!!HBO
M#7+<!'D]?A;Q'26'XFC4%^/A>/(,WE&;]%' .WH"KY/G+)-Z14X@6W%CK;%B
M9JR-E''BK^G">0OF_+VO#'&1R?Y%>#>=N5(F=-G#=G%D'ZAW]?+%Z,WP_)D4
M)FT*D^?0_UO?_B>DN*.$M(?1-#6EW[7ZI5*IU F)6RT^F@<J%F2Y7T=]X3,2
M[Y7&6R7S_<C7!G_BU<L7I^/Q\/S]='X=+D?GKX5Z)J#[,I6>6K_I_+YUXZ4/
MAB=],:<51,0C^-+8X/_JLRE5(L:GP]=GXK8H+8<+$R>\J<WD(J?6\YUR26Y<
MA2[VV41%%VA2:^IJT[0UQ=NOE;(1N"]*JR!Z"K7SF375*A.D,ZY7VO$!#1<0
M3N'42JNE2B00&V1ZA X[<H?B,\J)3%$80<LE!5D3D&=P6%<H<$E6&11G02NE
M-2<LEQ[-P"Z*71D=]^O.,.N5QDM5M&YKY3.EQ1)1 6Q#TOX8:A*CFIFBE'HC
M9$T/;CR72KFPF\PRQ%UW)H3,%CMA=Y:"9O\F\<INQ*A994X$=J'EH].SMC^W
M.@XG5OE0AS15? -0U7EE:072,/+WW4)9([GW4AHKBC\Q(!O:@^)M!3H4!VM;
MMK9YONW#/#$%B<_R$1VNR7<RV4>^K>5WI*OI$E:")&E(BR6=;$(/4TI"C47E
M:%GEFERHMHIP'G [J?XL!J$AH22\\DYSWX)%>2XTZI9)8$N,+&89L.."W%R_
M90SOVM')N0/K&IDHC5,1V*)S#D,VI(2O$1O:B32^49K)DVV8' R/VC9 /7RH
MN#CH: ('8BGCKXT':DP/Q$W<==P-N5HQ@T),G>:(5_-JX:.@C(<':*L(_:JW
M?Z?P??0C1(BR4&CW-EO7!(5F(TM7HJ%+1>D.@:,X) 3- 5)BG(]SZ^=+PYO]
MTO CMY,805?Y(A$6H$!9YIP0",_9<6000Q:;4).:1<O0;;^UB7Y)*,"NR"#'
MI,*H#@.)'F1>R=!)1H-"8VA''>)G'1[$@ (KL9[R;E\7=K?+SF"<Y8JY?'!'
MN60MV%)!W%5Y&'\?I$VR#B/O#^>L7(@6C&Z^-1Z3\.7!Z11@*R??C+'YS>S;
MZ2=#E+FPO$2L+^=55@L4!U3@DJA(JCIT$DD=J:TC[5(I,E%QL5>*/W'"TRT+
M0XPU:>*80QWP&2QR:1&T3!)\5]L NU2X<C%3I9$A7+IC$!$##E?/,K(9!CQO
MH'5!IEMZU9]^QV'+3S%*\TYU42WQ8')H=IRO2&)3SYY.S<H:DQ]SN7)J5.N?
M*E6A^Y8>^!2QV-3*5%D?5*TL2>;;"&_X.S\3,V632OGO.%D8U,#89JV4P'-3
M!E(!+$=]5LTXBFU!R^HT6A7DB.L=^ S)8SV#*GZ3;$WLM#M"L.\2C(6:?N$N
M#?3>]S$ZZ!PH"D+'^=B$4'@RQK-%^[0]F4WC@61K'H]UV P0#2=R6L)U>'AR
MW!,V'I7B#;0S'$\6QN.P$RXSG"[)L@'>+PWDLK[A!=KSZM6_4$L#!!0    (
M !A*8UJXW0%&Y0(  *<&   9    >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM
M;)55;6_3,!#^*Z=,VZ>I>6FVCJZMU'8@D)B86@8"Q <WN;QHCAUL9UW_/6<G
M#47:"OOBV.>[Q\_=V4\F6ZD>=(%HX*GB0D^]PIAZ[/LZ*;!B>B!K%+23254Q
M0TN5^[I6R%(75'$_"H)+OV*E\&839[M3LXEL#"\%WBG0354QM5L@E]NI%WI[
MPZK,"V,-_FQ2LQS7:.[K.T4KOT=)RPJ%+J4 A=G4FX?C16S]G<.7$K?Z8 XV
MDXV4#W;Q(9UZ@26$'!-C$1A]'G&)G%L@HO&KP_3Z(VW@X7R/_L[E3KELF,:E
MY%_+U!13[\J#%#/6<+.2V_?8Y7-A\1+)M1MAV_K&(P^21AM9=<'$H"I%^V5/
M71T. JZ"%P*B+B!RO-N#',L;9MALHN06E/4F-#MQJ;IH(E<*VY2U4;1;4IR9
MK? 118.PPD3FHK25FOB&@.VVGW0@BQ8D>@$DC.!6"E-H>"M23/\&\(E13RO:
MTUI$1Q%O,!G ,#R'*(CB(WC#/LVAPQO^(\U,R0J6Q%71=:!2FP*6KLBHX,=\
MHYW]YW,5:/'CY_'MTQGKFB4X]>AM:%2/Z,W.3L++X/H(^[AG'Q]#_]\FO1H$
M/A=(U:AJ)G9G)U=1.+K6H&6C$@29@2!-J)5,&RJ5ZJ+31I4B!T.!.V1* ]J.
M _4+JPT5<=\S8"*UDR$DDEZP-A:8(]]98,TX:COY>'^[^O8=2N$ [P?K =!;
M>PWZ.3DKQ.ZI((6P))&-,!1&D@5A$)SV1PY<PIGD)$4N"[;A"*YA@@BRO339
M ,NA1JJ$,"1.SB(-XY KJ767@9$'YXYA[8R;77^EQBU91W3)%,FI>H XAE,8
MOJ%AGB0*4PG#$2WBD(9/M6DJ".UF%-!PT!\H6 I"_D]37JA:!(/G[J)_(![$
M.7<2J<$5L=61WMJK\+P5GS_NK83?,I670@/'C$*#P>C" ]7*8KLPLG92M)&&
M"N2F!?U)4%D'VL^D-/N%/:#_-\U^ U!+ P04    "  82F-:_61K^-\'  !$
M%   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,RYX;6R=6-N2VS82_164DDK9
M5;+NOF1N5>/Q.INJ=3+QQ,G#UCY )"2B3 (T $HC?WU.-T"*LB4YFP=[2 HX
MZ,LYW4U>;:W[Z NE@GBL2N.O!T4(]<5X[+-"5=*/;*T,?EE95\F 6[<>^]HI
MF?.FJAS/)I,7XTIJ,[BYXF?W[N;*-J'41MT[X9NJDF[W6I5V>SV8#MH'[_6Z
M"/1@?'-5R[5Z4.%#?>]P-^Y0<ETIX[4UPJG5]>!V>O%Z0>MYP1]:;7WO6I G
M2VL_TLW/^?5@0@:I4F6!$"3^;-2=*DL"@AF?$N:@.Y(V]J];]+?L.WQ92J_N
M;/FGSD-Q/7@U$+E:R:8,[^WVWRKY\YSP,EMZ_E]LX]KY8B"RQ@=;I<VPH-(F
M_I6/*0Z]#:\F)S;,TH89VQT/8BO?R"!OKIS="D>K@487["KOAG':4%(>@L.O
M&OO"S5NIG?A#EHT2[Y3TC5.(>/!7XP!P6C+.$M#K"#0[ 32=B7?6A,*+?YE<
MY8< 8UC5F39K37L].XOX1F4C,9\.Q6PR6YS!FW>NSAEO_FU7WVB?E9:\]>*_
MMTL?'-CQOV-.1\C%<4A2S(6O9::N!Y"$5VZC!C<_?#=],;D\8_"B,WAQ#OW_
MR<T_ A*_%TK<V:J69B>TA\8^-=JI7 0KJKA.9,H%2%M([Q5V2).+4LNE+G70
M")X,8D7@&P(?"J5#H9QH:NA-&RR1)5 SNZ9K/+-.H(Z@ BP]SH(-4&5F&Q.T
M6=./3M76T<U(0'-"/<JJ+H$;>H8V'N?N#\6B0#5BH\J=V!;*]"'I,#*YP^W\
M66DC34;V:8/T-QR0802(OO=79Y;QR&!<>ITK)]FA@UC@(*PE6X_ZOA(&1;8-
M9)9B3;$5R\8C9=X#O5K",MJ $.R=1':4#QI5"%N6.R'KNMR1A71:H6&.RXH=
MRI'/G%[2&BJWY(_."E$[;1VL^ PKHWEU QL0R8-<]X*J#9Z'PBDE2H701N^H
M_$6$#(:L@?DYAF&+O"?7]\8P"^@1+('Q$8C"P,?C%Y '?LF-U*5<EHJ/\!KQ
M6NE,(M1LPH%9U9Z](W'[<"=>S29#<8K>A-=7^I#*-<6Y#RFQ#@75?53A&?F7
M]P^)1OK"-B6%%/N#<JC"*L8B%\E#)+6I:@J%CULB8%VB-(A:@GJ9!GEATY:A
M$'E*//*241)ETA=)H&74;B3^)#*FM#.;>TK+%=IRSK*))H TE$/R&22":AZ!
M0=%.]GV!?JBI2NX$V(W,E24K#*B*UBL)^B20E2V122:=R@JC(6!_(7[X[M5L
M]N)2_&QPK")B.HM-+?60X(-(<9E$8&/P@2S%JF'+H4(EJU8FF?2%6.$\/^J.
M>,=!/7M$C#L'-BG2<D72)LXO1-:5LU6[$(7?>)G%S&FSL>6&'(3 (?@,"D8,
M*)S2189&\?8"">&#B<0AV !+5KPAEHA6GWUVL.:B5!#E?2!C/GR R=+EE'4<
MJ-'7"9J%^ QGN3YS]TK[MLIUOZH=LC^FM9?)_[!.I^*9^*VQ5&]2-,FU?6".
MAH*K&<]9*<"][$78V5%8KRO4 /=W08>TXM,9X_X.9,**>I4@H+$AG</X*7R1
M/UADOCBQVY>CCF<!NN%-^[LES0-$FS[<?A?XL8EHAHH#"8^8.8R4<\XNK4OE
M?M@#:YF;8]JC3D!+52G;]AK-1:[-5Z&?(_0?3 ^I;Q)F81J4NRX3Q=-C[HBG
MA5X-8(@XRW>4.]I5VX*:'TX+)%=)';)QS,JHGZS$F6@ G4J.,_Y)(BF&0_)Z
M_O2PRO2I3\R@[3%$"91F!"Y]W.7AGBUU'J,M2[@ SVBDABJ@;90DS**J6B*R
M[3QZXOG\5#.ZZ&35ZJ!-RJGGL=K%*%.0(G&?>+3D7\!#\?RI^,ENE#/<J'I+
MD.71PTA\+V:SX6+R A?$@^GL\N#JY7SXXV)Q],??;=@+_)_#W"*Y&WHO0YR.
M)K'-=293_:7YQ^1-%F(F)12'WJD<I,'L&(D[Z' =]4MI;,G,+8W.Z2>:*4"=
M#2T'[VAQT@+?#DZ-!?NKH?!$H7_3=$5]IU!<%+WJ?$T.+N;0^%9Q68E=9J5<
M+&74E##_P-H]B5GU\Z\.\*=/(+(-&0Q7L\-VGNN<JUD:/S_36("9D:1+W$Y=
M"HK4F,HL7(5K#]2]4Z=/.)S(EY?^U+#L&W0==!#NU3QXT 6]1" -<4F:Q>G=
M(E-ZTXUYW?-:[F*)I)J8BM!>^V>42<4DD\ZQ@M-0%/L@SP>/J8KUB)?C7QPI
M\0@SG0O/:)I+D]-(O+<[68)&;Z.W@/T5+7@=:7*J#*0$S(=I+.X;U(;3)>!5
M!VSWP T2['A9>_Y] W6@FHG;-=H^J_L)5_+)Y?O[6[Z:7C[MNXEXA<.A%E9M
M9:_RTOM%I-6^P),L+?(B/2$8'ILLJ8]TJPQ@NII*-3J]_/"K<D,2H6D](';!
MNEW[[M@RHU8924Q\-';;366$FL9RS'HFQT+TRP:,VG$[&Z(V>*!Q"V]7M$?3
M+O581WK4B!T]S%7%;#)YWY7XV01173:[.%[3CAU'$CN1=!2;)VV=C87B*130
M5M;IY.(\&?BU,L_YO8Y%L1\NG5IC?FN#_:60SC%A=.R+P;CW90<>K?G[%95)
MB"=^Y.F>=I_(;N.7H?WR^'T-_60-^>(U;(6MD]'+YP/AXC>K>!-LS=^)EC8@
M?'Q9* EVT@+\OK((3KJA [H/AS=_ 5!+ P04    "  82F-:^S/#C7\%  "M
M#@  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6S%5VUOVS80_BN$&Q0;
MH/A%MA,G30PDZ2O0 D73=AB&?:"ED\5%(EV2LN/]^CU'R8[BVFFW+P."F*1X
M=\_=/7<D+U;&WKF<R(O[LM#NLI-[OSCO]5R24RE=URQ(XTMF;"D]IG;><PM+
M,@U"9=&+^_V37BF5[DPOPMI'.[TPE2^4IH]6N*HLI5U?4V%6EYU!9[/P2<US
MSPN]Z<5"SNF6_)?%1XM9;ZLE525IIXP6EK++SM7@_'K$^\.&KXI6KC46[,G,
MF#N>O$LO.WT&1 4EGC5(_"SIAHJ"%0'&MT9G9VN2!=OCC?;7P7?X,I..;DSQ
MFTI]?MF9=$1*F:P*_\FLWE+CSYCU):9PX;]8U7O'L)A4SINR$<:\5+K^E?=-
M'%H"D_X!@;@1B /NVE! ^5)Z.;VP9B4L[X8V'@17@S3 *<U)N?467Q7D_/2#
MM'?DY:P@<4M)9957Y"YZ'JIY0R]IU%S7:N(#:@:Q^&"TSYUXI5-*'ROH =,6
M6+P!=AT_J?$E)5TQ'$0B[L>C)_0-MXX.@[[A 7WO])*<!YV\B\1+FGDA=2I>
M?:N47[=<%W]<S9RW(,N?^Z)0VQCMM\$%=.X6,J'+#BK$D5U29_K\V>"D_^()
M#T9;#T9/:?_Y5/T'->)S3N+&E NIUR*73JB'<&$LY%*J@F6.T0>.G81PRC%T
M#QI\+A%32RC5Q%B00&">265!5[8HEK*HJ!LL);G4<V+%'K.P*7P5)CMHZA$B
MU[+B4-I)55:%])@::+0B@2N6<FX>2Q*%<<$+EP-?;HJ4K'O^;!(/3E\("@R(
MA 9"6%<:HB2\O!>496@=KBNN''\!(:F<0?>&E(% & RCX,4F>HF!45A@:)BF
ME*!9.@H VIYJH>!)^9"-=BR-F,%M"_!:S-:02[RQKG$.D=8"6E/EA57N+F+4
M194J/=_$FI?K4&>F0./E3\&*0Q! NQ;@)A!N7^ ?(&W")=._T)3@6V*<C\3<
M<F@K#1<+]3>6YS@'W)YU3@&,<\A:08!K3LVURE0B=3O%(D$RY\:N.;U/!O^\
MGNYE];FXVL"] 5SQY0'/&\;97GA? WS-X+X&<&_,DJP.:%JI.19?NK==<23B
M.(I',0:#DQ'^AP#%+^H/H_Z)^&R\+'YB'SOQ/\ _C:.SLSX&9^/'L$Z'T=EH
MM(7_PWTMZJ?DR>*0(B[/-B&$L1L&F+KF [V0V/W\Y^-:N 4ES R!:M(^<"0<
MY"7YW*3=1Y9QE/,YSUT(?;<QRA39\ Y_H2D8S0$)A;[E&N^K*ZNI_E_H'I<>
M1[_6;:%I4^@RM34N)JYR4Z@T]!SG\5-W)FAFD[OH$@.6AW"$PMB-3B:.!M%)
M/([$T=ED$@ =C2<C%*\-IM<D4?W$1^OWI1#5%&H*(HZ@G4/'MYUB'8 XVK6X
M0G^"V<S!/12A-KO FKBU 1RR'RSO%V?'XNCT;%"[%$?#X>2GG'K2G=V>UMPH
M83CD7R"OJ@R)>7RR[&MZ.^=<BXX[YUL4\E_IH!8>R+T-<_=09"^20CH'^D(0
MH680($^X8E2H, #ES2@>(-Z@;&LXT/_.T3/\9E.K?82K3;N'O"?GZB-C('[G
M- Z.QV'@Q/AXT&^&;Y ZOSE;MJMU$_AQ(^0^UNX-^T;?M\5_([5S/6G%5/EV
M%@]<5@[GE0.,L0V- *2M>=!DZ:'$9[*0.D%F^*8=A';RI F[ZG-[:S\0I7*$
M SH#C7'3P*$=\:ZL8F(T9O'"LJ&UU6T#E<G7*-0DF.^M"L^7[QHG1Z)EOL%\
MF-YB8:Q'X2C3W7<7[;6>$"79>7@H(3+,^/HUL5W=OL6NZB?(P_;Z(0<RSKG'
M%)1!M-\]'7=P'PF/HWKBS2(\2&;&XWD3ACG>DV1Y [YGQOC-A UL7ZC3?P!0
M2P,$%     @ &$IC6CU<'6J+ @  G 4  !D   !X;"]W;W)K<VAE971S+W-H
M965T,34N>&ULA51-;]LP#/TKA%?L%-1?29IDB8&F7;$="A1MMQZ&'12;MH7*
MDB<I=?OO1\F)EP%I>K$HDN_I43*Y[)1^-C6BA==&2+,*:FO;11B:O,:&F7/5
MHJ1(J73#+&UU%9I6(RL\J!%A$D73L&%<!MG2^^YTME1;*[C$.PUFVS1,OZU1
MJ&X5Q,'><<^KVCI'F"U;5N$#VA_MG:9=.+ 4O$%IN)*@L5P%E_%B/7;Y/N$G
MQ\X<V. JV2CU[#;?BU40.4$H,+>.@='R@E<HA",B&7]VG,%PI ,>VGOV&U\[
MU;)A!J^4>.*%K5?!+( "2[85]EYUWW!7S\3QY4H8_X6NSTV3 /*ML:K9@4E!
MPV6_LM?=/1P 9M$[@&0'2+SN_B"O\II9EBVUZD"[;&)SAB_5HTD<E^Y1'JRF
M*"><S;[+%Y16:8YF&5HB=.XPWX'7/3AY!QPG<*NDK0U\E046_Q.$I&20D^SE
MK).3C->8GT,:CR")DO$)OG0H+_5\Z0?EO<$U-[E09JL1?EUNC-7T/_P^5G)/
M.#Y.Z'ID85J6XRJ@)C"H7S#(/G^*I]&7$W+'@]SQ*?:/7N,D^+BT T9XK!%:
MS67.6R8@9Q:K/J!*X =YS *] S8;U,-; ).%,U+HD*XP5PTQ&2P<UA)OJ03U
M-Y?5 H8[7_1(C[IG'?VV%C5GPG@RLVU;X8X[@\DHGL_]FLQC>*(V)CTD5>5H
M#(Q'\VD*R2A*+^"&2TX_>P&54H6!.!K%Z132431)X%%9*NN,SB.:&1D436<1
M''N7\*!C&M25GPN&RMI*VS?/X!U&SV7?<?_2^[EURW3%I0&!)4&C\XM) +J?
M!?W&JM;WWT99ZF9OUC0^4;L$BI=*V?W&'3 ,Y.PO4$L#!!0    ( !A*8UK4
MP: ZH (   @&   9    >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)54VV[;
M, S]%<(KA@[(:L=VNB!+ C2]8 -6(&B[[6'8@V+3L5!;<B6Z:?]^E)QZ*9!F
MV$-D4N(Y/)1"3C?:W-L2D>"IKI2=!251,PE#FY58"WNB&U1\4FA3"V+7K$/;
M&!2Y!]55&$?1:5@+J8+YU.\MS7RJ6ZJDPJ4!V]:U,,\+K/1F%@R#EXT;N2[)
M;83S:2/6>(OTO5D:]L*>)9<U*BNU H/%+#@;3A:IB_<!/R1N[(X-KI*5UO?.
M^9K/@L@)P@HS<@R"/X]XCE7EB%C&PY8SZ%,ZX*[]PG[E:^=:5L+BN:Y^RIS*
M63 .(,="M!7=Z,T7W-8S<GR9KJQ?8=/%IIPQ:RWI>@MFOY:J^XJG[3WL ,;1
M&X!X"XB][BZ15WDA2,RG1F_ N&AF<X8OU:-9G%3N46[)\*ED',V7AM_7T#,(
ME</E0RL;OG$:@$*:AL0)7%B8;<D6'5G\!MDPAFNMJ+1PJ7+,7Q.$K*R7%[_(
M6\0'&2\P.X%D.( XBM,#?$E?;N+YDG^4.X!E)12]KAI^G:TL&?ZC_-Y7>\><
M[F=VS3.QC<AP%G!W6#2/&,S?OQN>1I\/Z$Y[W>DA]O]]IH-D^Z4>R !W)4)C
MI,ID(RK(!.%:&XD6=,'[.SA\C1,$_(!8K]#TC^CCV$A & 1AH= 53P8[@0,*
M)AW4PVYU01O&#CA[(3/TX9FNFY8X3:\ CF"<Q-OUJC5*4NM A7QRAO6P0A))
MM;9PFJ3^]PVMA8\\*[*V;BLN-.<6YTO*I/!#Y'@XB(;)!S@>CX<?X$X3W\<1
MI*.$U]%X!/N>.MSISAK-VL\@RY);15VC]KO]F#OKNOMO>#<CKX592V6APH*A
MT<FG40"FFSN=0[KQO;[2Q)/#FR6/:C0N@,\+K>G%<0GZX3__ U!+ P04
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M!LSG4;W^80VNTJ57*G#96(CIC$T6;,=(JU "X\1_<.B8^5NDGB+*8NJC"9V
M_5Z&!EOL#<RF/&%GK%78%PK,/.2 P8'UTI(*FZ4MNGHK%>L0E/Z1J#V]>5BT
MF\#H*FQ<BUA@GLW"J8]?[#R@GB'1K>JV.YH_I[BW5#Q)X7V?G0VS%QXG3X>3
M%PG2L4U8*=<[);A+-DJ3HN)JX9T=Y/2^+W<VPRML1<G^N='UYIH=,7=+U%/D
MX)..3PR9>+IJ.A#\+)_UMM(KZU?XKEJ@R%2X([VCZ1+MNF+'.I*K(+C7]_$8
MFH^X\35FX$(H10^[G#EA>9Y,+E.\\).R:_9(9:OILWKOC/BOW#N@V%I,B\)
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M6BX/UV6I:##XI.4,\QAQO=B?Z/)T21<+60T"%WT>[Q56)$/U(VV-4O4H2HM
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MQYXQHB1$U=.#*\<(QW[P/'5O\#R3:.]&B:?F@C)$UM8U;SP<BJ*R)52B)_4
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M72F) -,!?+\H"EM_( '-'VV\_Q]02P,$%     @ &$IC6G3]&M5: P  G <
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MRI4LF^R5$G-5J$9)G8ERD5U4FXUJ@ &-?G+0P%SXQD'.<)\;N-,!N)-I]AI
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M>1'(9&P71A7.GE<-$W"P+-N6"@:R!KVU=BWTD3[6@?!1BM&GN)&^P/T<>5Z
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M+ZO-C^V8/YIJ2S]P,Z\@(MG01Q!TL+ X )XOJZJQ?^ $[A>/GOTO4$L#!!0
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MG=+WM&M5T1,Z'RV#HF3T!66(X& SZ!AV5#<J Z_E"I&2L$$OZX4"(<\\-SK
M;'UBZP=F^"^HJR<S0K(E5L&(A<R>#">OC\6"HR?FXM;HH]\X'F@+!<&K90Y8
M+HV6FD;(^EKHZE\+K3%"=6Q]2'@XO0\CZ1EPIFPJG.YJ?.\S#NIDQ=H<0,Y!
M0-(!>R 7(S03\A72!M6^#?2RP/2$PL$;&KO$XF@F?J$8;L39H?+ O<P;2J-_
M2$B_X+A:\[A82 S+MA87-SO53T_=@=KG)'\"[#D<[Y]_OFZIK%UM-Y>5=974
M7!CK3&&>N\85:+4A$0X)SJ(Y5THO 4.QLJ80'H==)CG\'^Y5';HF_1$J/RJ"
M<ZR7HKO'MU]N]O@V\&0P<.O:6J%!V/BI(3B.!L[ANNY_O?#0,51<R-D9YK.G
M9 F4".7S@#.9HEB*J43X%9@0%[)+G8;\IV%)4>DBULBOPE1X0%62Z&P4_=A@
M,+7&.3HX!DCJW9L]^#I$*FZWIDJ[SFU;0\^3P^Y9*',9LWO[(P4"_4&9ROT#
MNG:1,ZP[T =86FY!QXS?: >$V#OZIFS[=,A7'?BD;=24JK8_+C==BW=IK=-\
MZ@:_YW958EZ@F:\T.-<$O[]S9;#WK57=%@\/0\T8P7#GKLS-AT<NGG+"E@/#
MSG=&,7JT._,%#_L:&A!R4=0,Q+CHUN>AS#KF(-OE('>0@UY\4!CU6X.O(;/9
MT?3TU>3U&:9HI0CRG'@.VOMK-KE*\=6MX;HI3UPX@]++4.AI"<2Y)$/;T#>)
MK#4LH/2!,"?3CA)7E67.QJ%L+8'X8):HNH]K['5H<P=V=UN912O3 &\71 <X
MK!_]3#XPS>M.X7?HJ1XC0WT_F]1O$-OZ/&C,")<5 =YTY\]=[N^T&T[VZ7&T
M9UL? (>*(*EL@VOD$4!TA[=73EC=OK?#&6K%5WX2P$%)@]\2U"[&F*]*?/BH
M"HP(3G[/7@^G)]'^Z(&C=N,+>LRN]-T(T7JZ U#^EP['8PCN[AH^.O16.NY\
M.<"1/N7O(PY9&PDY?$1H5]M/,//PY6&[/7R_P=-2A2^0.:Q0-!J].AF$>:VY
M\:;D[Q!+X[TI^#(#B6[1!GR^,L8W-W1 ^V'J\F]02P,$%     @ &$IC6EU3
MA%/L#   GB@  !D   !X;"]W;W)K<VAE971S+W-H965T,C0N>&ULQ5KK<]LV
M$O]7,*[;L6=D6J0>EIW$,W:;]#&7UF,G[=S=W >(A$Q,2$(!0"NZO_YV%P!%
M2J+.[J5S'VSQ 2SV^=M=@*]72G\RN1"6?2F+RKPYRJU=7IV?FS07)3>16HH*
MWBR4+KF%6_UX;I9:\(PFE<5Y,AQ.STLNJZ/KU_3L3E^_5K4M9"7N-#-U67*]
MOA6%6KTYBH_"@WOYF%M\<'[]>LD?Q8.P'Y=W&N[.&RJ9+$5EI*J8%HLW1S?Q
MU>T8Q]. WZ58F=8U0TGF2GW"FY^S-T=#9$@4(K5(@<//D_A>% 42 C8^>YI'
MS9(XL7T=J+\CV4&6.3?B>U7\(3.;OSF:';%,+'A=V'NU^DEX>29(+U6%H?]L
MY<:.1T<LK8U5I9\,')2R<K_\B]=#:\)LV#,A\1,2XMLM1%S^P"V_?JW5BFD<
M#=3P@D2EV<"<K- H#U;#6PGS[/5#SK4XNP6Y,O:]*L'6AJ.Z7I];H(YCSE-/
MZ=912GHHQ0E[KRJ;&_:VRD36)7 .;#6\)8&WV^0@Q1]$&K%1/&#),!D?H#=J
M9!T1O=$S9+WC:W MRVZTYM6CH.M_WLR-U> G_]HGO:,]WD\;8^?*+'DJWAQ!
M<!BAG\31]7??Q-/AJP.<CQO.QX>HO\A*?XY2]T9\P6O!9)46-1@3+IC-!0WB
MU?J[;V9)?/'*L%151A4RXQ;&& L_J$C#U((5RA@&H,%X43!#J\YIU;2]$-^H
MW[ 5-XSCI *@PDW&1=>":\,$.A4#EQ#E7.C&+>C_:,!XE>%5<L4>6FMUA'KK
MA+JB>32-9K '@ 19/0[8HZB$Y@71XAD$FT1W0-1@QRR^'$Q&"5Y,!LEX!A?3
MP6P\9O=@;*[3G&9EX@E@;DG>-)M,V60Z8O'TDGU0EA_00E#W,3 T&,UF;I59
M',/%Q6 8C]@-Z72/]"VK$)D4]'B<)(,)3((9=:5%JAXK^6]8,RRC14$&LXH]
M@OKA<L#FM665JLZ>A"%;/LM@0&!.3E)K[9QD4=M:"[846JK,1.Q#+LW&FXQG
MT:T]1TX:YM03R,79BF 4[CG<0U;PI%"6)!HZ7XC8SQ69KBN^EX6I)7(*[B1M
MCM,I<U6I0&_-I'L'RXMR6:BU$*3952[!A)/AMPP5P.JE<@[/TUR"3<F@,"P5
MVD*B0Y640J<2C%K* F:H"NBT]/JWC^_O__X/\@DDH^"?WI"'T22)=W5PONV%
M;*Y 82W:)QASR? 5>>Q=2ZC?G+3T.GYU2KIYS]<^+/;(@(_V,XUO^NB#M5)>
M@CFTFO-Y(0:-;$']+5OBXX[7I,J@N^3<0I*NBXSE8%X@*:KVM)R[J6V;+0".
M 0=H***-S 2Z6F"#&8FC<!9>$*]!2+[B.B-]_%)7(N#$CC*Z>EX!>59",83B
MH<$\L5Z]N(#I+ -AV5AXR0W&D&/S18OCJEI@787^\1)6G@46.3=MW1_/!L/A
M)89P;^@'/.Y;'Z-=0(2G I#?\B]@M$HLI&V[6"]Q9$4CPL_7'38Q)U3*0LEC
M 0@@WOY45HC8QR7A+ 8MZ!S4 RI//P6L (/I3=!+8VH2#(9!+K=:I@TF.J\R
M.+[MINY=78&T;D!7V4@1[%M!D4HC05<WML="0(?\8#Q()I=^..,U(((F2Z$"
MVLP[W(,%][/:O$9='&+9#R07J.=&?*[131LD_[G*ZM2Y[EW!*_3W7P&SB7_@
M/78"WRJDA-XGP:(0N<#Z$H+UR:/"S1//1,'N8.T2BJ7:RI07ABV+E(CLK'*"
MDSST;;T+B#?PX,U=U=!6>TAP#(21=AUL!X\ET6(Y))MB??:YYH5<2(<K!C,4
MYGRU6$@ ?$.:VV2+5:X8:@Z]DA)?98MU>+_CO[ 63Q&8_ ABGTP!2@$PP\&E
M2U4<GRVU%!:Z(^ 0'!Z31;?T<D$&#8 LZY)5->D?W=GYB2\],U?#/'%9$$JB
MSS1>74/,N!@B%4-63B#VAQO/?!Y\9&PVCAO_/+P4K+%MV1XW^T& V*7#/%SO
M'9>:_<Z+FJ+Q@?P^X-V'%C^EX*9&3G"2I7)K@5.?PM1.O#,?Z<X[L'QEM0E+
MWA8\_73VD.:JP.* 9IR!75(<4"KT7]1N YZ 0@#LCE93&;<6YV9_M4<5C\]W
M6.)0>J1JP<4UPCEHY#>J'>!E=1C],V%2+>=H^SF0'C2RHK.&VFB[[FF;%(6"
M+*]*$8"2# H5,/RN';L+56L/O9O:94N3%"Y?E@  S$+6=J/YPGII-R/!VK4.
M! [A>1* ?+0'5K,MTV)T XSM0R*SF] P7"#*,7(J5UJ0&5!G;27LJ=B^FM3]
M2>S_)"L:6DAR.]ZJ9'PAKKL>87,MQ%=T"0SJT 2<A28 BJBZ]#)OX.L9@=J3
M+%$]^S&.VL)0-I!J-AWI50=_ "<;IG9[RMTUKZ@!=<T/0!P[(2V<LFF4^+]X
M,^))0<DD"TQ:\7 ,;[Z%WR']7HZB,?S<2_/I;(&Z;S*%1E6/HQ&\'467\#^)
M+N!_0S23F'% MK444(,35B6O=GZ[;%[YJJ[]S -'\$(M:,N#.L*\W;%966*5
M;U=8O>]Q"<)J'-.F1N[HO"_4:^1U8,H%/,=FU6U+4-L$<&J !%*$!7W[Z8=2
M/D /4+4U%A;$&2H4JS]"CG=<%;)$NE -@*MHK$B01>[BSTC 2U<<0&6>JXPJ
M9^I':N,0%2:D-9:X-*%1%<P"?]YGTBV=MMY HFRH9<S5R=AU5TT_['7?XK4U
MO8OH33)R$8"1X?(S#S:BVNP+JB\$;<?04:^7.0ETSUN0HF$=B7Z,'B"P-:7H
MM?<^*)V><!X3BP6LR'SN(W< ,9RG4!6#M3\@IEU[N&IX]ME^B^4^=[_JU NY
M[RLRW..1\YJV'.!YF&1\RR:I(@Z=)?)#K6NEH&;%C*Q:%%J3?=$&RH; $*XP
M(M^,MFJ8F[ ='FP'J#V7U1;2N\UK*F&! [>;@"[:=$/[+>XG(Z?=[;2^E(.6
MZ\>[-@^N*L$MYROV:U.%NO%_A#V<&^^S.P]N'A^U>$17>>B699M ';!?>%6C
M8@)O\7"07%[BEEB47+(??463#"ZG,8M'T<4$3!_PXN1B-#Z%@:,A>Q=P@YV,
MI[-3%L?1%(=B-H)GR70*SZ8X\@ ONYJ*X\'%)>X'SJ+)", ;-^U&X\$XCK?H
MM%+K/CH70 :%FB*9"0 VD$D&H]F0W)4WBH((@ZK!R'13TFZM@"[_O'IJIS^F
M-OMX,KB8P8#C9#"-$_?R>'9Q09VE;XJ*=3=#-[#40O9NW1V8#!7H_\8B& ^4
MS(XOHWCL.1Q'PP3QS+4BV\S>;YIBVAAF-ZX'O._IZYM<UB"%[W!\_45HASN!
M\/11'*ZGGU."12_K8GJW(P[T,X>RP1;J-C2B7@7M[22>//1ORD+.:)^8/"!4
MD#"EU3]@)\1IW[P"6VG3PL!V/;CW7()46>/D+E/2[&PITT[@$E)X2BB,G*)B
M7 *$9C=S6\*\*-:#;>=\467>-@UIN+7;L+]&IW3F-X1="52),UIWCT[\;N9.
MOMBV;I^']%:\&$3@S6 LLR,_7%1."0.GVT7A<JO/;Y9T.L>CW7VA]M\31E]X
M[F0,@GN<+MBOFV.*WG XE$>@1D?43H9-#HG'"8LGT6C*?G=T3^+XU UI9P_(
M$TDT';Z8@3W)8S+$,YYQ-)N]$$[[%NR!U]Y$[]"49&ZP,P+)>A>@/<D7@GBK
MDXHZ>Q;.UA\K# QO\;N]6Y,F+!_./^X>/C9G'7\U6+OM>A04,XKK 8!Z75CS
M0M@^N%7\%X WV'%WR6<8LF__I6]3<,0Z6]:3R:1_74*[3&94=E,1C5U-FJJZ
M(D1NB9_5(IQ'076=:D$(#2%<<>KOO+"=LSUH$/"  #A-\20!*"*@5ZHGE-#_
MP=,!OZ3)_7YI2Y+J@ );QU O4^.(T3'1.S'7!$@.?^/99)] N[HCQJQTN;<]
MM+6Z$7C(">HM%G1DBHO2O*9[_NK.,8:6RT>5C^N[6D/$&=$<%"3#^.(KG _$
M%^']P04#5+Q]N+O;'(M^:$)SLVD>XI?\!2WBX<,=*)1\3<?;#DLVVTY(%[-A
MC+OFCO R,- $IC^3\-I=R:)HT<+J1169[\4?:2-"01NL-Y5),Z7MI*VSA?9W
M&Z6T5C11X50<E-"\;D#S!%T=9<LD+LEXJ7!5KD'7<NG/BG [V6W$=Y;U*T'V
M1V@&&=H!>DH?$1#?,  B2#PA-(,,!9T(X@[V;-(<8^)#,L,5L'3JVF6,3RAN
M/@F[P4[NC1QJI* GC.A7J,J3^?-G-X9ZT?[SSK[@GO(OCJ%9&5^X>@IZT6V?
M:B>?[2;E[>Z'&8VCO>"\L]LKR3*<F4;[OD Z;WTS5@I(C_AE'((;P+'[?*QY
MVGQ\=^.^.=L,=U_NO8?L"JTI6'0!4X?0B1\Q[;Z&<S=6+>D+M+FR5I5TF0L(
M9(T#X/U"*1MN<('FD\3K_P!02P,$%     @ &$IC6K=&@2M?!0  ;@X  !D
M  !X;"]W;W)K<VAE971S+W-H965T,C4N>&ULK5=;;]LV%/XKA#L4*Z#8ENQ<
MFQA(VA0=L!9&LZX/PQYHZ=@B*HDN2<7Q?OV^0TJR$SO>VNW%%B_G.]^YDKQ<
M:?/5YD1./)1%9:]ZN7/+B\' ICF5TO;UDBJLS+4II</0+ 9V:4AF7J@L!LEP
M>#(HI:IZDTL_-S632UV[0E4T-<+692G-^H8*O;KJQ;UVXI-:Y(XG!I/+I5S0
M';G/RZG!:-"A9*JDRBI="4/SJ]YU?'$SYOU^P^^*5G;K6[ E,ZV_\N"7[*HW
M9$)44.H80>+OGMY043 0:'QK,'N=2A;<_F[1WWG;8<M,6GJCBR\J<_E5[ZPG
M,IK+NG"?].H]-?8<,UZJ"^M_Q2KL'0U[(JVMTV4C# :EJL*_?&C\L"5P]IQ
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MZ+]X/&FGXV&:T3.[ &\#S;VGBTP76TP>WKR:)O'DK2$MTBC!"Z^XY)(H<R;
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MZ3$RSHN/$W>FWAL:":>:P0,Y&R@->39%O!:'7"Y/>H:QJ<2X2%$&3(%K!L3
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M#3+\#(.]SZ()!&'W^SKA<V$2VT%RQ*;;F,4*&1&F;FKELC'2ORN8J<8]/WV
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MW@5(=+4N03^B";N5%M04O"Y:QZG$@FT@+JA6[0S6NG([PAY1J'0U,3CN_1C
M(=P<GI$9"W=(%5IK40*7C2%'?M>.H&J-XJ[U0!5_\H(-4!5W_M M9!=ITF,\
M$+/&<%7PA@DHB-56&W\A*-O-8;8']R-0U#Z9 [J6*#?$;'\U@QX)>4@0LWW(
M%-GQ<PM(L\XTF/UM E[!-,_Z\?V?@KW*Q^&[0VOA@CICT<I6A/27AZ=\EHZ2
M-#^'L^DT/8<'[2@?KV \R6F<3"=P["K'![U(HMF&CFLAE%?7EH;5H:E?=[WL
MEWKW(MPSL^7*@L"*3)/+UY,(3-=ENXG33>AL&^VH3P:QIH<)C5>@_4IKMY]X
M!\-3M_P)4$L#!!0    ( !A*8UHQ$RT]?P(  'D%   9    >&PO=V]R:W-H
M965T<R]S:&5E=#,U+GAM;(5436_;, S]*X2'#ALPU([C?BQ+#"3IANY0+$BZ
M[3#LH-B,;526/(ENVG\_2DZ\%$BSBRQ*Y.,CY<?Q5IL'6R(2/-52V4E0$C6C
M,+19B;6PY[I!Q3<;;6I!;)HBM(U!D?N@6H9Q%%V&M:A4D([]V<*D8]V2K!0N
M#-BVKH5YGJ'4VTDP"/8'RZHHR1V$Z;@1!:Z0OC<+PU;8H^15C<I66H'!S228
M#D:SQ/E[AQ\5;NW!'EPE:ZT?G/$UGP21(X02,W((@C^/.$<I'1#3^+/##/J4
M+O!POT?_XFOG6M;"XES+GU5.Y22X#B#'C6@E+?7V%G?U7#B\3$OK5]AVOA><
M,6LMZ7H7S'9=J>XKGG9]. BXCEX)B'<!L>?=)?(L;P2)=&ST%HSS9C2W\:7Z
M:"97*?<H*S)\6W$<I4M\1-4B+#'3A:I\I][=B[5$^WX<$F=P?F&V0YMU:/$K
M:(,8[K2BTL)GE6/^$B!D:CV_>,]O%I]$O,'L'(:##Q!'<7(";]C7._1XP__4
MNS&ZACES-?Q?<,^IA+GO-AKX-5U;?_[[6 <Z_.0XOM/0R#8BPTG (K%H'C%(
MW[X97$:?3K!/>O;)*?1TQ9K,6XF@-[! DZ$B5HZS[C4)"2O![P:D^UKLL0I.
MY[@ON3M:LEHK50"Y7P%\*8HLB+UZ74YBS^8%"_(L"J.M!;OGDNVYP&A'</W<
M$QSYAW7+$.;"\,0Q#Y D< ;#C[Q,L\Q@KF%XQ48RX.5;0VT- W<91W!VK*GA
M@1PX1>%%;R'3K:).&?UI/U>FG9S^N7=#Z4Z8HE(6)&XX-#J_N@C =$+O#-*-
M%]=:$]?CMR7/1C3.@>\W6M/>< GZ:9O^!5!+ P04    "  82F-:K D]NQ@#
M   ?!P  &0   'AL+W=O<FMS:&5E=',O<VAE970S-BYX;6R=5=MNVS ,_17"
M'8H6R.+$22]+DP!-NVX#VJ'H;0_#'F2;CH7*DB?)2;NO'R4[;@HD&; 7ZT8>
MG4.1]'BI]+/)$2V\%$*:29!;6X["T"0Y%LQT58F23C*E"V9IJ>>A*36RU#L5
M(HQZO>.P8%P&T['?N]73L:JLX!)O-9BJ*)A^G:%0RTG0#U8;=WR>6[<13L<E
MF^,]VL?R5M,J;%%27J T7$G0F$V"\_YH-G3VWN")X]*LS<$IB95Z=HMOZ23H
M.4(H,+$.@=&PP L4P@$1C=\-9M!>Z1S7YROT*Z^=M,3,X(42/WAJ\TEP&D"*
M&:N$O5/+K]CH.7)XB1+&?V%9VYX<!9!4QJJB<28&!9?UR%Z:.*PYG/:V.$2-
M0^1YUQ=YEI?,LNE8JR5H9TUH;N*E>F\BQZ5[E'NKZ923GYU>,:[AB8D*X0:9
MJ312Q*V!@P<6"S2'X]#2+<XV3!K$68T8;4'L1W"CI,T-?)8IIN\!0J+7<HQ6
M'&?13L1+3+HPZ'<@ZD7#'7B#5O/ XPW^K?F2FT0H)]O S_/86$UI\FN3Z!IR
MN!G2E<[(E"S!24"U85 O,)CN[_6/>V<[" ];PL-=Z--[*L6T$@@J@S?R'3@W
M!NFMF$SAFK.8"VXY"6D>,@7*^CM,*JVYG,.,&6XV*=MY]V9E#SE"I@15M$.V
M+E6:LN9_B(!UQUPRF7 F@$L*:U6G5;&BQBQD3LG"/X,K3RKQ%=78485$,&-X
MQLF:RQKSS2/GJ)E.\E<XN,8%"G#I 4K#X-!7J1?O?+@L*[JX<EO4P[P[\PVA
M 65)HHJ2R5=W<Z*D48*GS))YS 1)(&6NNLR(PNT>@+(1BQAUFY%;]@>PI;9&
MT#!NQJ@9!UOW;YA^QB;*+DCU,Q\81/BN+,+1(7Q1"]32X:^;?(3'[GT7/D 4
M=8:]8YKL[YU&_>CLW>QDT/DT'&X\?%"67I#5>?;_,)MJ(%QK6@7JN6_-].JJ
MDK;N7^UNV_W/ZZ;W9E[_.B@^<\HR$)B1:Z_KFJVNVW&]L*KT+3!6EAJJG^;T
M!T/M#.@\4Q3&9N$N:/^)T[]02P,$%     @ &$IC6H+<%7*Q P  YPD  !D
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M69F;SW+[&^[7XP@F,M?N"]O*=T S)J4VLM@'4[O@HOJS;_L\- (N@A<"HGU
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M='XQ"D!WPZ+;6-7X!ETK2^WNS8KF*VKG0/<;I>Q^XP+T$SO["U!+ P04
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MA-8K\'YE#!TFWL'XLJW_!5!+ P04    "  82F-:5[8-.TX#  #$!P  &0
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MS:)E ]I?&^/W$P[0?]S+_P!02P,$%     @ &$IC6FVY2+ Y P  ?0<  !D
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M+U;TF*%V!O2_5%3/7G$.AN=Q]0M02P,$%     @ &$IC6ITR7Y=7 P  K <
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M4+D%=KZ0TJP[[K9O'VOI?U!+ P04    "  82F-:;>#S+N\#   *%@  &0
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M$W]UD5-6$W=7HU?KE=B2!<P\M1P%\#UXR<\_A:/@URZJ'($9Q$4U<9$-/?E
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M#%P'J/=SQN331#=A1=,=_ 502P,$%     @ &$IC6GVRV_BM @  :@<  !D
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M_ JU'EM@(KBROV19Q?;.')*42HN\!F,%.2NJ+WVN^[ &\'I[ 'X-\+<!X1Y
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M3DZQ)%DY>S718FZ];B(T.J<=9O@8@C0!N#\50J\F)D'SO$9_ 5!+ P04
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M:@!^GS$FGQOJT%]=\OP_4$L#!!0    ( !A*8UHX[F-YAP(  - &   9
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M-\M"S6K@&J#>+QF3VT ?T$__Y!]02P,$%     @ &$IC6HCMV=F> @  3 <
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M07)/8TI OE]1*@X-9:"^&YO^!U!+ P04    "  82F-:HD '"AH#   T#0
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M@=<%?R3;'] $Y$N^A!1,/=&VL;4,E*P9)V4#%AZ4>56_\6LCQ![ #MX!. W
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MD&5*2?KX4XI:U9J*N-_>J=_KX&4P,\QA0K/?:2*6(ZMGH03F>)V)9[K]"65
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M7.G[V YSW6*!, #]?<:YVDS,!DW3%O\#4$L#!!0    ( !A*8UIG+BLV[0,
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M;GX2H&V"6=\H18? ]J'NMY/\!5!+ P04    "  82F-:YS&G9XH"  "4!@
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MN.\"_(YO#)9F;4Q<*3.E?KG)63X.(L<(.&3605"\W< I<.Z0D,?O!C1H<[K
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MVR3]P:/&"=<\EP"]\,[2I<!VK.U7N]JZUY/:LSULKZWO!=4+AA)RF&-HM'>
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M2;)>/LAA1LXR&A_:5"9/'Y/R%#*,XO A%M798Y3GZS"9UH-4O7GKR&2NNG?
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MK!=LZ+[VN[G^WBF#2F0HC34T;6U_[\SQ=RZ)0ROE*)H>'R67/<AZ#&9*[Q!
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M<B6C\S',YE&2DU@\RJI&9V-O0++R?O?7'XIT=360@7](BR)=5B\7(IR)K-Q
M_O]CFA:O/Y05/*?9]^KC7/\74$L#!!0    ( !A*8UK=Q;.Y5@,  &\-   9
M    >&PO=V]R:W-H965T<R]S:&5E=#<X+GAM;,5776_:,!3]*U8F39VTDD^@
M=! )FE:KM&JHU;J':0\FN8#5),YL ^7?SW9""M3-J!1I/)#8N>?XGF/'N1YN
M*'OB2P"!GK,TYR-K*41Q:=L\7D*&>8<6D,LG<\HR+&23+6Q>,,")!F6I[3E.
MS\XPR:UPJ/NF+!S2E4A)#E.&^"K+,-M.(*6;D>5:NXY[LE@*U6&'PP(OX '$
MCV+*9,NN61*20<X)S1&#^<@:NY>1ZRB CG@DL.%[]TA)F5'ZI!JWR<AR5$:0
M0BP4!9:7-5Q!FBHFF<>?BM2JQU3 _?L=^XT6+\7,,(<KFOXDB5B.K L+)3#'
MJU3<T\U7J 1U%5],4Z[_T::,[0\L%*^XH%D%EAED)"^O^+DR8@_@==\ >!7
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M-%5*TH^?A:A5CJD,C^]?U.]U\#*8!>9P1].O22S6$VMDH1B6>)N*1[K_&XJ
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MZ[;<M(J_:<J>_AL52U9(DD&"E$YOB/L699M<#A1?F<9QP16VH>8QQ9\6('0
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M;>#Y^*3^Q>5N<LFQ@AM!?Y!2-VGP,4 E5+BC>B_ZKS#DXP +097[HM[[SN,
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MEC7A"E&H3&@T^6!VE[XSO:%%Z[HA%]KTEALVYC$#:1W,>B6$/AEV@_%YS/X
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MPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*19V_K]JE<9 +&7D]/!+<'FE
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M1;V50&]%O95 ;T6]E4!O1;V50&]%O95 [X1Z)P*]$^J="/1.J'<BT#NAWHE
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M4._RG7H/X^>A#K>>KS4^_SNI'B_WUMOCK\NODQ-VKCB'^XKA^2]02P,$%
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MX^$?QR_/M#?M\)R?+?_BN/D%4$L! A0#%     @ &$IC6@=!36*!    L0
M !               ( !     &1O8U!R;W!S+V%P<"YX;6Q02P$"% ,4
M"  82F-:'4K>U.\    K @  $0              @ &O    9&]C4')O<',O
M8V]R92YX;6Q02P$"% ,4    "  82F-:F5R<(Q &  "<)P  $P
M    @ '- 0  >&PO=&AE;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( !A*8UI)
MFBC+6 <  ((O   8              " @0X(  !X;"]W;W)K<VAE971S+W-H
M965T,2YX;6Q02P$"% ,4    "  82F-:/4[0G3P"  "_!0  &
M    @(&<#P  >&PO=V]R:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @
M&$IC6FL4$)=]!0  ,A8  !@              ("!#A(  'AL+W=O<FMS:&5E
M=',O<VAE970S+GAM;%!+ 0(4 Q0    ( !A*8UK9FK+\;@,  )\+   8
M          " @<$7  !X;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4
M    "  82F-:E8$O:8L"  #)!@  &               @(%E&P  >&PO=V]R
M:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ &$IC6HLY1J,2!@  FAD
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M965T,3 N>&UL4$L! A0#%     @ &$IC6N=Z1*'9!0  NPX  !D
M     ("!46(  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !A*8UK4P: ZH (   @&   9              "
M@0M\  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L! A0#%     @ &$IC
M6GAY2'5A @  2@4  !D              ("!XGX  'AL+W=O<FMS:&5E=',O
M<VAE970Q-RYX;6Q02P$"% ,4    "  82F-:Z,\@V$@$   T"@  &0
M        @(%Z@0  >&PO=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0
M   ( !A*8UKJ*-C.\P8  %02   9              " @?F%  !X;"]W;W)K
M<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ &$IC6II]DG.)#   P"$
M !D              ("!(XT  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q0
M2P$"% ,4    "  82F-:=/T:U5H#  "<!P  &0              @('CF0
M>&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0    ( !A*8UHDF^&1
MIAD  /UH   9              " @72=  !X;"]W;W)K<VAE971S+W-H965T
M,C(N>&UL4$L! A0#%     @ &$IC6C/O^RHA!P  I!(  !D
M ("!4;<  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  8
M2F-:75.$4^P,  ">*   &0              @(&IO@  >&PO=V]R:W-H965T
M<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( !A*8UJW1H$K7P4  &X.   9
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M970R.2YX;6Q02P$"% ,4    "  82F-:+'5HOD,"  "*!@  &0
M    @(']X0  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    (
M !A*8UH\I3,X$0(  -T$   9              " @7?D  !X;"]W;W)K<VAE
M971S+W-H965T,S$N>&UL4$L! A0#%     @ &$IC6G2"SZ1F!P  TB4  !D
M             ("!O^8  'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"
M% ,4    "  82F-:+%;W$LT<  #Z6P  &0              @(%<[@  >&PO
M=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    ( !A*8UH4C.-A(P,
M /8&   9              " @6 + 0!X;"]W;W)K<VAE971S+W-H965T,S0N
M>&UL4$L! A0#%     @ &$IC6C$3+3U_ @  >04  !D              ("!
MN@X! 'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"% ,4    "  82F-:
MK D]NQ@#   ?!P  &0              @(%P$0$ >&PO=V]R:W-H965T<R]S
M:&5E=#,V+GAM;%!+ 0(4 Q0    ( !A*8UJ"W!5RL0,  .<)   9
M      " @;\4 0!X;"]W;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%
M  @ &$IC6A-V;G:C @  O04  !D              ("!IQ@! 'AL+W=O<FMS
M:&5E=',O<VAE970S."YX;6Q02P$"% ,4    "  82F-:,+J:&0L#  #E!@
M&0              @(&!&P$ >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+
M 0(4 Q0    ( !A*8UI7M@T[3@,  ,0'   9              " @<,> 0!X
M;"]W;W)K<VAE971S+W-H965T-# N>&UL4$L! A0#%     @ &$IC6FVY2+ Y
M P  ?0<  !D              ("!2"(! 'AL+W=O<FMS:&5E=',O<VAE970T
M,2YX;6Q02P$"% ,4    "  82F-:(=1XI+$&   A$@  &0
M@(&X)0$ >&PO=V]R:W-H965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( !A*
M8UJ *BEEIP,  *@)   9              " @: L 0!X;"]W;W)K<VAE971S
M+W-H965T-#,N>&UL4$L! A0#%     @ &$IC6F6O?N$Y!0  #@X  !D
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M=#0X+GAM;%!+ 0(4 Q0    ( !A*8UJ&Q1LOO0(  +@)   9
M  " @;-& 0!X;"]W;W)K<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @
M&$IC6FW@\R[O P  "A8  !D              ("!ITD! 'AL+W=O<FMS:&5E
M=',O<VAE970U,"YX;6Q02P$"% ,4    "  82F-:;@EG4_T"  !_"@  &0
M            @('-30$ >&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4
M Q0    ( !A*8UHP D+S[ ,  -P9   9              " @0%1 0!X;"]W
M;W)K<VAE971S+W-H965T-3(N>&UL4$L! A0#%     @ &$IC6MO/WA@1 P
M@ L  !D              ("!)%4! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX
M;6Q02P$"% ,4    "  82F-:?;+;^*T"  !J!P  &0              @(%L
M6 $ >&PO=V]R:W-H965T<R]S:&5E=#4T+GAM;%!+ 0(4 Q0    ( !A*8UI5
M.6W#-P,  / -   9              " @5!; 0!X;"]W;W)K<VAE971S+W-H
M965T-34N>&UL4$L! A0#%     @ &$IC6CCN8WF' @  T 8  !D
M     ("!OEX! 'AL+W=O<FMS:&5E=',O<VAE970U-BYX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( !A*8UJ([=G9G@(  $P'   9              "
M@6AN 0!X;"]W;W)K<VAE971S+W-H965T-C$N>&UL4$L! A0#%     @ &$IC
M6G@V(:>U!0  4"P  !D              ("!/7$! 'AL+W=O<FMS:&5E=',O
M<VAE970V,BYX;6Q02P$"% ,4    "  82F-:]CJC NH$   G&P  &0
M        @($I=P$ >&PO=V]R:W-H965T<R]S:&5E=#8S+GAM;%!+ 0(4 Q0
M   ( !A*8UJB0 <*&@,  #0-   9              " @4I\ 0!X;"]W;W)K
M<VAE971S+W-H965T-C0N>&UL4$L! A0#%     @ &$IC6@8/D"\: P  :@L
M !D              ("!FW\! 'AL+W=O<FMS:&5E=',O<VAE970V-2YX;6Q0
M2P$"% ,4    "  82F-:*/B<L6$$   '#P  &0              @('L@@$
M>&PO=V]R:W-H965T<R]S:&5E=#8V+GAM;%!+ 0(4 Q0    ( !A*8UI8%T'M
MB@8   0Q   9              " @82' 0!X;"]W;W)K<VAE971S+W-H965T
M-C<N>&UL4$L! A0#%     @ &$IC6E2XCR<8 P  P D  !D
M ("!18X! 'AL+W=O<FMS:&5E=',O<VAE970V."YX;6Q02P$"% ,4    "  8
M2F-:9RXK-NT#  !B#@  &0              @(&4D0$ >&PO=V]R:W-H965T
M<R]S:&5E=#8Y+GAM;%!+ 0(4 Q0    ( !A*8UK[!@N>>P(  ((&   9
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M970W-"YX;6Q02P$"% ,4    "  82F-:#W%PD\L&  "N/0  &0
M    @(% I $ >&PO=V]R:W-H965T<R]S:&5E=#<U+GAM;%!+ 0(4 Q0    (
M !A*8UJ QI %3@,  !0.   9              " @4*K 0!X;"]W;W)K<VAE
M971S+W-H965T-S8N>&UL4$L! A0#%     @ &$IC6D32E3CM#   Q9X  !D
M             ("!QZX! 'AL+W=O<FMS:&5E=',O<VAE970W-RYX;6Q02P$"
M% ,4    "  82F-:W<6SN58#  !O#0  &0              @('KNP$ >&PO
M=V]R:W-H965T<R]S:&5E=#<X+GAM;%!+ 0(4 Q0    ( !A*8UJ:P =V0P0
M /00   9              " @7B_ 0!X;"]W;W)K<VAE971S+W-H965T-SDN
M>&UL4$L! A0#%     @ &$IC6A3#;\3[ P  KA(  !D              ("!
M\L,! 'AL+W=O<FMS:&5E=',O<VAE970X,"YX;6Q02P$"% ,4    "  82F-:
MUU#'N[@#  "X#   &0              @($DR $ >&PO=V]R:W-H965T<R]S
M:&5E=#@Q+GAM;%!+ 0(4 Q0    ( !A*8UHW0J0FG0(  -X&   9
M      " @1/, 0!X;"]W;W)K<VAE971S+W-H965T.#(N>&UL4$L! A0#%
M  @ &$IC6@OAW.FK!   71@  !D              ("!Y\X! 'AL+W=O<FMS
M:&5E=',O<VAE970X,RYX;6Q02P$"% ,4    "  82F-:HH#),S<"   J!0
M&0              @(')TP$ >&PO=V]R:W-H965T<R]S:&5E=#@T+GAM;%!+
M 0(4 Q0    ( !A*8UH\NO)3# 8  /@=   9              " @3?6 0!X
M;"]W;W)K<VAE971S+W-H965T.#4N>&UL4$L! A0#%     @ &$IC6GQ^R2:K
M @  / H  !D              ("!>MP! 'AL+W=O<FMS:&5E=',O<VAE970X
M-BYX;6Q02P$"% ,4    "  82F-:I[N%X54#   2"@  &0
M@(%<WP$ >&PO=V]R:W-H965T<R]S:&5E=#@W+GAM;%!+ 0(4 Q0    ( !A*
M8UI-G08I(P,  .P1   -              "  >CB 0!X;"]S='EL97,N>&UL
M4$L! A0#%     @ &$IC6I>*NQS     $P(   L              ( !-N8!
M %]R96QS+RYR96QS4$L! A0#%     @ &$IC6AK9_N)\!@  '3D   \
M         ( !'^<! 'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( !A*8UI
MRG71C@(  $PS   :              "  <CM 0!X;"]?<F5L<R]W;W)K8F]O
M:RYX;6PN<F5L<U!+ 0(4 Q0    ( !A*8UHAV_FQ,0(  ,TQ   3
M      "  8[P 0!;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@    !? %\ $!H
' /#R 0    $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>212</ContextCount>
  <ElementCount>387</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>67</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Statements of Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedStatementsofLoss</Role>
      <ShortName>Consolidated Statements of Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Statements of Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical</Role>
      <ShortName>Consolidated Statements of Comprehensive Loss (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Shareholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity</Role>
      <ShortName>Consolidated Statements of Shareholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Newly Issued Accounting Standards</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/NewlyIssuedAccountingStandards</Role>
      <ShortName>Newly Issued Accounting Standards</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Revenue Recognition</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RevenueRecognition</Role>
      <ShortName>Revenue Recognition</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/FairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/MarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Inventories</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/Inventories</Role>
      <ShortName>Inventories</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Property and Equipment, net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/PropertyandEquipmentnet</Role>
      <ShortName>Property and Equipment, net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Goodwill</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/Goodwill</Role>
      <ShortName>Goodwill</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/Leases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Royalty Financing Obligation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RoyaltyFinancingObligation</Role>
      <ShortName>Royalty Financing Obligation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Other Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilities</Role>
      <ShortName>Other Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Contingent Liabilities and Commitments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ContingentLiabilitiesandCommitments</Role>
      <ShortName>Contingent Liabilities and Commitments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Equity Instruments and Transactions</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/EquityInstrumentsandTransactions</Role>
      <ShortName>Equity Instruments and Transactions</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>9952172 - Disclosure - Share-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensation</Role>
      <ShortName>Share-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>9952173 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>9952174 - Disclosure - Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ComprehensiveLoss</Role>
      <ShortName>Comprehensive Loss</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9952175 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>27</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9952176 - Disclosure - Schedule II - Valuation and Qualifying Accounts</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>995410 - Disclosure - Pay vs Performance Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/PvpDisclosure</Role>
      <ShortName>Pay vs Performance Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>32</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.avadel.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Revenue Recognition (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RevenueRecognitionTables</Role>
      <ShortName>Revenue Recognition (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/RevenueRecognition</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/FairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/FairValueMeasurements</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/MarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/MarketableSecurities</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Inventories (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/InventoriesTables</Role>
      <ShortName>Inventories (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/Inventories</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Property and Equipment, net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/PropertyandEquipmentnetTables</Role>
      <ShortName>Property and Equipment, net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/PropertyandEquipmentnet</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/LeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/Leases</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Royalty Financing Obligation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RoyaltyFinancingObligationTables</Role>
      <ShortName>Royalty Financing Obligation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/RoyaltyFinancingObligation</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/IncomeTaxes</ParentRole>
      <Position>42</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Other Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilitiesTables</Role>
      <ShortName>Other Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/OtherAssetsandLiabilities</ParentRole>
      <Position>43</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Share-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationTables</Role>
      <ShortName>Share-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/ShareBasedCompensation</ParentRole>
      <Position>44</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/NetLossPerShare</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Comprehensive Loss (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ComprehensiveLossTables</Role>
      <ShortName>Comprehensive Loss (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/ComprehensiveLoss</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.avadel.com/role/SegmentInformation</ParentRole>
      <Position>47</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails</Role>
      <ShortName>Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Revenue Recognition - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RevenueRecognitionNarrativeDetails</Role>
      <ShortName>Revenue Recognition - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Fair Value Measurement (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/FairValueMeasurementDetails</Role>
      <ShortName>Fair Value Measurement (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/FairValueMeasurementsTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Marketable Securities - Summary of Available-for-sale Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails</Role>
      <ShortName>Marketable Securities - Summary of Available-for-sale Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Marketable Securities - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails</Role>
      <ShortName>Marketable Securities - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Marketable Securities - Schedule of Contractual Maturity Dates (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails</Role>
      <ShortName>Marketable Securities - Schedule of Contractual Maturity Dates (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Inventories (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/InventoriesDetails</Role>
      <ShortName>Inventories (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/InventoriesTables</ParentRole>
      <Position>56</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Property and Equipment, net (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/PropertyandEquipmentnetDetails</Role>
      <ShortName>Property and Equipment, net (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/PropertyandEquipmentnetTables</ParentRole>
      <Position>57</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Goodwill (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/GoodwillDetails</Role>
      <ShortName>Goodwill (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/Goodwill</ParentRole>
      <Position>58</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Leases - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/LeasesNarrativeDetails</Role>
      <ShortName>Leases - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Leases - Components of lease costs (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/LeasesComponentsofleasecostsDetails</Role>
      <ShortName>Leases - Components of lease costs (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>60</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Leases - Maturities of operating lease liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails</Role>
      <ShortName>Leases - Maturities of operating lease liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Royalty Financing Obligation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails</Role>
      <ShortName>Royalty Financing Obligation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Royalty Financing Obligation - Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails</Role>
      <ShortName>Royalty Financing Obligation - Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails</Role>
      <ShortName>Income Taxes - Income (Loss) Before Income Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Income Taxes - Income Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Income Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails</Role>
      <ShortName>Income Taxes - Reconciliation of Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>67</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails</Role>
      <ShortName>Income Taxes - Unrecognized Tax Benefit (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Deferred Taxes (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails</Role>
      <ShortName>Income Taxes - Deferred Taxes (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails</Role>
      <ShortName>Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails</Role>
      <ShortName>Other Assets and Liabilities - Other Non-Current Assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>71</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails</Role>
      <ShortName>Other Assets and Liabilities - Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails</Role>
      <ShortName>Other Assets and Liabilities - Other Non-Current Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R74.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Contingent Liabilities and Commitments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails</Role>
      <ShortName>Contingent Liabilities and Commitments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/ContingentLiabilitiesandCommitments</ParentRole>
      <Position>74</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R75.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Equity Instruments and Transactions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails</Role>
      <ShortName>Equity Instruments and Transactions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/EquityInstrumentsandTransactions</ParentRole>
      <Position>75</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R76.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Share-Based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails</Role>
      <ShortName>Share-Based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>76</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R77.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Share-Based Compensation - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails</Role>
      <ShortName>Share-Based Compensation - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>77</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R78.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails</Role>
      <ShortName>Share-Based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>78</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R79.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Share-Based Compensation - Stock Options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails</Role>
      <ShortName>Share-Based Compensation - Stock Options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>79</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R80.htm</HtmlFileName>
      <LongName>9955558 - Disclosure - Share-Based Compensation - Restricted Share Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails</Role>
      <ShortName>Share-Based Compensation - Restricted Share Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>80</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R81.htm</HtmlFileName>
      <LongName>9955559 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>81</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R82.htm</HtmlFileName>
      <LongName>9955560 - Disclosure - Net Loss Per Share - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/NetLossPerShareNarrativeDetails</Role>
      <ShortName>Net Loss Per Share - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>82</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R83.htm</HtmlFileName>
      <LongName>9955561 - Disclosure - Comprehensive Loss (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ComprehensiveLossDetails</Role>
      <ShortName>Comprehensive Loss (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/ComprehensiveLossTables</ParentRole>
      <Position>83</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R84.htm</HtmlFileName>
      <LongName>9955562 - Disclosure - Segment Information - Narrative (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SegmentInformationNarrativeDetails</Role>
      <ShortName>Segment Information - Narrative (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>84</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R85.htm</HtmlFileName>
      <LongName>9955563 - Disclosure - Segment Information - Segment Reporting Information, About the Company???s Significant Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails</Role>
      <ShortName>Segment Information - Segment Reporting Information, About the Company???s Significant Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>85</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R86.htm</HtmlFileName>
      <LongName>9955564 - Disclosure - Segment Information - Long-Lived Assets by Geographic Region (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails</Role>
      <ShortName>Segment Information - Long-Lived Assets by Geographic Region (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>86</Position>
    </Report>
    <Report instance="avdl-20241231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R87.htm</HtmlFileName>
      <LongName>9955565 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails</Role>
      <ShortName>Schedule II - Valuation and Qualifying Accounts (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts</ParentRole>
      <Position>87</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="avdl-20241231.htm">avdl-20241231.htm</File>
    <File>avdl-20241231.xsd</File>
    <File>avdl-20241231_cal.xml</File>
    <File>avdl-20241231_def.xml</File>
    <File>avdl-20241231_lab.xml</File>
    <File>avdl-20241231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>avdl-20241231_g1.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2024</BaseTaxonomy>
    <BaseTaxonomy items="918">http://fasb.org/us-gaap/2024</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2024</BaseTaxonomy>
    <BaseTaxonomy items="38">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>124
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "avdl-20241231.htm": {
   "nsprefix": "avdl",
   "nsuri": "http://www.avadel.com/20241231",
   "dts": {
    "inline": {
     "local": [
      "avdl-20241231.htm"
     ]
    },
    "schema": {
     "local": [
      "avdl-20241231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd",
      "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd",
      "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd",
      "https://xbrl.sec.gov/country/2024/country-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd",
      "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd",
      "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd",
      "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "avdl-20241231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "avdl-20241231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "avdl-20241231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "avdl-20241231_pre.xml"
     ]
    }
   },
   "keyStandard": 353,
   "keyCustom": 34,
   "axisStandard": 27,
   "axisCustom": 0,
   "memberStandard": 36,
   "memberCustom": 30,
   "hidden": {
    "total": 9,
    "http://fasb.org/us-gaap/2024": 5,
    "http://xbrl.sec.gov/dei/2024": 4
   },
   "contextCount": 212,
   "entityCount": 1,
   "segmentCount": 67,
   "elementCount": 697,
   "unitCount": 7,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2024": 918,
    "http://xbrl.sec.gov/dei/2024": 38,
    "http://xbrl.sec.gov/cyd/2024": 15,
    "http://xbrl.sec.gov/ecd/2024": 5,
    "http://fasb.org/srt/2024": 1
   },
   "report": {
    "R1": {
     "role": "http://www.avadel.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.avadel.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
     "longName": "9952151 - Statement - Consolidated Statements of Loss",
     "shortName": "Consolidated Statements of Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SellingGeneralAndAdministrativeExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss",
     "longName": "9952152 - Statement - Consolidated Statements of Comprehensive Loss",
     "shortName": "Consolidated Statements of Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical",
     "longName": "9952153 - Statement - Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "shortName": "Consolidated Statements of Comprehensive Loss (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R6": {
     "role": "http://www.avadel.com/role/ConsolidatedBalanceSheets",
     "longName": "9952154 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952155 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
     "longName": "9952156 - Statement - Consolidated Statements of Shareholders' Equity",
     "shortName": "Consolidated Statements of Shareholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:SharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952157 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.avadel.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.avadel.com/role/NewlyIssuedAccountingStandards",
     "longName": "9952159 - Disclosure - Newly Issued Accounting Standards",
     "shortName": "Newly Issued Accounting Standards",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.avadel.com/role/RevenueRecognition",
     "longName": "9952160 - Disclosure - Revenue Recognition",
     "shortName": "Revenue Recognition",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.avadel.com/role/FairValueMeasurements",
     "longName": "9952161 - Disclosure - Fair Value Measurements",
     "shortName": "Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.avadel.com/role/MarketableSecurities",
     "longName": "9952162 - Disclosure - Marketable Securities",
     "shortName": "Marketable Securities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.avadel.com/role/Inventories",
     "longName": "9952163 - Disclosure - Inventories",
     "shortName": "Inventories",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:InventoryDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.avadel.com/role/PropertyandEquipmentnet",
     "longName": "9952164 - Disclosure - Property and Equipment, net",
     "shortName": "Property and Equipment, net",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.avadel.com/role/Goodwill",
     "longName": "9952165 - Disclosure - Goodwill",
     "shortName": "Goodwill",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.avadel.com/role/Leases",
     "longName": "9952166 - Disclosure - Leases",
     "shortName": "Leases",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.avadel.com/role/RoyaltyFinancingObligation",
     "longName": "9952167 - Disclosure - Royalty Financing Obligation",
     "shortName": "Royalty Financing Obligation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.avadel.com/role/IncomeTaxes",
     "longName": "9952168 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilities",
     "longName": "9952169 - Disclosure - Other Assets and Liabilities",
     "shortName": "Other Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OtherLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.avadel.com/role/ContingentLiabilitiesandCommitments",
     "longName": "9952170 - Disclosure - Contingent Liabilities and Commitments",
     "shortName": "Contingent Liabilities and Commitments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.avadel.com/role/EquityInstrumentsandTransactions",
     "longName": "9952171 - Disclosure - Equity Instruments and Transactions",
     "shortName": "Equity Instruments and Transactions",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "avdl:EquityTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "avdl:EquityTransactionsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.avadel.com/role/ShareBasedCompensation",
     "longName": "9952172 - Disclosure - Share-Based Compensation",
     "shortName": "Share-Based Compensation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.avadel.com/role/NetLossPerShare",
     "longName": "9952173 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.avadel.com/role/ComprehensiveLoss",
     "longName": "9952174 - Disclosure - Comprehensive Loss",
     "shortName": "Comprehensive Loss",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ComprehensiveIncomeNoteTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.avadel.com/role/SegmentInformation",
     "longName": "9952175 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts",
     "longName": "9952176 - Disclosure - Schedule II - Valuation and Qualifying Accounts",
     "shortName": "Schedule II - Valuation and Qualifying Accounts",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure",
     "longName": "995410 - Disclosure - Pay vs Performance Disclosure",
     "shortName": "Pay vs Performance Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R30": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-205",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-205",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "a",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "avdl:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "avdl:NatureOfBusinessPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R35": {
     "role": "http://www.avadel.com/role/RevenueRecognitionTables",
     "longName": "9955513 - Disclosure - Revenue Recognition (Tables)",
     "shortName": "Revenue Recognition (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.avadel.com/role/FairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Fair Value Measurements (Tables)",
     "shortName": "Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.avadel.com/role/MarketableSecuritiesTables",
     "longName": "9955515 - Disclosure - Marketable Securities (Tables)",
     "shortName": "Marketable Securities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.avadel.com/role/InventoriesTables",
     "longName": "9955516 - Disclosure - Inventories (Tables)",
     "shortName": "Inventories (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.avadel.com/role/PropertyandEquipmentnetTables",
     "longName": "9955517 - Disclosure - Property and Equipment, net (Tables)",
     "shortName": "Property and Equipment, net (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R40": {
     "role": "http://www.avadel.com/role/LeasesTables",
     "longName": "9955518 - Disclosure - Leases (Tables)",
     "shortName": "Leases (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.avadel.com/role/RoyaltyFinancingObligationTables",
     "longName": "9955519 - Disclosure - Royalty Financing Obligation (Tables)",
     "shortName": "Royalty Financing Obligation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.avadel.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilitiesTables",
     "longName": "9955521 - Disclosure - Other Assets and Liabilities (Tables)",
     "shortName": "Other Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationTables",
     "longName": "9955522 - Disclosure - Share-Based Compensation (Tables)",
     "shortName": "Share-Based Compensation (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.avadel.com/role/NetLossPerShareTables",
     "longName": "9955523 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.avadel.com/role/ComprehensiveLossTables",
     "longName": "9955524 - Disclosure - Comprehensive Loss (Tables)",
     "shortName": "Comprehensive Loss (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.avadel.com/role/SegmentInformationTables",
     "longName": "9955525 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
     "longName": "9955526 - Disclosure - Summary of Significant Accounting Policies - Narrative (Details)",
     "shortName": "Summary of Significant Accounting Policies - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "avdl:NumberOfFinancialInstitutions",
      "unitRef": "institution",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "avdl:NumberOfFinancialInstitutions",
      "unitRef": "institution",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails",
     "longName": "9955527 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment Useful Lives (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-76",
      "name": "us-gaap:PropertyPlantAndEquipmentUsefulLife",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R50": {
     "role": "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
     "longName": "9955528 - Disclosure - Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details)",
     "shortName": "Revenue Recognition - Schedule of Percentage of Total Sales to Customers (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-81",
      "name": "us-gaap:ConcentrationRiskPercentage1",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
     "longName": "9955529 - Disclosure - Revenue Recognition - Narrative (Details)",
     "shortName": "Revenue Recognition - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R52": {
     "role": "http://www.avadel.com/role/FairValueMeasurementDetails",
     "longName": "9955530 - Disclosure - Fair Value Measurement (Details)",
     "shortName": "Fair Value Measurement (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-93",
      "name": "us-gaap:AssetsFairValueDisclosure",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails",
     "longName": "9955531 - Disclosure - Marketable Securities - Summary of Available-for-sale Securities (Details)",
     "shortName": "Marketable Securities - Summary of Available-for-sale Securities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails",
     "longName": "9955532 - Disclosure - Marketable Securities - Narrative (Details)",
     "shortName": "Marketable Securities - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleRealizedGain",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
     "longName": "9955533 - Disclosure - Marketable Securities - Schedule of Contractual Maturity Dates (Details)",
     "shortName": "Marketable Securities - Schedule of Contractual Maturity Dates (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.avadel.com/role/InventoriesDetails",
     "longName": "9955534 - Disclosure - Inventories (Details)",
     "shortName": "Inventories (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfInventoryCurrentTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
     "longName": "9955535 - Disclosure - Property and Equipment, net (Details)",
     "shortName": "Property and Equipment, net (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.avadel.com/role/GoodwillDetails",
     "longName": "9955536 - Disclosure - Goodwill (Details)",
     "shortName": "Goodwill (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:Goodwill",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AssetImpairmentCharges",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.avadel.com/role/LeasesNarrativeDetails",
     "longName": "9955537 - Disclosure - Leases - Narrative (Details)",
     "shortName": "Leases - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails",
     "longName": "9955538 - Disclosure - Leases - Components of lease costs (Details)",
     "shortName": "Leases - Components of lease costs (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails",
     "longName": "9955539 - Disclosure - Leases - Maturities of operating lease liabilities (Details)",
     "shortName": "Leases - Maturities of operating lease liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails",
     "longName": "9955540 - Disclosure - Royalty Financing Obligation - Narrative (Details)",
     "shortName": "Royalty Financing Obligation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-106",
      "name": "avdl:RoyaltyFinancingProceedsMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-106",
      "name": "avdl:RoyaltyFinancingProceedsMaximum",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
     "longName": "9955541 - Disclosure - Royalty Financing Obligation - Activity (Details)",
     "shortName": "Royalty Financing Obligation - Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ProceedsFromIssuanceOfLongTermDebt",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-114",
      "name": "avdl:RepaymentOfRoyaltyLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
     "longName": "9955542 - Disclosure - Income Taxes - Income (Loss) Before Income Taxes (Details)",
     "shortName": "Income Taxes - Income (Loss) Before Income Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-119",
      "name": "us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails",
     "longName": "9955543 - Disclosure - Income Taxes - Income Tax Benefit (Details)",
     "shortName": "Income Taxes - Income Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfIncomeTaxPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentStateAndLocalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfIncomeTaxPaymentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails",
     "longName": "9955544 - Disclosure - Income Taxes - Reconciliation of Tax Rate (Details)",
     "shortName": "Income Taxes - Reconciliation of Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955545 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "avdl:IncreaseDecreaseInIncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails",
     "longName": "9955546 - Disclosure - Income Taxes - Unrecognized Tax Benefit (Details)",
     "shortName": "Income Taxes - Unrecognized Tax Benefit (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R69": {
     "role": "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Deferred Taxes (Details)",
     "shortName": "Income Taxes - Deferred Taxes (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R70": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails",
     "longName": "9955548 - Disclosure - Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details)",
     "shortName": "Other Assets and Liabilities - Prepaid Expenses and Other Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:PrepaidExpenseCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails",
     "longName": "9955549 - Disclosure - Other Assets and Liabilities - Other Non-Current Assets (Details)",
     "shortName": "Other Assets and Liabilities - Other Non-Current Assets (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails",
     "longName": "9955550 - Disclosure - Other Assets and Liabilities - Accrued Expenses (Details)",
     "shortName": "Other Assets and Liabilities - Accrued Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccruedProfessionalFeesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails",
     "longName": "9955551 - Disclosure - Other Assets and Liabilities - Other Non-Current Liabilities (Details)",
     "shortName": "Other Assets and Liabilities - Other Non-Current Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:OtherNoncurrentLiabilitiesTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R74": {
     "role": "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails",
     "longName": "9955552 - Disclosure - Contingent Liabilities and Commitments (Details)",
     "shortName": "Contingent Liabilities and Commitments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "74",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongtermPurchaseCommitmentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LongtermPurchaseCommitmentPeriod",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R75": {
     "role": "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails",
     "longName": "9955553 - Disclosure - Equity Instruments and Transactions (Details)",
     "shortName": "Equity Instruments and Transactions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "75",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:CommonStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-136",
      "name": "avdl:AmericanDepositorySharesConversionRatio",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R76": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails",
     "longName": "9955554 - Disclosure - Share-Based Compensation - Stock-based Compensation Expense (Details)",
     "shortName": "Share-Based Compensation - Stock-based Compensation Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "76",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-144",
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R77": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
     "longName": "9955555 - Disclosure - Share-Based Compensation - Narrative (Details)",
     "shortName": "Share-Based Compensation - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "77",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R78": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
     "longName": "9955556 - Disclosure - Share-Based Compensation - Fair Value Assumptions (Details)",
     "shortName": "Share-Based Compensation - Fair Value Assumptions (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "78",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-164",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "avdl:ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R79": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails",
     "longName": "9955557 - Disclosure - Share-Based Compensation - Stock Options (Details)",
     "shortName": "Share-Based Compensation - Stock Options (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "79",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R80": {
     "role": "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails",
     "longName": "9955558 - Disclosure - Share-Based Compensation - Restricted Share Activity (Details)",
     "shortName": "Share-Based Compensation - Restricted Share Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "80",
     "firstAnchor": {
      "contextRef": "c-168",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-169",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R81": {
     "role": "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails",
     "longName": "9955559 - Disclosure - Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Reconciliation of Basic and Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "81",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R82": {
     "role": "http://www.avadel.com/role/NetLossPerShareNarrativeDetails",
     "longName": "9955560 - Disclosure - Net Loss Per Share - Narrative (Details)",
     "shortName": "Net Loss Per Share - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "82",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "ix:continuation",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R83": {
     "role": "http://www.avadel.com/role/ComprehensiveLossDetails",
     "longName": "9955561 - Disclosure - Comprehensive Loss (Details)",
     "shortName": "Comprehensive Loss (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "83",
     "firstAnchor": {
      "contextRef": "c-7",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-188",
      "name": "us-gaap:StockholdersEquity",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R84": {
     "role": "http://www.avadel.com/role/SegmentInformationNarrativeDetails",
     "longName": "9955562 - Disclosure - Segment Information - Narrative (Details)",
     "shortName": "Segment Information - Narrative (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "84",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:NumberOfReportableSegments",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R85": {
     "role": "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails",
     "longName": "9955563 - Disclosure - Segment Information - Segment Reporting Information, About the Company\u2019s Significant Expenses (Details)",
     "shortName": "Segment Information - Segment Reporting Information, About the Company\u2019s Significant Expenses (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "85",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-200",
      "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    },
    "R86": {
     "role": "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails",
     "longName": "9955564 - Disclosure - Segment Information - Long-Lived Assets by Geographic Region (Details)",
     "shortName": "Segment Information - Long-Lived Assets by Geographic Region (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "86",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:NoncurrentAssets",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true,
      "unique": true
     }
    },
    "R87": {
     "role": "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails",
     "longName": "9955565 - Disclosure - Schedule II - Valuation and Qualifying Accounts (Details)",
     "shortName": "Schedule II - Valuation and Qualifying Accounts (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "87",
     "firstAnchor": {
      "contextRef": "c-206",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:ValuationAllowancesAndReservesBalance",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "avdl-20241231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "avdl_A163jCreditsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "A163jCreditsMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "163(j) Credits",
        "label": "163(j) Credits [Member]",
        "documentation": "163(j) Credits"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_A2017AvadelEmployeeSharePurchasePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "A2017AvadelEmployeeSharePurchasePlanMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2017 Avadel Employee Share Purchase Plan",
        "label": "2017 Avadel Employee Share Purchase Plan [Member]",
        "documentation": "2017 Avadel Employee Share Purchase Plan [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AOCIAttributableToParentNetOfTaxRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AOCIAttributableToParentNetOfTaxRollForward",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss:",
        "label": "AOCI Attributable to Parent, Net of Tax [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingChangesAndErrorCorrectionsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingChangesAndErrorCorrectionsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Changes and Error Corrections [Abstract]",
        "label": "Accounting Changes and Error Corrections [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r940"
     ]
    },
    "us-gaap_AccountsReceivableMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableMember",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Accounts Receivable [Member]",
        "documentation": "Due from customers or clients for goods or services that have been delivered or sold."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable, net",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1127"
     ]
    },
    "avdl_AccredoHealthGroupInc.Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AccredoHealthGroupInc.Member",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accredo",
        "label": "Accredo Health Group, Inc. [Member]",
        "documentation": "Accredo Health Group, Inc."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_AccredoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AccredoMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accredo",
        "label": "Accredo [Member]",
        "documentation": "Accredo"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "totalLabel": "Total",
        "label": "Accrued Liabilities, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r81"
     ]
    },
    "us-gaap_AccruedSalariesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccruedSalariesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued compensation",
        "label": "Accrued Salaries, Current",
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r885"
     ]
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less - accumulated depreciation",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r44",
      "r204",
      "r741"
     ]
    },
    "us-gaap_AccumulatedNetUnrealizedInvestmentGainLossMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedNetUnrealizedInvestmentGainLossMember",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain (loss) on marketable debt securities, net",
        "label": "AOCI, Accumulated Gain (Loss), Debt Securities, Available-for-Sale, Parent [Member]",
        "documentation": "Accumulated unrealized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r220",
      "r221",
      "r223",
      "r231",
      "r232",
      "r1099"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossLineItems",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r22",
      "r103",
      "r213",
      "r737",
      "r770",
      "r773"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeLossTable",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "label": "Accumulated Other Comprehensive Income (Loss) [Table]",
        "documentation": "Disclosure of information about components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r230",
      "r231",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive loss",
        "verboseLabel": "Accumulated other comprehensive loss",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r12",
      "r22",
      "r591",
      "r594",
      "r651",
      "r766",
      "r767",
      "r1099",
      "r1100",
      "r1101",
      "r1114",
      "r1115",
      "r1116",
      "r1117"
     ]
    },
    "us-gaap_AccumulatedTranslationAdjustmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AccumulatedTranslationAdjustmentMember",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation adjustment:",
        "label": "Accumulated Foreign Currency Adjustment Attributable to Parent [Member]",
        "documentation": "Accumulated other comprehensive income (loss) resulting from foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r12",
      "r22",
      "r101",
      "r102",
      "r231",
      "r232",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r1099"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital, Common Stock",
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital."
       }
      }
     },
     "auth_ref": [
      "r92"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r784",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1200",
      "r1262"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "avdl_AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in fair value of October 2023 Notes conversion feature",
        "label": "Adjustments to Additional Paid in Capital, Adjustments In Fair Value Of Convertible Debt Conversion Feature",
        "documentation": "Adjustments to Additional Paid in Capital, Adjustments In Fair Value Of Convertible Debt Conversion Feature"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation expense",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r59",
      "r490"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Amortization of deferred issuance costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r134"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AdvertisingCostsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingCostsPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising Expenses",
        "label": "Advertising Cost [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for advertising cost."
       }
      }
     },
     "auth_ref": [
      "r154"
     ]
    },
    "us-gaap_AdvertisingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AdvertisingExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Advertising expenses",
        "label": "Advertising Expense",
        "documentation": "Amount charged to advertising expense for the period, which are expenses incurred with the objective of increasing revenue for a specified brand, product or product line."
       }
      }
     },
     "auth_ref": [
      "r533",
      "r923"
     ]
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r997",
      "r1007",
      "r1040"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1000",
      "r1010",
      "r1043"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1035",
      "r1044",
      "r1048",
      "r1056"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r522",
      "r531"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_AmericanDepositarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AmericanDepositarySharesMember",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "American Depositary Shares",
        "label": "American Depositary Shares [Member]",
        "documentation": "American Depositary Shares [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_AmericanDepositorySharesConversionRatio": {
     "xbrltype": "pureItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AmericanDepositorySharesConversionRatio",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ADSs, conversion ratio",
        "label": "American Depository Shares, Conversion Ratio",
        "documentation": "American Depository Shares, Conversion Ratio"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AmortizationOfFinancingCostsAndDiscounts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AmortizationOfFinancingCostsAndDiscounts",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of debt discount and debt issuance costs",
        "label": "Amortization of Debt Issuance Costs and Discounts",
        "documentation": "Amount of amortization expense attributable to debt discount (premium) and debt issuance costs."
       }
      }
     },
     "auth_ref": [
      "r453",
      "r909",
      "r910",
      "r1102",
      "r1213"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.avadel.com/role/NetLossPerShareNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Potential ordinary shares excluded from the computation of weighted average shares (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r285"
     ]
    },
    "avdl_April2027NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "April2027NotesMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "April 2027 Notes",
        "label": "April 2027 Notes [Member]",
        "documentation": "April 2027 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetImpairmentCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetImpairmentCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment loss related to goodwill",
        "label": "Asset Impairment Charges",
        "documentation": "Amount of write-down of assets recognized in the income statement. Includes, but is not limited to, losses from tangible assets, intangible assets and goodwill."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r139",
      "r150",
      "r207",
      "r245",
      "r289",
      "r297",
      "r315",
      "r319",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r586",
      "r588",
      "r622",
      "r734",
      "r820",
      "r898",
      "r899",
      "r940",
      "r965",
      "r1160",
      "r1161",
      "r1219"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "ASSETS",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r218",
      "r245",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r586",
      "r588",
      "r622",
      "r940",
      "r1160",
      "r1161",
      "r1219"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsFairValueDisclosure": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AssetsFairValueDisclosure",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/FairValueMeasurementDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets, Fair Value Disclosure",
        "documentation": "Fair value portion of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r926"
     ]
    },
    "avdl_AtTheMarketOfferingProgramMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AtTheMarketOfferingProgramMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-market offering program",
        "label": "At-The-Market Offering Program [Member]",
        "documentation": "At-The-Market Offering Program"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.avadel.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.avadel.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AuditorName",
     "presentation": [
      "http://www.avadel.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r334"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r335"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Adjusted Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r331",
      "r372",
      "r733"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "5-10 Years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 5 Through 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in sixth through tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r730"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "1-5 Years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year One Through Five",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r729"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Greater than 10 Years",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, after Year 10",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing after tenth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r341",
      "r731"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails": {
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtSecurities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less than 1 Year",
        "label": "Debt Securities, Available-for-Sale, Fair Value, Maturity, Allocated and Single Maturity Date, Year One",
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r338",
      "r728"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/FairValueMeasurementDetails": {
       "parentTag": "us-gaap_AssetsFairValueDisclosure",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails",
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "terseLabel": "Fair Value",
        "totalLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r372",
      "r603",
      "r723",
      "r926",
      "r931",
      "r1129",
      "r1204",
      "r1205",
      "r1206"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessAcquisitionAcquireeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAcquireeDomain",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition, Acquiree [Domain]",
        "label": "Business Acquisition, Acquiree [Domain]",
        "documentation": "Identification of the acquiree in a material business combination (or series of individually immaterial business combinations), which may include the name or other type of identification of the acquiree."
       }
      }
     },
     "auth_ref": [
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r583",
      "r917",
      "r918"
     ]
    },
    "us-gaap_BusinessAcquisitionAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "BusinessAcquisitionAxis",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Business Acquisition [Axis]",
        "label": "Business Acquisition [Axis]",
        "documentation": "Information by business combination or series of individually immaterial business combinations."
       }
      }
     },
     "auth_ref": [
      "r61",
      "r62",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r583",
      "r917",
      "r918"
     ]
    },
    "avdl_CaremarkLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "CaremarkLLCMember",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Caremark",
        "label": "Caremark LLC [Member]",
        "documentation": "Caremark LLC"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_CaremarkMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "CaremarkMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Caremark",
        "label": "Caremark [Member]",
        "documentation": "Caremark"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r202",
      "r882"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "us-gaap_CashCashEquivalentsAndMarketableSecuritiesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsAndMarketableSecuritiesTextBlock",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecurities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable Securities",
        "label": "Cash, Cash Equivalents, and Marketable Securities [Text Block]",
        "documentation": "The entire disclosure of cash, cash equivalents, and debt and equity securities, including any unrealized or realized gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r1128"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash and cash equivalents at January 1",
        "periodEndLabel": "Cash and cash equivalents at December 31",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents",
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r116",
      "r242"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net change in cash and cash equivalents",
        "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r116"
     ]
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfStockDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockDomain",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Domain]",
        "label": "Class of Stock [Domain]",
        "documentation": "Share of stock differentiated by the voting rights the holder receives. Examples include, but are not limited to, common stock, redeemable preferred stock, nonredeemable preferred stock, and convertible stock."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r210",
      "r211",
      "r212",
      "r245",
      "r277",
      "r278",
      "r281",
      "r284",
      "r291",
      "r292",
      "r362",
      "r422",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r622",
      "r778",
      "r779",
      "r780",
      "r781",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r808",
      "r829",
      "r847",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1078",
      "r1103",
      "r1118"
     ]
    },
    "us-gaap_ClassOfStockLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ClassOfStockLineItems",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Line Items]",
        "label": "Class of Stock [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r210",
      "r211",
      "r212",
      "r291",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r778",
      "r779",
      "r780",
      "r781",
      "r911",
      "r1078",
      "r1103"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Contingent Liabilities and Commitments",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r129",
      "r413",
      "r414",
      "r866",
      "r1152",
      "r1158"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommitmentsAndContingenciesPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingencies",
        "label": "Commitments and Contingencies, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for commitments and contingencies, which may include policies for recognizing and measuring loss and gain contingencies."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r867"
     ]
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum number of shares reserved and available for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r957",
      "r959",
      "r960",
      "r961",
      "r962",
      "r1114",
      "r1115",
      "r1117",
      "r1200",
      "r1260",
      "r1262"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, nominal value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r808"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r91"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ordinary shares, shares outstanding (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r808",
      "r826",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Ordinary shares, nominal value of $0.01 per share; 500,000 shares authorized;\u00a096,518 issued and outstanding at December\u00a031, 2024 and 89,825 issued and outstanding at December\u00a031, 2023",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r736",
      "r940"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r226",
      "r228",
      "r234",
      "r725",
      "r747",
      "r748"
     ]
    },
    "us-gaap_ComprehensiveIncomeNoteTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ComprehensiveIncomeNoteTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Comprehensive Loss",
        "label": "Comprehensive Income (Loss) Note [Text Block]",
        "documentation": "The entire disclosure for comprehensive income, which includes, but is not limited to, 1) the amount of income tax expense or benefit allocated to each component of other comprehensive income, including reclassification adjustments, 2) the reclassification adjustments for each classification of other comprehensive income and 3) the ending accumulated balances for each component of comprehensive income."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r233",
      "r724",
      "r745"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r65",
      "r66",
      "r326",
      "r865"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r65",
      "r66",
      "r326",
      "r775",
      "r865"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r65",
      "r66",
      "r326",
      "r865",
      "r1080"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentrations of Risk",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r157"
     ]
    },
    "us-gaap_ConcentrationRiskLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskLineItems",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Line Items]",
        "label": "Concentration Risk [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r865"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r65",
      "r66",
      "r326"
     ]
    },
    "us-gaap_ConcentrationRiskTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTable",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk [Table]",
        "label": "Concentration Risk [Table]",
        "documentation": "Disclosure of information about concentration risk. Includes, but is not limited to, percentage of concentration risk and benchmark serving as denominator in calculation of percentage of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r31",
      "r32",
      "r33",
      "r34",
      "r65",
      "r138",
      "r865"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r32",
      "r33",
      "r65",
      "r66",
      "r326",
      "r865"
     ]
    },
    "avdl_ContractualObligationAnnualAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ContractualObligationAnnualAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contractual obligation, annual amount",
        "label": "Contractual Obligation, Annual Amount",
        "documentation": "Contractual Obligation, Annual Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CostOfGoodsAndServicesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CostOfGoodsAndServicesSold",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cost of products sold",
        "label": "Cost of Goods and Services Sold",
        "documentation": "The aggregate costs related to goods produced and sold and services rendered by an entity during the reporting period. This excludes costs incurred during the reporting period related to financial services rendered and other revenue generating activities."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r107",
      "r687"
     ]
    },
    "dei_CountryRegion": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CountryRegion",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Country Region",
        "label": "Country Region",
        "documentation": "Region code of country"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current:",
        "label": "Current Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r568",
      "r1106"
     ]
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "U.S. - State",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1081",
      "r1106",
      "r1199"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r326"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r1067"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r1067"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r1071"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r1069"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r1062"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1063"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1063"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1061"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1061"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1061"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1064"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r1067"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r1070"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1068"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2024",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1065"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Royalty Financing Obligation",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r130",
      "r244",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r420",
      "r421",
      "r431",
      "r437",
      "r438",
      "r439",
      "r440",
      "r441",
      "r442",
      "r447",
      "r454",
      "r455",
      "r457",
      "r630"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r80",
      "r81",
      "r140",
      "r143",
      "r247",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r938",
      "r1104",
      "r1153",
      "r1154",
      "r1155",
      "r1212",
      "r1214"
     ]
    },
    "avdl_DebtInstrumentIncreaseDecreaseNetRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "DebtInstrumentIncreaseDecreaseNetRollForward",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Increase (Decrease), Net [Roll Forward]",
        "label": "Debt Instrument, Increase (Decrease), Net [Roll Forward]",
        "documentation": "Debt Instrument, Increase (Decrease), Net"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateEffectivePercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateEffectivePercentage",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective interest rate",
        "label": "Debt Instrument, Interest Rate, Effective Percentage",
        "documentation": "Effective interest rate for the funds borrowed under the debt agreement considering interest compounding and original issue discount or premium."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r459",
      "r630",
      "r631",
      "r938"
     ]
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r433"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r247",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r938",
      "r1104",
      "r1212",
      "r1214"
     ]
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r247",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r938",
      "r1104",
      "r1153",
      "r1154",
      "r1155",
      "r1212",
      "r1214"
     ]
    },
    "avdl_DebtInstrumentNumberOfTranches": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "DebtInstrumentNumberOfTranches",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of tranches",
        "label": "Debt Instrument, Number Of Tranches",
        "documentation": "Debt Instrument, Number Of Tranches"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-term Debt Instruments [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r52",
      "r55",
      "r68",
      "r132",
      "r133",
      "r247",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r438",
      "r443",
      "r444",
      "r445",
      "r446",
      "r448",
      "r449",
      "r450",
      "r451",
      "r452",
      "r453",
      "r456",
      "r906",
      "r907",
      "r908",
      "r909",
      "r910",
      "r938",
      "r1104",
      "r1212",
      "r1214"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross realized gains",
        "label": "Debt Securities, Available-for-Sale, Realized Gain",
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleRealizedLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross realized losses",
        "label": "Debt Securities, Available-for-Sale, Realized Loss",
        "documentation": "Amount of realized loss on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r360"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Table]",
        "label": "Debt Securities, Available-for-Sale [Table]",
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Available-for-sale Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142"
     ]
    },
    "us-gaap_DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in unrecognized tax benefits is reasonably possible",
        "label": "Decrease in Unrecognized Tax Benefits is Reasonably Possible",
        "documentation": "Amount of decrease reasonably possible in the next twelve months for the unrecognized tax benefit."
       }
      }
     },
     "auth_ref": [
      "r151"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. - Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1198",
      "r1199"
     ]
    },
    "us-gaap_DeferredFederalStateAndLocalTaxExpenseBenefitAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredFederalStateAndLocalTaxExpenseBenefitAbstract",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Federal, State and Local, Tax Expense (Benefit) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r163",
      "r1106"
     ]
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Gross deferred tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r87",
      "r88",
      "r141",
      "r559"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. - State",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1106",
      "r1198",
      "r1199"
     ]
    },
    "us-gaap_DeferredTaxAssetInterestCarryforward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetInterestCarryforward",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest expense carryforward",
        "label": "Deferred Tax Asset, Interest Carryforward",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible interest carryforward."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "avdl_DeferredTaxAssetsAmortizationOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "DeferredTaxAssetsAmortizationOfIntangibleAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization",
        "label": "Deferred Tax Assets, Amortization Of Intangible Assets",
        "documentation": "Deferred Tax Assets, Amortization Of Intangible Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross deferred tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r560"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research costs",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net deferred tax assets",
        "label": "Deferred Tax Assets, Net",
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net operating loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "avdl_DeferredTaxAssetsRoyaltyIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "DeferredTaxAssetsRoyaltyIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty income",
        "label": "Deferred Tax Assets, Royalty Income",
        "documentation": "Deferred Tax Assets, Royalty Income"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan drug and R&amp;D tax credit",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug And Research",
        "documentation": "Deferred Tax Assets, Tax Credit Carryforwards, Orphan Drug And Research"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research tax credit receivable",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-based compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserves and Other Accruals",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Reserves and Accruals",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: valuation allowances",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r561"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Deferred tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPrepaidExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DeferredTaxLiabilitiesPrepaidExpenses",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesDeferredTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Prepaid expenses",
        "label": "Deferred Tax Liabilities, Prepaid Expenses",
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from prepaid expenses."
       }
      }
     },
     "auth_ref": [
      "r1197"
     ]
    },
    "us-gaap_Depreciation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Depreciation",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Depreciation",
        "label": "Depreciation",
        "documentation": "The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43"
     ]
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r43"
     ]
    },
    "srt_DirectorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "DirectorMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Board of Directors",
        "label": "Director [Member]",
        "documentation": "Person serving on board of directors."
       }
      }
     },
     "auth_ref": [
      "r1093",
      "r1126",
      "r1261"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Share-Based Compensation",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r492",
      "r523",
      "r524",
      "r526",
      "r920"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disclosure of Compensation Related Costs, Share-based Payments [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Restricted Share Awards",
        "label": "Disclosure of Share-Based Compensation Arrangements by Share-Based Payment Award [Table Text Block]",
        "documentation": "Tabular disclosure of share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r10",
      "r56"
     ]
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993",
      "r1036"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share - basic (in dollars per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r275",
      "r277",
      "r281",
      "r283",
      "r284",
      "r288",
      "r581",
      "r585",
      "r600",
      "r601",
      "r726",
      "r749",
      "r891"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r235",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r268",
      "r277",
      "r281",
      "r283",
      "r284",
      "r288",
      "r581",
      "r585",
      "r600",
      "r601",
      "r726",
      "r749",
      "r891"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.avadel.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r285",
      "r286",
      "r287"
     ]
    },
    "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Effect of foreign currency exchange rate changes on cash and cash equivalents",
        "label": "Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Continuing Operations",
        "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "avdl_EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Orphan drug and R&amp;D tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Amount, Orphan Drug and Research And Development Tax Credit",
        "documentation": "Effective Income Tax Rate Reconciliation, Amount, Orphan Drug and Research And Development Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible interest expense",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount",
        "documentation": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Interest Expense, Amount"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Unrecognized compensation expense",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r525"
     ]
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Option",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCountry": {
     "xbrltype": "countryCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCountry",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Country",
        "label": "Entity Address, Country",
        "documentation": "ISO 3166-1 alpha-2 country code."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock, Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1076"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r967"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1077"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "us-gaap_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r195",
      "r230",
      "r231",
      "r232",
      "r254",
      "r255",
      "r256",
      "r260",
      "r267",
      "r269",
      "r271",
      "r290",
      "r363",
      "r366",
      "r399",
      "r468",
      "r569",
      "r570",
      "r576",
      "r577",
      "r578",
      "r582",
      "r584",
      "r585",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r599",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r634",
      "r651",
      "r745",
      "r766",
      "r767",
      "r768",
      "r784",
      "r847"
     ]
    },
    "avdl_EquityTransactionsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "EquityTransactionsDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactions"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Instruments and Transactions",
        "label": "Equity Transactions Disclosure [Text Block]",
        "documentation": "Equity Transactions Disclosure"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r997",
      "r1007",
      "r1040"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1004",
      "r1037"
     ]
    },
    "srt_EuropeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "EuropeMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "Europe [Member]",
        "documentation": "Continent of Europe."
       }
      }
     },
     "auth_ref": [
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1264",
      "r1265",
      "r1266",
      "r1267"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "country_FR": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "FR",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "France",
        "label": "FRANCE"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r614",
      "r926"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Recurring and Nonrecurring [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r614",
      "r926"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r613",
      "r614",
      "r616",
      "r657",
      "r658",
      "r659",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r926",
      "r931"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r607",
      "r926",
      "r1205",
      "r1208"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Disclosures [Abstract]",
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r609",
      "r611",
      "r612",
      "r613",
      "r616",
      "r617",
      "r618",
      "r619",
      "r620",
      "r721",
      "r926",
      "r932"
     ]
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel1Member",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 1",
        "label": "Fair Value, Inputs, Level 1 [Member]",
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r481",
      "r486",
      "r604",
      "r614",
      "r657",
      "r914",
      "r915",
      "r916",
      "r926"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r481",
      "r486",
      "r604",
      "r605",
      "r614",
      "r658",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r926"
     ]
    },
    "us-gaap_FairValueInputsLevel3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueInputsLevel3Member",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 3",
        "label": "Fair Value, Inputs, Level 3 [Member]",
        "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r604",
      "r605",
      "r606",
      "r607",
      "r614",
      "r659",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r926",
      "r931"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r603",
      "r604",
      "r605",
      "r607",
      "r926",
      "r1205",
      "r1208"
     ]
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r445",
      "r481",
      "r482",
      "r483",
      "r484",
      "r485",
      "r486",
      "r602",
      "r604",
      "r605",
      "r606",
      "r607",
      "r613",
      "r614",
      "r616",
      "r657",
      "r658",
      "r659",
      "r907",
      "r908",
      "r914",
      "r915",
      "r916",
      "r926",
      "r931"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r926",
      "r1202",
      "r1203",
      "r1204",
      "r1205",
      "r1206",
      "r1208"
     ]
    },
    "avdl_February2023NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "February2023NotesMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "February 2023 Notes",
        "label": "February 2023 Notes [Member]",
        "documentation": "Four Point Fifty Percent Exchangeable Senior Notes Due 2023 [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails",
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r367",
      "r368",
      "r369",
      "r370",
      "r371",
      "r373",
      "r374",
      "r375",
      "r456",
      "r466",
      "r597",
      "r621",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r746",
      "r904",
      "r926",
      "r929",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r941",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1201",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208"
     ]
    },
    "avdl_FirstJazzComplaintMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "FirstJazzComplaintMember",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "First Jazz Complaint",
        "label": "First Jazz Complaint [Member]",
        "documentation": "First Jazz Complaint"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fixed Assets and Right Of Use Assets, Contract Manufacturing Organizations",
        "label": "Fixed Assets And Right Of Use Assets, Contract Manufacturing Organizations [Member]",
        "documentation": "Fixed Assets And Right Of Use Assets, Contract Manufacturing Organizations"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1044"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1044"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1044"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1044"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1044"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "avdl_FscHoldingsLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "FscHoldingsLlcMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "FSC",
        "label": "FSC Holdings, LLC [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "FurnitureAndFixturesMember",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Furniture, fixtures and fittings",
        "label": "Furniture and Fixtures [Member]",
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainsLossesOnExtinguishmentOfDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GainsLossesOnExtinguishmentOfDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Loss on extinguishment of debt",
        "negatedTerseLabel": "Loss on extinguishment of debt",
        "label": "Gain (Loss) on Extinguishment of Debt",
        "documentation": "Difference between the fair value of payments made and the carrying amount of debt which is extinguished prior to maturity."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r47",
      "r48"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative expenses",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r110",
      "r831"
     ]
    },
    "us-gaap_GeographicAreasLongLivedAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GeographicAreasLongLivedAssetsAbstract",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Long-lived Assets by Geographic Region:",
        "label": "Geographic Areas, Long-Lived Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Goodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Goodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/GoodwillDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "terseLabel": "Goodwill",
        "label": "Goodwill",
        "documentation": "Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r205",
      "r381",
      "r722",
      "r899",
      "r905",
      "r928",
      "r940",
      "r1148",
      "r1149"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill and Intangible Assets Disclosure [Abstract]",
        "label": "Goodwill and Intangible Assets Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GoodwillAndIntangibleAssetsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/Goodwill"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets Disclosure [Text Block]",
        "documentation": "The entire disclosure for goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1150"
     ]
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r1147",
      "r1150"
     ]
    },
    "us-gaap_GoodwillImpairmentLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GoodwillImpairmentLoss",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Goodwill impairment loss",
        "label": "Goodwill, Impairment Loss",
        "documentation": "Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r382",
      "r388",
      "r392",
      "r905",
      "r928"
     ]
    },
    "us-gaap_GranteeStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Axis]",
        "label": "Grantee Status [Axis]",
        "documentation": "Information by status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_GranteeStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GranteeStatusDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grantee Status [Domain]",
        "label": "Grantee Status [Domain]",
        "documentation": "Status of recipient to whom award is granted."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Gross profit",
        "label": "Gross Profit",
        "documentation": "Aggregate revenue less cost of goods and services sold or operating expenses directly attributable to the revenue generation activity."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r108",
      "r149",
      "r245",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r622",
      "r893",
      "r898",
      "r1120",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1160"
     ]
    },
    "us-gaap_GuarantyLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "GuarantyLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Guaranty Liabilities",
        "documentation": "This item represents a non-contingent liability for the fair value of an obligation to stand ready to perform over the term of a guaranty issued in the event that specified triggering events or conditions occur."
       }
      }
     },
     "auth_ref": [
      "r142",
      "r1159"
     ]
    },
    "country_IE": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "IE",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Europe",
        "label": "IRELAND"
       }
      }
     },
     "auth_ref": []
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r970",
      "r993"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsHeldForUse": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOfLongLivedAssetsHeldForUse",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived asset impairment",
        "label": "Impairment, Long-Lived Asset, Held-for-Use",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long lived assets held for use (including those held for disposal by means other than sale)."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r42",
      "r126",
      "r927"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r128"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss before income taxes",
        "label": "Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r145",
      "r149",
      "r727",
      "r743",
      "r893",
      "r898",
      "r1120",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement [Abstract]",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsLineItems",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "label": "Income Statement, Balance Sheet and Additional Disclosures by Disposal Groups, Including Discontinued Operations [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementBalanceSheetAndAdditionalDisclosuresByDisposalGroupsIncludingDiscontinuedOperationsTable",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Disposal Groups, Including Discontinued Operations [Table]",
        "label": "Disposal Groups, Including Discontinued Operations [Table]",
        "documentation": "Disclosure of information about a disposal group. Includes, but is not limited to, a discontinued operation, disposal classified as held-for-sale or disposed of by means other than sale or disposal of an individually significant component."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r17",
      "r19",
      "r70",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r76",
      "r77",
      "r78",
      "r127"
     ]
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r400",
      "r407",
      "r408",
      "r608",
      "r610",
      "r615",
      "r763",
      "r765",
      "r832",
      "r879",
      "r930",
      "r1231"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount has been reported."
       }
      }
     },
     "auth_ref": [
      "r407",
      "r408",
      "r608",
      "r610",
      "r615",
      "r763",
      "r765",
      "r832",
      "r879",
      "r930",
      "r1231"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r541",
      "r542",
      "r552",
      "r565",
      "r925",
      "r1196"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r241",
      "r541",
      "r542",
      "r552",
      "r565",
      "r925",
      "r1196"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r246",
      "r536",
      "r541",
      "r548",
      "r549",
      "r550",
      "r557",
      "r563",
      "r571",
      "r573",
      "r574",
      "r575",
      "r783",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeTaxBenefitDetails",
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) provision",
        "totalLabel": "Income tax (benefit) provision",
        "negatedLabel": "Income tax benefit",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r164",
      "r270",
      "r271",
      "r289",
      "r305",
      "r319",
      "r540",
      "r541",
      "r572",
      "r750",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effective Income Tax Rate Reconciliation, Amount [Abstract]",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r229",
      "r538",
      "r539",
      "r557",
      "r558",
      "r562",
      "r567",
      "r777"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in valuation allowances",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r546",
      "r925",
      "r1190"
     ]
    },
    "us-gaap_IncomeTaxReconciliationForeignIncomeTaxRateDifferential": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationForeignIncomeTaxRateDifferential",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Differences in international tax rates",
        "label": "Effective Income Tax Rate Reconciliation, Foreign Income Tax Rate Differential, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to foreign income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r542",
      "r545",
      "r925",
      "r1190"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax (benefit) provision - at statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r541",
      "r925"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nondeductible share-based compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1190",
      "r1192"
     ]
    },
    "us-gaap_IncomeTaxReconciliationOtherReconcilingItems": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationOtherReconcilingItems",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Other Reconciling Items, Amount",
        "documentation": "Amount of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying statutory federal (national) tax rate to pretax income (loss) from continuing operation attributable to other reconciling item. Excludes state and local income tax expense (benefit), federal tax expense (benefit), statutory income tax expense (benefit) outside of country of domicile, tax credit, nondeductible expense, deduction, income tax settlement, income tax contingency, and cross-border tax law."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxReconciliationPriorYearIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationPriorYearIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Return to Provision",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r1190",
      "r1191"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local taxes (net of federal)",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r544",
      "r925",
      "r1190"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxContingencies",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesReconciliationofTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized tax benefits",
        "label": "Effective Income Tax Rate Reconciliation, Tax Contingency, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in income tax contingencies. Including, but not limited to, domestic tax contingency, foreign tax contingency, state and local tax contingency, and other contingencies."
       }
      }
     },
     "auth_ref": [
      "r547",
      "r925",
      "r1190"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross research tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r925",
      "r1190",
      "r1192"
     ]
    },
    "avdl_IncomeTaxesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "IncomeTaxesLineItems",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Line Items]",
        "label": "Income Taxes [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Income taxes refunded, net",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r241",
      "r564",
      "r565"
     ]
    },
    "avdl_IncomeTaxesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "IncomeTaxesTable",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes [Table]",
        "label": "Income Taxes [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable &amp; other current liabilities",
        "label": "Increase (Decrease) in Accounts Payable",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accrued expenses",
        "label": "Increase (Decrease) in Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInDeferredIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInDeferredIncomeTaxes",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Changes in deferred taxes",
        "label": "Increase (Decrease) in Deferred Income Taxes",
        "documentation": "The increase (decrease) during the reporting period in the account that represents the temporary difference that results from Income or Loss that is recognized for accounting purposes but not for tax purposes and vice versa."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "avdl_IncreaseDecreaseInIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "IncreaseDecreaseInIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Decrease in income tax benefit",
        "label": "Increase (Decrease) In Income Tax Expense (Benefit)",
        "documentation": "Increase (Decrease) In Income Tax Expense (Benefit)"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInInventories",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Inventories",
        "label": "Increase (Decrease) in Inventories",
        "documentation": "The increase (decrease) during the reporting period in the aggregate value of all inventory held by the reporting entity, associated with underlying transactions that are classified as operating activities."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Net changes in assets and liabilities",
        "label": "Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other assets and liabilities",
        "label": "Increase (Decrease) in Other Noncurrent Assets and Liabilities, Net",
        "documentation": "Amount of increase (decrease) in noncurrent operating assets after deduction of noncurrent operating liabilities classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other current assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1035",
      "r1044",
      "r1048",
      "r1056"
     ]
    },
    "avdl_InducementPlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "InducementPlanMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement Plan",
        "label": "Inducement Plan [Member]",
        "documentation": "Inducement Plan"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "us-gaap_InterestExpenseDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestExpenseDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Interest expense",
        "verboseLabel": "Interest expense",
        "terseLabel": "Accretion of imputed interest expense on royalty financing obligation",
        "label": "Interest Expense, Debt",
        "documentation": "Amount of the cost of borrowed funds accounted for as interest expense for debt."
       }
      }
     },
     "auth_ref": [
      "r113",
      "r451",
      "r460",
      "r909",
      "r910"
     ]
    },
    "us-gaap_InterestPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InterestPaidNet",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest paid",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount."
       }
      }
     },
     "auth_ref": [
      "r237",
      "r239",
      "r240"
     ]
    },
    "us-gaap_InventoryDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventory Disclosure [Abstract]",
        "label": "Inventory Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InventoryDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/Inventories"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Inventories",
        "label": "Inventory Disclosure [Text Block]",
        "documentation": "The entire disclosure for inventory. Includes, but is not limited to, the basis of stating inventory, the method of determining inventory cost, the classes of inventory, and the nature of the cost elements included in inventory."
       }
      }
     },
     "auth_ref": [
      "r376"
     ]
    },
    "us-gaap_InventoryFinishedGoodsNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryFinishedGoodsNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Finished goods",
        "label": "Inventory, Finished Goods, Net of Reserves",
        "documentation": "Carrying amount, net of valuation reserves and adjustments, as of the balance sheet date of merchandise or goods held by the company that are readily available for sale."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r886"
     ]
    },
    "us-gaap_InventoryNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.avadel.com/role/InventoriesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "totalLabel": "Inventories",
        "label": "Inventory, Net",
        "documentation": "Amount after valuation and LIFO reserves of inventory expected to be sold, or consumed within one year or operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r883",
      "r940"
     ]
    },
    "us-gaap_InventoryPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inventories",
        "label": "Inventory, Policy [Policy Text Block]",
        "documentation": "Disclosure of inventory accounting policy for inventory classes, including, but not limited to, basis for determining inventory amounts, methods by which amounts are added and removed from inventory classes, loss recognition on impairment of inventories, and situations in which inventories are stated above cost."
       }
      }
     },
     "auth_ref": [
      "r153",
      "r201",
      "r214",
      "r376",
      "r377",
      "r378",
      "r686",
      "r888"
     ]
    },
    "us-gaap_InventoryRawMaterialsAndSuppliesNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryRawMaterialsAndSuppliesNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Raw materials and supplies",
        "label": "Inventory, Raw Materials and Supplies, Net of Reserves",
        "documentation": "Aggregated amount of unprocessed materials to be used in manufacturing or production process and supplies that will be consumed. This amount is net of valuation reserves and adjustments."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r1097"
     ]
    },
    "us-gaap_InventoryWorkInProcessNetOfReserves": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InventoryWorkInProcessNetOfReserves",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/InventoriesDetails": {
       "parentTag": "us-gaap_InventoryNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/InventoriesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Work in process",
        "label": "Inventory, Work in Process, Net of Reserves",
        "documentation": "Carrying amount, net of reserves and adjustments, as of the balance sheet date of merchandise or goods which are partially completed. This inventory is generally comprised of raw materials, labor and factory overhead costs, which require further materials, labor and overhead to be converted into finished goods, and which generally require the use of estimates to determine percentage complete and pricing."
       }
      }
     },
     "auth_ref": [
      "r123",
      "r887"
     ]
    },
    "us-gaap_InvestmentIncomeNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentIncomeNet",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment and other income (expense), net",
        "label": "Investment Income, Net",
        "documentation": "Amount after accretion (amortization) of discount (premium), and investment expense, of interest income and dividend income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r111",
      "r112",
      "r113"
     ]
    },
    "us-gaap_InvestmentsClassifiedByContractualMaturityDateTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsClassifiedByContractualMaturityDateTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contractual Maturity Dates",
        "label": "Investments Classified by Contractual Maturity Date [Table Text Block]",
        "documentation": "Tabular disclosure of maturities of an entity's investments as well as any other information pertinent to the investments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investments, Debt and Equity Securities [Abstract]",
        "label": "Investments, Debt and Equity Securities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease cost",
        "label": "Lease, Cost",
        "documentation": "Amount of lease cost recognized by lessee for lease contract."
       }
      }
     },
     "auth_ref": [
      "r640",
      "r939"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Costs",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1216"
     ]
    },
    "avdl_LeaseholdImprovementsFurnitureFixturesAndFittingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "LeaseholdImprovementsFurnitureFixturesAndFittingsMember",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements, furniture, fixtures and fittings",
        "label": "Leasehold Improvements, Furniture, Fixtures And Fittings [Member]",
        "documentation": "Leasehold Improvements, Furniture, Fixtures And Fittings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r649"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee, Lease, Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r639",
      "r649"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease Obligations",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r638"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/LeasesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2025",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r647"
     ]
    },
    "us-gaap_LesseeOperatingLeaseTermOfContract": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeaseTermOfContract",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, term of contract",
        "label": "Lessee, Operating Lease, Term of Contract",
        "documentation": "Term of lessee's operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r1215"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.avadel.com/role/Leases"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r633"
     ]
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r80",
      "r81",
      "r82",
      "r84",
      "r85",
      "r86",
      "r89",
      "r245",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r587",
      "r588",
      "r589",
      "r622",
      "r807",
      "r892",
      "r965",
      "r1160",
      "r1219",
      "r1220"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and shareholders\u2019 equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r96",
      "r144",
      "r739",
      "r940",
      "r1105",
      "r1146",
      "r1209"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "LIABILITIES AND SHAREHOLDERS\u2019 EQUITY",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r200",
      "r245",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r587",
      "r588",
      "r589",
      "r622",
      "r940",
      "r1160",
      "r1219",
      "r1220"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_LiquidityAndGoingConcernPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "LiquidityAndGoingConcernPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Liquidity",
        "label": "Liquidity and Going Concern [Policy Text Block]",
        "documentation": "Liquidity and Going Concern"
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseAxis",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Axis]",
        "label": "Litigation Case [Axis]",
        "documentation": "Information by type of judicial proceeding, alternative dispute resolution or claim."
       }
      }
     },
     "auth_ref": []
    },
    "srt_LitigationCaseTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "LitigationCaseTypeDomain",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Litigation Case [Domain]",
        "label": "Litigation Case [Domain]",
        "documentation": "Judicial proceeding, alternative dispute resolution or claim. For example, but not limited to, name of case, category of litigation, or other differentiating information."
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongLivedAssetsByGeographicAreasTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongLivedAssetsByGeographicAreasTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-lived Assets by Geographic Areas",
        "label": "Long-Lived Assets by Geographic Areas [Table Text Block]",
        "documentation": "Tabular disclosure of long-lived assets, excluding financial instruments, long-term customer relationships of a financial institution, mortgage rights, deferred policy acquisition costs, and deferred tax assets, by geographic areas located in the entity's country of domicile and foreign countries in which the entity holds assets."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Royalty financing obligation \u2013 beginning balance",
        "periodEndLabel": "Royalty financing obligation \u2013 ending balance",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r143",
      "r444",
      "r458",
      "r907",
      "r908",
      "r938",
      "r1229"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedNetLabel": "Less: royalty payable to RTW classified within accrued expenses",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r208"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "netLabel": "Royalty financing obligation, non-current",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r209"
     ]
    },
    "us-gaap_LongtermDebtTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeAxis",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Axis]",
        "label": "Long-Term Debt, Type [Axis]",
        "documentation": "Information by type of long-term debt."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_LongtermDebtTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermDebtTypeDomain",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term Debt, Type [Domain]",
        "label": "Long-Term Debt, Type [Domain]",
        "documentation": "Type of long-term debt arrangement, such as notes, line of credit, commercial paper, asset-based financing, project financing, letter of credit financing. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the company, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r46",
      "r1153",
      "r1154",
      "r1155"
     ]
    },
    "us-gaap_LongtermPurchaseCommitmentPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LongtermPurchaseCommitmentPeriod",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase commitment, period (in years)",
        "label": "Long-Term Purchase Commitment, Period",
        "documentation": "Period covered by the long-term purchase commitment, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LossContingencyAccrualCarryingValueCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "LossContingencyAccrualCarryingValueCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency accrued",
        "label": "Loss Contingency, Accrual, Current",
        "documentation": "Amount of loss contingency liability expected to be resolved within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r415"
     ]
    },
    "srt_MajorCustomersAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MajorCustomersAxis",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Axis]",
        "label": "Customer [Axis]",
        "documentation": "Information by name or description of a single external customer or a group of external customers."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r913",
      "r950",
      "r954",
      "r1163",
      "r1230",
      "r1232",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1096"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.avadel.com/role/LeasesNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r178",
      "r179",
      "r181",
      "r193",
      "r194",
      "r416",
      "r417",
      "r418",
      "r419",
      "r487",
      "r532",
      "r607",
      "r685",
      "r762",
      "r764",
      "r774",
      "r799",
      "r800",
      "r850",
      "r852",
      "r854",
      "r855",
      "r857",
      "r877",
      "r878",
      "r903",
      "r911",
      "r919",
      "r931",
      "r932",
      "r936",
      "r937",
      "r951",
      "r1162",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.avadel.com/role/LeasesNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r178",
      "r179",
      "r181",
      "r193",
      "r194",
      "r416",
      "r417",
      "r418",
      "r419",
      "r487",
      "r532",
      "r607",
      "r685",
      "r762",
      "r764",
      "r774",
      "r799",
      "r800",
      "r850",
      "r852",
      "r854",
      "r855",
      "r857",
      "r877",
      "r878",
      "r903",
      "r911",
      "r919",
      "r931",
      "r932",
      "r936",
      "r951",
      "r1162",
      "r1221",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "us-gaap_MovementInValuationAllowancesAndReservesRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "MovementInValuationAllowancesAndReservesRollForward",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "label": "SEC Schedule, 12-09, Movement in Valuation Allowances and Reserves [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "srt_NameOfMajorCustomerDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "NameOfMajorCustomerDomain",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer [Domain]",
        "label": "Customer [Domain]",
        "documentation": "Single external customer or group of external customers."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r913",
      "r950",
      "r954",
      "r1163",
      "r1230",
      "r1232",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "avdl_NatureOfBusinessPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "NatureOfBusinessPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Operations",
        "label": "Nature Of Business Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for nature of business."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by financing activities",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from financing activities:",
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by (used in) investing activities",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r238"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from investing activities:",
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r117",
      "r118"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Cash flows from operating activities:",
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "verboseLabel": "Net loss",
        "terseLabel": "Net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r109",
      "r118",
      "r146",
      "r198",
      "r224",
      "r227",
      "r232",
      "r245",
      "r259",
      "r263",
      "r264",
      "r265",
      "r266",
      "r267",
      "r270",
      "r271",
      "r279",
      "r362",
      "r422",
      "r423",
      "r424",
      "r425",
      "r426",
      "r427",
      "r428",
      "r429",
      "r430",
      "r581",
      "r585",
      "r601",
      "r622",
      "r744",
      "r828",
      "r845",
      "r846",
      "r963",
      "r1160"
     ]
    },
    "us-gaap_NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock",
     "presentation": [
      "http://www.avadel.com/role/NewlyIssuedAccountingStandards"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Newly Issued Accounting Standards",
        "label": "Accounting Standards Update and Change in Accounting Principle [Text Block]",
        "documentation": "The entire disclosure for change in accounting principle. Includes, but is not limited to, nature, reason, and method of adopting amendment to accounting standards or other change in accounting principle."
       }
      }
     },
     "auth_ref": [
      "r165",
      "r196",
      "r257",
      "r258",
      "r261",
      "r262",
      "r272",
      "r273",
      "r327",
      "r364",
      "r365",
      "r579",
      "r580",
      "r582",
      "r585",
      "r595",
      "r598",
      "r650",
      "r652",
      "r653",
      "r688",
      "r689",
      "r690",
      "r769",
      "r770",
      "r771",
      "r772",
      "r773"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Recently Adopted Accounting Guidance, Recent Accounting Guidance Not Yet Adopted, Newly Issued Climate-Related Disclosure Rule",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r990",
      "r1001",
      "r1011",
      "r1035",
      "r1044"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-lived assets",
        "label": "Long-Lived Assets",
        "documentation": "Long-lived assets other than financial instruments, long-term customer relationships of a financial institution, mortgage and other servicing rights, deferred policy acquisition costs, and deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r325"
     ]
    },
    "avdl_NumberOfFinancialInstitutions": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "NumberOfFinancialInstitutions",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of financial institutions",
        "label": "Number Of Financial Institutions",
        "documentation": "Number Of Financial Institutions"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r899",
      "r1121"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r894",
      "r902",
      "r1121"
     ]
    },
    "avdl_October2023NotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "October2023NotesMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "October 2023 Notes",
        "label": "October 2023 Notes [Member]",
        "documentation": "October 2023 Notes"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating expenses:",
        "terseLabel": "Operating Expenses [Abstract]",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Operating loss",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r149",
      "r893",
      "r1120",
      "r1122",
      "r1123",
      "r1124",
      "r1125"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease costs",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r641",
      "r939"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Present value of lease liabilities",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-term operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r636"
     ]
    },
    "avdl_OperatingLeaseLiabilityToBePaidAfterYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OperatingLeaseLiabilityToBePaidAfterYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesMaturitiesofoperatingleaseliabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Thereafter",
        "label": "Operating Lease, Liability, to be Paid, after Year Four",
        "documentation": "Operating Lease, Liability, to be Paid, after Year Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, payments",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r637",
      "r643"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Operating lease right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r635"
     ]
    },
    "avdl_OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of use assets at contract manufacturing organizations",
        "label": "Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent",
        "documentation": "Operating Lease, Right-Of-Use Asset, Contract Manufacturing, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate, percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r646",
      "r939"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r645",
      "r939"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_OperatingLossCarryforwardsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OperatingLossCarryforwardsValuationAllowance",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating loss carryforwards, valuation allowance (decrease)",
        "label": "Operating Loss Carryforwards, Valuation Allowance",
        "documentation": "The portion of the valuation allowance pertaining to the deferred tax asset representing potential future taxable deductions from net operating loss carryforwards for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r1195"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityEquityAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity [Axis]",
        "label": "Option Indexed to Issuer's Equity [Axis]",
        "documentation": "Information by type of options indexed to an issuer's equity."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r63",
      "r64",
      "r137"
     ]
    },
    "us-gaap_OptionIndexedToIssuersEquityTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OptionIndexedToIssuersEquityTypeDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Indexed to Issuer's Equity, Type [Domain]",
        "label": "Option Indexed to Issuer's Equity, Type [Domain]",
        "documentation": "Description of the type of freestanding contract issued by a Company that is indexed to, and potentially settled in, a Company's own stock. Specifically, the pertinent rights and privileges of the securities outstanding."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_OptumFrontierTherapiesLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OptumFrontierTherapiesLLCMember",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Optum",
        "label": "Optum Frontier Therapies LLC [Member]",
        "documentation": "Optum Frontier Therapies LLC"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_OptumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OptumMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Optum",
        "label": "Optum [Member]",
        "documentation": "Optum"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_OrphanDrugTaxCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OrphanDrugTaxCreditMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Orphan Drug tax credit",
        "label": "Orphan Drug Tax Credit [Member]",
        "documentation": "Orphan Drug Tax Credit"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Assets, Current",
        "documentation": "Amount of current assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r940"
     ]
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherAssetsNoncurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 5.0
      },
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other non-current assets",
        "totalLabel": "Total",
        "label": "Other Assets, Noncurrent",
        "documentation": "Amount of noncurrent assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r206"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Foreign currency translation (loss) income",
        "label": "Other Comprehensive Income (Loss), Foreign Currency Transaction and Translation Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r136"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other comprehensive (loss) income, net of tax",
        "terseLabel": "Net other comprehensive (loss) income",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount after tax of other comprehensive income (loss) attributable to parent entity."
       }
      }
     },
     "auth_ref": [
      "r6",
      "r12",
      "r136",
      "r225",
      "r228",
      "r267"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other comprehensive (loss) income, net of tax:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss": {
       "parentTag": "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, after Tax",
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r219",
      "r222",
      "r361"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedStatementsofComprehensiveLossParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net other comprehensive (loss) income, tax benefit",
        "label": "OCI, Debt Securities, Available-for-Sale, Unrealized Holding Gain (Loss), before Adjustment, Tax",
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r220"
     ]
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other current liabilities",
        "label": "Other Liabilities, Current",
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r940"
     ]
    },
    "us-gaap_OtherLiabilitiesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Liabilities Disclosure [Abstract]",
        "label": "Other Liabilities Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Other Assets and Liabilities",
        "label": "Other Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for other liabilities."
       }
      }
     },
     "auth_ref": [
      "r81",
      "r85",
      "r1151"
     ]
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherLiabilitiesNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      },
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other non-current liabilities",
        "totalLabel": "Total",
        "label": "Other Liabilities, Noncurrent",
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "us-gaap_OtherNoncurrentLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherNoncurrentLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Other Non-Current Liabilities",
        "label": "Other Noncurrent Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of other noncurrent liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_OtherNoncurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "OtherNoncurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails": {
       "parentTag": "us-gaap_OtherAssetsNoncurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Other Noncurrent Receivables",
        "documentation": "The carrying amount of other noncurrent receivables."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherOperatingActivitiesCashFlowStatement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "OtherOperatingActivitiesCashFlowStatement",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other adjustments",
        "label": "Other Operating Activities, Cash Flow Statement",
        "documentation": "Other cash or noncash adjustments to reconcile net income to cash provided by (used in) operating activities that are not separately disclosed in the statement of cash flows (for example, cash received or cash paid during the current period for miscellaneous operating activities, net change during the reporting period in other assets or other liabilities)."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r999",
      "r1009",
      "r1042"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1002",
      "r1012",
      "r1045"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r991",
      "r1002",
      "r1012",
      "r1045"
     ]
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "avdl_PaymentsForRoyaltyOneTimeCommitmentFee": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "PaymentsForRoyaltyOneTimeCommitmentFee",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for royalty, one-time commitment fee",
        "negatedTerseLabel": "Less: one-time payment for expiration of second tranche",
        "label": "Payments For Royalty, One-Time Commitment Fee",
        "documentation": "Payments For Royalty, One-Time Commitment Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsOfDebtIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsOfDebtIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for debt issuance costs",
        "label": "Payments of Debt Issuance Costs",
        "documentation": "The cash outflow paid to third parties in connection with debt origination, which will be amortized over the remaining maturity period of the associated long-term debt."
       }
      }
     },
     "auth_ref": [
      "r26"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1130"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchases of property and equipment",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r114"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1035"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    },
    "us-gaap_PerformanceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PerformanceSharesMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Performance Shares",
        "label": "Performance Shares [Member]",
        "documentation": "Share-based payment arrangement awarded for meeting performance target."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1075"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "us-gaap_PreferredStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares",
        "label": "Preferred Stock [Member]",
        "documentation": "Preferred shares may provide a preferential dividend to the dividend on common stock and may take precedence over common stock in the event of a liquidation. Preferred shares typically represent an ownership interest in the company."
       }
      }
     },
     "auth_ref": [
      "r955",
      "r956",
      "r959",
      "r960",
      "r961",
      "r962",
      "r1260",
      "r1262"
     ]
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, nominal value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r461"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r808"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r461"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r808",
      "r826",
      "r1262",
      "r1263"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred shares, nominal value of $0.01 per share; 50,000 shares authorized; zero issued and outstanding at December\u00a031, 2024 and 5,194 issued and outstanding at December\u00a031, 2023",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r90",
      "r735",
      "r940"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      },
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "totalLabel": "Total",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_PrepaidExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PrepaidExpenseCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails": {
       "parentTag": "us-gaap_PrepaidExpenseAndOtherAssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesPrepaidExpensesandOtherCurrentAssetsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Prepaid and other expenses",
        "label": "Prepaid Expense, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r379",
      "r380",
      "r884"
     ]
    },
    "us-gaap_PriorPeriodReclassificationAdjustmentDescription": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PriorPeriodReclassificationAdjustmentDescription",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reclassifications",
        "label": "Reclassification, Comparability Adjustment [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for reclassification affecting comparability of financial statement. Excludes amendment to accounting standards, other change in accounting principle, and correction of error."
       }
      }
     },
     "auth_ref": [
      "r1094"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of shares, net of issue costs",
        "label": "Proceeds from Issuance of Common Stock",
        "documentation": "The cash inflow from the additional capital contribution to the entity."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfLongTermDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from royalty purchase agreement",
        "verboseLabel": "Proceeds from issuance of long-term debt",
        "netLabel": "Receipt of the first tranche of the royalty financing obligation",
        "label": "Proceeds from Issuance of Long-Term Debt",
        "documentation": "The cash inflow from a debt initially having maturity due after one year or beyond the operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r25",
      "r778"
     ]
    },
    "us-gaap_ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from stock option exercises and employee share purchase plan",
        "label": "Proceeds, Issuance of Shares, Share-Based Payment Arrangement, Including Option Exercised",
        "documentation": "Amount of cash inflow from issuance of shares under share-based payment arrangement. Includes, but is not limited to, option exercised."
       }
      }
     },
     "auth_ref": [
      "r5",
      "r16"
     ]
    },
    "us-gaap_ProceedsFromSaleOfAvailableForSaleSecuritiesDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ProceedsFromSaleOfAvailableForSaleSecuritiesDebt",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Proceeds from sales of marketable securities",
        "label": "Proceeds from Sale of Debt Securities, Available-for-Sale",
        "documentation": "Amount of cash inflow from sale of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r236",
      "r329",
      "r360"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnet"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment, net",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r124",
      "r158",
      "r161",
      "r162"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Total property and equipment",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r203",
      "r742"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r648",
      "r732",
      "r742",
      "r940"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and Equipment",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r158",
      "r161",
      "r740"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetTables",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property and Equipment Useful Life",
        "verboseLabel": "Schedule of Property and Equipment",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment, Type [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r125",
      "r648"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, plant and equipment, useful life (in years)",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_PublicOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "PublicOfferingMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Public offering",
        "label": "Public Offering [Member]",
        "documentation": "Public Offering [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.avadel.com/role/LeasesNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r178",
      "r179",
      "r181",
      "r193",
      "r194",
      "r416",
      "r417",
      "r418",
      "r419",
      "r480",
      "r487",
      "r518",
      "r519",
      "r520",
      "r532",
      "r607",
      "r660",
      "r669",
      "r685",
      "r762",
      "r764",
      "r774",
      "r799",
      "r800",
      "r850",
      "r852",
      "r854",
      "r855",
      "r857",
      "r877",
      "r878",
      "r903",
      "r911",
      "r919",
      "r931",
      "r932",
      "r936",
      "r937",
      "r951",
      "r957",
      "r1156",
      "r1162",
      "r1205",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "RangeMember",
     "presentation": [
      "http://www.avadel.com/role/ContingentLiabilitiesandCommitmentsDetails",
      "http://www.avadel.com/role/LeasesNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Range [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r174",
      "r176",
      "r178",
      "r179",
      "r181",
      "r193",
      "r194",
      "r416",
      "r417",
      "r418",
      "r419",
      "r480",
      "r487",
      "r518",
      "r519",
      "r520",
      "r532",
      "r607",
      "r660",
      "r669",
      "r685",
      "r762",
      "r764",
      "r774",
      "r799",
      "r800",
      "r850",
      "r852",
      "r854",
      "r855",
      "r857",
      "r877",
      "r878",
      "r903",
      "r911",
      "r919",
      "r931",
      "r932",
      "r936",
      "r937",
      "r951",
      "r957",
      "r1156",
      "r1162",
      "r1205",
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226"
     ]
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefit Activity [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1004",
      "r1037"
     ]
    },
    "avdl_RemainingPerformanceObligationReserveCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RemainingPerformanceObligationReserveCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reserve for variable consideration",
        "label": "Remaining Performance Obligation Reserve, Current",
        "documentation": "Remaining Performance Obligation Reserve, Current"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RepaymentOfRoyaltyLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RepaymentOfRoyaltyLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Less: royalty payments made to RTW",
        "label": "Repayment Of Royalty Liability",
        "documentation": "Repayment Of Royalty Liability"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfSeniorDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RepaymentsOfSeniorDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments for Notes",
        "label": "Repayments of Senior Debt",
        "documentation": "The cash outflow for a long-term debt where the holder has highest claim on the entity's asset in case of bankruptcy or liquidation during the period."
       }
      }
     },
     "auth_ref": [
      "r115"
     ]
    },
    "avdl_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Research and development expenses",
        "terseLabel": "Research and development expenses",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r535",
      "r879",
      "r898",
      "r1227"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development (\u201cR&amp;D\u201d)",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r534"
     ]
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development tax credits",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1196"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r995",
      "r1005",
      "r1038"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r996",
      "r1006",
      "r1039"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r992",
      "r1003",
      "r1013",
      "r1046"
     ]
    },
    "avdl_RestrictedShareAwardsGrantedToEmployeesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RestrictedShareAwardsGrantedToEmployeesMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Share Awards Granted to Employees",
        "label": "Restricted Share Awards Granted To Employees [Member]",
        "documentation": "Restricted Share Awards Granted To Employees"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestrictedStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestrictedStockMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Shares",
        "label": "Restricted Stock [Member]",
        "documentation": "Stock including a provision that prohibits sale or substantive sale of an equity instrument for a specified period of time or until specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r30"
     ]
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring expense",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r410",
      "r411",
      "r1157"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r93",
      "r134",
      "r738",
      "r769",
      "r773",
      "r782",
      "r809",
      "r940"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r195",
      "r254",
      "r255",
      "r256",
      "r260",
      "r267",
      "r269",
      "r271",
      "r363",
      "r366",
      "r399",
      "r569",
      "r570",
      "r576",
      "r577",
      "r578",
      "r582",
      "r584",
      "r585",
      "r590",
      "r592",
      "r593",
      "r596",
      "r599",
      "r632",
      "r634",
      "r766",
      "r768",
      "r784",
      "r1262"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net product revenue",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r289",
      "r298",
      "r299",
      "r313",
      "r319",
      "r322",
      "r324",
      "r326",
      "r477",
      "r478",
      "r687"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer Benchmark",
        "label": "Revenue from Contract with Customer Benchmark [Member]",
        "documentation": "Revenue from satisfaction of performance obligation by transferring promised product and service to customer, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r326",
      "r1079"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueFromContractWithCustomerTextBlock",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition",
        "label": "Revenue from Contract with Customer [Text Block]",
        "documentation": "The entire disclosure of revenue from contract with customer to transfer good or service and to transfer nonfinancial asset. Includes, but is not limited to, disaggregation of revenue, credit loss recognized from contract with customer, judgment and change in judgment related to contract with customer, and asset recognized from cost incurred to obtain or fulfill contract with customer. Excludes insurance and lease contracts."
       }
      }
     },
     "auth_ref": [
      "r166",
      "r469",
      "r470",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r479"
     ]
    },
    "us-gaap_RevenueRecognitionAndDeferredRevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionAndDeferredRevenueAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue Recognition and Deferred Revenue [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRecognitionPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenueRecognitionPolicyTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue and Cost of Products Sold",
        "label": "Revenue [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue. Includes revenue from contract with customer and from other sources."
       }
      }
     },
     "auth_ref": [
      "r830",
      "r880",
      "r889"
     ]
    },
    "us-gaap_RevenuesFromExternalCustomersAndLongLivedAssetsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RevenuesFromExternalCustomersAndLongLivedAssetsLineItems",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "label": "Revenues from External Customers and Long-Lived Assets [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/LeasesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase in operating lease liabilities",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r644",
      "r939"
     ]
    },
    "avdl_RoyaltyFinancingLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails": {
       "parentTag": "us-gaap_AccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesAccruedExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payable to RTW",
        "label": "Royalty Financing Liability, Current",
        "documentation": "Royalty Financing Liability, Current"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RoyaltyFinancingLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty financing obligation",
        "label": "Royalty Financing Liability, Noncurrent",
        "documentation": "Royalty Financing Liability, Noncurrent"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RoyaltyFinancingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingMember",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationActivityDetails",
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty Financing",
        "label": "Royalty Financing [Member]",
        "documentation": "Royalty Financing"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RoyaltyFinancingProceedsMaximum": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingProceedsMaximum",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum proceeds from royalty financing",
        "label": "Royalty Financing, Proceeds, Maximum",
        "documentation": "Royalty Financing, Proceeds, Maximum"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RoyaltyFinancingQuarterlyNetRevenueTarget": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingQuarterlyNetRevenueTarget",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly net revenue target for royalty financing",
        "label": "Royalty Financing, Quarterly Net Revenue Target",
        "documentation": "Royalty Financing, Quarterly Net Revenue Target"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Quarterly royalty payments for royalty financing, percentage",
        "label": "Royalty Financing, Quarterly Royalty Payment, Percentage",
        "documentation": "Royalty Financing, Quarterly Royalty Payment, Percentage"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockConsiderationReceivedOnTransaction",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net proceeds from shares issued",
        "label": "Sale of Stock, Consideration Received on Transaction",
        "documentation": "Cash received on stock transaction after deduction of issuance costs."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_SaleOfStockMaximumAggregateOfferingPrice": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "SaleOfStockMaximumAggregateOfferingPrice",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, maximum aggregate offering price",
        "label": "Sale Of Stock, Maximum Aggregate Offering Price",
        "documentation": "Sale Of Stock, Maximum Aggregate Offering Price"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares issued (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_SaleOfStockSalesAgentCommissionPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "SaleOfStockSalesAgentCommissionPercent",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales agent commission, as a percent of aggregate gross sales proceeds",
        "label": "Sale Of Stock, Sales Agent Commission, Percent",
        "documentation": "Sale Of Stock, Sales Agent Commission, Percent"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Accrued Expenses",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Accumulated Other Comprehensive Loss",
        "label": "Schedule of Accumulated Other Comprehensive Income (Loss) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accumulated other comprehensive income (loss)."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r1210",
      "r1211"
     ]
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "presentation": [
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Securities, Available-for-sale [Line Items]",
        "label": "Debt Securities, Available-for-Sale [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341"
     ]
    },
    "avdl_ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule Of Components Of (Loss) Income Before Income Tax",
        "label": "Schedule Of Components Of Income Before Income Tax [Table Text Block]",
        "documentation": "Tabular disclosure of components of income before income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Royalty Financing Obligation",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r18",
      "r52",
      "r55",
      "r68",
      "r132",
      "r133",
      "r907",
      "r909",
      "r1107",
      "r1212"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Deferred Tax Assets and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1194"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Reconciliation of Basic and Diluted Net Loss Per Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Effective Income Tax Rate Reconciliation",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r543",
      "r925",
      "r1190"
     ]
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Compensation Expense for Share-Based Compensation Arrangements",
        "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]",
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis",
        "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]",
        "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)."
       }
      }
     },
     "auth_ref": [
      "r1202",
      "r1203"
     ]
    },
    "avdl_ScheduleOfIncomeTaxPaymentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ScheduleOfIncomeTaxPaymentsTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Income Tax Provision (Benefit)",
        "label": "Schedule Of Income Tax Payments [Table Text Block]",
        "documentation": "Tabular disclosure of scheduled payments of income tax."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfInventoryCurrentTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfInventoryCurrentTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/InventoriesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Schedule of Principal Categories of Inventories",
        "label": "Schedule of Inventory, Current [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amount as of the balance sheet date of merchandise, goods, commodities, or supplies held for future sale or to be used in manufacturing, servicing or production process."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r97",
      "r98",
      "r99"
     ]
    },
    "us-gaap_ScheduleOfOtherAssetsNoncurrentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfOtherAssetsNoncurrentTextBlock",
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Other Non-Current Assets",
        "label": "Schedule of Other Assets, Noncurrent [Table Text Block]",
        "documentation": "Tabular disclosure of noncurrent assets."
       }
      }
     },
     "auth_ref": [
      "r1095"
     ]
    },
    "avdl_ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Prepaid Expenses and Other Current Assets",
        "label": "Schedule Of Prepaid Expenses and Other Current Assets [Table Text Block]",
        "documentation": "Tabular disclosure of the carrying amounts of prepaid expenses and other current assets."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r648"
     ]
    },
    "us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Percentage of Total Sales to Customers",
        "label": "Schedule of Revenue by Major Customers by Reporting Segments [Table Text Block]",
        "documentation": "Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfRevenuesFromExternalCustomersAndLongLivedAssetsTable",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "label": "Schedule of Revenues from External Customers and Long-Lived Assets [Table]",
        "documentation": "Disclosure of information about revenue from external customer and long-lived asset by geographical area. Long-lived asset excludes financial instrument, customer relationship with financial institution, mortgage and other servicing right, deferred policy acquisition cost, and deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r104"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, About The Company\u2019s Significant Expenses",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r38",
      "r39",
      "r40"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails",
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r15",
      "r135"
     ]
    },
    "avdl_ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Weighted-Average Assumptions",
        "label": "Schedule Of Share Based Payment Award Stock Options And Warrant Grants Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options and Warrants grants."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfStockByClassTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfStockByClassTable",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock, Class of Stock [Table]",
        "label": "Stock, Class of Stock [Table]",
        "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks."
       }
      }
     },
     "auth_ref": [
      "r50",
      "r51",
      "r52",
      "r53",
      "r54",
      "r55",
      "r131",
      "r132",
      "r133",
      "r134",
      "r210",
      "r211",
      "r212",
      "r291",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r778",
      "r779",
      "r780",
      "r781",
      "r911",
      "r1078",
      "r1103"
     ]
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r553",
      "r924"
     ]
    },
    "srt_ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccounts"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule II Valuation and Qualifying Accounts",
        "label": "SEC Schedule, 12-09, Schedule of Valuation and Qualifying Accounts Disclosure [Text Block]",
        "documentation": "The entire disclosure for valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r173",
      "r253"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r966"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r968"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r289",
      "r294",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r398",
      "r409",
      "r412",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r895",
      "r898",
      "r899",
      "r905",
      "r953",
      "r1230",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r177",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r324",
      "r325",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r796",
      "r797",
      "r798",
      "r851",
      "r853",
      "r856",
      "r858",
      "r864",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r881",
      "r912",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r952",
      "r957",
      "r1163",
      "r1230",
      "r1232",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting [Abstract]",
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r150",
      "r289",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r309",
      "r311",
      "r312",
      "r317",
      "r318",
      "r319",
      "r320",
      "r321",
      "r322",
      "r323",
      "r326",
      "r894",
      "r896",
      "r897",
      "r898",
      "r900",
      "r901",
      "r902"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment items",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r289",
      "r311",
      "r312",
      "r319",
      "r898"
     ]
    },
    "us-gaap_SellingAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling and marketing expenses",
        "label": "Selling and Marketing Expense",
        "documentation": "The aggregate total amount of expenses directly related to the marketing or selling of products or services."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Selling, general and administrative expenses",
        "label": "Selling, General and Administrative Expense",
        "documentation": "The aggregate total costs related to selling a firm's product and services, as well as all other general and administrative expenses. Direct selling expenses (for example, credit, warranty, and advertising) are expenses that can be directly linked to the sale of specific products. Indirect selling expenses are expenses that cannot be directly linked to the sale of specific products, for example telephone expenses, Internet, and postal charges. General and administrative expenses include salaries of non-sales personnel, rent, utilities, communication, etc."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "us-gaap_SellingGeneralAndAdministrativeExpensesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SellingGeneralAndAdministrativeExpensesMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Selling, general and administrative",
        "label": "Selling, General and Administrative Expenses [Member]",
        "documentation": "Primary financial statement caption encompassing selling, general and administrative expense."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SeniorNotesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SeniorNotesMember",
     "presentation": [
      "http://www.avadel.com/role/RoyaltyFinancingObligationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Senior Notes",
        "label": "Senior Notes [Member]",
        "documentation": "Bond that takes priority over other debt securities sold by the issuer. In the event the issuer goes bankrupt, senior debt holders receive priority for (must receive) repayment prior to (relative to) junior and unsecured (general) creditors."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based compensation expense",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period",
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition."
       }
      }
     },
     "auth_ref": [
      "r920"
     ]
    },
    "avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards that did not have an accounting grant date (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award, Awards With No Grant Date",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award, Awards With No Grant Date"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in shares)",
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r510"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "avdl_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Grants In Period Weighted Average Exercise Price",
        "documentation": "The weighted average exercise price of equity instruments other than options granted in period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average grant fair value of free share awards (in dollars per share)",
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r508"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Outstanding, beginning balance (in shares)",
        "periodEndLabel": "Outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Free Share Activity and Other Data, Nonvested [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Nonvested free share award, beginning balance (in dollars per share)",
        "periodEndLabel": "Nonvested free share award, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r506"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Free Share Activity and Other Data, Weighted Average Grant Date Fair Value [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Vested (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vested (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement."
       }
      }
     },
     "auth_ref": [
      "r509"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected dividend yield",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Expected volatility",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate",
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Risk-free interest rate",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r520"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails",
      "http://www.avadel.com/role/ShareBasedCompensationStockbasedCompensationExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r489",
      "r491",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares authorized (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized",
        "documentation": "Number of shares authorized for issuance under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r922"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares available for issuance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r512"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Expired (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Expirations in Period",
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Grant date fair value of options granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r511"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options outstanding, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options outstanding, beginning balance (in shares)",
        "periodEndLabel": "Stock options outstanding, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Outstanding [Roll Forward]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Stock options outstanding, beginning balance (in dollars per share)",
        "periodEndLabel": "Stock options outstanding, ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r497",
      "r498"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercisable (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r514"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails",
      "http://www.avadel.com/role/ShareBasedCompensationRestrictedShareActivityDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Award [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Exercised (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expired (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired."
       }
      }
     },
     "auth_ref": [
      "r504"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r503"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r501"
     ]
    },
    "us-gaap_ShareBasedCompensationAwardTrancheOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheOneMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche One",
        "label": "Share-Based Payment Arrangement, Tranche One [Member]",
        "documentation": "First portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheThreeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheThreeMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Three",
        "label": "Share-Based Payment Arrangement, Tranche Three [Member]",
        "documentation": "Third portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationAwardTrancheTwoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationAwardTrancheTwoMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Two",
        "label": "Share-Based Payment Arrangement, Tranche Two [Member]",
        "documentation": "Second portion of award under share-based payment arrangement differentiated by vesting feature, including, but not limited to, performance measure or service period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r488",
      "r496",
      "r515",
      "r516",
      "r517",
      "r518",
      "r521",
      "r527",
      "r528",
      "r529",
      "r530"
     ]
    },
    "us-gaap_ShareBasedPaymentArrangementEmployeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ShareBasedPaymentArrangementEmployeeMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement, Employee",
        "label": "Share-Based Payment Arrangement, Employee [Member]",
        "documentation": "Recipient, of award granted under share-based payment arrangement, over whom grantor exercises or has right to exercise sufficient control to establish employer-employee relationship based on law of pertinent jurisdiction. Includes, but is not limited to, nonemployee director treated as employee when acting as member of board of directors, if elected by grantor's shareholders or appointed to board position to be filled by shareholder election when existing term expires."
       }
      }
     },
     "auth_ref": [
      "r491",
      "r493",
      "r494",
      "r495",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510",
      "r511",
      "r512",
      "r513",
      "r514",
      "r517",
      "r518",
      "r519",
      "r520",
      "r521"
     ]
    },
    "avdl_ShareBasedPaymentArrangementTrancheFourMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ShareBasedPaymentArrangementTrancheFourMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tranche Four",
        "label": "Share-Based Payment Arrangement, Tranche Four [Member]",
        "documentation": "Share-Based Payment Arrangement, Tranche Four"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage",
        "documentation": "Percentage of vesting of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1164"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration period (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period",
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r921"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationFairValueAssumptionsDetails",
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average period for unrecognized expense (in years)",
        "verboseLabel": "Expected term (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r517"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options exercisable, Aggregate Intrinsic Value",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options exercisable, Weighted Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r56"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Stock options outstanding, Weighted Average Remaining Contractual Life (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r513"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchase price of common stock, percentage",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Purchase Price of Common Stock, Percent",
        "documentation": "Purchase price of common stock expressed as a percentage of its fair value."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SharesOutstanding",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Shares, Outstanding",
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury."
       }
      }
     },
     "auth_ref": []
    },
    "avdl_ShelfRegistrationStatementOnFormS3Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ShelfRegistrationStatementOnFormS3Member",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shelf Registration Statement On Form S-3",
        "label": "Shelf Registration Statement On Form S-3 [Member]",
        "documentation": "Shelf Registration Statement On Form S-3"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r243"
     ]
    },
    "avdl_SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember",
     "presentation": [
      "http://www.avadel.com/role/PropertyandEquipmentnetDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPropertyandEquipmentUsefulLivesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Software, office and computer equipment",
        "label": "Software and Software Development Costs, Office Equipment, and Computer Equipment [Member]",
        "documentation": "Software and Software Development Costs, Office Equipment, and Computer Equipment [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r541"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.avadel.com/role/SegmentInformationSegmentReportingInformationAbouttheCompanysSignificantExpensesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r149",
      "r150",
      "r197",
      "r289",
      "r294",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r302",
      "r303",
      "r304",
      "r305",
      "r306",
      "r307",
      "r308",
      "r310",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r316",
      "r317",
      "r319",
      "r320",
      "r321",
      "r326",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r398",
      "r401",
      "r409",
      "r412",
      "r751",
      "r752",
      "r753",
      "r754",
      "r755",
      "r756",
      "r757",
      "r758",
      "r759",
      "r760",
      "r761",
      "r895",
      "r898",
      "r899",
      "r905",
      "r953",
      "r1230",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_StatementClassOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementClassOfStockAxis",
     "presentation": [
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Stock [Axis]",
        "label": "Class of Stock [Axis]",
        "documentation": "Information by the different classes of stock of the entity."
       }
      }
     },
     "auth_ref": [
      "r167",
      "r210",
      "r211",
      "r212",
      "r245",
      "r277",
      "r278",
      "r281",
      "r284",
      "r291",
      "r292",
      "r362",
      "r422",
      "r424",
      "r425",
      "r426",
      "r429",
      "r430",
      "r461",
      "r462",
      "r464",
      "r465",
      "r467",
      "r622",
      "r778",
      "r779",
      "r780",
      "r781",
      "r784",
      "r785",
      "r786",
      "r787",
      "r788",
      "r789",
      "r790",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r808",
      "r829",
      "r847",
      "r859",
      "r860",
      "r861",
      "r862",
      "r863",
      "r1078",
      "r1103",
      "r1118"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r94",
      "r95",
      "r195",
      "r230",
      "r231",
      "r232",
      "r254",
      "r255",
      "r256",
      "r260",
      "r267",
      "r269",
      "r271",
      "r290",
      "r363",
      "r366",
      "r399",
      "r468",
      "r569",
      "r570",
      "r576",
      "r577",
      "r578",
      "r582",
      "r584",
      "r585",
      "r590",
      "r591",
      "r592",
      "r593",
      "r594",
      "r596",
      "r599",
      "r624",
      "r625",
      "r626",
      "r627",
      "r628",
      "r629",
      "r632",
      "r634",
      "r651",
      "r745",
      "r766",
      "r767",
      "r768",
      "r784",
      "r847"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r175",
      "r177",
      "r180",
      "r182",
      "r183",
      "r184",
      "r185",
      "r186",
      "r187",
      "r188",
      "r189",
      "r190",
      "r191",
      "r192",
      "r324",
      "r325",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r698",
      "r699",
      "r700",
      "r701",
      "r702",
      "r703",
      "r704",
      "r705",
      "r706",
      "r707",
      "r708",
      "r709",
      "r710",
      "r711",
      "r712",
      "r713",
      "r714",
      "r715",
      "r716",
      "r717",
      "r718",
      "r719",
      "r720",
      "r796",
      "r797",
      "r798",
      "r851",
      "r853",
      "r856",
      "r858",
      "r864",
      "r868",
      "r869",
      "r870",
      "r871",
      "r872",
      "r873",
      "r874",
      "r875",
      "r876",
      "r881",
      "r912",
      "r942",
      "r943",
      "r944",
      "r945",
      "r946",
      "r947",
      "r948",
      "r949",
      "r952",
      "r957",
      "r1163",
      "r1230",
      "r1232",
      "r1233",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1243",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248",
      "r1249",
      "r1250",
      "r1251",
      "r1252",
      "r1253",
      "r1254",
      "r1255",
      "r1256",
      "r1257",
      "r1258",
      "r1259"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r290",
      "r634",
      "r687",
      "r776",
      "r795",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r808",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r830",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r847",
      "r958"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Comprehensive Income [Abstract]",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StatementTable",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r254",
      "r255",
      "r256",
      "r290",
      "r328",
      "r634",
      "r687",
      "r776",
      "r795",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r806",
      "r808",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r821",
      "r822",
      "r823",
      "r824",
      "r825",
      "r827",
      "r830",
      "r831",
      "r833",
      "r834",
      "r835",
      "r836",
      "r837",
      "r838",
      "r839",
      "r840",
      "r841",
      "r842",
      "r843",
      "r844",
      "r847",
      "r958"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange/Settlement of Notes (in shares)",
        "label": "Stock Issued During Period, Shares, Conversion of Convertible Securities",
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r52",
      "r91",
      "r94",
      "r134",
      "r448"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share purchase plan share issuance (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Ownership Plan",
        "documentation": "Number of shares of capital stock issued (purchased by employees) in connection with an employee stock ownership plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r60",
      "r90",
      "r91",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Issuance of common stock, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r134",
      "r778",
      "r847",
      "r860"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesOther": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesOther",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting of restricted shares (in shares)",
        "label": "Stock Issued During Period, Shares, Other",
        "documentation": "Number of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/ShareBasedCompensationStockOptionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options (in shares)",
        "negatedTerseLabel": "Exercised (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period",
        "documentation": "Number of share options (or share units) exercised during the current period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r134",
      "r502"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exchange/Settlement of Notes",
        "label": "Stock Issued During Period, Value, Conversion of Convertible Securities",
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r94",
      "r95",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee share purchase plan share issuance",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r134"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r90",
      "r91",
      "r134",
      "r784",
      "r847",
      "r860",
      "r964"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueOther",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Vesting of restricted shares",
        "label": "Stock Issued During Period, Value, Other",
        "documentation": "Value of shares of stock issued attributable to transactions classified as other."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise of stock options",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "documentation": "Value of stock issued as a result of the exercise of stock options."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r91",
      "r94",
      "r95",
      "r134"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ComprehensiveLossDetails",
      "http://www.avadel.com/role/ConsolidatedBalanceSheets",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total shareholders\u2019 equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r91",
      "r94",
      "r95",
      "r122",
      "r810",
      "r826",
      "r848",
      "r849",
      "r940",
      "r965",
      "r1105",
      "r1146",
      "r1209",
      "r1262"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Shareholders\u2019 equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockholdersEquityNoteAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "StockholdersEquityNoteAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' Equity Note [Abstract]",
        "label": "Stockholders' Equity Note [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubleaseIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubleaseIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails": {
       "parentTag": "us-gaap_LeaseCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/LeasesComponentsofleasecostsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Sublease income",
        "label": "Sublease Income",
        "documentation": "Amount of sublease income excluding finance and operating lease expense."
       }
      }
     },
     "auth_ref": [
      "r642",
      "r939"
     ]
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.avadel.com/role/ConsolidatedStatementsofShareholdersEquity",
      "http://www.avadel.com/role/EquityInstrumentsandTransactionsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Supplemental disclosures of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1034"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r566"
     ]
    },
    "avdl_TaxLiabilitiesAndOtherNoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "TaxLiabilitiesAndOtherNoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails": {
       "parentTag": "us-gaap_OtherLiabilitiesNoncurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/OtherAssetsandLiabilitiesOtherNonCurrentLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax liabilities",
        "label": "Tax Liabilities And Other Noncurrent Liabilities",
        "documentation": "Tax Liabilities And Other Noncurrent Liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_ThreeCustomersMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "ThreeCustomersMember",
     "presentation": [
      "http://www.avadel.com/role/RevenueRecognitionNarrativeDetails",
      "http://www.avadel.com/role/RevenueRecognitionScheduleofPercentageofTotalSalestoCustomersDetails",
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Three customers",
        "label": "Three Customers [Member]",
        "documentation": "Three Customers"
       }
      }
     },
     "auth_ref": []
    },
    "srt_TitleOfIndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title and Position [Axis]",
        "label": "Title and Position [Axis]",
        "documentation": "Information by title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": [
      "r1126",
      "r1218"
     ]
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Relationship to Entity [Domain]",
        "label": "Title and Position [Domain]",
        "documentation": "Title and position of individual or group within organization."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1033"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.avadel.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails",
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r330",
      "r331",
      "r332",
      "r333",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r339",
      "r340",
      "r341",
      "r342",
      "r343",
      "r344",
      "r345",
      "r346",
      "r347",
      "r348",
      "r349",
      "r350",
      "r351",
      "r352",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r359",
      "r456",
      "r466",
      "r597",
      "r621",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r661",
      "r662",
      "r663",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r746",
      "r926",
      "r929",
      "r931",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r941",
      "r1082",
      "r1083",
      "r1084",
      "r1085",
      "r1086",
      "r1087",
      "r1088",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1201",
      "r1204",
      "r1205",
      "r1206",
      "r1207",
      "r1208"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1058"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1059"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1057"
     ]
    },
    "avdl_U.S.HoldingsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "U.S.HoldingsMember",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Holdings",
        "label": "U.S. Holdings [Member]",
        "documentation": "U.S. Holdings [Member]"
       }
      }
     },
     "auth_ref": []
    },
    "country_US": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/country/2024",
     "localname": "US",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.avadel.com/role/IncomeTaxesIncomeLossBeforeIncomeTaxesDetails",
      "http://www.avadel.com/role/SegmentInformationLongLivedAssetsbyGeographicRegionDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S.",
        "label": "UNITED STATES"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "presentation": [
      "http://www.avadel.com/role/FairValueMeasurementDetails",
      "http://www.avadel.com/role/MarketableSecuritiesScheduleofContractualMaturityDatesDetails",
      "http://www.avadel.com/role/MarketableSecuritiesSummaryofAvailableforsaleSecuritiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government securities - U.S.",
        "label": "US Government Agencies Debt Securities [Member]",
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB)."
       }
      }
     },
     "auth_ref": [
      "r890",
      "r914",
      "r1228"
     ]
    },
    "us-gaap_UndistributedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UndistributedEarnings",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unremitted earnings",
        "label": "Undistributed Earnings, Basic",
        "documentation": "The earnings that is allocated to common stock and participating securities to the extent that each security may share in earnings as if all of the earnings for the period had been distributed."
       }
      }
     },
     "auth_ref": [
      "r280",
      "r282"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r537",
      "r553",
      "r924"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Settlements",
        "label": "Unrecognized Tax Benefits, Decrease Resulting from Settlements with Taxing Authorities",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from settlements with taxing authorities."
       }
      }
     },
     "auth_ref": [
      "r554",
      "r924"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax penalties and interest accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r924"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income tax penalties and interest expense",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r551",
      "r924"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsPeriodIncreaseDecrease",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases for tax positions of prior years",
        "label": "Unrecognized Tax Benefits, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in unrecognized tax benefits attributable to uncertain tax positions taken in tax returns."
       }
      }
     },
     "auth_ref": [
      "r1193"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesUnrecognizedTaxBenefitDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Statute of limitations expiration",
        "label": "Unrecognized Tax Benefits, Reduction Resulting from Lapse of Applicable Statute of Limitations",
        "documentation": "Amount of decrease in unrecognized tax benefits resulting from lapses of applicable statutes of limitations."
       }
      }
     },
     "auth_ref": [
      "r555"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits",
        "label": "Unrecognized Tax Benefits that Would Impact Effective Tax Rate",
        "documentation": "The total amount of unrecognized tax benefits that, if recognized, would affect the effective tax rate."
       }
      }
     },
     "auth_ref": [
      "r556",
      "r924"
     ]
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.avadel.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r35",
      "r36",
      "r37",
      "r155",
      "r156",
      "r159",
      "r160"
     ]
    },
    "us-gaap_ValuationAllowanceOfDeferredTaxAssetsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowanceOfDeferredTaxAssetsMember",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Valuation Allowance of Deferred Tax Assets",
        "label": "SEC Schedule, 12-09, Valuation Allowance, Deferred Tax Asset [Member]",
        "documentation": "Valuation allowance of deferred tax asset attributable to deductible temporary difference and carryforward."
       }
      }
     },
     "auth_ref": [
      "r1108",
      "r1109",
      "r1110",
      "r1111",
      "r1112"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesBalance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesBalance",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Balance at beginning of period",
        "periodEndLabel": "Balance at end of period",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Amount",
        "documentation": "Amount of valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r252"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesChargedToCostAndExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesChargedToCostAndExpense",
     "crdr": "credit",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Additions, Charge to Cost and Expense",
        "documentation": "Amount of increase in valuation and qualifying accounts and reserves from charge to cost and expense."
       }
      }
     },
     "auth_ref": [
      "r249"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDeductions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDeductions",
     "crdr": "debit",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Deductions",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Deduction",
        "documentation": "Amount of decrease in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r251"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesDomain",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves [Domain]",
        "documentation": "Valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesPeriodIncreaseDecrease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesPeriodIncreaseDecrease",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Changes",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves, Period Increase (Decrease)",
        "documentation": "Amount of increase (decrease) in valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r1113"
     ]
    },
    "us-gaap_ValuationAllowancesAndReservesTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "ValuationAllowancesAndReservesTypeAxis",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "label": "SEC Schedule, 12-09, Valuation Allowances and Reserves Type [Axis]",
        "documentation": "Information by valuation and qualifying accounts and reserves."
       }
      }
     },
     "auth_ref": [
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "srt_ValuationAndQualifyingAccountsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "srt_ValuationAndQualifyingAccountsDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureLineItems",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "srt_ValuationAndQualifyingAccountsDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2024",
     "localname": "ValuationAndQualifyingAccountsDisclosureTable",
     "presentation": [
      "http://www.avadel.com/role/ScheduleIIValuationandQualifyingAccountsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "label": "SEC Schedule, 12-09, Valuation and Qualifying Accounts Disclosure [Table]",
        "documentation": "Disclosure of information about valuation allowance and qualifying account and reserve."
       }
      }
     },
     "auth_ref": [
      "r168",
      "r169",
      "r170",
      "r171",
      "r172",
      "r248",
      "r249",
      "r250",
      "r251",
      "r252"
     ]
    },
    "avdl_VestOneYearFollowingAchievementOfMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "VestOneYearFollowingAchievementOfMilestonesMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest One Year Following Achievement of Milestones",
        "label": "Vest One Year Following Achievement Of Milestones [Member]",
        "documentation": "Vest One Year Following Achievement Of Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "avdl_VestUponTheAchievementOfCertainRegulatoryMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.avadel.com/20241231",
     "localname": "VestUponTheAchievementOfCertainRegulatoryMilestonesMember",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vest Upon the Achievement of Certain Regulatory Milestones",
        "label": "Vest Upon The Achievement Of Certain Regulatory Milestones [Member]",
        "documentation": "Vest Upon The Achievement Of Certain Regulatory Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_VestingAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingAxis",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Axis]",
        "label": "Vesting [Axis]",
        "documentation": "Information by vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "us-gaap_VestingDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "VestingDomain",
     "presentation": [
      "http://www.avadel.com/role/ShareBasedCompensationNarrativeDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting [Domain]",
        "label": "Vesting [Domain]",
        "documentation": "Vesting schedule of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1164",
      "r1165",
      "r1166",
      "r1167",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1172",
      "r1173",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178",
      "r1179",
      "r1180",
      "r1181",
      "r1182",
      "r1183",
      "r1184",
      "r1185",
      "r1186",
      "r1187",
      "r1188",
      "r1189"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment",
     "calculation": {
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Effect of dilutive securities\u2014employee and director equity awards outstanding, preferred shares and 2023 Notes (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment",
        "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation."
       }
      }
     },
     "auth_ref": [
      "r1119"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "calculation": {
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding - diluted (in shares)",
        "totalLabel": "Diluted shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r276",
      "r284"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingAbstract",
     "presentation": [
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average shares:",
        "label": "Weighted Average Number of Shares Outstanding, Diluted [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2024",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "calculation": {
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails": {
       "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.avadel.com/role/ConsolidatedStatementsofLoss",
      "http://www.avadel.com/role/NetLossPerShareReconciliationofBasicandDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted average number of shares outstanding - basic (in shares)",
        "terseLabel": "Basic shares (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r275",
      "r284"
     ]
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2024",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-12"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "20",
   "Topic": "205",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "205",
   "SubTopic": "20",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "210",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-16"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-21"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "275",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-4"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "460",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482425/460-10-50-8"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-5"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-2"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "470",
   "SubTopic": "50",
   "Section": "40",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481303/470-50-40-4"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "480",
   "SubTopic": "10",
   "Section": "55",
   "Paragraph": "63",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-63"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-12"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "20",
   "Section": "55",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481089/718-20-55-13"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "40",
   "Section": "25",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480637/718-40-25-10"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "805",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-4"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "815",
   "SubTopic": "40",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-20"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "825",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "825",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483475/205-20-45-11"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-3A"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4A"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-4B"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5A"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5B"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5C"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-5D"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/220/tableOfContent"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r106": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r107": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r108": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r109": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r110": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r111": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r112": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r113": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r114": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r115": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r116": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r117": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r118": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r119": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r120": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r121": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r122": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r123": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.BB)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480581/330-10-S99-2"
  },
  "r124": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r125": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r126": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-2"
  },
  "r127": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3A"
  },
  "r128": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r129": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r130": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r131": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r132": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r133": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r134": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r135": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r136": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r137": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-3"
  },
  "r138": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r139": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r140": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r141": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r142": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r143": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r144": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r145": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r146": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r147": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r148": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r149": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r150": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r151": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "270",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-6"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "SubTopic": "35",
   "Topic": "720",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "250",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/250/tableOfContent"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column C",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "09",
   "Publisher": "SEC"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-7"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483489/210-10-50-1"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-11"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-17"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "5",
   "Subparagraph": "(SAB Topic 11.M.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-5"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480530/250-10-S99-6"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-3"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "66",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-66"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-3"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476173/280-10-65-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/330/tableOfContent"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-1"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "330",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483080/330-10-50-4"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-1"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482598/350-20-45-2"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-2"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-1"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-6"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-12"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-15"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-9"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483406/720-35-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(8)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479907/805-20-50-5"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "230",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-1"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "330",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478411/912-330-50-1"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "926",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483194/926-20-65-2"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(10)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-3A"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-2"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "27",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-27"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478494/946-205-50-7"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478297/946-220-50-3"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-1"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "450",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477850/954-450-50-1"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-8"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-11"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-6"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "720",
   "SubTopic": "35",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483385/720-35-55-1"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "SubTopic": "825",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Subparagraph": "(ii)",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "1",
   "Publisher": "SEC"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "6",
   "Subsection": "04",
   "Paragraph": "12",
   "Subparagraph": "(b)(1)",
   "Publisher": "SEC"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483504/205-10-50-1"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column C)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "4",
   "Subparagraph": "(SX 210.12-09)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-4"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "55",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-55"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/320/tableOfContent"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-20/tableOfContent"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/350-30/tableOfContent"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405/tableOfContent"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "460",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482050/460-10-25-4"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-3"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>125
<FILENAME>0001012477-25-000010-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001012477-25-000010-xbrl.zip
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MM0X49#[N/6FHD%H@#7% ([^=BNB$BCY1<='4\>>SWZ4EC"YZ$?&PRH$E.RY
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MS'[,>3#]'VXU,P2\Z;-:F;;@VP8VTPTF,5_\YO2A/>K-\3?@@XNX1R,!'[$
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M9K-53DG(+W1)V].VS;88]102LL3I;'P VR4'WFB6/N<HT1F=:= \T=GA;8L
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M]=L_SVQV _]9UD7^P_\"4$L#!!0    ( !E*8UKAZSF0:P\  #-9   2
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M/\!4P%2+$9>.HJ=/>NJT,DT*J[PFCT2010$-R[21'U^012Y.^J1CL8PK51[
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M,%Y'!HX+:CC2B.M(XK#+I(17X\+;4 LQG6/LI"Y->G: BZXP( D2'@&'R$?
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M5S??NJOMW'%<759;E>'K_,ZN9G4]7,W\M@YIM=FW5J_=['89=5BYN2S,-_*
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M904#A(=TK(ZQ"++?[ A'(<UD*QCC!]Y;:8_[BD\[.]IPH>\,K/>^??,_RL#
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M^RU7)K)GJY-*PB<0LL%&_=HB:8RW.IC"<'D+FZ2P*0PZ1&>J\$Y-6!F/CRC
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M]U@:S=6>[:VW/88<!7XX-G<3P+V18\/9KY8K6*0X1C?28))JZ\7=2N:Q(-#
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M5<T'PN/RUC,(Y"F7I'G-<HBD<3J$T\$KY<4ZQ*XS\T*!]+@K@JTWX]Z5<V/
M3XK!1EDZ4<0$*><DOFSG&HS&Y=L<GJX_+]23 @D*QO:N9-(TDSBQ>E>&0O;<
MV@(S;T(AW0I\?N-U94&GE:<OL8IL/)U6+.)K!^P5VB@I]JQ%X0$[P*-_@K/W
MQN'+CA&3<N_[].U^_NL3 NF1P>RR8,E 90=(/SSBW8YN%C%OJH0;Z?LH504!
M3*XNHV1>$O!J2 2\["!.R%[JWE^,TYR:FDJQK/UC%O)CP;V)@:OQ)6MWZJ%^
M&."RNH],XC>1%O)=!E/Q[VL^1\BLC)WK!?](58,E<U$8$VJ#G_QOBE/9^<9B
M]F3OE+K[ \WC(Z\HQ1,KV=H*A9V7"3>A86CINB([=(R'R!Z'M,$+&! B!8U\
M-MD2X>P*/N:N[,YOZ.9!NO'< 4,U<,:8!K#C(XH,PYO@R,EI=]R?P[J#O0FS
M(.52%Q*A= FHGHJ497/@[>YZ7FT%322V$PH9*%SM^/3AP&QENQOAT(LPB[5&
ME8:^JHM]D",U_%XWW&Y*[MQR97I'#[!^TKOMKK\'O":/5W5<=?8M0S8VVGGL
M7-:E;S0,^("^%NRE^TRU5/C$JP2X^NNT.0:0E.52$?[6!F2&MFK9(1]%!(1/
MP>N5:H4OZ:JG:V!1G"/J10X,XGW-^"B*X1<82FQ =N=4&NDPP9YM+:4Q<[B0
M@3,M#.]K&^=*0XXB&%"C$INYP0QM7M:H)YA/26[A 8!=#J"_J[S+"H5YDYCC
M+0/O--JN5'U-S9V7I;FLHPD'?_Q6(),-\5LTXF5#F9K +;>4V^0S'$17(NWI
M2C:1QW<?[C2N@[CR_IKT#K14K+K(C%27VPK6>9D'=4WSN%I(T0WZ-[ 3[GE:
M9_?]D].09B&4TNJKJA*-!\5#Y%L?D;Q&[P^71&HO=2$#]9SD%&]'H\%#I[V,
M2%NO.TGVZ, O+(TZ0!HD-J<0#6-#4.59XN/U\49S'A;Q:FJU#FC*O8-0Y1@-
MBH](E"5.Y<&0!!=5VA5Y3O=2\%2LG_#+F]D Z%KW;6'?B6O86K@,98$5HX5D
M9&&U4D<B,+B0I5M":],LE')<9V!$6DK6$12-#TQB!*7C1#B'3;'#2M;#3@C'
MR%WW_B2:I,B,!=7!C:,H5-#F,753:H0($!O0V^X:G)*CM]XU>(YF-8$+< LM
MN7\*Y99P8YCG2@=(9G#R]X#$DQ(JLKO49,U"B]Q-B\U"+CZB!.8,2P\80[7A
M5'L#P8UMF._4FL$8"!L^@L/\G=.A&02;5O$%-]*4=,><7E=HLPY_%=-75(C:
MF?ATBZPK,C@3?>$>H<YF6 /9)W6@).PV/HTI+=XD3#\:V HZ._2-E_ #/M]1
M?!F;(E\9HF;!YPWF2,(XU>8<"2:&-HAK4B/8.<*]9;/$WL;TE@;WP%(U/);+
M4U49P5DLBZQI)&U?J9^K<V,Q#I5O#XF:L")YC4<5>:V)LM+V2< 6/4S!,[QK
M_;[9OOYB  [-D4@R>4=RLM-VV787\40L[]KCOLK_Y,YXURFYF&.C-^Q\9Y:'
M@4;DSDH%L:D.ME)"YK:%F) (NM7FN!MY!S[NQ4?(KFT5(<"51S>)+X)J@W7
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MGQ"686YI/8/0)5)<F3 F>:P:KA1)NR[KMCS?];WABI2 LXU+B)I*)XTC!>[
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MHUWNPKL&^;<6TLJ=W@0VFE:%IAK\LFH7#[[B][$,=H$_]Q37"Z.ZU/ /"1E
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M__-]I6$<[^+%^IHL;_@),:I=U:-X^-9W_=9#MG%PT;Z_"?7RX+5U:Z+WR =
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MR4 '8VK?/'1FP@\Y/-<L*^Y-I2.=B2H7QO'_FW>AC/("[ ]VD:$GSU[>3U/
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M)Q-7N\U\T4-4[ N?0CB 35:B''HEJF!8.-5 ,V_GP(HHH4I.!GL0(UL,[/Q
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MWJFL\D1Q]A=]@H43<H26S.@YE1_:1B4G2_6UI;0T-XZ 8L$58.74]%>$]RO
MX(V^EX%+5E@0BV*0,MW&&0ZD\HBS*O"3S50"0_ #\-Q(@89(PV6ERUM> T-
M]U"39^IFTF0/CH$'Q\ ?=PSX+2V *+TZQ]SC101#BYE3*9-A;F)@\=X+K,7/
MH-R;$H42EUU?:;A_?Y'3Q_<X<GK?.B,9*?YXGS5E3SL.M:=W@]K3EFO;WVLU
M^G%+][E;Q7G?]./'7Z8?;Z30MD)>#PJM4VCID'5 3RCV[0K;O:#FW9X'WR/D
MW#IG)$XWL$JJ<FB.SG83R!9!V6CH\)XF2'ZF5ARG6/)Z9*EMY[>>HA$-3'Y3
M2LS+,XMH-@ 3HR3Q&[BXU1S[_V#!+[.F,!3.!DDP%HTH8#T?ERHV#E^$P/JU
MH3C,.86+-=*A%*DS[JGNF+T3"(N;%3$%60S5T<B"9WNDB>:"B<;WWZ"BLLF$
MB@W26-EZ=K2SM(F936ZDDFN\,0Z:W"R*W%"/7*AJZMZ[2*5:(^V9:[[G!5@1
M*0DON4Y!/B"9P)-IW=(R;N;(XV.'2$;3:M0*M\/I*;L'G?Q\&1^(/CIF9Z!E
M%]6JC2YMVB9^C?5E27PL5K5$^D98XAU0?B[V4_GIYVIDMK/7\+=9@>0%_V5<
MFA4_AM_>-S%09 4F^/U7@WQ.&)ZZVVD=)I.[TFLD@9677Z9*C-HMLE(*1\E^
MC2))T)[#FM?N8-^0,* <C\W4NLW5Q+M03D(EA%8(]QV;/+4T1=($;IA@W;0M
MVL57 YOZ-FO# EKR+:FZ8=ATF9H#218';6GE]K3J>?^F^O.W7>A;:(&$,'*K
METG'/M3,^BD;=NMO")IH2M33NFK_!2/>.@4%7/Z3D<RK#Y!9Z[93'+23.5R+
MP#F: "'?^&6+4I-LUJ.^(NI45,$C)BGARA3!(*K^"7_''9/-ICZY=Z+Q-ZZN
ML?N2KR^[?YU0&X4P28\1M*MJCH)"(VUIUV?+"',V8I.,O4I2T'O,>G/AY@S0
MF8M;MI(] ?7564#8H>O97G2R?+IG3.'*94&U^,-N]LOY_D(&%_<F9+!/YWGH
M%+]>9UOE/=++JR#E=YPY'T6/D=E>W+W"W/8RMRRZ(7^S?UE+[!VXPEA?#LFX
MG<?Y<$-TQ!WC'WH,@M#UMO>ML@.)=;EG$@M.8-:0^V,']52GH7;:GYFSRSU_
M"?;;.?224RZ!^N&DD<L7P]I7JZ_I\6.8SZWI<C?[IE&5E$^<P&#*G2P#O()+
MZ$H#_Y$M2()%:KST'C]Y)_5XNKW^D K:Y,D:\P(1%EYZFV$XU <>W09LM<L@
M38<JG$35E!0\7!19&B]'MB/TR&NA$7IKQ+O7BX[]C'8\4-"RD)[V4MJ/F*)[
M+8WF=N_VUMO2.(.4S)IY)0G;J^/UO!=F+15+* 83+&QK326%I.OF'PWF77FX
M=6^*9F/'4I_-6#<LJ_RP$2V.)Z>LP86C-*O 6723M*QJ\@V5-0C(8WW<N=U"
M8QSXAJ;CKTZ)XTOGTJ,T:K4S;U67PZWFF7L574J1ICC'WH!(;;J(^/?X%5D&
M9"&.K=*(4(/1'=*&WU_&,]P49 7C80A PV6 I,(0:C"D3E%]48($-&4\4Y+Y
M2EUFD _1+_B)^?JP#<5<T2.N&\-'EI :/Z\R/:]L6M43F*!Y1MC*T)6*"F,+
M816EN@&R7U+Y+4X3GG,QKA"K>/_(8KA+1C]9M')"G>CI[7(0*-E$-(4E*=R#
MGKPZ"QCE#-7*Q6KI^%(@W6G4EH/SYT&HUK31=+W*@/U$:"K"@_M?GC0U59+,
MBJ7*O"QJK\PA7=(7I1^U>2USIK0T@@R3?JNZB#_9YDARPG@:Z./&87,RHP^O
M\/)U)=$;X1&Y>#;@/K-F%,Y":83+?9T66<!DOP-J'B[4OQ$UKZ?A V%,%,N3
M<(;[^G HE]2OO'PW3_3JDJVO34#U]H?3];IZD!YN610^7& H!]+JS[94]%@Y
M?^957VE!/=8M@*V%BX)'5H-TI /38-",3G2$RE=FG$HEQG>% 5E,;2RU%(,-
M %R:F]Q5$=9C,(V>W2M$S72B(T.'!/<Z; <JU^YLY6TN%Y-1D30HALNE03%K
MWZ83\-J:,X5TO_N"P1B\#>8]@T0$):TBWF.2H)5X0'I@*;U9T(5?CH/6B>4L
MT5O99)JY$?QQ?QG2<!N#C1B25T04A$A%G>Z*63I.3>&B@! ?',O.L?SDGCJ6
MO_ ,;-$5YQ7S[+$75]EV@[IF:&+>,-JIN-,:-)V6?-92!C;<Q'[=,%)F6Z9]
MUTFBJG7S0WMJU#;@Q>9N#V=%@'*!M?_RZ5&F)[ EC\^/G_:2QSW!*3S;,P?O
M%6\X6:"[T"SF. JJ[3*5"U7>+J7 AN8WCSRT,V/)?]"T/)<A6MNX :AM?'1P
M=G((FM"R\A0C.G&+VM0AM:HKM<"%0VZ5$_M'9;@$\@W__:#82B?.H/P9FF$I
M?FL/]]J9LN/,K-"XJ3LIE_:A/7=S.RKI=E-Q@0"J9JQID+!+?,5-47["0AG4
MA#01SQDYQ9(4*XJ)XX:T"BX#S?F;8=&;&T7]J$BAQLIE>JHE$Z1/Z0B=^[)$
MB8LLR;P.Q5V$5:J0JN!_5W>MV^Z"S7F_G7)'9SV.[%FR)((EFS'HEDA*@A2T
MGH!*VG>YI2C$DG$UDE"V6(%E$-]<4ET*4?M>V<T>@YUYL(*ZP7B;T,F0/JTW
M0,4BF+*=>/ ["!^,KDZ<B*D8ZEX'?42H5+7IIB2'W3LP+87>/PM^ W@9;ZT^
MV?*>4@T]])2;JYADZVZ)3CR&J7 .)*U@M8UC>#ADD9*N;-88A&_H.E(!2'ZA
MZ<:/#8C3)'5-,EH>IA$77VO&'TTH@IH8=<,  HGRP?LM'%/(D(3Q6I/*;9.S
MI<!84]-2+1P#XO+CU\2TI'L\KFN=9IL<F;8;0AHR"7*9HWXS02X'$,]G,@"*
M]0]6P_*F$58OA\_7U;_:4)\Y?SJ@[6ZDSMSJ4=O2:$"AWR^5AN@K0:@#LAL@
M(:\9 QS45PX]_Q+AMKL)O=HKK\)P$/D#)L)C^X^-7#0]&8K Z?"(MV2!LFGO
MQIXBGL$QHJ2-R*F**)X5A!7O90&G?0A7TI#:;Q%U-*L*5]_/?HEO#S47<O?7
M/E=MKT(H$7JZ1&P]+6HW8X2^C6#*SOJBSG4HU$:Q]9R/))M!=;G)C<YTYS6I
M0M;^9"<9^^G>,O9_H>IXY65)>F=OMR&U]Z^@^3#SIUUJL]#0-.WK9]3+HT_@
M/9@J$*36$J,G1AUFW*95H+JWPR-M-$^/_AC80T&JKC'3A*O@0W#H9#>[IB3]
MS)P5>K,BQ2+-Q>/H8E4=R27KYE*_V@MZRR4LI 55RQW14UVA95>'([.U+=T0
M^W;"K-: <$-3T7D=R(3IW\X5#QF1(;58FA!Z3T,KVM+VLGL)6F1PZI:1;#4)
M-N.JPA?6--2'\(8-;SR]-^&-G1'3H2V_(@D?^X<NC>>FK\1'X*B$$W!P&GHI
MNT>NSX<3%YBFCPJ5]:7UL3@)MKO@?UC=;<Y.F9Y3?ENNW+,.SIO@.7U,:N7
M^,@+Y3<B%[>.,#5V;B9%W,PY),-QDA1CT',9N$$&(3NT+LHD;'D  ZHUE2HA
MOR,&_+.B(CP^M6>01WB >84=\DP-CI M^9?E&F&HBOUE?3MY)?VPPZ;C?H9!
M7^MU=L7Y/<L/5SC2T<(2\C#-O#<D$$>E8QQ$6RP=I*6'5A+@4$@WJOHB:CED
MKYU?N UDP'CIN<A"^"R8<T469,3/5#F7Q&TT/F%?[XD]/VQWO0GKDH8N1_U9
MEW&*U.4E-EK3EXQA[XLU+N>UEG&@Y,09!0Y0]?)1F*>D\@Q1HB6]BNH4=R%-
MV/?4=Q_9&RS"N>672%G?I6A $,>:J^5H%0LVR@F^SJMA4YD"RB.CI;29@5-K
MR",L^F1X\T-]RX?ZEG^LOB7'_"V%2=%[5<%3J8025GR28,ZTA-.5N(I/O0>O
M<$?.&A)SK1U$ DPWV^AL?;-:[)>C)\0KO/S LSZWGF'Z;C+B9]1D28'<(N'%
M_J,F4R5%V:1%4:,RU^*< [.T!*PQ78TK2H"3@D;\*M@,7!OS-F9&TCO 7P;Q
M+,:4[3A@*DU" ]!-@<T3SBFDD/48\Z08R;>"_7FOQQTU77WTP!#\&E\<XFF1
M!0P#%R\IU0V#223 -5-5QW;JOQ4#EE0UA:8[VB"ZCNTE*3WD@!"/8X-:[D#[
MNR[C/L/9U+Q9)6ML2BE9U'0+"1H<@6LE8926C+L[.'1H;UPL=%"NCHMA"'"%
M/'-%WNSNFJ7UR-!;'-S[A:YY+.N#DA.J3FC;HQE\DMU*/RKKQF(,^%9V#;E0
M_"X!??/RDHQ,>@VL2)'FM>ENTZMG3EQ3$5_ >]7)J)F7AV>2JX,29J9 F_3W
M ,(DP6XZ8;>,EIL9*/=X@UV/BM-Z"E?51J;@F(!,9@,N(%&30+\1FH.!_<L$
MU)-&4\J(]E*V<,%M@;U%6'31M2,:BI&JGACI:+529=JU"/BA-.4692P36%S2
M#ZD19Y4*H*'33NS BW7+SG]QL_'#K^SFW]4([MG>.?IUU<P7<GR >%Y/)E+Z
M\B4B-L)2NP^._FT[^M_DQJ^CUCAUUAA]%E([0J^K9VXA/1C586/'6'\:0.C'
MGE&7I;'@!]5*Y:#'1QXXUU?IFZ&[PP:&QTV9Z%SX%]Y>1 6H_,"\Q1V^<$=A
MJ%:"++WPU7#]3?X[<\_P><= &2GQ8),N,P$VB2ZI5A8LY]_V,7MCUDLYB_#=
M#^YQZQZ_?'"/W_6:6HPFJVI=94<ZKB[:]; [_;!;A]P4I+6 V*!Z[EAW(*K(
M0N9BN_9H)ZQ*DSZ"FKN$WSC1$@W*5L!LV3YZ ]ZOOJ((;$:+<;5N*):[*EM0
MU*A8L7%SQU2VADQ:QX96O7G]&MQ[%^F'_B*380G7#4NWCI<>\!,!S]0UT-;:
MH<SP_#H5FP[^Y/+15&T9WS%MT@PKW^VFFI?#"+:IO.WHLJ#,QL->;K5')T6Y
M:M"O?F_2:Y4Q)LY"ZP]<V6,7XPJR FVYKI#IDI($S]79!$-M8 .C?TRQ?A]4
MM0JA=#VY2ALQIR1-N%IDW,YB;S<)8+_%-EL%X GN[\1HNU^%=7_;?#B)_F@K
MK'O"G8>K2"!WMO5Q?,\2"SWN$&+T8%Q]%)7"K?LR\]8W^PCS4>8+JOL01G$F
MK7+&1B4PC0]NE><\O(4[B4D\>_S8=U7L6J=,'-[JILI@ETJ]&+>CVQOKAICR
MI\=GNWV"AYT-[YT_T'-03@YM!IL7G$;#MFV6&C39IE#P33)K-@.WL^(?5M)R
M68I2PI@#1H,C?-;G9.!Z#WG1FBD6ZEKM;^GUTO<O3*]_PP1HJO0SNFJ?A/&9
MX<Q'/Q.ZS]-"2^[:9P]"[3M00*PUP61B,%&4RM@Q\<A>&9KL!7+Q)\9/GRF$
M-J+[(.?(_(9KTA?F7Y4+.IC1@";C]6&T8D)]DS#U3I_VC-!?@!6C;9\<-/0<
MF=S.%]???,J_ 2UBOUQ2F"$W#!R1^GJK4MF/HZL,)I(K$Y#S*^&$2E&QX-%B
M4*S2^A,-ZX:0N7D0*&%54'0HD]!7@7A%#)E<QV(]J.;R$CT5)05AKKRGO6LR
M5W/L"D.@,>H6WA57557$J6"Z>L!Y[ #AU?#".S@'#B.V^@:5@S,3BL 6%3-@
M9"9[E=@S'/+32T,EDR++N+:3*P"3=^NU<^&^F435K"XS..2.QR:(0SV 61[
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M=O6BW,IV?9"UXTXU]3U"3F$C'; MF/)?LGO9UM5A3+WKZ(I#I&JSRU'8YC0
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MA)[PT4K&02"PU1L@Z:K 5?#T'Z!P>DR*U1OH.6BK![@G-M^MBP#],;;R]="
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M06^6X6KQV-PRQWF\05I$VR=[BA&*+$Q!6[Q668VG1:S8-?OR>=LUB\:F!&Y
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MT7^X]G_WHU3_(*8 8V6'TDRBL>[RF6_H<;]^H4PW::$<'*U?*9_P0.4R*>[
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MF=DRS-CE-T4UFZ0A"KV9$Y!J^S?]LG048&P4-N%"F%DNXAU'W/BBILJ3TYX
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M;>AV$ZW@$,%#+)V%IQ:7-.S4+#99"^JK6BPKT0Q="D5C?BDTDBIC^H$A34)
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M<C0S*U@WQ)GB>I,AY"Q?YEWDCL4TB::MOV:[N,-BS'?<R%!7S*YI&L3&,A\
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MXO/X<'>E#!(I<\24T:1\8HE>1+C-*4]UH"*[-ME)7:',6@)1V"X_)?+QAYY
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MO& XH(%\--JJX6*.WE:!]L;<JDT=4(2%BSBYR"L$VY1,\SP6N]-A/BE_E)(
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M4H4/2I3,$YHERXW$= YSA)'@^DN:PJX#M/O2YNUKM\8K>$")B%+JBX.KDY*
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M$[!2",$OW/4*$B_\OJ3T6! 5Q%TM"+-NSUI\$"]4CCN/-4CV#K _^5*Y +Q
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M. 4BU2#0)H7B(9DQ39-FF2?V*^%=CY-B9J-QMB[(.PI4\FAQ<>U 5T]&SF_
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M'T3O9A#]J ^BR_^.\G@)_YF6L_3;_P]02P,$%     @ &4IC6N36C0,/!
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M=Q+KR#Q298PU$;(%W]40;FG4E!7P.(&%0*34' U5(.RSK0&X6-+"-9(H%00
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MW )AU#L0=+B)9V$$L"0?227=E"K)JFT)U#[B/I@!CT]$%WH/3Y8/E4%%:0J
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M\!&2IW3KIZQ[VV'M^SC59W@[:->_E?0K4$L#!!0    ( !E*8UIWI C,\@<
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M!^.+@^<$93@4PC'3+RHHD!67DCHJ@UE>B47=P(I0A9:+)_Z*N)L(ML%ZSEZ
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M5WY4LL@QOW5SL81&2+32KE^R[OY_[2]4JL_P>YD]_SN=_P)02P,$%     @
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MT91/?$S_C.X0QKVJ*.:#'CSEK'U8><WQ9@TI[5E[WK-75M,D]BTF;NF<H5N
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MPEM,VF;C[_4UXL<Q2_<J:#Y!"7U+&Y9R\Z^CI.4AO.0[)6P]IM*$S02F. S
MD+@KH/KB[$$POZY#1C(<,(1M-&[>HFHC+6VKI5FB.06;&/2<SG=\THB>((-0
M9CQ*$].^,9@=<'7!(X,=E6VM:=H(/HKC+5 !T[:%A<*<LYVC-SEY:\W18I9
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M80JP(P?5^X%Y#FR>IB=J9T.IH7V#W 0U:Z+B)CQ/%;_541\DWK,2T!(_7!:
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MAC7,O=920";)HU"/8V%=Z%A8#ZF(CP'?PUG$0=F9J*IRRY@8@<NF=,DAUK#
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ME:-4JQPW:R#N+T1<:B+X_E#LTS':K=J:Z:L=F[-CM3/UEVG'MA:0[K!5.X]
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M,G;.%MR;\R(+!T++I4I;VJVM 5V;E:^%H;=LYO>SY3JSSXRJKHH)O"%ZT:]
M!]&Y&.,T.EF&OC JN#+T\CK)X^.R^0'>*'DL2.WYN&S>BS=*'@LR##\NBQOE
M)2,I,VMKIFD%L>_@%B[\I='"2&"MK@;9JQ4VR^+?629RN4E?*;$LB]-IX<1B
MP*?F"R%#*B=I\4JSZ#XNB]=LX;3R<,9REKQ6*51;5]X#T7$[85@,L0I7TE[I
MF/<N^K/0.=Z]-,[NC[5UWBW#3K2?<B=JZ\Q;AIUH/>5.U-9?5]N=J(-0V:NM
M'VTYMFU!_JV]VOJWEF/;%N1WVJNMWZFVV_9,4<"]VKIT'K\37V3^-<FDB-6_
M9'2:7$O>B]^$2CZE>GER2/9JZSE9KCUY2@5[K[8>BN7:DZ=4M?=>D2/@Q?>D
M%DKW*_(?+'8#%Z5^OR*WPV(W<%&*^"OR5BQ2K#VA2M[>J+\KPK:!ON1'Z$IP
M9)1FN>C&TOSX*D57>Z/^CH<:;=)BQ!,\;;5)=1=![8W:>2 >V(_XZV7]?0GM
MC=KY$A;2[?FY5O?9O0*/%X>MC46(P]J:XO\4<<'.6833Q[Q2W4DB[,V1@88X
MG8 Z??U9[\BT'+X2MQVM9;XTKL3V1FTM["79EUKHFK6ULI=D$Y_+4*NM\;Q\
M^_*$OOIVJ[8&])+L2QULMU9M#>PEV<3G";JT6[6UJ9=D7U[8YOZ@;O<SJ=,B
M@_7@CP,I(AI\I*X/?H9_T=ZJ:+O=$WO=S2AL;VZU=K;V>KUHL_=1MK;V]C9%
MN_W_\$26]^A\',,>#U72'$C5'^3[K8^C_*<;%>6#_=;&QO]<H^L.?M8CD1S\
MW,T^P-W\-S]DZE$XX*:(53_9#V$%9;;&-]O?PS1.L_V_;= _/_5@ALV>&*IX
MO/_W*R ''7R1-\%%.A3)WQM:)+H).Z]Z?*%6_Y+[K18,D#[>\(AWX3FQ2J2;
M01N'':S^6?WS\O]\_7)Z=7P47%YUKHXOJT>EAH?D\OCPZ\7IU>GQ9=#Y<A0<
M_]?A[YTOOQT'AV>?/Y]>7IZ>?5G<%/8>-(,_A!ZHI)^G22,X6C]<#]H;VUM[
MM5_XD[.+S\'/P,:3-/E2#.$A86"X_87L451O+4@$RM](JOVC-"RHA@CDWQHQ
M^AY<<-#::/Z#A$'YE(.IJ<_GW;/7!;/?5&_\Y NS,;$P6S,7YO%KTDF20L3L
M9U\+J.XX!T%XF^_WU*V,FGE6N#4#M>??_[:WN[7ST[QE>](Y?WS0E(,7>?=L
M.NQ\^?*U\RFX.#X_N[@*SK]>7'[M?+D*KLX"8 U7</Z#UF9P=A&TMM]%[X.S
MD^#J]^/ XQJ.8W0.K_#GUM[FUAP*?.&9G:19D ]DT%,Z%'$PEB(+0-V2T4)W
M^M'4?4X:X3'KB57RCN";YA >,<#;FI$8-W&639E8<M]\S'DZ+$!G3O(36B_L
M7?K0EY;OVUH[.)(A:=7__K?6SL9/J.E6SUDC0/_-Y+>+/ (\4O[W]S'/D8@B
MD$'-6/;@H1OPVJ=FG@^;R=F%/Y?JC!9![=.C^9Y5?G$YM+'[77*(4L@5FJ+S
M95%/Q-H)HVTCC+:FA-'+'(?9$U_04:1W7UUTOER>DMAYQ1(I=X02L+T?_#_O
MGR!/*Y\?<'SN4VX?KOL]CT[\L.4Y3(=#I=$;!#([ED%2H!S9?X3,/":'S0G<
M_(7NM0=M!YU5K>;F[A[ZJNY1EYU+1&1]E32[:9ZGP_T=F$)=E[>U\Z#U?>PZ
M7LB^TDBK.<*XV;7<!9WQGYVCXT_!^>^=B\^=P^.O5Z>'G4^7P?FGPP<O;DU(
M[MWQK0ASFGF0]H+,S3@0.M C&:(S,PI4$JA<!^% 9##4]X^:%:7^V NZ:1;)
MK FSB\5(RWW[QT^1TJ-8C/=50H.DFWZJ4N VS.A:9CDF69B7T/OXY])CM[[!
M7KL\@_]']LWFYW7XZ</T]UN[ZZV=G9D_;:RW9GX_[U'M]<V=W2=Y$@WJ[D=]
MH$GR1&$M<5M^6=M<F]#+]MNCVZ UZP!/+6@Z>G%"W/B>LWF:A&D&2@9YOBD/
MYY S;@[3J*JPPX#"?1GU13;*TFN3EU-J[!_7#DXS&8LDFGMV\^@[UA=5X<G5
M94I][@6>UFI*)?_'YC2;9EYF5D]#-E?B]M3$:$(BG:J<W%L[V/O8;&UN@<ZT
M>2<]W'/P#)^#X[0/:QCH-%918%=C>4XE':P M+84U+8L^+/(E(Y42)H;B OE
M'T*Z+.N+1/V+/K_1X_-*=O[=Z?K%^N5Z8&" LJ!Z;((OZ?K[60?"#M,\;),\
M 7?O_@8NA1%R[K*=^9=]O\R[DZAJI9Q]%W/K1%$FM3;_^03/:SE7^0;ZRH-C
MD<4:9&,>7,DL$Z%<(GWU1Y;D$/X\RZ[2&R?V,2_CJ.C"&X+VM(?N>U_#RL6T
M^F&T#KRMU#PP!>$^U>-U;<-YJG,1_U\U8B7-+,,F[,1&.[C:_+AQ]SJ\,4FR
M5(K8ES0/.B/,*D'+[0VJ2N\,C:->-,I ,U(C$0?R5H9%KJ[1N@;9*?7[E5KT
M!+N\2$I_!_PK0 ;VK/K/CU\V\]CMO4(UJ733_?O?/K9;NS_I()>Q' W2Q/I0
M&VBJQ 5..!"9%+ @D=P/_M<C8H,LP?%=:2G!M]8.-K>G#,7F(QZ+PA$&5!&(
MVZ"K_< S/Z6P;><X^ZIQV]H!ZW:CU=QN;TP]?H:@K2=!?R#/X ]YJU_8Q7H)
M$B!3N8('LGM59C(*1D6F"_2SYFD 5Z!-Q;RTU7[7?8]"! ,EG3#??Z!_?@L&
M8[Y!)KO-^[04OM?V>GMS\TD\IJVG>Q2-:NM'G*]FO3DF/B7S7HG:<Z7RF$('
M4H2#((R%U@_7!EYD:1:I*UQE@F3.Y7C83>/@W8/4OP<M3L9O>:UD]<4$I.1M
M.$#X\"!-@IN! A(K>>ACC S+XD#DR?DBY_NN>EML8+8=\'#MQ(C#<:O=)=[A
MM)/=M8.S#*8KLG' /5,:09(.X8LXN!9Q(8/_ >*EA1D#@<;?OR->\_KXSH]N
MA^%0S*#<7GS$&/?1I^=:X5?#O)[J,!P;-L=Y!E/!2_AUPG6X![(%],,O0D?B
MK^"W..W"*?DLLF\R?TC8ZA%*_8/VY!Y5_N6?<;>ML+260;]B&01?0 (]8R[4
M,^7!/RQW\C2),-8D@^XX" <R_!: 1?(M4#Q]+U%%Z4 $-S*.F]^2] :&*86&
M=8G@!UV@Z2]T$,F>2CB/Y:( ?75K8]LNI+<)L*;KCW;]_P%O_@>^^-*\]Y1>
MZ_+M-]8._EOJR4/I9[,]-M_P#Z!TI';]0^O[[W]K;V_6,CGV2_H#Z;M/M3@F
M*_6QA^05'JXDS>&;OPJ%S EX$J4F9I3@J^]@5IN8#U#]BO)52_ZU7CD$<$CJ
M<"@J^UZG4_%8OO3/-"Z2')1IS ;-M.-'+8S5W,6.:L"-WLIYNQE(RJN9.'3O
M6N]Y*P8@NO"X18&(8W?F_,/8E>8">/",\U<Y<IZDL_HF'D/\&5/$@PA^3?IT
MZ2B3H23/1:L=4*V+#M[!\T S#70!5K@>I)@):M.W\X'()V=Q(_0TWZ";S43>
M@VA.HN!=VYMM%Y1<N*C[)\P%;Z+KX4X<BGD8X<O12&BD0N?!WD80B;%^O/ V
M%3]<KH!F$+75=&>E?8?LKL$QJ1-[J@KM17'OUL['%1/AXX>G"0[24.4YG#\9
MPX'*T@3-XWC<""38RN/@%,T"$5)\^DCD(CAAV5[A+^5#\+3Z M]7I2]DO^#N
M$<%E\RIXAWNQ^U-[L[WN=&U%">0C3"!_;E[#8W;<0^KWC^<-WN+@VAA6X7C#
MYAV\8:71UY$Y?*=*_\*+^/ *IR5B1F2CQR(#C4.$(3"C#)&NZ6BB@9[,_!8L
MCZ0Y\P<]!"X&;\FLW(;3/(0U&*/. T\#'0&#E_V@GZ4W^<#^N@XJD*2AD3^
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M]:X?R-I:S7:5VE,+(?4F<M2V-FR.VH\FJ2VADK7*+7TI8?0,?>4>HTAOKSP
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M&DB9?UXRK1[K7 [7RZ1\[.P32D?UI%!36J1K'&0 E2TCN'^+./L=[L=('R?
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MHYAG]6,U'><IRFF/P"2Z):V'H.I'O_V8!@W2M1)&-\U,#8ON:+5^"DY[!!W
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M,@<8D_V;^UB-E-%Z(S:I>8W(DJ7M;3<CS&O2_.2(L:N B&Z#KLC"U-9\<#=
MJF%"+9R[0)I(3#A _^ZR,[O32FP+;5WA'!:EG8L2R9<Q53P*)*),#KS*IOOL
MF'532^XZEU9K#YB9="N.;R)T5U3AU?*-O$)V)]S^?_;>M;F-Z]H6_2NH??8]
MVZYJ<NMA.W%4]U8QDAPKL2.5*,=WGR^W&D #[ CH1KH;I.!??]<<\['FZFZ
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MF.P 35?\/ []4C09N;\"E]#1QC_X<I+)M\1-)LL\7J*W:O<MT(A:BR0MQ&5
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M*6>1=V<J61!WY3ZI@*T*^71R#/FY?[VN@NO73OZ\G2^++NQ^$C<J5]QD";:
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M<]G<^H3Z9<$'N'_4V/SJTE)I\QRU90[3323J"[A$VM&UEAP]'R?S$C & "@
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M9]9*O\129G[L<!'78LD*EY?0=J-8^%C>3LK;W]Z[\O:]VRE+:@N>%KNZ8L>
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MN7M7O.J?%6-\_U_UIKFKJT+)!$A/ )FL(D0(G'<9A 3378RXN3N[*2Z$OL8
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M\H);>8H5 H#?@-C2\Y2>'(;I.H& $$)NP9<$W0O2E6#'+?Q3*0\9V3<C1ZP
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M/"5!TCI^*UKG7SS]$GK?D7[?>V*5!4,/W3Z]"]Y+P\ O8?9U:"%;$,ZQC@9
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MG\6#U3UQB#W@)@M:C)PS5B2-6HL\Y9I=P BL1/&TG ]@AFP%-,:.T#][8O-
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M_>YPN-=,PD5;)-62&HQQ:#"C1_"2PC)O@,V@(I%[J4Q7B&:+V'7L"=BTO6"
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MT!5I?[/(2O?W;[5=%V!M'@W5J).)I*V28R?\DF.5<,/-*J^<.JW$CF(>G]>
M7T_>*-406GBL(?3YFS/KZ,3DAB7Q*MSG8D+S'[:_,.=PJ*_QL#!ZU(Y23]3@
M=XS\H6.;ER0??L@N2_\X@$'Z";HD"(9H& FC6F1"_KG:>?I/D"+5W.$H;U:3
M[2X) DN,;T('0JPHTJZ@YZ/Z-YMM0R4=1AHQ:X \P"1G5BC5UC+P&JA6^*(X
MNILYMZ8154ZKI\#H<"3>+<YC_4=DQ<,TA0G@\U':V ")5!&6*P8E%[.M!O?4
M8$'XBWGBA_;6D^[]X)#0"93T *KFAI:S+!AWK'C3NGZOZY#R)IJ+2T5!J-D/
M8C:+%1KX5BOFT5&]\Y22U?MEJ56D0D4Y+W,F0Q;ZW6!PRK9(@AV")1BW5Z2*
ME8NM_-L:@\Y".:U';/!#MU'/>PY1I\NI;'O]<.;F9 X_Q[HP,0PPBS)CBP$K
MPP"]61U<IU^8DRTX">L>#Y#=6#J$6X_24Q&@PO#6/0:?L('",#9A@4P+E&(!
M,%]'UETLBY0\2"R=)7+[?87S&N*/GGQ%OC\IPJ#5N\(RN!79<%8Z2\U*V*#/
M]0PUS;;:/<A()V@_=(CWOZJ;]X[/+<&2:\8KN8^73]0GBBWV*_XR1GT$[W$Z
M.9<@#B>*11UN0!7MR3;D;Z>3/U-Z/7B/=#P\>?3X4>8$A(3^]+>S=_Z1,\2?
M:8,2LEGD5C\$DXN %"9?(IB$BES3X+W,]IA/H/%U6/=DG!(336U0,.%JH,C=
M7B3]V<#!ALA%HK5H-_E8V.G!UB99]Y[_)YG<8G;!"Q2-]EREX^9;#A(B&2)[
M0,[SX<U-A8<1CS'<Z'VQB[3P$FQ\I#_4]2B=L%:QDF_K$5-T^^\[Q"F]# /?
M:4BT]\+B'G;AI=(.)@O7>XG8\EAGO7F=]>FC8YWU!NQGEEKM[2)LF'VAJ#FJ
M1D':8S;S0JNQ!F(%CLA7PANTA;_!G?KS8AI.>,W:^9-,Z0C0.$>/?O[R.=M6
M!OBTT'(F/YKRCVV[)=O+!=R&:X3.%PXW@^TI/BAS-)E'QCEX!Y0.R?]JQYWA
M!W".W3(A$;F8QV-[3=<QK?=$3K24>-+7P094WXS,8B2/2K8\@&'<BT![PDHM
MG.;LB[(P 5&?P#;U8)'B=-G-!.8C0ZJ2SFUR#[U^52QKL- Q@4W8NWNA0I2_
M[8@"1#U7KM10<R:,GW+)%^%1(5@2\WD2B0M)*7?3F(S3S55+(B%J?)$]G07:
M'M#SBR=>L*0U1-K)0+%$<HCD?3)$8TR5Q&56[1'I[;29?F]^JZ?E&QLWMU6\
MD3:Z<<#=SH)[@SX(T+%JSZ<.$:V# @J_VQ &=V7+(O0[)N!MTT[/"%"EU73K
MW.@]L#? CWXW?OC,PPH).WHF+I$_>B"@J\W'ZL/BL!+!ADIP)6G6>49MT#,5
M1.&"'KS8Y:J>,DEE3-C'<ZR[$ D#:W[SA8!#)]M#-VKO+@X*D2R:?%T@+-4$
MF8PP8GK$X=0:3C7B.7QIB5\RSO(L1 >>=Z9,B!A+'[V$.ZSFI"]%NX/V[)R@
M*50-U&)V^'V4!V\*2O=$76Y[. K/PR9G\#;2X^Q!>"QKD@[9N\QZ\)&N@#\R
M*>C=F[IB"O8)J>5@T\=787FL78B23TAV;O9>PI/H_T>X9PC9ZAG3 #!#097D
MR<5ETR4_>L@>; E7^J01$9C)ZVU_0L(?6Y;\X[!/45T>\*X"0!K"O0SWJM=A
M!Y\%UQJ6[N7+LV3L]*)"NTK7SGIG87)%:(49U.POK!LT>4&/]$;F(;Q85)#@
MF_XT^<N+-V^I8N^5Z%-&#UCV"E;Z;^$3P?C$GHOT]KCFGYOB0]F)DAE?/Z']
MKT,\S?FE8+GJD:L[U.$5L^/\]#=<)BP(ZO"/5=N_#=Y/\BM_U%3GDJ7Y+(4G
M#X21;(JPS>0TS:-8&OU=L_;73[>:8L&!QV-0SNI6:CS>?(_OGB1/$A?"=-NA
M!*X')0D(X ;,P<Q$7$5CUX2M]_FGY\%<AFU6E3F)&O"'W\B'?;7BN:M6G$YZ
MDMPURV)6X-+XI="45WP00:*J&H+#5G#993YO9 C%]QL.0.08=G8ARK@)Q3)5
M[NJ&?>L0EZ!<3(A!(>>,>@5Q.)33#D^2EMZ**JJ@X\&2R;TRLTWK99G3.X>7
M6PFS/#T],[F)HV\&I-5,NYA 885.+HX]M"Y;S745'S:K6AB$>-WM"3WI.7D1
MTY1%C&WKLY(<\K&IX%?U)S-X?=F\6J@I?N.O;3']6@::!_0NK+1'+>B<5)VL
M2FVY.YV\)!0/DUIB41G.T0#\$= HR'N7QLKBGO!WZ%,I]=K\?,^F'ZDDC38/
M%J.:IWT7AI3:;*<DC12!CCV% -=PHUD_JU;=?V?HXWHV4"GA=U7[E0SHA@@V
MBY1Y("*CM!"V$MD<W/T7$/I[W+#)]4[%-*@ %$<8B71E4W#917%.\(W*B[J>
M2UER]C"FX["$%)=Z;/_HT-N^S83\O=&T*GE_>0,&^WF25K79BLGF8%D1+XOP
MKWUUXX7!F2BVX(VZJ&?!!&G(6/4(KU)XGSBF"2Z\\;"?R(O%>?0H7"1Q,OFR
MRSI"(;'&@*0/5HEHB+955 @6!SM>4\OBR>):8:TPU$\-CZX@3S:G[W28MZH7
MK[MPFEY\7M;A# OK=7*QPX&QII,[_(5XFOA<T$F!N.5,!89F4H&. E)L]\<W
MD-LC C!*!H=OA(PAW)Y*Y4N]"L3>51,IH:/M%XZL7@O5*'U%9KB_74E=I>+>
MRS"'4^F2VTR])L.H:D3$N,5!UIR&-(.XLGO"XC4VK=RKV@2?4L<L7M:6GQ2S
M5I",:B\ NV",*>W0-G):T4F(YA5R,?)IW8B_LR*^L5:0#=*<4.\@;Y7PX-*>
M(.!@K"V'17X5B5A979OL83C.PU$6]CL5Y01^AVB0">'J59',GN !K=]0B'Q[
MCQ\VGZI=,&KODW# /B3RUX,'Y%LB>@CAF!&=O9'*V7.#UKR(<W+_7_:6_H'Q
M)";\J<I&!#4@H-_V$0[3%JVWW8RB+\0$EM.@'ACG.(O1)BL>"4"',BE)P9)<
MP'PA7KFF3;'?!N!E6O*ZUN5Q;^\\_\9(C_?X)M\^'>''1 -N J>Q'#Q *HSE
MUP HN/^#Z>><LDV^9DSI,C79]HF(3#/%XC9"L])36&)\E7:WZ1B#MF-= .,S
M(.19C"THAV(/EYL+J:ID5MR]X&:$G41]"[TKGYI]<-<-*Y(]$WRE'5,OAT.D
MP@ 7]94PN+:H(@@YI2QS)JTD.C'0,1(0IXB2W#74$,$-R:?6OH%A3\=S%14M
MER2/Q?F;%^<?'XOSUPV22U"AY$H%[;:'NHG;2^/U^8@=SX:&G1LY$$ P-Q?1
M*@M&**>.G%)H70F-TLMR</^#M@*(;->1<O,SLG01V0?50X(-XXJD4+*/=A&A
MYQSD'^2U]XX)9OV-Y&PUC&]7MBK)F:]V;3B1"#5^)"&ZRUF5#:UU+M'IZ36F
M245&JN;[.\>DA4L803:49.PZI2WBR%V#3,("]%;%<:+OE*SH8!\KNX9K8"=S
MF8ZAIW&<CSLUIZG)I!Q]JV5B#EN$F)K5<BQME&J;6QWJ[>LVZ9KIF>#@S"F$
MB.]DM2$YM5V%-(H4.120M86AL3:E8N(VV]@92P_#$4>\]W%]?:+]3FI)9;<U
M0#.ZEZ<UB9=2>I62I$RJ0L:ZB#8A1'SHZ:+9.D[6'1N#6;-EHA-*LG-:5MOQ
M*?V2:BT>+?2GHO?S.N9J>>NF%6Q%"OV*I>5]?<Z0B>&+H!<OBL(=?9^[G$E-
MO^B.,I5%V4C2_+AM&,JU(:!GK*<M .HYV6Z.^^U.9RGFP<@]F,R;>K-!_6:+
MG/;1Z'V*2>#?05Q-O+2P(8XC_DD<-=L 1B;'I$:N6PP$L\$3(+OT+])4E60+
M"]NZI+8P%(ZDZ3XV@WP?,Y:9IW'IUPI00]VK&615X6U4 B5Z& +>-4A$,6B2
M-9>DPZ>?C<? "]^>@/T9 I538[BJ5C6Q+C CM:J&BE)3F+71I\\\B,Q+V-''
M(^"J;F);*'Y^]?;/[9A+S[BUV+C$Z"\D8ZIEG:P\72(O+RG%7T819>JSFB-D
M(/(HYLC2EB;R2",[2](6XCDB<+(2MHN,>ZP@]4J78^Q!& Z3 @B?G%L+\IXW
M,)U98! DR;BX/=D29I.X'QFWAHPT5R?M0EQWXT'>AJ'[(9^]YWL)#0"IRW+#
M/T"!!&SHTRB+0X)T0#]0KYLQ4 AH)I6E><(]' H^Q(JAIA!Y[CRRF3$;1*DA
M/!Q2OC7W'8R]/IZ8^(=$*$TOVZF*(3]B5>Y7+O123"/4T"E4(N7H&=\B#Z!^
M>WNHGZB'3PM#:3&EQ=V<6$\^\D'OF5CMT%H -*>T44.N*-:!).L[_%MF_()*
MER8<@REQ^(B->@ +\N"A^K/J0UP2U6P/Y"Q(BX@YI0UK/6+A<,,):28AL><C
M>W=R8*T31DT@<E3YVXLNN6Z2'_ATO+O9P<BM28.*+4$/8AH/:5H;H&9/9C>>
MU)YYVK=B8-)W-^-[[%%Y8,J5)CNI"^EA,/)R_M[4%+VBS>GHX(R5+DS/W\.S
MQL=F^ F@*K[74[I'Q_1TE;Q/7DQY5I*W(H", $_P(6HIZ78;:5HAL$TK0)M%
MT@:DA14#YXX0L,P+<L["'39A_(UJ2X[U/O;?M[T[OO+>V>O4@-,NE$@Y*MY8
MCUQ$^4)W&UY@W$>:/#D*@E5!4!]*_E-#<3*R ,^RI);'"M74R[IG+4=Z[S%,
M6U)K&"'Q?.C[_8R7,)#ARNH<]Z;W59-2#N:!Z[: '7.Z/W8#T@YO:;42A/;0
MH*<8)M?A3'$DJ@"*=HH 8X*NQJ>&EZB/[L\/_SRQJP_KX:)8ETRKE :YO!L=
M/98CTW='KF/F'#$':% @5J?N(MP@1<?%UDT!K&5*7>E 9ONHG:,C0=!=\X#;
MHIN2ZY]\=E%Z /7$(I(^+'B/?=]+;O" 6EZN/>>4SWB/69-C  (,?;;DOF5T
M^7C15Q<B' 0H*9?IV'@O.-^R4SQ2KP-!3HLC".GSY8C_?_;>M<EMZ\H:_BNL
MFLR45 5U)/D2)_ZDR$[BI\8CER_Q^Q5-@MVP2( !B&XSO_X]>^W+V>< 8'?;
M;EE4.%4S8S5)7,YEGWU9>RVANLT5:,2=[&B;2&O,=]++^LGS3YY</GWR\JD_
M':DWY);WK?2N\!]ZM0$]6JW!5A5S&T5*21$7SKE\\\XGG3,9\6@!7\X*TK[D
M@6KV!1@SEG7PG@7G4)>2],$2N*64'4$-*TGV!"\#G-^5,(_/G)!'3$DJS7%>
M)(^Y2/3@#B<N ]MC=_!EW1I1[++R,.L_3F3\7(8=:5,X5NIW!W]%R5?%S6@[
M%UI,*(S,T;Y3[T2-Q& ?%W3BY;%AN@RK;%WO9]=9.^PQ5O3[NM-E>H< ZG\F
M&OSE>XL&/QN W\8 !+<1<#J&80# X?#&L802IG5'?7OJ>T=;,5$6*!YF0 HN
MVAV\IG2" L')H.8!4AO,BA7\5'*#&: E<J"<.X"\4&--)U>-*1CP+<\GRZ,O
MK)''R3I0-&9,>PK"EXX2$\)]C8"% @_TXB'R*_=)!$(3./92Q=T<,Z#YU%B_
MN-RTR[>,QB98&.=+B:E5_E7]'(Z:GK07K4HT]V!6Q*2R%%'.;C+)^SXR9D"
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M95 G((4&:IX0J#7* -@.&6ROQS;HVN!?C5HCBC$J+CZ5F"A@]:%4JU4_[FG
M&4_5 X?PD#SU3*W9WR<\T%57;FV'GQ /QL-;6-F$TC#0*HV=9VA<IT10E:Y6
MPJCJLI)3I-QSA9F+ZZ@<)-<J9@K""?;,-%HF;O?^C_N==( =:W=DH$#IP-]1
M6P=7//X>G!$*T+\(*UVDKUY?U]5Z\24F@TZ+-U0 )LQ*&.[OK\/C]8NOE_\8
MKJ[]U_]FV ?Y>N&QN"@SP]^BB=I69%S,,+%)8&]C4UV58?YZ0&8IZ^>:=3(
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M#'$;AE_,31BJ]+"<R,\OKFK6>ZVBJT]?@[12&-FJ"TM&)0-4B I<*W7KT +
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M#7OQA7LDQ0J)\B=D9P5QTB>8!Q=@$TF\94SSTW)B%R?O=317IAY@=>,*V,&
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M[O?$8+FN!OA#F:ZYN</3)FIV2$8G7/0\(U%L>FQUU<QH4=W.DFXN0Q$\C>;
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M=$U]^OGOQ!\='N'S9+A>?'SQ"8U%\)/0+;:I&&.)\DF81D*UR-\^/T_ (T[
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MT3$&?^9,W+XVX(#AS/ K0"NQ5-R8'Q2Z%YNT/"9#4U6S#R;.EAE'YU)_:-U
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MM-\[\Y0F>#9[O0<;R(KADG4;S]*[\\P/Y[-IAJJ.50T:4%CPRA^G[-NF#N+
M?'T&;H6?G3CP%=UQS001^!6J$<R>7D+'?BQZ%468F.U- X]?$((=DO]?WC,_
MPP%&V!@0O9SZ3>X*)DY]C":JH3>3%H[%H=$BXZ0;11&2*=>HP^_]=*;KN8T,
M2;*<+$>G +#="9>??#K9TPSMPEX4P0H3,X<Z<I;LSC6-[U,,(J^VP0;O]WU=
M?3N!?."8 G6#,A6=:-23 \^SW?X)F^Y@'3XW146"0XIM]-^,8Z4(7C$AU9/W
MV[;YESV*@XT4UC8CTR=N^])_)99]UN$+SC2]54I8<112HK?N% MWPS>]PU_Z
M\KIW=16K*P.Z12TXO6"F!.P+%HC-D/#LD^)-2C1]D"F1&X25;NV/L_4$#_O"
M<ZANSG?%FKX0#H;GL:DS;-"OY0-//<)=-NL%H3-+Y&ZPC<$S0"ITOL8^VPQ?
MAFDT /)O<?J/"_+,#T8QO'_M858C[/YQ8=]AAG @[5[G3;O==8&H"B85O,+B
MD.:9OQW6_F@CWL<,RIC1PNBN9R/A51K@6G3_UE%AJ#5##.;9<A:'<[A_+'GT
MBOMPXIQS*ZW<AE WW)4[ E?C(7=D]12_:"YVEWCF[;4B[5NN+?>VH5DB,T8\
MMI3 _DB7GDQG E4\1T:-P,5#^FB0%5;O-VO;4A6Y2+W)%#2W=!%N?Y]6O8'R
MD9B52G]C<CI,O;DGU&'1>5XL&[]LWJ%BO+5+U BZ!1["/P=B!;!/HN!_>'_Y
MCC64P6R>>\[$TC&MK^2EO+VV$/3,U@L\8.UD4>( ERF9;EFQ2A8<8M_/G"=/
MN0,D?<H_51;,VVX;5D_&U9VK5VR&Z1)N6NUBF@N'KK28;_YDE#<JNR&/FCC6
MI?R*Y.BR *6>+GGMKA!P6<4Y_0MA_6=A:JPS*X!LD:EO=03D$"=M312[VE\]
MI%;@8YL88>=OO3G_4&MU.$0@#0+"W I<2J_1C6MU=HA\:[\9X986^D;$CN1E
M=CJ]CI*RX#3&".!95(S07WCEWTBK"%5&CVLBJ+>Z'^JJ +F&&AU$T7=1,8&:
M,'5(-Y4C>BF;+L>.6!_AHD1N;:<O%&MGH'=Y%!HV:AZJM5$L[;\H2TRZ=\F4
MLE!6.-+7"]%7%WYO]BNU:AX33]M/..>ERV(P3$;6=QA9?Z 8'39$KXKLRKRX
MJ[FV[HN>\7)2L!G5!G2 1R]4\X244)C%_<_/77N UD*7'^'"9M[QW#ZA&HF[
M8:";+>,W]F*=>0)F1S+VV886KF8'X73AR<(1I,BLB15SVH).@7,7CH/,;$GF
MP2%FR7Y=X#I_(I<_<5;G3ZR3F1;+0*4"LX:%5BE0MUX,V.S!=%;.;K*7^<S6
MWP=YJ;3ZO7!KRKABDJE/K#*Z)>QF$RZUQV4HC"-(_/,K=[(AM]^OL3>]KM+$
M]QL;(%_G<H6;R_GGL;A>A[/)C#FKTSVFLK98I;,XM-2!*.\=@4O"3<P,6,NB
M4) OBNRSQD@C],#S$"814) J,-$3>;<".3M2/XQ_47[]BQ]9W:/H$6IP-D#@
M_1N2<)26,*)2&$^RDR91DN;\H.8!"C^E64*2S,V^@;(59L7:Z 5Y.E$>HI6)
M8WOY%#/G&S=BHKH/]L#[:1:8@P>QE X3@/XUB^BIW+>HS@=F-O&&:I:"(A%D
M901@8(=V^0!\Z 7P>N<E16RQ'-;^%5I<)EN#XAQ>DLRD?(!\<S3;"49Y_?+<
M3BW4/8S@\A'2$JCNPF"@<B5DPR!*&*J86M<=_92Q-_RNLN#PDH)*VF<F79]<
MOW 6MZ;9 E,V'CI72Y$?&W2L-(IILZA% T4]D>_.N!>949@LC M[<B4C2(XH
M$9'4 (U=W:P[E.N"J7' W$5MRW#RN>H\-X0N;,<9/*'!>Y?W_,F5D\3#OQUY
M-Z/@&,^DV6HW__>J>?+7].H(Z"K]V]%7?XA+E!_E5;KV67OZXTV^LAZ5DQM$
M088SD@%I;/ZUZ"V]L\[T!RHY!^4($/8,!&73 U,9W+,LY5F*>R1&B6T71QH8
MEYPW$M"@9AV2JM$\T_?RPP^N2W/.A^F)\WN4(D_0:"^<EZ@KM RWQJQGNNV,
M\Y->4RO(K#(:ID XIEFB=%;UB^-H[<@>FR_;A/#,K7I]?27DD_E:GI6E^2Y'
M]R-VM,/?4462@K U&YK#"\@!!9 W@#8%$P;T.M4/["B/6IOX]]0/S(9, GN+
M,/-%]U:Q/UC\W)-#!'=Z6\'O/3D, 0(S]+;&#OVFL(GAH>8-&XS/\PTP/I]:
M..00&,NA4?( C!E,:MWTOL3V[S\,6FE_QVBE>WCOUH%VGFX/:?QX8/A/+CBZ
MK:T;<3SV3=H\NDPG^?(3N2UG\%6LAA0Y;K#KR"AX52%+?NGRR@GU?Z*9-DCA
MBH]TDJ1-;9Y%;:RZ:8H;YB@NSB@N,A275P#98\W=%]+HBK,>3%?P]9#K6;80
M.]= &6/L$<6@72I(%'N]]6"K<)DNHBP68-?_H_(*=KUV2&-NT[(=B:WU;3.X
MK:3:0XNUS5%\*:GBNF(JF.>&A'.#G&G2IWG_ WOGJ.T[0]13O=>M%X^.@RCZ
MSHB,9D^YXSKW$9!N\/BU62CY88Q!P ,8E31AVUZT?9WZR#8QJOT9%#L"\PH
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M$R5)&E1ICID7F%T08@EOC%[=@)Q8A'*#?IJ(0 T2Q70-%,+(8891S^#/(+M
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MQBP6\L)L3X1#Y)P&^&::E!'5B?,KU<;@1_AJDC=6MU8-Y@A6#A.A?;4"..6
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M]R[JRU$H('OV: XY=#*;2P;ADG]*NI5N4'*">QX06:<S8K.M%#W]-AW9]#8
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M3^$KYRO[HT?.+_.'*O':BW.NJR/KZLBZ.O)95T=6MD#P,(=Z7F6/7[1GP'(
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M26]5QUIQQ^!GD!V"E+"/ZLY3S_-/)977 X9'C9PI\ N&<@Q\!E!$&<>XLD&
M%NC01U1FQO.R$>[@2PR9%\U2%AL$_,SUXH+EZ-TB- 9+BV'@^1.TRAA4",<6
M$!,]\MQ%M)*$H 7]\*]9/$<G8PC"<)BZ%J*D2RA] 1:>(]@"? 9>P[=3[X<K
M4@FY,[LHX>NA@'8PM.&$KRN#P^(BE!;@1O9GX.L9\"!#CL<SUAK*]^WV6H'D
M0UZ+LQHP*"$.(QO"K/=E!A0:J"O$451:H@I8XBL&WAS@S A+9$2_3F8$FY@0
M/%.(OT8TR C!#^<&^7!TXIRGE1.< D]6IOCN\N+2MN[/7K5WN5?5T\88QP7N
MM')N\3]A1/P"+A8RHMS%1$ C8%!387N(.188V8%X% ,_C05R)W:\T<0/_81^
M@K"*&MQ55&-V"Q'WR%W!P/^.&$SP_<U039=@SFAOCRMV#;N=V)T/;[@V;@>B
MFVI@=XX7^"'PIPDO!5'\8XO19/-/-":<']Y$ =M%NR6NI)I@1<WV:^==1E2?
M+:(B'/V*0*<],9I1M0YJ!:#Z(]DPIXV]LF&.WN+)LB@Y/3_AORS^]__.$/$U
M9::'U T_"/2_W_O),(B2&;H8S@>H]/W&G@5$';^#$;D# ;*MI?1)@T%_0WA9
M7.?3>S1W+E\7;88<1C8"9W\O1D^0%2'/& ,/BI;&:Q@"E$/BB >,WP=*,U$6
MWZ"PPL> $\QI(I[&_DU>.XDW5M+0A,R/^,:@YEF=:] #XJ/\)2!U_0#.^TTF
M/+.@#_-'"]!8 QD;L9L#*7[#U@W&[^'NX$V9^RI +3Q(KZ/9U75A+4EQ.\5!
MA_-QEZP;]1:8/&S-$&P!,##^11=S[E 7'1#Q@E)8' @F1MCY"3L$30L?^0J8
M&W2AV=.'.A$:= %[%97+?Q""N@;$3^=3E>2WBG'U2\Z*SD@ X2?P,GW R]/%
M%ICU]/(-V&M*'Q;V1Q",WLRB^N/DX@0,JA':K\X51@3#B3%+Y<<>B'+<50OZ
M^L,,K4BX=K]FKPRB<(3:5A1/(R)U^@%MA[%%G:F'")NT4^3;IO'A$?-!_3JK
M;I,H5'-]Y+DEZ"VFHQW/<2VYAR<SLG8)<S][.E:+V,8)6<+'Z@>8PC8&)4<^
M4P:VISU@&#?<\EE(2-^!V6LD&%H+_IH7PX_B:='M99EQ[ES/IZ@=4_*<TVT@
MOB[:OY&/6.#L9Z=@L VL[]P2^'\8I58'"$M?SAH=(&G)WS5*G.?'0 @!XPTC
MS5M4(@%C?$Z<&$YR#13'P)JA1V9X&7\1HMQ!3DJ%!2#H>_!@F#4**Y6!>[<-
M*P4=,45V4(UE^0SG"AS#!(ZTT"-ZG(5#:8AA'BQ5N;DI7A0>T[W"-BH@>5#T
MP77!B$]B/&/TP C! &.1DEZ2*,/1,Q-$:^IE7P4;E$)LI1/473X\ZZ;S@(79
M$)*Z/1_'2_/=]F)N%*>P'0D-R+^7'B-P_5!VHB4B'4_XUV @Q\"#"I_18;"8
M3 X*5W$?*OR%1AFW/&6Z"Z#LTG VF7%.Q>+9Z351PP&3D(:KS;KWH1:#DASX
M+@M*^#Q_4FGO(>7RJ6L8'$>A[#G@2Q0!NXX"N#G4>:=Y^H89Y9PGQNM1(]NB
M7WIPF>]O#$P.]E##-0/?LU>Q>#3PF%GO! 29J %7'DJ:XD&SX-;J5^D^&07!
MSSEN$;C8FB^Y0JY1+UL@-&+)*HPF<!\$)52!+ 'E",S(G^!RP$-7,"]LPO/S
MK?*^T]\TIV=1,9/;:(A2*"1SC<SBDGW$H65F-V67=,G4D C@F\LRJK*>-=<>
MM=ST)T9H99U@3&+EQM'_1;ES(%SU$D_-TWMO"(K\[N0P1W3S[!G8?+AR*)OM
M<RIPJQ*&!M?,_@CVD\HS '+8Q':KSLW86-99)#=/?:V1"+6JEN)E6,*H/;U,
MBZL2&T3T=KB#Q/Q*^+27YF>8;,1I:?@T-T'B 3PM[K#%FR%LR=]M_,S2Q$R<
MYFGFLP:_>3>;06W(7HJ(>T6I'Y5TO6\ ^HS$IBV%%8R5#5\MBVRQHQD_7SM6
MO"Q11"P;V>VZ"W@--CG*QSI+T\[2/&WL7Y9F9<@_IVI(\PY;D2X54]\4K.G?
M$M"=A;'^IQ97AMLSP\X8.*=\E4M3BGY9FL@]U([G;.Y^TBT!#]K.S5:9I7EP
M?TKRUE'9 7E<.+DCSA+& F\0Q9*),)T&.@:FNYT:91PLFQC[,L4<>T4] RN>
M0D.7([#D@FC*21IVGQOS;=.959)$. %C%)'+2+>[(_7>]'%DC3SS(95WD'0M
MV]QT]73(NBR)M3JC6:R+ -9?ILSE>[M^KDEQOOE&DHOAX.63!#G(]C4,BZTJ
M47, ID0Z(:H2LA,BK:DKIB2DO*20N,^I/E9/3-$U44E_I7UJ9.SH*69G3HUA
M0TKD&0*QD1<PQ04E;O$I[33%4#FWI-;=PIBR^-%;R7JA,5/*_N$.G<KRC_I8
M3$?)0J$*[/ZX9EOH?!,D'$/PG-I#Z3-DQZWISUI&*#R1DD.XHP'W/+6.Y@JM
M8XL@;/MH3U25IX_RGITXRZ*\R_[[T9#[1:;"([U?($.F?^,%>N^EWLDN[:-]
M2;9<-L\-B;M7EF'P]%>XG-#._WG^_L-GY^O?S[_]=O[NPQ^7G]Z=?[YPOGY^
MM\FY['3J[[[\?O'E\Z?WYY<?WCL7E_#';Q]^O[QPOGQT/G^YN*C"_+=,?WGY
M">5Q-(.O8F@0JQRG*37^X\(,T V\5X]S8UN/=F/WHD]2KWG2/-NNT<YS[B-4
MR4G=J[E1);NEW*G?SX8(?\WN?C;"X;Y :G5?H/JP#[]51]TIY_$ZY=2;5MBT
MUCW[PCQ1@Y.G:J2RNW$>$OZTV3II51S_]'>N%2>GG&3-;')]Z_8(A]D>X;_\
M']C \F,L0=19Z*??U/AO1[-D=$0E4S!Y^L'PN'F$R9?^Q N2OQT= W&$WD3A
MD\=7GC=]_8VIZ6,<3=Y):>:??GK]#NRV:*+B#S\D#_<<<PP2-;KT?APY7)#T
MMR/_1_HZG$V.1Q%%8' 0(#[8(T5DB(Z1\7&W>?2VV>N[S>;I?_V<G_@2M>8N
ME[AN)E+?E@>X+9V=WY86*!JG;K_7KB]+?5FJ?5FZCWQ9QOX/-3K^MXJCDGO2
M1J/XK-5LO:G(1=E:)94T@3U52=]%B<!$<#P?U?71G932PCYL#7]=LH_[ 7_]
M@&H<GL:7\:]1-$K.P]&%BF_\H4HNX$BVE3\=ZC70.KVWLK:"O!]#_M14='_U
M9A45+1!*]^CM6:=74\GA4<D:N;XIKUDIOGL/)KX?B(*>5T.=7V.L9@'9/?;3
MA_8D;721Y/WU+K_#O&)KQ#D=SU<ZG6WE]RG*[[9[UFD\D%Z\V1'M07^4YTIK
M:X3^/6CMC'P5#^?8.WQ2.WQJ6Z,\+*6VE=I"_Z&-_6VBDCOU!%1?E<AZ^6BT
MP]>/Y@;8X/U[!ROKF3U9X+5=>>+^IA+EQ<-K@5TV52Z&UG>I/!^V(%D;N.23
M 1/T?78N'_A8ME1D>@UR>C7[]W9G5"?H4A/2QC&]!R0DC'6WW5:O61/2X1'2
MVGC7 Q(2AH$;[FGCH:SX*NFT>R#W+U004),/#3I&2$=Y%.%[J0"U(_K^*H <
MTJ]\1'#MSG,'=,>;UP86?M9T&YU[9V#4L8WJD=0:9>!Q2(IBJDW@YMV:I Z/
MI-:H!8]#4MVCMZ<=M]NL2@#V^?D%TGB&&!>6XZOV!>S.%Y"=QKMK+[Y2R>;>
MY=[#Q:)KJZUZM+/>_+\/[9S6M'/ M+/>XE]#.^L%^=G1V[;;[MQ;,ZR@G7]:
M;1E^&5'/^X7PU2[M^>>:H[!&P)L8HVC+6]^R/EA@_9[;:O<?2%_>?:I"37&/
MJ1;<E^*PH5"SUW'[O8>RT&J*VW.*6Z-,W)OBFD=O^V=N]_ZQIT<GN ?-M:VV
MDI%EQR!R<IUJ^S"[^O)>ND4"TX>_+;V GPBP^S.<U[97L'7TMM-RV_U%+>-5
MG0OYW.AN0<-X/+K#F%7[U#WKU(17$]ZBHO%XA-=9JG-4B.Z>6>["IY+F&\[*
M)A1UYL(3^S.R(^*K][O:MO;BM NJAMOLWCL_J(XH5X]ZUO@F2JEG@4!Z1V_/
MZB+N/:&.1Y'OF]')Z=';;GO12;6Y_*XS".XFI:5_:IT\\.0.@.(UX9,0O]M[
M-=A:&)^!_=5PS]J+TGAK-7C/C*P#)YVUDOC>I-,'"\H].[L/ ZXIIX*4L\;;
M?W_*.<,(4\MM=UJ[)YUG9F&CI\2A=KKH/9GYR?5$^@N/X!QKJWI7J!G88>\S
M=4/]$G[(G<V7\>(-6Y77==:L&CY-34B[\,UO25+KF7:+"@2;K?LXZFN*JAYK
M6@=[\8"LZ>&0+RMHN5<\G$^2?Z"PN:MVJ:?>C]W" !P8V,RCQ/:S")>&H_7#
M&>S+%]/O\1<Z5'[N$H\4;FGLP=;ZV&82&_$EOT<ACAY'5-"C-?AM)4#GZ&VG
M[S9.'S-4>TC1VF= Q9MJ(Q6BXBZF-S;<TQ*<V)J,GRD9;QZ7J P9]X",FTVW
M4Y(77BTR?F8>ED]&MW)>#E2HQG[Z"N%*;_P$SJ;VL%1$H8*[*0[,7_B02J[8
MZ=';5N<^4J(V=RM()]NI+)O0R=G1VV[C/GED-9WLG5MD*75L)\7[P&)Z;J-5
M%7B-9^00P<YTCU'9\+AZ=M5V<>N&0ILOO]*LY%%4$R#).R<T]QM';SMG[EG[
M 8*J53=KZRM67[$[:G7WNF)-=AVU3A\@YZ6^8U6BM?J./:"7[%YWK,4%89U>
MI^)WK+R'=K.UHHGVH\&@/R",>ANV8A3-!H':NE]Z/;L-9O<,+2QGJN":7'NQ
M<HZ=@9?XP[H%^//MT[I2Y'Q5\042RDH+JK54\GSPXA!V(=&?^06)S0B9AA$R
M[:.WC9/N Y1^[H&B5M-^=99V)]KO/"SM=X[>MDY*T-EKVJ\ @=2TO\+DN#_M
M=Y'V[Y7!6L&R@WW4 D=^,$O5@W?=OG?(JFJ;MSD_*%OAX?&#.^J![YG<2CA"
M[]Z:8'6"MS7U'SCUWU$37$[]I_?6!6OJKZF_VKK@<NH_N[<V^+!9%_=S)6^2
M!ER___3O/R-5_T_ZAQHY'DS*NU)..)L,0.N/QJSX)TXT2Y/4"W%A]_(%UREL
M1<;)&[QEW;$^L',^K]_IN+Z,B6\F7[*S$GMZNT@>XD-TW6;GH5!]*Z!CU+2U
M.<+(8](6S/?H[5G#;9XN1HEKXCH$XEJ3?ONXQ-7<K^FVCM[V&FZCOW@7*G(Y
MGE',>UL5Z#Z.T&<+9_0D2I#8C0MW=.OKV7XH/:@Z<;>:O.ZM!ST8>74>2A.J
MR:N2Y'4WU>+!R*N[;Q/N/9HV])"QWY]3;Q H^'/DW[S]+_B/'M;ZSE^S)/7'
M\X>F4O0KKB;3%I)I87-6S'.HL(;]P:?9T-.D+[[V4QAMN,'$+Y1RO.$PFL!L
MYJAEA5$*XZ71_\_>NS<GCF3[HE]%P9U]3G6$[$$2SZJY1-"VJ]O[N,H^97=/
MS/UGAT")T920&$FXROWI[UHK4P] / 0"),C8>[JJ0$BI7(]<S]]"/J4:8!,-
MM)'MFN[0-AU8,7R @$;!]3:O.T^6WC\&/A)UQ>_$RAHZ;UR?>H&-K/?19PX-
M4?[TP[;"<:094C_D_/*QGOS$',#B0496_N2()%E+@*NV?C6_(>G_XH)15FVK
MJ8_,[L"PAKK1T%J-[FAD&:,.TQK=KF'J^O\@PJCXT3@.CD]!9UP-?&9^OS)'
M\(X?3>>'^1Z@8*6V8F*[5PM;O[AKJ\EW2EX7&]O.W-C^G_W;NP?EZ??^MR_]
MF[L_7NYO^@_/RM/#31G$=.W2;QZ_/C\^W-_V7^YNE><7^./+W=>79^7QLW+S
M^.7IV]WO=U^?[_^\4QX>GY_+\#8YE<Z'>U<)Q]X,[FH%O^13(W04)')/Y>3P
M)HXY#=C'Z"^?+#N8.N;[1]NEI].//DU,_Q5872@+9/.%8X<>R+].)."ZSJ5
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M%K:'&=H!&[S;4IO:<E:CE%9XH>]>N E>$,MTP/[N=-6.OMPT<%(#7%9G[6^
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MJO*<IF\(CQV7U;JU7MM0N_N/@Y:L5CY6TS9@?AR3U>!M:/92NWZ.N,-5MB[
MDF03;-8W=K,OUC@&.Z?PMZK#*-LN_^U@$YNV9NO2JZ0-6 7'U4@:#2HTVGL?
M?GGI>2(_78JC%,?2NCV-NEZ4VR/%48IC:=Z[JKYAHVX4Y1L>0QZSD]_-*B:_
M4_MDP$Y8WFS@L#(.@:S^ZB[(!WR>3:<.-7";CF+9P=#Q@AD?3\?=0IQ?J=@N
M5Q(@Y7)@9>5&,,K=D@,K-U/@'DP.$/Q0F9JV571*:>^(:]EV:WN[->L-2RV*
M!18%13SU!"SUE>5-/3?J#; U5>V<TA!2$,Y3$#:X:/L*0K/6:Y[7Z%@I".<I
M"!MJG?85A!;.4&ZURB((%P;Y>>\.O0E30O,GW-)G(W@Q9M'8+EEW?3(3"TGR
M@A3)E*EUH#J-NIS.<<ZLL]$HV8=UBL-CDJQ3PI+Z;;OI-C'1%F=ZM];3NVJ]
MN5P"=)IFN;^'YL!A\*=EO_7^ ?^)'INZS[]G06B/WHLFI%;?1$D](UJV9ITX
M9)7YAULFW?&C'<+3AELL_)DQQ1P"Q\!JWA$GR\4I($KH(?=1ZL<,F17A:)D.
MK!@^(!39ZY6O*YY@:-=H/DV]P*9 M<\<$P?,?OIA6^$X4I^IWW&R?ZPG/S$'
ML(99N/HG1]S9M?MXU6Y=S>]'^K^X8!0NVVKJ([,[,*RA;C2T5J,[&EG&J,.T
M1K=KF+K^/PB_(GXTCK-D4_.570U\9GZ_,D?PCA]-YX?Y'J!\I+9B8KO1FAHZ
MMUP7=XWO3>\? Q]%:WFU)]W8=N;&]O_LW]X]*$^_][]]Z=_<_?%R?]-_>%:>
M'F[*(&UKE_[U\>7N67EY5%Y^OU-N'K\^/S[<W_9?[FZ5S_=?^U]O[OL/RO,+
M?/#E[NO+<QE>)Z?R^'#O*N'8F\%=K4!%!!$&*G[*@'%Q@+0"NL/\9>F]5C-A
M#C%IU);N> KR*EJ<?CN%UE&BA_-C^NML O<9+OLK\Q;",["2/8+CU@W[H/IG
M;@B*_PET_=!FP0O\\%>'YG4*<T"K<U/$=F?,ZH?B,[PM ]-ABASJS]B)9.QY
M-IE@SXTW4E*OI23OI40O%K/:W%YMQ9?P"[$!E'%--@8W(6-K]-J6%#'?+.?C
M5S.<^>QQ].LL@-<+ EKP._]O!C66]_U$!M%*9;%"7.@UD5"/H"%H(Q,3XJ3"
MDW[X2D/V6*OJOYD6<Y0G4* 3<\AF9!8'RM09*A^^FH%E_N>CTO_S]N$7Y0-Z
M>WK]$_^%2O_2/H%"9HKXYH:;=?%7XN,?;/$3;^;''WE^].DL$)_]HMB!8BH#
MVYO.+4L1=N-IR?@"+RS>%-?ILU<[P)BFI9BP:E>Y]VU$A>6C[1U[8J-!&ZT\
M_6ORGMN? F7,3.L_,].'N\ =? (XN,7?NRK<#:Q8UU)^V.%8\6).SKH$__<<
M7BL/WLR&X_&+'02PT;:J_.'2&I[1E YB.OYQ_7P=;?AJVWJEA*\Z4$OD*FDZ
MT.OACR_?_O7_$4>Y8#*$#$.65[!EV"9+GNK,X6H65$7@6?9LHG@_WP>(2F:[
M%O =[ATX* .,>WYG<!U..#)#^, *8:4T_@BE( 2+.417A=?.A.;483_?D<'1
M4@D"<$7 1'FGWP0.8U-2OS$][FZ?$_YWE2DLBGHQ O8&#WUGID]%.6";$Z4]
MQP+#A]C"-7W8338-@+_.DI D>(*0/U#*I@BZS"&7<>>1E97/GL=EX-:?O2I]
M"_P3$$PN+_$F?[[MQYL,'W\QWQ5-Y?,H-Y,1*(24,:V9 W19VGH4;;B_ OK3
M4UY]L M@A8\^Z#"7K^GNY]"!0_?-#M_C!3W>WL4+ B83+TEKV6T=]%L3K6(;
M]@-Y.L4_:*,XR5L;]6L%;.K_GKF,]D"E#8B4&^@LL";0"W?>%<><N<,QO% D
M3VZT\[DWSH$= $-I:?_6$!BW%1\S"UCTY(U/PXNFS+)-K'M-;]#4FT8BOU:V
MX/MH8*G6(B9IJ/0UKC"F[^V=V #0,$)FTT\(QW"ZOXX7[F1H9RJI6A,D-1*$
ML8G'XW]F-AZ.]B2J,XR4K5DZBXA6_\T.OBMW;Z8CK&^D^!<[M%_Y/Y]1I;#7
M1(*_W7V)%?>)#!-:-ZJ/,7.F"G.Q@I/X?\!<-K)#8F[\MX5JR)N%="/Z!(R5
M[P%7$Z P9B!ZUAN8(0ROPL N4C  L46)I0E MDO".?5M/"&G\.W0MP?PM:I,
M[  $%&1DP/^ C0/VA+L)@N/S G!$KL$B00'#?PNAQTU4T1!RPO$032"!J@]R
M^6/LQ8]AR5M,@,7Q3 ZF3*BH(09U1S8F)(7=:&-H<0Q'-<XI@&W9]N>X\J4K
MHWN >G#A<MCM^(C&)8Y-.-Z9ZWN.@]SN+KX=;[3T4 I0;\ C^<="0"C$J<+O
M!&Z'8GG#V9RX!.:(D0($Y\ZRN3]SGDJ$.R8)TR*CT=]!Q?9=\(IAZ]C4\\.Y
M\RHVIXD\R>$%S[20G:S9$"=4"IK,6>*Q4TV1:,9E'YXYQ8=@DL06W_R<(A51
MH*(;XA4C\)V]!1-ZT>W?E33;^_4/-C 2,,9[W[5^\X"%;M!0]=V5GKU>4<\^
M?M'KS /D6 R*_#.7RMB8P5"X8F-3T^<J G_N6S0QE:PA,PDC@7Z%GX.R %,#
ME+A/*@J^9],P42]D]Z;].>6W?O\IMB=!4<..8BX+F==47CVQ3&0+%;26/1QS
ME@*M1+XAG0@,928YI8. X=*%2@S@BV D\H?PM6.; ]OA$B)6Y6+V#YWU&9TC
M(V4@(DWGZ64FS&"!*C>'[Y'>6M1+U$X!!QGL"[B#BL7@.+$(\AJO%N<M6;-P
M$IFPF=&^I31^ZH# '^&<W56/\UQ.;W$&I16B,&QBT/YL/4HW!P\*U!S8$_Q4
M].!"7T'Z>SZZIB$:O\"YL-K('$+SZ3._((KQ('/#%4^F'RKWJG(/#*=H_6R=
MCOOQ&3A(T>I7_^= 2G73[W*%MW\U SMX'"V$ME<'5(UC!;)SJE5Z#Z3)$_!H
M9'B</-3&[9T->I5LKP$#5ZYP[1KIO;29AIN4L"@9$IO7R 676Z!B)<&"Z-+#
MT# ,9H, 3CC3!]F\5OKPB8V)N&%T6?1S6APXH@'7Q^F-8!AY='$YUZLR$>5@
MN^U+&0HREI+I=+;G<_2\;VSHP#E'V1S<R+Z%ST*ZW9+?,<4/$PENE-YPRI:G
MQ=<,SMA]N!%GZ!2I3!$>Q9QPJ4F$Q(\WA%G1(<4M&%&4$FXEVKQZQ2('$U<"
M#@*;!&F/%UB/LE'\2@PZ<Y5$]Z>)&"%?XS1+]Y[ HXA;R]%8=$44%8_V&U"N
M=HA_2^2AF9&5;&8D;,LF)=D*:>Z5B8KXMJ?W-;+,234#N@G.A(GI?V=4Q 8F
M&O 7-\_1^Q@SQ\+<Q<I*0-L%:H0SKO#6@/3<?_T\GU6>(5C4X^AS)"#WR8WF
M,09@#X98%?@##F?@];@@L)XP5*O6"\<^8TOU@"GY2RT4SLC;&1/R:OL*[NQ\
M*'L QR%[XPX.9GTR[P+J0(B?@KD#\F&(VRE(-A\PP- F: F," !%&7 ,YA[>
M%<<#=XEL>@P29)-(Q2!U)HG.W$%*94W!PODW3@9"A9CLL8@P(A=')@ZH: 8;
MA_M$]7P\%\?UJD/>4E8\A^?Y@NC>\ LB!^P N%@^4$"$_7"2>1PJO%9NQ 7B
M=S_0M>$>&"QYXH&,>'X4'X2-P^7XR$2<%Z)0-UALXJ3Q?B3+C6T\'@- -H,O
M74;^&] #[#[O!QFK%+$4YB)E+=$%#X(HUX$L-Z2<,G\YSG+PT/0],"4Q]STN
MD@7(<': :9R!R2.9R>VB^]S-?T +AE^"/(0\(>.S-YO]0#,:\Z-OMH7.6T0P
ME<Y+C-S2%-17"@PG\A9[LG%PCPU@4U5E:K[3"X(_"/]^5^-C$?<:AT>!%(&X
MP>^]"3^V(H\X<4LQJ?N&Y3C"/P6>X'M/[!#RC4W3 I;I4LQ7A(GIL^2=(G[Y
MWS$C@7_O8/8.Q=]B(1J/F VPYK5-LL]!0I(@V7*\-O48XOPAL"&L&NX(6ST4
MQ@,L*5K#/']/S.\L$)$<I H;H1LN+!''0<E"/\*;A; 4E\(% ]/AR[! 59*<
MQ>+P21D#I[XQ($-D(R'1?X!2"C'?/<+,F(FJDGLO,9?]&#-7>$=<-..'X.]=
M#UC(?07"6 PL)2M:F@W"#.Q*[QBA#'(OP-"B-%MZ.RW;$O(U]%Y=T#E$I]3&
MIIA]O<GT]X7*JJPJXJB6]4+*B-MKRHA/4!&\NO1-SRQ],VJK?]/,+)=K4KE<
M&8_(6)%OD PPC!+9C10O(RVYVJYSR3Y;,NDZ*VRZE?8_.,SX ?"#%EMN2)MH
MT]NU'E![R7#[+WRE5Q_>,.MH5Y4;4!AH$BD/#S=Q1#OZ, IH1R'K_5ZYFWYE
M?>\7[M1ZS65D_/7O^PD+1D%A><KOE/%4?O.]V515[MUA$L\7EQ3Z\NUZL2^/
MG3O+P]0VO3R>V(_3<#91/OLHGG!"P.'FFU,\B-,,0!<5NP%:H1N@UV$#])P;
ML%;"C8(EO*T7+.&ZMI^$%T-&HU@RPI'0S$O&6(B+>:-&L6\$!Z.^W$^WM606
M\T[-8M^I@3.<<@O;LDFXT@2LLI=-Q:YK;"%]W@<W0\SZ<I=A K8]!4LG6.@S
MQ9 $HL+9J'R0[-PA1QM862C(!L<"[6YTKN)CZ^D^24!3+,J=H3\V\[G'J! 4
M'SV6%U6QN Z)JES&6%"!S@M56K@\NTSE-K2H=Q$Y <:".X/C-9B%"P$%NI4U
M$TGOJ *;LR@^(BXMXCX5+!AO(/Q->D"T8E& ^,,C3XKRMA;Q./(>K."-.=YT
M$GFI\V_J^:^F*U*M29'OS>V7QR!=YALGFEZB>J.HLH2\FCAI"ZY4R,,0"ZOS
M7)9>'3Y@*8&5=0W^&W8A\L/QVF7A*"A!D"OD_ UK,F?L&_?V<!FK4JEZLZ(A
M9O&*ITVNBD4DD28,J 7IB%K_^49IU5N\CH0G1% P(P$0I<>IJ)KHR..<&UW$
M(RL^2R=8@J$W)=;C@1L*4I@^-O4%,SQU H7*\ZD@+ICYZ.:K/.(V\$1%M^G[
M.-=J$@>]YX.Z_HPW#8M20_$J*C4! (.'[TDX 8\+OA5Q/&/*?(I88Y##&SBB
M]C-)"45QPB25Q.MB,(\45?SR(F6@T(BK'=H1SXD$[M7SL/C#Q\++-WO(>+2*
M@DH3S"%1I"55:1FMT4_D@I=ZI_=A*<(5![Y7$2#>F!_Q6],%(P_C*U3UB7H_
M"-DT^*A\L'^)@F;O47*,R/PA^$4DV>/- 2W7;7R"GRS^9M7FBJ5%MZ2?PF_G
MMR25[L;<WI#%CWG[A6)"P^A$6;HRHMZ6SQ<W1M;Z /=.HD]SW/(!20 O3V%&
MSE@1*P2\##_C6?/!O%B\<-MALZ]PLY6)AWU9/&$H)(D*&V,>31<-I*/;<8*(
MH Y$?#3UFK.X]C8^R88@%5CA&NVTB&?&WV.X,W4487E"R&62/QS/)>#4 2\U
M6^3!'S8I#1Z6C#*J>  +$X5^3GOG\'"YC5%I,>LU:BY8$A?\721>2X*)W2"9
M.BAY1='2LU8F5L:*J3YY8F,\-V-A\WR$#TIXV";IYVF  &M5J(IZ!4>B[26N
M![MHYEBXX@$0T&%11QCI3[X&I$5J$63]!"#!SJH'S+-A..89\4@IFHE>)%U$
MD>%(>V4(%V4M@E@&X\2'SS#9PJW'S&4L"]**Z]#,B]3L<JJL6$O=PO\[:G7&
MD[#[GO$8OHQ$8, <)RK()@L_(RLGDFU<8Z#L>0'+OI +]%RB;^GXCSB:$B"1
MI<T-'^KE%-QO)6HV/NN] ?I(P>(Y+FX2.<S>$!P)6,O[%!TDT->SJ>=R?Q0L
M(]'.E)G4B?4V]V7G%T?J(G%Q3.4-B\/"=^[/H/R9<<T2-]1\'R7.Q+0)EE6*
M7&-T5[$/UZ+$+OWCJ% MROF121BEYQ A7.3YEFCPKHP8FFQ1%U1BD&&-#3\Q
M< &OOCD)D!0#NCO2-UD6^#4BI[>0=XR29Y%:I:1CRO911>J0_-+09P(B0N0R
MP5]-%S63E2D>FLX@_GMFO286I>F:SCNL_%HY8:'4\171-X:GB,BK_0E\1L?Z
M3?K0/E_U)+RB($M#($>BBO M1D4T9//%'(KBA0I-U)>B=<150NQ@^>F-37[X
M%FWQO%V$D0P&3V>9"@&^S9#GQ6:MXXIMI$WB]\0-F\MZ1^EE9OIH@GF^4-I#
MQ[0GR651.EELNU &J5H]LDWPT5&)5E:]"#>=(L.%VC/?HV:(92T\M^CY1YEQ
ME\/[VIN"N6_ZJ)-)EX38]VNFGO)/^'3.IU-%.5+""O$BL-.<VW#S3+%8XA#[
MRU&YQ)QZ1(,P-,,95E0L-)H1&XSLH?+=]7ZX45 -N2BN*^8JU'8M> /X/:+K
M9"K9=*5&K' C;N)ANKDJ#HRA18?J8$:M,\1,@E>G&)HD;GI\H\KL:)OBS?'9
M*/8E%@_/ 2+8)T?7HA#-"6@D1',?<FX0.[CTK8+2A;>F."'6)HS0O2=A\V:)
M5%>]-2]WS23O0WF*CM1GS[%.6S(9+2D^Y0-84J*+%[MG^D_WZD($E_>OXMBD
M 14(TO6D*(??J;")?\!YVZ=G;VQB7\ <B+H+DG#-*^[4V)Y..<MQ_;I8OX8N
M9MRT?ZUL>%7;1:E&%3"=^>!6!USS\JLI8 5G&2X8A9<:7$U^5IG^D,\'34>Z
M^3OSLFI8%P$>T(N:3AD*EN^CEUT9-&XM%X7HK<I6*T?OFZX>/4DX.;40?F9Q
MGO3-'PHJ1#CP')"='Y[_G=!-? \A4:+ +:])C/@W3CZBTQ/2P6AB'>./*)"*
MM_9).8MF13R L6L7CE3LF7L5L30_"*\0(8?_#5,>RH2!!PFJZ5MZ7=A6';?]
MB%4(3V'JLZLAO"Z=>.2*1O](W =T5+86G85"U52IX)QYF AM8AUP6\G#XC*&
MUL/,35418P0*MNAJXA&ZAD>V!T+<@/;A?YKDRNQ1(;?KP769E76=JE36&9F5
M=8W5V612E^5TW^::^LTIJ=&_YLY <68'@3>T2:HHCAH+,\5]1C/JUEENF;6#
MV![G^HJ'O*-C7/PNKE(6\!L4WXX,8R[$7&]AH%WXB.F0T0\>B7U%#!E<<G2^
MXE4\"B7J,4R>,1YBB2_V)U%E$7H$B]T/:%7$VY%8+JF*^F2#;&ZBD'U"P:OT
M$9].#WZ9LY:R]W63[9%I1R@_V)RGO4:E"KVKQ)U>'/=HL9.B.+66,Y7-E]UW
MK=MDT7=\S=Q 2>R2=H9=TJZL7?(M3;'4RR>P.?_+G$P_W<8(="=U%L1B(G9*
M+!A@*CACX8&1X3$G-%$-191U49'] L]UF1/?2DTLAB"<65%$F\<(%I\+/N_"
M+>=MCN@.Z96DUH@A].AW(H?"W8_X!K$@S9>GX$.B]XJO]?PY49LLB[N:,J$H
MV,#+A@*TN,AGYI&EE"K#*PBX)=F#<&S[UA6/G.#UU\K3TB9FOZKI4(>TFL <
MT2(0"_B*AYVP8QIN(+)=CYE[GKII%/H&K\U'4,8HF45[)%B"C*L1!>T0+DF\
M$#=DS:& PKB*-Y.;?'//M.R0)FQ2H D6^RJ8*0%W-"D*CV&5PUJJT;+$*I6L
M7NQC82Z<0NQ7&CBH=^=LB;EB$1Q[0^=^M'^A^5,TH$0!2'% !T1N;H[;K@N'
M&^5!H]]QP%!O- IX&]B2.LBHR#I27"G7.=>W:*!"0*!#P$HK?>].QAG7.1ZT
M<\XS+/5:REVLH8\,I[ ; W<6&3C6=E'@BX?-4V^85CH9?/>K;[IDC:5^$M^4
M#+:_%3C5*+7U8N?S3A71N[6>IJM:I[7<18S:,==J-PS2V7^U1KW6:ZF-C"+T
MN *&HU02?.V*YB!Z+QX2W$RM F>Z;7K]C#E"2;.W 8QJ3Z(#;OWK+[R](EY<
M+RK8GA,:83*Q><X<[/L;$I97YF(IPBK]9^P'N78,:,S\8 G):V?;\">'.%_=
M>C[UL"^8JJM3,&8)(A""!%E\-+H(P<>07&#^D5!A3)$;7T'<K<RC ([Y(YA%
M1BDE..=\ARBV'Z<6(^>!"EC_/:,>:)',4U.A")6P@*B8;L9M._@9_AJ,$%5!
M)#>/\F@J!YNT*7V;6-L3RJ[%%7%V J@+SK;MFA0A60)NFZ]7' []F0A39N\@
M!3"RR@+CP J>/Q\2++-AQ$8AN0!Q*A'5U2^\@'# XN-)^!H$7A<0S((K8BJX
M?0,G%3.]5OKA23W+;$U=2CFA;2W=7AFEW"L*L&%)->.-[BD&GA,$C(&) DBJ
M$$"(D!A+&+Q@?V!'$.48STN!EK]12)\++65+F$#]$Y6L*6YW[.^,N\14CV[&
M[F(,YLM&(UR!YV;FS%<@'$5!=U54E9#%F'BI MADY'@_J%+5B6$Y*P#:]XQ!
M@E\Q1G"3"A$\$M 7G.;WU)D&-'AR@$D6(G5&1L#<,$KKQ3RGXB$W<_&0*G@R
MM+&]A>.'E_J0@[TBV#-?=I2DT BV_8H0A4>F[?.D(3_>DG]3A6 (AAMPNV@-
M"%+WX!G&7QW005?/P[%'73-TX176B."7"7HXE?$G_5_SOZ(ODPAH/P67+FH&
M,JY74^4MJ @F9M+%1;7]#I74O'F87*.:)2QIYV->Z*U [5"/W-4(^XRI )V7
MZ*22%,R?1/?DKX82_H/J+<.E#&94:S-F"W?@.X55Z&B)4#D5S[^JZ&W.87QX
MC(/H"!AMZJ!)U1JQGVC]!'S&E\A]3,Q_P[?\_<@:B*A%60N>5T'09K' I1><
M?X]4A&>.D=#$4%,X/0D?P"I&C&)YM(GIU#-"23J,H&'$&U-,,4&2!,T:QWA3
MLQKHM[#-F1[X*9R<>+KG2I>FD:$,&^O3%A/3?[7=*Y'=[<Y/32U;(D.,O*8!
MIR='0\U6@G9Z*G?2WD/(S23:2?EB)'Y<.H2VB7"?D\8R8$6+C1@9VQC<3(%
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MZ++?_.OCRYVB?\Q9H08/[W.0&I"%)]]SO9GP#@@NE;/VO9N^!N$VIV D+[O
MS8QRKZ:V?.S 0\'RO =>PW!X?&OE.1HPOZK<;)4.U;(*S>!3_41&QP(7+@M-
M_A#$&D+QB,2JN$1S&<UV]39N4YE7CO/_&V&1 !OU+7 ;Y_GHMQEH2=B=2L_V
M6\M@]Z[R%<N1$%X9HV(\5O Y/A2RA$KYU8,_8HR[S_WG7R-0.W#85LJB\L>4
M0AW1[_K/?\0_PT=?U=OJR3J(LG?G6:3MO\5)^@\OWA1D3._4?_FHW*=JN?#4
MYI>)CCS^RUL[&(*7AH5=!W^YM:^"P6^^7&%MB8Z\UWA@+%_FPMS0U 2.L4\H
M?<P=HTA8J=\@[ @"(Z?MFNC.R:@3-#Z!YA2>)],/DP2$-$-U!['I-F!P#%*P
MB_RG!/Y;:ZJ"1RG*C[Z@/8E_AH8I=L/8&%P6Z.F;;M580#H6&F .FX>,45RW
MX-&XFV%NV:E'@1[\;Q.^\J.YC_"49\9*QMI?/1!%K?,QYM3[Q. ]*>P=<83%
M#47"QD[L\*19:YEO%^,@%5/2.QU:64<5J/-0^1<+H^.LTKNRZ>B*Y3EU=,%I
M%)]"L=1VRW:RI&$FHT.EW<@Z5)(K2W68B&. YP1\N!>VL+G#=^$4#SFN&4_W
MNJ(V+P4TDA;<PDX&4+3$]2*TD2(_3Q(D %J)J[P>*GL9'9LWB&;@8U\?J]NL
M!&9B8Z6L-:[J1DEE[3E&]+Q*&70W<TW^XM*K:/X/BISY^NHSGM%,2^!)#\ER
M;?"'Y]D@Y':Q7K\"+7;*O5$YDA^/M"5J1HU29J $>(PM*_*E$A ";QZFS%0J
M"$@F;I0F3*I-BC=P6]D&[J:?M?D*TO9[@G!(@_IHA"D-)^" C'&%L="9(])M
M87(-_]U0X,>G364LS.$E4D[<HA[%8$7TD:QI_"RE&OB"2 <+D,8LQ-W36G4E
M[':8BW/=.!1SO?HFVMH3G:1\FSGG':OX0L,LDQ.($A'/*5@9[#G^*5"1:6)3
M0'9(%'-XOKM9#%68Q(*.XL^<2'B0::>S@4/!-.1WFVL,P9<,1RT2"2)D@;2>
MX&K&1DEZ%;,]/#>=3^'E@"Z/K^,Q%/"2#<)#G(.2']D.B^ 5HDJ#M*<^<R*L
MZ'7J9G&B%K[=XDBM)B%!],';=U*["[N%<P7 P^ A 'B)=^$>I_8LRG_P7/5D
MZK#( /OWS+))M'E)2%28>N/-?"K?ZD^G#"&(HQ7>(;''R@TV&-CADL*9>+ '
M7ISJ2;=%8"X\GK.R"/@@B$X&':Y8C:H$5VHPOI]Q/TGJ92-HV;0E+J ^!?O1
MOZP,W;4YG5A8?L'8*K]P"LS5;/VF4,[!R)MS^,:S@9]];W(C"E3^"4?:#;P+
M6'%^1@@[8Y1+,V.4B[@QF(DQJ.E.C>MT[WV)</+A1UDU- '(\)"RG BP%0TW
M$^G9=$)VKDDQUVM9^'^'-*+Y=,%2SIM:4[MZ2MNZM/.Y(L1&@BYC?'PWPEL%
MR0#[R/Y'DV%+7&I-+T0^#\W(G_--#*TD QUZ#U4!M#D49T<0C5P1[4(KB^?=
M&6[S8OU\IYXNH->79XG2P#%N&WZS@^]/'-C:?&5:7!U_I2?G5@,;P.M+Y?#_
M%?/Y=<ZC\WDX!B/%88\C<=;]^OX%YRM%9V?PZWL<(Q$9@N %4T89AVI&A5<S
MHX'N90XAAN>?XB9>4PEFDXG)@=Q$(8_8$?K$P^)0X) @$'(-MEU,J[Q9_F9F
MEK^YE.4_N5K[N$7F?\4;ZIEV1^A-"<>F!$@YP,_7=5[LF <JIVE<=]K97ZV"
MREG]>=/(=Z<UH#NMCE'&1;7W00**2 VBQ<1M2GG5AM<H!5!,=Y,CQ&&+2+>!
MGQSIX40#K$: B=ZOCF^W>M?6; ,OK"[31J2GYE[>JQMSKR[8>Z'XWJ "P168
M0%QYH[:'UU6HVE/!A7_*N6$;+EOYG",^:ODY!>&;*?AGF]?FET)E9$,CW9C8
M'>9_+P+*+),&>KZ=JRL94D:=767:M;SVO%:L/=^J]1J-)7-^H=I3$'(7MJV7
M>O/_2_+J(7E5+Y97V[6>T96\6B16846.%ASLPRRO"!#"W-*:L7'G*:U&L=+:
M 6EM[RNM:[BV2M(J>;5@7FT4RZM=L((TR:N[G2R5=EH>I^%L(JW 0\IJLU!9
M;=5K/4U:@9)7#\*KK6)Y5<,@FN358L&@JU!6N34>%/;+N]XVM2MKJD1.6@RB
ME[(.XZ"C6;>M?FM5LOJMD;?Z[;-I^W\B0EBJ*6$Y.]_* "5O98"2X]T4NIWR
MA9EX,\KYKR][NWA((*U<D$ KR@&(WN6LZ5XH\4W/_)MP-HQ;+E)H>W/H>O,3
M007R)\VLC&JFT[/I/9\/%YT- G@6094D3934_R"J7GA1-OMI8D7S/(3>#&M]
M4X"O!&T7B)X*!)A+W9(79%LIG/?H?9+.A]3H3Y7?@+][^FI.U]?T-#Y.X[F]
M<&-DN,QWY]6:BVCW!%0?H^,.O<D \?FHY>/SW!2V!+(-1_%-I\Y[=%*.;5B.
M/QPC#%PP].T!7L,<[T<TF'3JVQ[6Z/_% K&\Z0S6, OF:9V>^N92^38693E8
MZ<W?;D#P>QR/.62O<$\!'RO:O^<7$T\NA94PFM(%-^*=B/!X =D?I-'DX!'I
M+G9109Y:UB11CM7N.%XKEOWG&Z6CU\O6R;?BD"*RE:0U3^56FL5&A#::XAP:
M.3P'L9WB)<Z+P9B E@8L#2X\ATVUA*+%;SAUS"&"1:(38L-;8^L7W0J1-$$L
M0/R&U#GF)IC?D>)XOU;^2<,>N'23TDHIU%4 5]% +8?]1%RP143Q^.[SJA.A
M%CE2.:*DX^H\EQ"_F0E:(NJW2*H$V7#LVJ"G@X]*D:/%4[\3#MX5AL@^&JU,
MPY!_9+LX]OCCE=8Y C;3*CR@CJZW/IV.P3_-;9?6N&[B7HBVV0@L/E+Z:?3.
M3%Q;4QG-B)G@_&/F)#J@TH#NDMXEI#<?/;^6W@)A'Q6/,$PX$FJZ58Z0Y,2%
MA"' (S4(.?CF.6\TE9DFC2.BB^>+$0G\H.8V3$K1V%6' %E_(./AP:%[:=:N
M, $C^RM]+,P22'M"]HTTJ!A>+>"8"*AVX-C!&,G##:TKV$1_;IYT;$EMMN+L
MM-4Z?^QQ?2Y5>)E%^H%,8TVY4O[OS NI59PDEV:EQ$*8*7;D0/#V4R[,4FV7
MF<9Z)HT#&Q9A^MM2F,#;_[.&4[:YI;A7 CV/ "W\.71_H5[XP4'3O^>?&/_.
M C]VB'V\]*/D7^#C^V]X7J1OE_P*=O:-WPV1*,DBQ2-)Y6>-[WL#+YJHHZ9N
M%AU9EAF:Z GCI13EXN$%,4N'F:Z4@S++@0%R\(>;(FN:/WPV<A 7:"5L\$G&
MAR1=6W'PEP]=Z;O60R);PC>V'MUO"(V )_*O:#JL:.!J&649.+(Q5+C8/\:;
MQF)[)#.D%KG9UGRHD,]&\*,-$L;5T $:1^ OB[&?Q!SZ((Y+%;0IB+SQR[RC
MD[:+4"T*=($8'8("A.004X@OC<<\-Q<B^%BX_IC/@S3*T0O6[5YWFD;>5C"C
M>=UJY)N:OJ[K2B^DZZISW:[+-<DUG?F:M,8^C85%M 9IS;T;_(Z94MRN]ZM/
M@ 79S?L9D[[EMFW<-B-CV\ZG7W1%0J3 KM&M6OPJT5<I3+9M*OD*:&L\MWW3
MY;[MM&^&%$4IBE(4R[!O!^NJS[&G%6JLEX^J^*,.9.;&=8@'$^+LNG:>=!9C
M2V+$UP_!H49KQ*O:ODBI'D_6:/Y2C+LF+ROY96<"H22O*A1RZO0+E%>=@.QG
MUJ7[&TX)=ZD\-77B7LU#J!;4$)EG!S.;(,NV>7_;I].PW!V&*]L[9X&UU-O9
M3O=V7AF+*>U^5'O_V?,1_2X!\[]E@S#Y5TWA=8/_;\W^&7YT9Y,KRPNOQ)WC
M+E C26HW:CU=5QOU5AD:05=;]%)&I(QT.H>0D9']DUE7?S'?RQ*/)J_.T?1/
M4CZD?)1</KK'EX^6E \I'Q61CV[]1#96N]9K&VJW'%"64D:DC*R1$>WX9TA'
MGB%2/JHB'_KQY:-;-OF04=V+O*I(5%]-O]9+'M9]H6$ZO"NK:+S43;\1&6S1
M'&# IEG>#%.ZT5MOQOD_PY.EX,TYGT/)V' H$0]G &'E]63:]:*BQ<62\I!&
MGI1B*<7'D>)&(5*\UI9L:X79DE*"I01+"9Z7X.81)%B7$BPE6$KP@22X=2Q+
MVB@J)R"E6$JQE.)Y*=Y43%7$.=R0Y["48"G!!Y+@3:5>14AP<;5=IY?@%?,K
MTI#T9X7SB',H;+B7-\I&'HH BH:F@,I$Q&X7)UAP^"%3^<_,]$/F.^\<TNB:
MD_QF;+JO''8- 8@BV"N"Z,6'I2&*"+P(D7I]%LR<D .$^VS^T1R'<@G+/!N8
M4[G-G*J1#71!0)4^4WXP@H3CT* CYG,8.D02G86P9/XC:NWD?\6?$W:;D7X>
M_PX?&FQX*J)%J/0 G*\QCUMLV1:ATPDX];\0__A=,1&-"N&:!"JGSRP[5$!@
M@[,&(WU&L%^!U2PVB/1-^U.P"M4^F W'" 5*T+X$'8U_0;1_8#Q^B0#-QR$
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M\@8UP1?L=):VAP0]URJ;AUQEJ]9K=I8//)JLE7N(9VJ&I\]0<^+(&.>=M&3
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MUM/JJF:4I=%)\M,)U'&!_-2I]0RUWM1+PD[YPMWGULBSSE]=5^YP$14^16S
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M;C@>-1QU>1RUFTUQ8!76(Q6FU46%75GLXC?;9;"*/\&,P/(&40O<!"UJ6^$
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MI77?P8?I)_7=S[OP^/AHU.H#'ZA:>Z#G38P%:L6()$765WY[4O['L=". RH
MO5X7YG11<H]Z]VA['""2D][+F1Z+.Z0IF;D,SV<$T\1,5,!KV>75M"RNKAG*
MB=;5>_!1N**?%_B//G^6RY:&:>,;2$ED7TK,DJM<UM\,'>4^+\>CF!Z-T79Q
M!+<Y;RM\>('#!9E?6;@#X\4P+9HBR5[,&<Z[;"NFC]]>.K AR_P#>=M'Y#U<
M!%U51DXPC9,!/S+!S7+\)MPZ/ D_X'DTCA3^%2X$]Q*MW.%JTT*D%_P'?!&E
M#8X47T(KC(TM7;G.OQ@=I4>#@.>!'[@L]<F.\DG,",9YY!O&D:?GCQ/A##HH
M>!KLR N9((_<<G3ZR@5>=$VDF:-, R 2[)I>GZM88:/',JCV3P[ !0RWHIJC
M,#B/%W V:@Z4MF#R+QIOZ^#)&S88\A;PU]+T!2WA8V(XJV0&%*^XQ('5RUR%
MP"5L^/(WX!4P^N'89DQYXNR@Z".-."3.C_/ @@,!A<Y1Q29LCKP-;W@3@MN!
MARKHG](C8(6%)DN>A*8M=T\8 ARP$M'H8B"5*>$NS0#ZAK'V55I!H]:=WN[F
M]!CB8;TR(+#<J\1J(AK%T)K$IG?9IW:\?5(O95?/PB1POHX?)'\G!R#=M.?,
MS=#KQFZ&7J_"^>*U<W._1Q+Q?SQ0A,N QUCX72?C*'@?>+!8<PZ*'BAGLV?^
M*7D9(=WX]8%RZ-,<:!S=#'K=R-7#^$P_MS6SH_P-GIR^_QQ22MR">\&MFG2!
MQ&X?(?PT+5JH!+AULC(?NS10WY1>78QBG'- <=%:0!VYP%VNQPIOG]<%PR?3
M.KR%\\I?PP.'=!,],QM7GKXAZ1I&R?-@O\BZ<#F;9.Z+"Q7V:SHSL;J\-\\<
MH$W</#%A!SBYW(X3Z/\D%B,4L8([S;\57<4AX':BC^^[YB3PX??P76<^1VMC
M:G@+_"O\<F6\T8Y@Z_ =.<I<&'@D@2 .IB DT#0 \Z-S%8(79\F\LS.>P23U
M?/P-384'EMD0JF@KH!KIJQ2V$%>^0>I]P]SU)(.;H.OM&9VHC-TI:"#[PDA>
M+T/XY@?7]!:X'E 37 47FQ]P)Y@6?LLEN]@+YJ!O3.3W4,_ 0KQ@A18_/9T+
MG$%T(?*XBH?R(ET";J  LT5%51?,4UO'+)'4X.F8/IK"<#GB6>YP]Z^_^7^S
M9Z"MN$Z8?10O*7OG@Q,*MLVPGQ,K< +? Z[ 9<L('6QL"1Y X K/A?/:W^[O
MOW*-V5&4?R!W<1TD/XM/"(F 5]8J<.'FXV8_*F+)2N!0R1WA;Y;&&RJJF3F'
M:P*Y%+^+JE!^ORV83SZ\+?QPU'FDS,%,QMN%])UIOS /S\,$ZWD.XN7#70??
M< (+36&Z!F*VN;@8\'7FG-O(%#P)CQ7V"#R*8C,C3<T_%5U=^&&4)C0/4:7
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MN^S9Q&C1_1H[)G'345I]^(Z;2R%&>>*)4JB$9J+#*74)[C!1)P<0/\+ S]Z
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M$JJ-3&T(W/XM,%S#]M\2XI.5D%[K3F\&M%P@>VR(#6[)'GT,_-4%8ZI)&S8
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M^#1(Z P^ 1^ 3YN^ITP"#Y[O 9N[ID<#)P(:3K%RF8>2@-P_#WR09L4R7KT
MOX._FUJ&N?04 E=C,WJWZ\P"6(9\\UM;63'7(XP.T_Y7X,(OY) +_&D)3#J%
MI;;AKSZS+-A" !^%Q\#7\-N^\:.ML.7*<MY0\N@[*WBZ/66T!(>RWG %^_ :
MQ5\8/FV"P?/@7TR!^\^T#?<-OA>X\&O8E=QM1XG3T*!2(8\:HO,I^+I@(#<^
M4AO6-^&]'?A"09JIXP%=?@+R6@%>K4*L2)<@/@FMEPFTHY^55].RE DNE(R)
M&?W9"Z8+\: I,!O\V64&DF\"!\> $9=(Z8YR[Q\&0'=+YOO IFPY82Z7(EUM
M*_%$>ZWDA,A:.UKIM:15&T4&./D5_V,[<09."(+I+X OO950."@^5JA:VR"
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M5+(?XBJ:,M<'/UC!GJIG!X?.\TYO&U$BXHV5*-PF5PY"-'PG))*R-/Z@DH^
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MJ%AOJ8KD1"%RHC+_5R?$B18RU!Q0/H8->'AABU/^Z+=L-6Z^UKDN'<X[Y=9
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M7NS.XJNU*7CSA/7,7GKVH<0##'\-;WL/ZFLY,8W$>SZ\CX91TM,E1H,(1R-
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M"G[>=NPOB.1K3BEJ %OYQN:PY!NUI=AP\?]W*_!NG@UC=?O9L9_A:)=? U
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M"$^^\0-N4YO-33]^]Q?2$[G&G44X)I*CL/W3=GQE*:?L[=X >I5'\AN!;_U
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M"7P1H]+J2^6C^E+YL+TAE>LC_PI4E,!FRG!,G@,H@'.;X&C^#(@6\5:J;\
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MJYQ36\:FX9OW@ZXY'!0'6NU_W&L/%($;[KKHEA*5_#AU6'=2-6Z G>D $C!
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MW MLB[FND4AB^'@..PCS2R@1INY+0G0E//5K"F-7 ,_!_TM24^D;^*<4/ML
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M1FO5&Q7MN'H7'!62P<EN3\/G/U3&\OY6()$WL*P":?W4_^4@IPHDTA/;[[1
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M#+?M4W,AZK$'%"=T5_A(-!V$)0(.]@W:UTY"J0X/<UR%<$@"3+;*++&[\")
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MQ>)[' 5.ZLTDZY%[7KAP[QDN0;EBA71*CVHIU]O!5Q]'J-QQG$ F4U $+[S
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M.(.GS+OCQ+*NT5<.I^:BL>$/Q<_P%JA8G(OO+1FHN,?74\[HO_O>GHOS%:$
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MB_P19E'V:KI"AB.+-K.9;XJMB:2@*'#&L9JK0YT+[E'+=U.A0%* (O,19M(
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ME>G9Q<:3E6-2)&%79$0FU4%I8;D(ZR7"IU@!*[:5Z_*3[E)KZX*F>,OXJ_\
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MJ7PX+(P2V1ED-.DY/MED#3!K8<UT(<L)K'@61C1P4.>D^D):MIUA$>88CN2
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M: 7.G&;$PS9HMV$8S^8""@_<B$..ZZJW !;BM^"/; :(&H6F$0+POOMPI,[
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M(VL3L#TG %<EH=M(Y-11)2H;2Q&4LK$VQ,N@U7ZYG%+#8"45O3%4)M;>(3]
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M!%=;@DO(@KH#S)  :[  S_%)HL7,L7_'-92$RU*%^9859X?R3'8Q1:9#A%W
MNP -[$K8'2<F7 7,ZA';NO[]Z=-\R$Z<4UK"%%9(IY0G[.3G*3%?9 :W/!(2
M"%\G.E<0MO".O/R!7X6&IMW,YR DB/*L=*V67*O8C<9.'I[WD@*$)GD9+=Y
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MH)8<EPL%#AZK;'S(<;GL.FJQSWX,S#7C8&6@\QIAS E^Q@7=G8(IDH(+6[J
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M,O$<6@%/G"[I<.:H)I<T&O];UDIP3.3*6;@3N!B0Z]BHXO-Z RE&T<!+VM6
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MCETJ>1'WX'G V]$=2G$K4BT)>O/B%*R/>PY>[C0IIMM,A8UY=,^YQWXS85E
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MO%#.W()_.59+'[!7 2TX=Y(H7^2>E;$CMA<7WX13 .5G()8.FN!!E!LJ'FC
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M*@C4=N>V#4*7%%"9S57+6MP7[^&ZGWQ*10JS&T,61KW)XC"'_(3UCG$7; .
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M%(6K*,A^'PPG.H=%8D)TI\:C0(##* Y0R(41X(W.>,P1JZ+$,?D])4(Z3_B
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MVXS,UWI;-[J#P6M8KZYWNT:[J_=U';[KO;[K=CO=3N]?_*=QIK>F$>#JPO<
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M8!D3?L?^OW??/[-/7ABAPG_O6S&>==L&*$I35X2HKR]^540-1'UC_O0]?_8
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MB!<+Q%;0(,@L)#YT-R$?N=(Q2<+9'9C*A76Y&5V&6%K./HH%&HG<@$8QPX+
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M'W%M\O]H+RLO18B@GU^@3]_]&U!+ P04    "  92F-:;,/ /38F  "Q=@$
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M2+;=N41W+_B$NK58D()K8RUUKHQ[ 6W%G*,5 7LTE;2OB([@AU^>@AQ%59(
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MRA!C0)<FO)QX:CR)-M(,,BO!5;>2[<?8'69O15>5ZW&:B0@EHI(I$IX8(LJ
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MT=]L_BP49RDS3H0NN8"4<AG,'8C74FC'A([56Y%V O;TZ51=/2<UHP;&TI"
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M"VVU$9DGW<TRZ_S(QTV 'L5;L>9CCG)5/?>F:9> 2\=B]%=>-A<7PVGYW1L
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M0?1>$F\Q*OR)!7'-_:^S^4K\#PAH1$,*$'TB*GF%-IA3$H1R1%!F$^@D1/6
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M&"A1RB7<V;5959KA]@[:NL1,XOU"[ O/ZY%4UN;M\A)0TO_]M_\'4$L#!!0
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MX3\7X> $S^'BWLW-O5MX#_\>X?_MC=T("/)R\_,R.#GD@5V"')R"'.Q6  8
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MZ=I_].R_UK&P_U<]^Q\=^W_Z-0H(<'* D\<I", !6M DO!$3#:N&MZT$71Y
M&;[!Q^Z)&YW]E3OE4!SV)<\M_Y:$0M)3SZP+XIS VC&.'766=#$%SXK$1K$!
MVO$&-C"C#9^,Q:[YL@ZS@3*-)39PZ1V26A@"%\&3OF"EV,"\.PW#!IY(K;+.
MY?_[N<SBO+^A?T/_AOX-_1OZ-_1OZ-_0OZ%_0_^&_@W]&_HW]&_HW]"_H7]#
M_X;^#?T;^C?T;^C_#T+W-!S -,FCCS$TR9 8%**8EM*XOE#+\_+AVQ]&[IB
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M4G3?H_:<9P\DGJ3$P9X].ABB7YF'/^2+'^V9:D@O&KO!!II=@GT//#L3-J-
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M]O]86\.-$EAF3M/*S)B,'M:S;D2W"^8BIC*1D4%HMZ#OU\0R#V3@,[X =#;
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MQ<..Y\,-D -L8#)?5H?52\%$Z2IQO7QJ7H5<BKA*R#P\FD./N,Q4Q!F#8QG
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M+1+FC4PI!,(Y4G4S0C@@VG36T=[N=-5]4#7Y;X,)2AA!SD%IRNJ)^B,D_/Z
MLX]/*,4M%8VIR%[VV9/,L2PAS'0NQO^'FNPA1_U1DR_2K3[]49,]J?M -2F*
M8CKE0)^QN -X&>:T.E(B5%O"HQ0G\COR!#W\:_+<8FS+HA&ZD.'$@8;2)@%
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M"=/_>#*?M>L0)TE5ZNH@2S+@=__VOJ:2^<"P#B>G+9=8\VMTEPN:=#%2=^!
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M)AN9]T,K*< &8Q$,&*V.[X/HU8Q9WXI2MGW@X,#$D9Y:NZ8!?H^:L/(DT6Y
M-MNH.F=SS6+(]/;9HA:C\P R'/(WSE1J'GX_><IL>R\<RM8-SVW-GW$19S#Q
MD+K<4Q'TVJ='J!N_/!6FMH62_[T"IZR"(C!2P_&*..J&V[;*WBX%2(]H_!V
MD>1P9]H?B+\O4/F%^-,:G*C@(KE="7QP[NP!->M5IV;^SY(0'#!Y7\VMI:$G
M=Q8;!DY##GC*MLG,]257):*(+@6>QEZ<,]S6\MN<OO?[U6@,1\USR%,HVLUF
M&1BD:M17]]C7CSFJZ=WN$;)>M(^_YR9M;HG0S+O0IDEM$]"(#@K 1N3%/5K+
MHL.,&"5:,>?4)?MZOQ'Q]99EY#5>T:2E8], E_MA$40.A'EXB&=+EM4')<6O
M^YGGZI>D$T^^Z_[*37S/2_5*#4,CU[46XNE&(<N-\RI:%"!TCTICDL>_A)[%
M&<:%*@;B=OFWU:LQ M>UXI1E<GN5>707M4X!*B!O;[V+-+MP(KO95ZHC.O'@
M>NIQ:1%6'7K4,#/MC^[O4H-_/UMSA91)9JUMA4369)DN7"VSZ_'TX[I:)UT"
ML$6LQ'$&+J1T^"'5_FXJ-$S=DI0 8W]#S6T6Y7[8G1X1&JO:7/_QC:#6(A80
M7J?ZR&&\G#P^7V$83919F(0Y+<33OCV7K;.7])J_L@O'1=NGH7?V=FKJB*>J
MQZ5M^-_4Y22M/5(KC/%U(YTEGU9+W %YJ.KD=:V:1F.8<T!]GA,CBQGC[:!8
MQ4<"N]/PM@ME7VI&VC:V-%7NVC\_WJUBFKQ_TW"6AZ2([/*,L3O6A/=9+/5L
MSWS!??G^="OJ[2[CDM?ZY^KH<LZ#EP1E(O7^1%9CX9KC]]._C)K)5D /XF/(
MYA*DG^ 53!A$'O7?8&'A<!^2_\#;7K[?>V ,/68MD6/:N;@J2=M)O$L0))[%
MO5ZT'4 7C#QX':^:9=/G7II=KZ4"$6,HK_*<L$:?RWB8UI<_[_KRYA4[:&_5
M]LQI&PJP6]\70JL%W ]T:LM2BKA8M-/'HE\U+"WRS6,=8S&NGG\\?U\BW:K*
M6$/0!<>R]Q#OAU-?M>X+;E<<=I4#91V,9<WYJY<,I391@(]9VV\(-$0I@F;Z
MYZ_7[04-IYNAR-F!-:@N5=@'N[D7A _!5O@V8/>C-DHW!^] ;;BRO;+S5=+,
M(>N8CWQQDK3@SKF3PU1N^GF#T;;2]JK>1XWT:?D*1B#JU#NZ$QJ7Z 2E'N.#
M"++$2WA;C'+U)FC%T[/X2DFJ35_0Q;?G/YE^*.GP9N8545@=-:*Q4UL$3TJ@
M Y*:M +*7+,%[-_9Z=ZO3YO;<C9S4K-X7P=D+]&DZ:F.?QC2X+7CQ-9D+"!
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MK[!"U3 >=47LN0@<O\;+:SCQEUS%;Z^W3C'KG^/QO?-)\Y::)D-3(YFG>&&
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MF[53Q3*^%$,Z &2'-R@KU&*?PPI%H!5"][?^-*#O%PV(E?#)W[/9^^/D430
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M[F%WZ\"QDZI"XW4"X>[23_2^B.L^O0\.8>A<SKH#[%NANZCLGA5PV&.C=AK
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MR]XZ-&T!=VV8>$JNQXH)_GA27QS&XI#1<6@:FS6GI.1;:!0<IM.9(:BT=JF
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M%YH#[J_8#Q!/$6RZBCC-=E%H%%SB;55VH??:Q4 _I:T-"]V4E:P',NE6(\X
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MAA_7B:&V]F"HGV/M!_%N@]5 (7JMGR/Z'J>Q_^6=\G_;JED)%0B/-/JPH3.
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M9T"L=T>/4ZD[1^;LXU^=!'RL7/'LD#0-\LJ]IP4+3W_W8*+^9!&'\1.*U>U
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M-U,A5XE>ZH@@O9"3^)F>N$^=BW PD?MBJ.'YEE!-(CJF+,1I!*O(3,-M#+]
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M>*##_0+UB+0JO*L/5+%<RG%C0B+X1XTSO>_'1+$(7!F'.^?.ZX4<8=+8L6U
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M/AH<&:/D4QXQ!'#<_[($C?^$/2:Y],29,'[80[12#$P&R7?M1&_,>U]A2#K
M+L$RY,4#/YYFF@CN?<O.BPF<HA1(WVD!U#TP\P!WTE(,MWW/_N]D[B\9YS0
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MXE<!NC:98-3QZJ2WXFO#O:J 3U).GW"7WH5,*QJR9?D7*$F6QL^3BPH=#O3
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M2#+Z/U6T*:Q&EL@1R)>(\QUD>.VH_J<BJ>7EGI;)#KT[04GJEB9Z2OV)B72
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M<8K?O.GCI8[//U9,2G'N]=8F;W?[%=WXC!/>5Z98I[7+A0PRL0;]#0#VE$,
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MJDBE5AOE#V:S!HC5=Z:Y95V2EB$Z9RB!5'UH:1NBECN7],)!>S?V_?C,_98
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M(28O0W_;31W\FO#!:DY-36W?.>UK]CM>+-:NI^H:BP*OS(V3]^^+_^T/-RK
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M-)J^'O5MY>*F ,$ZT'M+VY6]!#$R\T%^'8Y"II@MLC4= NB?;AZC]*;J_<F
M(@9).H-P,^FZJQ[V=.VX9Z&7:K^T[HZFG!<8X@X<,)&\:4+R\_"W"ZM[V[*D
M8S5EBGQB)@:CL.(YSZ*'R=,]8THA1GT D0NN!&WHMLU-@MTMI<3;-@7-0NXW
MIY/7?^WW*2;8S&S)QRW#+]&D)G588/IC,,%%FZ<@^]$(A ?2K)$?S:_!RO8
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M:[A%2PX/DLGM!L<>50Z34BU)S0&^)'RKQKXH[>LX:CX95*N3^<!NY>6Q3TR
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MO+D92YQ6N5]S7N+K@M6)RFW[N$YDE*AA-.Q:R<>JDJFW:17XY)]<(FE8E0R
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MU&W]OTU/!=:"V2V6FZ%USHS3;I3;:Z]7?IKM#PKP.7!*-U D[*5V._U;<]\
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M:'F4#908B9>GISUEM[6) ONPZ4FYAG[YE<7LRZ\+LH9/,_CD?00OS"'I$.@
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M=W/SG1V J[YISEM0$QASS@+&^8MSC<5<3R6'F0-SZ:]P2KM@2*Q TD,,KYM
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M1BFZ8G^L)?X!S-&NTP'/+9T7L/'S=L+PNL36>C$KG=,?]^(&M(HN0@XTUV$
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M=#="D&E?FL2W(/>08?1TV91XI<5-IWP85/\B%>TTX)P8W.NOW-OTTJLO:#>
MF+C,%Y+<A)H;:,\B7$:-:;4O?L$099=,@Q^Q!9AD5*;9QHII>T50Q^._8C-/
MD#_C&$ DY ;1((ZJAY5)7I5]^P[S(']\_W?'L6#H:R4)Q%<D>Z.P?R'6(0HA
M/'!/LI=BAA>:_2#$ /).IB0S '%46J/,GR(:<L#T;L>T"M2NQM\+]]5YDS^"
MC]KT)]50I52W^*>51C'8U'8>4?*5F=4HU7%_"/YK7MK1:JJ3?"E"MC&)C&2.
MR%@R'OM4$"(5<98@\++PA[%:^5OILN.P;JU#:WMTY[AZXK^;[TG%<S.EVCUR
M(C&GQ7KN\3H4Y ;A(-#?WR.E*ATLLYMZ;GNS[Z+O(:[<MY(G[ION1845FK5M
M!X4G8W5,.R\,HJL>CKNG':X:A">#QG(L#COM-3HFQ!5LI*&:]O\&;"YV(.@K
MC<DJG&N=/$16?W<ARO\&IFB^;5KXYH/=;?:SMH7QN5'@LN&%#>1)!O"WN<4_
MR(+^'0_3_R[X9WG*AK4Q@/?(IL"T[^EFC^U!;M*WEI%EAX6EOS, [D"=@RS8
M+$([F 4Z_X0,98ZGD\@P\)_]'6CW?_HC'R@(Z8(.1W)4^F\X[(&!= D=^=JR
MD\:?E5LTG%RCN,S+8O$R5Q.7=>3["OYK_FY??Z@,)[&'8X7FPLBNL^8?I\SO
M6!]A[=4VHJC#9?]D@2H3X@OP0S89^T>_@PV.UB#V,&US,,$$-5K7%D+_0FCI
M^#J>L[!9[5MGNK>+YT(.^NQ)O,-%YGC?3PZE[UTEL%I-D,S(%RJ.OTQ8IEVS
M\3Q$G-.3R]/<0*D2V:D\G,V6A]&E=%GW,2^H'^5L"V?]_8#EDRXO$0;#"?T?
MC[#^E&?6=6Z5?UR WDK.SUF$3M#[^F<K,*9U$K9^U B4A#L61)9"=A:+G2RK
M(\37G@YQ>OLQ-H !8%S-74*F:N:*$5-?=,&8ZDCH=!JZ(C7"3P7-?4_IEG!;
M.B+'Q:LN7\\HQF^%'7EA+<Z/9$P>G:F2,B>;X RO^CQ3D4^36M17?\>/D:BD
M'?GU: 11/HTY +O/5^AJG9("L+T8USS<),>ZRC(57?T:;DQ$AE<A;\,*;?JK
M'#U'*H5?C8>$Q!5I>3D,*GA;#[>:[84]/?&5>O3UG5?E-?8+?9\SO7MG=;:R
M07-^>K3WB-,P^*%R<AWN1%3U73^1B;;Y5P% V2E YWTT7B6+?%00+_/Z,07:
MKG#6)*US;+E8,6![ZTD54N(9Q:D8T>G JJUKAX+PP$[4K4Q)B\C4[V^O3?KR
M+BEH+1VGZDF690#+$\7L@F!.%?(F#GJ[OJYJ86'V4PV5J?[.AJ<RAY8++:=B
MG1,:55%LB.>L7=*KNFRVB?9]VTUM**SH_^4FQ$'L^'/.8M9FD<=.(9ZGS&H-
M.N_O^Q8,R16A%/YR*G21WBL2P^<Y$W3EXN[J6P/6'VZP;R)AJYU+J[:^OV)0
MW2 +!X9ZEL"FS Z)[?41=68C]5*<M0-Y=,%JUW\%PT-(ZJ-(F(A,H8RHK8M\
MW\ZS#Q\?I<GG,2V11]_O>'6_F H=2N6H%JHF<I[W"_@^KBX.Z\391_VZ_F-
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M)OF.([\G 3@O.3QD"H$7"!WFNC;')$)P4V):E#ETL7'B*AVIS11*H49(<CL
M5_@OQV%PGT/]F8#@7X"6(ZE\K*1@\E'B<+.$JHECR] )-Y&75^RZ/0N,I2K?
M:MV3XOP>-XYUXQ,&!Q8LZ8)+?L\[Z+\+_GE>3O_^L(RC#SN \5#GK&"$++&B
M6/2.>2O)3G;2]/QF_Z[2$JW@!\O0.E'+,DML!)4?]Z==] SBN_&9WD2?'S!D
M<V#24H]GBH=1TYK1QL_4NXC//[;[V)NW,_/]BN]8!H31VE+]AKVUU[Y=',^T
M$HXY=7+%2#IY]=K_.#:'I/\*OH1@3JS/4Q6^<<@".W^)@\->.4LV+SC$+I_X
M.0?)O/KB>F:=7\@0.KOOO[N;OX,_*GZB_F(F(2\@_^+-+$!A /2];QF G!DV
MB\*GB%ZO[4#?<2?:_&6BZS\_L'WT$9:]78=X=3KO4'.&T--1F9)#E2]H9^=P
MXL43[1-MR=U>WJ^UC.5/"1R?P\Q&:<H-#B_BF1J2/%-_/ST,G2]>8&I*4D@Z
MU("JL63+ %Y7,V7F=!PSD8:HO/0[0G7]SP-8+EW[O>(<].FM:((IWIVD2WY6
M!,O$88\C#I<-/JP:^-Z/K_A1;> M>;JKK6M4_GUP$Z;7?Q$T7O%/WS[:P1]W
MBVT'._@=_",\!NY@!_]U_#LK\3OXE\/?TRG,#G;POX$=U7$'?R#\HU1'H_Y@
M^3NU&551;R;OJ"?YJZ4\:6CKOY%1$&T5SYZ]YP,ZW(%?6YV(;%USMQ>L#US:
M>\^ZWR")/;(H^EW;S28=<5,#L>$N)#_4'2E O3GLDP7 3Q"V[XAX+)\:J>R*
MROM0&_G6(%&3D_> *><N?_9#+Z]!@R6DR'44K25K4.A&%FL/.&PC[M:1O$P;
M"^>H'[=C:S^+'NQB,1WJ]<W,<&5=O2/?R0#N8*("YEJ0CP4#-B/>1'-?M#NS
MRUCEK.ZK%\D5!%/V@"T;7?(&Q116:%C]]6'0Z<W+ _=83DS8N%[2?G S^N6!
ME]./?D4'X7A=KT2R(EJVFQUTFSSL&37VD*3<>ERRZ9N50J'&82KF*<N3$R]Q
M'TKX2/FTX@W/",31A";ZGNIH7-MULTJ[;L&7-_V!D^UB02)G]V6> 9\0DB:P
M; 3Q;VV6T/N@%7[-QGBYR\1O$$2J+P-0J,1GO.X\(5;F&7+&H.,^!P8N9CGN
MP-DHN8#FIW*\@>5< (D7K]]^?EL*KEAT[<O[;R>D=#I  <#BSB[=#GX/?^^=
MP0)/A92?_8&^SM>>B2A_O*\K)7;UJ\.E087U#,B/[9_7'O6/R::[V;R6?&25
M4 JD ]0:@E\DW(HB"G>N#3+0MYHSS"U/Y]B4]JOZ-+T:?O&AS,'PYODSXGI!
M[00_4BT!W,'9I5(7&%6A$V#/9SH8?$7>C\>0PY(D=I*.][O;N)L\,Q.2F$-N
MU4M.W%3DYZ!=0DO*KX627A.4PNE\5!<ZAJ"P%.D8+I_#=2I-I&4N$+'@H%6V
M*X<K27^E@H4$Q<_GTC%^N;MT!Q6,.CV?#X=2.6DU*N@P,'>%$H<]V>+GNEO/
ML8;9AC%NRJR_QMF&:MRJ+^J#"+W]88;L0)OW]79_>&(GR:9:5_;E$>>K%I2V
M Z8 AK^7ZD"H?G0/(>Z.P69HF9C(RFO:&^6%'6SS?:FLI@S6Z-#L/:G+158G
M#K>@Q2K\5^&:7D<R!POJWM>9)(^G]$XT\>[5T#AF.+V);3Q$]BCO %=7)-FR
M:KNT!<0NU*P?*%H%S\ZB9BW0TYD\]NH=Q9<-.02B7G]2/-47>ES+8%B;QE(T
MQ3G52N@D+=5D77$JJS3CM>^X_>S1.P/O'T5WC::YRX_*]0=#WM)JU[L\&8"+
MW2W_@X)E=169DOKW.ZXE2-%9I1 ^O;]<'Z^FSTUG%K*^A[H,RUYC(QQL9;V!
MD$&?[J<U:E]QRX%S9%U(N2V8WKY\H'6__H_KWRY\3CA3NBOH>L 7"LL\G^L4
MR^[!+T(=;]_9VNN;$0]=C8%>;'-E71#Y'Z_[#J60)ME'9=HN56_:-:E@\%K0
M+4HHG:Y$_FIWKM57)*,[$ROKOY?U<-?T-4_RV8JL7^=ZFT1T1[ * ZA89@!S
M*R *&8TS(&5D46G-#  I2'4_13]0+$>'06E43V+.;_Z=S0W]C_*_T/*9QBOT
M/G*JG0&(?&( C^6-&,"ONQY(4:KKG_W):D8QQ= 1S+K1,705I-LH \!\ V\2
MD1WET)E]_<A?)XA3'<QR_O-?P !]@"E@LVJ@JU@&$ <>\T6N;;+3J [$(LQO
MR23L,-MAML-LA]D.LQUF.\QVF.TPVV&VPVR'V0ZS'68[S':8[3#;8;;#;(?9
M#K,=9CO,=ICM,/L',5-]W5"=03+P.AA'&[QO8F85@ Q?5NE)U*F_F 3H&R<W
M%U_XIQVYOK,>2O9$S0]OVV'+K>W'NSV4"V\\]3DVHE,C6_)%%YSF4,F^_/DF
M0="<L/7%AU*LI]KM$LYI4W#M=I3Y(<U$4U&(*_@AHG)]LWEJQ*$EBUN58N=M
M,3A'-,UW75(HZ]G[:/(H^V%JZ:?KH;%.I:=Q&IWH)3IWG[:EZLO:R8B\)=[1
MDX&6Z(IXWY!XCB.VXKEX>WW(_'HQDS9T#$I"1I!""!U9>1DWUVV*(3,EAU[J
MRNK+^#YS^I8_\ 2VKKJ6]"M8I+;5VXLIV_EM\GX#.8?R#J<[V_NWG ).9]*6
M5M*/L/8V<E#W$>::4/M[\N;=CV^J'Y>N'U0T/&5[0DBX"3C2W1*?IF,D3<BJ
M\%R.RX$_J$^P>=\@PAZ5>/Z!W9:^8<D3KF-='X2D@L6\X_=J"&WOB@;(R:U(
M@BE-?_5Z56J'A*I@^ETVI41'T8J28$+(=XU8QSXUJ#5%_=R7XW#5'"LW:Z<R
MJP62>9$ B9B0HG(IF'W&\K_H7V('_]<!=.PO;_E9KN?_WOVK;!#Z3VX>?SZD
M'V6F*R\Q .,B=U(>FA_].ZE_@%#7._A7Q-_=:_(.=O"_@W_3MZD[^-<#ZT?T
MG[\.>48[2O_SN_M'6%=_.5G)IV9 HY'+%VN9 GQ)A/86U>[YEXG_= UD!_^:
MV-$<=_#'PH[FN(,_%'8TQQW\0;"C.>[@CX)_L.9X+*6R^#K,^\*'P0WC+A4:
M9)0KV?9;%Z_&\&!R$RH$Z6XV%GB.G/ .=GF@.6"RD#O^A7:_PX0-AT+]YXY#
M89H6TKN3"\3UC["N2T3/0/C@=PE9'0V*BYLMFQ@ODO[5VNI,*;%2@6Z[)F)H
MQ?0C _9,[LOD3B(#: &S%MU(;;-\4#G[,:5ZH&C@4\WS_;F[="]E*K?M ]:C
MY6=7]R.;ST+$ET1RU5*W$>6O6P]SDGHB'9.DYPKO/F@*#'9?J-/J4N4T5"QV
MCL>./;2ZE2[+E23%57A4[, 9-A$@_0_0DSOXX^$?.[L@EDR%.7+BCCD<_ 5;
MZ6('\; 36+MY2$TR,='FJQ_7VH3EV >'D?$+9"4L*L*BUK3XS;QZHZJ;DTV7
MS_.<)/^RN9L1G\1*/N=P=!V:*S$;1APGI"3BLD#V\P'X6.OX5-@+V>K45\)=
MA^+/L.W:^_W 7E0,Y/BO$SA%E7&;!K,FZX')R&=O[*0N Q>\>D=F;??H!#N)
M-]X!MGMF,,W(O519]-!*O7P>T@GI_CSNTU%Y;?\$Q,2KJ''Z^QHQ;X=][B>4
M\)R4>SVY=[92C44JAB 7/@!C8_))V1LL;<=-M3Z@SM,>T;7($;9$F:G@C?&M
M2IO#SL,6?!.:2=>%A<_IU?PT+[R]"V'W7-P= V'!&=(^9'*F])24%XZGW*LC
MV8(&B>0^]E+$-R0;_.AKN%0E<4_(# UZOJ%_53)JRK3*D.T)Y&IA&*NOT"NV
MGYH;)0R )$BTZXRB ]?//1B?,JQ_86K9:Z0W+AFZSANVS6)*JUV1"B7Y#/&,
MNYOXN4;JF*47)W2;S=HR "I?1S>^D7WQRDFM>S[=W\T#;IS;Q0!455@VN/_G
MLWK^;EJ=]9"J,;E(\695_)#9\<("S>^QM(&%*T&A[>!UWDH&T&C  'ATQ57Y
M/]'^4Y+!B/8E!G!&WH'R'4D\R#)PR1;SGU)V"M@IX-^V@/;KMN08\[JZZG@Z
M?Z#SV&SB?5-#W'=2(0.X032@L14C5Q,90)LYNXF>-_2W*9=(H(/(O@O#]"TP
M50]X.&AYZK<)X)W,.YG_A3)[7?I&CK:SMM-P:)WK>-%ST*X&1XO=7-^9!3N9
M_R_*O#,+=C+O9/:ZPIP%4]<>-:-F3EVL>_9(L4]SZ6>@"/I?I?T[F7<R_W<S
MRY'P[@9?CTNB/X3_T'JK75J0[?CDU*9!L<_3?[*W3_8PQ& 5F%\O*WPC(:Q:
M$.PVX)2!*L)_/^NBSU'Z/&OV"7=Q!X=HC;C7FBVR4K!S-=(R(/71>C$OV_ K
M(\DZ 1%OF8D:-JF4R5G'9HW>/9P!./ K51QZ'P-P@34*4Z\1\^-Z:[??=$;.
MIIRY._1:J9Q#=LW*SU-KJTE,B?4-X#^W[$517$2SKRC57\&BCHD'D,:72Z^?
M.Y2\_$7 (FA90_%"P981P-H]$?(#70EJ2A EG\(I48]/L;A5JQ,^:_O-44[S
MJ52E7MCS\TNPL13_-].]6\_%N%Q6MH^PKKWHS)0BXRB62"?8O;GF,K<JM8&M
MDIOOTX>F/@.HM.-)[UE=E<+8M3,Y4!\:]U/5*LD&!-QY0F71(V\GP=4Y5HF'
MGXP-&<#9MFE?(?'"\O_8PM+,VH?L<G%@ *@$6MI27H'"L@=>)MWPUO5)QUI]
M<)O_TE9ZYM_][%HSBPO9%6C' $JF**<L3<S/.'JZJ_2W\^8FO:S;7X3L?CO_
M=S\A2JM@ (D_-^D-G3\O++S;_;[:N+J6YTC-S<K<%0/P]+& O_MQZ0\/Z'=X
M [,?O*A)M7="[GKTXU<>7U 4\G#32NPD[_L'=$*&&=T@Z!2])HN6R6S LL=L
M;?SL:XO,DV%/-EBSB*HZ?W<7U=X0>0;PI#>$ 3B *<K,<6![?7RBAROY?)FV
MW,.[R,?$@9_\?[T5.PZN=_ 'PC_:P;6A(9!T?[<"7($XWIXEA-"$U;5/\A$F
M,R#)TPW[ F,"ZR*[P^7#8GQ_I#@^VF*55%G6/]/ARKI,D^J8%"?NQEF[!9#2
MWMJ]2W554))*T65IEKD6U=15_([ZE1:,_HY6HCTJ0:9;+EP#^'\ZM*V.2[6=
M9N_4)["'J2B<LCQ?'VJZ5F)M\M-6TWQ1K1205YN,>";;^(S( &+P]2S3&=YM
M?L]/N*4DV3Z3$_WX]ECH1/S!P'2R*$F,$(9I2X@?2XA5O3C!+7,;G>XL#/+3
MO)&V^<-R.SL;],7*R5#*7]HG7F5WVL@TR[=DVW=4.X+\E*@,$15A31 3]7K7
M_(-UH1H1.!Q&'V( [(U2<#>B0X2*&1>&A.3BM P<552L+[SV KE'S[8\HZ9I
MS MC:@(?)5:33A %F[/8H-%@Z[*A(H4)7OR-N-<POU*]FR_#[=H-'%/$_+)!
M T>^6UVR$SI]8K>5Z1F)UU'2UQ,S1B2/R*3% Q)YC6(,X!$,;CZDI%KLV31<
M?7EBP<M*7/^SS*TI9WE)J=?)7VP^78E/8XOE]4ZDP. N7WW0XG*M&1*+URMZ
MI&.GSK'RD.K2 "?]SLEK%A>53-KFGIQ@(3U$"M9S*)#?FXF0?5:-[PKTO&NZ
MC<F;V/KL\ZYY4/G)U=A'6L-SG3'H&]PV+5.<GO#SVOJIZ1MQ:0TU_4G#/#.6
M#Q-S7W0[ V+BZ)-"39]]L@AFJ-CTE%>!;^&0K_>^UU:&#TXN.+M\N[GO8]G9
M7 ; P57$?J:RP945__%O)DA*P#C/!,]&(:KB<+U)GMO2NSL")SN_6S?ZUM6_
M%9)6DN:F1 K)"74MZ8KK5V*YE5I3>KP+[U@$V-6IM:>3'H9Q^C0=U\6P)]Q)
M-?Y:Y-,CM/IP?#SH;._%Y9K*9TYQI??O?S34.)30@I9O/#U"O3)4K((6IAH*
MFAN\NT"\;CV1=;PM>X_6(0:08MRUR*+1C;&F($DBS"7=JP^YA%UE  8-0.#,
MH5U&3?P?[:C6!-6PK?>UQ*R(8M29YJH75T.DV6G]6ZBC-%0C&*Y+SGA%]M8E
M&'>+O_G\*>>:Y/P9@<^%Y9\U>V3]X-EB+^_#4,\1TH@6B:/DP&GQ<VTY=@.5
MS@/9[B_J-*0>RO/&UDF!&RIN/SE+ "&.L*[?&5KA7(*M*.3%8SGV?$^1Y2K2
M.2,FDH[69  W$J)%&F.(]E/->8M&%3K.PI$5B3'2IPQ$+TB?^6*TMPE7HA^P
MCR:4#=*D94,4\IO-PD\G1%D(E: NX:K+JYX_*?N$#]ZOV63^R6O4Y $#**ON
M6.6A^A(:WQ>[I^O%IWEX^%95H9S0O$]>Y';="KAG>F8E2'XN@7P$U2950,YI
M;=Q7^:3"ET>4DFOOK9)U_$[05U9P;N7Z:@LF(B"B%30ZAFD=N^QO+YE@E'+O
M!&@\5_^!,@RKOX]C^76PUNH!\GAK(\\U#S_[ 95KGK4^HEW3[ L-8=!6^HD^
MN)6HT:NE -^R:.7/^1.=&JS?7JD2?,,HNZEZQ&^7EQ#'B=PEJ>_L?NC';TS^
MG'W. # 6[ !-&/T&IECH@D6-+F'??'[IEV]*%(BXSY[E=G@$QS)(^A;_QK1?
MDYW--QLT<JR=*!A7KS6]$5>)#[SX1<"LAED_OC5(O?3S?80&>:B1CY;1V7:%
M"^GVH5^A!%_<ZYNVPJ-=V7F9U9!#_#XW7(F@->T2B717XH>%6@]1#50K+)91
M?F\QX#&9%$NYNW?JG@* #B'["&LF #6BZF!IG.U]VF,"E?GNYJ]:C9B43B>\
M/>MNCY:G2\%._0JUO=FA=2K77>'X6UY[*X>.<-4/C]]SB[U-.OG,R:F[JQDG
M!<Z;W$?4EE C(**PG-=&][QUXL8>UCPBSNH!P6E +P!C?QMM]@=$EESKR0*'
M$$&1Q<OT*4B:D\Q'&U[=Q&</6 ZY2#0.LE06+@7X12Q_GGR+=,\;V[//I2[M
MEJ[9F0^1PKE?-B;4V]20[OV5G':FPUYFD%Z?9^K[<QXDG>K"HI40FM7M6:+S
M @@=<@A_>V:<CZ_"0PIS##^(M!)>.RA^S3=_ZIY-O$W!=B>= \< I-4O,8#2
M90:P+;L/V$9\\##&HAY5N#/3ILBMNN\;>J?*;1?O&\@&J:6PJ\XY5.8_AOO@
M4!%C]Z*F#=(45S:DXRG=-0>0.?X/7 *3(";CRGN,<*']C=>)EE2^S?9)88()
MO:J6GHH,<KJWJ;Q D Y6?K=R(^F \@@[4-![>DT7_*I*)*ZDT$W\Z[-/ZBEE
M7+FDG^SZ$I\T5&^AE:&WD%%CG8\AR@LB7)8/JB)*M&QL1T_Q2= >YT8WL.XQ
M/S5OB!H( +"(4U2CB!FY5AWO=N6.Y&ZGO13M_2.\GSX)J&K,B3YW$0]!J=*>
M(EV5^.!!$6WJUKTQ-_-&%CYSF6.<?H"4];FL#&\% /FQ03-+]L8,8+<(.:(,
MQ$66G+2WK2J$99.$XWFVMO(E>NSQE&-PK>093)/=?DS/@<7T6(6WWU+$MLJ!
MJSR+!5)7Z'@@P"]2V^X5S)3_A>U0!5Y$@%)V1_!24_Z\;71,*UV#,!?CA[Q)
M#C4>\HWKI$!(FH13L=38P.$6:[EE'2(4^WA@B:XV/-WOP_G:*OR5E-V$NNV]
M?;X%"\&B(2.._#,0+8)?%-H%%37@YHGP4&TXF>0>=,[TV5/E4JZ2_$?*^_="
M<.D #?%N<SNLY)F+P@3^DYKODY(%N9HGTJXZQA+ ]K XH;.S6N(D6><5K.P'
ML)EJ;3WQF>L<RQN.M3"Q:0%VL#69'2<7A5""WR?XYN#B$+U!4DTI(-$S+LF[
M/R@=BMMW>"OO;K6R6$COW@5=<&ZZ7-2Z)Y\T*F=QZ/2[\[J)1?<NWWB\SNZF
ML3!9L81-(,NBJ##J&:;%F +^B&T<_AM=()&7:A_#P1Q; H;*4G[@UY>.KK37
MOA2^Z%6.9Y\2HKKN6GGSSLJUZK+]'<'[U\?T'FT**A=YY9GNL8ID30_5(PH\
MPQK[U?2K:NE8L'G$*3QKN?ANI)?CLJZ&5$( %4,>0!(#L9C'L\3-6(\? W Y
MKOD4BWM<!QY]#SMY%N&,HUNK7_J2<&%;E,[1S)PY:^U($K\9C;>"96/"^S2&
MN;RPPWPWEP.J8U1TE-<T*#H_WG INPRXGU!M1PR>!L52+Q'R<!<(1VM$/D]\
M.VE$<FL#?>?UHWZ/W9\VEQ?HW&A>R]17?,G]8&XSIOW#L><9I#0Q3?^%2->Y
MEWRE%W2W:EE^XN1*-+-!Z/4&^TZ;"IN&TZ0I\\I[ H%6%N>A^I?U;% ?4:/J
M6.=BPBK.(**X6%%:Q+<\</^+(&>CH\<^SO!',P!_JQ!VU*6^)\AKKJPOR DX
M8\\(>];A>N.'K'IYUD;WI>0D'$-^RB+';A62AZ,0'Y$5^=$(J'O NG5)1+[;
MMO,+3]&@O)Y/$S_J#A3XG63CMX0&;Y18TO=)$4$4N:9MN5#\;-MV0W/=AVO0
MGRW'/=A'<X\9T+Q5IQ!M:!!T9C=9.&\"(YB*1&D.SDI[SY;NXEG_^=6&OL>5
M=6QCBL^5+EA)L2A_-[(@\(V^O3U[V QQ/>1J/93(VD(_GMKS1=LHUUWY1D9Z
MT/J5K&ZAX;8KB [H0<@)6/GUX7J'XM;<J'NS!QI?':W-R)GTQ>MI7.T\4^.+
MXY_.$H3PDR-(@>10@61_^.MM#5QCV>!=\>0' H?MS+B*A(4"^1=A*BS;J]<G
M#Q/S(^HEH[=7ZO)<"Z9\*G_)RFK1+A24K([#>V*1RPMYY"C359X)MVJ>PG=A
M4]["28?(VO!/P=O>#G+SX%+/-J1$NV(U=O7 N)MUQM#MDU.&FZG'O8;TV5FK
MB2?!X4=85\59.TZSQ_"\.#^L,N%T]795EI_8-.A*:9;U"*IS(M"(:+"\0;0(
ME*FGL$=6:(7=_E#A_;[LU==PKZ=.-Y\8''IB<,FA*',7\3 Q-:1>"_6\S>2=
MV]!FWHF]^V['V89DF0RR-/Q-0J[P[]YH+B^KR7 \I7*I/'*X\(8+ZY+N[@U:
M5:J+ZL1LFT5*Z5M_N8P62:7"D].@XLM]U$LYL#19#[!EZ=<47K8XQP?);')Y
M^%R<ADZ0_!H2!XJBGX _)#B_Q7D\^!@$;CKM%8>M8&N^.SY[O>]U5KKO-YSB
M@SVBH@A\P"J5SY*NC6#JA\/&H%DO7;#[L"8*;D1("+N'P!3#\O6^K$#GGM%S
MN$!;6JRVPWB^?%BY)5D'-0H[U*MM=/]P_-1R6>2;,><SLL/2N[?4UQ([O#[#
M0ST8 !N>6+D2I8!?C5)Y7IEZ[E 9Y';(R^]X?Z_FA2068;GDH6 (N5_ULWJ;
M0-:=_@U.NPOC6O ES92KF+Q9:6>4Y??\)G2D]68S.J;6-F6@YR[:TUC!M-/_
MJ(H3R3 V>SHQZ<P<&ZM#\4.6-*SG 6N866MZ7C6";I>2X2$S^)G><M0Q ;YO
MJY5TB_8.;DE<ZJP-?Q8X0U-K-:PH#TQ3]+ VF1__>LGHUADYN5)*+JG=C!)$
M/<< 'EO.L$' C^Q2&R4_''BR'S2*;>U"KJ*.(F+=H#>@$4A"-/5P5ILZS]T&
M(G]WFI$0U"7FJ! #:*P?VCZ1#<KQB0N\2,"_JOWJ(VJB/"@FO"IW_0FRZ7F(
M50"H#<D!>S=M,]]XY(M/5*]N=*MYN*^&L+847W^C&C%B.89X#N?9KG307>+P
M5VQ_1<A;6]D,!6J'K]JDVT_J\Z<S5YPU9,RJI8<Q#("Y%C*5A?+.V.-%GI[8
M#VLX08O3<<G* JTWB%^%#3=TSK#WL6Z4E?DP (%Y!'^8T]!&!M0@JNS<U(3T
M/J_A5,GZ'I(9.>XMU9Q\./=.0'T'SJ+:[;C+AQM&SSONETP672TQ\TZ>; SX
M@KR!$H;1?^!LR1&X,^Z%MN]=XE74^S.1T6<7<T849V(?,D62,RRP$R)*]+KY
M"A9Z82@ZKLUM^#TFY.7M9<<.6/%':BJYCC!E2TMK/-:>;^U^<3.%V!ET\YTU
M*^?36TV\'[1,KX4(2\5/#R]LMJ#XS7!9X9D"Q-W];'6#%2.*+M?L"G\H[R)+
MO"A/N&O.?NUO%->(S4_PI-5XC_;/W /GWWQ/T=]7D'T[R0Q@F2Q7,1-TM9?U
MOV+ U".L9H"N*O5+G\PE'N/EA)N7'++00E0;8@3I47^]42$D"Q)%6--;<W)5
MOAG2=IOV0\-M*J3/@[ULF"E[V2890.)X!Y2T/X8!Z/>Q3ZEBR!%8P;!ZF1,Q
M=D3%A-<?O1X/*F%#$J:7Y95PJNC($KH +!W,4=&#/7H\XVY<'5NJ/QW'>V*D
M=S],1QZ+EZ=S+."*_4R2+PU1C?-&%M="#U<][;[?CG&3$7,IN;"RG0Y0,.>)
MLHE8=T>OG,44Z^(:#>61;](?H?S2%L\0NK!S[8TRM"SZD0K2@)'+.]?-8O>@
M.TE\8EAU>6E3EM:CS>!$H4,B-'CXM<R#B=Z5@R>ZFINS]U9R4H(46WZ05JX]
M&AJ33;?Z%>[B>M8-%M6?F&4:Q9Z<A4.V8\@&EJWI026/)3-_&$>.F4&$KMY2
M;GM_V5CE#@P,PS)%Z[@?%DP]-,7JPZDA,XI$==7>UI4X?Y?S(N+%0125RY*=
M^;56R/ZTY.D@SPY!GEM!]M/6-J= 6S<%_'B6^P78Z1^B@>W6JU^7'VJIU0UZ
M>JQ3KLWDUSYS/+/A?,A"-H8(;9Z4KK7QD&I/ERA\T.D:WG,YW$5N8%_;<+>#
M -(I*VI*'*$,BZ>8?Y4<@)_:W?%9S>.LM^26C>4NH2L:$KGX;LR5]*TYW.;R
M6@D"<[KWF?C*JSUOW KDN]V"[HB<JE6N>_;T9Y'ZX>E$C/U^ 'K=%070HNBR
M=]"\C=Q[ADJD&P958H8'XKZUE7\6.O_0V7'S.?MX9KZK7')R ^4RU<4L%,SI
MJ>3QAA-U1[-\@*_F24*Z;8#D=YIO_#K+O"7R@+;23?C=$KA1KLTD:\5X3Q!O
MUWZON#?E@R*3%OM?/0V_K+Q7D\T2QQY)57CG*I"N2B^($Q["F[[R_,%KAU6N
M9;_+ & =;0&Q$AO;>$(^W<@O%+W,[<( 7O,&GW[WSWX!)P_J=/@I38Z@-P^#
MMX\6/BBE,A<C2;-(Y+*X%[.)Z<%0;>0-I2VE'J:=7YCUX]GV-8=T=*D@-766
M:01=PZQ=H!W+!B4CIU^A#S -2(CX H2W.M6CM]I[SO8(].?J_OV@H7/"X!61
M)>1-=$06X3$55#XH%^/$ ")E/?2ZP2=B5EH@+RQA3$4XO-&23'EK2^^;JGQ$
M#C1[VE#DE^AJT5L?V:\&^7_8>\^PIKJM;711%.E-NA IBM*1)C6 TE40I9>H
MH#1I2B<0E"8(1. 1%)2@@'0BO1.:H((B'4(/O2>4$"#EY'G/=\[Y]M[OC^_'
M_LYYKW.]/^:?7&O-K#E'N>\QYAIC!>3,*[ZM7CL3F>:1%=@&_X*VM>L6K:E-
MN!BGLO8J5^K% 6!Q)NN8G<Q$@XOKO85UA;"7%=K5.MTQWI'/NX$0F^'7.'OP
M)-"2X7/ZM-L(S&, K=$U#X[CU?077DVLI1?K_-%X7YAE"/:576\43I>4N@?>
M6L1>7EV<>^T#]5XDW:R+\1'TR-GP2_=\[O;VPDMQ86:6 '3KSZBP(R+WU,*E
MV=C/&V3-D0?N0E9)=NL_%\_D6L](O#MPNT]';DS_DWA\VI.>[(4?:N"N6/(5
MN.'3T5PR(P'[X74P=:MQ"!/'+*SC99#(W^WO,-6TP&D(6 D#=+G(?@0< XD'
MU=:5%T_?_)F!'FVKR#::TW?)%A]O.'EYA>Y@UZ8^9=>D]:45^_FO&AHY\\7T
M-BMN6TI:J9&#:*8O07W>07"XN>C /BU*7^<BT7"P10V;9XT+QB>Q?V%5WY'U
M$?>S?O8=FAO?^.@^>SE4B6K?!.QH3S'N\[ZU[<"D<OFU>Q(-\UJQ=_DV#/<I
M  V5 JK_.[]9US.'M30_YFGAI@"0>M )K<V7R"[(GH\&.PGJ1 '6CI#4)WJ9
M!OM>/H\X(350@#]<K4K_D@G;ANZ>>A$?51(BL%\H0-=@?Y77K%AL&::>029C
MN[OJZU;SL^B1>F$VS5TX^$( [(4.<P3$@G;3HN&R+/B.=9=C'WR0[V)U$+^P
M,<,">RR"K47OU %Z!X4#O:[U]\J7^83<_=CI"F.M;=!BN[YS_MDS8Q::-0C6
M'!YCDSE[I840'<X(OUV9:*9YUH>ENH'6$&)19+HZ2DJ.6 X,Y'E;,\[]_6L'
MDX!$ZF_:(@&)4QI;,G\=]B@N()R5_::7M!FS<;?J6,:>'(_1 Z4T<\NP-!.M
M\?1(-)AJ1PNT!)[2;RQM3N2Z+M,HNM_C]#\C<^P;!DJ9@&/VA<=EJ!KD=B"I
M,EC(K+ M]Z3F^Z*F[$/QG\FM#7%*A\AA*0(%(#..8W=/E3H%CY(JQ+K1^9B?
MH^^>B;[.%)_\L$B>M!E7&Z\[\7[[;7EZ<,I^JF?HEW(9C[B!P!-JJ$\C\>>,
M.2<!?AN;$AM1MG'D/[%>=U>@L.&O>3'XBKDN@\0;ALLH&=]/8V!/!)H+?UMN
M\C/"J756;4_6V^(,VY+_GF$IPE)!7:P9B99<W*D]-0N9'>X@<YJ@%BXX(.2&
MYC19#QJI,I?SKP5^T+2M]5T003A$_J*J7XLBEJ_K$JRFS)=H%I:[(?CJK?_F
MLE'.S0=DF5#M*  #]IFRA4J?JJVAM1.OV1D4VTWTM ;U7KCV=H!TR@,B<N=,
M\LVOH/R ?9#S6\;>ZPXAYZA:DQR J-=)F14E?=S=*0<:S9C[PCL'/\Y=7A1X
MF-*PKX[_%4KEU/ >:_D%"#?!:H=3A1\95W"!Q6_($)?_]*=FK&)%A)I\.? <
MC+5TOPN],>^A_T+<?N:JKX7(-88-F,:)&=XLRX0"N$'HE?,S>%/RP#-<#9 _
M3,>:9":A16G9<(Q/_&>[::-G)]JO(PK['D ;"Z#O!D[U[C*"MIE.S>=MXGRT
MA+'/.]#:TX;,?=[7.+5N/LA/:OYHWO!$+$JSZ=^4U-:QI-I2$@7X<1%+ 4CQ
M5#09"MV@NJY>LK%/'@5X.$D!#F[Q&)&9J#8G$=U% ?#"< I@LEHZAS4''8LV
MP4GQ5-P95+!@&#[$(&H1/9J@6!!3X/66)8V=:OH,C8BO8!V[H)8&\H:TF[::
MM_!F%:$7%WZ3(#W?C.#PDG.,7K:?_-2=>8_#M*?MXS7S!XQX,,*9!WN4B'J*
M?%VO4==:] 51T-.';Z[SJ[2;6GK[$NC-Z/%37\KP.08VP \0,3:15PFIU*"_
MH/^2LC?=LUYQO\M- 5(EVD&EO#KQ;N61B6F Q <:Q]X7!Q!F G-7%BP>JH,/
MRHKX_&HA3OVO:NZ1] _5BDLY^5F+,$_X*QBVO(V! +=(A$B1]^2W-J^Q"?W*
MED[=*6VE //G:7!GIM2V]4Z=GUKZ*&?_,G_0.\/+NYB^W72="LNAI,V#A?MB
ML1:T+Z(8/ G19,8^[.ZUD,R>(T6_7 _KIT:1$N_@Q!BEG5'\056^8DN:1J\@
M;?^6WWFV_"P 6>*9$78Y.[#(D\IK)] ]P^;^2F>,!PW-N,( Z;UFC$]K<>0P
M!:BYU$>('%V.L%Z6.5C[X/+T7+/5W&F>YWNA8<FA5G%\ :E GJQ&2 33$"3Z
MY.,C_WS=B8\;O3S @+X8:A&VZ+\-SX,]GHMR!A&$/L'</=7P?&V*;:^82U,U
MKDV)KOYXM5IX^Q?Q9AB-KLCP/(3)(82O(TLROIR_M>V]&\_GQHW3\[2]TV_,
M%YUOG_I0-::6D$=NLJ, Z_>M=BP<#0(YT@2X; >,#%G8,=)=,.^Y8U74>=BX
M&9@DE1BE%4YF+*4 (F .V&9!_%X#LO9_7Z+K2B[[1[ OY%BM#W5Z#DT%#$,J
M1A D&8CI SP48,(*?& Z_O TC+J"-BJ<3!B.4P!]E5X*T'$=O)03@B1W%E/)
MC7643C-2B?1)1W&"R$/P+?+BOH5 5QO^\<CH)@X[<NY]@ 4^;X3G]EI*YQ'>
MX\0-".;SF[M<7L/ORLKC>)4%TD+99Y(9@EP(;";M]..KNKY\9#2,WSF\N:CF
MEZH,[1[J1/6]5P[/,\,C<+:J.9..!3.B$MPI/?<*PKL5>/Q(_"9VJ31<:_N#
MUN)E_I$C[W9U/,0?,6R*:1,,N=<)8R**NRR@V >\6#\V+&>Y7C,7/1U2%[:#
M'] !-!;00,)+%',;=TAF]\-.QRG[*OO5UBYBJO_<Z@/SK\HT6)N>UU2C=I]#
MCZP%7:O),#S1YIWYL^K*R;UJK&T(73VQ6;=*3A)\G-SZL<R+M;;%Z_Q=Y$T#
M?@N=*":"))EQ#DO8U%$=;_$(BET<FC^]5(U2SW%V>G%X[ASX<*R-E'NNPN=1
M=7T&!G/_Y;DW/R2J%*P,Z"32P@#-\>7>;>[%QK__&?Y82\7G",LM L_/=UGY
M:)6]BF?9V4X?-/ZMZ/SIU)D\P@?B4%&/%":(V5T:@B[XA@=[IZ%C&GO3131Z
MA*))>^ F'5]G4CK*S4EH?B4G1PQW9CMY(*D"TS.H<<T#]W5%67WY^\([&-4J
M'[#[$&[,GR<X88>[9GE->*V'R_7-Q-R\?G:WE"E--"N*]-03;V"$-3NSA'<J
M2YUZ7;Y,WGR2@[D7:P#JQP//3(#[0YYU=VW-H>-^KZ]SYF<L]@MQWG^<H W0
MI4,^@FI\>[==\.FX\L)HK0MI]?&\JWUU,<+)1:;@Y9KW/2,7WK(FL50_P.9>
M8*LE59[>)_^IK_)0[=%,#L*>BTZ1+;^K+_TCI4^0-L+\CC%RE)U]+6-6\(_R
MC%@_3_7P]N>:&)%/XKJE)S3.:J<J4';L>+LOJV+ZO4H43GN/O7Z#UJI=&/IN
M_[LNC%=<\JO((LO@M&'5S4T)[^\!Z@RX7(;!?]-)/P94AR1FJR6AM@<H@-D#
M)!\5+CPI0"^\&W2R_I!8(8T&>T..57T%8%,(<D:'LSP5K4<I !ST"GPXU'7L
M:,& /NPF/B04%T"%L;QY&&U+@\OGKWH]=6!]KL[@ZG6H377YVPXZ:KB*5.Q^
M)SK^5>#4)[<OMKUM=NP2'Q:LC((>Z=(UBJ'46JPP"%XR&L0ONS7O.AQ0])K9
MUBV=]R2PSG!=0GL:ESZ:<M[O+'"%W(=B.92GXIE0&;)"W"-@6V<[T-MZ*4F>
MO?7>QHXB_'9O;>07FX]$,2Q[C Y+B.I<UXGP<L4WG<>_IM,ELP.O LHIS[>C
M- "@(AH#3I9M$R$P.^-D?UB_OEV=MG _1\)/YR8%>*%H172GHS)??!WNS%P/
M#.W,SKANOE*0]'4MJ/U96_CU?5N2<"+"??/ J$L'5(-%Q"NW<G5H-<MJH#5M
M;4@Q%GDZ!!XLPY;H?#-<A.@QJO6X>*=14,O\V?#UWZ>-?5+IN_6_?(MX3B[I
MGNOG-%.DT?TA61OYB#R../^9,(7+8 :Q27NJ"GI69#[R[MD/5GS>^H;MT[M8
MQT"F<YO.U:>/R:/R@;)'7<BSTY5./7,V(P^T&M?&!E.GJE/'WZY_.(1526Y-
M%D#5ZNMP\-=R3^>^W3-J&OJQ8JF\]'!DGUP3'4WZ8[R9!1R!)G<7/B 8=3C7
M1"XTH@//?59R/J\N DUR:M?N7'77[DS$@=#,^.\XM4[V5^C>N ,J!J.=)B=E
M1)P_!0W%OFDQ7MV9?\ K/4ZX'7'W<J6+<.RW36<]O%F Q^5WQDP])==,Q+\P
MJ-ATY4@-0A]_N?SITT9&6&M2=,+6BIW-FE^(3F\60/Q* 6(JV-$,&/0&!> B
M6K''>_O<\O_ASUI:9<1_G=.PA*UC?.61KD1ZCM>A61>OX)/,A5:I 0-%89'9
ML2ME_6PB2DRYC+7Q]-YT.8?'N--(CQR.X4B)=?&NP4F],A//59NX;JFHJ?@,
M1WE:?;75-MK5V@CU4U8G3S5(=4^2+]HH6<['I<:#$=S(Q0%(?O6>#W,1+J*;
M*_HWO16W+X]V(1NSIU" +1[Y/>1?5(:1/;>G&=)+[AB$K:%/JO'O*$ :W2+J
M](P9L7093+A\1$R95:3&U@&0$]4HG>,*7XPD_  >)\(^ C4JGSXG\W11MAZL
MC"0JYN[TAX#F6=T)F=UAOC'*S"0OFR8S6=6>RUFA2VLEX/=;P%(:@/R%3(1Q
MMUB=/B!:5O\YL$W^DG"^3$:F\(V$7Z%A8X//B\KQ"AJF1LD58%6'B\!WGU00
MJ?E]ORO;:^I8Q=OY[L=4W:'=-VZC]4\ASS3I(*5.TGV1#% Y++Q]@.%+:@$$
M[>C\J\Z,9+"L=VDD-U +FR<AA6=HE,BA -TYXE585%RM;!!>5T9&UK7Y[4C*
MW?.5O16ZF"@PF )0R86@8\C^HG7V/$DM<&@-=ZE$/UYS9U6JGZ%-JP!_<7R&
M K"V\/EB=]LU&.+*Z]X=]%W?GAQYH/EB'T5D?*VV"$%0@"J;^ JR$GEHGX"T
M,E>1>9+MU"3Y=I^*? &YIYIG10:S2)=R:5%J*!_(ZPP$=YO$.EGDSQ+?F B(
MR^'X#['3JU@ VMYPVO[4X"2N%U41.0FK]0IYZAQ"UW%D$/CDGDAI\<T)U9]&
M"CVP-KWC;((1W<IO-*1R=VO@"\'=CK#94V6?_ #CI&268T4!#(2_I%(# ;N9
M^Z39PI737)'E4UFH=/;\0$<K^-9(9T>)D^:&?91LM^5U.@_PUF>QG,E[D"N$
MQ)5-_!"I<'[XZ5(ZF6-&XB^N3^T.UR="T^"&;[_2]!@N#<RHX.N_%<D1[V*S
M>^QA\:X.,Y:KIHTOSVWG6_9O"P&YJR_#F AT"T=="+30@FWKWVGQ+G1/BF]0
MQ*?/=;'HVXUHQ@=WSB[VM@(!$*Q%LU"$$@8>6[8M:N9E!F._P:+0W6RM;+?"
ME!L$ -([J%CPGEF+, 5XX 4F<;P]]L#]W,1HCR=L96,\9^5J9-KK3Y_ZYQT+
MS?&? WJV*4!Y1.LIKQ/1O.%/[7G<D!,KHZP,ZBMZX_KP43ADQQMX.[E,VO6]
MIPLR&_S_[KTR"#_T/BFZ=O<5B+/% &,&X[75.UL<<F3"@C5V5NC5-&&X$$"4
MWCJY0C?O2P@Z2@"O^0^AL(*F>-2Y$.M=O"8I6\OA<EYI5\FL0Y_V=EGJ)]LQ
M.Z[KGY+.;J\ YJ<];2D5#(LV'=N:B[#H]*ZF+WD17]"R0TY\7Q^S+-\ RAN-
MI??=1')%1FAPJT3N\79Y#/LKC=5D>:L"N$GT]Y<FZK+/58-5P]^\Z* 2Y)<H
M7:\8@A(VV( @.K]+,*HQD9,3]8IOREK9*LZP$Z*3=*>+M:)+>=G<!!R_QF>1
M4FO-4V8UJW!L"(S0;471X:$?VSN?@M3M)"+:B]>@OW-F#Y=@V.U=+MB?Q0+8
MO/+;HU_4X(9*@=DGHAT)5C@S?9S5>.)3G^V#U50TL[NP\^U!#1>)19":SN@Z
M-0J!;]7G$Z%Q8V3-N2T(UV3O4A=4?)_+=L\XQ>"[!*T)_87DWNBAUIY$@'A<
M_1\GLV2O=]M(Z-W<KB_2Z4T"/I<>'W&^&W$CGR&,3T#H=<ZM06B)XJ3DO,S&
MAO<Q]4TQ[8QRKCW7=$]+-*12HALETM?^^K<EEV@<S7L0@"/1DO 0&6(_=!PP
ME6PJD2SGR%6:P//]XO.7YZ,/*]") $&(+-R*,3^Y$( DGDTKI +1RV>$E+&3
M69=%696;SZ0S4F9O=S&H7SA$MA3ELB-0GKZ3650^\*(!N]V#*)]:O^;AI>63
MJ:A4]E(_AN,^UG"@5WRH!?0_S]EV3 V^);#LQ+^S7%AX"E2[8@ SHV,;\,MP
M]G Q;E9W1SS5L4@">V?:;;9A;FJU9S]D +.3/C^C&=BYABU[PG\L'ZPS)KT3
M=*P;G@[Y5#M?-U<Y%RM&Z)SCV*&Z9PIP5^.UY\NA98Q"PFM>YU=LHT]Y!!;=
ME_XP%!%EL3?!K&1A0GB7@K?X[6IC5]>UO<5K8")CG]KB/:@1-CWDJ%U$%(MQ
M)"4?.C"6\\Y7+ @$2/&G7*/12EQ;RV5_@5J8FI6@ )]Z32E N\<5"A#O&Y).
MCA>6I@ T^<@V]UQV)8(>]AD8(/)48<\V:@EN,?/TJ]T4M2TPR4]-C+KC']^[
M"9$/&2<SCE=,;:8YADAVX\4Z/M3<]=R64-)%S<P)ZA##%KQVT%?H%JD[#_EZ
M,Y(+IU+X2LN_=,KK'MI8,OYVI;6"<NZ2<LH\'[!?[_Z#3B(I&G_FWZ4B<]U(
M)K-%9/RL.':+3_^GMV6GEW+# V/]M?M<#'<'=$:'[NJ"Z&!=]2U4KWXCY2T%
MB!JZ2P'89G&2)#8-&S*="00ZJ"O">&I(_I5)I:(MH@M.4@/.B3V;-R6TQOVK
MR^9[2FSGEU0M0-WC413@'^:QF5.V8.C4 !.Y2[OM@Y N 63%X9=Z&J8]TJ%T
M"[:@S)P6?RO4_&<81THA9H"=(#>F/^CQ)WLS_]Z8AX[M"-Q*UWS(_G2VA:\;
M4CD>0[3"^1,CBC>::D<79PW"\%Q:3\ZZ=V[?V/.9W+O2$\;R)$H31D7$A7EJ
M@!3=Y0P*Z0Y.=6!$,L!J3/:_LU<(),(?\TR$( RIR 'O"JM+>Z**(0\Y0-0-
M37WUFZ/PO[WN_)^6TOQ_:S7\?_:3IRN)P!Y\<G^^=;4#$3M$L-ZWOFV(<4A8
M/;W==*WL83MP15++!6SIM3S\]WD;3E22+"TL0P&F:O[#'6'5B)KAW8B#Z^L0
M NNE" 06V5%-U"8\7YACG9YE/C[H4ZX+CZ5GD-*D^\V@MW4F\/Z_1_AVD5<&
MY[IU!$8/BE95JR!VOYY6IU1FZG]"L:S47OE?TOVSA&^GJG/$VP31!1"=7L4W
MK_!<4GK@<O>M=;^']>XF%R^\#/89T/FX#P'_9[)O[R(SMF)NP0EE 94[LOGE
M*,*58#AKQOL%,(V>GZLW"FU3J/75PB4>?&_E0SC3:5B+$,9W*WP!DDAER) >
MP;'RTO>N"@DRXFG@BV6>? ]^\C)-/3,,J^9,PM)4GEXF:E& 6'^L4M=8VK=E
MR 8CJ3#H7,?^):!(9Y,_V?RT=G.H=Z5[/:WYKZ24SQ]*./6+F'(?  I 02[[
M2^JB7_H08HPQ8 &/9)$[0V-5M$9/DS[<@_W#ADCO9EVA6YV+@52+?,+NS\.3
MM1C#D5V!X%<&/PM&.+X:T]=M<FB:_%AR/?C^+<3H'R2\;P! 6?_1C!R@M(2'
M@=C@A:"W"PZ_]+7O8 97@G(N22&TRN:!T,7@U:P#C7]/G4Q1Q4,UWJ%NX<]R
ML3>05M][#,RH3\,VA[U-W58EJHMFS,B8U+Y=TZB,^&?8G)^]1LI&$N^=JKDC
M6&V<$H5(*MX48#CGLJ*QBZ1TTA*+B,[+-MA_HB?_I$K2I:3&EOM43-2<GXM7
MG"%]WEFY'CDNA5NY\30Q-W5MR/LA!7#\%?'160"'P)M@__Z"B$ '1M;+?DSV
M2^*,;.0O+XE'BH+5JGS/N*[950^$ :6G7'^+.X9O_DEVL):S$[E5W/-9FOK>
M!,VY@<*,DCFLDO.IA>VDWI=)![1]]]<IAYY* \$D>@-^(!PX8ZX+8@Z))S-.
M(C>:R 7A#$G*"ZR_^M,E/WI?)BIQJ3TX7*$B^W\B>0HP.8Y_U$C07@#QK=F/
M5;,A&5Z=OXD9%%04#/5)[@L6)6DR8?\^#^S0(-[[LG'-9,&<WV/?(4U?6-?,
M2PKY2;$T^G"1NF$'5'04QO(1N=,"1AYE]T1*OM@:/K.M?-]["&2N:B!D1*1/
MWX9XKC7)PN.57VO+WZI-Z3.O3GCX<E8T-OG\ QH;]W]?,C$V\._T8?"KVHA@
MRS9S_O4IN0K7#Z%U>WQ=BEK[XUF?_M7SGP,_Z3LB9< 6[O<A;_JV?Q^!UBG2
MRI'_\/D\KP?);VX[T_W+/?^,)S:^IU8;Z5!>4J:6/'9_&[-[KRU%6,-D6+KM
M'&U-@9XZ77!&PX$+Y*'-:V( *5,9!+=?R2[>U/A=_@"ONC)YL2J$6,7,*QMW
M(TZ]0WV-+^4*W6M2%)G*WCNEL7$PCFF#JJ-NF\N/)1Z0<F3R7<@G^PYKG6T?
MRN98"9%]G3F@X0 G#;!4EWE=RAB]MKY8K./)![;;'A8,W7,<J'G$R>KKEE",
M;-#XMSJ.J8VLF*/B\_@]/CV)6'P:&YN:BS;N[\9%_VS9AZ<RY/XPQ!8%* J)
M6[48]ZZU&L'$*2>.7=9M9DYS"(:T]BY"] >I5_:>6I)_"L[U(@36-5;>ED]X
M_/!Z5&=Y(P2>(Q$\S12-0"5="-B$Z!-NW/1E(9@;#,[>U5S'6]@KERA<Z!6L
MF-=T$R@/^^\6B?\]_DN._VZN_=_CO];X[^;:_SW^2XW_VLVU"?)D)M2IG2>"
MKNW"&OD<-JCV>5[(0'>%6\:I^;MOSQ\_%%A.'8DS3,5^>O&;RSG^/,U1 <^>
M&Y'; 8] X%,)-+1>]=L1BQ 68^49>SN':].B]%/3:L4!9TRT,A,&PDY^_ZN-
MEHJ4/E;NY-^5G;7T$[>[7Q?Y'JE)*M 1A756$60QWH_4H:6K]:I!KA?4$/+?
M\\,KS*ALG#72><*#2E:Z3F&,A-GSJH..,S]TWOL/_+I4\[J!1,<!U@!(;SY7
M:8EBO" "!!OC\;([WBK2QA6+JQ(,%A,ZB]=U,(T#+$1_K&12RUVU>&5?KLFY
MS;M\K&XB\]U?@KTE@(F.WXSKNL*C/*D8%*\[F>&/3VUY&%E8R:R.>67Z]YW1
MOC-T*2824<!AB3,[(7D!"0H)<PK6&Y,]9!63=%]JMKPK_ACXZMWN D0/N.@*
M7^)9"NO==L/"]5&GP@/)9:[90?UH ]G^4 H0*?&XM\W?:?QEI%B(%\;P'3H^
M+K#T]I-1MG$OMS[#<(9[<?=Z#6FC-*1^X&P2 U#TA+!3Q[&*V)2W+J!L?[^[
MB$=++-L6)DLI@ JDQUD3>]3U2_S4O#NKM0+^R-&P:KI-K9+,(VP[SQW%.#\>
M _4CK,Z#$R$ --QK <Z%]LSTMXWW>B!R-2C!@I=1K)1SYZRZ2 T-E<2RZ<B$
MW,/,O@\L"C&W$JPM*)N].1218VNJ\V>B.S$?:W3Q4=/&,?<_EKO4'KAUL[]N
M8R,XL%P+*>SFS=)[QYMXE3'4E:[8=H17?)K%@@'B.-<->I7%WKG+>AL9DG8P
MX9&JT?/8-L?2*85'/U<2\;,2>@:WV@[B1AH@XEK,W8J=_Y*3-0YY(J7Q)DVJ
MLO<K\AJI%;8T)T<!ML2]J*&9(("'Q5, C@-0HHY@O#-V9ATU?"DHR710ZZ;&
MAVMO_=CTB-K2^<B/X ?(8[4^\]-S,[ U_;;7N4SC&LD%V;$-37%GQ44?O[DJ
MCBMT@#@X[YQJ=]_;/IV]%]<[SG.<?:J_9KZ(FA*WP)*^3;_Y4EAFZ_$9ZJN0
MG\ 2"J1^\/E]33I\$;:56D[^31:!"!+"OPT[=WE<,Y)YTST6K#KUW2HP\'EJ
MPXN)Y"ZD,LW)U?!0MH]NVC-=Q]98PZ'O2]RU]UUSM&/]$"PZV@3Q19YE$C(V
M,&A$3N:^UF!KV=<W,?,*LWD7$;TC3'MSD[V+(L6X:'PP3J9I"^4Q5O/.Y^F7
MIGF5SE"A-$, 8.,O/IS,.9R?^\J7J QG\"*KC0;^,ITR'?XT_&GN>?"59)K]
M$ %MDRT&R5H@,F[0^?D\"BV^,- MZ^XAR)"XM5M[6>)2M<R;EIAG0:&)S01Z
M8N.ZTTIQR:1[$#?$4RWC).(OYB:'[&+KZXLB9?VZ=)NZO$5(X682,I+##A*1
M9BYD7]-"''0PEX =X5RD3\:_A$"^9:DE!X0$.C'<JQVM60]Q>&U"5Q$>G1+C
M]B94>(W./G%1G- W7PQU"5VXB]%4&=\:7&JH#I)RN>_TVXRS?MG"9#5*JCXJ
M4B.$#Q-7&Y%/@'1S;!SA[[Y_DGC]L2Z'@N7/_ER%'W12QDL6#*$&?B>2/;NT
M(2E'=C7#1/.'RFAE;[E/C?U>/HE!U4H*=.Y:7&S2(%U2H0Y?"*+[ZJ?U-L5*
MA&5JMW]/GX2'N$ABFD;,(W. ]KFNR"<#JCW"(W6@8,+CHB\(#.2\O<?X;C3>
M JE<PJ[?)UAI$>% V^3+&-)W [?R6J1\8=MRRGHX_Y(U9O((Z"K)F8??B-85
MNF_#OHA*GJ4G>*BE4J>P]<BTG?8V>R])5ZEXT:UCR__7$X(T_@W!"\=\+_[.
MGQ8'MT"8&J?#K32''Z*_%3Y;6?9.4!_EK0'/2HX2*;]-$*HSLC)<.\<[B9[K
MG'I<%RO1D*9Z\)"K\MZ6.]W06AGH+&&_:XZCYD4QP=>F=DPFV/L:^D>S"RPP
MWDJGF\X6Q*&C26!8\!Y"$Q#=8UG>BU=@5;&A7YC"N"]X]M-L&:]$::*EX5CV
M;Q3@+-&"&]8ICQ'2=C:^K_6UV_1GXAV:*^T*(H1B8@3N1N<<\U9Y!?%>64=>
MQ[.5Z_8/^ET?7--E8KP^4  $*EL)<SM\Q5U.]2CQR+P[NW[DGY#;$+/L>N.[
M6*,O$_$I%IQ,- M<(+%W!V5E5#Z]\,.+XVE4(8O>Q;,=!Y>C-,.D%V#H87S)
M6(WOA?4Q"!OT2<)#UE+9C4FC"U&."8X<9J)+0.MU9$F; -0-F]G]KGPK ,8Y
MZ7G2'^3A'^A+!]T\NE')?^'L@^N'YVE@77-\+3R8 4Y'=PUP0LV,D6UTY.EU
M218*<+7+Y71B-VD< KE('D QD'E#((O?9H[BR**JJ I;4N&/0>+'.-GVO)4[
M:=LL1GTIH<ABXCW,-E^'H%93!:H8O:X1X"KMZ/2=\UD834[^"9L[G7/BWAQK
MY B(&>I4_B6U@-#ST^&87\+_=UI[E>):R9Y8*?<$[7.GPB2M\(4!P -SVATV
MD_'Z:7=,^(^W+#&!Y]AE(J(N1ZD5(4'#*"]DC$8!MB:^9RSAJE]VA>SJ2RT$
M?E:AX>BW]+CLCECS2_7YU,MQ5FQIAAUO1Y)>GMLXMZLK$CP_AP:U.X-Q!7.Q
MRMH>%8?-ODH!K![*GK-V7=M/+ H9YG(FD<;(W\A)=O*=52L*T)!)CO/:@8L0
M;;'QG031S&\:I!SX*JPDY8FL3'3C_^6D'0Q"5Z/ [N!XQ'D5T<(0KV^\37&Y
M]ZO06L_TI%_\0*>59+33?Z!K_Q4F_+_6'L9F?F#;Y?01U.L/!?" )YQ8O\6I
M=6?=R?Q"B,/W#/5TDA;B^!^]SS.PL@2.[[L>J:LL40 LF@*(4( U9$@7536'
M*$ R #,:L=F/I@"L2-PN.?$H"8SUEB>,;]L0N?,P[*_(5R*_ZYS#L2<>AG\,
M=OR(_)QMT>*];RK>\I[[>;"HE:&YUG-=D.D_O_X#.=4?<21E;RN0\@K?KK"2
ME(:1II60I*8\S_I9B?' 5Y<:TC9^+^]*-AOIN+KVGS=U*-*<.1MA:[/!L/4-
M%QNI1)0:/E1?9BV?I&*1IU?[Y<=T1^\. D5;KQEOZXH4"A_6U+/2.M[<1\XF
M./*"[HX5(@<0DS.O(V=$+DFDW?E4MH0X6D+^L=1_:0*PF2C3.*]:UE3[9?)9
MZ"ZYRJ2=D0C;\PP(3.5Y&RW-$L=P,9'XB=!<M($2)DL2]7'.[Y*#"SU>C3M4
M=TX:2?@9&CU=>/N= D#QR&K4@X%7$&PFE$]0>6^W%7O89\]QQ^$[M.7FZ;,-
M[;Q<]OQ2L?UO)VP?PV1V#ELUQK8^G+O<G"PA.>RACJ0A-;5);X+8(H4\T)&Q
MP9<1X16.-5Q.G:8_+EQI_B!.MU=YZ6R$6H17=R139+<JF)?,[S$KTX:#XNNS
M"K/%C'R?5N7;!IE_R#B3+66R/BY<K0O*-?V[^\5/0SWJ HKE*A_2)U^HKQO\
M7GC&V8H^PM"K#_4$'J.QVP$^XZDC/%;[KK:HY_/^1!^W#M=T+S]S;=O"=$70
M2R/U@<LH'3(']"HD!26PVZ(96M+WY?VOT>%9&>?GO-:2;XQ_/Q^G0FRC;R#K
M=*0K5_Z/#S[)T2PD S-(#HR3&O;M"D&Y!]UP;C%:=G+EI ]QX=&/A29F;@@F
M93H:3[U\D;Y/M\8:#MF"G)IN@'G+=J'RF-#8@5<U$P;=:@U,XT''3&8O>@XO
M/8.]4M#6DZ#;$"Q1<1 'OY&7[9^J"XWTW!GXHC36"$MRUH(O9':Q<X6\G6"4
MD9G)91TL],VX1'3ZRV:I;TT#C\CU(*N1-NRG/2VGNL+34=N*YY9DTRF $PU#
MH_5!+OMDHG0&P6'1/5*<2.5Q"0^GDDU_J^=;K:6Y<$D2SW2Q=[9%D.K![K_,
M%]Y^A,= %0/&-%8*&!N:VEYAS+R>F1;=(,IUJ_T:U<?]H <B%$M"\@S_+-L>
MRMKWFJ=6ULI56(H]\U/@3RE,;/8*/4-D5JG!3>O/2"1T73WAA- 0%4G1*@.O
M9H7J<&J)1,L3E=]?7FYH^E8+%?]L^-E2\;OA$5O07JC Q24V/@R(:I$BD=]F
MM8=]#Y(C"FI:^M!S4\4ITKGOYLYCTXR$XG^:\%^,?N-'<Q)J\ S&I'/1 7J/
M$/PII&0,?%G;=-H8NZIS/^JO5*4YKU*6HV^!?P'68.)E#09\_ 2X7GFNW@WT
MY-0QTN=YDO?O,!R$F3P.$FFY@>/&V!&\YIO[8H<_-3AIN)?E7T''+JJ.)=49
MWK6-08?(\'](<KEW^^\C',][:XRR1\GEVRH9NCUCLEH_F%35S97ZZ?>)>N$!
MRC1'CWD6854#42U>V/%VOA.&9)]O6_BFOZ+-_W(\WO"&-N"W)=\T'RW8TJK/
MLU@/O(9Y@..<&5 9O;:X% 3KDFR5\<4Y/UR=?QRG](.4^0.J$\XT>-9VAE"X
M()_PQEP^]O!4VU4/KG(1-FN4$_MF(4HG/TCGK4LOA*-%$SML>-NA^Z1,PS!G
M7[;IEX)+DSXC$^U+D\[*^8"S5((O/4 TQQTM[$8'>*M9C1*M7+S<BG7ERK[/
M2*1WAVGT1#6*$,I!3%!'K&\R43T8Z=XF_K5ER)M&S>:RN8Q#DMLUAHX[ZL=1
MN6QMB7O;#/@<@@/&*2+ 2;/'6LE3_F("YYAQFI'6&1-A?47)%R^?.\TEMMCD
M$\1UF\<.I]9J9J3^2)L'J@9]L;VRGMZG + M69RMY6EWAH83(@H)&L/?U$2D
MOK[6;WEB%I[QI+\_/XY11*V2_AGMDA4B?DX0RHF[NPSOG!6K&2U,T!JO=QKL
M+_[@H]A@W6,LT.NO*US+<V9[NRW;0V5TIMNZ[G]4"%_9L(,#X5E[I0/H@07A
M9$)U>@^>]:J$3YSZ8SC\Q+W(YC"7W?%SM98ZQEORVXF68$5"T91G5L"BXC3Z
MN[#0B&N >(-6RF'V(B+!F8_@4=@;CHGP&3:L3ZWKQ<<?+VFYBK%4NXA?9Z#2
MS8**&U1^PP?EFQ>V'+^#XTNHV18Y6;[Q[<S(@FWQ=1984R.]Z[Q?!.NC$!"5
MF'GC0+9P4RP%2-SV51&X)EZ;<=5[5O^LL9Z4W&**G]*?$T&</+IYP::3 IPG
MWAZJ9>>'WM#A'+U<E:):N0>=4^5)[6RX3IJ]<]CG"FV]K@Z<3'"T<^@QO#&0
M#6'8OH>+FUI@Z)QJ%=?#G;<W2N*=':TYA;U=50C]F=2N<#&Y].*/ Y4?Y)^P
M6EY$18AP.5DT9&B2:*Y:A'4P"N)5%Q&K?-7#H]OQ;/%RE$[IY^I#:NCCD<,[
MY*-R^Q%Y[M9P^7A O9HE_4V1)7)T:VA.]JD=46*T%E2IM^AU">%W:]I 63$M
M+!+W1TY[/Q$X_'FU:%-,.H_!4("E\"+</O!_ <V-[YPUIXWB321&D1IA\\6S
M5\:T[$H)0O,[7Y1![.O[M;6]B3+3*F.YFUVA[$D&5)+7E_'T+ O--^C= O(H
M6*#&V];3&L%#=,]LKE=&(IU,6E;!U]U$>\(5+OYA."@WB(R$=6B@YO."834B
M)0@V'7%F6RV?C%]RB-).>I-2>H$ ]W::)TS,1)3TF4>TVZL';/^82?!JZDG:
MZ> T-%-LIQL9+EVE %.?,;9@-R=7(W%#B:9:(R;_1NCH=9U)NKU<]M"ZUOI6
M%N_51+\6;NZXWF7+'U(WA$S$2\22JJFW3X\O(=N1"5E_5W>',20(/+DMAGVT
MP7%GJE1_6^B-YEO71V"T'B0751MX()BY]0.SV6>2AAG#_&1\E*7Z\WNRLH&M
MR/Q+5B"<I[5?S?_XC6FZT=^0Q-Y_OW:?X?^I/IF"D[C/A!EMF^#.$54(HIC;
MIE=OV1PI4 "WR3=^LT]1EXV:BH,I0-0?AB]=)9..M\02]V;M[O@E2&7HM#PI
MMUG,2/= 0E6R.]JNIXBSV/"QAG[YE4:?[*M@PS#EUX%7.3E:*(\<_N8L/*Q2
MRC?WN,C!*)@Y+*_HX8D@@%(>G.H>ZA/[)IA4W0C0[-Q^LMXF,ZA2FE$_?/A1
MYV0A\L!ZW$0\1>F[I;F^]#P[NKK7?O<;$BTH'R]^7\,ZVK?(P<.O>\<:I*K_
MHO"MWO&K)XO:Y_U?FFBO-%( ^M5T\THS)',(YOY8;E<O?@HFI>K_)S[YM=$
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M*(LJ1 '2:71.N4N(!<82B &?L;>W\[2Q[<]W%VGTH'ES._&2DCJ-DM^KQP:
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M_F)8,[(]TK28?]&E*X1;?0I37/IX^?A:ELFD9&TJGO/XAE6%UVTM6JKT5V[
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M\%VWOMQ\VJ9F;N/%);%:M<6P1(R>\^<.7K&"DFFU$X"UD)0'7[LY"<(&4K*
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MC;QBI[]JU#:)=+4J?E>;].IFS53?C/*KJMG(-K3)'%WZ"%&/AA3Z21A")'<
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M1[H[I\,/AV^X6X*< .5H+;J.EUD7)2>P':Y.;@:UV->K<R'.BCX6&*4A27@
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M@;:J]F"=[K=ZQ7@V<:V\K.K_Q/_XAXK-K7"^3;(7(6GJBD#N90PBDOHP"[B
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MBYRSGY]OBW63*;/!*^GS-4154G9SL6I7&#9!F$1I*"#S(]7O+/)AFH4)#,+
MBX*(\(29=0B^@IFI599^X6RSXFK_,N '] PU%S\L-H36V.OO#^= U'R[V'$%
M=FRIFSIGH>TN8$[43=@!2@YWD]:LS+ZYO!:T4WO-J\>T[-^A[J[<RW=OON75
MTH]]$?!,P! 'TJV@L8 9Y4R:MYBDJ4\B@2(3R[8W^L2FJJ$%%#'P69$SS,+=
M!T+/S%B+9V8W]"4S;\IQ2@)7S3CVQIZW"<<IL8Z:;YQ\:*)KT]6Y>V/=[;#7
MWWA)\XI79RZ(]7__4.94;@0(#3(O"V$81I[T0+" !'DI#)/4R[Q 9$F8.KX;
M[50 $UVQRN#MJ<UT!]KM[.H9G^]WQ@PW3!JWF:L+UYFW%Y:W,HW>6>Z? HUH
M,UY6GF1*YKJ1[);Y[^O:\2038WRW>!HN7+2<^%@\XY6ZWJQ2+I8$$1+[J0_#
M "40>6$&B9\DT*.^EPCFB3#2.O;4H#7U(6=+2UH+1>R:U@7["&D<#[B3V\S>
MGFPWT./PUC$.US1IL,;#81L&35RN;+%P4E*S)@K[0[Q@FX23LHPW0CC]RO=6
MOVC;7/.C]";?M-T:ECCV_$!.#PP94XGGH5!%%3#,>))FQ!.1\-'W4J3HE "3
M.^)O5(_NAF%P0^O\JPILJ:/:MMK,*USC8=?<SXHUT/%FN(&?>>8=.>DO-ION
MG70W)8>V<LD?-^H0386>NPP\S:_'=U1D:&R6OOM*0B>9_[[\]DDF9KZ:0*-<
M7)G ^->B_)O<)Y0%Y=5!DEW J9_1D,L%*Z80<1'!5. 0H@1E 8HPCZCQ =8%
MFA/[\8JPVO(_M:0M,Q1'(-,_=W((A/GQ4I>-V,/1,3!'"N)EB5TG'HY0?)ET
MP\L0G$TRU'C5]EY#\<3+^OF#_*K4-VNV;:<BB2PCXH6>$"%,<.A#%! /XC#$
M, H3&I,,T4RO.:0.L8D-0$^Z<2[YKM70FFM>HM0"S,^R*!4A@E&&,40B22#&
M*(&$$2[24"09B4UN?3D#S/S:USR Z9E-5S"8V<N>Z@(T=!L@!DVJWH\ 87'-
MX[*$SNYXC)":^8+'9:&/;W=HO&.>3O>6BO)FPW(Y2S=U+5VNQH5[L\(/RR",
M?()0"./0CR"B00S3F/@0QT&0\"!B(M Z\QXG,['Y>WO[YB/H*(,!::!HZV?8
MC< TKLGNA#?T>:SD-DJZNRR65>K=R+"S)>!=%FV8AJ?Q]%6=5,9;(2RY1X+8
M"PE,HM!3-S#EVNME1!5FC!A"/(T\;-4Z99SNY!&RW_[XZ8\ MBU K/JE7,!-
M;PEVCH69'O<=40X:H9SN@^*\^8F>U&Z[G5R@^1+M3?1@.-//1/-ERW)576&9
M7.[$/1)Z+$ "\I1G$/DJ^Y:IJB\H$XPCQDD:F?C@@[$G=KG;2@NK'3W#"E,#
M$/24VE(T,]5]IR&/>6FG8\Y=56L:C#QO :9CD8YJ*IUXQ$YAWDN>6KULC]CD
M5A^3D&<<1I[<M*)$54B*0@JS) Y3')*0>48AOT,"$_NW[XKU USE7SD#N*%G
MICI'<.CISS5"&BJ1DN]=(]_-N'S&JG1."$?Z=#3\K$IU3KA#S3K[G'5EH,=B
MW10@^(#+N[)9_%A3=_4#+YO#@&4:I9@SFD%"FC:>7@K3C&+H$<X8#7"$,V:B
M<1HT)U;"NY+E:UP^;XN&K(M'^<$*?&UJ +O(M-0!5M.A=0N7H3O;$._KATCZ
M\MO5^K:L*Y@L>6A/-9V6$-*5V%TIH8L4YRXII O!B=)"VJ]>W7M<.L?R^]*U
M%59W2C&M<]H53]Q==K)K/JXW^,2VXK!=MDK-W;*ECJ(.&;-N-ZZ)Y;C5F 5&
M,QMBC"#X[/26V-60N.@WKDGQI1J.FP$RTG'<<*#)VH#N]"6+*2),<"CDS@ B
MCP1RPT!BR*(TB3&/,Q$%IHU/],E/'G4;7FP]T1?TDV79=R.(]1R9J6 SLT;Z
MS4*GN:MJ@\)\#41?Z"ZJ#2@6+45=V1^5TB!?^G*S9J_X5[XJFH.]+E"XC.*,
MAFD00NZKRO*$QS#S8@KC@*,DSHC G)L9G%%ZDUN8GGH3S68[^H"W#!A:EG'P
M?"ZR,)"&.N*$0A3+?6:*1 )][J4>RY!/B5%W'6?0V=S)F!,X/1OL# XSH[N'
MQ(!P?R3BSKQJ">C(GH[3FM6 :HE]:#'U7K*\OM"Y)7?"_K)8VX \\5 <X"B&
MA&=8FE,60)SY"/HA2I.$9D'*C?JY.^-L8NLQ=.S:;'2B>[64'*>MVS6(=S>+
M>N;I1>;&S)0=3\LU-W[=]Z5W#J&K['YG?,V;N.\:SJ.<?.<$S(-Z]R639*3A
MS\N&IBK.HANS._7NQ)9Q1ZPI+:0?<#LIY^5XVK4BFAF8^Q(W5<N'%Y)T)3:*
MB8V)917R.CG@;!&M,7&& :O1YRP/J7E]BZLO'\KB:\Y4P:/?*M4@NZV&).>R
MNS"8#]IAIA2%D8B$W-V$TJN)4 :Q[P>0B00E7IA*7\<P"<R<B<EWCHH?(%;%
M[Q50<P7RGA> M\S\R?  W!QJ/==C6OC,3("ZY-)@UW.C?(@?%$,2PA_!EB>P
M8VJ29J7VF+@ZDS=G8-Y3>VN CL[U[4>RLUF_% 7[/5^MY.;O[;J6W[Y<^A!M
M3L&NX^I6AS#"H0@R::0(XA"%-(*I1QCTDRRA/J.,$:-Z:D;4)W8G>EZ:X,2.
MFRY_9= 1V+HQLAG6>O9J,@3-3)53\(P-E!4(CFR3&>U9S9(5+(<6R6X0BQH]
MNQU06SCC'G_KVRX>U:L-XTAX'HQCP2!BA$NG*0RA3S,2!6&&:*(5'#8C.U><
MYT[T?;M4LGBS$E3*X[^<+GX-IN/69CJD+*,N!R!U;)B<V%T#ED$5H$E LRL(
M).EM5K@$;&>,"P&JCD$&GGH4Y:=M_2A0XV]_=%0DR!B(T7I!^J/-5SK(6,*]
M*D+F;]LY?&<ZW/:]W)-(\)BIVPBAET"4!BE,@SB%G'+/X]+N>HG1%>IQ<A/;
MU/X6SE-1]DE&Q;:[\THQM+V]H)FOI8FBGN_F#ALS*SK6X;HC[LXWTQ/2D3-V
M@=BLWI>>X(?NEN9;%L%==5FGB1NKOA^\_%BO;QYK[?#NR;<G5M_V?M& *OC(
MZTVY!C>/Q4:WF?2([!HAWZO%-@SZ6DIL%O =%<HNY'MZR/F"OJ,B[85]QY^\
M^OI$6]GK;55M.%O*#4F0,!K!$$5(I0!1F+*80<Q9DF0X#++(*(OE#)V)U?#H
MFD376S5OB-NW53V'FM[BZ0 +,]W<OP/QJ<.BI3K)I8=38KF_Z+!'Y:4N-YP2
M=>1"P\G';<N+=<[V_OU>U:HB7V_D.MPMR,6ZVCZJDIS75*[+[<EL'[!#.(Q"
MFF:0A"F#<L,2P(S%!"8DQBD60902(]?9'6M3'\0*P55<F@_WY!_5Q?=]=A;=
M,F8=0'4X67I&YF6FP,PN#3 _JBRP %/,C451-=<P.JN]YHRQF4NTN0;TN)*;
M<PJ6#7T.,KAWN=TJT[OK(Z3.PX2T7/=\_5\<E]4;G)?-5;<E1GZ:<)_ ,!,^
M1$F@.EJ3!(:J#!(E?LKU8L5NV)GZ"*ODJK-O6X'6]T!#W+!MT'5PZYG5^4 T
M,Z4:ET(60/'17GI=;'N;R2=7C1E4]_E5KVRI("N^W_IL ; 2IYD4.3D.>QXY
M0=-5DZ3KF)FWJY(3X([:,+D9U3S"\_KO]?/-[R6K;MA_OUD;W[H]\_K4OF-;
M1;O)7ZR )+WI&L=)12N*>EV8)/:=0^!RH,>!\&:F1D/N">Z_7A#3*O9S;LS9
M@C\7A!I&?RX]:AO^D3RJUH;*[?F85W_[P$OU 7[@_C()&(\8\F#"8M7:S.<P
M#02!5.X5HXR+#&-J%@,Z3VSJXY0A:5!*V@M5&*.C;AK\&<%,-P+D!@G3,- 0
MA(\-"!\N@V 1"+HLG;-HT BIF4-"EX4^C@MIO&-9IJU8/T@]>?P@OPM?<,55
M""IOS'3;KFK)LRP),D(@XVDHE3LF$*MLWH1BAA#!-..>B7)?(CBQ@O=D =W2
M;31<4F["O,_*53&,\E[$4$_972)CIO!-*:M[21ILX;D=P-.2=U@I3E-05^7C
M+I&;MZ:<IO!'A>9TW[,M-''0X6EW2EM4U2TNRV?1-KNHEAY#@J4LAEZ02),0
M(@Q)0@-( B\B*0]0R RO?1M0-]$"JU3^IN_"+H5"T@=TR(!I=0E]7/7,Q$18
MF8813G1>&R1=*-1NM5"S*"MA++^SJA+ZE&<N*F$,R7%-"?,AIBAI\Y'C5?X/
MSG[!^7HI4HXCED20>UQ5P$0"DI0@&(=(>#'FQ!?$Q/?0)SUY%%,I2-D1! ^2
MHM.J-7LHZIJ5*;"9(#C9LP(4+W-5JSDE_RRU:O8(?T>5:DX!8E:GYN0(5YYP
M[Q_/-*V[MA^M'][6_+%:<@_[ 4,4AKY'(.(<09Q0"K. Q%Q00@.]YA$VQ*=.
M8U$T+<^;=:#3LR13 6(8?=0^%6Y;&@XX PUK"V<9:=< X_H46(?TRYSS&H!R
M]B379 SSTX>WZRJ73]Z7[$.QRJFT::K[UPTKGFK.FHXKFN<0%P>:V$YT]$%_
M ;_GHCG8:SJ:L8U*?^LXTC^=N(S0Y7,*I^"8V0Q#7,!GQ8ZC<PMML:U.,"Z/
M/MM9AK:@PU,-_9<L4S HW3QN5NIT^Q5_*CEM+8C\><6;3(\UDZM!6>?_:#X_
MV_)J&7JQEPF40"_R4U75S8,I"P2,0CD?F/&,DF2YY@^*DIY_X8HU+;7)6K49
M,J@?1>1R3P,!WO$+V(!APR0-5Q.BY[/,"K*5;1IP"(8L+L"6R<9,#=E<@(.&
M>8O]CGD.$S0<X^<J5<,56_,F;3@&\RA]P_7XCON<-M&1)8ZI\ (:0L20NED@
MS6E&_ SB+/0(3JG'O=@LRCQ.</+ <GOSY>ED$T]'_3M;Y/1,GCLTS S9A1Z>
M#?49NGCN23EU'\^6V/?1R7-/<.U>GOMO65;*5!<;VBL-KS:E=+#;DZOVJL/K
MQZ=5\<QY\]#=[VNYJ_F2/RD^EGZ2\*8N9N+Q"*(4AQ"G/(24$!%QSC'* J.Z
MF'9\3)TFUA%N;QJ!I_XD5E69[SY3UY&PG'W["TFV4Z!G4F8 ULS6-+2Z"TR@
M9:D[S=Y=;]KBWCZ\Y:PQ3PZK55Z'C:O:E)9<S%N)\CJHCNI.7CG<!,:NI?;4
MW"UX_8V7-*\X6V(<XR -/95;DT$4)01B%#-(,A[Q-$69'QLU?#-G86H3U]%I
MBG(TVE:T#$QDT$[#G @>1FD80D^$ B*Y*8>8>!P2N8P0+XIQR$2_1;]_<;3W
M=^3W]J!?<8W5 F0'"\;5WU##M4*CQ/%HA6.5 -$PJ]K^M.Q60$+N.GW*'K0Y
M%I'3#'P_Z\<H0$9+Q_A(]LD1;]=573;%C][E:]Z>O$72,&&1!')I4-?L!8LA
MP7$"$X1#2B.1^B(QS80X06=B^]^<[^_(@L^*<'O:9GA-]AQ.>F;'@?1FML5*
M<*L4AA&Q'.8KG*(R>W+"B*BG,A'&'C<_"WR/'SF36D\WZHSY3HB<2GVPN)-T
M<:")=;*A#[8,@)X#F\M)ET&Y?/SG% \S+;T,Q03WE;3EM3KWNSSZ;.=^VH(.
MS_WT7[+<I5WJ1'"N$4&W[M]MZJK&:W5:_%>>/WR1+OK-5U[B!]Y[!!]*R?+'
M8K7JTB>72<!I$C,$<9 QB)+(AYFG@MN4"92D* @\8;3+FUV$B2U2%X?I?>D!
M?PO0<P@Z%K>>-FB8M"Z[\0+? \T=TG<]NR^WPW+]K3#?A;W8Q+C:Q<TOP+R[
MP!>;H*-=Y,MQ,D'7QU_Y(^'E,@T#/_ 2 5,B-Z/(3S,HMZ(A]*,@Y@F+L)?X
MSMH7MC0G7G?.-3%TV+NPPT[/]#M&Q,Q67^IC"#ZW'#BTJ ;RSM'6L*/X_30W
MW(? J,7AP:O.^V@T27F#SNT1#QDAA,,P% 0BG"40"XI@[ D2")XF<6!4DDB?
M],0VHF?$65>,0^3T3,,T>)A9B/%^&(LV>?89?.[^G:3%M#D.T[?$."3\O?3#
M. .(03.,<R/8F9/?UB6GQ<-:W0&ZQ]^ZZFO51\XVM'%[I$7;K-0-Q#=2S'?X
MJ9+[_YNG)\F#ND7TJ<;UII8?O<L?\[9-0+6,(RQ8YOO0\XBZF1QPZ9Y@"C%C
M:41B3'Q*+8[V)F!UGK._CK(Z;UWM:*NNS%U+.#,[-L64Z1F\EYH!*\LX9+:Y
M=M2SJRXO=@R#+<-MP[B&935/.Z;!8/8&?+NSGA."ZLC,3L'AK/9X0H@/#?>4
MI,PL?%76R]<;E4G8[7>"&/D\H0D,_-2'"(D,IL@/(>4Q$GZ$"?*9CCMX./#4
MZ2H-*3T3>23SN%V[1A(S8]12<;A=.\?ZF,K+=P;J+G_;J?K1<+/HYSDA>J4Z
M^W='U?-O-O67HE2JNJ2!0!YE$<1!+)4#)P22B/B0>6&(8M]'7G9=!?T=K8GU
MY5P5?;QEP&$E_0&">BZ$(US,M.]417VP(SQA4?UCZ:8JK#^@]++%]8]%OEA@
M_\0K=AK^,Z[R2JZGE*H[XRI3J-DL'6[O,R]$C,04)KY*9<<I@R3(FHHF./0(
MY6%B5'Q C^S$>M\PH;S4#_*AOF>;F7IKPJ>GZ>Y!,5/Z+1X[#N8)AY@)[L@>
M:!*=U328 7%H)0S?MC,8!R<Y[S?*S;@3K_*5],*[#,/!P<\2^W'H,VDO_!1C
MB+C'I</@(<@8]ST1)%&<!&;7X0PY,-$7J_MQVU-<W)WBKAN.FF3Q=N$L=MP
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MPGO09T)/Y&C9@%D[(QS-3)IK=&!VJU\)L"'J8;H;1$I'UL:(Y*@F!0+"OMT
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M.[.6IT S%;Q4/]6>)IF_!AUW746/>1@!A-_YP((OZ* ;IA5J'J8GV>!A%9L
M$1HM6F$C?C]^8?7^!>D&;>HR-,M@E-SWWL6Z1>J 40K[A4+!E+2?*. NEWI
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MSMI<7""IRSRZ,Q3?+L/.#(K!W#O#)> Y.VU".:171.\5WYLXJ#E$7Y1AU;Q
M"IC:=346[KH\'&';*JVFO\YHR31'F.^GT!S[YPN.HM=S_D5A.?N_Z^6TXE.F
M=:>]60FCK$SR,D%1ILZBF#.)RDQB)$F49F6&F=HMP0?2T_1\)["LC =-FP($
M.(RZ$1NF5S7A>CNK20=]VAZ22PWE='E0': V_G'UO.A'#ZT&K\&+]9M]K^YX
M3-2*+^(C69%V4O9$QF$6Q5&&<"F9^G]ABDB8891(Y>J&I<RR.#6MW1\BY%FA
M6P^V1UL/5B=!2]V\MG\0K&$==PD!\*AJ*3VH%8"):%:= 087'JU1@(EX_;X!
M1L];WE(WJVS:F;<-/MJ.'I,\(RDE7&EK+(3NL!JCLDB5!N."9I05,6<Q9#3$
M,#F0XMH.$640-36$R6Q#=B<\,$3<T.T-3.CZ!P5_:8F?#J_!+[&-I'1UFSU,
M;-QK;2/!#^ZWS=Z"GQWO1-7%IC\N1/5UL;H3_UQ/EZ)KNP9N0F"^HO>8TH:1
M@"M.@OEB%2P;7C:-_,R/I@"DSI]<_8 $4_@^/IJ)^G[^;@\?#ZT%X+);G8X!
M9$8[/,-%[Y^M+=ZVV^YOEPLF!*^'FWPG.HIU_4*F,YT5^WFQU'_S7:@-<KJ:
MBNJCH*M)%%,:YUF&2!&'"$>A1)3)%,51*B,9X0A+"FN "&4!HB96S0T[AIJ1
M0Y5BH+Y/?2++?XA579)0;1B">0U@M,W\")\(P@S-+G2:LD9.TPRV+%P%&_:0
M7"R1?LR=NV$+AB,'!$Q^5)?$%IQ])\5ZG0M:UM.!!LYM_V9ZM']SVSK_3M>*
MZ2L]G;5&'L2$9#D3A$B$65DBG*8I*M3Q!L4)$:$HLD+]+[AGO6LN/7M.W9"&
MYPU!BX[USK^,83SSK?$&1D%/M5_M#SRFKSMM6G?JZ*[:<KKNFS6L7P6WY[^=
M70]\7]BZ;(+OG,?QN^#[@OEH&WQOQ"PSK]<ZP/Q-MN/TY@_?Q4.=\CA)0QF5
M9:A<A)0+A',J$$V*",4B9T6<QQ$I08E-)RGYOA6MZ6HW:-%15OYC0QJ8Z7P2
M*S-[Z00!F,W;"K\A&GP_)SP\/?F<8*[RD$_2&3?A^)RX!YG%9U^PJ'?\)*6H
M8\^;2-6=.K'J\^F<36?3VK9\7<RYX&OUF'(,VT!6-_VR_<]FR-HD#..R2&6,
MXC(F",=E@F@6"50F!8\*'*6"&%T%N6?-MWGH\Q%,6PX"T;  J$AT^SV&+<K;
MH@R\G^K8[(>[-:?!+JOUQ.#>I]ATU._XW?X-9#BBAV\#*#1]LV]D5Z,Z_K>"
ME;MZ@7.P4M8MQ?&*;+T@M5.?ZX>";12U'8=09_O73G35U+I-6,(DH31%89E&
M""=)@@@C!<K2+(](CG%(C1I4GB?E>:/:$&[R[]6YL_G?8-H4]>DL_>9O@*GY
M ^"9AC]=0 (-='9HU$3;X2I56^'H,IIY3C9G<<N3A$:.4)X3^# 6>?8->+[^
MK^3OB^6'=;52IF59U15?-(FR@F48L1)G"!.6(9+E"9)%6!91QCD+C5/R#Y?W
MK+T=+7!WV2- #&OEY>+!--%4,E!^_&D!+DB!/[+H:%GNIP7J)[(//&49N-^T
MZ_E,IDO=@$<T(X1TLN&44+51ZRN"-I68?YO?Z6L#W3CJ9U)-]YMNL5B*%*M#
M(DW3$.$,AXB20IT9,:8DBG*2DQ 4L'?)G6<%[K>]T]S6/=.T?ULSW"37;EGN
MQ@7P8#$/-EP'-=O  +_3+V@8V'^K[P(,Z#O[))!6=_!0O@\T787PG?(V;NC>
M!ZP'(7LO1"RB?7>+5S);O7Z>SHDZ7M7]">H+X%_)C^G3^FD2B2(5$<E0QG&"
M<!D+5,BX1"+-\R@58<J%T3''A)AG2]M2"9YW<AF6#4^![)@"A'_.@6<0;',(
M"<S(M82##>6KH*-]%;34'4(!B&TYA,0N6G41-+# DZ&L@Z&D<VN,%QPRE&8G
MW&/ZSH7-4)2A;2B065=Z>TVKE4ZSGS <AEE*.9(RX0B+7-FX(BQ0699IQHL2
MIPQT(VE"U+=7N4D+U3Y,QT1_0D?+AVW?E"$\#9U!QR@!?;S+ ;)OL6(@L>MN
M*T,DWZ;QB@$()WNPF+Q[Z<'V3KR(^5K\_+I[>/[Y]4X\+Y;]V]:]LQ MXH*'
M6898E*C3+,;ZRC,K41&5-"I26;+,\C1KR]*(1]AM HG^KZ80YWN=:;M:!!N.
M;8^JUM\$>CX= VG[0VG+G4XJJ_G; JO_:L/B)B-CI&/HI: Y/WM:,_1&!\Y+
M 3Q]RKQXY0OR>P_FA$](PJ(L+QA*0Z$<KC+!B)99A!C'*26,8AK#'*ZC9'Q;
MO3J=L\ZI"U@_[1.4XG$&*4.[=;'\0%MT+)-UFVY8W^(S4CUVM_6.TU=/2NHR
M__20R/@)I"<%/9H!>OII.^7=WK_OW+VKOVB[9]^)2JA5'R<L)(PG)$(\91CA
MB.5*+[("A:5NX5%FI8#UJC.F[%G%?UGJUG7+EEBP(C\"5C, TVUS(,W4W0L\
M, M@GM"C_Z%A2S<6;OARE[UC#8DC4V%.=U3K 89CWZ# %["S,;_-EXK PWSZ
M+\'5XFTQM$Y#GRZX8F(IE%'[*)K_G12"$<E3W4X_90@S6:*RQ#$2.L6T3'B2
M20FQ,R#JGFU-1ZX*I'+HM:EY;D^V=9'BLV)I60_< 1Z>8 B;&2!ON,&,4)^-
MVLYTC-2E,XJ5H.,E^$O'C</^!U8H.+([,-JCVAXK6/;MC]TBEH<4,5/_^G ]
MY[_6E<#JSZW?.DEQF*09S1&G18ZPC'10F$9(L)QS%M.H-)O.=YZ4[\-*0[B^
MNW[J2'<G%6@XYC1>AL<5)R@ CRP] #94/9Q/SHKFZHQRFM"XYY2S A^<5<Z_
MX> >>S/+FN",DA@E@G"$><@0C4B"0D:4RR"+(LOLKZ]'Z2IX<!EYP:6L^="N
MRT6%J>>!E#:SNT[]!NROGL>:X67^D2^[7@:,\CKQZMM=)@^,]#KSJ,O893-?
M>*GH/(K[/Q;M3RPJ\P03EB-&8N4GT$@B$L<AHDF6)Y+SC&8. II':7LV/RVY
M0-%S$= \#M\E4<Z+07$<^NP!YJ,%*AP#KT'1XY3?0:1T$!*S\.GP$A8^RB:H
M(II;E@D6C,E4EH@768AP2"DJ8L*4=Y+0(J5IG@@CLW%T=?_QBC;N)[K[1<A>
M?8"%@5-RB80P+0<)!]N23PDQN!D?O#3>-GR*WYT-^.1#%EKRE:S62_%-_KRN
MIG-1G1CVEO(\Q&$N4!HFL3J9AR$JRK! 41J3,!09#Z71H#YSDI[UJ>&AUU$!
M-NK>##4#)7..!4SS6AB^R:!CP&80GBT^@*."<YSL3@X?=X:WD^TXP><&+1U,
MGF]^6K1EUM70=1 (@Q;.;*7QS!Y(LAU;"'OSPJO9O?;$98FS)&898EBW<LY"
MADA&)2H9R5DFRY3'H-0S%^V;K5T+?0?R%]JV+=99^R_32JF&Y=WK'E(<"RRR
MF**RS".$21PA*C*,(HY+AHN2LI! ^EV_3:/K,9#"(I11PDL4%7&*, YC5'":
MHRB2+"Z8H%$N)W/QH">^^L>J;+#JT[-!JP7+#4)FQ]?1NX&/TP5\G/;?[Z+O
M-[#AM]M.W]VJNNOFS;Q:+6MGH6MZH5,OZNQHWNNVR)*")ZDL$&<RU[N!KMU2
MNP$MRU)9N$@F.2@J94[:^P;1=H-9@B?N . S4VL_H, TO>[#NV6BURY'\W$5
M-)QXZ2<)%]^110 0'M5(P '9MQL6*]B9DCOQW$0P]3A;,9\NEG5OZHS2G.A^
M&+B07/T_EB!"BQ2%22:YR'-:)KS;\._-K<=Q:A:;_CW<8+21VB:WYNMB!;WR
M/H&4F86X0'#+H0 =O7I:=$VQ;M7M3NN'17*DX2>(C*K-PX+N:^Z9IVV"86V'
MQTVYDS8,T]6Z#@]-,E8FI%"JB2-,$>:).NG)D"/)RCQ,XS3)RL@\"#9$RG?P
M:]-.5&Y*\:8]\I! SR!B)@$P5S@  U\-!-_ZU8@W/B" Q+A<06$7V[*&!!C$
M,I%R.'@UN,*(02L327:#549O6%Z@KY^?9_6M*)E](-7CY]GBCYNYVH&?R$ZY
ML&!QFLF,(Y;C&.$P$8A&^BJ,,2R+/(Q8F<(FCQA2AOR"K0:.]/D(^"926^_+
M=7V,5(PI0[?A[#^ =^R&")OY*1Y0@YG ';@T!X%F(>CQX*<L&R:WJ_MT0ZKC
MWJ7#H#BX1P>^;N$0;5I=?]&9OUVKG-?[Q<_BEDSYM53>Q]\$67Y6/S)UDBE*
M*778@]%"61:9((HI0X2+,(_C*(M"\TM""&7?23F/ZDA(-$& 5P!"SL!/\H4'
MS&9LV\_7;%QM.G.]7NF*<RH"S<Q54*,5:'X"S9 OW #.E2_\['PMUSC"7# ;
M+ 8],M""XSEH-G+N^&M6"S@MS>J*+G0%V'JF6:EG18G5JK'\U?],5X_J>9WB
MO5X]+II949.HR%)11!+17-],2HP12;!  DL6Y1D.<QI:!)6<,CE.+*K'A9-*
M+LL/8N83CH^OZTJPCM5@PVH[PV[+;/"'XC9HV UZ_'HO%;L,1K^E9):\O8=2
ML\M@-2Q%NY"(;<2^;N.A*7U8S&MG6I/I^GE\^L%F:ZXI5HJQJN9W(K,\*@L=
MSA>I<H)97J B+-1IF[!2=W>,4D8@MX 6//B.'HJ53GK0\P""9<,=-+P/A]4T
M]N\5+.C%0-,VJ+9_'3N-\>L8N@HV+ 4=3]HRNKPZL$;$V;T"G(.1+QVL(3J\
MD;!?RC8_H6G:KU9J.MK>S.N6CM6F9<#UG']4;,T6S]I.3A*.&4NX1 1G4G=?
MS!"A>8E$0D5:)GG)2U!1/Y0!S\;I WF>KLBL]DPVG438HH)Z?V!<S0R43[1@
MUJGCI/;?:EYT'@-JN=GT#JDK>'L,N4QEL(/"64(#D/S(:0UVX!PF-UBN<W'_
MUR8=2ZVN:WR6XE',J\V0H4VD/$ORC,5QCG1A,,(94W\218QD23A-8Q;QB%JV
M@C6A[]D6[30]W6&C:^/CH"^L$<Z&-Q+^T />3+@ [I)^L1#QW;>.-:+^5EUD
M(= ,-)0%+6-GC#YHV;03IB.S=]/J'^HLR1YU.XZ/BR<RG4\BDA4L3R4J4ATD
M8Q%!E.DR8B9SFK-<A)A!K,\Y@KY=GS[Y0-,/-@P$OS<L .W,60C-#(M+8&"6
MY#),P";$5%!'-N,LN5&-A*GP^U;!^#WX^+%M1U8]\Z.Y%9WS_UZK X)\U>>P
MIH"KVI9U;8O3HE+9!BY*5.2)\DWBC* RXW6R1)IEA2Q#;.2;7,B';Q^EZW-\
M<Q-L>*N=_BUW0<>>^;BS2X ?MBDCP@ET6CY]"#K&KH(H1F%Y%?3;2)^%-^A5
M%_[NM'FT(] N&-IV"?71IKLY@*@_!L[%<C";Q\5T<KWF4_4K^#Q=/MWP"2TX
M#^-2HB2).,*XS!")28PRFA0RBPMERA(3*W:PLF>[U-(*-+'@YJ.9Y3D4?]B6
M7"04S#J8RF.LTB=Y/Z*DE6 _/2Q>_G_U3J.CZ@];]3Q<:12%.RE IT*G'[ [
M#WP5*YTE=:OK-;G@/[_^5@E^,[^9OXAJ5:OC:OK2W-92+$0>AC'B(M&-" E'
M1.01BDLL,8V*G.<9I%S5G#1(K> 5K/KNIDZ%?&Y9T1,,_K+6UP[3^;^K_VL9
M"LB&(]B) 0"RV=G!#W0PY=6HU0F2MWW4?NM0V_ 27)]'#7RF@ /@Z'0!(#SJ
M.0,.R/Z)PV(%.Y.SR1]J AM?%E4U2:(\I"*/422*!.&P)(A$28P83TN9A5S]
M.8'8EB,T/!N1;?*:\EJ ]N$8(F:&X$(Y81J_%;$-./Y%TW-8QST@C2/U/49A
M5#T=$'%?(8<>O;!E1Y<-\EK/W,8%I5)F I&0A;K8DJGCO<[.2 L2XRA4_P'J
M,'R<C&??N-=IX/^NE].*3UF;K6\^D_P,3F8J>;GT,*VT%-R^R<)1N5SW6-@E
M\C8M%HX*>K+#PO&GG8X]^?"H>SS>S \N,+='Z=EL\0=18DXX25*>4X(DC=6.
M2@5'A=ID44Q++J)<,"R-ZC+=L>0[TE]SHGS/X&4;4^IH S=D!_@#C<4HJ,(,
MB_E\E2WTAPD452_$MV%ZM.$K%D#ZG<H"8>@]C&NQ -!PCHO-RI8QCK; M)DS
MIWM#=H/F)DRF6:K<'Y2F3"(<%2&B:<Y1+K@RF4G!DAQTVWF:E&?KMZU>7VY(
M!U5+&QBM. V7873""0C :,1&_BW5S>Q)AW&'LZ*YBC.<)C1N7.&LP =QA/-O
MV*EQ5VDT%=7UG']?+=@_'A<S]7[UZ9]KY7=-2D%B%N<9BO)$*7.>8$32E**0
M8)'2(HU(*B%!A',$/4<4FL&ULRT3]159I?M$MVS\V_\IXBC_ST#4[,"T_"R:
M9KKN$B.8QG_9 ^;3, A@53>5S)'"GR4WJMJ;"K^O_,;O688.5X_*M'1QD6U$
MLBOTWN123=*<Y0F7R@+$0G>1R@DJ1!FC)*%9G'.&$P'*Z#:F['F?K_D("/_[
MNEI9[.WF !K&'WW  HQ*UHAL8Y-;)JYZ#1PVC#B,5D)E=Q7#-*8[;F03"L=!
MO!.\ ,R(",8G=^N9B$*:1M?+Y?WR:;[BGV?DP<00G'[;L\9KHH&FBJ+^E(_@
M7BR?IG-= &QF @;$']9U-Y+#E/J\T,'OF@,'\<WSX@TD#ZB76Y5E?*NI TN.
MHI+G1>ITS^!)N)*I<_LU__O]0F<QM]-U#!7L\$W?&36S67"]W4QUFXG^^!5S
MS3HB\WFMNDQ<F$:=D=3AG*!AR:R4Z<ARHRG2:5'Z2C3PE)VK^YE,ESH2)GY^
MW?SQOZ9J<URRQ]<ONCBIOI-21]Z"A"1"1 J*<)H4J""8(!9168@HQ9E90BZ,
MK&>MU)3KL+$(-K3K,][7Z[]:7>@9@FGF\[J'"*;)EZ #=G)APCKR< V)CNK>
MPH#8]VV!;]N9C&:6:1-Q8^NFV4,S\V,2X["D&!<H+8E49B)*$8WB$!&>YJ7
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MG3X\KK[)WRI11V&_T151!RM^,__T@]5U5)\7RQ-S62:9#(M(X!+ED2P0SIE
MA#&L3DE9P3DOBXR *D$OX,6SP=O<9$SGP6+;CZ'^JUX=!3 L>P'TAM';<0 %
M!GDU4V@AD6*KN?$).L8TO!UK]33CO<%-V[E-#H/"EV/D*G9\ 2?CAI@OA^P@
M$NU@27@^Z6]SOIR]/K17ZZ^__F-UNYPR\>%Q_G"K#C"&N:7#JWBV3(JX4-2U
MBG0,!$W20%!ST990F^>;GL%DV/"XA0-F5PR1N K:$?-N\E'-I+7*33VS]&AY
MJF8B]G-6#=^P.&3=S/F:U1G[M^KC=R<K)CC&688*D>AQX50BFJ81BED6<U[P
ME.;"^&1UC()W[Z(C&6B:@,/$43@,3E.7"@G3S#WY;$Y-1P4%')4N%=CN?&3Z
M86%'HB%9!L]!1U\<[_ SQ/?.B6?P00NC\9WHKK!US>BOY,?T:?UT_?"PK+/"
MODDI].5W;9\F+!,9BP5'G&.)<*(-28P+),LBBB0+,6:EL2$QI>K9N&@V=/>"
M2C-R%3PUK 2DXT7]6\-,\*RY >BD,:P&!LD'6# C5>/T30;?&YQ:+H(-&T''
M1^--^, )8,]\X&5GXUSA!K.!4/D'[:+Q8N/92JA\._83_++#F_.OY$FTTRJ8
MP%G,*-%]?!G"L8P1X05%6<JCI!0IHQR4V7.&WMO<HE\%F@/+@1_G$#2+\CC$
M!68R+X3$S0W[H: ^[]E[U-[^MOU0=*,[]R.OP4,GRD>;ODSYFC0%;H:ADMVW
M_!^K6F+_81[^V)/K?+C#7B3P(:JEXRQSY33[5O&*O:5&BT\<%Z$?CSCQA,51
MXLOTG^LIU[TXY_R7A<Z:U?PMYTU-SG:J2EZD)(S*$,6Z50PN2(F*J,Q0R7$B
M\CQ,"<Z,3Q*&1#VKTX8+@.MK"I?!"<$#"# %W#!0YX?4+ 0M#Z R.7N4 .<#
M#VC9'0\&4'-T% "*.G@2,%UKO(, 4+J=<P#T76\9_VV\+N-Y+ 6GB(A$&47,
MB/J3#!$M21J2E%*:&67 @"E[MHS]U/2V1' G-1W>MQ^ :1GG0E*."EF$""=Y
M@4I&<\2*C"4XC'23]<F+6-+%FZ+:Y^!/@:O9T<L+5K!MZ?K;AYO@>K5:3NFZ
M*>->+8);4E>HNFN]8BWP>*4/8\:SK>&P*':X//[]5U&MOLW%WP19?E[HUL=U
M%[3'J7AIQ\/^.IVI1Q9S4756)6=4Y#)"6/(284X*W>XP0PR'!8F5;RN)N?L*
M)N_97&M^ L50H#D*-BP%/9YTP'S+%<"5@T-MX/IZ!1!F;4RP^];'SN:R#PXB
MP#/V"J:=CPP&U9'G; W%H \-7W4\;]I:XAV_VGX5.P_[N^[,_#.I!.\W5NMU
M+ZQ^?MT^<TM>]=]=ZU#?MV?]9/5YL91BNEJKW^#-_%8LIPO^/T)G7 E^K3PS
M\B ^_1!+-JU$<Q%5I(R798D1YU&.,*%,F7_,41KAJ,BR),1)"',JQQ;!NV_:
M\J,\T[],YP%7/P.RK()GY:/6?;1/SZYZ'U_8S+U]SU\-MF_57**:S=WNA'UA
M])S!_H.M0,%U<ZO1RG05]*2J^YG4<ET%G61!*UK0R>;JYO.M/XLC7WYT]D<]
M$KS5Q]D_6;P9'Q?L<72 W99;NL_MINO==56MGQK6=7\9IOC437VC25JR1):,
M(8QEK#M9$E32.$-QRI,H++DH0U#8R1^KG@\^&P-%6@/U7'_5.M-^/5\*MGB8
M3_\E-DVOZJWM57DY Z,8Q_Z8C$6,8<$0I;KF)-43MAF+45K0L&"R))R7%J[)
MFW].*R>DHQ:H'\/3>_Q: #?CS;^ >X?BC#_1:[?:X_\JV'Q5+8)CK\$KRB[]
M S^,CN\)> 7\Z)[OEZ)MM\D716JQ?/TJ5A/,"TDI%2@E489PKL>]TT(;<U(F
M(2NBG(%:QO87]YY2TI "U_KM ,"IS$02"91%HE3'ZRA%!$N&<AZ'25;(*('-
MN[<& #XZR@T 9MN"K5@P0[ZA<A4H.BY[3QYR[ZRC9&_ID?M$'@IUV/WQR#-V
M9N.W[[\LE&,TK^U4U[1!T-6V%VY7 51P'I(L15+B%&'U7]K%IPC34,01"6.*
M04.93 E[-C=;)H)J0SE P6\_??\)IG[&2)JII@]\8&K[V_>@A\[UIE&+8J+7
MQ]K##2A4=$<Z;TQV5'L !6/?5H#?MQSPN)@_Z".27OI>+=&F5PO"<9&6"<(B
MU;><RB4A.**(DRR+2)JF&4\A5N,X&=]I>8HHJL]_FNQ5H E;IJ.?@,G,)%PN
M/,P U'+?0^6&#VL<%,O5B,;C1,8=S#@HZ,$XQN&G[=3T=JE[:ZQ>==7?ZGK.
M]63'9VT:OFRZELJ$2)Z1')5A$B&<<8)(D7/$,RX$3@H94U#[MO,D/:MOQ\!5
M72&ZV@P<K9FXH!^L 99F>NT6(9B..P 'K/#F\CI2?@."HQH"<P#VC0+@3<M+
M@FY0X_9'G..X+$1.4<@9T?-G"E3&<8[2F!/.1!2S$E1D=DC"LP'8$+Q V8_@
M8AAYO4A:8,04)B@\OGE2%E=QR4,"X\833PIX$ <\_:1%^F S8/E^2>85875H
M<-LX<5N<D-*(*Z$X"FE>ZF9@%%%]U1;1C!!>AED>$^.402.2GA6SX2&XF>L>
M^=O&H'VF #EM9B .:ZT?:&!:W*+2I[_3'=6N L8,'4"6GW.4[#+[AM%RE,8'
MDG4P=<]LI?'2]4"2[:3HP=Z$E[]^6M:IVM=S,GNMIM7V-VI8"'OJ?=\V;;E<
MS,5B7>W=6;9LF)?)GI1_V(*Y$AUHLX:E-C-:H*K:<S):U=>>7'2T2MMS8O5K
M;L\^:W<$V#0!;&=(59MVXU*RF,0B1R6-]"3*,$%E$F&4%.J 0#$1O(A@F2$G
M:7E/[-CVO>SFSQF6L)^'2;EAE)2R0(G0$12%&"H$P;I0F1.6)2D)C9JE.07)
MJ@=U!U%'V+JM_6FPS$Y13B" F30[Z<%GJK.2.3I:G:8SZ@GKK+C[!ZWS+SB.
MA&XWVC!/<D&+4/<5R+6YXZ@()48BD9R&,941 651G"?I.Q#"'@5?-\W*.F;V
M(GZ_54*N9\&7J01.P#/ ,PLQRV3)D?K_:OL@!5;;1Q&A,L]ICJGZR88<MGVX
M1=1J'SF/J7,<+XPJC^ .GHDJW]=%M%X&'IM+[3NV/++S" ? .+;LXC17.ZIL
MM2:SV>LMF?*_5O<Z-:K.E7M<S-0B=ZLY^(P'6]6S==T]^;1<!9JMX*7Z*:@Y
M"WJL!7=BM1[HT7$IAN?/B?[@@YD+2^0\G"KM$+$Z:P))C78"M8.@?RZU7,&R
M1:(.0$FEK<IB?1?+ERE3ON(W^7DZ)W,V);-><%G?HE?'_ZGKIQ@2P4H9(R9T
M/T5<Y(AFE*.4ES0O<<9X"9M'Z) YS]9K0W@G'&_9=-'E-S'S=MX*:9BALP09
MWL;1 QJN>CZZ9&W<!I$>0#WH)NF#ADT_[T<QDW?B8:K/VGI;WMQW?IM_7BR?
MOB=M,FN>XI"%(4&)#''3@;8@(D1I2%C.1"$Q,[^3-*7J^YBLV0CZ? 3;F_5O
M<UV<_!1\1PFD0;4IG@;7DSY0@IDQ4X!L.I,8(P5IY>T!,<M6WI?^M( ]O(&"
M#_?P-EULQ![>0/EV>WA#7[;,J%K3>HI9TVIJPCEE*4DH(ESF"(<\1T499HB7
M(:-E28@HB\F\[B2NZ\*,DZIVJ!C]D,OFAWQ R_S'W-(,IC518$+5+BQF7IZ%
ME'8&KI/L9E@R> ;540%<94_M+CYNYM11P0ZRIHX_9:=8ND>0\H[:8T+!62B+
MO$19B0N$2Z5A95ZD2(B<I\I#"8L"U()@9W7/#D=+R_*TM8N#F2)92P?3(V/!
MP(IT5 !'>K2[]JAJ=%2L?2TZ_I"GQE>G6I@TZ3^]0T?=7/'^D<S;YB9?%_,7
MQ:C8;VGRBUIZ]5%M.9N*Z$DI228X#U&>R1!AGDA4Q@*C+..$QCA/,"LF32<-
MM4<O5X9;XCL0#:):^P(::]F&G4 NA6BZ8P6DZ8! E7\SGVL=I$2]Q,0XS;3&
M^-70F">8)@R1^E<CLQ05HBA1S J9XRQ*.>U^-9_F_'_S;Z83S\DO1LSY_\J?
MBZ&'^0Y8]7EPO[BERI&<[5K28*5$W39PVTA[I&E;+7&@1>XU:!FQ=]N(GW"L
M?FYCB/2^>KR-^!'!?=_&Y,VR7'L[45U'FO4<L^9FKFIXW*3G9:D@92D8RD68
M(HQ+@0A7_QEQ$B=9*(HP-YK7""7L^<3UY>;ZYYLO-_<WG[X'UU\_!M__Z_KN
MTW]]^_+QT]WW?_L_11SE_QE\^N_?;N[_!JSO-L75;#?R@19LQ^AQL,GB4>;?
M1R8D5%A7E>&F9,>M%0>"<5 ]#GT?9D>JY6KRZW2N!Q^VX7A,>9&D)44)I13A
M6*@S' X+A&E!XZS@19D:&8J#E3U;@I:6F9H?BCVLQQ<) U/4EHS#=BPGF1]2
M//523^G4?VT5[G"]433JI!B=RIQ^ )[F=J=V[_82X:/0W1NF\]HYT'NW:5+;
MT!J>E:%'.MBA77OKYIEJ@S ,JXQ+!& :9"D\*+_,1#*K;++!A4?+'3,1KY\I
M9O2\Y>V \I(;OUR/#]"A#+T1*H)BJ5SL#\H_?Q#\?O%A4=6YKDUQP80205C&
M!,(15KM8D@I4,H$1#:F4))91)CGH%L&&"\]*?LWY%%!;?1F@AM<1OF$"ADD^
M?0BZO/ZK((I16%X%&QZ#+9.U2]RQ>15LD+T*&I[UH"C-=.,Z-VP[O .Y!#57
M=R56/(Q[IW()3 =W+Q<M!G<H[I?\>KF\YHMGJ!MQ^*9WN]*0 OH*1R0\[R%<
M)AS,&MPO21T1[\=(S60%N0:G1;)R"(XL-YH;<%J4_N8_\!1<3VY?GNNJ(E/M
MZ)[WK!.WY#5XJ?3\$KE8/M47*@;-*4Y+=UXS; 2#Z<.@3&UQEZ-RC'UAK#1A
ML\AHO_]]MON_^H-_L[RW;]V3;_)TV5;]BXE8@;E4F&0D+G3?WA(5/(P51&D>
MB50*4H"*T4T)^U8L@PI#:(LO4T@-;Q(]  54U(LP@M^[ 05V=3=F2G;<^RL@
M& =W3-#W1T[_:2^LOJU7Z@1?9PP,#D,+I8R3E(=(#S=55BB6J!!9C$J9)%**
M),OQF!D^,.Y'2>*I0_1!XPM5P6++V;O+X0%^>AG%!<:I.D2'$4%8QEQ?#*A?
M0L29S*.\R!,Y6IJ.[P\/SL09^.SO*1$'^,T-=\CW]Q6!<:++TVDV"3/?^I_^
M_<PY=/L)WCH=!LCUGR/CQ>Y3.$MJL21OYZ]<OY#I3/L]GQ?+[V0FME,,=)OT
M7\FJ_:]KJ<X4GZ<OXOYQN5@_/-Z+N9XE7&W3 8M(1 F."D3#1'DD6!!$4DZ1
MS 4NLTSD.(D@YR)GG'D^.*4H"NLIV,#POSODS3:'-\$39O[W)J%<!1N>D5PL
MD>:Z/X+N*FBY5@<R'3UFI!X4J0YEWY72S,3FG^N@XE5 M&3-P/(T:*4+HM"=
M\7<.L2/S[HZO40VX<SCW3;1[ G9&^(/&8]X63=Y-JW\T81'EU(>BR&.4UY-@
MP[! 92@+%,HLD[2(HY*"[DZ/D_%L'G>(!IJJ73#I!$9FMN]RR6&&S$)HL+$9
MELF1Y3A!9%0S,"SHODZ?>?K"#JY?=+'EG?;&OLG?*CUZ4JPF><A(6$B)<JDK
MD#&6J*1$.4(X4:Y/P1E)4\LNKL?H07ZV%W9R;6IVEYH^6DBT5O]!- M 5V<8
M/C,5=@8)3).W6-1TKX*[#@Q%.ZB)>VA=.B2CZ_:E1VF]30O3(;%/MC$=?,FZ
M2_J=8'K*VROH#O38NYZWUTV?\-EK$P'9CYQTS(#[I.\B</Z>]%+A87II++?;
M^],A(2]ID+Z[X-C-T8^*<Z0Q^O'GWORBY.NZSAP/:9J($I>Z>SI'F-(<D:)(
M4"1Q+G&6I1'+WO1*I.'S?5Y^U,'OZNVBW]TW9!D+]=V&P%@@7$B&RC(I499C
M5H9$)!2/5X+L[@MZOL5X)Q]O]$L*^.=X)]<1#>/O\M9A%]/W=[_0\O=GO4G8
MA=?CG<$>H0N'%_Z\KJ9S457?Q4-=9WO]8ZH'FX98F>48I519;"R3&-%(_2D3
M!<=%G$J6@N)3@]0\^]$=J>!W3<QVEN%1F S-HBOA@2;.4&[[T89#\KB><GB4
MUML,/!P2^^3LP\&7+'K$/\X?;N:?=8SZNOHF_UJMY@\?5SH#:OFWY:=_KEZO
M_UCR2OTUOYE_>%GRORW;(DS3;O&6Z_L..3]J<QDHQVA[5Q202@^4Z/IGU;TR
MZ@$3TT5[)=068M?FM*H?5+NY6N.#/O*H/^J' *WE;:$_?] > W5@N-L;X ZK
M;UU 9]>7WI;H>!WJ+X1EIU?]I6O9>2K;A/EO\JP759URH[:S'HJ$)4R$(>(1
MU1W4J$04<XSR*"L+2BB1"8;X-H[Y\^T-K9^>R/)5*ZRN*%U.F=;-FJ=67V$.
MDNNO8^92O2'F,/O9J_90B)N<.JO!8Z?7@4">4'7D"KKF;E3GT1.T^^ZF+S*.
MY\9M6OL(F8M,B@)E45DBG.01*AG/4,E%F152,)J AHB<I>C9NIXI([&<"'D>
M1S.KZ10=F!V\&!AWT\T\]48Z3^]]S#8[UPW)_$7XJ;7I[/9CR9K4=\.SZ.Y;
MOF]=S;+'SXEV_JQG+Q5,\QJWP752_&D)K Y2>TN-=CPZ+D+_T'/BB4LK43\*
M*9;J*'Q/?M1I#;HS0J\/6>WD]8XL#(=E1 @228D1SEB(2,$*%)5YDN8AHP5C
ML#0D2TZ\)RCU1X1VG 6*M28?IVDBTN/.MFH5!K]AF-<_I,  , Q+KT>+"\%Q
M7O\*X^*-RF&MH#I='6NWG)VE^T26.A&ANA7+^HS1FVR<9%SR,$5$B AAR1DJ
MBBQ"E)5%5,;JGZF$V;*3M+Q;JZ]B%7Q95'6#A^;,#C-(IU$R,SE.)(<9E8[D
M5F3'HT6-97-D$T[3&57KSXJ[K]?G7[#MH/1QW:18P[HG=6]Y]L_[^1D=26@#
MI8V Y[UT>]E@:G6L<=)9\2QZ)NU+<D&_I,U2(_=*VA?AL$_2P1.V*1)*FVZJ
M:BVX6E%]G=LZXZN^ _OT]#Q;O I1/W.K/NHCJ80^,D^RF*:,,8%8$E.$"Y8A
MJGUU7L9Q1G B<6$TY?$B+GP?DENZ[32,YY9R\*R>:O]NJCC666S0= L;R W]
M<]]  KWS.@^PX2=H& H:CJZZ&L@-S,VS'5]U",UE.L<%N#A+\[#A8>3TCPM@
M.DP+N62Q2RN=E,?Z@2R7KW*QK&_\)BDO!15IBG 42823(D>$Y G*L"0AI2R,
MHA!BLTZ3\FR8M$.^V-8X:=><]<G;%C<=(&9F<MS@ +,KO;(F+?X'(_$OJ&<Z
M)9GS8J8#0F]4R71*X--E3"??<.^7U/_6IHQV,5\^*03!0N81DD(JGT3B%)6\
MX"@3>2)"1B3'N2N?Y"@'8P7M%S*H^OGU[KR/X\!>[GE<#)=SKZ-YI&5I<W'
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M488CBK!@L7(G8H["$*<D*PL><J-YCW#2G@U&QXB.IK:LG,_7OA1-PRBW%XR
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M!38!MW[@R%:BY2/8%F/NTBC,#L*PI.2+OCW0G 4M:_:EI_:H]=N)T0"#GA7
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M&/)4*A$AA?6>%%.J$&<J0SD5I(ARF5,N89T_SI$9V42TK3%:RB8]W] .-/'
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MIF0^1T06#.%42A'%,J2I /6=MR([LF(V3 0M%Z8?>,/'OU5!PX.3KEHB:J?
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M7$$8NS[KF.S/4:1U 0SK2JU+]SL,-=+GC!NQ>6'+Y>L]6\B_-KU@?U/,[!G
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MA;<3LOU)U33;ULU@6C]@S;<IQ&8KG0_@8&O::\S:X/_C@%"K2(O<3A6'U=U
MXUV5=9N*G;>>&PC&02$W]'W;UJ2LUIU;WHGN[X^K]E#\JXK.U7SMFJ^/6% 6
MF8AX$.8,%U04. GR !,9<,RC1'"99)0)T.U8H'S/"\Z@#?IYT$<?5:*Q2G]#
MG5+H]S%3$+B[*0QUL\7'(Y:P-<@#C!8-4JW <-8T%29]YD:J5M <-E>U&\;Z
M ER]%?RV7DO1Z-(INOP@Q(ZX/,IID.1J-2KS,L*)B I<D##$$2UR65(1B(2
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M"L;DKY<__:>+'_]^[^=_EYN?YM[[7S=_>_6CJ^E#/TB?Y;_^K[^^^9B^X%F
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MZ+.(+80["I3\QV)&<4U8;JYCEZL)$5FDPEHOK#4HB4B!C8P@<S*&6TE6+S5
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MK^)- IS,F6,1/NY\#G\XA.^1,E!C]_[Q=YS01^#3D1MZ(W[!H +S18#FNC[
M<Q9\[02!4CI!7,78O*3B%@$#M7KO$R>'"W@$EN5E6,[),*[>XW+S[.JWL)JF
MB6=.H$BJ)D42*,,5A2U:@ @\)"9C=*&U77F0D(%:P?>)EN,%/@*;<I>)%]/9
M.844$XF< EV>049)QZIQ]8F>M2"X(:OH.8]F5\UC"]Q<D#)0M_A3(N<0H8\
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M8+]%\!P_UVK53Z<YQZ^]E%L.S$=,]*.;63F6V>"R]V#8)E]!_!+3 H1-MIB
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M'0O)3@00(4?E'!)+S1]//454-]#](6ZEVBIHS)C;[J.79U]GBQ]X8=1_GY-
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MH2H9,\S>+_%KF.;+G,'+[S5XPV?S[>SZ9^1%KU<3R3FFPAGD8A$4)X'2EC)
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MB ]\I8$1?(JV1H;O8IE:D_!\,=\@Z^_3]9?GYZLU^>S+*[3Y:)%.545';"W
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M&KCF]F_SY;9P_+\P$ZN_X1S+=+WZL)C-7BV6OX=EOFO@!<N>G$=(R$L=^:?
M1\'!"J$",\+8U%_Q\K[4#MM,O'^L]JJ]4=G5%Q<$$)</%2C>85,1E]Z*!,D4
M!XK7>TE.; 8E/"^.\^CZ,ZE[D3IL/_+^$=J?WL8:L;Y;?\'EEM=PG]>#XM>G
M/MD@FMV+ZD:Q[6;-&TL] $+-$+'48=6.\*<T%O E<6")AU*XM46T+E![FJI&
M(<?[)7X-TWS1K[ANC,W2%Y466UW<V1^,QQQE[6 FZB@<'0M$5QWD%'.IG;.E
M8WM&(?M3,6R\VQ@TC\0G/>MF5$?KC:W_EGS<BT*?Z^MTE9@**4.V]9D[167@
MHD=@.@>?N"K%MBXZZTK;L"%R3TCL54&C MZSE);GN,,=$%@$RJ @D=-*[@ C
M;U6;2!Y)XLEG0?Y)?V[<4]0-&P>?#'Q-E30"^&T$=[V-'N?+)U5\*@IX9(F"
M>EF'4&?:5JFP&#)30K:>V-V5MF'#VIZAUXN"QAHL/-QQ^XC^)[N^UZ+?26=Z
M6]VG7X%K>Q=QN>0'G(5UI6*U7FV(BI6HRVSR%1 #<FZ58,"YCZ!$?8M=&!V5
MO'COI$*'S=]?'45QPTPTX67Q _$C+K]-$SZLN6>SS2=KE_?RX2J5M)U4MZ'T
MQN/.X%(I3$!QEH/*/D!DOMY8HR@:?<RR]9"DWI@9N!K@=)C>D>8>$!Y#S_B]
MEL(UVQ=B?E:3IA_7Q-%V[$$-_?X>ELLP7_^E_K*ZGL.^6IV?;7_FSL%4T&O'
M6 16%$6"T3MP%!U"%%)EFW/4DC]ER$] Y[#1TP";8&RZ'X$W_) T;FKCEC3J
MK=C] L>,R?%,'AX:6?,>JH CUQ^*$(&)@M(V3]$=3_6PP=LH#H"3*'P$$+\I
M[$=.N;K%/V^;Q_SVXV&S<*-E;')!.^4HW@V2=KB3$'U*$+ PZ931OOF@F,8L
M#!L^#@C^(:$PSMKNM[A^LUBMR*/;\'IXX/GPAQI$G!TH;!1JO@S+^73^^6JI
M*\A%FR+6](4MM9F-$1R\,A$T^;LLL52'@33>\8_1TC \O+-"[>>3ZB3-Z>Q\
MC7?K!ISG(5HOP=G-P$,;()"I!QM8DL878U/KL8 'DCIL:-<$0SN"MMZ4-M8$
M637.2_Q"]GGZ#:LA.-Q$/?:I!D:J$Y6-S-3&0_NRF!&05]L&)&\7ZVN@.5\2
MFD3>64W"JX04@AM>4Z.>4*:#][EY?=9.BIK>%YV?G6^\A.UM[$VI;TM9KF1_
MXWY"<:6#46"$YN2N9@^!!P=&QA*SU,S;UB_3CR1Y6!/6$%\[;Y5Z5N4X_:V+
MOJ&OYV6Q/#LVU__8MUKD^3O1V<JB;1>[:JYZA37A4 :+%KC?^/J\0""'&Y3W
MB!EY?<O9>NL^0DO#1,N=%6[(F"*.[5_>N-P/'A4O%-\43B+(0E&XXQ.8&*-,
M2;%<^BNWW8O4@:U6"PSM2);TIK019$CNC%OZ[<=?</%Y&;Y^(=]RB>'^O6L*
M%'$38V3J:XI3D423!52&<16$R;%U5<9^% Z;V.X%B3VJ:*0'9:?!&F]K=KZ^
MU7B!ZS"=]3@RY-Y*)QL>LIO'$XP1$1*M"!$*>7B@ZA '7QS9-@PAJY@$SZW'
M:O0W1N2&1:]N[F\_-BT6-[MGDBTJ%"8 E\E3N,P1G$D)A'?16UZBE:V?T^X@
M9[R#0_; PXX#]2CQ#WAHKI;KR>VQ ,^^3U<3Z:2Q41MP-1^L? D4FB@Z\FV(
MB<<Z)+B3JTJ?OP$<^MTU:!Y>>6"WJY5"%\VD.S VWH8SDL8M'EXLSL)T/O'&
M,U\DG<*<UV&5="@[SS,H9K2.)M<;C 80>92 89#20J.+UN(=N@#E$^D7KP3R
M5SR+N)P@RUX+3R(A\THB80:"504B+XJGD(PVZBEGYM&O#Z?\1AI;M!3?T/I_
M3E(CU^\?;]X\OZ ^,1Y9==%S8+5\"LECYR00K4(.0C%1=.FD_'N?'B8:ZDGS
MQPEN:+776GK,BW_',%M_^<MR<?[U]3S]^8*1G'V6DB+#S#U)HM@$/@0#!9UA
M47-9.C8RV;7*,'4O/8&AF3B'QL6[K^OSLU?+!3G<N/ST!2FP)X_[&N-%Y61#
M)M=)^CJ4@/XMQ$*0+Y43GI44IA,TGEAHF,*0GM#14J@C2-(]7\P3UA$ FUJ9
MZ8I\[=]PGKY4:[CQJ,C;SD5K!4:2-53<<@AH'<B@,9I(OT^MX_2G:!HX$=<X
M-NE%$Z-$UB4W%UM0H I"6$NV,Q<2%D9P*C'Z115CA;<^MF[&^Q1-PT:];1'P
M)+R.4,<(X'612EI]P(33;W7W71C@X)TH)09 K+<D*7"(T6E@0@O+=5*N>>_T
MQV@9&YR.T?BB!_&/ $8/[+E/])]NMEM$QK@R"AA/E94:!')#\BF\,,U=]K'U
M<,$=Y Q;6W["4^\@^8\12I61BZV&J=1!A0Z$JZ^9(VIP3F1(W#+!4A#D-/8-
MI6MRQF:7#E3Y4U Z4/YC@-)%L'*/I<OL1/#(5)'@L$Y9=P[!^["9C5E$\,%0
ME-$:3KM)&AFD#E7]74@UU,,(8/7HE),;.U"7% (+$@(KJL:O%GQ$"[HP@9A2
MXOYD$W?V//QZ>UO2U^'76A]CAMB-'2F%MD+F"!QK?_+(+#A;-&@F..=:H7&M
MK5<'LD8ZWNA0*'0><'287H;.;;Z:?K^L6B)N/DP_?UF_*W];78R9OIQJ^=<P
M/R]UNF4=+?UN^3G,I_^U4>GE[4YTTE-0K<":^M0J! U!&0ZI"(%%93+BW2['
MVM S4@P>BI'%L H;@3G<'!07Q\:;Z1Q?K_%L-9%%)6$T!<5:Z>HL"')). =F
MN:VU[DDU[[#_("'#=@GM+:0\6N9#&[>WYQ7K[\K%C)DPJW,XINOSS4:8%&Z3
ML'4$IW6U#+A>7>B(D+(T3D82G>MV;;-SF8$=^N-UN.A%H&.P*7>#D?>XK'\0
M/B.?E) #SY%XT;5=9*90VG/F:B=FBZ'D^K"X[T3##7J&O:IIAZ+FLA\!CI[E
M;W3:3U=TTEXT))TP27B/P8/V]707*H.CJ!:8XI(H*":(UE<R]ZD8-M'9'C-'
MRGD$2/G+8I%_G\YFK\^^ANFR>H3U%=U$9?2L]F;*PKK:IZ! # Y!*^ZMDT%I
MUMJ->9B28;,#[1'30-XC0,TU]>_*G8<F_XZS_&JQ)/=_X@)G]>$2*/).2$[.
M0DQ) 5K.Z]0RQ7/K_F^="!O6-VZ/J?;:& '$'HU8B9=R/GLS+3@QDADT0A(.
ML(Z%CHYV#0G-1&&PSLF3S4?C=B"K$[S,SP.OUIKXF9^/7<HB/""&;[CJ_5%9
MQ_5/]M3L$'GT_P M9H;2:_*\(CGJ2E/4YV7*FR8 FTGRB;>^Z#C% [3'DWC;
MQ(I,4C'EP&7%R8?@%FI/8V Q2ALL,RKT-T5U-VVC?9JV#U(>?YK64#%C/GEO
MW%<$ERUB8N2@(M)YPFJM-/D6EBFTUJJ@2NM<1*NKQ!.\;&N)AP/N%?=1SICQ
M=N-NPFA7C$H! M9]BDY#]#G6P>@F8O0:[SYU^.][Q;VA<,"]XCYZ&3KU_G%1
MUK^39,E7N?S7%_@-9XL-4YLNDN\*.3IXQ2C]9&TS=$X$7/W9Q6658T$XSR.0
M#,FAQD .KV827/(V:ZF%P/B4R]><JI'B\5"\+,:@O*%1^P;#"FMS+8KREXMO
MVT:CK\Z7\^GZ?(FOIM_K/^J]ZZOINKHXE[>IDMF8T#.PJ"W%_)9#K#VP$N><
M#AKA><>WH0<2,.SU0*]8/(5*!GZ3_J'VM-V<($Q)GX3)("-7-3,IB&@TH%,2
M0>3 4'2:A_'$&_2K!<?R J@''^YPP8X!#9>/I@OC/&@#AHPH14S&D4=A)7"1
MO4F6%1$[M;;M@H>A'Z(?J*R[ZCY <D.W*YG.IV?G9U>$"Z=*?>TH'0-EZ*0,
M"3D4QXOS+$5U=Y+]89U*;BXZL-(/4=FBA?R&5GSX?H/PH C>2">DQEKYS L1
M+E4"$HG7R1N)K%.4_V2+FN][*KZ7Y@--%'^P_,8<B%_?(^B0,9HB0 I-\23!
M%US,M?8^&1]4+J%YK^"GJ1K+\ZDATCZ'J6;,8+MQJY1MM%(6!JA]()94KH]B
M?=U.%+-%P;5KW4:_U?W>Z:/L Y%PP&7?/FH9YV7?!_R&\W.\&%"VF6)SL8L7
MY;KL:U$^+=9A]C',<+5>7'4/.N*2K\FZ#2[WVO/?Z%+O@K!7!/O+NO&_3]=?
M+M>^NK?)R1FCL(!FTM69+A:B+:Z6KEL6 K<AMBXMZ4A:^Z>FF\,C"*U2(2^"
M,?)%E&*B7K 'D-+$R+Q 99L_"WR0DF&M7Q_X>/JQZ=X:&,'Y^F3'B6 8-UQR
M2(@2E"L)O")AQ91%HH"6ZVZ)G>.>P._?_>6$+TWWU_N^C5_V4<(H076G[P1'
MCHP["G63RT"<:/#:Y]I@C4)>G;EJ7I'UDS=^V0L!^S9^V4<=(X#7$];]*C8/
M+'%T4$Q(Q)36X&1BD+(CBU^*4*%U)7LGPL8&M&.PL.A;,2- VZYF%26CJ2\>
M(<>L0%GO(3(M(3L1G/96R7B"PW&ONI;^GMJ<Y%P\2/1C1-&-&T:O;37?D;@0
MKG:45!"$\$ !=$&6F%6V=Q2-I5JEF<KW: VSC_S' *4G6I($%8VT!2&52/;5
M8R17(7- GIBS+-5GTJWA]+.VAME+]7NVAME'#X/?Y]SKHRXTTX7.>SK]<ZI-
M<P11'SA8M"H6ZT6\VQKVE','^GO\U^X4:R#8T8X<8-Q:EY4 OFFI)&IS;$F_
M*),+JNQ2*9VZF?TA1@[LI=%.(P?V$>_0E6</]LQGI2 *"AN<#D2V3(Z$DP(P
MC &-\5;F.P]#?_*1 WMI[,F1 _N(;VC]7W;.OR#=E!)<$AFX(/],&45.6@QD
M,U&:9$UM'N,[:?[V=X?1>2,-/31HX !Q#:WIB[;XEWUX<K0LNCKZV1'EFHCV
MN3 HDO%8I*IYJ4Z*OO7986+8'O1\N+"&5O.FO_TEW4I+Y14#%UE]$LP\'6VZ
M0. F%B^RSJ@[*?G&1X=Q\'I0\:&"&D,,>=?-?7/]!MB(E)/E8#)F"EO(RW76
M%I#):VW(X36L]T:U;_:JV>FOK\,)4EJ'"7Z,$+K5",<Z'JQ1-<?KMUU\8[5\
M7A:AD_><E]X;9^_;A.AT"8@#=;Y7)Z(]%# ",#UQ<_#R>YJ=YSKS=K5"^O_\
M*7R?&%,2RI* \5HVR2R%7;%.I>4L.&FKW6V=YSJ S)$EY=M KV]U_2SE8"W&
M!'?X:B^E7"<9_WM_V6?S_.)"HQ=_>?W*WAJ;#)<0F=2@BH_@7,K 8F+UJ97E
MS5_O[D-?3R5;605IT%K(MO8SU2)"+*(^-Q/&I< 2-N]",>*2K?9(Z5BWM8\:
MQI>M5TGFQ+V@D]YP4$Y&"*8.,W->FMK#DMM.(/K)I@2WT.7N;/T^@AUMMMX[
M;GVJE1S,U(?,)(^@*3@5R,@7U-Z';F-L_A#9^KTTVFU \![B'3JY\V &) 8?
MA<\:A*VC3@5+X.HO1I)1]84S?7?&^$^>K=]+8T]FZ_<1WPABK2=K#:-E&6WM
M<<1CC1VU@VBB!DS&<IN#+*SW(O)1#7QL>,STHH11@NI.7:$SF)'L+A@* FOK
MOP+!(0=9*.J,PB:-_UWR>S@"]BWYW4<=(X!7M\K2@B9;C B^*-J0B66((?+-
MI.: G#G%>PH@?^J2W[VP<%#)[SZ*&0':=A4A"I5=8(JVH7#$BD130\\(WF84
M4J#+_8?K8QD)>9IS\2#1CQ%%-^H.F:H^IC20C"%68BT>"BX#6H6I^"1%:FVI
M?LJ2W[U4OD?)[S[R'P.4GB@UY12X&)\=&$UQAW*.@>.T]^J#"JETL?QNF[G_
M_Y;\[J7Z/4M^]]'#&&#U^.V0LQJEJ\7+7J3:^PXA1(4U:2(8(H7(KGD1^<]5
M!=#TE#M,\&.$T,U+:&2)$^(C<!$-**-KFD4),N9>&)]\X9']=Q7 GCK?IPI@
M'P6, $R'7"OG*!4%R (HBJESX@(Y!X6,+X;HA!-6\;OS&_^["J 1]/I6USBK
M %Z%Z?(_PNP<_XIA=;[<M/4\XOI_U^<:W/MWIK;1A?_5>B^FJS1;K#8M3B^O
M;7U!KIP,P ,GB"DMZ;0D3XP;79PM)6%N716VBYYCS=75MZ^&FKZ9ACB=3==3
M7%W(.[^;?\!TOJS33.D'WB[FR\O?_A96TXMAE]*2-Q'_/_;>K+FM)4<7_2LW
M[CNZ<QXB[HOWX'U\8M>VC^W=%?W$R %I\[1,NDG*M5V__B)):K0H<<C%E5)U
M585*HN2U,'S(!)!( ",D48==UDD#(5@#Q13!M?9*J-9WU9L1/^ZNV@QO]Q>W
M<93;P29\S?A/WV^M&:\7^-^7.$O?UV&Y<3XQ),%FCYSV"N++UV@J%*Y]T=+*
MU+I&> ^R.D'B>0&S"[:-M-<3(!]B:!O4!XPZ!:?!56=")41PN3C I-![(0W+
MK;W /<CJ!)"MH+ +:HWTTBG4EM<6>W7<+S(R%C*(;$L=%EP[I!0RS\RMR"(&
M95N?9.Y#5R=@:P6&/<!VDF9Z0MM/WZ^__5]37!!1G[__7L=6K&U4YR*=H>A,
MJ++.@=<0K5X19%ZS&+),IG4693_*Q@UJN]MO6^FP)V3>MK8?^=O:M:3=@OLD
M(>O$ZDT"#TX[!1BY)59+RF?9?'<2V,G*V! A^RR.3=35$Q;?S+Y>KI9KB?&K
MN@*EBB>JR7*9(*%E UYR3NM_]BXBDZ*T[IST"#F=X*P]"';![42-= HN<36'
M1WAMM5)@M"41N<3!*^9 "Q')SP@L8.LRR$?(Z62S'05<QVBD4W#)JTOG2@56
MH@!N"J]CMC5$%==?:O]_%-[O-2SE1'#),:_D]P&N8S32 [BFLS!+TW#Q9K9<
M+2ZKS-9^1([6<(X,HE>F5HT:"![)F=4F9,>-,LW[->\@I1-0C1L>--!2!V#[
MN BS9:DW:&;Y RZ^31.)Z&UY@+MEK;19/ORKK0'GI)5A+$)DJ5Z^\(JD4-MO
MD-_ N(FVW&\<<S)"6](_LI?7 E#S3K3; ;+__/#;_!LN9FM!?L)9'?O]"\;5
MA[H0;->*3==BYU.1@;8'7=M%<F'!9Z[!!<>RHM_2(M$8M?O2-BXBQT//_ RJ
M[ "B+7:R6P4?CFG4D?PE6?M[QR3 .R-HM5"%'.B0I1XL>]V"@7%K 3OQ*D9#
M1 ?F\.I;F%Y4$;Z>+^K,H1OSOFOLM);X0G9=,VJUYQJK;9H,K27,.5D2S\;;
MUD/H]J6MDTS1^>$S/X,NC\8H;1YQW@JE:]$^4)TRL0R5\$6"*R0TQ3G)*PD%
MLF1$;IQPNG6 MI.83I)*X^.PB;:.7QSK_+2AZA7_%A;_A:MJ9#?V].'RRY>P
M^#XOUP98YHOE/0,\NJ3QQ#<VJ'ILR7.CPL@WLV^X7&U\75K;MC,35]]OWGY=
MMH;:,*W(*T#K7#W&=A!JH:S3.4CC129?N/$*L3]UIRZ,=Q?V^QO QC?R+#'A
M20 IA]H@S"($)B58+5$9KB2*ULG1/<@:=],>"#_W5\+6ZNG 8=R5,I&"<T>>
M-JWEEL+ K$PM2A?$5:ZS3XMU]SM5CYHI'0Q9S56^9P[T$/EW *.F>0Z+T<K@
M.9 (R$0CTQ!KEX<412H\.8O-NV&\_!SH08 :,@=ZB'8[0/;>B;.8LJUU*L!3
ME*#0!G"TEX ..0F;7;"A==GWOV .]"#T')L#/425'4#T:N[TV[([97 3"@:=
MF'<)0:NB03G.:AVHA<P#_3<J[G5KG!Y$X+AA]]#[_7"ZZ@"(]UFZ)\PO\\5J
M^D_,/\^7JW5^8B*,C\&+ L$F7EO-U3POZEK"PB6/B2G?>J<_E,9QU\X!X?)$
MMK&I[IHE?P;#9DJ77RXOP@KS;XOY<OGG;('AHC+\&^TZ/]5L"-8;NJC0L5 4
M)"MJ$3V:>AMDW;HI.^\Q9WEFP.Y'^+B+:C<H'D#+_2^[.YG^G7ZZ85IB=BIP
M#]ZO=S41P-O:7(C<'^&<UURT;FK2A/!Q*ZGZA_;Q6CX<VGX#[1E^JH1\//^Q
M)D<T: J%M:7V/O?.0'0J@7>1%UW;%ULY,(A/.M8<[&Q^/)PVT56?W2X>.DEI
M,?5BK^<.=!)TELD7!^3KE=/,16G!<TR@5%VP4 =@VFJGLS+.MKX_U<MYS_M;
MSLD$,V/*9$'N2*HSU$@BT5'0:42(2DIA@\F-Y; _=<_F].<0-!UV^G.TLCIP
M(/?CK#H2$^:5CMDZ8-P29Q3Q@4./M0TS_9"8*^Z\IX^WJ1LWRND*A@<KZ_GL
ML%>NS+Q<-=:Z#!=_"ZOZZ^^_D./9O#QC[Q<.59UQ',?GWZQ9S(D%;D"F.KPL
MTI)'2&>0C),L>N-1M6ZUVLMFO4D-.ZZ39K& ==Z"0J7 %?)IF56AWEVVN?E\
MT)=4G'$(?HXISCA$/1WLR[O.<I-,)A96(.=ZU3.'4CO&!\@4.'%>AR:7UF;V
M;(LS#E+YGL49A\B_ QBUO802<N)Z;:*^GHWR $&29)-1N= W1IC_*<XXM#CC
M($ ->D'M .UV@.R]3_0YSU%($K 1M7]K70""0 3CA5-.^9)2Z^3VOV!QQD'H
M.;8XXQ!5=@#1PQ*O.;"L1?'@:J-\E='5:6FV7L83%KVW.K4.KU]8<<8I^_UP
MNNH B(_GY;?1)/U4NU1/9V]G^)\8%M>W/B::6R:,JX./>)TJ6[/U)00@QYP^
M35*:T+H@^#2*GU/AQD%0.NB\I:E>GQ&*7Q5Z)S'[\?-B?OGI\^OIMS7?-]>8
M)DZ:R'6T8'-M[BXR[2,\D ATL$G2+F:;]P)I1OQS*N<X![;;:ONYP;RRN^7\
M(\[N,9ZT\)YD#2+P HKG6C";)<1H&+HBA6>MAVDU(_XYE7:<#>;-M/W<8/XC
MMU+23I5+ @J>PV:B5%#:0D!O>:'_,-WZ3/0TBI]3#<C9 'V:7KM'\:V*%\4M
M3RHYD+JVM8@"(2(3P%3P4?M:8]AUTP7]TI%YI*[ZO-M>SUUFA-S3[JL_\)0&
MIYQ/T=;PZ+*^YOM-TX+KLZ8@5.9"4+BCZV#ZE",$(P-HZ;+(1F(VK0/:1\@Y
M=0VZ?O3[\ ]:7W$Q#1?KG-[EUZ\7M:P+5V_+>U+6XAN!.R9:5'FJMYY1D#?L
M,@29"B0N:(UUA>32>M;0002.?V#9 C7WUY[A=-3!)GC-W-_GB_]Z,WNWF"=<
MWF/)Z)*B50E*D;5?2-$0ZC$'#S&*@HQ'-T3OAB?(&K]J:%"P-=)'3Q![/9U-
ME^0Q_#:?YWLLH6.9)>X@29,IND<$[^L1!.;LHH_(F[?;WX.L<0/9P2'62!]=
M]*:Z9HKXF)!;B3+6&6G(B'HA:#7.2H/F7DH*M65@K;N<WW[_N.'BX+ Y5,)]
MNMFTLG[%Q>I[V-0U?:T'F#,\9>KE$T]LX'X?0G,C5_SJE>\NPNRJ!FS]WFM,
M"<*!7L_7RA9IJ?"N-K"7H!U:I7,2KGGKXR>):G?ZN_-5FV-+X4(0N>:G2R;F
M<R$[<&YM%H7E8JW6K0L4]J5M7&>\+6YVG_@VU$\'KM).;G[Z7LLXUD5'L1:?
MAYPA1U9 &9$A,H=0N_J9G$(IS5VE/<CJY=BV)1[FPRJG9[Q5AJXFW"742AKB
MP61+T49@$$3((#47RA4GM&V=K=^#K$Y7MV.AL"_4CM3+B%"K?M+DP[RL_D&2
M)<?EZMM?ZIR2^9JIVIQB^;:4:<)K1NDO?YY_^7I)!%Q_MJTD4V3 R,C9="*N
M[T(["(KD(+Q(WF6KN<M/^6K-J>H4C\?B9=Z#\CI8(%]?+F;350VA9OGU]*_Z
MW55!HQ$J8 X(%$4Y4,XF\,F2.V-"=$6N_]>ZFG\G->,FPX:"7V,M=("GG9*Z
M.29C/J (Q8*TO%XRY 9<[7DJ'<76D;.@F]^<?IJJ7BJ7QG#OCE--SV!;MQJ9
MF) %X]H3#W4NB8X"(HHZ7IC'@K4?&CM;X+ZFJ-,]]$C][PNOPY711<+U5N>:
M7Y#(2-.UINC["URK;):WW<?6G^]D?T(VF;+4$J+"3#9+\HS):-"6L<"T<MZV
M3M:VHKW37;<-8$=1\*F]BX9=-VOFF_S46(H7X%#7@>^NGHPX!B5$8\@'R=Z<
M;7O>]ZQAL".JL=;,0Q7102/#VS8TR3)G9KP$;R691,@./$H/L7 GZ)=<Y]9%
M[+??/^X!U<"@.5K0#;?5IB=5]7CV'].+BQ..INX_HL%9U*-4-3I\NGH'@>1-
MS2I\FI*3OYEK\\#A)@H5$4G-3B-%F,I&"$[)>D,F,9]9*JFU41U$X*DKR-7+
M)DC 5<@=:&X,*,'KX"BK*/ -,7H=HS:MN^5=O7M<%WTX/-Q?1(Z2=0<AWUH8
M;[Y\#=/%.CGW.2P^U:(T3Y$Q\P5,5"2*(FA!K/<L/2;4R*71[1LV/TC)N![S
M^?#30 ]]=G;Z'<.R3;?$'4]JL#7M0V.C'6KSJFO(9,N,#J10YD0M<2</QI.?
M40MD;/'1:,=:WP._2\&IZ\?O2,#%]3-_P65:3+]6X6^2:Z;8()2UP!T&4*:.
M5S#THS%2)LE9<JQU]?$CY(R[$YV@]_M+12N1C[C[+!>KR7M:3C<'G]G2*F9U
M@6),K"(P$'-"2(S6.%&81-RKS1$]]19&Z*<;?-QYX=A(:*2^^:FR[ $ 5Z=\
M)2HMB5V%BH&2)4'0"D'&* 3*D'+<RT/=!P)CGK^>H*S[ZCY"<B,K_&_3V?3+
MY9<MX3)F7GPV@.0?@[*.4\C.$G =!!:;I?9[15]/J/S.2T=6^C$JF[>0W]B*
M#W_=(CRFJ)S$"%E*(EP*#2[;!"F@*4HJ#&JOV.(IQ=]^Z3AA1#/%'RV_#B+,
MA_>[F]1=RCI[;VI@(]>3OD@HF7N07A7KC.0\MKZ?]P1)X\:<K?V#(?30#:S>
M?L4:L\T^K?GZB(LO;Z][YTZL5-XSXL/7YF1*>@Z!88'(M,BL<&M-ZR:M3U/5
MH_-Y) @>!%@SC72 L;N\O O?UTWPR I1UOMT8((5H!+7)"3E0.9 ]#L=5?.@
M_6%*>ERHVF"I@>0[P,_[Z:?/J[?ES^4F9_@VK@)))[^9_?I7^ES]@M?SQ5U.
M?Y^&.+V8KKY/6%&*%:^!)TF^ M(7A\X#LRPF%"J1#!N#[ 1RQSU5'A*)Y])A
M!W"]R\;?L7*.^=4W^O03OL=:E7E[7><3QX-CW'B2JR'^-'>TL#M+GJ@4Z$N4
MPK9VW0ZE<=R3Z_,MD8VUU3L:Z^G+_'*V>A]6^ X7J98-F9PP>&& .17J_;!"
MT56AZ,JZ$GDR)?/6*^:A-([;?6<T-)ZJK9Y/MNJ]A?FL>B?S<E$_2?5^P\G'
M7(\_MMF9UP'4#W, IHWQ12<.T0@.*C,'L39MU%H55Y)"X5J7)K0] +L+_'JY
M98(62XC1@-%UVS?)0O0Q @H9E$K)*(V#+D25BK'CS*.U_/C*<K" .]C)/ES&
MM6V]F9'UX208C+%H11NO,D!+*U$OD $YA3(;96EE;.TUW:5@[+"Q&31.$&P_
M,T]O8.V\B%%2.,N9\A0NA #!UA;-QFAAH@A2MVZ;=-AR,6  UPP3QXFSSY8C
M&['<M-&<E_G58KC&_<4VTCRM\]\1;VGF?QS/VS#NB/<B9Z8(>2(0\H*0$$3T
MM5T61IMR\'(0$VQ<C[,C(7&51_OE$O\@^7W\!UY\P[_-9ZO/RXD4$B.G3=3D
M4*OC@P57@@-GI1&9(_WV',GR?6CMRK4Y!#'[9,R;*ZL#!VA?/FM[X(__F$^B
M8>39U8F9Z[H(1GNX8YQ$3*QE$;/)N77UZ8$D=N5"G0."QZCFN2&/H(03++H4
M;PL$3/7:N??@<VUIEV,("ADWN77OYH.)[,I9.QOZ#E;/,\/?Z_GE8F(X3RZH
M EG7,2V)1XAH$_"$5BE4F)K?23F4QK%3ZJ.@[V#EC-U!9P=;'^<_X;LPS>N.
M_->,H2F^MCL "I*J%-&"M[2J4Y!@O2@,LV5/A1$'OW7L9/C).!I6SL]H]9I8
M)[)5CKP";<@P&'FF@?Q38LX7J8E9;]M?8]B/MKU09CI&V:#*Z.">\Z-\_3G+
MV[,CS+_^53M;O_I2?YJ$E!77VH%2F54F,[F@5H)1F%TPBA5]5L3M(G0O^-GG
M#K\F:NHG);NKGL/7^:9%<G(Y:V,*4Y L*V<*NW71SME0>.M6#J?4V[AG *L6
MHN[S>/C]_'NX6'W?CM&=?7H;+Z:?UL]L<1GR@*<W2-8>RTNC)&T=V?/ ?5MG
MN$&E(JBB;2UH*1"+#> =TRPZKEEN?<[Z,"6GM_J(JYLIRYM2[V!LELYF8"[[
MV@1'030>(9MD(\LB:=DZ'_L &>.F6AOH_<=F'Z>)N@>O?#[[1$_[4EFY;A[K
MR+<+1A,/+-%NFY2NT[(C%)Z\<RD(UKS%PT-TC(^7DY1[W^<Y5=(=HF7;75,P
M)4.."M#67@6Y,'#:>Q!:.-K!F96V>9[I04I&/LPY6<-/0.8(<8^=.;J_V6^O
MG3ERU7W29$-%U8:#+(-7G('5+F&R6@OEGO):'GE^7S@X1FWSMC+L8.WX@+/I
M?/''?'7=/9<KCMGF ACKW</D(CARSL%QGBP6@^Y^*^W3:Y?N$S'RV5L[I+01
M<P<XN;OO;IK91V.4D@C)U_NN4A('@M>Q'24+%9TPOG6SZQ^I&!<IK;V1$Z7<
M'4[^"%^NK$=+GHUW&I+RAJBWD>)^LAZ7,O-*ZWIG<%"TW-#2DP=[N(X?A<R1
M A_;'WF-<7$9%M])A?+V(DD^61;U!H%GFH-BKH"WR8!EVDDAO31\OT.K'2_H
M"0G'JF[>6(YC8^%M6LV)YOLL6%:"XK+>"XWU-(V65>>CA.12$29HS9#O!86'
MG]_3/M(""0VDV-UN\OOU-29?N^IHY(3B6J+$:WHH<T=?HLNE0KIYV[$=I(Q;
MIS.L_W&<O,=>/^['9>MQN9B7VPXKDZ"2-Y(,2;!20)&_#<ZD!"YP%#;%XES8
M:R%YXD4][2U':O*Q</<4L8X-D7O+[65=&M^6CPOB[#,N)[2L&A*%!3(D <IF
M 35V!YF=81R523'MA9#'W]/3EM, ( V%VL'.<P7OUR2X-\OE)7&!;TO-#'S<
M9@8FZ)4@(06P/&9"/,DLUHNN$94F2R#F4NNSJ:>IZFD_.@U4 VEBU$$I#ZZD
M_X<\=@+N11VB_!Z_X>P2/];6P*L)"4MI%\E(K/%U326Q)2Y!2..,E45DLU_X
ML_<KQRW\''S3:B/JL;>OJTJPU_/%EL&W,_PX_8(_S[]\F:[J[UXC4NR@&"\^
M04**]Q0R4^>UT[)KBQ AR>"\V@L]^[UOW%K/YM 90,ACXV:G-6Q_L65YV[XA
M?,()UTESE FRKM=MR13(*J2#P)5S!I7(\LDREN->/6Y-Y_D6HB:B[\!?NBNQ
M-S-Z,B[7W4!^+053+1^ZQ5R4/CA1ZIR>>F]7D1_HC$8*626/@CXKHG4?EX,(
M'+>D<P@O:CC]= "^*W9^_>LKSFKG&_()E1#1\YPAEE#JW:':0I4B4Y:X9<G*
M4$3KXJH'R!BWB',(()TJZRX&%>ZVA@^K6F=\RQ0".B>#CR"9D>08"C(*Y15D
MD5/V23O;O.IJ?^KV@I=_3O :2#//K7[X55V1IZOO@Y0/WW_XH-7#CW(R;/%P
ML4RXR"SH7 ]38R0(EBS )&G0%ZX5MK[G>\;BX:PD8TX#]RG4(=<"/%H-VE/$
M6G11A/)_T>+A0_2^5_'P :+NP!MZN.#11.-321!%3/52?\W,ASK"3$5CI32J
M-+_S_CR*AP]1[E[%PP=(ND.T; ^>8V8N"Q*&P=H)0C,*/ST38%,N 65-B?WK
M%@\?HN']BH</$7=O::2K@L90N V./#%)2Z]BRH*7W-"/W/ 2)&=&/^6S/+?B
MX8/4MD?Q\"$R[&#MV!4 !"RR%&20F<VURH1!-'7^66 INRAEYJW;'YY2GG'>
M\M 3]IL6\AY[];@?X*7%IEGQYO_KN<S\XN+U?/&/L,@3D[1'GSTDXJ=V5\\0
MHW: H1:R4/AW:^;S 2?QC[^U)Q_E2!WO/I=O*/ .%J [I\#92(XQ!F JR]H9
M@23$$@<FLO;*"*UU\RE#AYZ\-X?-P"I^P'LY2MY'8^4K+J;S_&$5%JMSU74X
MP9U.K(Z&IZU<J8 079T[GVS-9Y:DFM]K:%37T7PC.R^Z&NOFA&83;;#V4*I<
M&J992!:,KUP4\O6"$:F.]\+L.+F1K'7:YMACB>950N=%TZG2']M1>H]?-X?"
M;\LV6KAIG:&T$H3T!,*31Z"LMG4,>>W_DYR,PCB1]_.+'GG).*5 Y\%(4P&/
MW]3FD(*5DI)<BRM&=&0"V4&(TH$NQNDB#7=[]H'KN2KHC"@:0.SC ^I!?T^@
MR2I'!.<*I\@U: B*>^!6LAA*,>Q^,=#Y_>OF%4$C^M>'R/M$__K766Z.EY\O
M%U6P$RX%"J7K0$A9PP17R&7C :3+3*,P"6/S3L\_DM%3(NBTH+Z5K$]=9?YH
MY"7?YN./^2QM65$HHB^6@ZLC1%5A!0*) S)J)@(Z]+%U%/8P)7U6U+="SI$2
M;Q1;-:VFV(R(^1C^PN7FV]_GR^5/6.8+O/6K$RHJ#GM!@ZJ*$SAJ5%EQ_9H'
MCMDCA4LN2 ZQ1E3*BUHDR!-8ZY324@C#6S<*>82<DWSG6]+<9.E+*3988<"X
M.L786$%<<C((EAT+2N=\OW1DAY=\_\GC)I=;J?..!WR2\$:,LI>+U61=5%97
MUM]P_FD1OGZ>IG"QZ<F@-'%O#:V&F=RX5"1%@+25&F8%!N-1L+T.P.DMMY!-
M/]V@^E$"1DPGGZ;0>6OIC@T1_'2?A>WI+[<ZH&>*]DIC: ^F[=?5*L0D=%92
MV:!QKTE"3T%D%P'C0*2A8N>MI3PR5'Z]7,R_XE7/#9^8USY T"E1^%8[VU+L
M!]I&9Z6PPHN]ML<GT''[G2,"HHWZY@UD.2(&UNVQ%]\G?WZ8%*5CBLH ?5.;
M&PM7C_DC6,S<1)UB>G3HZ1+3OWV:?_OW[1,W -C^<*/_F_>-$]ZVU_R1$AP[
M5W]KQ[P)T2SW&#$DR,:2$%*V$#FMAR5*A3YYBL[+H3[D[^,6MK1S#]J(K8,2
MA)O K!Y;_CR?K::SRUH!O^EZ/I_]&+#]^A=YW*2BZ2PLOJ^9KE$X_4LBC5[S
MZ>KD:N*S8B'1.I<MH5_QJ""F%,![$V+*N>3FHPH'9*</C_9(H/UPN-B'UOL<
M:OI#WH*^_0EG6*:KENF7'Y\Z1,[E"=K/D&A)RCDFHP F) '"JPA1R4(;(]*.
M*+4,V+K;U0")EJM';W/5KY'L/5RL(XE7L_P[_;L+>M_VM'XK\6L1A)@QJ8B0
MA</J2]0;AF2P-K Z9TD9=*W/GHZAL]_LSB$8NK_8#:ZQ+NZ$;KE\G+T)D4Y\
MD5/+(Z-(1)+7$WGBD+V@O0,QVN;W(O8B;%SD#8^0AR'94%D]8?#:D._Q@RE[
M5B_6)EM[BV?KP,5(8562TC%KE16MCU(?IVC<4]6Q4-="/1U,9?ME^]K#Y"<+
M]R;K0!M)8"0_E<#;D@&UM"('+DQNW_7["$+'A>906_'P.NL@I+['Y"YSL\9)
MU$Q#\>O\DD>28Q*@4#!?DBG6M^_,L ]E8U\@&1PBCX.RA;XZ0N$= >[BC7G.
M9'8)G+(2%&,('J4 Z6RM.%;D:+0?Y;4_?6-7/XV%R.:ZZPB7.]FQ10L9R<*L
MRL1.<1"T-. ""FLMIX];)PV?(&GL"JJQT-="0QWXB;O8D-D'CCZ 2D&1NXNB
M%AMZX"D$4^M>58Q#I:5Z MA0OEX+N7>?'WZ/:3Y+TXOI^I'S0A_69D]MTL1/
M/+QMMO@03LZ0-$96K+2Q "*7=?I\I#B4@EW&N75"YV1CZQ:+ R:-=]C"0P<O
MUW]Z5R$W=6Z^E&AHS<VISJL.QD*H U&"-9)GEDI[5ZT=]?TFF _!VYXKW=#:
M[<"9V\'.#H&\NIWKNJ0G?[_Y][343,@MX1AKA0R+M-L85<#ER*$D%BTCGT7L
M5Y!V#+1;,- )NL^,PEW&<'9(]&L/K^<+G'Z:W6'MEVDA$DFOTW Q06Y\HB .
MK/'D4GO+R<]2#E+4AC%E6/:MVYL=26HG><DN,=Y4S?VB^=UB.E_\)X;%+>]Q
MDD42W.0(/JU'M$4%9+L!.+'&F4Y)L3,A^"'R.HFPND3MR>KL%ZD_?PZS3_AF
M=I71H#]XM5SB:OD?X>)R(]B+B_D_:J.."1<YL9)H?T&!]8:SAI@P A<V^^Q<
M8G:P=,#15(\[[Z1O7 ^E_'[A_L>\!N67:36-%[C5R8?/I,J?PA+SS_,O]9.-
M;.;+U:1@\IP'!C(6 2K7!M162&#D5,G"4G)!G ?QAQ$^[J26OD$_( 3ZQ3U]
ML!'_)Z0/L=XNEBAEB&!+J .).0/G&)FS%#ZKXK5H?H:P)VGCSH7I&[LGJ;%?
M=#Y\B$?LB<)]J&/?HJHI)QD1HBX6F-3<LU#'3K3OI740B>/.D>D;K4W4.O;%
MG^OA.7=BUJ>WE'O-R5Y]J?>>)C&Q9$HB*^76@!*"OM,L$^>!8U#)_5!<NN/&
M4%.RQIUA,S*(1];R<\#WAJVWBZ\4+_RRN/Q$-OV>,$)$?Z9O?\%O>#'_NFF
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MOOEU(GAQ/O-UE&?KK#0!$04'EH+602KOW6-=$PYK!_GFUQX;@1ZDM/E)$NQ
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M.UM(;L[W*-BTA=D, J6%>KL6'.,)>%&>_,"L>6GM)S](R+B]B8;:A4Z7>0_
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M@'K6+]L3[&3?*&<BS0)[/,Q /?A^XBFD0A2'KMK&A;Z/:.@)%81@R<(0$T^
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MX1YN5T_3O-)^4U;7^>4/C=8RK1XU?-=),R_I!RXAE"AT7-WOP.<(1TQG4Y/
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M/?KZ%_H/1BOYO__U;U!+ 0(4 Q0    ( !E*8UI+(L$1X0(  $\)   2
M          "  0    !A,3(S,3(T97@M,3 Q,RYH=&U02P$"% ,4    "  9
M2F-:(J]B]\XI   > P$ $@              @ $1 P  83$R,S$R-&5X+3$P
M,3@N:'1M4$L! A0#%     @ &4IC6N'K.9!K#P  ,UD  !(
M ( !#RT  &$Q,C,Q,C1E>"TQ,#$Y+FAT;5!+ 0(4 Q0    ( !E*8UJ#N<]O
MUP\  /J/   1              "  :H\  !A,3(S,3(T97@M,3 R+FAT;5!+
M 0(4 Q0    ( !E*8UJ(04[5XPD  ( Q   2              "  ;!,  !A
M,3(S,3(T97@M,3 R,"YH=&U02P$"% ,4    "  92F-:!EZ=U,,Q  !P40$
M$@              @ '#5@  83$R,S$R-&5X+3$P,C$N:'1M4$L! A0#%
M  @ &4IC6H5 : J5-P  =7X! !(              ( !MH@  &$Q,C,Q,C1E
M>"TQ,#(R+FAT;5!+ 0(4 Q0    ( !E*8UJ;I954Y$<  *3E 0 1
M      "  7O   !A,3(S,3(T97@M,3 X+FAT;5!+ 0(4 Q0    ( !E*8UKH
M^>SVP%,  %1N @ 1              "  8X( 0!A,3(S,3(T97@M,3DQ+FAT
M;5!+ 0(4 Q0    ( !E*8UKDUHT##P0  %0B   1              "  7U<
M 0!A,3(S,3(T97@M,C$Q+FAT;5!+ 0(4 Q0    ( !E*8UH7A%\&Y (  .X'
M   1              "  ;M@ 0!A,3(S,3(T97@M,C,Q+FAT;5!+ 0(4 Q0
M   ( !E*8UJ#9-E-S <  )PD   1              "  <YC 0!A,3(S,3(T
M97@M,S$Q+FAT;5!+ 0(4 Q0    ( !E*8UIWI C,\@<  *XC   1
M      "  <EK 0!A,3(S,3(T97@M,S$R+FAT;5!+ 0(4 Q0    ( !E*8UJ4
M!RV#N@0  +X8   1              "  >IS 0!A,3(S,3(T97@M,S(Q+FAT
M;5!+ 0(4 Q0    ( !E*8UK$Q*(LQ00  + 8   1              "  =-X
M 0!A,3(S,3(T97@M,S(R+FAT;5!+ 0(4 Q0    ( !E*8UH8_I>G,D$  &&;
M 0 0              "  <=] 0!A,3(S,3(T97@M-#$N:'1M4$L! A0#%
M  @ &4IC6ECD^HB>D@, "3DD !$              ( !)[\! &%V9&PM,C R
M-#$R,S$N:'1M4$L! A0#%     @ &4IC6E"RZ'0Z$P  3MP  !$
M     ( !]%$% &%V9&PM,C R-#$R,S$N>'-D4$L! A0#%     @ &4IC6FS#
MP#TV)@  L78! !4              ( !764% &%V9&PM,C R-#$R,S%?8V%L
M+GAM;%!+ 0(4 Q0    ( !E*8UK(1PHL_V   /0\!  5              "
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7;%!+!08     %P 7 ,$%  ",T0D    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>avdl-20241231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:avdl="http://www.avadel.com/20241231"
  xmlns:country="http://xbrl.sec.gov/country/2024"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2024"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2024"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2024"
  xmlns:us-gaap="http://fasb.org/us-gaap/2024"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="avdl-20241231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2024-06-28</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2025-02-26</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:April2027NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:AtTheMarketOfferingProgramMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoHealthGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumFrontierTherapiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoHealthGroupInc.Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumFrontierTherapiesLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:AccountsReceivableMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:LeaseholdImprovementsFurnitureFixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:LeaseholdImprovementsFurnitureFixturesAndFittingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:FixedAssetsAndRightOfUseAssetsContractManufacturingOrganizationsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:ThreeCustomersMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:CaremarkMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:AccredoMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:MajorCustomersAxis">avdl:OptumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:RevenueFromContractWithCustomerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">avdl:SoftwareandSoftwareDevelopmentCostsOfficeEquipmentandComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-03-29</instant>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-08-01</startDate>
            <endDate>2023-08-01</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2023-03-29</startDate>
            <endDate>2023-03-29</endDate>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2024-08-31</startDate>
            <endDate>2024-08-31</endDate>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:February2023NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">avdl:October2023NotesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:SeniorNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">avdl:RoyaltyFinancingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">srt:EuropeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avdl:A163jCreditsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:FscHoldingsLlcMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:U.S.HoldingsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BusinessAcquisitionAxis">avdl:U.S.HoldingsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">avdl:OrphanDrugTaxCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:FR</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:LitigationCaseAxis">avdl:FirstJazzComplaintMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2024-04-15</startDate>
            <endDate>2024-04-15</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:PreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-03-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-05-08</startDate>
            <endDate>2024-05-08</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-08</instant>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementClassOfStockAxis">avdl:AmericanDepositarySharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-03-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">avdl:ShelfRegistrationStatementOnFormS3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:SellingGeneralAndAdministrativeExpensesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestOneYearFollowingAchievementOfMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-06-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:VestUponTheAchievementOfCertainRegulatoryMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:InducementPlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:OptionIndexedToIssuersEquityEquityAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-02-01</startDate>
            <endDate>2024-02-29</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:A2017AvadelEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">avdl:A2017AvadelEmployeeSharePurchasePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:GranteeStatusAxis">us-gaap:ShareBasedPaymentArrangementEmployeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">avdl:ShareBasedPaymentArrangementTrancheFourMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">avdl:RestrictedShareAwardsGrantedToEmployeesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VestingAxis">us-gaap:ShareBasedCompensationAwardTrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedTranslationAdjustmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedNetUnrealizedInvestmentGainLossMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">avdl:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:US</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">country:IE</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
        </entity>
        <period>
            <startDate>2024-10-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001012477</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ValuationAllowancesAndReservesTypeAxis">us-gaap:ValuationAllowanceOfDeferredTaxAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="institution">
        <measure>avdl:institution</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="tranche">
        <measure>avdl:tranche</measure>
    </unit>
    <unit id="segment">
        <measure>avdl:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-32">0001012477</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="c-1" id="f-33">false</dei:AmendmentFlag>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-34">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-35">2024</dei:DocumentFiscalYearFocus>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-104" id="f-539">P1Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-182" decimals="2" id="f-901" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-183" decimals="2" id="f-902" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-184" decimals="2" id="f-903" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-185" decimals="2" id="f-904" unitRef="number">0.25</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2024-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-37977</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">AVADEL PHARMACEUTICALS PLC</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">L2</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">98-1341933</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">10 Earlsfort Terrace</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-11">Dublin 2</dei:EntityAddressCityOrTown>
    <dei:EntityAddressCountry contextRef="c-1" id="f-12">IE</dei:EntityAddressCountry>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-13">D02 T380</dei:EntityAddressPostalZipCode>
    <dei:CountryRegion contextRef="c-1" id="f-14">353</dei:CountryRegion>
    <dei:CityAreaCode contextRef="c-1" id="f-15">1</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">901-5201</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Ordinary Shares, nominal value $0.01 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">AVDL</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Large Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="0" id="f-30" unitRef="usd">1342171790</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">96629435</dei:EntityCommonStockSharesOutstanding>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-37">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At Avadel, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain cybersecurity policies and procedures as part of our overall risk management process. We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments which are designed to identify, assess, and manage cybersecurity risks. We perform cybersecurity risk analyses of select third-party service providers and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We did not experience any material cybersecurity threats or incidents for the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-36">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At Avadel, we recognize the importance of assessing, identifying, and managing risks from cybersecurity threats. We have implemented a cybersecurity risk management process in accordance with our risk profile and business that is informed by industry standards.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We maintain cybersecurity policies and procedures as part of our overall risk management process. We leverage the support of third-party information technology and security providers, including for periodic security testing and risk assessments which are designed to identify, assess, and manage cybersecurity risks. We perform cybersecurity risk analyses of select third-party service providers and maintain an incident response and notification plan designed to assist us in identifying, responding to, and recovering from cybersecurity incidents.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-39">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-41">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-43">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Senior Director of Information Technology (&#x201c;IT&#x201d;), who reports to the Chief Financial Officer,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is responsible for the strategic leadership and direction of the Company&#x2019;s cybersecurity program. The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company&#x2019;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management. The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-42">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Our Senior Director of Information Technology (&#x201c;IT&#x201d;), who reports to the Chief Financial Officer,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;is responsible for the strategic leadership and direction of the Company&#x2019;s cybersecurity program. The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As part of the Company&#x2019;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management. The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.&lt;/span&gt;&lt;/div&gt;</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-44">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-45">The Senior Director of IT has over 30 years of professional experience in IT, including the development of data protection strategies, identification of cybersecurity matters, management of IT environments, (including corresponding data relied on in the environment), and timely deployment of responses to cybersecurity incidents. Further, the Senior Director of IT has education related qualifications specific to cybersecurity, including a Master of Science in Cybersecurity Management.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-46">As part of the Company&#x2019;s incident response and notification plan, the Senior Director of IT has a process to assess potential cybersecurity incidents through a cybersecurity incident decision matrix. The Senior Director of IT escalates cybersecurity incidents to our Cybersecurity Response Committee, which consists of key members of executive management.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-47">The Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-48">Cybersecurity Response Committee, informed by information and recommendations from the Senior Director of IT, determines appropriate actions and responses, as needed.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-49">The audit committee of our Board of Directors has responsibility for oversight of the Company&#x2019;s cybersecurity risk management and receives cybersecurity updates from management at regularly scheduled meetings.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-50">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-1" decimals="-3" id="f-51" unitRef="usd">169117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-4" decimals="-3" id="f-52" unitRef="usd">27963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-5" decimals="-3" id="f-53" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-1" decimals="-3" id="f-54" unitRef="usd">15277000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-4" decimals="-3" id="f-55" unitRef="usd">846000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-5" decimals="-3" id="f-56" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-1" decimals="-3" id="f-57" unitRef="usd">153840000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-4" decimals="-3" id="f-58" unitRef="usd">27117000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-5" decimals="-3" id="f-59" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-3" id="f-60" unitRef="usd">15196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-4" decimals="-3" id="f-61" unitRef="usd">13261000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-5" decimals="-3" id="f-62" unitRef="usd">20700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-1" decimals="-3" id="f-63" unitRef="usd">181043000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-4" decimals="-3" id="f-64" unitRef="usd">151705000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:SellingGeneralAndAdministrativeExpense contextRef="c-5" decimals="-3" id="f-65" unitRef="usd">74516000</us-gaap:SellingGeneralAndAdministrativeExpense>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-3" id="f-66" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-4" decimals="-3" id="f-67" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-5" decimals="-3" id="f-68" unitRef="usd">3345000</us-gaap:RestructuringCharges>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-3" id="f-69" unitRef="usd">196239000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-4" decimals="-3" id="f-70" unitRef="usd">164966000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-5" decimals="-3" id="f-71" unitRef="usd">98561000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-3" id="f-72" unitRef="usd">-42399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-4" decimals="-3" id="f-73" unitRef="usd">-137849000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-5" decimals="-3" id="f-74" unitRef="usd">-98561000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-1" decimals="-3" id="f-75" unitRef="usd">4150000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-4" decimals="-3" id="f-76" unitRef="usd">87000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-5" decimals="-3" id="f-77" unitRef="usd">-536000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseDebt contextRef="c-1" decimals="-3" id="f-78" unitRef="usd">10830000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-4" decimals="-3" id="f-79" unitRef="usd">9886000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-5" decimals="-3" id="f-80" unitRef="usd">12342000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-81" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-4" decimals="-3" id="f-82" unitRef="usd">-13129000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-5" decimals="-3" id="f-83" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-84" unitRef="usd">-49079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-85" unitRef="usd">-160777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-86" unitRef="usd">-111439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-87" unitRef="usd">-247000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-88" unitRef="usd">-501000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-89" unitRef="usd">26025000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-90" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-91" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-92" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-93"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-94"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-95"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-96"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-97"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-98"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-99" unitRef="shares">95141000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="-3" id="f-100" unitRef="shares">80174000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-101" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-102" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-103" unitRef="shares">95141000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="-3" id="f-104" unitRef="shares">80174000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-105" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-106" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-107" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-108" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-109" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-110" unitRef="usd">-623000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-4" decimals="-3" id="f-111" unitRef="usd">331000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-112" unitRef="usd">-597000</us-gaap:OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-1" decimals="-3" id="f-113" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-4" decimals="-3" id="f-114" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-5" decimals="-3" id="f-115" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-1" decimals="-3" id="f-116" unitRef="usd">-790000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-4" decimals="-3" id="f-117" unitRef="usd">2843000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax contextRef="c-5" decimals="-3" id="f-118" unitRef="usd">-1804000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-119" unitRef="usd">-1413000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-4" decimals="-3" id="f-120" unitRef="usd">3174000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-121" unitRef="usd">-2401000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-3" id="f-122" unitRef="usd">-50245000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-4" decimals="-3" id="f-123" unitRef="usd">-157102000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-5" decimals="-3" id="f-124" unitRef="usd">-139865000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-3" id="f-125" unitRef="usd">51371000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-7" decimals="-3" id="f-126" unitRef="usd">31167000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-3" id="f-127" unitRef="usd">22406000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-7" decimals="-3" id="f-128" unitRef="usd">73944000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-3" id="f-129" unitRef="usd">34097000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-7" decimals="-3" id="f-130" unitRef="usd">12103000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-131" unitRef="usd">20298000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-132" unitRef="usd">10380000</us-gaap:InventoryNet>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-133" unitRef="usd">6036000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-134" unitRef="usd">6608000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-3" id="f-135" unitRef="usd">134208000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-7" decimals="-3" id="f-136" unitRef="usd">134202000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-137" unitRef="usd">453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-138" unitRef="usd">585000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-3" id="f-139" unitRef="usd">1702000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-7" decimals="-3" id="f-140" unitRef="usd">2591000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-141" unitRef="usd">16836000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-142" unitRef="usd">16836000</us-gaap:Goodwill>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-143" unitRef="usd">11037000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-144" unitRef="usd">10484000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="c-6" decimals="-3" id="f-145" unitRef="usd">164236000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-7" decimals="-3" id="f-146" unitRef="usd">164698000</us-gaap:Assets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-3" id="f-147" unitRef="usd">582000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-7" decimals="-3" id="f-148" unitRef="usd">934000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-3" id="f-149" unitRef="usd">7328000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-7" decimals="-3" id="f-150" unitRef="usd">11433000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-151" unitRef="usd">40651000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-152" unitRef="usd">24227000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-153" unitRef="usd">273000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-154" unitRef="usd">261000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-155" unitRef="usd">48834000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-156" unitRef="usd">36855000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-157" unitRef="usd">1122000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-158" unitRef="usd">1690000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <avdl:RoyaltyFinancingLiabilityNoncurrent contextRef="c-6" decimals="-3" id="f-159" unitRef="usd">35249000</avdl:RoyaltyFinancingLiabilityNoncurrent>
    <avdl:RoyaltyFinancingLiabilityNoncurrent contextRef="c-7" decimals="-3" id="f-160" unitRef="usd">32760000</avdl:RoyaltyFinancingLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-161" unitRef="usd">5183000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-162" unitRef="usd">5654000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="c-6" decimals="-3" id="f-163" unitRef="usd">90388000</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-7" decimals="-3" id="f-164" unitRef="usd">76959000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-165"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="INF"
      id="f-166"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-167" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-7" decimals="-3" id="f-168" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="-3" id="f-169" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-170" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-171" unitRef="shares">5194000</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-7" decimals="-3" id="f-172" unitRef="shares">5194000</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-3" id="f-173" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-7" decimals="-3" id="f-174" unitRef="usd">52000</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="2"
      id="f-175"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-7"
      decimals="2"
      id="f-176"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="-3" id="f-177" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-7" decimals="-3" id="f-178" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-3" id="f-179" unitRef="shares">96518000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-180" unitRef="shares">96518000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-7" decimals="-3" id="f-181" unitRef="shares">89825000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-7" decimals="-3" id="f-182" unitRef="shares">89825000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-3" id="f-183" unitRef="usd">965000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-7" decimals="-3" id="f-184" unitRef="usd">898000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-6" decimals="-3" id="f-185" unitRef="usd">891791000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="c-7" decimals="-3" id="f-186" unitRef="usd">855452000</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-3" id="f-187" unitRef="usd">-794328000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-7" decimals="-3" id="f-188" unitRef="usd">-745496000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-3" id="f-189" unitRef="usd">-24580000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-7" decimals="-3" id="f-190" unitRef="usd">-23167000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-191" unitRef="usd">73848000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-192" unitRef="usd">87739000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-3" id="f-193" unitRef="usd">164236000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-7" decimals="-3" id="f-194" unitRef="usd">164698000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-8" decimals="-3" id="f-195" unitRef="shares">58620000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-8" decimals="-3" id="f-196" unitRef="usd">586000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-9" decimals="-3" id="f-197" unitRef="shares">488000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-3" id="f-198" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-3" id="f-199" unitRef="usd">549349000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-3" id="f-200" unitRef="usd">-447756000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-3" id="f-201" unitRef="usd">-23940000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-3" id="f-202" unitRef="usd">78244000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-14" decimals="-3" id="f-203" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-204" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-15" decimals="-3" id="f-205" unitRef="usd">-2401000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-5" decimals="-3" id="f-206" unitRef="usd">-2401000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature contextRef="c-16" decimals="-3" id="f-207" unitRef="usd">5508000</avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature>
    <avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature contextRef="c-5" decimals="-3" id="f-208" unitRef="usd">5508000</avdl:AdjustmentsToAdditionalPaidInCapitalAdjustmentsInFairValueOfConvertibleDebtConversionFeature>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-17" decimals="-3" id="f-209" unitRef="shares">3588000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-17" decimals="-3" id="f-210" unitRef="usd">36000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-16" decimals="-3" id="f-211" unitRef="usd">25282000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-5" decimals="-3" id="f-212" unitRef="usd">25318000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-16" decimals="-3" id="f-213" unitRef="usd">45000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-5" decimals="-3" id="f-214" unitRef="usd">45000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-18" decimals="-3" id="f-215" unitRef="shares">451000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-18" decimals="-3" id="f-216" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-16" decimals="-3" id="f-217" unitRef="usd">2456000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-5" decimals="-3" id="f-218" unitRef="usd">2460000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c-18" decimals="-3" id="f-219" unitRef="shares">144000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-18" decimals="-3" id="f-220" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-16" decimals="-3" id="f-221" unitRef="usd">-1000</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodValueOther contextRef="c-5" decimals="-3" id="f-222" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueOther>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-18" decimals="-3" id="f-223" unitRef="shares">75000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-18" decimals="-3" id="f-224" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-16" decimals="-3" id="f-225" unitRef="usd">221000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-5" decimals="-3" id="f-226" unitRef="usd">222000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-16" decimals="-3" id="f-227" unitRef="usd">7013000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-5" decimals="-3" id="f-228" unitRef="usd">7013000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-19" decimals="-3" id="f-229" unitRef="shares">62878000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-3" id="f-230" unitRef="usd">628000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-20" decimals="-3" id="f-231" unitRef="shares">488000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-3" id="f-232" unitRef="usd">5000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-3" id="f-233" unitRef="usd">589783000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-3" id="f-234" unitRef="usd">-585220000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-235" unitRef="usd">-26341000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-24" decimals="-3" id="f-236" unitRef="usd">-21145000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-25" decimals="-3" id="f-237" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-238" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-3" id="f-239" unitRef="usd">3174000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-4" decimals="-3" id="f-240" unitRef="usd">3174000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-27" decimals="-3" id="f-241" unitRef="shares">1564000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-27" decimals="-3" id="f-242" unitRef="usd">16000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-28" decimals="-3" id="f-243" unitRef="usd">11897000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-29" decimals="-3" id="f-244" unitRef="usd">11913000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-30" decimals="-3" id="f-245" unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-4" decimals="-3" id="f-246" unitRef="usd">16000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-31" decimals="-3" id="f-247" unitRef="shares">12205000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-31" decimals="-3" id="f-248" unitRef="usd">122000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-32" decimals="-3" id="f-249" unitRef="shares">4706000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-32" decimals="-3" id="f-250" unitRef="usd">47000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-33" decimals="-3" id="f-251" unitRef="usd">133982000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-34" decimals="-3" id="f-252" unitRef="usd">134151000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-35" decimals="-3" id="f-253" unitRef="shares">12347000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-35" decimals="-3" id="f-254" unitRef="usd">123000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-36" decimals="-3" id="f-255" unitRef="usd">101689000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-37" decimals="-3" id="f-256" unitRef="usd">101812000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-38" decimals="-3" id="f-257" unitRef="shares">408000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-38" decimals="-3" id="f-258" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-39" decimals="-3" id="f-259" unitRef="usd">18000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-40" decimals="-3" id="f-260" unitRef="usd">22000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-41" decimals="-3" id="f-261" unitRef="shares">343000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-41" decimals="-3" id="f-262" unitRef="usd">4000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-30" decimals="-3" id="f-263" unitRef="usd">2058000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-4" decimals="-3" id="f-264" unitRef="usd">2062000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c-41" decimals="-3" id="f-265" unitRef="shares">33000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-41" decimals="-3" id="f-266" unitRef="shares">47000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-41" decimals="-3" id="f-267" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-30" decimals="-3" id="f-268" unitRef="usd">230000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-4" decimals="-3" id="f-269" unitRef="usd">231000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-30" decimals="-3" id="f-270" unitRef="usd">15811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-4" decimals="-3" id="f-271" unitRef="usd">15811000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-42" decimals="-3" id="f-272" unitRef="shares">89825000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-42" decimals="-3" id="f-273" unitRef="usd">898000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-43" decimals="-3" id="f-274" unitRef="shares">5194000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-43" decimals="-3" id="f-275" unitRef="usd">52000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-44" decimals="-3" id="f-276" unitRef="usd">855452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-45" decimals="-3" id="f-277" unitRef="usd">-745496000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-278" unitRef="usd">-23167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-7" decimals="-3" id="f-279" unitRef="usd">87739000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-47" decimals="-3" id="f-280" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-281" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-48" decimals="-3" id="f-282" unitRef="usd">-1413000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-3" id="f-283" unitRef="usd">-1413000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-49" decimals="-3" id="f-284" unitRef="shares">640000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-49" decimals="-3" id="f-285" unitRef="usd">6000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-50" decimals="-3" id="f-286" unitRef="usd">9244000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-1" decimals="-3" id="f-287" unitRef="usd">9250000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-51" decimals="-3" id="f-288" unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-1" decimals="-3" id="f-289" unitRef="usd">3000</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-52" decimals="-3" id="f-290" unitRef="shares">5194000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-52" decimals="-3" id="f-291" unitRef="usd">52000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities contextRef="c-53" decimals="-3" id="f-292" unitRef="shares">-5194000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-53" decimals="-3" id="f-293" unitRef="usd">-52000</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities contextRef="c-1" decimals="-3" id="f-294" unitRef="usd">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-52" decimals="-3" id="f-295" unitRef="shares">735000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-52" decimals="-3" id="f-296" unitRef="usd">8000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-51" decimals="-3" id="f-297" unitRef="usd">5351000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised contextRef="c-1" decimals="-3" id="f-298" unitRef="usd">5359000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesOther contextRef="c-52" decimals="-3" id="f-299" unitRef="shares">11000</us-gaap:StockIssuedDuringPeriodSharesOther>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan contextRef="c-52" decimals="-3" id="f-300" unitRef="shares">113000</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockOwnershipPlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-52" decimals="-3" id="f-301" unitRef="usd">1000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-51" decimals="-3" id="f-302" unitRef="usd">1360000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan contextRef="c-1" decimals="-3" id="f-303" unitRef="usd">1361000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-51" decimals="-3" id="f-304" unitRef="usd">20387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-3" id="f-305" unitRef="usd">20387000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:SharesOutstanding contextRef="c-54" decimals="-3" id="f-306" unitRef="shares">96518000</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-54" decimals="-3" id="f-307" unitRef="usd">965000</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding contextRef="c-55" decimals="-3" id="f-308" unitRef="shares">0</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-55" decimals="-3" id="f-309" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-56" decimals="-3" id="f-310" unitRef="usd">891791000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-57" decimals="-3" id="f-311" unitRef="usd">-794328000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-312" unitRef="usd">-24580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-3" id="f-313" unitRef="usd">73848000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-314" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-315" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-316" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-3" id="f-317" unitRef="usd">2681000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-4" decimals="-3" id="f-318" unitRef="usd">1766000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-5" decimals="-3" id="f-319" unitRef="usd">1493000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-1" decimals="-3" id="f-320" unitRef="usd">0</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-4" decimals="-3" id="f-321" unitRef="usd">2796000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:AmortizationOfFinancingCostsAndDiscounts contextRef="c-5" decimals="-3" id="f-322" unitRef="usd">6052000</us-gaap:AmortizationOfFinancingCostsAndDiscounts>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-1" decimals="-3" id="f-323" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-4" decimals="-3" id="f-324" unitRef="usd">0</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:IncreaseDecreaseInDeferredIncomeTaxes contextRef="c-5" decimals="-3" id="f-325" unitRef="usd">-26025000</us-gaap:IncreaseDecreaseInDeferredIncomeTaxes>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-3" id="f-326" unitRef="usd">20387000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-4" decimals="-3" id="f-327" unitRef="usd">15811000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-5" decimals="-3" id="f-328" unitRef="usd">7013000</us-gaap:ShareBasedCompensation>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-1" decimals="-3" id="f-329" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-4" decimals="-3" id="f-330" unitRef="usd">-13129000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-5" decimals="-3" id="f-331" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-1" decimals="-3" id="f-332" unitRef="usd">-828000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-4" decimals="-3" id="f-333" unitRef="usd">1262000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:OtherOperatingActivitiesCashFlowStatement contextRef="c-5" decimals="-3" id="f-334" unitRef="usd">2042000</us-gaap:OtherOperatingActivitiesCashFlowStatement>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-3" id="f-335" unitRef="usd">21994000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-4" decimals="-3" id="f-336" unitRef="usd">12103000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-5" decimals="-3" id="f-337" unitRef="usd">0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-1" decimals="-3" id="f-338" unitRef="usd">9219000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-4" decimals="-3" id="f-339" unitRef="usd">9532000</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories contextRef="c-5" decimals="-3" id="f-340" unitRef="usd">0</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-3" id="f-341" unitRef="usd">-416000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-4" decimals="-3" id="f-342" unitRef="usd">2155000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-5" decimals="-3" id="f-343" unitRef="usd">-30950000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-1" decimals="-3" id="f-344" unitRef="usd">-4093000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-4" decimals="-3" id="f-345" unitRef="usd">1545000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable contextRef="c-5" decimals="-3" id="f-346" unitRef="usd">-3108000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-1" decimals="-3" id="f-347" unitRef="usd">16424000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-4" decimals="-3" id="f-348" unitRef="usd">16892000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities contextRef="c-5" decimals="-3" id="f-349" unitRef="usd">227000</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet contextRef="c-1" decimals="-3" id="f-350" unitRef="usd">1849000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet contextRef="c-4" decimals="-3" id="f-351" unitRef="usd">-2354000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet contextRef="c-5" decimals="-3" id="f-352" unitRef="usd">3534000</us-gaap:IncreaseDecreaseInOtherNoncurrentAssetsAndLiabilitiesNet>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-3" id="f-353" unitRef="usd">-46907000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-4" decimals="-3" id="f-354" unitRef="usd">-128511000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-5" decimals="-3" id="f-355" unitRef="usd">-70304000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-3" id="f-356" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-4" decimals="-3" id="f-357" unitRef="usd">0</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-5" decimals="-3" id="f-358" unitRef="usd">716000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-1" decimals="-3" id="f-359" unitRef="usd">327781000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-4" decimals="-3" id="f-360" unitRef="usd">187136000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt contextRef="c-5" decimals="-3" id="f-361" unitRef="usd">83828000</us-gaap:ProceedsFromSaleOfAvailableForSaleSecuritiesDebt>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-3" id="f-362" unitRef="usd">276001000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-4" decimals="-3" id="f-363" unitRef="usd">237229000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-5" decimals="-3" id="f-364" unitRef="usd">3414000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-3" id="f-365" unitRef="usd">51780000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-4" decimals="-3" id="f-366" unitRef="usd">-50093000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-5" decimals="-3" id="f-367" unitRef="usd">79698000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-59" decimals="-3" id="f-368" unitRef="usd">9250000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-29" decimals="-3" id="f-369" unitRef="usd">11913000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-60" decimals="-3" id="f-370" unitRef="usd">25318000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-1" decimals="-3" id="f-371" unitRef="usd">6720000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-4" decimals="-3" id="f-372" unitRef="usd">2293000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions contextRef="c-5" decimals="-3" id="f-373" unitRef="usd">2682000</us-gaap:ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-61" decimals="-3" id="f-374" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-34" decimals="-3" id="f-375" unitRef="usd">134151000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock contextRef="c-62" decimals="-3" id="f-376" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-63" decimals="-3" id="f-377" unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-64" decimals="-3" id="f-378" unitRef="usd">17500000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-65" decimals="-3" id="f-379" unitRef="usd">8653000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-66" decimals="-3" id="f-380" unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-40" decimals="-3" id="f-381" unitRef="usd">21165000</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:RepaymentsOfSeniorDebt contextRef="c-67" decimals="-3" id="f-382" unitRef="usd">0</us-gaap:RepaymentsOfSeniorDebt>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-1" decimals="-3" id="f-383" unitRef="usd">0</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-4" decimals="-3" id="f-384" unitRef="usd">4357000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:PaymentsOfDebtIssuanceCosts contextRef="c-5" decimals="-3" id="f-385" unitRef="usd">4804000</us-gaap:PaymentsOfDebtIssuanceCosts>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-1" decimals="-3" id="f-386" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-4" decimals="-3" id="f-387" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-5" decimals="-3" id="f-388" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-3" id="f-389" unitRef="usd">15970000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-4" decimals="-3" id="f-390" unitRef="usd">135335000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-5" decimals="-3" id="f-391" unitRef="usd">14543000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-1" decimals="-3" id="f-392" unitRef="usd">-639000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-4" decimals="-3" id="f-393" unitRef="usd">455000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-3" id="f-394" unitRef="usd">-664000</us-gaap:EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-3" id="f-395" unitRef="usd">20204000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-4" decimals="-3" id="f-396" unitRef="usd">-42814000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-5" decimals="-3" id="f-397" unitRef="usd">23273000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-398" unitRef="usd">31167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-399" unitRef="usd">73981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-3" id="f-400" unitRef="usd">50708000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-3" id="f-401" unitRef="usd">51371000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-7" decimals="-3" id="f-402" unitRef="usd">31167000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-24" decimals="-3" id="f-403" unitRef="usd">73981000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet contextRef="c-1" decimals="-3" id="f-404" unitRef="usd">7181000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-4" decimals="-3" id="f-405" unitRef="usd">5250000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet contextRef="c-5" decimals="-3" id="f-406" unitRef="usd">9660000</us-gaap:InterestPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-407" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-4" decimals="-3" id="f-408" unitRef="usd">0</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-5" decimals="-3" id="f-409" unitRef="usd">-29058000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-410">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Operations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#x201c;Avadel,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us&#x201d;) is a biopharmaceutical company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is registered as an Irish public limited company. The Company&#x2019;s headquarters are in Dublin, Ireland with operations in Dublin, Ireland and St. Louis, Missouri, United States (&#x201c;U.S.&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (&#x201c;EDS&#x201d;) in patients seven years of age and older with narcolepsy. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LUMRYZ was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted Orphan Drug Exclusivity (&#x201c;ODE&#x201d;) to LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy for a period of seven years until May 1, 2030. In June 2023, the Company commercially launched LUMRYZ in the U.S for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The FDA has required implementation of a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of this Annual Report, the Company&#x2019;s only commercialized product is LUMRYZ. The Company continues to evaluate opportunities to expand its product portfolio.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adequacy of the Company&#x2019;s cash resources depends on the outcome of certain business conditions including the cost of the Company&#x2019;s ongoing LUMRYZ commercialization activities, the Company&#x2019;s cost structure, and other factors set forth in &#x201c;Risk Factors&#x201d; within Part I, Item 1A of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. and the requirements of Form 10-K. The consolidated financial statements include the accounts of the Company and all subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified within the notes to the consolidated financial statements to condense line items of the same nature to conform with the current year presentation.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and marketable securities are held at three financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. The Company has not experienced any losses on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to the sale of LUMRYZ. The Company extends credit to its customers, specialty pharmacies. Customer creditworthiness is monitored, and collateral is not required. Amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible. As of December&#160;31, 2024, the Company did not recognize any allowances for credit &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;losses. As of December&#160;31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#x201c;Caremark&#x201d;), which accounted for 53% of gross accounts receivable; Accredo Health Group, Inc. (&#x201c;Accredo&#x201d;), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (&#x201c;Optum&#x201d;), which accounted for 22% of gross accounts receivable. As of December&#160;31, 2023, three customers accounted for 100% of gross accounts receivable, Caremark, which accounted for 52% of gross accounts receivable; Accredo, which accounted for 28% of gross accounts receivable; and Optum, which accounted for 20% of gross accounts receivable. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company attempts to maintain multiple suppliers for its active pharmaceutical ingredient (&#x201c;API&#x201d;) and manufacturing in order to mitigate the risk of shortfall and inability to supply market demand, but is subject to risk due to a limited number of providers. The API is currently manufactured by two outsourced contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) in the U.S. The drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue includes sales of LUMRYZ. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer&#x37e; (ii) identify the performance obligations in the contract; (iii) determine the transaction price&#x37e; (iv) allocate the transaction price to the performance obligations in the contract&#x37e; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#x2019;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells LUMRYZ to specialty pharmacies and considers those specialty pharmacies to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. The Company&#x2019;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold includes the cost of the API, manufacturing and distribution costs, packaging costs and freight. LUMRYZ was approved by the FDA on May 1, 2023 and the Company began shipping product to its customers in June 2023. Cost of products sold includes inventory purchased or produced that was expensed as research and development costs prior to FDA approval.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventories consist of raw materials, work in process and finished products, which are stated at lower of cost or net realizable value, using the first-in, first- out method. Raw materials used in the production of pre-clinical and clinical products are expensed as research and development costs. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development (&#x201c;R&amp;amp;D&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of costs related to outside services, personnel expenses, clinical studies and other R&amp;amp;D expenses. Outside services and clinical studies costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third-party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other R&amp;amp;D expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&amp;amp;D expenditures are charged to operations as incurred. Raw materials used in the production of pre-clinical and clinical products are expensed as R&amp;amp;D costs.  &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes refundable R&amp;amp;D tax credits received for spending on innovative R&amp;amp;D as an offset of R&amp;amp;D expenses.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expenses. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses the costs of advertising as incurred. Branded advertising expenses were $12,186 and $6,452 for the years ended December&#160;31, 2024 and 2023. Branded advertising expenses were immaterial for the year ended December 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations, cash flows or liquidity.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for share-based compensation based on the estimated grant-date fair value. The fair value of stock options is estimated using Black-Scholes option-pricing valuation models (&#x201c;Black-Scholes model&#x201d;). As required by the Black-Scholes model, estimates are made of the underlying volatility of Avadel stock, a risk-free rate and an expected term of the option or warrant. The Company estimates the expected term using a simplified method, as the Company does not have enough historical exercise data for a majority of such options upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of December&#160;31, 2024, the Company's cumulative loss position was significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax expense line in the consolidated statements of loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities are considered to be available for sale and are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in shareholders&#x2019; equity, with the exception of unrealized gains and losses on equity instruments and allowances for expected credit losses, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Property and equipment is stated at historical cost less accumulated depreciation. Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, office and computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements, furniture, fixtures and fittings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable. The Company determined that no impairment of goodwill existed at December&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Long-lived assets include fixed assets and right of use assets at contract manufacturing organizations. Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset or other market-based value approaches. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. Certain long-lived assets are amortized using the straight-line method over a five year useful life. Amortization on long-lived assets is considered to be manufacturing overhead costs and is either capitalized into inventory or expensed in the period incurred. The Company determined that no impairment of long-lived assets existed at December&#160;31, 2024 and 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if a contract is a lease at the inception of the arrangement. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. Short term leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease payments are recognized in the consolidated statements of loss on a straight-line basis over the lease term. The Company&#x2019;s lease contracts do not provide a readily determinable implicit rate. The Company&#x2019;s estimated incremental borrowing rate is based on information available at the inception of the lease. The Company&#x2019;s lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the consolidated statements of loss.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. These estimates and assumptions are based on the best information available to management and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company&#x2019;s consolidated financial statements. Actual results could differ from those estimates under different assumptions or&#160;conditions.</us-gaap:SignificantAccountingPoliciesTextBlock>
    <avdl:NatureOfBusinessPolicyPolicyTextBlock contextRef="c-1" id="f-411">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Nature of Operations.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avadel Pharmaceuticals plc (Nasdaq: AVDL) (&#x201c;Avadel,&#x201d; the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us&#x201d;) is a biopharmaceutical company.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company is registered as an Irish public limited company. The Company&#x2019;s headquarters are in Dublin, Ireland with operations in Dublin, Ireland and St. Louis, Missouri, United States (&#x201c;U.S.&#x201d;).&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;LUMRYZ is an extended-release formulation of sodium oxybate indicated to be taken once at bedtime for the treatment of cataplexy or excessive daytime sleepiness (&#x201c;EDS&#x201d;) in patients seven years of age and older with narcolepsy. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;LUMRYZ was approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) on May 1, 2023 for the treatment of cataplexy or EDS in adults with narcolepsy. The FDA also granted Orphan Drug Exclusivity (&#x201c;ODE&#x201d;) to LUMRYZ for treatment of cataplexy or EDS in adults with narcolepsy for a period of seven years until May 1, 2030. In June 2023, the Company commercially launched LUMRYZ in the U.S for the treatment of cataplexy or EDS in adults living with narcolepsy. LUMRYZ was approved by the FDA for use in the treatment of cataplexy or EDS in the pediatric narcolepsy population seven years of age and older on October 16, 2024, and was granted ODE for this patient population through October 16, 2031. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;The FDA has required implementation of a &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Risk Evaluation and Mitigation Strategy (&#x201c;REMS&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; to help ensure the benefits of the drug outweigh the risks of serious adverse outcomes resulting from inappropriate prescribing, misuse, abuse, and diversion of the same. Under the LUMRYZ REMS, healthcare providers who prescribe the drug must be specially certified, pharmacies that dispense the drug must be specially certified, and the drug must be dispensed only to patients who have enrolled in the LUMRYZ REMS and completed all REMS requirements, including documentation of safe use conditions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of the date of this Annual Report, the Company&#x2019;s only commercialized product is LUMRYZ. The Company continues to evaluate opportunities to expand its product portfolio.&lt;/span&gt;&lt;/div&gt;</avdl:NatureOfBusinessPolicyPolicyTextBlock>
    <avdl:LiquidityAndGoingConcernPolicyTextBlock contextRef="c-1" id="f-412">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Liquidity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accompanying consolidated financial statements are prepared in accordance with accounting principles generally accepted in the U.S. (&#x201c;U.S. GAAP&#x201d;) applicable to a going concern, which contemplates the realization of assets and the satisfaction of liabilities in the normal course of business.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The adequacy of the Company&#x2019;s cash resources depends on the outcome of certain business conditions including the cost of the Company&#x2019;s ongoing LUMRYZ commercialization activities, the Company&#x2019;s cost structure, and other factors set forth in &#x201c;Risk Factors&#x201d; within Part I, Item 1A of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;</avdl:LiquidityAndGoingConcernPolicyTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-413">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Basis of Presentation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; These consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the U.S. and the requirements of Form 10-K. The consolidated financial statements include the accounts of the Company and all subsidiaries. All intercompany accounts and transactions have been eliminated.&lt;/span&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="c-1" id="f-414">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reclassifications &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Certain prior year amounts have been reclassified within the notes to the consolidated financial statements to condense line items of the same nature to conform with the current year presentation.&lt;/span&gt;&lt;/div&gt;</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-415">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Concentrations of Risk. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s cash, cash equivalents and marketable securities are held at three financial institutions. Due to their size, the Company believes these financial institutions represent minimal credit risk. The Company has not experienced any losses on its cash, cash equivalents, or marketable securities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to credit risk from its accounts receivable related to the sale of LUMRYZ. The Company extends credit to its customers, specialty pharmacies. Customer creditworthiness is monitored, and collateral is not required. Amounts owed to the Company are presented net of an allowance that includes an assessment of expected credit losses. An allowance for credit losses is established based on expected losses. Expected losses are estimated by reviewing individual accounts, considering aging, financial condition of the debtor, payment history, current and forecast economic conditions and other relevant factors. To the extent that the Company identifies that any individual customer's credit quality has deteriorated, the Company establishes allowances based on the individual risk characteristics of that customer. The Company makes concerted efforts to collect all outstanding balances due from customers; however, amounts are written off against the allowance when the related balances are no longer deemed collectible. As of December&#160;31, 2024, the Company did not recognize any allowances for credit &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;losses. As of December&#160;31, 2024, three customers accounted for 100% of gross accounts receivable, Caremark LLC (&#x201c;Caremark&#x201d;), which accounted for 53% of gross accounts receivable; Accredo Health Group, Inc. (&#x201c;Accredo&#x201d;), which accounted for 25% of gross accounts receivable; and Optum Frontier Therapies LLC (&#x201c;Optum&#x201d;), which accounted for 22% of gross accounts receivable. As of December&#160;31, 2023, three customers accounted for 100% of gross accounts receivable, Caremark, which accounted for 52% of gross accounts receivable; Accredo, which accounted for 28% of gross accounts receivable; and Optum, which accounted for 20% of gross accounts receivable. &lt;/span&gt;&lt;/div&gt;The Company attempts to maintain multiple suppliers for its active pharmaceutical ingredient (&#x201c;API&#x201d;) and manufacturing in order to mitigate the risk of shortfall and inability to supply market demand, but is subject to risk due to a limited number of providers. The API is currently manufactured by two outsourced contract development and manufacturing organizations (&#x201c;CDMOs&#x201d;) in the U.S. The drug product for commercial lots is manufactured by one outsourced CDMO in the U.S. and one outsourced CDMO outside of the U.S.</us-gaap:ConcentrationRiskCreditRisk>
    <avdl:NumberOfFinancialInstitutions
      contextRef="c-6"
      decimals="INF"
      id="f-416"
      unitRef="institution">3</avdl:NumberOfFinancialInstitutions>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-68"
      decimals="INF"
      id="f-417"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-69" decimals="2" id="f-418" unitRef="number">0.53</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-70" decimals="2" id="f-419" unitRef="number">0.25</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-71" decimals="2" id="f-420" unitRef="number">0.22</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1
      contextRef="c-72"
      decimals="INF"
      id="f-421"
      unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-73" decimals="2" id="f-422" unitRef="number">0.52</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-74" decimals="2" id="f-423" unitRef="number">0.28</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-75" decimals="2" id="f-424" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="c-1" id="f-425">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenue.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Revenue includes sales of LUMRYZ. ASC 606 applies to all contracts with customers, except for contracts that are within the scope of other standards, such as leases, insurance, collaboration arrangements and financial instruments. Under ASC 606, an entity recognizes revenue when the performance obligations to the customer have been satisfied through the transfer of control of the goods or services. To determine the appropriate revenue recognition for arrangements that the Company believes are within the scope of ASC 606, we perform the following five steps: (i) identify the contract(s) with a customer&#x37e; (ii) identify the performance obligations in the contract; (iii) determine the transaction price&#x37e; (iv) allocate the transaction price to the performance obligations in the contract&#x37e; and (v) recognize revenue when (or as) the entity satisfies a performance obligation. The Company applies the five-step model to contracts only when the Company and its customer&#x2019;s rights and obligations under the contract can be determined, the contract has commercial substance, and it is probable that the Company will collect the consideration it is entitled to in exchange for the goods or services it transfers to the customer. For contracts that are determined to be within the scope of ASC 606, the Company identifies the promised goods or services in the contract to determine if they are separate performance obligations or if they should be bundled with other goods and services into a single performance obligation. The Company then recognizes as revenue the amount of the transaction price that is allocated to the respective performance obligation when (or as) the performance obligation is satisfied.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Product Sales&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company sells LUMRYZ to specialty pharmacies and considers those specialty pharmacies to be its customers. Under ASC 606, revenue from product sales is recognized when the customer obtains control of the product, which occurs typically upon receipt by the customer. The Company&#x2019;s gross product sales are subject to a variety of price adjustments to arrive at reported net product revenue. These adjustments include estimates of payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns and are estimated based on contractual arrangements, historical trends, expected utilization of such products and other judgments and analysis.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Reserves for Variable Consideration&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenues from product sales are recorded at the estimated net selling price, which includes reserves for estimated variable consideration to reduce gross product sales to net product revenue resulting from payment discounts, specialty pharmacy fees, patient financial assistance programs, rebates and product returns. These reserves are based on the amounts earned or to be claimed on the related sales and are classified as reductions of accounts receivable if the amount is payable to the customer. The reserves are classified as a liability if the amount is payable to a party other than a customer. Where appropriate, these estimated reserves take into consideration relevant factors such as current contractual and statutory requirements, specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns. Overall, these reserves reflect the Company&#x2019;s best estimates to reduce gross selling price to net selling price. The actual net selling price ultimately may differ from our estimates. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cost of Products Sold. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Cost of products sold includes the cost of the API, manufacturing and distribution costs, packaging costs and freight. LUMRYZ was approved by the FDA on May 1, 2023 and the Company began shipping product to its customers in June 2023. Cost of products sold includes inventory purchased or produced that was expensed as research and development costs prior to FDA approval.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:InventoryPolicyTextBlock contextRef="c-1" id="f-426">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inventories.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Inventories consist of raw materials, work in process and finished products, which are stated at lower of cost or net realizable value, using the first-in, first- out method. Raw materials used in the production of pre-clinical and clinical products are expensed as research and development costs. The Company establishes reserves for inventory estimated to be obsolete, unmarketable or slow-moving on a case by case basis. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company capitalizes inventory costs associated with products when future commercialization is considered probable and the future economic benefit is expected to be realized, which is typically when regulatory approval is obtained for a drug candidate. As such, the Company began capitalizing costs related to inventory in May 2023 upon FDA approval of LUMRYZ. Manufacturing costs associated with inventory purchased or produced prior to FDA approval were recorded as research and development expense in prior periods.&lt;/span&gt;&lt;/div&gt;</us-gaap:InventoryPolicyTextBlock>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-427">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Research and Development (&#x201c;R&amp;amp;D&#x201d;). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;R&amp;amp;D expenses consist primarily of costs related to outside services, personnel expenses, clinical studies and other R&amp;amp;D expenses. Outside services and clinical studies costs relate primarily to services performed by clinical research organizations and related clinical or development manufacturing costs, materials and supplies, filing fees, regulatory support, and other third-party fees. Personnel expenses relate primarily to salaries, benefits and share-based compensation. Other R&amp;amp;D expenses primarily include overhead allocations consisting of various support and facilities-related costs. R&amp;amp;D expenditures are charged to operations as incurred. Raw materials used in the production of pre-clinical and clinical products are expensed as R&amp;amp;D costs.  &#160;&lt;/span&gt;&lt;/div&gt;The Company recognizes refundable R&amp;amp;D tax credits received for spending on innovative R&amp;amp;D as an offset of R&amp;amp;D expenses.</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:AdvertisingCostsPolicyTextBlock contextRef="c-1" id="f-428">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Advertising Expenses. &lt;/span&gt;The Company expenses the costs of advertising as incurred.</us-gaap:AdvertisingCostsPolicyTextBlock>
    <us-gaap:AdvertisingExpense contextRef="c-1" decimals="-3" id="f-429" unitRef="usd">12186000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-4" decimals="-3" id="f-430" unitRef="usd">6452000</us-gaap:AdvertisingExpense>
    <us-gaap:AdvertisingExpense contextRef="c-5" decimals="-3" id="f-431" unitRef="usd">0</us-gaap:AdvertisingExpense>
    <us-gaap:CommitmentsAndContingenciesPolicyTextBlock contextRef="c-1" id="f-432">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Contingencies. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations, cash flows or liquidity.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-433">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Share-based Compensation. &lt;/span&gt;The Company accounts for share-based compensation based on the estimated grant-date fair value. The fair value of stock options is estimated using Black-Scholes option-pricing valuation models (&#x201c;Black-Scholes model&#x201d;). As required by the Black-Scholes model, estimates are made of the underlying volatility of Avadel stock, a risk-free rate and an expected term of the option or warrant. The Company estimates the expected term using a simplified method, as the Company does not have enough historical exercise data for a majority of such options upon which to estimate an expected term. The Company recognizes compensation cost, net of an estimated forfeiture rate, using the accelerated method over the requisite service period of the award.</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-434">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company accounts for income taxes under the asset and liability method, which requires the recognition of deferred tax assets and liabilities for the expected future tax consequences of events that have been included in the financial statements. Under this method, the Company determines deferred tax assets and liabilities on the basis of the differences between the financial statement and tax bases of assets and liabilities by using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect of a change in tax rates on deferred tax assets and liabilities is recognized in income in the period that includes the enactment date.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes deferred tax assets to the extent that the Company believes that these assets are more likely than not to be realized. In making such a determination, the Company considers all available positive and negative evidence, including future reversals of existing taxable temporary differences, projected future taxable income, tax-planning strategies, and results of recent operations. If the Company determines that it would be able to realize its deferred tax assets in the future in excess of their net recorded amount, the Company would make an adjustment to the deferred tax asset valuation allowance, which would reduce the provision for income taxes. As of December&#160;31, 2024, the Company's cumulative loss position was significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company continues to record a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company records uncertain tax positions on the basis of a two-step process in which (1) the Company determines whether it is more likely than not that the tax positions will be sustained on the basis of the technical merits of the position and (2) for those tax positions that meet the more-likely-than-not recognition threshold, the Company recognizes the largest amount of tax benefit that is more than 50 percent likely to be realized upon ultimate settlement with the related tax authority.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties related to unrecognized tax benefits in the income tax expense line in the consolidated statements of loss. Accrued interest and penalties are included on the related tax liability line in the consolidated balance sheets.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-435">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents.&lt;/span&gt; Cash and cash equivalents consist of cash on hand, cash on deposit and fixed term deposits which are highly liquid investments with original maturities of less than three months.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-436">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Marketable Securities. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s marketable securities are considered to be available for sale and are carried at fair value, with unrealized gains and losses, net of taxes, reported as a component of accumulated other comprehensive loss in shareholders&#x2019; equity, with the exception of unrealized gains and losses on equity instruments and allowances for expected credit losses, if any, which are reported in earnings in the current period. The cost of securities sold is based upon the specific identification method.  &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;For available-for-sale debt securities in an unrealized loss position, the Company assesses whether it intends to sell or if it is more likely than not that the Company will be required to sell the security before recovery of its amortized cost basis. If either of the criteria regarding intent or requirement to sell is met, the security&#x2019;s amortized cost basis is written down to fair value. If the criteria are not met, the Company evaluates whether the decline in fair value has resulted from a credit loss or other factors. In making this assessment, management considers, among other factors, the extent to which fair value is less than amortized cost, any changes to the rating of the security by a rating agency, and adverse conditions specifically related to the security. If this assessment indicates that a credit loss exists, the present value of cash flows expected to be collected from the security are compared to the amortized cost basis of the security. If the present value of the cash flows expected to be collected is less than the amortized cost basis, a credit loss exists and an allowance for credit losses is recorded for the credit loss, limited by the amount that the fair value is less than the amortized costs basis.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-437">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Property and Equipment.&lt;/span&gt; Property and equipment is stated at historical cost less accumulated depreciation.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-438">Depreciation and amortization are computed using the straight-line method over the following estimated useful lives:  &lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:77.639%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.161%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Software, office and computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3 years&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Leasehold improvements, furniture, fixtures and fittings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2-10 years&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Property and Equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software, office and computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and fittings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-76" id="f-439">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-77" id="f-440">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-78" id="f-441">P10Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="c-1" id="f-442">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Goodwill.&lt;/span&gt; Goodwill represents the excess of the acquisition consideration over the fair value of assets acquired and liabilities assumed. The Company has determined that it operates in a single segment and have a single reporting unit associated with the development and commercialization of pharmaceutical products. The Company tests goodwill for impairment annually and when events or changes in circumstances indicate that the carrying value may not be recoverable.</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-4" decimals="INF" id="f-443" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:GoodwillImpairmentLoss contextRef="c-1" decimals="INF" id="f-444" unitRef="usd">0</us-gaap:GoodwillImpairmentLoss>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-445">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Long-Lived Assets. &lt;/span&gt;Long-lived assets include fixed assets and right of use assets at contract manufacturing organizations. Long-lived assets are reviewed for impairment whenever conditions indicate that the carrying value of the assets may not be fully recoverable. Such impairment tests are based on a comparison of the pretax undiscounted cash flows expected to be generated by the asset to the recorded value of the asset or other market-based value approaches. If impairment is indicated, the asset value is written down to its market value if readily determinable or its estimated fair value based on discounted cash flows. Any significant changes in business or market conditions that vary from current expectations could have an impact on the fair value of these assets and any potential associated impairment. Certain long-lived assets are amortized using the straight-line method over a five year useful life. Amortization on long-lived assets is considered to be manufacturing overhead costs and is either capitalized into inventory or expensed in the period incurred.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-79" id="f-446">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-1" decimals="INF" id="f-447" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:ImpairmentOfLongLivedAssetsHeldForUse contextRef="c-4" decimals="INF" id="f-448" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsHeldForUse>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-449">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Lease Obligations. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines if a contract is a lease at the inception of the arrangement. Right-of-use assets and operating lease liabilities are recognized at commencement date based on the present value of remaining lease payments over the lease term. For this purpose, the Company considers only payments that are fixed and determinable at the time of commencement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. Short term leases with an initial term of 12 months or less are not recorded on the balance sheet and the associated lease payments are recognized in the consolidated statements of loss on a straight-line basis over the lease term. The Company&#x2019;s lease contracts do not provide a readily determinable implicit rate. The Company&#x2019;s estimated incremental borrowing rate is based on information available at the inception of the lease. The Company&#x2019;s lease agreements may contain variable costs such as common area maintenance, insurance, real estate taxes or other costs. Variable lease costs are expensed as incurred on the consolidated statements of loss.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-450">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Use of Estimates. &lt;/span&gt;The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenues and expenses during the periods presented. These estimates and assumptions are based on the best information available to management and depending on the nature of the estimate can require significant judgments. Changes to these estimates and judgments can have and have had a material impact on the Company&#x2019;s consolidated financial statements. Actual results could differ from those estimates under different assumptions or&#160;conditions.</us-gaap:UseOfEstimates>
    <us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock contextRef="c-1" id="f-451">Newly Issued Accounting Standards&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the provisions of ASU 2023-07 for the annual period beginning on January 1, 2024. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18: Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding segment disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for annual periods beginning after December 15, 2024. Adoption of ASU 2023-09 will not have a material effect on the Company&#x2019;s financial position or results of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact adopting ASU 2024-03 will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Newly Issued Climate-Related Disclosure Rule&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) issued a final rule requiring public companies to disclose climate-related information in their registration statements and annual reports. For large accelerated filers, the initial disclosure rules are effective for annual periods for the year ending December 31, 2025. In April 2024, the SEC voluntarily stayed the final rule pending the completion of judicial review by the Court of Appeals for the Eighth Circuit. The Company is monitoring the development of litigation related to the SEC&#x2019;s rule, and is currently evaluating the effects of the final rule on its disclosures, processes and procedures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsAndChangesInAccountingPrinciplesTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-452">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Guidance&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Financial Accounting Standards Board (&#x201c;FASB&#x201d;) issued Accounting Standards Update (&#x201c;ASU&#x201d;) 2023-07, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. The ASU is effective for annual periods beginning after December 15, 2023, and interim periods within fiscal years beginning after December 15, 2024. The Company adopted the provisions of ASU 2023-07 for the annual period beginning on January 1, 2024. See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 18: Segment Information&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding segment disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recent Accounting Guidance Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2023, the FASB issued ASU 2023-09, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Taxes (Topic 740): Improvements to Income Tax Disclosures, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;to enhance the transparency and decision usefulness of income tax disclosures. The ASU is effective for annual periods beginning after December 15, 2024. Adoption of ASU 2023-09 will not have a material effect on the Company&#x2019;s financial position or results of operations.  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2024, the FASB issued ASU 2024-03, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, to require disclosure, in the notes to financial statements, of specified information about certain costs and expenses. The ASU is effective for annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027. The requirements will be applied prospectively with the option for retrospective application. The Company is currently evaluating the impact adopting ASU 2024-03 will have on its financial statement disclosures.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Newly Issued Climate-Related Disclosure Rule&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, the U.S. Securities and Exchange Commission (&#x201c;SEC&#x201d;) issued a final rule requiring public companies to disclose climate-related information in their registration statements and annual reports. For large accelerated filers, the initial disclosure rules are effective for annual periods for the year ending December 31, 2025. In April 2024, the SEC voluntarily stayed the final rule pending the completion of judicial review by the Court of Appeals for the Eighth Circuit. The Company is monitoring the development of litigation related to the SEC&#x2019;s rule, and is currently evaluating the effects of the final rule on its disclosures, processes and procedures.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:RevenueFromContractWithCustomerTextBlock contextRef="c-1" id="f-453">Revenue Recognition&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s source of net product revenue during the years&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ended &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; consists solely of sales of LUMRYZ in the U.S.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:12pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2024 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#0d0d0d;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, three customers accounted for 100% of sales. The following table presents a summary of the percentage of total gross sales to customers&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sales by Customer:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Caremark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accredo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had no net product revenue during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-80" decimals="2" id="f-454" unitRef="number">1</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock contextRef="c-1" id="f-455">The following table presents a summary of the percentage of total gross sales to customers&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:53.870%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:20.687%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Sales by Customer:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Caremark&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;44&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;39&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accredo&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Optum&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-81" decimals="2" id="f-456" unitRef="number">0.44</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-82" decimals="2" id="f-457" unitRef="number">0.39</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-83" decimals="2" id="f-458" unitRef="number">0.37</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-84" decimals="2" id="f-459" unitRef="number">0.41</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-85" decimals="2" id="f-460" unitRef="number">0.19</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-86" decimals="2" id="f-461" unitRef="number">0.20</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-462">Fair Value Measurements&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to measure certain assets and liabilities at fair value, either upon initial recognition or for subsequent accounting or reporting. For example, the Company uses fair value extensively when accounting for and reporting certain financial instruments, when measuring certain contingent consideration liabilities and in the initial recognition of net assets acquired in a business combination. Fair value is estimated by applying the hierarchy described below, which prioritizes the inputs used to measure fair value into three levels and bases the categorization within the hierarchy upon the lowest level of input that is available and significant to the fair value measurement.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ASC 820, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fair Value Measurements and Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;,&#160;defines fair value as a market-based measurement that should be determined based on the assumptions that marketplace participants would use in pricing an asset or liability. When estimating fair value, depending on the nature and complexity of the asset or liability, the Company may generally use one or each of the following techniques: &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Income approach, which is based on the present value of a future stream of net cash flows. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Market approach, which is based on market prices and other information from market transactions involving identical or comparable assets or liabilities.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a basis for considering the assumptions used in these techniques, the standard establishes a three-tier fair value hierarchy which prioritizes the inputs used in measuring fair value as follows: &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 1 - Quoted prices for identical assets or liabilities in active markets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 2 - Quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are directly or indirectly observable, or inputs that are derived principally from, or corroborated by, observable market data by correlation or other means. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;Level 3 - Unobservable inputs that reflect estimates and assumptions. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Note 5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A review of fair value hierarchy classifications is conducted on a quarterly basis.&#160;Changes in the observability of valuation inputs may result in a reclassification for certain financial assets or liabilities. During the year ended December&#160;31, 2024, there were no transfers in and out of&#160;Level&#160;1, 2, or 3. During the&#160;years ended December&#160;31, 2024, 2023, and 2022, the Company did not recognize any allowances for credit losses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Some of the Company&#x2019;s financial instruments, such as cash and cash equivalents, accounts receivable and accounts payable, are reflected in the consolidated balance sheets at carrying value, which approximates fair value due to their short-term nature. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Royalty Financing Obligation&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024 and 2023, the carrying value of the royalty financing obligation under the Royalty Purchase Agreement (&#x201c;RPA&#x201d;) approximated its fair value and was measured using the estimates of forecasted net product revenue based on current contractual and statutory requirements, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;specific known market events and trends, industry data, historical trends, current and expected patient demand and forecasted customer buying and payment patterns (Level 3 inputs). &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;See &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Note 10: Royalty Financing Obligation&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for additional information regarding the Company&#x2019;s royalty financing obligation.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock contextRef="c-1" id="f-463">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the financial instruments measured at fair value on a recurring basis classified in the fair value hierarchy (Level 1, 2 or 3) based on the inputs used for valuation in the accompanying consolidated balance sheets:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:35.649%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.709%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:8.714%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;As of December&#160;31, 2023&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value Measurements:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Level 3&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Marketable securities (see &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-style:italic;font-weight:400;line-height:100%"&gt;Note 5)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-3" id="f-464" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-3" id="f-465" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-3" id="f-466" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-3" id="f-467" unitRef="usd">73944000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-3" id="f-468" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-3" id="f-469" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-93" decimals="-3" id="f-470" unitRef="usd">22406000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-94" decimals="-3" id="f-471" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-95" decimals="-3" id="f-472" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-96" decimals="-3" id="f-473" unitRef="usd">73944000</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-97" decimals="-3" id="f-474" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:AssetsFairValueDisclosure contextRef="c-98" decimals="-3" id="f-475" unitRef="usd">0</us-gaap:AssetsFairValueDisclosure>
    <us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock contextRef="c-1" id="f-476">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities&#160;&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has investments in available-for-sale debt securities that are recorded at fair market value. The change in the fair value of available-for-sale debt investments is recorded as accumulated other comprehensive loss in shareholders&#x2019; equity, net of &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;income tax effects. As of December&#160;31, 2024 and 2023, the Company considered any decreases in fair value on its marketable securities to be driven by factors other than credit risk, including market risk.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s available-for-sale securities&#x2019; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines realized gains or losses on the sale of marketable securities on a specific identification method. The Company reflects these gains and losses as a component of investment and other income (expense), net in the accompanying consolidated statements of loss.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognized gross realized gains of&#160;&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1,625,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $988 and $584 for the&#160;years ended December&#160;31, 2024, 2023 and 2022, respectively. These realized gains were offset by no gross realized losses for the year ended December&#160;31, 2024 and gross realized losses of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$2,791 and $2,338 for the years ended December&#160;31, 2023 and 2022, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of the Company&#x2019;s investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1-5 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5-10 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Greater than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has classified its investment in available-for-sale marketable debt securities as current assets in the consolidated balance sheets as the securities need to be available for use, if required, to fund current operations. There are no restrictions on the sale of any securities in the Company&#x2019;s investment portfolio.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashCashEquivalentsAndMarketableSecuritiesTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-477">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following tables show the Company&#x2019;s available-for-sale securities&#x2019; adjusted cost, gross unrealized gains, gross unrealized losses and fair value by significant investment category as of&#160;December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:15pt;margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.73pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,242&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:44.861%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.675%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="21" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Adjusted Cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Gains&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Unrealized Losses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 6.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;72,990&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;73,944&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-99" decimals="-3" id="f-478" unitRef="usd">22242000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-99" decimals="-3" id="f-479" unitRef="usd">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-99" decimals="-3" id="f-480" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="-3" id="f-481" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-6" decimals="-3" id="f-482" unitRef="usd">22242000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-6" decimals="-3" id="f-483" unitRef="usd">164000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-6" decimals="-3" id="f-484" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-485" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-100" decimals="-3" id="f-486" unitRef="usd">72990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-100" decimals="-3" id="f-487" unitRef="usd">954000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-100" decimals="-3" id="f-488" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-100" decimals="-3" id="f-489" unitRef="usd">73944000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-7" decimals="-3" id="f-490" unitRef="usd">72990000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-7" decimals="-3" id="f-491" unitRef="usd">954000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-7" decimals="-3" id="f-492" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-7" decimals="-3" id="f-493" unitRef="usd">73944000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-1" decimals="-3" id="f-494" unitRef="usd">1625000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-4" decimals="-3" id="f-495" unitRef="usd">988000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain contextRef="c-5" decimals="-3" id="f-496" unitRef="usd">584000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-1" decimals="-3" id="f-497" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-4" decimals="-3" id="f-498" unitRef="usd">2791000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss contextRef="c-5" decimals="-3" id="f-499" unitRef="usd">2338000</us-gaap:DebtSecuritiesAvailableForSaleRealizedLoss>
    <us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock contextRef="c-1" id="f-500">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the estimated fair value of the Company&#x2019;s investments in marketable debt securities, accounted for as available-for-sale debt securities and classified by the contractual maturity date of the securities as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:33.554%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.234%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.240%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturities&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Marketable Debt Securities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Less than 1 Year&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;1-5 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;5-10 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Greater than 10 Years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Government securities - U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;22,406&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InvestmentsClassifiedByContractualMaturityDateTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-99" decimals="-3" id="f-501" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-99" decimals="-3" id="f-502" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-99" decimals="-3" id="f-503" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-99" decimals="-3" id="f-504" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-99" decimals="-3" id="f-505" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue contextRef="c-6" decimals="-3" id="f-506" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue contextRef="c-6" decimals="-3" id="f-507" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughFiveYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue contextRef="c-6" decimals="-3" id="f-508" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterFiveThroughTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue contextRef="c-6" decimals="-3" id="f-509" unitRef="usd">0</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesAfterTenYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-6" decimals="-3" id="f-510" unitRef="usd">22406000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:InventoryDisclosureTextBlock contextRef="c-1" id="f-511">Inventories&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal categories of inventories at December&#160;31, 2024 and 2023 were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="c-1" id="f-512">&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal categories of inventories at December&#160;31, 2024 and 2023 were comprised of the following:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.269%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.251%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.487%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.536%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.490%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Inventory:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Raw materials and supplies&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,199&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Work in process&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Finished goods&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,136&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,052&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,298&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-6" decimals="-3" id="f-513" unitRef="usd">5199000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves contextRef="c-7" decimals="-3" id="f-514" unitRef="usd">5291000</us-gaap:InventoryRawMaterialsAndSuppliesNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-6" decimals="-3" id="f-515" unitRef="usd">4963000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryWorkInProcessNetOfReserves contextRef="c-7" decimals="-3" id="f-516" unitRef="usd">2037000</us-gaap:InventoryWorkInProcessNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-6" decimals="-3" id="f-517" unitRef="usd">10136000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="c-7" decimals="-3" id="f-518" unitRef="usd">3052000</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="c-6" decimals="-3" id="f-519" unitRef="usd">20298000</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="c-7" decimals="-3" id="f-520" unitRef="usd">10380000</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-521">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property and Equipment, net&lt;/span&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The principal categories of property and equipment, net at December&#160;31, 2024 and 2023 are as&#160;follows:&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:66.103%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.567%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Property and Equipment, net:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Software, office and computer equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;832&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Furniture, fixtures and fittings&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;634&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less - accumulated depreciation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,013)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(881)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;453&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;585&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;Depreciation expense for the years ended December&#160;31, 2024, 2023 and 2022 was $132, $254 and $162, respectively.</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-76" decimals="-3" id="f-522" unitRef="usd">832000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-101" decimals="-3" id="f-523" unitRef="usd">832000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-102" decimals="-3" id="f-524" unitRef="usd">634000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-103" decimals="-3" id="f-525" unitRef="usd">634000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-3" id="f-526" unitRef="usd">1013000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-7" decimals="-3" id="f-527" unitRef="usd">881000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-3" id="f-528" unitRef="usd">453000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-7" decimals="-3" id="f-529" unitRef="usd">585000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:Depreciation contextRef="c-1" decimals="-3" id="f-530" unitRef="usd">132000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-4" decimals="-3" id="f-531" unitRef="usd">254000</us-gaap:Depreciation>
    <us-gaap:Depreciation contextRef="c-5" decimals="-3" id="f-532" unitRef="usd">162000</us-gaap:Depreciation>
    <us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock contextRef="c-1" id="f-533">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Goodwill &lt;/span&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s goodwill is $16,836 at December&#160;31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;No impairment loss related to goodwill was recognized during the years ended December&#160;31, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:GoodwillAndIntangibleAssetsDisclosureTextBlock>
    <us-gaap:Goodwill contextRef="c-7" decimals="-3" id="f-534" unitRef="usd">16836000</us-gaap:Goodwill>
    <us-gaap:Goodwill contextRef="c-6" decimals="-3" id="f-535" unitRef="usd">16836000</us-gaap:Goodwill>
    <us-gaap:AssetImpairmentCharges contextRef="c-1" decimals="INF" id="f-536" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:AssetImpairmentCharges contextRef="c-4" decimals="INF" id="f-537" unitRef="usd">0</us-gaap:AssetImpairmentCharges>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-538">Leases&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company leases office space and a production suite. All leased facilities are classified as operating leases with remaining lease terms between&#160;&lt;span style="-sec-ix-hidden:f-539"&gt;one&lt;/span&gt;&#160;and&#160;four years. The Company determines if a contract is a lease at the inception of the arrangement. The Company reviews all options to extend, terminate, or purchase its right-of-use assets at the inception of the lease and will include these options in the lease term when they are reasonably certain of being exercised. The Company&#x2019;s lease agreements do not contain any material residual value guarantees or material variable lease payments. For the Company&#x2019;s leased production suite, contract consideration was allocated to lease and non-lease components on the basis of relative standalone price. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs, which are included in selling, general and administrative expenses in the consolidated statements of loss for the years ended December&#160;31, 2024, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2024, the Company reduced its operating lease liabilities by $1,091 for cash paid. During the year ended December&#160;31, 2023, the Company increased its operating lease liabilities by $1,803 due to an increase in the lease term for the production suite, offset by $1,036 for cash paid. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company&#x2019;s operating leases have a weighted-average remaining lease term of&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; 3.3 years&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and a weighted-average discount rate of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;8.4%&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company&#x2019;s lease contracts do not provide a readily determinable implicit rate. The Company&#x2019;s estimated incremental borrowing rate is based on information available at the inception of the lease.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s operating lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseTermOfContract contextRef="c-105" id="f-540">P4Y</us-gaap:LesseeOperatingLeaseTermOfContract>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-541">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease costs, which are included in selling, general and administrative expenses in the consolidated statements of loss for the years ended December&#160;31, 2024, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.707%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:42.888%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.935%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.386%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.937%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Lease cost:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating lease costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,058&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,039&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Sublease income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(128)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(123)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(116)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease cost&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;930&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;916&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;912&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-3" id="f-542" unitRef="usd">1058000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-4" decimals="-3" id="f-543" unitRef="usd">1039000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-5" decimals="-3" id="f-544" unitRef="usd">1028000</us-gaap:OperatingLeaseCost>
    <us-gaap:SubleaseIncome contextRef="c-1" decimals="-3" id="f-545" unitRef="usd">128000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-4" decimals="-3" id="f-546" unitRef="usd">123000</us-gaap:SubleaseIncome>
    <us-gaap:SubleaseIncome contextRef="c-5" decimals="-3" id="f-547" unitRef="usd">116000</us-gaap:SubleaseIncome>
    <us-gaap:LeaseCost contextRef="c-1" decimals="-3" id="f-548" unitRef="usd">930000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-4" decimals="-3" id="f-549" unitRef="usd">916000</us-gaap:LeaseCost>
    <us-gaap:LeaseCost contextRef="c-5" decimals="-3" id="f-550" unitRef="usd">912000</us-gaap:LeaseCost>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-3" id="f-551" unitRef="usd">1091000</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-4" decimals="-3" id="f-552" unitRef="usd">1803000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeasePayments contextRef="c-4" decimals="-3" id="f-553" unitRef="usd">1036000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-6" id="f-554">P3Y3M18D</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-6" decimals="3" id="f-555" unitRef="number">0.084</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-556">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of the Company&#x2019;s operating lease liabilities are as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:80.076%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.989%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Maturities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Operating Leases&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;683&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;477&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;316&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,953&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(249)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Present value of lease liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,704&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-6" decimals="-3" id="f-557" unitRef="usd">683000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-6" decimals="-3" id="f-558" unitRef="usd">477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-6" decimals="-3" id="f-559" unitRef="usd">477000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-6" decimals="-3" id="f-560" unitRef="usd">316000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <avdl:OperatingLeaseLiabilityToBePaidAfterYearFour contextRef="c-6" decimals="-3" id="f-561" unitRef="usd">0</avdl:OperatingLeaseLiabilityToBePaidAfterYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-6" decimals="-3" id="f-562" unitRef="usd">1953000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-6" decimals="-3" id="f-563" unitRef="usd">249000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-6" decimals="-3" id="f-564" unitRef="usd">1704000</us-gaap:OperatingLeaseLiability>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-565">Royalty Financing Obligation&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 29, 2023, the Company and Avadel CNS Pharmaceuticals, LLC entered into the RPA with RTW Investments, L.P. (&#x201c;RTW&#x201d;) for up to $75,000 of royalty financing in two tranches. The first tranche of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$30,000&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; became available upon satisfaction of certain conditions which included the Company&#x2019;s first shipment of LUMRYZ. The second tranche became available to use, at the Company&#x2019;s election, when the Company achieved quarterly net revenue of $25,000 prior to the quarter ending June 30, 2024. The Company allowed the second tranche to expire on August 31, 2024 and paid a one-time commitment fee of $2,000 to RTW in accordance with the terms of the RPA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 1, 2023, the Company received the first tranche of $30,000. The Company is required to make quarterly royalty payments calculated as 3.75% of worldwide net product revenue of LUMRYZ, up to a total payback of $75,000. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The RPA is recorded as a royalty financing obligation on the consolidated balance sheets based on the Company&#x2019;s evaluation of the terms of the RPA. The accounts receivable and inventory balances of LUMRYZ are pledged as collateral for the RPA. There are no subjective acceleration clauses or provisions, and there are no covenants in violation or other clauses that would cause the full amount of the royalty financing obligation to be callable. As such, the RPA is recorded as a long-term obligation on the consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company imputes interest using the effective interest method and records interest expense based on the unamortized royalty financing obligation. The Company&#x2019;s estimate of the interest rate under the RPA is based primarily on forecasted net revenue and the calculated amounts and timing of net royalty payments to reach the total payback of $75,000. As of December&#160;31, 2024 and December&#160;31, 2023 the effective interest rate is estimated as 25.2% and 30.4%, respectively. The Company accounts for changes in the imputed interest rate resulting from changes in forecasted net product revenue using the prospective method. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following table shows the activity within the royalty financing obligation account:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty Financing Obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receipt of the first tranche of the royalty financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of imputed interest expense on royalty financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: royalty payments made to RTW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: one-time payment for expiration of second tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: royalty payable to RTW classified within accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The accretion of imputed interest expense is reflected as interest expense in the consolidated statements of loss. For the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, the total interest expense related to the royalty financing obligation was $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;10,830&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and $&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;3,743, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;respectively. The remaining interest expense incurred for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2023 was related to &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;the 4.50% exchangeable senior notes due February 2023 (&#x201c;February 2023 Notes&#x201d;) and the 4.50%  exchangeable senior notes due October 2023 (&#x201c;October 2023 Notes&#x201d;, together, the &#x201c;2023 Notes&#x201d;). The Company had no interest expense related to the royalty financing obligation during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <avdl:RoyaltyFinancingProceedsMaximum contextRef="c-106" decimals="-3" id="f-566" unitRef="usd">75000000</avdl:RoyaltyFinancingProceedsMaximum>
    <avdl:DebtInstrumentNumberOfTranches
      contextRef="c-107"
      decimals="INF"
      id="f-567"
      unitRef="tranche">2</avdl:DebtInstrumentNumberOfTranches>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-108" decimals="-3" id="f-568" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <avdl:RoyaltyFinancingQuarterlyNetRevenueTarget contextRef="c-109" decimals="-3" id="f-569" unitRef="usd">25000</avdl:RoyaltyFinancingQuarterlyNetRevenueTarget>
    <avdl:PaymentsForRoyaltyOneTimeCommitmentFee contextRef="c-110" decimals="-3" id="f-570" unitRef="usd">2000</avdl:PaymentsForRoyaltyOneTimeCommitmentFee>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-108" decimals="-3" id="f-571" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <avdl:RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage contextRef="c-106" decimals="4" id="f-572" unitRef="number">0.0375</avdl:RoyaltyFinancingQuarterlyRoyaltyPaymentPercentage>
    <avdl:RoyaltyFinancingProceedsMaximum contextRef="c-106" decimals="-3" id="f-573" unitRef="usd">75000000</avdl:RoyaltyFinancingProceedsMaximum>
    <avdl:RoyaltyFinancingProceedsMaximum contextRef="c-106" decimals="-3" id="f-574" unitRef="usd">75000000</avdl:RoyaltyFinancingProceedsMaximum>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-111" decimals="3" id="f-575" unitRef="number">0.252</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:DebtInstrumentInterestRateEffectivePercentage contextRef="c-112" decimals="3" id="f-576" unitRef="number">0.304</us-gaap:DebtInstrumentInterestRateEffectivePercentage>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-577">&lt;div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:107%"&gt;The following table shows the activity within the royalty financing obligation account:&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.549%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.344%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:18.347%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Royalty Financing Obligation:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation &#x2013; beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Receipt of the first tranche of the royalty financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,000&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accretion of imputed interest expense on royalty financing obligation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,830&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,743&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: royalty payments made to RTW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,181)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(253)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: one-time payment for expiration of second tranche&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,000)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation &#x2013; ending balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;37,139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;33,490&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: royalty payable to RTW classified within accrued expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,890)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(730)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty financing obligation, non-current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;35,249&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,760&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:LongTermDebt contextRef="c-112" decimals="-3" id="f-578" unitRef="usd">33490000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-113" decimals="-3" id="f-579" unitRef="usd">0</us-gaap:LongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-114" decimals="-3" id="f-580" unitRef="usd">0</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:ProceedsFromIssuanceOfLongTermDebt contextRef="c-115" decimals="-3" id="f-581" unitRef="usd">30000000</us-gaap:ProceedsFromIssuanceOfLongTermDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-114" decimals="-3" id="f-582" unitRef="usd">10830000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-115" decimals="-3" id="f-583" unitRef="usd">3743000</us-gaap:InterestExpenseDebt>
    <avdl:RepaymentOfRoyaltyLiability contextRef="c-114" decimals="-3" id="f-584" unitRef="usd">5181000</avdl:RepaymentOfRoyaltyLiability>
    <avdl:RepaymentOfRoyaltyLiability contextRef="c-115" decimals="-3" id="f-585" unitRef="usd">253000</avdl:RepaymentOfRoyaltyLiability>
    <avdl:PaymentsForRoyaltyOneTimeCommitmentFee contextRef="c-1" decimals="-3" id="f-586" unitRef="usd">2000000</avdl:PaymentsForRoyaltyOneTimeCommitmentFee>
    <avdl:PaymentsForRoyaltyOneTimeCommitmentFee contextRef="c-4" decimals="-3" id="f-587" unitRef="usd">0</avdl:PaymentsForRoyaltyOneTimeCommitmentFee>
    <us-gaap:LongTermDebt contextRef="c-111" decimals="-3" id="f-588" unitRef="usd">37139000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-112" decimals="-3" id="f-589" unitRef="usd">33490000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-111" decimals="-3" id="f-590" unitRef="usd">1890000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-112" decimals="-3" id="f-591" unitRef="usd">730000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-111" decimals="-3" id="f-592" unitRef="usd">35249000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-112" decimals="-3" id="f-593" unitRef="usd">32760000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:InterestExpenseDebt contextRef="c-114" decimals="-3" id="f-594" unitRef="usd">10830000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-115" decimals="-3" id="f-595" unitRef="usd">3743000</us-gaap:InterestExpenseDebt>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-116" decimals="4" id="f-596" unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-117" decimals="4" id="f-597" unitRef="number">0.0450</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:InterestExpenseDebt contextRef="c-118" decimals="-3" id="f-598" unitRef="usd">0</us-gaap:InterestExpenseDebt>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-599">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes&lt;/span&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income taxes for the following years ended December 31, are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Loss Before Income Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax (benefit) provision consists of the following for the years ended December 31:&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Income Tax (Benefit) Provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between income taxes at the statutory rate and the Company&#x2019;s (benefit) provision for income taxes is as follows for the following years ended December 31:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Reconciliation to Effective Income Tax Rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision - at statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differences in international tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Return to Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local taxes (net of federal)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan drug and R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision - at effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2024, the income tax benefit was $247, a decrease of $254 from income tax benefit of $501. The change in the effective tax rate for the year ended December 31, 2024 is primarily driven by the reversal of unrecognized tax benefits during the year. The effective tax rate for 2022 was impacted by the valuation allowance.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Unrecognized Tax Benefits&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company or one of its subsidiaries files income tax returns in Ireland, France, U.S. and various states. The Company is no longer subject to Irish, French, U.S. Federal, and state and local examinations for years before 2020. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Unrecognized Tax Benefit Activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statute of limitations expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expects that within the next twelve months the unrecognized tax benefits could decrease by approximately $1,637 and the interest could increase by an immaterial amount.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, 2023 and 2022, there are $2,724, $3,035,and $3,143 of unrecognized tax benefits that if recognized would affect the annual effective tax rate.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest and penalties accrued related to unrecognized tax benefits in income tax provision. During the years ended December&#160;31, 2024, 2023 and 2022, the Company recognized approximately $56, $268 and $258 in interest and penalties, respectively. The Company had approximately $2,427 and $2,372 for the payment of interest and penalties accrued at December&#160;31, 2024 and 2023, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Deferred Tax Assets (Liabilities)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income tax provisions reflect the effect of temporary differences between consolidated financial statement and tax reporting of income and expense items. The net deferred tax assets (liabilities) at December&#160;31, 2024 and 2023 resulted from the following temporary differences:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Net Deferred Tax Assets and Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserves and Other Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan drug and R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the Company had &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$71,588&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of net operating losses in Ireland that do not have an expiration date and $227,344 of net operating losses and $5,809 163(j) carryforwards in the U.S. Of the $227,344 of net operating losses in the U.S., $10,365 were acquired due to the acquisition of FSC Therapeutics and FSC Laboratories, Inc., (collectively &#x201c;FSC&#x201d;) and $212,637 are due to the losses at US Holdings, of which $4,342 are state net operating losses. The portion due to the acquisition of FSC will expire in 2034 through 2035. The remaining U.S. net operating loss and 163(j) carryforwards do not have an expiration date. A valuation allowance is recorded if, based on the weight of available evidence, it is more likely than not that a deferred tax asset will not be realized. This assessment is based on an evaluation of the level of historical taxable income and projections for future taxable income. For the year ended December&#160;31, 2024, the Company recorded a net increase to the valuation allowance related primarily to current year net operating losses of $5,137. The U.S. net operating losses are subject to an annual limitation as a result of the FSC acquisition under Internal Revenue Code Section 382 and will not be fully utilized before they expire. In addition to net operating losses and 163(j) carryforwards, the Company has U.S. Orphan Drug tax credit carryforwards of $3,059 as well as U.S. Research and Development credits of $1,036. The Orphan Drug Credit and Research and Development credits will expire in 2040 through 2044. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's cumulative loss position is significant negative evidence in assessing the need for a valuation allowance on its deferred tax assets. Given the weight of objectively verifiable historical losses from operations, the Company has recorded a full valuation allowance on its deferred tax assets. The Company will be able to reverse the valuation allowance when it has shown its ability to generate taxable income on a consistent basis in future periods. The valuation allowance does not have an impact on the Company's ability to utilize any net operating losses or other tax attributes to offset cash taxes payable as these items are still eligible to be used.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recorded a valuation allowance against all of its net operating losses in Ireland, France and the U.S. as of December&#160;31, 2024 and 2023. The Company intends to continue maintaining a full valuation allowance on the Irish, French and U.S. net operating losses until there is sufficient evidence to support the reversal of all or some portion of these allowances.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, the Company has unremitted earnings of $3,755 outside of Ireland as measured on a U.S. GAAP basis.  Whereas the measure of earnings for purposes of taxation of a distribution may be different for tax purposes, these earnings, which are considered to be invested indefinitely, would become subject to income tax if they were remitted as dividends or if the Company were to sell its stock in the subsidiaries, net of any prior income taxes paid. It is not practicable to estimate the amount of deferred tax liability on such earnings, if any.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;R&amp;amp;D Tax Credits Receivable&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The French and Irish governments provide tax credits to companies for spending on innovative R&amp;amp;D. These credits are recorded as an offset of R&amp;amp;D expenses and are credited against income taxes payable in years after being incurred or, if not so utilized, are recoverable in cash after a specified period of time, which may differ depending on the tax credit regime. As of December&#160;31, 2024, the Company&#x2019;s net research tax credit receivable amounts to $587 and represents an Irish gross research tax credit. As of December&#160;31, 2023, the Company&#x2019;s net research tax credit receivable amounts to $1,654 and represents a French gross research tax credit of $837 and an Irish gross research tax credit of $817.</us-gaap:IncomeTaxDisclosureTextBlock>
    <avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock contextRef="c-1" id="f-600">&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of loss before income taxes for the following years ended December 31, are as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Loss Before Income Taxes:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Europe&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(3,708)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45,835)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(53,684)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(45,371)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(114,942)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(57,755)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avdl:ScheduleOfComponentsOfIncomeBeforeIncomeTaxTableTextBlock>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-119" decimals="-3" id="f-601" unitRef="usd">-3708000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-120" decimals="-3" id="f-602" unitRef="usd">-45835000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-121" decimals="-3" id="f-603" unitRef="usd">-53684000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-122" decimals="-3" id="f-604" unitRef="usd">-45371000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-123" decimals="-3" id="f-605" unitRef="usd">-114942000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-124" decimals="-3" id="f-606" unitRef="usd">-57755000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-1" decimals="-3" id="f-607" unitRef="usd">-49079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-4" decimals="-3" id="f-608" unitRef="usd">-160777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-5" decimals="-3" id="f-609" unitRef="usd">-111439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <avdl:ScheduleOfIncomeTaxPaymentsTableTextBlock contextRef="c-1" id="f-610">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The income tax (benefit) provision consists of the following for the years ended December 31:&#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Income Tax (Benefit) Provision:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(661)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;25,896&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S. - State&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;129&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:15pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avdl:ScheduleOfIncomeTaxPaymentsTableTextBlock>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-611" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-612" unitRef="usd">-661000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-613" unitRef="usd">0</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-614" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-615" unitRef="usd">-661000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-616" unitRef="usd">0</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-617" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-618" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-619" unitRef="usd">25896000</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-620" unitRef="usd">-247000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-621" unitRef="usd">160000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-622" unitRef="usd">129000</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-623" unitRef="usd">-247000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-624" unitRef="usd">160000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-625" unitRef="usd">26025000</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-626" unitRef="usd">-247000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-627" unitRef="usd">-501000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-628" unitRef="usd">26025000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-629">&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The reconciliation between income taxes at the statutory rate and the Company&#x2019;s (benefit) provision for income taxes is as follows for the following years ended December 31:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Reconciliation to Effective Income Tax Rate:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision - at statutory tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,135)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(20,097)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,916)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Differences in international tax rates&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2,991)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,635)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,921)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Return to Provision&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,632&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Change in valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,982&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,332&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,444&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;798&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,424&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized tax benefits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(218)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;160&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;258&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;State and local taxes (net of federal)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;778&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(5,614)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4,467)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Nondeductible interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(848)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,362&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan drug and R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(30)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;899&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;139&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;438&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(225)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Income tax (benefit) provision - at effective income tax rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(247)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(501)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;26,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-3" id="f-630" unitRef="usd">-6135000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-4" decimals="-3" id="f-631" unitRef="usd">-20097000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-5" decimals="-3" id="f-632" unitRef="usd">-13916000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-1" decimals="-3" id="f-633" unitRef="usd">-2991000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-4" decimals="-3" id="f-634" unitRef="usd">-6635000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential contextRef="c-5" decimals="-3" id="f-635" unitRef="usd">-9921000</us-gaap:IncomeTaxReconciliationForeignIncomeTaxRateDifferential>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-1" decimals="-3" id="f-636" unitRef="usd">2632000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-4" decimals="-3" id="f-637" unitRef="usd">856000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes contextRef="c-5" decimals="-3" id="f-638" unitRef="usd">-101000</us-gaap:IncomeTaxReconciliationPriorYearIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-3" id="f-639" unitRef="usd">4982000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-4" decimals="-3" id="f-640" unitRef="usd">24332000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-3" id="f-641" unitRef="usd">48734000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-3" id="f-642" unitRef="usd">1444000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-4" decimals="-3" id="f-643" unitRef="usd">798000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-5" decimals="-3" id="f-644" unitRef="usd">1424000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-1" decimals="-3" id="f-645" unitRef="usd">-218000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-4" decimals="-3" id="f-646" unitRef="usd">160000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationTaxContingencies contextRef="c-5" decimals="-3" id="f-647" unitRef="usd">258000</us-gaap:IncomeTaxReconciliationTaxContingencies>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-3" id="f-648" unitRef="usd">778000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-4" decimals="-3" id="f-649" unitRef="usd">-5614000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-5" decimals="-3" id="f-650" unitRef="usd">-4467000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount contextRef="c-1" decimals="-3" id="f-651" unitRef="usd">-848000</avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount>
    <avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount contextRef="c-4" decimals="-3" id="f-652" unitRef="usd">4362000</avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount>
    <avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount contextRef="c-5" decimals="-3" id="f-653" unitRef="usd">4239000</avdl:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseInterestExpenseAmount>
    <avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit contextRef="c-1" decimals="-3" id="f-654" unitRef="usd">30000</avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit>
    <avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit contextRef="c-4" decimals="-3" id="f-655" unitRef="usd">-899000</avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit>
    <avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit contextRef="c-5" decimals="-3" id="f-656" unitRef="usd">0</avdl:EffectiveIncomeTaxRateReconciliationAmountOrphanDrugAndResearchAndDevelopmentTaxCredit>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-1" decimals="-3" id="f-657" unitRef="usd">139000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-4" decimals="-3" id="f-658" unitRef="usd">438000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxReconciliationOtherReconcilingItems contextRef="c-5" decimals="-3" id="f-659" unitRef="usd">-225000</us-gaap:IncomeTaxReconciliationOtherReconcilingItems>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-660" unitRef="usd">-247000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-661" unitRef="usd">-501000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-5" decimals="-3" id="f-662" unitRef="usd">26025000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-663" unitRef="usd">-247000</us-gaap:IncomeTaxExpenseBenefit>
    <avdl:IncreaseDecreaseInIncomeTaxExpenseBenefit contextRef="c-1" decimals="-3" id="f-664" unitRef="usd">-254000</avdl:IncreaseDecreaseInIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-4" decimals="-3" id="f-665" unitRef="usd">-501000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-666">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the activity related to the Company&#x2019;s unrecognized tax benefits for the years ended December 31:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.826%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.859%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.860%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Unrecognized Tax Benefit Activity&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at January 1: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Increases for tax positions of prior years&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Statute of limitations expiration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(311)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(108)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Settlements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,724&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,035&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3,143&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-667" unitRef="usd">3035000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-3" id="f-668" unitRef="usd">3143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-3" id="f-669" unitRef="usd">3143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c-1" decimals="-3" id="f-670" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c-4" decimals="-3" id="f-671" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease contextRef="c-5" decimals="-3" id="f-672" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsPeriodIncreaseDecrease>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-1" decimals="-3" id="f-673" unitRef="usd">311000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-4" decimals="-3" id="f-674" unitRef="usd">108000</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations contextRef="c-5" decimals="-3" id="f-675" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsReductionsResultingFromLapseOfApplicableStatuteOfLimitations>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-1" decimals="-3" id="f-676" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-4" decimals="-3" id="f-677" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities contextRef="c-5" decimals="-3" id="f-678" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsDecreasesResultingFromSettlementsWithTaxingAuthorities>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-3" id="f-679" unitRef="usd">2724000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-7" decimals="-3" id="f-680" unitRef="usd">3035000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-24" decimals="-3" id="f-681" unitRef="usd">3143000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible contextRef="c-6" decimals="-3" id="f-682" unitRef="usd">1637000</us-gaap:DecreaseInUnrecognizedTaxBenefitsIsReasonablyPossible>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-6" decimals="-3" id="f-683" unitRef="usd">2724000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-7" decimals="-3" id="f-684" unitRef="usd">3035000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate contextRef="c-24" decimals="-3" id="f-685" unitRef="usd">3143000</us-gaap:UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-1" decimals="-3" id="f-686" unitRef="usd">56000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-4" decimals="-3" id="f-687" unitRef="usd">268000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense contextRef="c-5" decimals="-3" id="f-688" unitRef="usd">258000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="-3" id="f-689" unitRef="usd">2427000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-7" decimals="-3" id="f-690" unitRef="usd">2372000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-691">The net deferred tax assets (liabilities) at December&#160;31, 2024 and 2023 resulted from the following temporary differences:&#160;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Net Deferred Tax Assets and Liabilities: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net operating loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;68,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Share-based compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,791&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,347&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,334&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8,378&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserves and Other Accruals&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Orphan drug and R&amp;amp;D tax credit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,095&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,065&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Capitalized research costs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,568&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,738&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense carryforward&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,460&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,368&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,176&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,322&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;970&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,159&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross deferred tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Deferred tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross deferred tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Less: valuation allowances&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(101,565)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(96,428)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:8pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net deferred tax assets &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-3" id="f-692" unitRef="usd">68568000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-7" decimals="-3" id="f-693" unitRef="usd">71051000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-3" id="f-694" unitRef="usd">9791000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-7" decimals="-3" id="f-695" unitRef="usd">7347000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <avdl:DeferredTaxAssetsRoyaltyIncome contextRef="c-6" decimals="-3" id="f-696" unitRef="usd">9334000</avdl:DeferredTaxAssetsRoyaltyIncome>
    <avdl:DeferredTaxAssetsRoyaltyIncome contextRef="c-7" decimals="-3" id="f-697" unitRef="usd">8378000</avdl:DeferredTaxAssetsRoyaltyIncome>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-6" decimals="-3" id="f-698" unitRef="usd">4603000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals contextRef="c-7" decimals="-3" id="f-699" unitRef="usd">0</us-gaap:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals>
    <avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch contextRef="c-6" decimals="-3" id="f-700" unitRef="usd">4095000</avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch>
    <avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch contextRef="c-7" decimals="-3" id="f-701" unitRef="usd">4065000</avdl:DeferredTaxAssetsTaxCreditCarryforwardsOrphanDrugAndResearch>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-3" id="f-702" unitRef="usd">1568000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-7" decimals="-3" id="f-703" unitRef="usd">1738000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-6" decimals="-3" id="f-704" unitRef="usd">1460000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetInterestCarryforward contextRef="c-7" decimals="-3" id="f-705" unitRef="usd">1368000</us-gaap:DeferredTaxAssetInterestCarryforward>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-3" id="f-706" unitRef="usd">1176000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-7" decimals="-3" id="f-707" unitRef="usd">1322000</us-gaap:DeferredTaxAssetsOther>
    <avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets contextRef="c-6" decimals="-3" id="f-708" unitRef="usd">970000</avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets>
    <avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets contextRef="c-7" decimals="-3" id="f-709" unitRef="usd">1159000</avdl:DeferredTaxAssetsAmortizationOfIntangibleAssets>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-3" id="f-710" unitRef="usd">101565000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-7" decimals="-3" id="f-711" unitRef="usd">96428000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-6" decimals="-3" id="f-712" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredTaxLiabilitiesPrepaidExpenses contextRef="c-7" decimals="-3" id="f-713" unitRef="usd">0</us-gaap:DeferredTaxLiabilitiesPrepaidExpenses>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-3" id="f-714" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-7" decimals="-3" id="f-715" unitRef="usd">0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-3" id="f-716" unitRef="usd">101565000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-3" id="f-717" unitRef="usd">96428000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-6" decimals="-3" id="f-718" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:DeferredTaxAssetsLiabilitiesNet contextRef="c-7" decimals="-3" id="f-719" unitRef="usd">0</us-gaap:DeferredTaxAssetsLiabilitiesNet>
    <us-gaap:OperatingLossCarryforwards contextRef="c-125" decimals="-3" id="f-720" unitRef="usd">71588000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-126" decimals="-3" id="f-721" unitRef="usd">227344000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-127" decimals="-3" id="f-722" unitRef="usd">5809000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-126" decimals="-3" id="f-723" unitRef="usd">227344000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-128" decimals="-3" id="f-724" unitRef="usd">10365000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-129" decimals="-3" id="f-725" unitRef="usd">212637000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-130" decimals="-3" id="f-726" unitRef="usd">4342000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwardsValuationAllowance contextRef="c-125" decimals="-3" id="f-727" unitRef="usd">5137000</us-gaap:OperatingLossCarryforwardsValuationAllowance>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-131" decimals="-3" id="f-728" unitRef="usd">3059000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-132" decimals="-3" id="f-729" unitRef="usd">1036000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:UndistributedEarnings contextRef="c-1" decimals="-3" id="f-730" unitRef="usd">3755000</us-gaap:UndistributedEarnings>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-6" decimals="-3" id="f-731" unitRef="usd">587000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch contextRef="c-7" decimals="-3" id="f-732" unitRef="usd">1654000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-133" decimals="-3" id="f-733" unitRef="usd">837000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-134" decimals="-3" id="f-734" unitRef="usd">817000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:OtherLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-735">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Other Assets and Liabilities&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various other assets and liabilities are summarized for the years ended December 31, as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prepaid Expenses and Other Current Assets: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Non-Current Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use assets at contract manufacturing organizations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accrued Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty payable to RTW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.670%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Non-Current Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherLiabilitiesDisclosureTextBlock>
    <avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock contextRef="c-1" id="f-736">&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Various other assets and liabilities are summarized for the years ended December 31, as follows:&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Prepaid Expenses and Other Current Assets: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Prepaid and other expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,154&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,373&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;882&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,235&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,036&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,608&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avdl:ScheduleOfPrepaidExpensesAndOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-6" decimals="-3" id="f-737" unitRef="usd">5154000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="c-7" decimals="-3" id="f-738" unitRef="usd">4373000</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-739" unitRef="usd">882000</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-740" unitRef="usd">2235000</us-gaap:OtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-3" id="f-741" unitRef="usd">6036000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-7" decimals="-3" id="f-742" unitRef="usd">6608000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="c-1" id="f-743">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Non-Current Assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Right of use assets at contract manufacturing organizations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,905&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;337&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;579&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:11.25pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,037&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,484&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent contextRef="c-6" decimals="-3" id="f-744" unitRef="usd">10700000</avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent>
    <avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent contextRef="c-7" decimals="-3" id="f-745" unitRef="usd">9905000</avdl:OperatingLeaseRightOfUseAssetContractManufacturingNoncurrent>
    <avdl:OtherNoncurrentReceivables contextRef="c-6" decimals="-3" id="f-746" unitRef="usd">337000</avdl:OtherNoncurrentReceivables>
    <avdl:OtherNoncurrentReceivables contextRef="c-7" decimals="-3" id="f-747" unitRef="usd">579000</avdl:OtherNoncurrentReceivables>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-6" decimals="-3" id="f-748" unitRef="usd">11037000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="c-7" decimals="-3" id="f-749" unitRef="usd">10484000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-750">&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.418%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.908%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.910%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accrued Expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,028&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Reserve for variable consideration&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14,218&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,044&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accrued compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,515&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,492&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Royalty payable to RTW&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;1,890&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;730&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;40,651&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,227&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-3" id="f-751" unitRef="usd">18028000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-7" decimals="-3" id="f-752" unitRef="usd">11961000</us-gaap:AccruedProfessionalFeesCurrent>
    <avdl:RemainingPerformanceObligationReserveCurrent contextRef="c-6" decimals="-3" id="f-753" unitRef="usd">14218000</avdl:RemainingPerformanceObligationReserveCurrent>
    <avdl:RemainingPerformanceObligationReserveCurrent contextRef="c-7" decimals="-3" id="f-754" unitRef="usd">4044000</avdl:RemainingPerformanceObligationReserveCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-6" decimals="-3" id="f-755" unitRef="usd">6515000</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent contextRef="c-7" decimals="-3" id="f-756" unitRef="usd">7492000</us-gaap:AccruedSalariesCurrent>
    <avdl:RoyaltyFinancingLiabilityCurrent contextRef="c-6" decimals="-3" id="f-757" unitRef="usd">1890000</avdl:RoyaltyFinancingLiabilityCurrent>
    <avdl:RoyaltyFinancingLiabilityCurrent contextRef="c-7" decimals="-3" id="f-758" unitRef="usd">730000</avdl:RoyaltyFinancingLiabilityCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-6" decimals="-3" id="f-759" unitRef="usd">40651000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:AccruedLiabilitiesCurrent contextRef="c-7" decimals="-3" id="f-760" unitRef="usd">24227000</us-gaap:AccruedLiabilitiesCurrent>
    <us-gaap:OtherNoncurrentLiabilitiesTableTextBlock contextRef="c-1" id="f-761">&lt;div style="margin-bottom:4pt;margin-top:3pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.895%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.667%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.670%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Non-Current Liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,151&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,407&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;247&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,183&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5,654&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:OtherNoncurrentLiabilitiesTableTextBlock>
    <avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities contextRef="c-6" decimals="-3" id="f-762" unitRef="usd">5151000</avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities>
    <avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities contextRef="c-7" decimals="-3" id="f-763" unitRef="usd">5407000</avdl:TaxLiabilitiesAndOtherNoncurrentLiabilities>
    <us-gaap:GuarantyLiabilities contextRef="c-6" decimals="-3" id="f-764" unitRef="usd">32000</us-gaap:GuarantyLiabilities>
    <us-gaap:GuarantyLiabilities contextRef="c-7" decimals="-3" id="f-765" unitRef="usd">247000</us-gaap:GuarantyLiabilities>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-6" decimals="-3" id="f-766" unitRef="usd">5183000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="c-7" decimals="-3" id="f-767" unitRef="usd">5654000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-768">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Contingent Liabilities and Commitments&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Litigation &#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;The Company is subject to potential liabilities generally incidental to its business arising out of present and future lawsuits and claims related to product liability, personal injury, contract, commercial, intellectual property, tax, employment, compliance and other matters that arise in the ordinary course of business. The Company accrues for potential liabilities when it is probable that future costs (including contingent fees and expenses) will be incurred and such costs can be reasonably estimated. At &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;, there were no contingent liabilities with respect to any litigation, arbitration or administrative or other proceeding that are reasonably likely to have a material adverse effect on the Company&#x2019;s consolidated financial position, results of operations, cash flows or liquidity. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;First Jazz Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 12, 2021, Jazz Pharmaceuticals, Inc. (&#x201c;Jazz&#x201d;) filed a formal complaint (the &#x201c;First Complaint&#x201d;) initiating a lawsuit in the United States District Court for the District of Delaware (the &#x201c;Court&#x201d;) against Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Management Corporation, Avadel Legacy Pharmaceuticals, LLC, Avadel Specialty Pharmaceuticals, LLC, and Avadel CNS Pharmaceuticals, LLC (collectively, the &#x201c;Avadel Parties&#x201d;). In the First Complaint, Jazz alleges the sodium oxybate product (&#x201c;Proposed Product&#x201d;) described in the NDA owned by Avadel CNS Pharmaceuticals, LLC (&#x201c;Avadel CNS&#x201d;) will infringe at least one claim of U.S. Patent No. 8731963, 10758488, 10813885, 10959956 and/or 10966931 (collectively, the &#x201c;patents-in-suit&#x201d;). The First Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#x2019; fees, costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 3, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#x201c;Avadel Answer&#x201d;) with the Court in response to the First Complaint. The Avadel Answer generally denies the allegations set forth in the First Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patents-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of each patent-in-suit, and ii) a declaratory judgment of invalidity of each patent-in-suit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 18, 2021, Jazz filed its Answer (&#x201c;Jazz Answer&#x201d;) with the Court in response to the Avadel Answer. The Jazz Answer generally denies the allegations set forth in the Avadel Answer and sets forth a single affirmative defense asserting that Avadel has failed to state a claim for which relief can be granted.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 21, 2021, the Court issued an oral order requiring the parties to i) confer regarding proposed dates to be included in the Court&#x2019;s scheduling order for the case, and ii) submit a proposed order, including a proposal for the length and timing of trial, to the Court by no later than July 21, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 30, 2021, the Court issued a scheduling order establishing timing for litigation events including i) a claim construction hearing date of August 2, 2022, and ii) a trial date of October 30, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 18, 2021, consistent with the scheduling order, Jazz filed a status update with the Court indicating that Jazz did not intend to file a preliminary injunction with the Court at this time. Jazz further indicated that it would provide the Court with an &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;update regarding whether preliminary injunction proceedings may be necessary after receiving further information regarding the FDA&#x2019;s action on Avadel CNS&#x2019;s NDA.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 4, 2022, the Court entered an agreed order dismissing this case with respect to Avadel Pharmaceuticals plc, Avadel US Holdings, Inc., Avadel Specialty Pharmaceuticals, LLC, Avadel Legacy Pharmaceuticals, LLC, and Avadel Management Corporation. A corresponding order was entered in the two below cases on the same day.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2022, Jazz filed an amended Answer to the Avadel Parties&#x2019; Counterclaims (&#x201c;the Jazz First Amended Answer&#x201d;). The Jazz First Amended Answer is substantially similar to the Jazz Answer except insofar as it adds an affirmative defense for judicial estoppel and unclean hands. Corresponding amended answers were filed in the two below cases on the same day.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 23, 2022, Avadel CNS filed a Renewed Motion for Judgment on the Pleadings, with respect to its counterclaim against Jazz seeking to have U.S. Patent No. 8731963 (the &#x201c;REMS Patent&#x201d;) delisted from the Orange Book and seeking to have the motion resolved concurrent with the parties&#x2019; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing on August 31, 2022. On July 7, 2022, Jazz filed a response styled as Objections to Avadel CNS&#x2019; Motion for Judgment on the Pleadings. On July 14, 2022, Avadel CNS replied to Jazz&#x2019;s response, and on July 21, 2022, Avadel CNS requested oral argument on its delisting motion simultaneous with the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing. On August 24, 2022, the Court ordered Jazz to respond substantively to Avadel CNS&#x2019; motion, which Jazz did on August 26, 2022. Avadel CNS filed its reply on August 28, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 23, 2022, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing was postponed. On September 7, 2022, the case was reassigned to a new judge, and the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing was held on October 25, 2022. At the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing, Avadel CNS reiterated its request for an expedited hearing on the Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent. On October 28, 2022, the Court granted Avadel CNS&#x2019; request and scheduled the hearing for November 15, 2022.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Court held the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; hearing on November 15, 2022 and issued a claim construction ruling on November 18, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Also, on November 18, 2022 the Court granted Avadel&#x2019;s Renewed Motion for Judgment on the Pleadings and ordered Jazz to request delisting of the REMS Patent from the Orange Book. On November 22, 2022, Jazz appealed that decision and on December 14, 2022, the Federal Circuit issued a stay of the delisting order until further notice. Oral argument was held February 14, 2023. On February 24, 2023, the United States Court of Appeals for the Federal Court affirmed the previous ruling from the Court, ordering the delisting of the REMS Patent from the Orange Book, which has since occurred. On March 7, 2023, in response to a joint stipulation filed by the parties, the Court issued an order dismissing Jazz&#x2019;s infringement claims against the Avadel Parties relating to the REMS Patent as well as Avadel Parties&#x2019; noninfringement and invalidity counterclaims relating to the REMS Patent.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 15, 2023, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule to accommodate additional claim construction proceedings. That stipulation remains pending before the Court. On April 26, 2023, the parties filed their Supplemental Joint Claim Construction Brief.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2023, the Court issued a modified scheduling order establishing a new trial date of February 26, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On July 21, 2023, in response to a Court order, the parties submitted a Stipulation and Proposed Order Modifying the Case Schedule with an updated proposed schedule to accommodate additional claim construction proceedings.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 4, 2023, the Court entered a modified version of the parties&#x2019; proposed schedule, which was revised on August 28, 2023. The parties&#x2019; Second Supplemental Joint Claim Construction Brief was filed on October 10, 2023, and a &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%"&gt;Markman&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; hearing regarding the disputed terms occurred on November 1, 2023. The Court issued its claim construction order on December 15, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On August 15, 2023, Avadel renewed its request to consolidate this litigation with the litigation described in the Avadel Complaint below. On November 3, 2023, the Court denied that request.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 30, 2023, the parties filed cross motions for summary judgment. The parties filed opposition briefs on December 15, 2023. The parties filed reply briefs on December 22, 2023.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 14, 2024, the Court denied the parties&#x2019; summary judgment motions. On February 15, 2024, the Court held its Pretrial Conference. Trial was held from February 26, 2024 to March 1, 2024 (the &#x201c;February Patent Trial&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 4, 2024, the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;jury returned a verdict of no infringement for U.S. Patent No. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;10758488 and infringement of U.S. Patent No. 11147782, with&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; damages of $234,&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; which are included in the consolidated balance sheets in accrued expenses at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 19, 2024, the Court issued a Supplemental Scheduling Order setting a June 4, 2024 hearing on Jazz&#x2019;s request for a permanent injunction or ongoing royalty. Briefing on Jazz&#x2019;s request closed on May 20, 2024, and the hearing was held June 4, 2024. On August 27, 2024, the Court issued an opinion and order enjoining Avadel from infringing claim 24 of U.S. Patent No. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;11147782. That injunction excluded certain categories of conduct, including permitting Avadel to continue making, using and selling LUMRYZ for the treatment of narcolepsy and for use in ongoing clinical trials and studies. The August 27, 2024 opinion and order also granted Jazz&#x2019;s motion for an ongoing royalty, pending additional briefing on the appropriate royalty rate. That briefing closed on September 23, 2024. While a future ongoing royalty is pending briefing and a decision by the Court, the Company recorded an estimated liability for a royalty based on information available as of December 31, 2024. It is reasonably possible that a change in the estimate may occur pending the Court&#x2019;s decision. On August 28, 2024, Avadel filed a notice of appeal concerning the August 27, 2024 injunction (the &#x201c;Patent Appeal&#x201d;). On September 3, 2024, Avadel moved in District Court to stay the August 27, 2024 injunction pending appeal. Briefing on that motion closed on September 16, 2024. On September 24, 2024, the District Court denied Avadel&#x2019;s motion to stay the injunction pending appeal.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 6, 2024, Avadel moved the U.S. Court of Appeals for the Federal Circuit to stay the injunction pending appeal. Briefing on that motion closed on September 27, 2024. On October 2, 2024, the Federal Circuit granted Avadel&#x2019;s motion in part, staying the injunction with respect to Avadel&#x2019;s initiating new clinical trials or studies.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 10, 2024, the Federal Circuit entered a briefing schedule concerning the Patent Appeal. On September 30, 2024, Avadel filed its opening brief. Jazz filed its response brief on November 7, 2024. Avadel filed its reply brief on November 18, 2024. On October 2, 2024, the Federal Circuit placed the Patent Appeal on the February 2025 oral argument calendar. On February 7, 2025, the Federal Circuit heard oral argument in the Patent Appeal. The Patent Appeal remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Jazz Complaint &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 4, 2021, Jazz filed another formal complaint (the &#x201c;Second Complaint&#x201d;) initiating a lawsuit in the Court against the Avadel Parties. In the Second Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11077079. The Second Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#x2019; fees, costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 9, 2021, the Avadel Parties timely filed their Answer and Counterclaims (the &#x201c;Second Avadel Answer&#x201d;) with the Court in response to the Second Complaint. The Second Avadel Answer generally denies the allegations set forth in the Second Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity of the patent-in-suit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 22, 2021, the Court issued an oral order stating that this case should proceed on the same schedule as the case filed on May 12, 2021.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 7, 2022, the case was reassigned to a new judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Third Jazz Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 10, 2021, Jazz filed another formal complaint (the &#x201c;Third Complaint&#x201d;) initiating a lawsuit in the Court against the Avadel Parties. In the Third Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at least one claim of U.S. Patent No. 11147782. The Third Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#x2019; fees, costs and expenses. This case will proceed on the same schedule as the cases associated with the First and Second Complaints above.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On December 21, 2021, the Court entered a revised schedule for the First, Second and Third Complaints, setting a new claim construction date of August 31, 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 7, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#x201c;Third Avadel Answer&#x201d;) with the Court in response to the Third Complaint. The Third Avadel Answer generally denies the allegations set forth in the Third Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims seeking i) a declaratory judgment of non-infringement of the patent-in-suit, and ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2022, the case was reassigned to a new judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fourth Jazz Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 15, 2022, Jazz filed another formal complaint (the &#x201c;Fourth Complaint&#x201d;) initiating a lawsuit in the Court against Avadel CNS. In the Fourth Complaint, Jazz alleges the Proposed Product described in the NDA owned by Avadel CNS will infringe at &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;least one claim of the REMS Patent, which was asserted in the First Complaint. The FDA required Avadel CNS to file a Paragraph IV certification against the REMS Patent, which Avadel CNS did under protest, consistent with its Renewed Motion for Judgment on the Pleadings for the delisting of the REMS Patent from the Orange Book, which was later ordered to be delisted in the above First Jazz Complaint action. Avadel CNS provided the required notice of its Paragraph IV certification to Jazz, and Jazz reasserted the REMS Patent in a separate action following receipt of that notice. The Fourth Complaint further includes typical relief requests such as preliminary and permanent injunctive relief, monetary damages and attorneys&#x2019; fees, costs and expenses. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2022, the case was reassigned to a new judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On September 21, 2022, Jazz served the Fourth Complaint. On October 21, 2022, Avadel CNS timely filed its Answer and Counterclaims (the &#x201c;Fourth Avadel Answer&#x201d;) with the Court in response to the Fourth Complaint. The Fourth Avadel Answer generally denies the allegations set forth in the Fourth Complaint, includes numerous affirmative defenses (including, but not limited to, non-infringement and invalidity of the patent-in-suit), and asserts a number of counterclaims for i) a declaratory judgment of non-infringement of the patent-in-suit, ii) a declaratory judgment of invalidity/unenforceability of the patent-in-suit, iii) delisting of the patent-in-suit from the Orange Book; iv) monopolization under the Sherman Antitrust Act of 1890 (the &#x201c;Sherman Act&#x201d;); and v) attempted monopolization under the Sherman Act.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On December 9, 2022, Jazz filed a Motion to Dismiss Avadel&#x2019;s Antitrust Counterclaims.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;Avadel filed its opposition brief on December 27, 2022, and Jazz filed its reply brief on January 6, 2022.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On January 11, 2023, Avadel filed a request for oral argument on the motion. On May 24, 2024, the Court denied Jazz&#x2019;s Motions to Dismiss.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On June 7, 2024, Jazz filed its Answer to Avadel&#x2019;s Counterclaims.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;On March 6, 2023, the parties filed a stipulation of dismissal, dismissing Jazz&#x2019;s claims with respect to the REMS Patent and Avadel CNS&#x2019;s related non-infringement and invalidity counterclaims. The Court entered that stipulation on March 7, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 19, 2023, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by March 14, 2024, and ii) a deadline for case dispositive motions of September 20, 2024. On January 23, 2024, the parties submitted a stipulation to extend the case schedule. On January 24, 2024, the Court ordered an extension of the case schedule, including i) completion of fact discovery by June 20, 2024 and ii) a deadline for case dispositive motions by January 31, 2025. On January 24, 2024, the Court issued an order setting a pretrial conference for October 30, 2025 and a 5-day trial to begin on November 3, 2025. On April 22, 2024, the parties submitted a stipulation extending certain pretrial deadlines, including i) extending completion of fact discovery to September 27, 2024 and ii) extending the deadline for case dispositive motions to April 4, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 29, 2023, Jazz filed a Motion to Stay the case, pending resolution of its Motion to Dismiss. Briefing on that Motion to Stay closed on August 10, 2023. On March 13, 2024, Jazz filed a Supplemental Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#x2019;s Motions to Stay.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 7, 2024, Jazz filed a Motion for Reargument or in the Alternative to Certify an Appeal. Avadel filed its opposition brief on June 28, 2024. Jazz filed its reply brief on July 12, 2024. On September 25, 2024, Jazz sought leave to file a supplemental brief in support of its Motion to Stay.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;  &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On October 4, 2024, the Court granted leave to Jazz to file its supplemental brief, which Jazz filed on October 7, 2024. Avadel filed its response on October 21, 2024. Jazz filed its reply on October 28, 2024. Jazz&#x2019;s motion remains pending.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Avadel Complaint&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On April 14, 2022, Avadel CNS and Avadel Pharmaceuticals plc (collectively the &#x201c;Avadel Plaintiffs&#x201d;) filed a formal complaint (the &#x201c;Avadel Complaint&#x201d;) initiating a lawsuit in the Court against Jazz and Jazz Pharmaceuticals Ireland Ltd. (collectively, the &#x201c;Jazz Parties&#x201d;). In the Avadel Complaint, the Avadel Plaintiffs allege that the Jazz Parties breached certain confidential disclosure agreements and misappropriated certain of the Avadel Plaintiffs&#x2019; trade secrets. The Avadel Complaint further includes typical relief requests such as injunctive relief, monetary damages and attorneys&#x2019; fees, costs and expenses, as well as seeking correction of inventorship of certain Jazz patents, for which the Jazz Parties claim ownership, to include former Avadel Plaintiffs&#x2019; scientists.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 2, 2022, Jazz answered the Avadel Complaint. The Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 8, 2022, Jazz filed a Motion for Judgment on the Pleadings seeking to have all Counts dismissed for failure to state a claim upon which relief can be granted. The Avadel Plaintiffs&#x2019; response to that Motion was filed with the Court on July 29, &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022. Jazz&#x2019;s reply was filed with the Court on August 5, 2022. On February 2, 2023, the Court held a hearing on Jazz&#x2019;s Motion for Judgment on the Pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 7, 2022, the case was reassigned to a new judge.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 2, 2023, the Court held a hearing on Jazz&#x2019;s Motion for Judgment on the Pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 18, 2023, the Court denied Jazz&#x2019;s Motion for Judgment on the Pleadings.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On August 15, 2023, the parties submitted competing proposed scheduling orders, and Avadel requested consolidation with the above First Jazz Complaint litigation.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;That request for consolidation was denied on November 3, 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 17, 2023, the parties submitted an updated joint proposed scheduling order. On January 30, 2024, the parties agreed to a 6-week stay of discovery and submitted a proposed stipulation extending certain case deadlines to accommodate the same. On February 9, 2024, the parties submitted an updated proposed scheduling order consistent with that stipulation,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;setting the close of fact discovery for August 9, 2024 and a trial date of December 15, 2025.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;That proposed scheduling order remains pending before the Court as of the date of this Annual Report on Form 10-K.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On March 19, 2024, Jazz filed a Motion to Stay, pending the resolution of the post-trial briefing and any appeals from the February Patent Trial. On May 24, 2024, the Court denied Jazz&#x2019;s Motions to Stay.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 10, 2024, the Court issued a scheduling order establishing timing for litigation events including i) completion of fact discovery by August 9, 2024, ii) a deadline for case dispositive motions of May 30, 2025, and iii) a 5-day jury trial beginning December 15, 2025.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 11, 2024, the Court entered a stipulation by the parties extending certain case deadlines, including i) extending close of fact discovery to November 1, 2024 and ii) dispositive motions to July 18, 2025. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 3, 2024, Jazz filed an Amended Answer to the Avadel Complaint. The Amended Answer generally denies the allegations set forth in the Avadel Complaint and includes various affirmative defenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 6, 2024, Avadel and Jazz stipulated to stay proceedings pending the resolution of the Patent Appeal above, which the Court entered on September 9, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Second Avadel Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 3, 2025, Avadel CNS and Flamel Ireland Limited (&#x201c;Flamel&#x201d;) filed a formal complaint (the &#x201c;Second Avadel Complaint&#x201d;) initiating a lawsuit in the Court against the Jazz Parties. In the Second Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12167991 through, inter alia, the sale of XYWAV&#xae; in conjunction with its FDA-approved labeling. The Second Avadel Complaint includes typical requests for monetary damages and attorneys&#x2019; fees, as well as costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Jazz Parties&#x2019; Answer is due on April 21, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Third Avadel Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 14, 2025, Avadel CNS and Flamel filed a formal complaint (the &#x201c;Third Avadel Complaint&#x201d;) initiating a lawsuit in the Court against the Jazz Parties. In the Third Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent No. 12186298 through, inter alia, the sale of XYWAV&#xae; in conjunction with its FDA-approved labeling. The Third Avadel Complaint includes typical requests for monetary damages and attorneys&#x2019; fees, as well as costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Jazz Parties&#x2019; Answer is due on April 21, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Fourth Avadel Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On February 25, 2025, Avadel CNS and Flamel filed a formal complaint (the &#x201c;Fourth Avadel Complaint&#x201d;) initiating a lawsuit in the Court against the Jazz Parties. In the Fourth Avadel Complaint, Avadel CNS and Flamel allege that the Jazz parties infringe one or more claims of U.S. Patent Nos. 12226388 and 12226389 through, inter alia, the sale of XYWAV&#xae; in conjunction with its FDA-approved labeling. The Fourth Avadel Complaint includes typical requests for monetary damages and attorneys&#x2019; fees, as well as costs and expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Jazz&#x2019;s Administrative Procedure Act Complaint&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On June 22, 2023, Jazz filed an Administrative Procedure Act suit against the FDA, the U.S. Department of Health and Human Services, the Secretary of Health and Human Services and the Commissioner of Food and Drugs (the &#x201c;Federal Defendants&#x201d;) in the United States District Court for the District of Columbia (the &#x201c;DC Court&#x201d;) related to the NDA for LUMRYZ. This suit alleges that the FDA&#x2019;s approval of LUMRYZ was an unlawful agency action and asks the DC Court to set aside FDA&#x2019;s approval of LUMRYZ. On June 28, 2023, the DC Court granted Avadel CNS&#x2019;s unopposed motion to intervene in the case to defend the FDA&#x2019;s decision. On August 14, 2023, the Court entered a scheduling order establishing timing for litigation events including early summary judgment briefing closing December 22, 2023. On September 22, 2023, Jazz filed its Motion for Summary Judgment. On October 20, 2023, the FDA and Avadel filed their Cross Motions for Summary Judgment. Briefing on the parties&#x2019; motions closed January 4, 2024. On February 14, 2024, the Court set hearing for oral argument on the parties&#x2019; motions for February 27, 2024. On February 21, 2024, the Court rescheduled the oral argument to April 9, 2024. On April 2, 2024, the Court rescheduled the oral argument to May 10, 2024. On May 10, 2024, the Court heard oral argument on the parties&#x2019; motions. On October 30, 2024, the Court granted FDA and Avadel&#x2019;s Motions for Summary Judgment with respect to the sole count in Jazz&#x2019;s complaint and denied Jazz&#x2019;s Motion for Summary Judgment regarding the same. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On November 15, 2024, Jazz filed a notice of appeal concerning the Court&#x2019;s October 30, 2024 ruling (the &#x201c;APA Appeal&#x201d;).&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On January 31, 2025, Jazz filed its opening brief in the APA Appeal.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Avadel&#x2019;s response brief is due March 17, 2025.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Jazz&#x2019;s reply brief is due April 7, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Material Commitments &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;The Company has a four year commitment with a CDMO to manufacture the LUMRYZ drug product of approximately $3,000 to $4,200 per year as determined by the terms of the agreement with the CDMO</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualCarryingValueCurrent contextRef="c-135" decimals="-3" id="f-769" unitRef="usd">234000</us-gaap:LossContingencyAccrualCarryingValueCurrent>
    <us-gaap:LongtermPurchaseCommitmentPeriod contextRef="c-1" id="f-770">P4Y</us-gaap:LongtermPurchaseCommitmentPeriod>
    <avdl:ContractualObligationAnnualAmount contextRef="c-104" decimals="-3" id="f-771" unitRef="usd">3000000</avdl:ContractualObligationAnnualAmount>
    <avdl:ContractualObligationAnnualAmount contextRef="c-105" decimals="-3" id="f-772" unitRef="usd">4200000</avdl:ContractualObligationAnnualAmount>
    <avdl:EquityTransactionsDisclosureTextBlock contextRef="c-1" id="f-773">Equity Instruments and Transactions&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Capital Shares&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has 500,000 authorized ordinary shares&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (&#x201c;ordinary shares&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; with a nominal value of $0.01 per ordinary share. Effective April 15, 2024, the Company&#x2019;s ordinary shares became directly listed on the Nasdaq Stock Market. The Company caused a mandatory exchange of its &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;American Depositary Shares (&#x201c;ADSs&#x201d;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for the underlying ordinary shares&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;on a one-for-one basis. Accordingly, the Bank of New York Mellon (&#x201c;BNY Mellon&#x201d;), as Depositary for the ADSs, issued a notice of termination of its American Depository Receipt program (&#x201c;ADR Program&#x201d;) of ADSs to the registered holders of ADSs according to the requirements under the deposit agreement dated January 3, 2017 (the &#x201c;Deposit Agreement&#x201d;) among the Company, BNY Mellon and holders of ADSs. The Deposit Agreement terminated on July 15, 2024. As of December&#160;31, 2024, the Company had 96,518 ordinary shares issued and outstanding. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Board of Directors is authorized to issue preferred shares in series, and with respect to each series, to fix its designation, relative rights (including voting, dividend, conversion, sinking fund, and redemption rights), preferences (including dividends and liquidation) and limitations. The Company has 50,000 authorized preferred shares, with a nominal value of $0.01 per preferred share. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In March 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Series A Non-Voting Convertible Preferred Shares and Series B Non-Voting Convertible Preferred Shares were converted to &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;5,194&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; ordinary shares at the option of the holders. Accordingly, there were no preferred shares issued and outstanding at &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:112%"&gt;Shelf Registration Statement on Form S-3&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On May 8, 2024, the Company entered into an Open Market Sale Agreement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; (the &#x201c;Sales Agreement&#x201d;) with Jefferies LLC (&#x201c;Jefferies&#x201d;) pursuant to which the Company may offer and sell its ordinary shares, from time to time, with respect to an at-the-market offering program (&#x201c;ATM Program&#x201d;) under which Jefferies will act as sales agent. The Sales Agreement provides that Jefferies will be entitled to aggregate compensation for its services of an amount up to 3.0% of the gross proceeds of any ordinary shares sold through Jefferies under the Sales Agreement. The Sales Agreement replaces the Company&#x2019;s previous Open Market Sale Agreement&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;SM &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;with Jefferies, dated February 4, 2020 (the &#x201c;ADS Sales Agreement&#x201d;), which provided for the sale of ADSs by the Company. The Company terminated the ADS Sales Agreement upon effectiveness of the Sales Agreement following the mandatory exchange of the ADSs and the direct listing of the ordinary shares on the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Nasdaq Stock Market on April 15, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The ordinary shares will be offered and sold pursuant to the Company&#x2019;s shelf registration statement on Form S-3 &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(File No. 333-267198), filed with the SEC on August 31, 2022, as amended, and declared effective by the SEC on September 12, 2022, as supplemented by the prospectus supplement dated May 8, 2024 (the &#x201c;Prospectus Supplement&#x201d;). The Company may offer and sell ordinary shares having an aggregate offering price of up to $100,000 under the Prospectus Supplement. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Prior to termination, the Company issued and sold 640 ordinary shares pursuant to the ADS Sales Agreement during the three months ended March 31, 2024, resulting in net proceeds to the Company of approximately $9,250. The Company has not issued or sold ordinary shares under at-the-market offering programs subsequent to March 31, 2024.&lt;/span&gt;&lt;/div&gt;</avdl:EquityTransactionsDisclosureTextBlock>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-774" unitRef="shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-775"
      unitRef="usdPerShare">0.01</us-gaap:CommonStockParOrStatedValuePerShare>
    <avdl:AmericanDepositorySharesConversionRatio
      contextRef="c-136"
      decimals="INF"
      id="f-776"
      unitRef="number">1</avdl:AmericanDepositorySharesConversionRatio>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-3" id="f-777" unitRef="shares">96518000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-3" id="f-778" unitRef="shares">96518000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-779" unitRef="shares">50000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-780"
      unitRef="usdPerShare">0.01</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-137"
      decimals="-3"
      id="f-781"
      unitRef="shares">5194000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="c-138"
      decimals="-3"
      id="f-782"
      unitRef="shares">5194000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <avdl:SaleOfStockSalesAgentCommissionPercent contextRef="c-139" decimals="3" id="f-783" unitRef="number">0.030</avdl:SaleOfStockSalesAgentCommissionPercent>
    <avdl:SaleOfStockMaximumAggregateOfferingPrice contextRef="c-140" decimals="-3" id="f-784" unitRef="usd">100000</avdl:SaleOfStockMaximumAggregateOfferingPrice>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-141"
      decimals="-3"
      id="f-785"
      unitRef="shares">640000</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockConsiderationReceivedOnTransaction contextRef="c-142" decimals="-3" id="f-786" unitRef="usd">9250000</us-gaap:SaleOfStockConsiderationReceivedOnTransaction>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-143"
      decimals="INF"
      id="f-787"
      unitRef="shares">0</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-788">Share-Based Compensation&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense included in the Company&#x2019;s consolidated statements of loss for all share-based compensation arrangements was as follows for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Share-based Compensation Expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2024, the Company expects $22,513 of unrecognized expense related to granted, but non-vested share-based compensation arrangements to be incurred in future periods. This expense is expected to be recognized over a weighted average period of 2.0 years.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2022, the Company granted options with performance conditions to employees of which 50% vest upon the achievement of certain commercial milestones related to LUMRYZ and the other 50% vest one year following achievement of those milestones (&#x201c;2022 Performance Options&#x201d;). In May 2023, the achievement of the milestones related to the 2022 Performance Options became probable, and the Company recognized the compensation costs that would have been recognized had the performance factor been considered probable since the inception of the award. In June 2023, achievement of these milestones were met and 50% of the 2022 Performance Options vested. In June 2024, one year passed since achievement of these milestones were met and the remaining 50% of the 2022 Performance Options vested. As of December&#160;31, 2024, the Company has recognized $8,009 in share-based compensation for the 2022 Performance Options. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The excess tax benefit related to share-based compensation recorded by the Company was not material for the years ended December&#160;31, 2024, 2023, and 2022. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Upon exercise of stock options, or upon the issuance of restricted share awards or performance share unit awards, the Company issues new shares.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;At December&#160;31, 2024, there were 4,259 shares authorized for stock option grants, restricted share award grants, and performance share unit award grants in subsequent periods.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Inducement Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2021, the Board of Directors approved the Avadel Pharmaceuticals plc 2021 Inducement Plan (the &#x201c;Inducement Plan&#x201d;), which allows the Company to grant equity awards to induce highly-qualified prospective officers and employees who are not currently employed by the Company to accept employment and provide them with a proprietary interest in the Company. The maximum number of shares reserved and available for issuance under the Plan is 2,000 shares. As of December&#160;31, 2024, the Company had 841 shares available for issuance under this Inducement Plan in subsequent periods.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Determining the Fair Value of Stock Options&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures the total fair value of stock options on the grant date using the Black-Scholes option-pricing model and recognizes each grant&#x2019;s fair value as compensation expense over the period that the option vests. Other than the 2022 Performance Options described above, options are granted to employees of the Company and become exercisable ratably over four years following the grant date and expire ten years after the grant date. During the years ended December 31, 2022 and 2023, the Company issued stock options to its Board of Directors as compensation for services rendered that are exercisable one year following the grant date and expire ten years after the grant date. During the year ended December&#160;31, 2024, the Company &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;issued stock options to its Board of Directors as compensation for services rendered that are exercisable over either a one year period or ratably over three years following the grant date and expire ten years after the grant date. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions under the Black-Scholes option-pricing model for stock option grants as of December&#160;31, 2024, 2023 and 2022 are as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Option Assumptions: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected term&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected term of the options represents the period of time between the grant date and the time the options are either exercised or forfeited, including an estimate of future forfeitures for outstanding options. Given the limited historical data, the simplified method has been used to calculate the expected life.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected volatility&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The expected volatility is calculated based on an average of the historical volatility of the Company&#x2019;s stock price for a period approximating the expected term.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Risk-free interest rate&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The risk-free interest rate is based on the U.S. Treasury yield curve in effect at the time of grant and a maturity that approximates the expected term.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Expected dividend yield&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;: The Company has not distributed any dividends since its inception and have no plan to distribute dividends in the foreseeable future.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the combined stock option activity and other data for the Company&#x2019;s stock option plans for the year ended December&#160;31, 2024 is as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.196%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Stock Option Activity and Other Data: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(468)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate intrinsic value of options exercised during the years ended December&#160;31, 2024, 2023, and 2022 was $5,781, $2,612, and $877, respectively. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of options granted during the years ended December&#160;31, 2024, 2023, and 2022 was $11.34, $9.14, and $4.02 per share, respectively.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Share Awards&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted share awards represent Company shares issued free of charge to employees of the Company as compensation for services rendered. The Company measures the total fair value of restricted share awards on the grant date using the Company&#x2019;s stock price at the time of the grant. Restricted share awards granted to employees vest ratably over a range of one year to four years on each anniversary of the grant date. Compensation expense for such awards granted is recognized over the applicable vesting period. Additionally, during the year ended December&#160;31, 2024, the Company issued restricted stock awards to its Board of Directors that vest on the &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;one-year anniversary of the award.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted share awards as of December&#160;31, 2024, and changes during the year then ended, is reflected in the table below.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Share Activity and Other Data: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Restricted Share Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share awards outstanding, January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share awards outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted average grant date fair value of restricted share awards granted during the year ended December&#160;31, 2024 was $15.36 per share. No restricted share awards were granted during the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Performance Share Units Awards&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Performance share units awards (&#x201c;PSUs&#x201d;) represent Company shares issued free of charge to employees of the Company as compensation for achieving specified results. The Company measures the total fair value of performance share unit awards on the grant date using the Company&#x2019;s stock price at the time of the grant. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;No performance share awards were granted during the year ended December&#160;31, 2022. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;, there were &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;555&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; performance share awards that did not have an accounting grant date due to the discretionary nature of the performance criteria. Accordingly, no grant date fair value was established and there were no performance share awards considered granted during the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;December&#160;31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;. In February 2024, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;185 of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;performance share awards&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; that were tied to performance during the second half of 2023 were forfeited. No&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; performance share awards were granted during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Employee Share Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In 2017, the Board of Directors approved the Avadel Pharmaceuticals plc 2017 Avadel Employee Share Purchase Plan (&#x201c;ESPP&#x201d;). The total number of Company ordinary shares which may be issued under the ESPP is 1,000. The purchase price at which a share will be issued or sold for a given offering period will be established by the Compensation Committee of the Board (&#x201c;Committee&#x201d;) (and may differ among participants, as determined by the Committee in its sole discretion) but will in no event be less than 85% of the lesser of: (a) the fair market value of a Share on the offering date; or (b) the fair market value of a Share on the purchase date. During the years ended December&#160;31, 2024, 2023 and 2022 the Company issued 113, 47, and 75 ordinary shares to employees, respectively. Expense related to the ESPP for the years ended December&#160;31, 2024, 2023 and &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2022&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="c-1" id="f-789">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Compensation expense included in the Company&#x2019;s consolidated statements of loss for all share-based compensation arrangements was as follows for the years ended December&#160;31, 2024, 2023, and 2022:&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Share-based Compensation Expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling, general and administrative &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,532&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,248&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6,844&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;856&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;563&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total share-based compensation expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,388&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,811&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,013&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-144" decimals="-3" id="f-790" unitRef="usd">19532000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-145" decimals="-3" id="f-791" unitRef="usd">15248000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-146" decimals="-3" id="f-792" unitRef="usd">6844000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-147" decimals="-3" id="f-793" unitRef="usd">856000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-148" decimals="-3" id="f-794" unitRef="usd">563000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-149" decimals="-3" id="f-795" unitRef="usd">169000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-3" id="f-796" unitRef="usd">20388000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-4" decimals="-3" id="f-797" unitRef="usd">15811000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-5" decimals="-3" id="f-798" unitRef="usd">7013000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-6" decimals="-3" id="f-799" unitRef="usd">22513000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-1" id="f-800">P2Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-150" decimals="2" id="f-801" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-151" decimals="2" id="f-802" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-151" id="f-803">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-152" decimals="2" id="f-804" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-153" decimals="2" id="f-805" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-151" id="f-806">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-152" decimals="2" id="f-807" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage contextRef="c-153" decimals="2" id="f-808" unitRef="number">0.50</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardAwardVestingRightsPercentage>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-154" decimals="-3" id="f-809" unitRef="usd">8009000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized
      contextRef="c-155"
      decimals="-3"
      id="f-810"
      unitRef="shares">4259000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-156"
      decimals="-3"
      id="f-811"
      unitRef="shares">2000000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-156"
      decimals="-3"
      id="f-812"
      unitRef="shares">841000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-157" id="f-813">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-157" id="f-814">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-158" id="f-815">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-816">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-160" id="f-817">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-161" id="f-818">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-159" id="f-819">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-162" id="f-820">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-158" id="f-821">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-158" id="f-822">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-823">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-160" id="f-824">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-161" id="f-825">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-163" id="f-826">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-159" id="f-827">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-162" id="f-828">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod contextRef="c-158" id="f-829">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <avdl:ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-830">&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average assumptions under the Black-Scholes option-pricing model for stock option grants as of December&#160;31, 2024, 2023 and 2022 are as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.900%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Stock Option Assumptions: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock option grants:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.1&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;104.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;100.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;93.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Risk-free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;3.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</avdl:ScheduleOfShareBasedPaymentAwardStockOptionsAndWarrantGrantsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-164" id="f-831">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-165" id="f-832">P6Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-166" id="f-833">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-164" decimals="3" id="f-834" unitRef="number">1.041</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-165" decimals="3" id="f-835" unitRef="number">1.001</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-166" decimals="3" id="f-836" unitRef="number">0.934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate contextRef="c-166" decimals="4" id="f-837" unitRef="number">0.934</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-164" decimals="3" id="f-838" unitRef="number">0.043</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-165" decimals="3" id="f-839" unitRef="number">0.039</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-166" decimals="4" id="f-840" unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate contextRef="c-166" decimals="3" id="f-841" unitRef="number">0.027</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-164"
      decimals="INF"
      id="f-842"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-165"
      decimals="INF"
      id="f-843"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-166"
      decimals="INF"
      id="f-844"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="c-166"
      decimals="INF"
      id="f-845"
      unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-846">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the combined stock option activity and other data for the Company&#x2019;s stock option plans for the year ended December&#160;31, 2024 is as follows: &#160;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:34.782%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.194%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.535%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.196%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;&#160;Stock Option Activity and Other Data: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number&#160;of Stock&lt;br/&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Exercise Price per Share&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average&lt;br/&gt;Remaining&lt;br/&gt;Contractual Life&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;10,299&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.29&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,961&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13.75&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Exercised&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(734)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(468)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11.65&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Expired&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(266)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;16.30&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,792&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.8&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;34,411&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Stock options exercisable, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7,799&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;6.53&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;5.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;32,380&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-7" decimals="-3" id="f-847" unitRef="shares">10299000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-7"
      decimals="2"
      id="f-848"
      unitRef="usdPerShare">7.29</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross contextRef="c-1" decimals="-3" id="f-849" unitRef="shares">2961000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-850"
      unitRef="usdPerShare">13.75</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised contextRef="c-1" decimals="-3" id="f-851" unitRef="shares">734000</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-852"
      unitRef="usdPerShare">7.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod contextRef="c-1" decimals="-3" id="f-853" unitRef="shares">468000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-854"
      unitRef="usdPerShare">11.65</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod contextRef="c-1" decimals="-3" id="f-855" unitRef="shares">266000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="c-1"
      decimals="2"
      id="f-856"
      unitRef="usdPerShare">16.30</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="c-6" decimals="-3" id="f-857" unitRef="shares">11792000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-858"
      unitRef="usdPerShare">8.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-859">P6Y9M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-6" decimals="-3" id="f-860" unitRef="usd">34411000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber contextRef="c-6" decimals="-3" id="f-861" unitRef="shares">7799000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="c-6"
      decimals="2"
      id="f-862"
      unitRef="usdPerShare">6.53</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-1" id="f-863">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-6" decimals="-3" id="f-864" unitRef="usd">32380000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-3" id="f-865" unitRef="usd">5781000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-4" decimals="-3" id="f-866" unitRef="usd">2612000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-5" decimals="-3" id="f-867" unitRef="usd">877000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-868"
      unitRef="usdPerShare">11.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-4"
      decimals="2"
      id="f-869"
      unitRef="usdPerShare">9.14</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-5"
      decimals="2"
      id="f-870"
      unitRef="usdPerShare">4.02</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-158" id="f-871">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-159" id="f-872">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-160" id="f-873">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-161" id="f-874">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-167" id="f-875">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1 contextRef="c-162" id="f-876">P1Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock contextRef="c-1" id="f-877">&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the Company&#x2019;s restricted share awards as of December&#160;31, 2024, and changes during the year then ended, is reflected in the table below.&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:48.533%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.350%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.532%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:23.353%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Restricted Share Activity and Other Data: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Number of Restricted Share Awards&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Weighted Average Grant Date&lt;br/&gt;Fair Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share awards outstanding, January 1, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;23&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;142&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15.36&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Vested&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(11)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;8.20&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(4)&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12.60&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:6.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Non-vested restricted share awards outstanding, December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;14.88&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-168"
      decimals="-3"
      id="f-878"
      unitRef="shares">23000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-168"
      decimals="2"
      id="f-879"
      unitRef="usdPerShare">8.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-880"
      unitRef="shares">142000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-881"
      unitRef="usdPerShare">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-882"
      unitRef="shares">11000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-883"
      unitRef="usdPerShare">8.20</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-169"
      decimals="-3"
      id="f-884"
      unitRef="shares">4000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-885"
      unitRef="usdPerShare">12.60</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-170"
      decimals="-3"
      id="f-886"
      unitRef="shares">150000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-170"
      decimals="2"
      id="f-887"
      unitRef="usdPerShare">14.88</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-169"
      decimals="2"
      id="f-888"
      unitRef="usdPerShare">15.36</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-171"
      decimals="INF"
      id="f-889"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-172"
      decimals="INF"
      id="f-890"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-173"
      decimals="2"
      id="f-891"
      unitRef="usdPerShare">0</avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate
      contextRef="c-174"
      decimals="-3"
      id="f-892"
      unitRef="shares">555000</avdl:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardsWithNoGrantDate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-175"
      decimals="INF"
      id="f-893"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-176"
      decimals="INF"
      id="f-894"
      unitRef="shares">185000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-154"
      decimals="INF"
      id="f-895"
      unitRef="shares">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-177"
      decimals="INF"
      id="f-896"
      unitRef="shares">1000000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent
      contextRef="c-178"
      decimals="INF"
      id="f-897"
      unitRef="number">0.85</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-179"
      decimals="-3"
      id="f-898"
      unitRef="shares">113000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-180"
      decimals="-3"
      id="f-899"
      unitRef="shares">47000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-181"
      decimals="-3"
      id="f-900"
      unitRef="shares">75000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-905">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per share is calculated by dividing net loss by the weighted average number of shares outstanding during each period. Diluted net loss per share is calculated by dividing net loss by the diluted number of shares outstanding during each period. Except where th&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;e result would be anti-dilutive to net loss, diluted net loss per share would be calculated assuming the impact of the conversion of the 2023 Notes, the conversion of the  Company&#x2019;s preferred shares, the exercise of outstandi&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ng equity compensation awards, and ordinary shares expected to be issued under the Company&#x2019;s ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had a choice to settle the conversion obligations under the 2023 Notes in cash, shares or any combination of the two. The Company utilized the if-converted method to reflect the impact of the conversion of the 2023 Notes, unless the result was anti-dilutive. This method assumed the conversion of the 2023 Notes into shares of the Company&#x2019;s ordinary shares and reflected the elimination of the interest expense related to the 2023 Notes. The Company had no 2023 Notes remaining as of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2024 and 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The dilutive effect of the stock options, restricted share awards, preferred shares and ordinary shares expected to be issued under the Company&#x2019;s ESPP has been calculated using the treasury stock method.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands for the years ended December&#160;31, 2024, 2023 and 2022, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Loss Per Share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&#x2014;employee and director equity awards outstanding, preferred shares and 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Potential ordinary shares of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;1,410&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, 513, and 17,941 were excluded from the calculation of weighted average shares for the years ended December&#160;31, 2024, 2023 and 2022, respectively, because their effect was considered to be anti-dilutive or they were related to shares from PSUs for which the contingent vesting condition had not been achieved. For the years ended December&#160;31, 2024, 2023 and 2022, the effects of dilutive securities were entirely excluded from the calculation of net loss per share as a net loss was reported in these periods.&lt;/span&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-906">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of basic and diluted net loss per share, together with the related shares outstanding in thousands for the years ended December&#160;31, 2024, 2023 and 2022, is as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.771%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.788%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.496%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.501%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Net Loss Per Share: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(48,832)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,276)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137,464)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Weighted average shares:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Basic shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Effect of dilutive securities&#x2014;employee and director equity awards outstanding, preferred shares and 2023 Notes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Diluted shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;95,141&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;80,174&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;60,094&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share - basic&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net loss per share - diluted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(0.51)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.00)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(2.29)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-3" id="f-907" unitRef="usd">-48832000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-4" decimals="-3" id="f-908" unitRef="usd">-160276000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-5" decimals="-3" id="f-909" unitRef="usd">-137464000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-3" id="f-910" unitRef="shares">95141000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-4" decimals="-3" id="f-911" unitRef="shares">80174000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-912" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-5" decimals="-3" id="f-913" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-1" decimals="-3" id="f-914" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-4" decimals="-3" id="f-915" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment contextRef="c-5" decimals="-3" id="f-916" unitRef="shares">0</us-gaap:WeightedAverageNumberDilutedSharesOutstandingAdjustment>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-3" id="f-917" unitRef="shares">95141000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-4" decimals="-3" id="f-918" unitRef="shares">80174000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-919" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-5" decimals="-3" id="f-920" unitRef="shares">60094000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-921"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-4"
      decimals="2"
      id="f-922"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-5"
      decimals="2"
      id="f-923"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-924"
      unitRef="usdPerShare">-0.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-4"
      decimals="2"
      id="f-925"
      unitRef="usdPerShare">-2.00</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-5"
      decimals="2"
      id="f-926"
      unitRef="usdPerShare">-2.29</us-gaap:EarningsPerShareDiluted>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-3" id="f-927" unitRef="shares">1410000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-4" decimals="-3" id="f-928" unitRef="shares">513000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-5" decimals="-3" id="f-929" unitRef="shares">17941000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:ComprehensiveIncomeNoteTextBlock contextRef="c-1" id="f-930">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Comprehensive Loss&lt;/span&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the components of accumulated other comprehensive loss for the year ended December 31, net of tax effects:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) on marketable debt securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The effect on the Company&#x2019;s consolidated financial statements of amounts reclassified out of accumulated other comprehensive loss was immaterial for all periods presented.&lt;/span&gt;&lt;/div&gt;</us-gaap:ComprehensiveIncomeNoteTextBlock>
    <us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock contextRef="c-1" id="f-931">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table shows the components of accumulated other comprehensive loss for the year ended December 31, net of tax effects:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:5pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:49.338%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.689%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.384%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.840%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Accumulated Other Comprehensive Loss:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Foreign currency translation adjustment:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,855)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(623)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;331&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(597)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,744)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,121)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,452)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:14pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Unrealized gain (loss) on marketable debt securities, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(85)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:24.75pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net other comprehensive (loss) income, net of income tax expense of $0, $0, and $0, respectively&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(790)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2,843&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,804)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Balance at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;954&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,889)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Accumulated other comprehensive loss at December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(24,580)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(23,167)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(26,341)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccumulatedOtherComprehensiveIncomeLossTableTextBlock>
    <us-gaap:StockholdersEquity contextRef="c-186" decimals="-3" id="f-932" unitRef="usd">-24121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-187" decimals="-3" id="f-933" unitRef="usd">-24452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-188" decimals="-3" id="f-934" unitRef="usd">-23855000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-189" decimals="-3" id="f-935" unitRef="usd">-623000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-190" decimals="-3" id="f-936" unitRef="usd">331000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-191" decimals="-3" id="f-937" unitRef="usd">-597000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-192" decimals="-3" id="f-938" unitRef="usd">-24744000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-186" decimals="-3" id="f-939" unitRef="usd">-24121000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-187" decimals="-3" id="f-940" unitRef="usd">-24452000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-193" decimals="-3" id="f-941" unitRef="usd">954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-194" decimals="-3" id="f-942" unitRef="usd">-1889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-195" decimals="-3" id="f-943" unitRef="usd">-85000</us-gaap:StockholdersEquity>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-1" decimals="-3" id="f-944" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-4" decimals="-3" id="f-945" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax contextRef="c-5" decimals="-3" id="f-946" unitRef="usd">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-196" decimals="-3" id="f-947" unitRef="usd">-790000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-197" decimals="-3" id="f-948" unitRef="usd">2843000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent contextRef="c-198" decimals="-3" id="f-949" unitRef="usd">-1804000</us-gaap:OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent>
    <us-gaap:StockholdersEquity contextRef="c-199" decimals="-3" id="f-950" unitRef="usd">164000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-193" decimals="-3" id="f-951" unitRef="usd">954000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-194" decimals="-3" id="f-952" unitRef="usd">-1889000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-58" decimals="-3" id="f-953" unitRef="usd">-24580000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-46" decimals="-3" id="f-954" unitRef="usd">-23167000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-23" decimals="-3" id="f-955" unitRef="usd">-26341000</us-gaap:StockholdersEquity>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-956">&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Segment Information&lt;/span&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has determined that it operates in one segment, the development and commercialization of pharmaceutical products, including controlled-release therapeutic products based on its proprietary polymer-based technology. The Company&#x2019;s Chief Operating Decision Maker is the Chief Executive Officer (&#x201c;CEO&#x201d;). The CEO reviews profit and loss information on a consolidated basis to assess performance and make overall operating decisions as well as resource allocations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All products are included in one segment because the Company&#x2019;s products have similar economic and other characteristics, including the nature of the products and production processes, type of customers, distribution methods and regulatory environment.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about the Company&#x2019;s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other segment items*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&lt;br/&gt;*For the years ended December&#160;31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December&#160;31, 2022, the other segment items category also includes restructuring expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:14pt;text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Non-monetary long-lived assets primarily consist of property and equipment, goodwill, and operating right-of use-assets.&#160;The following table summarizes non-monetary long-lived assets by geographic region as of December&#160;31, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-lived Assets by Geographic Region: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amortization expense on long-lived assets was immaterial for the years ended December&#160;31, 2024, 2023 and 2022.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-957"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-958"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-959"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-960"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-961">&lt;div style="text-align:justify"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides information about the Company&#x2019;s significant expenses provided to the CEO and includes the reconciliation to loss before income taxes.&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:61.180%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.742%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.746%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Years ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Net product revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;169,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,963&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Cost of products sold&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,277&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;846&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Gross profit&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;153,840&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;27,117&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating expenses:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,196&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;13,261&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;20,700&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;General and administrative expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;84,962&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;79,596&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;52,655&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Selling and marketing expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;76,478&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;56,419&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Other segment items*&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;19,603&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;15,690&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;9,915&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total operating expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;196,239&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;164,966&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;98,561&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Operating loss&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(42,399)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(137,849)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(98,561)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Investment and other income (expense), net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;4,150&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;87&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(536)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Interest expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(10,830)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(9,886)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(12,342)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss on extinguishment of debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(13,129)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Loss before income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(49,079)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(160,777)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(111,439)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;&lt;br/&gt;*For the years ended December&#160;31, 2024, 2023 and 2022, the other segment items category includes quality and regulatory expenses and medical affairs expenses. For the year ended December&#160;31, 2022, the other segment items category also includes restructuring expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-200" decimals="-3" id="f-962" unitRef="usd">169117000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-201" decimals="-3" id="f-963" unitRef="usd">27963000</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-202" decimals="-3" id="f-964" unitRef="usd">0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-200" decimals="-3" id="f-965" unitRef="usd">15277000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-201" decimals="-3" id="f-966" unitRef="usd">846000</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:CostOfGoodsAndServicesSold contextRef="c-202" decimals="-3" id="f-967" unitRef="usd">0</us-gaap:CostOfGoodsAndServicesSold>
    <us-gaap:GrossProfit contextRef="c-200" decimals="-3" id="f-968" unitRef="usd">153840000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-201" decimals="-3" id="f-969" unitRef="usd">27117000</us-gaap:GrossProfit>
    <us-gaap:GrossProfit contextRef="c-202" decimals="-3" id="f-970" unitRef="usd">0</us-gaap:GrossProfit>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-200" decimals="-3" id="f-971" unitRef="usd">15196000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-201" decimals="-3" id="f-972" unitRef="usd">13261000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-202" decimals="-3" id="f-973" unitRef="usd">20700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-200" decimals="-3" id="f-974" unitRef="usd">84962000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-201" decimals="-3" id="f-975" unitRef="usd">79596000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-202" decimals="-3" id="f-976" unitRef="usd">52655000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-200" decimals="-3" id="f-977" unitRef="usd">76478000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-201" decimals="-3" id="f-978" unitRef="usd">56419000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense contextRef="c-202" decimals="-3" id="f-979" unitRef="usd">15291000</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-200" decimals="-3" id="f-980" unitRef="usd">19603000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-201" decimals="-3" id="f-981" unitRef="usd">15690000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-202" decimals="-3" id="f-982" unitRef="usd">9915000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:OperatingExpenses contextRef="c-200" decimals="-3" id="f-983" unitRef="usd">196239000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-201" decimals="-3" id="f-984" unitRef="usd">164966000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-202" decimals="-3" id="f-985" unitRef="usd">98561000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-200" decimals="-3" id="f-986" unitRef="usd">-42399000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-201" decimals="-3" id="f-987" unitRef="usd">-137849000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-202" decimals="-3" id="f-988" unitRef="usd">-98561000</us-gaap:OperatingIncomeLoss>
    <us-gaap:InvestmentIncomeNet contextRef="c-200" decimals="-3" id="f-989" unitRef="usd">4150000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-201" decimals="-3" id="f-990" unitRef="usd">87000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InvestmentIncomeNet contextRef="c-202" decimals="-3" id="f-991" unitRef="usd">-536000</us-gaap:InvestmentIncomeNet>
    <us-gaap:InterestExpenseDebt contextRef="c-200" decimals="-3" id="f-992" unitRef="usd">10830000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-201" decimals="-3" id="f-993" unitRef="usd">9886000</us-gaap:InterestExpenseDebt>
    <us-gaap:InterestExpenseDebt contextRef="c-202" decimals="-3" id="f-994" unitRef="usd">12342000</us-gaap:InterestExpenseDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-200" decimals="-3" id="f-995" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-201" decimals="-3" id="f-996" unitRef="usd">-13129000</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:GainsLossesOnExtinguishmentOfDebt contextRef="c-202" decimals="-3" id="f-997" unitRef="usd">0</us-gaap:GainsLossesOnExtinguishmentOfDebt>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-200" decimals="-3" id="f-998" unitRef="usd">-49079000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-201" decimals="-3" id="f-999" unitRef="usd">-160777000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest contextRef="c-202" decimals="-3" id="f-1000" unitRef="usd">-111439000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock contextRef="c-1" id="f-1001">The following table summarizes non-monetary long-lived assets by geographic region as of December&#160;31, 2024 and 2023:&lt;div style="margin-bottom:4pt;text-align:justify"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:65.566%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.835%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.530%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.839%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Long-lived Assets by Geographic Region: &lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;U.S.&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;17,513&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;18,413&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Ireland&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,210&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;11,751&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;29,723&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,164&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LongLivedAssetsByGeographicAreasTableTextBlock>
    <us-gaap:NoncurrentAssets contextRef="c-126" decimals="-3" id="f-1002" unitRef="usd">17513000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-203" decimals="-3" id="f-1003" unitRef="usd">18413000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-125" decimals="-3" id="f-1004" unitRef="usd">12210000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-204" decimals="-3" id="f-1005" unitRef="usd">11751000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-6" decimals="-3" id="f-1006" unitRef="usd">29723000</us-gaap:NoncurrentAssets>
    <us-gaap:NoncurrentAssets contextRef="c-7" decimals="-3" id="f-1007" unitRef="usd">30164000</us-gaap:NoncurrentAssets>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-205" id="f-1008">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-205" id="f-1009">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-205" id="f-1010">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-205" id="f-1011">false</ecd:NonRule10b51ArrTrmntdFlag>
    <dei:AuditorName contextRef="c-1" id="f-1012">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-1013">St. Louis, Missouri</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="c-1" id="f-1014">34</dei:AuditorFirmId>
    <srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock contextRef="c-1" id="f-1015">&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Schedule II&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:3pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Valuation and Qualifying Accounts&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:6pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;(In thousands)&#160;&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.561%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:26.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.961%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.472%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:10.206%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.024%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.534%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.561%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deferred Tax Asset Valuation Allowance:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, &lt;br/&gt;Beginning of Period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Additions&lt;br/&gt;(a)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Deductions&lt;br/&gt;(b)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Other Changes&lt;br/&gt;(c)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:700;line-height:100%"&gt;Balance, &lt;br/&gt;End of Period&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:3pt"&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;12,587&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(7,457)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;101,565&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;30,918&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(6,586)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;755&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;96,428&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7.75pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;2022&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;24,025&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;48,734&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;(1,418)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:9pt;font-weight:400;line-height:100%"&gt;71,341&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;a.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Additions to the deferred tax asset valuation allowance relate to movements on certain French, Irish and U.S. deferred tax assets where we continue to maintain a valuation allowance until sufficient positive evidence exists to support reversal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;b.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:10.5pt"&gt;Deductions to the deferred tax asset valuation allowance include movements relating to utilization of net operating losses and tax credit carryforwards, release in valuation allowance and other movements including adjustments following finalization of tax returns.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-bottom:9pt;padding-left:45pt;text-align:justify;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;c.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:11.07pt"&gt;Other changes to the deferred tax asset valuation allowance including currency translation adjustments recorded directly in equity, account method changes and the impact of corporate restructuring.&lt;/span&gt;&lt;/div&gt;</srt:ScheduleOfValuationAndQualifyingAccountsDisclosureTextBlock>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-206" decimals="-3" id="f-1016" unitRef="usd">96428000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-207" decimals="-3" id="f-1017" unitRef="usd">12587000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-207" decimals="-3" id="f-1018" unitRef="usd">7457000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="c-207" decimals="-3" id="f-1019" unitRef="usd">7000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-208" decimals="-3" id="f-1020" unitRef="usd">101565000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-209" decimals="-3" id="f-1021" unitRef="usd">71341000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-210" decimals="-3" id="f-1022" unitRef="usd">30918000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-210" decimals="-3" id="f-1023" unitRef="usd">6586000</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="c-210" decimals="-3" id="f-1024" unitRef="usd">755000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-206" decimals="-3" id="f-1025" unitRef="usd">96428000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-211" decimals="-3" id="f-1026" unitRef="usd">24025000</us-gaap:ValuationAllowancesAndReservesBalance>
    <us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense contextRef="c-212" decimals="-3" id="f-1027" unitRef="usd">48734000</us-gaap:ValuationAllowancesAndReservesChargedToCostAndExpense>
    <us-gaap:ValuationAllowancesAndReservesDeductions contextRef="c-212" decimals="-3" id="f-1028" unitRef="usd">0</us-gaap:ValuationAllowancesAndReservesDeductions>
    <us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease contextRef="c-212" decimals="-3" id="f-1029" unitRef="usd">-1418000</us-gaap:ValuationAllowancesAndReservesPeriodIncreaseDecrease>
    <us-gaap:ValuationAllowancesAndReservesBalance contextRef="c-209" decimals="-3" id="f-1030" unitRef="usd">71341000</us-gaap:ValuationAllowancesAndReservesBalance>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-1031">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
